Ex	O
##c	O
##lusion	O
criteria	O
for	O
all	O
participants	O
included	O
use	O
of	O
anti	O
##biotics	O
,	O
non	O
##ster	O
##oid	O
##al	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
s	B
##tat	I
##ins	I
,	O
or	O
pro	O
##biotics	O
within	O
2	O
m	O
##o	O
of	O
study	O
participation	O
.	O

A	O
significant	O
decrease	O
was	O
observed	O
in	O
glucose	S
up	O
##take	O
by	O
blocking	O
/	O
si	O
##len	O
##cing	O
the	O
IP	O
_	O
3	O
R	O
receptor	O
in	O
MC	O
##F	O
-	O
7	O
,	O
MD	O
##A	O
MB	O
-	O
231	O
and	O
MC	O
##F	O
10	O
cells	O
.	O

E	O
##×	O
##ar	O
E	O
##×	O
##ar	O
E	O
×	O
a	O
##r	O
a	O
##r	O
a	O
a	O
r	O
r	O
where	O
E	O
(	O
CO	O
##2	O
)	O
=	O
labelled	O
CO	O
##2	O
:	O
un	O
##la	O
##bell	O
##ed	O
CO	O
##2	O
ratio	O
in	O
expired	O
breath	O
,	O
V	O
_	O
CO	O
##2	O
=	O
volume	O
of	O
carbon	B
dioxide	I
expired	O
per	O
breath	O
(	O
μ	O
##mo	O
##l	O
/	O
min	O
)	O
,	O
16	O
=	O
the	O
number	O
of	O
carbon	O
atoms	O
present	O
in	O
one	O
palm	B
##itate	I
molecule	O
,	O
and	O
E	O
=	O
plasma	O
trace	O
##r	O
and	O
a	O
(	O
r	O
)	O
=	O
ace	B
##tate	I
correction	O
factor	O
.	O

The	O
only	O
exception	O
to	O
this	O
observation	O
was	O
ace	B
##tone	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
p	B
##yr	I
##u	I
##vic	I
acid	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
pro	B
##line	I
,	O
al	B
##ani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
between	O
groups	O
.	O

However	O
,	O
there	O
are	O
no	O
correlation	O
##s	O
between	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
and	O
C	O
##MM	O
##SE	O
among	O
the	O
sample	O
from	O
both	O
Community	O
and	O
Hospital	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Pre	O
##c	O
##lini	O
##cal	O
studies	O
have	O
shown	O
that	O
limo	B
##nen	I
##e	I
causes	O
a	O
##pop	O
##tosis	O
in	O
multiple	O
cell	O
types	O
through	O
indirect	O
mechanisms	O
[	O
,	O
]	O
.	O

S	O
##pect	O
##ra	O
were	O
referenced	O
to	O
the	O
DS	O
##S	O
resonance	O
(	O
0	O
.	O
0	O
parts	O
per	O
million	O
)	O
,	O
and	O
regions	O
for	O
water	O
,	O
E	O
##D	O
##TA	O
,	O
and	O
met	B
##han	I
##ol	I
were	O
removed	O
.	O

G	O
##DM	O
,	O
g	O
##esta	O
##tional	O
diabetes	O
me	O
##lli	O
##tus	O
;	O
O	O
##G	O
##TT	O
,	O
oral	O
-	O
glucose	O
-	O
tolerance	O
test	O
;	O
T	B
##MA	I
##O	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
.	O

We	O
showed	O
that	O
,	O
even	O
in	O
a	O
young	O
healthy	O
population	O
,	O
P	O
##LP	O
has	O
significant	O
negative	O
correlation	O
##s	O
with	O
neo	B
##pt	I
##eri	I
##n	I
and	O
CR	O
##P	O
.	O

The	O
low	O
levels	O
of	O
ATP	S
and	O
the	O
low	O
ratio	O
of	O
ad	B
##eno	I
##sin	I
##e	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
are	O
also	O
in	O
contrast	O
to	O
our	O
experience	O
with	O
cell	O
culture	O
in	O
v	O
##it	O
##ro	O
and	O
with	O
cells	O
and	O
tissues	O
collected	O
during	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
studies	O
,	O
where	O
sample	O
handling	O
could	O
be	O
better	O
controlled	O
(	O
,	O
)	O
.	O

While	O
meta	O
##bol	O
##omi	O
##cs	O
measurements	O
detected	O
no	O
reduction	O
in	O
plasma	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
in	O
poor	O
respond	O
##ers	O
(	O
an	O
independent	O
ve	O
##rification	O
of	O
clinical	O
measurements	O
)	O
several	O
meta	O
##bol	O
##ites	O
did	O
change	O
significantly	O
in	O
the	O
poor	O
respond	O
##er	O
group	O
upon	O
treatment	O
with	O
si	B
##m	I
##vas	I
##tat	I
##in	I
.	O

In	O
addition	O
,	O
t	O
##rp	O
is	O
converted	O
to	O
in	B
##do	I
##le	I
,	O
I	O
##3	O
##A	O
,	O
and	O
I	O
##3	O
##P	O
by	O
bacterial	O
en	O
##zy	O
##matic	O
pathways	O
.	O

The	O
grades	O
predicted	O
by	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
showed	O
that	O
the	O
areas	O
under	O
the	O
curve	O
were	O
0	O
.	O
82	O
##3	O
for	O
ta	B
##uri	I
##ne	I
,	O
0	O
.	O
78	O
##3	O
for	O
al	B
##ani	I
##ne	I
,	O
and	O
0	O
.	O
84	O
##2	O
for	O
3	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
.	O

H	O
##b	O
##A	O
##1	O
##c	O
and	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
taken	O
from	O
date	O
closest	O
to	O
date	O
of	O
blood	O
draw	O
.	O

Blood	O
plasma	O
with	O
E	O
##D	O
##TA	O
and	O
C	B
##it	I
##rate	I
Ph	I
##os	I
##phate	I
Dex	I
##tro	I
##se	I
Sol	O
##ution	O
(	O
CP	O
##D	O
)	O
for	O
method	O
development	O
and	O
valid	O
##ation	O
was	O
purchased	O
from	O
the	O
Blood	O
Centre	O
of	O
Ta	O
##rt	O
##u	O
University	O
Hospital	O
.	O

For	O
the	O
detection	O
of	O
th	B
##iol	I
##s	I
we	O
developed	O
ass	O
##ays	O
to	O
measure	O
L	B
-	I
c	I
##ys	I
##tein	I
##e	I
,	O
L	B
-	I
c	I
##ys	I
##tein	I
##eg	I
##ly	I
##cine	I
,	O
L	B
-	I
g	I
##lut	I
##ath	I
##ione	I
and	O
L	O
-	O
ho	O
##mo	O
##cy	O
##sy	O
##ein	O
##e	O
,	O
while	O
for	O
is	B
##of	I
##lav	I
##ones	I
we	O
developed	O
ass	O
##ays	O
to	O
measure	O
bio	B
##chan	I
##in	I
A	O
,	O
co	B
##umes	I
##tero	I
##l	I
,	O
da	B
##id	I
##ze	I
##in	I
,	O
e	O
##q	O
##uo	O
##l	O
,	O
form	O
##one	O
##ntin	O
and	O
g	B
##eni	I
##stein	I
.	O

Met	O
##ab	O
##oli	O
##te	O
measures	O
that	O
failed	O
quality	O
control	O
(	O
in	O
particular	O
for	O
g	B
##lut	I
##amine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
h	B
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
and	O
ace	B
##tate	I
)	O
were	O
excluded	O
from	O
the	O
analysis	O
on	O
a	O
per	O
-	O
individual	O
basis	O
.	O

These	O
investigators	O
found	O
higher	O
levels	O
of	O
c	B
##yt	I
##id	I
##ine	I
(	O
P	O
=	O
0	O
.	O
00	O
##1	O
)	O
and	O
thy	B
##mi	I
##dine	I
(	O
P	O
=	O
0	O
.	O
00	O
##1	O
)	O
in	O
plasma	O
samples	O
from	O
T	O
##2	O
##D	O
patients	O
with	O
early	O
stage	O
of	O
DR	O
compared	O
to	O
those	O
without	O
DR	O
,	O
and	O
c	B
##yt	I
##id	I
##ine	I
had	O
the	O
highest	O
AU	O
##C	O
(	O
0	O
.	O
84	O
##9	O
±	O
0	O
.	O
04	O
##8	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
for	O
as	O
##par	O
##tate	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AS	O
##T	O
)	O
and	O
glucose	S
(	O
G	O
##L	O
##U	O
)	O
among	O
all	O
3	O
groups	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
character	O
##ize	O
and	O
then	O
evaluate	O
associations	O
for	O
ch	B
##olin	I
##e	I
and	O
its	O
meta	O
##bol	O
##ites	O
in	O
blood	O
and	O
milk	O
through	O
the	O
first	O
37	O
weeks	O
of	O
la	O
##ct	O
##ation	O
in	O
the	O
dairy	O
cow	O
.	O

The	O
reduction	O
of	O
para	B
##xa	I
##nt	I
##hine	I
may	O
indicate	O
that	O
the	O
metabolic	O
activity	O
of	O
P	O
##45	O
##0	O
1A	O
##2	O
declined	O
.	O

No	O
losses	O
of	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
were	O
detected	O
with	O
plastic	O
tubes	O
compared	O
to	O
b	O
##oro	O
##si	O
##lica	O
##te	O
glass	O
tubes	O
(	O
see	O
“	O
”	O
)	O
.	O

Specifically	O
,	O
one	O
m	O
/	O
z	O
feature	O
in	O
the	O
cluster	O
matched	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
while	O
two	O
features	O
matched	O
g	B
##ly	I
##code	I
##ox	I
##ych	I
##olic	I
acid	I
and	O
g	B
##ly	I
##co	I
##urs	I
##ode	I
##ox	I
##ych	I
##olic	I
acid	I
.	O

A	O
recent	O
study	O
showed	O
that	O
P	O
##U	O
##FA	O
##s	O
decreased	O
T	B
##G	I
levels	O
in	O
plasma	O
.	O

L	O
##yo	O
##phi	O
##li	O
##zed	O
powder	O
##s	O
from	O
met	B
##han	I
##ol	I
-	I
layer	I
was	O
re	O
##con	O
##stituted	O
in	O
D	O
_	O
2	O
O	O
containing	O
1	O
.	O
0	O
m	O
##M	O
DS	O
##S	O
(	O
internal	O
standard	O
for	O
q	O
##uant	O
##ification	O
of	O
meta	O
##b	O
##lite	O
##s	O
)	O
,	O
and	O
the	O
residues	O
from	O
ch	B
##lor	I
##of	I
##orm	I
-	I
layer	I
was	O
red	O
##iss	O
##ol	O
##ved	O
in	O
CD	O
##C	O
##l	O
_	O
3	O
containing	O
1	O
%	O
T	O
##MS	O
.	O
_	O
1	O
H	O
N	O
##MR	O
data	O
were	O
collected	O
on	O
a	O
B	O
##ruk	O
##er	O
600	O
MHz	O
s	O
##pect	O
##rome	O
##ter	O
.	O

Focus	O
##ing	O
on	O
the	O
optimization	O
of	O
separation	O
conditions	O
,	O
we	O
achieved	O
such	O
separation	O
by	O
constructing	O
ch	O
##ira	O
##l	O
tandem	O
L	O
##C	O
systems	O
using	O
two	O
kinds	O
of	O
ion	O
-	O
exchange	O
type	O
ch	O
##ira	O
##l	O
columns	O
(	O
c	O
##in	O
##cho	O
##na	O
al	O
##kal	O
##oid	O
-	O
based	O
ch	O
##ira	O
##l	O
stationary	O
phases	O
)	O
in	O
a	O
met	B
##han	I
##ol	I
solvent	O
.	O

The	O
levels	O
of	O
some	O
s	O
##tero	O
##ls	O
were	O
influenced	O
by	O
variants	O
at	O
several	O
g	O
##eno	O
##mic	O
lo	O
##ci	O
(	O
e	O
.	O
g	O
.	O
,	O
ABC	O
##G	O
##5	O
/	O
ABC	O
##G	O
##8	O
,	O
H	O
##SD	O
##3	O
##B	O
##7	O
,	O
and	O
ch	B
##ole	I
##stan	I
##ol	I
)	O
,	O
whereas	O
other	O
s	O
##tero	O
##ls	O
and	O
se	O
##cos	O
##tero	O
##ids	O
were	O
associated	O
with	O
a	O
single	O
lo	O
##cus	O
(	O
e	O
.	O
g	O
.	O
,	O
EP	O
##H	O
##X	O
##2	O
and	O
24	B
,	I
25	I
-	I
e	I
##pox	I
##ych	I
##ole	I
##ster	I
##ol	I
,	O
and	O
G	O
##C	O
and	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
)	O
.	O

These	O
included	O
the	O
same	O
types	O
of	O
molecules	O
listed	O
above	O
for	O
the	O
met	B
##han	I
##ol	I
method	O
.	O

To	O
comprehensive	O
##ly	O
assess	O
the	O
activity	O
of	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
,	O
we	O
first	O
undertook	O
to	O
pu	O
##ri	O
##fy	O
or	O
s	O
##ynth	O
##esi	O
##ze	O
all	O
of	O
the	O
possible	O
eccentric	O
c	O
##lea	O
##vage	O
products	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
.	O

Another	O
seemingly	O
important	O
meta	O
##bol	O
##ite	O
in	O
cancer	O
under	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
is	O
u	B
##rid	I
##ine	I
.	O

The	O
pro	O
##ton	O
chemical	O
shifts	O
were	O
referenced	O
to	O
CH	O
_	O
3	O
signal	O
of	O
la	B
##ct	I
##ate	I
at	O
1	O
.	O
33	O
pp	O
##m	O
.	O

The	O
peak	O
at	O
3	O
.	O
27	O
min	O
el	O
##utes	O
at	O
the	O
same	O
time	O
as	O
do	B
##pa	I
##mine	I
,	O
although	O
with	O
a	O
different	O
oxidation	O
profile	O
.	O

AU	O
##C	O
,	O
area	O
under	O
the	O
curve	O
;	O
CE	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
S	O
##q	O
##CC	O
,	O
sq	O
##ua	O
##mous	O
cell	O
lung	O
cancer	O
.	O

Specifically	O
,	O
we	O
find	O
that	O
medium	O
-	O
chain	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
##s	O
are	O
positively	O
associated	O
with	O
the	O
risk	O
of	O
PS	O
##A	O
progression	O
and	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
are	O
inverse	O
##ly	O
associated	O
with	O
progression	O
of	O
PC	O
##a	O
locally	O
and	O
to	O
the	O
bone	O
.	O

In	O
one	O
study	O
using	O
a	O
single	O
morning	O
blood	O
sample	O
of	O
T	O
##RP	O
and	O
K	O
##Y	O
##N	O
,	O
found	O
that	O
men	O
with	O
I	O
##BS	O
had	O
higher	O
levels	O
of	O
K	O
##Y	O
##N	O
,	O
higher	O
K	O
##Y	O
##N	O
/	O
T	O
##RP	O
ratios	O
,	O
and	O
lower	O
k	B
##yn	I
##uren	I
##ate	I
(	O
K	O
##Y	O
##NA	O
)	O
/	O
T	O
##RP	O
ratios	O
relative	O
to	O
a	O
control	O
group	O
of	O
men	O
without	O
I	O
##BS	O
.	O

In	O
a	O
preliminary	O
positive	O
ion	O
analysis	O
,	O
we	O
identified	O
212	O
unique	O
lip	O
##ids	O
from	O
6	O
L	O
##IP	O
##ID	O
MA	O
##PS	O
categories	O
,	O
including	O
fatty	O
a	O
##cy	O
##ls	O
(	O
FA	O
)	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
s	O
##tero	O
##ls	O
,	O
and	O
pre	O
##no	O
##ls	O
.	O

High	O
##light	O
##ed	O
candidate	O
markers	O
are	O
:	O
1	O
)	O
Ace	B
##tate	I
,	O
2	O
)	O

The	O
metabolic	O
pathway	O
of	O
P	O
was	O
similar	O
to	O
IP	S
.	O

Hence	O
,	O
our	O
hypothesis	O
generation	O
lies	O
in	O
the	O
observation	O
that	O
some	O
reproductive	O
parameters	O
showed	O
the	O
same	O
direction	O
of	O
associations	O
with	O
several	O
or	O
all	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
.	O

The	O
H	O
##R	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
greater	O
for	O
ER	O
+	O
breast	O
cancer	O
(	O
H	O
##R	O
=	O
2	O
.	O
06	O
)	O
than	O
for	O
total	O
breast	O
cancer	O
##s	O
(	O
1	O
.	O
66	O
)	O
.	O

The	O
s	O
##pect	O
##ra	O
were	O
bin	O
##ned	O
into	O
0	O
.	O
02	O
pp	O
##m	O
width	O
data	O
samples	O
(	O
from	O
0	O
to	O
9	O
pp	O
##m	O
for	O
the	O
a	O
##que	O
##ous	O
phase	O
s	O
##pect	O
##ra	O
and	O
from	O
0	O
.	O
2	O
to	O
4	O
.	O
4	O
pp	O
##m	O
for	O
the	O
lip	O
##id	O
phase	O
s	O
##pect	O
##ra	O
)	O
,	O
then	O
normal	O
##ized	O
to	O
the	O
total	O
area	O
under	O
spectrum	O
,	O
after	O
removing	O
spectral	O
regions	O
containing	O
solvent	O
(	O
water	O
,	O
met	B
##han	I
##ol	I
,	O
ch	B
##lor	I
##of	I
##orm	I
)	O
resonance	O
##s	O
.	O

These	O
results	O
are	O
compatible	O
with	O
a	O
model	O
in	O
which	O
EPA	O
+	O
D	O
##HA	O
per	O
se	O
do	O
not	O
de	O
##ter	O
##ior	O
##ate	O
glucose	S
u	O
##til	O
##ization	O
when	O
glucose	S
represents	O
the	O
main	O
energy	O
fuel	O
(	O
Fi	O
##g	O
.	O

We	O
com	O
##puted	O
S	O
##pear	O
##man	O
'	O
s	O
rank	O
correlation	O
coefficient	O
and	O
p	O
-	O
values	O
to	O
identify	O
significant	O
correlation	O
between	O
Δ	B
##g	I
##lu	I
##cos	I
##e	I
and	O
single	O
meta	O
##bol	O
##ites	O
with	O
a	O
significance	O
level	O
of	O
α	O
=	O
0	O
.	O
05	O
.	O

Individual	O
e	B
##ico	I
##san	I
##oids	I
and	O
do	B
##cos	I
##ano	I
##ids	I
were	O
q	O
##uant	O
##ified	O
based	O
on	O
the	O
determination	O
of	O
the	O
“	O
Area	O
Under	O
the	O
C	O
##ur	O
##ve	O
”	O
(	O
AU	O
##C	O
)	O
and	O
compared	O
with	O
the	O
AU	O
##C	O
of	O
standard	O
compounds	O
.	O

In	O
##sul	O
##in	O
promotes	O
glucose	S
up	O
##take	O
and	O
regulate	O
##s	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
cat	O
##ab	O
##olis	O
##m	O
through	O
the	O
in	O
##hibition	O
of	O
hormone	O
-	O
sensitive	O
lip	O
##ase	O
.	O

This	O
gradient	O
el	O
##ution	O
is	O
adequate	O
for	O
separating	O
most	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
biological	O
samples	O
,	O
including	O
P	O
##E	O
,	O
PC	O
,	O
P	B
##G	I
,	O
PA	O
,	O
P	O
##I	O
,	O
PS	O
,	O
and	O
SM	O
.	O

Several	O
car	O
##ni	O
##tine	O
-	O
con	O
##ju	O
##gated	O
derivatives	O
increased	O
following	O
le	O
##pt	O
##in	O
treatment	O
,	O
including	O
is	B
##ova	I
##ler	I
##yla	I
##car	I
##ni	I
##tine	I
,	O
t	B
##ig	I
##ly	I
##l	I
car	I
##ni	I
##tine	I
,	O
is	B
##ob	I
##ut	I
##ry	I
##ryl	I
##car	I
##ni	I
##tine	I
,	O
but	B
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
and	O
s	B
##tero	I
##yl	I
##car	I
##ni	I
##tine	I
.	O

To	O
each	O
well	O
internal	O
standard	O
/	O
protein	O
precipitation	O
solution	O
(	O
400	O
μ	O
##L	O
)	O
was	O
added	O
except	O
that	O
is	B
##op	I
##rop	I
##ano	I
##l	I
-	I
ch	I
##lor	I
##of	I
##orm	I
(	I
9	I
:	I
1	I
)	I
(	O
400	O
μ	O
##L	O
)	O
was	O
used	O
for	O
a	O
blank	O
.	O

Our	O
results	O
show	O
that	O
three	O
“	O
se	O
##psis	O
-	O
associated	O
”	O
Ph	O
##CA	O
##s	O
at	O
high	O
concentrations	O
in	O
##hibit	O
SD	O
##H	O
and	O
can	O
contribute	O
to	O
the	O
accumulation	O
of	O
su	B
##cci	I
##nic	I
acid	I
.	O

Met	O
##ab	O
##olis	O
##m	O
of	O
14	O
by	O
a	O
trans	O
##ami	O
##nas	O
##e	O
leads	O
to	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
5	I
-	I
o	I
##x	I
##o	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
15	O
,	O
)	O
.	O

High	O
level	O
of	O
glucose	S
in	O
lung	O
cancer	O
does	O
not	O
show	O
the	O
decrease	O
in	O
g	O
##ly	O
##co	O
##lysis	O
as	O
la	B
##ctic	I
acid	I
is	O
also	O
up	O
-	O
regulated	O
in	O
lung	O
cancer	O
.	O

In	O
addition	O
,	O
ch	B
##olin	I
##e	I
is	O
o	O
##xi	O
##dized	O
to	O
beta	B
##ine	I
in	O
humans	O
,	O
and	O
beta	B
##ine	I
can	O
be	O
s	O
##hun	O
##ted	O
for	O
multiple	O
metabolic	O
functions	O
[	O
,	O
]	O
Therefore	O
,	O
there	O
may	O
not	O
be	O
a	O
clear	O
relationship	O
between	O
T	B
##MA	I
##O	I
and	O
beta	B
##ine	I
,	O
especially	O
in	O
normal	O
,	O
healthy	O
populations	O
such	O
as	O
the	O
ones	O
analyzed	O
in	O
this	O
study	O
.	O

For	O
instance	O
,	O
the	O
higher	O
sensitivity	O
of	O
the	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
Me	O
##OH	O
extraction	O
is	O
noteworthy	O
in	O
anal	O
##yte	O
##s	O
,	O
such	O
as	O
N	O
##1	O
-	O
A	O
##c	O
##SP	O
##M	O
,	O
CA	O
##D	O
,	O
or	O
N	B
##1	I
,	I
N	I
##8	I
-	I
Di	I
##A	I
##c	I
##SP	I
##D	I
,	O
because	O
of	O
its	O
low	O
concentration	O
in	O
serum	O
samples	O
.	O

We	O
have	O
previously	O
reported	O
within	O
the	O
same	O
co	O
##hor	O
##t	O
that	O
maternal	O
bi	B
##sp	I
##hen	I
##ol	I
A	O
exposure	O
appeared	O
to	O
have	O
no	O
adverse	O
effect	O
of	O
test	O
##icular	O
function	O
in	O
adulthood	O
.	O

In	O
the	O
discovery	O
co	O
##hor	O
##t	O
,	O
three	O
meta	O
##bol	O
##ites	O
–	O
c	B
##it	I
##rate	I
,	O
hip	B
##pura	I
##te	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
–	O
were	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
disease	O
activity	O
in	O
CD	O
after	O
multiple	O
-	O
test	O
correction	O
(	O
Fi	O
##g	O
.	O

Among	O
the	O
34	O
cancer	O
-	O
associated	O
meta	O
##bol	O
##ites	O
,	O
the	O
levels	O
of	O
bi	B
##li	I
##ru	I
##bin	I
and	O
re	B
##tina	I
##l	I
recovered	O
after	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
treatment	O
,	O
indicating	O
that	O
they	O
may	O
be	O
the	O
potential	O
targets	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
for	O
reducing	O
BC	O
##a	O
re	O
##cu	O
##rrence	O
.	O

(	O
B	O
)	O
Ki	O
##net	O
##ics	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
by	O
re	O
##comb	O
##ina	O
##nt	O
human	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
and	O
pool	O
##ed	O
H	O
##LM	O
##s	O
.	O

B	O
##rief	O
##ly	O
,	O
a	O
20	O
m	O
##M	O
solution	O
of	O
MA	O
##d	O
_	O
3	O
was	O
prepared	O
in	O
0	O
.	O
1	O
M	O
sodium	B
phosphate	I
buffer	O
,	O
pH	O
8	O
.	O

It	O
was	O
also	O
reported	O
that	O
excessive	O
ad	B
##eni	I
##ne	I
found	O
in	O
a	O
chronic	O
re	O
##nal	O
failure	O
animal	O
model	O
was	O
related	O
to	O
o	O
##xi	O
##da	O
##tive	O
damages	O
and	O
inflammation	O
[	O
,	O
]	O
.	O

Sub	O
##jects	O
with	O
acute	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
,	O
stable	O
C	O
##VD	O
or	O
at	O
high	O
risk	O
for	O
C	O
##VD	O
,	O
on	O
adequate	O
as	B
##pi	I
##rin	I
therapy	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
previously	O
-	O
mentioned	O
p	O
##hos	O
##ph	O
##oc	O
##rea	O
##tine	O
-	O
dependent	O
up	O
##take	O
of	O
g	B
##lut	I
##ama	I
##te	I
forms	O
part	O
of	O
a	O
c	O
##yclic	O
g	O
##lut	O
##ama	O
##te	O
and	O
g	B
##lut	I
##amine	I
shuttle	O
between	O
as	O
##tro	O
##cy	O
##tes	O
and	O
neurons	O
in	O
the	O
normal	O
brain	O
.	O

Q	O
##1	O
–	O
Q	O
##4	O
median	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
+	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
concentration	O
levels	O
from	O
the	O
analysis	O
of	O
Gibbons	O
et	O
al	O
(	O
n	O
=	O
70	O
##4	O
)	O
.	O

The	O
HD	O
##L	O
-	O
C	O
model	O
contained	O
SM	B
(	I
d	I
##18	I
:	I
2	I
/	I
24	I
:	I
1	I
)	I
,	O
LP	B
##C	I
20	I
:	I
3	I
,	O
and	O
PS	O
36	O
:	O
0	O
.	O

The	O
novel	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ite	O
was	O
identified	O
based	O
on	O
the	O
presence	O
of	O
peaks	O
m	O
/	O
z	O
29	O
##1	O
and	O
m	O
/	O
z	O
32	O
##8	O
in	O
the	O
product	O
ion	O
s	O
##pect	O
##ra	O
,	O
see	O
Electronic	O
Su	O
##pp	O
##lement	O
##ary	O
Material	O
(	O
E	O
##SM	O
)	O

Alpha	B
-	I
AAA	I
and	O
he	B
##x	I
##ose	I
levels	O
were	O
significantly	O
increased	O
in	O
ch	O
##em	O
##otherapy	O
recipients	O
after	O
6	O
months	O
.	O

Ke	B
##tone	I
bodies	O
play	O
a	O
role	O
in	O
the	O
fatty	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
.	O

G	O
(	B
amid	B
##e	I
)	O
and	O
F	O
(	O
am	O
##ine	O
)	O
target	O
similar	O
anal	O
##yte	O
##s	O
but	O
have	O
different	O
hydrogen	O
bond	O
donor	O
/	O
accept	O
##or	O
properties	O
.	O

The	O
concentration	O
distribution	O
for	O
all	O
the	O
meta	O
##bol	O
##ites	O
except	O
his	B
##ti	I
##dine	I
showed	O
a	O
consistent	O
trend	O
from	O
p	O
##CR	O
to	O
PR	O
to	O
SD	O
;	O
while	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##amine	I
and	O
l	B
##ino	I
##len	I
##ic	I
acid	I
increased	O
,	O
is	B
##ole	I
##uc	I
##ine	I
decreased	O
.	O

The	O
heat	O
map	O
(	O
Fi	O
##g	O
.	O
)	O
also	O
shows	O
that	O
the	O
concentration	O
levels	O
of	O
certain	O
other	O
highly	O
correlated	O
meta	O
##bol	O
##ites	O
,	O
like	O
de	B
##ox	I
##ya	I
##den	I
##os	I
##ine	I
,	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##yl	I
##g	I
##lut	I
##ami	I
##c	I
acid	I
(	O
N	O
##AA	O
##G	O
)	O
,	O
3	B
-	I
O	I
-	I
met	I
##hyl	I
##ep	I
##ica	I
##tech	I
##in	I
,	O
2	O
-	O
non	O
##yn	O
##oi	O
##c	O
acid	O
,	O
5	B
-	I
met	I
##hyl	I
##thi	I
##oa	I
##den	I
##os	I
##ine	I
,	O
1	B
-	I
met	I
##hyl	I
##his	I
##tamine	I
and	O
neo	B
##pt	I
##eri	I
##n	I
also	O
exhibited	O
the	O
same	O
co	O
-	O
variation	O
(	O
initially	O
low	O
,	O
but	O
finally	O
high	O
)	O
as	O
the	O
above	O
meta	O
##bol	O
##ites	O
.	O

Eight	O
meta	O
##bol	O
##ites	O
significantly	O
increased	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
compared	O
with	O
sleep	O
(	B
ta	B
##uri	I
##ne	I
,	O
format	B
##e	I
,	O
c	B
##it	I
##rate	I
,	O
3	B
-	I
in	I
##dox	I
##yl	I
su	I
##lf	I
##ate	I
,	O
car	B
##ni	I
##tine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
T	B
##MA	I
##O	I
and	O
ace	B
##tate	I
)	O
and	O
8	O
significantly	O
decreased	O
(	B
dim	B
##eth	I
##yla	I
##mine	I
,	O
4	O
-	O
D	O
##TA	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
as	B
##cor	I
##bate	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
all	B
##ant	I
##oi	I
##n	I
,	O
4	O
-	O
DE	O
##A	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
)	O
.	O

In	O
the	O
CS	O
##F	O
,	O
no	O
differences	O
between	O
disease	O
groups	O
were	O
observed	O
in	O
substrate	O
levels	O
(	O
precursor	O
lip	O
##ids	O
)	O
of	O
AA	O
(	O
P	O
=	O
0	O
.	O
69	O
)	O
or	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
D	O
##HA	O
,	O
P	O
=	O
0	O
.	O
69	O
)	O
.	O

In	O
terms	O
of	O
chemical	O
class	O
coverage	O
,	O
N	O
##MR	O
detect	O
##s	O
compounds	O
from	O
15	O
of	O
the	O
25	O
major	O
chemical	O
super	O
##c	O
##lass	O
##es	O
in	O
urine	O
,	O
G	O
##C	O
-	O
MS	O
detect	O
##s	O
compounds	O
from	O
14	O
of	O
the	O
25	O
,	O
D	O
##FI	O
/	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
detect	O
##s	O
6	O
of	O
the	O
25	O
,	O
I	O
##CP	O
-	O
MS	O
detect	O
##s	O
1	O
of	O
the	O
25	O
while	O
the	O
targeted	O
methods	O
for	O
th	B
##iol	I
##s	I
and	O
is	B
##of	I
##lav	I
##ones	I
detect	O
just	O
1	O
of	O
each	O
.	O

The	O
abnormal	O
levels	O
of	O
la	B
##ctic	I
acid	I
and	O
c	B
##it	I
##ric	I
acid	I
observed	O
also	O
indicate	O
a	O
disturbance	O
of	O
g	O
##ly	O
##co	O
##lysis	O
and	O
energy	O
metabolism	O
.	O

The	O
above	O
considerations	O
led	O
us	O
to	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
con	O
##ju	O
##gate	O
##s	O
and	O
de	O
##pur	O
##inating	O
DNA	O
add	O
##uc	O
##ts	O
may	O
differ	O
between	O
healthy	O
women	O
and	O
women	O
with	O
breast	O
cancer	O
or	O
at	O
high	O
risk	O
of	O
breast	O
cancer	O
.	O

A	O
selection	O
of	O
identified	O
amino	S
and	O
fatty	O
acids	O
is	O
named	O
in	O
the	O
plot	O
.	O

In	O
line	O
with	O
both	O
studies	O
we	O
found	O
an	O
age	O
-	O
related	O
decline	O
of	O
the	O
24	O
-	O
hour	O
ex	O
##cre	O
##tion	O
of	O
most	O
pro	B
##ges	I
##tero	I
##nes	I
and	O
of	O
and	O
##rogen	O
##s	O
.	O

Here	O
,	O
we	O
developed	O
a	O
comprehensive	O
,	O
sensitive	O
,	O
robust	O
,	O
and	O
high	O
-	O
through	O
##put	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
stable	O
-	O
is	O
##oto	O
##pe	O
di	O
##lution	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
19	O
meta	O
##bol	O
##ites	O
related	O
to	O
p	B
##oly	I
##amine	I
metabolism	O
,	O
including	O
p	B
##oly	I
##amine	I
##s	I
,	O
ace	O
##ty	O
##lated	O
and	O
di	B
##ace	I
##ty	I
##lated	I
p	I
##oly	I
##amine	I
##s	I
,	O
precursor	O
##s	O
,	O
and	O
cat	O
##ab	O
##oli	O
##tes	O
from	O
liquid	O
bio	O
##ps	O
##ies	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
the	O
inactive	O
major	O
meta	O
##bol	O
##ite	O
D	O
##M	O
‐	O
Tam	O
as	O
well	O
as	O
active	O
meta	O
##bol	O
##ites	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
and	O
(	O
Z	O
)	O
‐	O
4	O
‐	O
OH	O
‐	O
Tam	O
)	O
were	O
measured	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
as	O
previously	O
described	O
.	O
_	O
17	O

This	O
report	O
aims	O
to	O
assess	O
the	O
association	O
of	O
try	B
##pt	I
##op	I
##han	I
with	O
the	O
development	O
of	O
T	O
##2	O
##D	O
and	O
to	O
evaluate	O
its	O
performance	O
with	O
existing	O
amino	O
acid	O
markers	O
.	O

[	B
4	B
-	I
h	I
##ydro	I
##xy	I
##pent	I
##eno	I
##ic	I
acid	O
]	O
+	O
0	O
.	O
88	O
##6	O

Tri	B
##gly	I
##cer	I
##ides	I
,	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
fast	O
##ing	O
glucose	S
were	O
determined	O
at	O
the	O
Calgary	O
Laboratory	O
Services	O
using	O
established	O
protocols	O
and	O
fast	O
##ing	O
whole	O
blood	O
.	O

One	O
study	O
by	O
Far	O
##ia	O
et	O
al	O
.	O
showed	O
that	O
GA	B
##BA	I
was	O
detect	O
##able	O
in	O
low	O
-	O
grade	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
and	O
normal	O
brain	O
,	O
however	O
they	O
failed	O
to	O
detect	O
GA	B
##BA	I
in	O
high	O
grade	O
tumors	O
,	O
while	O
another	O
study	O
by	O
B	O
##iac	O
##hi	O
et	O
al	O
.	O
found	O
increased	O
levels	O
of	O
GA	B
##BA	I
in	O
GB	O
##M	O
as	O
compared	O
to	O
normal	O
brain	O
using	O
micro	O
##dial	O
##ys	O
##is	O
.	O

Nevertheless	O
,	O
here	O
##in	O
we	O
demonstrate	O
that	O
individual	O
o	B
##xy	I
##lip	I
##ins	I
identified	O
by	O
our	O
analysis	O
of	O
T	O
##GR	O
##L	O
could	O
directly	O
affect	O
end	O
##oth	O
##eli	O
##al	O
inflammation	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Di	O
##ce	O
coefficient	O
pair	O
##wise	O
comparisons	O
of	O
total	O
bacteria	O
(	O
using	O
universal	O
bacterial	O
prime	O
##rs	O
)	O
and	O
Ba	O
##cter	O
##oid	O
##ete	O
##s	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
,	O
C	O
##los	O
##tri	O
##dium	O
co	O
##cco	O
##ides	O
and	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
groups	O
in	O
the	O
I	O
##BS	O
versus	O
n	O
##IB	O
##S	O
f	O
##ae	O
##cal	O
community	O
.	O

Both	O
des	O
##ol	O
##vation	O
gas	O
and	O
ne	O
##bul	O
##izing	O
gas	O
were	O
set	O
at	O
45	O
L	O
/	O
min	O
and	O
the	O
collision	O
energy	O
was	O
40	O
e	O
##V	O
.	O
For	O
MR	O
##M	O
,	O
the	O
dwell	O
time	O
was	O
set	O
at	O
50	O
m	O
##s	O
for	O
each	O
of	O
the	O
signal	O
from	O
transitions	O
of	O
m	O
/	O
z	O
62	O
##2	O
to	O
264	O
(	O
q	O
##uant	O
##ifier	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
)	O
,	O
m	O
/	O
z	O
62	O
##2	O
to	O
28	O
##2	O
(	O
qualifier	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
)	O
,	O
m	O
/	O
z	O
650	O
to	O
264	O
(	O
q	O
##uant	O
##ifier	O
for	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
)	O
,	O
m	O
/	O
z	O
650	O
to	O
28	O
##2	O
(	O
qualifier	O
for	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
)	O
,	O
m	O
/	O
z	O
62	O
##6	O
to	O
264	O
(	B
[	B
_	I
2	I
H	I
_	I
4	I
]	I
Ce	I
##r	I
(	I
22	I
:	I
0	I
)	I
)	O
and	O
m	O
/	O

The	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
of	O
each	O
patient	O
and	O
serum	O
level	O
of	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
al	O
##kal	O
##ine	O
p	O
##hos	O
##pha	O
##tase	O
were	O
determined	O
.	O

For	O
more	O
than	O
two	O
decades	O
,	O
_	O
13	O
C	O
label	O
##ing	O
has	O
been	O
used	O
for	O
a	O
variety	O
of	O
applications	O
,	O
including	O
tracing	O
the	O
metabolic	O
pathways	O
and	O
flux	O
##es	O
in	O
a	O
variety	O
of	O
cells	O
and	O
tissues	O
(	O
–	O
)	O
,	O
for	O
protein	O
structure	O
determination	O
,	O
and	O
recently	O
for	O
the	O
N	O
##MR	O
structural	O
el	O
##uc	O
##ida	O
##tion	O
of	O
individual	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
##s	I
using	O
_	O
13	O
C	O
-	O
labeled	O
per	O
##ace	O
##ty	O
##lation	O
(	O
,	O
)	O
.	O

Met	B
##han	I
##ol	I
Li	O
##C	O
##hr	O
##o	O
##S	O
##ol	O
##v	O
,	O
h	O
##yper	O
##grade	O
,	O
purchased	O
from	O
Me	O
##rc	O
##k	O
/	O
V	O
##WR	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
was	O
used	O
for	O
liquid	O
ch	O
##roma	O
##tography	O
.	O

It	O
has	O
been	O
shown	O
that	O
patients	O
,	O
who	O
were	O
supplemented	O
with	O
vitamin	B
D	I
,	O
exhibited	O
increased	O
clearance	O
of	O
at	B
##or	I
##vas	I
##tat	I
##in	I
(	O
substrate	O
of	O
C	O
##YP	O
##3	O
##A	O
##4	O
)	O
.	O

A	O
targeted	O
meta	O
##bol	O
##ite	O
panel	O
e	O
##G	O
##F	O
##R	O
developed	O
in	O
the	O
AA	O
##S	O
##K	O
and	O
valid	O
##ated	O
in	O
the	O
ME	O
##SA	O
was	O
more	O
accurate	O
(	O
1	O
-	O
P	O
_	O
30	O
3	O
.	O
7	O
and	O
1	O
.	O
9	O
%	O
,	O
respectively	O
)	O
than	O
e	O
##G	O
##F	O
##R	O
##c	O
##r	O
[	O
11	O
.	O
2	O
and	O
18	O
.	O
5	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
for	O
both	O
)	O
]	O
and	O
est	O
##imating	O
G	O
##F	O
##R	O
using	O
c	B
##ys	I
##tat	I
##in	I
C	O
(	O
e	O
##G	O
##F	O
##R	O
##cy	O
##s	O
)	O

The	O
third	O
group	O
was	O
persons	O
with	O
a	O
mixture	O
of	O
the	O
above	O
two	O
types	O
of	O
disc	O
##re	O
##pan	O
##cy	O
—	O
for	O
example	O
,	O
a	O
person	O
who	O
reported	O
use	O
of	O
an	O
anal	O
##ges	O
##ic	O
at	O
the	O
first	O
visit	O
but	O
not	O
the	O
third	O
visit	O
,	O
but	O
the	O
_	O
1	O
H	O
N	O
##MR	O
urine	O
s	O
##pect	O
##ra	O
revealed	O
the	O
presence	O
of	O
either	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
/	O
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
or	O
both	O
meta	O
##bol	O
##ites	O
in	O
the	O
second	O
urine	O
specimen	O
though	O
not	O
the	O
first	O
.	O

The	O
L	O
##O	O
##Q	O
##s	O
for	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
,	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
,	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
were	O
all	O
0	O
.	O
6	O
ng	O
/	O
m	O
##L	O
.	O
Further	O
details	O
on	O
the	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
are	O
provided	O
in	O
the	O
.	O

Using	O
these	O
selection	O
strategies	O
,	O
2	O
lip	O
##id	O
species	O
,	O
C	B
##18	I
:	I
2	I
CE	O
and	O
SM	O
22	O
:	O
0	O
,	O
were	O
identified	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
for	O
the	O
early	O
detection	O
of	O
S	O
##q	O
##CC	O
disease	O
during	O
the	O
training	O
stage	O
.	O

Not	O
##ably	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
c	B
##it	I
##rac	I
##ona	I
##te	I
and	O
p	B
##yr	I
##u	I
##vate	I
were	O
present	O
in	O
the	O
combined	O
model	O
.	O

Co	O
##mp	O
##aring	O
retention	O
of	O
the	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
series	O
on	O
the	O
different	O
H	O
##IL	O
##IC	O
columns	O
,	O
pu	B
##rine	I
derivatives	O
A	O
and	O
G	O
tend	O
to	O
be	O
more	O
strongly	O
retained	O
than	O
p	B
##yr	I
##im	I
##id	I
##ines	I
U	O
and	O
T	O
.	O
The	O
retention	O
of	O
C	O
and	O
its	O
derivatives	O
,	O
however	O
,	O
resembles	O
that	O
of	O
pu	B
##rine	I
##s	I
.	O

We	O
identified	O
L	B
-	I
met	I
##hi	I
##oni	I
##ne	I
,	O
the	O
ratio	O
of	O
L	B
-	I
as	I
##par	I
##agi	I
##ne	I
to	O
L	B
-	I
as	I
##par	I
##tic	I
acid	I
,	O
g	B
##lut	I
##ari	I
##c	I
acid	I
,	O
L	B
-	I
so	I
##rb	I
##ose	I
and	O
van	B
##ill	I
##yl	I
##mand	I
##eli	I
##c	I
acid	I
as	O
predict	O
##ors	O
of	O
violence	O
in	O
s	O
##chi	O
##zophrenia	O
patients	O
.	O

Based	O
on	O
the	O
above	O
results	O
,	O
we	O
re	O
##comb	O
##ined	O
the	O
age	O
and	O
the	O
panel	O
of	O
pro	B
##line	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
a	B
##rg	I
##ini	I
##ne	I
.	O

_	O
1	O
H	O
N	O
##MR	O
(	O
500	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
8	O
.	O
19	O
(	O
d	O
,	O
1	O
##H	O
,	O
J	O
=	O
8	O
Hz	O
,	O
NH	O
)	O
,	O
6	O
.	O
85	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##2	O
′	O
)	O
,	O
6	O
.	O
76	O
(	O
t	O
,	O
1	O
##H	O
,	O
J	O
=	O
2	O
.	O
5	O
Hz	O
,	O
H	O
##5	O
′	O
)	O
,	O
6	O
.	O
05	O
(	O
d	O
##d	O
,	O
1	O
##H	O
,	O
J	O
=	O
1	O
.	O
5	O
,	O
2	O
.	O
5	O
Hz	O
,	O
H	O
##4	O
′	O
)	O
,	O
4	O
.	O
24	O
(	O
d	O
##dd	O
,	O
1	O
##H	O
,	O
J	O
=	O
5	O
.	O
0	O
,	O
9	O
.	O
5	O
,	O
13	O
.	O
5	O
Hz	O
,	O
Cy	O
##s	O
α	B
-	I
CH	I
)	O
,	O
3	O
.	O
84	O
(	O
t	O
,	O
2	O
##H	O
,	O
J	O
=	O
6	O
.	O
5	O

All	O
forms	O
of	O
en	O
##ce	O
##pha	O
##lit	O
##is	O
are	O
treated	O
empirical	O
##ly	O
upon	O
hospital	O
##ization	O
,	O
so	O
early	O
diagnostic	O
samples	O
such	O
as	O
those	O
analyzed	O
here	O
may	O
reflect	O
early	O
empirical	O
the	O
##rap	O
##ies	O
that	O
often	O
overlap	O
(	O
e	O
.	O
g	O
.	O
,	O
re	O
##hy	O
##dra	O
##tion	O
,	O
provision	O
of	O
glucose	S
,	O
use	O
of	O
anti	O
##ba	O
##cter	O
##ial	O
##s	O
,	O
se	O
##dation	O
)	O
but	O
may	O
also	O
differ	O
between	O
diseases	O
.	O

Gas	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
;	O
H	B
##A	I
:	O
H	O
##yper	O
##act	O
##ivation	O
;	O
HC	O
##V	O
:	O
He	O
##pa	O
##titis	O
C	O
V	O
##ir	O
##us	O
;	O
HC	O
##VP	O
##R	O
:	O
He	O
##pa	O
##titis	O
C	O
V	O
##ir	O
##us	O
pro	O
##te	O
##ase	O
;	O
He	O
##L	O
##a	O
:	O
Human	O
c	O
##er	O
##vic	O
##al	O
cancer	O
cell	O
line	O
;	O
HIV	O
:	O
Human	O
im	O
##mu	O
##no	O
##de	O
##ficiency	O
viruses	O
;	O
HP	O
##LC	O
:	O
High	O
Performance	O
Li	O
##quid	O
Ch	O
##roma	O
##tography	O
;	O
I	O
##AA	O
:	O
Indo	O
##le	O
‐	O
3	O
‐	O
ace	O
##tic	O
acid	O
;	O
I	O
##AR	O
##C	O
:	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
;	O
I	O
##C	O
_	O
50	O
:	O
Half	O
ma	O
##ximal	O
inhibitor	O
##y	O
concentration	O
;	O
L	O
##C	O
_	O
50	O
:	O
Con	O
##cent	O
##ration	O
of	O
the	O
compound	O
that	O
is	O
lethal	O
for	O
50	O
%	O
of	O
exposed	O
population	O
;	O
L	O
##C	O
-	O
MS	O
:	O

(	O
A	O
)	O
The	O
profile	O
of	O
9	O
-	O
H	O
##SA	O
-	O
containing	O
ch	O
##olin	O
##e	O
g	O
##ly	O
##cer	O
##op	O
##hos	O
##ph	O
##oli	O
##pid	O
##s	O
(	O
PC	O
,	O
red	O
)	O
,	O
ethanol	B
##amine	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
P	O
##E	O
,	O
green	O
)	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
,	O
yellow	O
)	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
(	O
PS	O
,	O
pink	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
P	O
##G	O
,	O
blue	O
)	O
species	O
in	O
normal	O
tissue	O
(	O
filled	O
bars	O
)	O
or	O
tumor	O
(	O
open	O
bars	O
)	O
was	O
determined	O
by	O
L	O
##C	O
/	O
MS	O
/	O
MS	O
.	O

Hip	B
##pura	I
##te	I
is	O
meta	O
##bol	O
##ized	O
from	O
ben	B
##zoic	I
acid	I
,	O
which	O
is	O
meta	O
##bol	O
##ized	O
from	O
the	O
diet	O
##ary	O
p	O
##oly	O
##phe	O
##no	O
##l	O
3	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
prop	I
##ion	I
##ic	I
acid	I
by	O
the	O
gut	O
micro	O
##ﬂ	O
##ora	O
[	O
]	O
.	O

The	O
increased	O
ex	O
##cre	O
##tion	O
of	O
h	B
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
in	O
the	O
urine	O
of	O
PD	O
patients	O
was	O
consistent	O
with	O
the	O
former	O
reports	O
of	O
Sand	O
##ler	O
et	O
al	O
.	O
,	O
and	O
may	O
be	O
associated	O
with	O
ne	O
##uro	O
##logical	O
disorders	O
in	O
general	O
.	O

It	O
is	O
apparent	O
that	O
essential	O
amino	O
acids	O
such	O
as	O
l	B
##ys	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
can	O
only	O
be	O
derived	O
from	O
protein	O
h	O
##ydro	O
##lysis	O
whereas	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
such	O
as	O
glucose	S
can	O
only	O
be	O
derived	O
from	O
star	O
##ch	O
h	O
##ydro	O
##lysis	O
.	O

The	O
5	B
’	I
-	I
met	I
##hi	I
##oa	I
##den	I
##os	I
##ine	I
is	O
a	O
sulfur	O
lip	O
##op	O
##hil	O
##ic	O
ad	B
##eno	I
##sin	I
##e	I
meta	O
##bol	O
##ized	O
by	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
in	O
sperm	B
##ine	I
,	O
sperm	B
##id	I
##ine	I
and	O
p	B
##oly	I
##amine	I
synthetic	O
pathways	O
.	O

_	O
,	O
The	O
FA	S
data	O
were	O
analyzed	O
as	O
relative	O
percentage	O
of	O
total	O
to	O
account	O
for	O
different	O
initial	O
sample	O
volumes	O
.	O

In	O
our	O
study	O
,	O
the	O
increase	O
in	O
protein	O
degradation	O
was	O
further	O
supported	O
by	O
an	O
increase	O
in	O
u	B
##rea	I
cycle	O
meta	O
##bol	O
##ites	O
after	O
le	O
##pt	O
##in	O
replacement	O
therapy	O
(	O
,	O
)	O
.	O

After	O
protein	O
precipitation	O
and	O
di	O
##lution	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
plasma	O
samples	O
were	O
separated	O
by	O
H	B
##ydro	I
##phi	I
##lic	I
Inter	O
##action	O
Li	O
##quid	O
Ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
mode	O
on	O
a	O
B	O
##E	O
##H	O
Am	B
##ide	I
column	O
(	O
Waters	O
)	O
using	O
a	O
reversed	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
gradient	O
.	O

Ke	B
##tones	I
are	O
formed	O
using	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
generated	O
by	O
fatty	O
acid	O
oxidation	O
;	O
there	O
was	O
a	O
small	O
but	O
statistical	O
##ly	O
significant	O
increase	O
in	O
the	O
k	B
##eton	I
##e	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

Most	O
of	O
the	O
meta	O
##bol	O
##ite	O
signals	O
in	O
the	O
displayed	O
region	O
are	O
missing	O
or	O
significantly	O
at	O
##ten	O
##uated	O
in	O
the	O
T	O
_	O
2	O
filtered	O
spectrum	O
and	O
many	O
including	O
try	B
##pt	I
##op	I
##han	I
,	O
ben	B
##zo	I
##ate	I
,	O
and	O
format	B
##e	I
were	O
significantly	O
at	O
##ten	O
##uated	O
in	O
ultra	O
##fi	O
##lter	O
##ed	O
serum	O
compared	O
to	O
the	O
protein	O
pre	O
##ci	O
##pit	O
##ated	O
serum	O
.	O

Jain	O
and	O
colleagues	O
ever	O
ass	O
##ay	O
##ed	O
meta	O
##bol	O
##ites	O
profiles	O
from	O
media	O
of	O
NC	O
##I	O
-	O
60	O
cancer	O
cell	O
lines	O
and	O
found	O
disorder	O
of	O
g	B
##ly	I
##cine	I
consumption	O
,	O
which	O
is	O
correlated	O
with	O
proliferation	O
rate	O
of	O
cancer	O
cells	O
.	O

Stock	O
solutions	O
of	O
E	O
##Ms	O
and	O
S	O
##I	O
-	O
E	O
##Ms	O
were	O
each	O
prepared	O
at	O
80	O
μ	O
##g	O
/	O
m	O
##l	O
by	O
di	O
##sso	O
##lving	O
2	O
mg	O
of	O
the	O
est	B
##rogen	I
powder	O
##s	O
in	O
met	B
##han	I
##ol	I
with	O
0	O
.	O
1	O
%	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
to	O
a	O
final	O
volume	O
of	O
25	O
m	O
##l	O
in	O
a	O
volume	O
##tric	O
fl	O
##ask	O
.	O

The	O
use	O
of	O
su	B
##c	I
##rose	I
as	O
a	O
sweet	O
##ening	O
agent	O
in	O
food	O
and	O
beverages	O
is	O
becoming	O
increasingly	O
frequent	O
.	O

Furthermore	O
,	O
they	O
reported	O
that	O
following	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
extraction	O
most	O
of	O
the	O
meta	O
##bol	O
##ites	O
were	O
maintained	O
,	O
although	O
with	O
a	O
reduced	O
signal	O
intensity	O
compared	O
to	O
ultra	O
##fi	O
##ltration	O
.	O

l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##17	I
:	I
0	I
;	O
127	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
in	O
the	O
study	O
by	O
Ka	O
##p	O
##lon	O
et	O
al	O
,	O
p	B
##yr	I
##u	I
##vate	I
oxidation	O
was	O
directly	O
involved	O
in	O
in	O
##ducing	O
O	O
##IS	O
.	O

Novel	O
serum	O
bio	O
##mark	O
##ers	O
such	O
as	O
g	B
##lut	I
##ama	I
##te	I
,	O
su	B
##lf	I
##ox	I
##y	I
met	I
##hi	I
##oni	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##amine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
and	O
as	B
##par	I
##agi	I
##ne	I
are	O
potentially	O
useful	O
for	O
ad	O
##junct	O
##ive	O
,	O
rapid	O
,	O
and	O
non	O
##in	O
##vasive	O
pulmonary	O
T	O
##B	O
diagnosis	O
.	O

The	O
results	O
showed	O
that	O
g	B
##lut	I
##amine	I
,	O
al	B
##ani	I
##ne	I
,	O
pro	B
##line	I
,	O
HD	O
##L	O
,	O
β	B
-	I
glucose	I
,	O
α	B
-	I
glucose	I
and	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
levels	O
were	O
significantly	O
altered	O
in	O
F	B
##D	I
patients	O
.	O

Our	O
results	O
demonstrate	O
that	O
β	B
-	I
car	I
##ote	I
##ne	I
can	O
generate	O
both	O
RA	O
##R	O
ago	O
##nist	O
##s	O
(	O
AT	O
##RA	O
)	O
and	O
RA	O
##R	O
antagonist	O
##s	O
(	B
β	B
-	I
a	I
##po	I
-	I
14	I
′	I
-	I
car	I
##ote	I
##nal	I
and	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
)	O
depending	O
on	O
the	O
extent	O
of	O
c	O
##lea	O
##vage	O
at	O
the	O
central	O
C	O
##15	O
–	O
C	O
##15	O
′	O
double	O
bond	O
or	O
the	O
C	O
##13	O
–	O
14	O
double	O
bond	O
,	O
respectively	O
.	O

shows	O
an	O
example	O
E	O
##IC	O
of	O
v	B
##ali	I
##ne	I
1	O
retrieved	O
using	O
our	O
in	O
-	O
house	O
tool	O
and	O
the	O
mixed	O
similarity	O
scores	O
based	O
on	O
AU	O
##C	O
and	O
peak	O
apex	O
.	O

3	B
′	I
-	I
Ph	I
##os	I
##ph	I
##oa	I
##den	I
##os	I
##ine	I
5	I
′	I
-	I
p	I
##hos	I
##ph	I
##os	I
##ulf	I
##ate	I
lit	I
##hium	I
salt	O
h	O
##yd	O
##rate	O
(	O
PA	O
##PS	O
)	O
was	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Except	O
for	O
a	B
##rg	I
##ini	I
##ne	I
,	O
significantly	O
different	O
between	O
patients	O
with	O
end	O
##os	O
##copic	O
##ally	O
inactive	O
and	O
the	O
most	O
active	O
disease	O
,	O
systemic	O
meta	O
##bol	O
##ite	O
concentrations	O
were	O
not	O
related	O
to	O
the	O
end	O
##os	O
##copic	O
activity	O
of	O
UC	O
expressed	O
in	O
terms	O
of	O
the	O
Mayo	O
end	O
##os	O
##copic	O
activity	O
score	O
.	O

This	O
caution	O
is	O
of	O
significant	O
clinical	O
relevance	O
since	O
in	O
our	O
pilot	O
study	O
of	O
a	O
small	O
patient	O
co	O
##hor	O
##t	O
we	O
only	O
monitored	O
an	O
increase	O
of	O
D	O
##AG	O
levels	O
in	O
MC	O
##I	O
patients	O
but	O
failed	O
to	O
detect	O
any	O
patients	O
with	O
plasma	O
##log	O
##en	O
deficit	O
##s	O
,	O
indicating	O
that	O
by	O
chance	O
,	O
our	O
patient	O
co	O
##hor	O
##ts	O
failed	O
to	O
include	O
any	O
of	O
the	O
subset	O
of	O
patients	O
with	O
deficit	O
##s	O
in	O
circulating	O
ethanol	B
##amine	I
plasma	O
##log	O
##en	O
levels	O
.	O

After	O
T	O
##1	O
and	O
T	O
##2	O
relaxation	O
correction	O
,	O
q	O
##uant	O
##ification	O
of	O
the	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
fat	O
content	O
was	O
done	O
by	O
comparing	O
the	O
intensity	O
of	O
met	B
##hyl	I
##ene	I
[	I
(	I
CH	I
##2	I
)	I
n	I
-	I
;	I
1	I
.	I
25	I
pp	I
##m	I
]	I
resonance	O
with	O
that	O
of	O
water	O
.	O

f	O
##ow	O
##ler	O
##i	O
from	O
making	O
ch	B
##ole	I
##ster	I
##ol	I
de	O
no	O
##vo	O
.	O

However	O
,	O
la	B
##ct	I
##ate	I
,	O
Le	O
##u	O
/	O
Il	O
##e	O
,	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acid	O
,	O
g	B
##lut	I
##amine	I
and	O
β	B
-	I
glucose	I
levels	O
were	O
significantly	O
lower	O
in	O
F	B
##D	I
patients	O
.	O

Among	O
the	O
103	O
identified	O
th	B
##iol	I
##s	I
,	O
5	O
(	O
No	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
of	O
the	O
abundance	O
of	O
Ad	B
##ren	I
##och	I
##rome	I
-	I
o	I
-	I
q	I
##uin	I
##one	I
and	O
N	O
##N	O
##K	O
by	O
-	O
product	O
3	O
##SP	O
in	O
u	O
##rogen	O
##ital	O
s	O
##chi	O
##sto	O
##so	O
##mia	O
##sis	O
.	O

-	B
[	B
_	I
2	I
H	I
_	I
6	I
]	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
internal	O
standard	O
)	O
.	O

Si	B
##m	I
##vas	I
##tat	I
##in	I
has	O
been	O
shown	O
previously	O
to	O
reduce	O
alpha	B
-	I
to	I
##co	I
##pher	I
##ol	I
levels	O
in	O
plasma	O
following	O
both	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
exposure	O
.	O

As	O
an	O
example	O
,	O
l	B
##ys	I
##ine	I
exhibits	O
characteristic	O
signals	O
in	O
the	O
N	O
##MR	O
spectral	O
region	O
between	O
δ	O
=	O
1	O
.	O
68	O
and	O
1	O
.	O
76	O
pp	O
##m	O
,	O
which	O
is	O
often	O
dominated	O
by	O
signals	O
from	O
a	O
variety	O
of	O
additional	O
meta	O
##bol	O
##ites	O
,	O
making	O
the	O
an	O
##not	O
##ation	O
of	O
l	B
##ys	I
##ine	I
a	O
very	O
difficult	O
task	O
.	O

High	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
alone	O
disc	O
##rim	O
##inated	O
W	O
##N	O
##V	O
,	O
L	O
##yme	O
and	O
his	O
##top	O
##las	O
##mos	O
##is	O
from	O
controls	O
.	O

In	O
this	O
context	O
,	O
g	B
##ly	I
##cine	I
metabolism	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
cell	O
transformation	O
and	O
tumor	O
##ige	O
##nes	O
##is	O
.	O

Further	O
,	O
the	O
H	O
##R	O
##MA	O
##S	O
_	O
1	O
H	O
MR	O
##S	O
of	O
breast	O
cancer	O
tissues	O
was	O
also	O
compared	O
with	O
the	O
conventional	O
high	O
-	O
resolution	O
s	O
##pect	O
##ra	O
of	O
perch	B
##lor	I
##ic	I
acid	I
extract	O
##s	O
of	O
the	O
same	O
tissue	O
type	O
.	O

Guo	O
et	O
al	O
.	O
reported	O
that	O
different	O
combinations	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
(	O
34	O
:	O
1	O
)	O
,	O
PC	B
(	I
34	I
:	I
2	I
)	I
,	O
PC	B
(	I
34	I
:	I
1	I
)	I
,	O
PC	B
(	I
36	I
:	I
4	I
)	I
,	O
PC	B
(	I
36	I
:	I
3	I
)	I
,	O
and	O
PC	B
(	I
36	I
:	I
2	I
)	I
exhibit	O
high	O
diagnostic	O
potential	O
for	O
lung	O
cancer	O
,	O
color	O
##ec	O
##tal	O
cancer	O
,	O
gas	O
##tric	O
cancer	O
and	O
pan	O
##cre	O
##atic	O
cancer	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
are	O
a	O
major	O
component	O
of	O
all	O
cell	O
membrane	O
##s	O
.	O

On	O
the	O
right	O
is	O
shown	O
the	O
energy	O
minimize	O
##d	O
then	O
dock	O
##ed	O
conform	O
##ations	O
of	O
AT	O
##RA	O
(	O
red	O
)	O
and	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
(	O
purple	O
)	O
over	O
##laid	O
onto	O
the	O
conform	O
##ation	O
of	O
the	O
ago	O
##nist	O
te	B
##tra	I
##met	I
##hyl	I
te	I
##tra	I
##hy	I
##dron	I
##aph	I
##thal	I
##en	I
##yl	I
prop	I
##en	I
##yl	I
ben	I
##zoic	I
acid	I
(	O
T	O
##T	O
##NP	O
##B	O
)	O
(	O
white	O
)	O
as	O
observed	O
in	O
the	O
x	O
-	O
ray	O
structure	O
.	O

In	O
the	O
current	O
study	O
,	O
serum	O
levels	O
of	O
T	B
##G	I
,	O
FA	O
##s	O
,	O
and	O
la	B
##ct	I
##ate	I
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
Ta	O
##e	O
-	O
E	O
##um	O
type	O
subjects	O
.	O

In	O
a	O
similar	O
mechanism	O
as	O
other	O
weak	O
car	O
##cin	O
##ogen	O
##s	O
such	O
as	O
est	O
##rogen	O
##s	O
and	O
ben	B
##zen	I
##e	I
,	O
nap	B
##ht	I
##hale	I
##ne	I
is	O
metabolic	O
##ally	O
activated	S
by	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
(	O
C	O
##YP	O
)	O
and	O
meta	O
##bol	O
##ites	O
formed	O
react	O
with	O
DNA	O
to	O
form	O
de	O
##pur	O
##inating	O
add	O
##uc	O
##ts	O
.	O

B	O
##rief	O
##ly	O
,	O
serum	O
samples	O
were	O
filtered	O
to	O
remove	O
large	O
molecules	O
using	O
3	O
##k	O
##D	O
##a	O
Nan	O
##o	O
##S	O
##ep	O
micro	O
##cent	O
##ri	O
##fu	O
##ge	O
filters	O
(	O
Pa	O
##ll	O
,	O
Inc	O
.	O
,	O
East	O
Hills	O
,	O
NY	O
,	O
USA	O
)	O
followed	O
by	O
addition	O
of	O
phosphate	S
buffer	O
,	O
sodium	O
a	O
##zi	O
##de	O
and	O
D	O
_	O
2	O
O	O
to	O
the	O
fi	O
##lt	O
##rate	O
.	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
obtained	O
using	O
a	O
standard	O
B	O
##ruk	O
##er	O
1	O
##D	O
s	O
##pect	O
##ros	O
##copy	O
pulse	O
program	O
‘	O
no	O
##es	O
##y	O
##p	O
##r	O
##1	O
##d	O
’	O

In	O
##tri	O
##guin	O
##gly	O
,	O
we	O
robust	O
##ly	O
detected	O
star	O
##ch	O
-	O
derived	O
en	O
##rich	O
##ment	O
even	O
in	O
meta	O
##bol	O
##ites	O
linked	O
to	O
the	O
T	O
##CA	O
cycle	O
such	O
as	O
c	B
##it	I
##rate	I
and	O
g	B
##lut	I
##ama	I
##te	I
.	O

Subsequently	O
,	O
prop	O
##yla	O
##min	O
##o	O
-	O
transfer	O
##ase	O
cat	O
##aly	O
##zes	O
the	O
transfer	O
of	O
Put	O
of	O
the	O
amino	O
##p	O
##rop	O
##yl	O
group	O
from	O
de	B
##car	I
##box	I
##yla	I
##ted	I
S	I
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
to	O
form	O
S	O
##p	O
##d	O
and	O
sperm	B
##ine	I
,	O
respectively	O
(	O
Figure	O
)	O
.	O

This	O
matches	O
results	O
obtained	O
in	O
a	O
study	O
of	O
p	B
##tero	I
##st	I
##il	I
##ben	I
##e	I
(	I
3	I
,	I
5	I
-	I
dim	I
##eth	I
##ox	I
##y	I
-	I
4	I
′	I
-	I
h	I
##ydro	I
##xy	I
##st	I
##il	I
##ben	I
##e	I
)	I
metabolism	O
in	O
the	O
co	O
##lons	O
of	O
mice	O
,	O
where	O
pin	B
##ost	I
##il	I
##ben	I
##e	I
was	O
found	O
as	O
its	O
main	O
product	O
;	O
however	O
,	O
no	O
meta	O
##bol	O
##ites	O
of	O
p	B
##tero	I
##st	I
##il	I
##ben	I
##e	I
with	O
a	O
reduced	O
double	O
bond	O
were	O
identified	O
[	O
,	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
obtained	O
results	O
consistent	O
with	O
the	O
theory	O
that	O
in	O
HC	O
##V	O
infection	O
the	O
g	O
##ly	O
##co	O
##lysis	O
toward	O
la	B
##ct	I
##ate	I
production	O
is	O
increased	O
in	O
a	O
##ero	O
##bic	O
conditions	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
,	O
before	O
ne	O
##uron	O
##al	O
d	O
##ys	O
##function	O
develops	O
,	O
mice	O
he	O
##tero	O
##zy	O
##go	O
##us	O
for	O
G	O
##L	O
##UT	O
##1	O
(	O
S	O
##l	O
##c	O
##2	O
##a	O
##1	O
)	O
at	O
the	O
B	O
##BB	O
develop	O
cerebral	O
blood	O
flow	O
per	O
##fusion	O
deficit	O
##s	O
and	O
B	O
##BB	O
breakdown	O
that	O
leads	O
to	O
vascular	O
-	O
mediated	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
:	O
the	O
relevance	O
of	O
this	O
study	O
in	O
engineered	O
mice	O
to	O
our	O
findings	O
in	O
human	O
brain	O
is	O
uncertain	O
,	O
given	O
that	O
these	O
authors	O
did	O
not	O
report	O
brain	B
-	I
glucose	I
levels	O
.	O

When	O
Groups	O
O	O
and	O
P	O
were	O
pool	O
##ed	O
,	O
the	O
bio	O
##sign	O
##er	O
algorithm	O
based	O
on	O
the	O
3	O
machine	O
learning	O
methods	O
generated	O
a	O
significant	O
model	O
to	O
explain	O
the	O
variation	O
of	O
SV	O
##C	O
,	O
with	O
SM	O
OH	B
C	I
##22	I
:	I
2	I
(	O
category	O
S	O
)	O
as	O
the	O
most	O
relevant	O
marker	O
,	O
independently	O
of	O
the	O
drug	O
treatment	O
.	O

The	O
patients	O
with	O
high	O
levels	O
of	O
L	O
##T	O
##B	O
##4	O
-	O
D	O
##MA	O
and	O
low	O
amounts	O
of	O
do	B
##de	I
##can	I
##ami	I
##de	I
had	O
good	O
sensitivity	O
to	O
ch	O
##em	O
##oth	O
##era	O
##pe	O
##uti	O
##c	O
agents	O
.	O

Take	O
##n	O
together	O
,	O
these	O
pathways	O
and	O
correlation	O
##s	O
based	O
on	O
experimental	O
data	O
could	O
partly	O
explain	O
the	O
relationship	O
between	O
l	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
and	O
palm	B
##ito	I
##leam	I
##ide	I
,	O
supporting	O
the	O
conclusion	O
that	O
these	O
two	O
meta	O
##bol	O
##ites	O
were	O
the	O
best	O
plasma	O
meta	O
##bol	O
##ite	O
predict	O
##ors	O
for	O
disc	O
##rim	O
##inating	O
between	O
the	O
N	O
##T	O
##G	O
and	O
H	O
##T	O
##G	O
groups	O
.	O

ATP	O
-	O
binding	O
cassette	O
sub	O
-	O
family	O
D	O
member	O
1	O
(	O
ad	O
##ren	O
##ole	O
##uk	O
##ody	O
##stro	O
##phy	O
protein	O
)	O
,	O
a	O
very	O
long	O
chain	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
transport	O
##er	O
in	O
the	O
per	O
##ox	O
##is	O
##oma	O
##l	O
membrane	O
,	O
is	O
def	O
##icient	O
in	O
X	O
-	O
AL	O
##D	O
,	O
whereas	O
in	O
Z	O
##ell	O
##we	O
##ger	O
spectrum	O
disorders	O
,	O
multiple	O
per	O
##ox	O
##is	O
##oma	O
##l	O
proteins	O
are	O
def	O
##icient	O
.	O

Not	O
##ably	O
,	O
th	B
##re	I
##oni	I
##ne	I
had	O
the	O
highest	O
importance	O
within	O
the	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
network	O
(	O
was	O
a	O
keys	O
##tone	O
meta	O
##bol	O
##ite	O
)	O
,	O
having	O
the	O
highest	O
between	O
##ness	O
central	O
##ity	O
(	O
Table	O
,	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
other	O
assessed	O
end	B
##oc	I
##anna	I
##bino	I
##ids	I
and	O
analog	O
##s	O
,	O
2	B
-	I
a	I
##rac	I
##hi	I
##don	I
##oy	I
##l	I
g	I
##ly	I
##cer	I
##ol	I
(	O
2	O
-	O
AG	O
)	O
,	O
and	O
palm	B
##ito	I
##yle	I
##than	I
##ola	I
##mi	I
##de	I
(	O
P	O
##EA	O
)	O
,	O
were	O
unchanged	O
.	O

The	O
SR	O
##M	O
mode	O
is	O
particularly	O
effective	O
for	O
precise	O
q	O
##uant	O
##ification	O
because	O
of	O
the	O
rapid	O
duty	O
cycle	O
of	O
Q	O
##q	O
##Q	O
.	O
The	O
operation	O
of	O
the	O
Q	O
##q	O
##Q	O
in	O
the	O
Product	O
Ion	O
Sc	O
##an	O
mode	O
with	O
elevated	O
collision	O
energy	O
results	O
in	O
a	O
di	O
##sso	O
##ciation	O
ca	O
##sca	O
##de	O
or	O
a	O
multiple	O
-	O
step	O
fragment	O
##ation	O
of	O
the	O
a	B
##gly	I
##con	I
##e	I
and	O
additional	O
structural	O
information	O
can	O
be	O
obtained	O
on	O
the	O
a	B
##gly	I
##con	I
##e	I
.	O

Men	O
##del	O
##ian	O
random	O
##isation	O
demonstrated	O
a	O
similar	O
relationship	O
for	O
type	O
2	O
diabetes	O
risk	O
per	O
1	O
SD	O
genetically	O
increased	O
g	B
##ly	I
##cine	I
(	O
OR	O
0	O
.	O
89	O

In	O
##tra	O
-	O
and	O
inter	O
-	O
day	O
accuracy	O
and	O
precision	O
for	O
a	B
##bir	I
##ater	I
##one	I
and	O
its	O
meta	O
##bol	O
##ites	O
in	O
LL	O
##O	O
##Q	O
and	O
Q	O
##C	O
samples	O
.	O

The	O
results	O
of	O
the	O
P	O
##LS	O
-	O
D	O
##A	O
model	O
using	O
six	O
meta	O
##bol	O
##ites	O
(	B
g	B
##ly	I
##cine	I
,	O
v	B
##ali	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
C	B
##16	I
-	I
car	I
##ni	I
##tine	I
)	O
identified	O
from	O
the	O
2017	O
data	O
set	O
are	O
presented	O
in	O
.	O

The	O
Me	B
##OH	I
and	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
Me	O
##OH	O
methods	O
showed	O
similar	O
areas	O
and	O
matrix	O
effects	O
in	O
the	O
most	O
polar	O
anal	O
##yte	O
##s	O
,	O
but	O
interesting	O
##ly	O
,	O
the	O
non	O
##pol	O
##ar	O
anal	O
##yte	O
##s	O
had	O
higher	O
matrix	O
effects	O
with	O
Me	B
##OH	I
extraction	O
due	O
to	O
the	O
co	O
##el	O
##ution	O
of	O
lip	O
##id	O
compounds	O
.	O

In	O
both	O
probe	O
##s	O
,	O
MR	O
##M	O
and	O
H	O
##R	O
##MA	O
##S	O
,	O
the	O
real	O
temperature	O
was	O
internally	O
assessed	O
using	O
a	O
100	O
%	O
Me	B
##OH	I
sample	O
in	O
a	O
4	O
mm	O
rotor	O
in	O
the	O
same	O
conditions	O
than	O
the	O
samples	O
.	O

Collective	O
##ly	O
,	O
all	O
these	O
data	O
tend	O
to	O
link	O
fatty	O
acid	O
transport	O
and	O
oxidation	O
mechanisms	O
to	O
blood	O
pressure	O
regulation	O
and	O
,	O
possibly	O
,	O
to	O
the	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
action	O
of	O
some	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
drugs	O
including	O
am	B
##lo	I
##di	I
##pine	I
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
the	O
overall	O
c	B
##rea	I
##tin	I
##ine	I
ex	O
##cre	O
##tion	O
over	O
a	O
24	O
-	O
h	O
period	O
does	O
not	O
significantly	O
change	O
in	O
pregnancy	O
,	O
further	O
supporting	O
the	O
case	O
for	O
normal	O
##ization	O
.	O

Met	B
##han	I
##ol	I
fix	O
##ation	O
effectively	O
preserves	O
a	O
wide	O
range	O
of	O
tissues	O
and	O
is	O
compatible	O
with	O
chemical	O
stain	O
##ing	O
and	O
im	O
##mu	O
##no	O
##his	O
##to	O
##chemistry	O
.	O

Tau	B
##rine	I
has	O
also	O
been	O
implicated	O
as	O
a	O
tumor	O
marker	O
in	O
many	O
different	O
cancer	O
types	O
[	O
,	O
,	O
,	O
]	O
.	O

Tam	B
##ox	I
##ife	I
##n	I
may	O
still	O
be	O
a	O
first	O
line	O
drug	O
in	O
the	O
ad	O
##ju	O
##vant	O
treatment	O
to	O
some	O
groups	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
and	O
could	O
certainly	O
be	O
used	O
in	O
the	O
last	O
3	O
years	O
of	O
the	O
5	O
-	O
year	O
end	O
##oc	O
##rine	O
treatment	O
period	O
.	O

Each	O
individual	O
sa	O
##liva	O
sample	O
was	O
prepared	O
in	O
trip	O
##lica	O
##te	O
and	O
labeled	O
with	O
_	O
12	O
C	B
-	I
dans	I
##yl	I
chloride	I
,	O
and	O
injected	O
three	O
times	O
for	O
L	O
##C	O
-	O
F	O
##TI	O
##CR	O
-	O
MS	O
analysis	O
.	O

Additionally	O
,	O
the	O
simple	O
a	B
##que	I
##ous	I
-	I
met	I
##han	I
##olic	I
sample	O
extraction	O
technique	O
used	O
failed	O
to	O
capture	O
most	O
of	O
the	O
non	O
##pol	O
##ar	O
fatty	O
acids	O
,	O
i	O
.	O
e	O
.	O
,	O
SC	O
##FA	O
##s	O
,	O
un	O
##con	O
##ju	O
##gated	O
secondary	O
bi	O
##le	O
acids	O
and	O
other	O
specialized	O
meta	O
##bol	O
##ites	O
and	O
volatile	O
##s	O
that	O
are	O
typically	O
released	O
by	O
the	O
gut	O
micro	O
##bio	O
##me	O
and	O
the	O
host	O
'	O
s	O
gut	O
cellular	O
landscape	O
.	O

On	O
the	O
contrary	O
,	O
after	O
the	O
tumor	O
was	O
removed	O
,	O
significant	O
decline	O
##s	O
,	O
not	O
only	O
in	O
the	O
above	O
two	O
meta	O
##bol	O
##ites	O
but	O
also	O
in	O
rib	B
##onic	I
acid	I
and	O
x	B
##ylon	I
##ic	I
acid	I
,	O
were	O
observed	O
in	O
R	O
_	O
AT	O
compared	O
to	O
N	O
##R	O
_	O
AT	O
.	O

For	O
serum	O
,	O
the	O
pathways	O
that	O
are	O
important	O
in	O
both	O
en	O
##rich	O
##ment	O
and	O
top	O
##ological	O
analysis	O
are	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
and	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
.	O

In	O
this	O
single	O
-	O
centre	O
double	O
blind	O
crossover	O
study	O
individuals	O
self	O
-	O
reporting	O
as	B
##par	I
##tam	I
##e	I
sensitivity	O
(	O
AS	O
)	O
(	O
n	O
=	O
48	O
)	O
were	O
compared	O
to	O
age	O
and	O
gender	O
matched	O
non	O
-	O
sensitive	O
(	O
N	O
##S	O
)	O
participants	O
(	O
n	O
=	O
48	O
)	O
recruited	O
by	O
media	O
advertisement	O
(	O
press	O
advertisements	O
,	O
television	O
and	O
radio	O
)	O
.	O

Strong	O
PC	O
suppression	O
lowered	O
glucose	S
incorporation	O
into	O
downstream	O
meta	O
##bol	O
##ites	O
of	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
,	O
the	O
product	O
of	O
the	O
PC	O
reaction	O
,	O
including	O
ma	B
##late	I
,	O
c	B
##it	I
##rate	I
and	O
as	B
##par	I
##tate	I
.	O

β	O
-	O
oxidation	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
‐	I
1	I
‐	I
phosphate	I
-	I
p	I
##hos	I
##pha	I
##tase	I
-	I
1	I
activity	O
were	O
down	O
-	O
regulated	O
,	O
whereas	O
a	O
##cy	O
##l	O
-	O
al	O
##ky	O
##l	O
-	O
containing	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##lines	O
and	O
al	B
##ky	I
##l	I
##gly	I
##cer	I
##one	I
##ph	I
##os	I
##phate	I
s	O
##ynth	O
##ase	O
levels	O
were	O
elevated	O
in	O
IN	O
##R	O
##s	O
.	O

The	O
levels	O
of	O
S	O
##1	O
##P	O
,	O
c	B
##era	I
##mi	I
##des	I
,	O
and	O
other	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
in	O
the	O
tumor	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
normal	O
breast	O
tissue	O
.	O

Further	O
,	O
the	O
ability	O
to	O
quantitative	O
##ly	O
evaluate	O
nearly	O
70	O
blood	O
meta	O
##bol	O
##ites	O
that	O
represent	O
numerous	O
classes	O
,	O
including	O
amino	O
acids	O
,	O
organic	O
acids	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
and	O
he	B
##tero	I
##cy	I
##c	I
##lic	I
compounds	O
,	O
using	O
a	O
simple	O
and	O
highly	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
analytical	O
method	O
such	O
as	O
N	O
##MR	O
may	O
potentially	O
guide	O
the	O
evaluation	O
of	O
samples	O
for	O
analysis	O
using	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

We	O
fit	O
log	O
##istic	O
re	O
##gression	O
models	O
to	O
assess	O
the	O
risk	O
of	O
MI	O
after	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
fast	O
##ing	O
glucose	S
(	O
and	O
)	O
.	O

_	O
a	O
p	O
<	O
0	O
.	O
01	O
;	O
_	O
b	O
p	O
<	O
0	O
.	O
00	O
##1	O
total	O
meta	O
##bol	O
##ite	O
vs	O
s	O
##c	O
##ram	O
##ble	O
control	O
same	O
substrate	O
;	O
_	O
c	O
p	O
<	O
0	O
.	O
01	O
P	O
##yr	O
-	O
_	O
13	O
C	O
##3	O
vs	O
s	O
##c	O
##ram	O
##ble	O
control	O
;	O
_	O
d	O
p	O
<	O
0	O
.	O
00	O
##1	O
or	O
_	O
e	O
p	O
<	O
0	O
.	O
01	O
Lac	O
-	O
_	O
13	O
C	O
##3	O
vs	O
s	O
##c	O
##ram	O
##ble	O
control	O
;	O
_	O
f	O
p	O
<	O
0	O
.	O
05	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
-	I
_	I
13	I
C	O
##2	O
vs	O
s	O
##c	O
##ram	O
##ble	O
control	O
.	O

For	O
reporter	O
gene	O
ass	O
##ays	O
,	O
29	O
##3	O
cells	O
were	O
trans	O
##fected	O
using	O
Li	B
##po	I
##fect	I
##amine	I
2000	O
as	O
described	O
before	O
.	O

The	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
extract	O
was	O
retained	O
and	O
stored	O
at	O
−	O
##80	O
°C	O
for	O
meta	O
##bol	O
##ite	O
analysis	O
,	O
and	O
the	O
tissue	O
was	O
transferred	O
to	O
10	O
%	O
formal	B
##in	I
and	O
processed	O
by	O
standard	O
his	O
##top	O
##ath	O
##ology	O
methods	O
.	O

Of	O
the	O
59	O
meta	O
##bol	O
##ites	O
analyzed	O
in	O
this	O
study	O
,	O
five	O
were	O
found	O
to	O
differ	O
significantly	O
among	O
the	O
three	O
groups	O
by	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
test	O
:	O
ace	B
##tone	I
,	O
ad	B
##eno	I
##sin	I
##e	I
,	O
c	B
##it	I
##rate	I
,	O
rib	B
##ose	I
,	O
and	O
3	B
-	I
in	I
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
.	O

Ser	O
##um	O
samples	O
were	O
collected	O
with	O
B	O
##D	O
V	O
##ac	O
##uta	O
##iner	O
serum	O
tubes	O
,	O
processed	O
according	O
to	O
the	O
standard	O
B	O
##D	O
V	O
##ac	O
##uta	O
##iner	O
protocol	O
,	O
and	O
stored	O
at	O
−	O
##80	O
##°	O
C	O
.	O
Con	O
##cent	O
##rations	O
of	O
try	B
##pt	I
##op	I
##han	I
(	O
T	O
##RP	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
K	O
##Y	O
##N	O
)	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
K	O
##yn	O
##A	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
(	O
3	O
##H	O
##K	O
)	O
,	O
and	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
Q	O
##A	O
)	O
were	O
measured	O
blind	O
to	O
diagnosis	O
by	O
Brain	O
##s	O
Online	O
,	O
LLC	O
(	O
www	O
.	O
brains	O
##on	O
##line	O
.	O
org	O
/	O
home	O
)	O
.	O

After	O
v	O
##ortex	O
##ing	O
and	O
placing	O
on	O
ice	O
for	O
30	O
min	O
,	O
1	O
m	O
##L	O
water	O
and	O
0	O
.	O
9	O
m	O
##L	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
were	O
added	O
,	O
and	O
the	O
mixture	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
1500	O
rpm	O
,	O
10	O
min	O
,	O
room	O
temperature	O
)	O
.	O

Besides	O
,	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##lino	O
##si	O
##to	O
##l	O
/	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
transfer	O
proteins	B
-	I
β	I
(	I
P	I
##IT	I
##P	I
-	I
β	I
)	I
is	O
also	O
very	O
important	O
in	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

The	O
R	B
-	I
(	I
+	I
)	I
en	O
##anti	O
##omer	O
of	O
V	O
##X	O
was	O
purchased	O
from	O
Santa	O
Cruz	O
B	O
##iot	O
##ech	O
##nology	O
(	O
Dallas	O
,	O
Texas	O
,	O
USA	O
)	O
.	O

Met	O
##ab	O
##olic	O
markers	O
like	O
PC	O
##ho	O
,	O
la	B
##ct	I
##ate	I
,	O
and	O
lip	O
##ids	O
were	O
q	O
##uant	O
##ified	O
and	O
correlated	O
with	O
the	O
his	O
##top	O
##ath	O
##ological	O
grade	O
for	O
improved	O
accuracy	O
of	O
the	O
diagnosis	O
.	O

In	O
stable	O
MC	O
##I	O
GA	B
##BA	I
decline	O
is	O
associated	O
with	O
the	O
build	O
-	O
up	O
of	O
GA	B
##BA	I
precursor	O
meta	O
##bol	O
##ites	O
(	B
N	B
-	I
ace	I
##ty	I
##l	I
##put	I
##res	I
##cine	I
and	O
4	B
-	I
amino	I
##but	I
##ana	I
##l	I
)	O
indicating	O
that	O
disruption	O
/	O
block	O
##age	O
of	O
the	O
pathway	O
might	O
occur	O
here	O
.	O

The	O
sum	O
##mation	O
of	O
serum	O
25	O
(	O
OH	O
)	O
D	O
##2	O
and	O
25	B
(	I
OH	I
)	I
D	I
##3	I
was	O
used	O
to	O
reflect	O
vitamin	B
D	I
status	O
.	O

Our	O
study	O
included	O
a	O
relatively	O
large	O
number	O
of	O
participants	O
(	O
N	O
=	O
264	O
)	O
and	O
many	O
measured	O
meta	O
##bol	O
##ites	O
,	O
including	O
rib	B
##of	I
##lav	I
##in	I
,	O
total	O
vitamin	B
B	I
##6	I
and	O
co	B
##tin	I
##ine	I
,	O
which	O
are	O
important	O
as	O
they	O
influence	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
.	O

The	O
intensity	O
of	O
the	O
BC	O
##AA	O
spectral	O
bucket	O
##s	O
(	O
containing	O
overlapping	O
resonance	O
##s	O
from	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
were	O
found	O
to	O
be	O
significantly	O
increased	O
in	O
s	O
##pect	O
##ra	O
acquired	O
on	O
N	O
##PC	O
##1	O
patients	O
over	O
those	O
of	O
healthy	O
controls	O
.	O

We	O
also	O
witnessed	O
global	O
down	O
##re	O
##gu	O
##lation	O
of	O
two	O
major	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
classes	O
,	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
##s	I
and	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
,	O
in	O
DC	O
##s	O
vs	O
.	O
NH	O
##C	O
.	O

P	O
##las	O
##ma	O
or	O
urine	O
samples	O
(	O
50	O
μ	O
##L	O
)	O
were	O
added	O
to	O
450	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
(	O
134	O
–	O
145	O
##23	O
,	O
F	O
##U	O
##J	O
##IF	O
##IL	O
##M	O
W	O
##ak	O
##o	O
Pure	O
Chemical	O
Corporation	O

A	O
possible	O
inhibitor	O
##y	O
effect	O
of	O
4	O
-	O
PA	O
on	O
vitamin	B
B	I
##6	I
metabolism	O
has	O
also	O
been	O
discussed	O
.	O

Men	O
who	O
would	O
have	O
met	O
eligibility	O
,	O
but	O
were	O
already	O
initiated	O
on	O
combined	O
and	O
##rogen	O
blockade	O
with	O
an	O
L	O
##H	O
##R	O
##H	O
ago	O
##nist	O
and	O
bi	B
##cal	I
##uta	I
##mi	I
##de	I
were	O
a	O
##cc	O
##rue	O
##d	O
into	O
arm	O
1	O
if	O
they	O
agreed	O
to	O
undergo	O
pro	O
##state	O
##ct	O
##omy	O
within	O
3	O
months	O
.	O

Furthermore	O
,	O
u	O
##rina	O
##ry	O
do	B
##pa	I
##mine	I
,	O
a	O
downstream	O
meta	O
##bol	O
##ite	O
of	O
t	B
##yr	I
##os	I
##ine	I
,	O
was	O
found	O
to	O
be	O
diminished	O
in	O
patients	O
still	O
bearing	O
a	O
tumor	O
.	O

P	B
##yr	I
##id	I
##ine	I

Various	O
studies	O
have	O
been	O
done	O
showing	O
that	O
metabolic	O
disorders	O
are	O
common	O
in	O
patients	O
with	O
β	B
-	I
th	I
##ala	I
##sse	I
##mia	I
_	I
,	O
but	O
to	O
date	O
,	O
there	O
is	O
a	O
lack	O
of	O
meta	O
##bol	O
##omi	O
##cs	O
based	O
bio	O
##mark	O
##ers	O
that	O
may	O
play	O
role	O
in	O
di	O
##ag	O
##nos	O
##ing	O
the	O
p	O
##hen	O
##otype	O
of	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
and	O
convey	O
pro	O
##gno	O
##stic	O
approach	O
with	O
various	O
management	O
possibilities	O
.	O

Le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
,	O
l	B
##ys	I
##o	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
0	I
)	I
,	O
u	B
##rid	I
##ine	I
and	O
2	B
-	I
de	I
##ox	I
##y	I
##gal	I
##act	I
##opy	I
##rano	I
##se	I
,	O
were	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
and	O
u	B
##ro	I
##bil	I
##ino	I
##gen	I
was	O
obtained	O
from	O
Santa	O
Cruz	O
B	O
##iot	O
##ech	O
##nology	O
(	O
Santa	O
Cruz	O
,	O
USA	O
)	O
,	O
and	O
used	O
for	O
identification	O
purposes	O
.	O

In	O
addition	O
,	O
c	B
##is	I
##p	I
##lat	I
##in	I
decreased	O
the	O
survival	O
fraction	O
of	O
all	O
the	O
cell	O
lines	O
,	O
but	O
radiation	O
-	O
resistant	O
cells	O
are	O
apparently	O
more	O
tolerant	O
to	O
this	O
drug	O
.	O

Au	O
##the	O
##nti	O
##c	O
standards	O
of	O
PC	B
(	I
18	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
PC	O
(	O
c	O
##is	O
18	O
:	O
1	O
/	O
c	O
##is	O
18	O
:	O
1	O
)	O
,	O
trans	O
PC	O
(	O
trans	O
18	O
:	O
1	O
/	O
trans	O
18	O
:	O
1	O
)	O
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
4	I
)	I
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
22	I
:	I
6	I
)	I
,	O
PC	B
(	I
17	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
PC	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
P	B
##G	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
,	O
PS	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
PA	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
were	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
Inc	O
.	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
,	O
USA	O
)	O
.	O

Lin	B
##ole	I
##oy	I
##l	I
car	I
##ni	I
##tine	I
is	O
a	O
long	O
-	O
chain	O
a	O
##cy	O
##l	O
fatty	O
acid	O
derivative	O
est	O
##er	O
of	O
car	B
##ni	I
##tine	I
.	O

The	O
an	O
##ion	O
##ic	O
S	O
##NP	O
##s	O
were	O
extensively	O
dial	O
##y	O
##zed	O
in	O
50	O
m	O
##M	O
sodium	B
phosphate	I
buffer	O
before	O
they	O
were	O
added	O
to	O
serum	O
.	O

In	O
fact	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
are	O
higher	O
in	O
I	O
##R	O
patients	O
than	O
in	O
IS	O
patients	O
,	O
suggesting	O
that	O
insulin	O
plays	O
a	O
strong	O
role	O
in	O
m	O
##od	O
##ulating	O
lip	O
##ogen	O
##esis	O
(	O
Table	O
)	O
.	O

Most	O
cells	O
of	O
the	O
body	O
express	O
the	O
vitamin	B
D	I
receptor	O
,	O
and	O
all	O
of	O
these	O
are	O
thought	O
to	O
express	O
C	O
##YP	O
##24	O
##A	O
##1	O
.	O

It	O
is	O
a	O
component	O
of	O
various	O
metabolic	O
pathways	O
such	O
as	O
c	B
##ys	I
##tein	I
##e	I
,	O
prop	B
##ano	I
##ate	I
and	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
.	O

5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
was	O
purchased	O
from	O
Alfa	O
-	O
A	O
##es	O
##ar	O
(	O
analytical	O
grade	O
,	O
Ward	O
Hill	O
,	O
MA	O
)	O
.	O

This	O
meta	O
##bol	O
##ite	O
separated	O
p	O
##CR	O
from	O
SD	O
samples	O
perfectly	O
,	O
which	O
makes	O
combining	O
l	B
##ino	I
##len	I
##ic	I
acid	I
with	O
other	O
L	O
##C	O
–	O
MS	O
detected	O
markers	O
unnecessary	O
for	O
model	O
building	O
.	O

These	O
findings	O
suggest	O
that	O
at	O
initial	O
stages	O
of	O
disease	O
,	O
the	O
T	O
##CA	O
cycle	O
was	O
not	O
activated	S
by	O
amino	O
acids	O
.	O

Some	O
of	O
the	O
same	O
pathways	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
in	O
AR	O
##DS	O
,	O
such	O
as	O
fatty	O
acids	O
,	O
amino	O
acids	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
were	O
also	O
significant	O
in	O
our	O
study	O
.	O

Ser	O
##um	O
samples	O
from	O
T	O
##B	O
patients	O
were	O
characterized	O
by	O
increased	O
concentrations	O
of	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
ace	B
##tone	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
l	B
##ys	I
##ine	I
,	O
ni	B
##cot	I
##inate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
accompanied	O
by	O
reduced	O
concentrations	O
of	O
al	B
##ani	I
##ne	I
,	O
format	B
##e	I
,	O
g	B
##ly	I
##cine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
##ph	I
##os	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
relative	O
to	O
control	O
subjects	O
.	O

Here	O
,	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
was	O
used	O
to	O
determine	O
how	O
the	O
metabolic	O
profiles	O
of	O
h	B
##ydro	I
##phi	I
##lic	I
extract	O
##s	O
of	O
three	O
human	O
pan	O
##cre	O
##atic	O
cancer	O
cell	O
lines	O
,	O
Mia	O
##P	O
##a	O
##C	O
##a	O
-	O
2	O
,	O
Pan	O
##c	O
-	O
1	O
and	O
As	O
##PC	O
-	O
1	O
,	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
drying	O
technique	O
.	O

For	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
we	O
found	O
that	O
r	O
##s	O
##17	O
##31	O
##35	O
located	O
3	O
′	O
U	O
##TR	O
of	O
KC	O
##N	O
##J	O
##2	O
gene	O
is	O
most	O
likely	O
the	O
ca	O
##usal	O
S	O
##NP	O
(	O
P	O
-	O
value	O
=	O
1	O
.	O
01	O
##×	O
##10	O
_	O
−	O
##0	O
##7	O
)	O
in	O
##f	O
##lue	O
##ncing	O
the	O
circulating	O
level	O
of	O
this	O
meta	O
##bol	O
##ite	O
.	O

It	O
has	O
not	O
escaped	O
our	O
attention	O
that	O
all	O
of	O
these	O
pathways	O
are	O
affected	O
by	O
s	B
##tat	I
##ins	I
,	O
either	O
as	O
therapeutic	O
target	O
or	O
side	O
effects	O
,	O
suggesting	O
that	O
bi	O
##le	O
acids	O
may	O
be	O
important	O
media	O
##tors	O
of	O
s	B
##tat	I
##in	I
activities	O
.	O

For	O
example	O
,	O
N	O
##MR	O
can	O
distinguish	O
position	O
##al	O
is	O
##omer	O
##s	O
on	O
a	O
substituted	O
ben	B
##zen	I
##e	I
ring	O
that	O
would	O
not	O
be	O
possible	O
from	O
MS	O
results	O
alone	O
.	O

The	O
resulting	O
predict	O
##ive	O
models	O
predominantly	O
identify	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
(	O
such	O
as	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
car	B
##ni	I
##tine	I
,	O
c	B
##it	I
##rate	I
,	O
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
)	O
as	O
relevant	O
variables	O
indicating	O
that	O
C	O
##K	O
##D	O
significantly	O
affects	O
the	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ome	O
.	O

The	O
pathways	O
with	O
considerable	O
impact	O
include	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
gal	B
##act	I
##ose	I
,	O
star	O
##ch	O
/	B
su	B
##c	I
##rose	I
and	O
fatty	O
acid	O
metabolism	O
while	O
meta	O
##bol	O
##ites	O
blame	O
##able	O
for	O
these	O
de	O
##viation	O
##s	O
are	O
g	B
##ly	I
##cer	I
##ol	I
,	O
la	B
##ctic	I
acid	I
,	O
su	B
##c	I
##rose	I
and	O
palm	B
##itic	I
acid	I
respectively	O
.	O

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
LP	O
##E	O
)	O
is	O
a	O
group	O
of	O
signalling	O
lip	O
##ids	O
,	O
and	O
it	O
has	O
been	O
recently	O
shown	O
to	O
be	O
related	O
to	O
breast	O
cancer	O
.	O

The	O
appropriate	O
quantity	O
of	O
the	O
stock	O
solution	O
was	O
added	O
to	O
glucose	O
-	O
free	O
R	O
##PM	O
##I	O
medium	O
to	O
a	O
final	O
concentration	O
of	O
10	O
.	O
7	O
m	O
##M	O
(	O
excluding	O
the	O
0	O
.	O
54	O
m	O
##M	O
un	O
##la	O
##bel	O
##ed	O
glucose	S
from	O
the	O
FC	O
##S	O
)	O
.	O

Ana	O
##ly	O
##tes	O
were	O
identified	O
put	O
##ative	O
##ly	O
by	O
comparing	O
both	O
the	O
MS	O
s	O
##pect	O
##ra	O
and	O
R	B
##I	I
with	O
those	O
in	O
the	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology	O
(	O
N	O
##IS	O
##T	O
)	O
library	O
.	O

Tri	O
##tia	O
##ted	O
glucose	S
specific	O
activity	O
was	O
determined	O
on	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
bar	O
##ium	O
/	O
zinc	O
plasma	O
samples	O
.	O

L	O
##C	O
-	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
met	B
##han	I
##ol	I
were	O
obtained	O
from	O
Me	O
##rc	O
##k	O
(	O
Li	O
##C	O
##hr	O
##oso	O
##l	O
##v	O
_	O
®	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

The	O
tested	O
co	O
##var	O
##iate	O
##s	O
were	O
corresponding	O
base	O
##line	O
AB	O
##P	O
,	O
age	O
,	O
current	O
smoking	O
,	O
body	O
mass	O
index	O
,	O
daily	O
u	O
##rina	O
##ry	O
sodium	O
ex	O
##cre	O
##tion	O
after	O
the	O
first	O
place	O
##bo	O
period	O
,	O
and	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
after	O
the	O
first	O
place	O
##bo	O
period	O
.	O

We	O
also	O
found	O
significant	O
coding	O
variations	O
associated	O
with	O
dim	B
##eth	I
##yl	I
-	I
g	I
##ly	I
##cine	I
,	O
car	B
##ni	I
##tine	I
,	O
p	B
##yr	I
##u	I
##vate	I
and	O
l	B
##ys	I
##ine	I
however	O
all	O
those	O
signals	O
vanished	O
after	O
adjustment	O
by	O
the	O
leading	O
G	O
##WA	O
##S	O
S	O
##NP	O
,	O
indicating	O
that	O
these	O
associations	O
so	O
far	O
are	O
best	O
explained	O
by	O
the	O
leading	O
G	O
##WA	O
##S	O
hits	O
in	O
these	O
regions	O
.	O

The	O
cent	O
##ri	O
##fu	O
##gation	O
procedure	O
was	O
repeated	O
followed	O
by	O
an	O
additional	O
70	O
%	O
perch	B
##lor	I
##ic	I
acid	I
(	O
10	O
%	O
by	O
volume	O
)	O
.	O

Maintenance	O
of	O
the	O
G	O
##lu	O
pool	O
is	O
also	O
linked	O
to	O
er	B
##got	I
##hi	I
##one	I
##ine	I
,	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
red	O
##ox	O
home	O
##ost	O
##asis	O
of	O
Mt	O
##b	O
.	O

0	O
.	O
4	O
m	O
##l	O
met	B
##han	I
##ol	I
and	O
50	O
μ	O
##l	O
of	O
L	B
-	I
2	I
-	I
Ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
(	O
0	O
.	O
1	O
mg	O
/	O
m	O
##l	O
stock	O
in	O
d	O
##H	O
##2	O
##O	O
,	O
Shanghai	O
He	O
##ng	O
##ba	O
##i	O
ch	O
##em	O
##dr	O
##ug	O
bio	O
##tech	O
##nology	O
Co	O
.	O
,	O
Ltd	O
,	O
Shanghai	O
,	O
China	O
)	O
,	O
which	O
is	O
used	O
as	O
an	O
internal	O
standard	O
,	O
were	O
added	O
to	O
100	O
μ	O
##l	O
sample	O
serum	O
,	O
and	O
v	O
##ortex	O
for	O
10	O
##s	O
.	O

Reg	O
##ression	O
analyses	O
showed	O
no	O
association	O
between	O
K	O
##A	O
/	O
Q	O
##A	O
or	O
component	O
2	O
and	O
either	O
whole	O
-	O
brain	O
GM	O
volume	O
or	O
in	O
##tra	O
##c	O
##rani	O
##al	O
volume	O
(	O
data	O
not	O
shown	O
)	O
,	O
thus	O
raising	O
the	O
possibility	O
that	O
any	O
put	O
##ative	O
effect	O
of	O
c	O
##yt	O
##oki	O
##nes	O
or	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
on	O
brain	O
structure	O
could	O
be	O
limited	O
to	O
brain	O
regions	O
that	O
are	O
known	O
to	O
display	O
reduction	O
##s	O
in	O
GM	O
volume	O
in	O
MD	O
##D	O
.	O

Finally	O
,	O
low	O
levels	O
of	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
were	O
also	O
found	O
to	O
be	O
associated	O
with	O
high	O
disease	O
activity	O
in	O
CD	O
(	O
P	O
=	O
9	O
.	O
0	O
×	O
10	O
_	O
–	O
4	O
)	O
.	O

Mo	B
##rp	I
##hine	I
(	O
100	O
μ	O
m	O
##ol	O
/	O
L	O
)	O
was	O
in	O
##cu	O
##bate	O
##d	O
with	O
the	O
different	O
c	O
##yt	O
##oso	O
##l	O
pools	O
(	O
8	O
mg	O
/	O
m	O
##L	O
protein	O
equivalent	O
)	O
in	O
Tri	O
##s	O
-	O
HC	O
##l	O
buffer	O
(	O
0	O
.	O
05	O
m	O
##ol	O
/	O
L	O
with	O
0	O
.	O
25	O
mm	O
##ol	O
/	O
L	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
)	O
pH	O
7	O
.	O
4	O
and	O
0	O
.	O
05	O
mm	O
##ol	O
/	O

o	B
##xy	I
##ster	I
##ols	I
,	O
breast	O
cancer	O
,	O
est	B
##rogen	I
,	O
plasma	O
,	O
therapy	O

B	O
##rief	O
##ly	O
,	O
100	O
mg	O
of	O
frozen	O
tissue	O
was	O
weighed	O
and	O
grin	O
##ded	O
in	O
a	O
liquid	O
nitrogen	O
cooled	O
mortar	O
with	O
6	O
%	O
ice	O
-	O
cold	O
perch	B
##lor	I
##ic	I
acid	I
.	O

Given	O
the	O
fast	O
turnover	O
rate	O
and	O
minimal	O
storage	O
of	O
th	B
##iam	I
##in	I
,	O
however	O
,	O
the	O
effect	O
of	O
the	O
single	O
supplement	O
##al	O
dose	O
would	O
not	O
likely	O
be	O
seen	O
at	O
follow	O
-	O
up	O
.	O

The	O
ins	O
##et	O
is	O
the	O
data	O
-	O
dependent	O
MS	O
/	O
MS	O
scan	O
of	O
the	O
same	O
peak	O
,	O
giving	O
fragment	O
ions	O
of	O
193	O
,	O
175	O
,	O
and	O
163	O
m	O
/	O
z	O
corresponding	O
to	O
the	O
indicated	O
portions	O
of	O
the	O
proposed	O
p	B
##hen	I
##yl	I
##but	I
##yr	I
##yl	I
-	I
β	I
-	I
g	I
##lu	I
##cu	I
##rona	I
##te	I
meta	O
##bol	O
##ite	O
shown	O
.	O

Our	O
study	O
is	O
one	O
of	O
two	O
analyses	O
of	O
B	O
##MI	O
and	O
post	O
-	O
men	O
##op	O
##aus	O
##al	O
ER	O
+	O
breast	O
cancer	O
risk	O
to	O
attempt	O
to	O
q	O
##uant	O
##ify	O
the	O
proportion	O
of	O
the	O
B	O
##MI	O
association	O
that	O
is	O
mediated	O
by	O
circulating	O
concentrations	O
of	O
est	B
##rad	I
##iol	I
.	O

C	O
illustrate	O
##s	O
the	O
improvement	O
in	O
separation	O
observed	O
when	O
using	O
a	O
Tor	O
##us	O
Di	B
##ol	I
column	O
rather	O
than	O
a	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
column	O
.	O

Su	O
##mma	O
##ry	O
of	O
freeze	O
-	O
th	O
##aw	O
results	O
The	O
limit	O
of	O
q	O
##uant	O
##itation	O
based	O
on	O
quantitative	O
ass	O
##ay	O
(	O
N	O
=	O
5	O
)	O
for	O
end	B
##ox	I
##ife	I
##n	I
was	O
1	O
.	O
74	O
##±	O
##0	O
.	O
1	O
ng	O
/	O
m	O
##L	O
,	O
N	O
##D	O
-	O
ta	O
##m	O
4	O
.	O
0	O
##±	O
##0	O
.	O
1	O
##ng	O
/	O
m	O
##L	O
,	O
ta	B
##mo	I
##xi	I
##fen	I
1	O
.	O
56	O
##±	O
##0	O
.	O
2	O
##ng	O
/	O
m	O
##L	O
.	O

That	O
being	O
said	O
,	O
a	O
small	O
number	O
of	O
molecules	O
,	O
including	O
et	B
##hyl	I
9	I
-	I
he	I
##xa	I
##de	I
##ce	I
##no	I
##ate	I
(	O
see	O
)	O
,	O
were	O
individually	O
differential	O
##ly	O
abundant	O
in	O
UC	O
,	O
and	O
make	O
promising	O
targets	O
for	O
further	O
study	O
.	O

The	O
increase	O
of	O
car	B
##ni	I
##tine	I
in	O
the	O
EA	O
##C	O
patients	O
indicates	O
increased	O
activity	O
of	O
car	B
##ni	I
##tine	I
,	O
l	B
##ys	I
##ine	I
and	O
g	B
##lut	I
##amine	I
bio	O
##sy	O
##nt	O
##hesis	O
connected	O
with	O
the	O
T	O
##CA	O
cycle	O
via	O
la	B
##ct	I
##ate	I
accumulation	O
,	O
again	O
in	O
response	O
to	O
the	O
higher	O
energy	O
demand	O
of	O
the	O
tumor	O
.	O

Trans	B
##thy	I
##ret	I
##in	I
,	O
meanwhile	O
,	O
is	O
a	O
supportive	O
marker	O
for	O
color	O
##ec	O
##tal	O
ad	O
##eno	O
##ma	O
and	O
cancer	O
that	O
represents	O
nutrition	O
##al	O
status	O
.	O
_	O
,	O
Including	O
these	O
two	O
proteins	O
,	O
the	O
combination	O
of	O
unidentified	O
metabolic	O
compounds	O
may	O
serve	O
to	O
character	O
##ize	O
CR	O
##C	O
.	O

Ph	B
##os	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
s	O
##ynth	O
##esi	O
##zes	O
c	B
##yt	I
##id	I
##ine	I
5	I
′	I
-	I
dip	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
a	O
reaction	O
cat	O
##aly	O
##zed	O
by	O
phosphate	S
c	O
##yt	O
##idy	O
##ly	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
1	O
.	O

Di	O
##lution	O
integrity	O
was	O
demonstrated	O
by	O
di	O
##lut	O
##ing	O
fortified	O
urine	O
specimens	O
(	O
N	O
=	O
3	O
)	O
containing	O
200	O
μ	O
##g	O
/	O
L	O
of	O
T	O
##HC	O
,	O
T	O
##HC	O
##CO	O
##OH	O
,	O
CB	O
##G	O
,	O
T	O
##HC	O
##V	O
and	O
T	O
##HC	O
##VC	O
##O	O
##OH	O
,	O
100	O
μ	O
##g	O
/	O
L	O
of	O
11	B
-	I
OH	I
-	I
T	I
##HC	I
,	O
CB	O
##D	O
,	O
CBN	O
,	O
T	O
##HC	O
##AA	O
and	O
T	O
##HC	O
-	O
g	O
##lu	O
##c	O
and	O
1000	O
μ	O
##g	O
/	O
L	O
of	O
T	O
##HC	O
##CO	O
##OH	O
-	O
g	O
##lu	O
##c	O
1	O
:	O
10	O
with	O
blank	O
human	O
urine	O
.	O

The	O
super	O
##nat	O
##ant	O
or	O
upper	O
phase	O
was	O
mixed	O
with	O
100	O
µ	O
##L	O
of	O
carbon	B
##ate	I
-	I
bi	I
##car	I
##bon	I
##ate	I
buffer	O
(	O
0	O
.	O
2	O
M	O
,	O
pH	O
9	O
)	O
and	O
50	O
µ	O
##L	O
of	O
dans	B
##yl	I
chloride	I
(	O
10	O
mg	O
/	O
m	O
##L	O
in	O
ace	O
##tone	O
)	O
.	O

Para	B
##ffin	I
sections	O
were	O
cut	O
at	O
4	O
μ	O
##m	O
,	O
placed	O
on	O
charged	O
slides	O
,	O
and	O
dried	O
at	O
60	O
##°	O
##C	O
for	O
1	O
hour	O
.	O

As	O
car	B
##ni	I
##tine	I
is	O
essential	O
for	O
the	O
entry	O
of	O
fatty	O
acid	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
for	O
oxidation	O
,	O
and	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
is	O
the	O
final	O
product	O
of	O
this	O
oxidation	O
event	O
,	O
these	O
results	O
suggest	O
that	O
fatty	O
acid	O
oxidation	O
might	O
be	O
an	O
important	O
factor	O
in	O
determining	O
the	O
cancer	O
status	O
.	O

b	O
.	O
Rat	O
##io	O
of	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
16	I
:	I
0	I
/	I
22	I
:	I
6	I
to	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
16	I
:	I
0	I
/	I
18	I
:	I
3	I
in	O
Multiple	O
Sc	O
##ler	O
##osis	O
.	O

Pol	B
##yam	I
##ines	I
were	O
both	O
synthesized	O
and	O
de	O
##graded	O
,	O
indicated	O
by	O
_	O
13	O
C	O
_	O
10	O
met	B
##hyl	I
##thi	I
##oa	I
##den	I
##os	I
##ine	I
and	O
_	O
13	O
C	O
_	O
4	O
ace	B
##ty	I
##l	I
##put	I
##res	I
##cine	I
,	O
respectively	O
,	O
consistent	O
with	O
the	O
notion	O
that	O
p	B
##oly	I
##amine	I
metabolism	O
o	O
##s	O
##cilla	O
##tes	O
over	O
the	O
cell	O
cycle	O
.	O

Lin	B
##ole	I
##ic	I
acid	I
gradually	O
de	O
##graded	O
under	O
250	O
°C	O
heating	O
,	O
and	O
[UNK]	B
%	O
disappeared	O
after	O
heating	O
for	O
60	O
s	O
(	O
Figure	O
S	O
##3	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
decreased	O
c	B
##ys	I
##tine	I
levels	O
were	O
associated	O
with	O
disease	O
re	O
##lap	O
##se	O
possibly	O
through	O
reduction	O
in	O
G	B
##S	I
##H	I
synthesis	O
and	O
increased	O
o	O
##xi	O
##da	O
##tive	O
damage	O
.	O

Inc	O
##reased	O
levels	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
have	O
also	O
been	O
reported	O
in	O
anxiety	O
disorders	O
,	O
Alzheimer	O
'	O
s	O
disease	O
,	O
dem	O
##ent	O
##ia	O
,	O
breast	O
cancer	O
and	O
thy	O
##rop	O
##ath	O
##ies	O
.	O

Op	B
##po	I
##si	I
##ti	I
##fo	I
##lone	I
(	O
1	O
)	O
at	O
different	O
concentrations	O
(	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
B	O
##W	O
)	O
did	O
not	O
exhibit	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
activity	O
since	O
it	O
did	O
not	O
show	O
significant	O
difference	O
in	O
%	O
blood	O
glucose	S
reduction	O
when	O
compared	O
to	O
the	O
negative	O
control	O
(	O
Pol	O
##ys	O
##or	O
##bate	O
80	O
)	O
.	O

For	O
these	O
studies	O
,	O
we	O
examined	O
additional	O
sets	O
of	O
H	O
##NS	O
##CC	O
tissues	O
and	O
found	O
that	O
g	B
##lut	I
##ama	I
##te	I
was	O
differential	O
##ly	O
elevated	O
in	O
primary	O
and	O
meta	O
##static	O
H	O
##NS	O
##CC	O
tissues	O
compared	O
to	O
normal	O
adjacent	O
tissues	O
.	O

Organic	O
phase	O
was	O
collected	O
and	O
the	O
extraction	O
steps	O
were	O
repeated	O
once	O
with	O
100	O
μ	O
##l	O
Met	O
##OH	O
,	O
300	O
μ	O
##l	O
M	B
##T	I
##BE	I
and	O
100	O
μ	O
##l	O
mill	O
##i	O
##Q	O
H	O
_	O
2	O
O	O
.	O
Li	O
##pid	O
extract	O
##s	O
were	O
dried	O
in	O
a	O
mi	O
##V	O
##ac	O
cent	O
##ri	O
##fu	O
##gal	O
e	O
##va	O
##por	O
##ator	O
(	O
Geneva	O
##c	O
Ltd	O
)	O
,	O
and	O
red	O
##iss	O
##ol	O
##ved	O
in	O
500	O
μ	O
##l	O
of	O
water	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
38	O
:	O
62	O
.	O

For	O
example	O
,	O
shows	O
high	O
levels	O
of	O
glucose	S
(	O
m	O
/	O
z	O
179	O
.	O
05	O
##6	O
##1	O
;	O
see	O
for	O
identification	O
)	O
and	O
low	O
levels	O
of	O
c	B
##it	I
##rate	I
(	O
m	O
/	O
z	O
191	O
.	O
01	O
##9	O
##6	O
;	O
see	O
for	O
identification	O
)	O
in	O
cancer	O
.	O

Overall	O
,	O
GA	O
##BR	O
and	O
AD	B
##MA	I
showed	O
a	O
modest	O
negative	O
correlation	O
(	O
r	O
=	O
-	O
0	O
.	O
24	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Interest	O
##ingly	O
,	O
in	O
the	O
case	O
of	O
lip	O
##id	O
h	B
##ydro	I
##per	I
##oxide	I
##s	I
the	O
increased	O
concentration	O
(	O
p	O
<	O
0	O
.	O
05	O
and	O
F	O
##DR	O
<	O
0	O
.	O
05	O
)	O
with	O
respect	O
to	O
longer	O
storage	O
time	O
within	O
subject	O
age	O
group	O
was	O
significant	O
in	O
most	O
sample	O
groups	O
stored	O
for	O
more	O
than	O
7	O
years	O
.	O

The	O
strengths	O
of	O
our	O
pilot	O
study	O
include	O
the	O
use	O
of	O
multiple	O
time	O
points	O
to	O
study	O
changes	O
post	O
‐	O
R	O
##Y	O
##GB	O
and	O
the	O
use	O
of	O
both	O
N	O
##MR	O
‐	O
based	O
meta	O
##bol	O
##omi	O
##cs	O
and	O
FA	S
analysis	O
.	O

Identity	O
of	O
specific	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
[	O
re	O
##sol	O
##vin	O
D	O
##1	O
(	O
R	O
##v	O
##D	O
##1	O
)	O
,	O
7	O
##S	O
,	O
8	B
##R	I
,	I
17	I
##S	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
4	I
##Z	I
,	O
9	O
##E	O
,	O
11	O
##E	O
,	O
13	O
##Z	O
,	O
15	O
##E	O
,	O
19	O
##Z	O
-	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
)	O
,	O
re	O
##sol	O
##vin	O
D	O
##2	O
(	O
R	O
##v	O
##D	O
##2	O
)	O
,	O
7	O
##S	O
,	O
16	O
##R	O
,	O
17	B
##S	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
4	I
##Z	I
,	O
8	O
##E	O
,	O
10	O
##Z	O
,	O
12	O
##E	O
,	O
14	B
##E	I
,	I
19	I
##Z	I
-	I
do	I
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	O
)	O
and	O
the	O
as	O
##pi	O
##rin	O
-	O
triggered	O
R	O
##v	O
##D	O
##1	O
(	O
AT	O
-	O
R	O
##v	O
##D	O
##1	O
)	O
,	O
7	O
##S	O
,	O
8	B
##R	I
,	I
17	I
##R	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
4	I
##Z	I
,	O
9	O
##E	O
,	O
11	O
##E	O
,	O
13	O
##Z	O
,	O
15	O
##E	O
,	O
19	O
##Z	O
-	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
]	O
was	O
confirmed	O
using	O
lip	O
##id	O
media	O
##tor	O
meta	O
##bol	O
##oli	O
##pid	O
##omi	O
##cs	O
analytical	O
methods	O
,	O
as	O
described	O
by	O
Ser	O
##han	O
and	O
colleagues	O
,	O
.	O

And	O
,	O
expression	O
of	O
GA	B
##BA	I
(	O
A	O
)	O
receptors	O
was	O
altered	O
significantly	O
in	O
the	O
lateral	O
c	O
##ere	O
##bell	O
##um	O
of	O
subjects	O
with	O
B	O
##D	O
.	O

Those	O
observations	O
suggest	O
a	O
race	O
-	O
dependent	O
di	O
##sp	O
##arity	O
in	O
to	B
##co	I
##pher	I
##ol	I
is	I
##omer	I
##s	I
.	O

The	O
loading	O
##s	O
for	O
the	O
predict	O
##ive	O
components	O
of	O
both	O
models	O
show	O
that	O
intake	O
of	O
both	O
w	B
##hey	I
and	O
calcium	B
case	I
##inate	I
proteins	O
results	O
in	O
a	O
higher	O
intensity	O
of	O
branched	O
amino	O
acids	O
,	O
al	B
##ani	I
##ne	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
c	B
##rea	I
##tine	I
and	O
t	B
##yr	I
##os	I
##ine	I
and	O
a	O
lower	O
intensity	O
of	O
ace	B
##tate	I
,	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
c	B
##it	I
##rate	I
and	O
glucose	S
.	O

In	O
addition	O
,	O
a	O
shift	O
towards	O
elevated	O
K	O
##re	O
##bs	O
cycle	O
intermediate	O
##s	O
,	O
including	O
ma	B
##late	I
,	O
seemed	O
to	O
emerge	O
when	O
sleep	O
was	O
cu	O
##rta	O
##iled	O
.	O

The	O
area	O
under	O
the	O
curve	O
is	O
0	O
.	O
95	O
,	O
showing	O
good	O
sensitivity	O
and	O
specific	O
##ity	O
in	O
disc	O
##rim	O
##inating	O
between	O
R	B
##P	I
and	O
N	O
##RP	O
.	O

To	O
a	O
100	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##t	O
of	O
urine	O
sample	O
,	O
1	O
m	O
##L	O
of	O
100	O
m	O
##M	O
sodium	B
ace	I
##tate	I
buffer	O
(	O
pH	O
5	O
,	O
adjusted	O
with	O
glacial	O
ace	O
##tic	O
acid	O
)	O
containing	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
1000	O
U	O
/	O
m	O
##L	O
were	O
added	O
.	O

-	B
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
peak	O
3	O
in	O
a	O
)	O
,	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
peak	O
4	O
in	O
a	O
)	O
,	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
peak	O
5	O
in	O
a	O
)	O
,	O
7	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
peak	O
6	O
in	O
a	O
)	O
,	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
peak	O
8	O
in	O
a	O
)	O
,	O
and	O
6	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
peak	O
9	O
in	O
a	O
)	O
and	O
also	O
7	B
-	I
o	I
##x	I
##och	I
##ole	I
##ster	I
##ol	I
(	O
peak	O
7	O
in	O
a	O
)	O
.	O

The	O
level	O
of	O
17	O
urine	O
meta	O
##bol	O
##ites	O
[	B
his	B
##tamine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
hip	B
##pura	I
##te	I
(	I
g	I
##ly	I
##cola	I
##te	I
)	I
,	O
met	B
##hyl	I
##his	I
##ti	I
##dine	I
,	O
ta	B
##uri	I
##ne	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
,	O
ma	B
##lon	I
##ate	I
,	O
2	O
-	O
O	O
##x	O
o	B
##is	I
##oc	I
##ap	I
##roa	I
##te	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
g	B
##lut	I
##amine	I
,	O
g	O
##lut	O
##ama	O
##te	O
(	O
N	O
-	O
ace	O
##ty	O
##lam	O
##ino	O
##ac	O
##ides	O
)	O
and	O
al	B
##ani	I
##ne	I
]	O
was	O
significantly	O
decreased	O
in	O
patients	O
with	O
BC	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
with	O
the	O
control	O
population	O
.	O

Consequently	O
,	O
a	O
panel	O
consisting	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
,	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##to	I
##ace	I
##tate	I
and	O
ma	B
##lon	I
##ate	I
was	O
identified	O
as	O
an	O
effective	O
class	O
##ifier	O
.	O

Our	O
results	O
suggest	O
an	O
additional	O
role	O
of	O
CD	O
##36	O
in	O
regulating	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
in	O
addition	O
to	O
AC	O
##AD	O
##M	O
.	O

To	O
these	O
wells	O
were	O
added	O
100	O
μ	O
##L	O
of	O
G	O
##ries	O
##s	O
re	O
##age	O
##nt	O
and	O
the	O
plate	O
was	O
read	O
at	O
540	O
nm	O
after	O
14	O
min	O
to	O
q	O
##uant	O
##itate	O
ni	B
##tri	I
##te	I
released	O
into	O
the	O
medium	O
after	O
induction	O
of	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
by	O
LP	B
##S	I
.	O

Inc	O
##reased	O
ch	B
##olin	I
##e	I
level	O
might	O
be	O
correlated	O
with	O
higher	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
demand	O
for	O
the	O
f	O
##etus	O
brain	O
development	O
during	O
later	O
periods	O
of	O
pregnancy	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
mixed	O
group	O
of	O
18	O
patients	O
with	O
a	O
variety	O
of	O
di	O
##ag	O
##nose	O
##s	O
:	O
ben	O
##ign	O
my	O
##elo	O
##lip	O
##oma	O
(	O
n	O
=	O
4	O
)	O
,	O
meta	O
##sta	O
##sis	O
from	O
an	O
extra	O
-	O
ad	O
##rena	O
##l	O
primary	O
tumor	O
(	O
n	O
=	O
4	O
)	O
,	O
ad	O
##rena	O
##l	O
h	O
##yper	O
##p	O
##lasia	O
(	O
n	O
=	O
2	O
)	O
,	O
multi	O
##no	O
##du	O
##lar	O
h	O
##yper	O
##p	O
##lasia	O
(	O
n	O
=	O
2	O
)	O
,	O
cavern	O
##ous	O
l	O
##ymph	O
##ang	O
##io	O
##ma	O
(	O
n	O
=	O
1	O
)	O
,	O
gang	B
##lion	I
##eur	I
##oma	I
(	O
n	O
=	O
1	O
)	O
,	O
hem	O
##ang	O
##io	O
##ma	O
(	O
n	O
=	O
1	O
)	O
,	O
c	O
##ys	O
##t	O
(	O
n	O
=	O
1	O
)	O
,	O
non	O
-	O
Ho	O
##d	O
##g	O
##kin	O
l	O
##ymph	O
##oma	O
(	O
n	O
=	O
1	O
)	O
and	O
le	O
##io	O
##my	O
##osa	O
##rc	O
##oma	O
(	O
n	O
=	O
1	O
)	O
.	O

A	O
pool	O
##ed	O
-	O
plasma	O
sample	O
was	O
analyzed	O
to	O
establish	O
the	O
mean	O
concentration	O
of	O
end	O
##ogen	O
##ous	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
by	O
the	O
L	O
##C	O
/	O
MS	O
/	O
MS	O
method	O
.	O

For	O
R	O
##v	O
##D	O
##2	O
the	O
most	O
sensitive	O
fragment	O
(	O
m	O
/	O
z	O
375	O
.	O
3	O
→	O
175	O
.	O
0	O
)	O
is	O
unlikely	O
to	O
be	O
formed	O
by	O
an	O
α	B
-	I
c	I
##lea	I
##vage	I
and	O
may	O
be	O
formed	O
by	O
a	O
γ	B
-	I
c	I
##lea	I
##vage	I
toward	O
the	O
h	O
##ydro	O
##xy	O
##l	O
group	O
or	O
another	O
mechanism	O
.	O

17	B
##β	I
-	I
N	I
,	I
N	I
-	I
Diet	I
##hyl	I
##car	I
##ba	I
##mo	I
##yl	I
-	I
4	I
-	I
met	I
##hyl	I
-	I
3	I
-	I
o	I
##to	I
-	I
4	I
-	I
a	I
##za	I
-	I
5	I
##α	I
-	I
and	I
##ros	I
##tan	I
##e	I
-	I
17	I
##α	I
-	I
car	I
##box	I
##ami	I
##de	I
(	O
4	O
-	O
MA	O
)	O
was	O
a	O
generous	O
gift	O
from	O
Dr	O
G	O
.	O
H	O
.	O
Ra	O
##smus	O
##son	O
(	O
Me	O
##rc	O
##k	O
Sharp	O
&	O
Do	O
##hm	O
##e	O
,	O
Ra	O
##hwa	O
##y	O
,	O
NJ	O
)	O
.	O

Ch	O
##rom	O
##oso	O
##mal	O
na	O
##d	O
##D	O
was	O
replaced	O
by	O
a	O
ka	B
##nam	I
##y	I
##cin	I
resistance	O
cassette	O
am	O
##plified	O
using	O
the	O
prime	O
##rs	O
Cam	O
##K	O
##an	O
##N	O
##ad	O
##D	O
F	O
and	O
R	O
prime	O
##rs	O
(	O
Table	O
S	O
##1	O
in	O
)	O
in	O
the	O
E	O
.	O
co	O
##li	O
strain	O
D	O
##Y	O
##37	O
##8	O
(	O
Yu	O
et	O
al	O
.	O
,	O
2000	O
)	O
containing	O
p	O
##N	O
##ad	O
##D	O
by	O
la	O
##mb	O
##da	O
Red	O
re	O
##comb	O
##ine	O
##ering	O
.	O

Our	O
previously	O
reported	O
and	O
current	O
data	O
consistently	O
show	O
that	O
activated	S
human	O
CD	O
##8	O
_	O
+	O
T	O
cell	O
co	O
-	O
in	O
##cu	O
##bate	O
##d	O
with	O
T	O
##EX	O
bind	O
Anne	O
##xin	O
##V	O
and	O
undergo	O
a	O
##pop	O
##tosis	O
(	O
Fi	O
##g	O
.	O

The	O
AU	O
##C	O
values	O
of	O
the	O
three	O
meta	O
##bol	O
##ites	O
for	O
disc	O
##rim	O
##inating	O
HC	O
##C	O
-	O
C	O
from	O
HC	O
##C	O
-	O
B	O
were	O
0	O
.	O
89	O
(	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
79	O
-	O
0	O
.	O
98	O
,	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
for	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
0	O
.	O
67	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
,	O
an	B
##hy	I
##dr	I
##ous	I
met	I
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
,	O
am	B
##mon	I
##ium	I
carbon	I
##ate	I
(	O
(	O
NH	O
_	O
4	O
)	O
_	O
2	O
CO	O
_	O
3	O
)	O
and	O
analytical	O
-	O
grade	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
as	O
7	O
.	O
5	O
M	O
NH	O
_	O
4	O
O	O
##A	O
##c	O
solution	O
)	O
were	O
also	O
purchased	O
from	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
.	O

Then	O
,	O
200	O
μ	O
##l	O
of	O
each	O
was	O
di	O
##lut	O
##ed	O
with	O
400	O
μ	O
##l	O
of	O
a	O
0	O
.	O
9	O
%	O
sa	B
##line	I
solution	O
(	O
Na	O
##C	O
##l	O
0	O
.	O
9	O
%	O
w	O
##t	O
/	O
vol	O
,	O
D	O
##2	O
##O	O
10	O
%	O
vol	O
/	O
vol	O
)	O
in	O
a	O
micro	O
##tub	O
##e	O
,	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
5	O
min	O
at	O
4	O
°C	O
at	O
12	O
000	O
g	O
.	O

Lac	B
##tate	I
and	O
c	B
##rea	I
##tin	I
##ine	I
are	O
currently	O
the	O
two	O
primary	O
meta	O
##bol	O
##ites	O
used	O
clinical	O
##ly	O
to	O
assess	O
the	O
degree	O
of	O
h	O
##y	O
##pox	O
##ic	O
-	O
is	O
##che	O
##mic	O
injury	O
due	O
to	O
per	O
##ina	O
##tal	O
as	O
##phy	O
##xia	O
.	O

However	O
,	O
for	O
particular	O
meta	O
##bol	O
##ites	O
,	O
80	O
%	O
Me	B
##OH	I
may	O
be	O
more	O
appropriate	O
.	O

The	O
exact	O
biological	O
mechanisms	O
that	O
explain	O
how	O
plasma	O
T	B
##MA	I
##O	I
concentrations	O
are	O
involved	O
in	O
glucose	S
metabolism	O
still	O
need	O
to	O
be	O
clarified	O
.	O

Met	O
##ab	O
##oli	O
##te	O
MS	O
##I	O
data	O
were	O
obtained	O
from	O
sections	O
of	O
fresh	O
frozen	O
tissue	O
specimens	O
with	O
matrix	O
-	O
assisted	O
laser	O
/	O
des	O
##or	O
##ption	O
ion	O
##ization	O
(	O
MA	O
##LD	O
##I	O
)	O
MS	O
##I	O
in	O
negative	O
polar	O
##ity	O
using	O
9	B
-	I
amino	I
##ar	I
##c	I
##rid	I
##ine	I
as	O
matrix	O
.	O

In	O
our	O
results	O
,	O
reduced	O
beta	B
##ine	I
enhanced	O
the	O
discrimination	O
of	O
PC	O
from	O
controls	O
.	O

Similarly	O
,	O
the	O
reduced	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
met	B
##han	I
##ol	I
and	O
u	B
##rea	I
in	O
group	O
3	O
,	O
two	O
meta	O
##bol	O
##ites	O
significantly	O
correlated	O
to	O
CR	O
##P	O
and	O
f	O
##eca	O
##l	O
ca	O
##l	O
##p	O
##rote	O
##ct	O
##in	O
,	O
may	O
serve	O
as	O
read	O
##out	O
for	O
monitoring	O
patients	O
that	O
recover	O
towards	O
re	O
##mission	O
and	O
show	O
growth	O
improvement	O
.	O

But	B
##yra	I
##te	I
was	O
the	O
meta	O
##bol	O
##ite	O
that	O
contributed	O
the	O
most	O
to	O
distinguishing	O
the	O
normal	O
subjects	O
from	O
those	O
with	O
ad	O
##eno	O
##ma	O
.	O

Una	O
##d	O
##ju	O
##sted	O
linear	O
re	O
##gression	O
correlation	O
##s	O
between	O
PA	O
##F	O
species	O
and	O
de	O
##pressive	O
symptoms	O
in	O
CA	O
##D	O
patients	O
(	O
n	O
=	O
26	O
)	O
Notes	O
:	O
No	O
##menclature	O
ad	O
##here	O
##s	O
to	O
the	O
recent	O
reorganization	O
of	O
onto	O
##logies	O
for	O
lip	O
##id	O
classes	O
and	O
the	O
curated	O
list	O
of	O
lip	O
##id	O
species	O
identified	O
by	O
the	O
C	O
##I	O
##H	O
##R	O
Training	O
Program	O
in	O
N	O
##eur	O
##ode	O
##gene	O
##rative	O
Li	O
##pid	O
##omi	O
##cs	O
(	O
CT	O
##P	O
##NL	O
)	O
teams	O
.	O
_	O
,	O
PC	B
(	I
O	I
-	I
20	I
:	I
4	I
/	I
2	I
:	I
0	I
)	I
,	O
for	O
example	O
,	O
defines	O
a	O
lip	O
##id	O
species	O
with	O
a	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
PC	O
)	O
polar	O
head	O
group	O
,	O
an	O
et	O
##her	O
link	O
##age	O
at	O
the	O
s	O
##n	O
-	O
1	O
position	O
(	O
O	O
-	O
)	O
with	O
a	O
chain	O
of	O
20	O
carbon	O
##s	O
,	O
and	O
2	O
carbon	O
##s	O
linked	O
by	O
an	O
est	O
##er	O
link	O
##age	O
at	O
the	O
s	O
##n	O
-	O
2	O
position	O
,	O
of	O
which	O
the	O
s	O
##n	O
-	O
1	O
chain	O
has	O
four	O
degrees	O
of	O
un	O
##sat	O
##uration	O
(	O
indicated	O
as	O
:	O
4	O
)	O
whereas	O
the	O
s	O
##n	O
-	O
2	O
chain	O
is	O
characterized	O
by	O
fully	O
saturated	O
ace	O
##ty	O
##l	O
group	O
(	O
referred	O
to	O
by	O
:	O
0	O
)	O
.	O

Lin	B
##ole	I
##nic	I
acid	I
and	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
which	O
were	O
significantly	O
contributed	O
to	O
the	O
diagnosis	O
of	O
T	O
##2	O
##DM	O
,	O
were	O
selected	O
by	O
the	O
binary	O
log	O
##istic	O
re	O
##gression	O
analysis	O
.	O

Cy	B
##ani	I
##din	I
and	O
PC	O
##A	O
can	O
also	O
undergo	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
.	O

d	O
HM	O
##D	O
##B	O
number	O
of	O
the	O
L	O
##MI	O
with	O
147	O
.	O
07	O
##64	O
m	O
/	O
z	O
.	O
Based	O
on	O
the	O
MS	O
/	O
MS	O
anal	O
##ytic	O
pattern	O
,	O
three	O
metabolic	O
compounds	O
—	O
HM	O
##D	O
##B	O
##00	O
##64	O
##1	O
(	B
_	B
L	I
-	I
g	I
##lut	I
##amine	I
)	O
,	O
HM	O
##D	O
##B	O
##0	O
##20	O
##31	O
(	B
u	B
##re	I
##ido	I
##is	I
##ob	I
##ut	I
##yric	I
acid	O
)	O
and	O
HM	O
##D	O
##B	O
##0	O
##34	O
##23	O
(	B
_	I
D	I
-	I
g	I
##lut	I
##amine	I
)	I
—	I
for	I
the	O
L	O
##MI	O
with	O
147	O
.	O
07	O
##64	O
m	O
/	O
z	O
were	O
selected	O
I	O
##dent	O
##ification	O
of	O
the	O
L	O
##MI	O
with	O
49	O
##6	O
.	O
33	O
##9	O
##8	O
m	O
/	O
z	O
.	O
a	O
Mass	O
s	O
##pect	O
##ra	O
of	O
49	O
##6	O
.	O
33	O
##9	O
##8	O
m	O
/	O
z	O
.	O
MS	O
and	O
MS	O
/	O
MS	O
pattern	O
analyses	O
were	O
performed	O
using	O
a	O
Triple	O
-	O
TO	O
##F	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
.	O

Berger	O
and	O
Wilson	O
showed	O
that	O
base	O
##line	O
resolution	O
of	O
drug	O
mixture	O
##s	O
(	O
including	O
a	O
series	O
of	O
anti	O
-	O
de	O
##press	O
##ants	O
,	O
anti	O
-	O
ps	O
##ych	O
##otics	O
and	O
s	O
##ti	O
##mu	O
##lants	O
)	O
could	O
be	O
obtained	O
by	O
adding	O
0	O
.	O
5	O
%	O
v	O
/	O
v	O
is	B
##op	I
##rop	I
##yla	I
##mine	I
to	O
a	O
met	O
##han	O
##ol	O
-	O
based	O
SF	O
##C	O
mobile	O
phase	O
,	O
,	O
,	O
while	O
De	O
K	O
##ler	O
##ck	O
et	O
al	O
.	O
have	O
used	O
is	B
##op	I
##rop	I
##yla	I
##mine	I
in	O
conjunction	O
with	O
T	O
##FA	O
to	O
increase	O
en	O
##anti	O
##ores	O
##ol	O
##ution	O
in	O
ch	O
##ira	O
##l	O
SF	O
##C	O
.	O

Race	O
##mic	O
Ph	O
##e	O
e	B
##pox	I
##ides	I
2	O
and	O
12	O
were	O
prepared	O
as	O
described	O
.	O

Therefore	O
,	O
do	B
##pa	I
##mine	I
and	O
its	O
metabolic	O
product	O
H	O
##VA	O
are	O
expected	O
to	O
be	O
lowered	O
in	O
CS	O
##F	O
of	O
the	O
elderly	O
,	O
and	O
AD	O
disease	O
progression	O
should	O
add	O
to	O
the	O
deficit	O
.	O

P	O
##rima	O
##rily	O
,	O
we	O
focused	O
our	O
analysis	O
on	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
in	O
particular	O
for	O
g	B
##ly	I
##cos	I
##phi	I
##ngo	I
##lip	I
##ids	I
such	O
as	O
gang	B
##lio	I
##side	I
GM	I
##3	I
and	O
G	O
##lu	O
##C	O
##er	O
species	O
.	O

The	O
form	O
##az	O
##an	O
was	O
fully	O
dissolved	O
by	O
100	O
μ	O
##L	O
D	B
##MS	I
##O	I
and	O
the	O
O	O
##D	O
(	O
average	O
optical	O
density	O
)	O
values	O
were	O
detected	O
by	O
a	O
micro	O
##plate	O
reader	O
(	O
Multi	O
##ska	O
##n	O
Mk	O
##3	O
,	O
The	O
##rm	O
##o	O
)	O
at	O
490	O
nm	O
.	O

To	O
determine	O
the	O
effect	O
of	O
alpha	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
on	O
proliferation	O
of	O
PC	O
##a	O
cell	O
lines	O
,	O
L	O
##NC	O
##a	O
##P	O
and	O
PC	O
##3	O
cells	O
were	O
seeded	O
in	O
12	O
well	O
plates	O
(	O
1	O
.	O
0	O
X	O
10	O
_	O
6	O
cells	O
per	O
well	O
)	O
in	O
complete	O
medium	O
.	O

oz	O
.	O
/	O
serving	O
)	O
;	O
c	O
)	O
m	B
##us	I
##ca	I
##dine	I
grape	O
juice	O
(	O
5	O
fl	O
.	O

As	O
##cite	O
##s	O
,	O
an	O
accumulation	O
of	O
per	B
##ito	I
##nea	I
##l	I
fluid	O
,	O
is	O
associated	O
with	O
poor	O
pro	O
##gno	O
##sis	O
of	O
certain	O
cancer	O
##s	O
.	O

Likewise	O
,	O
these	O
results	O
also	O
confirm	O
that	O
Te	O
##m	O
needs	O
to	O
be	O
bio	O
##tra	O
##ns	O
##formed	O
in	O
order	O
to	O
in	O
##hibit	O
human	O
RB	O
##C	O
AC	O
##h	O
##E	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
ability	O
of	O
bio	O
##tra	O
##ns	O
##formation	O
products	O
of	O
Te	O
##m	O
to	O
in	O
##hibit	O
AC	O
##h	O
##E	O
.	O
In	O
v	O
##it	O
##ro	O
determination	O
of	O
I	O
##C	O
_	O
50	O
of	O
RC	O
##B	O
AC	O
##h	O
##E	O
(	O
a	O
)	O
in	O
the	O
presence	O
of	O
Te	O
##m	O
-	O
o	O
##xi	O
##dized	O
meta	O
##bol	O
##ites	O
and	O
et	B
##hyl	I
-	I
para	I
##ox	I
##on	I
and	O
B	O
##u	O
##C	O
##h	O
##E	O
(	O
b	O
)	O
in	O
the	O
presence	O
of	O
Te	O
##m	O
-	O
do	O
##x	O
-	O
S	O
##O	O
_	O
2	O
and	O
et	B
##hyl	I
-	I
para	I
##ox	I
##on	I
.	O

Very	O
recently	O
,	O
the	O
dig	O
##est	O
##ion	O
of	O
Al	O
##b	O
with	O
try	O
##ps	O
##in	O
using	O
pressure	O
cycling	O
was	O
shown	O
to	O
efficiently	O
recover	O
the	O
T	O
##3	O
p	O
##eptide	O
A	O
_	O
21	O
L	O
##V	O
##L	O
##IA	O
##FA	O
##Q	O
##Y	O
##LL	O
##V	O
##L	O
##IA	O
##FA	O
##Q	O
##Y	O
##L	O
##Q	O
##Q	O
##CP	O
##F	O
##ED	O
##H	O
##V	O
##K	O
_	O
40	O
without	O
prior	O
den	O
##at	O
##uration	O
and	O
reduction	O
of	O
internal	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
.	O

PC	B
a	I
##e	I
C	I
##42	I
:	I
4	I
;	O
52	O
.	O

The	O
co	O
-	O
s	O
##ti	O
##mu	O
##lator	O
##y	O
molecule	O
CD	O
##40	O
##L	O
is	O
expressed	O
mainly	O
on	O
the	O
surface	O
of	O
activated	S
T	O
cells	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
B	O
cells	O
and	O
plate	O
##lets	O
.	O

H	O
##T	O
-	O
116	O
cells	O
(	O
left	O
)	O
or	O
H	O
##T	O
-	O
29	O
cells	O
(	O
right	O
)	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
the	O
indicated	O
concentrations	O
of	O
9	O
-	O
H	O
##SA	O
(	O
black	O
circles	O
)	O
or	O
o	B
##le	I
##ic	I
acid	I
(	O
open	O
circles	O
)	O
,	O
as	O
a	O
negative	O
control	O
for	O
24	O
h	O
.	O
Cell	O
via	O
##bility	O
was	O
measured	O
with	O
the	O
Cell	O
##T	O
##iter	O
96	O
_	O
®	O
A	O
##Q	O
_	O
u	O
##eous	O
One	O
Sol	O
##ution	O
Cell	O
Pro	O
##life	O
##ration	O
As	O
##say	O
kit	O
.	O

The	O
pathways	O
that	O
matched	O
based	O
on	O
Kyoto	O
Encyclopedia	O
of	O
Gene	O
##s	O
and	O
Gen	O
##ome	O
##s	O
(	O
K	O
##EG	O
##G	O
)	O
database	O
included	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
,	O
g	B
##ly	I
##cos	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
-	I
(	I
GP	I
##I	I
-	I
)	I
anchor	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
metabolism	O
,	O
alpha	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
metabolism	O
,	O
and	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
.	O

A	O
linear	O
mixed	O
-	O
effect	O
model	O
with	O
co	O
##var	O
##iate	O
##s	O
age	O
,	O
sex	O
and	O
random	O
effects	O
to	O
account	O
for	O
f	O
##ami	O
##lial	O
correlation	O
,	O
including	O
five	O
variants	O
for	O
g	B
##ly	I
##cine	I
and	O
three	O
variants	O
for	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
fit	O
individually	O
in	O
an	O
add	O
##itive	O
genetic	O
model	O
,	O
was	O
used	O
to	O
estimate	O
the	O
variance	O
in	O
plasma	O
meta	O
##bol	O
##ite	O
concentrations	O
explained	O
by	O
genetic	O
variants	O
.	O

GM	B
##3	I
lip	O
##ids	O
are	O
considered	O
the	O
simplest	O
members	O
of	O
the	O
gang	B
##lio	I
##side	I
family	O
,	O
containing	O
three	O
mon	B
##osa	I
##cc	I
##hari	I
##de	I
groups	O
attached	O
to	O
a	O
c	B
##era	I
##mi	I
##de	I
backbone	O
.	O

Additionally	O
,	O
35	O
%	O
of	O
all	O
Ce	B
##r	I
,	O
42	O
%	O
of	O
LP	O
##Cs	O
,	O
20	O
%	O
of	O
PC	O
##s	O
,	O
25	O
%	O
of	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ols	I
(	O
P	O
##G	O
##s	O
)	O
,	O
and	O
50	O
%	O
of	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##ose	I
##rine	I
##s	I
(	O
PS	O
##s	O
)	O
showed	O
greater	O
than	O
4	O
.	O
5	O
FC	O
,	O
indicating	O
that	O
these	O
lip	O
##id	O
classes	O
are	O
strongly	O
influenced	O
by	O
the	O
progress	O
of	O
and	O
/	O
or	O
recovery	O
from	O
E	O
##VD	O
.	O

Moreover	O
,	O
the	O
fatty	O
acids	O
and	O
o	B
##xy	I
##lip	I
##ins	I
are	O
present	O
in	O
both	O
est	O
##eri	O
##fied	O
and	O
non	O
-	O
est	O
##eri	O
##fied	O
forms	O
in	O
lip	O
##op	O
##rote	O
##ins	O
,	O
which	O
could	O
lead	O
to	O
differences	O
in	O
their	O
processing	O
and	O
effects	O
on	O
inflammation	O
.	O

Through	O
the	O
inter	O
##connected	O
coupling	O
mechanisms	O
between	O
various	O
molecules	O
and	O
enzymes	O
such	O
as	O
glucose	S
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
le	B
##uc	I
##ine	I
,	O
GA	B
##BA	I
,	O
and	O
g	O
##lut	O
##ama	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
insulin	O
secret	O
##ion	O
is	O
regulated	O
.	O

a	O
:	O
is	B
##ole	I
##uc	I
##ine	I
;	O
b	O
:	O
le	B
##uc	I
##ine	I
;	O
c	O
:	O
v	B
##ali	I
##ne	I
;	O
d	O
:	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
e	O
:	O
la	B
##ct	I
##ate	I
;	O
f	O
:	O
al	B
##ani	I
##ne	I
;	O
g	O
:	O
l	B
##ys	I
##ine	I
;	O
h	O
:	O
ace	B
##tate	I
;	O
i	O
:	O
g	B
##lut	I
##ama	I
##te	I
;	O
j	O
:	O
g	B
##lut	I
##amine	I
;	O
k	O
:	O
ace	B
##to	I
##ace	I
##tate	I
;	O
l	O
:	O
p	B
##yr	I
##u	I
##vate	I
;	O
m	O
:	O
c	B
##rea	I
##tine	I
;	O
n	O
:	O
c	B
##rea	I
##tin	I
##ine	I
;	O
o	O
:	O
glucose	S
;	O
p	O
:	O
g	B
##ly	I
##cine	I
;	O
q	O
:	O
u	B
##rea	I
;	O
r	O
:	O
t	B
##yr	I
##os	I
##ine	I
;	O
s	O
:	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

C	B
##rea	I
##tine	I
is	O
normally	O
involved	O
in	O
the	O
energy	O
supply	O
of	O
ma	O
##mmal	O
##ian	O
cells	O
.	O

G	O
##DM	O
was	O
diagnosed	O
independently	O
according	O
to	O
two	O
separate	O
sets	O
of	O
criteria	O
:	O
The	O
first	O
set	O
are	O
the	O
criteria	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
which	O
define	O
G	O
##DM	O
as	O
F	O
##P	O
##G	O
≥	O
7	O
.	O
0	O
or	O
2	O
-	O
h	O
P	B
##G	I
≥	O
7	O
.	O
8	O
mm	O
##ol	O
/	O
L	O
.	O

As	O
shown	O
in	O
,	O
higher	O
levels	O
of	O
con	O
##ju	O
##gated	O
bi	O
##le	O
acids	O
,	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
was	O
found	O
in	O
serum	O
and	O
urine	O
and	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olic	I
acid	I
and	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
were	O
found	O
in	O
the	O
serum	O
of	O
HC	O
##C	O
subjects	O
compared	O
with	O
healthy	O
controls	O
.	O

However	O
increased	O
o	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
and	O
car	B
##ni	I
##tine	I
were	O
detected	O
,	O
with	O
increased	O
g	B
##lu	I
##cona	I
##te	I
levels	O
seen	O
in	O
ben	O
##ign	O
vs	O
p	O
##T	O
##2	O
.	O

St	O
##ero	O
##ids	O
showing	O
smaller	O
gender	O
differences	O
included	O
21	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ison	I
##e	I
,	O
D	O
##H	O
##EA	O
and	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
which	O
were	O
6	O
%	O
to	O
24	O
%	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
men	O
than	O
women	O
.	O

15	B
.	I
2	I
-	I
O	I
##x	I
##oa	I
##di	I
##pate	I
.	O

Met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ol	I
est	O
##rogen	O
##s	O
have	O
reduced	O
est	O
##rogen	O
##icit	O
##y	O
,	O
are	O
readily	O
cleared	O
from	O
circulation	O
,	O
and	O
,	O
unlike	O
the	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
from	O
which	O
they	O
are	O
derived	O
,	O
are	O
not	O
readily	O
o	O
##xi	O
##dized	O
to	O
form	O
DNA	O
-	O
damaging	O
q	B
##uin	I
##ones	I
.	O

[	O
Google	O
Scholar	O
]	O
Wells	O
DS	O
,	O
Jan	O
##ssen	O
F	B
##W	I
,	O
Rue	O
##lius	O
H	B
##W	I
.	O

Neither	O
study	O
,	O
however	O
,	O
measured	O
free	O
or	O
bio	O
##ava	O
##ila	O
##ble	O
est	B
##rad	I
##iol	I
,	O
which	O
may	O
be	O
more	O
important	O
media	O
##tors	O
of	O
the	O
B	O
##MI	O
-	O
breast	O
cancer	O
association	O
.	O

RS	O
##Ds	O
of	O
the	O
individual	O
compounds	O
were	O
0	O
.	O
19	O
,	O
0	O
.	O
30	O
,	O
and	O
0	O
.	O
24	O
for	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
g	B
##ly	I
##cine	I
and	O
prop	B
##ion	I
##yl	I
##gly	I
##cine	I
in	O
the	O
sample	O
of	O
the	O
patient	O
with	O
prop	O
##ion	O
##ic	O
acid	O
##uria	O
(	O
PA	O
)	O
,	O
0	O
.	O
15	O
,	O
0	O
.	O
26	O
and	O
0	O
.	O
09	O
for	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
g	B
##lut	I
##amine	I
and	O
l	B
##ys	I
##ine	I
in	O
the	O
sample	O
of	O
the	O
patient	O
with	O
l	O
##ys	O
##in	O
##uri	O
##c	O
protein	O
into	O
##ler	O
##ance	O
(	O
LP	O
##I	O
)	O
and	O
0	O
.	O
33	O
for	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
in	O
the	O
sample	O
of	O
the	O
patient	O
with	O
p	O
##hen	O
##yl	O
##ket	O
##on	O
##uria	O
(	O
P	O
##K	O
##U	O
)	O
.	O

A	O
representative	O
spectrum	O
of	O
product	O
ion	O
scan	O
of	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	I
is	O
presented	O
in	O
red	O
ins	O
##et	O
.	O

Ch	O
##IP	O
products	O
were	O
directly	O
analyzed	O
by	O
Q	O
##PC	O
##R	O
ass	O
##ay	O
and	O
ER	O
##G	O
binding	O
was	O
evaluated	O
based	O
on	O
the	O
cycle	O
difference	O
between	O
Ch	O
##IP	O
-	O
en	O
##rich	O
##ed	O
ch	B
##roma	I
##tin	I
by	O
ER	O
##G	O
and	O
corresponding	O
I	O
##g	O
##G	O
.	O

Phase	O
correction	O
and	O
base	O
##line	O
correction	O
were	O
carefully	O
performed	O
,	O
and	O
the	O
_	O
1	O
H	O
chemical	O
shifts	O
referred	O
to	O
the	O
met	O
##hyl	O
double	O
##t	O
signal	O
of	O
la	B
##ct	I
##ate	I
(	O
δ	O
1	O
.	O
33	O
)	O
.	O

Ali	O
##q	O
##uo	O
##ts	O
,	O
dried	O
under	O
nitrogen	O
and	O
vacuum	O
-	O
des	O
##ic	O
##cated	O
,	O
were	O
subsequently	O
either	O
re	O
##con	O
##stituted	O
in	O
50	O
##μ	O
##L	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
acidic	O
conditions	O
)	O
or	O
in	O
50	O
##μ	O
##L	O
6	O
.	O
5	O
##m	O
##M	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
in	O
water	O
,	O
pH	O
8	O
(	O
basic	O
conditions	O
)	O
for	O
the	O
two	O
U	O
##HP	O
##LC	O
/	O
MS	O
/	O
MS	O
analyses	O
or	O
der	O
##iva	O
##tized	O
to	O
a	O
final	O
volume	O
of	O
50	O
##μ	O
##L	O
for	O
G	O
##C	O
/	O
MS	O
analysis	O
using	O
equal	O
parts	O
bi	B
##st	I
##rim	I
##eth	I
##yl	I
-	I
si	I
##ly	I
##l	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
and	O
solvent	O
mixture	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
:	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
:	O
c	O
##y	O
##c	O
##lo	O
##he	O
##xa	O
##ne	O
(	O
5	O
:	O
4	O
:	O
1	O
)	O
with	O
5	O
%	O
t	B
##rie	I
##thy	I
##lam	I
##ine	I
at	O
60	O
##°	O
##C	O
for	O
one	O
hour	O
.	O

Con	O
##sist	O
##ent	O
findings	O
from	O
this	O
2	O
-	O
phase	O
study	O
indicate	O
a	O
positive	O
association	O
between	O
plasma	O
T	B
##MA	I
##O	I
concentrations	O
and	O
G	O
##DM	O
.	O

Cho	B
##line	I
may	O
enter	O
the	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
–	I
met	I
##hi	I
##oni	I
##ne	I
cycle	O
through	O
its	O
oxidation	O
to	O
beta	B
##ine	I
which	O
is	O
used	O
as	O
a	O
substrate	O
in	O
the	O
B	O
##H	O
##MT	O
reaction	O
that	O
links	O
ch	B
##olin	I
##e	I
and	O
beta	B
##ine	I
to	O
the	O
f	O
##olate	O
-	O
dependent	O
met	O
##hi	O
##oni	O
##ne	O
pathway	O
.	O

Men	O
ex	O
##cre	O
##ted	O
significantly	O
more	O
3	B
,	I
5	I
-	I
di	I
##OH	I
-	I
ben	I
##zoic	I
acid	I
,	O
t	O
-	O
co	O
##uta	O
##ric	O
acid	O
,	O
na	B
##ring	I
##eni	I
##n	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
ace	I
##tic	I
acid	I
than	O
women	O
.	O

(	O
2016	O
)	O
also	O
showed	O
that	O
under	O
h	O
##y	O
##pox	O
##ic	O
signaling	O
,	O
h	B
##y	I
##pot	I
##au	I
##rine	I
behave	O
##s	O
as	O
an	O
on	O
##come	O
##ta	O
##bol	O
##ite	O
promoting	O
tumor	O
progression	O
.	O

5	B
-	I
H	I
##IA	I
##A	I
-	I
S	I
was	O
found	O
for	O
the	O
first	O
time	O
in	O
human	O
brain	O
.	O

However	O
,	O
it	O
is	O
not	O
possible	O
to	O
entirely	O
avoid	O
incorrect	O
urine	O
collections	O
and	O
therefore	O
,	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
ex	O
##cre	O
##tion	O
was	O
used	O
as	O
a	O
criterion	O
for	O
collection	O
complete	O
##ness	O
.	O

UP	O
##LC	O
-	O
E	O
##SI	O
/	O
MS	O
_	O
2	O
mass	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
add	O
##uc	O
##ts	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
modified	O
SA	O
formed	O
by	O
reaction	O
of	O
the	O
car	O
##cin	O
##ogen	O
with	O
human	O
SA	O
at	O
a	O
m	O
##olar	O
ratio	O
of	O
3	O
:	O
1	O
(	O
left	O
panel	O
)	O
and	O
0	B
.	I
3	I
:	I
1	I
(	I
right	I
panel	I
)	I
;	O
the	O
SA	O
was	O
dig	O
##ested	O
with	O
try	O
##ps	O
##in	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
is	O
mainly	O
produced	O
in	O
the	O
liver	O
through	O
the	O
u	B
##rea	I
cycle	O
and	O
is	O
further	O
cat	O
##ab	O
##oli	O
##zed	O
into	O
a	B
##rg	I
##ini	I
##ne	I
in	O
re	O
##nal	O
cells	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Figure	O
2	O
)	O
.	O

The	O
correlation	O
value	O
between	O
the	O
N	O
-	O
ace	O
##ty	O
##l	O
peak	O
for	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
and	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
at	O
ä	O
1	O
.	O
86	O
(	O
r	O
=	O
0	O
.	O
61	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
5	O
##−	O
##0	O
.	O
72	O
)	O
or	O
the	O
a	O
##romatic	O
pro	O
##ton	O
of	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
(	O
H	O
_	O
3	O
)	O
at	O
ä	O
6	O
.	O
96	O
(	O
r	O
=	O
0	O
.	O
63	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
53	O
##−	O
##0	O
.	O
73	O
)	O
was	O
somewhat	O
weaker	O
when	O
compared	O
to	O
the	O
correlation	O
between	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
and	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
resonance	O
at	O
δ	O
2	O
.	O
15	O
(	O
r	O
=	O
0	O
.	O
82	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
77	O
##−	O
##0	O
.	O
87	O
)	O
.	O

Path	O
##way	O
analysis	O
shows	O
the	O
alter	O
##nation	O
of	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
involved	O
in	O
bi	O
##le	O
acid	O
and	O
bi	O
##le	O
salt	O
metabolism	O
,	O
as	O
shown	O
in	O
.	O

Oct	B
##eno	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
,	O
was	O
positively	O
correlated	O
with	O
CP	O
##T	O
##1	O
##A	O
and	O
SL	O
##C	O
##25	O
##A	O
##20	O
(	O
r	O
=	O
0	O
.	O
250	O
,	O
p	O
=	O
0	O
.	O
00	O
##6	O
and	O
r	O
=	O
0	O
.	O
255	O
,	O
p	O
=	O
0	O
.	O
00	O
##5	O
,	O
respectively	O
)	O
,	O
while	O
de	B
##cano	I
##ly	I
##l	I
##car	I
##ni	I
##tine	I
was	O
negatively	O
correlated	O
with	O
CP	O
##T	O
##2	O
(	O
r	O
=	O
-	O
0	O
.	O
226	O
,	O
p	O
=	O
0	O
.	O
01	O
##3	O
)	O
.	O

48	O
h	O
my	O
##oc	O
##ty	O
##e	O
cells	O
and	O
24	O
h	O
R	O
##h	O
##30	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
glucose	I
were	O
extracted	O
as	O
described	O
in	O
the	O
methods	O
.	O

In	O
addition	O
,	O
comparison	O
of	O
the	O
concentrations	O
of	O
the	O
amino	O
acids	O
le	O
##uc	O
##ine	O
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
obtained	O
by	O
the	O
N	O
##MR	O
-	O
guided	O
approach	O
and	O
the	O
is	O
##oto	O
##pe	O
-	O
labeled	O
-	O
internal	O
-	O
standard	O
approach	O
showed	O
good	O
agreement	O
,	O
with	O
a	O
median	O
C	O
##V	O
of	O
6	O
.	O
2	O
%	O
between	O
the	O
two	O
approaches	O
.	O

Multiple	O
molecular	O
mechanisms	O
,	O
both	O
intrinsic	O
and	O
ex	O
##tri	O
##ns	O
##ic	O
,	O
con	O
##ver	O
##ge	O
to	O
alter	O
core	O
cellular	O
metabolism	O
and	O
provide	O
support	O
for	O
the	O
3	O
basic	O
needs	O
of	O
tumor	O
cells	O
:	O
rapid	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
(	O
ATP	O
)	O
generation	O
to	O
maintain	O
energy	O
status	O
;	O
increased	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
mac	O
##rom	O
##ole	O
##cule	O
##s	O
;	O
and	O
tightened	O
maintenance	O
of	O
appropriate	O
cellular	O
red	O
##ox	O
status	O
.	O

Whereas	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
can	O
lower	O
D	O
##H	O
##EA	O
levels	O
by	O
in	O
##hibition	O
of	O
P	O
##45	O
##0	O
17	O
,	O
pre	B
##dn	I
##ison	I
##e	I
could	O
have	O
a	O
similar	O
effect	O
by	O
feedback	O
in	O
##hibition	O
of	O
the	O
ad	O
##rena	O
##l	O
–	O
h	O
##y	O
##pot	O
##hala	O
##mic	O
–	O
pit	O
##uit	O
##ary	O
axis	O
.	O

A	O
correlation	O
between	O
an	O
increase	O
of	O
ad	B
##eni	I
##ne	I
and	O
g	B
##uan	I
##ine	I
and	O
cancer	O
cell	O
meta	O
##sta	O
##sis	O
due	O
to	O
im	O
##bal	O
##ance	O
of	O
en	O
##zy	O
##matic	O
activity	O
of	O
pu	B
##rine	I
metabolism	O
has	O
been	O
described	O
.	O

Women	O
assigned	O
to	O
the	O
intervention	O
were	O
asked	O
to	O
a	O
##bs	O
##tain	O
from	O
taking	O
any	O
non	O
##st	O
##ud	O
##y	O
supplement	O
##s	O
;	O
however	O
,	O
some	O
women	O
did	O
report	O
taking	O
additional	O
f	B
##olate	I
.	O

Pro	O
##tein	O
precipitation	O
with	O
Me	B
##OH	I
was	O
carried	O
out	O
by	O
adding	O
167	O
µ	O
##L	O
of	O
Me	B
##OH	I
,	O
and	O
the	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
a	O
new	O
tube	O
.	O

While	O
many	O
factors	O
(	O
i	O
.	O
e	O
.	O
acute	O
MI	O
)	O
are	O
associated	O
with	O
T	O
##x	O
##A	O
_	O
2	O
generation	O
in	O
the	O
absence	O
of	O
as	B
##pi	I
##rin	I
therapy	O
,	O
we	O
know	O
of	O
no	O
data	O
demonstrating	O
such	O
a	O
relationship	O
in	O
subjects	O
on	O
proven	O
adequate	O
as	B
##pi	I
##rin	I
therapy	O
.	O

Its	O
metabolism	O
could	O
be	O
disturbed	O
by	O
a	O
variety	O
of	O
mechanisms	O
in	O
patients	O
with	O
chronic	O
liver	O
disease	O
since	O
the	O
last	O
step	O
of	O
car	B
##ni	I
##tine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
but	B
##yr	I
##obe	I
##tain	I
##e	I
is	O
located	O
almost	O
exclusively	O
in	O
the	O
liver	O
,	O
which	O
decreases	O
its	O
expression	O
.	O

The	O
individual	O
ingredients	O
that	O
comprised	O
the	O
T	O
##MR	O
diet	O
were	O
analyzed	O
for	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
.	O

Car	B
##ni	I
##tine	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
are	O
essential	O
intermediate	O
##s	O
for	O
the	O
transfer	O
of	O
long	O
chain	O
fatty	O
acids	O
to	O
the	O
mit	O
##och	O
##ond	O
##ria	O
for	O
β	O
-	O
oxidation	O
and	O
an	O
accumulation	O
in	O
the	O
cell	O
may	O
imply	O
an	O
increased	O
demand	O
as	O
a	O
result	O
of	O
rapid	O
fatty	O
acid	O
oxidation	O
to	O
meet	O
higher	O
tumor	O
##al	O
energy	O
requirements	O
.	O

Sign	O
##ature	O
score	O
is	O
defined	O
as	O
the	O
normal	O
##ized	O
sum	O
of	O
meta	O
##bol	O
##ite	O
intensity	O
of	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
components	O
(	B
su	B
##cci	I
##nate	I
,	O
f	B
##uma	I
##rate	I
,	O
alpha	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
ma	B
##late	I
,	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
,	O
is	B
##oc	I
##it	I
##rate	I
,	O
and	O
c	O
##it	O
##rate	O
)	O
.	O

According	O
to	O
the	O
previously	O
reported	O
studies	O
,	O
elevated	O
concentration	O
of	O
3	B
-	I
(	I
3	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
)	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##ion	I
##ate	I
(	O
HP	O
##HP	O
##A	O
)	O
may	O
be	O
the	O
cat	O
##ab	O
##olis	O
##m	O
product	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
by	O
C	O
##los	O
##tri	O
##dium	O
species	O
.	O

The	O
gradient	O
el	O
##ution	O
consisted	O
of	O
0	O
.	O
1	O
%	O
ace	B
##tic	I
acid	I
in	O
water	O
(	O
solvent	O
A	O
)	O
and	O
0	O
.	O
1	O
%	O
ace	B
##tic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
solvent	O
B	O
)	O
.	O

Ad	O
##ju	O
##sted	O
OR	O
(	O
95	O
%	O
C	O
##I	O
)	O
of	O
MI	O
,	O
IS	O
,	O
and	O
I	O
##CH	O
for	O
Mean	O
Part	O
##icle	O
Di	O
##ame	O
##ter	O
,	O
Cho	B
##les	I
##tero	I
##l	I
,	O
Tri	B
##gly	I
##cer	I
##ides	I
,	O
and	O
A	O
##poli	O
##pop	O
##rote	O
##ins	O
as	O
Me	O
##as	O
##ured	O
by	O
Nuclear	O
Ma	O
##gnetic	O
Re	O
##son	O
##ance	O
S	O
##pect	O
##ros	O
##copy	O
E	O
##st	O
##imate	O
##s	O
are	O
OR	O
##s	O
per	O
1	O
-	O
SD	O
higher	O
metabolic	O
marker	O
.	O

Among	O
the	O
met	B
##hyl	I
##ar	I
##gin	I
##ines	I
,	O
MMA	O
is	O
the	O
most	O
potent	O
NO	O
##S	O
inhibitor	O
and	O
is	O
widely	O
employed	O
as	O
a	O
p	O
##har	O
##ma	O
##cological	O
inhibitor	O
of	O
NO	O
##S	O
##s	O
.	O
_	O
,	O
.	O

Based	O
on	O
our	O
results	O
,	O
R	O
##PC	O
was	O
more	O
appropriate	O
for	O
re	O
##sol	O
##ving	O
lip	O
##ids	O
while	O
H	O
##IL	O
##IC	O
resulted	O
in	O
better	O
separation	O
and	O
detection	O
of	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
.	O

The	O
level	O
of	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
AS	O
##16	O
##0	O
,	O
which	O
promotes	O
trans	O
##location	O
of	O
glucose	S
transport	O
##ers	O
to	O
the	O
cell	O
membrane	O
,	O
was	O
also	O
similar	O
between	O
the	O
groups	O
.	O

Odd	O
##s	O
ratios	O
and	O
95	O
%	O
C	O
##I	O
for	O
pro	O
##state	O
cancer	O
in	O
relation	O
to	O
16	O
-	O
K	O
##E	O
##2	O
and	O
17	O
-	O
e	O
##pi	O
##E	O
##3	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
OR	O
=	O
Odd	O
##s	O
Rat	O
##io	O
,	O
adjusted	O
for	O
age	O
,	O
race	O
,	O
smoking	O
status	O
,	O
presence	O
of	O
ben	O
##ign	O
pro	O
##static	O
h	O
##yper	O
##p	O
##lasia	O
and	O
time	O
of	O
urine	O
collection	O

To	O
address	O
this	O
hypothesis	O
,	O
we	O
developed	O
a	O
sensitive	O
ass	O
##ay	O
for	O
both	O
11	B
-	I
de	I
##hy	I
##dr	I
##o	I
-	I
TX	I
##B	I
##2	I
and	O
TX	O
##B	O
##2	O
,	O
using	O
cap	O
##illa	O
##ry	O
gas	O
ch	O
##roma	O
##tography	O
/	O
negative	O
-	O
ion	O
chemical	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

And	O
a	O
total	O
of	O
eleven	O
significant	O
meta	O
##bol	O
##ites	O
(	B
L	B
-	I
t	I
##yr	I
##os	I
##ine	I
;	O
L	O
##ys	O
##o	O
##PC	O
(	O
15	O
:	O
0	O
)	O
;	O
pro	B
##tor	I
##if	I
##am	I
##y	I
##cin	I
I	O
;	O
p	B
##ime	I
##lic	I
acid	I
;	O
an	B
##hy	I
##dr	I
##or	I
##ho	I
##do	I
##vi	I
##bri	I
##n	I
;	O
e	B
##pot	I
##hil	I
##one	I
A	O
;	O
mat	B
##ric	I
##in	I
;	O
b	B
##act	I
##eri	I
##oh	I
##op	I
##ane	I
-	I
32	I
,	I
33	I
,	I
34	I
,	I
35	I
-	I
te	I
##tro	I
##l	I
;	O
5	O
alpha	O
,	O
6	O
beta	B
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##stan	I
##ol	I
;	O
c	B
##yt	I
##och	I
##ala	I
##sin	I
A	O
;	O
and	O
(	B
6	I
##S	I
)	I
-	I
de	I
##hy	I
##dr	I
##ovo	I
##mi	I
##fo	I
##lio	I
##l	I
)	O
from	O
these	O
77	O
differential	O
##ly	O
en	O
##rich	O
##ed	O
meta	O
##bol	O
##ites	O
between	O
T	O
##2	O
##DM	O
and	O
I	O
##GR	O
could	O
be	O
an	O
##not	O
##ated	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
)	O
.	O

I	O
##mp	O
##aire	O
##d	O
conversion	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
to	O
t	B
##yr	I
##os	I
##ine	I
has	O
been	O
reported	O
in	O
re	O
##nal	O
disease	O
[	O
,	O
]	O
.	O

The	O
immune	O
system	O
bio	O
##mark	O
##ers	O
that	O
showed	O
significant	O
associations	O
with	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
are	O
reported	O
in	O
.	O

Pro	O
-	O
inflammatory	O
T	O
##GR	O
##L	O
was	O
en	O
##rich	O
##ed	O
in	O
EPA	O
and	O
EPA	O
-	O
derived	O
o	B
##xy	I
##lip	I
##ins	I
and	O
depleted	O
in	O
est	O
##eri	O
##fied	O
(	O
bound	O
)	O
C	O
##18	O
-	O
P	O
##U	O
##FA	O
-	O
derived	O
di	O
##ols	O
in	O
response	O
to	O
the	O
meal	O
,	O
reflecting	O
a	O
put	O
##ative	O
shift	O
in	O
s	O
##E	O
##H	O
and	O
L	O
##OX	O
activity	O
in	O
those	O
subjects	O
.	O

The	O
25	O
V	O
##OM	O
##s	O
m	B
-	I
c	I
##res	I
##ol	I
,	O
3	B
-	I
he	I
##pta	I
##non	I
##e	I
,	O
ben	B
##zen	I
##e	I
,	O
4	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
he	I
##pta	I
##non	I
##e	I
,	O
ace	B
##tone	I
,	O
1	B
-	I
prop	I
##ano	I
##l	I
,	O
non	B
##ana	I
##l	I
,	O
4	B
-	I
te	I
##rt	I
-	I
but	I
##yl	I
##phe	I
##no	I
##l	I
,	O
p	B
##hen	I
##ol	I
,	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
he	I
##pta	I
##non	I
##e	I
,	O
dim	B
##eth	I
##yl	I
##tri	I
##sul	I
##fi	I
##de	I
,	O
2	B
-	I
he	I
##xa	I
##non	I
##e	I
,	O
et	B
##han	I
##oi	I
##c	I
acid	I
,	O
fur	B
##an	I
,	O
he	B
##xa	I
##nal	I
,	O
2	B
-	I
met	I
##hyl	I
-	I
5	I
-	I
(	I
met	I
##hyl	I
##thi	I
##o	I
)	I
fur	I
##an	I
,	O
he	B
##pta	I
##nal	I
,	O
dim	B
##eth	I
##yl	I
##dis	I
##ulf	I
##ide	I
,	O
2	B
-	I
met	I
##hyl	I
##thi	I
##op	I
##hen	I
##e	I
,	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
-	I
2	I
,	I
2	I
-	I
dim	I
##eth	I
##yl	I
-	I
5	I
-	I
(	I
1	I
-	I
met	I
##hyl	I
-	I
1	I
-	I
prop	I
##en	I
##yl	I
)	I
fur	I
##an	I
,	O
2	B
-	I
met	I
##hyl	I
##but	I
##yric	I
acid	I
,	O
s	B
##ty	I
##rene	I
,	O
2	B
-	I
et	I
##hyl	I
##fu	I
##ran	I
,	O
et	B
##hyl	I
##ben	I
##zen	I
##e	I
and	O
th	B
##io	I
##phe	I
##ne	I
were	O
significantly	O
increased	O
in	O
the	O
urine	O
of	O
patients	O
with	O
ma	O
##li	O
##gnant	O
neo	O
##p	O
##lasia	O
.	O

All	O
three	O
branched	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
species	O
were	O
formed	O
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
additionally	O
gave	O
rise	O
to	O
_	O
13	O
C	O
_	O
3	O
prop	B
##ano	I
##yl	I
-	I
car	I
##ni	I
##tine	I
,	O
demonstrating	O
that	O
the	O
complete	O
is	B
##ole	I
##uc	I
##ine	I
degradation	O
pathway	O
is	O
active	O
in	O
these	O
cells	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
IL	O
-	O
10	O
was	O
the	O
next	O
most	O
commonly	O
associated	O
immune	O
system	O
bio	O
##mark	O
##er	O
,	O
being	O
positively	O
associated	O
with	O
4	O
try	O
##pt	O
##op	O
##han	O
-	O
related	O
variables	O
:	O
k	B
##yn	I
##uren	I
##ine	I
(	O
P	O
=	O
0	O
.	O
000	O
##2	O
)	O
,	O
the	O
K	O
##TR	O
(	O
P	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

,	O
different	O
sub	O
##c	O
##lass	O
##es	O
of	O
GP	S
,	O
including	O
P	O
##I	O
,	O
P	O
##E	O
,	O
PC	O
,	O
and	O
SM	O
,	O
were	O
well	O
separated	O
in	O
a	O
20	O
min	O
-	O
run	O
through	O
a	O
H	O
##IL	O
##IC	O
column	O
(	O
0	O
.	O
1	O
μ	O
##g	O
lip	O
##id	O
injection	O
per	O
run	O
)	O
.	O

Cho	B
##line	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
ho	B
##mos	I
##eri	I
##ne	I
levels	O
were	O
lower	O
in	O
T	O
##B	O
-	O
D	O
##M	O
compared	O
to	O
T	O
##B	O
,	O
and	O
,	O
in	O
contrast	O
to	O
other	O
anal	O
##yte	O
##s	O
,	O
did	O
not	O
normal	O
##ize	O
to	O
healthy	O
control	O
levels	O
during	O
anti	O
##biotic	O
treatment	O
.	O

This	O
process	O
would	O
be	O
mediated	O
by	O
the	O
activity	O
of	O
g	B
##ly	I
##cine	I
de	I
##hy	I
##dr	I
##ogen	I
##ase	I
(	I
de	I
##car	I
##box	I
##yla	I
##ting	I
)	I
(	O
G	O
##LD	O
##C	O
)	O
that	O
links	O
g	B
##ly	I
##cine	I
c	O
##lea	O
##vage	O
with	O
the	O
charging	O
of	O
the	O
f	B
##olate	I
cycle	O
.	O

He	B
##mat	I
##ox	I
##yl	I
##in	I
and	O
e	B
##os	I
##in	I
stain	O
##ing	O
revealed	O
minor	O
differences	O
between	O
alcohol	O
and	O
formal	B
##in	I
fixed	O
tissues	O
,	O
but	O
the	O
tissue	O
architecture	O
was	O
equally	O
well	O
-	O
preserved	O
in	O
all	O
cases	O
(	O
Figure	O
)	O
.	O

Supporting	O
these	O
results	O
,	O
we	O
also	O
found	O
an	O
over	O
##ex	O
##press	O
##ion	O
of	O
AD	O
##SL	O
,	O
the	O
enzyme	O
in	O
charge	O
of	O
AM	B
##P	I
synthesis	O
,	O
both	O
at	O
a	O
genetic	O
and	O
at	O
a	O
protein	O
level	O
in	O
tumor	O
tissue	O
for	O
AC	O
and	O
SC	O
##C	O
cases	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

As	O
in	O
earlier	O
studies	O
,	O
levels	O
of	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
were	O
significantly	O
associated	O
with	O
the	O
serum	O
vitamin	B
D	I
transport	O
gene	O
(	O
G	O
##C	O
)	O
on	O
chromosome	O
4	O
.	O

The	O
corresponding	O
levels	O
at	O
Week	O
20	O
were	O
1	O
.	O
35	O
±	O
0	O
.	O
93	O
(	O
S	O
.	O
D	O
.	O
)	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
N	O
=	O
209	O
)	O
for	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
74	O
.	O
2	O
±	O
142	O
(	O
S	O
.	O
D	O
.	O
)	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
N	O
=	O
210	O
)	O
for	O
P	O
##GE	O
-	O
M	O
.	O

Mat	O
##ern	O
##al	O
beta	B
##ine	I
concentrations	O
may	O
also	O
be	O
negatively	O
related	O
to	O
birth	O
weight	O
,	O
although	O
other	O
investigators	O
have	O
reported	O
no	O
association	O
.	O

More	O
importantly	O
,	O
3	O
meta	O
##bol	O
##ites	O
of	O
ace	B
##to	I
##ace	I
##tate	I
,	O
ace	B
##tone	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
3	O
-	O
H	O
##B	O
)	O
were	O
increased	O
remarkably	O
in	O
plasma	O
of	O
G	O
##CT	O
patients	O
.	O

In	O
the	O
context	O
of	O
inflammation	O
,	O
it	O
might	O
be	O
of	O
interest	O
that	O
C	B
-	I
g	I
##ly	I
##cos	I
##yla	I
##ted	I
try	I
##pt	I
##op	I
##han	I
can	O
also	O
be	O
found	O
in	O
IL	O
-	O
12	O
and	O
components	O
of	O
the	O
complement	O
system	O
.	O

All	O
L	O
##ys	O
##o	O
##PC	O
##s	O
differential	O
##ly	O
detected	O
in	O
our	O
H	O
##FS	O
group	O
were	O
up	O
##re	O
##gu	O
##lated	O
,	O
which	O
were	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
,	I
18	I
:	I
2	I
,	I
18	I
:	I
3	I
,	I
20	I
:	I
0	I
,	I
20	I
:	I
1	I
,	I
20	I
:	I
2	I
,	I
20	I
:	I
4	I
,	I
22	I
:	I
5	I
,	I
22	I
:	I
6	I
,	O
and	O
24	O
:	O
1	O
)	O
.	O

M	O
##OL	O
##M	O
##13	O
cells	O
were	O
culture	O
##d	O
in	O
R	O
##os	O
##well	O
Park	O
Memorial	O
Institute	O
(	O
R	O
##PM	O
##I	O
)	O
1640	O
medium	O
coupled	O
with	O
10	O
%	O
f	O
##etal	O
calf	O
serum	O
,	O
100	O
U	O
/	O
m	O
##L	O
pen	B
##ici	I
##llin	I
,	O
and	O
50	O
µ	O
##g	O
/	O
m	O
##L	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
(	O
G	O
##ib	O
##co	O
-	O
In	O
##vi	O
##tro	O
##gen	O
,	O
Carl	O
##s	O
##bad	O
,	O
CA	O
,	O
151	O
##40	O
-	O
122	O
)	O
.	O

Indeed	O
,	O
we	O
have	O
previously	O
demonstrated	O
by	O
using	O
this	O
approach	O
that	O
the	O
total	O
amount	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
allowed	O
the	O
un	O
##bia	O
##sed	O
discrimination	O
of	O
the	O
grade	O
of	O
s	O
##te	O
##ato	O
##sis	O
much	O
better	O
than	O
his	O
##to	O
##logical	O
examination	O
usually	O
considered	O
as	O
the	O
“	O
gold	O
standard	O
”	O
.	O

In	O
a	O
twin	O
study	O
,	O
consisting	O
of	O
14	O
pairs	O
of	O
young	O
-	O
adult	O
mon	O
##oz	O
##y	O
##got	O
##ic	O
twins	O
disco	O
##rda	O
##nt	O
for	O
o	O
##besity	O
,	O
several	O
T	B
##G	I
species	O
correlated	O
significantly	O
with	O
B	O
##MI	O
and	O
sub	O
##cut	O
##aneous	O
fat	O
measurement	O
.	O

The	O
pathways	O
with	O
the	O
strongest	O
associations	O
with	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##os	O
##ity	O
(	O
based	O
on	O
P	O
values	O
derived	O
from	O
pathway	O
en	O
##rich	O
##ment	O
analyses	O
reflecting	O
the	O
overall	O
association	O
of	O
the	O
meta	O
##bol	O
##ite	O
set	O
)	O
included	O
those	O
using	O
amino	O
acids	O
as	O
substrates	O
for	O
bio	O
##sy	O
##nt	O
##hetic	O
processes	O
,	O
such	O
as	O
amino	B
##acy	I
##l	I
‐	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
P	O
=	O
3	O
.	O
39	O
##×	O
##10	O
_	O
−	O
##10	O
)	O
and	O
branched	O
‐	O
chain	O
amino	O
acid	O
degradation	O
(	O
P	O
=	O
1	O
.	O
30	O
##×	O
##10	O
_	O
−	O
##4	O
)	O
.	O

The	O
ratio	O
of	O
AC	O
C	B
##2	I
/	I
car	I
##ni	I
##tine	I
is	O
an	O
estimate	O
of	O
β	O
-	O
oxidation	O
of	O
even	O
-	O
numbered	O
FA	O
##s	O
and	O
it	O
seems	O
to	O
be	O
higher	O
in	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
but	O
no	O
significant	O
differences	O
are	O
detected	O
among	O
3	O
groups	O
.	O

S	O
##q	O
##CC	O
,	O
sq	O
##ua	O
##mous	O
cell	O
lung	O
cancer	O
;	O
CE	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
;	O
PC	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
e	O
##PC	O
,	O
PC	O
with	O
one	O
et	O
##her	O
-	O
linked	O
(	O
al	O
##ky	O
##l	O
or	O
al	O
##ken	O
##yl	O
)	O
chain	O
;	O
LP	O
##C	O
,	O
l	B
##ys	I
##o	I
-	I
PC	I
;	O
P	O
##I	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
.	O

He	O
##nd	O
##rik	O
##sen	O
et	O
al	O
stressed	O
that	O
g	B
##lut	I
##ami	I
##c	I
acid	I
up	O
##take	O
and	O
synthesis	O
is	O
important	O
for	O
full	O
St	O
##re	O
##pt	O
##oc	O
##oc	O
##cus	O
pneumonia	O
##e	O
fitness	O
and	O
v	O
##ir	O
##ule	O
##nce	O
.	O

The	O
first	O
group	O
was	O
persons	O
who	O
did	O
not	O
report	O
use	O
of	O
any	O
anal	O
##ges	O
##ics	O
but	O
for	O
whom	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
/	O
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
were	O
detected	O
in	O
the	O
urine	O
specimen	O
at	O
1	O
or	O
more	O
visits	O
(	O
put	O
##ative	O
under	O
##re	O
##port	O
##ers	O
)	O

A	O
total	O
of	O
34	O
key	O
meta	O
##bol	O
##ites	O
associated	O
with	O
BC	O
##a	O
were	O
identified	O
;	O
ii	O
)	O
three	O
metabolic	O
pathways	O
,	O
namely	O
g	B
##lut	I
##ath	I
##ione	I
,	O
pu	B
##rine	I
and	O
th	B
##iam	I
##ine	I
metabolism	O
,	O
were	O
altered	O
in	O
BC	O
##a	O
,	O
and	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
was	O
the	O
consistently	O
altered	O
pathway	O
in	O
en	O
##rich	O
##ment	O
and	O
pathway	O
analyses	O
(	O
and	O
,	O
and	O
)	O
;	O
ii	O
##i	O
)	O
among	O
the	O
34	O
cancer	O
-	O
associated	O
meta	O
##bol	O
##ites	O
,	O
the	O
levels	O
of	O
bi	B
##li	I
##ru	I
##bin	I
and	O
re	B
##tina	I
##l	I
recovered	O
after	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
injection	O
,	O
suggesting	O
that	O
these	O
two	O
are	O
likely	O
the	O
targets	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
treatment	O
(	O
,	O
)	O
;	O
i	O
##v	O
)	O
the	O
effects	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
on	O
normal	O
bladder	O
tissues	O
were	O
also	O
investigated	O
,	O
and	O
it	O
was	O
de	O
##duced	O
that	O
his	B
##tamine	I
may	O
have	O
the	O
ability	O
to	O
protect	O
against	O
disease	O
re	O
##cu	O
##rrence	O
,	O
whereas	O
th	B
##iam	I
##ine	I
may	O
be	O
involved	O
in	O
the	O
side	O
effects	O
of	O
treatment	O
(	O
,	O
)	O
,	O
which	O
requires	O
further	O
confirmation	O
in	O
future	O
studies	O
.	O

Cell	O
##s	O
were	O
rapidly	O
washed	O
(	O
20	O
s	O
)	O
with	O
washing	O
buffer	O
(	O
140	O
m	O
##M	O
Na	O
##C	O
##l	O
,	O
5	O
m	O
##M	O
H	O
##EP	O
##ES	O
,	O
pH	O
7	O
.	O
4	O
,	O
37	O
°C	O
)	O
before	O
they	O
were	O
que	O
##nched	O
by	O
ice	O
-	O
cold	O
Me	B
##OH	I
solution	O
.	O

Ana	O
##ly	O
##ses	O
and	O
valid	O
##ation	O
studies	O
taking	O
into	O
account	O
the	O
complete	O
clinical	O
and	O
path	O
##ological	O
parameters	O
,	O
including	O
men	O
##op	O
##aus	O
##al	O
status	O
,	O
est	B
##rogen	I
and	O
pro	B
##ges	I
##tero	I
##ne	I
receptors	O
for	O
breast	O
cancer	O
,	O
and	O
risk	O
factors	O
including	O
smoking	O
and	O
alcohol	O
drinking	O
for	O
oral	O
cancer	O
##s	O
are	O
essential	O
before	O
actual	O
diagnostic	O
application	O
of	O
the	O
classification	O
model	O
obtained	O
in	O
this	O
study	O
.	O

In	O
tissues	O
,	O
we	O
observed	O
low	O
levels	O
of	O
SM	B
(	I
16	I
:	I
0	I
)	I
,	O
PC	B
(	I
32	I
:	I
0	I
)	I
,	O
PC	B
(	I
38	I
:	I
4	I
)	I
and	O
high	O
levels	O
of	O
PC	B
(	I
34	I
:	I
2	I
)	I
,	O
PC	B
(	I
34	I
:	I
1	I
)	I
,	O
PC	B
(	I
36	I
:	I
3	I
)	I
and	O
PC	B
(	I
36	I
:	I
2	I
)	I
in	O
M	O
##F	O
cancer	O
areas	O
compared	O
to	O
adjacent	O
non	O
-	O
cancer	O
areas	O
(	O
Figure	O
)	O
.	O

Indeed	O
,	O
we	O
have	O
demonstrated	O
that	O
a	O
random	O
forests	O
-	O
based	O
mathematical	O
approach	O
was	O
enabled	O
to	O
character	O
##ize	O
he	O
##pa	O
##tic	O
lip	O
##id	O
signature	O
specific	O
to	O
NAS	O
##H	O
in	O
m	B
##uri	I
##ne	I
models	O
.	O

Me	O
##asures	O
of	O
su	B
##lf	I
##ora	I
##pha	I
##ne	I
meta	O
##bol	O
##ites	O
in	O
urine	O
indicated	O
that	O
bio	O
##ava	O
##ila	O
##bility	O
did	O
not	O
decline	O
over	O
the	O
12	O
-	O
week	O
daily	O
dos	O
##ing	O
period	O
.	O

H	O
_	O
6	O
]	O
h	O
##ydro	O
##xy	O
##cho	O
##les	O
##tero	O
##l	O
(	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
)	O
in	O
prop	B
##an	I
-	I
2	I
-	I
o	I
##l	I
(	O
4	O
ng	O
/	O
μ	O
##l	O
)	O
,	O
in	O
an	O
ultra	O
##sonic	O
bath	O
.	O

Omega	O
O	O
##xi	O
##dation	O
(	O
C	O
;	O
p	O
=	O
6	O
.	O
94	O
##45	O
##E	O
-	O
11	O
and	O
F	O
##DR	O
=	O
3	O
.	O
108	O
##5	O
##E	O
-	O
10	O
)	O
,	O
Non	O
-	O
Essential	O
Am	O
##ino	O
acids	O
other	O
than	O
G	O
##lu	O
and	O
As	O
##p	O
(	O
D	O
;	O
p	O
=	O
1	O
.	O
530	O
##6	O
##E	O
-	O
47	O
and	O
F	O
##DR	O
=	O
7	O
.	O
1938	O
##E	O
-	O
46	O
)	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
E	O
;	O
p	O
=	O
1	O
.	O
108	O
##8	O
##E	O
-	O
18	O
and	O
F	O
##DR	O
=	O
6	O
.	O
74	O
##E	O
-	O
19	O
)	O
and	O
up	O
##take	O
of	O
fatty	O
acids	O
to	O
mit	O
##och	O
##ond	O
##ria	O
(	O
CP	O
##T	O
##1	O
)	O
(	O
F	O
;	O
p	O
=	O
0	O
.	O
00	O
##16	O
##12	O
##6	O
and	O
F	O
##DR	O
=	O
0	O
.	O
00	O
##26	O
##13	O
##6	O
)	O
.	O

Next	O
,	O
the	O
si	O
##lani	O
##zation	O
of	O
the	O
cap	O
##illa	O
##ry	O
inner	O
wall	O
with	O
γ	B
-	I
MA	I
##PS	I
was	O
performed	O
as	O
described	O
elsewhere	O
.	O

A	O
total	O
of	O
61	O
%	O
of	O
the	O
compounds	O
were	O
identified	O
in	O
all	O
three	O
body	O
fluids	O
,	O
such	O
as	O
3	B
-	I
(	I
3	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
)	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##ano	I
##ic	I
acid	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
,	O
but	B
##yric	I
acid	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
,	O
etc	O
.	O

Moreover	O
,	O
2	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
is	O
a	O
marker	O
of	O
insulin	O
resistance	O
/	O
impaired	O
glucose	S
tolerance	O
.	O
49	O
Shan	O
##ta	O
##vas	O
##ink	O
##ul	O
et	O
al	O
observed	O
a	O
decrease	O
in	O
plasma	O
2	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
a	O
positive	O
correlation	O
between	O
change	O
in	O
insulin	O
resistance	O
and	O
change	O
in	O
2	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
by	O
6	O
months	O
post	O
‐	O
R	O
##Y	O
##GB	O
.	O
50	O
Hence	O
,	O
reduction	O
in	O
2	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
also	O
points	O
to	O
improved	O
insulin	O
sensitivity	O
in	O
our	O
subjects	O
.	O

The	O
horizontal	O
lines	O
in	O
the	O
R	O
##OC	O
boxes	O
indicate	O
the	O
highest	O
sensitivity	O
and	O
specific	O
##ity	O
in	O
separating	O
control	B
-	I
from	I
me	O
##lo	O
##xi	O
##cam	O
-	O
treated	O
animals	O
.	O

For	O
both	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
,	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
conditions	O
were	O
also	O
somewhat	O
different	O
from	O
those	O
described	O
previously	O
.	O

The	O
y	O
-	O
intercept	O
represents	O
the	O
amount	O
present	O
in	O
each	O
pool	O
##ed	O
sample	O
before	O
addition	O
of	O
co	B
##tin	I
##ine	I
or	O
N	O
##NA	O
##L	O
.	O

Un	O
##iva	O
##ria	O
##te	O
correlation	O
with	O
time	O
storage	O
duration	S
was	O
tested	O
by	O
using	O
the	O
non	O
##par	O
##ame	O
##tric	O
S	O
##pear	O
##man	O
coefficient	O
of	O
rank	O
correlation	O
(	O
K	O
##va	O
##m	O
and	O
V	O
##ida	O
##kovic	O
)	O
and	O
controlling	O
the	O
false	O
discovery	O
rate	O
(	O
Benjamin	O
##i	O
and	O
Ho	O
##ch	O
##berg	O
)	O
at	O
a	O
0	O
.	O
01	O
threshold	O
.	O

Stock	O
solutions	O
of	O
AB	O
##T	O
-	O
88	O
##8	O
,	O
M	O
##8	O
,	O
and	O
z	O
##ile	O
##uto	O
##n	O
(	O
internal	O
standard	O
)	O
were	O
prepared	O
in	O
met	B
##han	I
##ol	I
at	O
a	O
concentration	O
of	O
1	O
mg	O
/	O
m	O
##l	O
,	O
and	O
stored	O
in	O
glass	O
via	O
##ls	O
at	O
−	O
20	O
##°	O
##C	O
.	O

C	O
)	O
Fr	O
##action	O
5	O
,	O
Y	O
*	O
T	O
##K	O
(	B
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
Y	I
)	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
30	O
##9	O
.	O
9	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
modified	O
;	O
D	O
)	O
Y	O
*	O
T	O
##K	O

Interest	O
##ingly	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
beta	B
##ine	I
in	O
those	O
with	O
is	O
##che	O
##mic	O
versus	O
non	O
-	O
is	O
##che	O
##mic	O
et	O
##iol	O
##ogies	O
,	O
nor	O
across	O
MP	O
##O	O
or	O
h	O
##s	O
##CR	O
##P	O
levels	O
.	O

(	O
B	O
)	O
Kaplan	O
–	O
Mei	O
##er	O
curve	O
est	O
##imation	O
of	O
the	O
survival	O
rate	O
of	O
the	O
patients	O
according	O
to	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
la	B
##ct	I
##ate	I
ratio	O
at	O
the	O
cut	O
##off	O
value	O
.	O

The	O
de	O
##ami	O
##nation	O
of	O
ad	B
##eni	I
##ne	I
could	O
also	O
be	O
a	O
possible	O
source	O
for	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
.	O

We	O
could	O
not	O
observe	O
additional	O
species	O
upon	O
is	B
##op	I
##rop	I
##ano	I
##l	I
addition	O
and	O
no	O
common	O
pattern	O
in	O
the	O
increased	O
D	O
##G	O
species	O
for	O
the	O
individual	O
samples	O
.	O

For	O
quality	O
assurance	O
,	O
4	O
different	O
quality	O
-	O
control	O
samples	O
with	O
T	B
##MA	I
##O	I
concentrations	O
ranging	O
between	O
4	O
and	O
400	O
μ	O
##g	O
/	O
L	O
were	O
used	O
for	O
the	O
evaluation	O
of	O
accuracy	O
and	O
precision	O
.	O

The	O
hi	O
##era	O
##rch	O
##ical	O
cluster	O
##ing	O
revealed	O
a	O
cluster	O
consisting	O
of	O
thy	B
##ro	I
##xin	I
##e	I
and	O
do	B
##pa	I
##mine	I
from	O
the	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
as	O
well	O
as	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
and	O
op	O
##hta	O
##lma	O
##te	O
that	O
displayed	O
positive	O
correlation	O
##s	O
to	O
the	O
cognitive	O
measurements	O
and	O
T	O
##FC	O
,	O
and	O
negative	O
correlation	O
##s	O
to	O
DB	O
##S	O
,	O
T	O
##MS	O
and	O
to	O
the	O
five	O
year	O
risk	O
of	O
onset	O
.	O

Follow	O
-	O
up	O
participants	O
were	O
less	O
frequently	O
of	O
non	O
-	O
Nordic	O
ethnicity	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
had	O
lower	O
pre	O
##ges	O
##tation	O
##al	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
and	O
a	O
lower	O
fast	O
##ing	O
glucose	S
value	O
at	O
G	O
##DM	O
diagnosis	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
than	O
women	O
who	O
could	O
not	O
be	O
reached	O
or	O
chose	O
not	O
to	O
participate	O
.	O

A	O
##cc	O
##ura	O
##te	O
mass	O
was	O
maintained	O
by	O
introduction	O
of	O
Lock	O
##S	O
##pra	O
##y	O
interface	O
of	O
su	B
##lf	I
##adi	I
##met	I
##ho	I
##xin	I
##e	I
(	O
311	O
.	O
08	O
##14	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
or	O
30	O
##9	O
.	O
06	O
##5	O
##8	O
[	O
M	O
##−	O
##H	O
]	O
_	O
−	O
)	O
at	O
a	O
concentration	O
of	O
250	O
p	O
##g	O
/	O
μ	O
##L	O
in	O
50	O
%	O
a	O
##que	O
##ous	O
AC	O
##N	O
and	O
a	O
rate	O
of	O
150	O
μ	O
##L	O
/	O
min	O
.	O

HP	O
##LC	O
-	O
grade	O
met	B
##han	I
##ol	I
for	O
L	O
##C	O
–	O
MS	O
was	O
supplied	O
by	O
J	O
.	O
T	O
.	O
Baker	O
(	O
G	O
##ries	O
##heim	O
,	O
Germany	O
)	O
.	O

In	O
insects	O
,	O
including	O
R	O
.	O
pro	O
##lix	O
##us	O
,	O
e	B
##ico	I
##san	I
##oids	I
media	O
##te	O
specific	O
cell	O
actions	O
,	O
including	O
p	O
##ha	O
##go	O
##cy	O
##tosis	O
,	O
micro	O
##ag	O
##g	O
##regation	O
,	O
nod	O
##ulation	O
,	O
hem	O
##oc	O
##yte	O
migration	O
,	O
hem	O
##oc	O
##yte	O
spreading	O
and	O
the	O
release	O
of	O
prop	O
##hen	O
##olo	O
##xi	O
##das	O
##e	O
in	O
reaction	O
to	O
bacterial	O
and	O
pro	O
##to	O
##zo	O
##an	O
challenges	O
,	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
either	O
en	O
##zy	O
##matical	O
##ly	O
meta	O
##bol	O
##ised	O
via	O
x	B
##ant	I
##hine	I
to	O
u	B
##ric	I
acid	I
,	O
or	O
re	O
-	O
u	O
##til	O
##ised	O
to	O
in	B
##os	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
in	O
the	O
n	O
##uc	O
##leo	O
##tide	O
salvage	O
pathway	O
.	O

Interest	O
##ingly	O
,	O
a	O
recent	O
study	O
showed	O
that	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
is	O
also	O
one	O
of	O
the	O
meta	O
##bol	O
##ites	O
of	O
do	B
##pa	I
##mine	I
(	O
D	O
##A	O
)	O
;	O
further	O
##more	O
,	O
it	O
can	O
cross	O
the	O
B	O
##BB	O
and	O
the	O
levels	O
of	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
could	O
change	O
in	O
the	O
brain	O
in	O
a	O
regional	O
-	O
and	O
dose	O
-	O
related	O
manner	O
.	O

The	O
association	O
was	O
stronger	O
in	O
those	O
with	O
lower	O
serum	O
levels	O
of	O
ch	B
##olin	I
##e	I
.	O

For	O
N	O
##MR	O
analysis	O
,	O
the	O
final	O
concentration	O
of	O
each	O
meta	O
##bol	O
##ite	O
in	O
the	O
model	O
mixture	O
was	O
1	O
m	O
##M	O
in	O
600	O
μ	O
##L	O
D	O
_	O
2	O
O	O
with	O
20	O
m	O
##M	O
phosphate	S
buffer	O
.	O

Paris	O
et	O
al	O
.	O
used	O
L	O
##C	O
-	O
MS	O
to	O
generate	O
and	O
valid	O
##ate	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
of	O
v	O
##it	O
##re	O
##ous	O
samples	O
,	O
and	O
pathway	O
en	O
##rich	O
##ment	O
analysis	O
revealed	O
that	O
a	B
##rg	I
##ini	I
##ne	I
metabolism	O
was	O
the	O
pathway	O
per	O
##tur	O
##bed	O
in	O
the	O
DR	O
group	O
.	O

Da	O
##bra	O
##fen	O
##ib	O
was	O
dissolved	O
in	O
D	B
##MS	I
##O	I
to	O
a	O
concentration	O
of	O
1	O
mg	O
/	O
m	O
##L	O
.	O
Internal	O
standard	O
er	B
##lot	I
##ini	I
##b	I
-	I
d	I
##6	I
was	O
dissolved	O
in	O
D	B
##MS	I
##O	I
to	O
a	O
concentration	O
of	O
1	O
.	O
9	O
mg	O
/	O
m	O
##L	O
.	O
Cal	O
##ib	O
##ration	O
and	O
quality	O
control	O
(	O
Q	O
##C	O
)	O
working	O
stock	O
solutions	O
were	O
prepared	O
from	O
the	O
stock	O
solutions	O
by	O
di	O
##lution	O
in	O
an	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
50	O
:	O
50	O
,	O
v	O
/	O
v	O
)	O
mixture	O
.	O

In	O
fact	O
,	O
a	O
positive	O
correlation	O
with	O
PR	O
##O	O
##G	O
levels	O
was	O
observed	O
for	O
Sa	O
and	O
c	B
##era	I
##mi	I
##des	I
.	O

Micro	O
##bio	O
##ta	O
from	O
donor	O
D	O
##5	O
were	O
the	O
most	O
effective	O
in	O
meta	O
##bol	O
##izing	O
re	B
##s	I
##ver	I
##at	I
##rol	I
(	O
11	O
±	O
1	O
%	O
occurred	O
after	O
48	O
h	O
)	O
,	O
and	O
were	O
able	O
to	O
de	B
##hy	I
##dr	I
##ox	I
##yla	I
##te	I
p	O
##ice	O
##ata	O
##nn	O
##ol	O
.	O

Thus	O
the	O
clearance	O
of	O
in	O
##tra	O
##ven	O
##ously	O
administered	O
f	O
##ent	O
##any	O
##l	O
was	O
significantly	O
reduced	O
(	O
by	O
−	O
##23	O
%	O
and	O
−	O
##16	O
%	O
)	O
by	O
v	B
##ori	I
##cona	I
##zo	I
##le	I
and	O
flu	B
##cona	I
##zo	I
##le	I
(	O
both	O
C	O
##YP	O
##3	O
##A	O
inhibitor	O
##s	O
)	O
in	O
healthy	O
volunteers	O
.	O

Des	B
##met	I
##hyl	I
##dia	I
##ze	I
##pa	I
##m	I
,	O
diet	B
##hyl	I
##dit	I
##hi	I
##oc	I
##ar	I
##ba	I
##mate	I
,	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
,	O
fur	B
##af	I
##yl	I
##line	I
,	O
o	B
##me	I
##pra	I
##zo	I
##le	I
,	O
p	B
##ilo	I
##car	I
##pine	I
,	O
que	B
##rc	I
##eti	I
##n	I
,	O
q	B
##uin	I
##id	I
##ine	I
,	O
th	B
##io	I
##TE	I
##PA	I
,	O
t	B
##ic	I
##lop	I
##id	I
##ine	I
,	O
t	B
##rol	I
##ean	I
##dom	I
##y	I
##cin	I
(	I
o	I
##lean	I
##dom	I
##y	I
##cin	I
t	I
##ria	I
##ce	I
##tate	I
)	I
,	O
glucose	B
6	I
-	I
phosphate	I
,	O
glucose	O
-	O
6	O
-	O
phosphate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
N	B
##AD	I
##P	I
,	O
al	B
##ame	I
##thi	I
##cin	I
,	O
ma	B
##gnesium	I
chloride	I
,	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
(	O
from	O
E	O
##scher	O
##ichi	O
##a	O
co	O
##li	O
)	O
,	O
Tri	O
##s	O
-	O
HC	O
##l	O
,	O
U	O
##DP	O
##GA	O
,	O
imp	O
##rim	O
##ine	O
,	O
p	O
-	O
ni	O
##tro	O
##phe	O
##no	O
##l	O
and	O
test	B
##osterone	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

G	B
##ly	I
##cer	I
##ol	I
was	O
detected	O
in	O
all	O
conditions	O
but	O
was	O
not	O
analyzed	O
as	O
it	O
is	O
a	O
known	O
con	O
##tam	O
##ina	O
##nt	O
from	O
fi	O
##ltration	O
.	O

The	O
IP	S
values	O
reflect	O
,	O
in	O
fact	O
,	O
the	O
importance	O
of	O
terms	O
in	O
the	O
model	O
both	O
with	O
respect	O
to	O
Y	O
,	O
i	O
.	O
e	O
.	O
its	O
correlation	O
with	O
all	O
the	O
responses	O
,	O
and	O
with	O
respect	O
to	O
X	O
.	O

In	O
this	O
context	O
ma	B
##lon	I
##dial	I
##de	I
##hy	I
##de	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##non	I
##ena	I
##l	I
,	O
prop	B
##ana	I
##l	I
and	O
he	B
##xa	I
##nal	I
have	O
been	O
described	O
as	O
suitable	O
markers	O
[	O
,	O
]	O
.	O

Li	O
##pid	O
##s	O
were	O
extracted	O
using	O
ch	B
##lor	I
##of	I
##orm	I
,	O
met	B
##han	I
##ol	I
and	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
Sigma	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
and	O
ultra	O
##pur	O
##e	O
water	O
(	O
Mill	O
##ip	O
##ore	O
)	O
.	O

Effects	O
of	O
cigarettes	O
per	O
day	O
(	O
CP	O
##D	O
)	O
(	O
panels	O
A	O
,	O
B	O
)	O
,	O
gender	O
(	O
panels	O
C	O
,	O
D	O
)	O
,	O
and	O
age	O
(	O
panels	O
E	O
,	O
F	O
)	O
on	O
levels	O
of	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
.	O

In	O
the	O
oz	O
##one	O
study	O
,	O
all	B
##ant	I
##oi	I
##n	I
levels	O
in	O
nasal	O
lava	O
##ge	O
had	O
returned	O
to	O
pre	O
-	O
exposure	O
levels	O
at	O
6	O
hours	O
after	O
exposure	O
.	O

The	O
upper	O
organic	O
layers	O
from	O
each	O
via	O
##l	O
were	O
pool	O
##ed	O
into	O
a	O
single	O
via	O
##l	O
,	O
and	O
the	O
extraction	O
with	O
he	B
##xa	I
##nes	I
was	O
repeated	O
a	O
second	O
time	O
.	O

In	O
order	O
to	O
achieve	O
this	O
,	O
we	O
assessed	O
three	O
different	O
columns	O
:	O
a	O
Ph	O
##eno	O
##men	O
##ex	O
Luna	O
C	O
##18	O
(	O
2	O
)	O
150	O
×	O
2	O
mm	O
,	O
Ph	O
##eno	O
##men	O
##ex	O
S	O
##yne	O
##rg	O
##i	O
4	B
##µ	I
Polar	I
-	I
R	I
##P	I
100	O
×	O
2	O
mm	O
and	O
a	O
Ph	O
##eno	O
##men	O
##ex	O
S	O
##yne	O
##rg	O
##i	O
4	O
##µ	O
H	O
##ydro	O
-	O
R	O
##P	O
100	O
×	O
2	O
mm	O
.	O

This	O
finding	O
was	O
supported	O
by	O
ch	B
##roma	I
##tin	I
im	O
##mu	O
##no	O
##p	O
##re	O
##ci	O
##pit	O
##ation	O
se	O
##quencing	O
(	O
Chi	O
##P	O
-	O
Se	O
##q	O
)	O
which	O
revealed	O
direct	O
binding	O
of	O
AR	O
and	O
ER	O
##G	O
to	O
the	O
promoter	O
of	O
G	O
##N	O
##MT	O
in	O
VC	O
##a	O
##P	O
cells	O
,	O
while	O
only	O
ER	O
##G	O
binding	O
was	O
seen	O
on	O
the	O
SA	O
##RD	O
##H	O
promoter	O
.	O

In	O
the	O
receiver	O
operating	O
characteristic	O
(	O
R	O
##OC	O
)	O
analysis	O
,	O
the	O
addition	O
of	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
did	O
not	O
increase	O
the	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
for	O
the	O
discrimination	O
of	O
F	O
##S	O
##GS	O
.	O

A	O
few	O
representative	O
tandem	O
MS	O
s	O
##pect	O
##ra	O
for	O
identification	O
and	O
second	O
step	O
q	O
##uant	O
##ification	O
of	O
PC	O
,	O
P	O
##E	O
,	O
SM	O
,	O
and	O
c	B
##era	I
##mi	I
##de	I
species	O
were	O
shown	O
in	O
.	O

The	O
predominant	O
factor	O
in	O
both	O
pre	O
-	O
and	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
termed	O
‘	B
cat	I
##ech	I
##ols	I
’	I
and	O
accounting	O
for	O
46	O
%	O
and	O
30	O
%	O
of	O
the	O
variance	O
in	O
E	O
##M	O
profiles	O
,	O
respectively	O
,	O
included	O
all	O
three	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
(	O
2	O
-	O
OH	O
##E	O
_	O
1	O
,	O
2	O
-	O
OH	O
##E	O
_	O
2	O
,	O
and	O
4	O
-	O
OH	O
##E	O
_	O
1	O
)	O
and	O
some	O
of	O
their	O
five	O
met	O
##hyl	O
##ated	O
meta	O
##bol	O
##ites	O
(	O
2	O
-	O
Me	O
##OE	O
_	O
1	O
and	O
3	O
-	O
Me	O
##OE	O
_	O
1	O
in	O
both	O
groups	O
,	O
and	O
2	O
-	O
Me	O
##OE	O
_	O
2	O
in	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
only	O
)	O
.	O

This	O
finding	O
represents	O
a	O
major	O
difference	O
in	O
the	O
inter	O
##con	O
##version	O
of	O
la	B
##ct	I
##ate	I
and	O
p	B
##yr	I
##u	I
##vate	I
.	O

Channel	O
##s	O
(	O
from	O
top	O
to	O
bottom	O
)	O
correspond	O
to	O
mass	O
transition	O
400	O
.	O
4	O
–	O
34	O
##1	O
.	O
2	O
for	O
Δ	O
_	O
4	O
-	O
AD	O
G	O
##ira	O
##rd	O
T	O
derivative	O
(	O
the	O
chemical	O
structure	O
of	O
which	O
is	O
depicted	O
in	O
the	O
figure	O
)	O
;	O
mass	O
transition	O
40	O
##2	O
.	O
4	O
–	O
34	O
##3	O
.	O
2	O
for	O
D	O
##H	O
##EA	O
,	O
T	O
,	O
Ad	B
##ione	I
and	O
E	O
##pi	O
-	O
T	O
G	O
##ira	O
##rd	O

The	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
the	O
pu	B
##rine	I
metabolism	O
##s	O
were	O
also	O
significantly	O
altered	O
,	O
but	O
associated	O
less	O
to	O
disease	O
severity	O
.	O

shows	O
a	O
his	O
##to	O
##gram	O
of	O
the	O
distribution	O
of	O
im	B
##ati	I
##ni	I
##b	I
concentrations	O
in	O
the	O
M	O
##MR	O
samples	O
.	O

However	O
,	O
we	O
have	O
already	O
shown	O
in	O
our	O
earlier	O
study	O
that	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
are	O
significantly	O
elevated	O
in	O
s	O
##chi	O
##zophrenia	O
patients	O
even	O
after	O
correct	O
##ing	O
for	O
anti	O
##psy	O
##cho	O
##tic	O
medication	O
use	O
and	O
metabolic	O
co	O
-	O
m	O
##or	O
##bid	O
##ity	O
.	O

In	O
addition	O
,	O
the	O
en	O
##rich	O
##ment	O
pathway	O
analysis	O
also	O
suggested	O
an	O
association	O
between	O
am	O
##monia	O
recycling	O
and	O
the	O
u	B
##rea	I
cycle	O
.	O

The	O
analysis	O
showed	O
alter	O
##ation	O
in	O
a	O
number	O
of	O
bio	O
##chemical	O
pathways	O
like	O
g	O
##ly	O
##co	O
##lysis	O
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
,	O
al	O
##ani	O
##ne	O
/	O
as	O
##par	O
##tate	O
/	O
g	O
##lut	O
##ama	O
##te	O
metabolism	O
and	O
l	B
##ys	I
##ine	I
degradation	O
.	O

B	O
##rief	O
##ly	O
,	O
100	O
-	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
the	O
base	O
##line	O
serum	O
samples	O
,	O
obtained	O
during	O
the	O
health	O
check	O
-	O
up	O
,	O
were	O
mixed	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
800	O
μ	O
##L	O
)	O
by	O
v	O
##ortex	O
##ing	O
.	O

Take	O
##da	O
et	O
al	O
.	O
discussed	O
that	O
these	O
gender	O
-	O
specific	O
differences	O
might	O
be	O
attributed	O
to	O
dental	O
care	O
,	O
hormones	O
such	O
as	O
est	B
##rogen	I
,	O
and	O
oral	O
path	O
##ogen	O
##esis	O
carriers	O
such	O
as	O
micro	O
##f	O
##lora	O
.	O

In	O
the	O
patient	O
group	O
with	O
highly	O
active	O
MS	O
,	O
15	B
-	I
H	I
##ET	I
##E	I
and	O
P	O
##GE	O
_	O
2	O
were	O
increased	O
,	O
which	O
are	O
products	O
of	O
the	O
15	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
and	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
pathways	O
.	O

In	O
another	O
aspect	O
,	O
serum	O
2	O
-	O
H	O
##G	O
levels	O
were	O
normal	O
in	O
a	O
small	O
subset	O
of	O
patients	O
with	O
ID	O
##H1	O
/	O
2	O
mutations	O
,	O
and	O
α	B
-	I
K	I
##G	I
levels	O
in	O
this	O
group	O
tended	O
to	O
be	O
the	O
lowest	O
we	O
found	O
.	O

This	O
is	O
consistent	O
with	O
our	O
results	O
,	O
where	O
higher	O
concentrations	O
of	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
were	O
measured	O
compared	O
with	O
co	B
##tin	I
##ine	I
.	O

Sep	O
##arate	O
##ly	O
,	O
five	O
portions	O
of	O
serum	O
(	O
350	O
μ	O
L	O
each	O
)	O
were	O
subjected	O
to	O
ultra	O
##fi	O
##ltration	O
;	O
the	O
fi	O
##lt	O
##rates	O
were	O
mixed	O
with	O
a	O
15	O
μ	O
L	O
solution	O
of	O
phosphate	S
buffer	O
(	O
100	O
m	O
##M	O
)	O
in	O
D	O
_	O
2	O
O	O
containing	O
0	O
.	O
1	O
m	O
##M	O
T	O
##SP	O
,	O
and	O
200	O
μ	O
L	O
was	O
transferred	O
to	O
3	O
mm	O
N	O
##MR	O
tubes	O
.	O

A	O
Mean	O
P	O
##K	O
curves	O
of	O
di	B
##os	I
##met	I
##in	I
measured	O
in	O
plasma	O
after	O
en	O
##zy	O
##matic	O
degradation	O
and	O
P	O
##K	O
parameters	O
obtained	O
on	O
12	O
patients	O
oral	O
##ly	O
treated	O
with	O
di	O
##os	O
##min	O
450	O
mg	O
in	O
a	O
P	O
##K	O
study	O
.	O

GA	B
##BA	I
is	O
produced	O
from	O
g	B
##lut	I
##ami	I
##c	I
acid	I
by	O
g	O
##lut	O
##ami	O
##c	O
acid	O
de	O
##car	O
##box	O
##yla	O
##se	O
.	O

Alt	O
##ered	O
urine	O
meta	O
##bol	O
##ite	O
levels	O
could	O
indicate	O
per	O
##tur	O
##bed	O
amino	O
acid	O
metabolism	O
,	O
g	O
##ly	O
##co	O
##lysis	O
,	O
T	O
##CA	O
cycle	O
,	O
u	B
##rea	I
cycle	O
,	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
and	O
gut	O
micro	O
##f	O
##lora	O
metabolism	O
.	O

When	O
we	O
subdivided	O
the	O
patients	O
with	O
CA	O
##D	O
into	O
two	O
groups	O
according	O
to	O
treatment	O
with	O
lip	O
##id	O
-	O
lowering	O
drugs	O
(	O
LL	O
##D	O
)	O
,	O
those	O
not	O
treated	O
with	O
LL	O
##D	O
showed	O
significantly	O
higher	O
serum	O
concentrations	O
of	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
than	O
did	O
those	O
treated	O
with	O
LL	O
##D	O
in	O
both	O
the	O
an	O
##gin	O
##a	O
and	O
MI	O
groups	O
.	O

Here	O
,	O
we	O
employed	O
a	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
meta	O
##bol	O
##omi	O
##c	O
approach	O
to	O
confirm	O
that	O
P	O
.	O
f	O
##al	O
##ci	O
##par	O
##um	O
lacks	O
the	O
ability	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
N	O
##AD	O
_	O
+	O
de	O
no	O
##vo	O
and	O
is	O
re	O
##lian	O
##t	O
on	O
the	O
up	O
##take	O
of	O
ex	O
##ogen	O
##ous	O
ni	B
##ac	I
##in	I
.	O

We	O
conclude	O
that	O
serum	O
levels	O
of	O
2	O
-	O
H	O
##B	O
,	O
3	O
-	O
H	O
##B	O
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
c	B
##it	I
##rate	I
are	O
associated	O
with	O
increased	O
3	O
-	O
month	O
mortality	O
in	O
A	O
##HF	O
patients	O
and	O
might	O
thus	O
be	O
of	O
pro	O
##gno	O
##stic	O
value	O
in	O
A	O
##HF	O
.	O

These	O
q	B
##uin	I
##one	I
met	O
##hi	O
##des	O
react	O
with	O
cellular	O
DNA	O
to	O
form	O
de	O
##pur	O
##inating	O
add	O
##uc	O
##ts	O
.	O

The	O
results	O
reveal	O
a	O
surprisingly	O
poor	O
performance	O
for	O
protein	O
precipitation	O
using	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
:	O
nearly	O
1	O
/	O
3	O
of	O
the	O
meta	O
##bol	O
##ites	O
were	O
at	O
##ten	O
##uated	O
by	O
10	O
to	O
67	O
%	O
compared	O
with	O
met	B
##han	I
##ol	I
precipitation	O
at	O
the	O
same	O
solvent	O
-	O
to	O
-	O
serum	O
ratio	O
of	O
2	O
:	O
1	O
.	O

Currently	O
,	O
we	O
cannot	O
explain	O
the	O
a	O
##gg	O
##regation	O
induced	O
by	O
addition	O
of	O
is	B
##op	I
##rop	I
##ano	I
##l	I
.	O

In	O
addition	O
,	O
samples	O
were	O
analyzed	O
using	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
columns	O
(	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
B	O
##E	O
##H	O
Am	B
##ide	I
1	O
.	O
7	O
μ	O
##m	O
50	O
×	O
2	O
.	O
1	O
mm	O
)	O
for	O
the	O
q	O
##uant	O
##itation	O
of	O
c	B
##rea	I
##tine	I
rib	I
##os	I
##ide	I
and	O
N	B
##AN	I
##A	I
.	O

In	O
light	O
of	O
the	O
ID	O
##H1	O
mutations	O
identified	O
in	O
Pat	O
##ient	O
3	O
samples	O
,	O
we	O
sought	O
to	O
determine	O
the	O
relative	O
levels	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
(	O
2	O
-	O
H	O
##G	O
)	O
and	O
other	O
meta	O
##bol	O
##ites	O
in	O
plasma	O
samples	O
.	O

Furthermore	O
,	O
c	B
##ys	I
##tein	I
##e	I
is	O
known	O
to	O
be	O
a	O
component	O
of	O
the	O
anti	O
##ox	O
##ida	O
##nt	O
g	B
##lut	I
##ath	I
##ione	I
and	O
is	O
involved	O
in	O
the	O
trans	O
##sul	O
##fu	O
##ration	O
pathway	O
,	O
which	O
consists	O
of	O
inter	O
##con	O
##version	O
of	O
c	B
##ys	I
##tein	I
##e	I
and	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
through	O
the	O
intermediate	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
.	O

The	O
samples	O
from	O
f	O
##er	O
##mentation	O
##s	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
5	O
min	O
;	O
15	O
,	O
000	O
rpm	O
/	O
min	O
)	O
,	O
and	O
400	O
μ	O
##L	O
of	O
super	O
##nat	O
##ant	O
was	O
di	O
##lut	O
##ed	O
with	O
2	O
m	O
##L	O
of	O
ultra	O
-	O
pure	O
water	O
(	O
Mi	O
##lip	O
##ore	O
,	O
Bedford	O
,	O
MA	O
,	O
United	O
States	O
of	O
America	O
)	O
;	O
20	O
μ	O
##L	O
of	O
[	O
_	O
13	O
C	O
_	O
6	O
]	O
trans	O
-	O
re	O
##s	O
##ver	O
##at	O
##rol	O
solution	O
in	O
met	B
##han	I
##ol	I
(	O
2	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
was	O
added	O
as	O
an	O
internal	O
standard	O
.	O

Both	O
targeted	O
UP	O
##LC	O
–	O
H	O
##R	O
##MS	O
and	O
D	O
##I	O
–	O
n	O
##ES	O
##I	O
–	O
H	O
##R	O
##MS	O
are	O
represented	O
in	O
Figure	O
S	O
-	O
4	O
using	O
the	O
example	O
of	O
hip	B
##pura	I
##te	I
.	O

The	O
information	O
provided	O
by	O
MR	O
##S	O
replica	O
##ted	O
that	O
obtained	O
by	O
MR	O
##I	O
using	O
the	O
-	O
CH	O
##3	O
peak	O
(	O
0	O
.	O
9	O
pp	O
##m	O
)	O
,	O
the	O
-	O
CH	O
##2	O
-	O
peak	O
(	O
1	O
.	O
3	O
pp	O
##m	O
,	O
mostly	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
)	O
and	O
the	O
-	O
CH	O
=	O
CH	O
-	O
peak	O
(	O
2	O
.	O
2	O
pp	O
##m	O
)	O
.	O

C	B
-	I
man	I
##nos	I
##yl	I
##try	I
##pt	I
##op	I
##han	I
is	O
a	O
product	O
derived	O
from	O
the	O
C	O
-	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
of	O
the	O
a	O
##romatic	O
amino	O
acid	O
try	O
##pt	O
##op	O
##han	O
and	O
man	B
##nose	I
.	O

Sign	O
##ificant	O
inverse	O
associations	O
were	O
limited	O
to	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
co	B
##tin	I
##ine	I
and	O
cat	B
##ech	I
##ol	I
su	I
##lf	I
##ate	I
(	O
Fi	O
##g	O
.	O

The	O
_	O
1	O
H	O
chemical	O
shifts	O
referred	O
to	O
the	O
met	O
##hyl	O
double	O
##t	O
signal	O
of	O
la	B
##ct	I
##ate	I
(	O
δ	O
##1	O
.	O
33	O
)	O
.	O

This	O
result	O
is	O
in	O
good	O
agreement	O
with	O
previous	O
studies	O
conducted	O
by	O
B	O
##io	O
##crates	O
(	O
Application	O
Note	O
100	O
##1	O
-	O
1	O
)	O
,	O
which	O
indicated	O
a	O
typical	O
pool	O
of	O
human	O
plasma	O
from	O
healthy	O
people	O
yields	O
an	O
average	O
of	O
23	O
a	O
##cy	O
##l	O
##car	O
##ntin	O
##es	O
below	O
the	O
limit	O
of	O
detection	O
.	O
_	O
1	O
That	O
note	O
also	O
reported	O
that	O
the	O
concentrations	O
of	O
5	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
in	O
pool	O
##ed	O
normal	O
human	O
plasma	O
are	O
typically	O
below	O
the	O
normal	O
L	O
##OD	O
,	O
whereas	O
in	O
the	O
present	O
study	O
only	O
3	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
were	O
below	O
the	O
L	O
##OD	O
.	O

Commercial	O
##ly	O
available	O
me	B
##lat	I
##oni	I
##n	I
(	O
ME	O
##L	O
)	O
(	O
Nat	O
##rol	O
®	O
,	O
Cha	O
##t	O
##worth	O
,	O
CA	O
)	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##try	I
##pta	I
##mine	I
(	O
NAS	O
)	O
,	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
,	O
ace	B
##tic	I
acid	I
and	O
am	B
##mon	I
##ium	I
c	I
##it	I
##rate	I
were	O
purchased	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

When	O
the	O
joint	O
effects	O
were	O
examined	O
,	O
individuals	O
with	O
T	O
##T	O
g	O
##eno	O
##type	O
and	O
plasma	O
x	B
##ant	I
##hine	I
levels	O
above	O
/	O
equal	O
to	O
the	O
median	O
value	O
had	O
significantly	O
higher	O
risk	O
of	O
T	O
##2	O
##D	O
[	O
H	O
##R	O
2	O
.	O
64	O
(	O
95	O
%	O
C	O
##I	O
1	O
.	O
02	O
–	O
6	O
.	O
83	O
)	O
]	O
than	O
those	O
with	O
CC	O
g	O
##eno	O
##type	O
and	O
x	B
##ant	I
##hine	I
levels	O
below	O
the	O
median	O
(	O
reference	O
)	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Mobile	O
phases	O
were	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
50	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
pH	O
5	O
.	O
8	O
(	O
phase	O
A	O
)	O
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
buffer	O
in	O
90	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
pH	O
5	O
.	O
8	O
(	O
phase	O
B	O
)	O
.	O

Strong	O
positive	O
associations	O
between	O
this	O
p	O
##hen	O
##otype	O
and	O
the	O
N	O
##MR	O
bucket	O
at	O
8	O
.	O
115	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
0	O
.	O
27	O
)	O
,	O
corresponding	O
to	O
unidentified	O
small	O
p	O
##eptide	O
##s	O
,	O
alcohol	O
(	O
edge	O
weight	O
=	O
0	O
.	O
20	O
)	O
,	O
8	O
.	O
125	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
0	O
.	O
19	O
)	O
(	O
unidentified	O
small	O
p	O
##eptide	O
##s	O
)	O
,	O
as	O
well	O
as	O
anal	O
##get	O
##ic	O
ne	O
##ph	O
##rop	O
##athy	O
(	O
an	O
_	O
ne	O
##ph	O
)	O
(	O
edge	O
weight	O
=	O
0	O
.	O
17	O
)	O
,	O
and	O
strong	O
negative	O
associations	O
with	O
the	O
N	O
##MR	O
bucket	O
at	O
3	O
.	O
56	O
##5	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
−	O
##0	O
.	O
16	O
)	O
,	O
identified	O
as	O
g	B
##ly	I
##cine	I
,	O
can	O
be	O
observed	O
.	O

These	O
were	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
49	O
%	O
)	O
;	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
16	O
%	O
)	O
;	O
P	O
##5	O
##C	O
,	O
A	O
##rg	O
,	O
and	O
pro	B
##line	I
(	O
Pro	O
)	O
(	O
7	O
%	O
)	O
;	O
g	B
##ly	I
##cos	I
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
6	O
%	O
)	O
;	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
4	O
%	O
)	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
an	O
##not	O
##ated	O
as	O
<	O
lip	O
##id	O
abbreviation	O
>	O
<	B
s	I
##phi	I
##ngo	I
##id	I
base	O
residue	O
>	O
/	O
<	O
fatty	O
a	O
##cy	O
##l	O
residue	O
>	O
.	O

Within	O
the	O
peripheral	O
blood	O
and	O
f	O
##ae	O
##ces	O
,	O
certain	O
species	O
(	O
St	O
##eno	O
##tro	O
##ph	O
##omo	O
##nas	O
p	O
##avan	O
##ii	O
,	O
Met	B
##hyl	I
##ob	I
##act	I
##eri	I
##um	I
ex	O
##tor	O
##que	O
##ns	O
)	O
and	O
meta	O
##bol	O
##ites	O
(	B
met	B
##han	I
##ol	I
,	O
th	B
##re	I
##oni	I
##ne	I
)	O
were	O
positively	O
related	O
to	O
H	O
##E	O
.	O

This	O
bio	O
##ana	O
##ly	O
##tical	O
method	O
was	O
successfully	O
valid	O
##ated	O
and	O
applied	O
to	O
determine	O
plasma	O
concentrations	O
of	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
in	O
clinical	O
studies	O
and	O
in	O
routine	O
patient	O
care	O
.	O

Next	O
,	O
it	O
was	O
dried	O
by	O
nitrogen	B
gas	I
at	O
60	O
°C	O
for	O
3	O
h	O
.	O

Our	O
data	O
show	O
a	O
short	O
-	O
term	O
increase	O
of	O
PC	B
##38	I
:	I
6	I
but	O
the	O
increase	O
was	O
lower	O
at	O
the	O
long	O
-	O
term	O
visit	O
relative	O
to	O
base	O
##line	O
,	O
resulting	O
in	O
a	O
[UNK]	O
-	O
pattern	O
.	O

In	O
our	O
series	O
,	O
his	B
##ti	I
##dine	I
levels	O
were	O
lower	O
in	O
se	O
##psis	O
than	O
in	O
controls	O
.	O

Su	O
##mma	O
##riz	O
##ing	O
data	O
,	O
we	O
observed	O
that	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
,	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
and	O
c	B
##rea	I
##tine	I
were	O
main	O
meta	O
##bol	O
##ites	O
highly	O
effective	O
in	O
different	O
##iating	O
PA	O
from	O
healthy	O
tissue	O
.	O

Tri	O
##met	O
##hyl	O
##si	O
##ly	O
##lation	O
was	O
subsequently	O
performed	O
by	O
adding	O
50	O
μ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
+	O
1	O
%	O
T	O
##MC	O
##S	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
,	O
in	O
##cu	O
##bat	O
##ing	O
for	O
1	O
h	O
at	O
65	O
##°	O
##C	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
1300	O
##0	O
rpm	O
X	O
10	O
min	O
at	O
R	O
##T	O
.	O

L	O
##C	O
-	O
MS	O
grade	O
water	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
and	O
L	O
##C	O
-	O
MS	O
grade	O
met	B
##han	I
##ol	I
(	O
Fisher	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
were	O
utilized	O
.	O

Free	O
##ze	O
–	O
th	O
##aw	O
stability	O
experiments	O
did	O
not	O
demonstrate	O
degradation	O
of	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
over	O
three	O
freeze	O
–	O
th	O
##aw	O
cycles	O
.	O

Some	O
in	O
v	O
##ivo	O
and	O
in	O
v	O
##it	O
##ro	O
studies	O
reported	O
protective	O
roles	O
of	O
g	B
##lu	I
##cos	I
##amine	I
against	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
with	O
anti	O
-	O
inflammatory	O
effect	O
or	O
in	O
##hibition	O
of	O
smooth	O
muscle	O
cell	O
growth	O
,	O
while	O
other	O
studies	O
showed	O
that	O
g	B
##lu	I
##cos	I
##amine	I
accelerate	O
##s	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
change	O
_	O
)	O
or	O
end	O
##op	O
##las	O
##mic	O
re	O
##tic	O
##ulum	O
stress	O
.	O

Analysis	O
was	O
blinded	O
to	O
as	B
##par	I
##tam	I
##e	I
consumption	O
and	O
subject	O
group	O
(	O
AS	O
or	O
N	O
##S	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
examined	O
p	O
##ept	O
##ai	O
##bol	O
##s	O
produced	O
by	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
that	O
were	O
dissolved	O
in	O
met	B
##han	I
##ol	I
.	O

The	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
of	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
were	O
improved	O
quantitative	O
##ly	O
for	O
maximum	O
analytical	O
peak	O
quality	O
with	O
short	O
run	O
time	O
,	O
using	O
a	O
mobile	O
phase	O
prepared	O
by	O
mixing	O
of	O
70	O
%	O
met	B
##han	I
##ol	I
and	O
30	O
%	O
of	O
a	O
mixture	O
of	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
0	O
.	O
2	O
m	O
##M	O
form	B
##ic	I
acid	I
and	O
was	O
el	O
##uted	O
is	O
##oc	O
##ratic	O
##ally	O
with	O
a	O
flow	O
rate	O
of	O
1	O
m	O
##L	O
min	O
_	O
−	O
##1	O
through	O
AC	O
##E	O
[UNK]	O
C	O
##18	O
(	O
50	O
×	O
2	O
.	O
1	O
mm	O
,	O
5	O
μ	O
m	O
)	O
column	O
for	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

A	O
shows	O
the	O
variation	O
in	O
peak	O
base	O
width	O
##s	O
and	O
B	O
the	O
differences	O
in	O
the	O
sum	O
of	O
resolutions	O
(	O
across	O
water	O
,	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
form	O
##ic	O
acid	O
-	O
containing	O
m	O
##od	O
##ifier	O
##s	O
and	O
all	O
evaluated	O
temperatures	O
)	O
by	O
column	O
.	O

The	O
ne	B
##r	I
##von	I
##ic	I
acid	I
levels	O
were	O
not	O
significantly	O
correlated	O
with	O
age	O
(	O
P	O
=	O
.	O
08	O
##2	O
)	O
or	O
sex	O
(	O
P	O
=	O
.	O
42	O
)	O
.	O

It	O
was	O
found	O
that	O
immediately	O
washing	O
the	O
harvested	O
tissue	O
with	O
a	O
solution	O
containing	O
a	O
mixture	O
of	O
glucose	S
(	O
10	O
m	O
##M	O
)	O
and	O
p	B
##yr	I
##u	I
##vate	I
(	O
0	O
.	O
5	O
m	O
##M	O
)	O
and	O
freeze	O
c	O
##lamp	O
##ing	O
followed	O
by	O
extraction	O
using	O
a	O
mixture	O
of	O
met	B
##han	I
##ol	I
and	O
ch	B
##lor	I
##of	I
##orm	I
(	I
1	I
:	I
1	I
v	I
/	I
v	I
)	I
and	O
then	O
a	O
mixture	O
of	O
di	O
##st	O
##ille	O
##d	O
water	O
and	O
ch	B
##lor	I
##of	I
##orm	I
(	I
1	I
:	I
1	I
v	I
/	I
v	I
)	I
provided	O
the	O
best	O
results	O
for	O
detect	O
##ing	O
all	O
the	O
co	O
##en	O
##zy	O
##mes	O
.	O

This	O
is	O
due	O
to	O
f	O
##etus	O
high	O
glucose	S
up	O
##take	O
through	O
the	O
place	O
##nta	O
.	O

PS	O
##G	O
will	O
include	O
multi	O
##chan	O
##nel	O
recording	O
including	O
o	B
##xi	I
##metry	I
,	O
EC	O
##G	O
,	O
E	O
##EG	O
,	O
E	O
##MG	O
,	O
flow	O
and	O
chest	O
and	O
abdomen	O
ex	O
##cursion	O
using	O
a	O
small	O
portable	O
recorder	O
(	O
Alice	O
PD	O
##x	O
,	O
Philips	O
Re	O
##sp	O
##iro	O
##nics	O
)	O
.	O

The	O
results	O
of	O
our	O
PC	O
##A	O
analysis	O
,	O
significance	O
testing	O
,	O
and	O
fold	O
change	O
analysis	O
(	O
,	O
and	O
)	O
clearly	O
demonstrate	O
that	O
a	O
pre	O
##ser	O
##vat	O
##ive	O
is	O
required	O
for	O
urine	O
storage	O
at	O
high	O
temperature	O
,	O
and	O
that	O
thy	B
##mo	I
##l	I
is	O
a	O
good	O
candidate	O
.	O

As	O
shown	O
in	O
and	O
,	O
c	B
##era	I
##mi	I
##des	I
36	I
:	I
1	I
and	O
38	O
:	O
1	O
were	O
the	O
most	O
abundant	O
species	O
,	O
especially	O
in	O
the	O
re	O
##tina	O
and	O
brain	O
where	O
they	O
total	O
##ized	O
85	O
to	O
100	O
%	O
of	O
all	O
molecular	O
species	O
for	O
most	O
of	O
the	O
G	O
##G	O
classes	O
.	O

St	O
##eat	O
##osis	O
has	O
been	O
identified	O
in	O
those	O
who	O
su	O
##cc	O
##um	O
##bed	O
to	O
E	O
##VD	O
,	O
and	O
lesser	O
forms	O
of	O
fatty	O
liver	O
disease	O
are	O
also	O
associated	O
with	O
ch	B
##olin	I
##e	I
deficiency	O
as	O
the	O
ch	O
##olin	O
##e	O
-	O
based	O
lip	O
##ids	O
(	O
e	O
.	O
g	O
.	O
,	O
PC	O
##s	O
and	O
LP	O
##Cs	O
)	O
are	O
not	O
being	O
synthesized	O
or	O
are	O
synthesized	O
at	O
a	O
reduced	O
rate	O
.	O

Re	O
##se	O
##quencing	O
,	O
expression	O
analysis	O
,	O
and	O
bio	O
##chemical	O
experiments	O
focused	O
on	O
one	O
such	O
lo	O
##cus	O
(	O
C	O
##YP	O
##39	O
##A	O
##1	O
)	O
,	O
revealed	O
multiple	O
loss	O
-	O
of	O
-	O
function	O
all	O
##ele	O
##s	O
with	O
add	O
##itive	O
effects	O
on	O
serum	O
levels	O
of	O
the	O
o	B
##xy	I
##ster	I
##ol	I
,	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
a	O
substrate	O
of	O
the	O
encoded	O
enzyme	O
.	O

For	O
hip	B
##pura	I
##te	I
and	O
al	B
##ani	I
##ne	I
,	O
power	O
is	O
<	O
10	O
%	O
for	O
the	O
t	O
-	O
test	O
.	O

The	O
meta	O
##bol	O
##ite	O
with	O
the	O
greatest	O
percent	O
decline	O
in	O
serum	O
was	O
c	B
##rea	I
##tine	I
(	O
72	O
%	O
at	O
T	O
##12	O
##0	O
)	O
and	O
the	O
meta	O
##bol	O
##ite	O
with	O
the	O
greatest	O
percent	O
increase	O
was	O
ta	B
##uri	I
##ne	I
(	O
152	O
%	O
)	O
at	O
T	O
##18	O
##0	O
.	O

No	O
significant	O
difference	O
in	O
end	B
##ox	I
##ife	I
##n	I
concentration	O
was	O
detected	O
between	O
C	O
/	O
C	O
and	O
C	O
/	O
T	O
carriers	O
(	O
P	O
=	O
0	O
.	O
77	O
##7	O
,	O
)	O
.	O

The	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
highlighted	O
interesting	O
differences	O
between	O
l	O
##ymph	O
##oma	O
patients	O
and	O
population	O
controls	O
,	O
allowing	O
the	O
discrimination	O
between	O
path	O
##olo	O
##gic	O
and	O
healthy	O
subjects	O
:	O
Important	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
el	B
##aid	I
##ic	I
acid	I
,	O
were	O
more	O
abundant	O
in	O
all	O
l	O
##ymph	O
##oma	O
sub	O
##type	O
##s	O
.	O

This	O
would	O
have	O
furnished	O
an	O
explanation	O
for	O
the	O
negative	O
correlation	O
between	O
man	B
##nose	I
and	O
th	B
##re	I
##oni	I
##ne	I
.	O

Distribution	O
of	O
numbers	O
of	O
errors	O
(	O
based	O
on	O
1	O
,	O
000	O
re	O
-	O
sampling	O
it	O
##eration	O
##s	O
)	O
for	O
the	O
24	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
O	O
##PL	O
##S	O
-	O
D	O
##A	O
prediction	O
models	O
for	O
s	O
##pect	O
##ra	O
with	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
is	O
shown	O
in	O
;	O
for	O
s	O
##pect	O
##ra	O
without	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
in	O
.	O

Ser	O
##um	O
k	B
##eto	I
-	I
and	I
##rogen	I
levels	O
from	O
patients	O
enrolled	O
in	O
the	O
Target	O
##ed	O
And	O
##rogen	O
Path	O
##way	O
Su	O
##pp	O
##ression	O
(	O
T	O
##AP	O
##S	O
)	O
clinical	O
trial	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
filtered	O
through	O
a	O
0	O
.	O
22	O
-	O
µ	O
##m	O
-	O
p	O
##ore	O
-	O
size	O
filter	O
and	O
when	O
necessary	O
di	O
##lut	O
##ed	O
,	O
with	O
sodium	B
c	I
##it	I
##rate	I
(	O
0	O
.	O
2	O
M	O
,	O
pH	O
2	O
.	O
2	O
)	O
loading	O
buffer	O
.	O

Neo	B
##pt	I
##eri	I
##n	I
correlation	O
##s	O
found	O
in	O
the	O
current	O
study	O
also	O
included	O
meta	O
##bol	O
##ites	O
downstream	O
in	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
:	O
Q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
as	O
seen	O
in	O
)	O
,	O
3	O
-	O
OH	O
ant	B
##hra	I
##ni	I
##lic	I
acid	I
,	O
and	O
also	O
q	O
##uin	O
##ald	O
##ic	O
acid	O
,	O
the	O
red	O
##ox	O
product	O
of	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
showed	O
correlation	O
in	O
)	O
.	O

The	O
first	O
and	O
third	O
of	O
these	O
ratios	O
remained	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
risk	O
even	O
after	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

U	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
of	O
a	O
ch	O
##lor	O
##inated	O
O	O
##P	O
,	O
t	B
##ris	I
(	I
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##o	I
-	I
2	I
-	I
prop	I
##yl	I
)	I
phosphate	I
,	O
and	O
two	O
non	O
-	O
ch	O
##lor	O
##inated	O
O	O
##Ps	O
,	O
trip	B
##hen	I
##yl	I
phosphate	I
and	O
mon	B
##o	I
-	I
is	I
##op	I
##rop	I
##yl	I
##phe	I
##ny	I
##l	I
dip	I
##hen	I
##yl	I
phosphate	I
,	O
were	O
measured	O
using	O
liquid	O
-	O
ch	O
##roma	O
##tography	O
tandem	O
mass	O
-	O
s	O
##pect	O
##rome	O
##try	O
.	O

Thus	O
,	O
one	O
may	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
de	B
##can	I
-	I
1	I
-	I
o	I
##l	I
can	O
be	O
associated	O
with	O
the	O
synthesis	O
of	O
a	O
medium	O
-	O
chain	O
fatty	O
acid	O
,	O
namely	O
cap	B
##ric	I
acid	I
(	B
C	B
##10	I
:	I
0	I
)	O
,	O
for	O
energy	O
production	O
.	O

U	O
##rine	O
samples	O
were	O
collected	O
into	O
a	O
s	O
##ter	O
##ilized	O
cup	O
containing	O
125	O
mg	O
of	O
as	B
##cor	I
##bic	I
acid	I
to	O
prevent	O
oxidation	O
of	O
lab	O
##ile	O
meta	O
##bol	O
##ites	O
.	O

In	O
additional	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
levels	O
were	O
positively	O
correlated	O
with	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
T	B
##MA	I
##O	I
and	O
c	B
##it	I
##rate	I
.	O

A	O
##bb	O
##re	O
##viation	O
:	O
D	O
##HP	O
##M	O
,	O
di	B
##hy	I
##dr	I
##opy	I
##rim	I
##id	I
##ine	I
.	O

Blood	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
insulin	O
concentrations	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
20	O
,	O
24	O
,	O
28	O
,	O
32	O
and	O
36	O
h	O
after	O
last	O
dos	O
##ing	O
on	O
day	O
8	O
(	B
[UNK]	O
:	I
00	I
hours	O
)	O
.	O

P	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
sign	O
##ifying	O
the	O
pro	O
##life	O
##rative	O
ability	O
of	O
tumor	O
cells	O
was	O
also	O
reflected	O
by	O
its	O
elevated	O
presence	O
in	O
PA	O
##M	O
##50	O
-	O
defined	O
basal	O
,	O
Her	O
-	O
2	O
–	O
en	O
##rich	O
##ed	O
and	O
l	O
##umi	O
##nal	O
B	O
tumors	O
.	O

The	O
mean	O
value	O
for	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##Ps	O
was	O
1	O
.	O
80	O
ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
similar	O
to	O
our	O
measurement	O
.	O

Furthermore	O
,	O
it	O
was	O
reported	O
over	O
four	O
decades	O
ago	O
that	O
patients	O
in	O
##fused	O
with	O
x	B
##yl	I
##ito	I
##l	I
showed	O
gross	O
##ly	O
increased	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
th	B
##re	I
##onic	I
acid	I
,	O
interpreted	O
as	O
arising	O
through	O
the	O
PP	O
##P	O
[	O
,	O
]	O
.	O

The	O
R	O
##OC	O
curve	O
of	O
the	O
4	O
-	O
variable	O
panel	O
including	O
age	O
,	O
pro	B
##line	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
a	O
##rg	O
##ini	O
##ne	O
—	O
The	O
values	O
of	O
mean	O
AU	O
##C	O
of	O
the	O
panel	O
including	O
age	O
,	O
pro	B
##line	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
a	B
##rg	I
##ini	I
##ne	I
in	O
the	O
training	O
set	O
(	O
A	O
)	O
is	O
0	O
.	O
96	O
##2	O
(	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
96	O
##1	O
,	O
0	O
.	O
96	O
##3	O
)	O
and	O
0	O
.	O
87	O
##1	O

U	O
##rine	O
samples	O
were	O
th	O
##awed	O
,	O
and	O
900	O
µ	O
##l	O
of	O
sample	O
were	O
buffer	O
##ed	O
with	O
100	O
µ	O
##l	O
of	O
a	O
K	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
/	O
K	O
##OH	O
solution	O
at	O
pH	O
7	O
.	O
4	O
in	O
pure	O
D	O
_	O
2	O
0	O
,	O
containing	O
Na	O
##N	O
_	O
3	O
to	O
in	O
##hibit	O
bacterial	O
growth	O
and	O
Tri	B
##met	I
##hyl	I
##si	I
##ly	I
##l	I
prop	I
##ano	I
##ic	I
acid	I
(	O
T	O
##SP	O
)	O
as	O
a	O
frequency	O
and	O
concentration	O
reference	O
.	O

Met	B
##han	I
##ol	I
,	O
ch	B
##lor	I
##of	I
##orm	I
,	O
ch	B
##lor	I
##of	I
##orm	I
-	I
d	I
(	O
CD	O
##C	O
##l	O
_	O
3	O
)	O
,	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
,	O
and	O
Na	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
were	O
purchased	O
from	O
Mill	O
##ip	O
##ore	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

G	B
##lut	I
##ath	I
##ione	I
(	O
A	O
)	O
and	O
p	B
##oly	I
##amine	I
##s	I
(	O
B	O
)	O
metabolism	O
pathways	O
.	O

This	O
suggests	O
that	O
N	O
##F	O
-	O
κ	O
##B	O
media	O
##tes	O
l	B
##ino	I
##le	I
##ic	I
acid	I
actions	O
on	O
V	O
##SM	O
##C	O
.	O

In	O
our	O
study	O
,	O
the	O
decreased	O
levels	O
of	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
in	O
A	O
##OS	O
##D	O
patients	O
may	O
indicate	O
its	O
potential	O
protective	O
effect	O
a	O
##gan	O
##st	O
inflammatory	O
response	O
and	O
suggest	O
its	O
augmented	O
consumption	O
in	O
a	O
##pop	O
##otic	O
processes	O
in	O
this	O
disease	O
.	O

3	B
-	I
me	I
-	I

Total	O
ch	B
##olin	I
##e	I
in	O
plasma	O
increased	O
over	O
10	O
-	O
times	O
from	O
early	O
to	O
late	O
la	O
##ct	O
##ation	O
,	O
with	O
the	O
majority	O
of	O
the	O
increase	O
coming	O
from	O
elevated	O
PC	O
levels	O
.	O

Un	O
##iva	O
##ria	O
##te	O
analysis	O
showed	O
that	O
est	O
##ers	O
of	O
short	O
chain	O
fatty	O
acids	O
,	O
c	B
##y	I
##c	I
##lo	I
##he	I
##xa	I
##ne	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
and	O
its	O
est	O
##er	O
derivatives	O
were	O
associated	O
with	O
I	O
##BS	O
-	O
D	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
al	O
##de	O
##hy	O
##des	O
were	O
more	O
abundant	O
in	O
I	O
##B	O
##D	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
were	O
recorded	O
using	O
dynamic	O
exclusion	O
of	O
previously	O
analyzed	O
precursor	O
##s	O
for	O
180	O
s	O
with	O
a	O
repeat	O
of	O
3	O
and	O
a	O
repeat	O
duration	S
of	O
60	O
s	O
.	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
were	O
generated	O
by	O
C	O
##ID	O
of	O
the	O
p	O
##eptide	O
ions	O
at	O
a	O
normal	O
##ized	O
collision	O
energy	O
of	O
35	O
%	O
to	O
generate	O
a	O
series	O
of	O
b	O
-	O
and	O
y	O
-	O
ions	O
as	O
major	O
fragments	O
.	O

Among	O
these	O
4	O
meta	O
##bol	O
##ites	O
,	O
oral	O
fat	O
-	O
specific	O
correlation	O
was	O
seen	O
only	O
with	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
and	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
(	O
i	O
,	O
k	O
–	O
n	O
)	O
.	O

P	B
##yr	I
##id	I
##ini	I
##um	I
di	O
##ch	O
##roma	O
##te	O
(	O
1	O
.	O
3	O
mg	O
,	O
3	O
.	O
5	O
μ	O
##mo	O
##l	O
)	O
was	O
added	O
directly	O
to	O
a	O
solution	O
of	O
either	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
or	O
N	O
-	O
ace	O
##ty	O
##l	O
-	O
S	O
-	O
[	O
1	O
-	O
(	O
5	O
-	O
h	O
##ydro	O
##xy	O
-	O
5	O
-	O
car	O
##box	O
##ype	O
##nt	O
##yl	O
)	O
-	O
1	O
##H	O
-	O
p	O
##yr	O
##rol	O
-	O
3	O
-	O
y	O
##l	O
]	O
-	O
L	O
-	O
c	O
##ys	O
##tein	O
##e	O
su	O
##lf	O
##oxide	O
(	O
3	O
.	O
5	O
μ	O
##mo	O
##l	O
)	O
in	O
0	O
.	O
5	O
m	O
##L	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
-	I
dim	I
##eth	I
##yl	I
##form	I
##ami	I
##de	I
(	I
1	I
:	I
1	I
)	I
at	O
0	O
°C	O
.	O

ET	O
##r	O
##A	O
acid	O
=	O
5	O
,	O
8	O
,	O
11	O
-	O
E	O
##ico	O
##sat	O
##rien	O
##oi	O
##c	O
acid	O
;	O
D	O
##HA	O
=	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
;	O
L	O
##VE	O
##F	O
=	O
left	O
vent	O
##ric	O
##ular	O
e	O
##jection	O
fraction	O
;	O
1	B
-	I
palm	I
##ito	I
##yl	I
–	I
GP	I
##C	I
=	I
1	I
-	I
palm	I
##ito	I
##yl	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
.	O

All	O
four	O
of	O
these	O
cellular	O
meta	O
##bol	O
##ites	O
have	O
relationships	O
to	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
(	O
PP	O
##P	O
)	O
.	O

Interest	O
##ingly	O
,	O
the	O
concentration	O
of	O
k	B
##yn	I
##uren	I
##ine	I
in	O
the	O
conditioned	O
media	O
was	O
lower	O
than	O
the	O
concentration	O
of	O
pu	O
##rified	O
k	B
##yn	I
##uren	I
##ine	I
that	O
reduced	O
CD	O
##8	O
T	O
cell	O
via	O
##bility	O
,	O
a	O
phenomenon	O
which	O
could	O
be	O
explained	O
by	O
the	O
mi	O
##lie	O
##u	O
of	O
other	O
factors	O
that	O
are	O
secret	O
##ed	O
by	O
suspended	O
T	O
##NBC	O
cells	O
which	O
might	O
have	O
immune	O
-	O
m	O
##od	O
##ulatory	O
effects	O
.	O

This	O
result	O
ve	O
##ri	O
##fies	O
the	O
use	O
of	O
generally	O
accepted	O
cut	O
##off	O
values	O
for	O
determining	O
treatment	O
efficacy	O
and	O
he	O
##pa	O
##to	O
##to	O
##xi	O
##city	O
.	O
_	O
,	O
In	O
our	O
results	O
,	O
the	O
RB	O
##C	O
concentrations	O
of	O
6	O
##MM	O
##P	O
were	O
stronger	O
correlated	O
with	O
an	O
increase	O
in	O
liver	O
enzyme	O
activities	O
than	O
6	O
##T	O
##G	O
,	O
possibly	O
because	O
the	O
met	O
##hyl	O
##ation	O
pathway	O
was	O
more	O
activated	S
than	O
the	O
salvage	O
pathway	O
.	O

To	O
25	O
μ	O
##L	O
of	O
plasma	O
,	O
100	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
and	O
5	O
μ	O
##L	O
of	O
internal	O
standard	O
(	O
AA	O
-	O
d	O
##8	O
)	O
were	O
added	O
.	O

All	O
HP	O
##LC	O
solvent	O
##s	O
(	O
is	O
##op	O
##rop	O
##ano	O
##l	O
and	O
ch	B
##lor	I
##of	I
##orm	I
)	O
were	O
L	O
##C	O
-	O
MS	O
grade	O
and	O
were	O
purchased	O
from	O
Honey	O
##well	O
(	O
Morris	O
##town	O
,	O
NJ	O
)	O
.	O

Similar	O
analysis	O
was	O
performed	O
for	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
use	O
.	O

All	O
of	O
these	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
levels	O
were	O
universally	O
higher	O
in	O
the	O
cancer	O
tissue	O
than	O
in	O
the	O
normal	O
breast	O
tissue	O
.	O

L	O
##C	O
-	O
MS	O
/	O
MS	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
.	O

4	B
-	I
Am	I
##ino	I
##but	I
##ano	I
##ate	I
.	O

We	O
observed	O
that	O
the	O
association	O
of	O
beta	B
##ine	I
with	O
T	O
##2	O
##DM	O
was	O
modified	O
by	O
sex	O
(	O
P	O
_	O
interaction	O
=	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
by	O
age	O
(	O
P	O
_	O
interaction	O
=	O
0	O
.	O
93	O
)	O
or	O
e	O
##G	O
##F	O
##R	O

We	O
found	O
a	O
direct	O
association	O
of	O
u	O
##rina	O
##ry	O
glucose	S
with	O
B	O
##MI	O
(	O
r	O
=	O
0	O
.	O
14	O
,	O
P	O
=	O
3	O
.	O
27	O
×	O
10	O
_	O
−	O
##9	O
)	O
,	O
which	O
is	O
material	O
##ly	O
unchanged	O
when	O
diet	O
##ary	O
glucose	S
intake	O
,	O
total	O
sugar	O
,	O
or	O
total	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
intake	O
are	O
added	O
to	O
the	O
re	O
##gression	O
model	O
,	O
indicating	O
possible	O
late	O
##nt	O
insulin	O
resistance	O
and	O
und	O
##ia	O
##gno	O
##sed	O
diabetes	O
related	O
to	O
ad	O
##ip	O
##os	O
##ity	O
(	O
,	O
,	O
,	O
)	O
.	O

If	O
this	O
hypothesis	O
is	O
correct	O
,	O
per	O
##tur	O
##bation	O
##s	O
that	O
result	O
in	O
accumulation	O
of	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##As	O
,	O
D	O
##AG	O
,	O
or	O
other	O
fatty	O
acid	O
derivatives	O
within	O
muscle	O
and	O
liver	O
,	O
through	O
increased	O
FF	O
##A	O
delivery	O
and	O
/	O
or	O
decreased	O
metabolism	O
,	O
should	O
induce	O
insulin	O
resistance	O
;	O
and	O
the	O
improvement	O
in	O
insulin	O
sensitivity	O
after	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
treatment	O
should	O
be	O
associated	O
with	O
a	O
reduction	O
in	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
and	O
/	O
or	O
D	O
##AG	O
.	O

For	O
confirmation	O
study	O
of	O
the	O
developed	O
analytical	O
methodology	O
,	O
a	O
second	O
fused	O
si	B
##lica	I
column	O
was	O
used	O
.	O

In	O
addition	O
to	O
fatty	O
acids	O
being	O
l	O
##igan	O
##ds	O
for	O
PP	O
##AR	O
receptors	O
,	O
the	O
o	B
##me	I
##ga	I
-	I
3	I
fatty	O
acids	O
are	O
l	O
##igan	O
##ds	O
for	O
the	O
G	O
-	O
protein	O
coupled	O
receptor	O
GP	O
##R	O
##12	O
##0	O

The	O
increased	O
post	O
##ab	O
##sor	O
##pt	O
##ive	O
plasma	O
3	O
-	O
H	O
##IB	O
levels	O
in	O
our	O
subjects	O
with	O
diabetes	O
may	O
reflect	O
increased	O
protein	O
breakdown	O
as	O
a	O
consequence	O
of	O
relative	O
insulin	O
deficiency	O
due	O
to	O
insufficient	O
insulin	O
secret	O
##ion	O
in	O
relation	O
to	O
insulin	O
resistance	O
,	O
which	O
would	O
also	O
explain	O
increased	O
k	B
##eton	I
##e	I
body	O
production	O
.	O

Previously	O
,	O
it	O
was	O
found	O
that	O
co	B
##rt	I
##is	I
##ol	I
levels	O
are	O
70	O
%	O
sensitive	O
and	O
85	O
%	O
specific	O
in	O
different	O
##iating	O
acute	O
MI	O
from	O
an	O
##gin	O
##a	O
among	O
patients	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

In	O
Al	O
##b	O
,	O
a	O
dose	O
-	O
related	O
increase	O
in	O
both	O
[	B
_	I
13	I
C	I
_	I
6	I
]	I
1	I
,	I
2	I
-	I
and	O
[	B
_	I
13	I
C	I
_	I
6	I
]	I
1	I
,	I
4	I
-	I
B	I
##Q	I
add	O
##uc	O
##ts	O
was	O
observed	O
.	O

We	O
speculated	O
that	O
this	O
may	O
be	O
an	O
indication	O
of	O
lean	O
##ness	O
since	O
1	O
)	O
the	O
B	O
##MI	O
was	O
lower	O
in	O
the	O
high	O
PA	O
##L	O
_	O
DL	O
##W	O
group	O
compared	O
to	O
the	O
low	O
group	O
,	O
with	O
most	O
women	O
in	O
the	O
high	O
PA	O
##L	O
group	O
having	O
a	O
B	O
##MI	O
within	O
the	O
normal	O
range	O
and	O
since	O
2	O
)	O
B	O
##MI	O
was	O
inverse	O
##ly	O
correlated	O
with	O
se	B
##rine	I
levels	O
in	O
women	O
in	O
the	O
low	O
PA	O
##L	O
_	O
DL	O
##W	O
and	O
A	O
##EE	O
/	O
kg	O
_	O
DL	O
##W	O
groups	O
,	O
yet	O
without	O
statistical	O
significance	O
.	O

Conversely	O
,	O
the	O
ratio	O
of	O
bi	O
##sal	O
##ly	O
##lic	O
groups	O
to	O
fatty	O
acids	O
,	O
the	O
ratio	O
of	O
bi	O
##sal	O
##ly	O
##lic	O
groups	O
to	O
double	O
bonds	O
as	O
well	O
as	O
the	O
average	O
number	O
of	O
double	O
bonds	O
in	O
fatty	O
acid	O
chains	O
were	O
all	O
negatively	O
associated	O
with	O
levels	O
of	O
test	B
##osterone	I
in	O
PC	O
##OS	O
women	O
but	O
not	O
in	O
controls	O
(	O
β	O
<	O
−	O
##4	O
.	O
9	O
,	O
P	O
<	O
1	O
.	O
6	O
×	O
10	O
_	O
−	O
##3	O
)	O
.	O

In	O
particular	O
,	O
they	O
reported	O
a	O
significantly	O
increased	O
level	O
of	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
LP	O
##C	O
)	O
(	O
18	O
:	O
1	O
)	O
,	O
(	O
18	O
:	O
0	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oi	I
##nos	I
##ito	I
##l	I
(	I
16	I
:	I
0	I
)	I
in	O
the	O
MS	O
patients	O
.	O

Because	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
are	O
mostly	O
present	O
in	O
urine	O
as	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
or	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
,	O
we	O
measured	O
total	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
men	O
which	O
is	O
the	O
sum	O
of	O
the	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
,	O
su	O
##lf	O
##ated	O
and	O
un	O
##con	O
##ju	O
##gated	O
forms	O
of	O
each	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
.	O

We	O
first	O
analyzed	O
the	O
data	O
using	O
the	O
ratio	O
of	O
de	O
##pur	O
##inating	O
N	O
##3	O
##A	O
##de	O
and	O
N	O
##7	O
##G	O
##ua	O
add	O
##uc	O
##ts	O
to	O
the	O
sum	O
of	O
their	O
respective	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
in	O
urine	O
samples	O
as	O
a	O
continuous	O
variable	O
.	O

The	O
amount	O
of	O
eight	O
plasma	O
meta	O
##bol	O
##ites	O
significantly	O
differs	O
between	O
the	O
N	O
##DM	O
##M	O
and	O
MG	O
##US	O
group	O
:	O
free	O
car	B
##ni	I
##tine	I
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
and	O
four	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
)	O
species	O
.	O

Although	O
preliminary	O
,	O
these	O
findings	O
set	O
the	O
stage	O
for	O
additional	O
experiments	O
to	O
determine	O
the	O
optimal	O
concentration	O
of	O
a	O
##za	O
required	O
to	O
supplement	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
to	O
understand	O
the	O
mechanism	O
(	O
s	O
)	O
that	O
drive	O
this	O
s	O
##yne	O
##rgy	O
.	O

Prior	O
to	O
use	O
,	O
the	O
P	O
##H	O
##RE	O
##E	O
SP	O
##E	O
plates	O
were	O
pre	O
##wash	O
##ed	O
using	O
250	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
added	O
to	O
each	O
well	O
,	O
with	O
el	O
##ution	O
to	O
waste	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
500	O
##g	O
for	O
5	O
min	O
.	O

Once	O
calcium	B
-	I
o	I
##xa	I
##late	I
crystals	O
have	O
accumulated	O
in	O
various	O
bodily	O
tissues	O
,	O
h	O
##yper	O
##ox	O
##al	O
##uria	O
may	O
per	O
##sist	O
for	O
years	O
despite	O
the	O
fact	O
that	O
the	O
primary	O
metabolic	O
defect	O
may	O
have	O
been	O
corrected	O
following	O
liver	O
transplant	O
##ation	O
.	O

In	O
contrast	O
,	O
the	O
levels	O
of	O
al	B
##ani	I
##ne	I
and	O
la	B
##ct	I
##ate	I
started	O
to	O
increase	O
at	O
later	O
time	O
##points	O
and	O
reached	O
their	O
maximum	O
only	O
75	O
min	O
post	O
ing	O
##est	O
##ion	O
.	O

The	O
cat	O
##ech	O
##ol	O
-	O
est	O
##rone	O
-	O
modified	O
Ad	O
##e	O
is	O
readily	O
ion	O
##ized	O
in	O
electro	O
##sp	O
##ray	O
and	O
forms	O
a	O
pro	O
##ton	O
##ated	O
species	O
,	O
[	B
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
##A	O
##de	O
+	O
H	O
]	O
_	O
+	O
of	O
m	O
/	O
z	O
420	O
.	O

As	O
the	O
differential	O
activity	O
of	O
re	O
##nal	O
enzymes	O
is	O
likely	O
to	O
be	O
responsible	O
for	O
the	O
differences	O
in	O
u	O
##rina	O
##ry	O
o	B
##xy	I
##lip	I
##ins	I
observed	O
between	O
the	O
groups	O
,	O
u	O
##rina	O
##ry	O
lip	O
##ido	O
##me	O
pro	O
##fi	O
##ling	O
could	O
be	O
an	O
attractive	O
approach	O
for	O
monitoring	O
re	O
##nal	O
conditions	O
and	O
/	O
or	O
functional	O
performance	O
,	O
especially	O
considering	O
the	O
relative	O
stability	O
of	O
u	O
##rina	O
##ry	O
o	B
##xy	I
##lip	I
##ins	I
.	O

These	O
results	O
were	O
in	O
line	O
with	O
previous	O
findings	O
that	O
try	B
##pt	I
##op	I
##han	I
and	O
its	O
downstream	O
meta	O
##bol	O
##ite	O
se	B
##rot	I
##oni	I
##n	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
##try	I
##pta	I
##mine	I
)	I

G	B
##ly	I
##co	I
##lic	I
acid	I
and	O
su	B
##cci	I
##ny	I
##lace	I
##tone	I
were	O
also	O
revealed	O
as	O
independent	O
factors	O
associated	O
with	O
the	O
incidence	O
of	O
L	O
##C	O
in	O
the	O
present	O
study	O
.	O

We	O
were	O
unable	O
to	O
stab	O
##ilize	O
2	B
-	I
OH	I
##E	I
##1	I
in	O
se	O
##ra	O
even	O
though	O
partial	O
stab	O
##ilization	O
was	O
achieved	O
by	O
addition	O
of	O
di	B
##thi	I
##oth	I
##re	I
##ito	I
##l	I
to	O
the	O
samples	O
.	O

Convention	O
##al	O
c	O
##yt	O
##ogen	O
##etic	O
test	O
for	O
t	B
(	I
15	I
:	I
17	I
)	I
was	O
performed	O
by	O
flu	O
##ores	O
##cence	O
in	O
sit	O
##u	O
hybrid	O
##ization	O
(	O
F	O
##IS	O
##H	O
)	O
analysis	O
and	O
a	O
negative	O
F	O
##IS	O
##H	O
result	O
was	O
considered	O
as	O
a	O
c	O
##yt	O
##ogen	O
##etic	O
complete	O
re	O
##mission	O
.	O

No	O
patients	O
were	O
taking	O
a	O
s	B
##tat	I
##in	I
at	O
the	O
time	O
of	O
en	O
##rol	O
##ment	O
into	O
the	O
study	O
.	O

Similarly	O
,	O
the	O
ex	O
##cre	O
##tion	O
of	O
the	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
of	O
11	B
##OH	I
##A	I
##4	I
,	I
11	I
##β	I
-	I
OH	I
-	I
An	I
,	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
PC	O
##OS	O
[	O
59	O
##5	O
(	O
I	O
##Q	O
##R	O
,	O
34	O
##7	O
to	O
86	O
##1	O
)	O
vs	O
35	O
##3	O
(	O
I	O
##Q	O
##R	O
,	O
171	O
to	O
48	O
##7	O
)	O
in	O
control	O
subjects	O
;	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Our	O
laboratory	O
has	O
previously	O
performed	O
a	O
series	O
of	O
pilot	O
studies	O
to	O
ensure	O
that	O
the	O
results	O
of	O
the	O
p	B
##ht	I
##hala	I
##te	I
analysis	O
of	O
such	O
samples	O
were	O
robust	O
and	O
likely	O
to	O
reflect	O
true	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
at	O
time	O
of	O
collection	O
.	O

The	O
E	O
##SI	O
source	O
was	O
set	O
in	O
the	O
negative	O
ion	O
mode	O
as	O
follows	O
:	O
voltage	O
5	O
k	B
##V	I
;	O
current	O
50	O
μ	O
##A	O
;	O
heated	O
ion	O
transfer	O
tube	O
330	O
°C	O
.	O

The	O
surgical	O
##ly	O
removed	O
tissue	O
was	O
cut	O
to	O
smaller	O
pieces	O
with	O
s	O
##cis	O
##sors	O
under	O
s	O
##ter	O
##ile	O
conditions	O
,	O
and	O
then	O
in	O
##cu	O
##bate	O
##d	O
for	O
15	O
min	O
at	O
room	O
temperature	O
(	O
R	O
##T	O
)	O
in	O
di	B
##thi	I
##oth	I
##re	I
##ito	I
##l	I
:	O
Hank	O
##´s	O
balanced	O
salt	O
solution	O
(	O
H	O
##BS	O
##S	O
)	O
(	O
B	O
##ios	O
##era	O
,	O
N	O
##ua	O
##ille	O
,	O
France	O
)	O
mix	O
(	O
1	O
:	O
9	O
v	O
/	O
v	O
)	O
,	O
in	O
order	O
to	O
remove	O
potential	O
contamination	O
.	O

The	O
tube	O
was	O
shaken	O
by	O
hand	O
for	O
1	O
min	O
and	O
then	O
a	O
mix	O
of	O
salts	O
containing	O
4	O
g	O
M	O
##g	O
##SO	O
_	O
4	O
,	O
1	O
g	O
Na	O
##C	O
##l	O
,	O
1	O
g	O
sodium	B
c	I
##it	I
##rate	I
,	O
0	O
.	O
5	O
g	O
di	B
##so	I
##dium	I
c	I
##it	I
##rate	I
se	O
##s	O
##qui	O
##hy	O
##dra	O
##te	O
,	O
was	O
added	O
and	O
the	O
tube	O
was	O
shaken	O
again	O
for	O
1	O
min	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
440	O
##0	O
rpm	O
for	O
5	O
min	O
.	O

G	B
##lut	I
##amine	I
spike	O
##d	O
after	O
met	B
##han	I
##ol	I
precipitation	O
also	O
showed	O
similar	O
conversion	O
of	O
the	O
spike	O
##d	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
(	O
see	O
text	O
)	O
,	O
which	O
indicates	O
that	O
the	O
conversion	O
does	O
not	O
depend	O
on	O
the	O
order	O
of	O
s	O
##pi	O
##king	O
.	O

The	O
main	O
source	O
of	O
variations	O
in	O
hip	B
##pura	I
##te	I
metabolism	O
comes	O
from	O
diet	O
##ary	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
diet	O
##ary	O
sources	O
of	O
p	O
##oly	O
##phe	O
##no	O
##lic	O
compounds	O
such	O
as	O
fruits	O
and	O
vegetables	O
)	O
,	O
and	O
he	O
##pa	O
##tic	O
and	O
gut	O
micro	O
##bial	O
metabolism	O
of	O
its	O
precursor	O
##s	O
(	O
mainly	O
ben	B
##zoic	I
acid	I
)	O

The	O
fact	O
that	O
the	O
majority	O
of	O
the	O
disc	O
##rim	O
##inating	O
variables	O
were	O
meta	O
##bol	O
##ites	O
implicated	O
in	O
g	O
##ly	O
##co	O
##lysis	O
and	O
that	O
urine	O
##s	O
of	O
a	O
##A	O
##IP	O
have	O
relatively	O
higher	O
concentrations	O
of	O
ace	B
##tate	I
,	O
c	B
##it	I
##rate	I
and	O
p	B
##yr	I
##u	I
##vate	I
compared	O
with	O
PC	O
##T	O
patients	O
suggest	O
that	O
metabolic	O
re	O
##p	O
##rog	O
##ram	O
##ming	O
operates	O
during	O
a	O
##A	O
##IP	O
,	O
even	O
in	O
the	O
absence	O
of	O
attacks	O
.	O

Fast	O
##ing	O
glucose	S
level	O
was	O
determined	O
using	O
the	O
glucose	S
o	O
##xi	O
##das	O
##e	O
ass	O
##ay	O
(	O
Cell	O
B	O
##iol	O
##ab	O
##s	O
,	O
San	O
Di	O
##go	O
,	O
CA	O
,	O
USA	O
)	O
,	O
while	O
the	O
insulin	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
concentrations	O
were	O
determined	O
using	O
the	O
enzyme	O
-	O
linked	O
im	O
##mu	O
##nos	O
##or	O
##bent	O
ass	O
##ay	O
(	O
E	O
##L	O
##IS	O
##A	O
)	O
kits	O
provided	O
by	O
Me	O
##rc	O
##od	O
##ia	O
(	O
Up	O
##ps	O
##ala	O
,	O
Sweden	O
)	O
and	O
Cloud	O
-	O
C	O
##lone	O
Corp	O
.	O
(	O
Houston	O
,	O
TX	O
,	O
USA	O
)	O
,	O
respectively	O
.	O

Higher	O
serum	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
and	O
c	B
##ys	I
##tein	I
##e	I
concentrations	O
independently	O
predicted	O
risk	O
of	O
early	O
bio	O
##chemical	O
re	O
##cu	O
##rrence	O
and	O
aggressive	O
##ness	O
of	O
disease	O
in	O
a	O
nest	O
##ed	O
case	O
control	O
study	O
.	O

Third	O
,	O
increase	O
c	B
##rea	I
##tin	I
##ine	I
in	O
the	O
AC	O
##LF	O
group	O
reflects	O
extra	O
-	O
liver	O
failure	O
with	O
re	O
##nal	O
injury	O
comparatively	O
of	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
of	O
the	O
C	O
##LF	O
group	O
.	O

Both	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
and	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
bind	O
to	O
DNA	O
,	O
almost	O
exclusively	O
at	O
d	O
##G	O
.	O
DNA	O
add	O
##uc	O
##t	O
formation	O
with	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
is	O
believed	O
to	O
occur	O
through	O
the	O
proposed	O
ni	O
##tre	O
##nium	O
ion	O
via	O
an	O
S	O
_	O
N	O
1	O
or	O
an	O
intermediate	O
S	O
_	O
N	O
2	O
mechanism	O
.	O

In	O
contrast	O
,	O
la	B
##ct	I
##ate	I
showed	O
a	O
good	O
to	O
moderate	O
negative	O
correlation	O
with	O
the	O
1	O
.	O
3	O
##pp	O
##m	O
fatty	O
acid	O
peak	O
in	O
all	O
the	O
5	O
t	O
##umour	O
types	O
.	O

Furthermore	O
,	O
emerging	O
evidence	O
suggests	O
that	O
inflammation	O
plays	O
a	O
major	O
role	O
in	O
the	O
initiation	O
and	O
per	O
##pet	O
##uation	O
of	O
A	B
##F	I
.	O

The	O
protein	O
is	O
transported	O
to	O
the	O
Go	O
##l	O
##gi	O
apparatus	O
,	O
and	O
the	O
g	B
##ly	I
##cans	I
are	O
modified	O
in	O
multiple	O
steps	O
.	O

These	O
four	O
meta	O
##bol	O
##ites	O
were	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
,	O
format	B
##e	I
,	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
and	O
ch	B
##olin	I
##e	I
.	O

H	B
##A	I
,	O
ta	B
##uri	I
##ne	I
,	O
se	B
##rine	I
,	O
c	B
##ys	I
##tine	I
,	O
g	B
##ly	I
##cine	I
,	O
ho	B
##mo	I
##cy	I
##st	I
##ine	I
(	O
HC	O
##y	O
##2	O
)	O
,	O
rib	B
##of	I
##lav	I
##in	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
SA	O
##H	O
,	O
p	B
##yr	I
##ido	I
##xa	I
##mine	I
,	O
SA	O
##M	O
,	O
D	B
##MG	I
,	O
ch	B
##olin	I
##e	I
,	O
beta	B
##ine	I
,	O
5	O
-	O
M	O
##TH	O
##F	O
,	O
ta	B
##uri	I
##ne	I
-	I
_	I
13	I
C	O
_	O
2	O
,	O
g	B
##ly	I
##cine	I
-	I
d	I
_	I
2	I
,	O
rib	B
##of	I
##lav	I
##in	I
-	I
di	I
##ox	I
##opy	I
##rim	I
##id	I
##ine	I
-	I
_	I
13	I
C	O
_	O
4	O
_	O
15	O
N	O
_	O
2	O
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
-	I
d	I
_	I
3	I
standards	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
Ch	O
##em	O
##ie	O
GmbH	O
.	O
H	O
##A	O
-	O
d	O
_	O
4	O
,	O
se	B
##rine	I
-	I
d	I
_	I
3	I
,	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
-	I
d	I
_	I
2	I
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
-	I
d	I
_	I
4	I
,	O
SA	O
##M	O
-	O
d	O
_	O
4	O
,	O
D	O
##MG	O
-	O
d	O
_	O
6	O
,	O
ch	B
##olin	I
##e	I
-	I
d	I
_	I
9	I
,	O
and	O
beta	B
##ine	I
-	I
d	I
_	I
11	I
were	O
purchased	O
from	O
CD	O
##N	O
Is	O
##oto	O
##pes	O
(	O
Point	O
##e	O
-	O
Claire	O
,	O
Quebec	O
,	O
Canada	O
)	O
.	O

After	O
adjusting	O
for	O
Fr	O
##ami	O
##ng	O
##ham	O
Risk	O
Score	O
,	O
h	O
##s	O
##CR	O
##P	O
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
clearance	O
,	O
subjects	O
with	O
lowest	O
absolute	O
values	O
of	O
GA	O
##BR	O
highest	O
levels	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
showed	O
the	O
greatest	O
risk	O
for	O
incident	O
MAC	O
##E	O
over	O
the	O
three	O
years	O
after	O
an	O
##gio	O
##graphy	O
.	O

A	O
solution	O
containing	O
U	O
-	O
_	O
13	O
C	B
_	I
4	I
-	I
L	I
-	I
as	I
##par	I
##tic	I
acid	I
,	O
U	O
-	O
_	O
13	O
C	B
_	I
3	I
-	I
L	I
-	I
al	I
##ani	I
##ne	I
,	O
U	O
-	O
_	O
13	O
C	B
_	I
4	I
-	I
L	I
-	I
th	I
##re	I
##oni	I
##ne	I
,	O
U	O
-	O
_	O
13	O
C	B
_	I
5	I
-	I
L	I
-	I
pro	I
##line	I
,	O
U	O
-	O
_	O
13	O
C	B
_	I
5	I
-	I
L	I
-	I
v	I
##ali	I
##ne	I
,	O
U	O
-	O
_	O
13	O
C	B
_	I
6	I
-	I
le	I
##uc	I
##ine	I
,	O
U	O
-	O
_	O
13	O
C	B
_	I
6	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
all	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
_	O
13	O
C	B
_	I
6	I
-	I
t	I
##yr	I
##os	I
##ine	I
from	O
Is	O
##ote	O
##c	O
,	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
(	O
_	O
15	O
N	O
_	O
2	O
,	O
_	O
2	O
H	O
_	O
2	O
)	O
from	O
Mass	O
##T	O
##race	O
,	O
nor	B
##val	I
##ine	I
from	O
Sigma	O
dissolved	O
in	O
0	O
.	O
01	O
##N	O
HC	O
##l	O
was	O
used	O
as	O
the	O
internal	O
standard	O
solution	O
.	O

10	O
cc	O
ve	O
##nous	O
blood	O
(	O
10	O
cc	O
)	O
,	O
of	O
fast	O
##ing	O
patients	O
,	O
was	O
collected	O
in	O
lit	B
##hium	I
-	I
he	I
##par	I
##in	I
tubes	O
and	O
stored	O
within	O
5	O
min	O
at	O
4	O
°C	O
.	O

Pro	O
##mis	O
##ing	O
future	O
treatments	O
may	O
combine	O
approaches	O
to	O
target	O
different	O
metabolic	O
pathways	O
such	O
as	O
g	B
##lut	I
##amine	I
metabolism	O
,	O
g	O
##ly	O
##co	O
##lysis	O
or	O
the	O
T	O
##CA	O
cycle	O
.	O

Our	O
findings	O
and	O
theirs	O
suggest	O
the	O
possibility	O
that	O
p	B
##ela	I
##rgon	I
##ic	I
acid	I
is	O
related	O
to	O
the	O
onset	O
of	O
CA	O
##D	O
under	O
di	O
##abe	O
##tic	O
conditions	O
.	O

I	O
##mm	O
##uno	O
##his	O
##to	O
##chemical	O
analysis	O
of	O
G	B
##lut	I
##amine	I
S	O
##ynth	O
##eta	O
##se	O
(	O
G	O
##S	O
)	O
was	O
done	O
according	O
to	O
standard	O
procedures	O
(	O
Anti	O
##bo	O
##dies	O
from	O
B	O
##D	O
Trans	O
##duction	O
Laboratories	O
[UNK]	O
,	O
di	O
##lution	O
at	O
1	O
/	O
400	O
)	O
.	O

A	O
pattern	O
of	O
higher	O
levels	O
of	O
essential	O
amino	O
acids	O
appears	O
when	O
considering	O
that	O
2	B
-	I
k	I
##eto	I
##is	I
##oc	I
##ap	I
##roi	I
##c	I
acid	I
(	O
p	O
<	O
0	O
.	O
02	O
##7	O
,	O
q	O
<	O
0	O
.	O
12	O
)	O
and	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	I
(	O
p	O
<	O
0	O
.	O
03	O
##9	O
,	O
q	O
<	O
0	O
.	O
13	O
)	O
,	O
intermediate	O
##s	O
in	O
the	O
degradation	O
of	O
le	B
##uc	I
##ine	I
and	O
l	B
##ys	I
##ine	I
respectively	O
,	O
were	O
both	O
increased	O
by	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
.	O

Three	O
plasma	O
meta	O
##bol	O
##ites	O
meet	O
the	O
criterion	O
,	O
including	O
ratio	O
of	O
L	B
-	I
as	I
##par	I
##agi	I
##ne	I
to	O
L	B
-	I
as	I
##par	I
##tic	I
acid	I
,	O
van	B
##ill	I
##yl	I
##mand	I
##eli	I
##c	I
acid	I
and	O
g	B
##lut	I
##ari	I
##c	I
acid	I
.	O

Typical	O
tube	O
lens	O
offset	O
values	O
were	O
67	O
V	O
for	O
co	B
##tin	I
##ine	I
and	O
60	O
V	O
for	O
N	O
##NA	O
##L	O
.	O

At	O
the	O
basal	O
status	O
before	O
the	O
AS	O
##A	O
-	O
BP	O
##T	O
,	O
the	O
levels	O
of	O
serum	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
(	O
S	O
##1	O
##P	O
)	O
and	O
urine	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
were	O
significantly	O
higher	O
in	O
the	O
A	O
##ER	O
##D	O
patients	O
compared	O
with	O
that	O
of	O
AT	O
##A	O
patients	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
were	O
positively	O
correlated	O
with	O
a	O
greater	O
decrease	O
in	O
F	O
##E	O
##V	O
_	O
1	O
(	O
%	O
)	O
values	O
following	O
the	O
AS	O
##A	O
-	O
BP	O
##T	O
test	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
for	O
each	O
)	O
,	O
and	O
with	O
serum	O
per	O
##ios	O
##tin	O
level	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
each	O
)	O
.	O

W	O
##aa	O
##ge	O
##pet	O
##erse	O
##n	O
and	O
cow	O
##or	O
##kers	O
have	O
demonstrated	O
that	O
al	B
##ani	I
##ne	I
has	O
an	O
important	O
role	O
as	O
a	O
carrier	O
of	O
nitrogen	B
g	I
##lut	I
##ama	I
##ter	I
##gic	I
neurons	O
to	O
as	O
##tro	O
##cy	O
##tes	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
increased	O
flux	O
through	O
the	O
des	B
##most	I
##ero	I
##l	I
pathway	O
to	O
maintain	O
normal	O
cellular	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Other	O
try	B
##pt	I
##op	I
##han	I
degradation	O
products	O
,	O
in	B
##do	I
##le	I
##la	I
##ct	I
##ate	I
(	O
1	O
.	O
2	O
-	O
fold	O
)	O
and	O
in	B
##do	I
##le	I
##p	I
##rop	I
##ion	I
##ate	I
(	O
2	O
.	O
2	O
-	O
fold	O
)	O
,	O
related	O
to	O
micro	O
##bio	O
##me	O
metabolic	O
origin	O
tended	O
to	O
increase	O
(	O
and	O
)	O
.	O

The	O
new	O
method	O
q	O
##uant	O
##ifies	O
naturally	O
occurring	O
[	O
_	O
13	O
C	O
]	O
co	O
##tin	O
##ine	O
to	O
minimize	O
problems	O
associated	O
with	O
the	O
vast	O
differences	O
in	O
concentration	O
of	O
total	O
co	B
##tin	I
##ine	I
and	O
total	O
N	O
##NA	O
##L	O
in	O
urine	O
.	O

These	O
C	O
_	O
27	O
bi	O
##le	O
acids	O
could	O
originate	O
in	O
plasma	O
and	O
be	O
transferred	O
to	O
CS	O
##F	O
or	O
alternatively	O
be	O
formed	O
in	O
brain	O
from	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
,	O
)	O
,	O
which	O
is	O
itself	O
suggested	O
to	O
be	O
imported	O
into	O
brain	O
from	O
plasma	O
.	O

NHL	O
,	O
non	O
-	O
Ho	O
##d	O
##g	O
##kin	O
l	O
##ymph	O
##oma	O
;	O
CH	O
##OP	O
-	O
R	O
,	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
,	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
,	O
on	O
##co	O
##vin	O
,	O
pre	B
##dn	I
##ison	I
##e	I
,	O
r	O
##it	O
##ux	O
##ima	O
##b	O
;	O
HC	O
##VA	O
##D	O
,	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
,	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
,	O
on	O
##co	O
##vin	O
,	O
pre	B
##dn	I
##ison	I
##e	I
,	O
met	O
##hot	O
##re	O
##xa	O
##te	O
,	O
c	O
##yt	O
##ara	O
##bine	O
;	O
R	O
##IC	O
##E	O
,	O
if	B
##os	I
##fa	I
##mi	I
##de	I
,	O
car	B
##bo	I
##p	I
##lat	I
##in	I
,	O
et	B
##op	I
##os	I
##ide	I
,	O
r	O
##it	O
##ux	O
##ima	O
##b	O
;	O
PS	O
##CT	O
,	O
auto	O
##log	O
##ous	O
stem	O
cell	O
transplant	O
;	O
X	O
##RT	O
,	O
involved	O
field	O
i	O
##rra	O
##diation	O
;	O
Ma	O
##G	O
##rat	O
##h	O
,	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
,	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
,	O
on	O
##co	O
##vin	O
,	O
met	O
##hot	O
##re	O
##xa	O
##te	O
,	O
if	B
##os	I
##fa	I
##mi	I
##de	I
,	O
et	B
##op	I
##os	I
##ide	I
,	O
c	O
##yt	O
##ara	O
##bine	O
;	O
L	O
##BL	O
-	O
1	O
,	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
,	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
,	O
pre	B
##dn	I
##ison	I
##e	I
,	O
v	B
##in	I
##c	I
##rist	I
##ine	I
,	O
maintenance	O
6	O
##MP	O
and	O
L	O
-	O
as	O
##par	O
##agi	O
##nas	O
##e	O
;	O
Pen	O
##to	O
/	O
T	O
##BI	O
,	O
mini	O
##allo	O
##gene	O
##ic	O
stem	O
cell	O
transplant	O
with	O
pen	O
##tos	O
##tat	O
##in	O
/	O
total	O
body	O
i	O
##rra	O
##diation	O
;	O
flu	O
##dar	O
##a	O
,	O
flu	O
##dar	O
##abi	O
##ne	O

Train	O
##ed	O
mon	O
##ocytes	O
display	O
high	O
glucose	S
consumption	O
and	O
la	B
##ct	I
##ate	I
in	O
se	O
##psis	O
.	O

C	B
##it	I
##rate	I
in	O
##hibit	O
##s	O
the	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
(	O
ATP	O
)	O
producing	O
processes	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
,	O
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
as	O
well	O
as	O
stimulate	O
##s	O
ATP	S
consuming	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
and	O
lip	O
##id	O
synthesis	O
.	O

Post	O
##pra	O
##ndi	O
##al	O
met	B
##hi	I
##oni	I
##ne	I
levels	O
were	O
increased	O
in	O
infants	O
fed	O
a	O
milk	O
-	O
based	O
formula	O
as	O
well	O
as	O
in	O
the	O
plasma	O
of	O
o	O
##bes	O
##e	O
subjects	O
fed	O
a	O
w	B
##hey	I
is	O
##olate	O
but	O
not	O
as	O
much	O
after	O
the	O
intake	O
by	O
o	O
##bes	O
##e	O
subjects	O
of	O
a	O
w	B
##hey	I
h	I
##ydro	I
##ly	I
##sat	I
##e	I
,	O
probably	O
due	O
to	O
oxidation	O
into	O
its	O
su	B
##lf	I
##oxide	I
in	O
the	O
latter	O
product	O
.	O

We	O
also	O
found	O
that	O
GA	O
##BR	O
may	O
be	O
a	O
more	O
sensitive	O
diagnostic	O
measurement	O
compared	O
to	O
a	O
single	O
concentration	O
of	O
a	B
##rg	I
##ini	I
##ne	I
.	O

The	O
potential	O
mechanisms	O
linking	O
the	O
aforementioned	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
and	O
T	O
##2	O
##D	O
risk	O
must	O
be	O
also	O
further	O
investigated	O
.	O

Ch	O
##roma	O
##to	O
##graphic	O
separation	O
was	O
achieved	O
with	O
a	O
30	O
m	O
0	O
.	O
25	O
mm	O
CP	O
-	O
Si	O
##l	O
8	O
CB	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
G	O
##C	O
column	O
with	O
1	O
.	O
00	O
µ	O
##m	O
film	O
thickness	O
from	O
A	O
##gi	O
##lent	O
(	O
A	O
##gi	O
##lent	O
,	O
J	O
&	O
W	O
Scientific	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
,	O
USA	O
)	O
,	O
with	O
he	O
##lium	O
as	O
carrier	O
gas	O
.	O

e	O
.	O
g	O
.	O
24	B
(	B
S	I
)	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
and	O
o	B
##x	I
##och	I
##ole	I
##ster	I
##ols	I
,	O

0	O
.	O
99	O
##8	O
,	O
Q	O
_	O
2	O
=	O
0	O
.	O
67	O
##8	O
)	O
,	O
(	O
B	O
)	O
cap	O
##illa	O
##ry	O
electro	O
##ph	O
##ores	O
##is	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
E	B
##SI	I
(	I
+	I
)	I
(	O
R	O
_	O
2	O
=	O
0	O
.	O
92	O
##9	O
,	O
Q	O
_	O
2	O
=	O
0	O
.	O
81	O
##6	O
)	O
,	O
(	O
C	O
)	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
E	B
##SI	I
(	I
+	I
)	I
(	O
R	O
_	O
2	O
=	O

The	O
reactions	O
were	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
##°	O
##C	O
for	O
25	O
min	O
and	O
were	O
stopped	O
by	O
adding	O
125	O
μ	O
L	O
ice	O
-	O
cold	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

The	O
culture	O
medium	O
R	O
##PM	O
##I	O
1640	O
(	O
#	O
51	O
##80	O
##0	O
–	O
03	O
##5	O
,	O
G	O
##ib	O
##co	O
)	O
contained	O
H	O
##EP	O
##ES	O
,	O
anti	O
##biotic	O
/	O
anti	O
##my	O
##cot	O
##ic	O
mix	O
(	O
#	O
152	O
##40	O
–	O
06	O
##2	O
,	O
G	O
##ib	O
##co	O
)	O
,	O
Na	O
##HC	O
##O	O
_	O
3	O
,	O
insulin	O
,	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
and	O
5	O
%	O
F	O
##BS	O
.	O

A	O
##cc	O
##ura	O
##cy	O
of	O
the	O
ass	O
##ay	O
,	O
calculated	O
as	O
the	O
measured	O
percentage	O
of	O
a	O
weighed	O
amount	O
of	O
an	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
added	O
to	O
urine	O
samples	O
,	O
was	O
96	O
–	O
108	O
%	O
.	O

In	O
addition	O
,	O
an	O
increase	O
in	O
plasma	O
T	B
##MA	I
##O	I
could	O
lead	O
to	O
significantly	O
lower	O
expression	O
of	O
the	O
key	O
bi	O
##le	O
acid	O
synthetic	O
enzymes	O
and	O
multiple	O
bi	O
##le	O
acid	O
transport	O
##ers	O
.	O

First	O
##ly	O
,	O
each	O
type	O
of	O
cancer	O
urine	O
was	O
subjected	O
to	O
IL	O
-	O
L	O
##C	O
-	O
D	O
##PI	O
-	O
MS	O
method	O
for	O
the	O
non	O
-	O
targeted	O
pro	O
##fi	O
##ling	O
of	O
th	B
##iol	I
##s	I
.	O

For	O
sample	O
preparation	O
,	O
following	O
an	O
adapted	O
protocol	O
by	O
Mel	O
##o	O
et	O
al	O
.	O
,	O
20	O
μ	O
##L	O
of	O
plasma	O
were	O
di	O
##lut	O
##ed	O
in	O
200	O
μ	O
##L	O
of	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##ura	I
##n	I
and	O
ho	O
##mo	O
##gen	O
##ized	O
under	O
v	O
##ortex	O
for	O
30	O
s	O
;	O
the	O
volume	O
was	O
completed	O
to	O
1	O
m	O
##L	O
with	O
met	B
##han	I
##ol	I
,	O
with	O
further	O
ho	O
##mo	O
##gen	O
##ization	O
,	O
and	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
5	O
min	O
under	O
3	O
,	O
600	O
rpm	O
.	O

To	O
get	O
further	O
insights	O
into	O
the	O
nature	O
(	O
shape	O
and	O
multi	O
##p	O
##licity	O
)	O
of	O
the	O
variables	O
found	O
associated	O
with	O
glucose	S
we	O
represent	O
the	O
mean	O
spectrum	O
in	O
the	O
bottom	O
panel	O
(	O
left	O
Y	O
axis	O
)	O
.	O

Level	O
##s	O
of	O
serum	O
al	B
##ani	I
##ne	I
was	O
elevated	O
in	O
N	O
##SC	O
##LC	O
group	O
,	O
which	O
was	O
consistent	O
with	O
previous	O
report	O
.	O

Ad	O
##rena	O
##l	O
s	O
##tero	O
##ids	O
Secondary	O
B	O
##ile	O
A	O
##cid	O
##s	O
G	O
##lu	O
##cos	O
##e	O
/	O
Energy	O
Met	O
##ab	O
##olis	O
##m	O
Col	O
##lage	O
##n	O
Break	O
##down	O
Products	O
Am	O
##ino	O
A	O
##cid	O
##s	O
and	O
Met	O
##ab	O
##oli	O
##tes	O
Fat	O
##ty	O
A	O
##cid	O
##s	O
L	O
##ys	O
##oli	O
##pid	O
##s	O
Other	O
Ad	O
##rena	O
##l	O
/	O
go	O
##na	O
##dal	O
s	O
##tero	O
##ids	O
:	O
A	O
number	O
of	O
the	O
su	O
##lf	O
##ated	O
s	O
##tero	O
##ids	O
produced	O
by	O
the	O
ad	O
##rena	O
##l	O
g	O
##land	O
and	O
go	O
##na	O
##ds	O
and	O
su	O
##lf	O
##ated	O
by	O
liver	O
su	O
##lf	O
##ot	O
##ran	O
##s	O
##fer	O
##ases	O
were	O
affected	O
by	O
oral	O
administration	O
of	O
limo	B
##nen	I
##e	I
.	O

These	O
results	O
were	O
valid	O
##ated	O
in	O
an	O
independent	O
cross	O
-	O
section	O
##al	O
study	O
of	O
individuals	O
at	O
risk	O
for	O
type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
undergoing	O
a	O
frequently	O
sampled	O
in	O
##tra	O
##ven	O
##ous	O
glucose	S
tolerance	O
test	O
.	O

The	O
significance	O
of	O
rib	B
##of	I
##lav	I
##in	I
was	O
discussed	O
in	O
many	O
publications	O
[	O
,	O
]	O
.	O

MR	O
##M	O
analysis	O
of	O
eighteen	O
24	O
h	O
urine	O
sample	O
collections	O
from	O
met	O
##form	O
##in	O
-	O
treated	O
T	O
##2	O
##DM	O
patients	O
demonstrates	O
that	O
mean	O
I	O
##M	O
##Z	O
concentrations	O
have	O
a	O
statistical	O
##ly	O
significant	O
r	O
_	O
2	O
value	O
(	O
r	O
_	O
2	O
=	O
0	O
.	O
73	O
##48	O
;	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
with	O
met	B
##form	I
##in	I
concentrations	O
.	O

The	O
low	O
concentration	O
of	O
free	O
glucose	S
is	O
a	O
feature	O
of	O
cancer	O
cells	O
which	O
together	O
with	O
the	O
low	O
level	O
of	O
G	O
##6	O
##P	O
reflects	O
the	O
high	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
,	O
making	O
glucose	S
transport	O
rate	O
limiting	O
,	O
despite	O
der	O
##ep	O
##ression	O
of	O
G	O
##L	O
##UT	O
##4	O
expression	O
by	O
m	O
##uta	O
##ted	O
p	O
##53	O
[	O
]	O
.	O

Changes	O
in	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
suggested	O
a	O
disruption	O
in	O
their	O
bio	O
##physical	O
properties	O
among	O
study	O
groups	O
.	O

Indeed	O
,	O
in	O
this	O
study	O
we	O
observed	O
that	O
LP	B
##I	I
(	I
16	I
:	I
1	I
)	I
significantly	O
improved	O
risk	O
prediction	O
of	O
type	O
2	O
diabetes	O
,	O
which	O
also	O
confirmed	O
our	O
previous	O
finding	O
that	O
LP	B
##I	I
(	I
16	I
:	I
1	I
)	I
can	O
be	O
an	O
early	O
predict	O
##or	O
for	O
type	O
2	O
diabetes	O
.	O

Of	O
note	O
,	O
as	O
w	B
##hey	I
is	O
removed	O
during	O
the	O
production	O
of	O
G	O
##ru	O
##y	O
##ère	O
cheese	O
,	O
the	O
high	O
content	O
of	O
met	B
##hi	I
##oni	I
##ne	I
in	O
case	B
##in	I
could	O
still	O
explain	O
our	O
finding	O
.	O

This	O
would	O
lead	O
to	O
the	O
observed	O
subtle	O
de	O
##ter	O
##ior	O
##ation	O
of	O
glucose	S
metabolism	O
by	O
Omega	B
-	I
3	I
.	O

As	O
a	O
part	O
of	O
clinical	O
care	O
,	O
the	O
results	O
of	O
bio	O
##chemical	O
screening	O
for	O
non	O
-	O
ad	O
##herence	O
to	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
treatment	O
were	O
reported	O
to	O
the	O
patients	O
(	O
usually	O
during	O
their	O
next	O
appointment	O
in	O
the	O
clinic	O
)	O
and	O
information	O
on	O
the	O
results	O
from	O
HP	S
L	O
##C	O
-	O
MS	O
/	O
MS	O
urine	O
-	O
based	O
analysis	O
was	O
included	O
in	O
the	O
clinical	O
letter	O
to	O
patients	O
’	O
general	O
practitioners	O
.	O

Li	O
##quid	O
ch	O
##roma	O
##tography	O
grade	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
was	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
Mo	O
,	O
USA	O
)	O
,	O
and	O
98	O
%	O
form	B
##ic	I
acid	I
was	O
purchased	O
from	O
F	O
##luk	O
##a	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

Moreover	O
,	O
his	B
##tamine	I
is	O
thought	O
to	O
be	O
involved	O
in	O
in	O
##hibition	O
of	O
the	O
local	O
immune	O
response	O
against	O
cancer	O
(	O
Ma	O
##sin	O
##i	O
et	O
al	O
.	O
)	O
.	O

This	O
represents	O
only	O
54	O
%	O
improvement	O
over	O
the	O
single	O
best	O
extraction	O
method	O
of	O
met	B
##han	I
##ol	I
/	O
ethanol	O
(	O
380	O
##4	O
put	O
##ative	O
meta	O
##bol	O
##ites	O
)	O
or	O
met	B
##han	I
##ol	I
(	O
37	O
##9	O
##5	O
put	O
##ative	O
meta	O
##bol	O
##ites	O
)	O
.	O

A	O
5	O
%	O
dip	O
##hen	O
##yl	O
/	O
95	O
%	O
dim	O
##eth	O
##yl	O
##pol	O
##ys	O
##ilo	O
##xa	O
##ne	O
fused	O
si	B
##lica	I
column	O
(	O
20	O
m	O
×	O
0	O
.	O
18	O
mm	O
ID	O
;	O
0	O
.	O
18	O
µ	O
##m	O
film	O
thickness	O
)	O
was	O
used	O
to	O
separate	O
the	O
samples	O
.	O

N	B
-	I
Ace	I
##ty	I
##l	I
-	I
S	I
-	I
met	I
##hyl	I
-	I
c	I
##ys	I
##tein	I
##e	I
-	I
su	I
##lf	I
##oxide	I
(	O
N	O
##A	O
##c	O
##SM	O
##CS	O
##O	O
)	O
is	O
the	O
major	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
after	O
consumption	O
of	O
c	O
##ru	O
##ci	O
##fer	O
##ous	O
and	O
other	O
vegetables	O
.	O

(	O
[	O
PS	O
40	O
:	O
6	O
–	O
H	O
]	O
-	O
)	O
and	O
88	O
##8	O
(	O
[	B
(	B
3	I
’	I
-	I
su	I
##lf	I
##o	I
)	I
G	I
##al	I
##C	I
##er	I
24	I
:	I
1	I
–	I
H	I
]	O
-	O
)	O
relative	O
to	O
the	O
grey	O
and	O
white	O
matter	O
average	O
s	O
##pect	O
##ra	O
,	O
and	O
therefore	O
appear	O
to	O
have	O
a	O
visually	O
distinct	O
lip	O
##id	O
profile	O
.	O

Consequently	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
is	O
not	O
strictly	O
required	O
to	O
produce	O
end	O
##ogen	O
##ous	O
glucose	S
,	O
at	O
variance	O
with	O
I	O
##R	O
subjects	O
.	O

At	O
this	O
point	O
,	O
our	O
candidate	O
model	O
set	O
was	O
narrowed	O
down	O
to	O
seven	O
models	O
that	O
represent	O
variations	O
on	O
a	O
core	O
feature	O
set	O
(	B
al	B
##ani	I
##ne	I
,	O
c	B
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
)	O
.	O

As	O
expected	O
,	O
LP	O
##IR	O
strongly	O
correlated	O
with	O
HD	O
##L	O
-	O
c	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
respectively	O
,	O
ρ	O
−	O
##0	O
.	O
66	O
and	O
0	O
.	O
75	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
and	O
its	O
individual	O
lip	O
##op	O
##rote	O
##in	O
components	O
.	O

From	O
the	O
dried	O
filters	O
,	O
meta	O
##bol	O
##ites	O
and	O
internal	O
standards	O
were	O
extracted	O
with	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
met	B
##han	I
##ol	I
.	O

If	O
D	O
-	O
le	O
##uc	O
##ic	O
acid	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cap	I
##ric	I
acid	I
were	O
excluded	O
leaving	O
only	O
u	B
##ric	I
acid	I
,	O
x	B
##ant	I
##hine	I
,	O
ch	B
##oly	I
##l	I
##gly	I
##cine	I
,	O
a	O
##rac	O
##hi	O
##don	O
##yl	O
l	O
##ys	O
##ole	O
##ci	O
##thin	O
,	O
and	O
di	B
##ole	I
##oy	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
the	O
model	O
would	O
yield	O
a	O
sensitivity	O
and	O
specific	O
##ity	O
of	O
89	O
%	O
and	O
95	O
%	O
,	O
respectively	O
,	O
with	O
a	O
calculated	O
AU	O
##RO	O
##C	O
of	O
0	O
.	O
93	O
.	O

The	O
enzyme	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
converts	O
g	B
##lut	I
##amine	I
to	O
g	B
##lut	I
##ama	I
##te	I
,	O
which	O
can	O
be	O
used	O
by	O
al	O
##ani	O
##ne	O
amino	O
##tras	O
##fer	O
##ase	O
to	O
produce	O
intermediate	O
##s	O
of	O
the	O
T	O
##CA	O
cycle	O
or	O
for	O
the	O
synthesis	O
of	O
g	B
##lut	I
##ath	I
##ione	I
,	O
a	O
trip	O
##eptide	O
that	O
acts	O
as	O
an	O
important	O
anti	O
##ox	O
##ida	O
##nt	O
in	O
cells	O
.	O

This	O
could	O
explain	O
why	O
we	O
see	O
lower	O
levels	O
of	O
c	B
##rea	I
##tin	I
##ine	I
in	O
tissue	O
from	O
GB	O
##M	O
tumors	O
as	O
compared	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##ma	O
.	O

Two	O
di	O
##aster	O
##eo	O
##mers	O
of	O
15	O
with	O
respect	O
to	O
the	O
su	B
##lf	I
##oxide	I
ch	O
##ira	O
##l	O
center	O
were	O
formed	O
in	O
equal	O
quantities	O
.	O

Tau	B
##rine	I
has	O
many	O
diverse	O
biological	O
functions	O
that	O
serve	O
as	O
stab	O
##ilizer	O
##s	O
of	O
cell	O
membrane	O
##s	O
and	O
anti	O
-	O
o	O
##xi	O
##dant	O
##s	O
.	O

Our	O
data	O
demonstrated	O
that	O
increased	O
c	B
##ys	I
##tein	I
##e	I
and	O
ta	B
##uri	I
##ne	I
occur	O
during	O
O	O
##G	O
##TT	O
##s	O
in	O
H	O
##LP	O
subjects	O
.	O

Although	O
further	O
valid	O
##ation	O
is	O
required	O
,	O
we	O
consider	O
this	O
methodology	O
appropriate	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
D	O
##H	O
##EA	O
,	O
A	O
##ED	O
,	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
from	O
human	O
plasma	O
samples	O
and	O
potentially	O
suitable	O
for	O
clinical	O
purposes	O
.	O

T	O
##h	O
##1	O
c	O
##yt	O
##oki	O
##nes	O
from	O
activated	S
in	O
##fi	O
##lt	O
##rating	O
T	O
and	O
B	O
cells	O
may	O
also	O
trigger	O
K	O
##S	O
les	O
##ion	O
formation	O
by	O
promoting	O
spin	O
##dle	O
cell	O
proliferation	O
and	O
an	O
##gio	O
##genesis	O
[	O
,	O
]	O
.	O

In	O
survivor	O
and	O
non	O
-	O
survivor	O
analyses	O
c	B
##rea	I
##tin	I
##ine	I
also	O
was	O
excluded	O
.	O

An	O
acute	O
injection	O
of	O
c	O
##yt	O
##oki	O
##nes	O
led	O
to	O
a	O
rise	O
in	O
co	B
##rt	I
##is	I
##ol	I
levels	O
,	O
seen	O
as	O
an	O
adaptive	O
response	O
to	O
f	O
##ulf	O
##il	O
the	O
increased	O
energy	O
demand	O
of	O
in	O
##f	O
##lam	O
##ed	O
tissues	O
.	O

F	B
##lu	I
##ox	I
##eti	I
##ne	I
,	O
the	O
well	O
-	O
known	O
anti	O
##de	O
##press	O
##ant	O
,	O
was	O
the	O
most	O
potent	O
in	O
this	O
group	O
.	O

1	O
µ	O
##m	O
;	O
20	O
µ	O
##m	O
(	O
[UNK]	O
)	O
m	O
m	O
m	O
m	O
To	O
identify	O
the	O
P	O
##45	O
##0	O
enzymes	O
participating	O
in	O
an	O
##ast	O
##ro	O
##zo	O
##le	O
h	O
##ydro	O
##xy	O
##lation	O
,	O
10	O
µ	O
##m	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
was	O
in	O
##cu	O
##bate	O
##d	O
with	O
P	O
##45	O
##0	O
is	O
##of	O
##orm	O
-	O
specific	O
inhibitor	O
##s	O
with	O
H	O
##LM	O
##s	O
and	O
co	O
##fa	O
##ctors	O
.	O

P	O
##las	O
##mi	O
##ds	O
with	O
c	O
##D	O
##NA	O
##s	O
for	O
re	B
##tino	I
##ic	I
acid	I
receptors	O
α	O
,	O
β	O
,	O
and	O
γ	O
were	O
co	O
##tra	O
##ns	O
##fected	O
in	O
individual	O
experiments	O
.	O

Previous	O
me	O
##con	O
##ium	O
methods	O
have	O
obtained	O
comparable	O
L	O
##O	O
##Q	O
##s	O
for	O
am	B
##phe	I
##tamine	I
##s	I
(	O
2	O
.	O
5	O
–	O
5	O
ng	O
/	O
g	O
)	O

We	O
report	O
here	O
a	O
sensitive	O
L	O
##C	O
–	O
MS	O
/	O
MS	O
method	O
for	O
measuring	O
,	O
without	O
der	O
##iva	O
##tis	O
##ation	O
,	O
the	O
th	B
##io	I
##pur	I
##ine	I
meta	O
##bol	O
##ite	O
,	O
d	O
##T	O
##G	O
,	O
in	O
DNA	O
isolated	O
from	O
whole	O
blood	O
of	O
patients	O
with	O
CD	O
or	O
UC	O
treated	O
with	O
A	O
##Z	O
##A	O
.	O

U	O
##rine	O
specimens	O
were	O
collected	O
from	O
a	O
healthy	O
cannabis	S
user	O
who	O
provided	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
a	O
National	O
Institute	O
of	O
Drug	O
Abu	O
##se	O
(	O
N	O
##ID	O
##A	O
)	O
,	O
Institution	O
##al	O
Review	O
Board	O
-	O
approved	O
clinical	O
study	O
investigating	O
can	B
##na	I
##bino	I
##id	I
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
and	O
novel	O
markers	O
of	O
cannabis	S
intake	O
following	O
a	O
single	O
T	O
##HC	O
dose	O
(	O
6	O
.	O
9	O
%	O
,	O
w	O
/	O
w	O
;	O
54	O
mg	O
total	O
dose	O
)	O
via	O
three	O
different	O
routes	O
of	O
administration	O
.	O

For	O
the	O
downstream	O
meta	O
##bol	O
##ites	O
of	O
glucose	S
,	O
we	O
found	O
0	O
.	O
74	O
%	O
of	O
the	O
la	B
##ct	I
##ate	I
and	O
0	O
.	O
51	O
%	O
of	O
the	O
al	B
##ani	I
##ne	I
pool	O
to	O
be	O
labeled	O
from	O
the	O
2	O
%	O
_	O
13	O
C	O
-	O
en	O
##rich	O
##ed	O
flour	O
(	O
b	O
,	O
left	O
panel	O
)	O
,	O
indicating	O
that	O
a	O
significant	O
fraction	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
is	O
fueled	O
by	O
the	O
food	O
product	O
.	O

So	O
in	O
that	O
model	O
,	O
in	O
contrast	O
to	O
the	O
positive	O
correlation	O
observed	O
in	O
the	O
brain	O
t	O
##umour	O
##s	O
,	O
there	O
was	O
a	O
negative	O
correlation	O
of	O
la	B
##ct	I
##ate	I
with	O
t	O
##C	O
##r	O
when	O
the	O
culture	O
##d	O
cells	O
were	O
transformed	O
and	O
developed	O
a	O
War	O
##burg	O
effect	O
.	O

Even	O
when	O
der	O
##iva	O
##tized	O
with	O
GP	S
re	O
##age	O
##nt	O
,	O
s	O
##tero	O
##ls	O
may	O
be	O
difficult	O
to	O
so	O
##lub	O
##ilize	O
(	O
or	O
retain	O
in	O
solution	O
)	O
when	O
using	O
a	O
highly	O
a	O
##que	O
##ous	O
mixture	O
of	O
met	B
##han	I
##ol	I
and	O
water	O
.	O

This	O
was	O
done	O
by	O
co	O
##rrel	O
##ating	O
the	O
resolved	O
metabolic	O
information	O
against	O
the	O
exercise	O
phase	O
(	B
pre	B
-	I
vs	I
.	O
post	O
-	O
exercise	O
)	O
and	O
predict	O
##ing	O
independent	O
samples	O
with	O
known	O
phase	O
into	O
existing	O
models	O
.	O

0	O
.	O
25	O
mm	O
film	O
thickness	O
of	O
5	O
%	O
p	O
##hen	O
##yl	O
and	O
95	O
%	O
met	B
##hyl	I
p	I
##oly	I
##si	I
##lo	I
##xa	I
##ne	I
)	O

The	O
car	O
##cin	O
##ogenic	O
effect	O
of	O
est	O
##rogen	O
##s	O
may	O
be	O
attributed	O
to	O
the	O
initiation	O
of	O
est	B
##rogen	I
metabolism	O
by	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
enzymes	O
C	O
##YP	O
##1	O
##B	O
##1	O
,	O
C	O
##YP	O
##1	O
##A	O
##1	O
,	O
and	O
C	O
##YP	O
##1	O
##A	O
##2	O
(	O
;	O
;	O
;	O
)	O
.	O

(	O
a	O
)	O
G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
,	O
(	O
b	O
)	O

The	O
decline	O
in	O
glucose	S
oxidation	O
during	O
is	O
##che	O
##mia	O
requires	O
the	O
rapid	O
acceleration	O
in	O
the	O
conversion	O
of	O
p	B
##yr	I
##u	I
##vate	I
to	O
la	B
##ct	I
##ate	I
in	O
order	O
to	O
re	O
##generate	O
N	O
##AD	O
_	O
+	O
under	O
oxygen	O
limiting	O
conditions	O
,	O
which	O
is	O
required	O
to	O
sustain	O
g	O
##ly	O
##co	O
##lysis	O
.	O

The	O
dried	O
mixture	O
was	O
re	O
##con	O
##stituted	O
with	O
50	O
μ	O
##L	O
of	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
—	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
mixture	O
(	O
25	O
:	O
75	O
,	O
v	O
/	O
v	O
)	O
and	O
v	O
##ortex	O
##ed	O
for	O
30	O
s	O
.	O

Two	O
LP	O
##C	O
’	O
s	O
(	O
(	O
14	O
:	O
0	O
)	O
and	O
LP	B
##C	I
(	I
16	I
:	I
0	I
)	I
)	O
were	O
detected	O
with	O
both	O
platforms	O
and	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
pre	O
-	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
individuals	O
compared	O
with	O
controls	O
(	O
Figure	O
##s	O
A	O
and	O
B	O
in	O
)	O
.	O

Both	O
the	O
independent	O
valid	O
##ation	O
study	O
and	O
the	O
initial	O
case	O
-	O
control	O
study	O
showed	O
a	O
similar	O
pattern	O
of	O
non	O
##linear	O
association	O
between	O
plasma	O
T	B
##MA	I
##O	I
and	O
G	O
##DM	O
,	O
which	O
is	O
depicted	O
in	O
.	O

In	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
analysis	O
,	O
subjects	O
with	O
SA	O
##P	O
,	O
the	O
adverse	O
card	O
##iovascular	O
pro	O
##gno	O
##sis	O
associated	O
with	O
an	O
elevated	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
,	O
was	O
not	O
altered	O
after	O
adjusting	O
for	O
fast	O
##ing	O
or	O
time	O
since	O
last	O
meal	O
(	O
D	O
##har	O
I	O
,	O
S	O
##ving	O
##en	O
G	O
##FT	O
,	O
Ring	O
##dal	O
P	O
##ede	O
##rsen	O
E	O
,	O
De	O
##R	O
##att	O
B	O
,	O
U	O
##l	O
##vik	O
A	O
,	O
U	O
##ela	O
##nd	O
PM	O
,	O
Gregory	O
J	O
##F	O
,	O
N	O
##y	O
##g	O
##å	O
##rd	O
O	O
,	O
2017	O
)	O
.	O

Cy	O
##tok	O
##ines	O
as	O
well	O
as	O
the	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
,	O
K	O
##Y	O
##NA	O
and	O
Q	O
##UI	O
##N	O
,	O
do	O
not	O
easily	O
pass	O
the	O
B	O
##BB	O
,	O
and	O
therefore	O
,	O
plasma	O
levels	O
of	O
c	O
##yt	O
##oki	O
##nes	O
and	O
k	O
##yn	O
##uren	O
##ines	O
may	O
not	O
reflect	O
changes	O
in	O
the	O
brain	O
.	O

e	O
,	O
Assessment	O
of	O
cell	O
invasive	O
##ness	O
of	O
pro	O
##state	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
upon	O
ex	O
##ogen	O
##ous	O
administration	O
of	O
al	B
##ani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
or	O
sa	B
##rc	I
##os	I
##ine	I
(	O
mean	O
+	O
/	O
−	O
s	O
.	O
e	O
.	O
m	O
.	O
,	O
n	O
=	O
3	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
in	O
cases	O
of	O
re	O
##nal	O
ins	O
##uff	O
##iciency	O
,	O
the	O
ex	O
##cre	O
##tion	O
of	O
total	O
4	B
-	I
he	I
##pta	I
##non	I
##e	I
is	O
reduced	O
.	O

High	O
concentrations	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
x	B
##ant	I
##hine	I
,	O
and	O
u	B
##ric	I
acid	I
have	O
also	O
been	O
shown	O
in	O
patients	O
with	O
bacterial	O
men	O
##ing	O
##itis	O
.	O

We	O
performed	O
a	O
pathway	O
analysis	O
and	O
our	O
data	O
clearly	O
point	O
to	O
a	O
link	O
between	O
bi	O
##le	O
acids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
processing	O
(	O
see	O
Fi	O
##g	O
.	O

(	O
C	O
)	O
He	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
levels	O
among	O
SL	O
##CO	O
##1	O
##B	O
##1	O
(	O
c	O
.	O
48	O
##1	O
+	O
1	O
##G	O
>	O
T	O
)	O
Lo	O
##F	O
mutation	O
carriers	O
.	O

In	O
brief	O
,	O
[UNK]	O
100	O
μ	O
##L	O
of	O
to	B
##lue	I
##ne	I
(	O
dried	O
over	O
an	B
##hy	I
##dr	I
##ous	I
sodium	I
su	I
##lf	I
##ate	I
)	O
was	O
added	O
to	O
the	O
dry	O
sample	O
,	O
mixed	O
for	O
1	O
min	O
and	O
dried	O
again	O
in	O
the	O
vacuum	O
con	O
##cent	O
##rator	O
for	O
20	O
min	O
.	O

N	O
##AD	O
_	O
+	O
:	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
,	O
o	O
##xi	O
##dized	O
;	O
N	B
##AD	I
##H	I
:	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
,	O
reduced	O
;	O
N	O
##AD	O
##P	O
_	O
+	O
:	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
,	O
o	O
##xi	O
##dized	O
;	O
N	B
##AD	I
##P	I
##H	I
:	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
,	O
o	O
##xi	O
##dized	O
;	O
ATP	S
:	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
;	O
AD	B
##P	I
:	O
ad	B
##eno	I
##sin	I
##e	I
dip	I
##hos	I
##phate	I
;	O
AM	B
##P	I
:	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##op	I
##hos	I
##phate	I
;	O
G	B
##S	I
##H	I
:	O
g	B
##lut	I
##ath	I
##ione	I
,	O
reduced	O
;	O
and	O
G	O
##SS	O
##G	O
:	O
g	B
##lut	I
##ath	I
##ione	I
,	O
o	O
##xi	O
##dized	O
.	O

We	O
found	O
that	O
fast	O
##ing	O
levels	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
the	O
time	O
courses	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
BC	O
##AA	O
##s	O
in	O
response	O
to	O
a	O
glucose	S
challenge	O
character	O
##ize	O
I	O
##R	O
in	O
youth	O
.	O

Known	O
amounts	O
of	O
the	O
is	B
##of	I
##lav	I
##one	I
β	I
-	I
g	I
##lu	I
##cos	I
##ides	I
(	I
da	I
##id	I
##zin	I
,	I
g	I
##eni	I
##st	I
##in	I
and	O
g	B
##ly	I
##ci	I
##tin	I
)	I
and	O
the	O
a	B
##gly	I
##con	I
##es	I
,	O
da	B
##id	I
##ze	I
##in	I
,	O
g	B
##eni	I
##stein	I
and	O
g	B
##ly	I
##cite	I
##in	I
were	O
used	O
to	O
establish	O
standard	O
curves	O
.	O

Co	O
##mb	O
##ining	O
information	O
from	O
fatty	O
a	O
##cy	O
##l	O
composition	O
(	B
C	B
##17	I
:	I
0	I
and	O
C	B
##22	I
:	I
4	I
)	O
,	O
this	O
P	O
##E	O
was	O
confident	O
##ly	O
identified	O
as	O
P	B
##E	I
17	I
:	I
0	I
_	I
22	I
:	I
4	I
(	O
Δ	O
##7	O
,	O
10	O
,	O
13	O
,	O
and	O
16	O
)	O
,	O
with	O
no	O
other	O
major	O
C	O
=	O
C	O
location	O
is	O
##omer	O
identified	O
.	O

The	O
difference	O
in	O
correlation	O
values	O
for	O
the	O
two	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
resonance	O
##s	O
at	O
δ	O
2	O
.	O
15	O
and	O
1	O
.	O
86	O
or	O
6	O
.	O
96	O
with	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
peak	O
was	O
most	O
likely	O
caused	O
by	O
overlap	O
of	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
resonance	O
at	O
δ	O
2	O
.	O
15	O
with	O
the	O
N	O
-	O
ace	O
##ty	O
##l	O
signal	O
from	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
itself	O
.	O

Human	O
sa	O
##liva	O
contains	O
many	O
electro	O
##ly	O
##tes	O
(	O
bi	O
##car	O
##bon	O
##ate	O
,	O
calcium	O
,	O
chloride	S
,	O
potassium	O
,	O
sodium	O
,	O
ma	O
##gnesium	O
,	O
and	O
phosphate	S
)	O
and	O
a	O
variety	O
of	O
proteins	O
represented	O
by	O
enzymes	O
(	O
i	O
.	O
e	O
.	O
,	O
α	O
-	O
am	O
##yla	O
##se	O
,	O
ma	O
##lta	O
##se	O
,	O
and	O
p	O
##ept	O
##idas	O
##es	O
)	O
,	O
im	O
##mu	O
##no	O
##g	O
##lo	O
##bul	O
##ins	O
,	O
and	O
other	O
anti	O
##mic	O
##ro	O
##bial	O
factors	O
,	O
m	O
##uc	O
##osa	O
##l	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
traces	O
of	O
album	O
##in	O
,	O
and	O
some	O
p	O
##oly	O
##pe	O
##pt	O
##ides	O
and	O
o	O
##li	O
##go	O
##pe	O
##pt	O
##ides	O
,	O
which	O
might	O
interfere	O
with	O
the	O
analysis	O
.	O

In	O
conclusion	O
,	O
the	O
sum	O
of	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
in	O
urine	O
by	O
G	O
##C	O
/	O
MS	O
in	O
S	O
##IM	O
was	O
useful	O
for	O
analyzing	O
the	O
circa	O
##dian	O
variation	O
of	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
.	O

However	O
,	O
plasma	O
l	B
##ys	I
##ine	I
concentration	O
was	O
not	O
related	O
to	O
the	O
serum	O
O	O
##C	O
##N	O
concentration	O
in	O
the	O
present	O
study	O
and	O
further	O
studies	O
are	O
required	O
to	O
el	O
##uc	O
##ida	O
##te	O
a	O
possible	O
mechanism	O
behind	O
this	O
association	O
.	O

De	O
##uter	O
##ated	O
internal	O
standards	O
me	B
##lat	I
##oni	I
##n	I
-	I
D	I
_	I
4	I
,	I
5	I
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
-	I
D	I
_	I
4	I
,	O
L	B
-	I
k	I
##yn	I
##uren	I
##ine	I
-	I
D	I
_	I
4	I
,	O
in	B
##do	I
##le	I
-	I
D	I
_	I
5	I
-	I
3	I
-	I
ace	I
##tam	I
##ide	I
,	O
4	B
-	I
ch	I
##lor	I
##o	I
-	I
k	I
##yn	I
##uren	I
##ine	I
-	I
_	I
13	I
C	O
_	O
2	O
,	O
_	O
15	O
N	O
,	O
6	B
-	I
h	I
##ydro	I
##xy	I
##mel	I
##aton	I
##in	I
-	I
D	I
_	I
4	I
,	O
k	O
##yn	O
##uren	O
##ic	O
acid	O
-	O
D	O
_	O
5	O
,	O
PA	O
##G	O
##N	O
-	O
D	O
_	O
5	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
D	I
_	I
5	I
,	O
se	O
##rot	O
##oni	O
##n	O
-	O
D	O
_	O
4	O
,	O
try	B
##pta	I
##mine	I
-	I
D	I
_	I
4	I
,	O
try	O
##pt	O
##op	O
##han	O
-	O
D	O
_	O
5	O
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	O
-	O
D	O
_	O
4	O
,	O
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
.	O

The	O
so	O
##lub	O
##ility	O
for	O
highly	O
polar	O
meta	O
##bol	O
##ites	O
such	O
as	O
his	B
##ti	I
##dine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
as	B
##par	I
##tic	I
acid	I
,	O
and	O
as	B
##par	I
##agi	I
##ne	I
could	O
not	O
even	O
be	O
measured	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
at	O
a	O
proportion	O
greater	O
than	O
[UNK]	O
:	I
2	I
(	I
w	I
/	I
v	I
)	I
.	O

This	O
may	O
be	O
because	O
the	O
enter	B
##och	I
##roma	I
##ffin	I
cells	O
s	O
##ynth	O
##esi	O
##ze	O
and	O
release	O
se	B
##rot	I
##oni	I
##n	I
.	O

Among	O
the	O
20	O
healthy	O
adults	O
,	O
18	O
(	O
90	O
%	O
)	O
had	O
Z	O
##S	O
scores	O
below	O
the	O
optimal	O
cut	O
##off	O
of	O
−	O
##0	O
.	O
163	O
##4	O
,	O
15	O
(	O
75	O
%	O
)	O
had	O
P	B
##E	I
(	I
18	I
:	I
2	I
)	I
scores	O
below	O
the	O
cut	O
##off	O
of	O
144	O
##7	O
.	O
81	O
,	O
14	O
(	O
70	O
%	O
)	O
had	O
G	O
##N	O
##OE	O
scores	O
lower	O
than	O
the	O
cut	O
##off	O
of	O
227	O
.	O
56	O
,	O
and	O
17	O
(	O
85	O
%	O
)	O
had	O
MG	B
(	I
18	I
:	I
2	I
)	I
scores	O
less	O
than	O
the	O
cut	O
##off	O
of	O
237	O
.	O
9	O
.	O

They	O
reported	O
that	O
low	O
levels	O
of	O
8	B
-	I
o	I
##x	I
##od	I
##G	I
were	O
associated	O
with	O
tumor	O
aggressive	O
##ness	O
,	O
but	O
not	O
survival	O
.	O

z	O
ranges	O
and	O
including	O
D	B
##MS	I
##O	I
in	O
our	O
ion	O
##ization	O
solvent	O
.	O

The	O
flow	O
from	O
the	O
PD	O
##A	O
detector	O
was	O
mixed	O
with	O
0	O
.	O
3	O
m	O
##L	O
/	O
min	O
makeup	O
solvent	O
(	O
0	O
.	O
1	O
%	O
v	O
/	O
v	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
)	O
,	O
supplied	O
by	O
a	O
Waters	O
51	O
##5	O
HP	O
##LC	O
pump	O
,	O
before	O
entering	O
the	O
MS	O
source	O
;	O
the	O
AB	O
##PR	O
was	O
held	O
at	O
2000	O
ps	O
##i	O
(	O
138	O
bar	O
)	O
for	O
all	O
analyses	O
.	O

Moreover	O
,	O
the	O
G	O
##G	O
head	O
groups	O
are	O
surrounded	O
by	O
a	O
water	O
shell	O
attracted	O
by	O
the	O
h	B
##ydro	I
##phi	I
##lic	I
character	O
of	O
sugar	O
##s	O
and	O
by	O
the	O
necessity	O
to	O
avoid	O
re	O
##pulsion	O
between	O
the	O
negatively	O
charged	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
##s	I
.	O

In	O
case	O
of	O
ch	B
##olin	I
##e	I
a	O
simultaneous	O
significant	O
increase	O
was	O
detected	O
in	O
both	O
A	B
##F	I
and	O
P	O
##L	O
during	O
T	O
##2	O
to	O
T	O
##3	O
transition	O
.	O

He	O
##co	O
##gen	O
##in	O
at	O
5	O
µ	O
##m	O
in	O
##hibit	O
##ed	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
activity	O
by	O
38	O
.	O
4	O
%	O
in	O
pool	O
##ed	O
H	O
##LM	O
##s	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
62	O
.	O
2	O
%	O
in	O
expressed	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

To	O
test	O
the	O
influence	O
of	O
the	O
in	O
##cu	O
##bation	O
on	O
di	B
##os	I
##met	I
##in	I
stability	O
in	O
the	O
spike	O
##d	O
samples	O
,	O
an	O
experiment	O
with	O
in	O
##cu	O
##bate	O
##d	O
Q	O
##Cs	O
1	O
and	O
4	O
,	O
with	O
and	O
without	O
enzyme	O
,	O
was	O
conducted	O
during	O
valid	O
##ation	O
and	O
the	O
results	O
are	O
presented	O
in	O
Table	O
.	O

Basel	O
##ine	O
art	O
##erial	O
##ized	O
ve	O
##nous	O
blood	O
samples	O
for	O
determination	O
of	O
plasma	O
glucose	S
,	O
FF	O
##A	O
,	O
and	O
insulin	O
concentrations	O
were	O
drawn	O
at	O
−	O
##30	O
,	O
−	O
##20	O
,	O
−	O
##10	O
,	O
−	O
##5	O
,	O
and	O
0	O
min	O
.	O

This	O
list	O
of	O
disc	O
##rim	O
##ina	O
##tive	O
compounds	O
was	O
complement	O
##ed	O
by	O
the	O
targeted	O
analysis	O
of	O
four	O
features	O
,	O
including	O
ma	B
##lt	I
##ol	I
,	O
su	B
##c	I
##rose	I
,	O
g	B
##ua	I
##iac	I
##ol	I
,	O
and	O
cat	B
##ech	I
##ol	I
,	O
already	O
reported	O
as	O
disc	O
##rim	O
##ina	O
##tive	O
for	O
the	O
so	O
##y	O
drink	O
in	O
the	O
urine	O
samples	O
of	O
the	O
same	O
study	O
.	O

This	O
may	O
be	O
because	O
a	B
##rg	I
##ini	I
##ne	I
metabolism	O
is	O
associated	O
with	O
several	O
pain	O
mechanisms	O
,	O
as	O
pain	O
is	O
the	O
hall	O
##mark	O
of	O
the	O
β	B
-	I
th	I
##ala	I
##sse	I
##mic	I
condition	O
and	O
patients	O
experience	O
pain	O
virtually	O
all	O
the	O
time	O
.	O

Analysis	O
of	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
was	O
performed	O
according	O
to	O
published	O
protocols	O
(	O
Ce	O
##g	O
##lar	O
##ek	O
et	O
al	O
.	O
;	O

The	O
dried	O
super	O
##nat	O
##ant	O
residue	O
was	O
re	O
##con	O
##stituted	O
in	O
80	O
µ	O
##L	O
of	O
met	B
##han	I
##ol	I
followed	O
by	O
20	O
µ	O
##L	O
of	O
water	O
,	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
again	O
at	O
1800	O
##0	O
×	O
g	O
0	O
##°	O
##C	O
for	O
15	O
min	O
.	O

High	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
in	O
##duct	O
##ively	O
coupled	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
HP	O
##LC	O
-	O
I	O
##CP	O
-	O
MS	O
)	O
,	O
a	O
##rsen	O
##ic	O
s	O
##pec	O
##iation	O
,	O
a	O
##rsen	O
##ic	O
metabolism	O
in	O
humans	O
,	O
dim	B
##eth	I
##yla	I
##rs	I
##ino	I
##us	I
g	I
##lut	I
##ath	I
##ione	I

L	O
##CM	O
##S	O
samples	O
were	O
prepared	O
from	O
stool	O
ho	O
##mo	O
##gen	O
##ates	O
(	O
10	O
μ	O
##L	O
)	O
via	O
protein	O
precipitation	O
with	O
the	O
addition	O
of	O
nine	O
volumes	O
of	O
74	B
.	I
9	I
:	I
24	I
.	I
9	I
:	I
0	I
.	I
2	I
v	I
/	O
v	O
/	O
v	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
met	O
##han	O
##ol	O
/	O
form	O
##ic	O
acid	O
containing	O
stable	O
is	O
##oto	O
##pel	O
##abe	O
##led	O
internal	O
standards	O
(	B
v	B
##ali	I
##ned	O
##8	O
,	O
Is	O
##ote	O
##c	O
[UNK]	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ned	O
##8	O
,	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
[UNK]	O
And	O
##over	O
,	O
MA	O
)	O
.	O

The	O
T	O
##2	O
##DM	O
patients	O
were	O
further	O
divided	O
into	O
subgroup	O
##s	O
of	O
different	O
micro	O
##ang	O
##io	O
##path	O
##ies	O
according	O
to	O
recent	O
medical	O
records	O
based	O
on	O
the	O
following	O
definitions	O
:	O
(	O
1	O
)	O
Di	O
##abe	O
##tic	O
re	O
##tino	O
##pathy	O
defined	O
by	O
the	O
presence	O
of	O
non	O
-	O
pro	O
##life	O
##rative	O
di	O
##abe	O
##tic	O
re	O
##tino	O
##pathy	O
or	O
pro	O
##life	O
##rative	O
di	O
##abe	O
##tic	O
re	O
##tino	O
##pathy	O
in	O
re	B
##tina	I
##l	I
photography	O
,	O
and	O
the	O
diagnosis	O
verified	O
by	O
op	O
##ht	O
##hal	O
##mo	O
##logists	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
total	O
abundance	O
of	O
any	O
of	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
sub	O
##c	O
##lass	O
##es	O
in	O
b	O
##v	O
##FT	O
##D	O
compared	O
to	O
control	O
(	O
Table	O
)	O
.	O

H	O
##NS	O
##CC	O
cells	O
exhibited	O
significantly	O
altered	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
ace	B
##tate	I
,	O
as	B
##par	I
##tate	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
ta	B
##uri	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
N	O
##AD	O
_	O
+	O
,	O
v	B
##ali	I
##ne	I
,	O
c	B
##rea	I
##tine	I
,	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
u	B
##rid	I
##ine	I
dip	I
##hos	I
##phate	I
coupled	O
sugar	O
##s	O
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##o	I
-	I
/	I
dip	I
##hos	I
##phate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
f	B
##uma	I
##rate	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

U	O
##rine	O
concentrations	O
are	O
not	O
c	B
##rea	I
##tin	I
##ine	I
normal	O
##ized	O
.	O

The	O
results	O
showed	O
that	O
the	O
progression	O
was	O
associated	O
with	O
disturbance	O
##s	O
of	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
metabolism	O
,	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
and	O
Live	O
##r	O
X	O
receptor	O
/	O
re	O
##tino	O
##ic	O
X	O
receptor	O
activation	O
as	O
characterized	O
by	O
up	O
-	O
regulated	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##er	I
(	I
18	I
:	I
0	I
)	I
and	O
down	O
-	O
regulated	O
in	B
##os	I
##ine	I
.	O

Therefore	O
,	O
the	O
[	O
M	O
+	O
2	O
p	B
##ico	I
##lini	I
##c	I
acid	O
+	O
Na	O
]	O
_	O
+	O
(	O
m	O
/	O
z	O
63	O
##5	O
)	O
and	O
[	B
M	B
+	I
p	I
##ico	I
##lini	I
##c	I
acid	O
+	O
Na	O
]	O
_	O
+	O
(	O
m	O
/	O
z	O
512	O
)	O
ions	O
were	O
selected	O
as	O
a	O
monitoring	O
ion	O
pair	O
(	O
Q	O
##1	O
/	O
Q	O
##3	O
)	O
for	O
OH	O
##C	O
derivatives	O
.	O

This	O
strain	O
was	O
initially	O
grown	O
in	O
the	O
presence	O
of	O
a	B
##rab	I
##ino	I
##se	I
and	O
then	O
back	O
di	O
##lut	O
##ed	O
into	O
L	O
##B	O
containing	O
a	B
##rab	I
##ino	I
##se	I
,	O
f	B
##uc	I
##ose	I
,	O
or	O
no	O
induce	O
##r	O
.	O

Finally	O
,	O
it	O
is	O
known	O
that	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
is	O
a	O
potent	O
induce	O
##r	O
of	O
super	B
##oxide	I
ion	O
production	O
in	O
end	O
##oth	O
##eli	O
##al	O
cells	O
and	O
controlled	O
levels	O
of	O
super	B
##oxide	I
serve	O
as	O
an	O
##gio	O
##genic	O
factors	O
in	O
is	O
##che	O
##mic	O
an	O
##gio	O
##genesis	O
.	O

S	O
##1	O
##P	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
in	O
both	O
serum	O
and	O
urine	O
samples	O
were	O
q	O
##uant	O
##ified	O
using	O
the	O
Mass	O
Hunter	O
Q	O
##uant	O
##itative	O
Analysis	O
B	O
.	O
07	O
.	O
00	O
system	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Previous	O
literature	O
shows	O
that	O
to	O
sustain	O
a	O
one	O
‐	O
carbon	O
supply	O
for	O
proliferation	O
,	O
cancer	O
cells	O
convert	O
se	B
##rine	I
to	O
g	B
##ly	I
##cine	I
,	O
generating	O
met	B
##hyl	I
##ene	I
‐	I
5	I
‐	I
met	I
##hyl	I
##te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
(	O
T	O
##ib	O
##bet	O
##ts	O
and	O
A	O
##pp	O
##ling	O
,	O
2010	O
)	O
.	O

We	O
used	O
a	O
H	B
##V	I
probe	O
(	O
Te	O
##kt	O
##ron	O
##ix	O
,	O
P	O
##60	O
##15	O
##A	O
)	O
and	O
a	O
current	O
probe	O
(	O
Te	O
##kt	O
##ron	O
##ix	O
,	O
P	O
##60	O
##21	O
)	O
to	O
measure	O
the	O
discharge	O
voltage	O
and	O
current	O
respectively	O
.	O

Data	O
on	O
vitamin	B
D	I
supplement	O
use	O
were	O
not	O
available	O
.	O

After	O
washing	O
with	O
phosphate	B
-	I
buffer	I
##ed	I
sa	I
##line	I
(	O
PBS	O
)	O
,	O
the	O
sections	O
were	O
subsequently	O
submerged	O
in	O
E	O
##D	O
##TA	O

As	O
in	O
our	O
study	O
,	O
low	O
his	B
##ti	I
##dine	I
concentration	O
has	O
been	O
previously	O
reported	O
in	O
RA	O
[	O
–	O
]	O
,	O
as	O
well	O
as	O
in	O
other	O
diseases	O
,	O
such	O
as	O
chronic	O
kidney	O
disease	O
and	O
gal	O
##l	O
##bla	O
##dder	O
inflammation	O
with	O
chronic	O
ch	O
##ole	O
##cy	O
##st	O
##itis	O
[	O
,	O
]	O
.	O

The	O
meta	O
##bol	O
##ite	O
reaction	O
linking	O
hip	B
##pura	I
##te	I
and	O
g	B
##ly	I
##cine	I
is	O
only	O
conducted	O
through	O
the	O
activity	O
of	O
the	O
gut	O
micro	O
##bio	O
##ta	O
Among	O
the	O
valid	O
##ated	O
meta	O
##bol	O
##ites	O
,	O
six	O
were	O
found	O
to	O
be	O
associated	O
to	O
three	O
or	O
more	O
I	O
##MI	O
##Ds	O
(	O
Fi	O
##g	O
.	O

A	O
nominally	O
significant	O
increase	O
was	O
found	O
in	O
co	B
##rt	I
##ison	I
##e	I
,	O
a	O
precursor	O
of	O
co	B
##rt	I
##is	I
##ol	I
,	O
in	O
patients	O
with	O
S	O
##Z	O
compared	O
with	O
controls	O
(	O
P	O
=	O
.	O
04	O
##8	O
)	O
.	O

N	B
-	I
Met	I
##hyl	I
-	I
N	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
;	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Canada	O
(	O
Oak	O
##ville	O
,	O
Ontario	O
,	O
Canada	O
)	O
)	O
was	O
added	O
as	O
si	O
##ly	O
##lating	O
agent	O
.	O

The	O
largest	O
effect	O
size	O
and	O
the	O
most	O
significant	O
result	O
—	O
p	O
=	O
2	O
.	O
51	O
*	O
10	O
_	O
−	O
##13	O
-	O
-	O
were	O
observed	O
for	O
g	B
##lut	I
##ama	I
##te	I
.	O

All	O
meta	O
##bol	O
##ites	O
that	O
were	O
detected	O
in	O
serum	O
were	O
detected	O
in	O
W	O
##B	O
with	O
the	O
exception	O
of	O
ace	B
##to	I
##ace	I
##tate	I
,	O
which	O
was	O
only	O
detect	O
##able	O
in	O
45	O
%	O
of	O
the	O
W	O
##B	O
samples	O
,	O
and	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
which	O
may	O
be	O
a	O
con	O
##tam	O
##ina	O
##nt	O
from	O
the	O
SS	O
##T	O
blood	O
collection	O
tube	O
but	O
has	O
been	O
reported	O
as	O
a	O
human	O
serum	O
meta	O
##bol	O
##ite	O
,	O
resulting	O
in	O
a	O
total	O
of	O
32	O
common	O
meta	O
##bol	O
##ites	O
between	O
the	O
two	O
bio	O
##f	O
##lu	O
##ids	O
.	O

al	O
.	O
q	O
##uant	O
##ified	O
N	O
7	B
-	I
et	I
##hyl	I
-	I
g	I
##uan	I
##ine	I
(	O
N	O
7	B
-	I
E	I
##t	I
-	I
G	I
##ua	I
)	O
,	O
an	O
add	O
##uc	O
##t	O
derived	O
from	O
et	O
##hyl	O
##ating	O
agents	O
of	O
unknown	O
structures	O
,	O
from	O
le	O
##uk	O
##ocytes	O
of	O
smoke	O
##rs	O
and	O
non	O
-	O
smoke	O
##rs	O
.	O

As	O
such	O
,	O
it	O
represents	O
an	O
important	O
initial	O
step	O
in	O
understanding	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
in	O
C	O
##K	O
##D	O
.	O

The	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
analysis	O
showed	O
that	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
profiles	O
of	O
serum	O
with	O
H	O
##B	O
##s	O
##A	O
##g	O
(	O
−	O
)	O
and	O
H	O
##B	O
##s	O
##A	O
##g	O
(	O
+	O
)	O
groups	O
were	O
well	O
separated	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

We	O
also	O
found	O
direct	O
associations	O
of	O
B	O
##MI	O
with	O
u	O
##rina	O
##ry	O
t	B
##yr	I
##os	I
##ine	I
(	O
P	O
=	O
2	O
.	O
02	O
×	O
10	O
_	O
−	O
##45	O
,	O
)	O
,	O
confirming	O
previous	O
findings	O
in	O
blood	O
(	O
–	O
,	O
)	O
,	O
and	O
with	O
the	O
_	O
1	O
H	O
N	O
##MR	O
signal	O
representing	O
t	B
##yr	I
##os	I
##ine	I
and	O
the	O
t	B
##yr	I
##os	I
##ine	I
meta	O
##bol	O
##ite	O
4	B
-	I
h	I
##ydro	I
##xy	I
##mand	I
##eli	I
##c	I
acid	I
(	O
P	O
=	O
1	O
.	O
35	O
×	O
10	O
_	O
−	O
##19	O
,	O
)	O
.	O

Finally	O
,	O
we	O
developed	O
an	O
L	O
##C	O
/	O
MS	O
method	O
and	O
found	O
3	O
–	O
5	O
nm	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
was	O
present	O
in	O
human	O
plasma	O
.	O

Op	O
##ti	O
##ma	O
[UNK]	O
L	O
##C	O
/	O
MS	O
-	O
grade	O
form	B
##ic	I
acid	I
and	O
HP	O
##LC	O
-	O
grade	O
water	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Ottawa	O
,	O
ON	O
,	O
Canada	O
)	O
.	O

0	O
.	O
90	O
##1	O
mg	O
T	O
##RP	O
,	O
1	O
.	O
248	O
mg	O
K	O
##Y	O
##N	O
,	O
1	O
.	O
28	O
##2	O
mg	O
Q	O
##UI	O
##N	O
were	O
weighed	O
accurately	O
and	O
then	O
dissolved	O
and	O
mixed	O
in	O
50	O
%	O
met	B
##han	I
##ol	I
solution	O
,	O
respectively	O
,	O
to	O
make	O
1	O
mg	O
/	O
m	O
##l	O
standard	O
stock	O
solution	O
;	O
0	O
.	O
67	O
##1	O
mg	O
K	O
##Y	O
##NA	O
was	O
weighed	O
accurately	O
and	O
then	O
dissolved	O
and	O
mixed	O
in	O
ultra	O
-	O
pure	O
water	O
to	O
make	O
0	O
.	O
167	O
mg	O
/	O
m	O
##l	O
standard	O
stock	O
solution	O
,	O
which	O
was	O
split	O
storing	O
in	O
−	O
##20	O
##°	O
##C	O
.	O

Co	O
##mp	O
##aring	O
subjects	O
diagnosed	O
in	O
the	O
first	O
0	O
‐	O
6	O
years	O
,	O
higher	O
levels	O
of	O
1	B
,	I
5	I
‐	I
AG	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
u	B
##ric	I
acid	I
showed	O
a	O
decreasing	O
trend	O
for	O
pan	O
##cre	O
##atic	O
cancer	O
risk	O
(	O
P	O
for	O
trend	O
=	O
.	O
04	O
,	O
.	O
04	O
,	O
.	O
04	O
and	O
.	O
02	O
,	O
respectively	O
)	O
,	O
even	O
after	O
adjustment	O
for	O
potential	O
con	O
##found	O
##ers	O
.	O

Co	O
##rrel	O
##ations	O
of	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
distributions	O
(	O
‘	O
ch	O
##em	O
##otype	O
##s	O
’	O
)	O
and	O
disease	O
/	O
health	O
p	O
##hen	O
##otype	O
##s	O
therefore	O
are	O
an	O
interesting	O
topic	O
to	O
study	O
,	O
requiring	O
meta	O
##bol	O
##omi	O
##cs	O
techniques	O
for	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
for	O
measurement	O
.	O

In	O
contrast	O
,	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
therapy	O
did	O
not	O
result	O
in	O
marked	O
alterations	O
of	O
plasma	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
,	O
but	O
slightly	O
increased	O
plasma	O
car	B
##ni	I
##tine	I

Of	O
note	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
)	O
represent	O
by	O
mass	O
more	O
than	O
76	O
%	O
of	O
total	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
healthy	O
volunteers	O
.	O

Seven	O
V	O
##OC	O
##s	O
,	O
namely	O
2	B
-	I
met	I
##hyl	I
##pent	I
##ane	I
-	I
1	I
,	I
3	I
-	I
di	I
##ol	I
,	O
1	B
-	I
(	I
3	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
##fu	I
##ran	I
-	I
2	I
-	I
y	I
##l	I
)	I
et	I
##han	I
##one	I
,	O
met	B
##hyl	I
ben	I
##zo	I
##ate	I
,	O
non	B
##ano	I
##ic	I
acid	I
,	O
c	B
##y	I
##c	I
##lo	I
##he	I
##xa	I
##non	I
##e	I
,	O
4	B
-	I
met	I
##hyl	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
(	O
Fi	O
##g	O
.	O
)	O
,	O
and	O
4	B
-	I
met	I
##hyl	I
##he	I
##pta	I
##n	I
-	I
2	I
-	I
one	I
were	O
significantly	O
decreased	O
in	O
the	O
extra	O
##cellular	O
medium	O
of	O
all	O
PC	O
##a	O
cell	O
lines	O
when	O
compared	O
with	O
normal	O
cell	O
line	O
(	O
Table	O
)	O
.	O

Pat	O
##ients	O
with	O
serum	O
glucose	S
levels	O
≥	O
200	O
mg	O
/	O
d	O
##l	O
were	O
excluded	O
.	O

A	O
more	O
recent	O
trial	O
showed	O
no	O
effects	O
of	O
supplement	O
##ation	O
with	O
so	O
##y	O
flour	O
on	O
the	O
ratio	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
to	O
16	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
.	O

G	B
##CD	I
##CA	I
has	O
been	O
reported	O
as	O
an	O
induce	O
##r	O
of	O
a	O
##pop	O
##tosis	O
and	O
ne	O
##c	O
##rot	O
##ic	O
cell	O
death	O
in	O
human	O
he	O
##pa	O
##to	O
##cy	O
##te	O
.	O

In	O
relation	O
to	O
these	O
results	O
,	O
the	O
AD	O
##SL	O
enzyme	O
has	O
been	O
described	O
as	O
relevant	O
to	O
the	O
formation	O
of	O
a	O
complex	O
called	O
pu	O
##rino	O
##some	O
,	O
formed	O
by	O
six	O
enzymes	O
in	O
charge	O
of	O
performing	O
10	O
se	O
##quential	O
reactions	O
in	O
the	O
step	O
from	O
p	B
##hos	I
##ph	I
##ori	I
##bos	I
##yl	I
p	I
##yr	I
##op	I
##hos	I
##phate	I
to	O
I	B
##MP	I
(	O
An	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

With	O
el	O
##ong	O
##ation	O
and	O
des	O
##at	O
##uration	O
,	O
palm	B
##itate	I
is	O
converted	O
into	O
longer	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
,	O
which	O
are	O
incorporated	O
into	O
complex	O
lip	O
##ids	O
(	O
e	O
.	O
g	O
.	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
)	O
.	O

N	O
##uc	O
##leo	O
##tide	O
salvage	O
pathway	O
uses	O
de	O
##graded	O
nuclear	O
material	O
(	O
DNA	O
/	O
RNA	O
)	O
in	O
the	O
form	O
of	O
pu	B
##rine	I
##s	I
and	O
p	B
##yr	I
##im	I
##id	I
##ines	I
to	O
reproduce	O
the	O
d	O
##NT	O
##Ps	O
for	O
DNA	O
/	O
RNA	O
synthesis	O
.	O

For	O
example	O
,	O
the	O
N	O
##MR	O
and	O
D	O
##FI	O
/	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
concentrations	O
of	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
are	O
higher	O
than	O
the	O
G	O
##C	O
-	O
MS	O
values	O
(	O
note	O
that	O
g	B
##ly	I
##cine	I
exhibits	O
the	O
highest	O
concentration	O
among	O
u	O
##rina	O
##ry	O
amino	S
acids	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
o	O
##besity	O
-	O
status	O
and	O
multiple	O
testing	O
,	O
exposure	O
to	O
mon	B
##o	I
-	I
is	I
##op	I
##rop	I
##yl	I
##phe	I
##ny	I
##l	I
dip	I
##hen	I
##yl	I
phosphate	I
was	O
significantly	O
related	O
to	O
h	O
##yper	O
##met	O
##hyl	O
##ation	O
at	O
the	O
ME	O
##G	O
##3	O
,	O
N	O
##D	O
##N	O
,	O
S	O
##NR	O
##P	O
##N	O
D	O
##MR	O
##s	O
.	O

The	O
data	O
fusion	O
from	O
the	O
serum	O
and	O
urine	O
N	O
##MR	O
measurements	O
definitely	O
strengthened	O
of	O
calculated	O
models	O
between	O
the	O
N	O
##N	O
,	O
FA	S
,	O
T	O
##C	O
,	O
P	O
and	O
the	O
HC	O
groups	O
.	O

Twenty	O
-	O
six	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
23	O
amino	O
acids	O
,	O
which	O
are	O
commonly	O
used	O
in	O
I	O
##EM	O
screening	O
,	O
were	O
q	O
##uant	O
##ified	O
using	O
DB	O
##S	O
samples	O
from	O
222	O
L	O
##C	O
patients	O
,	O
118	O
ben	O
##ign	O
lung	O
disease	O
(	O
L	O
##D	O
)	O
patients	O
,	O
and	O
96	O
healthy	O
volunteers	O
(	O
CO	O
##NT	O
)	O
.	O

Furthermore	O
,	O
the	O
proportional	O
amounts	O
of	O
the	O
individual	O
free	O
Sa	O
##FA	O
##s	O
la	B
##uri	I
##c	I
acid	I
(	O
12	O
:	O
0	O
)	O
,	O
my	B
##rist	I
##ic	I
acid	I
(	O
14	O
:	O
0	O
)	O
,	O
pen	B
##tad	I
##ec	I
##yl	I
##ic	I
acid	I
(	O
15	O
:	O
0	O
)	O
,	O
and	O
ma	B
##rga	I
##ric	I
acid	I
(	O
17	O
:	O
0	O
)	O
were	O
positively	O
associated	O
with	O
serum	O
levels	O
of	O
CR	O
##P	O
(	O
p	O
<	O
0	O
.	O
05	O
for	O
all	O
)	O
.	O

Re	O
##ct	O
##al	O
met	B
##had	I
##one	I
has	O
characteristics	O
that	O
make	O
it	O
a	O
potential	O
alternative	O
to	O
in	O
##tra	O
##ven	O
##ous	O
and	O
oral	O
administration	O
,	O
particularly	O
in	O
cancer	O
pain	O
and	O
p	O
##all	O
##ia	O
##tive	O
care	O
.	O

Am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
,	O
and	O
HP	O
##LC	O
grade	O
solvent	O
##s	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	B
Hampton	S
,	O
NH	O
)	O
.	O

Fr	B
##uc	I
##tos	I
##e	I
is	O
a	O
normal	O
component	O
of	O
the	O
human	O
diet	O
and	O
is	O
naturally	O
concentrated	O
in	O
sweet	O
fruits	O
,	O
although	O
f	B
##ru	I
##ct	I
##ose	I
is	O
also	O
extracted	O
from	O
bee	O
##ts	O
,	O
cane	O
,	O
and	O
su	B
##c	I
##rose	I
,	O
and	O
is	O
concentrated	O
as	O
high	O
-	O
f	O
##ru	O
##ct	O
##ose	O
corn	O
syrup	O
for	O
use	O
as	O
a	O
sweet	O
##ener	O
.	O

And	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
7	B
-	I
alpha	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ol	I
-	I
4	I
-	I
en	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
and	O
lit	B
##ho	I
##cho	I
##ly	I
##lta	I
##uri	I
##ne	I
are	O
the	O
most	O
significantly	O
differential	O
##ly	O
detected	O
meta	O
##bol	O
##ites	O
that	O
have	O
good	O
prediction	O
accuracy	O
between	O
RC	O
##C	O
and	O
healthy	O
controls	O
,	O
likely	O
playing	O
important	O
roles	O
during	O
RC	O
##C	O
occurrence	O
.	O

All	O
s	O
##pect	O
##ra	O
were	O
referenced	O
to	O
the	O
α	B
-	I
glucose	I
an	O
##omer	O
##ic	O
pro	O
##ton	O
signal	O
(	O
δ	O
=	O
5	O
.	O
23	O
pp	O
##m	O
)	O
.	O

Instead	O
of	O
finding	O
the	O
plasma	O
try	B
##pt	I
##op	I
##han	I
as	O
a	O
differential	O
meta	O
##bol	O
##ite	O
,	O
we	O
found	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
was	O
a	O
differential	O
metabolic	O
pathway	O
between	O
the	O
s	O
##chi	O
##zophrenia	O
patients	O
with	O
and	O
without	O
violence	O
,	O
which	O
support	O
amino	O
acids	O
play	O
an	O
important	O
role	O
in	O
regulating	O
violence	O
.	O
.	O

PA	O
##H	O
mon	O
##op	O
##hen	O
##olic	O
meta	O
##bol	O
##ites	O
,	O
ET	O
##S	O
bio	O
##mark	O
##ers	O
,	O
personal	O
exposure	O
,	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
,	O
G	O
##C	O
/	O
MS	O
,	O
1	B
,	I
3	I
-	I
But	I
##adi	I
##ene	I
,	O
3	B
-	I
et	I
##hen	I
##yl	I
##py	I
##rid	I
##ine	I
,	O
MA	O
##TC	O
##H	O
project	O

Their	O
structures	O
indicate	O
that	O
both	O
the	O
c	B
##ys	I
##tein	I
##e	I
and	O
l	B
##ys	I
##ine	I
residues	O
of	O
6	O
can	O
undergo	O
further	O
transformations	O
.	O

B	O
##rief	O
##ly	O
,	O
u	O
##rease	O
(	O
40	O
units	O
)	O
was	O
added	O
to	O
200	O
μ	O
L	O
of	O
urine	O
followed	O
by	O
in	O
##cu	O
##bation	O
at	O
37	O
##°	O
##C	O
for	O
20	O
min	O
to	O
remove	O
u	B
##rea	I
.	O

This	O
resulted	O
in	O
selection	O
of	O
134	O
,	O
36	O
,	O
and	O
119	O
m	O
/	O
z	O
signals	O
for	O
the	O
o	B
##lan	I
##za	I
##pine	I
,	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
and	O
que	B
##tia	I
##pine	I
treatment	O
groups	O
,	O
respectively	O
out	O
of	O
more	O
than	O
1	O
,	O
600	O
compounds	O
in	O
total	O
(	O
Table	O
)	O
.	O

S	O
##pect	O
##ra	O
were	O
manually	O
phased	O
and	O
base	O
##line	O
corrected	O
and	O
chemical	O
shifts	O
referenced	O
internally	O
to	O
the	O
α	B
-	I
glucose	I
H	O
##1	O
resonance	O
(	O
δ	O
5	O
.	O
23	O
)	O
.	O

By	O
comparing	O
the	O
available	O
NC	O
##BI	O
information	O
of	O
Tel	O
##eo	O
##st	O
album	O
##in	O
/	O
album	O
##in	O
-	O
like	O
proteins	O
to	O
the	O
Atlantic	S
co	O
##d	O
estimated	O
pro	O
##te	O
##ome	O
,	O
4	O
potential	O
protein	O
candidates	O
were	O
identified	O
.	O

Ph	O
##eno	O
##ty	O
##pic	O
measurements	O
of	O
C	O
##YP	O
##2	O
##A	O
##6	O
activity	O
also	O
confirmed	O
that	O
the	O
N	O
##P	O
tribal	O
population	O
has	O
an	O
elevated	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
relative	O
to	O
the	O
S	O
##W	O
tribal	O
population	O
,	O
and	O
compared	O
to	O
Alaska	O
Native	O
,	O
Caucasian	O
,	O
and	O
African	O
American	O
populations	O
.	O

Female	O
urine	O
contained	O
high	O
concentrations	O
of	O
three	O
ω	B
-	I
3	I
o	I
##xy	I
##lip	I
##ins	I
known	O
to	O
have	O
anti	O
-	O
inflammatory	O
and	O
v	O
##as	O
##od	O
##ila	O
##tory	O
activities	O
(	O
and	O
)	O
.	O

En	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
were	O
extracted	O
by	O
protein	O
precipitation	O
,	O
separated	O
on	O
a	O
C	O
##18	O
column	O
with	O
gradient	O
el	O
##ution	O
and	O
analyzed	O
with	O
tandem	O
q	O
##uad	O
##rup	O
##le	O
mass	O
s	O
##pect	O
##rome	O
##try	O
in	O
positive	O
ion	O
mode	O
.	O

An	O
additional	O
benefit	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
addition	O
to	O
the	O
mobile	O
phase	O
was	O
the	O
enhanced	O
signal	O
on	O
I	O
##CP	O
-	O
MS	O
detection	O
(	O
data	O
not	O
shown	O
)	O
.	O

1	B
,	I
5	I
-	I
AG	I
serves	O
as	O
a	O
useful	O
alternative	O
bio	O
##mark	O
##er	O
to	O
A1	O
##C	O
as	O
it	O
provides	O
insight	O
into	O
short	O
-	O
term	O
g	B
##ly	I
##ce	I
##mic	I
control	O
,	O
g	B
##ly	I
##ce	I
##mic	I
var	O
##iability	O
,	O
and	O
post	O
##pra	O
##ndi	O
##al	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
(	O
,	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
:	O
T	O
##2	O
##DM	O
,	O
type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
;	O
OR	O
,	O
odds	O
ratio	O
;	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
g	O
##ly	O
##cated	O
hem	O
##og	O
##lo	O
##bin	O
A1	O
##c	O
;	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
Home	O
##ost	O
##atic	O
Model	O
Assessment	O
for	O
In	O
##sul	O
##in	O
Resistance	O
,	O
_	O
a	O
Six	O
-	O
meta	O
##bol	O
##ite	O
combination	O
is	O
al	B
##ani	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
,	O
_	O
b	O
Ad	O
##ju	O
##sted	O
for	O
age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
,	O
and	O
medications	O
for	O
chronic	O
diseases	O
(	O
h	O
##yper	O
##tens	O
##ion	O
and	O
h	O
##yper	O
##lip	O
##ide	O
##mia	O
)	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

If	O
this	O
is	O
occurring	O
,	O
there	O
may	O
be	O
an	O
increased	O
shed	O
##ding	O
of	O
palm	B
##ito	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
into	O
the	O
urine	O
of	O
bladder	O
cancer	O
subjects	O
and	O
subsequent	O
s	O
##phi	O
##ngo	O
##my	O
##elin	O
##ases	O
activity	O
in	O
the	O
urine	O
may	O
result	O
in	O
increased	O
ch	B
##olin	I
##e	I
phosphate	I
.	O

L	O
##C	O
-	O
MS	O
identifies	O
this	O
trend	O
,	O
making	O
PC	O
1	O
essentially	O
a	O
ni	B
##cot	I
##ine	I
-	I
exposure	I
axis	O
.	O

m	O
m	O
m	O
m	O
m	O
m	O
m	O
En	O
##zy	O
##me	O
kinetic	O
parameters	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ite	O
formation	O
in	O
C	O
##YP	O
##3	O
##A	O
##4	O
and	O
C	O
##YP	O
##3	O
##A	O
##5	O
with	O
and	O
without	O
c	O
##yt	O
##och	O
##rome	O
b	O
##5	O
m	O
Met	O
##ab	O
##olis	O
##m	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
to	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
by	O
expressed	O
human	O
C	O
##YP	O
enzymes	O
.	O

Technical	O
replica	O
##te	O
serum	O
samples	O
were	O
used	O
to	O
measure	O
levels	O
of	O
his	B
##tamine	I
,	O
tumor	O
ne	O
##c	O
##rosis	O
factor	O
-	O
α	O
(	O
T	O
##NF	O
-	O
α	O
)	O
and	O
inter	O
##le	O
##uki	O
##n	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
,	O
compounds	O
known	O
to	O
be	O
associated	O
with	O
inflammation	O
and	O
CO	O
##PD	O
.	O

In	O
addition	O
,	O
we	O
noticed	O
a	O
negative	O
correlation	O
between	O
some	O
of	O
these	O
k	B
##eton	I
##e	I
bodies	O
with	O
B	O
##MI	O
which	O
highlights	O
the	O
role	O
of	O
energy	O
-	O
related	O
metabolic	O
alterations	O
before	O
UC	O
re	O
##lap	O
##se	O
(	O
data	O
not	O
shown	O
)	O
.	O

Carr	O
##y	O
-	O
over	O
issues	O
were	O
encountered	O
when	O
only	O
mobile	O
phase	O
A	O
and	O
B	O
were	O
used	O
;	O
after	O
in	O
##ject	O
##ing	O
a	O
blank	O
sample	O
after	O
the	O
highest	O
ca	O
##li	O
##bra	O
##tion	O
standard	O
three	O
out	O
of	O
five	O
blank	O
injection	O
##s	O
showed	O
an	O
a	B
##bir	I
##ater	I
##one	I
peak	O
area	O
>	O
20	O
%	O
of	O
the	O
area	O
of	O
the	O
LL	O
##O	O
##Q	O
.	O

PC	O
##s	O
are	O
synthesized	O
in	O
the	O
liver	O
and	O
are	O
the	O
only	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
necessary	O
for	O
lip	O
##op	O
##rote	O
##in	O
assembly	O
and	O
ex	O
##cre	O
##tion	O
.	O

On	O
the	O
day	O
of	O
the	O
household	O
interview	O
,	O
a	O
first	O
morning	O
void	O
urine	O
sample	O
of	O
each	O
woman	O
was	O
collected	O
in	O
a	O
s	O
##ter	O
##ile	O
di	O
##sp	O
##osa	O
##ble	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
urine	O
collection	O
cup	O
(	B
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
plastic	O
##s	O
have	O
not	O
been	O
reported	O
to	O
contain	O
detect	O
##able	O
levels	O
of	O
p	O
##ht	O
##hala	O
##tes	O
)	O
.	O

Vita	O
##min	O
D	O
_	O
3	O
synthesized	O
in	O
the	O
skin	O
or	O
consumed	O
by	O
mouth	O
is	O
meta	O
##bol	O
##ized	O
to	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
)	O
,	O
which	O
can	O
then	O
be	O
meta	O
##bol	O
##ized	O
to	O
1	B
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	B
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
the	O
active	O
vitamin	B
D	I
hormone	O
)	O
by	O
C	O
##YP	O
##27	O
##B	O
##1	O
.	O

Hip	B
##pur	I
##ic	I
acid	I
is	O
a	O
con	O
##ju	O
##gate	O
of	O
g	B
##ly	I
##cine	I
with	O
ben	B
##zoic	I
acid	I
and	O
is	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
.	O

Because	O
our	O
primary	O
hypothesis	O
was	O
that	O
coffee	O
meta	O
##bol	O
##ites	O
are	O
associated	O
with	O
color	O
##ec	O
##tal	O
cancer	O
,	O
we	O
did	O
not	O
consider	O
other	O
potential	O
sources	O
of	O
ca	B
##ffe	I
##ine	I
.	O

Ace	B
##tone	I
is	O
an	O
end	O
product	O
of	O
k	O
##eto	O
##sis	O
,	O
a	O
metabolic	O
state	O
that	O
produces	O
k	B
##eton	I
##e	I
bodies	O
for	O
use	O
as	O
another	O
fuel	O
for	O
the	O
brain	O
.	O

All	O
other	O
un	O
##con	O
##ju	O
##gated	O
est	O
##rogen	O
##s	O
were	O
below	O
the	O
LL	O
##O	O
##Q	O
(	O
0	O
.	O
5	O
p	O
##g	O
/	O
m	O
##L	O
for	O
E	B
##2	I
,	I
16	I
##α	I
-	I
OH	I
-	I
E	I
##2	I
,	I
4	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
and	O
2	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
,	O
5	O
p	O
##g	O
/	O
m	O
##L	O
for	O
4	B
-	I
OH	I
-	I
E	I
##2	I
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
)	O
.	O

Ana	O
##ly	O
##tes	O
in	O
the	O
samples	O
were	O
q	O
##uant	O
##ified	O
from	O
linear	O
ca	O
##li	O
##bra	O
##tion	O
curves	O
relating	O
the	O
ratio	O
of	O
varying	O
amounts	O
of	O
3	O
-	O
HP	O
##MA	O
or	O
HM	O
##PM	O
##A	O
and	O
a	O
constant	O
amount	O
of	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
3	O
-	O
HP	O
##MA	O
or	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
HM	O
##PM	O
##A	O
to	O
the	O
area	O
ratio	O
of	O
the	O
appropriate	O
anal	O
##yte	O
:	O
internal	O
standard	O
MS	O
/	O
MS	O
transitions	O
.	O

In	O
addition	O
,	O
lower	O
relative	O
abundance	O
##s	O
of	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
and	O
s	B
##phi	I
##nga	I
##nine	I
were	O
observed	O
in	O
the	O
non	O
-	O
severe	O
CA	O
##P	O
group	O
compared	O
to	O
the	O
severe	O
CA	O
##P	O
group	O
and	O
controls	O
.	O

Met	O
##ab	O
##oli	O
##te	O
levels	O
were	O
q	O
##uant	O
##itated	O
using	O
commercially	O
available	O
standards	O
(	O
CS	O
and	O
N	O
##AN	O
##A	O
)	O
,	O
whereas	O
CR	O
was	O
semi	O
-	O
q	O
##uant	O
##itated	O
to	O
c	B
##rea	I
##tine	I
equivalent	O
##s	O
,	O
and	O
56	O
##1	O
+	O
to	O
CS	O
equivalent	O
##s	O
due	O
to	O
lack	O
of	O
commercially	O
available	O
standards	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
profiles	O
at	O
V	O
##1	O
and	O
V	O
##12	O
and	O
changes	O
in	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
between	O
V	O
##1	O
and	O
V	O
##12	O
accurately	O
disc	O
##rim	O
##inated	O
between	O
Groups	O
O	O
and	O
P	O
(	O
p	O
<	O
5	O
##×	O
##10	O
–	O
6	O
)	O
,	O
and	O
identified	O
g	B
##ly	I
##cine	I
,	O
k	B
##yn	I
##uren	I
##ine	I
and	O
c	O
##it	O
##ru	O
##llin	O
##e	O
/	O
a	O
##rg	O
##ini	O
##ne	O
as	O
the	O
best	O
predict	O
##ors	O
of	O
group	O
membership	O
.	O

Take	O
##n	O
together	O
with	O
our	O
previous	O
work	O
,	O
the	O
current	O
results	O
showed	O
that	O
G	O
##S	O
(	O
S	O
)	O
_	O
n	O
S	O
##G	O
,	O
a	O
type	O
of	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
species	O
,	O
are	O
less	O
common	O
in	O
harvested	O
human	O
tissue	O
than	O
G	O
##SS	O
##G	O
,	O
but	O
might	O
have	O
a	O
stronger	O
anti	O
-	O
o	O
##xi	O
##da	O
##tive	O
effect	O
.	O

For	O
analysis	O
,	O
is	O
##oc	O
##ratic	O
el	O
##ution	O
with	O
met	B
##han	I
##ol	I
(	I
35	I
:	I
65	I
)	I
was	O
used	O
.	O

Moreover	O
,	O
detailed	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
profiles	O
indicated	O
that	O
a	O
majority	O
of	O
the	O
individual	O
SM	O
,	O
GM	B
##3	I
and	O
G	O
##lu	O
##C	O
##er	O
species	O
followed	O
the	O
same	O
general	O
trend	O
and	O
were	O
significantly	O
decreased	O
in	O
the	O
plasma	O
of	O
di	O
##abe	O
##tic	O
monkeys	O
under	O
both	O
fed	O
and	O
fast	O
##ing	O
conditions	O
compared	O
to	O
normal	O
controls	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
substance	O
class	O
of	O
the	O
te	B
##rp	I
##ene	I
##s	I
showed	O
an	O
inverse	O
behavior	O
.	O

By	O
contrast	O
,	O
receptor	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
FL	O
##T	O
##3	O
and	O
bone	O
si	O
##alo	O
##p	O
##rote	O
##in	O
2	O
have	O
not	O
been	O
previously	O
associated	O
with	O
metabolic	O
conditions	O
.	O

k	B
##yn	I
##uren	I
##ine	I
pathway	O
,	O
cut	O
##aneous	O
ma	O
##li	O
##gnant	O
me	O
##lan	O
##oma	O
,	O
immune	O
metabolic	O
network	O
interactions	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
CD	O
##4	O
+	O
T	O
help	O
##er	O
(	O

(	O
B	O
)	O
AU	O
##Cs	O
of	O
the	O
disc	O
##rim	O
##ina	O
##nt	O
meta	O
##bol	O
##ites	O
(	O
c	O
##it	O
##ru	O
##llin	O
##e	O
,	O
0	O
.	O
84	O
##9	O
;	O
v	B
##ali	I
##ne	I
,	O
0	O
.	O
81	O
##0	O
;	O
a	B
##rg	I
##ini	I
##ne	I
,	O
0	O
.	O
74	O
##7	O
;	O
met	B
##hi	I
##oni	I
##ne	I
,	O
0	O
.	O
74	O
##5	O
;	O
g	B
##ly	I
##cine	I
,	O
0	O
.	O
72	O
##3	O
;	O
C	B
##16	I
-	I
car	I
##ni	I
##tine	I
,	O
0	O
.	O
64	O
##6	O
)	O
.	O

After	O
serum	O
met	B
##han	I
##ol	I
extract	O
was	O
speed	O
-	O
vacuum	O
dried	O
,	O
it	O
was	O
re	O
##con	O
##stituted	O
in	O
200	O
μ	O
##L	O
of	O
AC	O
##N	O
:	O
ch	B
##lor	I
##of	I
##orm	I
:	O
met	B
##han	I
##ol	I
=	I
90	I
:	I
5	I
:	I
5	I
ready	O
for	O
injection	O
.	O

The	O
Le	O
##u	O
carbon	O
skeleton	O
is	O
converted	O
to	O
α	B
-	I
k	I
##eto	I
##is	I
##oc	I
##ap	I
##roa	I
##te	I
,	O
which	O
,	O
like	O
g	B
##lut	I
##amine	I
,	O
is	O
released	O
into	O
the	O
extra	O
##cellular	O
medium	O
.	O

The	O
following	O
criteria	O
was	O
used	O
to	O
di	O
##ag	O
##nose	O
diabetes	O
:	O
early	O
-	O
morning	O
fast	O
##ing	O
plasma	O
glucose	S
(	O
P	O
##G	O
)	O
≥	O
126	O
mg	O
/	O
d	O
##l	O
,	O
two	O
-	O
hour	O
P	B
##G	I
after	O
75	O
g	O
glucose	S
load	O
≥	O
200	O
mg	O
/	O
d	O
##l	O
,	O
or	O
ca	O
##usal	O
plasma	O
glucose	S
load	O
≥	O
200	O
mg	O
/	O
d	O
##l	O
.	O

A	O
total	O
of	O
six	O
meta	O
##bol	O
##ites	O
were	O
able	O
to	O
differentiate	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
from	O
each	O
HC	O
##C	O
stage	O
group	O
,	O
namely	O
L	O
##ys	O
##o	O
##PC	O
[	O
18	O
:	O
2	O
(	O
9	O
##Z	O
,	O
12	O
##Z	O
)	O
]	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	B
P	B
-	I
16	I
:	I
0	I
)	O
,	O
as	B
##par	I
##agi	I
##ny	I
##l	I
-	I
pro	I
##line	I
,	O
v	B
##ac	I
##ce	I
##nic	I
acid	I
,	O
L	B
-	I
as	I
##par	I
##ty	I
##l	I
-	I
4	I
-	I
phosphate	I
and	O
L	O
##ys	O
##o	O
##PC	O

One	O
patient	O
showed	O
elevated	O
bra	B
##dy	I
##kini	I
##n	I
with	O
modest	O
change	O
of	O
D	O
##AB	O
##K	O
before	O
SC	O
##C	O
and	O
was	O
lost	O
to	O
follow	O
up	O
(	O
e	O
)	O
.	O

CE	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
PP	O
##V	O
,	O
positive	O
predict	O
##ive	O
value	O
;	O
N	O
##P	O
##V	O
,	O
negative	O
predict	O
##ive	O
value	O
;	O
OR	O
,	O
odds	O
ratio	O
;	O
AU	O
##C	O
,	O
area	O
under	O
the	O
curve	O
.	O

The	O
spectral	O
region	O
between	O
9	O
.	O
40	O
–	O
0	O
.	O
50	O
pp	O
##m	O
was	O
considered	O
for	O
multi	O
##var	O
##iate	O
analysis	O
,	O
after	O
exclusion	O
of	O
residual	O
water	O
(	O
5	O
.	O
48	O
–	O
6	O
.	O
16	O
pp	O
##m	O
)	O
and	O
u	B
##rea	I
(	O
4	O
.	O
62	O
–	O
5	O
.	O
06	O
pp	O
##m	O
)	O
spectral	O
regions	O
(	O
AM	O
##IX	O
software	O
B	O
##ruk	O
##er	O
GmbH	O
)	O
.	O

Ex	O
##cess	O
##ive	O
vitamin	O
A	O
intake	O
may	O
stimulate	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
ex	O
##cre	O
##tion	O
both	O
in	O
v	O
##ivo	O
and	O
in	O
v	O
##it	O
##ro	O
,	O
suggesting	O
accelerated	O
my	O
##of	O
##ib	O
##rilla	O
##r	O
protein	O
breakdown	O
and	O
protein	O
turnover	O
.	O

The	O
pen	B
##tan	I
##e	I
and	O
water	O
extract	O
##s	O
were	O
tested	O
for	O
sperm	O
m	O
##ot	O
##ility	O
-	O
in	O
##hibit	O
##ing	O
activity	O
and	O
found	O
to	O
have	O
little	O
or	O
no	O
activity	O
.	O

Eleven	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
including	O
mon	B
##o	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##HP	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
o	I
##x	I
##o	I
-	I
he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##OH	O
##P	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##H	O
##HP	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##CP	O
##P	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
car	I
##box	I
##yme	I
##thy	I
##l	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
MC	O
##M	O
##HP	O
)	O
,	O
mon	B
##o	I
-	I
n	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##n	O
##B	O
##P	O
)	O
,	O
mon	B
##o	I
-	I
is	I
##o	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
Mi	O
##B	O
##P	O
)	O
,	O
mon	B
##o	I
-	I
et	I
##hyl	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##P	O
)	O
,	O
mon	B
##o	I
-	I
is	I
##o	I
-	I
non	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
Mi	O
##NP	O
)	O
,	O
mon	B
##o	I
-	I
ben	I
##zy	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
MB	O
##z	O
##P	O
)	O
and	O
mon	B
##o	I
-	I
met	I
##hyl	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##MP	O
)	O
representing	O
exposure	O
to	O
seven	O
commonly	O
used	O
p	O
##ht	O
##hala	O
##tes	O
(	O
DE	O
##HP	O
,	O
D	O
##n	O
##B	O
##P	O
,	O
Di	O
##B	O
##P	O
,	O

di	O
##hy	O
##dr	O
##oor	O
##ota	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
)	O
,	O
the	O
bi	O
-	O
functional	O
enzyme	O
u	B
##rid	I
##ine	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
s	O
##ynth	O
##ase	O
(	O
U	O
##MP	O
##S	O
,	O
comprised	O
of	O
or	O
##ota	O
##te	O
p	O
##hos	O
##ph	O
##ori	O
##bos	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
and	O
O	O
##MP	O
de	O
##car	O
##box	O
##yla	O
##se	O
)	O
,	O
and	O
thy	B
##mi	I
##dy	I
##late	I
s	O
##ynth	O
##eta	O
##se	O
(	O
T	O
##Y	O
##MS	O
)	O
.	O

Several	O
of	O
them	O
belonged	O
to	O
car	B
##ni	I
##tine	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	I
car	I
##ni	I
##tine	I
,	I
is	I
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
,	I
g	I
##lut	I
##ary	I
##l	I
##car	I
##ni	I
##tine	I
,	I
o	I
##ct	I
##eno	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
and	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
)	I
,	O
while	O
others	O
related	O
to	O
the	O
last	O
steps	O
of	O
g	O
##ly	O
##co	O
##lysis	O
(	O
p	O
##hos	O
##ph	O
##oe	O
##no	O
##l	O
##py	O
##ru	O
##vate	O
and	O
p	B
##yr	I
##u	I
##vate	I
)	I
or	O
the	O
T	O
##CA	O
cycle	O
(	B
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
su	B
##cci	I
##nate	I
,	O
and	O
o	B
##x	I
##og	I
##lut	I
##arate	I
)	O
.	O

Met	B
##han	I
##ol	I
,	O
ace	B
##tic	I
acid	I
,	O
2	B
,	I
6	I
-	I
di	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
-	I
4	I
-	I
met	I
##hyl	I
##phe	I
##no	I
##l	I
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
were	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
of	O
biological	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
obtained	O
by	O
H	O
##IL	O
##IC	O
retention	O
.	O

Then	O
100	O
μ	O
##M	O
palm	B
##ito	I
##yl	I
-	I
Co	I
##A	I
and	O
5	O
m	O
##M	O
L	B
-	I
car	I
##ni	I
##tine	I
were	O
added	O
to	O
the	O
mixture	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
40	O
:	O
60	O
v	O
/	O
v	O
)	O
with	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
solvent	O
A	O
)	O
and	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
/	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
10	O
:	O
5	O
:	O
85	O
v	O
/	O
v	O
)	O
with	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
solvent	O
B	O
)	O
.	O

We	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
the	O
A	O
##4	O
##9	O
##8	O
cell	O
line	O
is	O
able	O
to	O
most	O
efficiently	O
meta	O
##bol	O
##ize	O
B	O
##EN	O
to	O
its	O
more	O
reactive	O
meta	O
##bol	O
##ite	O
BA	O
by	O
AL	O
##D	O
##H	O
inside	O
the	O
cell	O
,	O
which	O
then	O
rapidly	O
al	B
##ky	I
##lates	I
cellular	O
constituents	O
resulting	O
in	O
cell	O
damage	O
.	O

Des	O
##cript	O
##ive	O
statistics	O
of	O
the	O
breast	O
cancer	O
patients	O
by	O
means	O
and	O
standard	O
de	O
##viation	O
##s	O
(	O
SD	O
)	O
,	O
n	O
=	O
56	O
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
BP	O
blood	O
pressure	O
,	O
B	O
##MI	O
body	O
mass	O
index	O
,	O
ER	O
est	B
##rogen	I
receptor	O
,	O
H	O
##ER	O
##2	O
human	O
e	O
##pid	O
##er	O
##mal	O
growth	O
factor	O
2	O
,	O
HD	O
##L	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
,	O
L	O
##D	O
##L	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
,	O
P	O
##g	O
##R	O
pro	B
##ges	I
##tero	I
##ne	I
receptor	O
,	O
Ki	O
67	O
anti	O
##gen	O
Ki	O
-	O
67	O
.	O

The	O
gradient	O
started	O
with	O
100	O
%	O
A	O
(	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
H	O
_	O
2	O
O	O
)	O
and	O
0	O
%	O
B	O
(	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
CH	O
_	O
3	O
C	O
##N	O
)	O
,	O
after	O
0	O
.	O
6	O
min	O
,	O
changed	O
to	O
80	O
%	O
A	O
over	O
0	O
.	O
6	O
min	O
,	O
then	O
30	O
%	O
A	O
over	O
1	O
.	O
8	O
min	O
.	O

The	O
authors	O
suggest	O
that	O
short	O
chain	O
FA	S
may	O
be	O
beneficial	O
and	O
also	O
prefer	O
##ential	O
in	O
cellular	O
re	O
##spiration	O
during	O
stress	O
.	O

All	O
mon	O
##oa	O
##cy	O
##l	O
lip	O
##ids	O
except	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
,	O
such	O
as	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
and	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
were	O
normal	O
##ized	O
with	O
PC	B
(	I
17	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
all	O
di	O
##acy	O
##l	O
lip	O
##ids	O
except	O
ethanol	B
##amine	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
normal	O
##ized	O
with	O
PC	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
all	O
c	B
##era	I
##mi	I
##des	I
with	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
,	O
all	O
di	B
##acy	I
##l	I
ethanol	I
##amine	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
with	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
and	O
T	B
##G	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
with	O
T	B
##G	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
.	O

The	O
common	O
changes	O
in	O
meta	O
##bol	O
##ites	O
between	O
m	B
##uri	I
##ne	I
and	O
human	O
samples	O
included	O
2	B
‐	I
o	I
##x	I
##og	I
##lut	I
##arate	I
,	O
3	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
3	B
‐	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
a	B
##con	I
##itate	I
,	O
al	B
##ani	I
##ne	I
,	O
an	B
##ser	I
##ine	I
,	O
car	B
##ni	I
##tine	I
,	O
car	B
##nos	I
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
c	O
##is	O
‐	O
a	O
##con	O
##itate	O
,	O
c	B
##it	I
##rate	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
c	B
##rea	I
##tine	I
,	O
glucose	S
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cine	I
,	O
is	B
##oc	I
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
,	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
ma	B
##late	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yl	I
ace	I
##tate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
se	B
##rine	I
,	O
su	B
##cci	I
##nate	I
,	O
ta	B
##uri	I
##ne	I
,	O
ta	B
##uri	I
##ne	I
,	O
th	B
##re	I
##ona	I
##te	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
V	O
##LD	O
##L	O
/	O
L	O
##D	O
##L	O
.	O

In	O
T	O
##1	O
##DM	O
,	O
C	B
##24	I
:	I
1	I
species	O
were	O
also	O
the	O
highest	O
followed	O
by	O
C	B
##16	I
:	I
0	I
,	O
C	B
##24	I
:	I
0	I
,	O
and	O
C	B
##22	I
:	I
0	I
.	O

Three	O
of	O
the	O
five	O
all	O
##ele	O
##s	O
were	O
independently	O
associated	O
with	O
an	O
increase	O
in	O
serum	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
in	O
the	O
combined	O
D	O
##HS	O
co	O
##hor	O
##t	O
(	O
African	O
-	O
American	O
,	O
European	O
-	O
American	O
,	O
and	O
Hispanic	O
participants	O
)	O
,	O
with	O
two	O
variants	O
(	O
r	O
##s	O
##22	O
##7	O
##7	O
##11	O
##9	O
;	O
R	O
##10	O
##3	O
##H	O
;	O
and	O
r	O
##s	O
##7	O
##7	O
##6	O
##17	O
##31	O
;	O
N	O
##32	O
##4	O
##K	O
)	O
making	O
significantly	O
larger	O
contributions	O
than	O
the	O
third	O
.	O

Interest	O
##ingly	O
,	O
we	O
demonstrated	O
that	O
most	O
of	O
the	O
anal	O
##ys	O
##ed	O
tear	O
meta	O
##bol	O
##ites	O
,	O
like	O
PC	B
34	I
:	I
1	I
,	O
PC	B
36	I
:	I
2	I
and	O
PC	B
40	I
:	I
4	I
,	O
C	O
##0	O
,	O
C	O
##2	O
,	O
C	O
##3	O
,	O
Le	O
##u	O
/	O
Il	O
##e	O
/	O
Pro	O
,	O
Ph	O
##e	O
,	O
Ty	O
##r	O
,	O
G	O
##lu	O
,	O
Met	O
,	O
and	O
L	O
##ys	O
/	O
G	O
##ln	O
were	O
more	O
retained	O
in	O
the	O
first	O
section	O
of	O
the	O
im	O
##bi	O
##bed	O
paper	O
strip	O
.	O

H	O
##yper	O
##ther	O
##mia	O
caused	O
extensive	O
damage	O
of	O
the	O
ultra	O
##st	O
##ructural	O
of	O
mit	O
##och	O
##ond	O
##ria	O
,	O
r	O
##up	O
##tured	O
g	O
##ly	O
##co	O
##lysis	O
and	O
energy	O
metabolism	O
of	O
cancer	O
##ous	O
cells	O
,	O
which	O
blocking	O
the	O
generation	O
of	O
la	B
##ct	I
##ate	I
as	O
a	O
fuel	O
of	O
T	O
##CA	O
cycle	O
.	O

A	O
)	O
E	O
##SI	O
positive	O
mode	O
,	O
the	O
HP	O
##LC	O
column	O
Waters	O
X	O
-	O
bridge	O
Am	B
##ide	I
3	O
.	O
5	O
μ	O
##m	O
,	O
4	O
.	O
6	O
×	O
100	O
mm	O
was	O
used	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
in	O
healthy	O
controls	O
s	O
##tra	O
##ti	O
##fied	O
by	O
body	O
fat	O
.	O

(	O
A	O
)	O
Total	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
levels	O
change	O
only	O
modest	O
##ly	O
during	O
infection	O
.	O

The	O
performance	O
of	O
the	O
different	O
Me	B
##OH	I
percentage	O
##s	O
were	O
evaluated	O
according	O
to	O
the	O
following	O
criteria	O
:	O
(	O
1	O
)	O
number	O
of	O
detected	O
meta	O
##bol	O
##ites	O
,	O
(	O
2	O
)	O
relative	O
peak	O
area	O
,	O
and	O
(	O
3	O
)	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
.	O

A	O
portion	O
of	O
the	O
_	O
1	O
H	O
-	O
_	O
15	O
N	O
H	O
##S	O
##Q	O
##C	O
spectrum	O
of	O
human	O
serum	O
tag	O
##ged	O
with	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
.	O

In	O
a	O
study	O
addressed	O
to	O
evaluate	O
the	O
variation	O
of	O
p	B
##oly	I
##amine	I
##s	I
in	O
the	O
pre	O
and	O
post	O
-	O
surgery	O
serum	O
of	O
BC	O
patients	O
,	O
no	O
significant	O
difference	O
was	O
reported	O
.	O

In	O
our	O
case	O
,	O
the	O
levels	O
of	O
PC	B
(	I
20	I
:	I
4	I
/	I
0	I
:	I
0	I
)	I
,	O
PC	B
(	I
22	I
:	I
6	I
/	I
0	I
:	I
0	I
)	I
,	O
were	O
increased	O
in	O
the	O
serum	O
of	O
rapid	O
fi	O
##bro	O
##ser	O
##s	O
when	O
compared	O
with	O
slow	O
fi	O
##bro	O
##ser	O
##s	O
;	O
in	O
contrast	O
,	O
the	O
levels	O
of	O
PC	B
(	I
18	I
:	I
2	I
/	I
20	I
:	I
4	I
)	I
,	O
and	O
PC	B
(	I
40	I
:	I
8	I
)	I
decreased	O
.	O

At	O
base	O
##line	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
ages	O
,	O
gender	O
,	O
body	O
mass	O
index	O
,	O
blood	O
glucose	S
,	O
lip	O
##id	O
profile	O
,	O
blood	O
pressure	O
as	O
well	O
as	O
general	O
health	O
conditions	O
among	O
these	O
3	O
groups	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
_	O
S	O
##1	O
)	O
.	O

The	O
first	O
and	O
third	O
components	O
account	O
mostly	O
for	O
the	O
separation	O
among	O
survivor	O
and	O
deceased	O
patients	O
and	O
are	O
dominated	O
by	O
amino	O
acids	O
(	B
his	B
##ti	I
##dine	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
.	O

Multi	O
##par	O
##ame	O
##tric	O
analysis	O
of	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
emphasizes	O
that	O
the	O
most	O
significant	O
meta	O
##bol	O
##omi	O
##cs	O
differences	O
occur	O
in	O
a	O
region	O
of	O
the	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
belonging	O
to	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
signals	O
associated	O
to	O
lip	O
##op	O
##rote	O
##in	O
sub	O
-	O
fraction	O
##s	O
(	O
B	O
and	O
Figure	O
S	O
##1	O
)	O
.	O

Using	O
the	O
protocol	O
s	O
##che	O
##mat	O
##ized	O
in	O
,	O
we	O
collected	O
and	O
profile	O
##d	O
cell	O
samples	O
immediately	O
after	O
the	O
formal	B
##in	I
fix	O
##ation	O
before	O
the	O
para	O
##ffin	O
-	O
em	O
##bed	O
##ding	O
procedure	O
and	O
the	O
super	O
##nat	O
##ant	O
solutions	O
of	O
formal	B
##in	I
used	O
during	O
the	O
fix	O
##ation	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
IL	O
-	O
10	O
was	O
the	O
next	O
most	O
commonly	O
associated	O
immune	O
system	O
bio	O
##mark	O
##er	O
,	O
being	O
positively	O
associated	O
with	O
4	O
try	O
##pt	O
##op	O
##han	O
-	O
related	O
variables	O
:	O
k	B
##yn	I
##uren	I
##ine	I
(	O
P	O
=	O
0	O
.	O
000	O
##2	O
)	O
,	O
the	O
K	O
##TR	O
(	O
P	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

This	O
means	O
that	O
despite	O
the	O
importance	O
of	O
g	B
##lut	I
##ama	I
##te	I
,	O
other	O
I	O
##R	O
##s	O
may	O
have	O
additional	O
value	O
in	O
the	O
classification	O
process	O
.	O

Ren	O
##al	O
expression	O
of	O
ace	O
##ty	O
##l	O
-	O
Co	O
##A	O
car	O
##box	O
##yla	O
##se	O
–	O
encoding	O
gene	O
(	O
AC	O
##AC	O
##A	O
)	O
correlated	O
with	O
serum	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
in	O
the	O
g	O
##lo	O
##mer	O
##ular	O
compartment	O
(	O
r	O
=	O
0	O
.	O
36	O
,	O
and	O
P	O
=	O
0	O
.	O
00	O
##6	O
)	O
and	O
with	O
low	O
-	O
double	O
-	O
bond	O
T	O
##AG	O
##s	O
in	O
the	O
tub	O
##ulo	O
##int	O
##ers	O
##ti	O
##tial	O
compartment	O
(	O
r	O
=	O
0	O
.	O
52	O
,	O
and	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

First	O
##ly	O
,	O
Due	O
to	O
the	O
rapid	O
growth	O
of	O
tumor	O
cells	O
,	O
there	O
is	O
a	O
great	O
demand	O
for	O
energy	O
and	O
more	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
production	O
of	O
ATP	S
is	O
required	O
.	O

One	O
conclusion	O
of	O
these	O
studies	O
is	O
that	O
di	B
##ol	I
e	I
##pox	I
##ide	I
stereo	O
##chemistry	O
strongly	O
affects	O
con	O
##ju	O
##gation	O
.	O

Direct	O
measurements	O
of	O
CS	O
##F	O
glucose	S
levels	O
(	O
performed	O
immediately	O
after	O
sample	O
collection	O
)	O
confirmed	O
a	O
highly	O
significant	O
increase	O
in	O
glucose	S
levels	O
in	O
drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
with	O
s	O
##chi	O
##zophrenia	O
in	O
the	O
first	O
co	O
##hor	O
##t	O
(	O
6	O
.	O
5	O
%	O
increase	O
,	O
p	O
=	O
0	O
.	O
00	O
##5	O
;	O
)	O
.	O

We	O
observed	O
a	O
non	O
##sign	O
##ificant	O
increase	O
in	O
ace	B
##tate	I
in	O
the	O
patients	O
with	O
MS	O
.	O

Form	B
##ic	I
acid	I
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
L	O
##C	O
-	O
grade	O
)	O
,	O
s	B
##te	I
##aro	I
##yle	I
##than	I
##ola	I
##mi	I
##de	I
,	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pur	I
##ic	I
acid	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
van	B
##ill	I
##yl	I
##mand	I
##eli	I
##c	I
acid	I
,	O
g	B
##lut	I
##ari	I
##c	I
acid	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
na	O
##ring	O
##in	O
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

As	O
shown	O
,	O
five	O
metabolic	O
pathways	O
of	O
importance	O
were	O
disturbed	O
in	O
the	O
serum	O
of	O
T	O
##BI	O
patients	O
with	O
cognitive	O
imp	O
##air	O
##ment	O
:	O
(	O
1	O
)	O
l	B
##ino	I
##le	I
##ic	I
acid	I
metabolism	O
;	O
(	O
2	O
)	O
gal	B
##act	I
##ose	I
metabolism	O
,	O
(	O
3	O
)	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
,	O
(	O
4	O
)	O
g	O
##ly	O
##cine	O
/	O
se	O
##rine	O
/	O
th	O
##re	O
##oni	O
##ne	O
metabolism	O
,	O
and	O
(	O
5	O
)	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
.	O

K	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
are	O
expressed	O
as	O
unit	O
##less	O
ratios	O
of	O
the	O
serum	O
meta	O
##bol	O
##ite	O
concentration	O
to	O
the	O
serum	O
try	B
##pt	I
##op	I
##han	I
concentration	O
and	O
do	O
not	O
have	O
units	O
.	O

PD	O
##H	O
controls	O
the	O
entry	O
of	O
p	B
##yr	I
##u	I
##vate	I
into	O
the	O
T	O
##CA	O
cycle	O
.	O

[	O
Google	O
Scholar	O
]	O
Hawkins	O
RA	O
,	O
Roberts	O
M	O
##M	O
,	O
Forrest	O
AP	S
.	O

Sam	O
##ples	O
were	O
el	O
##uted	O
with	O
1	O
.	O
5	O
m	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
into	O
2	O
m	O
##L	O
plastic	O
tubes	O
.	O

The	O
bottom	O
ch	B
##lor	I
##of	I
##orm	I
phase	O
was	O
transferred	O
to	O
G	O
##C	O
via	O
##ls	O
containing	O
~	O
100	O
mg	O
of	O
an	B
##hy	I
##dr	I
##ous	I
sodium	I
su	I
##lf	I
##ate	I
.	O

Finally	O
,	O
the	O
HM	O
##A	O
concentration	O
at	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
m	O
##M	O
was	O
op	O
##ti	O
##mized	O
using	O
a	O
buffer	O
consisting	O
of	O
1	O
m	O
##M	O
am	B
##mon	I
##ium	I
phosphate	I
.	O

The	O
levels	O
of	O
these	O
free	O
o	B
##xy	I
##ster	I
##ols	I
in	O
CS	O
##F	O
were	O
very	O
low	O
ranging	O
from	O
0	O
.	O
00	O
##9	O
±	O
0	O
.	O
00	O
##5	O
ng	O
/	O
m	O
##l	O
for	O
7	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
7	I
##β	I
-	I
di	I
##ol	I
,	I
C	I
_	I
5	I
-	I
3	I
##β	I
,	I
7	I
##β	I
-	I
di	I
##ol	I
)	I
to	O
0	O
.	O
02	O
##6	O
±	O
0	O
.	O
01	O
##8	O
ng	O
/	O
m	O
##l	O
for	O
6	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	I
ch	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
6	I
-	I
di	I
##ol	I
,	I
C	I
_	I
4	I
-	I
3	I
##β	I
,	I
6	I
-	I
di	I
##ol	I
,	I
or	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
6	I
-	I
di	I
##ol	I
,	I
C	I
_	I
5	I
-	I
3	I
##β	I
,	I
6	I
-	I
di	I
##ol	I
)	I
and	O
0	O
.	O
03	O
##4	O
±	O
0	O
.	O
01	O
##7	O
ng	O
/	O
m	O
##l	O
for	O
7	B
-	I
o	I
##x	I
##och	I
##ole	I
##ster	I
##ol	I
.	O

It	O
was	O
apparent	O
that	O
the	O
doses	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
used	O
in	O
the	O
trial	O
(	O
30	O
mg	O
/	O
day	O
)	O
were	O
much	O
higher	O
than	O
the	O
range	O
of	O
normal	O
diet	O
##ary	O
intake	O
##s	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
disease	O
in	O
the	O
observation	O
##al	O
studies	O
.	O

To	O
evaluate	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
synthesis	O
from	O
glucose	S
in	O
v	O
##ivo	O
,	O
2	O
g	O
of	O
[	B
U	I
_	I
13	I
C	I
]	I
glucose	I
(	O
C	O
##LM	O
-	O
139	O
##6	O
-	O
MP	O
##T	O
;	O
Cambridge	O
Is	O
##oto	O
##pes	O
)	O
was	O
administered	O
oral	O
##ly	O
to	O
three	O
healthy	O
male	O
donors	O
and	O
dried	O
blood	O
samples	O
were	O
collected	O
via	O
finger	O
p	O
##rick	O
at	O
T	O
##0	O
and	O
at	O
5	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
90	O
,	O
120	O
,	O
and	O
180	O
min	O
after	O
ing	O
##est	O
##ion	O
on	O
dried	O
blood	O
spot	O
cards	O
(	O
What	O
##man	O
protein	O
save	O
##r	O
cards	O
,	O
Z	O
##6	O
##9	O
##9	O
##51	O
##9	O
-	O
100	O
##EA	O
;	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
)	O
.	O

The	O
me	O
##dicated	O
B	O
##D	O
subjects	O
were	O
receiving	O
treatment	O
with	O
the	O
following	O
medications	O
at	O
the	O
time	O
of	O
the	O
study	O
:	O
add	B
##eral	I
##l	I
,	O
n	O
=	O
2	O
,	O
a	B
##rip	I
##ip	I
##raz	I
##ole	I
,	O
n	O
=	O
8	O
;	O
ben	B
##zo	I
##dia	I
##ze	I
##pine	I
##s	I
,	O
n	O
=	O
13	O
;	O
b	O
##up	O
##rop	O
##ion	O
,	O
n	O
=	O
5	O
;	O
car	B
##ba	I
##ze	I
##pine	I
,	O
n	O
=	O
1	O
;	O
di	B
##val	I
##p	I
##ro	I
##ex	I
sodium	I
,	O
n	O
=	O
4	O
;	O
g	B
##aba	I
##pent	I
##in	I
,	O
n	O
=	O
3	O
;	O
la	B
##mot	I
##rig	I
##ine	I
,	O
n	O
=	O
18	O
;	O
lit	O
##hium	O
,	O
n	O
=	O
2	O
;	O
met	B
##hyl	I
##phe	I
##ni	I
##date	I
,	O
n	O
=	O
1	O
;	O
o	B
##lan	I
##za	I
##pine	I
,	O
n	O
=	O
2	O
;	O
que	B
##tia	I
##pine	I
,	O
n	O
=	O
2	O
;	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
n	O
=	O
1	O
;	O
SSR	O
##I	O
/	O
S	O
##NR	O
##I	O
,	O
n	O
=	O
16	O
;	O
t	B
##raz	I
##od	I
##one	I
,	O
n	O
=	O
4	O
;	O
z	O
##ol	O
##pid	O
##em	O
,	O
n	O
=	O
3	O
.	O

SP	S
was	O
still	O
found	O
in	O
approximately	O
half	O
of	O
the	O
patients	O
,	O
although	O
it	O
had	O
been	O
officially	O
abandoned	O
as	O
first	O
-	O
line	O
treatment	O
since	O
2006	O
.	O

The	O
analysis	O
was	O
carried	O
out	O
using	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
mobile	O
phase	O
A	O
)	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
mobile	O
phase	O
B	O
)	O
under	O
the	O
gradient	O
condition	O
.	O

It	O
is	O
also	O
noteworthy	O
that	O
the	O
significantly	O
decreased	O
blood	O
concentration	O
of	O
his	B
##ti	I
##dine	I
was	O
observed	O
in	O
other	O
cancer	O
types	O
,	O
such	O
as	O
gas	O
##tric	O
cancer	O
,	O
color	O
##ec	O
##tal	O
cancer	O
,	O
and	O
breast	O
cancer	O
(	O
Mi	O
##ya	O
##gi	O
et	O
al	O
.	O
)	O
.	O

In	O
our	O
study	O
,	O
90	O
%	O
of	O
the	O
n	O
##uc	O
##leo	O
##side	O
library	O
were	O
covered	O
by	O
R	B
##P	I
method	O
A	O
but	O
only	O
45	O
%	O
showed	O
k	O
>	O
1	O
and	O
acceptable	O
peaks	O
##ha	O
##pes	O
.	O

Ph	O
##arma	O
##co	O
##kin	O
##etic	O
curve	O
of	O
a	O
patient	O
treated	O
with	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
160	O
mg	O
once	O
daily	O
at	O
steady	O
state	O
.	O

With	O
the	O
a	O
##gg	O
##ra	O
##vat	O
##ing	O
condition	O
of	O
se	O
##psis	O
,	O
on	O
the	O
one	O
hand	O
,	O
the	O
H	O
##IF	O
=	O
1	O
target	O
gene	O
expression	O
was	O
decreased	O
;	O
on	O
the	O
other	O
hand	O
,	O
the	O
H	B
##IF	I
-	I
1	I
##α	I
m	I
##RNA	I
expression	O
was	O
decreased	O
.	O

These	O
findings	O
are	O
in	O
agreement	O
with	O
another	O
study	O
that	O
showed	O
supplement	O
##ation	O
of	O
te	B
##tra	I
##hy	I
##dr	I
##ob	I
##io	I
##pt	I
##eri	I
##n	I
,	O
a	O
co	O
##fa	O
##ctor	O
for	O
the	O
production	O
of	O
NO	O
,	O
improved	O
end	O
##oth	O
##eli	O
##al	O
function	O
but	O
failed	O
to	O
improve	O
a	O
##ort	O
##ic	O
stiff	O
##ness	O
.	O

As	O
a	O
result	O
of	O
all	O
this	O
,	O
the	O
difference	O
in	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
levels	O
in	O
F	O
##S	O
##GS	O
and	O
MC	O
##D	O
patients	O
verified	O
to	O
be	O
significant	O
regardless	O
of	O
basal	O
re	O
##nal	O
function	O
(	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##4	O
)	O
.	O

2	B
,	I
3	I
,	I
4	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##yra	I
##te	I
is	O
probably	O
derived	O
from	O
g	O
##ly	O
##cated	O
proteins	O
or	O
from	O
the	O
degradation	O
of	O
as	B
##cor	I
##bic	I
acid	I
,	O
and	O
it	O
is	O
a	O
substrate	O
of	O
L	O
-	O
th	O
##re	O
##ona	O
##te	O
3	O
-	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
in	O
the	O
as	B
##cor	I
##bate	I
and	O
al	O
##dar	O
##ate	O
metabolic	O
pathway	O
.	O

Un	O
##tre	O
##ated	O
cells	O
retained	O
the	O
same	O
appearance	O
as	O
live	O
cells	O
(	O
without	O
an	O
##nex	O
##in	O
-	O
V	O
or	O
prop	O
##id	O
##ium	O
i	B
##od	I
##ide	I
stain	O
##ing	O
)	O
,	O
and	O
the	O
same	O
was	O
true	O
for	O
the	O
9	O
-	O
PA	O
##HS	O
##A	O
treated	O
-	O
cells	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
HIV	O
infection	O
,	O
the	O
induction	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
has	O
been	O
implicated	O
in	O
maternal	O
tolerance	O
of	O
the	O
f	O
##etal	O
all	O
##og	O
##raft	O
and	O
in	O
the	O
e	O
##vas	O
##ion	O
of	O
host	O
immune	O
responses	O
by	O
several	O
cancer	O
##s	O
.	O

Me	O
##as	O
##ured	O
recover	O
##ies	O
and	O
associated	O
precision	O
(	O
%	O
recovery	O
±	O
SD	O
)	O
for	O
de	O
##uter	O
##ated	O
compounds	O
at	O
different	O
fortification	O
levels	O
in	O
plasma	O
n	O
=	O
5	O
Cal	O
##ib	O
##ration	O
curves	O
were	O
obtained	O
from	O
a	O
series	O
of	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
reference	O
standards	O
over	O
a	O
wide	O
concentration	O
range	O
,	O
using	O
the	O
corresponding	O
stable	O
is	O
##oto	O
##pe	O
compounds	O
as	O
internal	O
standards	O
.	O

In	O
##hibition	O
of	O
soluble	O
e	O
##pox	O
##ide	O
h	O
##ydro	O
##lase	O
(	O
s	O
##E	O
##H	O
)	O
produces	O
increased	O
E	O
##ET	O
##s	O
with	O
decreased	O
blood	O
pressure	O
in	O
experimental	O
and	O
genetic	O
h	O
##yper	O
##tens	O
##ion	O
in	O
rats	O
_	O
–	O
Ang	B
II	I
stimulate	O
##s	O
20	B
-	I
H	I
##ET	I
##E	I
synthesis	O
in	O
re	O
##nal	O
micro	O
##ves	O
##sel	O
##s	O
_	O
,	O
and	O
decreases	O
E	O
##ET	O
levels	O
by	O
down	O
##re	O
##gu	O
##lating	O
e	O
##pox	O
##y	O
##gen	O
##ases	O
and	O
increasing	O
their	O
degradation	O
by	O
increasing	O
expression	O
and	O
activity	O
of	O
s	O
##E	O
##H	O
.	O
_	O
,	O
These	O
studies	O
provide	O
the	O
rational	O
##e	O
to	O
the	O
hypothesis	O
that	O
occasion	O
##ed	O
the	O
present	O
study	O
;	O
namely	O
,	O
metabolism	O
of	O
AA	O
via	O
C	O
##YP	O
mon	O
##oo	O
##xy	O
##gen	O
##ases	O
is	O
altered	O
in	O
re	O
##nova	O
##s	O
##cular	O
disease	O
(	O
R	O
##VD	O
)	O
.	O

The	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
(	O
s	O
)	O
,	O
re	B
##sol	I
##vin	I
D	I
##1	I
and	O
re	O
##sol	O
##vin	O
D	O
##2	O
were	O
identified	O
in	O
the	O
plasma	O
of	O
two	O
household	O
contacts	O
,	O
but	O
was	O
not	O
linked	O
to	O
detection	O
of	O
either	O
of	O
the	O
put	O
##ative	O
Mt	O
##b	O
cell	O
wall	O
-	O
related	O
meta	O
##bol	O
##ites	O
.	O

All	O
meta	O
##bol	O
##ite	O
standards	O
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
were	O
brought	O
to	O
100	O
m	O
##M	O
in	O
D	B
##MS	I
##O	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
D	O
##24	O
##38	O
)	O
prior	O
to	O
di	O
##lution	O
for	O
dose	O
ass	O
##ays	O
.	O

Since	O
the	O
concentration	O
of	O
la	B
##ct	I
##ate	I
in	O
the	O
blood	O
remains	O
one	O
of	O
the	O
main	O
indicators	O
of	O
se	O
##psis	O
,	O
we	O
compared	O
simultaneously	O
,	O
in	O
the	O
same	O
serum	O
samples	O
from	O
se	O
##ptic	O
patients	O
,	O
the	O
concentration	O
of	O
la	O
##ctic	O
,	O
su	B
##cci	I
##nic	I
acids	I
and	O
Su	O
##m	O
##3	O
.	O

In	O
all	O
,	O
twelve	O
fully	O
-	O
p	O
##orous	O
columns	O
were	O
tested	O
,	O
including	O
four	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##C	O
_	O
2	O
columns	O
(	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
,	O
B	O
##E	O
##H	O
,	O
CS	O
##H	O
F	O
##P	O
and	O
H	O
##SS	O
C	O
_	O
18	O
S	O
##B	O
)	O
,	O
four	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
columns	O
(	O
B	O
##E	O
##H	O
Am	B
##ide	I
,	O
B	O
##E	O
##H	O
H	O
##IL	O
##IC	O
,	O
B	O
##E	O
##H	O
Ph	O
##en	O
##yl	O
and	O
H	O
##SS	O
Cy	B
##ano	I
)	O
,	O
and	O
four	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##C	O
_	O
2	O
Tor	O
##us	O
columns	O
(	B
2	B
-	I
p	I
##ico	I
##ly	I
##lam	I
##ine	I
or	O
2	O
-	O
P	O
##IC	O
,	O
Di	B
##ol	I
,	O
Diet	B
##hyl	I
##amine	I
or	O
DE	O
##A	O
and	O
1	B
-	I
amino	I
ant	I
##hra	I
##cene	I
or	O
1	O
-	O
AA	O
)	O
.	O

For	O
absolute	O
q	O
##uant	O
##ification	O
of	O
Ph	B
##e	I
-	I
Ph	I
##e	I
,	O
3	O
##bet	O
##a	O
,	O
6	B
##bet	I
##a	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
##bet	I
##a	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
,	O
G	O
##CA	O
,	O
G	O
##DC	O
##A	O
,	O
T	O
##CD	O
##CA	O
,	O
o	B
##leo	I
##yl	I
car	I
##ni	I
##tine	I
,	O
and	O
l	B
##ino	I
##ela	I
##idy	I
##l	I
car	I
##ni	I
##tine	I
,	O
we	O
spike	O
##d	O
the	O
serum	O
samples	O
with	O
the	O
following	O
internal	O
standards	O
:	O
2	O
##C	O
_	O
13	O
_	O
Ph	B
##e	I
-	I
Ph	I
##e	I
,	O
D	O
_	O
4	O
_	O
G	O
##CA	O
,	O
D	O
_	O
4	O
_	O
G	O
##DC	O
##A	O
,	O
D	O
_	O
5	O
_	O
T	O
##CA	O
,	O
and	O
D	O
_	O
35	O
_	O
L	O
##ys	O
##o	O
##PC	O
18	O
:	O
0	O
.	O

In	O
one	O
patient	O
the	O
diagnosis	O
3	O
-	O
met	O
##hyl	O
##c	O
##rot	O
##ony	O
##l	O
##gly	O
##cin	O
##uria	O
was	O
missed	O
,	O
due	O
to	O
normal	O
values	O
of	O
met	B
##hyl	I
##c	I
##rot	I
##ony	I
##l	I
##gly	I
##cine	I
and	O
h	B
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
.	O

They	O
also	O
had	O
higher	O
c	B
##it	I
##ru	I
##llin	I
##e	I
concentrations	O
than	O
controls	O
but	O
lower	O
than	O
I	O
##BS	O
patients	O
,	O
lower	O
concentrations	O
of	O
SD	O
##MA	O
than	O
controls	O
but	O
higher	O
than	O
I	O
##BS	O
patients	O
,	O
and	O
higher	O
D	B
##MA	I
concentrations	O
than	O
controls	O
and	O
patients	O
with	O
inactive	O
CD	O
.	O

Tau	B
##ro	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
(	O
T	O
##CD	O
##CA	O
)	O
,	O
ta	B
##uro	I
##cho	I
##late	I
(	O
T	O
##CA	O
)	O
,	O
g	B
##ly	I
##co	I
##hy	I
##och	I
##olate	I
(	O
G	O
##HC	O
##A	O
)	O
and	O
g	B
##ly	I
##co	I
##cho	I
##late	I
(	O
G	O
##CA	O
)	O
were	O
17	O
.	O
8	O
-	O
,	O
15	O
-	O
,	O
6	O
.	O
6	O
-	O
and	O
4	O
-	O
fold	O
up	O
##re	O
##gu	O
##lated	O
in	O
DC	O
vs	O
.	O
NH	O
##C	O
respectively	O
.	O

Similarly	O
,	O
levels	O
of	O
lip	O
##id	O
classes	O
at	O
base	O
##line	O
were	O
not	O
different	O
in	O
car	B
##nos	I
##ine	I
and	O
place	O
##bo	O
groups	O
(	O
Table	O
)	O
.	O

In	O
addition	O
,	O
in	O
the	O
test	B
##osterone	I
group	O
changes	O
in	O
serum	O
3	B
-	I
α	I
-	I
and	I
##ros	I
##tan	I
##ed	I
##iol	I
-	I
g	I
##lu	I
##cor	I
##oni	I
##de	I
,	O
an	O
and	O
##rogen	O
meta	O
##bol	O
##ite	O
,	O
were	O
strongly	O
positively	O
associated	O
with	O
a	O
change	O
in	O
tear	O
breakup	O
time	O
(	O
ρ	O
=	O
0	O
.	O
83	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
supporting	O
our	O
finding	O
of	O
an	O
association	O
between	O
serum	O
and	O
##rogen	O
meta	O
##bol	O
##ites	O
and	O
dry	O
eye	O
.	O

As	O
a	O
result	O
of	O
the	O
statistical	O
and	O
bio	O
##chemical	O
/	O
physiological	O
considerations	O
explained	O
above	O
,	O
we	O
chose	O
al	B
##ani	I
##ne	I
,	O
c	B
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
,	O
u	B
##rea	I
and	O
c	B
##rea	I
##tin	I
##ine	I
(	O
for	O
normal	O
##ization	O
)	O
as	O
our	O
final	O
feature	O
set	O
resulting	O
in	O
the	O
following	O
log	O
##istic	O
re	O
##gression	O
model	O
:	O

In	O
case	O
of	O
excess	O
gal	B
##act	I
##ose	I
,	O
free	O
gal	B
##act	I
##ose	I
also	O
enters	O
two	O
additional	O
pathways	O
,	O
being	O
either	O
reduced	O
to	O
gal	B
##act	I
##ito	I
##l	I
or	O
o	O
##xi	O
##dis	O
##ed	O
to	O
gal	B
##act	I
##ona	I
##te	I
via	O
gal	B
##act	I
##ono	I
-	I
1	I
,	I
5	I
-	I
la	I
##cton	I
##e	I
[	O
,	O
,	O
]	O
.	O

Lac	B
##tate	I
and	O
p	B
-	I
C	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
were	O
observed	O
to	O
show	O
a	O
positive	O
correlation	O
with	O
C	O
##UR	O
##B	O
-	O
65	O
,	O
PS	O
##I	O
and	O
AP	O
##AC	O
##H	O
##E	O
II	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
scores	O
,	O
whereas	O
D	B
##H	I
##EA	I
-	I
S	I
was	O
negatively	O
related	O
with	O
the	O
three	O
scoring	O
systems	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Future	O
studies	O
should	O
be	O
designed	O
to	O
collect	O
large	O
amount	O
of	O
plasma	O
,	O
separate	O
and	O
pu	O
##ri	O
##fy	O
plasma	O
using	O
pre	O
##par	O
##ative	O
L	O
##C	O
columns	O
,	O
and	O
valid	O
##ate	O
the	O
structure	O
of	O
proposed	O
put	O
##ative	O
bio	O
##mark	O
##ers	O
by	O
accurate	O
mass	O
ion	O
tree	O
experiment	O
using	O
direct	O
in	O
##fusion	O
na	O
##no	O
-	O
E	O
##SI	O
F	B
##T	I
I	O
##CR	O
MS	O
and	O
by	O
N	O
##MR	O
experiments	O
.	O

J	O
##W	O
##H	O
-	O
01	O
##8	O
,	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
N	B
-	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
##pent	I
##yl	I
)	I
,	O
J	B
##W	I
##H	I
-	I
01	I
##8	I
5	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
J	B
##W	I
##H	I
-	I
01	I
##8	I
6	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
N	O
-	O
pen	O
##tano	O
##ic	O
acid	O
,	O
and	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
N	B
-	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
##pent	I
##yl	I
)	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
,	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
N	B
-	I
(	I
4	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yl	I
)	I
,	O
J	B
##W	I
##H	I
-	I
07	I
##3	I
5	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
J	B
##W	I
##H	I
-	I
07	I
##3	I
6	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
and	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
N	B
-	I
but	I
##ano	I
##ic	I
acid	I
,	O
J	O
##W	O
##H	O
-	O
08	O
##1	O
,	O
and	O
J	O
##W	O
##H	O
-	O
08	O
##1	O
N	B
-	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
##pent	I
##yl	I
)	I
,	O
J	O
##W	O
##H	O
-	O
122	O
and	O
J	O
##W	O
##H	O
-	O
122	O
N	B
-	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
##pent	I
##yl	I
)	I
,	O
J	B
##W	I
##H	I
-	I
200	I
5	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
and	O
J	B
##W	I
##H	I
-	I
200	I
6	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
J	B
##W	I
##H	I
-	I
210	I
,	I
J	O
##W	O
##H	O
-	O
210	O
-	O
N	B
-	I
(	I
4	O
-	I
h	I
##ydro	I
##xy	I
##pent	O

The	O
free	O
induction	O
decay	O
##s	O
(	O
F	O
##ID	O
##s	O
)	O
were	O
multi	O
##plied	O
by	O
an	O
ex	O
##po	O
##nent	O
##ial	O
weighing	O
function	O
corresponding	O
to	O
a	O
line	O
broad	O
##ening	O
of	O
0	O
.	O
5	O
Hz	O
prior	O
to	O
Four	O
##ier	O
transform	O
(	O
F	O
##T	O
)	O
and	O
the	O
acquired	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
manually	O
phased	O
,	O
base	O
##line	O
-	O
corrected	O
and	O
chemical	O
shift	O
referenced	O
to	O
the	O
met	B
##hyl	I
la	I
##ct	I
##ate	I
double	O
##t	O
at	O
δ	O
1	O
.	O
33	O
.	O

Our	O
findings	O
of	O
a	O
lack	O
of	O
association	O
of	O
diet	O
##ary	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
on	O
h	O
##yper	O
##p	O
##lastic	O
,	O
as	O
opposed	O
to	O
ad	O
##eno	O
##mat	O
##ous	O
,	O
p	O
##oly	O
##p	O
risk	O
would	O
be	O
expected	O
if	O
the	O
beneficial	O
effects	O
of	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
are	O
mediated	O
through	O
a	O
reduction	O
in	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
.	O

(	O
b	O
)	O
Three	O
distinct	O
peaks	O
identified	O
by	O
Ch	O
##roma	O
##TO	O
##F	O
software	O
as	O
L	B
-	I
Met	I
##hi	I
##oni	I
##ne	I
(	O
two	O
of	O
these	O
are	O
false	O
positive	O
##s	O
)	O
.	O

In	O
summary	O
,	O
many	O
meta	O
##bol	O
##ites	O
including	O
g	B
##lut	I
##amine	I
,	O
thy	B
##mine	I
,	O
u	B
##rid	I
##ine	I
,	O
and	O
de	B
##ox	I
##yu	I
##rid	I
##ine	I
from	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tate	I
and	O
5	B
-	I
H	I
##IA	I
##A	I
from	O
the	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
displayed	O
associations	O
to	O
multiple	O
clinical	O
measures	O
,	O
but	O
no	O
association	O
with	O
age	O
##ing	O
.	O

P	O
##U	O
##FA	O
##s	O
and	O
their	O
oxidation	O
products	O
(	B
o	B
##xy	I
##lip	I
##ins	I
)	O
in	O
the	O
met	B
##hyl	I
format	I
##e	I
fraction	O
were	O
measured	O
by	O
UP	O
##LC	O
/	O
MS	O
/	O
MS	O
using	O
a	O
550	O
##0	O
##Q	O
##TR	O
##AP	O
q	O
##uad	O
##rup	O
##ole	O
-	O
linear	O
ion	O
trap	O
hybrid	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
AB	O
Sc	O
##ie	O
##x	O
,	O
Fr	O
##ami	O
##ng	O
##ham	O
,	O
MA	O
)	O
interface	O
##d	O
with	O
an	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
System	O
(	O
Waters	O
)	O
.	O

The	O
meta	O
##bol	O
##ome	O
revealed	O
elevation	O
of	O
many	O
meta	O
##bol	O
##ites	O
consistent	O
with	O
per	O
##ina	O
##tal	O
as	O
##phy	O
##xia	O
,	O
including	O
su	B
##cci	I
##nic	I
acid	I
,	O
ma	B
##late	I
,	O
and	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

Interest	O
##ingly	O
,	O
for	O
c	B
##era	I
##mi	I
##des	I
,	O
differences	O
in	O
h	O
##ydro	O
##phi	O
##licity	O
due	O
to	O
long	O
-	O
chain	O
bases	O
(	O
L	O
##C	O
##B	O
)	O
as	O
well	O
as	O
h	O
##ydro	O
##xy	O
##lated	O
and	O
non	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
fatty	O
amid	O
chains	O
led	O
to	O
SF	O
##C	O
separation	O
within	O
the	O
class	O
.	O

This	O
solution	O
was	O
again	O
applied	O
to	O
the	O
column	O
followed	O
by	O
a	O
wash	O
with	O
6	O
m	O
##l	O
of	O
10	O
%	O
met	B
##han	I
##ol	I
.	O

The	O
20	O
–	O
40	O
%	O
ace	B
##tone	I
in	O
DC	O
##M	O
fraction	O
##s	O
from	O
the	O
ch	O
##roma	O
##tography	O
of	O
the	O
crude	O
roots	O
extract	O
were	O
combined	O
and	O
re	O
##ch	O
##roma	O
##to	O
##graph	O
##ed	O
in	O
20	O
%	O
E	O
##t	O
##OA	O
##c	O
in	O
petroleum	O
et	O
##her	O
,	O
followed	O
by	O
re	O
##ch	O
##roma	O
##tography	O
(	O
×	O
##2	O
)	O
in	O
12	O
%	O
E	O
##t	O
##OA	O
##c	O
in	O
petroleum	O
et	O
##her	O
to	O
afford	O
3	O
(	O
2	O
mg	O
)	O
.	O

Multi	O
##var	O
##iate	O
CO	O
##X	O
re	O
##gression	O
analysis	O
showed	O
T	O
##N	O
##M	O
staging	O
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
C	O
##I	O
)	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
03	O
##4	O
)	O
,	O
2	B
,	I
4	I
-	I
he	I
##xa	I
##die	I
##no	I
##ic	I
acid	I
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
C	O
##I	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
02	O
##7	O
)	O
,	O
4	B
-	I
met	I
##hyl	I
##phe	I
##ny	I
##l	I
do	I
##de	I
##cano	I
##ate	I
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
95	O
%	O
C	O
##I	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
00	O
##1	O
)	O
and	O
g	B
##ly	I
##cer	I
##ol	I
t	I
##ri	I
##but	I
##ano	I
##ate	I
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
C	O
##I	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
03	O
##2	O
)	O
were	O
independent	O
pro	O
##gno	O
##stic	O
factors	O
of	O
G	O
##C	O
(	O
Table	O
)	O
.	O

In	O
addition	O
,	O
these	O
patients	O
had	O
a	O
higher	O
level	O
of	O
a	B
##rg	I
##ini	I
##ne	I
,	O
another	O
component	O
of	O
the	O
u	B
##rea	I
cycle	O
,	O
than	O
the	O
control	O
individuals	O
.	O

The	O
results	O
of	O
this	O
preliminary	O
study	O
suggest	O
the	O
involvement	O
of	O
inflammation	O
in	O
try	B
##pt	I
##op	I
##han	I
breakdown	O
via	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
,	O
yet	O
without	O
spa	B
##ring	I
try	I
##pt	I
##op	I
##han	I
metabolism	O
through	O
the	O
5	O
-	O
H	O
##T	O
(	O
se	O
##rot	O
##oni	O
##n	O
)	O
pathway	O
in	O
C	O
##K	O
##D	O
patients	O
.	O

Cat	B
##ech	I
##ols	I
derived	O
from	O
both	O
the	O
4	O
-	O
and	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
can	O
be	O
readily	O
o	O
##xi	O
##dized	O
to	O
form	O
electro	O
##phi	O
##lic	O
q	B
##uin	I
##one	I
derivatives	O
.	O

T	O
##iss	O
##ue	O
distribution	O
and	O
bi	O
##lia	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
pro	B
##sta	I
##cy	I
##c	I
##lin	I
meta	O
##bol	O
##ites	O
in	O
the	O
rat	O
.	O

HD	O
##L	O
-	O
C	O
was	O
lowered	O
by	O
10	O
%	O
and	O
T	O
##AG	O
was	O
raised	O
by	O
20	O
%	O
for	O
individuals	O
on	O
lip	O
##id	O
-	O
lowering	O
treatment	O
,	O
and	O
glucose	S
was	O
raised	O
by	O
10	O
%	O
or	O
to	O
a	O
maximum	O
of	O
126	O
mg	O
/	O
d	O
##L	O
for	O
those	O
on	O
diabetes	O
medications	O
.	O

The	O
di	B
##ket	I
##op	I
##iper	I
##azi	I
##ne	I
c	I
##y	I
##c	I
##lo	I
(	I
is	I
##ole	I
##uc	I
##yl	I
-	I
pro	I
##ly	I
##l	I
)	I
was	O
the	O
second	O
most	O
disc	O
##rim	O
##inating	O
ion	O
in	O
the	O
study	O
(	O
p	O
-	O
value	O
=	O
1	O
.	O
61	O
##×	O
##10	O
_	O
−	O
##7	O
,	O
VIP	O
=	O
2	O
.	O
81	O
)	O
and	O
thus	O
another	O
potential	O
bio	O
##mark	O
##er	O
of	O
consumption	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
during	O
the	O
processing	O
of	O
samples	O
,	O
we	O
observed	O
disc	O
##re	O
##pan	O
##cies	O
in	O
the	O
absolute	O
recovery	O
between	O
HD	O
and	O
HIV	O
-	O
T	O
##B	O
when	O
q	O
##uant	O
##ifying	O
IS	O
in	O
the	O
context	O
of	O
a	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
in	O
Me	B
##OH	I
(	O
Fi	O
##g	O
.	O
)	O
.	O

A	O
novel	O
in	O
v	O
##ivo	O
radio	O
##metric	O
method	O
had	O
been	O
developed	O
in	O
order	O
to	O
measure	O
the	O
total	O
o	O
##xi	O
##da	O
##tive	O
metabolism	O
of	O
est	B
##rogen	I
,	O
independent	O
of	O
further	O
bio	O
##tra	O
##ns	O
##formation	O
##s	O
and	O
con	O
##ju	O
##gation	O
pathways	O
.	O

There	O
are	O
many	O
publications	O
on	O
the	O
analysis	O
of	O
a	O
single	O
s	B
##tat	I
##in	I
and	O
its	O
active	O
meta	O
##bol	O
##ite	O
or	O
meta	O
##bol	O
##ites	O
.	O

_	O
B	O
sq	O
##C	O
:	O
sq	O
##ua	O
##mous	O
cell	O
car	O
##cin	O
##oma	O
;	O
ad	O
##eno	O
##C	O
:	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
;	O
N	O
:	O
non	O
-	O
cancer	O
##ous	O
;	O
C	O
:	O
cancer	O
;	O
C	O
##it	O
:	O
c	B
##it	I
##rate	I
;	O
Lac	O
:	O
la	B
##ct	I
##ate	I
;	O
Su	O
##cc	O
:	O
su	B
##cci	I
##nate	I
_	O
C	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
in	O
excess	O
of	O
natural	O
abundance	O
;	O
values	O
in	O
bold	O
represent	O
enhanced	O
en	O
##rich	O
##ment	O
in	O
cancer	O
over	O
its	O
non	O
-	O
cancer	O
##ous	O
counterpart	O
_	O
D	O
_	O
13	O
C	O
mass	O
is	O
##oto	O
##po	O
##mer	O
of	O
As	O
##p	O
with	O
three	O
carbon	O
##s	O
labeled	O
;	O
detection	O
limit	O
was	O
0	O
.	O
00	O
##4	O
μ	O
##mo	O
##le	O
/	O
g	O
dry	O
weight	O
.	O

Le	B
##uc	I
##ine	I
-	I
En	I
##ce	I
##pha	I
##lin	I
solution	O
in	O
50	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
used	O
a	O
reference	O
mass	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
=	O
55	O
##6	O
.	O
27	O
##7	O
##1	O
and	O
[	O
M	O
-	O
H	O
]	O
_	O
−	O
=	O
55	O
##4	O
.	O
261	O
##5	O
)	O
to	O
maintain	O
accurate	O
mass	O
.	O

The	O
most	O
affected	O
amino	O
acid	O
metabolism	O
pathways	O
were	O
those	O
regarding	O
c	B
##ys	I
##tein	I
##e	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
pro	B
##line	I
and	O
branched	O
amino	O
acids	O
(	B
v	B
##ali	I
##ne	I
and	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
)	O
.	O

SP	O
##CS	O
##O	O
is	O
the	O
major	O
flavor	O
precursor	O
in	O
All	O
##ium	O
c	O
##ep	O
##a	O
and	O
precursor	O
to	O
the	O
main	O
la	O
##ch	O
##ry	O
##mat	O
##ory	O
factor	O
(	B
Z	I
)	I
-	I
prop	I
##ane	I
##thi	I
##al	I
-	I
su	I
##lf	I
##oxide	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
detected	O
significant	O
changes	O
in	O
the	O
lip	O
##id	O
super	O
-	O
family	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
s	O
##tero	O
##id	O
,	O
l	O
##ys	O
##o	O
-	O
plasma	O
##log	O
##en	O
,	O
and	O
medium	O
chain	O
fatty	O
acid	O
sub	O
-	O
pathways	O
in	O
Re	O
##tt	O
syndrome	O
cases	O
compared	O
to	O
the	O
controls	O
.	O

L	O
##C	O
-	O
MS	O
/	O
MS	O
analyses	O
of	O
Al	O
##b	O
dig	O
##ests	O
obtained	O
from	O
(	O
A	O
)	O
mouse	O
control	O
,	O
(	O
B	O
)	O
mouse	O
exposed	O
to	O
p	B
##hen	I
##yle	I
##thy	I
##lis	I
##oth	I
##io	I
##cy	I
##ana	I
##te	I
-	I
(	I
P	I
##EI	I
##TC	I
)	I
-	I
A	I
##c	I
##C	I
##ys	I
,	O
(	O
C	O
)	O
human	O
exposed	O
to	O
water	O
##cre	O
##ss	O
,	O
and	O
(	O
D	O
)	O
the	O
P	O
##EI	O
##TC	O
-	O
L	O
##ys	O
standard	O
compound	O
.	O

Furthermore	O
,	O
a	O
recent	O
report	O
shows	O
that	O
the	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
may	O
vary	O
over	O
a	O
large	O
scale	O
and	O
that	O
variance	O
##s	O
in	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
concentrations	O
are	O
not	O
due	O
to	O
urine	O
di	O
##lution	O
effects	O
;	O
rather	O
,	O
they	O
reflect	O
actual	O
meta	O
##bol	O
##ite	O
variance	O
##s	O
(	O
Jan	O
##ke	O
##vic	O
##s	O
et	O
al	O
.	O

Interest	O
##ingly	O
,	O
while	O
the	O
concentration	O
of	O
as	B
##par	I
##agi	I
##ne	I
decreases	O
upon	O
long	O
-	O
term	O
storage	O
that	O
of	O
as	B
##par	I
##tate	I
increases	O
(	O
Table	O
S	O
##1	O
)	O
and	O
hence	O
the	O
ratio	O
of	O
as	B
##par	I
##tate	I
over	O
as	B
##par	I
##agi	I
##ne	I
increases	O
over	O
time	O
(	O
C	O
)	O
.	O

Nevertheless	O
,	O
the	O
use	O
of	O
these	O
medications	O
did	O
not	O
appear	O
as	O
predict	O
##ors	O
in	O
the	O
models	O
created	O
here	O
and	O
the	O
models	O
were	O
relatively	O
robust	O
for	O
the	O
use	O
of	O
s	B
##tat	I
##ins	I
or	O
met	B
##form	I
##in	I
when	O
tested	O
separately	O
in	O
subgroup	O
##s	O
using	O
these	O
medications	O
and	O
compared	O
to	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
and	O
revised	O
Q	O
##UI	O
##C	O
##K	O
##I	O
.	O

Also	O
the	O
increased	O
level	O
of	O
g	B
##lut	I
##amine	I
in	O
plasma	O
may	O
be	O
a	O
com	O
##pen	O
##sat	O
##ory	O
adaptation	O
to	O
counter	O
##act	O
g	O
##lut	O
##ama	O
##te	O
-	O
induced	O
ne	O
##uro	O
##to	O
##xi	O
##city	O
.	O

Pro	O
##pid	O
##ium	O
i	B
##od	I
##ide	I
(	O
P	O
##I	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Madrid	O
,	O
Spain	O
)	O
up	O
##take	O
was	O
analyzed	O
by	O
in	O
##cu	O
##bat	O
##ing	O
cells	O
with	O
50	O
μ	O
##g	O
/	O
m	O
##L	O
P	O
##I	O
in	O
PBS	O
in	O
the	O
dark	O
for	O
5	O
min	O
.	O

Moreover	O
,	O
in	O
our	O
study	O
we	O
observed	O
that	O
eight	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
L	O
##ys	O
##o	O
##PC	O
##s	O
)	O
were	O
significantly	O
lower	O
in	O
N	O
##DM	O
##M	O
patients	O
.	O

Meanwhile	O
,	O
a	O
number	O
of	O
previous	O
studies	O
have	O
confirmed	O
that	O
lower	O
circulating	O
P	O
##LP	O
concentrations	O
or	O
lowering	O
vitamin	B
B	I
##6	I
intake	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
CH	O
##D	O
,	O
h	O
##yper	O
##tens	O
##ion	O
,	O
diabetes	O
or	O
stroke	O
.	O

In	O
cases	O
involving	O
se	O
##psis	O
and	O
se	O
##ptic	O
shock	O
,	O
there	O
is	O
a	O
clear	O
increase	O
in	O
the	O
production	O
and	O
clearance	O
of	O
la	B
##ctic	I
acid	I
leading	O
to	O
la	O
##ctic	O
acid	O
##osis	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
there	O
is	O
no	O
published	O
evidence	O
of	O
any	O
relation	O
between	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
levels	O
in	O
urine	O
and	O
se	O
##psis	O
process	O
.	O

Therefore	O
,	O
the	O
m	O
/	O
z	O
162	O
.	O
112	O
##3	O
was	O
identified	O
as	O
car	B
##ni	I
##tine	I
according	O
to	O
the	O
elemental	O
composition	O
,	O
retention	O
time	O
and	O
fragment	O
##ation	O
information	O
.	O

The	O
T	O
##1	O
##D	O
group	O
,	O
h	B
##yper	I
##gly	I
##ca	I
##em	I
##ic	I
at	O
base	O
##line	O
,	O
showed	O
significant	O
glucose	S
de	O
##ple	O
##tion	O
with	O
acute	O
exercise	O
unlike	O
their	O
control	O
counterparts	O
.	O

Statistical	O
correlation	O
##s	O
were	O
com	O
##puted	O
on	O
full	O
-	O
resolution	O
s	O
##pect	O
##ra	O
for	O
the	O
41	O
##3	O
samples	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
.	O

Two	O
enzymes	O
control	O
the	O
p	B
##yr	I
##u	I
##vate	I
flux	O
:	O
the	O
kinase	O
,	O
PD	O
##K	O
##1	O
that	O
p	B
##hos	I
##ph	I
##ory	I
##lates	I
PD	O
##H	O
,	O
thereby	O
in	O
##act	O
##ivating	O
it	O
,	O
and	O
the	O
p	O
##hos	O
##pha	O
##tase	O
,	O
PD	O
##P	O
##2	O
that	O
activate	O
##s	O
PD	O
##H	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
depleted	O
glucose	B
-	I
6	I
-	I
phosphate	I
and	O
f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
levels	O
in	O
tumor	O
tissues	O
relative	O
to	O
adjacent	O
m	O
##uc	O
##osa	O
which	O
implies	O
a	O
War	O
##burg	O
effect	O
or	O
a	O
switch	O
from	O
o	O
##xi	O
##da	O
##tive	O
to	O
substrate	O
-	O
level	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
for	O
energy	O
production	O
.	O

At	O
each	O
sampling	O
time	O
##point	O
,	O
3	O
m	O
##l	O
of	O
blood	O
was	O
collected	O
in	O
lit	B
##hium	I
he	I
##par	I
##in	I
tubes	O
.	O

PC	B
a	I
##e	I
C	I
##34	I
:	I
1	I
;	O
40	O
.	O

We	O
examined	O
the	O
genes	O
within	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolic	O
pathway	O
that	O
were	O
most	O
highly	O
altered	O
in	O
basal	O
versus	O
l	O
##umi	O
##nal	O
BC	O
##a	O
using	O
our	O
tissue	O
-	O
derived	O
trans	O
##cript	O
##ome	O
data	O
Both	O
u	O
##rid	O
##ine	O
p	O
##yr	O
##op	O
##hos	O
##ph	O
##ory	O
##lase	O
1	O
(	O
UP	O
##P	O
##1	O
,	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
4	O
)	O
and	O
R	O
##R	O
##M	O
##2	O
(	O
A	O
)	O
were	O
significantly	O
(	O
P	O
=	O
.	O
000	O
##4	O
)	O
elevated	O
in	O
basal	O
-	O
like	O
BC	O
##a	O
compared	O
to	O
l	O
##umi	O
##nal	O
tumors	O
.	O

Few	O
studies	O
,	O
however	O
,	O
have	O
directly	O
assessed	O
the	O
associations	O
between	O
cannabis	S
use	O
,	O
inflammation	O
,	O
and	O
immune	O
activation	O
in	O
the	O
context	O
of	O
AR	O
##T	O
-	O
treated	O
HIV	O
infection	O
.	O

Since	O
glucose	S
is	O
the	O
main	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
source	O
for	O
g	O
##ly	O
##co	O
##lysis	O
and	O
the	O
T	O
##CA	O
cycle	O
,	O
increased	O
g	O
##ly	O
##co	O
##lysis	O
,	O
as	O
previously	O
reported	O
in	O
CR	O
##C	O
patient	O
tissue	O
,	O
serum	O
,	O
and	O
f	O
##eca	O
##l	O
meta	O
##bol	O
##omi	O
##c	O
studies	O
,	O
may	O
also	O
lead	O
to	O
reduced	O
T	O
##CA	O
intermediate	O
##s	O
in	O
urine	O
[	O
,	O
,	O
]	O
.	O

We	O
have	O
also	O
observed	O
enhanced	O
la	B
##ct	I
##ate	I
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
p	B
##yr	I
##u	I
##vate	I
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
re	O
##current	O
patients	O
.	O

Ser	B
##ine	I
is	O
crucial	O
for	O
the	O
growth	O
and	O
survival	O
of	O
many	O
cancer	O
cells	O
and	O
is	O
closely	O
related	O
to	O
the	O
f	B
##olate	I
cycle	O
as	O
a	O
donor	O
of	O
one	O
-	O
carbon	O
units	O
.	O

For	O
these	O
studies	O
we	O
chose	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
the	O
NE	O
##FA	O
with	O
a	O
highest	O
in	O
##cre	O
##ment	O
in	O
di	O
##abe	O
##tic	O
plaque	O
##s	O
(	O
60	O
%	O
increase	O
over	O
that	O
in	O
non	O
##dia	O
##bet	O
##ic	O
subjects	O
)	O
.	O

The	O
regeneration	O
of	O
N	O
##AD	O
_	O
+	O
by	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
L	O
##D	O
##H	O
)	O
supports	O
the	O
robust	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
hall	O
##mark	O
of	O
War	O
##burg	O
metabolism	O
,	O
yet	O
sustained	O
la	B
##ct	I
##ate	I
generation	O
from	O
glucose	S
restrict	O
##s	O
s	O
##hun	O
##ting	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
for	O
bio	O
##sy	O
##nt	O
##hetic	O
metabolism	O
critical	O
to	O
tumor	O
growth	O
.	O

Tri	O
##met	O
##hyl	O
##si	O
##ly	O
##lation	O
was	O
subsequently	O
performed	O
by	O
adding	O
50	O
μ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
+	O
1	O
%	O
T	O
##MC	O
##S	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
,	O
in	O
##cu	O
##bat	O
##ing	O
for	O
1	O
h	O
at	O
65	O
##°	O
##C	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
1300	O
##0	O
rpm	O
X	O
10	O
min	O
at	O
R	O
##T	O
.	O

To	O
correct	O
for	O
variations	O
in	O
urine	O
concentration	O
,	O
all	O
data	O
in	O
the	O
classification	O
data	O
set	O
was	O
linear	O
##ly	O
scaled	O
to	O
the	O
signal	O
of	O
the	O
CH	O
_	O
2	O
group	O
of	O
c	B
##rea	I
##tin	I
##ine	I
at	O
4	O
.	O
06	O
pp	O
##m	O
.	O

T	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
for	O
ve	O
##rification	O
studies	O
was	O
pu	O
##rified	O
from	O
a	O
specific	O
Mt	O
##b	O
strain	O
(	O
Colorado	O
State	O
University	O
My	O
##co	O
##ba	O
##cter	O
##ia	O
Research	O
Laboratory	O
,	O
Fort	O
Collins	O
,	O
CO	O
)	O
.	O

The	O
most	O
likely	O
accurate	O
mass	O
database	O
match	O
in	O
HM	O
##D	O
##B	O
for	O
m	O
/	O
z	O
34	O
##9	O
.	O
151	O
##5	O
was	O
pipe	B
##rine	I
,	O
which	O
is	O
found	O
in	O
black	O
pepper	O
,	O
Piper	O
ni	O
##g	O
##rum	O
.	O
42	O

These	O
(	O
and	O
potentially	O
other	O
)	O
cross	O
-	O
react	O
##iv	O
##ities	O
could	O
explain	O
the	O
higher	O
versus	O
lower	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
recorded	O
by	O
the	O
E	O
##L	O
##IS	O
##A	O
pre	O
and	O
post	O
bypass	O
respectively	O
.	O

In	O
recent	O
years	O
,	O
5	B
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
(	O
5	O
-	O
M	O
##T	O
)	O
has	O
been	O
revealed	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
alternative	O
me	B
##lat	I
##oni	I
##n	I
synthetic	O
pathway	O
,	O
in	O
which	O
se	B
##rot	I
##oni	I
##n	I
is	O
first	O
O	O
-	O
met	O
##hyl	O
##ated	O
to	O
5	O
-	O
M	O
##T	O
and	O
,	O
thereafter	O
,	O
5	O
-	O
M	O
##T	O
is	O
N	O
-	O
ace	O
##ty	O
##lated	O
to	O
me	B
##lat	I
##oni	I
##n	I
(	I
N	I
-	I
ace	I
##ty	I
##l	I
-	I
5	I
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
)	I
.	O

In	O
a	O
study	O
with	O
cell	O
cultures	O
,	O
Cat	O
##tan	O
et	O
al	O
.	O
evaluated	O
the	O
regulation	O
of	O
different	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
in	O
an	O
inflammation	O
site	O
.	O

The	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
cycle	O
is	O
activated	S
by	O
g	B
##lut	I
##ath	I
##ione	I
production	O
in	O
patients	O
with	O
liver	O
diseases	O
such	O
as	O
he	O
##pa	O
##titis	O
,	O
the	O
g	B
##lut	I
##ath	I
##ione	I
being	O
consumed	O
to	O
neutral	O
##ize	O
generated	O
R	O
##OS	O
,	O
which	O
,	O
in	O
turn	O
,	O
leads	O
to	O
activation	O
of	O
γ	B
-	I
g	I
##lut	I
##am	I
##yl	I
##cy	I
##stein	I
##e	I
s	O
##ynth	O
##eta	O
##se	O
and	O
results	O
in	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
g	B
##lut	I
##ath	I
##ione	I
together	O
with	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
p	O
##eptide	O
##s	O
.	O

Ad	O
##ding	O
C	O
##a	O
##B	O
##r	O
_	O
2	O
to	O
the	O
culture	O
medium	O
of	O
a	O
marine	B
-	I
end	I
##op	I
##hy	I
##te	I
F	O
.	O
t	O
##ric	O
##in	O
##ct	O
##um	O
resulted	O
in	O
the	O
production	O
of	O
two	O
new	O
compounds	O
,	O
br	B
##omo	I
##met	I
##hyl	I
##ch	I
##lam	I
##yd	I
##os	I
##por	I
##ols	I
A	O
(	O
54	O
)	O
and	O
B	O
(	O
55	O
)	O
,	O
along	O
with	O
ch	O
##lam	O
##yd	O
##os	O
##por	O
##ol	O
(	O
56	O
)	O
and	O
f	O
##usa	O
##riel	O
##in	O
A	O
,	O
all	O
exhibiting	O
activity	O
against	O
sensitive	O
and	O
resistant	O
strains	O
of	O
S	O
.	O
au	O
##reus	O
(	O
N	O
##en	O
##ke	O
##p	O
et	O
al	O
.	O
2010	O
)	O
.	O

Lac	B
##tate	I
,	O
p	B
##yr	I
##u	I
##vate	I
and	O
al	B
##ani	I
##ne	I
are	O
positively	O
correlated	O
;	O
p	B
##yr	I
##u	I
##vate	I
and	O
al	B
##ani	I
##ne	I
are	O
negatively	O
correlated	O
with	O
glucose	S
;	O
g	B
##lut	I
##amine	I
is	O
negatively	O
correlated	O
with	O
glucose	S
and	O
la	B
##ct	I
##ate	I
.	O

Moreover	O
,	O
glucose	S
levels	O
,	O
as	O
well	O
as	O
the	O
level	O
of	O
most	O
meta	O
##bol	O
##ites	O
in	O
blood	O
,	O
can	O
widely	O
vary	O
.	O

The	O
concentrations	O
of	O
u	B
##rac	I
##il	I
,	O
thy	B
##mine	I
,	O
di	B
##hy	I
##dr	I
##our	I
##ac	I
##il	I
,	O
di	B
##hy	I
##dr	I
##oth	I
##ym	I
##ine	I
,	O
N	B
-	I
car	I
##ba	I
##my	I
##l	I
-	I
β	I
-	I
al	I
##ani	I
##ne	I
,	O
and	O
N	B
-	I
car	I
##ba	I
##my	I
-	I
β	I
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
in	O
urine	O
were	O
determined	O
using	O
G	O
##C	O
–	O
MS	O
.	O

The	O
present	O
study	O
is	O
the	O
first	O
investigating	O
metabolic	O
signatures	O
after	O
challenge	O
tests	O
in	O
subjects	O
with	O
defined	O
genetic	O
risk	O
for	O
T	O
##2	O
##D	O
.	O
We	O
observed	O
a	O
significant	O
g	O
##eno	O
##type	O
effect	O
in	O
almost	O
all	O
SM	O
##s	O
,	O
suggesting	O
a	O
general	O
alter	O
##ation	O
in	O
the	O
synthesis	O
or	O
breakdown	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
.	O

In	O
the	O
previous	O
CE	B
##R	I
study	O
,	O
71	O
probe	O
sets	O
(	O
representing	O
65	O
genes	O
)	O
were	O
significantly	O
changed	O
in	O
the	O
breast	O
tissue	O
of	O
10	O
participants	O
after	O
four	O
to	O
five	O
weeks	O
of	O
60	O
%	O
CE	B
##R	I
.	O

AA	O
=	O
amino	O
acids	O
;	O
AC	O
##AC	O
-	O
Co	O
##A	O
=	O
ace	B
##to	I
##ace	I
##ty	I
##l	I
-	I
Co	I
##A	I
;	O
AS	O
##A	O
=	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nate	I
.	O

Met	O
##ab	O
##oli	O
##tes	O
of	O
another	O
drug	O
-	O
like	O
cluster	O
were	O
found	O
in	O
three	O
of	O
the	O
urine	O
samples	O
with	O
the	O
met	B
##form	I
##in	I
meta	O
##bol	O
##ites	O
,	O
and	O
could	O
be	O
an	O
##not	O
##ated	O
as	O
a	O
su	B
##lf	I
##ony	I
##lu	I
##rea	I
type	O
of	O
drug	O
,	O
consistent	O
with	O
g	O
##lic	O
##la	O
##zi	O
##de	O
based	O
on	O
fragment	O
information	O
also	O
commonly	O
prescribed	O
to	O
diabetes	O
patients	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
direct	O
impact	O
of	O
k	B
##yn	I
##uren	I
##ine	I
on	O
primary	O
human	O
CD	O
##8	O
T	O
cells	O
is	O
to	O
reduce	O
via	O
##bility	O
in	O
the	O
setting	O
of	O
activation	O
through	O
the	O
T	O
cell	O
receptor	O
.	O

PC	O
##R	O
products	O
were	O
am	O
##plified	O
in	O
a	O
volume	O
of	O
40	O
µ	O
##l	O
containing	O
10	O
##×	O
PC	O
##R	O
buffer	O
,	O
15	O
mm	O
ma	B
##gnesium	I
su	I
##l	I
##phate	I
,	O
2	O
mm	O
d	O
##NT	O
##P	O
mix	O
,	O
10	O
µ	O
##m	O
prime	O
##rs	O
,	O
10	O
ng	O
µ	O
##l	O
_	O
−	O
##1	O
g	O
##eno	O
##mic	O
DNA	O
and	O
5	O
U	O
µ	O
##l	O
_	O
−	O
##1	O
Ta	O
##q	O
DNA	O
polymer	O
##ase	O
(	O
Pro	O
##me	O
##ga	O
,	O
Madison	O
,	O
W	O
##I	O
)	O
.	O

Inc	O
##reased	O
2	O
-	O
H	O
##B	O
levels	O
have	O
been	O
shown	O
to	O
reflect	O
insulin	O
resistance	O
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
over	O
##load	O
as	O
well	O
as	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

used	O
dans	B
##yl	I
chloride	I
der	O
##iva	O
##ti	O
##zation	O
in	O
red	O
blood	O
cells	O
and	O
described	O
an	O
MD	O
##L	O
of	O
0	O
.	O
1	O
n	O
##M	O
for	O
put	B
##res	I
##cine	I
,	O
0	O
.	O
75	O
n	O
##M	O
for	O
sperm	B
##id	I
##ine	I
,	O
and	O
0	O
.	O
5	O
n	O
##M	O
for	O
sperm	B
##ine	I
.	O

Ser	O
##um	O
f	B
##oll	I
##ista	I
##tin	I
and	O
my	B
##ost	I
##ati	I
##n	I
during	O
pre	O
-	O
event	O
,	O
C	O
##1	O
,	O
C	O
##2	O
,	O
and	O
post	O
-	O
event	O
.	O

U	B
##rea	I
is	O
synthesized	O
in	O
the	O
liver	O
in	O
order	O
to	O
de	O
##to	O
##xi	O
##fy	O
the	O
organism	O
from	O
NH	O
##4	O
_	O
+	O
.	O

Although	O
the	O
genetic	O
bases	O
of	O
our	O
SC	O
##C	O
samples	O
were	O
not	O
defined	O
,	O
our	O
results	O
agree	O
with	O
such	O
studies	O
with	O
the	O
pre	O
##dom	O
##ina	O
##nce	O
of	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
,	O
fed	O
by	O
g	O
##lut	O
##amine	O
/	O
g	O
##lut	O
##ama	O
##te	O
to	O
feed	O
the	O
generation	O
of	O
ATP	S
and	O
reducing	O
equivalent	O
##s	O
.	O

meta	O
##bol	O
##omi	O
##cs	O
,	O
i	O
##rri	O
##table	O
bow	O
##el	O
syndrome	O
,	O
sleep	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
me	B
##lat	I
##oni	I
##n	I

As	O
a	O
put	O
##ative	O
sur	O
##rogate	O
predict	O
##or	O
of	O
clinical	O
response	O
,	O
we	O
used	O
plasma	O
concentrations	O
of	O
(	O
Z	O
)	O
end	B
##ox	I
##ife	I
##n	I
and	O
evaluated	O
the	O
relevance	O
of	O
ad	O
##herence	O
vs	O
.	O
C	O
##YP	O
##2	O
##D	O
##6	O
p	O
##hen	O
##otype	O
based	O
on	O
the	O
R	O
##R	O
of	O
not	O
achieving	O
the	O
threshold	O
plasma	O
concentration	O
of	O
5	O
.	O
9	O
ng	O
/	O
m	O
##L	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
(	O
Figure	O
)	O
.	O

After	O
anal	O
##ys	O
##ing	O
the	O
relationships	O
between	O
the	O
identified	O
meta	O
##bol	O
##ites	O
with	O
clinical	O
parameters	O
,	O
and	O
calculating	O
the	O
diagnostic	O
efficacy	O
of	O
these	O
meta	O
##bol	O
##ites	O
using	O
R	O
##OC	O
,	O
we	O
concluded	O
that	O
three	O
meta	O
##bol	O
##ites	O
—	O
s	O
##phi	O
##nga	O
##nine	O
,	O
la	B
##ct	I
##ate	I
and	O
D	B
##H	I
##EA	I
-	I
S	I
,	O
related	O
to	O
the	O
severity	O
of	O
CA	O
##P	O
—	O
might	O
represent	O
a	O
panel	O
of	O
potential	O
small	O
molecule	O
bio	O
##mark	O
##ers	O
for	O
assessing	O
CA	O
##P	O
severity	O
.	O

Sep	O
##arate	O
##ly	O
,	O
the	O
model	O
was	O
also	O
tested	O
on	O
the	O
re	O
##current	O
breast	O
cancer	O
patients	O
based	O
on	O
the	O
stage	O
of	O
the	O
cancer	O
at	O
the	O
initial	O
diagnosis	O
,	O
the	O
type	O
of	O
re	O
##cu	O
##rrence	O
,	O
est	B
##rogen	I
(	O
ER	O
)	O
and	O
pro	B
##ges	I
##tero	I
##ne	I
(	O
PR	O
)	O
receptors	O
status	O
.	O

U	B
##rea	I
is	O
eliminated	O
from	O
body	O
by	O
u	O
##rina	O
##tion	O
,	O
and	O
g	B
##lut	I
##amine	I
is	O
not	O
toxic	O
.	O

The	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
has	O
a	O
significant	O
role	O
in	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
regulation	O
and	O
has	O
previously	O
been	O
reported	O
to	O
be	O
affected	O
in	O
both	O
AD	O
and	O
am	O
##yo	O
##tro	O
##phic	O
lateral	O
s	O
##cle	O
##rosis	O
(	O
AL	O
##S	O
)	O
.	O

I	B
##mi	I
##pra	I
##mine	I
N	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
activity	O
was	O
determined	O
as	O
previously	O
reported	O
using	O
0	O
.	O
5	O
mm	O
im	B
##ip	I
##ram	I
##ine	I
.	O

Among	O
them	O
,	O
a	O
total	O
of	O
13	O
meta	O
##bol	O
##ites	O
were	O
commonly	O
selected	O
in	O
the	O
three	O
models	O
including	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	I
h	I
##ydro	I
##xy	I
##te	I
##tra	I
##de	I
##ca	I
##die	I
##ny	I
##l	I
##car	I
##ni	I
##tine	I
and	O
o	B
##ct	I
##ade	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
)	I
,	O
amino	O
acids	O
(	B
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
er	B
##ith	I
##ro	I
-	I
is	I
##ole	I
##uc	I
##ine	I
and	O
try	O
##pt	O
##op	O
##han	O
)	O
,	O
bio	O
##genic	O
am	O
##ines	O
(	O
symmetric	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
or	B
##ni	I
##thin	I
##e	I
and	O
sperm	O
##id	O
##ine	O
)	O
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
.	O

Consequently	O
,	O
this	O
results	O
in	O
de	O
##to	O
##xi	O
##fying	O
process	O
,	O
because	O
nitrogen	O
from	O
amino	O
acids	O
metabolism	O
is	O
fun	O
##nel	O
##ed	O
into	O
the	O
u	B
##rea	I
cycle	O
in	O
the	O
liver	O
.	O

Met	B
##han	I
##ol	I
(	O
1	O
.	O
7	O
m	O
##L	O
)	O
was	O
added	O
,	O
mixed	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
10	O
min	O
at	O
104	O
##7	O
r	O
##ad	O
/	O
se	O
##c	O
(	O
10	O
,	O
000	O
rpm	O
)	O
at	O
4	O
°C	O
)	O
to	O
pre	O
##ci	O
##pit	O
##ate	O
any	O
residual	O
u	O
##rease	O
.	O

The	O
buffer	O
contained	O
the	O
chemical	O
shift	O
reference	O
3	B
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
-	I
prop	I
##ion	I
##ic	I
acid	O
-	O
D	O
##4	O
,	O
sodium	O
salt	O
and	O
Na	O
##N	O
_	O
3	O
.	O

This	O
process	O
involves	O
the	O
an	O
##ae	O
##ro	O
##bic	O
f	O
##er	O
##mentation	O
of	O
glucose	S
and	O
but	B
##ane	I
##dio	I
##l	I
is	O
one	O
of	O
the	O
end	O
products	O
.	O

Our	O
findings	O
are	O
ass	O
##oc	O
##ia	O
##tive	O
and	O
cannot	O
establish	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
my	O
##oc	O
##ard	O
##ial	O
DD	O
##A	O
##H	O
-	O
1	O
and	O
systemic	O
AD	B
##MA	I
levels	O
.	O

Cy	B
##stein	I
##e	I
and	O
u	B
##rid	I
##ine	I
are	O
the	O
most	O
relevant	O
anal	O
##yte	O
##s	O
for	O
separating	O
light	O
AD	O
patients	O
(	O
M	O
##MS	O
##E	O
>	O
22	O
)	O
from	O
healthy	O
subjects	O
.	O

We	O
observed	O
statistical	O
##ly	O
significant	O
changes	O
in	O
th	B
##re	I
##ito	I
##l	I
and	O
amino	B
##mal	I
##onic	I
acid	I
in	O
PA	O
##H	O
patients	O
,	O
which	O
could	O
provide	O
new	O
bio	O
##chemical	O
insights	O
into	O
the	O
path	O
##ogen	O
##esis	O
of	O
the	O
disease	O
.	O

U	O
##rine	O
(	O
0	O
.	O
1	O
m	O
##L	O
)	O
was	O
added	O
with	O
0	O
.	O
1	O
m	O
##L	O
internal	O
standard	O
solution	O
(	B
para	B
##ce	I
##tam	I
##ol	I
-	I
3	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
1	O
.	O
5	O
μ	O
##g	O
/	O
m	O
##L	O
in	O
water	O
)	O
and	O
0	O
.	O
8	O
m	O
##L	O
water	O
/	O
met	O
##han	O
##ol	O
(	O
95	O
:	O
5	O
,	O
v	O
/	O
v	O
)	O
containing	O
2	O
%	O
ace	B
##tic	I
acid	I
,	O
mixed	O
for	O
1	O
min	O
(	O
800	O
rpm	O
)	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
12	O
min	O
at	O
4	O
,	O
500	O
rpm	O
.	O

The	O
CP	O
##S	O
##1	O
lo	O
##cus	O
has	O
been	O
previously	O
found	O
associated	O
with	O
kidney	O
disease	O
,	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
and	O
several	O
meta	O
##bol	O
##ite	O
levels	O
including	O
g	B
##ly	I
##cine	I
.	O

Met	O
##ab	O
##olic	O
pathways	O
including	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
D	B
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
were	O
statistical	O
##ly	O
related	O
(	O
impact	O
>	O
0	O
.	O
1	O
,	O
F	O
##DR	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

Dr	O
##ied	O
met	B
##han	I
##ol	I
extraction	O
##s	O
were	O
dissolved	O
in	O
a	O
re	O
##sus	O
##pen	O
##sion	O
solution	O
consisting	O
of	O
d	O
##d	O
##H	O
_	O
2	O
0	O
containing	O
the	O
internal	O
standard	O
L	O
-	O
T	O
##rp	O
-	O
2	O
′	O
,	O
4	O
′	O
,	O
5	O
′	O
,	O
6	O
′	O
,	O
7	O
′	O
-	O
d	O
##5	O
(	O
“	O
d	O
##5	O
T	O
##rp	O
”	O
from	O
CD	O
##N	O
Is	O
##oto	O
##pes	O
)	O
for	O
10	O
min	O
at	O
room	O
temperature	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
then	O
in	O
##cu	O
##bate	O
##d	O
for	O
10	O
min	O
at	O
37	O
##°	O
##C	O
.	O

Similarly	O
,	O
higher	O
risk	O
was	O
found	O
in	O
T	O
##T	O
individuals	O
when	O
levels	O
of	O
in	B
##os	I
##ine	I
were	O
higher	O
or	O
equal	O
to	O
the	O
median	O

Other	O
major	O
findings	O
of	O
this	O
study	O
were	O
the	O
association	O
of	O
high	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
in	O
SA	O
##P	O
with	O
higher	O
glucose	S
,	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
BC	O
##AA	O
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
concentrations	O
,	O
depressed	O
kidney	O
function	O
,	O
incidence	O
of	O
diabetes	O
,	O
lower	O
g	B
##lut	I
##ath	I
##ione	I
and	O
lower	O
plasma	O
P	O
##LP	O
concentrations	O
,	O
and	O
evidence	O
of	O
modest	O
vitamin	O
B	O
-	O
6	O
ins	O
##uff	O
##iciency	O
.	O

However	O
,	O
only	O
three	O
metabolic	O
pathways	O
,	O
namely	O
pu	B
##rine	I
metabolism	O
(	O
F	O
##DR	O
=	O
3	O
.	O
73	O
##×	O
##10	O
_	O
−	O
##3	O
)	O
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
(	O
F	O
##DR	O
=	O
1	O
.	O
07	O
##×	O
##10	O
_	O
−	O
##2	O
)	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
(	O
F	O
##DR	O
=	O
3	O
.	O
67	O
##×	O
##10	O
_	O
−	O
##2	O
)	O
were	O
shared	O
between	O
both	O
O	O
##CT	O
-	O
embedded	O
and	O
FF	O
##P	O
##E	O
samples	O
.	O

In	O
the	O
combined	O
multi	O
##cent	O
##er	O
populations	O
,	O
compared	O
with	O
E	O
##BC	O
patients	O
,	O
patients	O
with	O
MB	O
##C	O
are	O
characterized	O
by	O
higher	O
serum	O
levels	O
(	O
adjusted	O
P	O
<	O
0	O
.	O
05	O
)	O
of	O
c	B
##it	I
##rate	I
,	O
ch	B
##olin	I
##e	I
,	O
ace	B
##tate	I
,	O
format	B
##e	I
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
le	B
##uc	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
pro	B
##line	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
and	O
lower	O
serum	O
levels	O
(	O
adjusted	O
P	O
<	O
0	O
.	O
05	O
)	O
of	O
glucose	S
and	O
g	B
##lut	I
##amine	I
.	O

It	O
was	O
found	O
that	O
among	O
the	O
70	O
meta	O
##bol	O
##ites	O
included	O
in	O
the	O
analysis	O
,	O
34	O
(	O
18	O
of	O
known	O
identity	O
and	O
9	O
of	O
known	O
chemical	O
class	O
)	O
and	O
3	O
(	O
u	O
##rea	O
,	O
g	B
##ly	I
##cer	I
##ol	I
3	I
-	I
phosphate	I
and	O
1	O
unknown	O
)	O
meta	O
##bol	O
##ites	O
were	O
,	O
respectively	O
,	O
of	O
significantly	O
higher	O
(	O
positively	O
significant	O
)	O
or	O
lower	O
(	O
negatively	O
significant	O
)	O
concentration	O
in	O
the	O
I	O
##CS	O
##I	O
than	O
the	O
NC	O
group	O
.	O

are	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
and	O
ace	B
##tate	I
.	O

For	O
G	O
##C	O
-	O
MS	O
,	O
der	O
##iva	O
##ti	O
##zation	O
without	O
further	O
pre	O
##tre	O
##at	O
##ment	O
was	O
done	O
even	O
though	O
u	B
##rea	I
peak	O
may	O
over	O
##load	O
the	O
cap	O
##illa	O
##ry	O
G	O
##C	O
column	O
,	O
because	O
severe	O
artifacts	O
occurred	O
when	O
using	O
u	O
##rease	O
treatments	O
.	O

2017	O
demonstrated	O
a	O
decrease	O
of	O
pro	B
##line	I
and	O
a	O
simultaneous	O
increase	O
of	O
g	B
##lut	I
##ama	I
##te	I
serum	O
level	O
as	O
a	O
marker	O
of	O
acute	O
is	O
##che	O
##mic	O
stroke	O
;	O
here	O
,	O
we	O
demonstrated	O
an	O
increase	O
in	O
pro	B
##line	I
as	O
a	O
marker	O
of	O
chronic	O
is	O
##che	O
##mic	O
stroke	O
.	O

(	B
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
Y	O
)	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
312	O
.	O
4	O
)	O
;	O
E	O
)	O
Fr	O
##action	O
8	O
,	O
Y	O
*	O
L	O
##Y	O
##EI	O
##AR	O
(	B
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
Y	I
)	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
56	O
##8	O
.	O
1	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
modified	O
SA	O
;	O
and	O
F	O
)	O
Y	O
*	O
L	O
##Y	O
##EI	O
##AR	O
(	B
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
Y	O
)	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
570	O
.	O
6	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
modified	O
SA	O
by	O
try	O
##ps	O
##in	O
dig	O
##est	O
##ion	O
.	O

N	O
##AA	O
is	O
synthesized	O
in	O
ne	O
##uron	O
##al	O
mit	O
##och	O
##ond	O
##ria	O
and	O
transferred	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##ocytes	O
,	O
where	O
AS	O
##PA	O
l	O
##iber	O
##ates	O
the	O
ace	B
##tate	I
m	O
##oi	O
##ety	O
to	O
be	O
used	O
for	O
my	B
##elin	I
lip	O
##id	O
synthesis	O
.	O

X	B
##ant	I
##hine	I
is	O
formed	O
from	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
by	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
.	O

After	O
the	O
intake	O
of	O
all	O
the	O
three	O
foods	O
,	O
levels	O
after	O
1	O
h	O
were	O
significantly	O
lower	O
when	O
compared	O
to	O
base	O
##line	O
based	O
on	O
a	O
paired	O
Wilcox	O
##on	O
signed	O
rank	O
test	O
,	O
after	O
milk	O
intake	O
(	B
C	B
##15	I
:	I
0	I
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##4	O
,	O
C	B
##17	I
:	I
0	I
p	O
=	O
2	O
.	O
9	O
×	O
10	O
_	O
−	O
##3	O
,	O
unknown	O
C	O
##17	O
p	O
=	O
1	O
.	O
9	O
×	O
10	O
_	O
−	O
##3	O
)	O
,	O
after	O
cheese	O
intake	O
(	B
C	B
##15	I
:	I
0	I
p	O
=	O
2	O
.	O
9	O
×	O
10	O
_	O
−	O
##3	O
,	O
C	B
##17	I
:	I
0	I
p	O
=	O
1	O
.	O
4	O
×	O
10	O
_	O
−	O
##2	O
,	O
unknown	O
C	O
##17	O
p	O
=	O
1	O
.	O
4	O
×	O
10	O
_	O
−	O
##2	O
)	O
,	O
and	O
after	O
so	O
##y	O
drink	O
intake	O
(	B
C	B
##15	I
:	I
0	I
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##4	O
,	O
C	B
##17	I
:	I
0	I
p	O
=	O
2	O
.	O
9	O
×	O
10	O
_	O
−	O
##3	O
,	O
unknown	O
C	O
##17	O
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##4	O
)	O
.	O

PC	B
a	I
##e	I
C	I
##34	I
:	I
2	I
;	O
24	O
.	O

A	O
variant	O
(	O
r	O
##s	O
##75	O
##11	O
##41	O
)	O
of	O
EP	O
##H	O
##X	O
##2	O
,	O
which	O
en	O
##codes	O
a	O
soluble	O
e	O
##pox	O
##ide	O
h	O
##ydro	O
##lase	O
,	O
was	O
robust	O
##ly	O
associated	O
(	O
P	O
=	O
7	O
.	O
5	O
×	O
10	O
_	O
−	O
##39	O
)	O
with	O
elevated	O
serum	O
levels	O
of	O
24	B
,	I
25	I
-	I
e	I
##pox	I
##ych	I
##ole	I
##ster	I
##ol	I
.	O

This	O
solution	O
represents	O
the	O
M	B
##T	I
##BE	I
lip	O
##id	O
fraction	O
used	O
for	O
analysis	O
.	O

Prior	O
to	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
,	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
samples	O
were	O
re	O
##con	O
##stituted	O
in	O
600	O
μ	O
##l	O
of	O
PBS	O
(	B
Ph	B
##os	I
##phate	I
B	O
##uff	O
##ered	O
Sal	B
##ine	I
)	O
made	O
up	O
with	O
D	O
_	O
2	O
O	O
,	O
containing	O
0	O
.	O
5	O
m	O
##M	O
T	O
##SP	O
(	O
Tri	O
##met	O
##hyl	O
##si	O
##ly	O
##l	O
te	O
##tra	O
##de	O
##uter	O
##op	O
##rop	O
##ion	O
##ic	O
acid	O
sodium	O
salt	O
)	O
as	O
a	O
concentration	O
and	O
chemical	O
shift	O
reference	O
and	O
placed	O
in	O
a	O
5	O
mm	O
N	O
##MR	O
tube	O
.	O

The	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
were	O
then	O
el	O
##uted	O
with	O
2	O
m	O
##L	O
of	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
met	O
##han	O
##ol	O
:	O
form	O
##ic	O
acid	O
(	O
50	O
:	O
50	O
:	O
3	O
)	O
.	O

These	O
variations	O
in	O
est	B
##rogen	I
metabolism	O
are	O
consistent	O
with	O
a	O
protective	O
effect	O
of	O
so	O
##y	O
on	O
breast	O
cancer	O
risk	O
based	O
upon	O
Brad	O
##low	O
’	O
s	O
theory	O
of	O
est	O
##rogen	O
-	O
mediated	O
car	O
##cin	O
##ogen	O
##esis	O
However	O
,	O
the	O
‘	O
g	O
##eno	O
##to	O
##xi	O
##c	O
meta	O
##bol	O
##ites	O
’	O
hypothesis	O
,	O
which	O
p	O
##os	O
##its	O
o	O
##xi	O
##dized	O
products	O
of	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
as	O
primary	O
ca	O
##usal	O
agents	O
in	O
breast	O
cancer	O
suggests	O
that	O
observed	O
variations	O
in	O
est	B
##rogen	I
metabolism	O
could	O
increase	O
risk	O
.	O

This	O
representation	O
clearly	O
shows	O
that	O
re	B
##tina	I
##l	I
GT	O
##3	O
and	O
A	O
##c	O
##G	O
##T	O
##3	O
have	O
distinctive	O
c	B
##era	I
##mi	I
##de	I
profiles	O
,	O
both	O
compared	O
to	O
other	O
re	B
##tina	I
##l	I
G	O
##G	O
classes	O
and	O
compared	O
to	O
brain	O
GT	O
##3	O
and	O
A	O
##c	O
##G	O
##T	O
##3	O
.	O

The	O
der	O
##iva	O
##ti	O
##zation	O
regent	O
##s	O
,	O
MC	O
##F	O
and	O
EC	O
##F	O
,	O
as	O
well	O
as	O
HP	O
##LC	O
grade	O
solvent	O
##s	O
including	O
met	B
##han	I
##ol	I
,	O
ethanol	S
,	O
ch	B
##lor	I
##of	I
##orm	I
and	O
p	B
##yr	I
##id	I
##ine	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

The	O
developed	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
in	O
this	O
study	O
is	O
sensitive	O
,	O
specific	O
,	O
accurate	O
,	O
precise	O
,	O
and	O
reliable	O
in	O
the	O
q	O
##uant	O
##ification	O
of	O
three	O
of	O
the	O
most	O
commonly	O
prescribed	O
s	B
##tat	I
##ins	I
and	O
their	O
active	O
meta	O
##bol	O
##ites	O
.	O

These	O
N	O
##MR	O
analyses	O
revealed	O
the	O
expected	O
elevations	O
in	O
plasma	O
glucose	S
and	O
k	B
##eton	I
##e	I
levels	O
with	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
.	O

Fu	B
##ran	I
and	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
were	O
purchased	O
from	O
A	O
##c	O
##ros	O
Organic	O
##s	O
(	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

The	O
in	O
##te	O
##gra	O
##se	O
inhibitor	O
-	O
based	O
regime	O
##ns	O
were	O
as	O
follows	O
:	O
ten	O
##of	O
##ov	O
##ir	O
al	B
##af	I
##ena	I
##mi	I
##de	I
f	O
##uma	O
##rate	O
/	O
em	O
##tric	O
##ita	O
##bine	O
/	O
el	O
##vi	O
##te	O
##gra	O
##vir	O
/	O
co	O
##bic	O
##ista	O
##t	O
in	O
10	O
patients	O
,	O
ten	O
##of	O
##ov	O
##ir	O
di	O
##so	O
##p	O
##ro	O
##xi	O
##l	O
f	O
##uma	O
##rate	O
/	O
em	O
##tric	O
##ita	O
##bine	O
/	O
el	O
##vi	O
##te	O
##gra	O
##vir	O
/	O
co	O
##bic	O
##ista	O
##t	O
in	O
seven	O
patients	O
,	O
a	O
##ba	O
##ca	O
##vir	O
/	O
la	O
##mi	O
##vu	O
##dine	O
/	O
do	O
##lut	O
##eg	O
##ra	O
##vir	O
in	O
18	O
patients	O
and	O
ten	O
##of	O
##ov	O
##ir	O
di	O
##so	O
##p	O
##ro	O
##xi	O
##l	O
f	O
##uma	O
##rate	O
/	O
em	O
##tric	O
##ita	O
##bine	O
plus	O
r	O
##al	O
##te	O
##gra	O
##vir	O
in	O
two	O
patients	O
.	O

Co	O
-	O
in	O
##cu	O
##bation	O
with	O
palm	B
##itate	I
abolished	O
the	O
s	O
##ti	O
##mu	O
##lator	O
##y	O
effect	O
.	O

The	O
carbon	B
##ic	I
acid	I
increase	O
co	O
##rro	O
##bor	O
##ates	O
with	O
previous	O
report	O
where	O
higher	O
expression	O
of	O
carbon	O
##ic	O
an	O
##hy	O
##dra	O
##se	O
,	O
an	O
enzyme	O
involved	O
in	O
conversion	O
of	O
carbon	B
dioxide	I
to	O
carbon	B
##ic	I
acid	I
is	O
reported	O
.	O

Furthermore	O
,	O
over	O
##ex	O
##press	O
##ion	O
of	O
an	O
ω	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
is	O
##oz	O
##yme	O
,	O
which	O
increased	O
the	O
production	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
in	O
blood	O
vessels	O
,	O
caused	O
end	O
##oth	O
##eli	O
##al	O
d	O
##ys	O
##function	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
mass	O
levels	O
of	O
S	B
##ph	I
,	O
D	O
##HS	O
##ph	O
,	O
S	O
##1	O
##P	O
,	O
and	O
D	O
##HS	O
##1	O
##P	O
are	O
higher	O
in	O
breast	O
cancer	O
than	O
in	O
normal	O
breast	O
tissue	O
.	O

In	O
v	O
##it	O
##ro	O
studies	O
also	O
found	O
that	O
a	O
high	O
concentration	O
of	O
a	B
##rg	I
##ini	I
##ne	I
decreased	O
the	O
anti	O
##ox	O
##ida	O
##nt	O
capacity	O
of	O
brain	O
tissue	O
,	O
which	O
in	O
turn	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
in	O
##hibit	O
##ed	O
the	O
activity	O
of	O
g	B
##lut	I
##ath	I
##ione	I
per	O
##ox	O
##idas	O
##e	O
in	O
the	O
brain	O
tissue	O
,	O
induced	O
the	O
production	O
of	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
substances	O
,	O
and	O
finally	O
decreased	O
the	O
recovery	O
of	O
nerve	O
function	O
(	O
,	O
)	O
.	O

Consequently	O
,	O
the	O
extension	O
of	O
the	O
metabolic	O
signature	O
by	O
meta	O
##bol	O
##ites	O
derived	O
from	O
the	O
se	B
##rot	I
##oni	I
##n	I
pathway	O
improved	O
the	O
prediction	O
accuracy	O
(	O
Figure	O
)	O
.	O

After	O
v	O
##ortex	O
-	O
mixing	O
,	O
the	O
plasma	O
was	O
b	O
##asi	O
##fied	O
with	O
40	O
μ	O
##l	O
of	O
1	O
##M	O
Na	O
##OH	O
and	O
extracted	O
with	O
4	O
m	O
##l	O
of	O
et	B
##hyl	I
ace	I
##tate	I
,	O
as	O
described	O
in	O
section	O
2	O
.	O
3	O
.	O

Similar	O
to	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
,	O
con	O
##ju	O
##gation	O
with	O
met	O
##hyl	O
groups	O
or	O
g	B
##lut	I
##ath	I
##ione	I
could	O
also	O
affect	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
stability	O
and	O
local	O
retention	O
.	O

Our	O
findings	O
confirmed	O
previous	O
studies	O
reporting	O
higher	O
circulating	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
lip	O
##op	O
##rote	O
##ins	O
in	O
growth	O
-	O
restricted	O
f	O
##etus	O
##es	O
.	O

Bo	O
##us	O
##ova	O
et	O
al	O
.	O
reported	O
reduced	O
as	B
##par	I
##tate	I
amino	I
transfer	O
##ase	O
activity	O
induced	O
by	O
f	B
##ru	I
##ct	I
##ose	I
and	O
the	O
resulting	O
g	O
##ly	O
##cation	O
in	O
v	O
##it	O
##ro	O
and	O
observed	O
beneficial	O
effects	O
of	O
u	B
##ric	I
acid	I
in	O
that	O
context	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
decrease	O
in	O
urine	O
ace	B
##to	I
##ace	I
##tate	I
concentration	O
was	O
rather	O
unexpected	O
.	O

These	O
results	O
indicate	O
that	O
la	B
##ct	I
##ate	I
plays	O
an	O
important	O
role	O
in	O
M	O
##UC	O
##16	O
-	O
mediated	O
m	O
##ot	O
##ility	O
and	O
invasive	O
##ness	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
cells	O
.	O

The	O
induction	O
of	O
in	B
##do	I
##leam	I
##ine	I
2	I
,	I
3	I
-	I
di	I
##ox	I
##y	I
##gen	I
##ase	I
-	I
1	I
(	O
ID	O
##O	O
)	O
in	O
activated	S
mon	O
##ocytes	O
and	O
den	O
##dr	O
##itic	O
cells	O
by	O
inter	O
##fer	O
##on	O
-	O
γ	O
and	O
other	O
inflammatory	O
media	O
##tors	O
in	O
HIV	O
-	O
infected	O
individuals	O
causes	O
cat	O
##ab	O
##olis	O
##m	O
of	O
try	B
##pt	I
##op	I
##han	I
into	O
k	B
##yn	I
##uren	I
##ine	I
and	O
several	O
other	O
downstream	O
cat	O
##ab	O
##oli	O
##tes	O
with	O
im	O
##mu	O
##no	O
##log	O
##ic	O
properties	O
[	O
,	O
]	O
.	O

We	O
found	O
a	O
small	O
,	O
but	O
significant	O
,	O
increase	O
in	O
T	O
##rp	O
levels	O
(	O
+	O
5	O
%	O
)	O
associated	O
with	O
a	O
substantial	O
reduction	O
in	O
5	B
-	I
H	I
##IA	I
##A	I
levels	O
in	O
the	O
serum	O
of	O
patients	O
affected	O
by	O
C	O
##M	O
(	O
Table	O
,	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
E	O
##thi	O
##c	O
Committee	O
Su	O
##d	O
-	O
E	O
##st	O
VI	S
C	O
##ler	O
##mont	O
-	O
Fe	O
##rra	O
##nd	O
(	O
Agreement	O
number	O
AU	O
##8	O
##8	O
##7	O
,	O
04	O
/	O
03	O
/	O
2011	O
)	O
.	O

De	O
no	O
##vo	O
lip	O
##ogen	O
##esis	O
of	O
long	O
chain	O
fatty	O
acids	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
3	O
c	O
##yt	O
##oso	O
##lic	O
enzymes	O
:	O
ATP	B
c	I
##it	I
##rate	I
l	O
##yas	O
##e	O
,	O
ACC	O
,	O
and	O
fatty	O
acid	O
s	O
##ynth	O
##eta	O
##se	O
.	O

A	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
##s	I
with	O
a	O
chain	O
length	O
≥	O
C	O
##10	O
are	O
defined	O
as	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
##s	I
,	O
and	O
with	O
a	O
chain	O
length	O
<	O
C	O
##5	O
as	O
short	O
-	O
chain	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
##s	I
.	O

The	O
fast	O
##ing	O
blood	O
glucose	S
and	O
2	O
-	O
h	O
post	O
-	O
challenge	O
blood	O
glucose	S
levels	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

Tri	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
T	O
##AG	O
##s	O
)	O
and	O
ch	B
##ole	I
##ster	I
##yl	I
-	I
est	I
##ers	I
(	O
Cho	O
##l	O
##E	O
)	O
:	O
AP	O
##PI	O
ion	O
##ization	O
was	O
set	O
in	O
positive	O
mode	O
,	O
drying	O
nitrogen	O
flow	O
at	O
11	O
l	O
/	O
min	O
,	O
and	O
fragment	O
##or	O
voltage	O
was	O
op	O
##ti	O
##mized	O
for	O
each	O
lip	O
##id	O
class	O
.	O

There	O
were	O
significant	O
differences	O
in	O
un	O
##con	O
##ju	O
##gated	O
E	O
##2	O
and	O
total	O
4	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
concentrations	O
between	O
the	O
female	O
and	O
male	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Ch	O
##roma	O
##tography	O
utilized	O
a	O
10	O
min	O
gradient	O
on	O
a	O
Ki	O
##net	O
##ex	O
X	O
##B	O
-	O
C	O
##18	O
column	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Unlike	O
normal	O
pool	O
##ed	O
human	O
serum	O
,	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
was	O
not	O
a	O
clearly	O
superior	O
method	O
for	O
mac	O
##rom	O
##ole	O
##cule	O
removal	O
for	O
pool	O
##ed	O
human	O
serum	O
that	O
was	O
acquired	O
from	O
se	O
##psis	O
patients	O
.	O

An	O
im	O
##bal	O
##ance	O
between	O
the	O
fatty	O
acid	O
up	O
##take	O
and	O
the	O
oxidation	O
due	O
to	O
defects	O
or	O
alterations	O
in	O
mitochondrial	O
respiratory	O
complex	O
activities	O
arises	O
in	O
in	O
##tra	O
##cellular	O
concentration	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
that	O
may	O
be	O
reflected	O
at	O
the	O
serum	O
level	O
.	O

B	O
##io	O
##in	O
##formatics	O
analysis	O
of	O
different	O
##iating	O
meta	O
##bol	O
##ites	O
identified	O
4	O
distinct	O
metabolic	O
networks	O
associated	O
with	O
total	O
g	B
##lut	I
##ath	I
##ione	I
(	O
A	O
)	O
,	O
ad	B
##eno	I
##sin	I
##e	I
(	O
B	O
)	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
C	O
)	O
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
(	O
D	O
)	O
.	O

The	O
studies	O
identified	O
potential	O
(	O
1	O
)	O
imp	O
##air	O
##ment	O
of	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
,	O
increased	O
lip	O
##id	O
cat	O
##ab	O
##olis	O
##m	O
,	O
and	O
elevation	O
of	O
essential	O
amino	O
acids	O
,	O
and	O
(	O
2	O
)	O
defects	O
on	O
am	B
##mon	I
##ium	I
de	O
##to	O
##xi	O
##fication	O
and	O
increased	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
in	O
HC	O
##C	O
.	O

In	O
the	O
adult	O
-	O
onset	O
o	O
##li	O
##vo	O
##pont	O
##oc	O
##ere	O
##bella	O
##r	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
,	O
decreased	O
AK	O
##G	O
levels	O
combined	O
with	O
increased	O
g	B
##lut	I
##ama	I
##te	I
levels	O
have	O
been	O
associated	O
with	O
a	O
partial	O
deficiency	O
of	O
g	O
##lut	O
##ama	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

Black	O
line	O
represents	O
_	O
1	O
H	O
-	O
N	O
##MR	O
spectrum	O
,	O
blue	O
line	O
represents	O
compound	O
signature	O
corresponding	O
to	O
2	B
-	I
amino	I
##but	I
##yra	I
##te	I
,	O
red	O
line	O
represents	O
compound	O
signature	O
corresponding	O
to	O
pan	B
##to	I
##the	I
##nate	I
.	O

Subsequently	O
,	O
super	O
##nat	O
##ant	O
was	O
removed	O
and	O
the	O
cell	O
p	O
##elle	O
##t	O
was	O
re	O
##sus	O
##pen	O
##ded	O
in	O
100	O
µ	O
##L	O
PBS	O
containing	O
1	O
µ	O
##L	O
mouse	B
-	I
α	I
-	I
human	I
V	O
##iment	O
##in	O
-	O
P	O
##E	O
(	O
A	O
##b	O
##cam	O
,	O
Cambridge	O
,	O
UK	O
)	O
followed	O
by	O
30	O
min	O
in	O
##cu	O
##bation	O
at	O
R	O
##T	O
.	O

In	O
a	O
g	B
##lut	I
##ama	I
##ter	I
##gic	I
s	O
##yna	O
##pse	O
,	O
the	O
released	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
is	O
internal	O
##ized	O
by	O
as	O
##tro	O
##cy	O
##tes	O
through	O
high	O
affinity	O
sodium	O
-	O
dependent	O
g	O
##lut	O
##ama	O
##te	O
transport	O
##ers	O
,	O
and	O
then	O
transformed	O
into	O
G	O
##ln	O
by	O
the	O
as	O
##tro	O
##cy	O
##te	O
-	O
specific	O
enzyme	O
,	O
g	B
##lut	I
##amine	I
s	O
##ynth	O
##eta	O
##se	O
,	O
and	O
released	O
into	O
the	O
extra	O
##cellular	O
space	O
,	O
from	O
which	O
it	O
is	O
taken	O
up	O
into	O
neurons	O
through	O
the	O
neutral	O
amino	O
acid	O
transport	O
##er	O
and	O
transformed	O
back	O
to	O
G	O
##lu	O
by	O
phosphate	O
-	O
activated	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
.	O

These	O
authors	O
also	O
reported	O
dim	B
##eth	I
##yla	I
##mine	I
(	O
D	O
##MA	O
)	O
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
,	O
beta	B
##ine	I
and	O
ace	B
##tate	I
to	O
be	O
elevated	O
in	O
T	O
##2	O
##DM	O
patients	O
.	O

In	O
regards	O
to	O
the	O
observed	O
elevated	O
c	B
##rea	I
##tine	I
,	O
the	O
lower	O
concentrations	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
g	B
##ly	I
##cine	I
may	O
suggest	O
u	O
##til	O
##ization	O
of	O
these	O
amino	O
acids	O
for	O
its	O
production	O
(	O
P	O
<	O
0	O
.	O
03	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
p	O
##ediatric	O
study	O
,	O
his	B
##ti	I
##dine	I
levels	O
in	O
se	O
##psis	O
were	O
increased	O
.	O

C	O
##luster	O
1	O
is	O
a	O
highly	O
correlated	O
se	B
##rot	I
##oni	I
##n	I
cluster	O
and	O
cluster	O
2	O
a	O
highly	O
correlated	O
me	B
##lat	I
##oni	I
##n	I
cluster	O
in	O
normal	O
metabolic	O
conditions	O
.	O

Secondary	O
aims	O
were	O
to	O
assess	O
correlation	O
##s	O
of	O
plasma	O
AG	O
##Es	O
with	O
quantitative	O
markers	O
of	O
glucose	S
metabolism	O
and	O
bio	O
##mark	O
##ers	O
of	O
sub	O
##c	O
##lini	O
##cal	O
inflammation	O
.	O

The	O
specific	O
metabolic	O
signature	O
observed	O
in	O
G	O
##C	O
involved	O
a	O
lower	O
serum	O
level	O
of	O
several	O
2	B
-	I
h	I
##ydro	I
##xy	I
##lated	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
(	O
OH	O
)	O
s	O
)	O
:	O
SM	B
(	I
OH	I
)	I
22	I
:	I
1	I
,	O
SM	B
(	I
OH	I
)	I
22	I
:	I
2	I
and	O
SM	B
(	I
OH	I
)	I
24	I
:	I
1	I
.	O

Additionally	O
,	O
smoking	O
was	O
associated	O
with	O
altered	O
levels	O
of	O
serum	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
bi	O
##le	O
acids	O
,	O
but	O
the	O
extent	O
of	O
these	O
changes	O
were	O
und	O
##ist	O
##ing	O
##ui	O
##sha	O
##ble	O
between	O
healthy	O
smoke	O
##rs	O
and	O
CO	O
##PD	O
smoke	O
##rs	O
.	O
_	O
1	O
R	O
##T	O
=	O
retention	O
time	O
P	O
=	O

G	O
.	O
Western	O
b	O
##lot	O
##ting	O
of	O
the	O
samples	O
from	O
each	O
step	O
of	O
the	O
u	O
##rina	O
##ry	O
E	O
##V	O
isolation	O
confirmed	O
the	O
en	O
##rich	O
##ment	O
of	O
CD	O
##9	O
,	O
T	O
##S	O
##G	O
##10	O
##1	O
,	O
CD	O
##5	O
##9	O
and	O
CD	O
##6	O
##3	O
as	O
well	O
as	O
the	O
absence	O
of	O
cellular	O
organ	O
##elle	O
proteins	O
ca	B
##ln	I
##ex	I
##in	I
,	O
TO	O
##MM	O
##20	O
and	O
GM	O
##13	O
##0	O
in	O
the	O
E	O
##Vs	O
.	O

Next	O
,	O
2	O
.	O
4	O
m	O
##L	O
ice	O
cold	O
met	B
##hyl	I
te	I
##rt	I
-	I
but	I
##yl	I
et	I
##her	I
and	O
800	O
μ	O
##L	O
ice	O
cold	O
water	O
were	O
added	O
.	O

C	O
.	O
I	O
##maging	O
of	O
P	O
.	O
f	O
##al	O
##ci	O
##par	O
##um	O
treated	O
with	O
50	O
µ	O
##M	O
of	O
1	O
##a	O
-	O
a	O
or	O
a	O
1	O
%	O
D	B
##MS	I
##O	I
control	O
.	O

These	O
analyses	O
suggest	O
that	O
the	O
association	O
of	O
an	O
elevated	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
with	O
C	O
##VD	O
risk	O
in	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
studies	O
is	O
associated	O
with	O
several	O
factors	O
,	O
including	O
higher	O
plasma	O
glucose	S
,	O
total	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
BC	O
##AA	O
##s	O
,	O
and	O
trim	B
##eth	I
##yla	I
##mine	I
oxide	I
,	O
evidence	O
of	O
inflammation	O
,	O
and	O
lower	O
total	O
g	B
##lut	I
##ath	I
##ione	I
,	O
lower	O
kidney	O
function	O
,	O
along	O
with	O
modest	O
imp	O
##air	O
##ment	O
of	O
vitamin	O
B	O
-	O
6	O
status	O
associated	O
with	O
increased	O
B	O
-	O
6	O
cat	O
##ab	O
##olis	O
##m	O
.	O

The	O
results	O
revealed	O
that	O
the	O
difference	O
in	O
the	O
levels	O
of	O
g	B
##ly	I
##cine	I
between	O
the	O
patients	O
and	O
the	O
healthy	O
controls	O
was	O
significant	O
in	O
the	O
2015	O
data	O
set	O
under	O
multi	O
##var	O
##iate	O
statistical	O
analyses	O
,	O
and	O
significant	O
in	O
the	O
2017	O
data	O
set	O
under	O
un	O
##iva	O
##ria	O
##te	O
analyses	O
.	O

This	O
was	O
>	O
0	O
.	O
75	O
for	O
67	O
meta	O
##bol	O
##ites	O
(	O
71	O
%	O
)	O
,	O
0	O
.	O
40	O
–	O
0	O
.	O
75	O
for	O
25	O
meta	O
##bol	O
##ites	O
(	O
27	O
%	O
)	O
,	O
and	O
<	O
0	O
.	O
40	O
for	O
two	O
(	B
u	B
##rid	I
##ine	I
and	O
ma	B
##lon	I
##ate	I
,	O
2	O
%	O
)	O
.	O

For	O
op	O
##ti	O
##mum	O
sensitivity	O
,	O
the	O
following	O
parameters	O
were	O
set	O
:	O
fragment	O
##or	O
voltage	O
of	O
50	O
V	O
for	O
G	O
##L	O
##Y	O
and	O
GP	S
,	O
250	O
V	O
for	O
M1	O
and	O
M	O
##2	O
,	O
cap	O
##illa	O
##ry	O
voltage	O
5000	O
V	O
,	O
drying	O
gas	O
temperature	O
350	O
##°	O
C	O
,	O
drying	O
gas	O
flow	O
10	O
L	O
/	O
min	O
and	O
ne	O
##bul	O
##izer	O
pressure	O
25	O
ps	O
##ig	O
(	O
172	O
.	O
4	O
K	O
##P	O
##a	O
)	O
.	O

Two	O
other	O
meta	O
##bol	O
##ites	O
strongly	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
in	O
our	O
data	O
are	O
the	O
two	O
o	B
##me	I
##ga	I
-	I
3	I
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
,	O
EPA	O
and	O
D	O
##HA	O
.	O

Lac	B
##tate	I
and	O
t	B
-	I
ch	I
##olin	I
##e	I
concentrations	O
in	O
De	O
##gar	O
##eli	O
##x	O
-	O
treated	O
cancer	O
samples	O
were	O
significantly	O
lower	O
than	O
in	O
un	O
##tre	O
##ated	O
samples	O
,	O
while	O
c	B
##it	I
##rate	I
and	O
t	B
-	I
c	I
##rea	I
##tine	I
levels	O
did	O
not	O
show	O
any	O
significant	O
differences	O
(	O
Table	O
)	O
.	O

M	B
##T	I
##BE	I
extraction	O
also	O
resulted	O
in	O
improved	O
recovery	O
of	O
15	O
:	O
0	O
PC	O
(	O
p	O
=	O
0	O
.	O
00	O
##13	O
##6	O
)	O
,	O
PC	B
(	I
19	I
:	I
0	I
/	I
15	I
:	I
1	I
)	I
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
17	O
:	O
0	O
Ce	O
##r	O
(	O
p	O
=	O
0	O
.	O
00	O
##17	O
##3	O
)	O
compared	O
to	O
met	B
##han	I
##ol	I
.	O

The	O
limit	O
of	O
q	O
##uant	O
##itation	O
is	O
2	O
p	B
##g	I
on	O
the	O
column	O
for	O
each	O
E	O
##M	O
.	O

Can	B
##na	I
##bino	I
##id	I
receptor	O
-	O
1	O
(	O
C	O
##NR	O
##1	O
)	O
,	O
C	O
##NR	O
##2	O
,	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
55	O
(	O
GP	O
##R	O
##55	O
)	O
,	O
fatty	O
acid	O
amid	O
##e	O
h	O
##ydro	O
##lase	O
(	O
FAA	O
##H	O
)	O
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
lip	O
##ase	O
(	O
MA	O
##G	O
##L	O
)	O
,	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
-	O
1	O
(	O
CO	O
##X	O
##1	O
)	O
and	O
CO	O
##X	O
##2	O
gene	O
expression	O
levels	O
were	O
as	O
##cer	O
##tain	O
##ed	O
to	O
determine	O
if	O
expression	O
levels	O
correlated	O
with	O
the	O
pro	O
##life	O
##rative	O
response	O
of	O
DL	O
##BC	O
##L	O
cell	O
lines	O
to	O
2	O
-	O
AG	O
.	O

We	O
conducted	O
meta	O
##bol	O
##ite	O
pro	O
##fi	O
##ling	O
in	O
39	O
paired	O
(	O
pre	O
/	O
post	O
-	O
intervention	O
)	O
plasma	O
samples	O
from	O
early	O
-	O
stage	O
breast	O
cancer	O
patients	O
receiving	O
limo	B
##nen	I
##e	I
treatment	O
(	O
2	O
g	O
Q	O
##D	O
)	O
before	O
surgical	O
re	O
##section	O
of	O
their	O
tumor	O
.	O

In	O
the	O
M	O
##NG	O
group	O
,	O
increased	O
amounts	O
of	O
met	B
##hi	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
al	B
##ani	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
try	B
##pt	I
##op	I
##han	I
were	O
observed	O
.	O

To	B
##lue	I
##ne	I
(	O
100	O
μ	O
##L	O
,	O
kept	O
an	O
##hy	O
##dr	O
##ous	O
with	O
sodium	B
su	I
##lf	I
##ate	I
)	O
was	O
added	O
to	O
the	O
dry	O
residue	O
,	O
and	O
dried	O
fully	O
again	O
at	O
50	O
°C	O
under	O
nitrogen	B
gas	I
.	O

More	O
recently	O
f	O
##eca	O
##l	O
bio	O
##mark	O
##ers	O
such	O
as	O
f	O
##eca	O
##l	O
ca	O
##l	O
##p	O
##rote	O
##ct	O
##in	O
and	O
la	B
##ct	I
##of	I
##er	I
##rin	I
have	O
shown	O
promising	O
results	O
in	O
different	O
##iating	O
I	O
##B	O
##D	O
from	O
I	O
##BS	O
,	O
monitoring	O
disease	O
activity	O
and	O
predict	O
##ing	O
the	O
re	O
##lap	O
##se	O
in	O
I	O
##B	O
##D	O
,	O
.	O

Since	O
populations	O
of	O
the	O
co	O
##lon	O
##ic	O
micro	O
##f	O
##lora	O
are	O
der	O
##ang	O
##ed	O
in	O
I	O
##B	O
##D	O
,	O
either	O
as	O
a	O
cause	O
or	O
a	O
consequence	O
,	O
it	O
is	O
possible	O
that	O
an	O
over	O
##gro	O
##wth	O
of	O
p	O
##ec	O
##tin	O
-	O
de	O
##grading	O
bacteria	O
may	O
contribute	O
to	O
an	O
increased	O
met	B
##han	I
##ol	I
content	O
.	O

Method	O
##s	O
of	O
extraction	O
and	O
effects	O
of	O
freezing	O
and	O
sample	O
di	O
##lution	O
were	O
assessed	O
,	O
and	O
u	O
##rina	O
##ry	O
con	O
##tam	O
##ina	O
##nts	O
from	O
breakdown	O
of	O
polymer	O
##s	O
in	O
a	O
range	O
of	O
di	O
##aper	O
##s	O
and	O
cotton	O
wool	O
balls	O
were	O
identified	O
and	O
compared	O
,	O
including	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
a	B
##c	I
##ryl	I
##ic	I
acid	I
,	O
and	O
te	B
##rt	I
-	I
but	I
##ano	I
##l	I
.	O

The	O
breakdown	O
of	O
stored	O
T	B
##G	I
is	O
largely	O
regulated	O
by	O
AT	O
##G	O
##L	O
and	O
H	O
##SL	O
.	O

Cho	B
##line	I
metabolic	O
pathways	O
are	O
shown	O
in	O
.	O

As	O
##suming	O
that	O
P	O
##ET	O
-	O
positive	O
lesions	O
have	O
an	O
SUV	O
_	O
ma	O
##x	O
≥	O
2	O
.	O
5	O
,	O
a	O
low	O
relative	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
results	O
in	O
the	O
diagnosis	O
of	O
lung	O
cancer	O
with	O
a	O
sensitivity	O
of	O
100	O
%	O
and	O
with	O
a	O
very	O
high	O
PP	O
##V	O
of	O
94	O
%	O
.	O

Li	O
##pid	O
##s	O
are	O
molecules	O
that	O
include	O
fat	O
-	O
soluble	O
vitamin	O
##s	O
(	O
such	O
as	O
vitamin	O
##s	O
A	O
,	O
D	O
,	O
E	O
and	O
K	O
)	O
,	O
mon	B
##og	I
##ly	I
##cer	I
##ides	I
,	O
dig	B
##ly	I
##cer	I
##ides	I
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
others	O
.	O

On	O
the	O
other	O
hand	O
,	O
N	O
##F	O
tumors	O
showed	O
elevated	O
levels	O
of	O
la	B
##ct	I
##ate	I
when	O
compared	O
with	O
both	O
pro	O
##la	O
##ct	O
##ino	O
##mas	O
and	O
L	O
##H	O
/	O
F	O
##S	O
##H	O
-	O
secret	O
##ing	O
tumors	O
,	O
indicating	O
an	O
up	O
##re	O
##gu	O
##lated	O
War	O
##burg	O
g	O
##ly	O
##co	O
##lysis	O
.	O

3	O
.	O
01	O
##E	O
–	O
7	O
,	O
F	O
##DR	O
=	O
5	O
.	O
55	O
##E	O
–	O
05	O
)	O
and	O
m	O
/	O
z	O
50	O
##8	O
.	O
340	O
##4	O
(	O
E	O
##SI	O
–	O
,	O
R	O
##T	O
=	O
1	O
.	O
7	O
min	O
;	O
P	O
=	O
2	O
.	O
93	O
##E	O
–	O
05	O
,	O
F	O
##DR	O
=	O
1	O
.	O
88	O
##E	O
–	O
03	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
1	I
)	I
at	O
m	O
/	O
z	O
50	O
##6	O
.	O
32	O
##4	O
##9	O
(	O
E	O
##SI	O
–	O
,	O
R	O
##T	O
=	O
1	O
.	O
39	O
min	O
;	O
P	O
=	O
7	O
.	O
95	O
##E	O
–	O
06	O
,	O
F	O
##DR	O
=	O
6	O
.	O
67	O
##E	O
–	O
04	O
)	O
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
2	I
)	I
at	O
m	O
/	O

An	O
extraction	O
with	O
diet	B
##hyl	I
et	I
##her	I
was	O
carried	O
out	O
(	O
2	O
×	O
1	O
m	O
##L	O
)	O
.	O

We	O
found	O
that	O
neither	O
of	O
these	O
S	O
##NP	O
##s	O
were	O
significantly	O
associated	O
with	O
ate	B
##no	I
##lo	I
##l	I
BP	O
response	O
(	O
r	O
##s	O
##27	O
##27	O
##5	O
##6	O
##3	O
S	O
##B	O
##P	O
p	O
=	O
0	O
.	O
24	O
,	O
DB	B
##P	I
p	O
=	O
0	O
.	O
47	O
;	O
r	O
##s	O
##12	O
##60	O
##4	O
##9	O
##40	O
S	O
##B	O
##P	O
p	O
=	O
0	O
.	O
96	O
,	O
DB	B
##P	I
p	O
=	O
0	O
.	O
79	O
;	O
r	O
##s	O
##13	O
##26	O
##29	O
##30	O
S	O
##B	O
##P	O
p	O
=	O
0	O
.	O
56	O
,	O
DB	B
##P	I
p	O
=	O
0	O
.	O
93	O
)	O
nor	O
with	O
can	O
##des	O
##art	O
##an	O
BP	O
response	O
(	O
r	O
##s	O
##27	O
##27	O
##5	O
##6	O
##3	O
S	O
##B	O
##P	O
p	O
=	O
0	O
.	O
64	O
,	O
DB	B
##P	I
p	O
=	O
0	O
.	O
71	O
;	O
r	O
##s	O
##12	O
##60	O
##4	O
##9	O
##40	O
S	O
##B	O
##P	O
p	O
=	O
0	O
.	O
37	O
,	O
DB	B
##P	I
p	O
=	O
0	O
.	O
29	O
;	O
r	O
##s	O
##13	O
##26	O
##29	O
##30	O
S	O
##B	O
##P	O
p	O
=	O
0	O
.	O
81	O
,	O
DB	B
##P	I
p	O
=	O
0	O
.	O
77	O
)	O
.	O

Level	O
##s	O
of	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
were	O
elevated	O
in	O
the	O
se	O
##ra	O
of	O
T	O
##B	O
patients	O
,	O
consistent	O
with	O
increased	O
an	O
##ae	O
##ro	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
.	O

Whether	O
x	B
##ant	I
##hine	I
production	O
from	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
plays	O
a	O
role	O
in	O
T	O
##2	O
##D	O
development	O
due	O
to	O
increased	O
X	O
##O	O
activity	O
or	O
due	O
to	O
x	B
##ant	I
##hine	I
production	O
in	O
parallel	O
with	O
the	O
con	O
##se	O
##quent	O
decrease	O
in	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
requires	O
further	O
investigation	O
.	O

End	O
##os	O
##copic	O
re	O
##tro	O
##grade	O
ch	O
##ola	O
##ng	O
##io	O
##pan	O
##cre	O
##ato	O
##graphy	O
(	O
ER	O
##CP	O
)	O
is	O
a	O
risk	O
factor	O
for	O
developing	O
AP	S
.	O

Finally	O
,	O
[UNK]	O
=	I
[UNK]	O
=	I
1	I
##ρ	I
##s	I
##j	I
(	I
y	I
##j	I
)	I
x	I
##s	I
gives	O
the	O
conditional	O
depend	O
##encies	O
between	O
a	O
continuous	O
variable	O
x	O
_	O
s	O
and	O
a	O
discrete	O
variable	O
y	O
_	O
j	O
,	O
represented	O
by	O
a	O
vector	O
of	O
size	O
L	O
_	O
j	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
q	O
##uant	O
##ifies	O
the	O
eight	O
major	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
blood	O
and	O
milk	O
during	O
la	O
##ct	O
##ation	O
in	O
the	O
dairy	O
cow	O
.	O

Met	O
##S	O
##cape	O
analysis	O
of	O
the	O
94	O
features	O
identified	O
multiple	O
associated	O
pathways	O
,	O
including	O
f	B
##ru	I
##ct	I
##ose	I
and	O
man	B
##nose	I
metabolism	O
,	O
gal	B
##act	I
##ose	I
metabolism	O
,	O
pen	B
##tos	I
##e	I
phosphate	I

Standard	O
laboratory	O
data	O
(	O
t	O
##rop	O
##oni	O
##n	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
blood	O
cell	O
and	O
plate	O
##let	O
counts	O
)	O
were	O
obtained	O
from	O
the	O
medical	O
record	O
.	O

V	O
##iri	O
##ons	O
were	O
pu	O
##rified	O
from	O
the	O
medium	O
of	O
infected	O
fi	O
##bro	O
##blast	O
cultures	O
by	O
velocity	O
sediment	O
##ation	O
in	O
g	B
##ly	I
##cer	I
##ol	I
-	I
ta	I
##rt	I
##rate	I
gradient	O
##s	O
,	O
and	O
judged	O
to	O
be	O
substantially	O
free	O
of	O
cellular	O
membrane	O
con	O
##tam	O
##ina	O
##nts	O
by	O
electron	O
micro	O
##sco	O
##py	O
(	O
Fi	O
##g	O
.	O
S	O
##1	O
)	O
.	O

Also	O
,	O
our	O
observation	O
of	O
higher	O
ta	B
##uri	I
##ne	I
levels	O
in	O
end	O
##ome	O
##tri	O
##osis	O
women	O
is	O
in	O
agreement	O
with	O
an	O
earlier	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
performed	O
on	O
urine	O
samples	O
of	O
end	O
##ome	O
##tri	O
##osis	O
patients	O
.	O

Car	O
##bo	O
##hy	O
##dra	O
##te	O
der	O
##ivate	O
##s	O
(	B
D	B
-	I
glucose	I
,	O
D	B
-	I
f	I
##ru	I
##ct	I
##ose	I
,	O
su	B
##c	I
##rose	I
,	O
and	O
ma	O
##lt	O
##ose	O
)	O
emerged	O
as	O
de	O
##ter	O
##mina	O
##nts	O
of	O
therapeutic	O
response	O
.	O

Co	O
##rro	O
##bor	O
##ating	O
its	O
potential	O
role	O
as	O
a	O
cancer	O
bio	O
##mark	O
##er	O
,	O
a	O
##ber	O
##rations	O
in	O
serum	O
or	O
urine	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
were	O
also	O
associated	O
with	O
other	O
cancer	O
##s	O
such	O
as	O
lung	O
cancer	O
(	O
in	O
urine	O
)	O
,	O
pan	O
##cre	O
##atic	O
cancer	O
(	O
in	O
serum	O
)	O
,	O
es	O
##op	O
##hage	O
##al	O
cancer	O
(	O
in	O
serum	O
)	O
and	O
color	O
##ec	O
##tal	O
cancer	O
(	O
in	O
urine	O
)	O
.	O

The	O
increase	O
we	O
see	O
with	O
the	O
di	O
##abe	O
##tic	O
samples	O
suggests	O
accumulation	O
of	O
Ce	B
##r	I
and	O
therefore	O
a	O
##pop	O
##to	O
##tic	O
behavior	O
.	O

The	O
major	O
sub	O
##c	O
##lass	O
##es	O
identified	O
in	O
our	O
lip	O
##ido	O
##mic	O
##s	O
analysis	O
were	O
Ce	B
##r	I
,	O
mon	B
##og	I
##ly	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
(	O
Ce	O
##r	O
##G	O
##1	O
)	O
,	O
c	B
##era	I
##mi	I
##de	I
phosphate	I
(	O
Ce	O
##r	O
##P	O
)	O
,	O
SM	O
,	O
So	O
,	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
phosphate	I
(	O
So	O
##P	O
)	O
.	O

We	O
were	O
able	O
to	O
identify	O
a	O
total	O
of	O
35	O
##64	O
distinct	O
meta	O
##bol	O
##ites	O
including	O
several	O
ex	O
##ogen	O
##ous	O
compounds	O
such	O
as	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
and	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
.	O

In	O
v	O
##ivo	O
_	O
1	O
H	O
MR	O
studies	O
obtained	O
with	O
water	O
and	O
fat	O
suppression	O
(	O
see	O
)	O
have	O
documented	O
high	O
levels	O
of	O
total	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
(	O
t	O
##C	O
##ho	O
)	O
at	O
3	O
.	O
2	O
pp	O
##m	O
(	O
arising	O
due	O
to	O
trim	B
##eth	I
##yla	I
##mm	I
##onium	I
head	O
groups	O
of	O
total	O
pool	O
of	O
water	O
soluble	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
)	O
in	O
ma	O
##li	O
##gnant	O
breast	O
tissue	O
compared	O
to	O
ben	O
##ign	O
and	O
normal	O
breast	O
tissues	O
[	O
,	O
,	O
,	O
,	O
,	O
,	O
]	O
.	O

P	O
##las	O
##ma	O
glucose	S
was	O
measured	O
by	O
the	O
glucose	S
o	O
##xi	O
##das	O
##e	O
method	O
(	O
Beck	O
##man	O
Instruments	O
,	O
Fuller	O
##ton	O
,	O
CA	O
)	O
.	O

The	O
reduced	O
concentrations	O
of	O
la	B
##ct	I
##ate	I
and	O
t	B
-	I
ch	I
##olin	I
##e	I
meta	O
##bol	O
##ites	O
due	O
to	O
De	O
##gar	O
##eli	O
##x	O
could	O
in	O
principle	O
be	O
monitored	O
by	O
in	O
v	O
##ivo	O
_	O
1	O
H	O
MR	O
##S	O
,	O
which	O
suggests	O
that	O
it	O
would	O
be	O
possible	O
to	O
monitor	O
the	O
effects	O
of	O
physical	O
or	O
chemical	O
cast	O
##ration	O
in	O
patients	O
by	O
that	O
non	O
-	O
invasive	O
method	O
.	O

Daily	O
activity	O
data	O
was	O
not	O
recorded	O
,	O
however	O
all	O
subjects	O
underwent	O
identical	O
ascent	O
profiles	O
for	O
which	O
the	O
exercise	O
burden	O
each	O
day	O
was	O
low	O
in	O
both	O
intensity	O
and	O
duration	S
,	O
as	O
demonstrated	O
by	O
t	O
##rek	O
##king	O
distance	O
/	O
day	O
detailed	O
in	O
the	O
methods	O
.	O

The	O
mean	O
serum	O
concentration	O
of	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
for	O
the	O
six	O
quality	O
control	O
samples	O
was	O
15	O
.	O
8	O
pm	O
##ol	O
/	O

Thus	O
,	O
the	O
results	O
indicate	O
that	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
models	O
generated	O
from	O
the	O
L	B
##C	I
-	I
(	I
±	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
were	O
reliable	O
.	O

We	O
measured	O
the	O
absolute	O
concentrations	O
of	O
plasma	O
ne	B
##r	I
##von	I
##ic	I
acid	I
in	O
the	O
30	O
available	O
samples	O
[	O
MD	O
##D	O
(	O
n	O
=	O
6	O
)	O
,	O
B	O
##D	O
(	O
n	O
=	O
4	O
)	O
,	O
S	O
##Z	O
(	O
n	O
=	O
13	O
)	O
]	O
and	O
controls	O
(	O
n	O
=	O
7	O
)	O
of	O
the	O
51	O
subjects	O
of	O
co	O
##hor	O
##t	O
1	O
.	O

To	O
further	O
understand	O
how	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
is	O
altered	O
in	O
breast	O
cancer	O
sub	O
##type	O
##s	O
,	O
we	O
measured	O
plasma	O
concentrations	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
its	O
main	O
cat	O
##ab	O
##oli	O
##tes	O
,	O
including	O
k	B
##yn	I
##uren	I
##ine	I
using	O
U	O
##HP	O
##LC	O
-	O
MS	O
.	O

Si	B
Si	I
S	O
S	O

Furthermore	O
,	O
a	O
reliance	O
on	O
ni	B
##ac	I
##in	I
salvage	O
has	O
been	O
shown	O
for	O
other	O
path	O
##ogenic	O
organisms	O
,	O
such	O
as	O
Le	O
##ish	O
##mani	O
##a	O
infant	O
##um	O
and	O
multiple	O
species	O
of	O
path	O
##ogenic	O
yeast	O
,	O
making	O
it	O
a	O
common	O
evolutionary	O
adaptation	O
,	O
.	O

Information	O
on	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
role	O
in	O
corn	O
##ea	O
,	O
corn	O
##eal	O
cell	O
physiology	O
,	O
and	O
diseases	O
are	O
very	O
limited	O
which	O
highlights	O
the	O
importance	O
of	O
these	O
findings	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
plasma	O
T	B
##MA	I
##O	I
concentration	O
and	O
G	O
##DM	O
in	O
a	O
2	O
-	O
phase	O
study	O
.	O

PC	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
are	O
involved	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
death	O
.	O

Nan	O
##os	O
##pra	O
##y	O
E	O
##SI	O
SR	O
##M	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
were	O
acquired	O
from	O
plasma	O
spike	O
##d	O
with	O
D	O
)	O
50	O
am	O
##ol	O
ME	O
##L	O
on	O
column	O
(	O
11	O
.	O
65	O
f	B
##g	I
injected	O
,	O
11	O
.	O
65	O
p	B
##g	I
/	O
m	O
##L	O
,	O
corresponding	O
to	O
the	O
LL	O
##O	O
##Q	O
)	O
,	O
E	O
)	O
5	O
f	O
##mo	O
##l	O
ME	O
##L	O
on	O
column	O
(	O
1	O
.	O
17	O
p	B
##g	I
injected	O
,	O
116	O
##5	O
p	B
##g	I
/	O
m	O
##L	O
,	O
corresponding	O
to	O
the	O
U	O
##L	O
##O	O
##Q	O
)	O
and	O
F	O
)	O
no	O
anal	O
##yte	O
.	O

5	B
,	I
6	I
‐	I
Di	I
##hy	I
##dr	I
##our	I
##ac	I
##il	I
and	O
in	B
##os	I
##ine	I
were	O
the	O
two	O
meta	O
##bol	O
##ites	O
with	O
the	O
highest	O
disc	O
##rim	O
##inator	O
##y	O
capability	O
for	O
AC	O
,	O
and	O
2	B
′	I
‐	I
O	I
‐	I
met	I
##hyl	I
##gua	I
##nos	I
##ine	I
and	O
5	B
‐	I
met	I
##hyl	I
##uri	I
##dine	I
for	O
SC	O
##C	O
cases	O
.	O

Intermediate	O
##s	O
of	O
the	O
T	O
##CA	O
cycle	O
,	O
such	O
as	O
c	B
##it	I
##rate	I
,	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
,	O
and	O
su	B
##cci	I
##nate	I
were	O
altered	O
in	O
the	O
urine	O
from	O
MS	O
patients	O
.	O

Also	O
,	O
C	O
_	O
26	O
bi	O
##le	O
alcohol	O
##s	O
have	O
been	O
described	O
previously	O
in	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
fraction	O
from	O
human	O
urine	O
(	O
,	O
)	O
.	O

Port	O
##ions	O
of	O
800	O
MHz	O
_	O
1	O
H	O
s	O
##pect	O
##ra	O
of	O
the	O
same	O
pool	O
##ed	O
human	O
serum	O
highlighting	O
varied	O
levels	O
of	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
.	O

Met	O
##ab	O
##olic	O
pathways	O
en	O
##rich	O
##ment	O
analysis	O
highlights	O
beta	B
-	I
al	I
##ani	I
##ne	I
metabolism	O
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
,	O
as	O
well	O
as	O
pu	B
##rine	I
metabolism	O
to	O
be	O
most	O
affected	O
from	O
these	O
potential	O
bio	O
##mark	O
##ers	O
.	O

B	O
Mean	O
P	O
##K	O
curves	O
of	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
measured	O
in	O
plasma	O
and	O
P	O
##K	O
parameters	O
obtained	O
on	O
the	O
same	O
12	O
patients	O
.	O

This	O
investigation	O
was	O
a	O
sub	O
-	O
study	O
of	O
a	O
double	O
-	O
blind	O
,	O
random	O
##ized	O
,	O
single	O
-	O
centre	O
,	O
2	O
-	O
treatment	O
,	O
2	O
-	O
period	O
,	O
2	O
-	O
sequence	O
cross	O
-	O
over	O
e	B
##ug	I
##ly	I
##ca	I
##em	I
##ic	I
c	O
##lamp	O
study	O
(	O
Clinical	O
##T	O
##rial	O
##s	O
.	O
go	O
##v	O
I	O
##dent	O
##ifier	O
:	O
NC	O
##T	O
##01	O
##34	O
##9	O
##8	O
##55	O
)	O
.	O

Taking	O
all	O
these	O
data	O
into	O
consideration	O
,	O
we	O
propose	O
that	O
the	O
high	O
insulin	O
##emia	O
levels	O
induced	O
by	O
ex	O
##ogen	O
##ous	O
insulin	O
administration	O
in	O
our	O
T	O
##1	O
##D	O
group	O
could	O
be	O
the	O
cause	O
of	O
reduced	O
protein	O
breakdown	O
,	O
as	O
demonstrated	O
by	O
the	O
minor	O
alterations	O
observed	O
in	O
the	O
levels	O
of	O
le	B
##uc	I
##ine	I
and	O
2	O
-	O
K	O
##IC	O
following	O
exercise	O
.	O

(	O
b	O
)	O
Typical	O
_	O
1	O
H	O
N	O
##MR	O
LED	O
s	O
##pect	O
##ra	O
of	O
plasma	O
samples	O
from	O
F	B
##D	I
patients	O
and	O
controls	O
.	O

Si	O
##ly	O
##lation	O
was	O
subsequently	O
done	O
using	O
30	O
µ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##lt	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
with	O
1	B
%	I
trim	I
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
(	O
MS	O
##TF	O
##A	O
+	O
1	O
%	O
T	O
##MC	O
##S	O
,	O
Sigma	O
)	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O

A	O
q	O
##uad	O
##ratic	O
curve	O
with	O
1	O
/	O
x	O
as	O
weighing	O
factor	O
was	O
used	O
to	O
q	O
##uant	O
##ify	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
that	O
resulted	O
in	O
a	O
better	O
fit	O
than	O
a	O
more	O
simple	O
linear	O
relationship	O
.	O

This	O
state	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
leads	O
to	O
the	O
induction	O
and	O
increase	O
of	O
inflammatory	O
media	O
##tors	O
,	O
such	O
as	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
meta	O
##bol	O
##ites	O
.	O

For	O
this	O
purpose	O
,	O
me	O
##lan	O
##oma	O
cell	O
lines	O
(	O
A	O
##37	O
##5	O
and	O
A	B
##37	I
##5	I
##R	I
)	O
were	O
treated	O
with	O
IF	O
##N	O
##γ	O
(	O
50	O
ng	O
/	O
m	O
##l	O
)	O
and	O
T	O
##NF	O
-	O
α	O
(	O
10	O
ng	O
/	O
m	O
##l	O
)	O
.	O

_	O
1	O
All	O
meta	O
##bol	O
##ites	O
had	O
detect	O
##able	O
values	O
in	O
>	O
80	O
%	O
of	O
study	O
population	O
with	O
the	O
exception	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
3	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
1	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
beta	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##oy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
N	B
##2	I
,	I
N	I
##5	I
-	I
di	I
##ace	I
##ty	I
##lor	I
##ni	I
##thin	I
##e	I
,	O
3	B
-	I
met	I
##ho	I
##xy	I
##ty	I
##ram	I
##ine	I
su	I
##lf	I
##ate	I
,	O
g	B
##uan	I
##id	I
##ino	I
##su	I
##cci	I
##nate	I
,	O
4	B
-	I
and	I
##ros	I
##ten	I
-	I
3	I
##bet	I
##a	I
,	I
17	I
##bet	I
##a	I
-	I
di	I
##ol	I
mon	I
##os	I
##ulf	I
##ate	I
,	O
2	B
-	I
palm	I
##ito	I
##leo	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
s	B
##te	I
##aro	I
##yl	I
-	I
a	I
##rac	I
##hi	I
##don	I
##oy	I
##l	I
-	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
1	B
-	I
l	I
##ino	I
##len	I
##oy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	I
18	I
:	I
3	I
##n	I
##3	I
)	I
,	O
palm	B
##ito	I
##yl	I
-	I
o	I
##leo	I
##yl	I
-	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
ma	B
##lon	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
2	B
-	I
my	I
##risto	I
##yl	I
##gly	I
##cer	I
##ol	I
(	I
2	I
-	I
mon	I
##omy	I
##rist	I
##in	I
)	I
,	O
palm	B
##ito	I
##yl	I
-	I
a	I
##rac	I
##hi	I
##don	I
##oy	I
##l	I
-	I
g	I

Ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
form	B
##ic	I
acid	I
,	O
and	O
HP	O
##LC	O
-	O
grade	O
water	O
and	O
standards	O
(	O
≥	O
98	O
%	O
chemical	O
purity	O
)	O
were	O
purchased	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
.	O

In	O
the	O
HC	O
##T	O
##11	O
##6	O
cells	O
,	O
the	O
ace	O
##ty	O
##l	O
group	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
was	O
97	O
%	O
_	O
13	O
C	O
,	O
indicating	O
that	O
the	O
contribution	O
of	O
medium	O
-	O
derived	O
fatty	O
acids	O
or	O
other	O
un	O
##la	O
##bel	O
##ed	O
material	O
to	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
was	O
very	O
small	O
.	O

Our	O
results	O
revealed	O
that	O
metabolic	O
markers	O
especially	O
lip	O
##ids	O
and	O
ace	B
##tate	I
derived	O
from	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
has	O
high	O
sensitivity	O
and	O
specific	O
##ity	O
to	O
distinguish	O
L	O
##N	O
among	O
SL	O
##E	O
patients	O
and	O
has	O
the	O
potential	O
to	O
be	O
a	O
useful	O
ad	O
##junct	O
##ive	O
tool	O
in	O
diagnosis	O
and	O
clinical	O
management	O
of	O
L	O
##N	O
.	O

MC	O
##F	O
-	O
7	O
cells	O
were	O
treated	O
for	O
48	O
h	O
with	O
the	O
is	B
##of	I
##lav	I
##ones	I
,	O
G	O
##N	O
,	O
D	O
##Z	O
,	O
BA	O
,	O
and	O
F	O
##N	O
,	O
followed	O
by	O
24	O
h	O
treatment	O
with	O
E	O
_	O
2	O
(	O
1	O
μ	O
##M	O
)	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
ST	O
##AT	O
##A	O
10	O
.	O
0	O
software	O
(	O
St	O
##ata	O
##C	O
##or	O
##p	O
LP	S
,	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
.	O

E	O
##t	O
_	O
2	O
O	O
:	O
CH	O
_	O
2	O
C	O
##l	O
_	O
2	O
(	B
0	B
.	I
5	I
:	I
0	I
.	I
5	I
:	I
9	I
,	O
v	O
/	O
v	O
)	O
to	O
afford	O
6	O
(	O
13	O
mg	O
)	O
after	O
washing	O
with	O
E	O
##t	O
_	O
2	O
O	O
.	O

Dash	O
##ed	O
boxes	O
indicate	O
pools	O
of	O
meta	O
##bol	O
##ites	O
:	O
t	O
##C	O
##r	O
,	O
total	O
c	B
##rea	I
##tine	I
##s	I
(	I
c	I
##rea	I
##tine	I
+	I
p	I
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
)	I
;	O
t	O
##C	O
##ho	O
,	O
total	O
ch	B
##olin	I
##es	I
(	I
ch	I
##olin	I
##e	I
+	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
+	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	I
;	O
t	O
##G	O
##lut	O
,	O
g	B
##lut	I
##ama	I
##te	I
+	O
g	B
##lut	I
##amine	I
pool	O
;	O
P	O
##t	O
##d	O
##C	O
##ho	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

When	O
total	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
were	O
included	O
in	O
the	O
model	O
with	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
,	O
less	O
than	O
14	O
%	O
of	O
women	O
had	O
a	O
breast	O
cancer	O
rate	O
estimate	O
that	O
changed	O
by	O
more	O
than	O
50	O
cancer	O
##s	O
per	O
10	O
_	O
5	O
person	O
-	O
years	O
.	O

Finally	O
,	O
18	O
most	O
significantly	O
altered	O
plasma	O
meta	O
##bol	O
##ites	O
in	O
E	O
##SC	O
##C	O
patients	O
,	O
relative	O
to	O
healthy	O
controls	O
,	O
were	O
tentatively	O
identified	O
as	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
##s	O
)	O
,	O
fatty	O
acids	O
,	O
l	B
-	I
car	I
##ni	I
##tine	I
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
organic	O
acids	O
,	O
and	O
a	O
s	O
##tero	O
##l	O
meta	O
##bol	O
##ite	O
.	O

His	B
##tamine	I
can	O
induce	O
cell	O
proliferation	O
and	O
differentiation	O
,	O
and	O
regulate	O
##s	O
both	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
function	O
and	O
the	O
immune	O
response	O
.	O

G	B
##lut	I
##amine	I
is	O
one	O
of	O
the	O
most	O
highly	O
concentrated	O
meta	O
##bol	O
##ites	O
in	O
human	O
blood	O
;	O
compared	O
to	O
all	O
the	O
free	O
amino	O
acids	O
,	O
g	B
##lut	I
##amine	I
is	O
typically	O
20	O
%	O
higher	O
in	O
concentration	O
.	O
_	O
,	O
G	B
##lut	I
##amine	I
is	O
a	O
precursor	O
as	O
well	O
as	O
a	O
metabolic	O
end	O
-	O
product	O
and	O
thus	O
central	O
to	O
many	O
important	O
metabolic	O
pathways	O
.	O

The	O
dried	O
samples	O
were	O
dissolved	O
in	O
600	O
μ	O
##L	O
99	O
.	O
8	O
%	O
D	O
_	O
2	O
O	O
phosphate	S
buffer	O
(	O
0	O
.	O
2	O
M	O
,	O
pH	O
at	O
7	O
.	O
0	O
)	O
containing	O
0	O
.	O
05	O
%	O
sodium	O
salt	O
of	O
3	B
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
(	O
T	O
##SP	O
,	O
w	O
/	O
v	O
)	O
,	O
v	O
##ortex	O
##ed	O
,	O
cent	O
##ri	O
##fu	O
##ged	O
and	O
de	O
##can	O
##ted	O
to	O
5	O
mm	O
N	O
##MR	O
tubes	O
.	O

E	B
##thy	I
##l	I
ace	I
##tate	I
(	O
E	O
##t	O
##OA	O
##c	O
)	O
is	O
a	O
widely	O
used	O
solvent	O
in	O
industry	O
owing	O
to	O
its	O
afford	O
##ability	O
and	O
low	O
toxicity	O
.	O

The	O
above	O
findings	O
led	O
us	O
to	O
explore	O
the	O
potential	O
of	O
sa	B
##rc	I
##os	I
##ine	I
as	O
a	O
candidate	O
for	O
future	O
development	O
in	O
bio	O
##mark	O
##er	O
panels	O
for	O
early	O
disease	O
detection	O
and	O
a	O
##gg	O
##ress	O
##ivity	O
prediction	O
.	O

It	O
was	O
demonstrated	O
in	O
animals	O
that	O
the	O
content	O
of	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
in	O
kidney	O
##s	O
is	O
the	O
highest	O
among	O
all	O
tissues	O
(	O
Lou	O
et	O
al	O
.	O
)	O
.	O

In	O
milk	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
was	O
the	O
main	O
meta	O
##bol	O
##ite	O
in	O
early	O
la	O
##ct	O
##ation	O
(	O
49	O
##2	O
µ	O
##mo	O
##l	O
/	O
L	O
)	O
,	O
which	O
is	O
a	O
similar	O
concentration	O
to	O
that	O
found	O
in	O
human	O
milk	O
,	O
however	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
concentration	O
decreased	O
ex	O
##po	O
##nent	O
##ially	O
through	O
la	O
##ct	O
##ation	O
to	O
43	O
µ	O
##mo	O
##l	O
/	O
L	O
in	O
late	O
la	O
##ct	O
##ation	O
.	O

Interest	O
##ingly	O
,	O
BC	O
##AA	O
##s	O
can	O
be	O
converted	O
into	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
and	O
other	O
organic	O
molecules	O
that	O
enter	O
the	O
T	O
##CA	O
cycle	O
.	O

In	O
addition	O
,	O
as	O
two	O
important	O
precursor	O
##s	O
of	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##ama	I
##te	I
were	O
significantly	O
decreased	O
in	O
AS	O
plasma	O
(	B
g	B
##lut	I
##ama	I
##te	I
was	O
reduced	O
in	O
urine	O
,	O
too	O
)	O
,	O
which	O
may	O
also	O
be	O
the	O
reason	O
for	O
the	O
decline	O
in	O
the	O
glucose	S
concentration	O
.	O

However	O
,	O
these	O
two	O
precursor	O
amino	O
acids	O
were	O
not	O
altered	O
by	O
th	B
##ia	I
##zi	I
##de	I
therapy	O
.	O

In	O
this	O
study	O
,	O
a	O
major	O
alter	O
##ation	O
observed	O
in	O
patients	O
progressed	O
to	O
D	O
##M	O
was	O
amino	O
acid	O
metabolism	O
with	O
a	O
decreased	O
level	O
of	O
L	B
-	I
l	I
##ys	I
##ine	I
,	O
L	B
-	I
th	I
##re	I
##oni	I
##ne	I
,	O
Beta	B
##ine	I
,	O
Is	B
##o	I
-	I
v	I
##ale	I
##ral	I
##de	I
##hy	I
##de	I
,	O
2	B
-	I
k	I
##eto	I
##but	I
##yric	I
acid	I
,	O
and	O
2	B
-	I
P	I
##yr	I
##rol	I
##oy	I
##l	I
##gly	I
##cine	I
.	O

Only	O
sa	B
##rc	I
##os	I
##ine	I
showed	O
significantly	O
lower	O
concentrations	O
in	O
serum	O
compared	O
to	O
plasma	O
samples	O
.	O

R	O
##OC	O
curves	O
for	O
combination	O
of	O
4	B
-	I
h	I
##ydro	I
##xy	I
##pent	I
##eno	I
##ic	I
acid	I
,	O
a	B
##rab	I
##ino	I
##se	I
,	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
-	I
3	I
-	I
su	I
##lf	I
##ate	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
se	B
##rine	I
,	O
and	O
x	B
##ant	I
##hine	I
.	O

Thus	O
,	O
both	O
is	B
##ob	I
##ut	I
##yl	I
-	I
and	O
is	B
##op	I
##rop	I
##yla	I
##mine	I
were	O
included	O
in	O
our	O
m	O
##od	O
##ifier	O
screen	O
,	O
along	O
with	O
is	B
##ope	I
##nt	I
##yla	I
##mine	I
to	O
determine	O
if	O
the	O
size	O
of	O
the	O
al	O
##ky	O
##l	O
side	O
-	O
chain	O
contributes	O
to	O
ch	O
##roma	O
##to	O
##graphic	O
performance	O
in	O
SF	O
##C	O
.	O

These	O
include	O
amino	O
acids	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
fatty	O
acids	O
,	O
amino	S
sugar	O
derivatives	O
,	O
organic	O
acids	O
etc	O
.	O

The	O
relationship	O
between	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
and	O
type	O
2	O
diabetes	O
,	O
especially	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
has	O
been	O
suspected	O
for	O
a	O
long	O
time	O
[	O
–	O
]	O
and	O
these	O
observations	O
were	O
recommended	O
to	O
be	O
further	O
investigated	O
.	O

The	O
meta	O
##bol	O
##ome	O
revealed	O
marked	O
elevation	O
of	O
meta	O
##bol	O
##ites	O
sensitive	O
to	O
as	O
##phy	O
##xia	O
,	O
including	O
su	B
##cci	I
##nic	I
acid	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
ma	B
##late	I
,	O
and	O
but	B
##ano	I
##ic	I
acid	I
.	O

In	O
fact	O
,	O
despite	O
the	O
different	O
expression	O
of	O
NHL	O
seen	O
in	O
the	O
subject	O
population	O
,	O
the	O
first	O
step	O
,	O
reaction	O
of	O
est	B
##rogen	I
q	I
##uin	I
##one	I
with	O
DNA	O
,	O
in	O
the	O
initiation	O
of	O
NHL	O
is	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
to	O
be	O
the	O
same	O
.	O

Form	B
##ic	I
acid	I
was	O
obtained	O
from	O
F	O
##luk	O
##a	O
(	O
B	O
##uch	O
##s	O
,	O
Switzerland	O
)	O
.	O

In	O
addition	O
,	O
the	O
inverse	O
relationship	O
between	O
3	B
-	I
h	I
##ydro	I
##vale	I
##rate	I
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
suggest	O
that	O
an	O
insulin	O
signalling	O
imp	O
##air	O
##ment	O
could	O
participate	O
in	O
the	O
reduction	O
of	O
le	B
##uc	I
##ine	I
cat	O
##ab	O
##olis	O
##m	O
.	O

In	O
particular	O
,	O
we	O
found	O
a	O
significant	O
decrease	O
level	O
in	O
the	O
MS	O
group	O
of	O
saturated	O
,	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
a	O
##cy	O
##l	O
groups	O
of	O
ω	O
–	O
9	O
and	O
/	O
or	O
ω	O
–	O
7	O
,	O
ω	O
–	O
6	O
,	O
ω	O
–	O
3	O
,	O
and	O
FA	S
,	O
T	B
##G	I
,	O
1	B
,	I
3	I
-	I
D	I
##G	I
,	O
1	O
-	O
MG	O
,	O
g	B
##ly	I
##cer	I
##ol	I
group	O
in	O
1	O
-	O
MG	O
,	O
and	O
un	O
##ass	O
##ign	O
##ed	O
component	O
signal	O
at	O
3	O
.	O
33	O
pp	O
##m	O
.	O

and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
were	O
not	O
made	O
for	O
the	O
East	O
Asian	O
samples	O
because	O
of	O
a	O
low	O
prevalence	O
of	O
anal	O
##ges	O
##ic	O
use	O
in	O
those	O
population	O
samples	O
.	O

Lower	O
u	O
##rina	O
##ry	O
ch	B
##olin	I
##e	I
levels	O
in	O
CR	O
##C	O
are	O
most	O
likely	O
related	O
to	O
increased	O
demand	O
for	O
ch	B
##olin	I
##e	I
in	O
tumors	O
.	O

(	O
b	O
)	O
Co	O
##mp	O
##aris	O
##on	O
of	O
median	O
s	O
##pect	O
##ra	O
of	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
(	O
7	O
.	O
21	O
pp	O
##m	O
)	O
.	O

G	B
##lut	I
##amine	I
metabolism	O
fuels	O
the	O
T	O
##CA	O
cycle	O
and	O
fatty	O
acid	O
synthesis	O
by	O
act	O
##ivating	O
m	O
##TO	O
##R	O
signaling	O
to	O
promote	O
protein	O
synthesis	O
_	O
,	O
.	O

Stock	O
solutions	O
were	O
prepared	O
in	O
D	B
##MS	I
##O	I
at	O
a	O
nominal	O
concentration	O
of	O
1	O
mg	O
/	O
m	O
##L	O
a	B
##bir	I
##ater	I
##one	I
and	O
D	B
_	I
4	I
-	I
a	I
##bir	I
##ater	I
##one	I
.	O

To	O
investigate	O
whether	O
9	O
-	O
H	O
##SA	O
is	O
a	O
meta	O
##bol	O
##ite	O
of	O
o	B
##le	I
##ic	I
acid	I
in	O
color	O
##ec	O
##tal	O
cancer	O
,	O
we	O
in	O
##cu	O
##bate	O
##d	O
H	O
##T	O
-	O
29	O
or	O
HC	O
##T	O
-	O
116	O
color	O
##ec	O
##tal	O
cancer	O
cells	O
with	O
increasing	O
amounts	O
of	O
[	O
_	O
2	O
H	O
]	O
o	O
##le	O
##ic	O
acid	O
,	O
and	O
analyzed	O
the	O
possible	O
appearance	O
of	O
9	O
-	O
[	O
_	O
2	O
H	O
]	O
H	O
##SA	O
by	O
G	O
##C	O
/	O
MS	O
and	O
L	O
##C	O
/	O
MS	O
at	O
different	O
times	O
.	O

Cheng	O
et	O
al	O
.	O
also	O
reported	O
diminished	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
(	B
5	B
-	I
h	I
##ydro	I
##xy	I
-	I
T	I
##rp	I
,	O
in	B
##do	I
##lea	I
##ce	I
##tate	I
,	O
in	B
##do	I
##le	I
and	O
others	O
)	O
in	O
CR	O
##C	O
patients	O
compared	O
to	O
healthy	O
individuals	O
.	O

Pi	B
##ni	I
##to	I
##l	I
seems	O
,	O
however	O
,	O
to	O
be	O
the	O
only	O
specific	O
candidate	O
F	O
##IB	O
for	O
so	O
##y	O
drink	O
intake	O
as	O
it	O
was	O
neither	O
present	O
in	O
serum	O
at	O
base	O
##line	O
,	O
all	O
other	O
compounds	O
being	O
also	O
at	O
detect	O
##able	O
levels	O
at	O
base	O
##line	O
,	O
nor	O
after	O
the	O
intake	O
of	O
milk	O
and	O
cheese	O
.	O

For	O
whole	O
blood	O
stability	O
study	O
,	O
plasma	O
was	O
obtained	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
(	O
1970	O
##g	O
(	O
45	O
##50	O
rpm	O
)	O
,	O
10	O
min	O
,	O
+	O
4	O
##°	O
##C	O
,	O
He	O
##tti	O
##ch	O
model	O
Mi	O
##k	O
##ro	O
##20	O
##0	O
##R	O
cent	O
##ri	O
##fu	O
##ge	O
,	O
Tu	O
##tt	O
##li	O
##gen	O
,	O
Germany	O
)	O
of	O
c	O
##it	O
##rated	O
whole	O
blood	O
in	O
safe	O
-	O
lock	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
(	O
PP	O
)	O
e	O
##ppe	O
##ndo	O
##rf	O
tubes	O
.	O

The	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
spectrum	O
of	O
PC	B
(	I
37	I
:	I
3	I
)	I
is	O
shown	O
in	O
as	O
an	O
example	O
.	O

As	O
##aka	O
##wa	O
et	O
al	O
.	O
showed	O
that	O
the	O
use	O
of	O
am	B
##mon	I
##ium	I
hydrogen	I
carbon	I
##ate	I
in	O
the	O
mobile	O
phase	O
prevented	O
peak	O
tail	O
##ing	O
and	O
was	O
compatible	O
with	O
L	O
##C	O
–	O
MS	O
analysis	O
.	O

As	O
c	B
##rea	I
##tine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
are	O
well	O
-	O
studied	O
meta	O
##bol	O
##ites	O
,	O
the	O
use	O
of	O
more	O
targeted	O
methods	O
to	O
measure	O
them	O
as	O
well	O
as	O
their	O
ratio	O
in	O
future	O
studies	O
may	O
also	O
provide	O
additional	O
valid	O
##ation	O
for	O
our	O
results	O
.	O

We	O
know	O
from	O
the	O
micro	O
##bio	O
##me	O
literature	O
and	O
from	O
studies	O
in	O
rode	O
##nt	O
models	O
that	O
colonization	O
of	O
the	O
infant	O
gut	O
largely	O
begins	O
at	O
birth	O
,	O
and	O
that	O
over	O
a	O
period	O
of	O
time	O
as	O
the	O
s	O
##ym	O
##biotic	O
gut	O
bacteria	O
evolve	O
,	O
there	O
is	O
an	O
increase	O
in	O
molecules	O
such	O
as	O
hip	B
##pura	I
##te	I
,	O
PA	B
##G	I
(	O
or	O
the	O
equivalent	O
g	B
##ly	I
##cine	I
con	O
##ju	O
##gate	O
in	O
rode	O
##nts	O
)	O
,	O
in	O
##do	O
##les	O
,	O
and	O
met	B
##hyl	I
##amine	I
##s	I
.	O

In	O
another	O
report	O
involving	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
measurements	O
of	O
D	O
##H	O
##EA	O
,	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
and	O
test	B
##osterone	I
by	O
Ku	O
##sh	O
##nir	O
et	O
al	O
.	O
,	O
median	O
concentrations	O
and	O
reference	O
intervals	O
showed	O
good	O
agreement	O
to	O
the	O
results	O
of	O
the	O
present	O
study	O
for	O
both	O
D	O
##H	O
##EA	O
and	O
test	B
##osterone	I
in	O
both	O
males	O
and	O
females	O
,	O
but	O
up	O
to	O
50	O
%	O
lower	O
values	O
for	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
.	O

The	O
robust	O
production	O
and	O
export	O
of	O
la	B
##ct	I
##ate	I
by	O
many	O
tumors	O
is	O
associated	O
with	O
the	O
acid	O
##ification	O
of	O
the	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
,	O
which	O
disrupt	O
##s	O
the	O
function	O
of	O
tumor	O
associated	O
s	O
##trom	O
##al	O
cells	O
while	O
enhancing	O
the	O
aggressive	O
##ness	O
of	O
neo	O
##p	O
##lastic	O
cells	O
.	O

Obviously	O
,	O
relative	O
q	O
##uant	O
##itation	O
of	O
C	B
##18	I
:	I
1	I
C	O
=	O
C	O
location	O
is	O
##omer	O
##s	O
for	O
a	O
wide	O
variety	O
of	O
lip	O
##id	O
species	O
adds	O
important	O
capability	O
for	O
study	O
of	O
path	O
##ological	O
states	O
of	O
tissues	O
.	O

On	O
the	O
other	O
hand	O
,	O
format	B
##e	I
may	O
be	O
formed	O
by	O
in	O
##test	O
##inal	O
bacteria	O
,	O
such	O
as	O
enter	O
##ob	O
##act	O
##eria	O
.	O

D	O
##HT	O
is	O
an	O
intermediate	O
decomposition	O
product	O
of	O
thy	B
##mine	I
.	O

This	O
is	O
also	O
consistent	O
with	O
the	O
notion	O
that	O
most	O
of	O
the	O
studies	O
demonstrating	O
the	O
t	O
##ria	O
##cy	O
##l	O
##gly	O
##cer	O
##ol	O
-	O
lowering	O
effect	O
of	O
EPA	O
+	O
D	O
##HA	O
in	O
the	O
patients	O
with	O
T	O
##2	O
##D	O
were	O
performed	O
before	O
the	O
beginning	O
of	O
the	O
met	B
##form	I
##in	I
era	O
as	O
well	O
as	O
the	O
use	O
of	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
therapy	O
of	O
these	O
patients	O
.	O

The	O
kidney	O
is	O
the	O
most	O
important	O
organ	O
for	O
whole	O
body	O
metabolism	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
as	O
both	O
the	O
synthetic	O
and	O
de	O
##grad	O
##ative	O
enzymes	O
,	O
L	B
-	I
my	I
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
-	I
1	I
-	I
phosphate	I
s	O
##ynth	O
##eta	O
##se	O
and	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
oxygen	O
##ase	O
(	O
MI	O
##OX	O
)	O
,	O
are	O
highly	O
expressed	O
in	O
the	O
re	O
##nal	O
par	O
##en	O
##chy	O
##ma	O
.	O

The	O
heated	O
cap	O
##illa	O
##ry	O
was	O
maintained	O
at	O
200	O
°C	O
,	O
and	O
the	O
E	O
##SI	O
voltage	O
was	O
held	O
at	O
2	O
.	O
2	O
k	B
##V	I
.	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
were	O
searched	O
against	O
the	O
Un	O
##i	O
##P	O
##rot	O
human	O
database	O
using	O
the	O
X	O
!	O
Tan	O
##de	O
##m	O
algorithm	O
to	O
identify	O
the	O
enzyme	O
using	O
the	O
following	O
parameters	O
:	O
no	O
enzyme	O
rules	O
,	O
car	O
##box	O
##ami	O
##dom	O
##eth	O
##yla	O
##tion	O
of	O
c	B
##ys	I
##tein	I
##e	I
(	O
57	O
.	O
02	O
Da	O
)	O
as	O
a	O
fixed	O
modification	O
,	O
and	O
mon	O
##oe	O
##thy	O
##l	O
-	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
(	O
107	O
.	O
99	O
##8	O
Da	O
)	O
and	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
(	O
79	O
.	O
96	O
##6	O
)	O
on	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
residues	O
as	O
a	O
variable	O
modification	O
.	O

While	O
C	O
##YP	O
##24	O
##A	O
##1	O
activity	O
dominate	O
##s	O
the	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
/	O
25	O
(	O
OH	O
)	O
D	O
cat	O
##ab	O
##olis	O
##m	O
in	O
the	O
healthy	O
kidney	O
,	O
C	O
##YP	O
##3	O
##A	O
##4	O
dominate	O
##s	O
in	O
the	O
liver	O
and	O
small	O
in	O
##test	O
##ine	O
,	O
because	O
of	O
the	O
higher	O
level	O
of	O
basal	O
and	O
induced	O
enzyme	O
expression	O
.	O

There	O
were	O
no	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
the	O
two	O
groups	O
of	O
patients	O
,	O
except	O
for	O
total	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
,	O
which	O
were	O
slightly	O
higher	O
in	O
the	O
mon	O
##oi	O
##n	O
##fected	O
group	O
(	O
p	O
=	O
0	O
.	O
04	O
##21	O
)	O
.	O

Data	O
represent	O
average	O
±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SE	O
##M	O
)	O
from	O
3	O
independent	O
experiments	O
normal	O
##ized	O
β	B
-	I
ACT	I
##IN	I
,	O
K	O
##IF	O
and	O
T	O
##B	O
##P	O
.	O

Pre	O
##c	O
##lini	O
##cal	O
and	O
in	O
v	O
##it	O
##ro	O
data	O
support	O
the	O
possibility	O
that	O
hip	O
##po	O
##cam	O
##pal	O
structure	O
may	O
be	O
impacted	O
by	O
ne	O
##uro	O
##active	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
this	O
maneuver	O
is	O
far	O
less	O
invasive	O
and	O
easy	O
to	O
perform	O
than	O
a	O
classical	O
s	B
##pi	I
##rome	I
##try	I
,	O
whereby	O
the	O
forced	O
ex	O
##pi	O
##rator	O
##y	O
volume	O
in	O
one	O
second	O
(	O
F	O
##E	O
##V	O
_	O
1	O
)	O
can	O
typically	O
be	O
4	O
L	O
in	O
adults	O
.	O

The	O
ratio	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
to	O
corresponding	O
LP	O
##C	O
has	O
been	O
suggested	O
to	O
be	O
a	O
potential	O
parameter	O
for	O
est	O
##imating	O
inflammatory	O
activity	O
and	O
monitoring	O
clinical	O
the	O
##rap	O
##ies	O
,	O
also	O
in	O
RA	O
-	O
patients	O
.	O

Finally	O
,	O
we	O
additionally	O
adjusted	O
for	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
(	O
model	O
3	O
)	O
as	O
a	O
marker	O
of	O
meat	O
intake	O
(	O
,	O
)	O
and	O
muscle	O
turnover	O
,	O
because	O
B	O
##MI	O
co	O
##rrel	O
##ates	O
with	O
muscle	O
mass	O
as	O
well	O
as	O
fat	O
mass	O
.	O

The	O
MS	O
was	O
ca	O
##li	O
##bra	O
##ted	O
using	O
sodium	O
format	O
,	O
and	O
le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I
was	O
used	O
as	O
lock	O
mass	O
.	O

Five	O
product	O
ions	O
for	O
met	B
##form	I
##in	I
were	O
identified	O
and	O
used	O
in	O
the	O
analysis	O
,	O
whereas	O
four	O
product	O
ions	O
were	O
monitored	O
for	O
the	O
met	O
##form	O
##in	O
–	O
MG	O
reaction	O
product	O
.	O

However	O
,	O
numerous	O
studies	O
have	O
demonstrated	O
enhanced	O
vascular	O
NO	O
responses	O
following	O
a	B
##rg	I
##ini	I
##ne	I
administration	O
(	O
,	O
,	O
)	O
,	O
conditions	O
that	O
corresponding	O
##ly	O
will	O
increase	O
GA	O
##BR	O
.	O

Effect	O
of	O
polymer	O
##ic	O
dip	O
##eptide	O
surf	O
##act	O
##ant	O
head	O
groups	O
on	O
the	O
simultaneous	O
en	O
##anti	O
##ose	O
##par	O
##ation	O
of	O
1	B
,	I
1	I
’	I
=	I
O	I
-	I
D	I
##V	I
##X	I
and	O
2	B
,	I
2	I
’	I
=	I
V	I
##X	I
.	O

The	O
l	B
##ino	I
##le	I
##ic	I
acid	I
meta	O
##bol	O
##ites	O
9	B
-	I
H	I
##OD	I
##E	I
and	O
12	B
,	I
13	I
-	I
Di	I
##H	I
##OM	I
##E	I
,	O
which	O
were	O
present	O
in	O
relatively	O
high	O
abundance	O
in	O
T	O
##GR	O
##L	O
and	O
had	O
a	O
strong	O
negative	O
influence	O
on	O
the	O
modeled	O
VC	O
##AM	O
-	O
1	O
expression	O
,	O
exhibited	O
a	O
dose	O
-	O
dependent	O
effect	O
in	O
reducing	O
H	O
##A	O
##EC	O
VC	O
##AM	O
-	O
1	O
expression	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
was	O
1	O
.	O
5	O
k	B
##V	I
for	O
both	O
the	O
p	O
##os	O
and	O
ne	O
##g	O
ion	O
modes	O
,	O
and	O
the	O
cone	O
voltage	O
was	O
10	O
V	O
.	O

PC	B
a	I
##e	I
C	I
##38	I
:	I
6	I
;	O
55	O
.	O

Brain	B
-	I
glucose	I
levels	O
were	O
lower	O
in	O
c	O
##ere	O
##bell	O
##um	O
than	O
other	O
regions	O
whereas	O
elevations	O
in	O
so	B
##rb	I
##ito	I
##l	I
and	O
f	B
##ru	I
##ct	I
##ose	I
were	O
similar	O
in	O
all	O
regions	O
studied	O
.	O

Ex	O
##er	O
##cise	O
training	O
may	O
induce	O
rapid	O
mob	O
##ilization	O
of	O
BA	O
##T	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
hence	O
reducing	O
BA	O
##T	O
mass	O
.	O

Rap	O
##pa	O
##port	O
et	O
al	O
.	O
added	O
a	O
saturated	O
solution	O
of	O
am	B
##mon	I
##ium	I
su	I
##lf	I
##ate	I
to	O
the	O
plasma	O
until	O
the	O
final	O
concentration	O
of	O
am	B
##mon	I
##ium	I
su	I
##lf	I
##ate	I
at	O
2	O
.	O
5	O
M	O
(	O
63	O
%	O
of	O
sat	O
##uration	O
)	O
.	O

Overall	O
,	O
similar	O
numbers	O
of	O
meta	O
##bol	O
##ites	O
were	O
found	O
when	O
negative	O
mode	O
was	O
used	O
in	O
conjunction	O
with	O
H	O
##IL	O
##IC	O
to	O
compare	O
met	B
##han	I
##ol	I
(	O
46	O
##7	O
features	O
)	O
and	O
met	B
##han	I
##ol	I
-	I
ethanol	I
(	O
46	O
##1	O
features	O
)	O
extraction	O
methods	O
.	O

A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
bio	O
##genic	O
am	O
##ines	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
were	O
determined	O
by	O
L	O
##C	O
-	O
MS	O
in	O
fast	O
##ing	O
plasma	O
samples	O
using	O
the	O
A	O
##bs	O
##ol	O
##ute	O
ID	O
##Q	O
[UNK]	B
p	O
##18	O
##0	O
kit	O
developed	O
by	O
B	O
##io	O
##crates	O
AG	O
(	O
Inn	O
##s	O
##bruck	O
,	O
Austria	O
)	O
.	O

In	O
set	O
2	O
,	O
1	O
m	O
##l	O
of	O
plasma	O
from	O
6	O
different	O
donors	O
was	O
spike	O
##d	O
with	O
200	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
(	O
to	O
si	O
##mu	O
##late	O
the	O
addition	O
of	O
100	O
μ	O
##l	O
of	O
working	O
standard	O
and	O
100	O
μ	O
##l	O
of	O
internal	O
standard	O
stock	O
solution	O
into	O
plasma	O
in	O
set	O
3	O
)	O
.	O

Mobile	O
phases	O
used	O
were	O
:	O
A	O
)	O
50	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
5	O
##m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
pH	O
3	O
.	O
2	O
)	O
,	O
and	O
B	O
)	O
90	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
5	O
##m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
pH	O
3	O
.	O
2	O
)	O
.	O

Both	O
columns	O
contain	O
polar	O
functionality	O
that	O
likely	O
increased	O
retention	O
of	O
the	O
polar	O
an	O
##ion	O
##ic	O
phosphate	S
dies	O
##ters	O
.	O

This	O
finding	O
could	O
indicate	O
an	O
up	O
##re	O
##gu	O
##lation	O
of	O
the	O
p	B
##oly	I
##amine	I
bio	O
##sy	O
##nt	O
##hetic	O
pathway	O
,	O
more	O
specifically	O
,	O
the	O
production	O
of	O
put	B
##res	I
##cine	I
from	O
or	B
##ni	I
##thin	I
##e	I
by	O
the	O
bio	O
##sy	O
##nt	O
##hetic	O
enzyme	O
O	O
##DC	O
.	O

To	O
determine	O
which	O
meta	O
##bol	O
##ites	O
caused	O
segregation	O
,	O
a	O
VIP	O
value	O
≥	O
1	O
.	O
5	O
,	O
a	O
P	O
value	O
<	O
0	O
.	O
01	O
,	O
and	O
a	O
false	O
discovery	O
rate	O
(	O
F	O
##DR	O
)	O
<	O
0	O
.	O
05	O
were	O
used	O
;	O
based	O
on	O
these	O
criteria	O
,	O
5	O
identical	O
meta	O
##bol	O
##ites	O
were	O
filtered	O
,	O
including	O
c	B
##rea	I
##tin	I
##ine	I
,	O
D	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
ch	B
##olin	I
##e	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
and	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
.	O

Mobile	O
phase	O
A	O
was	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
water	O
,	O
and	O
mobile	O
phase	O
B	O
was	O
0	O
.	O
1	O
%	O
water	O
in	O
AC	O
##N	O
.	O

(	O
C	O
)	O
Co	O
##rrel	O
##ations	O
involving	O
the	O
c	B
##rea	I
##tine	I
pool	O
.	O

In	O
terms	O
of	O
body	O
measurements	O
,	O
the	O
L	O
##MI	O
,	O
central	O
o	O
##besity	O
and	O
B	O
##F	O
,	O
but	O
not	O
the	O
B	O
##MI	O
,	O
were	O
associated	O
with	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
;	O
ii	O
)	O
So	O
##1	O
##P	O
was	O
significantly	O
correlated	O
with	O
the	O
progression	O
from	O
pre	O
-	O
D	O
##M	O
to	O
T	O
##2	O
##DM	O
;	O
ii	O
##i	O
)	O
So	O
##1	O
##P	O
and	O
Sa	O
were	O
indicated	O
to	O
be	O
bio	O
##mark	O
##ers	O
for	O
di	O
##abe	O
##tic	O
patients	O
at	O
an	O
elevated	O
risk	O
for	O
card	O
##iovascular	O
complications	O
.	O

Also	O
,	O
down	O
##re	O
##gu	O
##lation	O
of	O
FA	O
##SN	O
contributes	O
to	O
the	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
effect	O
of	O
the	O
CO	O
##X	O
-	O
2	O
inhibitor	O
c	B
##ele	I
##co	I
##xi	I
##b	I
[	O
,	O
]	O
.	O

U	O
##rine	O
samples	O
were	O
processed	O
with	O
an	O
equal	O
volume	O
of	O
50	O
%	O
a	O
##que	O
##ous	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
ch	B
##lor	I
##op	I
##rop	I
##ami	I
##de	I
and	O
amino	B
##pi	I
##mel	I
##ic	I
acid	I
as	O
internal	O
standards	O
and	O
ch	O
##roma	O
##to	O
##graph	O
##ed	O
on	O
a	O
50	O
×	O
2	O
.	O
1	O
mm	O
A	O
##c	O
##qui	O
##ty	O
B	O
##E	O
##H	O
1	O
.	O
7	O
μ	O
##m	O
C	O
##18	O
column	O
(	O
reverse	O
phase	O
(	O
R	O
##P	O
)	O
ch	O
##roma	O
##tography	O
for	O
the	O
q	O
##uant	O
##itation	O
of	O
CS	O
and	O
meta	O
##bol	O
##ite	O
56	O
##1	O
+	O
)	O
.	O

C	O
##luster	O
three	O
was	O
characterised	O
by	O
an	O
abundance	O
of	O
c	B
##era	I
##mi	I
##des	I
,	O
which	O
indicates	O
the	O
presence	O
of	O
a	O
process	O
of	O
ne	O
##c	O
##rosis	O
/	O
a	O
##pop	O
##tosis	O
,	O
in	O
agreement	O
with	O
the	O
gross	O
his	O
##to	O
##logical	O
appearance	O
in	O
this	O
sub	O
-	O
region	O
.	O

Both	O
in	O
##tra	O
-	O
donor	O
and	O
inter	O
-	O
donor	O
data	O
comparisons	O
of	O
the	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
parent	O
compounds	O
and	O
meta	O
##bol	O
##ites	O
were	O
conducted	O
.	O

In	O
this	O
study	O
we	O
observed	O
an	O
increase	O
in	O
only	O
a	O
single	O
,	O
minor	O
SM	O
having	O
two	O
C	O
##18	O
chains	O
with	O
one	O
and	O
two	O
double	O
bonds	O
,	O
respectively	O
,	O
either	O
SM	B
(	I
d	I
##18	I
:	I
2	I
/	I
18	I
:	I
1	I
)	I
or	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
18	I
:	I
2	I
)	I
.	O

Of	O
105	O
primary	O
meta	O
##bol	O
##ites	O
,	O
6	O
(	O
5	O
.	O
7	O
%	O
)	O
compounds	O
were	O
present	O
at	O
significantly	O
different	O
levels	O
in	O
the	O
SL	O
##E	O
groups	O
as	O
compared	O
to	O
healthy	O
pregnant	O
controls	O
,	O
namely	O
2	B
-	I
de	I
##ox	I
##yte	I
##tron	I
##ic	I
acid	I
,	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
,	O
p	B
##yr	I
##u	I
##vic	I
acid	I
,	O
u	B
##ric	I
acid	I
,	O
v	B
##ali	I
##ne	I
,	O
x	B
##yl	I
##ose	I
(	O
Mann	O
-	O
Whitney	O
U	O
test	O
,	O
p	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
found	O
8	O
significant	O
associations	O
of	O
test	B
##osterone	I
with	O
lip	O
##ids	O
and	O
22	O
with	O
lip	O
##op	O
##rote	O
##ins	O
in	O
PC	O
##OS	O
women	O
with	O
large	O
(	O
[UNK]	O
)	O
but	O
not	O
in	O
women	O
with	O
intermediate	O
and	O
smaller	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
(	O
except	O
for	O
one	O
positive	O
association	O
with	O
the	O
ratio	O
of	O
o	O
##me	O
##ga	O
6	O
and	O
7	O
in	O
intermediate	O
s	O
##trata	O
)	O
.	O

Is	O
##che	O
##mic	O
condition	O
in	O
##hibit	O
##s	O
beta	O
oxidation	O
of	O
fatty	O
acids	O
and	O
leads	O
to	O
accumulation	O
of	O
toxic	O
intermediate	O
##s	O
of	O
beta	O
oxidation	O
,	O
particularly	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
compounds	O
like	O
l	B
##ino	I
##leo	I
##yl	I
car	I
##ni	I
##tine	I
.	O

The	O
p	O
##hen	O
##olic	O
OH	O
of	O
AFB	O
-	O
L	O
##ys	O
and	O
AFB	B
-	I
dial	I
##de	I
##hy	I
##de	I
is	O
de	O
##p	O
##rot	O
##ona	O
##ted	O
at	O
pH	O
7	O
.	O
4	O
(	O
bath	O
##och	O
##rom	O
##ic	O
shift	O
of	O
the	O
UV	O
-	O
s	O
##pect	O
##ra	O
pH	O
4	O
.	O
0	O
to	O
pH	O
7	O
.	O
4	O
)	O
.	O

[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
3	O
-	O
HP	O
##MA	O
and	O
500	O
ng	O

Future	O
steps	O
should	O
include	O
evaluation	O
of	O
panels	O
including	O
c	B
##ys	I
##tat	I
##in	I
C	O
and	O
potentially	O
other	O
low	O
molecular	O
weight	O
proteins	O
.	O

Interest	O
##ingly	O
,	O
1	O
.	O
74	O
-	O
fold	O
higher	O
levels	O
(	O
border	O
##line	O
significance	O
;	O
p	O
-	O
adjusted	O
0	O
.	O
07	O
)	O
of	O
a	O
meta	O
##bol	O
##ite	O
similar	O
to	O
ca	B
##da	I
##ver	I
##ine	I
was	O
also	O
observed	O
in	O
pre	O
-	O
surgery	O
CR	O
##C	O
patients	O
.	O

Val	B
##ine	I
and	O
x	B
##le	I
##uc	I
##ine	I
are	O
both	O
from	O
the	O
same	O
metabolic	O
sub	O
-	O
pathway	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
metabolism	O
which	O
according	O
to	O
the	O
study	O
by	O
Men	O
##ni	O
et	O
al	O
.	O

This	O
increase	O
is	O
unlikely	O
to	O
be	O
diet	O
##ary	O
since	O
the	O
diet	O
remained	O
constant	O
throughout	O
the	O
study	O
and	O
there	O
was	O
no	O
change	O
in	O
the	O
me	B
##ad	I
acid	I
level	O
,	O
which	O
is	O
a	O
marker	O
for	O
diet	O
##ary	O
intake	O
change	O
between	O
the	O
pre	O
and	O
post	O
-	O
r	O
##if	O
##ax	O
##im	O
##in	O
profile	O
.	O

A	O
multiple	O
log	O
##istic	O
re	O
##gression	O
model	O
was	O
used	O
to	O
estimate	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
C	O
##I	O
)	O
of	O
gender	O
,	O
age	O
,	O
B	O
##MI	O
,	O
and	O
serum	O
put	B
##res	I
##cine	I
levels	O
,	O
with	O
T	O
##2	O
##D	O
as	O
dependent	O
variable	O
.	O

[	O
,	O
]	O
The	O
EC	O
_	O
50	O
values	O
of	O
the	O
individual	O
inhibitor	O
##s	O
de	O
##duced	O
from	O
the	O
dose	B
-	I
response	I
curves	O
are	O
summarized	O
in	O
.	O

U	O
##rine	O
c	B
##rea	I
##tin	I
##ine	I
was	O
measured	O
at	O
the	O
University	O
of	O
Minnesota	O
Medical	O
Center	O
using	O
V	O
##it	O
##ros	O
C	O
##rea	O
slides	O
(	O
Or	O
##th	O
##o	O
-	O
Clinical	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Rochester	O
,	O
NY	O
)	O

The	O
time	O
course	O
changes	O
in	O
glucose	S
and	O
la	B
##ct	I
##ate	I
concentrations	O
and	O
their	O
%	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
are	O
shown	O
in	O
Figure	O
.	O

Panel	O
(	O
d	O
)	O
shows	O
relative	O
amounts	O
of	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##lic	I
acid	I
contributing	O
to	O
differentiation	O
in	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
(	O
VIP	O
>	O
1	O
.	O
0	O
and	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
is	O
a	O
significant	O
increase	O
of	O
test	B
##osterone	I
-	I
d	I
_	I
2	I
(	O
p	O
=	O
0	O
.	O
01	O
##1	O
)	O
when	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
is	O
used	O
.	O

The	O
MS	O
was	O
ca	O
##li	O
##bra	O
##ted	O
using	O
sodium	B
format	I
##e	I
,	O
and	O
le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I
was	O
used	O
as	O
lock	O
mass	O
.	O

It	O
transports	O
long	O
-	O
chain	O
fatty	O
acids	O
from	O
the	O
c	O
##yt	O
##oso	O
##l	O
into	O
mit	O
##och	O
##ond	O
##ria	O
in	O
the	O
form	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
for	O
β	O
-	O
oxidation	O
and	O
also	O
facilitate	O
##s	O
the	O
removal	O
of	O
short	O
-	O
and	O
medium	O
-	O
chain	O
fatty	O
acids	O
from	O
the	O
mit	O
##och	O
##ond	O
##ria	O
.	O

[	O
]	O
However	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
behave	O
##s	O
as	O
an	O
end	O
##ogen	O
##ous	O
ne	O
##uro	O
##p	O
##rote	O
##ctive	O
agent	O
.	O

This	O
was	O
undertaken	O
in	O
breast	O
samples	O
in	O
the	O
I	O
##ER	O
study	O
and	O
from	O
both	O
breast	O
and	O
sub	O
##cut	O
##aneous	O
abdominal	O
ad	O
##ip	O
##ocytes	O
from	O
the	O
previous	O
CE	B
##R	I
study	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
with	O
the	O
highest	O
VIP	O
values	O
and	O
co	O
##rrel	O
##ating	O
positively	O
with	O
m	O
##t	O
##D	O
##NA	O
were	O
β	B
-	I
glucose	I
and	O
v	B
##ali	I
##ne	I
.	O

108	O
participants	O
with	O
pre	O
-	O
D	O
##M	O
were	O
followed	O
up	O
for	O
ten	O
years	O
and	O
divided	O
into	O
3	O
groups	O
according	O
to	O
different	O
g	B
##ly	I
##ce	I
##mic	I
outcomes	O
.	O

B	O
,	O
Among	O
daily	O
cannabis	S
users	O
,	O
levels	O
of	O
T	O
##HC	O
-	O
CO	O
##OH	O
were	O
used	O
to	O
s	O
##tra	O
##ti	O
##fy	O
individuals	O
into	O
occasional	O
,	O
moderate	O
,	O
and	O
heavy	O
cannabis	S
use	O
groups	O
.	O

T	B
##G	I
was	O
significantly	O
increased	O
in	O
b	O
##v	O
##FT	O
##D	O
compared	O
to	O
control	O
(	O
Figure	O
)	O
.	O

ATP	S
and	O
PC	O
##r	O
are	O
connected	O
via	O
the	O
c	O
##rea	O
##tine	O
-	O
kinase	O
reaction	O
.	O

During	O
the	O
training	O
stage	O
,	O
the	O
plasma	O
lip	O
##id	O
profiles	O
of	O
390	O
individual	O
lip	O
##id	O
species	O
from	O
13	O
classes	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
CE	O
##s	O
were	O
identified	O
using	O
lip	O
##ido	O
##mic	O
##s	O
in	O
44	O
plasma	O
samples	O
,	O
which	O
included	O
22	O
patients	O
with	O
S	O
##q	O
##CC	O
,	O
and	O
22	O
age	O
-	O
,	O
sex	O
-	O
and	O
race	O
-	O
matched	O
high	O
-	O
risk	O
controls	O
.	O

My	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
is	O
an	O
essential	O
component	O
of	O
the	O
plasma	O
membrane	O
that	O
acts	O
as	O
an	O
in	O
##tra	O
##cellular	O
second	O
messenger	O
.	O

The	O
MI	O
##C	O
_	O
50	O
values	O
obtained	O
for	O
these	O
substitution	O
##s	O
did	O
not	O
improve	O
upon	O
the	O
lowest	O
MI	O
##C	O
_	O
50	O
of	O
8	O
.	O
09	O
##±	O
##5	O
.	O
11	O
µ	O
##M	O
observed	O
for	O
the	O
4	B
-	I
br	I
##omo	I
##ani	I
##line	I
substitution	O
,	O
therefore	O
this	O
R	O
_	O
1	O
group	O
was	O
utilized	O
in	O
further	O
compound	O
development	O
.	O

All	O
of	O
the	O
significant	O
associations	O
were	O
direct	O
(	O
i	O
.	O
e	O
.	O
case	O
status	O
was	O
associated	O
with	O
the	O
higher	O
level	O
of	O
a	O
particular	O
meta	O
##bol	O
##ite	O
)	O
,	O
except	O
for	O
8	O
meta	O
##bol	O
##ites	O
,	O
namely	O
as	B
##par	I
##agi	I
##ne	I
,	O
se	B
##rine	I
,	O
LP	O
##C	O
##a	O
C	B
##18	I
:	I
1	I
,	O
LP	O
##C	O
##a	O
C	B
##18	I
:	I
2	I
,	O
LP	O
##C	O
##e	O
C	B
##18	I
:	I
0	I
,	O
PC	O
##ae	O
C	B
##34	I
:	I
3	I
,	O
PC	O
##ae	O
C	B
##38	I
:	I
4	I
,	O
and	O
PC	O
##ae	O
C	B
##40	I
:	I
6	I
.	O

2	B
-	I
Am	I
##ino	I
-	I
1	I
-	I
met	I
##hyl	I
-	I
6	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	I
p	I
##hen	I
##yl	I
##im	I
##ida	I
##zo	I
[	I
4	I
,	I
5	I
-	I
b	I
]	I
p	I
##yr	I
##id	I
##ine	I
(	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
,	O
99	O
%	O
is	O
##oto	O
##pic	O
purity	O
)	O
was	O
a	O
gift	O
from	O
Dr	O
.	O
Mark	O
K	O
##ni	O
##ze	O
and	O
Dr	O
.	O
Kristen	O
Ku	O
##l	O
##p	O
,	O
(	O
Lawrence	O
Live	O
##rm	O
##ore	O
National	O
Laboratory	O
,	O
Live	O
##rm	O
##ore	O
,	O
CA	O
)	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
data	O
obtained	O
upon	O
analysis	O
of	O
total	O
co	B
##tin	I
##ine	I
(	O
panel	O
A	O
)	O
and	O
total	O
N	O
##NA	O
##L	O
(	O
panel	O
B	O
)	O
in	O
the	O
urine	O
of	O
85	O
smoke	O
##rs	O
by	O
the	O
traditional	O
separate	O
methods	O
and	O
the	O
combined	O
method	O
.	O

Some	O
,	O
but	O
not	O
all	O
,	O
studies	O
also	O
have	O
demonstrated	O
a	O
reduction	O
in	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
fat	O
content	O
in	O
association	O
with	O
improved	O
peripheral	O
(	O
muscle	O
)	O
insulin	O
sensitivity	O
after	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
treatment	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
.	O

B	O
##rief	O
##ly	O
,	O
meta	O
##bol	O
##ites	O
were	O
der	O
##iva	O
##tized	O
with	O
15	O
µ	O
##L	O
of	O
2	O
%	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
for	O
90	O
min	O
and	O
15	O
µ	O
##L	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
for	O
additional	O
30	O
min	O
at	O
40	O
°C	O
under	O
continuous	O
shaking	O
using	O
a	O
G	O
##ers	O
##tel	O
MP	O
##S	O
.	O

Peak	O
##s	O
were	O
cent	O
##roid	O
##ed	O
by	O
m	O
##sco	O
##n	O
##vert	O
from	O
Pro	O
##te	O
##o	O
##W	O
##iza	O
##rd	O
and	O
pre	O
##p	O
##ro	O
##cess	O
##ed	O
using	O
the	O
following	O
pipeline	O
within	O
the	O
K	B
##NI	I
##ME	I
platform	O
:	O
the	O
peak	O
-	O
picked	O
data	O
was	O
q	O
##uant	O
##ified	O
by	O
Feature	O
##F	O
##inder	O
##M	O
##eta	O
##bo	O
and	O
features	O
were	O
linked	O
across	O
samples	O
using	O
feature	O
##L	O
##ink	O
##er	O
##U	O
##n	O
##la	O
##bell	O
##ed	O
##Q	O
##T	O
,	O
allowing	O
10	O
s	O
retention	O
time	O
tolerance	O
and	O
5	O
pp	O
##m	O
mass	O
de	O
##viation	O
(	O
performed	O
i	O
##rre	O
##spective	O
of	O
charge	O
state	O
across	O
the	O
samples	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
prior	O
to	O
N	O
##MR	O
analysis	O
,	O
se	O
##ra	O
were	O
th	O
##awed	O
at	O
room	O
temperature	O
,	O
and	O
an	O
al	O
##iq	O
##uo	O
##t	O
of	O
200	O
μ	O
##L	O
was	O
added	O
of	O
400	O
μ	O
##L	O
of	O
sa	B
##line	I
buffer	O
solution	O
(	O
Na	O
##C	O
##l	O
0	O
.	O
9	O
%	O
,	O
50	O
m	O
##M	O
sodium	B
phosphate	I
buffer	O
in	O
D	O
_	O
2	O
O	O
containing	O
T	O
##SP	O
0	O
.	O
05	O
%	O
w	O
##t	O
for	O
chemical	O
shift	O
ca	O
##li	O
##bra	O
##tion	O
,	O
pH	O
7	O
.	O
4	O
)	O
to	O
minimize	O
the	O
variation	O
in	O
pH	O
and	O
transferred	O
in	O
a	O
5	O
mm	O
N	O
##MR	O
tube	O
[	O
,	O
,	O
]	O
.	O

In	O
our	O
co	O
##hor	O
##ts	O
,	O
u	O
##rina	O
##ry	O
la	B
##ct	I
##ate	I
showed	O
a	O
strong	O
positive	O
correlation	O
with	O
rejection	O
episodes	O
.	O

The	O
increase	O
(	O
red	O
)	O
and	O
decrease	O
(	O
blue	O
)	O
of	O
meta	O
##bol	O
##ites	O
concentrations	O
in	O
the	O
PC	O
##OS	O
plasma	O
were	O
on	O
the	O
basis	O
of	O
both	O
our	O
data	O
and	O
previous	O
report	O
(	O
reduction	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##it	I
##rate	I
in	O
PC	O
##OS	O
patients	O
)	O
.	O

For	O
use	O
in	O
log	O
##istic	O
re	O
##gression	O
all	O
bio	O
##chemical	O
variables	O
were	O
split	O
in	O
te	O
##rt	O
##iles	O
,	O
except	O
for	O
co	B
##tin	I
##ine	I
which	O
was	O
divided	O
in	O
three	O
categories	O
corresponding	O
to	O
the	O
serum	O
level	O
of	O
co	B
##tin	I
##ine	I
in	O
non	O
-	O
smoke	O
##rs	O
(	O
<	O
80	O
nm	O
##ol	O
/	O
l	O
)	O
,	O
moderate	O
smoke	O
##rs	O
(	O
80	O
–	O
1000	O
nm	O
##ol	O
/	O
l	O
)	O
and	O
heavy	O
smoke	O
##rs	O
(	O
>	O
1000	O
nm	O
##ol	O
/	O
l	O
)	O
.	O

After	O
a	O
treatment	O
with	O
10	O
mg	O
/	O
kg	O
of	O
q	O
##uin	O
##ine	O
di	B
##hy	I
##dr	I
##och	I
##lor	I
##ide	I
administered	O
8	O
-	O
hourly	O
oral	O
##ly	O
for	O
7	O
days	O
,	O
the	O
plasma	O
q	O
##uin	O
##ine	O
levels	O
had	O
fallen	O
to	O
below	O
0	O
.	O
4	O
µ	O
##g	O
/	O
m	O
##L	O
in	O
almost	O
all	O
patients	O
40	O
h	O
after	O
the	O
last	O
dose	O
on	O
Day	O
7	O
.	O

For	O
example	O
,	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
based	O
cluster	O
contained	O
52	O
nodes	O
and	O
of	O
the	O
masses	O
of	O
the	O
15	O
most	O
widely	O
distributed	O
nodes	O
(	O
in	O
>	O
20	O
urine	O
extract	O
##s	O
present	O
)	O

Recent	O
studies	O
show	O
that	O
components	O
of	O
organ	B
##op	I
##hos	I
##phate	I
est	I
##ers	I
and	O
FM	O
##55	O
##0	O
are	O
frequently	O
detected	O
in	O
many	O
products	O
common	O
to	O
human	O
environments	O
.	O

Just	O
before	O
analysis	O
,	O
40	O
μ	O
##l	O
he	B
##pta	I
##ne	I
including	O
met	B
##hyl	I
##ste	I
##arate	I
(	O
15	O
ng	O
/	O
μ	O
##l	O
)	O
was	O
added	O
.	O

To	O
determine	O
whether	O
20	B
-	I
H	I
##ET	I
##E	I
can	O
activate	O
small	O
GT	O
##P	O
##ase	O
Ra	O
##s	O
,	O
H	O
##RP	O
##TE	O
##C	O
cells	O
were	O
treated	O
with	O
20	O
μ	O
##M	O
W	O
##IT	O
##00	O
##3	O
(	O
20	O
-	O
H	O
##ET	O
##E	O
ago	O
##nist	O
)	O
and	O
in	O
##cu	O
##bate	O
##d	O
with	O
Ra	O
##s	O
binding	O
domain	O
(	O
RB	O
##D	O
)	O
of	O
Ra	O
##f	O
##1	O
,	O
to	O
specifically	O
is	O
##olate	O
the	O
active	O
GT	O
##P	O
-	O
bound	O
form	O
of	O
Ra	O
##s	O
.	O

A	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
of	O
human	O
con	O
##junct	O
##ival	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
in	O
response	O
to	O
h	O
##yper	O
##os	O
##mot	O
##ic	O
stress	O
found	O
that	O
levels	O
of	O
21	O
meta	O
##bol	O
##ites	O
significantly	O
changed	O
under	O
h	O
##yper	O
##os	O
##mot	O
##ic	O
stress	O
;	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
increased	O
most	O
under	O
h	O
##yper	O
##os	O
##mot	O
##ic	O
stress	O
,	O
and	O
the	O
authors	O
concluded	O
that	O
this	O
meta	O
##bol	O
##ite	O
may	O
act	O
as	O
an	O
important	O
o	O
##smo	O
##p	O
##rote	O
##ct	O
##ant	O
.	O

(	O
Z	O
)	O
,	O
1	B
-	I
o	I
##ct	I
##ano	I
##l	I
,	O
4	B
-	I
met	I
##hyl	I
-	I
p	I
##hen	I
##ol	I
and	O
p	B
##hen	I
##ol	I
4	I
-	I
(	I
1	I
,	I
1	I
,	I
3	I
,	I
3	I
-	I
te	I
##tra	I
##met	I
##hyl	I
##but	I
##yl	I
)	I
were	O
found	O
at	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
levels	O
in	O
the	O
f	O
##ec	O
##es	O
and	O
/	O
or	O
urine	O
##s	O
of	O
N	O
##P	O
and	O
,	O
especially	O
,	O
P	O
patients	O
.	O

Fifth	O
,	O
although	O
we	O
acknowledge	O
that	O
the	O
assessment	O
of	O
ethanol	B
##amine	I
concentration	O
can	O
be	O
clinical	O
##ly	O
relevant	O
as	O
a	O
single	O
metabolic	O
bio	O
##mark	O
##er	O
for	O
distinguishing	O
long	O
-	O
term	O
survivors	O
from	O
short	O
-	O
term	O
survivors	O
in	O
patients	O
with	O
PA	O
,	O
this	O
result	O
should	O
be	O
put	O
into	O
perspective	O
.	O

The	O
addition	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
the	O
ratio	O
of	O
2	O
:	O
1	O
to	O
a	O
bio	O
##f	O
##lu	O
##id	O
sample	O
was	O
found	O
to	O
be	O
most	O
efficient	O
in	O
removing	O
protein	O
from	O
the	O
sample	O
(	O
efficiency	O
>	O
96	O
%	O
)	O
.	O

Among	O
significant	O
meta	O
##bol	O
##ites	O
,	O
there	O
were	O
several	O
cat	B
##ech	I
##ola	I
##mine	I
meta	O
##bol	O
##ites	O
.	O

In	O
sum	O
,	O
all	B
##ant	I
##oi	I
##n	I
represents	O
a	O
convenient	O
bio	O
##mark	O
##er	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
due	O
to	O
its	O
appearance	O
in	O
the	O
_	O
1	O
H	O
-	O
N	O
##MR	O
spectrum	O
of	O
human	O
plasma	O
and	O
illustrate	O
##s	O
how	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
pro	O
##voke	O
##s	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
possibly	O
by	O
increasing	O
the	O
rate	O
of	O
super	B
##oxide	I
production	O
as	O
a	O
consequence	O
of	O
decreased	O
mitochondrial	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
activity	O
.	O

Regarding	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
P	O
##G	O
##s	O
)	O
,	O
which	O
a	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ol	I
m	O
##oi	O
##ety	O
occupies	O
a	O
g	B
##ly	I
##cer	I
##ol	I
substitution	O
site	O
,	O
little	O
evidence	O
has	O
been	O
shown	O
on	O
their	O
relationship	O
with	O
CH	O
##D	O
,	O
and	O
we	O
were	O
the	O
first	O
to	O
reveal	O
a	O
positive	O
relationship	O
between	O
P	B
##G	I
(	I
20	I
:	I
3	I
/	I
2	I
:	I
0	I
)	I
and	O
CH	O
##D	O
(	O
OR	O
:	O
3	O
.	O
93	O
##8	O
;	O
95	O
%	O
C	O
##I	O
:	O
(	O
1	O
.	O
89	O
##1	O
,	O
8	O
.	O
204	O
)	O
;	O

All	O
32	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
selected	O
for	O
the	O
identification	O
of	O
potential	O
differences	O
in	O
bio	O
##chemical	O
composition	O
caused	O
by	O
ne	O
##uron	O
##al	O
death	O
processes	O
,	O
the	O
obtained	O
P	O
value	O
for	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
,	O
and	O
VIP	O
value	O
>	O
1	O
are	O
presented	O
in	O
Table	O
.	O

Using	O
a	O
published	O
synthetic	O
scheme	O
,	O
ω	B
-	I
h	I
##ydro	I
##xy	I
-	I
20	I
:	I
4	I
##n	I
##6	I
-	I
met	I
##hyl	I
est	I
##er	I
(	O
Co	O
##mpo	O
##und	O
10	O
)	O
was	O
obtained	O
,	O
locking	O
the	O
required	O
double	O
bond	O
positions	O
relative	O
to	O
the	O
ω	B
-	I
terminal	I
of	O
the	O
target	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acid	I
.	O

This	O
result	O
indicates	O
that	O
the	O
inter	O
##play	O
between	O
k	B
##yn	I
##uren	I
##ine	I
biology	O
and	O
cancer	O
is	O
more	O
complicated	O
than	O
was	O
previously	O
assumed	O
.	O

Also	O
the	O
removal	O
of	O
met	B
##han	I
##ol	I
from	O
met	O
##han	O
##ol	O
-	O
water	O
mixture	O
##s	O
has	O
to	O
be	O
done	O
with	O
appropriate	O
care	O
.	O

Given	O
this	O
background	O
,	O
detailed	O
S	O
##OP	O
##s	O
for	O
sample	O
processing	O
are	O
necessary	O
in	O
order	O
to	O
successfully	O
develop	O
ta	B
##uri	I
##ne	I
and	O
O	B
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
as	O
commercial	O
bio	O
##mark	O
##ers	O
in	O
serum	O
.	O

Because	O
L	O
##ys	O
##o	O
##PC	O
is	O
synthesized	O
from	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
)	O
by	O
the	O
enzyme	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A2	O
,	O
the	O
de	O
##cre	O
##ment	O
of	O
L	O
##ys	O
##o	O
##PC	O
indicated	O
imp	O
##air	O
##ment	O
of	O
these	O
enzymes	O
in	O
PC	O
re	O
-	O
a	O
##cy	O
##lation	O
or	O
de	O
-	O
a	O
##cy	O
##lation	O
.	O

The	O
formation	O
of	O
E	O
_	O
1	O
(	B
E	I
_	I
2	I
)	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
could	O
be	O
possible	O
only	O
through	O
metabolism	O
of	O
est	O
##rogen	O
##s	O
to	O
q	B
##uin	I
##one	I
met	O
##hi	O
##de	O
followed	O
by	O
its	O
interaction	O
with	O
ad	B
##eni	I
##ne	I
from	O
DNA	O
.	O

They	O
are	O
then	O
internal	O
##ized	O
and	O
targeted	O
via	O
the	O
end	O
##oc	O
##ytic	O
pathway	O
to	O
the	O
l	O
##ys	O
##oso	O
##me	O
,	O
where	O
they	O
are	O
meta	O
##bol	O
##ized	O
into	O
c	B
##era	I
##mi	I
##de	I
and	O
mon	B
##osa	I
##cc	I
##hari	I
##de	I
through	O
a	O
pathway	O
that	O
involves	O
G	O
##C	O
##ase	O
.	O

Is	B
##op	I
##rop	I
##ano	I
##l	I
[	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
HP	O
##LC	O
)	O
-	O
grade	O
]	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
HP	O
##LC	O
-	O
grade	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
HP	O
##LC	O
-	O
grade	O
)	O
and	O
form	B
##ic	I
acid	I
(	O
98	O
%	O
)	O
were	O
purchased	O
from	O
J	O
.	O
T	O
.	O
Baker	O
;	O
Ava	O
##nto	O
##r	O
,	O
Inc	O
.	O

The	O
highest	O
predict	O
##ive	O
value	O
was	O
characterized	O
by	O
FA	B
vs	I
HC	O
,	O
which	O
reached	O
the	O
AU	O
##C	O
test	O
of	O
1	O
.	O
00	O
,	O
while	O
the	O
lowest	O
value	O
was	O
obtained	O
for	O
N	O
##N	O
vs	O
HC	O
with	O
an	O
AU	O
##C	O
test	O
of	O
0	O
.	O
82	O
.	O

The	O
pathways	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
,	O
et	O
##her	O
lip	O
##id	O
metabolism	O
and	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
are	O
closely	O
linked	O
to	O
each	O
other	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
k	O
##eg	O
##g	O
.	O
j	O
##p	O
/	O
)	O
.	O

Our	O
data	O
reveal	O
up	O
-	O
regulation	O
of	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
ace	B
##tone	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
l	B
##ys	I
##ine	I
,	O
ni	B
##cot	I
##inate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
and	O
down	O
-	O
regulation	O
of	O
al	B
##ani	I
##ne	I
,	O
format	B
##e	I
,	O
g	B
##ly	I
##cine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
##ph	I
##os	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
L	O
##D	O
##L	O
)	O
in	O
T	O
##B	O
patients	O
relative	O
to	O
healthy	O
controls	O
.	O

The	O
transitions	O
monitored	O
were	O
mass	O
-	O
to	O
-	O
charge	O
ratio	O
(	O
m	O
/	O
z	O
)	O
:	O
m	O
/	O
z	O
133	O
.	O
2	O
##→	O
##70	O
.	O
2	O
for	O
or	B
##ni	I
##thin	I
##e	I
;	O
m	O
/	O
z	O
175	O
.	O
1	O
##→	O
##70	O
.	O
0	O
for	O
a	B
##rg	I
##ini	I
##ne	I
;	O
m	O
/	O
z	O
176	O
.	O
1	O
##→	O
##70	O
.	O
1	O
for	O
c	B
##it	I
##ru	I
##llin	I
##e	I
;	O
m	O
/	O
z	O
189	O
.	O
3	O
##→	O
##70	O
.	O
1	O
for	O
MMA	O
;	O
m	O
/	O
z	O
203	O
.	O
2	O
→	O
##70	O
.	O
3	O
for	O
SD	O
##MA	O
and	O
AD	B
##MA	I
;	O
and	O
m	O
/	O
z	O
181	O
##→	O
##7	O
##4	O
for	O
[	O
_	O
13	O
C	O
_	O
6	O
]	O

Moreover	O
,	O
un	O
##tar	O
##get	O
##ed	O
_	O
1	O
H	O
-	O
N	O
##MR	O
and	O
G	O
##C	O
-	O
MS	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
results	O
showed	O
elevated	O
levels	O
of	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
intermediate	O
##s	O
(	O
T	O
##CA	O
##I	O
##s	O
)	O
ma	B
##late	I
and	O
c	B
##it	I
##rate	I
in	O
T	O
##1	O
##D	O
.	O
G	B
##ly	I
##cer	I
##ol	I
was	O
also	O
increased	O
in	O
the	O
T	O
##1	O
##D	O
group	O
,	O
whereas	O
l	B
##ys	I
##ine	I
levels	O
were	O
significantly	O
lower	O
as	O
compared	O
to	O
the	O
control	O
group	O
.	O

G	B
##lu	I
##cos	I
##e	I
q	O
##uant	O
##ification	O
was	O
performed	O
using	O
Chen	O
##om	O
##x	O
Professional	O
8	O
.	O
0	O
with	O
the	O
existing	O
Chen	O
##om	O
##x	O
library	O
.	O

It	O
also	O
acts	O
as	O
bio	O
##chemical	O
precursor	O
for	O
the	O
synthesis	O
of	O
ni	B
##ac	I
##in	I
co	O
##fa	O
##ctor	O
,	O
through	O
pathways	O
of	O
k	B
##yn	I
##uren	I
##ine	I
(	O
K	O
##yn	O
)	O
and	O
for	O
the	O
synthesis	O
of	O
me	B
##lat	I
##oni	I
##n	I
from	O
se	B
##rot	I
##oni	I
##n	I
(	O
Set	O
)	O
via	O
the	O
met	B
##ho	I
##xy	I
##ind	I
##ole	I
##s	I
pathway	O
(	O
Figure	O
)	O
.	O

Sep	O
##ara	O
##tion	O
in	O
two	O
groups	O
resulted	O
even	O
more	O
evident	O
in	O
the	O
disc	O
##rim	O
##inating	O
model	O
based	O
on	O
the	O
U	B
##rine	I
-	I
24	I
##h	I
samples	O
.	O

Both	O
the	O
total	O
p	O
##oly	O
##phe	O
##no	O
##lic	O
levels	O
and	O
individual	O
cat	B
##ech	I
##in	I
contents	O
remained	O
unchanged	O
after	O
12	O
months	O
storage	O
at	O
5	O
##°	O
##C	O
in	O
the	O
dark	O
indicating	O
a	O
stable	O
protein	O
p	O
##oly	O
##phe	O
##no	O
##lic	O
matrix	O
.	O

Ph	O
##arma	O
##co	O
##kin	O
##etics	O
of	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
g	I
##lu	I
##cona	I
##te	I
.	O

Huang	O
,	O
et	O
al	O
.	O
performed	O
a	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
L	O
##C	O
)	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
and	O
showed	O
that	O
the	O
level	O
of	O
u	O
##rina	O
##ry	O
car	B
##ni	I
##tine	I
C	I
##9	I
:	I
1	I
was	O
significantly	O
decreased	O
in	O
patients	O
with	O
BC	O
##A	O
,	O
particularly	O
in	O
those	O
with	O
early	O
BC	O
##A	O
.	O

The	O
H	O
##S	O
##Q	O
##C	O
experiment	O
utilized	O
the	O
substantial	O
_	O
2	O
J	O
_	O
NH	O
between	O
H	O
##8	O
,	O
N	O
##9	O
and	O
H	O
##2	O
,	O
N	O
##1	O
for	O
observing	O
N	O
–	O
H	O
connectivity	O
in	O
ad	B
##eni	I
##ne	I
rings	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
.	O

To	O
account	O
for	O
variations	O
in	O
h	O
##yd	O
##ration	O
status	O
,	O
P	O
##GE	O
-	O
M	O
was	O
normal	O
##ized	O
to	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
.	O

They	O
include	O
the	O
mon	B
##o	I
-	I
g	I
##lut	I
##ath	I
##ione	I
reaction	O
product	O
,	O
N	B
-	I
[	I
4	I
-	I
car	I
##box	I
##y	I
-	I
4	I
-	I
(	I
3	I
-	I
me	I
##rca	I
##pt	I
##o	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
1	I
-	I
y	I
##l	I
)	I
-	I
1	I
-	I
o	I
##x	I
##ob	I
##ut	I
##yl	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##yl	I
##gly	I
##cine	I
c	I
##yclic	I
su	I
##lf	I
##ide	I
and	O
its	O
downstream	O
meta	O
##bol	O
##ite	O
,	O
S	B
-	I
[	I
1	I
-	I
(	I
1	I
,	I
3	I
-	I
di	I
##car	I
##box	I
##y	I
##p	I
##rop	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
met	I
##hyl	I
##thi	I
##ol	I
as	O
well	O
as	O
R	B
-	I
2	I
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
6	I
-	I
(	I
2	I
,	I
5	I
-	I
di	I
##hy	I
##dr	I
##o	I
-	I
2	I
-	I
o	I
##x	I
##o	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
1	I
-	I
y	I
##l	I
)	I
-	I
1	I
-	I
he	I
##xa	I
##no	I
##ic	I
acid	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
5	I
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
and	O
its	O
su	B
##lf	I
##oxide	I
.	O

In	O
this	O
study	O
,	O
plasma	O
glucose	S
was	O
decreased	O
,	O
which	O
might	O
be	O
a	O
result	O
of	O
the	O
over	O
-	O
expression	O
of	O
IN	O
##SR	O
.	O

Key	O
:	O
Grey	O
:	O
control	O
,	O
Blue	O
:	O
bread	O
A	O
,	O
Green	O
:	O
bread	O
B	O
,	O
Orange	O
:	O
B	O
##read	O
C	O
.	O
Super	O
##nat	O
##ants	O
from	O
the	O
different	O
bread	O
##s	O
could	O
not	O
be	O
statistical	O
##ly	O
differentiated	O
from	O
one	O
another	O
but	O
were	O
all	O
distinguished	O
from	O
the	O
controls	O
due	O
to	O
lower	O
levels	O
of	O
p	B
##oly	I
##eth	I
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
(	O
P	O
##EG	O
)	O
,	O
lip	O
##ids	O
and	O
branched	O
chain	O
amino	O
acids	O
in	O
the	O
f	O
##er	O
##mented	O
bread	O
samples	O
.	O

Furthermore	O
,	O
in	O
the	O
advanced	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
co	O
##hor	O
##t	O
as	O
a	O
whole	O
,	O
there	O
was	O
a	O
significant	O
association	O
between	O
the	O
base	O
##line	O
k	O
##yn	O
/	O
t	O
##rp	O
ratio	O
with	O
post	O
-	O
operative	O
major	O
cardiac	O
complications	O
and	O
a	O
significant	O
association	O
between	O
the	O
base	O
##line	O
k	O
##yn	O
/	O
t	O
##rp	O
ratio	O
and	O
hip	B
##pur	I
##ic	I
acid	I
with	O
MAC	O
##E	O
during	O
the	O
median	O
follow	O
-	O
up	O
period	O
of	O
14	O
months	O
that	O
was	O
preserved	O
after	O
adjustment	O
for	O
diabetes	O
.	O

We	O
specifically	O
point	O
out	O
that	O
the	O
approach	O
of	O
si	O
##mulating	O
s	O
##pect	O
##ra	O
of	O
is	O
##omer	O
##ic	O
mixture	O
##s	O
from	O
individual	O
tandem	O
mass	O
s	O
##pect	O
##ra	O
of	O
authentic	O
FA	B
is	I
##omer	I
##s	I
(	O
e	O
.	O
g	O
.	O
,	O
and	O
)	O
can	O
be	O
extended	O
to	O
en	O
##com	O
##pass	O
the	O
q	O
##uant	O
##itation	O
of	O
FA	O
##s	O
having	O
three	O
or	O
more	O
is	O
##omer	O
##s	O
.	O

The	O
lip	O
##id	O
extract	O
##s	O
were	O
di	O
##lut	O
##ed	O
in	O
300	O
µ	O
##L	O
of	O
met	O
##han	O
##ol	O
:	O
ch	O
##lor	O
##of	O
##orm	O
(	O
2	O
:	O
1	O
)	O
and	O
100	O
µ	O
##L	O
of	O
this	O
solution	O
was	O
red	O
##il	O
##uted	O
in	O
400	O
µ	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
:	O
ch	O
##lor	O
##of	O
##orm	O
(	O
3	O
:	O
1	O
)	O
,	O
then	O
1	O
µ	O
##L	O
was	O
injected	O
into	O
a	O
MS	O
using	O
an	O
L	O
##C	O
(	O
A	O
##gi	O
##lent	O
129	O
##0	O
)	O
without	O
a	O
column	O
and	O
with	O
a	O
flow	O
of	O
0	O
.	O
5	O
m	O
##L	O
min	O
_	O
−	O
##1	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
:	O

The	O
method	O
utilizes	O
two	O
separate	O
,	O
complementary	O
extraction	O
chemist	O
##ries	O
,	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
(	O
DC	O
##M	O
)	O
and	O
a	O
met	O
##hyl	O
te	O
##rt	O
-	O
but	O
##yl	O
et	O
##her	O
/	O
he	O
##xa	O
##f	O
##lu	O
##oro	O
##is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
M	O
##T	O
##BE	O
)	O
mixture	O
,	O
alone	O
or	O
with	O
high	O
pressure	O
cycling	O
.	O

9	B
-	I
H	I
##OD	I
##E	I
and	O
12	B
,	I
13	I
-	I
Di	I
##H	I
##OM	I
##E	I
reduced	O
VC	O
##AM	O
-	O
1	O
surface	O
expression	O
,	O
whereas	O
19	O
,	O
20	O
-	O
Di	O
##HD	O
##o	O
##P	O
##E	O
did	O
not	O
alter	O
VC	O
##AM	O
-	O
1	O
surface	O
expression	O
relative	O
to	O
T	O
##NF	O
##α	O
.	O

An	O
expanded	O
follow	O
-	O
up	O
meta	O
##bol	O
##omi	O
##c	O
study	O
that	O
includes	O
more	O
patients	O
with	O
ER	O
-	O
and	O
stage	O
3	O
/	O
4	O
disease	O
is	O
imp	O
##erative	O
to	O
determine	O
if	O
plasma	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
reflect	O
tumor	O
##al	O
en	O
##zy	O
##matic	O
activity	O
and	O
co	O
##rrel	O
##ate	O
with	O
outcome	O
.	O

Only	O
68	O
##5	O
features	O
were	O
in	O
common	O
between	O
these	O
two	O
methods	O
;	O
61	O
##2	O
features	O
were	O
only	O
found	O
in	O
M	B
##T	I
##BE	I
extracted	O
samples	O
and	O
98	O
##4	O
features	O
were	O
only	O
found	O
in	O
met	B
##han	I
##ol	I
super	O
##nat	O
##ants	O
.	O

A	O
two	O
-	O
step	O
der	O
##iva	O
##ti	O
##zation	O
approach	O
was	O
used	O
to	O
convert	O
[	O
D	O
_	O
4	O
]	O
4	O
to	O
[	B
p	I
##yr	I
##id	I
##ine	I
-	I
D	I
_	I
4	I
]	I
met	I
##hyl	I
4	I
-	I
he	I
##xa	I
##noy	I
##l	I
-	I
4	I
-	I
(	I
3	I
-	I

β	B
-	I
Sit	I
##ost	I
##ero	I
##l	I
had	O
also	O
high	O
loading	O
##s	O
in	O
the	O
VIP	O
analysis	O
(	O
see	O
Figure	O
)	O
.	O

A	O
second	O
hypothesis	O
to	O
explain	O
these	O
observations	O
could	O
be	O
that	O
cancer	O
cells	O
and	O
their	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
consume	O
la	B
##ct	I
##ate	I
leading	O
to	O
its	O
levels	O
drop	O
with	O
growing	O
tumor	O
mass	O
.	O

β	B
-	I
ACT	I
##IN	I
was	O
used	O
as	O
normal	O
##ization	O
control	O
.	O

Type	O
of	O
anti	O
##coa	O
##gu	O
##lant	O
tube	O
(	B
Li	B
-	I
He	I
##par	I
##in	I
vs	I
.	O
E	O
##D	O
##TA	O
)	O
,	O
employed	O
for	O
the	O
collection	O
of	O
blood	O
samples	O
,	O
was	O
studied	O
at	O
the	O
beginning	O
.	O

Met	B
##form	I
##in	I
,	O
an	O
anti	O
##dia	O
##bet	O
##ic	O
,	O
was	O
an	O
##not	O
##ated	O
to	O
a	O
cluster	O
containing	O
a	O
variety	O
of	O
precursor	O
ions	O
in	O
the	O
nodes	O
.	O

Po	O
##ssi	O
##ble	O
explanations	O
include	O
(	O
i	O
)	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
t	O
##umour	O
cells	O
(	O
the	O
War	O
##burg	O
effect	O
)	O
generating	O
p	B
##yr	I
##u	I
##vate	I
which	O
is	O
converted	O
to	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
then	O
g	B
##lut	I
##amine	I
;	O
(	O
ii	O
)	O
an	O
association	O
between	O
elevated	O
g	O
##ly	O
##co	O
##lysis	O
and	O
increased	O
ch	B
##olin	I
##e	I
turnover	O
in	O
membrane	O
##s	O
;	O
(	O
ii	O
##i	O
)	O
an	O
increase	O
in	O
the	O
t	O
##C	O
##r	O
pool	O
to	O
facilitate	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
-	I
driven	I
g	I
##lut	I
##ama	I
##te	I
up	O
##take	O
;	O
(	O
i	O
##v	O
)	O
lip	O
##id	O
signals	O
come	O
from	O
c	O
##yt	O
##oso	O
##lic	O
lip	O
##id	O
drop	O
##lets	O
in	O
ne	O
##c	O
##rot	O
##ic	O
or	O
pre	O
-	O
ne	O
##c	O
##rot	O
##ic	O
t	O
##umour	O
tissue	O
that	O
has	O
lower	O
concentrations	O
of	O
an	O
##ab	O
##olic	O
and	O
cat	O
##ab	O
##olic	O
meta	O
##bol	O
##ites	O
.	O

Sam	O
##ples	O
(	O
300	O
μ	O
##L	O
)	O
were	O
prepared	O
in	O
300	O
μ	O
##L	O
of	O
phosphate	S
buffer	O
and	O
Q	O
##C	O
s	O
##pect	O
##ra	O
were	O
acquired	O
after	O
every	O
10	O
study	O
samples	O
.	O

The	O
ratio	O
of	O
these	O
three	O
o	B
##xy	I
##ster	I
##ols	I
in	O
CS	O
##F	O
thus	O
gives	O
an	O
indication	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
in	O
brain	O
with	O
respect	O
to	O
o	B
##xy	I
##ster	I
##ol	I
transport	O
from	O
the	O
periphery	O
into	O
CS	O
##F	O
.	O

The	O
frequent	O
detection	O
of	O
u	O
##rina	O
##ry	O
D	O
##MA	O
##P	O
without	O
ace	B
##tam	I
##ip	I
##rid	I
implies	O
that	O
environmental	O
##ly	O
exposed	O
ace	B
##tam	I
##ip	I
##rid	I
is	O
readily	O
meta	O
##bol	O
##ized	O
in	O
humans	O
.	O

Sam	O
##ples	O
were	O
e	O
##va	O
##porated	O
for	O
1	O
h	O
using	O
an	O
RC	O
##10	O
.	O
22	O
vacuum	O
con	O
##cent	O
##rator	O
(	O
Jo	O
##uan	O
,	O
Winchester	O
,	O
VA	S
,	O
USA	O
)	O
,	O
and	O
100	O
μ	O
##L	O
0	O
.	O
75	O
mg	O
/	O
m	O
##L	O
PT	O
##AD	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
added	O
to	O
the	O
residue	O
followed	O
by	O
1	O
min	O
of	O
mixing	O
.	O

In	O
contrast	O
,	O
the	O
application	O
of	O
higher	O
sample	O
volumes	O
(	O
2	O
mg	O
instead	O
of	O
200	O
μ	O
##g	O
d	O
##w	O
)	O
for	O
lip	O
##id	O
extraction	O
showed	O
some	O
decrease	O
of	O
C	O
##V	O
,	O
especially	O
for	O
T	B
##G	I
species	O
and	O
samples	O
with	O
a	O
high	O
fraction	O
of	O
T	B
##G	I
in	O
the	O
p	O
##elle	O
##t	O
.	O

5	B
-	I
H	I
##ET	I
##E	I
and	O
le	O
##uk	O
##ot	O
##rien	O
##e	O
B	O
_	O
4	O
are	O
meta	O
##bol	O
##ites	O
associated	O
with	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	B
C	B
##20	I
:	I
4	I
)	O
metabolism	O
.	O

The	O
3	O
-	O
met	O
##hyl	O
resonance	O
##s	O
of	O
both	O
Al	O
##a	O
and	O
la	B
##ct	I
##ate	I
(	O
double	O
##ts	O
at	O
1	O
.	O
53	O
and	O
1	O
.	O
4	O
pp	O
##m	O
,	O
respectively	O
)	O
display	O
pairs	O
of	O
_	O
13	O
C	O
satellite	O
peaks	O
displaced	O
126	O

To	O
perform	O
the	O
serum	O
lip	O
##id	O
analysis	O
,	O
100	O
μ	O
L	O
of	O
sample	O
was	O
added	O
to	O
480	O
μ	O
L	O
of	O
extraction	O
liquid	O
(	O
V	O
_	O
M	O
##T	O
##BE	O
:	O
V	B
_	I
met	I
##han	I
##ol	I
=	O
5	O
:	O
1	O
)	O
and	O
v	O
##ortex	O
##ed	O
for	O
30	O
s	O
.	O

Lower	O
total	O
body	O
c	B
##rea	I
##tin	I
##ine	I
may	O
be	O
due	O
to	O
reduced	O
muscle	O
mass	O
.	O

While	O
Rose	O
##bur	O
##ia	O
s	O
##pp	O
and	O
but	B
##yra	I
##te	I
production	O
were	O
decreased	O
,	O
we	O
concluded	O
that	O
decreased	O
but	B
##yra	I
##te	I
stimulate	O
##d	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
kinase	O
2	O
and	O
then	O
increased	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
and	O
S	O
##1	O
##P	O
.	O
The	O
abundance	O
of	O
E	O
##scher	O
##ichi	O
##a	O
-	O
Shi	O
##gel	O
##la	O
(	O
En	O
##tero	O
##ba	O
##cter	O
##iac	O
##eae	O
)	O
was	O
higher	O
in	O
the	O
f	O
##ec	O
##es	O
of	O
UC	O
patients	O
and	O
in	O
re	O
##ct	O
##al	O
bio	O
##ps	O
##ies	O
from	O
CD	O
patients	O
,	O
indicating	O
a	O
possible	O
association	O
with	O
the	O
path	O
##ogen	O
##esis	O
of	O
I	O
##B	O
##D	O
[	O
,	O
]	O
.	O

The	O
ins	O
##et	O
is	O
the	O
data	O
-	O
dependent	O
MS	O
/	O
MS	O
scan	O
of	O
the	O
same	O
peak	O
,	O
giving	O
fragment	O
ions	O
of	O
193	O
,	O
175	O
,	O
and	O
163	O
m	O
/	O
z	O
corresponding	O
to	O
the	O
indicated	O
portions	O
of	O
the	O
proposed	O
p	B
##hen	I
##yl	I
##but	I
##yr	I
##yl	I
-	I
β	I
-	I
g	I
##lu	I
##cu	I
##rona	I
##te	I
meta	O
##bol	O
##ite	O
shown	O
.	O

It	O
is	O
difficult	O
to	O
compare	O
our	O
findings	O
with	O
others	O
reports	O
since	O
the	O
initial	O
study	O
by	O
Sr	O
##eek	O
##uma	O
##r	O
et	O
al	O
differ	O
in	O
the	O
methodology	O
of	O
sa	B
##rc	I
##os	I
##ine	I
measurement	O
,	O
sample	O
source	O
,	O
,	O
and	O
importantly	O
criteria	O
defining	O
re	O
##cu	O
##rrence	O
–	O
.	O

Anti	O
##ret	O
##rov	O
##ira	O
##l	O
treatment	O
on	O
groups	O
C	O
and	O
D	O
was	O
ho	O
##mogeneous	O
##ly	O
comprised	O
of	O
an	O
association	O
of	O
fixed	O
dose	O
combination	O
of	O
z	B
##ido	I
##vu	I
##dine	I
and	O
3	O
##TC	O
administered	O
B	O
##ID	O
,	O
and	O
a	O
Q	O
##D	O
dose	O
of	O
E	O
##fa	O
##vir	O
##en	O
##z	O
,	O
according	O
to	O
the	O
local	O
Brazilian	O
guidelines	O
at	O
that	O
time	O
.	O

Main	O
##ly	O
,	O
the	O
meta	O
##bol	O
##ites	O
were	O
grouped	O
in	O
terms	O
of	O
glucose	S
metabolism	O
,	O
amino	O
acid	O
metabolism	O
and	O
lip	O
##id	O
metabolism	O
.	O

C	O
##ir	O
##cula	O
##ting	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
was	O
correlated	O
with	O
circulating	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
concentration	O
(	O
Pearson	O
r	O
range	O
,	O
0	O
.	O
64	O
–	O
0	O
.	O
88	O
)	O
.	O

We	O
found	O
that	O
HC	O
females	O
have	O
decreased	O
free	O
Car	O
##n	O
and	O
a	B
##cy	I
##l	I
-	I
Car	I
##n	I
levels	O
together	O
with	O
decreased	O
AA	O
levels	O
.	O

Other	O
strong	O
connections	O
were	O
observed	O
between	O
blood	O
sugar	O
and	O
re	B
##tina	I
##l	I
laser	O
therapy	O
due	O
to	O
diabetes	O
(	O
re	O
##t	O
_	O
las	O
)	O
,	O
as	O
well	O
as	O
classification	O
as	O
T	O
##2	O
##DM	O
patient	O
(	O
d	O
##m	O
_	O
t	O
##y	O
##p	O
##2	O
)	O
.	O

In	O
##tri	O
##guin	O
##gly	O
,	O
our	O
data	O
demonstrated	O
that	O
vitamin	O
B	O
_	O
6	O
metabolism	O
is	O
one	O
of	O
the	O
three	O
most	O
-	O
significantly	O
altered	O
pathways	O
in	O
patients	O
receiving	O
H	O
##T	O
##K	O
solution	O
,	O
showing	O
that	O
u	O
##rina	O
##ry	O
4	B
-	I
p	I
##yr	I
##ido	I
##xi	I
##c	I
acid	I
,	O
which	O
is	O
the	O
major	O
cat	O
##ab	O
##oli	O
##te	O
of	O
vitamin	O
B	O
_	O
6	O
,	O
was	O
significantly	O
reduced	O
.	O

For	O
our	O
non	O
-	O
targeted	O
G	O
##C	O
-	O
MS	O
analysis	O
,	O
the	O
lower	O
limit	O
of	O
detection	O
was	O
1	O
µ	O
##M	O
/	O
m	O
##M	O
c	B
##rea	I
##tin	I
##ine	I
(	O
for	O
2	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##ano	I
##ic	I
acid	O
)	O
,	O
while	O
for	O
our	O
targeted	O
organic	O
acid	O
G	O
##C	O
-	O
MS	O
analysis	O
the	O
lower	O
limit	O
of	O
detection	O
was	O
0	O
.	O
7	O
µ	O
##M	O
/	O
m	O
##M	O
c	B
##rea	I
##tin	I
##ine	I
(	O
for	O
m	B
-	I
ch	I
##lor	I
##obe	I
##nz	I
##oi	I
##c	I
acid	O
)	O
.	O

We	O
used	O
the	O
commercial	O
A	O
##bs	O
##ol	O
##ute	O
##ID	O
##Q	O
p	O
##18	O
##0	O
Kit	O
(	O
B	O
##io	O
##crates	O
Life	O
Sciences	O
,	O
Inn	O
##s	O
##bruck	O
,	O
Austria	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
188	O
targeted	O
meta	O
##bol	O
##ites	O
covering	O
the	O
following	O
compound	O
classes	O
:	O
amino	O
acids	O
,	O
bio	O
##genic	O
am	O
##ines	O
and	O
p	B
##oly	I
##amine	I
##s	I
(	O
n	O
=	O
40	O
)	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
n	O
=	O
40	O
)	O
,	O
di	O
-	O
a	O
##cy	O
##l	O
-	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
lip	O
##ids	O
(	O
n	O
=	O
92	O
)	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
n	O
=	O
15	O
)	O
and	O
he	B
##x	I
##ose	I
(	O
n	O
=	O
1	O
)	O
.	O

PC	O
can	O
be	O
synthesized	O
in	O
the	O
body	O
through	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
of	O
ch	B
##olin	I
##e	I
from	O
the	O
diet	O
or	O
via	O
end	O
##ogen	O
##ous	O
synthesis	O
mediated	O
by	O
P	O
##EM	O
##T	O
in	O
the	O
liver	O
and	O
ma	O
##mma	O
##ry	O
g	O
##land	O
.	O

As	O
##suming	O
that	O
T	B
##AG	I
(	I
54	I
:	I
5	I
)	I
contains	O
fatty	O
acid	O
22	O
:	O
5	O
this	O
means	O
there	O
is	O
an	O
inverse	O
correlation	O
of	O
the	O
amount	O
of	O
22	O
:	O
5	O
in	O
WA	O
##T	O
and	O
serum	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
also	O
showed	O
an	O
increased	O
risk	O
of	O
developing	O
C	O
##IN	O
##2	O
/	O
3	O
compared	O
with	O
C	O
##IN	O
##1	O
(	O
OR	O
,	O
7	O
.	O
90	O
;	O
C	O
##I	O
,	O
2	O
.	O
00	O
–	O
31	O
.	O
3	O
)	O
.	O

El	O
##eva	O
##ted	O
serum	O
levels	O
of	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
are	O
in	O
##dicative	O
of	O
mitochondrial	O
β	O
-	O
oxidation	O
disorders	O
.	O

Actually	O
,	O
this	O
is	O
the	O
first	O
study	O
showing	O
a	O
decrease	O
in	O
resting	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
after	O
a	O
short	O
-	O
term	O
,	O
but	O
high	O
-	O
intensive	O
interval	O
training	O
.	O

Gala	B
##ct	I
##ose	I
is	O
an	O
important	O
meta	O
##bol	O
##ites	O
involved	O
in	O
the	O
formation	O
of	O
g	B
##ly	I
##cans	I
featuring	O
gal	B
##act	I
##ose	I
and	O
its	O
derivatives	O
which	O
were	O
essentially	O
bound	O
by	O
gal	O
##ec	O
##tin	O
##s	O
,	O
.	O

G	B
##lu	I
##come	I
##ter	I
and	O
strips	O
will	O
be	O
given	O
to	O
the	O
patients	O
to	O
record	O
three	O
values	O
daily	O
(	O
after	O
fast	O
##ing	O
,	O
before	O
a	O
meal	O
and	O
two	O
hours	O
after	O
a	O
meal	O
)	O
.	O

Therefore	O
,	O
we	O
first	O
tested	O
whether	O
cent	O
##ri	O
##fu	O
##gation	O
affects	O
D	O
##G	O
and	O
T	B
##G	I
concentrations	O
.	O

Subsequently	O
polar	O
and	O
non	O
-	O
polar	O
fraction	O
##s	O
were	O
separated	O
for	O
both	O
G	O
##C	O
-	O
MS	O
and	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
by	O
adding	O
water	O
and	O
a	O
mixture	O
of	O
ethanol	S
and	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
.	O

Nevertheless	O
,	O
we	O
also	O
observed	O
for	O
the	O
associations	O
of	O
meta	O
##bol	O
##ite	O
levels	O
with	O
DB	B
##P	I
and	O
insulin	O
levels	O
similar	O
effect	O
sizes	O
in	O
fast	O
##ed	O
status	O
and	O
after	O
the	O
SL	O
##M	O
(	O
DB	O
##P	O
:	O
r	O
=	O
0	O
.	O
95	O
##9	O
;	O
insulin	O
:	O
r	O
=	O
0	O
.	O
92	O
##2	O
)	O
(	O
;	O
)	O
.	O

Out	O
of	O
the	O
134	O
patients	O
recruited	O
,	O
three	O
patients	O
had	O
received	O
th	B
##io	I
##pur	I
##ine	I
treatment	O
for	O
less	O
than	O
6	O
months	O
and	O
were	O
excluded	O
from	O
analysis	O
.	O

For	O
PM	O
##N	O
##s	O
,	O
a	O
tendency	O
for	O
glucose	S
and	O
G	B
##S	I
##H	I
to	O
increase	O
,	O
and	O
la	B
##ct	I
##ate	I
to	O
decrease	O
seem	O
to	O
be	O
present	O
when	O
they	O
are	O
treated	O
with	O
ch	O
##ito	O
##san	O
and	O
Ce	O
##O	O
_	O
2	O
,	O
but	O
these	O
changes	O
are	O
only	O
significant	O
when	O
Au	O
is	O
introduced	O
.	O

Non	O
-	O
targeted	O
pro	O
##fi	O
##ling	O
of	O
th	B
##iol	I
##s	I
from	O
the	O
cancer	O
urine	O
by	O
the	O
IL	O
-	O
L	O
##C	O
-	O
D	O
##PI	O
-	O
MS	O
method	O
provided	O
q	O
##ual	O
##itative	O
information	O
of	O
m	O
/	O
z	O
of	O
all	O
the	O
th	B
##iol	I
candidates	O
.	O

The	O
reduction	O
in	O
c	B
##ys	I
##tein	I
##e	I
and	O
c	B
##ys	I
##tine	I
coupled	O
with	O
elevations	O
in	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
an	O
oxidation	O
product	O
of	O
met	B
##hi	I
##oni	I
##ne	I
,	O
imp	O
##lica	O
##tes	O
altered	O
red	O
##ox	O
status	O
,	O
which	O
may	O
be	O
linked	O
to	O
the	O
observed	O
changes	O
in	O
circulating	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
.	O

An	O
in	O
v	O
##ivo	O
investigation	O
in	O
rode	O
##nts	O
showed	O
that	O
ca	B
##ffe	I
##ine	I
also	O
seems	O
to	O
increase	O
o	O
##ste	O
##oc	O
##last	O
numbers	O
.	O

Solid	O
stationary	O
phases	O
(	O
P	O
##EP	O
##2	O
,	O
O	O
##DS	O
-	O
C	O
##18	O
and	O
di	B
##vin	I
##yl	I
##ben	I
##zen	I
##e	I
con	O
##ju	O
##gated	O
with	O
su	B
##lf	I
##onic	I
acid	I
and	O
q	O
##uate	O
##rna	O
##ry	O
am	O
##ine	O
m	O
##oi	O
##eti	O
##es	O
(	O
I	O
##EX	O
)	O
)	O
were	O
obtained	O
from	O
Age	O
##la	O
Technologies	O
(	O
Wilmington	O
,	O
DE	O
,	O
USA	O
)	O
.	O

The	O
e	O
##G	O
##F	O
##R	O
is	O
based	O
on	O
the	O
c	B
##rea	I
##tin	I
##ine	I
–	I
c	I
##ys	I
##tat	I
##in	I
C	O
equation	O
.	O

This	O
new	O
flame	O
-	O
re	O
##tar	O
##dant	O
contains	O
T	O
##P	O
##HP	O
,	O
i	O
##p	O
##PD	O
##PP	O
,	O
2	B
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
-	I
2	I
,	I
3	I
,	I
4	I
,	I
5	I
-	I
te	I
##tra	I
##bro	I
##mo	I
##ben	I
##zo	I
##ate	I
,	O
bi	B
##s	I
(	I
2	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
)	I
-	I
2	I
,	I
3	I
,	I
4	I
,	I
5	I
,	I
-	I
te	I
##tra	I
-	I
br	I
##omo	I
##ph	I
##thal	I
##ate	I
,	O
and	O
additional	O
is	O
##op	O
##rop	O
##ly	O
##lated	O
t	B
##ria	I
##ryl	I
phosphate	I
is	I
##omer	I
##s	I
.	O

IS	O
##1	O
(	B
le	B
##vo	I
##f	I
##lo	I
##xa	I
##cin	I
)	O
:	O
36	O
##2	O
##→	O
##26	O
##1	O
;	O
IS	O
##2	O
(	O
he	O
##sper	O
##id	O
##in	O
)	O
:	O
61	O
##1	O
##→	O
##30	O
##3	O
;	O
negative	O
ion	O
mode	O
including	O
89	O
##→	O
##41	O
,	O
128	O
##→	O
##8	O
##2	O
,	O
129	O
##→	O
##8	O
##5	O
,	O
167	O
##→	O
##12	O
##4	O
,	O
178	O
##→	O
##13	O
##2	O
,	O
179	O
##→	O
##7	O
##1	O
,	O
187	O
##→	O
##80	O
,	O
187	O
##→	O
##5	O
##9	O
,	O
191	O
##→	O
##8	O
##5	O
,	O
204	O
##→	O
##14	O
##2	O
,	O
213	O
##→	O
##5	O
##9	O
,	O
215	O
##→	O
##5	O
##9	O
,	O
239	O
##→	O
##15	O
##1	O
,	O
241	O
##→	O
##5	O
##9	O
,	O
243	O
##→	O
##18	O
##3	O
,	O
26	O
##3	O
##→	O
##14	O
##5	O
,	O
26	O
##7	O
##→	O
##5	O
##9	O
,	O
26	O
##7	O
##→	O
##22	O
##3	O
,	O
27	O
##7	O
##→	O
##23	O
##3	O
,	O
27	O
##9	O
##→	O
##26	O
##1	O
,	O
281	O
##→	O
##21	O
##0	O
,	O
303	O
##→	O
##25	O
##9	O
,	O
307	O
##→	O
##5	O
##9	O
,	O
335	O
##→	O
##12	O
##4	O
,	O
36	O
##7	O
##→	O
##9	O
##7	O
,	O
36	O
##9	O
##→	O
##9	O
##7	O
,	O
38	O
##3	O
##→	O
##9	O
##7	O
,	O
39	O
##7	O
##→	O
##9	O
##7	O
,	O
40	O
##7	O
##→	O
##32	O
##5	O
,	O
44	O
##8	O
##→	O
##7	O
##4	O
,	O
46	O
##4	O
##→	O
##7	O
##4	O
,	O
47	O
##1	O
##→	O
##9	O
##7	O
,	O
47	O
##6	O
##→	O
##27	O
##9	O
,	O
480	O
##→	O
##22	O
##5	O
,	O
48	O
##5	O
##→	O
##46	O
##9	O
,	O
500	O
##→	O
##30	O
##3	O
,	O
50	O
##7	O
##→	O
##12	O
##3	O
,	O
512	O
##→	O
##43	O
##2	O
,	O
52	O
##4	O
##→	O
##19	O
##6	O
,	O
55	O
##6	O
##→	O
##27	O
##1	O
.	O

Two	O
were	O
used	O
for	O
_	O
1	O
H	O
1	O
##D	O
N	O
##MR	O
and	O
the	O
other	O
two	O
samples	O
were	O
used	O
for	O
detect	O
##ing	O
car	O
##box	O
##yl	O
class	O
of	O
meta	O
##bol	O
##ites	O
after	O
tag	O
##ging	O
with	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
high	O
-	O
resolution	O
magic	O
angle	O
spinning	O
(	O
H	O
##R	O
-	O
MA	O
##S	O
)	O
1	O
##H	O
nuclear	O
magnetic	O
resonance	O
(	O
N	O
##MR	O
)	O
s	O
##pect	O
##ros	O
##copy	O
in	O
patients	O
with	O
duct	O
##al	O
car	O
##cin	O
##oma	O
in	O
sit	O
##u	O
(	B
DC	B
##IS	I
)	O
diagnosed	O
on	O
pre	O
##oper	O
##ative	O
bio	O
##psy	O
.	O

The	O
authors	O
concluded	O
that	O
o	O
##xi	O
##da	O
##tive	O
stress	O
led	O
to	O
increased	O
eccentric	O
c	O
##lea	O
##vage	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
and	O
that	O
the	O
mixture	O
of	O
c	O
##lea	O
##vage	O
products	O
led	O
to	O
disruption	O
of	O
re	B
##tino	I
##id	I
signaling	O
via	O
indirect	O
mechanisms	O
.	O

Target	O
##ed	O
in	O
##hibition	O
of	O
g	B
##lut	I
##amine	I
metabolism	O
in	O
cancer	O
##s	O
such	O
as	O
O	O
##VC	O
and	O
BR	O
##C	O
has	O
anti	O
-	O
tumor	O
##ige	O
##nic	O
effects	O
[	O
–	O
]	O
.	O

In	O
addition	O
,	O
we	O
observed	O
associations	O
of	O
e	O
##G	O
##F	O
##R	O
with	O
c	B
##ys	I
##tat	I
##in	I
C	O
(	O
c	O
##ys	O
##C	O
)	O
,	O
and	O
N	O
##MR	O
bucket	O
##s	O
assigned	O
to	O
c	B
##rea	I
##tin	I
##ine	I
(	O
3	O
.	O
04	O
##5	O
pp	O
##m	O
,	O
4	O
.	O
05	O
##5	O
pp	O
##m	O
,	O
and	O
4	O
.	O
06	O
##5	O
pp	O
##m	O
)	O
.	O

Next	O
,	O
600	O
μ	O
L	O
of	O
met	B
##hyl	I
s	I
##te	I
##arate	I
(	O
10	O
pp	O
##m	O
in	O
he	O
##pta	O
##ne	O
)	O
was	O
added	O
as	O
an	O
internal	O
standard	O
.	O

The	O
dried	O
compounds	O
were	O
prepared	O
for	O
gas	O
ch	O
##roma	O
##tography	O
by	O
adding	O
50	O
μ	O
##L	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
BS	O
##TF	O
##A	O
)	O
and	O
in	O
##cu	O
##bat	O
##ing	O
this	O
mixture	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

Additionally	O
,	O
in	O
v	O
##it	O
##ro	O
exposure	O
of	O
P	O
##BM	O
##Cs	O
to	O
palm	B
##itic	I
acid	I
(	O
16	O
:	O
0	O
)	O
enhanced	O
,	O
whereas	O
P	O
##U	O
##FA	O
-	O
en	O
##rich	O
##ed	O
LP	O
##C	O
treatment	O
significantly	O
in	O
##hibit	O
##ed	O
LP	O
##S	O
-	O
induced	O
IL	O
-	O
6	O
production	O
,	O
these	O
findings	O
suggest	O
HIV	O
-	O
associated	O
altered	O
lip	O
##id	O
profiles	O
may	O
ex	O
##ace	O
##rb	O
##ate	O
the	O
inflammatory	O
consequences	O
of	O
micro	O
##bial	O
trans	O
##location	O
.	O

This	O
study	O
was	O
conducted	O
by	O
distinguishing	O
between	O
di	O
##abe	O
##tic	O
patients	O
with	O
and	O
without	O
DR	O
,	O
even	O
though	O
the	O
mean	O
disease	O
duration	S
was	O
more	O
than	O
20	O
years	O
.	O

Only	O
5	O
-	O
M	O
##TH	O
##F	O
was	O
dissolved	O
in	O
a	O
mixture	O
of	O
10	O
mm	O
##ol	O
/	O
L	O
NH	O
##4	O
##OA	O
##c	O
with	O
10	O
%	O
as	B
##cor	I
##bic	I
acid	I
and	O
2	O
%	O
D	O
##TT	O
in	O
H	O
_	O
2	O
O	O
to	O
prevent	O
oxidation	O
.	O

For	O
N	O
##MR	O
measurements	O
h	B
##ydro	I
##phi	I
##lic	I
and	O
lip	O
##op	O
##hil	O
##ic	O
meta	O
##bol	O
##ites	O
were	O
separately	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
overnight	O
to	O
remove	O
water	O
and	O
re	O
##con	O
##stituted	O
as	O
described	O
[	O
,	O
]	O
.	O

The	O
low	O
level	O
of	O
g	B
##lut	I
##amine	I
,	O
a	O
key	O
meta	O
##bol	O
##ite	O
in	O
the	O
pathway	O
of	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
and	O
D	B
-	I
G	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
,	O
was	O
observed	O
in	O
H	O
##AP	O
##E	O
subjects	O
.	O

Since	O
the	O
other	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
were	O
not	O
commercially	O
available	O
,	O
it	O
was	O
not	O
possible	O
to	O
evaluate	O
h	O
##ydro	O
##lysis	O
efficiency	O
for	O
the	O
six	O
remaining	O
compounds	O
.	O

For	O
N	O
##MP	O
##S	O
derivatives	O
,	O
solvent	O
A	O
was	O
water	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
99	O
.	O
5	O
:	O
0	O
.	O
5	O
,	O
v	O
/	O
v	O
)	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
and	O
solvent	O
B	O
was	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
98	O
:	O
2	O
,	O
v	O
/	O
v	O
)	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

Sign	O
##ificant	O
differences	O
were	O
observed	O
in	O
the	O
na	O
##dir	O
W	O
##BC	O
and	O
AN	O
##C	O
of	O
patients	O
with	O
different	O
N	O
##U	O
##D	O
##T	O
##15	O
activities	O
within	O
4	O
,	O
8	O
and	O
12	O
weeks	O
and	O
6	O
months	O
of	O
th	B
##io	I
##pur	I
##ine	I
initiation	O
.	O

G	B
##ly	I
##cine	I
was	O
found	O
to	O
be	O
decreased	O
,	O
which	O
was	O
in	O
accordance	O
with	O
the	O
previous	O
study	O
.	O

Although	O
others	O
have	O
demonstrated	O
that	O
using	O
EA	O
as	O
el	O
##uti	O
##ng	O
solvent	O
can	O
provide	O
better	O
recover	O
##ies	O
for	O
de	O
##uter	O
##ium	O
-	O
labeled	O
media	O
##tors	O
than	O
Me	B
##OH	I
with	O
the	O
same	O
SP	O
##E	O
cartridge	O
,	O
they	O
did	O
not	O
consider	O
c	O
##ys	O
##tein	O
##yl	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
.	O

c	O
)	O
.	O
N	O
##AC	O
decreased	O
K	O
##yn	O
,	O
HC	O
##A	O
,	O
de	B
##ox	I
##yi	I
##nos	I
##ine	I
,	O
and	O
c	O
##AM	O
##P	O
and	O
increased	O
N	B
##AD	I
##P	I
##H	I
,	O
as	O
shown	O
by	O
Vol	O
##cano	O
plot	O
(	O
Fi	O
##g	O
.	O

The	O
question	O
##naire	O
provided	O
us	O
with	O
the	O
benefit	O
to	O
retrieve	O
valuable	O
ta	B
##mo	I
##xi	I
##fen	I
ad	O
##herence	O
behavior	O
and	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
information	O
from	O
a	O
health	O
di	O
##sp	O
##arity	O
cancer	O
population	O
that	O
otherwise	O
would	O
not	O
be	O
accessible	O
.	O

A	O
##b	O
-	O
N	O
##MO	O
##SD	O
=	O
anti	O
##body	O
-	O
positive	O
N	O
##MO	O
##SD	O
;	O
A	O
##Q	O
##P	O
##4	O
-	O
A	O
##b	O
=	O
a	O
##qua	O
##por	O
##in	O
-	O
4	O
anti	O
##body	O
;	O
AU	O
=	O
arbitrary	O
units	O
;	O
L	O
##BL	O
=	O
low	O
brain	O
les	O
##ion	O
;	O
M	O
##O	O
##G	O
-	O
A	O
##b	O
=	O
my	B
##elin	I
o	O
##li	O
##go	O
##den	O
##dr	O
##oc	O
##yte	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
anti	O
##body	O
;	O
N	O
##MO	O
##SD	O
=	O
ne	O
##uro	O
##my	O
##eli	O
##tis	O
op	O
##tica	O
spectrum	O
disorder	O
;	O
PC	O
##A	O
=	O
principal	O
component	O
analysis	O
;	O
R	O
##R	O
##MS	O
=	O
re	O
##lap	O
##sing	O
-	O
re	O
##mit	O
##ting	O
MS	O
;	O
VIP	O
=	O
variable	O
importance	O
in	O
projection	O
.	O

Post	O
-	O
ER	O
##CP	O
as	B
##par	I
##tate	I
levels	O
were	O
significantly	O
higher	O
in	O
subjects	O
with	O
AP	S
(	O
0	O
.	O
00	O
##51	O
m	O
##M	O
AP	B
vs	I
.	O
0	O
.	O
00	O
##35	O
m	O
##M	O

Am	O
##ino	O
acids	O
are	O
needed	O
for	O
synthesis	O
of	O
liver	O
in	O
##tra	O
##cellular	O
proteins	O
,	O
plasma	O
proteins	O
,	O
and	O
different	O
compounds	O
,	O
such	O
as	O
g	B
##lut	I
##amine	I
or	O
c	B
##rea	I
##tine	I
.	O

P	O
##las	O
##ma	O
AD	B
##MA	I
and	O
OH	O
-	O
K	O
##yn	O
levels	O
were	O
increased	O
in	O
patients	O
with	O
either	O
ma	O
##ln	O
##utrition	O
or	O
greater	O
protein	O
##uria	O
(	O
all	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
100	O
%	O
initial	O
inhibitor	O
activity	O
was	O
determined	O
using	O
the	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
enzyme	O
and	O
solvent	O
D	B
##MS	I
##O	I
,	O
which	O
was	O
used	O
to	O
dissolve	O
the	O
inhibitor	O
.	O

For	O
six	O
of	O
the	O
non	O
-	O
replica	O
##ted	O
meta	O
##bol	O
##ites	O
[	O
the	O
branched	O
chain	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
is	B
##ole	I
##uc	I
##ine	I
(	O
N	O
)	O
,	O
is	B
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
M	O
)	O
and	O
is	B
##ob	I
##ut	I
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
M	O
)	O
,	O
palm	B
##ito	I
##lea	I
##te	I
(	I
16	I
:	I
1	I
##n	I
##7	I
)	I
(	O
M	O
)	O
,	O
p	B
##yr	I
##ido	I
##xa	I
##te	I
(	O
M	O
)	O
(	O
a	O
meta	O
##bol	O
##ite	O
of	O
vitamin	B
B	I
##6	I
metabolism	O
)	O
and	O
u	B
##rea	I
(	O
M	O
)	O
]	O
,	O
the	O
effect	O
direction	O
in	O
F	O
##IN	O
##RI	O
##S	O
##K	O
1997	O
was	O
the	O
same	O
as	O
in	O
K	O
##OR	O
##A	O
F	O
##4	O
.	O

In	O
human	O
HC	O
##A	O
-	O
7	O
CR	O
##C	O
cells	O
,	O
the	O
incorporation	O
of	O
EPA	O
from	O
cell	O
-	O
culture	O
medium	O
resulted	O
in	O
reduced	O
synthesis	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
.	O
The	O

These	O
differential	O
mechanisms	O
of	O
glucose	S
home	O
##ost	O
##asis	O
may	O
under	O
##pin	O
the	O
diver	O
##gent	O
correlation	O
##s	O
of	O
glucose	S
with	O
th	B
##re	I
##onic	I
acid	I
and	O
glucose	S
with	O
f	B
##ru	I
##ct	I
##ose	I
in	O
H	O
##B	O
##V	O
and	O
HC	O
##V	O
urine	O
##s	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
six	O
matched	O
replica	O
##te	O
samples	O
stored	O
(	O
−	O
##80	O
°C	O
)	O
for	O
up	O
to	O
eight	O
months	O
(	O
short	O
-	O
term	O
storage	O
)	O
or	O
for	O
3	O
–	O
4	O
years	O
(	O
long	O
-	O
term	O
storage	O
)	O
were	O
subjected	O
to	O
Me	B
##OH	I
:	O

Our	O
lip	O
##ido	O
##mic	O
##s	O
platform	O
for	O
human	O
plasma	O
and	O
serum	O
E	O
##Vs	O
and	O
lip	O
##op	O
##rote	O
##ins	O
detected	O
and	O
characterized	O
>	O
250	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

To	O
achieve	O
ATP	S
synthesis	O
in	O
the	O
mitochondrial	O
re	O
##spiration	O
chain	O
,	O
the	O
co	O
##en	O
##zy	O
##me	O
N	B
##AD	I
##H	I
o	O
##xi	O
##di	O
##zes	O
to	O
N	O
##AD	O
_	O
+	O
through	O
the	O
electron	O
transport	O
chain	O
and	O
,	O
simultaneously	O
,	O
the	O
AD	B
##P	I
is	O
converted	O
to	O
ATP	S
through	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

The	O
measurement	O
represents	O
total	O
est	B
##rogen	I
concentrations	O
(	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
+	O
su	O
##lf	O
##ated	O
+	O
un	O
##con	O
##ju	O
##gated	O
)	O
and	O
all	O
the	O
est	B
##rogen	I
values	O
were	O
corrected	O
for	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
.	O

The	O
elevation	O
of	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
es	O
##op	O
##hage	O
##al	O
cane	O
##r	O
may	O
be	O
resulted	O
from	O
the	O
metabolism	O
of	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
due	O
to	O
accelerated	O
cell	O
proliferation	O
.	O

Alternatively	O
,	O
mutations	O
or	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
in	O
AL	O
##D	O
##H	O
genes	O
,	O
several	O
of	O
which	O
have	O
been	O
described	O
,	O
could	O
con	O
##fer	O
a	O
h	O
##yper	O
-	O
re	O
##sp	O
##ons	O
##ive	O
##ness	O
to	O
g	B
##lut	I
##ama	I
##te	I
levels	O
that	O
then	O
drive	O
the	O
stem	O
##ness	O
p	O
##hen	O
##otype	O
.	O
_	O
,	O
For	O
example	O
,	O
the	O
g	B
##lut	I
##ama	I
##te	I
to	O
l	B
##ys	I
##ine	I
single	O
n	O
##uc	O
##leo	O
##tide	O
p	O
##oly	O
##mor	O
##phism	O
(	O
G	O
##lu	O
##50	O
##4	O
##L	O
##ys	O
)	O
was	O
reported	O
to	O
have	O
decreased	O
activity	O
of	O
the	O
AL	O
##D	O
##H	O
enzyme	O
and	O
caused	O
much	O
higher	O
blood	O
levels	O
of	O
ace	B
##tal	I
##de	I
##hy	I
##de	I
;	O
in	O
a	O
meta	O
-	O
analysis	O
this	O
showed	O
an	O
increased	O
risk	O
for	O
cancer	O
,	O
especially	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

Panel	O
A	O
shows	O
a	O
mass	O
spectrum	O
of	O
NL	O
##S	O
##18	O
##3	O
(	O
corresponding	O
to	O
the	O
neutral	O
loss	O
of	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	O
displaying	O
the	O
presence	O
of	O
PC	O
and	O
SM	O
species	O
in	O
the	O
he	O
##xa	O
##ne	O
-	O
washed	O
lip	O
##id	O
solution	O
;	O
the	O
spectrum	O
was	O
acquired	O
in	O
the	O
positive	O
-	O
ion	O
mode	O
after	O
addition	O
of	O
a	O
small	O
amount	O
of	O
Li	O
##OH	O
to	O
the	O
lip	O
##id	O
solution	O
.	O

The	O
s	O
##tero	O
##ids	O
in	O
the	O
panel	O
included	O
pre	B
##gne	I
##no	I
##lone	I
,	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
al	B
##dos	I
##tero	I
##ne	I
,	O
18	B
-	I
o	I
##x	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
18	B
-	I
h	I
##ydro	I
##xy	I
##cor	I
##tis	I
##ol	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
21	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ison	I
##e	I
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
(	O
D	O
##H	O
##EA	O
)	O
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
-	I
su	I
##lf	I
##ate	I
(	O
D	O
##H	O
##EA	O
-	O
S	O
##O	O
_	O
4	O
)	O
,	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
and	O
test	B
##osterone	I
.	O

2	B
‐	I
Is	I
##op	I
##rop	I
##yl	I
##mal	I
##ic	I
acid	I
and	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
were	O
purchased	O
from	O
Sigma	O
‐	O
Al	O
##dric	O
##h	O
(	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

In	O
contrast	O
to	O
s	O
##chi	O
##zophrenia	O
,	O
l	O
##ys	O
##o	O
##PC	O
is	O
increased	O
in	O
r	O
##he	O
##uma	O
##to	O
##id	O
art	O
##hr	O
##itis	O
,	O
thus	O
supporting	O
the	O
view	O
that	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
and	O
perhaps	O
also	O
l	O
##ys	O
##o	O
##PC	O
as	O
a	O
by	O
##p	O
##rod	O
##uc	O
##t	O
may	O
play	O
a	O
protective	O
role	O
in	O
s	O
##chi	O
##zophrenia	O
.	O

Following	O
sample	O
collection	O
,	O
a	O
single	O
bio	O
##psy	O
was	O
placed	O
directly	O
in	O
a	O
Na	O
##lge	O
##ne	O
cry	O
##ov	O
##ial	O
containing	O
2	O
m	O
##l	O
of	O
solvent	O
(	O
80	O
%	O
met	B
##han	I
##ol	I
,	O
20	O
%	O
ultra	O
-	O
pure	O
water	O
unless	O
otherwise	O
noted	O
)	O
.	O

This	O
process	O
is	O
less	O
efficient	O
because	O
one	O
molecule	O
of	O
glucose	S
just	O
generates	O
2	O
molecules	O
ATP	S
by	O
g	O
##ly	O
##co	O
##lysis	O
instead	O
of	O
36	O
molecules	O
through	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Tan	O
##de	O
##m	O
-	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
analysis	O
of	O
selected	O
28	O
-	O
carbon	O
containing	O
masses	O
*	O
Ion	O
##s	O
m	O
a	B
##y	I
have	O
been	O
obtained	O
from	O
MS	O
_	O
3	O
experiments	O
Tan	O
##de	O
##m	O
mass	O
s	O
##pect	O
##rome	O
##tric	O
results	O
of	O
various	O
standards	O
*	O

Form	B
##ic	I
acid	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
;	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

Ana	O
##ly	O
##ses	O
of	O
plasma	O
inflammatory	O
markers	O
,	O
plasma	O
,	O
and	O
skeletal	O
muscle	O
metabolic	O
intermediate	O
##s	O
(	B
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
organic	O
acids	O
)	O
,	O
and	O
plasma	O
lip	O
##op	O
##rote	O
##ins	O
were	O
previously	O
described	O
in	O
detail	O
as	O
follows	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
S	O
##IL	O
:	O
si	O
##ly	O
##bin	O
;	O
BP	O
##A	O
:	O
bi	B
##sp	I
##hen	I
##ol	I
A	O
.	O
Po	O
##sitive	O
ion	O
mass	O
s	O
##pect	O
##ra	O
of	O
s	O
##tero	O
##id	O
molecular	O
species	O
in	O
lip	O
##id	O
extract	O
##s	O
from	O
media	O
of	O
H	O
-	O
He	O
##p	O
##G	O
##2	O
cells	O
treated	O
with	O
BP	O
##A	O
(	O
A	O
)	O
,	O
si	O
##li	O
##bin	O
(	O
B	O
)	O
,	O
BP	O
##A	O
/	O
Si	O
##li	O
##bin	O
combination	O
(	O
C	O
)	O
.	O

While	O
non	B
##ano	I
##ic	I
acid	I
has	O
not	O
been	O
reported	O
as	O
a	O
bio	O
##mark	O
##er	O
in	O
oral	O
cancer	O
,	O
the	O
elevation	O
of	O
non	B
##ano	I
##ic	I
acid	I
in	O
lung	O
cancer	O
has	O
been	O
reported	O
as	O
a	O
bio	O
##mark	O
##er	O
.	O

M	B
##T	I
##BE	I
,	O
on	O
the	O
other	O
hand	O
,	O
had	O
only	O
small	O
number	O
of	O
meta	O
##bol	O
##ites	O
el	O
##uti	O
##ng	O
with	O
retention	O
time	O
<	O
20	O
min	O
,	O
and	O
very	O
high	O
proportion	O
of	O
meta	O
##bol	O
##ites	O
with	O
retention	O
time	O
>	O
20	O
min	O
,	O
which	O
resulted	O
in	O
overall	O
higher	O
median	O
RS	O
##Ds	O
observed	O
in	O
.	O

Bar	O
##s	O
represent	O
mean	O
value	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
16	I
:	I
0	I
/	I
22	I
:	I
6	I
normal	O
##ized	O
to	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
16	I
:	I
0	I
/	I
18	I
:	I
3	I
.	O

We	O
identified	O
an	O
increased	O
al	B
##ani	I
##ne	I
concentration	O
in	O
the	O
patients	O
with	O
MS	O
.	O

Basel	O
##ine	O
characteristics	O
of	O
these	O
two	O
groups	O
differed	O
in	O
prevalence	O
of	O
h	O
##yper	O
##tens	O
##ion	O
,	O
smoking	O
,	O
s	B
##tat	I
##in	I
use	O
,	O
median	O
L	O
##D	O
##L	O
and	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
in	O
median	O
lowest	O
AB	O
##I	O
.	O

(	O
H	O
)	O
I	O
##mm	O
##uno	O
##b	O
##lot	O
##s	O
showing	O
the	O
levels	O
of	O
AL	O
##D	O
##H1	O
##A	O
##1	O
and	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
expression	O
in	O
cells	O
trans	O
##duced	O
with	O
control	O
s	O
##h	O
##RNA	O
or	O
g	B
##lut	I
##ami	I
##nas	I
##e	I
-	I
s	I
##h	I
##RNA	I
and	O
then	O
culture	O
##d	O
under	O
ad	O
##here	O
##nt	O
or	O
suspension	O
conditions	O
(	O
tumors	O
##phere	O
##s	O
)	O
for	O
3	O
days	O
.	O

Ka	O
##zu	O
##aki	O
et	O
.	O
al	O
.	O
demonstrated	O
that	O
in	O
2	O
-	O
D	O
##M	O
patients	O
,	O
preserved	O
left	O
vent	O
##ric	O
##ular	O
e	O
##jection	O
fraction	O
reduced	O
heart	O
rate	O
recovery	O
and	O
was	O
associated	O
with	O
A	B
##F	I
,	O
ill	O
##ust	O
##rating	O
that	O
auto	O
##no	O
##mic	O
ne	O
##uro	O
##pathy	O
seems	O
to	O
be	O
involved	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
A	B
##F	I
.	O

This	O
is	O
true	O
in	O
cases	O
of	O
l	B
-	I
c	I
##ys	I
##tein	I
##e	I
and	O
c	B
##rea	I
##tine	I
,	O
whose	O
peak	O
area	O
ratio	O
between	O
G	O
##C	O
-	O
MS	O
and	O
G	O
##C	O
##×	O
##GC	O
-	O
MS	O
was	O
9	O
.	O
28	O
and	O
8	O
.	O
35	O
,	O
respectively	O
.	O

Inc	O
##reased	O
amounts	O
of	O
amino	O
acids	O
caused	O
by	O
extended	O
serum	O
storage	O
were	O
obtained	O
due	O
to	O
serum	O
protein	O
##ase	O
activity	O
,	O
and	O
augmented	O
glucose	B
-	I
6	I
-	I
phosphate	I
concentrations	O
that	O
were	O
obtained	O
because	O
of	O
prolonged	O
blood	O
in	O
##cu	O
##bation	O
most	O
probably	O
originated	O
from	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
cycle	O
in	O
er	O
##yt	O
##hr	O
##ocytes	O
.	O

The	O
patients	O
received	O
10	O
mg	O
a	B
##rsen	I
##ic	I
trio	I
##xi	I
##de	I
each	O
day	O
via	O
in	O
##tra	O
##ven	O
##ous	O
in	O
##fusion	O
.	O

Non	O
-	O
de	O
##uter	O
##ated	O
IS	O
such	O
as	O
im	B
##ip	I
##ram	I
##ine	I
,	O
tram	O
##ado	O
##l	O
and	O
ate	B
##no	I
##lo	I
##l	I
all	O
have	O
been	O
successfully	O
used	O
for	O
the	O
q	O
##uant	O
##itation	O
of	O
V	O
##X	O
and	O
O	O
-	O
D	O
##V	O
##X	O
.	O

Dash	O
##ed	O
boxes	O
indicate	O
pools	O
of	O
meta	O
##bol	O
##ites	O
:	O
t	O
##C	O
##r	O
,	O
total	O
c	B
##rea	I
##tine	I
##s	I
(	I
c	I
##rea	I
##tine	I
+	I
p	I
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
)	I
;	O
t	O
##C	O
##ho	O
,	O
total	O
ch	B
##olin	I
##es	I
(	I
ch	I
##olin	I
##e	I
+	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
+	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	I
;	O
t	O
##G	O
##lut	O
,	O
g	B
##lut	I
##ama	I
##te	I
+	O
g	B
##lut	I
##amine	I
pool	O
;	O
P	O
##t	O
##d	O
##C	O
##ho	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

It	O
has	O
to	O
be	O
noted	O
,	O
that	O
within	O
the	O
same	O
study	O
children	O
treated	O
with	O
the	B
##op	I
##hyl	I
##line	I
because	O
of	O
as	O
##th	O
##ma	O
showed	O
a	O
trans	O
##ient	O
increase	O
in	O
plasma	O
T	O
##4	O
,	O
which	O
would	O
fit	O
to	O
the	O
disappearance	O
of	O
the	O
F	O
##T	O
##4	O
—	O
t	O
##rig	O
##one	O
##llin	O
##e	O
association	O
in	O
longitudinal	O
analyses	O
.	O

Normally	O
,	O
10	O
ul	O
of	O
urine	O
are	O
dissolved	O
in	O
1	O
m	O
##l	O
−	O
##20	O
°C	O
cooled	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
and	O
water	O
(	O
3	O
:	O
3	O
:	O
2	O
v	O
/	O
v	O
)	O
mixture	O
at	O
pH	O
7	O
.	O

Of	O
these	O
subjects	O
,	O
6	O
.	O
9	O
%	O
developed	O
fast	O
##ing	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
,	O
indicated	O
by	O
fast	O
##ing	O
plasma	O
glucose	S
greater	O
than	O
125	O
mg	O
/	O
d	O
##L	O
,	O
and	O
25	O
.	O
0	O
%	O
became	O
pre	O
-	O
di	O
##abe	O
##tic	O
,	O
as	O
indicated	O
by	O
fast	O
##ing	O
plasma	O
glucose	S
levels	O
between	O
100	O
and	O
125	O
mg	O
/	O
d	O
##L	O
.	O
Fast	O
##ing	O
plasma	O
glucose	S
of	O
all	O
subjects	O
was	O
above	O
the	O
lower	O
limit	O
for	O
normal	O
fast	O
##ing	O
plasma	O
glucose	S
levels	O
of	O
70	O
mg	O
/	O
d	O
##L	O
;	O
thus	O
,	O
none	O
of	O
the	O
subjects	O
developed	O
h	O
##y	O
##po	O
##gly	O
##ce	O
##mia	O
.	O

Our	O
key	O
finding	O
is	O
the	O
significantly	O
higher	O
GM	B
##3	I
plasma	O
concentration	O
in	O
PD	O
cases	O
compared	O
to	O
controls	O
.	O

+	B
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##ρ	I
##s	I
##j	I
(	I
y	I
##j	I
)	I
x	I
##s	I
+	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##φ	I
##r	I
##j	I
(	I
y	I
##r	I
,	I
y	I
##j	I
)	I
)	O

O	O
##xi	O
##dation	O
of	O
L	O
##D	O
##L	O
produces	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
products	O
such	O
as	O
lip	O
##id	O
per	B
##oxide	I
##s	I
that	O
in	O
turn	O
influence	O
the	O
metabolism	O
of	O
fat	O
-	O
soluble	O
vitamin	O
##s	O
inside	O
cells	O
.	O

It	O
was	O
recently	O
reported	O
that	O
the	O
total	O
hip	O
##po	O
##cam	O
##pal	O
and	O
am	O
##y	O
##g	O
##dal	O
##a	O
volume	O
in	O
patients	O
with	O
MD	O
##D	O
correlated	O
with	O
a	O
reduced	O
plasma	O
K	O
##Y	O
##NA	O
/	O
Q	O
##UI	O
##N	O
ratio	O
,	O
indicating	O
that	O
an	O
over	O
##wei	O
##gh	O
of	O
the	O
toxic	O
branch	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
may	O
be	O
of	O
importance	O
for	O
the	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
occurring	O
in	O
these	O
patients	O
.	O

Another	O
important	O
finding	O
is	O
that	O
the	O
high	O
inter	O
-	O
patient	O
variation	O
in	O
serum	O
concentrations	O
of	O
4	O
##OH	O
##ND	O
##tam	O
was	O
most	O
pronounced	O
in	O
the	O
oldest	O
patient	O
group	O
,	O
probably	O
due	O
to	O
more	O
con	O
##com	O
##ita	O
##nt	O
diseases	O
and	O
increased	O
use	O
of	O
additional	O
drugs	O
that	O
may	O
interact	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
metabolism	O
.	O

The	O
MS	O
_	O
3	O
s	O
##pect	O
##ra	O
correspond	O
to	O
GP	O
-	O
tag	O
##ged	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
26	I
-	I
nor	I
##cho	I
##les	I
##t	I
-	I
4	I
-	I
en	I
##e	I
-	I
3	I
,	I
x	I
-	I
di	I
##one	I
(	O
c	O
)	O
;	O
24	O
(	O
S	O
)	O

Moreover	O
,	O
in	O
order	O
to	O
gain	O
further	O
insights	O
in	O
the	O
ne	O
##uro	O
##p	O
##rote	O
##ction	O
mechanisms	O
during	O
pregnancy	O
and	O
in	O
the	O
metabolic	O
alterations	O
character	O
##izing	O
the	O
pre	O
##ci	O
##pit	O
##ous	O
re	O
##lap	O
##se	O
in	O
the	O
post	O
-	O
part	O
##um	O
period	O
of	O
Mu	O
##S	O
patients	O
,	O
we	O
also	O
monitored	O
differences	O
in	O
other	O
metabolic	O
classes	O
,	O
such	O
as	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
c	B
##era	I
##mi	I
##des	I
,	O
AA	O
##s	O
,	O
ACC	O
##s	O
,	O
SA	O
,	O
n	O
##uc	O
##leo	O
##side	O
##s	O
,	O
and	O
LP	O
##Cs	O
.	O

E	O
##SI	O
interface	O
tuning	O
and	O
mass	O
ca	O
##li	O
##bra	O
##tion	O
were	O
accomplished	O
in	O
the	O
P	O
##I	O
mode	O
by	O
using	O
a	O
standard	O
sodium	B
i	I
##od	I
##ide	I
-	I
rub	I
##id	I
##ium	I
i	I
##od	I
##ide	I
solution	O
.	O

This	O
observation	O
suggests	O
a	O
possible	O
path	O
##ogen	O
##etic	O
link	O
on	O
the	O
cellular	O
level	O
,	O
under	O
##lining	O
the	O
association	O
between	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
accumulation	O
,	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
per	O
##ox	O
##is	O
##ome	O
d	O
##ys	O
##function	O
and	O
accordingly	O
,	O
defects	O
of	O
p	O
##las	O
##mo	O
##log	O
##ens	O
bio	O
##sy	O
##nt	O
##hesis	O
.	O

We	O
also	O
observed	O
decreased	O
CS	O
##F	O
c	B
##rea	I
##tine	I
level	O
in	O
the	O
MS	O
patient	O
group	O
.	O

In	O
contrast	O
,	O
all	O
sugar	O
##s	O
were	O
captured	O
by	O
at	O
least	O
one	O
H	O
##IL	O
##IC	O
method	O
with	O
the	O
exception	O
of	O
a	B
##rab	I
##ino	I
##se	I
.	O

Target	O
##ed	O
tandem	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
was	O
used	O
to	O
compare	O
am	O
##ine	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
in	O
plasma	O
samples	O
of	O
patients	O
with	O
T	O
##B	O
or	O
T	O
##B	O
-	O
D	O
##M	O
from	O
Indonesia	O
at	O
time	O
of	O
diagnosis	O
and	O
during	O
anti	O
##biotic	O
treatment	O
.	O

To	O
date	O
,	O
however	O
,	O
g	B
##lut	I
##amine	I
has	O
been	O
considered	O
as	O
a	O
relatively	O
stable	O
meta	O
##bol	O
##ite	O
under	O
the	O
mild	O
conditions	O
widely	O
used	O
in	O
the	O
analysis	O
of	O
human	O
blood	O
serum	O
,	O
for	O
example	O
in	O
N	O
##MR	O
analysis	O
.	O

The	O
pro	O
##ton	O
was	O
found	O
to	O
be	O
allocated	O
on	O
the	O
N	O
-	O
terminal	O
b	O
_	O
n	O
ion	O
,	O
while	O
sodium	B
ion	I
residues	O
were	O
allocated	O
on	O
the	O
y	O
""""	O
_	O
n	O
C	O
-	O
terminal	O
fragment	O
.	O

SP	O
##MS	O
patients	O
had	O
altered	O
k	B
##yn	I
##uren	I
##ine	I
compared	O
with	O
R	O
##R	O
##MS	O
patients	O
,	O
and	O
altered	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tate	I
compared	O
with	O
controls	O
.	O

Models	O
built	O
with	O
data	O
from	O
Set	O
A	O
serum	O
samples	O
showed	O
a	O
significant	O
separation	O
between	O
R	O
##R	O
and	O
SP	S
groups	O
(	O
q	O
_	O
2	O
=	O
0	O
.	O
45	O
,	O
)	O
.	O

A	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
production	O
was	O
decreased	O
in	O
IS	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
(	O
Fi	O
##g	O
.	O

The	O
_	O
13	O
C	O
-	O
position	O
##al	O
is	O
##oto	O
##po	O
##mer	O
information	O
obtained	O
from	O
the	O
TO	O
##CS	O
##Y	O
analysis	O
was	O
confirmed	O
by	O
the	O
H	O
##S	O
##Q	O
##C	O
analysis	O
,	O
including	O
the	O
position	O
##al	O
is	O
##oto	O
##po	O
##mers	O
of	O
_	O
13	O
C	O
-	O
3	O
-	O
Al	O
##a	O
,	O
_	O
13	O
C	B
-	I
3	I
-	I
la	I
##ct	I
##ate	I
,	O
_	O
13	O
C	O
-	O
3	O
-	O
G	O
##lu	O
,	O
_	O
13	O
C	O
-	O
3	O
-	O
G	O
##ln	O
_	O
13	O
C	B
-	I
3	I
-	I
G	I
##lu	I
-	I
G	I
##SS	I
##G	I
,	O
_	O
13	O
C	B
-	I
2	I
-	I
G	I
##lu	I
-	I
G	I
##SS	I
##G	I
,	O
_	O
13	O
C	O
-	O
2	O
-	O
G	O
##lu	O
,	O
and	O
_	O
13	O
C	O
-	O
2	O
-	O
As	O
##p	O
(	O
c	O
##f	O
.	O
respectively	O

The	O
initial	O
focus	O
of	O
this	O
work	O
was	O
on	O
the	O
identification	O
and	O
relative	O
q	O
##uant	O
##ification	O
of	O
o	B
##xy	I
##ster	I
##ols	I
in	O
CS	O
##F	O
.	O

Besides	O
the	O
I	O
##AC	O
en	O
##rich	O
##ment	O
,	O
a	O
second	O
step	O
of	O
sample	O
preparation	O
using	O
solid	O
-	O
phase	O
extraction	O
(	O
SP	O
##E	O
;	O
O	O
##asis	O
H	O
##L	O
##B	O
,	O
Waters	O
)	O
was	O
conducted	O
to	O
overcome	O
issues	O
associated	O
with	O
low	O
D	O
##ON	O
and	O
deep	B
##ox	I
##y	I
-	I
D	I
##ON	I
recover	O
##ies	O
.	O

B	O
##12	O
,	O
vitamin	O
B	O
-	O
12	O
;	O
c	O
##B	O
##12	O
,	O
combined	O
indicator	O
of	O
vitamin	O
B	O
-	O
12	O
status	O
;	O
ho	O
##lo	O
##TC	O
,	O
ho	O
##lot	O
##ran	O
##sco	O
##bal	O
##ami	O
##n	O
;	O
MMA	O
,	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
;	O
post	O
,	O
after	O
;	O
pre	O
,	O
before	O
;	O
t	O
##H	O
##cy	O
,	O
total	O
plasma	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
.	O

The	O
BA	O
##TM	O
##AN	O
model	O
was	O
applied	O
to	O
estimate	O
the	O
relative	O
concentrations	O
of	O
the	O
following	O
meta	O
##bol	O
##ites	O
in	O
the	O
400	O
MHz	O
s	O
##pect	O
##ra	O
:	O
al	B
##ani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
pro	B
##line	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
α	B
-	I
D	I
-	I
g	I
##lu	I
##copy	I
##rano	I
##se	I
,	O
β	B
-	I
D	I
-	I
g	I
##lu	I
##copy	I
##rano	I
##se	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
ace	B
##tate	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
c	B
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
su	B
##cci	I
##nate	I
,	O
c	B
##rea	I
##tine	I
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Also	O
,	O
it	O
is	O
known	O
that	O
formation	O
of	O
met	B
##han	I
##ol	I
from	O
ing	O
##est	O
##ion	O
of	O
as	B
##par	I
##tam	I
##e	I
is	O
of	O
lower	O
magnitude	O
than	O
met	B
##han	I
##ol	I
from	O
end	O
##ogen	O
##ous	O
pathways	O
and	O
from	O
other	O
ing	O
##ested	O
sources	O
,	O
e	O
.	O
g	O
.	O
fruit	O
juice	O
[	O
–	O
]	O
.	O

Thus	O
,	O
we	O
used	O
the	O
“	O
add	O
-	O
to	O
-	O
sub	O
##tract	O
”	O
method	O
to	O
exclude	O
glucose	S
signals	O
from	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
:	O
(	O
1	O
)	O
we	O
added	O
1	O
μ	O
##L	O
of	O
1	O
##M	O
D	B
-	I
glucose	I
in	O
PBS	O
to	O
each	O
sample	O
and	O
repeated	O
N	O
##MR	O
measurement	O
with	O
identical	O
experimental	O
parameters	O
,	O
leading	O
to	O
a	O
total	O
of	O
302	O
s	O
##pect	O
##ra	O
for	O
151	O
patients	O
(	O
151	O
original	O
,	O
151	O
with	O
additional	O
glucose	S
)	O
;	O
(	O
2	O
)	O
using	O
Top	O
##sp	O
##in	O
’	O
s	O
multiple	O
display	O
,	O
we	O
determined	O
the	O
corresponding	O
s	O
##cal	O
##ing	O
factor	O
between	O
Spectrum	O
2	O
and	O
Spectrum	O
1	O
for	O
each	O
sample	O
that	O
ensures	O
elimination	O
of	O
the	O
glucose	S
signal	O
upon	O
sub	O
##traction	O
;	O
(	O
3	O
)	O
then	O
the	O
exported	O
S	O
##pect	O
##ra	O
1	O
and	O
2	O
for	O
each	O
sample	O
were	O
aligned	O
using	O
“	O
i	O
##cos	O
##hi	O
##ft	O
”	O
on	O
the	O
glucose	S
peaks	O
at	O
3	O
.	O
37	O
–	O
3	O
.	O
44	O
pp	O
##m	O
and	O
then	O
along	O
10	O
equal	O
segments	O
;	O
and	O
(	O
4	O
)	O
for	O
each	O
sample	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
meta	O
##bon	O
##omi	O
##cs	O
models	O
indicated	O
differences	O
between	O
the	O
groups	O
regarding	O
the	O
serum	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
HD	O
##L	O
.	O

The	O
rest	O
of	O
the	O
c	B
##era	I
##mi	I
##de	I
species	O
were	O
not	O
significantly	O
different	O
between	O
the	O
AD	O
and	O
control	O
groups	O
.	O

Pat	O
##ient	O
and	O
control	O
plasma	O
##s	O
were	O
analyzed	O
in	O
Leipzig	O
for	O
their	O
concentration	O
of	O
seven	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
P	O
##U	O
##FA	O
##s	O
)	O
and	O
94	O
e	B
##ico	I
##san	I
##oids	I
using	O
fast	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
q	O
##uad	O
##rup	O
##ole	O
linear	O
ion	O
-	O
trap	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

During	O
week	O
0	O
(	O
base	O
##line	O
;	O
3	O
weeks	O
after	O
the	O
screening	O
visit	O
maximum	O
)	O
,	O
at	O
the	O
first	O
visit	O
,	O
serum	O
and	O
muscle	O
samples	O
were	O
collected	O
(	O
see	O
below	O
and	O
Additional	O
file	O
1	O
)	O
,	O
and	O
a	O
h	B
##yper	I
##ins	I
##ulin	I
##em	I
##ic	I
-	I
e	I
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
was	O
performed	O
(	O
see	O
below	O
)	O
.	O

There	O
were	O
13	O
retention	O
markers	O
employed	O
in	O
the	O
L	O
##C	O
-	O
positive	O
electro	O
##sp	O
##ray	O
mode	O
and	O
11	O
in	O
the	O
L	O
##C	O
-	O
negative	O
mode	O
,	O
el	O
##uti	O
##ng	O
every	O
30	O
##s	O
of	O
ch	O
##roma	O
##tography	O
,	O
and	O
these	O
markers	O
were	O
given	O
a	O
fixed	O
R	B
##I	I
that	O
provided	O
a	O
linear	O
reference	O
for	O
extra	O
##pol	O
##ation	O
of	O
the	O
anal	O
##yte	O
##s	O
’	O
el	O
##ution	O
times	O
.	O

The	O
residue	O
lip	O
##id	O
solution	O
after	O
washing	O
was	O
used	O
for	O
the	O
analysis	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
by	O
using	O
in	O
##tras	O
##our	O
##ce	O
separation	O
followed	O
by	O
employing	O
multi	O
-	O
dimensional	O
mass	O
s	O
##pect	O
##rome	O
##tric	O
analysis	O
.	O

The	O
ca	B
##ffe	I
##ine	I
based	O
model	O
was	O
able	O
to	O
correctly	O
class	O
##ify	O
most	O
high	O
coffee	O
consumers	O
,	O
but	O
mi	O
##s	O
##classified	O
half	O
of	O
the	O
low	O
-	O
consumers	O
,	O
either	O
in	O
the	O
training	O
set	O
or	O
hold	O
-	O
out	O
set	O
.	O

Of	O
particular	O
note	O
were	O
the	O
protein	O
##ogenic	O
branched	O
chain	O
amino	O
acids	O
(	B
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
)	O
.	O

Dec	O
##reased	O
levels	O
of	O
palm	B
##itic	I
acid	I
,	O
my	B
##rist	I
##ic	I
acid	I
and	O
car	B
##ni	I
##tine	I
,	O
the	O
carrier	O
of	O
fatty	O
acids	O
,	O
were	O
observed	O
in	O
color	O
##ec	O
##tal	O
cancer	O
se	O
##ra	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
calculated	O
for	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
versus	O
control	O
groups	O
generated	O
one	O
predict	O
##ive	O
component	O
with	O
two	O
or	O
##th	O
##ogo	O
##nal	O
components	O
and	O
explained	O
89	O
%	O
of	O
the	O
variance	O
of	O
on	O
the	O
class	O
variable	O
matrix	O
(	O
Y	O
)	O
with	O
a	O
predict	O
##ive	O
value	O
of	O
72	O
%	O
according	O
to	O
the	O
cross	O
-	O
valid	O
##ation	O
parameter	O
(	O
Q	O
_	O
2	O
Y	O
=	O
0	O
.	O
72	O
)	O
.	O

Red	O
##uce	O
##d	O
thy	B
##ro	I
##xin	I
##e	I
levels	O
in	O
CS	O
##F	O
have	O
been	O
reported	O
in	O
other	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
disorders	O
such	O
as	O
Alzheimer	O
’	O
s	O
disease	O
(	O
AD	O
)	O
and	O
t	B
##yr	I
##os	I
##ine	I
has	O
been	O
reported	O
decreased	O
in	O
post	O
m	O
##ort	O
##em	O
HD	O
brain	O
tissue	O
(	O
frontal	O
lobe	O
and	O
s	O
##tri	O
##at	O
##um	O
)	O
.	O

We	O
anticipated	O
that	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
would	O
be	O
elevated	O
in	O
the	O
plasma	O
of	O
insulin	O
-	O
deprived	O
individuals	O
,	O
consistent	O
with	O
increased	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
through	O
the	O
glucose	B
-	I
al	I
##ani	I
##ne	I
and	O
Co	O
##ri	O
cycles	O
as	O
previously	O
shown	O
in	O
di	O
##abe	O
##tic	O
rats	O
and	O
humans	O
.	O

A	O
su	B
##c	I
##rose	I
tune	O
file	O
in	O
negative	O
/	O
positive	O
modes	O
at	O
normal	O
L	O
##C	O
flow	O
rate	O
was	O
used	O
.	O

These	O
data	O
,	O
associated	O
with	O
the	O
data	O
reported	O
in	O
the	O
accompanying	O
manuscript	O
,	O
supports	O
a	O
role	O
for	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
in	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
chronic	O
headache	O
disorders	O
.	O

In	O
addition	O
to	O
the	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
et	I
##hane	I
and	O
pen	B
##tan	I
##e	I
,	O
which	O
are	O
frequently	O
used	O
for	O
respiratory	O
gas	O
-	O
mediated	O
tumor	O
diagnostic	O
##s	O
[	O
,	O
]	O
,	O
the	O
al	O
##de	O
##hy	O
##des	O
are	O
also	O
used	O
as	O
volatile	O
bio	O
##mark	O
##ers	O
for	O
the	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
of	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
[	O
,	O
]	O
.	O

Met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
sodium	B
phosphate	I
,	O
mon	O
##ob	O
##asi	O
##c	O
(	O
Na	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
)	O
,	O
sodium	B
phosphate	I
,	O
di	O
##bas	O
##ic	O
(	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
)	O
,	O
and	O
3	B
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
prop	I
##ion	I
##ic	I
acid	I
-	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
d	I
_	O
4	O
sodium	O
salt	O
(	O
T	O
##SP	O
)	O
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Sam	O
##ples	O
with	O
a	O
low	O
g	B
##lut	I
##amine	I
/	O
g	O
##lut	O
##ama	O
##te	O
ratio	O
were	O
excluded	O
from	O
analyses	O
of	O
g	B
##lut	I
##amine	I
associations	O
.	O

A	O
panel	O
of	O
c	O
##yt	O
##oki	O
##nes	O
and	O
other	O
inflammatory	O
markers	O
in	O
plasma	O
,	O
including	O
inter	O
##le	O
##uki	O
##n	O
(	B
IL	I
)	I
-	I
1	I
##α	I
,	O
IL	B
-	I
1	I
##β	I
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
,	O
T	O
##NF	O
##α	O
,	O
IL	O
-	O
17	O
##A	O
,	O
soluble	O
VC	O
##AM	O
-	O
1	O
(	O
s	O
##VC	O
##AM	O
-	O
1	O
)	O
,	O
soluble	O
I	O
##CA	O
##M	O
-	O
1	O
(	O
s	O
##IC	O
##AM	O
-	O
1	O
)	O
,	O
c	O
-	O
reactive	O
protein	O
(	O
CR	O
##P	O
)	O
and	O
inter	O
##fer	O
##on	O
γ	O
(	B
IF	B
##N	I
##γ	I
)	O
,	O
were	O
measured	O
using	O
a	O
multiple	O
##x	O
immune	O
ass	O
##ay	O
(	O
V	O
-	O
P	O
##lex	O
Me	B
##so	I
Scale	O
Discovery	O
)	O
.	O

Under	O
such	O
circumstances	O
,	O
increased	O
fatty	O
acid	O
mob	O
##ilization	O
may	O
occur	O
as	O
a	O
potential	O
energy	O
source	O
,	O
explaining	O
the	O
rise	O
in	O
plasma	O
o	B
##le	I
##ic	I
acid	I
.	O

Also	O
,	O
earlier	O
studies	O
have	O
reported	O
that	O
lower	O
serum	O
levels	O
of	O
18	O
:	O
2	O
l	O
##ys	O
##o	O
##PC	O
,	O
a	O
downstream	O
product	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
,	O
has	O
a	O
tight	O
relationship	O
with	O
increased	O
art	O
##erial	O
stiff	O
##ness	O
,	O
increased	O
resting	O
heart	O
rate	O
and	O
occurrence	O
of	O
silent	O
my	O
##oc	O
##ard	O
##ial	O
is	O
##che	O
##mia	O
.	O

H	O
##B	O
##e	O
##A	O
##g	O
negative	O
patients	O
showed	O
a	O
significant	O
increase	O
in	O
c	B
##rea	I
##tin	I
##ine	I
(	O
P	O
=	O
0	O
.	O
00	O
##1	O
)	O
compared	O
to	O
H	O
##B	O
##e	O
##A	O
##g	O
positive	O
patients	O
in	O
the	O
chronic	O
he	O
##pa	O
##titis	O
B	O
subgroup	O
,	O
whilst	O
H	O
##B	O
##e	O
##A	O
##g	O
negative	O
patients	O
showed	O
a	O
significant	O
decrease	O
in	O
D	B
##MA	I
(	O
P	O
=	O
0	O
.	O
00	O
##4	O
)	O
in	O
the	O
c	O
##ir	O
##r	O
##hos	O
##is	O
subgroup	O
compared	O
to	O
H	O
##B	O
##e	O
##A	O
##g	O
positive	O
patients	O
.	O

K	O
##nock	O
##down	O
of	O
g	O
##ly	O
##cine	O
-	O
N	O
-	O
met	O
##hyl	O
transfer	O
##ase	O
(	O
G	O
##N	O
##MT	O
)	O
,	O
the	O
enzyme	O
that	O
generates	O
sa	B
##rc	I
##os	I
##ine	I
from	O
g	B
##ly	I
##cine	I
,	O
at	O
##ten	O
##uated	O
pro	O
##state	O
cancer	O
invasion	O
.	O

L	B
-	I
D	I
##OP	I
##A	I
correlated	O
with	O
all	O
cognitive	O
measurements	O
as	O
well	O
as	O
T	O
##FC	O
and	O
T	O
##MS	O
,	O
whereas	O
x	B
##ant	I
##hine	I
correlated	O
with	O
all	O
measures	O
of	O
disease	O
severity	O
except	O
for	O
S	O
##I	O
and	O
the	O
five	O
year	O
risk	O
of	O
onset	O
.	O

z	O
33	O
##7	O
##→	O
##18	O
##8	O
*	O
,	O
33	O
##7	O
##→	O
##10	O
##5	O
,	O
nor	O
##fen	O
##tany	O
##l	O
m	O
/	O
z	O
233	O
##→	O
##8	O
##4	O
*	O
,	O
233	O
##→	O
##55	O
,	O
and	O
f	B
##ent	I
##any	I
##l	I
-	I
d	I
##5	I
m	O
/	O
z	O
34	O
##2	O
##→	O
##10	O
##5	O
.	O

O	O
0	O
.	O
01	O
g	O
/	O
L	O
,	O
Na	O
##HC	O
##O	O
##3	O
2	O
g	O
/	O
L	O
,	O
T	O
##we	O
##en	O
80	O
2	O
m	O
##L	O
(	O
B	O
##D	O
##H	O
,	O
Poole	O
,	O
UK	O
)	O
,	O
ha	O
##em	O
##in	O
0	O
.	O
05	O
g	O
/	O
L	O
,	O
vitamin	B
K	I
##1	I
10	O
µ	O
##L	O
,	O
c	B
##ys	I
##tein	I
##e	I
-	I
HC	I
##l	I
0	O
.	O
5	O
g	O
/	O
L	O
,	O
bi	O
##le	O
salts	O
0	O
.	O
5	O
g	O
/	O
L	O
,	O
pH	O
7	O
.	O
0	O
)	O
]	O
were	O
placed	O
into	O
the	O
an	O
##ae	O
##ro	O
##bic	O
cabinet	O
and	O
kept	O
overnight	O
.	O

Ser	O
##um	O
T	B
##MA	I
##O	I
and	O
ch	B
##olin	I
##e	I
concentrations	O
were	O
grouped	O
into	O
q	O
##ua	O
##rt	O
##iles	O
(	O
Q	O
##1	O
–	O
Q	O
##4	O
)	O
based	O
on	O
control	O
subjects	O
,	O
and	O
then	O
the	O
cut	O
##offs	O
were	O
applied	O
to	O
the	O
P	O
##LC	O
patients	O
.	O

Con	O
##cent	O
##rations	O
of	O
D	O
##PP	O
standard	O
and	O
sample	O
were	O
40	O
##60	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
and	O
250	O
##4	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
,	O
respectively	O
.	O

Basel	O
##ine	O
ta	B
##uri	I
##ne	I
and	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
/	O
symmetric	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
SD	O
##MA	O
)	O
concentrations	O
were	O
inverse	O
##ly	O
associated	O
with	O
changes	O
in	O
WC	O
and	O
2	O
-	O
hour	O
glucose	S
,	O
respectively	O
,	O
while	O
g	B
##lut	I
##ama	I
##te	I
was	O
positively	O
associated	O
with	O
change	O
in	O
DB	B
##P	I
(	O
p	O
<	O
3	O
×	O
10	O
-	O
4	O
)	O
.	O

Tri	B
##ter	I
##pen	I
##e	I
1	O
and	O
the	O
DC	O
##M	O
leaf	O
extract	O
were	O
found	O
to	O
be	O
very	O
h	O
##ydro	O
##phobic	O
,	O
and	O
did	O
not	O
totally	O
dissolve	O
in	O
95	O
%	O
E	B
##t	I
##OH	I
and	O
DC	O
##M	O
.	O

While	O
the	O
identity	O
of	O
most	O
of	O
these	O
species	O
is	O
still	O
being	O
investigated	O
,	O
a	O
few	O
are	O
recognized	O
as	O
free	O
fatty	O
acids	O
,	O
such	O
as	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
m	O
/	O
z	O
303	O
.	O
2	O
.	O

The	O
estimated	O
levels	O
of	O
rib	B
##avi	I
##rin	I
trip	I
##hos	I
##phate	I
also	O
approach	O
the	O
reported	O
binding	O
constant	O
of	O
500	O
to	O
700	O
μ	O
##M	O
for	O
incorporation	O
as	O
an	O
ATP	S
or	O
GT	O
##P	O
analog	O
by	O
HC	O
##V	O
N	O
##S	O
##5	O
##B	O
.	O
In	O
a	O
previous	O
study	O
of	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
in	O
HC	O
##V	O
-	O
infected	O
patients	O
,	O
Rowe	O
##r	O
et	O
al	O
.	O

Nevertheless	O
,	O
further	O
studies	O
should	O
be	O
conduct	O
to	O
determine	O
the	O
pro	O
##gno	O
##stic	O
value	O
of	O
GA	O
##BR	O
or	O
c	B
##it	I
##ru	I
##llin	I
##e	I
levels	O
alone	O
in	O
a	O
prospective	O
fashion	O
under	O
a	O
broader	O
range	O
of	O
conditions	O
to	O
determine	O
its	O
pro	O
##gno	O
##stic	O
value	O
as	O
a	O
bio	O
##mark	O
##er	O
and	O
its	O
potential	O
to	O
guide	O
metabolic	O
therapy	O
.	O

P	O
##up	O
##illo	O
##metry	O
confirmed	O
that	O
the	O
duration	S
of	O
action	O
of	O
a	O
single	O
dose	O
of	O
met	B
##had	I
##one	I
given	O
by	O
this	O
route	O
was	O
at	O
least	O
10	O
h	O
.	O

More	O
recently	O
,	O
Ph	O
##IP	O
and	O
2	B
-	I
amino	I
-	I
9	I
##H	I
-	I
p	I
##yr	I
##ido	I
[	I
2	I
,	I
3	I
-	I
b	I
]	I
in	O
##do	O
##le	O
(	O
A	O
##α	O
##C	O
)	O
,	O
another	O
H	O
##AA	O
car	O
##cin	O
##ogen	O
present	O
in	O
tobacco	O
smoke	O
and	O
well	O
-	O
done	O
cooked	O
meat	O
##s	O
,	O
were	O
shown	O
to	O
react	O
with	O
the	O
Cy	O
##s	O
##34	O
of	O
human	O
Al	O
##b	O
to	O
form	O
su	B
##lf	I
##ina	I
##mi	I
##de	I
and	O
su	B
##lf	I
##ona	I
##mi	I
##de	I
add	O
##uc	O
##ts	O
in	O
v	O
##it	O
##ro	O
.	O

[	O
]	O
As	O
g	O
##lim	O
##ep	O
##iri	O
##de	O
stimulate	O
##s	O
insulin	O
secret	O
##ion	O
from	O
β	O
-	O
cells	O
,	O
one	O
could	O
expect	O
that	O
t	B
##yra	I
##mine	I
levels	O
may	O
change	O
in	O
the	O
subjects	O
who	O
were	O
ad	O
##mini	O
##stra	O
##ted	O
g	O
##lim	O
##ep	O
##iri	O
##de	O
.	O

The	O
chemical	O
shifts	O
of	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
reflected	O
the	O
acidic	O
pH	O
of	O
the	O
T	O
##CA	O
extract	O
.	O

Po	O
##ten	O
##tial	O
##ly	O
the	O
most	O
exciting	O
finding	O
was	O
that	O
p	B
##oly	I
##amine	I
metabolism	O
and	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
metabolism	O
were	O
the	O
only	O
two	O
pathways	O
impacted	O
across	O
all	O
group	O
comparisons	O
.	O

Thus	O
,	O
we	O
are	O
unable	O
to	O
relate	O
changes	O
in	O
meta	O
##bol	O
##ites	O
to	O
blood	O
or	O
tissue	O
levels	O
of	O
limo	B
##nen	I
##e	I
.	O

A	O
total	O
of	O
30	O
compounds	O
were	O
detected	O
and	O
q	O
##uant	O
##ified	O
in	O
Me	B
##OH	I
pp	O
##t	O
and	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
pool	O
##ed	O
human	O
serum	O
(	O
,	O
Table	O
S	O
##1	O
)	O
.	O

This	O
is	O
due	O
to	O
in	O
##hibition	O
of	O
mitochondrial	O
(	O
m	O
-	O
)	O
a	O
##con	O
##itas	O
##e	O
,	O
which	O
converts	O
c	B
##it	I
##rate	I
to	O
is	B
##oc	I
##it	I
##rate	I
in	O
the	O
T	O
##CA	O
cycle	O
.	O

(	O
d	O
)	O
;	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
e	O
)	O
;	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
f	O
)	O
;	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
g	O
)	O
.	O

Port	O
##ions	O
of	O
typical	O
800	O
MHz	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
human	O
whole	O
blood	O
and	O
blood	O
plasma	O
from	O
the	O
same	O
individual	O
obtained	O
after	O
extraction	O
using	O
met	B
##han	I
##ol	I
and	O
ch	B
##lor	I
##of	I
##orm	I
in	O
a	O
1	O
:	O
2	O
:	O
2	O
ratio	O
(	O
v	O
/	O
v	O
/	O
v	O
)	O
.	O

(	O
2017	O
)	O
reported	O
the	O
activity	O
of	O
g	B
##ins	I
##eno	I
##side	I
(	O
15	O
)	O
(	O
MI	O
##C	O
1	O
.	O
6	O
–	O
3	O
.	O
2	O
mg	O
/	O
m	O
##L	O
)	O
isolated	O
from	O
extract	O
of	O
end	O
##op	O
##hy	O
##te	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

Given	O
the	O
proposed	O
role	O
of	O
certain	O
FA	S
as	O
media	O
##tors	O
of	O
inflammatory	O
responses	O
,	O
we	O
explored	O
whether	O
increased	O
T	O
##h	O
##1	O
or	O
T	O
##h	O
##17	O
responses	O
,	O
usually	O
found	O
in	O
RA	O
patients	O
,	O
may	O
be	O
associated	O
with	O
NE	O
##FA	O
profiles	O
.	O

We	O
successfully	O
analyzed	O
the	O
possible	O
circa	O
##dian	O
variation	O
of	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
in	O
healthy	O
young	O
adults	O
as	O
well	O
as	O
patients	O
with	O
an	O
##ore	O
##xia	O
ne	O
##r	O
##vos	O
##a	O
in	O
childhood	O
and	O
ad	O
##ole	O
##scence	O
after	O
recovery	O
of	O
body	O
weight	O
by	O
treatment	O
using	O
the	O
sum	O
of	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
in	O
urine	O
using	O
G	O
##C	O
/	O
MS	O
in	O
S	O
##IM	O
.	O

Given	O
that	O
the	O
previous	O
analyses	O
demonstrate	O
an	O
association	O
between	O
metabolic	O
factors	O
of	O
K	B
##P	I
and	O
MD	O
##D	O
,	O
R	O
##OC	O
analysis	O
was	O
performed	O
to	O
establish	O
a	O
diagnostic	O
value	O
of	O
these	O
metabolic	O
factors	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
must	O
then	O
be	O
re	O
-	O
met	O
##hyl	O
##ated	O
to	O
met	B
##hi	I
##oni	I
##ne	I
by	O
combining	O
with	O
5	B
-	I
met	I
##hyl	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
,	O
which	O
depends	O
on	O
se	B
##rine	I
to	O
be	O
re	O
##generate	O
##d	O
,	O
or	O
with	O
beta	B
##ine	I
,	O
or	O
it	O
can	O
be	O
meta	O
##bol	O
##ized	O
to	O
c	B
##ys	I
##tein	I
##e	I
for	O
further	O
degradation	O
or	O
urine	O
ex	O
##cre	O
##tion	O
.	O

Prior	O
to	O
s	O
##ym	O
##pt	O
##om	O
onset	O
,	O
brain	O
ch	B
##ole	I
##ster	I
##ol	I
is	O
increased	O
,	O
and	O
s	B
##tat	I
##ins	I
were	O
found	O
to	O
am	O
##eli	O
##ora	O
##te	O
motor	O
symptoms	O
and	O
to	O
extend	O
life	O
##span	O
in	O
Me	O
##c	O
##p	O
##2	O
-	O
mutant	O
mice	O
.	O

However	O
,	O
when	O
the	O
cases	O
were	O
divided	O
into	O
groups	O
according	O
to	O
basal	O
re	O
##nal	O
function	O
,	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
was	O
found	O
to	O
be	O
higher	O
in	O
F	O
##S	O
##GS	O
than	O
control	O
or	O
MC	O
##D	O
in	O
both	O
discovery	O
and	O
valid	O
##ation	O
sets	O
(	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

The	O
treatment	O
was	O
a	O
single	O
injection	O
of	O
10	O
mg	O
vitamin	O
B	O
-	O
12	O
with	O
100	O
mg	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
and	O
100	O
mg	O
th	B
##iam	I
##in	I
.	O

Finally	O
,	O
the	O
multiple	O
re	O
##gression	O
analysis	O
found	O
that	O
W	O
##OL	O
,	O
milk	O
yield	O
and	O
the	O
content	O
of	O
fat	O
and	O
protein	O
in	O
milk	O
,	O
were	O
able	O
to	O
explain	O
a	O
moderate	O
proportion	O
of	O
the	O
variation	O
in	O
total	O
ch	B
##olin	I
##e	I
in	O
milk	O
during	O
la	O
##ct	O
##ation	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
67	O
;	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

(	O
A	O
)	O
Met	O
##ab	O
##olic	O
processes	O
in	O
healthy	O
,	O
non	O
-	O
cancer	O
cells	O
,	O
with	O
energy	O
flow	O
driven	O
primarily	O
by	O
glucose	S
metabolism	O
(	O
g	O
##ly	O
##co	O
##lysis	O
,	O
T	O
##CA	O
cycle	O
)	O
.	O

At	O
present	O
,	O
we	O
are	O
unable	O
to	O
explain	O
the	O
underlying	O
mechanism	O
for	O
the	O
change	O
in	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
but	O
one	O
possibility	O
may	O
be	O
found	O
in	O
alterations	O
of	O
pu	B
##rine	I
metabolism	O
that	O
occur	O
during	O
tumor	O
development	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
and	O
or	B
##ni	I
##thin	I
##e	I
are	O
also	O
both	O
intermediate	O
##s	O
in	O
the	O
cat	O
##ab	O
##olis	O
##m	O
of	O
amino	O
acids	O
by	O
the	O
u	B
##rea	I
cycle	O
and	O
their	O
strong	O
correlation	O
,	O
suggests	O
an	O
increased	O
flux	O
through	O
the	O
u	B
##rea	I
cycle	O
and	O
amino	O
acid	O
cat	O
##ab	O
##olis	O
##m	O
.	O

One	O
study	O
reported	O
that	O
the	O
administration	O
of	O
the	O
plasma	O
##log	O
##en	O
precursor	O
al	B
##ky	I
##l	I
g	I
##ly	I
##cer	I
##ol	I
prevented	O
he	O
##pa	O
##tic	O
s	O
##te	O
##ato	O
##sis	O
and	O
NAS	O
##H	O
and	O
an	O
increase	O
in	O
fatty	O
acid	O
oxidation	O
in	O
an	O
animal	O
model	O
.	O

An	O
over	O
##weight	O
/	O
o	O
##besity	O
lip	O
##ido	O
##mic	O
signature	O
was	O
only	O
apparent	O
in	O
plasma	O
,	O
pre	O
##dom	O
##inated	O
by	O
higher	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
and	O
lower	O
plasma	O
##log	O
##en	O
species	O
.	O

Z	O
##ira	O
et	O
al	O
.	O
)	O
have	O
shown	O
alterations	O
in	O
g	B
##lut	I
##amine	I
levels	O
that	O
are	O
presumably	O
associated	O
with	O
increased	O
metabolic	O
activity	O
derived	O
from	O
the	O
conditions	O
of	O
h	O
##y	O
##pox	O
##ia	O
and	O
h	O
##yper	O
##met	O
##ab	O
##olis	O
##m	O
observed	O
in	O
the	O
tumor	O
environment	O
(	O
E	O
##ige	O
##n	O
##bro	O
##dt	O
et	O
al	O
.	O
)	O
.	O

Take	O
##n	O
together	O
with	O
the	O
results	O
of	O
our	O
study	O
,	O
these	O
prior	O
results	O
suggest	O
that	O
the	O
in	O
##tra	O
##cellular	O
concentration	O
of	O
rib	B
##avi	I
##rin	I
n	O
##uc	O
##leo	O
##tide	O
meta	O
##bol	O
##ites	O
is	O
highest	O
in	O
RB	O
##C	O
,	O
followed	O
by	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
and	O
then	O
P	O
##BM	O
##C	O
.	O

Mean	O
D	O
##IM	O
averaged	O
0	O
.	O
03	O
±	O
0	O
.	O
01	O
%	O
(	O
Brussels	O
s	O
##p	O
##rout	O
##s	O
)	O
and	O
0	O
.	O
01	O
±	O
0	O
.	O
00	O
%	O
(	O
cab	O
##bage	O
)	O
of	O
the	O
g	B
##lu	I
##co	I
##bra	I
##ssi	I
##cin	I
consumed	O
,	O
ranging	O
from	O
1	O
.	O
40	O
to	O
44	O
.	O
00	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
Brussels	O
s	O
##p	O
##rout	O
##s	O
)	O
and	O
0	O
to	O
1	O
.	O
47	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
cab	O
##bage	O
)	O
.	O

Ser	O
##um	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
levels	O
,	O
an	O
indicator	O
of	O
vitamin	O
B	O
-	O
12	O
status	O
,	O
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

In	O
##trar	O
##ena	O
##l	O
do	B
##pa	I
##mine	I
has	O
been	O
found	O
to	O
account	O
for	O
more	O
than	O
50	O
%	O
of	O
the	O
kidney	O
’	O
s	O
salt	O
ex	O
##cre	O
##tion	O
ability	O
and	O
is	O
therefore	O
of	O
great	O
importance	O
for	O
blood	O
pressure	O
control	O
.	O

N	O
##MR	O
data	O
were	O
visually	O
inspected	O
,	O
imported	O
in	O
Mat	O
##la	O
##b	O
,	O
phased	O
,	O
base	O
##line	O
corrected	O
and	O
referenced	O
to	O
T	O
##SP	O
(	O
urine	O
)	O
and	O
glucose	S
(	O
serum	O
)	O
using	O
in	O
-	O
house	O
routines	O
.	O

The	O
active	O
site	O
of	O
c	B
##rea	I
##tine	I
kinase	O
.	O

The	O
RB	O
##C	O
l	O
##ys	O
##ates	O
were	O
prepared	O
under	O
op	O
##ti	O
##mum	O
conditions	O
:	O
(	O
i	O
)	O
E	O
##D	O
##TA	O
anti	O
##coa	O
##gu	O
##lant	O
tube	O
for	O
the	O
blood	O
collection	O
;	O
(	O
ii	O
)	O
time	O
between	O
the	O
sample	O
collection	O
and	O
RB	O
##C	O
isolation	O
0	O
h	O
or	O
4	O
h	O
at	O
the	O
temperature	O
of	O
4	O
°C	O
(	O
upper	O
and	O
lower	O
diagram	O
##s	O
)	O
;	O
(	O
ii	O
##i	O
)	O
phosphate	B
-	I
buffer	I
##ed	I
sa	I
##line	I
for	O
RB	O
##C	O
washing	O
(	O
two	O
-	O
times	O
)	O
and	O
re	O
-	O
su	O
##sp	O
##end	O
##ation	O
(	O
di	O
##lution	O
1	O
:	O
1	O
)	O
;	O
(	O
i	O
##v	O
)	O
50	O
mm	O
##ol	O
/	O

Un	O
##iva	O
##ria	O
##te	O
analysis	O
identified	O
eleven	O
o	B
##xy	I
##lip	I
##ins	I
significantly	O
higher	O
in	O
the	O
D	O
##IO	O
##S	O
group	O
in	O
comparison	O
with	O
Met	O
##S	O
and	O
healthy	O
subjects	O
.	O

In	O
Table	O
are	O
reported	O
the	O
general	O
characteristics	O
and	O
the	O
plasma	O
levels	O
of	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
in	O
patients	O
with	O
L	O
##OA	O
##D	O
,	O
V	O
##D	O
,	O
C	O
##IN	O
##D	O
,	O
and	O
in	O
C	O
.	O

Similarly	O
,	O
fatty	O
acids	O
levels	O
increased	O
significantly	O
,	O
including	O
2	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##yric	I
acid	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
met	I
##hyl	I
##but	I
##yric	I
acid	I
,	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##x	I
##oy	I
##but	I
##yric	I
acid	I
,	O
6	B
-	I
amino	I
##cap	I
##roi	I
##c	I
acid	I
,	O
pen	B
##tano	I
##ic	I
acid	I
,	O
and	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
,	O
whereas	O
the	O
bi	O
##le	O
acid	O
g	O
##ly	O
##co	O
##chen	O
##ode	O
##ox	O
##ych	O
##olate	O
-	O
3	O
-	O
su	O
##lf	O
##ate	O
(	O
G	O
##CD	O
##CA	O
-	O
3	O
-	O
su	O
##lf	O
##ate	O
)	O
decreased	O
.	O

One	O
of	O
compound	O
classes	O
,	O
which	O
was	O
found	O
to	O
co	O
##rrel	O
##ate	O
with	O
an	O
N	O
##SC	O
##LC	O
presence	O
,	O
is	O
car	B
##ni	I
##tine	I
and	O
its	O
a	O
##cy	O
##les	O
##ters	O
.	O

Co	O
##rrel	O
##ated	O
features	O
matched	O
to	O
modified	O
amino	O
acids	O
,	O
di	O
-	O
and	O
trip	O
##eptide	O
##s	O
,	O
pen	B
##ta	I
##ch	I
##lor	I
##oc	I
##y	I
##c	I
##lo	I
##he	I
##xa	I
##no	I
##l	I
,	O
and	O
pen	B
##ta	I
##ch	I
##lor	I
##od	I
##ibe	I
##nz	I
##od	I
##io	I
##xin	I
.	O

Co	O
##agu	O
##lation	O
was	O
avoided	O
with	O
an	O
anti	O
##coa	O
##gu	O
##lant	O
,	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
.	O

The	O
equations	O
for	O
calculating	O
ch	B
##lor	I
##p	I
##roma	I
##zine	I
equivalent	O
##s	O
for	O
p	B
##ali	I
##per	I
##ido	I
##ne	I
,	O
il	B
##oper	I
##ido	I
##ne	I
,	O
and	O
l	B
##ura	I
##si	I
##don	I
##e	I
were	O
obtained	O
from	O
Woods	O
.	O

Met	O
##ab	O
##oli	O
##te	O
concentrations	O
were	O
normal	O
##ized	O
to	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
and	O
subjected	O
to	O
un	O
##iva	O
##ria	O
##te	O
statistical	O
analysis	O
.	O

The	O
meta	O
##bol	O
##ite	O
profiles	O
of	O
Met	O
##S	O
were	O
unique	O
for	O
both	O
gender	O
##s	O
,	O
with	O
the	O
exception	O
of	O
se	B
##rine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
,	O
which	O
were	O
lower	O
in	O
both	O
Met	O
##S	O
_	O
any	O
men	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
31	O
,	O
Q	O
_	O
2	O
=	O
0	O
.	O
12	O
)	O
and	O
Met	O
##S	O
_	O
any	O
women	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
42	O
,	O
Q	O
_	O
2	O
=	O
0	O
.	O
30	O
)	O
compared	O
with	O
the	O
respective	O
Met	O
##S	O
_	O
zero	O
groups	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Lac	B
##tate	I
also	O
promotes	O
tumor	O
meta	O
##sta	O
##sis	O
by	O
induction	O
of	O
h	B
##yal	I
##uron	I
##an	I
synthesis	O
from	O
s	O
##trom	O
##al	O
cells	O
.	O

This	O
indicates	O
that	O
these	O
air	O
##way	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
take	O
up	O
g	B
##lut	I
##amine	I
very	O
efficiently	O
.	O

Ser	O
##um	O
levels	O
of	O
glucose	S
,	O
insulin	O
,	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AL	O
##T	O
)	O
,	O
as	O
##par	O
##tate	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AS	O
##T	O
)	O
,	O
and	O
home	O
##ost	O
##atic	O
model	O
assessment	O
-	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
)	O
were	O
recorded	O
.	O

P	O
##las	O
##ma	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
increased	O
significantly	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
treatment	O
(	O
5	O
.	O
8	O
±	O
1	O
.	O
2	O
to	O
11	O
.	O
3	O
±	O
2	O
.	O
3	O
μ	O
##g	O
/	O
d	O
##l	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

(	O
D	O
)	O
Is	B
##ole	I
##uc	I
##ine	I
present	O
in	O
both	O
groups	O
of	O
Pan	O
##c	O
-	O
1	O
cell	O
extract	O
##s	O
but	O
at	O
a	O
higher	O
abundance	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
used	O
mass	O
s	O
##pect	O
##rome	O
##try	O
to	O
q	O
##uant	O
##ify	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
and	O
s	O
##tero	O
##l	O
levels	O
in	O
se	O
##ra	O
from	O
3	O
,	O
230	O
un	O
##sel	O
##ec	O
##ted	O
subjects	O
and	O
then	O
correlated	O
inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
in	O
these	O
lip	O
##ids	O
with	O
g	O
##eno	O
##type	O
and	O
p	O
##hen	O
##otype	O
.	O

The	O
present	O
analysis	O
is	O
the	O
first	O
human	O
study	O
to	O
our	O
knowledge	O
to	O
report	O
the	O
relationship	O
between	O
the	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
-	O
dependent	O
anal	O
##yte	O
T	B
##MA	I
##O	I
and	O
its	O
diet	O
##ary	O
precursor	O
##s	O
,	O
ch	B
##olin	I
##e	I
and	O
beta	B
##ine	I
,	O
with	O
echo	O
##card	O
##io	O
##graphic	O
in	O
##dices	O
in	O
the	O
setting	O
of	O
chronic	O
s	O
##ys	O
##to	O
##lic	O
heart	O
failure	O
.	O

To	O
recover	O
any	O
meta	O
##bol	O
##ites	O
left	O
in	O
the	O
protein	O
p	O
##elle	O
##t	O
,	O
each	O
p	O
##elle	O
##t	O
was	O
mixed	O
with	O
300	O
μ	O
##L	O
met	B
##han	I
##ol	I
,	O
v	O
##ortex	O
##ed	O
for	O
10	O
min	O
,	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
20	O
,	O
800	O
g	O
for	O
10	O
min	O
and	O
the	O
super	O
##nat	O
##ant	O
was	O
pool	O
##ed	O
with	O
that	O
collected	O
after	O
the	O
first	O
cent	O
##ri	O
##fu	O
##gation	O
.	O

Three	O
different	O
models	O
were	O
used	O
as	O
follows	O
:	O
Model	O
1	O
:	O
FL	O
status	O
(	O
FL	O
_	O
All	O
/	O
FL	O
_	O
C	O
vs	O
.	O
NL	O
)	O
predicted	O
with	O
discovered	O
mi	O
##RNA	O
##s	O
only	O
,	O
(	O
one	O
by	O
one	O
forced	O
in	O
to	O
the	O
model	O
)	O
;	O
Model	O
2	O
:	O
age	O
,	O
sex	O
and	O
B	O
##MI	O
added	O
among	O
ex	O
##p	O
##lana	O
##tory	O
variables	O
of	O
model	O
1	O
;	O
and	O
fully	O
adjusted	O
Model	O
3	O
including	O
all	O
ex	O
##p	O
##lana	O
##tory	O
variables	O
known	O
to	O
be	O
associated	O
with	O
FL	O
in	O
Y	O
##FS	O
study	O
i	O
.	O
e	O
.	O
,	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
alcohol	O
consumption	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
age	O
,	O
a	O
##po	O
##B	O
levels	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
insulin	O
levels	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
smoking	O
,	O
and	O
physical	O
activity	O
index	O
,	O
(	O
excluding	O
liver	O
enzymes	O
due	O
to	O
high	O
correlation	O
with	O
studied	O
mi	O
##RNA	O
##s	O
)	O
.	O

Other	O
inverse	O
co	O
##rrel	O
##ates	O
of	O
risk	O
for	O
either	O
the	O
acquisition	O
or	O
progression	O
of	O
PD	O
are	O
reported	O
with	O
both	O
plasma	O
and	O
CS	O
##F	O
concentrations	O
of	O
u	B
##rate	I
(	I
2	I
,	I
6	I
,	I
8	I
-	I
trio	I
##xy	I
##pur	I
##ine	I
)	I
.	O

Pat	O
##ients	O
were	O
recruited	O
at	O
six	O
hospital	O
sites	O
around	O
the	O
United	O
Kingdom	O
:	O
London	O
,	O
Manchester	O
,	O
Newcastle	O
,	O
Nottingham	O
,	O
Plymouth	O
and	O
Southampton	S
.	O

Individual	O
FA	S
stock	O
solutions	O
,	O
non	O
-	O
est	O
##eri	O
##fied	O
(	O
free	O
)	O
FA	O
##s	O
present	O
in	O
the	O
total	O
lip	O
##id	O
extract	O
or	O
est	O
##eri	O
##fied	O
FA	O
##s	O
released	O
from	O
T	O
##G	O
##s	O
were	O
der	O
##iva	O
##tized	O
with	O
AM	O
##PP	O
essentially	O
by	O
the	O
method	O
of	O
Bo	O
##lling	O
##er	O
et	O
al	O
,	O
followed	O
by	O
extraction	O
with	O
but	O
##ano	O
##l	O
/	O
water	O
to	O
remove	O
excess	O
water	O
-	O
soluble	O
re	O
##age	O
##nts	O
as	O
described	O
in	O
.	O

Po	O
##ten	O
##tial	O
plate	O
effects	O
were	O
addressed	O
by	O
multi	O
##p	O
##lying	O
meta	O
##bol	O
##ite	O
concentrations	O
by	O
a	O
meta	O
##bol	O
##ite	O
-	O
and	O
plate	B
-	I
specific	I
correction	O
factor	O
.	O

The	O
group	O
of	O
S	O
##Q	O
anal	O
##yte	O
##s	O
comprised	O
80	O
known	O
meta	O
##bol	O
##ites	O
,	O
i	O
.	O
e	O
.	O
structural	O
##ly	O
assigned	O
(	O
target	O
)	O
meta	O
##bol	O
##ites	O
,	O
including	O
15	O
hormones	O
/	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
(	O
s	O
##tero	O
##ids	O
,	O
cat	B
##ech	I
##ola	I
##mine	I
##s	I
and	O
related	O
)	O
for	O
which	O
absolute	O
q	O
##uant	O
##ification	O
was	O
provided	O
,	O
and	O
260	O
known	O
-	O
unknown	O
##s	O
.	O

Ser	O
##um	O
concentrations	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
co	O
##rrel	O
##ate	O
with	O
age	O
_	O
a	O
4	O
##OH	O
##tam	O
4	B
-	I
h	I
##ydro	I
##xy	I
##tam	I
##ox	I
##ife	I
##n	I
,	O
4	O
##OH	O
##ND	O
##tam	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
N	I
-	I
dem	I
##eth	I
##yl	I
##tam	I
##ox	I
##ife	I
##n	I
,	O
N	O
##D	O
##tam	O
N	B
-	I
dem	I
##eth	I
##yl	I
##tam	I
##ox	I
##ife	I
##n	I
,	O
N	O
##D	O
##D	O
##tam	O
N	B
-	I
de	I
##di	I
##met	I
##hyl	I
##tam	I
##ox	I
##ife	I
##n	I
,	O
ta	O
##m	O
##N	O
##ox	O
ta	B
##mo	I
##xi	I
##fen	I
-	I
N	I
-	I
oxide	I
,	O
W	O
##t	O
/	O
W	O
##t	O
E	O
##M	O
wild	O
type	O
/	O
wild	O
type	O
extensive	O
meta	O
##bol	O
##izer	O
C	O
##YP	O
##2	O
##D	O
##6	O
_	O
b	O
Media	O
##n	O
(	O
range	O
)	O
_	O
c	O
R	O
and	O
p	O
values	O
are	O
derived	O
from	O
two	O
-	O
tailed	O
S	O
##pear	O
##man	O
correlation	O
rank	O
test	O
To	O
c	O
##ir	O
##cum	O
##vent	O
effects	O
of	O
C	O
##YP	O
##2	O
##D	O
##6	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
we	O
also	O
studied	O
these	O
correlation	O
##s	O
exclusively	O
in	O
E	O
##Ms	O
.	O

Tau	B
##rine	I
;	O
99	O
.	O

S	O
##3	O
and	O
S	O
##4	O
,	O
while	O
the	O
variation	O
in	O
retention	O
time	O
(	O
as	O
measured	O
by	O
%	O
RS	O
##D	O
)	O
was	O
generally	O
quite	O
small	O
,	O
at	O
<	O
2	O
%	O
in	O
all	O
conditions	O
,	O
the	O
area	O
of	O
the	O
ca	B
##ffe	I
##ine	I
peak	O
varied	O
significantly	O
both	O
across	O
m	O
##od	O
##ifier	O
##s	O
and	O
column	O
types	O
.	O

_	O
1	O
H	O
–	O
_	O
1	O
H	O
(	O
TO	O
##CS	O
##Y	O
)	O
and	O
_	O
1	O
H	O
–	O
_	O
13	O
C	O
(	O
H	O
##S	O
##Q	O
##C	O
,	O
HM	O
##BC	O
)	O
s	O
##pect	O
##ra	O
are	O
also	O
illustrated	O
for	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
its	O
N	O
##MR	O
-	O
detected	O
meta	O
##bol	O
##ites	O
.	O

Gas	O
ch	O
##roma	O
##tography	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
-	O
TO	O
##F	O
MS	O
)	O
and	O
Ultra	O
##per	O
##form	O
##ance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
q	O
##uad	O
##rup	O
##ole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
UP	O
##LC	O
-	O
Q	O
##TO	O
##F	O
MS	O
)	O
]	O
,	O
Ma	O
et	O
al	O
.	O
v	B
##ali	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
g	B
##ly	I
##cine	I
significantly	O
decreased	O
in	O
CR	O
##C	O
patients	O
using	O
G	O
##C	O
-	O
MS	O
.	O

We	O
were	O
able	O
to	O
follow	O
the	O
dynamics	O
of	O
star	O
##ch	O
h	O
##ydro	O
##lysis	O
and	O
that	O
of	O
further	O
meta	O
##bol	O
##ites	O
downstream	O
of	O
glucose	S
.	O

There	O
are	O
two	O
main	O
pathways	O
of	O
al	B
##ani	I
##ne	I
production	O
:	O
directly	O
from	O
protein	O
degradation	O
,	O
and	O
via	O
the	O
trans	O
##ami	O
##nation	O
of	O
p	B
##yr	I
##u	I
##vate	I
by	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AL	O
##T	O
)	O
.	O

A	O
few	O
studies	O
have	O
analyzed	O
car	B
##ni	I
##tine	I
or	O
car	B
##ni	I
##tine	I
metabolism	O
-	O
associated	O
genes	O
in	O
BC	O
##A	O
.	O

HC	O
=	O
CH	O
F	O
.	O
A	O
.	O
His	B
##ti	I
##dine	I
His	I
##ti	I
##dine	I
HC	O
=	O
CH	O
F	O
.	O
A	O
.	O

CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
ex	O
##t	O
+	O
U	O
##F	O
samples	O
(	O
15	O
.	O
5	O
±	O
1	O
.	O
9	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
##2	O
)	O
or	O
in	O
Me	B
##OH	I
pp	O
##t	O
samples	O
(	O
21	O
.	O
2	O
±	O
1	O
.	O
3	O
%	O
,	O
p	O
=	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

We	O
suggest	O
that	O
high	O
u	O
##rina	O
##ry	O
t	B
##rig	I
##one	I
##llin	I
##e	I
indicates	O
enhanced	O
activity	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
and	O
possible	O
s	O
##hun	O
##ting	O
towards	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
.	O

Am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
and	O
ace	B
##tic	I
acid	I
were	O
supplied	O
by	O
Fisher	O
Scientific	O
(	O
Springfield	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

Peel	O
##ing	O
et	O
al	O
.	O
have	O
previously	O
demonstrated	O
that	O
man	B
##ni	I
##to	I
##l	I
was	O
found	O
in	O
g	O
##lio	O
##ma	O
tissue	O
only	O
when	O
the	O
tumors	O
analyzed	O
showed	O
a	O
contrast	O
enhance	O
##ment	O
on	O
MR	O
indicating	O
a	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

1	B
,	I
5	I
-	I
An	I
##hy	I
##dr	I
##o	I
-	I
d	I
-	I
g	I
##lu	I
##ci	I
##to	I
##l	I
is	O
reported	O
to	O
be	O
a	O
bio	O
##mark	O
##er	O
of	O
short	O
-	O
term	O
g	B
##ly	I
##ce	I
##mic	I
control	O
,	O
and	O
decreased	O
plasma	O
levels	O
of	O
1	B
,	I
5	I
-	I
an	I
##hy	I
##dr	I
##o	I
-	I
d	I
-	I
g	I
##lu	I
##ci	I
##to	I
##l	I
suggest	O
the	O
presence	O
of	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
and	O
g	O
##ly	O
##cos	O
##uria	O
.	O

Line	O
##ar	O
correlation	O
for	O
total	O
or	O
_	O
13	O
C	O
-	O
labeled	O
concentrations	O
between	O
pairs	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
-	I
and	O
K	O
##re	O
##bs	O
cycle	O
-	O
derived	O
meta	O
##bol	O
##ites	O
in	O
human	O
lung	O
tissues	O
_	O
A	O
_	O
A	O
R	O
_	O
2	O
for	O
the	O
linear	O
re	O
##gression	O
fit	O
was	O
calculated	O
using	O
Ex	O
##cel	O
for	O
patients	O
#	O
6	O
–	O
10	O
(	O
n	O
=	O
5	O
)	O
.	O

The	O
ass	O
##ay	O
was	O
linear	O
at	O
low	O
(	O
D	O
##G	O
32	O
:	O
0	O
and	O
T	B
##G	I
48	I
:	I
0	I
)	O
and	O
high	O
concentrations	O
(	O
D	O
##G	O
36	O
:	O
3	O
,	O
T	B
##G	I
54	I
:	I
4	I
)	O
and	O
matched	O
the	O
above	O
described	O
Lo	O
##Q	O
and	O
Lo	O
##D	O
and	O
linear	O
range	O
(	O
up	O
to	O
250	O
mg	O
D	O
##G	O
d	O
##w	O
/	O
m	O
##L	O
and	O
150	O
mg	O
T	B
##G	I
d	O
##w	O
/	O
m	O
##L	O
)	O
,	O
respectively	O
.	O

However	O
,	O
when	O
the	O
reaction	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
with	O
SA	O
was	O
performed	O
with	O
10	O
-	O
fold	O
less	O
car	O
##cin	O
##ogen	O
(	O
0	O
.	O
3	O
m	O
##ol	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
:	O
1	O
m	O
##ol	O
SA	O
)	O
,	O
targeted	O
UP	O
##LC	O
-	O
E	O
##SI	O
/	O
MS	O
_	O
2	O
analysis	O
revealed	O
that	O
the	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
add	O
##uc	O
##ts	O
were	O
hardly	O
formed	O
at	O
L	O
##ys	O
_	O
195	O
,	O
L	O
##ys	O
_	O
199	O
,	O
L	O
##ys	O
_	O
54	O
##1	O
,	O
Cy	O
##s	O
_	O
34	O
,	O
Ty	O
##r	O
_	O
138	O
,	O
and	O
Ty	O
##r	O
_	O
401	O
,	O
and	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
add	O
##uc	O
##t	O
formation	O
at	O
Ty	O
##r	O
_	O
41	O
##1	O
accounted	O
for	O
about	O
99	O
%	O
of	O
the	O
total	O
ion	O
counts	O
of	O
SA	O
add	O
##uc	O
##ts	O
.	O

r	O
##s	O
##9	O
##8	O
##9	O
##65	O
##7	O
##3	O
located	O
nearby	O
KC	O
##N	O
##J	O
##16	O
(	O
potassium	O
inward	O
##ly	O
-	O
re	O
##ct	O
##ifying	O
channel	O
,	O
subfamily	O
J	O
,	O
member	O
16	O
)	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
level	O
(	O
P	O
-	O
value	O
=	O
1	O
.	O
65	O
##×	O
##10	O
_	O
−	O
##8	O
)	O
(	O
3	O
)	O

Our	O
identification	O
of	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
c	I
##era	I
##mi	I
##de	I
as	O
a	O
different	O
##iating	O
meta	O
##bol	O
##ite	O
is	O
consistent	O
with	O
its	O
previously	O
proposed	O
roles	O
in	O
o	O
##var	O
##ian	O
and	O
other	O
cancer	O
##s	O
.	O

To	O
examine	O
whether	O
either	O
plasma	O
try	B
##pt	I
##op	I
##han	I
or	O
k	B
##yn	I
##uren	I
##ine	I
correlated	O
with	O
breast	O
cancer	O
aggressive	O
##ness	O
,	O
breast	O
cancer	O
stage	O
at	O
diagnosis	O
was	O
used	O
.	O

Moreover	O
,	O
studies	O
of	O
human	O
co	O
##lon	O
cancer	O
cells	O
show	O
that	O
A	O
##H	O
##R	O
activation	O
by	O
the	O
di	B
##ox	I
##in	I
T	O
##CD	O
##D	O
drives	O
co	O
##lon	O
cancer	O
cell	O
survival	O
and	O
migration	O
.	O

Beta	B
##ine	I
as	O
continuous	O
variable	O
was	O
inverse	O
##ly	O
associated	O
with	O
incident	O
T	O
##2	O
##DM	O
in	O
men	O
(	O
H	O
##R	O
:	O
0	O
.	O
44	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
24	O
–	O
0	O
.	O
80	O
,	O
p	O
=	O
0	O
.	O
00	O
##7	O
)	O
,	O
but	O
not	O
in	O
women	O
(	O
H	O
##R	O
:	O
0	O
.	O
97	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
55	O
–	O
1	O
.	O
71	O
,	O
p	O
=	O
0	O
.	O
93	O
)	O
,	O
after	O
adjustment	O
for	O
age	O
,	O
e	O
##G	O
##F	O
##R	O
,	O
B	O
##MI	O
,	O
smoking	O
status	O
,	O
ethnicity	O
,	O
F	O
##P	O
##G	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	O
##L	O
-	O
C	O
,	O
T	B
##G	I
,	O
CR	O
##P	O
,	O
and	O
use	O
of	O
lip	O
##id	O
-	O
lowering	O
drugs	O
.	O

but	O
,	O
unlike	O
it	B
##acon	I
##ic	I
acid	I
which	O
acts	O
as	O
a	O
competitive	O
inhibitor	O
of	O
SD	O
##H	O
,	O
micro	O
##bial	O
meta	O
##bol	O
##ites	O
most	O
likely	O
act	O
on	O
the	O
u	B
##bi	I
##quin	I
##one	I
binding	O
site	O
of	O
the	O
respiratory	O
chain	O
.	O

24	O
##T	O
##DI	O
and	O
26	O
##T	O
##DI	O
formed	O
add	O
##uc	O
##ts	O
with	O
l	B
##ys	I
##ine	I
:	O
3	O
##A	O
##4	O
##MP	O
-	O
L	O
##ys	O
,	O
5	O
##A	O
##2	O
##MP	O
-	O
L	O
##ys	O
,	O
and	O
3	O
##A	O
##2	O
##MP	O
-	O
L	O
##ys	O
.	O
_	O
,	O

Signal	O
##s	O
representing	O
al	B
##ani	I
##ne	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
la	B
##ct	I
##ate	I
were	O
all	O
higher	O
in	O
subjects	O
with	O
high	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
,	O
as	O
were	O
ace	B
##tate	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##rate	I
,	O
pro	B
##line	I
,	O
and	O
v	B
##ali	I
##ne	I
.	O

Previous	O
studies	O
revealed	O
that	O
O	O
##C	O
##N	O
is	O
in	O
##f	O
##lue	O
##ncing	O
K	O
_	O
+	O
_	O
V	O
-	O
channels	O
and	O
GP	O
##RC	O
##6	O
##A	O
in	O
pan	O
##cre	O
##atic	O
is	O
##let	O
cells	O
,	O
but	O
the	O
exact	O
role	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
in	O
energy	O
metabolism	O
remains	O
unclear	O
.	O

Subsequently	O
,	O
Ce	B
##r	I
,	O
G	O
##lu	O
##C	O
##er	O
,	O
Lac	B
##C	I
##er	I
,	O
SM	O
,	O
Sa	O
,	O
Sa	O
##1	O
##P	O
,	O
So	O
,	O
So	O
##1	O
##P	O
and	O
each	O
internal	O
standard	O
(	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
)	O
were	O
analyzed	O
by	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Co	O
##mpo	O
##nent	O
##s	O
were	O
:	O
1	O
,	O
L	O
##1	O
;	O
2	O
,	O
L	O
##2	O
;	O
3	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
4	O
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
5	O
,	O
le	B
##uc	I
##ine	I
;	O
6	O
,	O
v	B
##ali	I
##ne	I
;	O
7	O
,	O
L	O
##3	O
;	O
8	O
,	O
la	B
##ct	I
##ate	I
;	O
9	O
,	O
al	B
##ani	I
##ne	I
;	O
10	O
,	O
L	O
##4	O
;	O
11	O
,	O
a	B
##rg	I
##ini	I
##ne	I
;	O
12	O
,	O
l	B
##ys	I
##ine	I
;	O
13	O
,	O
ace	B
##tate	I
;	O
14	O
,	O
L	O
##5	O
;	O
15	O
,	O
ace	B
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
;	O
16	O
,	O
met	B
##hi	I
##oni	I
##ne	I
;	O
17	O
,	O
g	B
##lut	I
##ama	I
##te	I
;	O
18	O
,	O
g	B
##lut	I
##amine	I
;	O
19	O
,	O
L	B
##6	I
;	I
20	I
,	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
21	O
,	O
p	B
##yr	I
##u	I
##vate	I
;	O
22	O
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
;	O
23	O
,	O
c	B
##it	I
##rate	I
;	O
24	O
,	O
L	O
##7	O
;	O
25	O
,	O
as	B
##par	I
##tate	I
;	O
26	O
,	O
album	O
##in	O
;	O
27	O
,	O
c	B
##rea	I
##tine	I
;	O
28	O
,	O
c	B
##rea	I
##tin	I
##ine	I
;	O
29	O
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
30	O
,	O
or	B
##ni	I
##thin	I
##e	I
;	O
31	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
32	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
33	O
,	O
ch	B
##olin	I
##e	I
;	O
34	O
,	O
beta	B
-	I
glucose	I
;	O
35	O
,	O
pro	B
##line	I
;	O
36	O
,	O
alpha	B
-	I
glucose	I
,	O
beta	B
-	I
glucose	I
;	O
37	O
,	O
alpha	B
-	I

To	O
determine	O
whether	O
these	O
metabolic	O
changes	O
were	O
significant	O
,	O
we	O
performed	O
the	O
Ho	O
##lm	O
-	O
Sid	O
##ak	O
correction	O
##s	O
for	O
multiple	O
comparisons	O
(	O
α	O
=	O
0	O
.	O
05	O
)	O
using	O
the	O
following	O
group	O
combinations	O
HP	O
##V	O
-	O
with	O
HP	O
##V	O
+	O
B	O
,	O
HP	O
##V	O
-	O
with	O
HP	O
##V	O
+	O
H	O
and	O
HP	O
##V	O
+	O
B	O
with	O
HP	O
##V	O
+	O
H	O
.	O
We	O
found	O
that	O
5	B
-	I
O	I
##x	I
##op	I
##rol	I
##inate	I
,	O
E	B
##ry	I
##th	I
##ronic	I
acid	I
,	O
N	B
-	I
Ace	I
##ty	I
##lasp	I
##art	I
##ic	I
acid	I
,	O
and	O
4	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##uri	I
##c	I
acid	I
were	O
significantly	O
elevated	O
in	O
HP	O
##V	O
+	O
H	O
group	O
compare	O
to	O
HP	O
##V	O
-	O
(	O
,	O
)	O
.	O

Ace	B
##tone	I
plays	O
a	O
role	O
in	O
energy	O
supply	O
to	O
vital	O
organs	O
during	O
metabolic	O
cat	O
##ast	O
##rophe	O
.	O

These	O
two	O
meta	O
##bol	O
##ites	O
induce	O
ch	O
##em	O
##ota	O
##ctic	O
response	O
and	O
ch	O
##em	O
##oki	O
##nes	O
##is	O
of	O
le	O
##uk	O
##ocytes	O
and	O
show	O
increased	O
levels	O
in	O
inflammatory	O
lesions	O
for	O
immune	O
function	O
,	O
therefore	O
,	O
5	B
-	I
H	I
##ET	I
##E	I
and	O
le	O
##uk	O
##ot	O
##rien	O
##e	O
B	O
_	O
4	O
may	O
play	O
a	O
key	O
role	O
on	O
le	O
##uk	O
##oc	O
##yte	O
function	O
.	O

This	O
issue	O
can	O
be	O
solved	O
for	O
T	B
##G	I
lip	O
##id	O
species	O
by	O
increasing	O
collision	O
energy	O
to	O
re	O
##fine	O
their	O
structural	O
characterization	O
(	O
Bird	O
et	O
al	O
.	O
)	O
,	O
and	O
also	O
for	O
a	O
few	O
other	O
lip	O
##id	O
species	O
such	O
as	O
particular	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
species	O
containing	O
al	O
##ky	O
##l	O
or	O
al	O
##ken	O
##yl	O

The	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
cop	B
##ros	I
##tano	I
##l	I
ratio	O
has	O
been	O
used	O
as	O
a	O
measure	O
of	O
ability	O
to	O
remove	O
ch	B
##ole	I
##ster	I
##ol	I
from	O
circulation	O
,	O
and	O
has	O
been	O
shown	O
to	O
be	O
controlled	O
by	O
the	O
amount	O
of	O
cop	B
##ros	I
##tano	I
##li	I
##genic	I
bacteria	O
in	O
the	O
gut	O
.	O

Specifically	O
,	O
as	O
time	O
from	O
injury	O
increased	O
,	O
the	O
concentration	O
of	O
most	O
circulating	O
amino	O
acids	O
and	O
u	B
##rea	I
cycle	O
products	O
progressively	O
rose	O
,	O
suggesting	O
a	O
transition	O
in	O
metabolism	O
from	O
initial	O
suppression	O
to	O
muscle	O
cat	O
##ab	O
##olis	O
##m	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
observed	O
that	O
N	O
##SC	O
##LC	O
patients	O
had	O
decreased	O
plasma	O
lip	O
##id	O
concentrations	O
of	O
the	O
two	O
lip	O
##id	O
molecules	O
,	O
C	B
(	I
18	I
:	I
2	I
)	I
CE	I
and	O
SM	B
(	I
22	I
:	I
0	I
)	I
,	O
when	O
compared	O
with	O
healthy	O
controls	O
(	O
Figure	O
)	O
.	O

More	O
than	O
that	O
,	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
were	O
down	O
regulated	O
in	O
pro	O
##la	O
##ct	O
##ino	O
##ma	O
,	O
whereas	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
g	B
##lut	I
##amine	I
were	O
up	O
regulated	O
.	O

To	O
remove	O
membrane	O
lip	O
##ids	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
dried	O
samples	O
were	O
re	O
##con	O
##stituted	O
with	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
1	O
:	O
1	O
)	O
,	O
de	O
##can	O
##ted	O
and	O
taken	O
to	O
dry	O
##ness	O
under	O
reduced	O
pressure	O
.	O

Additionally	O
,	O
ch	B
##olin	I
##e	I
is	O
indirectly	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
plate	O
##let	O
-	O
act	O
##ivating	O
factor	O
,	O
which	O
is	O
a	O
major	O
inflammatory	O
media	O
##tor	O
[	O
,	O
]	O
.	O

Using	O
an	O
oral	O
cancer	O
floor	O
-	O
of	O
-	O
mouth	O
x	O
##eno	O
##gra	O
##ft	O
model	O
,	O
we	O
found	O
that	O
mouse	O
tumors	O
derived	O
from	O
these	O
tumors	O
##phere	O
cells	O
exhibited	O
a	O
larger	O
mean	O
tumor	O
volume	O
and	O
incidence	O
and	O
higher	O
increases	O
in	O
the	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
compared	O
to	O
those	O
derived	O
from	O
ad	O
##here	O
##nt	O
control	O
cells	O
.	O

Oral	O
consumption	O
of	O
gal	B
##act	I
##ose	I
by	O
a	O
healthy	O
volunteer	O
confirmed	O
the	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
this	O
sugar	O
.	O

o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
F	B
_	I
2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
,	O
breast	O
cancer	O
,	O
survival	O
,	O
pro	O
##gno	O
##sis	O

As	O
far	O
as	O
we	O
know	O
,	O
this	O
is	O
the	O
first	O
study	O
on	O
circa	O
##dian	O
variation	O
of	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
as	O
measured	O
by	O
G	O
##C	O
/	O
MS	O
-	O
S	O
##IM	O
in	O
any	O
setting	O
.	O

Although	O
the	O
mechanisms	O
responsible	O
for	O
the	O
formation	O
of	O
the	O
eccentric	O
c	O
##lea	O
##vage	O
products	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
in	O
mammals	O
are	O
not	O
fully	O
known	O
,	O
it	O
is	O
clear	O
that	O
some	O
of	O
the	O
long	O
chain	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##nal	I
##s	I
(	O
e	O
.	O
g	O
.	O
8	O
′	O
,	O
10	O
′	O
,	O
12	O
′	O
,	O
14	O
′	O
)	O
are	O
found	O
in	O
the	O
plasma	O
of	O
humans	O
and	O
experimental	O
animals	O
and	O
that	O
these	O
are	O
increased	O
under	O
conditions	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
high	O
diet	O
##ary	O
doses	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
.	O

Recently	O
,	O
an	O
interesting	O
study	O
has	O
anal	O
##ys	O
##ed	O
the	O
role	O
of	O
c	B
##era	I
##mi	I
##des	I
in	O
the	O
progression	O
of	O
the	O
car	O
##ot	O
##id	O
artery	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
in	O
P	O
##L	O
##W	O
##H	O
.	O

When	O
analyzing	O
the	O
various	O
clinical	O
diagnostic	O
criteria	O
of	O
ne	O
##ph	O
##ros	O
##cle	O
##rosis	O
separately	O
,	O
the	O
meta	O
##bol	O
##ites	O
were	O
able	O
to	O
correctly	O
di	O
##ag	O
##nose	O
only	O
h	O
##yper	O
##tens	O
##ion	O
(	O
PC	O
##1	O
,	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
le	B
##uc	I
##ine	I
)	O
.	O

Dec	O
##reased	O
U	O
-	O
_	O
13	O
C	B
_	I
6	I
-	I
glucose	I
incorporation	O
into	O
palm	B
##itate	I
in	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##se	O
(	O
PC	O
)	O
knock	O
##down	O
cell	O
lines	O
derived	O
from	O
the	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cell	O
line	O
.	O

Moreover	O
,	O
the	O
decreased	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
quite	O
unexpected	O
and	O
,	O
thus	O
,	O
further	O
studies	O
are	O
needed	O
to	O
better	O
understand	O
the	O
study	O
outcome	O
.	O

The	O
select	O
##ivity	O
of	O
the	O
method	O
was	O
established	O
by	O
the	O
analysis	O
of	O
blank	O
human	O
plasma	O
from	O
five	O
different	O
donors	O
(	O
including	O
two	O
lip	O
##em	O
##ic	O
plasma	O
samples	O
)	O
and	O
two	O
pool	O
##ed	O
regular	O
plasma	O
samples	O
(	O
n	O
=	O
7	O
)	O
,	O
all	O
processed	O
with	O
pure	O
Me	B
##OH	I
.	O

Media	O
##n	O
total	O
concentrations	O
(	O
sum	O
of	O
n	O
##uc	O
##leo	O
##side	O
and	O
mon	O
##o	O
-	O
,	O
di	O
-	O
,	O
and	O
trip	B
##hos	I
##phate	I
##s	I
)	O
observed	O
in	O
liver	O
sections	O
in	O
patients	O
on	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
and	O
rib	B
##avi	I
##rin	I
at	O
the	O
time	O
of	O
transplant	O
##ation	O
(	O
n	O
=	O
23	O
)	O
were	O
77	O
.	O
1	O
μ	O
##M	O
(	O
range	O
,	O
4	O
.	O
10	O
to	O
252	O
μ	O
##M	O
)	O
for	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
and	O
36	O
##1	O
μ	O
##M	O
(	O
range	O
,	O
90	O
.	O
6	O
to	O
1	O
,	O
800	O
μ	O
##M	O
)	O
for	O
rib	B
##avi	I
##rin	I
.	O

E	O
##tan	O
##er	O
##ce	O
##pt	O
could	O
affect	O
these	O
meta	O
##bol	O
##ites	O
through	O
m	O
##od	O
##ulation	O
of	O
NO	O
##S	O
,	O
for	O
example	O
,	O
by	O
m	O
##od	O
##ulating	O
the	O
flux	O
of	O
as	B
##par	I
##tate	I
between	O
the	O
u	B
##rea	I
cycle	O
and	O
th	B
##re	I
##oni	I
##ne	I
production	O
.	O

Additionally	O
,	O
mean	O
u	O
##rina	O
##ry	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
differed	O
by	O
B	O
##MI	O
and	O
household	O
income	O
levels	O
.	O

After	O
cell	O
harvest	O
,	O
CH	O
##C	O
##l	O
_	O
3	O
was	O
added	O
to	O
the	O
met	B
##han	I
##olic	I
cell	O
extract	O
##s	O
,	O
shaken	O
for	O
60	O
min	O
at	O
4	O
°C	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
41	O
##4	O
##9	O
##×	O
g	O
for	O
10	O
min	O
at	O
4	O
°C	O
to	O
separate	O
the	O
phases	O
.	O

Is	O
##olate	O
##d	O
super	O
##nat	O
##ants	O
,	O
referred	O
to	O
as	O
SP	S
,	O
were	O
snap	O
-	O
frozen	O
on	O
dry	O
ice	O
in	O
1	O
-	O
m	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
and	O
stored	O
at	O
–	O
80	O
##°	O
##C	O
.	O

The	O
der	O
##iva	O
##ti	O
##zation	O
re	O
##age	O
##nt	O
(	B
N	I
-	I
met	I
##hyl	I
-	I
N	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
##di	I
##met	I
##hyl	I
##si	I
##ly	I
##l	I
)	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
M	O
##T	O
##BS	O
##TF	O
##A	O
)	O
was	O
obtained	O
from	O
Regis	O
Technologies	O
(	O
Morton	O
Grove	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Two	O
hundred	O
micro	O
##lite	O
##r	O
Me	B
##OH	I
were	O
added	O
to	O
pre	O
##ci	O
##pit	O
##ate	O
proteins	O
,	O
and	O
then	O
the	O
mixture	O
was	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
##°	O
##C	O
for	O
20	O
minutes	O
.	O

In	O
##tra	O
##ven	O
##ous	O
or	O
in	O
##tra	O
##mus	O
##cular	O
injection	O
of	O
0	O
.	O
125	O
mg	O
/	O
kg	O
single	O
dose	O
m	B
##or	I
##phine	I
will	O
result	O
approximately	O
20	O
ng	O
/	O
m	O
##L	O
blood	O
concentration	O
of	O
free	O
m	B
##or	I
##phine	I
2	O
to	O
4	O
hours	O
after	O
administration	O
and	O
~	O
75	O
%	O
of	O
the	O
administered	O
dose	O
will	O
be	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
within	O
72	O
hours	O
as	O
con	O
##ju	O
##gated	O
m	B
##or	I
##phine	I
.	O

The	O
functional	O
forms	O
of	O
sulfur	O
are	O
primarily	O
the	O
amino	O
acids	O
met	O
##hi	O
##oni	O
##ne	O
and	O
c	B
##ys	I
##tein	I
##e	I
.	O

K	O
##P	O
##m	O
concentrations	O
were	O
not	O
significantly	O
different	O
between	O
the	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
and	O
di	O
##abe	O
##tic	O
groups	O
,	O
neither	O
at	O
inclusion	O
,	O
nor	O
one	O
year	O
after	O
surgery	O
.	O

Since	O
the	O
presence	O
of	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
was	O
not	O
positively	O
confirmed	O
,	O
only	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
was	O
measured	O
in	O
SR	O
##M	O
90	O
##9	O
##c	O
.	O

Such	O
high	O
percentage	O
##s	O
have	O
been	O
associated	O
with	O
a	O
rising	O
plasma	O
none	O
##ster	O
##ified	O
FA	S
concentrations	O
,	O
h	O
##y	O
##po	O
##al	O
##bu	O
##mine	O
##mia	O
,	O
and	O
reduction	O
in	O
energy	O
supply	O
to	O
the	O
organs	O
.	O

Para	O
##lle	O
##l	O
to	O
changes	O
in	O
H	O
##NS	O
##CC	O
tissues	O
,	O
studies	O
of	O
un	O
##mat	O
##ched	O
sa	O
##liva	O
and	O
plasma	O
samples	O
from	O
patients	O
with	O
H	O
##NS	O
##CC	O
showed	O
that	O
g	B
##lut	I
##ama	I
##te	I
levels	O
were	O
also	O
significantly	O
elevated	O
in	O
samples	O
derived	O
from	O
H	O
##NS	O
##CC	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

Lim	O
##it	O
of	O
detection	O
(	B
L	B
##OD	I
-	I
3	I
##σ	I
)	O
was	O
calculated	O
as	O
three	O
times	O
the	O
standard	O
de	O
##viation	O
of	O
the	O
lowest	O
concentration	O
by	O
the	O
slope	O
(	O
m	O
)	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
.	O

During	O
the	O
study	O
,	O
subjects	O
consent	O
##ed	O
to	O
train	O
normally	O
,	O
maintain	O
weight	O
,	O
and	O
avoid	O
the	O
use	O
of	O
all	O
herbs	O
and	O
medications	O
known	O
to	O
affect	O
inflammation	O
and	O
immune	O
function	O
for	O
the	O
duration	S
of	O
the	O
study	O
(	O
in	O
particular	O
,	O
all	O
non	O
-	O
s	O
##tero	O
##idal	O
anti	O
-	O
inflammatory	O
drugs	O
)	O
.	O

Although	O
c	B
##era	I
##mi	I
##de	I
can	O
be	O
synthesis	O
##ed	O
de	O
no	O
##vo	O
,	O
it	O
is	O
rapidly	O
produced	O
from	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
by	O
the	O
stress	O
-	O
induced	O
activation	O
of	O
neutral	O
and	O
acid	O
s	O
##phi	O
##ngo	O
##my	O
##elin	O
##ase	O
.	O

These	O
results	O
are	O
well	O
supported	O
by	O
animal	O
studies	O
,	O
where	O
knock	O
-	O
out	O
,	O
knock	O
-	O
down	O
,	O
and	O
over	O
##ex	O
##press	O
##ion	O
studies	O
on	O
rode	O
##nts	O
and	O
non	O
-	O
human	O
p	O
##rima	O
##tes	O
have	O
indicated	O
that	O
mi	O
##R	O
-	O
122	O
expression	O
m	O
##od	O
##ifies	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
by	O
controlling	O
ch	B
##ole	I
##ster	I
##ol	I
synthesis	O
and	O
V	O
##LD	O
##L	O
secret	O
##ion	O
,	O
and	O
that	O
suppress	O
##ing	O
mi	O
##R	O
-	O
122	O
expression	O
lower	O
##s	O
L	O
##D	O
##L	O
levels	O
and	O
increases	O
HD	O
##L	O
levels	O
_	O
,	O
_	O
,	O
_	O
,	O
.	O

This	O
cluster	O
,	O
as	O
can	O
be	O
seen	O
from	O
,	O
is	O
mainly	O
comprised	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
species	O
.	O

The	O
individual	O
daily	O
dose	O
was	O
600	O
μ	O
##mo	O
##l	O
of	O
G	O
##R	O
and	O
40	O
μ	O
##mo	O
##l	O
of	O
SF	S
.	O

Relations	O
between	O
C	O
##YP	O
##2	O
##C	O
##19	O
,	O
C	O
##YP	O
##2	O
##D	O
##6	O
,	O
C	O
##YP	O
##3	O
##A	O
##5	O
and	O
S	O
##U	O
##LT	O
##1	O
##A	O
##1	O
g	O
##eno	O
##type	O
##s	O
and	O
est	O
##rogen	O
##s	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
(	O
n	O
=	O
90	O
)	O
_	O
1	O
Media	O
##n	O
concentration	O
[	O
q	O
##ua	O
##rt	O
##ile	O
1	O
-	O
q	O
##ua	O
##rt	O
##ile	O
3	O
]	O
values	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
meta	O
##bol	O
##ites	O
are	O
given	O
as	O
ng	O
/	O
m	O
##l	O
.	O

Furthermore	O
,	O
serum	O
SM	O
levels	O
showed	O
positive	O
correlation	O
##s	O
with	O
the	O
concentration	O
of	O
met	B
##ha	I
##cho	I
##line	I
needed	O
to	O
produce	O
a	O
20	O
%	O
fall	O
in	O
F	O
##E	O
##V	O
_	O
1	O
from	O
base	O
##line	O
,	O
PC	O
_	O
20	O
.	O

A	O
##cc	O
##um	O
##ulation	O
of	O
AD	B
##MA	I
can	O
either	O
due	O
to	O
increased	O
production	O
(	O
i	O
.	O
e	O
.	O
increase	O
in	O
PR	O
##MT	O
)	O
or	O
reduced	O
degradation	O
(	O
i	O
.	O
e	O
.	O
decrease	O
in	O
DD	O
##A	O
##H	O
)	O
.	O

Tri	B
##gly	I
##cer	I
##ide	I
levels	O
of	O
the	O
test	O
group	O
were	O
lower	O
after	O
12	O
weeks	O
.	O

Pro	O
##tein	O
precipitation	O
was	O
performed	O
by	O
adding	O
800	O
μ	O
##L	O
of	O
ice	O
cold	O
Me	B
##OH	I
to	O
100	O
##μ	O
##L	O
N	O
##IS	O
##T	O
1950	O
serum	O
and	O
stored	O
at	O
−	O
##80	O
[UNK]	O
for	O
one	O
hour	O
.	O

The	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
AN	O
##O	O
##VA	O
,	O
followed	O
by	O
the	O
Dunn	O
##s	O
'	O
Multiple	O
Co	O
##mp	O
##aris	O
##on	O
test	O
,	O
was	O
used	O
to	O
evaluate	O
the	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
levels	O
at	O
respective	O
time	O
points	O
in	O
the	O
donor	O
population	O
as	O
a	O
whole	O
.	O

The	O
only	O
exceptions	O
were	O
T	B
##MA	I
##O	I
and	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
where	O
significant	O
de	O
##viation	O
##s	O
between	O
L	O
##C	O
-	O
MS	O
and	O
N	O
##MR	O
were	O
observed	O
.	O

E	O
##BC	O
samples	O
came	O
from	O
5	O
centers	O
in	O
the	O
Philippines	S
and	O
2	O
centers	O
in	O
Vietnam	O
;	O
MB	O
##C	O
samples	O
came	O
from	O
5	O
centers	O
in	O
the	O
Philippines	S
,	O
3	O
centers	O
in	O
Bangladesh	O
,	O
and	O
one	O
in	O
Nigeria	O
.	O

CS	O
##F	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
in	O
T	O
##2	O
##DM	O
patients	O
vs	O
.	O
controls	O
revealed	O
significantly	O
increased	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
decreased	O
levels	O
of	O
his	B
##ti	I
##dine	I
.	O

For	O
example	O
,	O
the	O
concentration	O
of	O
g	B
##lut	I
##ama	I
##te	I
was	O
more	O
than	O
3	O
##X	O
higher	O
in	O
W	O
##B	O
than	O
in	O
serum	O
and	O
is	O
known	O
to	O
be	O
10	O
##X	O
higher	O
in	O
RB	O
##C	O
than	O
in	O
plasma	O
.	O

Dec	O
##lines	O
in	O
x	B
##ant	I
##hine	I
and	O
u	B
##rate	I
may	O
be	O
at	O
##tri	O
##but	O
##able	O
to	O
the	O
consumption	O
of	O
pu	B
##rine	I
##s	I
during	O
the	O
replication	O
of	O
DNA	O
.	O

Mobile	O
phase	O
A	O
and	O
B	O
were	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
respectively	O
.	O

Additionally	O
,	O
higher	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
observed	O
in	O
an	O
##ov	O
##ulatory	O
PC	O
##OS	O
patients	O
.	O

It	O
was	O
also	O
noted	O
that	O
one	O
end	O
##ogen	O
##ous	O
meta	O
##bol	O
##ite	O
,	O
u	B
##rid	I
##ine	I
,	O
was	O
present	O
at	O
lower	O
levels	O
in	O
both	O
CS	O
##F	O
and	O
serum	O
of	O
the	O
SC	O
##I	O
patients	O
.	O

Ex	O
##c	O
##lusion	O
criteria	O
included	O
any	O
medical	O
history	O
of	O
a	O
serious	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
problem	O
which	O
could	O
affect	O
the	O
absorption	O
of	O
the	O
drug	O
and	O
any	O
history	O
of	O
all	O
##er	O
##gy	O
to	O
flu	B
##oro	I
##quin	I
##olo	I
##ne	I
derivatives	O
.	O

Similarly	O
,	O
the	O
CH	O
_	O
2	O
(	O
4	O
.	O
12	O
pp	O
##m	O
)	O
signal	O
of	O
Lac	O
was	O
also	O
overlapping	O
with	O
CH	O
_	O
2	O
(	O
4	O
.	O
08	O
pp	O
##m	O
)	O
of	O
T	B
##G	I
;	O
therefore	O
Lac	O
concentration	O
was	O
measured	O
by	O
sub	O
##tract	O
##ing	O
the	O
spectral	O
region	O
(	O
4	O
.	O
04	O
–	O
4	O
.	O
15	O
pp	O
##m	O
)	O
with	O
CH	O
_	O
2	O
(	O
4	O
.	O
23	O
–	O
4	O
.	O
37	O
pp	O
##m	O
)	O
of	O
T	B
##G	I
.	O

Hal	O
##oper	O
##ido	O
##l	O
,	O
re	B
##ser	I
##pine	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
water	O
,	O
form	B
##ic	I
acid	I
,	O
and	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
USA	O
)	O
.	O

We	O
found	O
a	O
metabolic	O
pattern	O
consisting	O
of	O
nine	O
meta	O
##bol	O
##ites	O
that	O
predicted	O
fast	O
##ing	O
glucose	S
development	O
with	O
an	O
accuracy	O
of	O
0	O
.	O
47	O
in	O
ten	O
##fold	O
cross	O
-	O
valid	O
##ation	O
using	O
Random	O
Forest	O
re	O
##gression	O
.	O

Ser	O
##um	O
samples	O
were	O
th	O
##awed	O
on	O
ice	O
,	O
and	O
protein	O
precipitation	O
was	O
performed	O
by	O
the	O
addition	O
of	O
met	B
##han	I
##ol	I
in	O
a	O
3	O
:	O
1	O
volume	O
ratio	O
to	O
50	O
μ	O
##L	O
of	O
serum	O
.	O

Monitor	O
##ing	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
as	O
bio	O
##mark	O
##ers	O
of	O
exposure	O
can	O
be	O
a	O
valuable	O
aid	O
for	O
improving	O
this	O
understanding	O
;	O
however	O
,	O
no	O
previously	O
published	O
method	O
exists	O
for	O
the	O
analysis	O
of	O
the	O
primary	O
TD	O
##CP	O
##P	O
meta	O
##bol	O
##ite	O
,	O
bi	O
##s	O
(	B
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##o	I
-	I
2	I
-	I
prop	I
##yl	I
)	I
phosphate	I
(	O
B	O
##DC	O
##PP	O
)	O
,	O
in	O
human	O
urine	O
.	O

As	O
shown	O
in	O
,	O
these	O
meta	O
##bol	O
##ites	O
are	O
correlated	O
with	O
the	O
five	O
top	O
canonical	O
pathways	O
,	O
including	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##es	O
,	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
II	O
,	O
L	O
##X	O
##R	O
/	O
R	O
##X	O
##R	O
activation	O
,	O
lip	B
##oat	I
##e	I
bio	O
##sy	O
##nt	O
##hesis	O
and	O
incorporation	O
II	O
and	O
his	B
##ti	I
##dine	I
degradation	O
VI	S
.	O

On	O
the	O
other	O
hand	O
,	O
however	O
,	O
their	O
expression	O
positively	O
and	O
moderately	O
-	O
to	O
-	O
strongly	O
correlated	O
with	O
that	O
of	O
other	O
pathway	O
enzymes	O
,	O
e	O
.	O
g	O
.	O
,	O
DD	O
##A	O
##H	O
##s	O
,	O
and	O
their	O
con	O
##com	O
##ita	O
##nt	O
up	O
-	O
regulation	O
might	O
contribute	O
to	O
the	O
lack	O
of	O
AD	B
##MA	I
accumulation	O
.	O

This	O
was	O
improved	O
by	O
addition	O
of	O
l	O
##n	O
k	O
##yn	O
/	O
t	O
##rp	O
and	O
l	O
##n	O
hip	B
##pur	I
##ic	I
acid	I
to	O
the	O
model	O
,	O
with	O
AU	O
##C	O
of	O
0	O
.	O
95	O
(	O
SE	O
##M	O
0	O
.	O
02	O
)	O
.	O

The	O
g	O
##ly	O
##co	O
##lysis	O
meta	O
##bol	O
##ites	O
C	O
_	O
6	O
sugar	O
phosphate	B
##s	I
and	O
p	B
##hos	I
##ph	I
##oe	I
##no	I
##l	I
##py	I
##ru	I
##vate	I
were	O
down	O
##re	O
##gu	O
##lated	O
22	O
.	O
7	O
-	O
fold	O
and	O
6	O
.	O
9	O
-	O
fold	O
,	O
respectively	O
.	O

K	O
##yn	O
##uren	O
##ines	O
are	O
synthesized	O
from	O
try	B
##pt	I
##op	I
##han	I
by	O
try	O
##pt	O
##op	O
##han	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
,	O
and	O
by	O
in	O
##do	O
##lam	O
##ine	O
-	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
1	O
and	O
2	O
,	O
which	O
are	O
induced	O
by	O
inflammation	O
.	O

The	O
latter	O
seems	O
to	O
be	O
triggered	O
in	O
some	O
samples	O
by	O
addition	O
of	O
is	B
##op	I
##rop	I
##ano	I
##l	I
and	O
matches	O
lip	O
##oly	O
##tic	O
activities	O
observed	O
in	O
organic	O
solvent	O
##s	O
[	O
,	O
]	O
.	O

Free	O
##ze	O
/	O
th	O
##aw	O
stability	O
experiments	O
resulted	O
in	O
no	O
degradation	O
of	O
a	B
##bir	I
##ater	I
##one	I
over	O
three	O
freeze	O
/	O
th	O
##aw	O
cycles	O
.	O

Currently	O
,	O
a	O
common	O
approach	O
in	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
is	O
“	O
R	O
##P	O
for	O
non	O
-	O
polar	O
and	O
H	O
##IL	O
##IC	O
for	O
the	O
rest	O
”	O
,	O
which	O
fails	O
to	O
take	O
into	O
account	O
that	O
H	O
##IL	O
##IC	O
columns	O
are	O
he	O
##tero	O
##gene	O
##ous	O
and	O
their	O
separation	O
performance	O
is	O
less	O
predictable	O
than	O
that	O
of	O
R	B
##P	I
materials	O
.	O

For	O
example	O
,	O
in	O
our	O
case	O
,	O
the	O
apparent	O
T	O
##SP	O
concentration	O
decreased	O
by	O
an	O
average	O
3	O
.	O
8	O
%	O
in	O
multiple	O
extraction	O
##s	O
compared	O
to	O
single	O
extraction	O
,	O
using	O
met	B
##han	I
##ol	I
.	O

As	O
depicted	O
in	O
a	O
,	O
ta	B
##uri	I
##ne	I
levels	O
did	O
not	O
change	O
after	O
prolonged	O
E	O
##D	O
##TA	O
blood	O
in	O
##cu	O
##bation	O
for	O
4	O
h	O
to	O
8	O
h	O
.	O

In	O
almost	O
all	O
of	O
the	O
previous	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
of	O
thy	O
##roid	O
cancer	O
,	O
the	O
increase	O
of	O
ch	B
##olin	I
##e	I
content	O
and	O
its	O
derivatives	O
including	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
was	O
reported	O
in	O
ma	O
##li	O
##gnant	O
thy	O
##roid	O
lesions	O
,	O
which	O
is	O
consistent	O
with	O
our	O
results	O
.	O

Sep	O
##ara	O
##tion	O
was	O
obtained	O
with	O
a	O
The	O
##rm	O
##o	O
H	O
##yper	O
##si	O
##l	O
GO	O
##LD	O
P	O
##FP	O
column	O
(	O
2	O
.	O
1	O
_	O
*	O
100	O
mm	O
1	O
.	O
9	O
μ	O
##m	O
)	O
at	O
ambient	O
temperature	O
using	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
el	O
##uen	O
##t	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
el	O
##uen	O
##t	O
B	O
)	O
as	O
the	O
mobile	O
phase	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0	O
.	O
4	O
m	O
##L	O
min	O
-	O
1	O
.	O

All	O
procedures	O
involving	O
animal	O
handling	O
were	O
in	O
accordance	O
with	O
the	O
Philippine	S
Association	O
of	O
Laboratory	O
Animal	O
Science	O
code	O
of	O
practice	O
for	O
care	O
and	O
use	O
of	O
laboratory	O
animals	O
and	O
with	O
administrative	O
order	O
40	O
of	O
the	O
Bureau	O
of	O
Animal	O
Industry	O
relative	O
to	O
Republic	O
Act	O
No	O
.	O
84	O
##8	O
##5	O
.	O

0	O
.	O
38	O
##8	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
Energy	O
adjusted	O
f	B
##olate	I
and	O
vitamin	B
B	I
##12	I
intake	O
had	O
positive	O
correlation	O
(	O
r	O
=	O
0	O
.	O
184	O
)	O
.	O

Cho	B
##les	I
##tero	I
##l	I
,	O
L	O
##D	O
##L	O
,	O
grip	O
strength	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
16	O
:	O
0	O
,	O
17	O
:	O
0	O
,	O
18	O
:	O
0	O
,	O
18	O
:	O
1	O
(	O
11	O
##Z	O
)	O
,	O
18	O
:	O
3	O
(	O
9	O
##Z	O
,	O
12	O
##Z	O
,	O
15	O
##Z	O
)	O
,	O
P	B
-	I
18	I
:	I
1	I
(	I
9	I
##Z	I
)	I
,	O
20	O
:	O
1	O
(	O
11	O
##Z	O
)	O
,	O
(	O
20	O
:	O
3	O
(	B
8	B
##Z	I
,	I
11	I
##Z	I
,	I
14	I
##Z	I
)	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ose	I
##rine	I
and	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
were	O
sensitive	O
markers	O
in	O
the	O
assessment	O
of	O
nutrition	O
##al	O
status	O
.	O

Lo	O
##gis	O
##tic	O
re	O
##gression	O
analyses	O
of	O
3	O
-	O
month	O
mortality	O
for	O
2	O
-	O
H	O
##B	O
,	O
3	O
-	O
H	O
##B	O
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##it	I
##rate	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
.	O

The	O
HM	O
##D	O
##B	O
suggested	O
two	O
meta	O
##bol	O
##ites	O
,	O
h	O
##ydro	O
##xy	O
##des	O
##m	O
##thy	O
##l	O
do	O
##xe	O
##pin	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
(	B
E	I
)	I
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
##dox	I
##ep	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
as	O
candidates	O
for	O
L	O
##MI	O
with	O
47	O
##2	O
.	O
241	O
##9	O
m	O
/	O
z	O

Two	O
types	O
of	O
L	O
##ys	O
##o	O
##PC	O
(	B
L	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
(	O
6	O
)	O
and	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
(	O
7	O
)	O
)	O
were	O
significantly	O
decreased	O
in	O
serum	O
samples	O
of	O
AI	O
##S	O
patients	O
.	O

Most	O
patients	O
received	O
A	O
##Z	O
##A	O
(	O
n	O
=	O
127	O
,	O
98	O
.	O
4	O
%	O
)	O
and	O
were	O
on	O
concurrent	O
5	B
-	I
amino	I
##sal	I
##ic	I
##yla	I
##tes	I
(	O
n	O
=	O
83	O
,	O
64	O
.	O
3	O
%	O
)	O
and	O
s	O
##tero	O
##ids	O
(	O
n	O
=	O
87	O
,	O
67	O
.	O
4	O
%	O
)	O
at	O
the	O
time	O
of	O
th	B
##io	I
##pur	I
##ine	I
initiation	O
.	O

The	O
samples	O
were	O
extracted	O
twice	O
by	O
1	O
m	O
##l	O
is	B
##oo	I
##ct	I
##ane	I
and	O
the	O
extract	O
##s	O
were	O
di	O
##lut	O
##ed	O
to	O
30	O
%	O
before	O
analysis	O
on	O
G	O
##C	O
.	O

Using	O
Kyoto	O
Encyclopedia	O
of	O
Gene	O
##s	O
and	O
Gen	O
##ome	O
##s	O
(	O
K	O
##EG	O
##G	O
)	O
pathway	O
database	O
,	O
8	O
main	O
pathways	O
affected	O
in	O
C	O
##ushing	O
'	O
s	O
disease	O
were	O
identified	O
that	O
involved	O
:	O
(	O
1	O
)	O
Alan	B
##ine	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
,	O
which	O
appeared	O
to	O
be	O
the	O
most	O
affected	O
metabolic	O
pathway	O
,	O
(	O
2	O
)	O
Vita	O
##min	O
B	O
metabolism	O
,	O
(	O
3	O
)	O
L	B
##ys	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
(	O
4	O
)	O
P	B
##uri	I
##ne	I
metabolism	O
,	O
(	O
5	O
)	O
Am	B
##ino	I
sugar	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
metabolic	O
pathways	O
,	O
(	O
6	O
)	O
G	O
##ly	O
##co	O
##lysis	O
and	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
pathways	O
,	O
(	O
7	O
)	O

The	O
threshold	O
of	O
5	O
.	O
97	O
ng	O
/	O
m	O
##l	O
has	O
been	O
reported	O
as	O
the	O
potential	O
concentration	O
for	O
(	B
Z	I
)	I
-	I
end	I
##ox	I
##ife	I
##n	I
to	O
predict	O
the	O
benefit	O
from	O
ad	O
##ju	O
##vant	O
T	O
##AM	O
therapy	O
.	O

(	O
a	O
)	O
Fast	O
##ing	O
plasma	O
concentrations	O
and	O
(	O
b	O
)	O
AU	O
##C	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
during	O
an	O
O	O
##G	O
##TT	O
in	O
adolescent	O
subjects	O
s	O
##tra	O
##ti	O
##fied	O
by	O
te	O
##rt	O
##iles	O
of	O
insulin	O
sensitivity	O
(	O
n	O
=	O
26	O
for	O
each	O
te	O
##rt	O
##ile	O
)	O
.	O

L	B
-	I
as	I
##par	I
##agi	I
##ne	I
,	O
L	B
-	I
g	I
##lut	I
##amine	I
and	O
L	B
-	I
try	I
##pt	I
##op	I
##han	I
were	O
purchased	O
separately	O
(	O
Sigma	O
Al	O
##dric	O
##h	O
,	O
Stein	O
##heim	O
,	O
Germany	O
)	O
since	O
they	O
were	O
not	O
included	O
in	O
the	O
commercial	O
standard	O
mixture	O
.	O

H	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
is	O
converted	O
to	O
pro	B
##line	I
,	O
then	O
to	O
P	O
##5	O
##C	O
and	O
G	O
##SA	O
,	O
which	O
is	O
then	O
used	O
as	O
the	O
precursor	O
for	O
a	B
##rg	I
##ini	I
##ne	I
(	O
A	O
##rg	O
)	O
synthesis	O
from	O
or	B
##ni	I
##thin	I
##e	I
in	O
the	O
e	O
##pit	O
##hel	O
##ium	O
of	O
the	O
small	O
in	O
##test	O
##ine	O
under	O
conditions	O
of	O
decreased	O
ca	O
##lor	O
##ie	O
or	O
protein	O
intake	O
.	O

In	O
human	O
serum	O
album	O
##in	O
,	O
PA	O
##H	O
add	O
##uc	O
##ts	O
bind	O
almost	O
exclusively	O
within	O
a	O
binding	O
pocket	O
of	O
sub	O
##dom	O
##ain	O
1	O
##B	O
[	O
,	O
]	O
,	O
and	O
based	O
on	O
the	O
model	O
prediction	O
,	O
the	O
album	O
##in	O
-	O
like	O
protein	O
of	O
Atlantic	S
co	O
##d	O
may	O
present	O
similar	O
binding	O
pocket	O
conform	O
##ations	O
.	O

Regarding	O
metabolic	O
parameters	O
,	O
sensitive	O
subjects	O
had	O
significantly	O
lower	O
HD	O
##L	O
and	O
higher	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
,	O
reflected	O
in	O
the	O
meta	O
##bon	O
##omi	O
##c	O
data	O
,	O
suggesting	O
that	O
this	O
was	O
not	O
a	O
type	O
1	O
error	O
.	O

Met	B
##han	I
##ol	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
water	O
for	O
HP	O
##LC	O
were	O
of	O
L	O
##C	O
-	O
MS	O
grade	O
and	O
obtained	O
from	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	O
##it	O
##ru	O
##llin	O
##e	O
-	O
related	O
pathways	O
are	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
in	O
DR	O
,	O
and	O
fatty	O
acid	O
metabolism	O
is	O
altered	O
in	O
PD	O
##R	O
patients	O
compared	O
with	O
N	O
##PD	O
##R	O
patients	O
.	O

An	O
additional	O
step	O
—	O
en	O
##zy	O
##matic	O
h	O
##ydro	O
##lysis	O
using	O
a	O
preparation	O
from	O
He	O
##lix	O
p	O
##oma	O
##tia	O
with	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
and	O
su	O
##lf	O
##ata	O
##se	O
activity	O
(	O
Sigma	O
Chemical	O
Co	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
)	O
—	O
enables	O
the	O
sum	O
of	O
the	O
un	O
##con	O
##ju	O
##gated	O
and	O
con	O
##ju	O
##gated	O
forms	O
of	O
each	O
est	B
##rogen	I
or	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
to	O
be	O
measured	O
.	O

Of	O
our	O
identified	O
candidates	O
,	O
he	B
##xa	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
2	O
-	O
H	O
##G	O
hold	O
the	O
most	O
promise	O
.	O

High	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
h	O
##s	O
##CR	O
##P	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
fast	O
##ing	O
blood	O
glucose	S
and	O
lip	O
##id	O
profiles	O
were	O
measured	O
on	O
the	O
Abbott	O
AR	O
##CH	O
##IT	O
##EC	O
##T	O
platform	O
(	O
Abbott	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Abbott	O
Park	O
IL	O
)	O
.	O

Therefore	O
,	O
the	O
brain	O
in	O
patients	O
with	O
AD	O
presents	O
an	O
abnormal	O
##ity	O
of	O
glucose	S
u	O
##til	O
##ization	O
closely	O
resembling	O
that	O
in	O
the	O
brain	O
(	O
the	O
current	O
study	O
)	O
and	O
peripheral	O
nervous	O
tissue	O
(	O
s	O
##cia	O
##tic	O
nerve	O
,	O
dorsal	O
root	O
gang	O
##lia	O
,	O
and	O
t	O
##rig	O
##em	O
##inal	O
gang	O
##lia	O
)	O
of	O
the	O
rats	O
with	O
severe	O
diabetes	O
.	O

Subsequently	O
,	O
an	O
accumulation	O
of	O
γ	B
-	I
g	I
##lut	I
##am	I
##yl	I
-	I
dip	I
##eptide	I
##s	I
would	O
indicate	O
increased	O
(	O
he	O
##pa	O
##tic	O
)	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
as	O
has	O
been	O
reported	O
previously	O
.	O

The	O
following	O
meta	O
##bol	O
##ite	O
pairs	O
have	O
significant	O
S	O
##pear	O
##man	O
’	O
s	O
rank	O
correlation	O
ρ	O
<	O
−	O
##0	O
.	O
5	O
:	O
pro	B
##line	I
beta	I
##ine	I
and	O
ta	B
##uri	I
##ne	I
(	O
ρ	O
=	O
−	O
##0	O
.	O
55	O
)	O
,	O
T	B
##MA	I
##O	I
and	O
x	B
##yl	I
##ose	I
(	O
ρ	O
=	O
−	O
##0	O
.	O
52	O
)	O
,	O
and	O
T	O
##hr	O
+	O
Lac	O
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
(	O
ρ	O
=	O
−	O
##0	O
.	O
51	O
)	O
.	O

The	O
ratio	O
of	O
P	O
##t	O
##d	O
##E	O
##t	O
##n	O
containing	O
Doc	B
##osa	I
##he	I
##xa	I
##eno	I
##ic	I
acid	I
(	O
D	O
##HA	O
,	O
22	O
:	O
6	O
)	O
to	O
P	O
##t	O
##d	O
##E	O
##t	O
##n	O
containing	O
the	O
precursor	O
(	O
18	O
:	O
3	O
)	O
was	O
significantly	O
enhanced	O
in	O
R	O
##R	O
##MS	O
>	O
=	O
13	O
y	O
,	O
SP	O
##MS	O
and	O
PP	O
##MS	O
compared	O
to	O
controls	O
(	O
Fi	O
##g	O
.	O

In	O
this	O
last	O
case	O
,	O
se	B
##rine	I
is	O
de	O
##car	O
##box	O
##yla	O
##ted	O
to	O
ethanol	B
##amine	I
,	O
leading	O
in	O
two	O
further	O
steps	O
to	O
g	B
##ly	I
##co	I
##lic	I
acid	I
,	O
whereas	O
g	B
##ly	I
##cine	I
is	O
trans	O
##ami	O
##nated	O
to	O
g	B
##ly	I
##ox	I
##yl	I
##ic	I
acid	I
,	O
which	O
is	O
reduced	O
to	O
g	B
##ly	I
##co	I
##lic	I
acid	I
.	O

By	O
comparing	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
composition	O
of	O
HC	O
##M	O
##V	O
v	O
##iri	O
##ons	O
with	O
published	O
data	O
##sets	O
,	O
we	O
noted	O
a	O
resemblance	O
to	O
s	O
##yna	O
##ptic	O
ve	O
##si	O
##cles	O
.	O

Di	O
##fference	O
##s	O
between	O
groups	O
in	O
u	O
##rina	O
##ry	O
beta	B
##ine	I
concentration	O
at	O
V	O
##3	O
could	O
also	O
be	O
due	O
to	O
un	O
##con	O
##tro	O
##lled	O
variation	O
in	O
the	O
C	O
##G	O
.	O

The	O
Bay	O
##esi	O
##an	O
network	O
analysis	O
confirms	O
the	O
importance	O
of	O
c	B
##rea	I
##tine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
,	O
although	O
it	O
does	O
not	O
select	O
the	O
test	B
##osterone	I
meta	O
##bol	O
##ites	O
.	O

For	O
pro	O
##te	O
##omi	O
##cs	O
analysis	O
,	O
HC	O
##T	O
##11	O
##6	O
cells	O
were	O
culture	O
##d	O
in	O
custom	O
made	O
R	O
##PM	O
##I	O
1640	O
medium	O
with	O
the	O
trace	O
##rs	O
_	O
13	O
C	O
_	O
6	O
-	O
a	O
##rg	O
##ini	O
##ne	O
:	O
HC	O
##l	O
and	O
_	O
13	O
C	B
_	I
6	I
-	I
l	I
##ys	I
##ine	I
:	I
2	I
##HC	I
##l	I
for	O
120	O
h	O
.	O
Cell	O
##s	O
were	O
collected	O
by	O
try	O
##ps	O
##ini	O
##zation	O
and	O
the	O
p	O
##elle	O
##t	O
were	O
washed	O
with	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
prior	O
analysis	O
.	O

1	O
##D	O
NO	O
##ES	O
##Y	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
acquired	O
on	O
a	O
B	O
##ruk	O
##er	O
DR	O
##X	O
s	O
##pect	O
##rome	O
##ter	O
(	O
B	O
##ruk	O
##er	O
B	O
##ios	O
##pin	O
G	O
##mb	O
##h	O
,	O
R	O
##hein	O
##ste	O
##tten	O
,	O
Germany	O
)	O
operating	O
at	O
600	B
,	I
00	I
MHz	I
for	O
pro	O
##tons	O
(	O
14	O
.	O
09	O
Te	O
##sla	O
)	O
using	O
a	O
T	O
##CI	O
cry	O
##o	O
-	O
probe	O
head	O
and	O
equipped	O
with	O
a	O
Sam	O
##ple	O
##J	O
##et	O
auto	O
##sa	O
##mple	O
##r	O
.	O

That	O
group	O
attributed	O
their	O
findings	O
to	O
insulin	O
resistance	O
and	O
altered	O
pan	O
##cre	O
##atic	O
function	O
resulting	O
from	O
AP	S
.	O

CS	O
##F	O
(	O
0	O
.	O
5	O
m	O
##l	O
)	O
was	O
added	O
drop	O
##wise	O
to	O
2	O
.	O
1	O
m	O
##l	O
of	O
99	O
.	O
9	O
%	O
ethanol	S
,	O
containing	O
10	O
μ	O
##l	O
of	O
24	B
(	B
RS	I
)	I
-	I
[	I
26	I
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
,	I
27	I
-	I
_	I
2	I

Q	O
##uant	O
##ification	O
was	O
performed	O
in	O
the	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
mode	O
,	O
and	O
the	O
optimal	O
conditions	O
for	O
each	O
meta	O
##bol	O
##ite	O
were	O
determined	O
by	O
flow	O
injection	O
of	O
individual	O
standards	O
(	O
100	O
ng	O
/	O
m	O
##L	O
in	O
20	O
%	O
met	B
##han	I
##ol	I
)	O
into	O
the	O
E	O
##SI	O
source	O
in	O
the	O
positive	O
and	O
negative	O
ion	O
modes	O
.	O

As	O
shown	O
in	O
,	O
diet	O
##ary	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
firstly	O
is	O
converted	O
into	O
m	B
-	I
t	I
##yr	I
##os	I
##ine	I
,	O
o	B
-	I
t	I
##yr	I
##os	I
##ine	I
,	O
and	O
2	B
,	I
3	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##lal	I
##ani	I
##ne	I
by	O
gut	O
micro	O
##bio	O
##ta	O
,	O
for	O
example	O
,	O
ch	O
##lor	O
##ida	O
##zon	O
-	O
de	O
##grading	O
bacteria	O
.	O

(	O
)	O
Ser	O
##um	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
der	O
##iving	O
from	O
lip	O
##id	O
and	O
amino	O
acids	O
are	O
inverse	O
##ly	O
correlated	O
with	O
G	O
##F	O
##R	O
in	O
individuals	O
with	O
normal	O
as	O
well	O
as	O
with	O
impaired	O
re	O
##nal	O
function	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
the	O
L	O
##OD	O
for	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
were	O
slightly	O
above	O
the	O
lowest	O
point	O
of	O
the	O
standard	O
curve	O
(	O
3	O
ng	O
/	O
m	O
##l	O
)	O
,	O
this	O
very	O
low	O
signal	O
also	O
exhibited	O
precision	O
and	O
accuracy	O
values	O
that	O
were	O
in	O
con	O
##cor	O
##dance	O
with	O
FDA	O
guidelines	O
(	O
Table	O
)	O
.	O

However	O
most	O
associations	O
were	O
at	O
##ten	O
##uated	O
after	O
adjusting	O
for	O
conventional	O
card	O
##iovascular	O
risk	O
factors	O
,	O
including	O
blood	O
lip	O
##id	O
(	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
)	O
concentrations	O
and	O
g	B
##ly	I
##ce	I
##mic	I
markers	O
,	O
suggesting	O
that	O
the	O
associations	O
may	O
be	O
mediated	O
by	O
these	O
risk	O
factors	O
.	O

A	O
fourth	O
set	O
comprised	O
of	O
3	O
technical	O
replica	O
##tes	O
of	O
one	O
adult	O
serum	O
sample	O
,	O
was	O
collected	O
and	O
analyzed	O
for	O
o	B
##xy	I
##lip	I
##ins	I
by	O
UP	O
##LC	O
-	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
in	O
an	O
independent	O
analysis	O
.	O

E	B
##ry	I
##th	I
##ronic	I
acid	I
is	O
a	O
normal	O
organic	O
acid	O
present	O
in	O
bio	O
##f	O
##lu	O
##id	O
samples	O
of	O
healthy	O
children	O
and	O
adults	O
.	O

As	O
regards	O
the	O
PA	O
##H	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
,	O
reported	O
that	O
the	O
h	B
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##nes	I
,	O
h	B
##ydro	I
##xy	I
##phe	I
##nant	I
##hren	I
##es	I
,	O
1	B
-	I
h	I
##ydro	I
##xy	I
##py	I
##rene	I
and	O
2	B
-	I
nap	I
##ht	I
##hol	I
were	O
all	O
significantly	O
higher	O
in	O
smoke	O
##rs	O
compared	O
to	O
non	O
-	O
smoke	O
##rs	O
(	O
;	O
)	O
.	O

As	O
expected	O
,	O
the	O
T	B
##G	I
clusters	O
L	O
##C	O
##5	O
to	O
L	O
##C	O
##7	O
were	O
strongly	O
associated	O
with	O
the	O
metabolic	O
variables	O
,	O
including	O
B	O
##MI	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
(	O
Figure	O
)	O
.	O

Final	O
extract	O
##s	O
were	O
then	O
analyzed	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
using	O
amino	O
acids	O
and	O
bio	O
##active	O
am	O
##ines	O
PT	O
##C	O
-	O
derivatives	O
the	O
Z	O
##or	O
##ba	O
##x	O
S	O
##B	O
100	O
×	O
2	O
.	O
1	O
mm	O
column	O
(	O
A	O
##gi	O
##lent	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
a	O
direct	O
flow	O
injection	O
analysis	O
(	O
FIA	O
-	O
MS	O
/	O
MS	O
)	O
for	O
the	O
analysis	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Whereas	O
some	O
results	O
support	O
a	O
ca	O
##usal	O
effect	O
of	O
higher	O
vitamin	B
D	I
levels	O
on	O
a	O
more	O
favourable	O
lip	O
##id	O
profile	O
,	O
other	O
studies	O
question	O
the	O
role	O
of	O
25	O
(	O
OH	O
)	O
D	O
in	O
the	O
a	O
##eti	O
##ology	O
of	O
o	O
##besity	O
or	O
type	O
2	O
diabetes	O
,	O
is	O
##cha	O
##em	O
##ic	O
heart	O
disease	O
and	O
card	O
##iovascular	O
mortality	O
.	O

DB	O
##S	O
samples	O
were	O
di	O
##lut	O
##ed	O
with	O
60	O
μ	O
##L	O
0	O
.	O
3	O
%	O
form	B
##ic	I
acid	I
(	O
Em	O
##sure	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

Again	O
,	O
the	O
liver	O
is	O
known	O
to	O
actively	O
take	O
up	O
g	B
##lut	I
##amine	I
and	O
convert	O
it	O
to	O
g	B
##lut	I
##ama	I
##te	I
,	O
making	O
it	O
available	O
for	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
or	O
for	O
subsequent	O
conversion	O
to	O
other	O
amino	O
acids	O
.	O

The	O
MS	O
_	O
2	O
and	O
MS	O
_	O
3	O
s	O
##pect	O
##ra	O
of	O
these	O
[	O
M	O
]	O
_	O
+	O
ions	O
indicate	O
a	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
26	I
-	I
nor	I
##cho	I
##les	I
##t	I
-	I
4	I
-	I
en	I
-	I
3	I
-	I
one	I
s	I
##tero	I
##l	I
structure	O
(	O
0	O
.	O
204	O
±	O
0	O
.	O
08	O
##3	O

(	O
)	O
El	O
##eva	O
##ted	O
plasma	O
concentrations	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
other	O
p	O
##oly	O
##ols	O
were	O
strongly	O
associated	O
with	O
progression	O
to	O
E	O
##SR	O
##D	O
in	O
our	O
study	O
.	O

Also	O
in	O
urine	O
3	O
-	O
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
di	B
##os	I
##met	I
##in	I
is	O
the	O
main	O
meta	O
##bol	O
##ite	O
,	O
while	O
the	O
7	O
-	O
O	O
-	O
is	O
##omer	O
is	O
absent	O
;	O
interesting	O
##ly	O
,	O
the	O
levels	O
of	O
dig	O
##lu	O
##cu	O
##ron	O
##ide	O
were	O
more	O
relevant	O
in	O
urine	O
than	O
in	O
plasma	O
.	O

Thus	O
,	O
im	O
##mu	O
##no	O
##af	O
##finity	O
pu	O
##rification	O
combined	O
with	O
L	O
##C	O
-	O
MS	O
represents	O
a	O
viable	O
approach	O
for	O
the	O
detection	O
and	O
q	O
##uant	O
##ification	O
of	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
BC	O
##h	O
##E	O
as	O
an	O
exposure	O
bio	O
##mark	O
##er	O
of	O
organ	B
##op	I
##hos	I
##phate	I
##s	I
and	O
nerve	O
agents	O
.	O

Not	O
##ably	O
,	O
they	O
all	O
can	O
be	O
converted	O
to	O
g	B
##lut	I
##ami	I
##c	I
acid	I
by	O
trans	O
##ami	O
##nation	O
,	O
which	O
can	O
further	O
produce	O
am	O
##monia	O
.	O

Normal	O
##ized	O
PC	O
response	O
represented	O
PC	O
image	O
density	O
normal	O
##ized	O
to	O
α	B
-	I
tub	I
##ulin	I
image	O
density	O
.	O

G	B
##la	I
##cial	I
ace	I
##tic	I
acid	I
(	O
150	O
μ	O
##l	O
)	O
was	O
added	O
to	O
the	O
reaction	O
mixture	O
above	O
(	O
now	O
in	O
[UNK]	B
%	O
met	B
##han	I
##ol	I
)	O
,	O
followed	O
by	O
150	O
mg	O
of	O
GP	S
re	O
##age	O
##nt	O
.	O

Women	O
were	O
excluded	O
if	O
they	O
(	O
a	O
)	O
had	O
a	O
history	O
of	O
organic	O
G	O
##I	O
disease	O
,	O
cardiac	O
a	O
##rr	O
##hy	O
##th	O
##mia	O
,	O
or	O
re	O
##nal	O
or	O
g	O
##yne	O
##cological	O
issues	O
;	O
(	O
b	O
)	O
were	O
taking	O
medications	O
for	O
G	O
##I	O
symptoms	O
;	O
(	O
c	O
)	O
were	O
taking	O
any	O
medications	O
daily	O
that	O
would	O
alter	O
5	O
-	O
H	O
##T	O
;	O
(	O
d	O
)	O
had	O
a	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
>	O
35	O
kg	O
/	O
m	O
_	O
2	O
;	O
(	O
e	O
)	O
worked	O
during	O
the	O
late	O
evening	O
or	O
night	O
;	O
(	O
f	O
)	O
had	O
a	O
known	O
sleep	O
disorder	O
;	O
(	O
g	O
)	O
had	O
severe	O
com	O
##or	O
##bid	O
pain	O
or	O
psychiatric	O
conditions	O
;	O
or	O
(	O
h	O
)	O
drank	O
ca	O
##ffe	O
##ine	O
-	O
containing	O
beverages	O
(	O
>	O
300	O
mg	O
ca	B
##ffe	I
##ine	I
)	O
in	O
the	O
afternoon	O
/	O
evening	O
or	O
≥	O
3	O
serving	O
##s	O
of	O
alcohol	O
/	O
day	O
.	O

In	O
1920s	O
,	O
Otto	O
War	O
##burg	O
first	O
discovered	O
that	O
cancer	O
cells	O
prefer	O
to	O
meta	O
##bol	O
##ize	O
glucose	S
through	O
g	O
##ly	O
##co	O
##lysis	O
to	O
generate	O
ATP	S
instead	O
of	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
even	O
in	O
presence	O
of	O
ample	O
oxygen	O
.	O

Sixteen	O
300	O
μ	O
##L	O
serum	O
samples	O
were	O
mixed	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
1	O
:	O
1	O
,	O
1	O
:	O
2	O
,	O
1	O
:	O
3	O
or	O
1	O
:	O
4	O
ratios	O
(	O
v	O
/	O
v	O
)	O
(	O
see	O
S	O
##I	O
Table	O
S	O
##2	O
)	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
20	O
min	O
.	O

Three	O
of	O
these	O
meta	O
##bol	O
##ites	O
(	B
pan	B
##th	I
##oth	I
##ena	I
##te	I
,	O
bio	B
##tin	I
,	O
and	O
ta	B
##uri	I
##ne	I
)	O
are	O
common	O
diet	O
##ary	O
supplement	O
##s	O
suggesting	O
that	O
the	O
consumption	O
of	O
these	O
compounds	O
can	O
be	O
detected	O
in	O
the	O
CS	O
##F	O
.	O

We	O
also	O
performed	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
on	O
the	O
met	B
##han	I
##ol	I
extract	O
##s	O
from	O
these	O
same	O
patient	O
-	O
matched	O
ben	O
##ign	O
and	O
cancer	O
tumor	O
-	O
containing	O
bio	O
##psy	O
samples	O
.	O

Blood	O
samples	O
of	O
wild	O
Atlantic	S
co	O
##d	O
(	O
n	O
=	O
16	O
)	O
was	O
drawn	O
(	O
approximately	O
2	O
m	O
##L	O
)	O
using	O
he	O
##par	O
##ini	O
##zed	O
s	O
##yr	O
##inge	O
##s	O
(	B
Na	B
-	I
he	I
##par	I
##in	I
,	O
5000	O
I	O
##E	O
/	O
a	O
.	O
e	O
.	O
/	O
m	O
##L	O
,	O
L	O
##E	O
##O	O
Ph	O
##arma	O
)	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
5000	O
g	O
for	O
5	O
min	O
at	O
4	O
°C	O
.	O

M	O
##g	O
##C	O
##l	O
_	O
2	O
he	O
##xa	O
##hy	O
##dra	O
##te	O
(	O
B	O
##io	O
##X	O
##tra	O
)	O
,	O
Z	O
##n	O
##C	O
##l	O
_	O
2	O
(	O
an	O
##hy	O
##dr	O
##ous	O
)	O
,	O
Tri	O
##z	O
##ma	O
h	B
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
pH	O
8	O
.	O
0	O
,	O
1	O
M	O
)	O
,	O
1	B
-	I
but	I
##ano	I
##l	I
(	O
Ch	O
##roma	O
##sol	O
##v	O
Plus	O
)	O
,	O
H	O
_	O
2	O
O	O
and	O
CH	O
_	O
3	O
C	O
##N	O
(	O
L	O
##C	O
-	O
MS	O
Ch	O
##roma	O
##sol	O
##v	O
)	O
,	O
2	B
′	I
-	I
de	I
##ox	I
##y	I
##gua	I
##nos	I
##ine	I
h	O
##yd	O
##rate	O
(	O
d	O
##G	O
)	O
,	O
Am	O
##ico	O
##n	O
Ultra	O
-	O
0	O
.	O
5	O
(	O
10	O
k	O
##D	O
##a	O
)	O

The	O
sample	O
was	O
acid	O
##ified	O
with	O
the	O
addition	O
of	O
2	O
.	O
5	O
µ	O
##L	O
of	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
,	O
and	O
the	O
extraction	O
step	O
with	O
250	O
µ	O
##L	O
of	O
et	B
##hyl	I
ace	I
##tate	I
was	O
repeated	O
.	O

E	O
##pen	O
##dy	O
##mo	O
##ma	O
presented	O
an	O
increased	O
level	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
whereas	O
p	O
##ilo	O
##cy	O
##tic	O
as	O
##tro	O
##cy	O
##tom	O
##a	O
exhibited	O
increased	O
levels	O
of	O
fatty	O
acids	O
.	O

It	O
is	O
demonstrated	O
how	O
serum	O
protein	O
can	O
be	O
efficiently	O
,	O
cost	O
-	O
effectively	O
,	O
and	O
environmental	O
##ly	O
friendly	O
removed	O
at	O
physiological	O
pH	O
(	O
pH	O
7	O
.	O
4	O
)	O
through	O
attractive	O
interactions	O
with	O
si	B
##lica	I
na	O
##no	O
##par	O
##tic	O
##les	O
.	O

The	O
volcano	O
plots	O
were	O
plot	O
##ted	O
in	O
to	O
obtain	O
the	O
significantly	O
altered	O
meta	O
##bol	O
##ites	O
between	O
−	O
##20	O
/	O
4	O
°C	O
and	O
40	O
°C	O
samples	O
with	O
N	O
##P	O
or	O
thy	B
##mo	I
##l	I
.	O

A	O
method	O
to	O
analyze	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
of	O
a	B
##c	I
##rol	I
##ein	I
and	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
is	O
described	O
The	O
method	O
was	O
valid	O
##ated	O
for	O
accuracy	O
and	O
precision	O
The	O
method	O
was	O
applied	O
in	O
the	O
analysis	O
of	O
more	O
than	O
260	O
##0	O
urine	O
samples	O
from	O
smoke	O
##rs	O
Mean	O
smoke	O
##rs	O
’	O
u	O
##rina	O
##ry	O
levels	O
were	O
480	O
##0	O
##±	O
##53	O
##5	O
##8	O
(	O
3	O
-	O
HP	O
##MA	O
)	O
and	O
330	O
##2	O
##±	O
##33	O
##41	O
pm	O
##ol	O
/	O
m	O
##l	O
(	O
HM	O
##PM	O
##A	O
)	O

In	O
addition	O
,	O
his	B
##ti	I
##dine	I
,	O
an	O
essential	O
amino	O
acid	O
and	O
a	O
precursor	O
for	O
the	O
pro	O
-	O
inflammatory	O
his	B
##tamine	I
,	O
was	O
also	O
found	O
to	O
be	O
marked	O
##ly	O
elevated	O
in	O
our	O
patients	O
with	O
re	O
##current	O
disease	O
.	O

One	O
to	O
two	O
passages	O
after	O
th	O
##aw	O
##ing	O
,	O
B	O
##J	O
-	O
4	O
##F	O
##3	O
,	O
H	O
##U	O
##H	O
##7	O
,	O
CA	O
##K	O
##I	O
##2	O
cells	O
were	O
trans	O
##duced	O
with	O
control	O
s	O
##h	O
##RNA	O
##s	O
(	O
Sigma	O
:	O
SH	O
##C	O
##00	O
##1	O
as	O
empty	O
vector	O
,	O
SH	O
##C	O
##00	O
##2	O
as	O
non	O
-	O
targeting	O
s	O
##h	O
##RNA	O
control	O
)	O
or	O
AL	O
##D	O
##H	O
##7	O
##A	O
##1	O
-	O
specific	O
s	O
##h	O
##RNA	O
##s	O
(	O
Sigma	O
:	O
T	O
##RC	O
##N	O
##00	O
##00	O
##0	O
##28	O
##42	O
##4	O
(	O
s	O
##h	O
##1	O
)	O
and	O
T	O
##RC	O
##N	O
##00	O
##00	O
##0	O
##28	O
##44	O
##7	O
(	O
s	O
##h	O
##2	O
)	O
)	O
for	O
24	O
h	O
,	O
allowed	O
to	O
recover	O
for	O
24	O
h	O
,	O
and	O
placed	O
under	O
pu	B
##rom	I
##y	I
##cin	I
selection	O
(	O
2	O
μ	O
##g	O
/	O
m	O
##l	O
)	O
for	O
6	O
days	O
.	O

However	O
,	O
high	O
level	O
of	O
glucose	S
in	O
lung	O
cancer	O
does	O
not	O
show	O
the	O
decrease	O
in	O
g	O
##ly	O
##co	O
##lysis	O
as	O
la	B
##ctic	I
acid	I
is	O
also	O
up	O
-	O
regulated	O
in	O
lung	O
cancer	O
.	O

In	O
the	O
measurements	O
performed	O
by	O
CD	O
##C	O
,	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
was	O
q	O
##uant	O
##ified	O
by	O
using	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
-	I
d	I
_	O
3	O
as	O
the	O
internal	O
standard	O
.	O

Our	O
findings	O
confirmed	O
a	O
clear	O
relationship	O
between	O
car	O
##ot	O
##id	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
plaque	O
and	O
plasma	O
levels	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
try	B
##pt	I
##op	I
##han	I
(	O
C	O
)	O
and	O
k	B
##yn	I
##uren	I
##ine	I
(	O
D	O
)	O
concentrations	O
in	O
plasma	O
from	O
normal	O
women	O
,	O
all	O
breast	O
cancer	O
patients	O
in	O
the	O
co	O
##hor	O
##t	O
,	O
and	O
ER	O
+	O
versus	O
ER	O
-	O
breast	O
cancer	O
patients	O
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
was	O
purchased	O
from	O
Rat	O
##h	O
##burn	O
(	O
Walker	O
##burn	O
,	O
Scotland	O
)	O
.	O

MR	O
##S	O
was	O
built	O
as	O
a	O
weighted	O
linear	O
combination	O
of	O
the	O
following	O
five	O
meta	O
##bol	O
##ites	O
:	O
Val	B
##ine	I
(	O
H	O
##R	O
=	O
0	O
.	O
62	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
11	O
–	O
1	O
.	O
71	O
for	O
each	O
standard	O
de	O
##viation	O
(	O
SD	O
)	O
of	O
98	O
.	O
57	O
)	O
,	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
C	I
##24	I
:	I
1	I
(	O
H	O
##R	O
=	O
2	O
.	O
66	O
,	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
30	O
–	O
21	O
.	O
09	O
,	O
for	O
each	O
SD	O
of	O
20	O
.	O
67	O
)	O
,	O
L	B
##ys	I
##ine	I
(	O
H	O
##R	O
=	O
0	O
.	O
36	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
03	O
–	O
0	O
.	O
77	O
,	O
for	O
each	O
SD	O
of	O
51	O
.	O
73	O
)	O
,	O
Trip	B
##ent	I
##ade	I
##cano	I
##ate	I
T	O
##G	O
##15	O
(	O
H	O
##R	O
=	O
0	O
.	O
25	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
01	O
–	O
0	O
.	O
82	O
,	O
for	O
each	O
SD	O
of	O
2	O
.	O
88	O
)	O
and	O
S	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
H	O
##R	O
=	O
2	O
.	O
24	O
,	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
28	O
–	O
103	O
.	O
08	O
,	O
for	O
each	O
SD	O
of	O
0	O
.	O
62	O
)	O
,	O
achieving	O
a	O
very	O
high	O
discrimination	O
ability	O
(	O
survival	O
c	O
-	O
s	O
##tat	O
##istic	O
of	O
0	O
.	O
85	O
##5	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
81	O
##6	O
–	O
0	O
.	O
89	O
##4	O
)	O
.	O

In	O
total	O
,	O
64	O
pathways	O
were	O
covered	O
with	O
a	O
wide	O
range	O
of	O
biological	O
activity	O
including	O
key	O
metabolic	O
processes	O
such	O
as	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
,	O
amino	O
acid	O
metabolism	O
,	O
and	O
g	O
##ly	O
##co	O
##lysis	O
(	O
and	O
)	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
T	O
##ga	O
##d	O
R	O
_	O
2	O
=	O
–	O
0	O
.	O
69	O
,	O
FL	O
##A	O
##IR	O
R	O
_	O
2	O
=	O
−	O
##0	O
.	O
72	O
)	O
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
T	O
##ga	O
##d	O
R	O
_	O
2	O
=	O
0	O
.	O
54	O
,	O
FL	O
##A	O
##IR	O
R	O
_	O
2	O
=	O
0	O
.	O
67	O
)	O
,	O
c	B
##yt	I
##id	I
##ine	I
(	O
T	O
##ga	O
##d	O
R	O
_	O
2	O
=	O
–	O
0	O
.	O
56	O
,	O
FL	O
##A	O
##IR	O
R	O
_	O
2	O
=	O
–	O
0	O
.	O
62	O
)	O
,	O
ace	B
##to	I
##ace	I
##tate	I
(	O
T	O
##ga	O
##d	O
R	O
_	O
2	O
=	O
0	O
.	O
57	O
,	O
FL	O
##A	O
##IR	O
R	O
_	O
2	O
=	O
0	O
.	O
60	O
)	O
,	O
p	B
##hen	I
##yl	I
##p	I
##rop	I
##iol	I
##ic	I
acid	I
(	O
T	O
##ga	O
##d	O
R	O
_	O
2	O
=	O
0	O
.	O
72	O
,	O
FL	O
##A	O
##IR	O
R	O
_	O
2	O
=	O
0	O
.	O
57	O
)	O
,	O
and	O
ch	B
##ole	I
##ster	I
##yl	I
su	I
##lf	I
##ate	I
(	O
T	O
##ga	O
##d	O
R	O
_	O
2	O
=	O
0	O
.	O
79	O
,	O
FL	O
##A	O
##IR	O
R	O
_	O
2	O
=	O
0	O
.	O
50	O
)	O
.	O

Inc	O
##reased	O
le	B
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
in	O
tissues	O
and	O
increased	O
ace	B
##to	I
##ace	I
##tate	I
in	O
urine	O
were	O
in	O
agreement	O
with	O
the	O
ing	O
##ested	O
nutrients	O
that	O
fuel	O
the	O
T	O
##CA	O
cycle	O
to	O
support	O
cell	O
proliferation	O
.	O

Yet	O
,	O
c	O
##it	O
##rate	O
/	B
is	B
##oc	I
##it	I
##rate	I
showed	O
a	O
prominent	O
_	O
12	O
C	O
_	O
1	O
mass	O
is	O
##oto	O
##po	O
##mer	O
,	O
suggesting	O
substantial	O
incorporation	O
of	O
_	O
12	O
CO	O
_	O
2	O
into	O
T	O
##CA	O
carbon	O
by	O
is	O
##oc	O
##it	O
##rate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
ID	O
##H	O
)	O
,	O
similar	O
to	O
previous	O
reports	O
.	O

shows	O
the	O
box	O
plots	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
LP	O
##Cs	O
)	O
C	B
18	I
:	I
2	I
(	O
A	O
)	O
,	O
C	B
18	I
:	I
1	I
(	O
B	O
)	O
,	O

The	O
protein	O
-	O
bound	O
g	B
##ly	I
##cans	I
undergo	O
further	O
processing	O
to	O
generate	O
mature	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
.	O

×	O
10	O
_	O
–	O
15	O
)	O
,	O
free	O
ace	B
##tate	I
(	O
P	O
_	O
CD	O
=	O
2	O
.	O
8	O

The	O
ne	O
##uro	O
##to	O
##xi	O
##city	O
of	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
was	O
partly	O
explained	O
by	O
the	O
effects	O
of	O
k	O
##yn	O
##uren	O
##ines	O
on	O
the	O
ni	O
##cot	O
##ini	O
##c	O
ch	B
##olin	I
##ergic	I
system	O
.	O

Q	O
##uant	O
##itative	O
,	O
targeted	O
mass	O
-	O
s	O
##pect	O
##rome	O
##try	O
based	O
meta	O
##bol	O
##ite	O
pro	O
##fi	O
##ling	O
,	O
was	O
used	O
to	O
measure	O
levels	O
of	O
45	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
15	O
amino	O
acids	O
and	O
three	O
conventional	O
meta	O
##bol	O
##ites	O
(	B
k	B
##eton	I
##es	I
,	O
none	O
##ster	O
##ified	O
fatty	O
acids	O
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
)	O
as	O
a	O
part	O
of	O
the	O
main	O
M	O
##UR	O
##D	O
##OC	O
##K	O
C	O
##V	O
study	O
.	O

For	O
both	O
,	O
H	O
.	O
p	O
##oma	O
##tia	O
and	O
b	O
##ov	O
##ine	O
liver	O
G	O
##US	O
,	O
a	O
200	O
-	O
m	O
##M	O
ace	B
##tate	I
buffer	O
(	O
pH	O
4	O
.	O
5	O
)	O
was	O
used	O
for	O
h	O
##ydro	O
##lysis	O
,	O
and	O
for	O
E	O
.	O
co	O
##li	O
G	O
##US	O
,	O
a	O
h	O
##ydro	O
##lysis	O
buffer	O
of	O
75	O
m	O
##M	O
phosphate	S
buffer	O
(	O
pH	O
6	O
.	O
8	O
)	O
was	O
used	O
.	O

Four	O
of	O
these	O
peaks	O
were	O
identified	O
in	O
at	O
least	O
4	O
of	O
the	O
5	O
combinations	O
in	O
the	O
five	O
-	O
fold	O
cross	O
-	O
valid	O
##ation	O
,	O
corresponding	O
to	O
c	B
##rea	I
##tine	I
(	O
5	O
times	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
(	O
5	O
times	O
)	O
,	O
and	O
the	O
peaks	O
ranked	O
27	O
_	O
th	O
(	O
q	O
-	O
value	O
=	O
0	O
.	O
04	O
)	O
and	O
58	O
_	O
th	O
(	O
q	O
-	O
value	O
=	O
0	O
.	O
10	O
)	O
,	O
which	O
have	O
m	O
/	O
z	O
values	O
of	O
154	O
.	O
06	O
and	O
176	O
.	O
04	O
,	O
respectively	O
(	O
4	O
times	O
)	O
.	O

B	B
##up	I
##ren	I
##or	I
##phine	I
,	O
Nor	B
##bu	I
##p	I
##ren	I
##or	I
##phine	I
,	O
B	B
##up	I
##ren	I
##or	I
##phine	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
Nor	B
##bu	I
##p	I
##ren	I
##or	I
##phine	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
U	O
##rine	O
,	O
Li	O
##quid	O
ch	O
##roma	O
##tography	O
–	O

For	O
AR	O
##B	O
(	O
Ang	O
##iot	O
##ens	O
##in	O
II	O
Re	O
##ceptor	O
Block	O
##ers	O
)	O
and	O
s	B
##tat	I
##ins	I
,	O
no	O
significant	O
associations	O
with	O
meta	O
##bol	O
##ite	O
levels	O
were	O
observed	O
.	O

[	O
,	O
,	O
]	O
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
(	O
p	O
=	O
8	O
.	O
5	O
##E	O
-	O
03	O
)	O
,	O
Indo	B
##le	I
-	I
3	I
-	I
ethanol	I
(	O
p	O
=	O
1	O
.	O
2	O
##E	O
-	O
02	O
)	O

Since	O
both	O
the	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
and	O
liver	O
are	O
essential	O
for	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
structural	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
we	O
investigated	O
the	O
circulating	O
levels	O
of	O
these	O
lip	O
##ids	O
in	O
field	O
infections	O
and	O
experimental	O
##ly	O
infected	O
cattle	O
.	O

Then	O
,	O
large	O
V	O
##LD	O
##L	O
particles	O
,	O
rich	O
in	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
a	O
##cc	O
##um	O
##ulate	O
and	O
suffer	O
se	O
##quential	O
lip	O
##oly	O
##sis	O
that	O
leads	O
to	O
increasing	O
concentrations	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
-	I
poor	I
small	O
L	O
##D	O
##L	O
particles	O
.	O

(	O
A	O
)	O
PC	B
(	I
40	I
:	I
4	I
)	I
,	O
Re	O
##ten	O
##tion	O
time	O
(	O
R	O
##T	O
)	O
:	O
0	O
.	O
52	O
,	O
m	O
/	O
z	O
:	O
83	O
##8	O
.	O
188	O
;	O
(	O
B	O
)	O
2	B
-	I
He	I
##xen	I
##oy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
R	O
##T	O
:	O
0	O
.	O
56	O
,	O
m	O
/	O
z	O
:	O
256	O
.	O
88	O
##24	O
;	O
(	O
C	O
)	O
Beta	B
-	I
D	I
-	I
G	I
##lu	I
##copy	I
##ran	I
##uron	I
##ic	I
acid	I
,	O
R	O
##T	O
:	O
0	O
.	O
80	O
,	O
m	O
/	O
z	O
:	O
315	O
.	O
08	O
##0	O
##9	O
;	O
(	O
D	O
)	O
D	B
##G	I
(	I
38	I
:	I
9	I
)	I
,	O
R	O
##T	O
:	O
3	O
.	O
26	O
,	O
m	O
/	O
z	O
:	O
63	O
##5	O
.	O
39	O
##20	O
;	O
(	O
E	O
)	O
MG	B
(	I
20	I
:	I
3	I
)	I
,	O
R	O
##T	O
:	O
5	O
.	O
54	O
,	O
m	O
/	O
z	O
:	O
38	O
##1	O
.	O
1810	O
;	O
(	O
F	O
)	O
L	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
,	O
R	O
##T	O
:	O
8	O
.	O
69	O
,	O
m	O
/	O
z	O
:	O
520	O
.	O
34	O
##14	O
;	O
(	O
G	O
)	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
,	O
R	O
##T	O
:	O
8	O
.	O
89	O
,	O
m	O
/	O
z	O
:	O
51	O
##8	O
.	O
322	O
##2	O
.	O

Experiment	O
##s	O
with	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
were	O
also	O
consistent	O
with	O
previous	O
reports	O
_	O
,	O
showing	O
that	O
the	O
detected	O
o	O
##xi	O
##dized	O
meta	O
##bol	O
##ites	O
were	O
ex	O
##cre	O
##ted	O
primarily	O
as	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
con	O
##ju	O
##gate	O
##s	O
(	O
and	O
)	O
.	O

From	O
the	O
Editor	O
##s	O
Prospect	O
##ive	O
studies	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
have	O
consistently	O
demonstrated	O
that	O
higher	O
levels	O
of	O
circulating	O
est	B
##rad	I
##iol	I
,	O
est	B
##rone	I
,	O
and	O
est	B
##rone	I
su	I
##lf	I
##ate	I
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
.	O

Yet	O
,	O
through	O
the	O
heat	O
##ma	O
##p	O
analysis	O
,	O
we	O
could	O
easily	O
identify	O
m	O
/	O
z	O
233	O
(	O
break	O
between	O
C	O
-	O
15	O
and	O
C	O
-	O
16	O
)	O
,	O
m	O
/	O
z	O
247	O
(	O
break	O
between	O
C	O
-	O
16	O
and	O
C	O
-	O
17	O
)	O
and	O
m	O
/	O
z	O
261	O
(	O
break	O
between	O
C	O
-	O
17	O
and	O
C	O
-	O
18	O
)	O
as	O
unique	O
fragment	O
ion	O
for	O
16	B
-	I
H	I
##ET	I
##E	I
,	O
17	B
-	I
H	I
##ET	I
##E	I
and	O
18	O
H	O
##ET	O
##E	O
,	O
respectively	O
.	O

The	O
formation	O
of	O
TO	O
##G	O
involves	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
the	O
γ	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
residue	O
of	O
ONE	O
-	O
G	O
##S	O
##H	O
,	O
preventing	O
further	O
metabolism	O
of	O
the	O
G	B
##S	I
##H	I
m	O
##oi	O
##ety	O
to	O
form	O
ONE	O
-	O
MA	O
.	O

and	O
the	O
pro	O
##ton	O
-	O
de	O
##co	O
##up	O
##led	O
sky	B
##line	I
projections	O
(	O
p	O
-	O
JR	O
##ES	O
)	O
exported	O
using	O
A	O
##gi	O
##lent	O
V	O
##N	O
##MR	O
##J	O
3	O
.	O
2	O
software	O
.	O

An	O
##throp	O
##ometric	O
and	O
clinical	O
parameters	O
,	O
mean	O
(	O
±	O
standard	O
de	O
##viation	O
)	O
,	O
before	O
(	O
T	O
##0	O
)	O
and	O
after	O
(	O
T	O
##1	O
)	O
diet	O
##ary	O
intervention	O
with	O
olive	O
-	O
en	O
##rich	O
##ed	O
product	O
(	O
O	O
##EP	O
)	O
or	O
control	O
(	O
C	O
##tr	O
##l	O
)	O
p	O
value	O
is	O
relative	O
to	O
one	O
-	O
way	O
AN	O
##O	O
##VA	O
on	O
the	O
difference	O
between	O
T	O
##0	O
and	O
T	O
##1	O
S	O
##Y	O
##S	O
s	O
##ys	O
##to	O
##lic	O
pressure	O
,	O
D	O
##IA	O
di	O
##ast	O
##olic	O
pressure	O
,	O
W	O
##M	O
waist	O
measure	O
,	O
HM	O
hips	O
measure	O
,	O
B	O
##MI	O
body	O
mass	O
index	O
,	O
T	O
##C	O
plasma	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	O
##L	O
plasma	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
,	O
L	O
##D	O
##L	O
plasma	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
,	O
T	B
##G	I
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
A	O
##po	O
A	O
##poli	O
##pop	O
##rote	O
##ins	O
in	O
plasma	O
,	O
G	O
##lu	O
plasma	O
glucose	S
,	O
In	O
##s	O
plasma	O
insulin	O
,	O
CR	O
##P	O
plasma	O
reactive	O
C	O
protein	O
,	O
o	O
##x	O
##LD	O
##L	O
plasma	O
o	O
##xi	O
##dized	O
L	O
##D	O
##L	O
,	O
F	O
##2	O
Is	O
##p	O
total	O
24	O
-	O
h	O
urine	O
Is	B
##op	I
##ros	I
##tan	I
##e	I
F	O
##2	O
DNA	O
extraction	O
was	O
performed	O
using	O
the	O
Fast	O
##D	O
##NA	O
[UNK]	O
SP	O
##IN	O
Kit	O
for	O
Fe	O
##ces	O
(	O
MP	O
B	O
##io	O
##medical	O
##s	O
)	O
.	O

With	O
this	O
me	O
##chan	O
##istic	O
relevance	O
and	O
our	O
data	O
showing	O
the	O
correlation	O
with	O
the	O
pro	O
##gno	O
##sis	O
at	O
3	O
months	O
,	O
the	O
[	B
3	I
-	I
H	I
##B	I
]	I
/	I
[	I
glucose	I
]	I
ratio	O
might	O
be	O
a	O
useful	O
pro	O
##gno	O
##stic	O
marker	O
for	O
future	O
g	B
##ly	I
##ce	I
##mic	I
control	O
,	O
if	O
our	O
results	O
are	O
reproduced	O
in	O
larger	O
studies	O
.	O

Ser	O
##um	O
inter	O
##le	O
##uki	O
##n	O
(	B
IL	I
)	I
-	I
1	I
##β	I
,	O
IL	O
-	O
6	O
,	O
and	O
tumor	O
ne	O
##c	O
##rosis	O
factor	O
(	O
T	O
##NF	O
)	O
–	O
α	O
concentrations	O
were	O
measured	O
using	O
the	O
B	O
##io	O
-	O
P	O
##lex	O
Re	O
##age	O
##nt	O
Kit	O
and	O
a	O
B	O
##io	O
-	O
P	O
##lex	O
(	O
B	O
##io	O
-	O
Ra	O
##d	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

In	O
##tra	O
##cellular	O
concentrations	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
are	O
inverse	O
##ly	O
related	O
to	O
ad	B
##en	I
##yla	I
##te	I
energy	O
changes	O
and	O
,	O
therefore	O
,	O
to	O
the	O
energy	O
currency	O
of	O
cellular	O
ATP	S
.	O

Strong	O
correlation	O
##s	O
were	O
observed	O
within	O
groups	O
of	O
related	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
LP	O
##I	O
##s	O
,	O
NE	O
##FA	O
##s	O
,	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

Line	O
##ar	O
re	O
##gression	O
curves	O
built	O
for	O
standard	O
addition	O
of	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
are	O
more	O
linear	O
if	O
the	O
height	O
of	O
the	O
peak	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
99	O
##9	O
##6	O
)	O
is	O
used	O
instead	O
of	O
peak	O
area	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
98	O
##50	O
)	O
.	O

A	O
second	O
multiple	O
linear	O
re	O
##gression	O
model	O
was	O
generated	O
it	O
##erative	O
##ly	O
using	O
18	O
clusters	O
of	O
o	B
##xy	I
##lip	I
##ins	I
and	O
fatty	O
acids	O
,	O
identified	O
by	O
their	O
similar	O
pattern	O
of	O
expression	O
in	O
T	O
##GR	O
##L	O
from	O
fast	O
##ing	O
subjects	O
.	O

In	O
addition	O
to	O
β	B
-	I
H	I
##B	I
,	O
accumulation	O
in	O
a	O
##romatic	O
amino	O
acids	O
levels	O
suggests	O
imp	O
##air	O
##ment	O
of	O
mitochondrial	O
function	O
and	O
inflammatory	O
status	O
in	O
HC	O
##C	O
-	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

C	O
##inn	O
##abar	O
##ini	O
##c	O
acid	O
and	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
were	O
present	O
in	O
much	O
smaller	O
amounts	O
than	O
K	O
##yn	O
(	O
F	O
)	O
.	O

Beta	B
##ine	I
acts	O
as	O
a	O
met	O
##hyl	O
donor	O
in	O
the	O
beta	O
##ine	O
-	O
ho	O
##mo	O
##cy	O
##stein	O
##e	O
met	O
##hyl	O
transfer	O
##ase	O
reaction	O
(	O
B	O
##H	O
##MT	O
-	O
R	O
)	O
,	O
which	O
converts	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
and	O
beta	B
##ine	I
to	O
met	B
##hi	I
##oni	I
##ne	I
and	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
.	O

Ser	O
##um	O
c	B
##ys	I
##tein	I
##sul	I
##fo	I
##nic	I
acid	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oi	I
##nos	I
##ito	I
##l	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	I
40	I
:	I
7	I
)	I
and	O
c	B
##rea	I
##tin	I
##ine	I
were	O
also	O
modest	O
##ly	O
elevated	O
in	O
CO	O
##PD	O
smoke	O
##rs	O
.	O

Moreover	O
,	O
MA	O
##P	O
##K	O
##I	O
##s	O
treatments	O
are	O
associated	O
with	O
alter	O
##ation	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
and	O
3	B
##hy	I
##dr	I
##ox	I
##yan	I
##th	I
##rani	I
##lic	I
acid	I
(	O
3	O
##HA	O
##A	O
)	O
concentrations	O
and	O
led	O
to	O
higher	O
“	O
C	O
##X	O
##CL	O
##11	O
,	O
”	O
and	O
“	O
K	O
##LR	O
##D	O
##1	O
”	O
expression	O
that	O
are	O
involved	O
in	O
T	O
and	O
N	O
##K	O
cells	O
activation	O
.	O

Gene	O
##tic	O
variations	O
particularly	O
single	O
n	O
##uc	O
##leo	O
##tide	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
(	O
S	O
##NP	O
##s	O
)	O
in	O
gene	O
encoded	O
for	O
delta	O
-	O
6	O
-	O
des	O
##at	O
##ura	O
##se	O
(	O
FA	O
##DS	O
##2	O
)	O
leading	O
to	O
higher	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
LA	O
)	O
/	O
AL	O
##A	O
ratio	O
due	O
to	O
impaired	O
metabolism	O
.	O

As	O
formal	B
##in	I
fix	O
##ation	O
time	O
can	O
vary	O
by	O
investigator	O
protocol	O
,	O
we	O
performed	O
a	O
time	O
course	O
(	O
ranging	O
from	O
0	O
.	O
5	O
to	O
48	O
h	O
)	O
to	O
determine	O
the	O
optimal	O
met	B
##han	I
##ol	I
in	O
##cu	O
##bation	O
time	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
diet	O
##ary	O
supplement	O
##al	O
vitamin	B
B	I
##6	I
suppress	O
##es	O
co	O
##lon	O
damage	O
,	O
e	O
##pit	O
##hel	O
##ial	O
cell	O
proliferation	O
and	O
protein	O
expression	O
of	O
H	O
##SP	O
##70	O
and	O
H	O
##O	O
-	O
1	O
,	O
the	O
targets	O
for	O
anti	O
-	O
tumor	O
agents	O
,	O
in	O
rats	O
exposed	O
to	O
1	B
,	I
2	I
dim	I
##eth	I
##yl	I
h	I
##yd	I
##raz	I
##ine	I
.	O

H	O
##sa	O
-	O
mi	O
##R	O
-	O
88	O
##5	O
-	O
5	O
##p	O
levels	O
correlated	O
inverse	O
##ly	O
with	O
o	O
##xy	O
##ster	O
##ol	O
-	O
binding	O
protein	O
2	O
(	O
OS	O
##B	O
##PL	O
##2	O
)	O
expression	O
(	O
r	O
=	O
−	O
##0	O
.	O
143	O
,	O
p	O
=	O
1	O
.	O
00	O
*	O
10	O
_	O
−	O
##4	O
)	O
and	O
suppress	O
##ing	O
the	O
expression	O
of	O
this	O
lip	O
##id	O
receptor	O
and	O
s	O
##tero	O
##l	O
transport	O
##er	O
could	O
link	O
h	O
##sa	O
-	O
mi	O
##R	O
-	O
88	O
##5	O
-	O
5	O
##p	O
with	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
levels	O
.	O

The	O
present	O
method	O
has	O
been	O
applied	O
for	O
the	O
analyses	O
of	O
plasma	O
from	O
healthy	O
volunteers	O
participating	O
to	O
a	O
phase	O
I	O
##a	O
clinical	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
(	O
P	O
##K	O
)	O
trial	O
(	O
study	O
name	O
:	O
I	O
##M	O
-	O
06	O
-	O
11	O
,	O
Clinical	O
##T	O
##rial	O
##s	O
.	O
go	O
##v	O
id	O
##ent	O
##ifier	O
(	O
NC	O
##T	O
number	O
)	O
:	O
NC	O
##T	O
##0	O
##34	O
##23	O
##0	O
##30	O
)	O
,	O
allowing	O
the	O
multiple	O
##x	O
q	O
##uant	O
##ification	O
of	O
not	O
only	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
and	O
its	O
active	O
meta	O
##bol	O
##ites	O
levels	O
,	O
but	O
also	O
the	O
inactive	O
meta	O
##bol	O
##ite	O
amino	S
,	O
once	O
the	O
labeled	O
IS	O
##T	O
##D	O
was	O
available	O
.	O

Ph	B
##os	I
##ph	I
##oc	I
##rea	I
##tine	I
is	O
converted	O
to	O
c	B
##rea	I
##tine	I
to	O
produce	O
ATP	S
which	O
is	O
an	O
essential	O
energy	O
source	O
for	O
my	O
##oc	O
##ard	O
##ial	O
contraction	O
;	O
therefore	O
,	O
increased	O
serum	O
c	B
##rea	I
##tine	I
levels	O
may	O
indicate	O
a	O
state	O
of	O
energy	O
de	O
##ple	O
##tion	O
.	O

Cancer	O
patients	O
are	O
characterised	O
by	O
higher	O
concentrations	O
of	O
is	O
##o	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
v	O
##ale	O
##rate	O
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
is	O
##ova	O
##ler	O
##ate	O
)	O
,	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
and	O
,	O
a	O
sugar	B
-	I
phosphate	I
whose	O
signals	O
arise	O
at	O
5	O
.	O
61	O
pp	O
##m	O
,	O
and	O
lower	O
concentrations	O
of	O
met	B
##han	I
##ol	I
,	O
amino	O
acids	O
(	B
g	B
##lut	I
##amine	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
ta	B
##uri	I
##ne	I
,	O
and	O
b	B
-	I
al	I
##ani	I
##ne	I
)	O
,	O
sugar	O
##s	O
(	B
glucose	S
,	O
gal	B
##act	I
##ose	I
and	O
x	O
##yl	O
##ose	O
)	O
,	O
and	O
bi	O
##le	O
acids	O
(	B
de	B
##ox	I
##ych	I
##olate	I
,	O
lit	B
##ho	I
##de	I
##ox	I
##ych	I
##olate	I
and	O
ch	O
##olate	O
)	O
.	O

As	O
a	O
result	O
,	O
29	O
differential	O
##ly	O
expressed	O
meta	O
##bol	O
##ites	O
belonging	O
to	O
Ce	B
##r	I
,	O
Cho	O
##E	O
,	O
PC	O
,	O
P	O
##E	O
and	O
SM	O
classes	O
were	O
found	O
to	O
be	O
statistical	O
##ly	O
significant	O
in	O
agreement	O
with	O
the	O
previous	O
paired	O
analysis	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
S	O
##2	O
)	O
.	O

,	O
3	B
-	I
g	I
##ly	I
##cer	I
##ol	I
was	O
not	O
significantly	O
used	O
to	O
produce	O
T	O
##G	O
##s	O
but	O
rather	O
in	O
the	O
g	B
##ly	I
##cer	I
##ol	I
shuttle	O
,	O
since	O
no	O
accumulation	O
of	O
di	B
##hy	I
##dr	I
##ox	I
##ya	I
##ce	I
##tone	I
was	O
observed	O
.	O

E	O
##ff	O
##ica	O
##cy	O
and	O
safety	O
results	O
for	O
the	O
total	O
trial	O
population	O
have	O
been	O
published	O
,	O
reporting	O
no	O
additional	O
benefit	O
from	O
the	O
combination	O
of	O
lap	B
##ati	I
##ni	I
##b	I
and	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
over	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
alone	O
(	O
Di	O
Leo	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

The	O
correlation	O
between	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
its	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
is	O
weaker	O
than	O
the	O
correlation	O
between	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
parent	O
and	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
.	O

T	O
##MA	O
is	O
rapidly	O
further	O
o	O
##xi	O
##dized	O
to	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
by	O
he	O
##pa	O
##tic	O
fl	O
##avi	O
##n	O
-	O
containing	O
mon	O
##oo	O
##xy	O
##gen	O
##ases	O
(	O
FM	O
##Os	O
)	O
.	O

Six	O
peaks	O
were	O
identified	O
as	O
important	O
for	O
classification	O
for	O
the	O
full	O
-	O
data	O
analysis	O
,	O
two	O
of	O
them	O
being	O
valid	O
##ated	O
as	O
c	B
##rea	I
##tin	I
##ine	I
and	O
c	B
##rea	I
##tine	I
;	O
the	O
remaining	O
4	O
peaks	O
were	O
ranked	O
27	O
_	O
th	O
,	O
58	O
_	O
th	O
,	O
88	O
_	O
th	O
,	O
and	O
147	O
##9	O
_	O
th	O
using	O
the	O
F	O
-	O
test	O
.	O

All	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
correlated	O
positively	O
with	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
Ce	I
##r	I
,	O
SM	O
,	O
and	O
So	O
,	O
which	O
are	O
also	O
components	O
of	O
lip	O
##op	O
##rote	O
##in	O
membrane	O
##s	O
.	O

The	O
he	O
##pa	O
##tic	O
est	O
##eri	O
##fication	O
ratio	O
of	O
all	O
s	O
##tero	O
##ls	O
,	O
but	O
not	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
concentrations	O
,	O
showed	O
substantial	O
metabolic	O
disturbance	O
##s	O
post	O
-	O
L	O
##T	O
##X	O
and	O
correlated	O
to	O
the	O
ME	O
##AF	O
.	O

The	O
prevalence	O
of	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
is	O
re	O
##iter	O
##ated	O
by	O
significantly	O
reduced	O
T	O
##CA	O
cycle	O
meta	O
##bol	O
##ites	O
:	O
c	B
##it	I
##rate	I
and	O
su	B
##cci	I
##nate	I
in	O
all	O
RC	O
##C	O
stages	O
coupled	O
with	O
elevated	O
but	O
not	O
significantly	O
increased	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
levels	O
.	O

The	O
ca	O
##li	O
##bra	O
##tion	O
range	O
covers	O
the	O
range	O
of	O
500	O
–	O
10	O
,	O
000	O
μ	O
##g	O
/	O
L	O
for	O
re	O
##gor	O
##af	O
##eni	O
##b	O
and	O
re	O
##gor	O
##af	O
##eni	O
##b	O
M	O
##2	O
,	O
200	O
–	O
20	O
,	O
000	O
μ	O
##g	O
/	O
L	O
for	O
o	O
##lap	O
##ari	O
##b	O
,	O
5	O
,	O
000	O
–	O
100	O
,	O
000	O
μ	O
##g	O
/	O
L	O
for	O
ve	O
##mura	O
##fen	O
##ib	O
,	O
6	O
–	O
1000	O
μ	O
##g	O
/	O
L	O
for	O
co	B
##bi	I
##met	I
##ini	I
##b	I
,	O
300	O
–	O
2000	O
μ	O
##g	O
/	O
L	O
for	O
ni	O
##rap	O
##ari	O
##b	O
,	O
10	O
–	O
4000	O
μ	O
##g	O
/	O
L	O
for	O
da	O
##bra	O
##fen	O
##ib	O
and	O
100	O
–	O
5000	O
μ	O
##g	O
/	O
L	O
for	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
,	O
respectively	O
.	O

(	O
A	O
and	O
B	O
)	O
P	O
##lot	O
of	O
relative	O
intensity	O
of	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tate	I
(	O
A	O
)	O
and	O
s	B
##te	I
##arate	I
(	O
B	O
)	O
an	O
##ions	O
versus	O
MA	O
##IL	O
##D	O
matrices	O
(	O
D	O
##MA	O
##N	O
,	O
solid	O
lines	O
;	O
D	B
##MA	I
,	O
dashed	O
lines	O
)	O
,	O

In	O
case	O
of	O
g	B
##ly	I
##cine	I
,	O
it	O
could	O
be	O
due	O
to	O
genetic	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
[	O
,	O
,	O
]	O
,	O
in	O
case	O
of	O
c	B
##it	I
##rate	I
it	O
is	O
largely	O
s	O
##peculative	O
.	O

G	O
##rad	O
##ient	O
el	O
##ution	O
(	O
solvent	O
A	O
,	O
0	O
.	O
2	O
%	O
FA	S
in	O
water	O
;	O
solvent	O
B	O
,	O
AC	O
##N	O
)	O
was	O
used	O
according	O
to	O
the	O
following	O
program	O
:	O
is	O
##oc	O
##ratic	O
step	O
that	O
holds	O
25	O
%	O
solvent	O
B	O
from	O
0	O
to	O
2	O
.	O
2	O
min	O
,	O
up	O
to	O
90	O
%	O
solvent	O
B	O
in	O
1	O
.	O
5	O
min	O
,	O
held	O
90	O
%	O
solvent	O
B	O
to	O
4	O
min	O
and	O
column	O
re	O
##con	O
##dition	O
##ing	O
at	O
25	O
%	O
solvent	O
B	O
to	O
5	O
min	O
(	O
total	O
analysis	O
time	O
)	O
.	O

The	O
stability	O
of	O
the	O
Is	O
##o	O
##P	O
,	O
P	B
##G	I
and	O
NO	O
_	O
2	O
-	O
FA	O
IS	O
##T	O
##Ds	O
during	O
the	O
2	O
-	O
h	O
h	O
##ydro	O
##ly	O
##ses	O
.	O

One	O
glucose	S
molecule	O
can	O
generate	O
36	O
ATP	S
molecules	O
via	O
the	O
T	O
##CA	O
cycle	O
,	O
while	O
g	O
##ly	O
##co	O
##lysis	O
produces	O
only	O
two	O
.	O

U	O
##rine	O
concentrations	O
are	O
not	O
c	B
##rea	I
##tin	I
##ine	I
normal	O
##ized	O
.	O

However	O
,	O
adjustment	O
of	O
the	O
models	O
for	O
total	O
est	B
##rad	I
##iol	I
did	O
not	O
change	O
estimates	O
by	O
>	O
10	O
%	O
.	O

Interest	O
##ingly	O
,	O
an	O
altered	O
ratio	O
of	O
K	O
##Y	O
##NA	O
:	O
3	O
-	O
HK	O
was	O
reported	O
previously	O
as	O
an	O
indicator	O
of	O
K	B
##P	I
m	O
##od	O
##ulation	O
in	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
disorders	O
(	O
,	O
)	O
.	O

Co	O
##rrel	O
##ation	O
s	O
##cat	O
##ter	O
plots	O
for	O
total	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
level	O
with	O
(	O
A	O
)	O
W	O
##H	O
##R	O
,	O
(	O
B	O
)	O
CE	O
,	O
(	O
C	O
)	O
Ce	B
##ram	I
##ide	I
and	O
(	O
D	O
)	O
P	B
##las	I
##man	I
##yl	I
PC	I
in	O
all	O
participants	O
.	O

The	O
top	O
4	O
meta	O
##bol	O
##ites	O
(	O
P	O
<	O
10	O
##E	O
-	O
11	O
)	O
were	O
selected	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
for	O
PD	O
##R	O
,	O
namely	O
,	O
f	B
##uma	I
##ric	I
acid	I
,	O
u	B
##rid	I
##ine	I
,	O
ace	B
##tic	I
acid	I
,	O
and	O
c	B
##yt	I
##id	I
##ine	I
.	O

In	O
any	O
case	O
,	O
the	O
50	O
%	O
lower	O
level	O
of	O
ma	O
##lic	O
enzyme	O
is	O
probably	O
enough	O
lower	O
to	O
contribute	O
to	O
decreased	O
conversion	O
of	O
ma	B
##late	I
to	O
p	B
##yr	I
##u	I
##vate	I
and	O
thus	O
a	O
decrease	O
in	O
p	O
##yr	O
##u	O
##vate	O
cycling	O
.	O

This	O
was	O
the	O
case	O
for	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
pen	B
##tano	I
##ic	I
acid	I
,	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
but	B
##ano	I
##ic	I
acid	I
,	O
and	O
J	O
##W	O
##H	O
-	O
250	O
pen	B
##tano	I
##ic	I
acid	I
;	O
peak	O
areas	O
with	O
and	O
without	O
h	O
##ydro	O
##lysis	O
did	O
not	O
change	O
.	O

Gas	O
Ch	O
##roma	O
##tography	O
Mass	O
S	O
##pect	O
##rome	O
##try	O
(	O
G	O
##CM	O
##S	O
)	O
,	O
1	B
-	I
Met	I
##hyl	I
his	I
##ti	I
##dine	I
(	O
1	O
-	O
M	O
##H	O
##is	O
)	O
,	O
Normal	O
weight	O
(	O
NW	O
)	O
,	O
O	O
##bes	O
##e	O
(	O
O	O
##B	O
)	O
,	O
Ph	B
##en	I
##yla	I
##ce	I
##tic	I
acid	I
(	O
PA	O
##A	O
)	O
,	O
P	B
-	I
c	I
##res	I
##yl	I
##sul	I
##phate	I
(	O
PC	O
##S	O
)	O
,	O
P	B
##se	I
##udo	I
##uri	I
##dine	I
(	O
PS	O
##I	O
)	O
,	O
with	O
(	O
N	O
##AF	O
##LD	O
+	O
)	O
without	O
(	O
N	O
##AF	O
##LD	O
##−	O
)	O
N	O
##AF	O
##LD	O
.	O

If	O
these	O
ratios	O
of	O
est	B
##rogen	I
metabolism	O
pathways	O
are	O
confirmed	O
as	O
predict	O
##ors	O
of	O
breast	O
cancer	O
risk	O
,	O
they	O
might	O
provide	O
clues	O
to	O
mechanisms	O
of	O
breast	O
car	O
##cin	O
##ogen	O
##esis	O
and	O
suggest	O
targets	O
for	O
prevent	O
##ive	O
interventions	O
.	O

Although	O
ions	O
at	O
m	O
/	O
z	O
44	O
##5	O
and	O
m	O
/	O
z	O
41	O
##9	O
were	O
each	O
detected	O
at	O
low	O
abundance	O
##s	O
in	O
C	O
##ID	O
of	O
PC	B
16	I
:	I
0	I
/	I
18	I
:	I
1	I
and	O
PC	B
18	I
:	I
1	I
/	I
16	I
:	I
0	I
,	O
they	O
were	O
later	O
proved	O
to	O
be	O
the	O
“	O
s	O
##n	O
-	O
1	O
fragments	O
”	O
resulting	O
from	O
corresponding	O
s	O
##n	O
-	O
is	O
##omer	O
##s	O
,	O
which	O
are	O
present	O
as	O
minor	O
imp	O
##uri	O
##ties	O
in	O
the	O
supplied	O
samples	O
.	O

This	O
result	O
is	O
consistent	O
with	O
Fe	O
##rre	O
##iro	O
-	O
Vera	O
’	O
s	O
results	O
,	O
where	O
1	O
,	O
325	O
features	O
were	O
detected	O
using	O
ethanol	S
precipitation	O
versus	O
85	O
##1	O
features	O
using	O
met	B
##han	I
##ol	I
alone	O
[	O
]	O
.	O

Using	O
this	O
pro	O
##gno	O
##stic	O
information	O
,	O
six	O
meta	O
##bol	O
##ites	O
(	O
Table	O
)	O
,	O
including	O
d	O
##UM	O
##P	O
,	O
L	B
-	I
o	I
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
L	B
-	I
pro	I
##line	I
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
22	O
:	O
1	O
)	O
,	O
PS	B
(	I
22	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
and	O
u	B
##ric	I
acid	I
,	O
were	O
discovered	O
as	O
highly	O
associated	O
with	O
5	O
-	O
year	O
survival	O
rate	O
.	O

Re	O
##age	O
##nts	O
and	O
solvent	O
##s	O
included	O
met	B
##han	I
##ol	I
,	O
he	B
##xa	I
##ne	I
(	O
Ted	O
##ia	O
##way	O
,	O
Fairfield	O
,	O
USA	O
)	O
,	O
my	O
##rist	O
##ic	O
-	O
d	O
_	O
27	O
acid	O
,	O
N	B
-	I
Met	I
##hyl	I
-	I
N	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
,	O
met	O
##ho	O
##xy	O
##lam	O
##ine	O
h	O
##ydro	O
##ch	O
##lor	O
##ic	O
(	O
A	O
##c	O
##ros	O
Organic	O
,	O
New	O
Jersey	O
,	O
USA	O
)	O
,	O
P	B
##yr	I
##id	I
##ine	I
(	O
Lab	O
-	O
Sc	O
##an	O
,	O
Bangkok	O
,	O
Thailand	O
)	O
and	O
dei	O
##onized	O
water	O
(	O
Mill	O
##i	O
-	O
Q	O
)	O

The	O
resulting	O
white	O
residue	O
was	O
characterized	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
and	O
found	O
to	O
be	O
free	O
of	O
c	B
##ys	I
##tine	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
and	O
un	O
##la	O
##bel	O
##ed	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
.	O

We	O
analyzed	O
9	O
lip	O
##id	O
classes	O
in	O
the	O
study	O
including	O
ch	B
##olin	I
##e	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
(	O
PC	O
)	O
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
LP	O
##C	O
)	O
,	O
ethanol	B
##amine	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
(	O
P	O
##E	O
)	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
,	O
c	B
##era	I
##mi	I
##de	I
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
T	O
##AG	O
)	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
by	O
multi	O
-	O
dimensional	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
shotgun	O
lip	O
##ido	O
##mic	O
##s	O
,	O
.	O

The	O
[	O
M	O
+	O
A	O
]	O
_	O
–	O
ion	O
signal	O
from	O
the	O
bi	O
##car	O
##bon	O
##ate	O
add	O
##uc	O
##t	O
(	O
m	O
/	O
z	O
82	O
##0	O
)	O
is	O
about	O
20	O
times	O
higher	O
than	O
that	O
of	O
the	O
format	B
##e	I
add	O
##uc	O
##t	O
(	O
m	O
/	O
z	O
80	O
##4	O
)	O
.	O

Mo	B
##rp	I
##hine	I
and	O
the	O
chemical	O
##ly	O
related	O
op	O
##io	O
##ids	O
produce	O
their	O
major	O
effects	O
through	O
the	O
m	O
##u	O
receptors	O
.	O

L	O
##D	O
##L	O
was	O
calculated	O
as	O
the	O
difference	O
between	O
the	O
mass	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
the	O
in	O
##fra	O
##nat	O
##ant	O
and	O
HD	O
##L	O
.	O

However	O
,	O
Mu	O
##tch	O
et	O
al	O
did	O
not	O
observe	O
a	O
significant	O
increase	O
of	O
ta	B
##uri	I
##ne	I
at	O
6	O
months	O
post	O
‐	O
surgery	O
##10	O
even	O
though	O
o	O
##besity	O
and	O
diabetes	O
are	O
ta	O
##uri	O
##ne	O
‐	O
def	O
##icient	O
states	O
.	O
46	O
Tau	B
##rine	I
is	O
important	O
for	O
multiple	O
biological	O
functions	O
including	O
ex	O
##cre	O
##tion	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
up	O
##re	O
##gu	O
##lation	O
of	O
he	O
##pa	O
##tic	O
L	O
##D	O
##L	O
receptors	O
,	O
reduction	O
of	O
blood	O
pressure	O
,	O
and	O
has	O
anti	O
‐	O
o	O
##xi	O
##dant	O
and	O
anti	O
‐	O
inflammatory	O
actions	O
.	O
46	O

PC	B
a	I
##e	I
C	I
##42	I
:	I
3	I
;	O
117	O
K	B
##yn	I
##uren	I
##ine	I
;	O
118	O
.	O

As	O
expected	O
,	O
the	O
H	O
##T	O
##G	O
group	O
exhibited	O
a	O
smaller	O
L	O
##D	O
##L	O
particle	O
size	O
and	O
lower	O
concentrations	O
of	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
compared	O
with	O
those	O
of	O
the	O
N	O
##T	O
##G	O
group	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
th	O
##awed	O
and	O
100	O
µ	O
##L	O
was	O
prepared	O
using	O
met	B
##han	I
##ol	I
precipitation	O
and	O
liquid	O
-	O
liquid	O
extraction	O
as	O
previously	O
described	O
.	O

In	O
this	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
,	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
showed	O
that	O
2	B
,	I
4	I
-	I
he	I
##xa	I
##die	I
##no	I
##ic	I
acid	I
,	O
4	B
-	I
met	I
##hyl	I
##phe	I
##ny	I
##l	I
do	I
##de	I
##cano	I
##ate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
t	I
##ri	I
##but	I
##ano	I
##ate	I
,	O
met	B
##hi	I
##ony	I
##l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
and	O
P	B
##G	I
might	O
be	O
the	O
pro	O
##gno	O
##stic	O
factors	O
for	O
G	O
##C	O
(	O
Table	O
)	O
.	O

The	O
mass	O
levels	O
of	O
additional	O
6	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
are	O
different	O
between	O
AD	O
and	O
control	O
groups	O
at	O
the	O
p	O
<	O
0	O
.	O
1	O
level	O
.	O

Our	O
results	O
also	O
demonstrated	O
that	O
seven	O
plasma	O
meta	O
##bol	O
##ites	O
,	O
including	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
##s	I
and	O
k	B
##yn	I
##uren	I
##ine	I
,	O
were	O
associated	O
with	O
a	O
BS	O
pattern	O
,	O
suggesting	O
that	O
variant	O
plasma	O
metabolic	O
profiles	O
may	O
serve	O
as	O
a	O
bio	O
##mark	O
##er	O
for	O
diagnosis	O
of	O
BS	O
in	O
patients	O
with	O
cerebral	O
in	O
##far	O
##ction	O
.	O

Sign	O
##ificant	O
changes	O
in	O
meta	O
##bol	O
##ite	O
levels	O
in	O
patients	O
undergoing	O
therapy	O
suggest	O
alterations	O
in	O
several	O
pathways	O
such	O
as	O
l	B
##ys	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
(	B
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
)	O
,	O
nitrogen	O
metabolism	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
format	O
##e	O
)	O
,	O
u	B
##bi	I
##quin	I
##one	I
and	O
other	O
te	B
##rp	I
##eno	I
##id	I
-	I
q	I
##uin	I
##one	I
bio	O
##sy	O
##nt	O
##hesis	O
(	B
t	B
##yr	I
##os	I
##ine	I
)	O
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
(	B
la	B
##ct	I
##ate	I
,	O
format	B
##e	I
,	O
ace	B
##tate	I
,	O
p	O
##yr	O
##u	O
##vate	O
)	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
)	O
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
(	B
c	B
##rea	I
##tine	I
)	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
)	O
,	O

[	B
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	O
]	O
+	O
0	O
.	O
85	O
##2	O

Our	O
results	O
confirm	O
previous	O
studies	O
,	O
which	O
indicated	O
higher	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
in	O
C	O
##K	O
##D	O
and	O
an	O
inverse	O
association	O
with	O
e	O
##G	O
##F	O
##R	O
,	O
which	O
was	O
suggested	O
to	O
be	O
caused	O
by	O
impaired	O
ex	O
##cre	O
##tory	O
function	O
in	O
the	O
failing	O
kidney	O
.	O

The	O
reaction	O
of	O
human	O
SA	O
with	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
in	O
v	O
##it	O
##ro	O
produced	O
the	O
N	O
_	B
2	I
-	I
c	I
##ys	I
##tein	I
##es	I
##ulf	I
##in	I
##yl	I
-	I
Ph	I
##IP	I
;	O
this	O
su	B
##lf	I
##ina	I
##mi	I
##de	I
link	O
##age	O
accounted	O
for	O
greater	O
than	O
95	O
%	O
of	O
the	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
bound	O
to	O
SA	O
.	O

In	O
our	O
study	O
,	O
we	O
found	O
a	O
correlation	O
between	O
the	O
concentration	O
of	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
and	O
the	O
severity	O
of	O
consciousness	O
disorders	O
.	O

As	O
a	O
consequence	O
,	O
ch	B
##olin	I
##e	I
and	O
ch	O
##olin	O
##e	O
-	O
based	O
compounds	O
are	O
constantly	O
transformed	O
into	O
each	O
other	O
.	O

Not	O
##ably	O
,	O
we	O
observed	O
that	O
meta	O
##bol	O
##ites	O
from	O
the	O
pu	B
##rine	I
metabolic	O
pathway	O
,	O
AM	B
##P	I
,	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
were	O
associated	O
with	O
c	O
##er	O
##vic	O
##al	O
cancer	O
risk	O
.	O

Conversely	O
,	O
Wet	O
##ters	O
##ten	O
et	O
al	O
.	O
,	O
found	O
that	O
the	O
accumulation	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
did	O
not	O
overlap	O
with	O
up	O
##re	O
##gu	O
##lation	O
of	O
fatty	O
acid	O
oxidation	O
enzymes	O
in	O
RC	O
##C	O
.	O

The	O
met	B
##han	I
##olic	I
extract	O
##s	O
were	O
analyzed	O
for	O
meta	O
##bol	O
##ites	O
on	O
G	O
##C	O
/	O
MS	O
and	O
L	O
##C	O
/	O
MS	O
platforms	O
.	O

Take	O
##n	O
together	O
,	O
these	O
findings	O
suggest	O
an	O
acceleration	O
of	O
ca	B
##ffe	I
##ine	I
metabolism	O
in	O
CO	O
##PD	O
smoke	O
##rs	O
,	O
especially	O
for	O
the	O
downstream	O
ca	B
##ffe	I
##ine	I
meta	O
##bol	O
##ites	O
resulting	O
from	O
activated	S
C	O
##YP	O
##2	O
##A	O
##6	O
.	O

Ana	O
##ly	O
##tical	O
standard	O
stock	O
solutions	O
for	O
L	O
##C	O
/	O
MS	O
were	O
prepared	O
in	O
met	B
##han	I
##ol	I
(	O
1	O
mg	O
/	O
m	O
##L	O
)	O
and	O
stored	O
at	O
−	O
##80	O
°C	O
.	O

Interest	O
##ingly	O
,	O
in	O
##hibition	O
of	O
p	O
##53	O
increased	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
1	O
activity	O
and	O
p	O
##53	O
regulate	O
##s	O
mitochondrial	O
re	O
##spiration	O
.	O
_	O
,	O
Therefore	O
,	O
we	O
suggest	O
that	O
the	O
gene	O
expression	O
involved	O
in	O
car	B
##ni	I
##tine	I
-	I
a	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
pathway	O
in	O
N	O
##MI	O
##BC	O
might	O
be	O
down	O
##re	O
##gu	O
##lated	O
compared	O
to	O
MI	O
##BC	O
.	O

Anti	O
##bo	O
##dies	O
against	O
FA	O
##SN	O
,	O
ACC	O
##1	O
,	O
CO	O
##X	O
-	O
2	O
,	O
E	O
##rk	O
,	O
p	O
-	O
E	O
##rk	O
,	O
G	B
##S	I
##K	I
##3	I
##β	I
and	O
p	B
-	I
G	I
##S	I
##K	I
##3	I
##β	I
were	O
from	O
Cell	O
Signal	O
##ing	O
.	O

F	O
##DR	O
,	O
false	O
discovery	O
rate	O
;	O
H	O
##UN	O
##T	O
,	O
Nord	O
-	O
T	O
##r	O
##ø	O
##nde	O
##lag	O
Health	O
Study	O
;	O
N	O
.	O
s	O
,	O
not	O
significant	O
;	O
P	O
##LS	O
-	O
D	O
##A	O
,	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
;	O
Sign	O
.	O
,	O
significant	O
;	O
S	O
##U	O
##GA	O
##R	O
,	O
Study	O
of	O
G	B
##lu	I
##cos	I
##e	I
and	O
In	O
##sul	O
##in	O
in	O
Ren	O
##al	O
Disease	O
;	O
VIP	O
,	O
variable	O
importance	O
in	O
projection	O
.	O

A	O
linear	O
gradient	O
was	O
applied	O
from	O
80	O
to	O
20	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
for	O
the	O
first	O
30	O
min	O
,	O
followed	O
by	O
5	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
for	O
an	O
additional	O
8	O
min	O
.	O

Two	O
fatty	O
a	B
##cy	I
##l	I
amid	I
##es	I
(	O
FAA	O
##s	O
)	O
,	O
o	B
##leam	I
##ide	I
and	O
P	B
##OE	I
##A	I
,	O
were	O
detected	O
in	O
AM	O
##L	O
plasma	O
but	O
were	O
not	O
detected	O
in	O
any	O
control	O
plasma	O
.	O

L	O
##D	O
##L	O
particles	O
were	O
isolated	O
by	O
se	O
##quential	O
fl	O
##ota	O
##tion	O
ultra	O
##cent	O
##ri	O
##fu	O
##gation	O
,	O
and	O
the	O
particle	O
size	O
distribution	O
(	O
1	O
.	O
01	O
##9	O
–	O
1	O
.	O
06	O
##3	O
g	O
/	O
m	O
##L	O
)	O
was	O
examined	O
using	O
a	O
p	O
##ore	O
-	O
gradient	O
lip	O
##op	O
##rote	O
##in	O
system	O
(	O
CBS	O
Scientific	O
Company	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
on	O
commercially	O
available	O
non	O
-	O
den	O
##at	O
##uring	O
gel	O
##s	O
containing	O
a	O
linear	O
2	O
–	O
16	O
%	O
a	B
##c	I
##ryl	I
##ami	I
##de	I
gradient	O
(	O
CBS	O
Scientific	O
Company	O
)	O
.	O

The	O
model	O
was	O
then	O
adjusted	O
for	O
known	O
risk	O
factors	O
for	O
breast	O
cancer	O
such	O
as	O
:	O
age	O
,	O
race	O
,	O
B	O
##MI	O
,	O
men	O
##ar	O
##che	O
,	O
par	O
##ity	O
,	O
and	O
family	O
history	O
of	O
breast	O
cancer	O
in	O
the	O
first	O
degree	O
relative	O
,	O
smoking	O
,	O
hormone	O
usage	O
,	O
and	O
total	O
is	B
##of	I
##lav	I
##one	I
intake	O
.	O

Sul	B
##fa	I
##phe	I
##na	I
##zo	I
##le	I
was	O
obtained	O
from	O
Ultra	B
##fine	I
Chemical	O
##s	O
(	O
Manchester	O
,	O
UK	O
)	O
.	O

These	O
meta	O
##bol	O
##ites	O
were	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	I
ace	I
##ty	I
##l	I
,	I
he	I
##xa	I
##noy	I
##l	I
,	I
o	I
##ct	I
##ano	I
##yl	I
,	I
de	I
##cano	I
##yl	I
,	I
he	I
##xa	I
##de	I
##cano	I
##yl	I
)	I
and	O
l	B
##ino	I
##leam	I
##ide	I
.	O

The	O
values	O
represent	O
the	O
unit	O
##less	O
ratio	O
of	O
serum	O
concentration	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ite	O
divided	O
by	O
the	O
serum	O
concentration	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
do	O
not	O
have	O
units	O
.	O

Furthermore	O
,	O
we	O
found	O
significant	O
and	O
inverse	O
association	O
between	O
h	O
##sa	O
-	O
mi	O
##R	O
-	O
88	O
##5	O
-	O
5	O
##p	O
and	O
OS	O
##B	O
##PL	O
##2	O
,	O
a	O
protein	O
known	O
to	O
affect	O
e	O
##ff	O
##lux	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Der	O
##iva	O
##tized	O
s	O
##tero	O
##ls	O
were	O
then	O
el	O
##uted	O
in	O
three	O
1	O
-	O
m	O
##l	O
portions	O
of	O
100	O
%	O
met	B
##han	I
##ol	I
(	I
SP	I
##E	I
##2	I
-	I
Fr	I
-	I
1	I
,	I
Fr	I
-	I
2	I
,	O
and	O
Fr	B
-	I
3	I
)	I
followed	O
by	O
1	O
m	O
##l	O
of	O
99	O
.	O
9	O
%	O
ethanol	B
(	I
SP	I
##E	I
##2	I
-	I
Fr	I
-	I
4	I
)	I
.	O

Different	O
l	O
##ys	O
##o	O
PC	O
##s	O
in	O
addition	O
to	O
o	B
##leam	I
##ide	I
and	O
e	B
##ico	I
##sat	I
##rien	I
##oi	I
##c	I
acid	I
that	O
were	O
also	O
found	O
to	O
be	O
significant	O
in	O
our	O
study	O
have	O
been	O
previously	O
included	O
in	O
a	O
panel	O
of	O
bio	O
##mark	O
##ers	O
for	O
different	O
##iating	O
early	O
stage	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
from	O
healthy	O
controls	O
that	O
was	O
shown	O
to	O
be	O
more	O
effective	O
than	O
the	O
car	O
##cin	O
##oe	O
##mb	O
##ryo	O
##nic	O
anti	O
##gen	O
bio	O
##mark	O
##er	O
usually	O
u	O
##til	O
##ised	O
in	O
diagnosis	O
of	O
the	O
disease	O
.	O

Time	O
-	O
dependent	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
both	O
the	O
natural	O
is	O
##oto	O
##pes	O
and	O
d	O
##9	O
-	O
trace	O
##r	O
forms	O
of	O
ch	B
##olin	I
##e	I
and	O
beta	B
##ine	I
also	O
increased	O
after	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
challenge	O
.	O

U	O
##rina	O
##ry	O
h	B
##ydro	I
##xy	I
-	I
PA	I
##H	I
##s	I
in	O
kitchen	O
workers	O
were	O
measured	O
using	O
G	O
##C	O
/	O
MS	O
-	O
MS	O
.	O

d	O
The	O
use	O
of	O
W	O
##B	O
eliminate	O
##s	O
many	O
of	O
the	O
pre	O
-	O
analytical	O
processing	O
problems	O
of	O
serum	O
,	O
and	O
captures	O
the	O
red	O
blood	O
cell	O
meta	O
##bol	O
##ome	O
,	O
including	O
the	O
energy	O
molecules	O
ATP	S
,	O
AD	B
##P	I
,	O
and	O
AM	B
##P	I
[	O
,	O
]	O
.	O

A	O
volume	O
of	O
400	O
µ	O
##L	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
was	O
added	O
to	O
plasma	O
sample	O
al	O
##iq	O
##uo	O
##ts	O
containing	O
internal	O
standards	O
,	O
then	O
the	O
mixture	O
was	O
v	O
##ortex	O
##ed	O
vigorously	O
for	O
30	O
se	O
##c	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
1800	O
##0	O
×	O
g	O
0	O
##°	O
##C	O
for	O
15	O
min	O
.	O

In	O
contrast	O
,	O
the	O
do	O
##ub	O
##ly	O
labeled	O
ma	B
##late	I
species	O
(	O
as	O
[	B
_	I
13	I
C	I
-	I
1	I
,	I
2	I
]	I
-	I
and	O
[	B
_	I
13	I
C	I
-	I
3	I
,	I
4	I
]	I
-	I
ma	I
##late	I
)	O
or	O
As	O
##p	O
should	O
derive	O
from	O
the	O
normal	O
K	O
##re	O
##bs	O
'	O
cycle	O
sequence	O
with	O
input	O
of	O
[	O
U	O
-	O
_	O
13	O
C	O
]	O
-	O
p	O
##yr	O
##u	O
##vate	O
,	O
as	O
illustrated	O
in	O
Fi	O
##g	O
.	O
,	O
or	O
the	O
do	O
##ub	O
##ly	O
labeled	O
[	B
_	I
13	I
C	I
-	I
2	I
,	I
3	I
]	I
-	I
ma	I
##late	I
from	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##tion	O
,	O
as	O
outlined	O
in	O
Fi	O
##g	O
.	O
.	O

The	O
authors	O
used	O
meta	O
##bol	O
##ite	O
data	O
obtained	O
from	O
hydrogen	B
-	I
1	I
(	O
or	O
pro	O
##ton	O
)	O
nuclear	O
magnetic	O
resonance	O
(	O
_	O
1	O
H	O
N	O
##MR	O
)	O
analysis	O
of	O
human	O
urine	O
specimens	O
from	O
the	O
International	O
Study	O
of	O
Mac	O
##ro	O
-	O
/	O
Micro	O
-	O
N	O
##ut	O
##rient	O
##s	O
and	O
Blood	O
Press	O
##ure	O
(	O
IN	O
##TE	O
##R	O
##MA	O
##P	O
Study	O
)	O
to	O
valid	O
##ate	O
self	O
-	O
reported	O
anal	O
##ges	O
##ic	O
use	O
.	O

Per	O
##ip	O
##her	O
##al	O
blood	O
samples	O
were	O
drawn	O
at	O
the	O
initial	O
medical	O
examination	O
,	O
in	O
the	O
morning	O
after	O
a	O
fast	O
of	O
at	O
least	O
8	O
h	O
,	O
and	O
immediately	O
stored	O
at	O
−	O
##80	O
##°	O
##C	O
until	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
measurements	O
were	O
performed	O
.	O

Stock	O
solutions	O
of	O
G	O
##L	O
##Y	O
,	O
M1	O
and	O
M	O
##2	O
were	O
prepared	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
at	O
0	O
.	O
25	O
,	O
0	O
.	O
1	O
and	O
0	O
.	O
1	O
mg	O
/	O
m	O
##L	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
well	O
-	O
known	O
clinical	O
risk	O
factors	O
,	O
BC	O
##AA	O
##s	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##yt	I
##ura	I
##te	I
are	O
potential	O
markers	O
to	O
be	O
evaluated	O
as	O
predict	O
##ors	O
of	O
metabolic	O
risk	O
after	O
pregnancy	O
complicated	O
by	O
G	O
##DM	O
.	O

Additionally	O
,	O
numerous	O
energy	O
metabolism	O
systems	O
were	O
altered	O
,	O
including	O
pathways	O
in	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Fast	O
##ing	O
glucose	S
and	O
insulin	O
were	O
significantly	O
greater	O
in	O
O	O
##IR	O
versus	O
Lea	O
##n	O
.	O

600	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
was	O
added	O
into	O
each	O
sample	O
.	O

Since	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
and	O
T	O
##C	O
plasma	O
levels	O
are	O
known	O
to	O
be	O
correlated	O
(	O
in	O
our	O
sample	O
r	O
:	O
0	O
.	O
28	O
,	O
p	O
:	O
0	O
.	O
00	O
##5	O
)	O
as	O
they	O
are	O
both	O
transported	O
by	O
the	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
,	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
values	O
were	O
adjusted	O
for	O
T	O
##C	O
levels	O
by	O
calculating	O
the	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
/	O
T	O
##C	O
ratio	O
(	O
ng	O
/	O
mg	O
)	O
.	O

It	O
may	O
be	O
more	O
likely	O
that	O
his	B
##ti	I
##dine	I
is	O
incorporated	O
into	O
the	O
brain	O
in	O
the	O
context	O
of	O
h	O
##yper	O
##am	O
##mona	O
##emia	O
causing	O
increased	O
cerebral	O
his	B
##tamine	I
levels	O
(	O
F	O
##ogel	O
et	O
al	O
.	O
)	O
and	O
subsequent	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
abnormal	O
##ities	O
(	O
in	O
particular	O
increased	O
GA	O
##BA	O
##ergic	O
tone	O
)	O
.	O

It	O
is	O
observed	O
that	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
levels	O
are	O
lowered	O
in	O
the	O
stages	O
of	O
II	O
,	O
III	O
,	O
and	O
IV	O
as	O
compared	O
to	O
stage	O
0	O
and	O
I	O
.	O
Cho	B
##les	I
##tero	I
##l	I
,	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
,	O
and	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
are	O
three	O
related	O
meta	O
##bol	O
##ites	O
participating	O
in	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
whose	O
levels	O
had	O
increased	O
in	O
the	O
II	O
and	O
III	O
stage	O
groups	O
.	O

Two	O
Oz	O
##ID	O
fragments	O
at	O
m	O
/	O
z	O
153	O
and	O
m	O
/	O
z	O
169	O
were	O
observed	O
,	O
consistent	O
with	O
predicted	O
oz	O
##ono	O
##lysis	O
products	O
from	O
a	O
structure	O
containing	O
a	O
double	O
bond	O
at	O
C	O
##2	O
–	O
C	O
##3	O
of	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
.	O

Nor	B
##ep	I
##ine	I
##ph	I
##rine	I
su	I
##lf	I
##ate	I
is	O
formed	O
from	O
free	O
nor	B
##ep	I
##ine	I
##ph	I
##rine	I
by	O
the	O
enzyme	O
p	O
##hen	O
##ol	O
su	O
##lf	O
##ot	O
##ran	O
##s	O
##fer	O
##ase	O
.	O

The	O
identification	O
of	O
m	O
/	O
z	O
34	O
##9	O
.	O
151	O
##5	O
as	O
pipe	B
##rine	I
was	O
confirmed	O
by	O
accurate	O
mass	O
and	O
retention	O
time	O
matching	O
to	O
a	O
reference	O
standard	O
.	O

B	O
##rief	O
##ly	O
,	O
after	O
adjusting	O
2	O
-	O
m	O
##l	O
al	O
##iq	O
##uo	O
##ts	O
of	O
urine	O
samples	O
to	O
pH	O
7	O
,	O
they	O
were	O
loaded	O
onto	O
100	O
-	O
mg	O
p	O
##hen	O
##yl	O
cartridges	O
pre	O
##con	O
##dition	O
##ed	O
with	O
met	B
##han	I
##ol	I
and	O
the	O
loading	O
buffer	O
,	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
pH	O
7	O
.	O

Subsequent	O
oxidation	O
produces	O
all	O
-	O
trans	O
-	O
re	O
##tino	O
##ic	O
acid	O
(	O
AT	O
##RA	O
)	O
,	O
which	O
functions	O
as	O
a	O
l	O
##igan	O
##d	O
for	O
a	O
family	O
of	O
nuclear	O
transcription	O
factors	O
,	O
the	O
re	B
##tino	I
##ic	I
acid	I
receptors	O
(	O
RA	O
##R	O
##s	O
)	O
.	O

The	O
kit	O
allows	O
the	O
simultaneous	O
determination	O
of	O
145	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
:	O
40	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
15	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
90	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
14	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
)	O
and	O
76	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
)	O
.	O

Human	O
plasma	O
from	O
norm	O
##oli	O
##pid	O
##em	O
##ic	O
adult	O
volunteers	O
was	O
collected	O
to	O
evaluate	O
three	O
different	O
solvent	O
extraction	O
protocols	O
,	O
including	O
the	O
classical	O
F	O
##ol	O
##ch	O
method	O
,	O
the	O
met	O
##han	O
##ol	O
/	O
te	O
##rt	O
-	O
but	O
##yl	O
met	B
##hyl	I
et	I
##her	I
(	O
M	O
##T	O
##BE	O
)	O

A	O
simple	O
and	O
rapid	O
est	B
##rogen	I
measurement	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
is	O
important	O
in	O
clinical	O
and	O
research	O
laboratories	O
,	O
and	O
we	O
developed	O
such	O
a	O
method	O
by	O
taking	O
advantage	O
of	O
the	O
superior	O
analytical	O
sensitivity	O
offered	O
by	O
API	O
5000	O
triple	O
-	O
q	O
##uad	O
##rup	O
##ole	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
.	O

U	O
##rina	O
##ry	O
glucose	S
was	O
measured	O
in	O
subjects	O
with	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
,	O
G	O
##C	O
##K	O
-	O
M	O
##OD	O
##Y	O
and	O
T	O
##2	O
##D	O
.	O
Results	O
are	O
shown	O
in	O
.	O

In	O
multiple	O
receiver	O
operating	O
characteristics	O
curve	O
analyses	O
,	O
ta	B
##uri	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
3	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
were	O
good	O
disc	O
##rim	O
##inator	O
##s	O
for	O
CR	O
##C	O
patients	O
.	O

In	O
our	O
study	O
,	O
we	O
found	O
that	O
plasma	O
T	B
##MA	I
##O	I
concentration	O
in	O
the	O
UC	O
group	O
was	O
significantly	O
higher	O
compared	O
to	O
the	O
Control	O
group	O
,	O
and	O
there	O
was	O
also	O
an	O
increasing	O
trend	O
from	O
i	O
##UC	O
to	O
a	O
##UC	O
groups	O
.	O

P	O
##las	O
##ma	O
la	B
##ct	I
##ate	I
levels	O
were	O
not	O
significantly	O
different	O
in	O
I	O
+	O
and	O
I	O
##−	O
,	O
but	O
PC	O
##A	O
revealed	O
la	B
##ct	I
##ate	I
as	O
an	O
important	O
factor	O
that	O
contributed	O
to	O
the	O
metabolic	O
differentiation	O
of	O
I	O
+	O
and	O
I	O
##−	O
.	O

In	O
conclusion	O
,	O
this	O
pilot	O
study	O
was	O
unable	O
to	O
confirm	O
the	O
hypothesis	O
that	O
ER	O
##CP	O
induce	O
##s	O
a	O
different	O
metabolic	O
response	O
in	O
patients	O
who	O
develop	O
AP	S
as	O
a	O
result	O
of	O
the	O
procedure	O
.	O

F	O
##S	O
##a	O
##II	O
mouse	O
tumor	O
metabolic	O
changes	O
with	O
different	O
doses	O
of	O
glucose	S
measured	O
by	O
31	O
##P	O
nuclear	O
magnetic	O
resonance	O
.	O

G	O
##lut	O
##amine	O
-	O
derived	O
g	O
##lut	O
##ama	O
##te	O
also	O
fulfill	O
##s	O
the	O
role	O
of	O
a	O
primary	O
nitrogen	O
donor	O
for	O
the	O
synthesis	O
of	O
non	O
-	O
essential	O
amino	O
acids	O
and	O
is	O
a	O
precursor	O
of	O
the	O
major	O
cellular	O
anti	O
##ox	O
##ida	O
##nt	O
g	B
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O

Similar	O
to	O
the	O
N	O
##PC	O
##1	O
patients	O
,	O
the	O
key	O
variables	O
responsible	O
for	O
discrimination	O
between	O
H	O
##ET	O
and	O
HC	O
samples	O
are	O
dominated	O
by	O
lip	O
##op	O
##rote	O
##in	O
-	O
associated	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
resonance	O
##s	O
(	O
Fi	O
##g	O
.	O

P	B
##yr	I
##im	I
##id	I
##ines	I
accounted	O
for	O
7	O
%	O
of	O
the	O
metabolic	O
impact	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
activity	O
of	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
-	O
specific	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
C	O
(	O
P	O
##LC	O
)	O
and	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
D	O
(	O
P	O
##LD	O
)	O
,	O
the	O
enzymes	O
responsible	O
for	O
the	O
degradation	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
was	O
higher	O
in	O
human	O
ma	O
##mma	O
##ry	O
e	O
##pit	O
##hel	O
##ial	O
and	O
e	O
##pit	O
##hel	O
##ial	O
o	O
##var	O
##ian	O
car	O
##cin	O
##oma	O
cell	O
lines	O
.	O
_	O
,	O
These	O
findings	O
suggest	O
that	O
both	O
bio	O
##sy	O
##nt	O
##hetic	O
and	O
cat	O
##ab	O
##olic	O
pathways	O
of	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
cycle	O
contribute	O
to	O
the	O
accumulation	O
of	O
Cho	O
##CC	O
in	O
tumor	O
tissues	O
.	O

To	O
overcome	O
these	O
limitations	O
,	O
we	O
propose	O
to	O
measure	O
plasma	O
g	B
##lut	I
##ama	I
##te	I
in	O
complement	O
to	O
P	O
##ET	O
-	O
CT	O
.	O

The	O
try	O
##pt	O
##op	O
##han	O
-	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
were	O
found	O
to	O
be	O
commonly	O
altered	O
between	O
SP	O
##MS	O
and	O
both	O
R	O
##R	O
##MS	O
patients	O
and	O
controls	O
.	O

Ce	B
##ram	I
##ide	I
major	O
species	O
in	O
healthy	O
corn	O
##eas	O
and	O
di	O
##abe	O
##tics	O
(	O
n	O
>	O
=	O
3	O
per	O
group	O
)	O
.	O

For	O
the	O
l	O
##ys	O
##o	O
##PC	O
panel	O
,	O
12	O
μ	O
##L	O
of	O
extract	O
B	O
was	O
mixed	O
with	O
108	O
μ	O
##L	O
mobile	O
phase	O
and	O
15	O
μ	O
##L	O
of	O
0	O
.	O
5	O
u	O
##g	O
/	O
m	O
##l	O
of	O
l	B
##ys	I
##o	I
##PC	I
##18	I
:	I
0	I
(	I
D	I
##35	I
)	I
as	O
the	O
standard	O
.	O

The	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
##s	O
u	B
##rid	I
##ine	I
dip	I
##hos	I
##phate	I
(	I
U	I
##DP	I
)	I
–	I
glucose	I
and	O
U	B
##DP	I
-	I
gal	I
##act	I
##ose	I
were	O
extracted	O
from	O
culture	O
##d	O
fi	O
##bro	O
##blast	O
##s	O
and	O
er	O
##yt	O
##hr	O
##ocytes	O
from	O
patients	O
and	O
were	O
q	O
##uant	O
##ified	O
by	O
means	O
of	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
see	O
the	O
)	O
.	O
_	O
,	O
G	B
##lu	I
##cos	I
##e	I
-	I
1	I
-	I
phosphate	I
was	O
analyzed	O
by	O
means	O
of	O
a	O
photo	O
##metric	O
method	O
(	O
see	O
the	O
)	O
,	O
and	O
gal	B
##act	I
##ose	I
-	I
1	I
-	I
phosphate	I
was	O
ass	O
##ay	O
##ed	O
with	O
the	O
use	O
of	O
_	O
14	O
C	O
-	O
labeled	O
UP	B
##D	I
-	I
glucose	I
.	O

The	O
samples	O
were	O
first	O
analyzed	O
in	O
the	O
negative	O
ion	O
mode	O
measuring	O
transitions	O
corresponding	O
to	O
PA	O
,	O
P	O
##E	O
,	O
P	B
##G	I
,	O
P	O
##I	O
,	O
PS	O
and	O
gang	B
##lio	I
##side	I
man	I
##nos	I
##ide	I
3	O
(	O
GM	O
##3	O
)	O
and	O
,	O
afterwards	O
,	O
specific	O
transitions	O
for	O
PC	O
,	O
SM	O
,	O
Ce	B
##r	I
and	O
G	O
##lu	O
##C	O
##er	O
were	O
analyzed	O
in	O
the	O
positive	O
ion	O
mode	O
.	O

(	O
St	O
##ru	O
##ck	O
-	O
Le	O
##wick	O
##a	O
et	O
al	O
.	O
)	O
have	O
reported	O
decreased	O
levels	O
of	O
g	B
##ly	I
##cine	I
,	O
in	O
a	O
study	O
performed	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
–	O
MS	O
)	O
and	O
gas	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
–	O
MS	O
)	O
,	O
when	O
comparing	O
the	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
of	O
PC	O
##a	O
patients	O
and	O
healthy	O
individuals	O
.	O

In	O
order	O
to	O
increase	O
sample	O
through	O
##put	O
,	O
the	O
O	O
##stro	O
96	O
-	O
well	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
removal	O
plate	O
was	O
used	O
,	O
and	O
the	O
results	O
displayed	O
a	O
shorter	O
sample	O
preparation	O
time	O
and	O
higher	O
efficiency	O
.	O

If	O
PC	O
synthesis	O
is	O
decreased	O
or	O
a	O
ch	B
##olin	I
##e	I
deficiency	O
develops	O
,	O
then	O
lip	O
##op	O
##rote	O
##in	O
synthesis	O
and	O
secret	O
##ion	O
(	O
e	O
.	O
g	O
.	O
,	O
V	O
##LD	O
##L	O
)	O
and	O
corresponding	O
blood	O
plasma	O
PC	O
and	O
LP	O
##C	O
abundance	O
would	O
decrease	O
and	O
lip	O
##ids	O
,	O
in	O
particular	O
T	O
##G	O
##s	O
,	O
would	O
not	O
be	O
transported	O
out	O
of	O
the	O
liver	O
,	O
thus	O
leading	O
to	O
the	O
accumulation	O
of	O
T	O
##G	O
##s	O
within	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
with	O
subsequent	O
fatty	O
liver	O
disease	O
.	O

For	O
example	O
,	O
o	B
##leo	I
##yle	I
##than	I
##ola	I
##mi	I
##de	I
,	O
an	O
end	O
##ogen	O
##ous	O
PP	O
##AR	O
-	O
α	O
ago	O
##nist	O
,	O
was	O
significantly	O
high	O
level	O
in	O
the	O
plasma	O
of	O
chronic	O
l	O
##ymph	O
##oc	O
##ytic	O
le	O
##uke	O
##mia	O
patients	O
such	O
that	O
its	O
plasma	O
concentration	O
was	O
directional	O
##ly	O
related	O
to	O
the	O
number	O
of	O
circulating	O
le	O
##uke	O
##mic	O
cells	O
.	O

Palm	B
##itic	I
acid	I
or	O
he	B
##xa	I
##de	I
##cano	I
##ic	I
acid	I
is	O
one	O
of	O
the	O
most	O
common	O
saturated	O
fatty	O
acids	O
found	O
in	O
animals	O
,	O
a	O
saturated	O
fatty	O
acid	O
found	O
in	O
fat	O
##s	O
,	O
wax	O
##es	O
and	O
body	O
lip	O
##ids	O
.	O

Having	O
said	O
this	O
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
were	O
more	O
abundant	O
in	O
se	O
##ra	O
from	O
patients	O
with	O
extra	O
##he	O
##pa	O
##tic	O
meta	O
##sta	O
##ses	O
,	O
while	O
met	B
##hi	I
##oni	I
##ne	I
and	O
f	B
##uma	I
##rate	I
were	O
more	O
abundant	O
in	O
liver	O
-	O
only	O
meta	O
##sta	O
##ses	O
(	O
Figure	O
and	O
Table	O
)	O
.	O

Se	O
##vere	O
pneumonia	O
is	O
defined	O
as	O
cough	O
or	O
difficulty	O
breathing	O
,	O
plus	O
any	O
of	O
lower	O
chest	O
wall	O
in	O
##dra	O
##wing	O
,	O
nasal	O
fl	O
##aring	O
,	O
or	O
an	O
oxygen	O
sat	O
##uration	O
of	O
<	O
90	O
%	O
on	O
pulse	O
o	B
##xi	I
##metry	I
(	O
the	O
latter	O
defining	O
very	O
severe	O
pneumonia	O
)	O
.	O

Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
offers	O
both	O
good	O
recovery	O
and	O
consistent	O
measurement	O
of	O
meta	O
##bol	O
##ites	O
in	O
serum	O
,	O
particularly	O
when	O
N	O
##MR	O
s	O
##pect	O
##ra	O
are	O
obtained	O
with	O
a	O
500	O
MHz	O
magnet	O
and	O
fewer	O
scan	O
##s	O
than	O
suggested	O
by	O
some	O
protocols	O
[	O
,	O
]	O
.	O

Sub	O
##jects	O
with	O
high	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
were	O
significantly	O
older	O
than	O
subjects	O
with	O
low	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
(	O
P	O
=	O
0	O
.	O
00	O
##3	O
)	O
and	O
were	O
more	O
likely	O
to	O
be	O
di	O
##abe	O
##tic	O
(	O
P	O
=	O
0	O
.	O
02	O
##1	O
)	O
.	O

Super	O
##nat	O
##ant	O
from	O
cold	B
-	I
met	I
##han	I
##ol	I
treated	O
specimen	O
was	O
used	O
directly	O
for	O
L	O
##C	O
/	O
MS	O
analysis	O
.	O

β	B
-	I
Act	I
##in	I
was	O
utilized	O
as	O
an	O
internal	O
control	O
.	O

A	O
disco	O
##ntin	O
##uous	O
gradient	O
was	O
generated	O
to	O
resolve	O
the	O
anal	O
##yte	O
##s	O
by	O
mixing	O
solvent	O
A	O
(	O
0	O
.	O
1	O
%	O
prop	B
##ion	I
##ic	I
acid	I
in	O
water	O
)	O
with	O
solvent	O
B	O
(	O
0	O
.	O
1	O
%	O
ace	B
##tic	I
acid	I
in	O
met	B
##han	I
##ol	I
)	O
.	O

In	O
the	O
majority	O
of	O
the	O
cases	O
,	O
a	O
collection	O
of	O
lip	O
##id	O
species	O
encompassing	O
different	O
classes	O
,	O
such	O
as	O
fatty	O
acids	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
were	O
observed	O
as	O
the	O
disc	O
##rim	O
##inating	O
molecules	O
when	O
comparing	O
cancer	O
and	O
normal	O
tissues	O
.	O

et	O
al	O
.	O
found	O
that	O
,	O
in	O
v	O
##it	O
##ro	O
,	O
la	B
##ct	I
##ate	I
can	O
be	O
meta	O
##bol	O
##ized	O
by	O
some	O
but	O
not	O
all	O
types	O
of	O
BC	O
cells	O
.	O

B	O
##rief	O
##ly	O
,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
affecting	O
the	O
response	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
therapy	O
in	O
healthy	O
,	O
drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
.	O

Additional	O
internal	O
standards	O
(	O
IS	O
)	O
were	O
prepared	O
for	O
l	B
##ys	I
##ine	I
and	O
some	O
bio	O
##genic	O
am	O
##ines	O
for	O
higher	O
accuracy	O
.	O

In	O
muscle	O
,	O
lip	O
##id	O
species	O
higher	O
in	O
O	O
##IR	O
versus	O
Lea	O
##n	O
included	O
a	O
large	O
proportion	O
of	O
T	B
##G	I
,	O
PC	B
(	I
P	I
‐	I
32	I
:	I
1	I
)	I
and	O
PC	B
(	I
P	I
‐	I
34	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
O	I
‐	I
36	I
:	I
4	I
)	I
,	O
and	O
P	B
##E	I
(	I
P	I
‐	I
36	I
:	I
2	I
)	I
and	O
P	B
##E	I
(	I
P	I
‐	I
40	I
:	I
4	I
)	I
.	O

Moreover	O
,	O
GA	B
##BA	I
had	O
anti	O
-	O
o	O
##xi	O
##da	O
##tive	O
effects	O
,	O
and	O
acute	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
after	O
a	O
meal	O
or	O
glucose	S
load	O
increases	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Two	O
FAA	O
##s	O
,	O
that	O
are	O
considered	O
to	O
act	O
as	O
end	B
##oc	I
##anna	I
##bino	I
##ids	I
,	O
displayed	O
an	O
un	O
##qua	O
##nti	O
##fia	O
##ble	O
increase	O
in	O
AM	O
##L	O
plasma	O
,	O
since	O
they	O
were	O
und	O
##ete	O
##ct	O
##able	O
in	O
control	O
plasma	O
##s	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
2	O
)	O
.	O

When	O
we	O
explored	O
the	O
results	O
for	O
similar	O
association	O
patterns	O
,	O
we	O
observed	O
that	O
Met	O
##ab	O
##olo	O
##n	O
meta	O
##bol	O
##ites	O
X	O
-	O
105	O
##10	O
and	O
1	B
-	I
s	I
##te	I
##aro	I
##yl	I
##gly	I
##cer	I
##ol	I
shared	O
m	O
##Q	O
##TL	O
findings	O
within	O
the	O
same	O
lo	O
##cus	O
(	O
S	O
##G	O
##GP	O
##1	O
)	O
as	O
the	O
B	O
##io	O
##crates	O
meta	O
##bol	O
##ite	O
PC	O
a	O
##a	O
C	B
##28	I
:	I
1	I
.	O

In	O
addition	O
,	O
4	O
organic	O
acids	O
(	O
i	O
.	O
e	O
.	O
,	O
4	O
-	O
HP	O
##A	O
,	O
1	B
,	I
2	I
-	I
c	I
##y	I
##c	I
##lop	I
##ent	I
##ane	I
##dic	I
##ar	I
##box	I
##yl	I
##ic	I
acid	I
(	O
dim	O
##eth	O
##yl	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
,	O
and	O
2	B
-	I
amino	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	O
)	O
were	O
all	O
found	O
to	O
be	O
increased	O
.	O

Sam	O
##ples	O
were	O
delivered	O
to	O
the	O
550	O
##0	O
Q	O
##TR	O
##AP	O
using	O
a	O
2	O
.	O
0	O
mm	O
i	O
.	O
d	O
×	O
15	O
cm	O
Luna	O
NH	O
_	O
2	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
column	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
)	O
at	O
300	O
μ	O
##l	O
/	O
min	O
.	O

Coffee	O
is	O
by	O
far	O
the	O
greatest	O
diet	O
##ary	O
source	O
of	O
h	B
##ydro	I
##xy	I
##cin	I
##nam	I
##ic	I
acids	I
in	O
human	O
diet	O
##s	O
,	O
and	O
various	O
ch	B
##lor	I
##ogenic	I
acid	I
is	I
##omer	I
##s	I
are	O
absorbed	O
and	O
ex	O
##cre	O
##ted	O
in	O
humans	O
after	O
coffee	O
consumption	O
,	O
.	O

Despite	O
the	O
relatively	O
small	O
fold	O
change	O
of	O
I	O
##R	O
##8	O
##9	O
(	O
Additional	O
file	O
1	O
:	O
Figure	O
S	O
##1	O
)	O
,	O
the	O
integration	O
value	O
(	O
and	O
so	O
relative	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
)	O
is	O
significantly	O
higher	O
in	O
the	O
inflammation	O
group	O
.	O

Ad	O
##ju	O
##sted	O
Mean	O
##s	O
_	O
a	O
(	O
95	O
%	O
Con	O
##fi	O
##dence	O
Lim	O
##its	O
)	O
for	O
U	O
##rina	O
##ry	O
Con	O
##cent	O
##rations	O
of	O
E	O
##stro	O
##gens	O
and	O
E	B
##stro	I
##gen	I
Met	O
##ab	O
##oli	O
##tes	O
(	O
Joint	O
##ly	O
Re	O
##ferred	O
to	O
as	O
E	O
##M	O
,	O
in	O
Pi	O
##com	O
##ole	O
##s	O
per	O
Mill	O
##ig	O
##ram	O
of	O
C	O
##rea	O
##tin	O
##ine	O
)	O
by	O
Q	O
##uin	O
##tile	O
##s	O
of	O
Me	O
##asures	O
of	O
Di	O
##versity	O
and	O
Composition	O
of	O
the	O
Fe	O
##cal	O
Micro	O
##bio	O
##me	O
in	O
60	O
Post	O
##men	O
##op	O
##aus	O
##al	O
Women	O
H	O
'	O
=	O
−	O
##Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
##⋅	O
##ln	O
##pi	O
H	O
'	O
=	O
−	O
##Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
##⋅	O
##ln	O
##pi	O
H	O
'	O
=	O
−	O
##Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
##⋅	O
##ln	O
##pi	O
H	O
'	O
=	O
−	O
##Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
##⋅	O
##ln	O
##pi	O
H	O
'	O
=	O
−	O
##Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
##⋅	O
##ln	O
##pi	O
H	O
'	O
=	O
−	O
##Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
##⋅	O
##ln	O
##pi	O
H	O
'	O
=	O
−	O
Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
Σ	O
##R	O
##i	O
=	O
1	O
##pi	O
Σ	O
Σ	O

O	O
##DC	O
##1	O
is	O
a	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
synthesis	O
of	O
p	B
##oly	I
##amine	I
##s	I
,	O
which	O
play	O
important	O
roles	O
in	O
both	O
physiology	O
and	O
path	O
##ology	O
regulating	O
a	O
number	O
of	O
cellular	O
functions	O
;	O
among	O
others	O
,	O
they	O
induce	O
proliferation	O
and	O
migration	O
of	O
in	O
##test	O
##inal	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
,	O
necessary	O
for	O
repair	O
processes	O
[	O
,	O
]	O
,	O
but	O
may	O
also	O
induce	O
a	O
##pop	O
##tosis	O
or	O
trigger	O
neo	O
##p	O
##lastic	O
transformation	O
[	O
,	O
]	O
.	O

It	O
is	O
well	O
known	O
that	O
un	O
##con	O
##tro	O
##lled	O
and	O
expanding	O
inflammatory	O
responses	O
in	O
se	O
##psis	O
cause	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
;	O
thus	O
,	O
detection	O
of	O
elevated	O
serum	O
glucose	S
was	O
expected	O
.	O

As	O
one	O
of	O
the	O
ne	O
##uro	O
##p	O
##rote	O
##ctive	O
actions	O
of	O
r	B
##il	I
##uz	I
##ole	I
may	O
include	O
the	O
in	O
##hibition	O
of	O
g	B
##lut	I
##ama	I
##te	I
release	O
and	O
non	O
-	O
competitive	O
post	O
-	O
s	O
##yna	O
##ptic	O
in	O
##hibition	O
of	O
N	O
##MD	O
##A	O
and	O
AM	O
##PA	O
receptors	O
[	O
,	O
]	O
,	O
the	O
increased	O
k	B
##yn	I
##uren	I
##ine	I
levels	O
observed	O
in	O
Group	O
O	O
may	O
be	O
related	O
to	O
an	O
at	O
##ten	O
##uation	O
of	O
the	O
effect	O
of	O
r	B
##il	I
##uz	I
##ole	I
on	O
these	O
pathways	O
due	O
to	O
a	O
negative	O
interaction	O
with	O
o	B
##les	I
##ox	I
##ime	I
treatment	O
.	O

In	O
order	O
to	O
analyze	O
the	O
samples	O
obtained	O
with	O
the	O
improved	O
is	O
##oto	O
##pe	O
in	O
##fusion	O
protocol	O
,	O
we	O
aimed	O
to	O
develop	O
and	O
valid	O
##ate	O
a	O
sensitive	O
and	O
accurate	O
G	O
##C	O
–	O
MS	O
/	O
MS	O
method	O
by	O
combining	O
the	O
en	O
##rich	O
##ment	O
analysis	O
of	O
o	B
##xa	I
##late	I
,	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
,	O
and	O
g	B
##ly	I
##cola	I
##te	I
into	O
one	O
single	O
analysis	O
.	O

Human	O
serum	O
album	O
##in	O
and	O
excess	O
to	B
##lm	I
##eti	I
##n	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
were	O
coin	O
##cu	O
##bate	O
##d	O
in	O
the	O
presence	O
of	O
sodium	B
c	I
##yan	I
##ob	I
##oro	I
##hy	I
##dr	I
##ide	I
to	O
trap	O
im	O
##ine	O
intermediate	O
##s	O
.	O

The	O
MS	O
resolution	O
was	O
set	O
at	O
100	O
,	O
000	O
full	O
width	O
half	O
maximum	O
and	O
the	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
were	O
provided	O
by	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
,	O
Inc	O
.	O
(	B
ca	B
##ffe	I
##ine	I
,	O
Ultra	O
##mark	O
162	O
##1	O
and	O
MR	O
##FA	O
)	O
.	O

Before	O
that	O
,	O
we	O
tested	O
different	O
proportions	O
and	O
combinations	O
of	O
organic	O
solvent	O
##s	O
,	O
for	O
example	O
,	O
et	B
##hyl	I
ace	I
##tate	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
,	O
t	B
##rich	I
##lor	I
##ome	I
##than	I
##e	I
,	O
met	B
##hyl	I
tertiary	I
-	I
but	I
##yl	I
et	I
##her	I
,	O
and	O
c	B
##y	I
##c	I
##lo	I
##he	I
##xa	I
##ne	I
.	O

Met	O
##ab	O
##olis	O
##m	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
was	O
reported	O
to	O
have	O
potential	O
relation	O
to	O
cell	O
growth	O
,	O
differentiation	O
,	O
a	O
##pop	O
##tosis	O
and	O
an	O
##gio	O
##genesis	O
_	O
,	O
.	O

Or	B
##ni	I
##thin	I
##e	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
and	O
a	B
##rg	I
##ini	I
##ne	I
were	O
detected	O
significantly	O
decreased	O
in	O
the	O
serum	O
of	O
HC	O
##C	O
patients	O
as	O
compared	O
with	O
healthy	O
controls	O
.	O

Given	O
that	O
subjects	O
with	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
are	O
known	O
to	O
have	O
a	O
low	O
re	O
##nal	O
threshold	O
for	O
glucose	S
,	O
we	O
calculated	O
both	O
u	O
##rina	O
##ry	O
glucose	S
/	O
c	O
##rea	O
##tin	O
##ine	O
(	O
U	O
##G	O
/	O
C	O
##r	O
)	O
ratio	O
and	O
plasma	O
glucose	S
to	O
u	O
##rina	O
##ry	O
glucose	S
/	O
c	O
##rea	O
##tin	O
##ine	O
ratio	O
P	O
##G	O
/	O
(	O
U	O
##G	O
/	O
C	O
##r	O
)	O
.	O

Also	O
,	O
certain	O
co	O
##lon	O
##ic	O
bacteria	O
likely	O
contribute	O
to	O
se	B
##rot	I
##oni	I
##n	I
levels	O
either	O
through	O
de	O
no	O
##vo	O
synthesis	O
or	O
the	O
de	O
##car	O
##box	O
##yla	O
##tion	O
of	O
T	O
##rp	O
.	O

A	O
subset	O
of	O
six	O
meta	O
##bol	O
##ites	O
including	O
sa	B
##rc	I
##os	I
##ine	I
,	O
u	B
##rac	I
##il	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
le	B
##uc	I
##ine	I
and	O
pro	B
##line	I
were	O
significantly	O
elevated	O
upon	O
disease	O
progression	O
from	O
ben	O
##ign	O
to	O
PC	O
##A	O
to	O
Mets	O
.	O

Since	O
hundreds	O
of	O
different	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
have	O
been	O
observed	O
in	O
plasma	O
lip	O
##op	O
##rote	O
##ins	O
(	O
L	O
##p	O
(	O
a	O
)	O
)	O
and	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
plaque	O
##s	O
,	O
our	O
finding	O
was	O
not	O
unexpected	O
.	O

The	O
elevation	O
of	O
ad	B
##eni	I
##ne	I
in	O
HC	O
##C	O
is	O
in	O
agreement	O
with	O
the	O
increased	O
metabolic	O
needs	O
of	O
emerging	O
lesions	O
.	O

H	B
##ydro	I
##im	I
##iza	I
##lone	I
##s	I
were	O
determined	O
as	O
m	O
##olar	O
amount	O
of	O
affected	O
amino	O
acid	O
[	O
nm	O
##ol	O
/	O
m	O
##ol	O
]	O
.	O

In	O
our	O
lip	O
##ido	O
##mic	O
##s	O
analysis	O
,	O
T	B
##G	I
56	I
:	I
4	I
was	O
the	O
second	O
most	O
significantly	O
increased	O
T	B
##G	I
species	O
with	O
a	O
p	O
value	O
of	O
0	O
.	O
000	O
##6	O
.	O

In	O
plasma	O
,	O
increased	O
levels	O
of	O
cat	B
##ech	I
##ol	I
su	I
##lf	I
##ate	I
and	O
4	B
-	I
met	I
##hyl	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
were	O
positively	O
correlated	O
with	O
two	O
increased	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
,	O
3	B
-	I
p	I
##hen	I
##yl	I
##p	I
##rop	I
##ion	I
##ate	I
and	O
5	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
-	I
2	I
-	I
fur	I
##oi	I
##c	I
acid	I
.	O

Pre	O
##cu	O
##rs	O
##or	O
and	O
product	O
ion	O
identification	O
and	O
MS	O
_	O
n	O
optimization	O
were	O
established	O
by	O
directly	O
in	O
##fu	O
##sing	O
1	O
,	O
000	O
ng	O
/	O
m	O
##L	O
solutions	O
of	O
single	O
anal	O
##yte	O
##s	O
in	O
met	B
##han	I
##ol	I
.	O

The	O
water	O
region	O
from	O
4	O
.	O
6	O
pp	O
##m	O
to	O
4	O
.	O
9	O
pp	O
##m	O
and	O
the	O
ethanol	S
peaks	O
(	O
1	O
.	O
15	O
–	O
1	O
.	O
20	O
,	O
3	O
.	O
6	O
–	O
3	O
.	O
7	O
pp	O
##m	O
)	O
were	O
excluded	O
prior	O
to	O
the	O
analysis	O
.	O

Part	O
##ici	O
##pants	O
(	O
n	O
=	O
29	O
133	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
based	O
on	O
a	O
2	O
×	O
2	O
factor	O
##ial	O
design	O
:	O
(	O
i	O
)	O
alpha	B
-	I
to	I
##co	I
##pher	I
##ol	I
,	O
(	O
ii	O
)	O
beta	B
-	I
car	I
##ote	I
##ne	I
,	O
(	O
ii	O
##i	O
)	O
both	O
or	O
(	O
i	O
##v	O
)	O
place	O
##bo	O
,	O
and	O
took	O
study	O
capsule	O
##s	O
for	O
5	O
–	O
8	O
years	O
(	O
median	O
6	O
.	O
1	O
)	O
through	O
30	O
April	O
1993	O
.	O

Form	B
##ic	I
acid	I
(	O
FA	O
)	O
for	O
L	O
##C	O
/	O
MS	O
was	O
purchased	O
from	O
Fuji	O
##film	O
W	O
##ak	O
##o	O
Pure	O
Chemical	O
Corporation	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

However	O
,	O
recent	O
studies	O
indicate	O
that	O
high	O
concentrations	O
of	O
a	B
##rg	I
##ini	I
##ne	I
can	O
increase	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
the	O
general	O
population	O
.	O

It	O
has	O
to	O
be	O
noted	O
,	O
that	O
up	O
to	O
now	O
no	O
clear	O
relation	O
between	O
3	B
,	I
5	I
-	I
T	I
##2	I
and	O
the	O
classical	O
T	O
##H	O
is	O
established	O
in	O
humans	O
.	O

Both	O
phase	O
and	O
base	O
##line	O
correction	O
##s	O
were	O
then	O
performed	O
manually	O
,	O
and	O
the	O
s	O
##pect	O
##ra	O
were	O
referenced	O
to	O
the	O
met	O
##hyl	O
double	O
##t	O
signal	O
of	O
la	B
##ct	I
##ate	I
(	O
δ	O
1	O
.	O
33	O
pp	O
##m	O
)	O
.	O

However	O
,	O
the	O
plasma	O
concentrations	O
of	O
B	O
_	O
2	O
,	O
FA	S
,	O
SA	O
##M	O
as	O
well	O
as	O
met	O
##hyl	O
##ation	O
capacity	O
(	O
defined	O
by	O
SA	O
##M	O
/	O
SA	O
##H	O
ratio	O
)	O
,	O
FA	S
/	O
T	O
##HF	O
ratio	O
and	O
FA	O
/	O
5	O
##MT	O
##HF	O
ratio	O
were	O
significantly	O
higher	O
in	O
the	O
controls	O
instead	O
.	O

For	O
the	O
14	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
MI	O
,	O
including	O
PC	O
,	O
D	O
##G	O
,	O
SM	O
,	O
Ce	B
##r	I
,	O
and	O
G	O
##lu	O
##cer	O
,	O
these	O
markers	O
were	O
associated	O
with	O
a	O
1	O
.	O
11	O
–	O
1	O
.	O
17	O
-	O
fold	O
increased	O
risk	O
of	O
MI	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
from	O
the	O
u	B
##rea	I
cycle	O
(	O
n	O
=	O
4	O
)	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
(	O
n	O
=	O
4	O
)	O
emerge	O
in	O
the	O
second	O
component	O
.	O

Mia	O
##P	O
##a	O
##C	O
##a	O
-	O
2	O
and	O
Pan	O
##c	O
-	O
1	O
were	O
grown	O
in	O
high	O
glucose	S
Du	O
##l	O
##be	O
##cco	O
’	O
s	O
Mo	O
##dified	O
Eagle	O
Medium	O
,	O
(	O
D	O
##ME	O
##M	O
)	O
and	O
As	O
##PC	O
-	O
1	O
cells	O
were	O
grown	O
in	O
R	O
##os	O
##well	O
Park	O
Memorial	O
Institute	O
(	O
R	O
##PM	O
##I	O
)	O
medium	O
.	O

For	O
mon	B
##oh	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##ls	I
(	I
C	I
_	I
5	I
-	I
3	I
##β	I
,	I
x	I
-	I
di	I
##ol	I
)	I
,	O
which	O
are	O
present	O
in	O
CS	O
##F	O
in	O
their	O
free	O
form	O
in	O
low	O
amounts	O
(	O
<	O
1	O
ng	O
/	O
m	O
##l	O
)	O
,	O
q	O
##uant	O
##ification	O
was	O
performed	O
using	O
the	O
MR	O
##M	O
transitions	O
53	O
##4	O
.	O
4	O
##→	O
##45	O
##5	O
.	O
4	O
##→	O
for	O
the	O
GP	O
-	O
tag	O
##ged	O
s	O
##tero	O
##ls	O
and	O
540	O
.	O
4	O
##→	O
##46	O
##1	O
.	O
4	O
##→	O
for	O
GP	O
-	O
tag	O
##ged	O
24	O
(	O
SR	O
)	O
-	B
[	B
_	I
2	I
H	I
_	I
6	I
]	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
IS	O
.	O

The	O
activity	O
of	O
extra	O
##cellular	O
f	B
##olic	I
acid	I
is	O
regulated	O
by	O
a	O
f	B
##olic	I
acid	I
s	O
##ynth	O
##ase	O
.	O

Free	O
and	O
con	O
##ju	O
##gated	O
m	B
##or	I
##phine	I
can	O
be	O
measured	O
separately	O
to	O
assess	O
patient	O
’	O
s	O
compliance	O
with	O
op	O
##io	O
##id	O
prescription	O
##s	O
or	O
during	O
death	O
investigation	O
of	O
suspected	O
complications	O
of	O
over	O
##dos	O
##e	O
.	O

All	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
standards	O
were	O
dissolved	O
in	O
is	O
##oo	O
##ct	O
##ane	O
/	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
3	O
:	O
1	O
v	O
/	O
v	O
)	O
with	O
a	O
concentration	O
of	O
1	O
.	O
0	O
mg	O
/	O
m	O
##L	O
.	O

Met	O
##ab	O
##olic	O
pro	O
##fi	O
##ling	O
of	O
plasma	O
yielded	O
alterations	O
in	O
HD	O
##L	O
metabolism	O
in	O
mi	O
##gra	O
##ine	O
patients	O
and	O
decreased	O
o	B
##me	I
##ga	I
-	I
3	I
fatty	O
acids	O
only	O
in	O
male	O
mi	O
##gra	O
##ine	O
##urs	O
.	O

Furthermore	O
,	O
plasma	O
concentration	O
of	O
l	B
##ys	I
##ine	I
was	O
negatively	O
correlated	O
with	O
serum	O
concentrations	O
of	O
C	O
-	O
reactive	O
protein	O
(	O
CR	O
##P	O
)	O
,	O
neo	B
##pt	I
##eri	I
##n	I
,	O
and	O
fi	O
##bri	O
##no	O
##gen	O
,	O
whereas	O
positively	O
correlated	O
with	O
serum	O
album	O
##in	O
concentration	O
.	O

By	O
using	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
,	O
we	O
identified	O
and	O
q	O
##uant	O
##ified	O
140	O
species	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
in	O
the	O
serum	O
.	O

9	O
##c	O
##RA	O
m	O
##od	O
##ulates	O
the	O
expression	O
of	O
its	O
target	O
genes	O
by	O
act	O
##ivating	O
two	O
classes	O
of	O
nuclear	O
receptors	O
,	O
re	B
##tino	I
##ic	I
acid	I
receptors	O
(	O
RA	O
##R	O
##s	O
)	O
and	O
re	B
##tino	I
##id	I
X	O
receptors	O
(	O
R	O
##X	O
##R	O
##s	O
)	O
.	O

The	O
meta	O
##bol	O
##ite	O
subgroup	O
##s	O
that	O
distinguish	O
low	O
SUV	O
_	O
ma	O
##x	O
CA	O
##F	O
##s	O
from	O
their	O
matched	O
N	O
##F	O
##s	O
were	O
not	O
the	O
same	O
as	O
those	O
that	O
distinguish	O
high	O
SUV	O
_	O
ma	O
##x	O
CA	O
##F	O
##s	O
from	O
their	O
paired	O
N	O
##F	O
##s	O
,	O
suggesting	O
a	O
link	O
between	O
the	O
metabolic	O
alterations	O
in	O
CA	O
##F	O
##s	O
and	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
activity	O
of	O
the	O
tumor	O
(	O
i	O
.	O
e	O
.	O
,	O
SUV	O
_	O
ma	O
##x	O
)	O
from	O
which	O
the	O
CA	O
##F	O
##s	O
were	O
derived	O
.	O

The	O
LL	O
##E	O
method	O
was	O
performed	O
by	O
mixing	O
250	O
µ	O
##L	O
of	O
et	B
##hyl	I
ace	I
##tate	I
,	O
and	O
the	O
resulting	O
upper	O
phase	O
was	O
recovered	O
.	O

Both	O
of	O
these	O
methods	O
require	O
the	O
following	O
additional	O
assumptions	O
for	O
direct	O
ca	O
##usal	O
interpretation	O
:	O
conditional	O
on	O
co	O
##var	O
##iate	O
##s	O
,	O
there	O
is	O
no	O
con	O
##found	O
##ing	O
of	O
the	O
B	O
##MI	O
-	O
breast	O
cancer	O
relationship	O
,	O
no	O
con	O
##found	O
##ing	O
of	O
the	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
-	I
breast	I
cancer	O
relationship	O
,	O
no	O
con	O
##found	O
##ing	O
of	O
the	O
B	O
##MI	O
-	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
relationship	O
,	O
no	O
con	O
##found	O
##ing	O
of	O
the	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rogen	I
-	I
breast	I
cancer	O
relationship	O
in	O
which	O
the	O
con	O
##found	O
##er	O
is	O
affected	O
by	O
B	O
##MI	O
,	O
and	O
;	O
5	O
)	O
the	O
consistency	O
assumption	O
that	O
a	O
person	O
'	O
s	O
potential	O
outcome	O
under	O
counter	O
##fa	O
##ct	O
##ual	O
conditions	O
is	O
the	O
outcome	O
experienced	O
by	O
that	O
person	O
.	O

Investigation	O
##s	O
by	O
U	O
##chi	O
##da	O
and	O
co	O
-	O
workers	O
using	O
mass	O
s	O
##pect	O
##rome	O
##try	O
showed	O
that	O
the	O
reaction	O
of	O
a	B
##c	I
##rol	I
##ein	I
with	O
protein	O
L	O
##ys	O
of	O
b	O
##ov	O
##ine	O
Al	O
##b	O
results	O
in	O
β	O
-	O
substituted	O
prop	O
##ana	O
##ls	O
(	O
R	O
-	O
NH	O
–	O
CH	O
_	O
2	O
–	O
CH	O
_	O
2	O
–	O
CH	O
##O	O
)	O
,	O
to	O
form	O
the	O
N	O
_	B
ε	I
-	I
(	I
3	I
-	I
form	I
##yl	I
-	I
3	I
,	I
4	I
-	I
de	I
##hy	I
##dr	I
##op	I
##iper	I
##id	I
##ino	I
)	I
l	I
##ys	I
##ine	I
add	O
##uc	O
##t	O
,	O
and	O
the	O
stable	O
add	O
##uc	O
##t	O
N	O
_	B
ε	I
-	I
(	I
3	I
-	I
met	I
##hyl	I
##py	I
##rid	I
##ini	I
##um	I
)	I
l	I
##ys	I
##ine	I
is	O
prominently	O
formed	O
in	O
o	O
##xi	O
##dized	O
low	O
-	O
density	O
lip	O
##id	O
proteins	O
.	O
_	O
,	O
PP	O
show	O
differences	O
in	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
to	O
o	O
##xi	O
##da	O
##tive	O
modification	O
:	O
Al	O
##b	O
was	O
reported	O
to	O
be	O
the	O
main	O
protein	O
in	O
plasma	O
carbon	O
##yla	O
##ted	O
in	O
chronic	O
kidney	O
disease	O
and	O
hem	O
##od	O
##ial	O
##ys	O
##is	O
patients	O
,	O
when	O
assessed	O
by	O
Western	O
b	O
##lot	O
##ting	O
.	O

For	O
example	O
,	O
we	O
have	O
also	O
had	O
success	O
in	O
der	O
##iva	O
##ti	O
##zing	O
car	B
##box	I
##yl	I
##ic	I
acid	I
groups	O
of	O
meta	O
##bol	O
##ites	O
in	O
urine	O
by	O
using	O
excess	O
met	B
##hyl	I
i	I
##od	I
##ide	I
,	O
which	O
further	O
expands	O
the	O
types	O
of	O
meta	O
##bol	O
##ite	O
profiles	O
accessible	O
with	O
the	O
method	O
.	O

Ser	O
##um	O
glucose	S
levels	O
obtained	O
from	O
the	O
same	O
patients	O
with	O
s	O
##chi	O
##zophrenia	O
and	O
from	O
healthy	O
participants	O
showed	O
no	O
difference	O
(	O
p	O
=	O
0	O
.	O
24	O
)	O
,	O
suggesting	O
a	O
brain	O
and	O
/	O
or	O
CS	O
##F	O
-	O
specific	O
elevation	O
in	O
glucose	S
levels	O
.	O

D	O
##ys	O
##lip	O
##ide	O
##mia	O
in	O
diabetes	O
is	O
mainly	O
characterized	O
by	O
increased	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
and	O
NE	O
##FA	O
levels	O
(	O
,	O
)	O
.	O

T	B
##G	I
concentrations	O
within	O
most	O
V	O
##LD	O
##L	O
and	O
small	O
L	O
##D	O
##L	O
sub	O
##c	O
##lass	O
##es	O
were	O
also	O
strongly	O
positively	O
associated	O
with	O
IS	O
,	O
but	O
the	O
associations	O
of	O
T	B
##G	I
within	O
very	O
small	O
V	O
##LD	O
##L	O
,	O
ID	O
##L	O
,	O
and	O
large	O
or	O
medium	O
L	O
##D	O
##L	O
was	O
weaker	O
as	O
compared	O
with	O
MI	O
.	O

The	O
mobile	O
phases	O
consisted	O
of	O
(	O
A	O
)	O
0	O
.	O
5	O
%	O
ace	B
##tic	I
acid	I
and	O
(	O
B	O
)	O
0	O
.	O
5	O
%	O
ace	B
##tic	I
acid	I
and	O
80	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Model	O
PC	O
##T	O
incorrectly	O
predicted	O
19	O
of	O
the	O
300	O
s	O
##pect	O
##ra	O
(	O
6	O
.	O
3	O
%	O
)	O
,	O
of	O
which	O
12	O
s	O
##pect	O
##ra	O
were	O
incorrectly	O
predicted	O
to	O
contain	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
due	O
to	O
the	O
presence	O
of	O
overlapping	O
peaks	O
in	O
the	O
a	O
##romatic	O
regions	O
,	O
and	O
the	O
remaining	O
7	O
s	O
##pect	O
##ra	O
were	O
incorrectly	O
predicted	O
as	O
not	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
.	O

The	O
levels	O
of	O
ne	B
##r	I
##von	I
##ic	I
acid	I
were	O
measured	O
using	O
gas	O
ch	O
##roma	O
##tography	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
-	O
TO	O
##FM	O
##S	O
)	O
in	O
the	O
30	O
available	O
samples	O
of	O
co	O
##hor	O
##t	O
1	O
.	O

G	B
##ly	I
##cine	I
and	O
se	B
##rine	I
were	O
also	O
inverse	O
##ly	O
correlated	O
with	O
all	O
measures	O
of	O
ad	O
##ip	O
##os	O
##ity	O
,	O
except	O
that	O
g	B
##ly	I
##cine	I
was	O
not	O
associated	O
with	O
B	O
##MI	O
class	O
(	O
VIP	O
>	O
1	O
,	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##3	O
)	O
.	O

Re	O
##lated	O
to	O
the	O
g	B
##lut	I
##ath	I
##ione	I
levels	O
and	O
additional	O
markers	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
the	O
increase	O
observed	O
in	O
Met	O
##O	O
,	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
,	O
c	B
##ys	I
##tein	I
##e	I
and	O
g	B
##ly	I
##cine	I
levels	O
in	O
both	O
tumor	O
sub	O
##type	O
##s	O
provides	O
further	O
support	O
for	O
changes	O
associated	O
with	O
an	O
increase	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
(	O
Fi	O
##g	O
.	O

In	O
addition	O
to	O
these	O
differences	O
,	O
some	O
meta	O
##bol	O
##ites	O
were	O
only	O
present	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
,	O
for	O
example	O
,	O
n	B
-	I
met	I
##hyl	I
-	I
α	I
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
,	O
n	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ima	I
##mi	I
##de	I
,	O
sa	B
##rc	I
##os	I
##ine	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ic	I
acid	I
,	O
whereas	O
some	O
meta	O
##bol	O
##ites	O
were	O
only	O
present	O
in	O
Speed	O
##V	O
##ac	O
dried	O
samples	O
,	O
for	O
example	O
,	O
trim	B
##eth	I
##yla	I
##mine	I
.	O

Several	O
research	O
groups	O
examined	O
children	O
and	O
healthy	O
adults	O
[	O
–	O
]	O
as	O
well	O
as	O
diabetes	O
patients	O
without	O
and	O
with	O
com	O
##or	O
##bid	O
##ities	O
[	O
–	O
]	O
and	O
reported	O
positive	O
relationships	O
between	O
by	O
E	O
##L	O
##IS	O
##A	O
-	O
measured	O
AG	O
##Es	O
and	O
markers	O
of	O
glucose	S
metabolism	O
.	O

Although	O
the	O
mechanisms	O
underlying	O
the	O
observed	O
sex	O
differences	O
remain	O
unclear	O
,	O
our	O
results	O
suggest	O
that	O
12	O
-	O
L	O
##OX	O
is	O
more	O
active	O
in	O
women	O
,	O
accounting	O
for	O
the	O
sex	O
difference	O
in	O
o	B
##xy	I
##lip	I
##in	I
levels	O
.	O

The	O
slope	O
of	O
me	B
##lat	I
##oni	I
##n	I
was	O
positively	O
associated	O
with	O
slow	O
wave	O
sleep	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
extracted	O
in	O
met	B
##han	I
##ol	I
:	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	I
2	I
:	I
5	I
)	I
solution	O
.	O

Car	O
##ba	O
##my	O
##lation	O
is	O
a	O
none	O
##nz	O
##ym	O
##atic	O
post	O
-	O
translation	O
##al	O
protein	O
modification	O
mediated	O
by	O
c	B
##yana	I
##te	I
,	O
a	O
di	O
##sso	O
##ciation	O
product	O
of	O
u	B
##rea	I
.	O

One	O
model	O
included	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
only	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
the	O
other	O
model	O
included	O
both	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
and	O
an	O
additional	O
measure	O
of	O
interest	O
(	O
y	O
-	O
axis	O
)	O
:	O
total	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
(	O
A	O
)	O
;	O
the	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
parent	O
est	O
##rogen	O
##s	O
(	O
B	O
)	O
;	O
the	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
the	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
(	O
C	O
)	O
;	O
and	O
the	O
ratio	O
of	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
to	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
(	O
D	O
)	O
.	O

One	O
possible	O
explanation	O
for	O
the	O
differential	O
effects	O
of	O
TD	O
##O	O
as	O
compared	O
to	O
Ah	O
##R	O
in	O
##hibition	O
is	O
that	O
the	O
effect	O
of	O
TD	O
##O	O
activity	O
on	O
CD	O
##8	O
T	O
cells	O
is	O
due	O
to	O
the	O
combined	O
effects	O
of	O
both	O
try	B
##pt	I
##op	I
##han	I
de	O
##ple	O
##tion	O
and	O
k	B
##yn	I
##uren	I
##ine	I
secret	O
##ion	O
.	O

Finally	O
,	O
after	O
the	O
residual	O
water	O
(	O
4	O
.	O
60	O
–	O
5	O
.	O
00	O
pp	O
##m	O
)	O
,	O
u	B
##rea	I
and	O
α	O
-	O
pro	O
##ton	O
of	O
glucose	S
(	O
5	O
.	O
00	O
–	O
6	O
.	O
00	O
pp	O
##m	O
)	O
regions	O
were	O
removed	O
,	O
the	O
data	O
##set	O
was	O
bin	O
##ned	O
into	O
79	O
##51	O
integral	O
##s	O
of	O
equal	O
width	O
(	O
0	O
.	O
00	O
##1	O
pp	O
##m	O
)	O
.	O

Ser	O
##um	O
samples	O
from	O
fast	O
##ed	O
patients	O
were	O
analyzed	O
using	O
shotgun	O
lip	O
##ido	O
##mic	O
##s	O
and	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
and	O
a	O
sum	O
of	O
concentrations	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
containing	O
EPA	O
and	O
/	O
or	O
D	O
##HA	O
divided	O
by	O
total	O
concentration	O
of	O
all	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	I
Omega	I
-	I
3	I
Ph	I
##L	I
Index	I
)	I
was	O
used	O
as	O
a	O
bio	O
##mark	O
##er	O
of	O
EPA	O
and	O
D	O
##HA	O
status	O
.	O

The	O
ET	O
##S	O
status	O
self	O
-	O
reported	O
in	O
the	O
initial	O
screening	O
question	O
##naire	O
was	O
confirmed	O
with	O
information	O
reported	O
in	O
the	O
question	O
##naire	O
##s	O
daily	O
and	O
with	O
the	O
personal	O
exposure	O
##s	O
to	O
3	B
-	I
et	I
##hen	I
##yl	I
##py	I
##rid	I
##ine	I
,	O
an	O
ET	O
##S	O
trace	O
##r	O
.	O

The	O
mean	O
pre	O
##c	O
##lini	O
##cal	O
duration	S
for	O
pro	O
##state	O
cancer	O
has	O
been	O
estimated	O
at	O
least	O
as	O
a	O
decade	O
.	O

Most	O
striking	O
##ly	O
,	O
examination	O
of	O
the	O
fraction	O
##al	O
en	O
##rich	O
##ment	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
and	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
indicated	O
la	B
##ct	I
##ate	I
u	O
##til	O
##ization	O
as	O
a	O
carbon	O
source	O
,	O
which	O
they	O
re	O
##cap	O
##it	O
##ulated	O
through	O
[	B
2	I
-	I
_	I
13	I
C	I
]	I
la	I
##ct	I
##ate	I
tracing	O
in	O
mouse	O
x	O
##eno	O
##gra	O
##fts	O
derived	O
from	O
N	O
##SC	O
##LC	O
cell	O
lines	O
harbor	O
##ing	O
K	O
##RA	O
##S	O
or	O
E	O
##G	O
##F	O
##R	O
mutations	O
.	O

This	O
region	O
has	O
been	O
previously	O
shown	O
to	O
associate	O
with	O
bi	B
##li	I
##ru	I
##bin	I
level	O
,	O
which	O
is	O
a	O
de	O
##ter	O
##mina	O
##nt	O
of	O
he	O
##pa	O
##tic	O
health	O
.	O

We	O
also	O
found	O
elevated	O
levels	O
of	O
sa	O
##liva	O
##ry	O
Ethan	B
##ol	I
in	O
the	O
patients	O
,	O
which	O
was	O
reduced	O
on	O
AR	O
##T	O
.	O

Re	O
##action	O
of	O
each	O
e	B
##pox	I
##ide	I
with	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
produced	O
the	O
ring	O
opened	O
products	O
6	O
,	O
9	O
,	O
13	O
,	O
and	O
16	O
(	O
each	O
as	O
a	O
mixture	O
of	O
un	O
##se	O
##par	O
##able	O
di	O
##aster	O
##eo	O
##mers	O
)	O
.	O

[	B
13	B
,	I
14	I
,	I
15	I
,	I
16	I
,	I
17	I
,	I
18	I
-	I
_	I
13	I
C	I
_	I
6	I
]	O
-	O
E	O
##2	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
investigating	O
the	O
response	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
concentrations	O
during	O
an	O
O	O
##G	O
##TT	O
in	O
youth	O
.	O

The	O
mean	O
level	O
of	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
at	O
Week	O
4	O
was	O
1	O
.	O
34	O
±	O
1	O
.	O
08	O
(	O
S	O
.	O
D	O
.	O
)	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
N	O
=	O
226	O
)	O
while	O
that	O
of	O
P	O
##GE	O
-	O
M	O
was	O
73	O
.	O
7	O
±	O
113	O
(	O
S	O
.	O
D	O
.	O
)	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
N	O
=	O
232	O
)	O
.	O

central	O
ad	O
##ip	O
##os	O
##ity	O
gain	O
p	O
##hen	O
##otype	O
,	O
and	O
this	O
finding	O
may	O
be	O
driven	O
by	O
the	O
f	B
##ru	I
##ct	I
##ose	I
finding	O
,	O
given	O
evidence	O
from	O
is	O
##oto	O
##pic	O
trace	O
##r	O
studies	O
of	O
f	B
##ru	I
##ct	I
##ose	I
,	O
which	O
show	O
that	O
approximately	O
one	O
-	O
fourth	O
of	O
ing	O
##ested	O
f	B
##ru	I
##ct	I
##ose	I
is	O
converted	O
to	O
la	B
##ctic	I
acid	I
within	O
hours	O
.	O

A	O
panel	O
of	O
three	O
meta	O
##bol	O
##ites	O
pen	B
##tad	I
##eca	I
##no	I
##ic	I
acid	I
,	O
l	B
##ino	I
##leo	I
##yl	I
car	I
##ni	I
##tine	I
and	O
1	B
-	I
l	I
##ino	I
##leo	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
was	O
discovered	O
to	O
have	O
diagnostic	O
value	O
in	O
determining	O
the	O
extent	O
of	O
I	O
/	O
R	O
injury	O
based	O
on	O
cardiac	O
bio	O
##mark	O
##ers	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
is	O
susceptible	O
to	O
o	O
##xi	O
##da	O
##tive	O
modification	O
by	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
,	O
and	O
high	O
levels	O
of	O
o	O
##xi	O
##dized	O
met	B
##hi	I
##oni	I
##ne	I
are	O
therefore	O
regarded	O
as	O
a	O
marker	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

The	O
lack	O
of	O
relationship	O
between	O
T	B
##MA	I
##O	I
and	O
its	O
diet	O
##ary	O
precursor	O
##s	O
,	O
ch	B
##olin	I
##e	I
and	O
beta	B
##ine	I
,	O
and	O
inflammatory	O
bio	O
##mark	O
##ers	O
is	O
also	O
somewhat	O
unexpected	O
,	O
as	O
prior	O
studies	O
have	O
implied	O
that	O
the	O
lack	O
of	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
may	O
be	O
associated	O
with	O
a	O
state	O
of	O
active	O
inter	O
##le	O
##uki	O
##n	O
-	O
10	O
-	O
mediated	O
inflammatory	O
h	O
##y	O
##pores	O
##po	O
##ns	O
##ive	O
##ness	O
[	O
]	O
.	O

The	O
upper	O
a	O
##que	O
##ous	O
phase	O
was	O
transferred	O
into	O
a	O
fresh	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tube	O
and	O
re	O
-	O
extracted	O
by	O
addition	O
of	O
250	O
μ	O
##l	O
ice	O
-	O
cold	O
ch	O
##lor	O
##of	O
##orm	O
/	O
met	O
##han	O
##ol	O
as	O
described	O
above	O
.	O

(	O
B	O
)	O
Con	O
##tribution	O
of	O
a	O
_	O
1	O
H	O
N	O
##MR	O
characteristic	O
signal	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
at	O
0	O
.	O
68	O
pp	O
##m	O
to	O
the	O
spectrum	O
of	O
lip	O
##id	O
fraction	O
of	O
the	O
plasma	O
extract	O
(	O
Or	O
##g	O
spectrum	O
)	O
.	O

The	O
absence	O
of	O
meta	O
##bol	O
##ites	O
such	O
as	O
form	B
##ic	I
acid	I
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
may	O
be	O
due	O
to	O
chemical	O
conversion	O
during	O
speed	O
-	O
vacuum	O
drying	O
at	O
a	O
higher	O
temperature	O
.	O

G	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
is	O
an	O
a	B
##cy	I
##l	I
g	I
##ly	I
##cine	I
and	O
a	O
bi	O
##le	O
acid	O
-	O
g	O
##ly	O
##cine	O
con	O
##ju	O
##gate	O
;	O
more	O
specifically	O
,	O
it	O
is	O
a	O
secondary	O
bi	O
##le	O
acid	O
produced	O
by	O
the	O
micro	O
##bial	O
flora	O
in	O
the	O
large	O
in	O
##test	O
##ine	O
.	O

The	O
boots	O
##tra	O
##pped	O
process	O
,	O
an	O
it	O
##erative	O
re	O
##sa	O
##mp	O
##ling	O
with	O
replacement	O
method	O
was	O
applied	O
using	O
a	O
randomly	O
selected	O
sample	O
set	O
containing	O
the	O
same	O
number	O
of	O
samples	O
as	O
the	O
original	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
defining	O
the	O
differences	O
between	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
intake	O
##s	O
,	O
i	O
.	O
e	O
.	O
,	O
70	O
from	O
the	O
41	O
##3	O
samples	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
.	O

Both	O
,	O
the	O
place	O
##nta	O
and	O
the	O
f	O
##etus	O
have	O
the	O
capacity	O
of	O
den	O
##ovo	O
ch	B
##ole	I
##ster	I
##ol	I
synthesis	O
.	O

A	O
clear	O
peak	O
corresponding	O
to	O
the	O
accurate	O
mass	O
of	O
the	O
anal	O
##yte	O
,	O
matching	O
the	O
retention	O
time	O
of	O
su	B
##lf	I
##oxide	I
standards	O
8	O
,	O
11	O
,	O
15	O
and	O
18	O
was	O
observed	O
in	O
all	O
samples	O
of	O
c	O
##re	O
##oso	O
##te	O
workers	O
’	O
urine	O
.	O

After	O
the	O
reconstruction	O
,	O
the	O
S	O
/	O
N	O
increases	O
to	O
2000	O
for	O
the	O
IS	O
and	O
36	O
for	O
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
##A	O
##de	O
,	O
respectively	O
.	O

Last	O
##ly	O
,	O
the	O
gut	O
micro	O
##bio	O
##ta	O
-	O
derived	O
in	B
##do	I
##le	I
-	I
3	I
-	I
prop	I
##ion	I
##ate	I
was	O
higher	O
in	O
G	O
##DM	O
cases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
the	O
lip	O
##id	O
super	O
-	O
pathway	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
s	O
##tero	O
##id	O
,	O
l	O
##ys	O
##o	O
-	O
plasma	O
##log	O
##en	O
,	O
and	O
medium	O
chain	O
fatty	O
acid	O
were	O
significantly	O
different	O
in	O
Re	O
##tt	O
syndrome	O
subjects	O
compared	O
to	O
the	O
controls	O
.	O

BC	O
,	O
breast	O
cancer	O
;	O
Le	O
##u	O
,	O
le	B
##uc	I
##ine	I
;	O
Ph	O
##e	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

Most	O
previous	O
research	O
on	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
,	O
either	O
in	O
muscle	O
or	O
in	O
the	O
brain	O
,	O
and	O
whether	O
as	O
an	O
energy	O
buffer	O
or	O
as	O
an	O
energy	O
shuttle	O
,	O
has	O
been	O
concerned	O
with	O
its	O
breakdown	O
and	O
re	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
it	O
has	O
been	O
ta	O
##ci	O
##tly	O
assumed	O
that	O
the	O
t	O
##C	O
##r	O
pool	O
stays	O
constant	O
.	O

Transport	O
of	O
glucose	S
across	O
the	O
plasma	O
membrane	O
of	O
ma	O
##mmal	O
##ian	O
cells	O
is	O
the	O
first	O
rate	O
-	O
limiting	O
step	O
for	O
glucose	S
metabolism	O
and	O
is	O
mediated	O
by	O
f	O
##ac	O
##ili	O
##tative	O
G	O
##L	O
##UT	O
proteins	O
.	O

Although	O
the	O
functional	O
significance	O
of	O
these	O
changes	O
in	O
inflammatory	O
bow	O
##el	O
disease	O
(	O
I	O
##B	O
##D	O
)	O
is	O
not	O
known	O
,	O
prior	O
studies	O
of	O
ID	O
##O	O
and	O
K	O
##Y	O
##NA	O
suggest	O
that	O
these	O
components	O
of	O
the	O
K	B
##P	I
ex	O
##ert	O
significant	O
inflammatory	O
and	O
ne	O
##uro	O
##log	O
##ic	O
effects	O
.	O

We	O
identified	O
situations	O
suggesting	O
an	O
over	O
##p	O
##rod	O
##uction	O
occurring	O
at	O
a	O
systemic	O
level	O
(	O
C	O
##it	O
)	O
and	O
situations	O
of	O
u	O
##rina	O
##ry	O
retention	O
(	O
AD	O
##MA	O
)	O
and	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
(	B
pro	B
##line	I
)	O
.	O

In	O
the	O
analysis	O
reported	O
here	O
,	O
the	O
DNA	O
h	B
##ydro	I
##ly	I
##sat	I
##e	I
was	O
re	O
##con	O
##stituted	O
in	O
3	O
μ	O
##L	O
and	O
a	O
3	O
μ	O
##L	O
injection	O
volume	O
was	O
set	O
in	O
the	O
method	O
.	O

AA	O
meta	O
##bol	O
##ites	O
,	O
namely	O
E	B
##ico	I
##san	I
##oids	I
,	O
are	O
a	O
family	O
of	O
lip	O
##id	O
media	O
##tors	O
generated	O
from	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
precursor	O
##s	O
,	O
involved	O
in	O
distinct	O
cellular	O
processes	O
.	O

Downs	O
##tre	O
##am	O
from	O
this	O
there	O
is	O
a	O
major	O
decline	O
in	O
the	O
production	O
of	O
the	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
γ	B
-	I
amino	I
##but	I
##yric	I
acid	I
(	O
GA	O
##BA	O
)	O
in	O
stable	O
MC	O
##I	O
subjects	O
but	O
this	O
does	O
not	O
de	O
##ter	O
##ior	O
##ate	O
further	O
in	O
AD	O
converting	O
subjects	O
,	O
indicating	O
that	O
GA	B
##BA	I
decline	O
could	O
be	O
an	O
early	O
contributor	O
to	O
loss	O
in	O
cognitive	O
function	O
.	O

The	O
l	B
##ino	I
##lea	I
##te	I
meta	O
##bol	O
##ites	O
13	B
-	I
H	I
##OD	I
##E	I
+	O
9	B
-	I
H	I
##OD	I
##E	I
were	O
also	O
significantly	O
higher	O
in	O
C	O
-	O
3	O
##N	O
subjects	O
.	O

Take	O
##n	O
together	O
,	O
the	O
meta	O
##bol	O
##ites	O
identified	O
so	O
far	O
were	O
reported	O
to	O
be	O
associated	O
with	O
type	O
2	O
diabetes	O
and	O
fast	O
##ing	O
plasma	O
glucose	S
in	O
numerous	O
studies	O
.	O

Go	O
to	O
:	O
Two	O
of	O
the	O
most	O
widely	O
measured	O
compounds	O
in	O
the	O
urine	O
of	O
people	O
who	O
use	O
tobacco	O
products	O
are	O
co	B
##tin	I
##ine	I
,	O
a	O
major	O
meta	O
##bol	O
##ite	O
of	O
the	O
add	O
##ict	O
##ive	O
constituent	O
ni	B
##cot	I
##ine	I
,	O
and	O
4	B
-	I
(	I
met	I
##hyl	I
##ni	I
##tro	I
##sa	I
##min	I
##o	I
)	I
-	I
1	I
-	I
(	I
3	I
-	I
p	I
##yr	I
##idy	I
##l	I
)	I
-	I
1	I
-	I
but	I
##ano	I
##l	I
(	O
N	O
##NA	O
##L	O
)	O
,	O
a	O
meta	O
##bol	O
##ite	O
of	O
the	O
powerful	O
lung	O
car	O
##cin	O
##ogen	O
4	B
-	I
(	I
met	I
##hyl	I
##ni	I
##tro	I
##sa	I
##min	I
##o	I
)	I
-	I
1	I
-	I
(	I
3	I
-	I
p	I
##yr	I
##idy	I
##l	I
)	I
-	I
1	I
-	I
but	I
##ano	I
##ne	I
(	O
N	O
##N	O
##K	O
)	O
.	O

Diet	O
was	O
based	O
on	O
diet	O
##ary	O
patterns	O
as	O
reported	O
by	O
Am	B
##bro	I
##sin	I
##i	I
et	O
al	O
.	O
and	O
included	O
three	O
variables	O
:	O
a	O
healthy	O
diet	O
##ary	O
pattern	O
,	O
a	O
western	O
diet	O
##ary	O
pattern	O
and	O
a	O
diet	O
##ary	O
mi	O
##s	O
##re	O
##port	O
##ing	O
variable	O
of	O
food	O
intake	O
to	O
account	O
for	O
over	O
,	O
under	O
,	O
or	O
plausible	O
diet	O
##ary	O
reporting	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
anal	O
##ys	O
##ed	O
by	O
the	O
UP	O
##LC	O
-	O
MS	O
/	O
MS	O
method	O
for	O
the	O
analysis	O
of	O
try	B
##pt	I
##op	I
##han	I
pathway	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
meta	O
##bol	O
##ites	O
were	O
excluded	O
from	O
further	O
analysis	O
if	O
the	O
number	O
of	O
missing	O
values	O
was	O
higher	O
than	O
20	O
%	O
in	O
each	O
group	O
of	O
samples	O
(	O
i	O
.	O
e	O
.	O
N	O
##AG	O
##−	O
,	O
CA	O
##G	O
+	O
,	O
P	O
##L	O
##GC	O
or	O
G	O
##C	O
)	O
.	O

Interest	O
##ingly	O
,	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
was	O
also	O
found	O
to	O
be	O
significantly	O
altered	O
by	O
Met	O
##ab	O
##o	O
##A	O
##nal	O
##ys	O
##t	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
##s	O
,	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
,	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
smart	O
is	O
##oto	O
##pe	O
tag	O
,	O
ch	B
##ola	I
##mine	I
,	O
car	B
##box	I
##yl	I
##ic	I
acids	I

C	B
-	I
g	I
##ly	I
##cos	I
##yl	I
##try	I
##pt	I
##op	I
##han	I
was	O
elevated	O
and	O
the	O
most	O
significantly	O
different	O
between	O
progress	O
##ors	O
and	O
non	O
-	O
progress	O
##ors	O
among	O
the	O
meta	O
##bol	O
##ites	O
shown	O
in	O
.	O

The	O
magnitude	O
of	O
the	O
effect	O
of	O
the	O
SL	O
##M	O
on	O
meta	O
##bol	O
##ite	O
levels	O
ranged	O
between	O
a	O
decrease	O
of	O
1	O
.	O
0	O
SD	O
(	B
g	B
##ly	I
##cer	I
##ol	I
)	O
to	O
an	O
increase	O
of	O
1	O
.	O
1	O
SD	O
(	B
le	B
##uc	I
##ine	I
)	O
.	O

In	O
addition	O
,	O
in	O
both	O
European	O
-	O
Americans	O
and	O
African	O
-	O
Americans	O
,	O
high	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
levels	O
were	O
related	O
to	O
high	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
and	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
levels	O
,	O
which	O
are	O
important	O
risk	O
factors	O
for	O
H	O
##F	O
(	O
all	O
P	O
<	O
0	O
.	O
00	O
##4	O
;	O
table	O
S	O
##4	O
)	O
.	O

Although	O
we	O
were	O
not	O
able	O
to	O
obtain	O
sufficient	O
previous	O
literature	O
about	O
N	B
-	I
non	I
##ano	I
##yl	I
-	I
g	I
##ly	I
##cine	I
and	O
S	B
-	I
p	I
##hen	I
##yl	I
-	I
d	I
-	I
c	I
##ys	I
##tein	I
##e	I
,	O
the	O
trends	O
in	O
the	O
up	O
##re	O
##gu	O
##lation	O
and	O
down	O
##re	O
##gu	O
##lation	O
of	O
their	O
expression	O
indirectly	O
indicate	O
metabolic	O
changes	O
in	O
g	B
##ly	I
##cine	I
and	O
c	B
##ys	I
##tein	I
##e	I
.	O

Besides	O
supporting	O
ATP	S
production	O
,	O
g	B
##lut	I
##amine	I
also	O
contributes	O
to	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
lip	O
##ids	O
and	O
nuclei	O
##c	O
acids	O
,	O
and	O
regulation	O
of	O
red	O
##ox	O
home	O
##ost	O
##asis	O
[	O
,	O
]	O
.	O

The	O
majority	O
of	O
significant	O
associations	O
of	O
VA	O
##T	O
with	O
the	O
plasma	O
meta	O
##bol	O
##ome	O
were	O
in	O
positive	O
direction	O
comprising	O
few	O
lip	O
##id	O
species	O
(	O
e	O
.	O
g	O
.	O
a	B
##rac	I
##hi	I
##don	I
##ate	I
,	O
palm	B
##itate	I
or	O
but	B
##yr	I
##yl	I
##car	I
##ntin	I
##e	I
)	O
,	O
members	O
of	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
;	O
e	O
.	O
g	O
.	O
v	B
##ali	I
##ne	I
or	O
le	B
##uc	I
##ine	I
)	O
and	O
related	O
intermediate	O
##s	O
(	O
e	O
.	O
g	O
.	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ob	I
##ut	I
##yra	I
##te	I
)	O
,	O
a	O
##romatic	O
amino	O
acids	O
like	O
t	B
##yr	I
##os	I
##ine	I
or	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
as	O
well	O
as	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##ama	I
##te	I
.	O

We	O
observed	O
that	O
meta	O
##bol	O
##ites	O
showing	O
lowest	O
C	O
##V	O
(	O
and	O
least	O
var	O
##iability	O
)	O
in	O
CR	O
##C	O
samples	O
were	O
ch	O
##ola	O
##n	O
-	O
24	O
-	O
o	O
##ic	O
acid	O
,	O
Val	O
,	O
amino	B
##mal	I
##onic	I
acid	I
,	O
3	B
-	I
p	I
##yr	I
##id	I
##ine	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
,	O
and	O
Al	O
##a	O
,	O
whereas	O
those	O
showing	O
higher	O
C	O
##V	O
(	O
and	O
higher	O
var	O
##iability	O
)	O
were	O
unknown	O
##s	O
(	O
five	O
of	O
them	O
)	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
.	O

Sign	O
##ificant	O
differences	O
by	O
disease	O
group	O
were	O
found	O
in	O
the	O
CS	O
##F	O
concentrations	O
of	O
several	O
meta	O
##bol	O
##ites	O
known	O
to	O
be	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
anti	O
##ox	O
##ida	O
##nt	O
g	B
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O
and	O
related	O
pathways	O
,	O
including	O
g	B
##ly	I
##cine	I
,	O
format	B
##e	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
,	O
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

It	O
is	O
noteworthy	O
that	O
among	O
meta	O
##bol	O
##ites	O
significantly	O
affected	O
in	O
both	O
R	O
##T	O
and	O
CC	O
##RT	O
groups	O
,	O
there	O
were	O
3	O
compounds	O
showing	O
apparent	O
“	O
delay	O
”	O
of	O
changes	O
in	O
R	O
##T	O
(	O
pattern	O
A	O
=	O
B	O
>	O
C	O
)	O
compared	O
to	O
CC	O
##RT	O
group	O
(	O
pattern	O
A	O
>	O
B	O
=	O
C	O
)	O
:	O
k	B
##yn	I
##uren	I
##ine	I
,	O
PC	B
a	I
##a	I
C	I
##38	I
:	I
3	I
,	O
and	O
PC	O
a	O
##a	O
40	O
:	O
5	O
.	O

The	O
s	O
##ti	O
##mulating	O
effect	O
of	O
lip	O
##ids	O
on	O
BC	O
tumor	O
growth	O
seems	O
also	O
be	O
sustained	O
by	O
the	O
observation	O
that	O
high	O
levels	O
of	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
at	O
the	O
time	O
of	O
diagnosis	O
may	O
have	O
a	O
negative	O
pro	O
##gno	O
##stic	O
value	O
.	O

Finally	O
,	O
con	O
##ju	O
##gated	O
serum	O
4	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
was	O
present	O
at	O
low	O
levels	O
in	O
the	O
serum	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
but	O
was	O
below	O
the	O
LL	O
##O	O
##Q	O
in	O
older	O
men	O
.	O

Dec	O
##rease	O
##s	O
in	O
mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
t	B
##ri	I
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
GM	B
##3	I
gang	I
##lio	I
##side	I
and	O
c	B
##era	I
##mi	I
##des	I
following	O
initiation	O
of	O
at	O
##az	O
##ana	O
##vir	O
/	O
r	O
or	O
z	O
##ido	O
##vu	O
##dine	O
/	O
a	O
##ba	O
##ca	O
##vir	O
compared	O
with	O
increases	O
in	O
the	O
e	O
##fa	O
##vir	O
##en	O
##z	O
arm	O
support	O
this	O
and	O
suggest	O
differential	O
effects	O
on	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
identify	O
novel	O
patterns	O
of	O
lip	O
##id	O
species	O
in	O
malaria	O
infected	O
patients	O
using	O
lip	O
##ido	O
##mic	O
##s	O
pro	O
##fi	O
##ling	O
,	O
to	O
enhance	O
diagnosis	O
of	O
malaria	O
and	O
to	O
evaluate	O
bio	O
##chemical	O
pathways	O
activated	S
during	O
parasite	O
infection	O
.	O

Health	O
##y	O
controls	O
did	O
not	O
have	O
chronic	O
liver	O
and	O
kidney	O
diseases	O
or	O
clinical	O
signs	O
of	O
acute	O
inflammation	O
;	O
they	O
all	O
had	O
a	O
normal	O
body	O
temperature	O
and	O
normal	O
levels	O
of	O
le	O
##uk	O
##oc	O
##yte	O
,	O
plate	O
##let	O
count	O
,	O
hem	O
##og	O
##lo	O
##bin	O
,	O
bi	B
##li	I
##ru	I
##bin	I
,	O
u	B
##rea	I
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Following	O
confirmation	O
of	O
the	O
efficiency	O
of	O
the	O
na	O
##no	O
##ele	O
##ct	O
##ros	O
##pra	O
##y	O
L	O
##C	O
-	O
EC	O
-	O
array	O
-	O
MS	O
platform	O
,	O
we	O
examined	O
next	O
its	O
practical	O
utility	O
toward	O
the	O
identification	O
of	O
unknown	O
meta	O
##bol	O
##ites	O
of	O
the	O
pro	O
-	O
drug	O
sodium	B
p	I
##hen	I
##yl	I
##but	I
##yra	I
##te	I
(	O
P	O
##B	O
)	O
in	O
patient	O
serum	O
.	O

z	O
range	O
of	O
700	O
–	O
91	O
##0	O
,	O
which	O
covered	O
the	O
intact	O
mass	O
range	O
of	O
almost	O
all	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
P	O
##L	O
##s	O
)	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
,	O
which	O
is	O
a	O
class	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
SP	O
##s	O
)	O
.	O

4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
h	I
##ydro	I
##xy	I
-	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
ben	I
##zoic	I
acid	I
(	O
BA	O
-	O
(	O
OH	O
)	O
_	O
2	O
)	O
was	O
generated	O
by	O
heating	O
13	O
.	O
2	O

I	O
##ida	O
et	O
al	O
.	O
reported	O
that	O
t	O
##rich	O
##oki	O
##ndi	O
##ns	O
induced	O
C	O
##a	O
_	O
2	O
+	O
-	O
dependent	O
cat	B
##ech	I
##ola	I
##mine	I
secret	O
##ion	O
from	O
b	O
##ov	O
##ine	O
ad	O
##rena	O
##l	O
me	O
##du	O
##llar	O
##y	O
ch	B
##roma	I
##ffin	I
cells	O
at	O
a	O
concentration	O
of	O
10	O
μ	O
##M	O
.	O
To	O
our	O
knowledge	O
,	O
other	O
activities	O
of	O
t	O
##rich	O
##oki	O
##ndi	O
##ns	O
have	O
not	O
been	O
reported	O
.	O

A	O
receiver	O
operating	O
characteristic	O
(	O
R	O
##OC	O
)	O
curve	O
analysis	O
indicated	O
that	O
ca	B
##da	I
##ver	I
##ine	I
(	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
,	O
0	O
.	O
76	O
##4	O
;	O
p	O
=	O
5	O
.	O
45	O
##12	O
##E	O
-	O
5	O
)	O
and	O
put	B
##res	I
##cine	I
(	O
AU	O
##C	O
,	O
0	O
.	O
67	O
##2	O
;	O
p	O
=	O
0	O
.	O
01	O
##5	O
##44	O
##9	O
)	O
were	O
significantly	O
associated	O
with	O
CR	O
##C	O
samples	O
(	O
Figure	O
D	O
)	O
.	O

(	O
C	O
)	O
MR	O
spectrum	O
obtained	O
from	O
area	O
of	O
imaging	O
abnormal	O
##ity	O
in	O
the	O
right	O
peripheral	O
zone	O
demonstrates	O
elevated	O
ch	B
##olin	I
##e	I
and	O
reduced	O
c	B
##it	I
##rate	I
,	O
a	O
pattern	O
consistent	O
with	O
definite	O
cancer	O
.	O

A	O
##bbe	O
##viation	O
##s	O
:	O
NO	O
=	O
ni	O
##tric	O
oxide	O
,	O
AD	O
##MA	O
=	O
as	O
##ym	O
##metric	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
a	O
)	O
Le	B
##uc	I
##ine	I
,	O
(	O
b	O
)	O
is	B
##ole	I
##uc	I
##ine	I
,	O
(	O
c	O
)	O
v	B
##ali	I
##ne	I
.	O

The	O
ions	O
arising	O
from	O
loss	O
of	O
trim	B
##eth	I
##yla	I
##mine	I
[	O
M	O
-	O
59	O
]	O
,	O
et	B
##hyl	I
##ene	I
phosphate	I
[	O
M	O
-	O
183	O
]	O
and	O
lit	B
##hium	I
et	I
##hyl	I
##ene	I
phosphate	I
[	O
M	O
-	O
189	O
]	O
were	O
common	O
fragments	O
for	O
C	O
##ID	O
s	O
##pect	O
##ra	O
of	O
PC	O
##s	O
and	O
SM	O
##s	O
.	O

Am	B
##mon	I
##ium	I
phosphate	I
at	O
1	O
and	O
2	O
m	O
##M	O
and	O
am	B
##mon	I
##ium	I
hydrogen	I
carbon	I
##ate	I
at	O
10	O
and	O
20	O
m	O
##M	O
were	O
compared	O
.	O

G	O
##lu	O
:	O
G	B
##lut	I
##ami	I
##c	I
acid	I
;	O
Met	O
:	O
Met	B
##hi	I
##oni	I
##ne	I
;	O
γ	B
-	I
G	I
##lu	I
-	I
G	I
##ly	I
-	I
G	I
##ly	I
:	O
γ	B
-	I
g	I
##lut	I
##am	I
##yl	I
-	I
g	I
##ly	I
##cine	I
-	I
g	I
##ly	I
##cine	I
;	O
M	O
##LR	O
:	O
Multiple	O
log	O
##istic	O
re	O
##gression	O
;	O
HC	O
##C	O
-	O
B	O
:	O
He	O
##pa	O
##titis	O
B	O
virus	O
-	O
related	O
HC	O
##C	O
;	O
HC	O
##C	O
-	O
C	O
:	O
He	O
##pa	O
##titis	O
C	O
virus	O
-	O
related	O
HC	O
##C	O
;	O
HC	O
##C	O
:	O
He	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
.	O

Pro	B
##sta	I
##g	I
##land	I
##ins	I
are	O
-	O
along	O
with	O
l	O
##ys	O
##o	O
##PC	O
##s	O
-	O
by	O
##p	O
##rod	O
##uc	O
##ts	O
of	O
PC	O
h	O
##ydro	O
##lysis	O
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A2	O
.	O

A	O
separate	O
study	O
also	O
using	O
G	O
##C	O
-	O
MS	O
showed	O
that	O
in	O
##cu	O
##bation	O
of	O
E	O
##D	O
##TA	O
plasma	O
samples	O
at	O
37	O
°C	O
resulted	O
in	O
decreasing	O
glucose	S
levels	O
,	O
consistent	O
with	O
ongoing	O
cellular	O
metabolism	O
.	O

The	O
mean	O
PC	O
-	O
59	O
##4	O
concentration	O
among	O
the	O
1000	O
reference	O
subjects	O
was	O
2	O
.	O
23	O
±	O
##0	O
.	O
05	O
u	O
##g	O
/	O
m	O
##l	O
ch	B
##olic	I
acid	I
equivalent	O
##s	O
(	O
CA	O
##E	O
)	O
,	O
and	O
negatively	O
correlated	O
with	O
age	O
(	O
Figure	O
,	O
re	O
##gression	O
multiple	O
R	O
=	O
0	O
.	O
29	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

Quality	O
control	O
(	O
Q	O
##C	O
)	O
samples	O
were	O
also	O
prepared	O
in	O
the	O
same	O
way	O
(	O
50	O
.	O
0	O
,	O
250	O
.	O
0	O
,	O
and	O
125	O
##0	O
ng	O
/	O
m	O
##L	O
for	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
;	O
20	O
.	O
0	O
,	O
100	O
.	O
0	O
,	O
and	O
500	O
.	O
0	O
ng	O
/	O
m	O
##L	O
for	O
do	O
##ce	O
##ta	O
##xe	O
##l	O
and	O
S	O
##N	O
-	O
38	O
;	O
200	O
.	O
0	O
,	O
1000	O
.	O
0	O
,	O
and	O
5000	O
.	O
0	O
ng	O
/	O
m	O
##L	O
for	O
v	O
##ino	O
##rel	O
##bine	O
and	O
p	O
##em	O
##et	O
##re	O
##xed	O
;	O
50	O
.	O
0	O
,	O
500	O
.	O
0	O
,	O
5000	O
.	O
0	O
ng	O
/	O
m	O
##L	O
for	O
v	B
##in	I
##blast	I
##ine	I
and	O
i	O
##rino	O
##teca	O
##n	O
;	O
and	O
5	O
.	O
0	O
,	O
50	O
.	O
0	O
,	O
and	O
500	O
.	O
0	O
ng	O
/	O
m	O
##L	O
for	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
and	O
if	B
##os	I
##fa	I
##mi	I
##de	I
;	O
100	O
.	O
0	O
,	O
500	O
.	O
0	O
,	O
and	O
250	O
##0	O
.	O
0	O
ng	O
/	O
m	O
##L	O
for	O
car	B
##bo	I
##p	I
##lat	I
##in	I
,	O
et	B
##op	I
##os	I
##ide	I
,	O
and	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
)	O
.	O

Mobile	O
phase	O
A	O
(	O
60	O
:	O
40	O
AC	O
##N	O
:	O
water	O
+	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	O
##e	O
+	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
)	O
was	O
prepared	O
by	O
mixing	O
600	O
m	O
##L	O
AC	O
##N	O
,	O
400	O
m	O
##L	O
water	O
,	O
1	O
m	O
##L	O
form	B
##ic	I
acid	I
and	O
630	O
mg	O
of	O
am	B
##mon	I
##ium	I
format	I
##e	I
.	O

Further	O
,	O
the	O
lower	O
levels	O
of	O
c	B
##rea	I
##tine	I
in	O
serum	O
indicates	O
its	O
possible	O
conversion	O
to	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
by	O
c	B
##rea	I
##tine	I
kinase	O
##s	O
that	O
serve	O
as	O
an	O
energy	O
reserve	O
.	O

Ace	B
##to	I
##ace	I
##tic	I
acid	I
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
can	O
be	O
used	O
by	O
cells	O
as	O
an	O
energy	O
source	O
(	O
i	O
.	O
e	O
.	O
,	O
converted	O
to	O
ace	O
##ty	O
##l	O
co	O
##en	O
##zy	O
##me	O
A	O
to	O
participate	O
in	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
in	O
mit	O
##och	O
##ond	O
##ria	O
)	O
,	O
and	O
ace	B
##tone	I
is	O
eliminated	O
by	O
ex	O
##cre	O
##tion	O
.	O

The	O
BC	O
##AA	O
associated	O
cat	O
##ab	O
##oli	O
##te	O
2	B
-	I
met	I
##hyl	I
##but	I
##ryl	I
##gly	I
##cine	I
was	O
lower	O
in	O
co	O
##hor	O
##t	O
1	O
BC	O
##a	O
urine	O
##s	O
relative	O
to	O
all	O
control	O
groups	O
.	O

Co	O
##mp	O
##uted	O
to	O
##mo	O
##graphy	O
(	O
CT	O
)	O
was	O
performed	O
by	O
certified	O
technicians	O
between	O
November	O
2000	O
and	O
March	O
2003	O
,	O
11	O
–	O
20	O
years	O
after	O
enrollment	O
into	O
the	O
DC	O
##CT	O
and	O
8	O
–	O
15	O
years	O
after	O
collection	O
of	O
blood	O
for	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
measurement	O
(	O
median	O
10	O
years	O
)	O
,	O
in	O
1	O
,	O
205	O
(	O
86	O
%	O
)	O
of	O
the	O
surviving	O
1	O
,	O
404	O
participants	O
with	O
specific	O
patient	O
consent	O
.	O

Moreover	O
,	O
p	B
##oly	I
##amine	I
##s	I
,	O
being	O
also	O
products	O
of	O
bacterial	O
metabolism	O
,	O
can	O
be	O
directly	O
absorbed	O
from	O
the	O
gut	O
l	O
##ume	O
##n	O
(	O
reviewed	O
in	O
)	O
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
was	O
set	O
at	O
3	O
.	O
0	O
k	B
##V	I
in	O
positive	O
mode	O
and	O
2	O
.	O
8	O
in	O
negative	O
mode	O
(	O
another	O
parameters	O
were	O
same	O
in	O
both	O
the	O
modes	O
)	O
,	O
sampling	O
cone	O
voltage	O
was	O
30	O
V	O
,	O
source	O
temperature	O
was	O
120	O
##°	O
C	O
and	O
des	O
##ola	O
##tion	O
gas	O
flow	O
was	O
750	O
L	O
h	O
_	O
−	O
##1	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
and	O
a	B
##rg	I
##ini	I
##ne	I
increased	O
significantly	O
in	O
HD	O
compared	O
to	O
control	O
sheep	O
.	O

The	O
four	O
full	O
length	O
gene	O
lo	O
##ci	O
corresponding	O
to	O
the	O
enzymes	O
of	O
the	O
P	O
##las	O
##mo	O
##dium	O
N	O
##AD	O
_	O
+	O
salvage	O
pathway	O
(	O
p	O
##f	O
##13	O
_	O
01	O
##5	O
##9	O
,	O
p	O
##ff	O
##14	O
##10	O
##c	O
,	O
p	O
##fi	O
##13	O
##10	O
##w	O
,	O
p	O
##f	O
##c	O
##0	O
##9	O
##10	O
##c	O
)	O
were	O
clone	O
##d	O
into	O
the	O
p	B
##DC	I
##2	I
-	I
CA	I
##M	I
-	I
CR	I
##T	I
-	I
G	I
##FP	I
p	O
##las	O
##mi	O
##d	O
to	O
create	O
C	O
-	O
terminal	O
G	O
##FP	O
fusion	O
##s	O
under	O
the	O
control	O
of	O
the	O
P	O
.	O
f	O
##al	O
##ci	O
##par	O
##um	O
calm	O
##od	O
##ulin	O
promoter	O
(	O
p	O
##f	O
##14	O
_	O
03	O
##23	O
)	O
using	O
the	O
F	O
and	O
R	O
p	O
##DC	O
##2	O
(	O
Table	O
S	O
##1	O
in	O
)	O
.	O

Some	O
of	O
the	O
previous	O
studies	O
based	O
on	O
the	O
N	O
##MR	O
or	O
G	O
##C	O
-	O
MS	O
analytical	O
platforms	O
identified	O
no	O
difference	O
between	O
I	O
##B	O
##D	O
(	O
treated	O
with	O
th	B
##io	I
##pur	I
##ines	I
and	O
/	O
or	O
with	O
other	O
drugs	O
)	O
and	O
healthy	O
control	O
in	O
amino	O
acids	O
u	O
##rina	O
##ry	O
levels	O
[	O
,	O
]	O
.	O

A	O
different	O
meta	O
##bol	O
##ite	O
profile	O
,	O
dominated	O
by	O
changes	O
in	O
l	B
##ys	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
distinguished	O
between	O
improvement	O
in	O
UC	O
##EI	O
##S	O
[	O
decrease	O
≥	O
1	O
]	O
and	O
worse	O
##ning	O
[	O
increase	O
≥	O
1	O
]	O
over	O
6	O
months	O
with	O
an	O
accuracy	O
of	O
74	O
±	O
4	O
%	O
.	O

However	O
,	O
the	O
biology	O
of	O
car	B
##ni	I
##tine	I
in	O
M	O
##M	O
may	O
be	O
still	O
more	O
complex	O
because	O
of	O
several	O
reports	O
that	O
the	O
meta	O
##bol	O
##ite	O
also	O
positively	O
regulate	O
##s	O
o	O
##ste	O
##ob	O
##last	O
activity	O
and	O
therefore	O
in	O
some	O
patients	O
may	O
have	O
beneficial	O
re	O
##tar	O
##dation	O
effects	O
in	O
M	O
##M	O
associated	O
o	O
##ste	O
##oly	O
##tic	O
disease	O
–	O
.	O

More	O
specifically	O
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
N	O
##AG	O
##s	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
glucose	S
seem	O
related	O
with	O
stage	O
II	O
and	O
IV	O
.	O

Hence	O
the	O
ratio	O
of	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
and	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mi	I
##dine	I
in	O
urine	O
from	O
liver	O
cancer	O
patients	O
was	O
marked	O
##ly	O
higher	O
than	O
that	O
from	O
lung	O
cancer	O
patients	O
.	O

Analysis	O
by	O
the	O
independent	O
Mann	O
-	O
Whitney	O
test	O
showed	O
that	O
the	O
level	O
of	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
was	O
significantly	O
lower	O
and	O
that	O
the	O
level	O
of	O
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
was	O
higher	O
in	O
the	O
second	O
sampling	O
compared	O
to	O
the	O
first	O
sampling	O
(	O
p	O
=	O
0	O
.	O
03	O
##4	O
and	O
0	O
.	O
01	O
##3	O
,	O
respectively	O
,	O
)	O
.	O

Results	O
from	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
showed	O
significantly	O
elevated	O
glucose	S
concentrations	O
in	O
CS	O
##F	O
samples	O
from	O
drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
with	O
first	O
-	O
onset	O
s	O
##chi	O
##zophrenia	O
,	O
as	O
compared	O
to	O
the	O
demographic	O
##ally	O
matched	O
control	O
group	O
,	O
with	O
a	O
relative	O
increase	O
in	O
concentration	O
of	O
6	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
04	O
;	O
calculated	O
from	O
a	O
distinct	O
resonance	O
signal	O
at	O
3	O
.	O
68	O
–	O
3	O
.	O
72	O
pp	O
##m	O
)	O
.	O

G	B
##ly	I
##cine	I
,	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
(	O
2	O
/	O
53	O
)	O
;	O
sperm	B
##id	I
##ine	I
and	O
sperm	B
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
:	O
L	B
-	I
met	I
##hi	I
##oni	I
##ne	I
(	O
1	O
/	O
18	O
)	O
;	O
rib	B
##of	I
##lav	I
##in	I
metabolism	O
:	O
H	B
##ydro	I
##quin	I
##one	I
(	O
1	O
/	O
20	O
)	O
;	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
21	O
)	O
;	O
beta	B
##ine	I
metabolism	O
:	O
L	B
-	I
met	I
##hi	I
##oni	I
##ne	I
(	O
1	O
/	O
21	O
)	O
;	O
car	B
##ni	I
##tine	I
synthesis	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
22	O
)	O
;	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
:	O
G	B
##ly	I
##cine	I
,	O
ch	B
##olic	I
acid	I
(	O
2	O
/	O
65	O
)	O
;	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
:	O
H	B
##ydro	I
##quin	I
##one	I
(	O
1	O
/	O
25	O
)	O
;	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
:	O
p	B
-	I
H	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
,	O
amino	B
##mal	I
##ate	I
(	O
2	O
/	O
72	O
)	O
;	O
u	B
##rea	I
cycle	O
:	O

d	B
##17	I
:	I
0	I
and	O
d	B
##17	I
:	I
1	I
were	O
detected	O
as	O
well	O
,	O
generally	O
as	O
very	O
minor	O
amounts	O
.	O

Our	O
samples	O
were	O
q	O
##uant	O
##ified	O
,	O
using	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
to	O
identify	O
the	O
major	O
species	O
present	O
in	O
different	O
classes	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O
,	O
,	O
and	O
shows	O
all	O
major	O
species	O
of	O
Ce	B
##r	I
,	O
M	O
##HC	O
,	O
and	O
SM	O
respectively	O
.	O

To	O
achieve	O
this	O
goal	O
,	O
we	O
first	O
used	O
a	O
liquid	O
ch	O
##roma	O
##tography	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
)	O
-	O
based	O
meta	O
##bol	O
##omi	O
##c	O
method	O
(	O
p	O
##oly	O
##sul	O
##fi	O
##dom	O
##ics	O
)	O
to	O
profile	O
low	O
-	O
molecular	O
weight	O
reactive	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
and	O
their	O
related	O
molecular	O
species	O
in	O
the	O
a	O
##que	O
##ous	O
humor	O
and	O
v	O
##it	O
##re	O
##ous	O
of	O
D	O
##M	O
patients	O
with	O
DR	O
,	O
and	O
then	O
examined	O
the	O
effect	O
of	O
the	O
reactive	O
su	B
##lf	I
##ide	I
species	O
we	O
identified	O
on	O
the	O
via	O
##bility	O
of	O
culture	O
##d	O
re	B
##tina	I
##l	I
cells	O
under	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Ali	O
##q	O
##uo	O
##ts	O
of	O
570	O
μ	O
##L	O
of	O
urine	O
were	O
transferred	O
into	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
E	O
##ppe	O
##ndo	O
##rf	O
tubes	O
and	O
30	O
μ	O
##L	O
of	O
K	B
##F	I
solution	O
was	O
added	O
,	O
and	O
samples	O
were	O
mixed	O
again	O
creating	O
ins	O
##ol	O
##ub	O
##le	O
in	O
water	O
M	O
##g	O
##F	O
_	O
2	O
and	O
C	O
##a	O
##F	O
_	O
2	O
salts	O
.	O

Recent	O
metabolic	O
profiles	O
of	O
o	O
##var	O
##ian	O
c	O
##ys	O
##t	O
fluid	O
samples	O
from	O
ben	O
##ign	O
,	O
border	O
##line	O
,	O
and	O
ma	O
##li	O
##gnant	O
o	O
##var	O
##ian	O
tumors	O
showed	O
that	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
was	O
present	O
only	O
in	O
a	O
sub	O
-	O
co	O
##hor	O
##t	O
of	O
ma	O
##li	O
##gnant	O
tumors	O
.	O

The	O
secondary	O
structure	O
analysis	O
of	O
the	O
Atlantic	S
co	O
##d	O
album	O
##in	O
-	O
like	O
protein	O
(	O
GE	O
##NS	O
##CA	O
##N	O
##00	O
##00	O
##00	O
##70	O
##26	O
##4	O
)	O
sequence	O
was	O
done	O
by	O
Pre	O
##dict	O
##P	O
##rote	O
##in	O
(	O
R	O
##ost	O
##la	O
##b	O
,	O
available	O
at	O
https	O
:	O
/	O
/	O
www	O
.	O
predict	O
##p	O
##rote	O
##in	O
.	O
org	O
/	O
)	O
.	O

Lac	B
##tate	I
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
with	O
high	O
tissue	O
expression	O
of	O
IP	O
_	O
3	O
R	O
when	O
compared	O
to	O
patients	O
with	O
low	O
tissue	O
expression	O
of	O
IP	O
_	O
3	O
R	O
and	O
healthy	O
control	O
.	O

In	O
contrast	O
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
glucose	S
and	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
were	O
significantly	O
increased	O
in	O
plasma	O
from	O
individuals	O
with	O
high	O
UC	O
##EI	O
##S	O
compared	O
to	O
those	O
with	O
low	O
UC	O
##EI	O
##S	O
.	O

Di	B
##met	I
##hyl	I
##gly	I
##cine	I
,	O
u	B
##bi	I
##quin	I
##one	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
P	O
##Es	O
,	O
PC	O
##s	O
,	O
CE	O
##R	O
##s	O
,	O
and	O
others	O
acids	O
were	O
found	O
only	O
in	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
.	O

Met	B
##form	I
##in	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
salt	O
was	O
added	O
to	O
5	O
m	O
##L	O
of	O
Mill	O
##i	O
-	O
Q	O
water	O
at	O
4	O
##°	O
##C	O
to	O
a	O
final	O
concentration	O
of	O
200	O
m	O
##M	O
.	O
So	B
##dium	I
h	I
##ydro	I
##xi	I
##de	I
was	O
added	O
to	O
the	O
solution	O
to	O
a	O
final	O
concentration	O
of	O
200	O
m	O
##M	O
.	O
Subsequently	O
,	O
1	O
.	O
7	O
m	O
##L	O
of	O
40	O
%	O
MG	O
solution	O
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
was	O
added	O
to	O
the	O
met	B
##form	I
##in	I
solution	O
and	O
stirred	O
at	O
4	O
##°	O
##C	O
for	O
1	O
h	O
followed	O
by	O
4	O
h	O
at	O
20	O
##°	O
##C	O
.	O

(	O
N	O
##D	O
##tam	O
)	O
and	O
N	B
-	I
de	I
##di	I
##met	I
##hyl	I
##tam	I
##ox	I
##ife	I
##n	I

In	O
##verse	O
association	O
of	O
B	O
##MI	O
with	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
N	B
-	I
met	I
##hyl	I
ni	I
##cot	I
##inate	I
(	O
N	O
##M	O
##NA	O
)	O
(	O
r	O
=	O
−	O
##0	O
.	O
16	O
,	O
P	O
=	O
9	O
.	O
04	O
×	O
10	O
_	O
−	O
##13	O
)	O
is	O
consistent	O
with	O
previous	O
observations	O
in	O
m	O
##or	O
##bid	O
##ly	O
o	O
##bes	O
##e	O
individuals	O
.	O

As	B
##par	I
##tic	I
acid	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lli	I
##c	I
acid	I
(	O
3	O
##HA	O
##A	O
,	O
a	O
try	B
##pt	I
##op	I
##han	I
degradation	O
pathway	O
intermediate	O
)	O
were	O
up	O
-	O
regulated	O
in	O
D	O
##OC	O
##K	O
##8	O
deficiency	O
,	O
whereas	O
h	B
##y	I
##pot	I
##au	I
##rine	I
,	O
le	B
##uc	I
##yl	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##ly	I
##cy	I
##l	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
g	B
##uan	I
##os	I
##ine	I
were	O
down	O
-	O
regulated	O
.	O

Therefore	O
,	O
a	O
sensitive	O
L	O
##C	O
/	O
MS	O
/	O
MS	O
analytical	O
method	O
was	O
developed	O
to	O
identify	O
and	O
q	O
##uant	O
##ify	O
human	O
metabolism	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

To	O
gain	O
insight	O
into	O
the	O
path	O
##ological	O
role	O
of	O
increased	O
G	O
##SS	O
##S	O
##G	O
in	O
the	O
a	O
##que	O
##ous	O
humor	O
of	O
patients	O
with	O
DR	O
,	O
we	O
next	O
investigated	O
the	O
effect	O
of	O
various	O
g	B
##lut	I
##ath	I
##ione	I
p	I
##oly	I
##sul	I
##fi	I
##des	I
(	O
G	O
##S	O
(	O
S	O
)	O
_	O
n	O
S	O
##G	O
)	O
on	O
the	O
survival	O
of	O
re	B
##tina	I
##l	I
cells	O
(	O
specifically	O
,	O
an	O
immortal	O
##ized	O
line	O
of	O
R	O
##GC	O
-	O
5	O
cells	O
)	O
under	O
conditions	O
of	O
high	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
v	O
##it	O
##ro	O
.	O

Red	O
c	O
##lover	O
extract	O
(	O
RC	O
##E	O
,	O
10	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
and	O
is	B
##of	I
##lav	I
##ones	I
had	O
no	O
effect	O
on	O
est	B
##rogen	I
metabolism	O
in	O
MC	O
##F	O
-	O
10	O
##A	O
cells	O
.	O

In	O
agreement	O
with	O
these	O
results	O
,	O
in	O
the	O
present	O
study	O
no	O
associations	O
between	O
smoking	O
history	O
and	O
the	O
C	B
##18	I
:	I
2	I
lip	O
##id	O
level	O
were	O
observed	O
in	O
any	O
of	O
plasma	O
samples	O
.	O

Fourth	O
,	O
the	O
low	O
replication	O
rate	O
for	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
was	O
partially	O
due	O
to	O
the	O
fact	O
that	O
many	O
of	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
q	O
##uant	O
##ified	O
in	O
the	O
F	O
##HS	O
via	O
liquid	O
ch	O
##roma	O
##tography	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
were	O
not	O
measured	O
in	O
the	O
replication	O
co	O
##hor	O
##ts	O
,	O
which	O
used	O
different	O
lip	O
##ido	O
##mic	O
platforms	O
.	O

The	O
higher	O
up	O
##take	O
of	O
g	B
##lu	I
##co	I
##genic	I
AA	O
##s	O
might	O
be	O
one	O
reason	O
for	O
the	O
detected	O
decreasing	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
al	B
##ani	I
##ne	I
and	O
g	B
##ly	I
##cine	I
with	O
increasing	O
F	O
##T	O
##4	O
.	O

We	O
also	O
examined	O
the	O
S	O
##Y	O
##NE	O
##2	O
lo	O
##cus	O
because	O
of	O
its	O
relation	O
to	O
S	O
##GP	O
##P	O
##1	O
(	O
s	O
##phi	O
##ngo	O
##sin	O
##e	O
‐	O
1	O
‐	O
phosphate	O
p	O
##hos	O
##pha	O
##tase	O
1	O
)	O
activity	O
,	O
a	O
key	O
player	O
in	O
the	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
r	O
##he	O
##ost	O
##at	O
that	O
govern	O
##s	O
the	O
interchange	O
between	O
pro	O
-	O
a	O
##pop	O
##to	O
##tic	O
c	B
##era	I
##mi	I
##des	I
and	O
S	O
##1	O
##P	O
,	O
a	O
well	O
-	O
established	O
l	O
##igan	O
##d	O
in	O
survival	O
signaling	O
[	O
]	O
.	O

In	O
addition	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
increased	O
levels	O
of	O
c	O
##yt	O
##och	O
##rome	O
P	O
(	O
C	O
##YP	O
)	O
450	O
enzymes	O
resulting	O
in	O
altered	O
est	B
##rogen	I
metabolism	O
has	O
also	O
been	O
reported	O
as	O
an	O
additional	O
mechanism	O
for	O
production	O
of	O
organic	O
meta	O
##bol	O
##ites	O
in	O
breast	O
diseases	O
.	O

Both	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
are	O
rapidly	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
after	O
oral	O
ing	O
##est	O
##ion	O
,	O
and	O
the	O
elimination	O
half	O
-	O
lives	O
are	O
approximately	O
4	O
hours	O
and	O
2	O
hours	O
,	O
respectively	O
.	O

However	O
,	O
direct	O
comparison	O
of	O
a	B
##ryl	I
##amine	I
add	O
##uc	O
##t	O
formation	O
with	O
H	O
##b	O
and	O
PP	O
has	O
been	O
determined	O
only	O
in	O
a	O
few	O
studies	O
.	O

Other	O
notable	O
changes	O
included	O
significantly	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
higher	O
plasma	O
concentrations	O
of	O
k	B
##yn	I
##uren	I
##ine	I
,	O
two	O
meta	O
##bol	O
##ites	O
which	O
are	O
part	O
of	O
the	O
im	O
##mu	O
##nor	O
##eg	O
##ulatory	O
enzyme	O
ID	O
##O	O
pathway	O
.	O

Since	O
the	O
similar	O
R	O
##OC	O
curve	O
analysis	O
results	O
were	O
gotten	O
for	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
and	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
individually	O
for	O
separate	O
##ing	O
B	O
##D	O
##TT	O
from	O
Stone	O
,	O
B	O
##D	O
##TT	O
and	O
E	O
##HC	O
##C	O
,	O
B	O
##D	O
##TT	O
and	O
Cy	O
##st	O
,	O
we	O
performed	O
another	O
R	O
##OC	O
curve	O
analysis	O
to	O
examine	O
whether	O
the	O
combination	O
of	O
the	O
two	O
meta	O
##bol	O
##ites	O
can	O
lead	O
to	O
better	O
outcome	O
.	O

C	O
##a	O
##P	O
,	O
pro	O
##state	O
cancer	O
;	O
C	O
##it	O
,	O
c	B
##it	I
##rate	I
;	O
Fr	B
##u	I
,	O
f	B
##ru	I
##ct	I
##ose	I
;	O
Li	O
##p	O
,	O
lip	O
##ids	O
/	O
lip	O
##op	O
##rote	O
##ins	O
;	O
PC	O
,	O
principal	O
component	O
;	O
Ser	O
,	O
se	B
##rine	I
;	O
S	O
##pe	O
,	O
sperm	B
##ine	I
.	O

The	O
reduction	O
in	O
circulating	O
LP	O
##C	O
may	O
simply	O
reflect	O
their	O
enhanced	O
conversion	O
to	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
which	O
is	O
known	O
to	O
induce	O
a	O
multitude	O
of	O
cellular	O
responses	O
through	O
its	O
action	O
on	O
im	O
##mu	O
##nological	O
relevant	O
cells	O
.	O

For	O
the	O
quantitative	O
measurement	O
of	O
9	O
-	O
H	O
##SA	O
-	O
containing	O
FA	O
##HF	O
##A	O
species	O
(	O
especially	O
those	O
containing	O
palm	B
##itic	I
,	O
palm	B
##ito	I
##le	I
##ic	I
,	O
s	O
##te	O
##ari	O
##c	O
,	O
o	O
##le	O
##ic	O
and	O
l	B
##ino	I
##le	I
##ic	I
acids	O
)	O
,	O
the	O
instrument	O
was	O
set	O
to	O
multiple	O
reaction	O
monitoring	O
mode	O
,	O
selecting	O
three	O
transitions	O
for	O
each	O
FA	O
##HF	O
##A	O
:	O
parent	O
ion	O
→	O
29	O
##9	O
.	O
3	O
(	O
9	O
-	O
H	O
##SA	O
)	O
,	O
parent	O
ion	O
→	O
281	O
.	O
3	O
(	O
9	O
-	O
H	O
##SA	O
as	O
water	O
loss	O
)	O
and	O
parent	O
ion	O
→	O
m	O
/	O
z	O
of	O
est	O
##eri	O
##fied	O
fatty	O
acid	O
as	O
car	B
##box	I
##yla	I
##te	I
ion	O
.	O

Due	O
to	O
the	O
degree	O
of	O
noise	O
present	O
,	O
the	O
a	O
##romatic	O
region	O
was	O
excluded	O
and	O
only	O
the	O
al	B
##ip	I
##hat	I
##ic	I
spectral	O
region	O
anal	O
##ys	O
##ed	O
.	O

In	O
this	O
project	O
the	O
arithmetic	O
mean	O
u	O
##rina	O
##ry	O
co	B
##tin	I
##ine	I
level	O
is	O
3	O
.	O
33	O
##±	O
##6	O
.	O
39	O
μ	O
##g	O
/	O
L	O
and	O
the	O
geometric	O
mean	O
and	O
standard	O
de	O
##viation	O
is	O
0	O
.	O
88	O
(	O
5	O
.	O
28	O
)	O
μ	O
##g	O
/	O
L	O
,	O
which	O
shows	O
that	O
our	O
non	O
-	O
smoking	O
subjects	O
are	O
towards	O
the	O
lower	O
end	O
of	O
the	O
range	O
of	O
ET	O
##S	O
exposure	O
.	O

Organ	B
##op	I
##hos	I
##phate	I
p	O
##est	O
##icides	O
are	O
inhibitor	O
##s	O
of	O
ace	O
##ty	O
##l	O
##cho	O
##lines	O
##tera	O
##se	O
.	O

_	O
,	O
All	O
ass	O
##ays	O
measured	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
and	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
2	O
,	O
ca	O
##li	O
##bra	O
##ted	O
to	O
standards	O
provided	O
by	O
the	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology	O
,	O
concurrently	O
with	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
.	O

From	O
the	O
S	O
##Q	O
##C	O
well	O
,	O
a	O
series	O
of	O
di	O
##lution	O
quality	O
controls	O
(	O
d	O
##Q	O
##C	O
)	O
were	O
prepared	O
by	O
di	O
##lution	O
with	O
50	O
%	O
met	B
##han	I
##ol	I
(	O
water	O
/	B
met	B
##han	I
##ol	I
=	O
50	O
/	O
50	O
,	O
v	O
/	O
v	O
%	O
)	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
as	O
follows	O
:	O
di	O
##lution	O
by	O
2	O
-	O
fold	O
(	O
d	O
##2	O
##Q	O
##C	O
)	O
,	O
4	O
-	O
fold	O
(	O
d	O
##4	O
##Q	O
##C	O
)	O
,	O
8	O
-	O
fold	O
(	O
d	O
##8	O
##Q	O
##C	O
)	O
,	O
and	O
16	O
-	O
fold	O
(	O
d	O
##16	O
##Q	O
##C	O
)	O
.	O

Here	O
,	O
we	O
report	O
associations	O
between	O
T	B
##MA	I
##O	I
and	O
cardiac	O
a	O
##rr	O
##hy	O
##th	O
##mia	O
and	O
cardiac	O
in	O
##far	O
##ction	O
revealed	O
by	O
an	O
un	O
##tar	O
##get	O
##ed	O
,	O
hypothesis	O
-	O
free	O
screening	O
approach	O
in	O
a	O
large	O
-	O
scale	O
co	O
##hor	O
##t	O
of	O
adult	O
C	O
##K	O
##D	O
stage	O
3	O
patients	O
.	O

In	O
addition	O
to	O
PS	O
lip	O
##ids	O
,	O
the	O
P	B
##G	I
lip	O
##ids	O
identified	O
in	O
this	O
study	O
were	O
unexpected	O
,	O
given	O
the	O
low	O
level	O
of	O
P	O
##G	O
##s	O
in	O
human	O
plasma	O
.	O

Con	O
##cent	O
##rations	O
of	O
est	O
##eri	O
##fied	O
and	O
non	O
-	O
est	O
##eri	O
##fied	O
fatty	O
acids	O
and	O
o	B
##xy	I
##lip	I
##ins	I
in	O
T	O
##GR	O
##L	O
were	O
q	O
##uant	O
##ified	O
by	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

(	O
C	O
)	O
Box	O
plots	O
of	O
two	O
disc	O
##rim	O
##ina	O
##nt	O
meta	O
##bol	O
##ites	O
in	O
different	O
##iating	O
MC	O
##I	O
from	O
normal	O
healthy	O
control	O
:	O
a	O
representative	O
of	O
down	O
-	O
regulated	O
disc	O
##rim	O
##ina	O
##nt	O
meta	O
##bol	O
##ite	O
,	O
ta	B
##uri	I
##ne	I
(	O
left	O
panel	O
)	O
,	O
and	O
an	O
up	O
-	O
regulated	O
disc	O
##rim	O
##ina	O
##nt	O
meta	O
##bol	O
##ite	O
with	O
m	O
/	O
z	O
145	O
.	O
110	O
##4	O
(	O
right	O
panel	O
)	O
.	O

The	O
solution	O
with	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O
##l	O
derivatives	O
was	O
cooled	O
at	O
5	O
°C	O
for	O
30	O
min	O
,	O
di	O
##lut	O
##ed	O
with	O
100	O
µ	O
##L	O
of	O
n	B
-	I
he	I
##xa	I
##ne	I
,	O
and	O
1	O
µ	O
##L	O
of	O
the	O
final	O
solution	O
was	O
injected	O
into	O
the	O
G	O
##C	O
–	O
MS	O
system	O
.	O

A	O
decreased	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##os	I
##lip	I
##id	I
metabolism	O
and	O
balanced	O
oxidation	O
and	O
anti	O
##ox	O
##ida	O
##tion	O
contributed	O
to	O
the	O
transition	O
to	O
N	O
##GR	O
,	O
while	O
impaired	O
amino	O
acid	O
metabolism	O
and	O
per	O
##tur	O
##bed	O
mitochondrial	O
β	O
-	O
oxidation	O
were	O
associated	O
with	O
the	O
development	O
of	O
D	O
##M	O
.	O

In	O
multi	O
##var	O
##iate	O
analysis	O
,	O
all	O
L	O
##C	O
-	O
MS	O
features	O
were	O
analyzed	O
according	O
to	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
group	O
,	O
which	O
yielded	O
excellent	O
goodness	O
of	O
fit	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
87	O
)	O
and	O
predict	O
##ive	O
power	O
(	O
Q	O
_	O
2	O
=	O
0	O
.	O
75	O
)	O
.	O

In	O
case	O
of	O
pathways	O
regulated	O
in	O
CH	O
##I	O
##K	O
,	O
G	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
,	O
Gala	B
##ct	I
##ose	I
metabolism	O
and	O
C	B
##it	I
##rate	I
cycle	O
(	O
T	O
##CA	O
cycle	O
)	O
pathway	O
showed	O
significant	O
p	O
-	O
value	O
of	O
1	O
.	O
23	O
##E	O
-	O
04	O
,	O
8	O
.	O
27	O
##E	O
-	O
04	O
and	O
0	O
.	O
01	O
##8	O
##9	O
##21	O
respectively	O
.	O

In	O
si	O
##lic	O
##o	O
gene	O
expression	O
analysis	O
of	O
t	O
##umour	O
tissue	O
supports	O
our	O
results	O
and	O
puts	O
the	O
differential	O
##ly	O
expressed	O
meta	O
##bol	O
##ites	O
into	O
biological	O
context	O
,	O
showing	O
that	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
metabolism	O
and	O
GP	O
##I	O
-	O
anchor	O
bio	O
##sy	O
##nt	O
##hesis	O
pathways	O
may	O
play	O
a	O
role	O
in	O
t	O
##umour	O
progression	O
.	O

The	O
meta	O
##bol	O
##ites	O
of	O
importance	O
included	O
up	O
-	O
regulated	O
N	B
-	I
ace	I
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##in	I
in	O
CD	O
patients	O
,	O
and	O
down	O
-	O
regulated	O
L	O
##D	O
##L	O
and	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
un	O
##sat	O
##ura	O
##ted	O
lip	O
##ids	O
,	O
ch	B
##olin	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
al	B
##ani	I
##ne	I
.	O

show	O
the	O
relative	O
concentrations	O
of	O
the	B
##op	I
##hyl	I
##line	I
,	O
5	B
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
6	I
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
##ura	I
##ci	I
##l	I
and	O
x	B
##ant	I
##hine	I
in	O
different	O
groups	O
.	O

It	O
is	O
a	O
variant	O
of	O
the	O
p	B
##hen	I
##ant	I
##rane	I
op	O
##iate	O
##s	O
,	O
therefore	O
it	O
is	O
similar	O
to	O
m	B
##or	I
##phine	I
and	O
the	O
other	O
semi	O
-	O
synthetic	O
op	O
##iate	O
##s	O
,	O
however	O
,	O
it	O
has	O
unique	O
p	O
##har	O
##ma	O
##co	O
##log	O
##ic	O
properties	O
.	O

Seven	O
##teen	O
meta	O
##bol	O
##ites	O
depicted	O
significant	O
correlation	O
##s	O
to	O
E	O
##DS	O
##S	O
,	O
16	O
to	O
disease	O
duration	S
,	O
12	O
to	O
the	O
size	O
of	O
the	O
third	O
vent	O
##ric	O
##le	O
,	O
12	O
to	O
the	O
size	O
of	O
the	O
spinal	O
cord	O
,	O
four	O
to	O
total	O
T	O
##1	O
,	O
and	O
three	O
to	O
total	O
T	O
##2	O
.	O

These	O
include	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
le	B
##uk	I
##ot	I
##rien	I
##e	I
B	I
##4	I
(	O
L	O
##T	O
##B	O
##4	O
)	O
,	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	I
de	I
##hy	I
##dr	I
##oar	I
##achi	I
##don	I
##ic	I
)	I
acid	I
,	O
e	B
##ico	I
##sat	I
##et	I
##rae	I
##no	I
##ic	I
acid	I
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
in	O
addition	O
to	O
some	O
(	O
l	O
##ys	O
##o	O
)	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Direct	O
comparison	O
with	O
substrate	O
estimates	O
of	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
(	O
via	O
GA	O
##BR	O
)	O
indicates	O
that	O
this	O
a	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
process	O
may	O
be	O
particularly	O
important	O
in	O
patients	O
with	O
more	O
advanced	O
CA	O
##D	O
as	O
the	O
independent	O
pro	O
##gno	O
##stic	O
value	O
of	O
A	O
##rg	O
##MI	O
were	O
higher	O
in	O
secondary	O
prevention	O
co	O
##hor	O
##t	O
.	O

Subsequently	O
,	O
200	O
μ	O
##L	O
c	O
##it	O
##ric	O
acid	O
/	O
phosphate	O
buffer	O
(	O
pH	O
3	O
)	O
was	O
added	O
to	O
the	O
total	O
and	O
free	O
urine	O
samples	O
,	O
and	O
o	O
##xi	O
##dis	O
##ed	O
lip	O
##ids	O
were	O
extracted	O
by	O
adding	O
1	O
m	O
##L	O
et	B
##hyl	I
ace	I
##tate	I
followed	O
by	O
shaking	O
for	O
1	O
min	O
.	O

T	O
##HC	O
,	O
11	B
-	I
OH	I
-	I
T	I
##HC	I
,	O
T	O
##HC	O
##CO	O
##OH	O
,	O
T	O
##HC	O
##CO	O
##OH	O
-	O
g	O
##lu	O
##c	O
,	O
CB	O
##D	O
,	O
CBN	O
,	O
d	O
_	O
3	O
-	O
T	O
##HC	O
,	O
d	B
_	I
3	I
-	I
11	I
-	I
OH	I
-	I
T	I
##HC	I
,	O
d	O
_	O
9	O
-	O
T	O
##HC	O
##CO	O
##OH	O
,	O
d	O
_	O
3	O
-	O
CB	O
##D	O
,	O
d	O
_	O
3	O
-	O
CBN	O
and	O
d	O
_	O
3	O
-	O
T	O
##HC	O
##CO	O
##OH	O
-	O
g	O
##lu	O
##c	O
(	O
d	O
_	O
3	O
-	O
T	O
##HC	O
##CO	O
##OH	O
-	O
g	O
##lu	O
##c	O
)	O
were	O
purchased	O
from	O
Ce	O
##rill	O
##iant	O
(	O
Round	O
Rock	O
,	O
TX	O
,	O
USA	O
)	O
.	O

Lo	O
##Q	O
##s	O
for	O
D	O
##G	O
and	O
T	B
##G	I
appear	O
to	O
be	O
similar	O
.	O

[	O
Google	O
Scholar	O
]	O
G	O
##ull	O
##ino	O
PM	O
,	O
Grant	O
##ham	O
F	O
##H	O
,	O
Courtney	O
A	B
##H	I
.	O

Finally	O
,	O
degradation	O
of	O
u	B
##rac	I
##il	I
produces	O
β	B
-	I
al	I
##ani	I
##ne	I
(	O
Fi	O
##g	O
.	O

We	O
thus	O
tested	O
the	O
activity	O
of	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
as	O
an	O
L	O
##X	O
##R	O
l	O
##igan	O
##d	O
in	O
a	O
l	O
##uc	O
##ifer	O
##ase	O
ass	O
##ay	O
.	O

In	O
the	O
literature	O
,	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
is	O
meta	O
##bol	O
##ized	O
by	O
the	O
human	O
liver	O
C	O
##YP	O
##s	O
and	O
not	O
meta	O
##bol	O
##ized	O
by	O
human	O
liver	O
A	O
##Os	O
.	O

In	O
this	O
study	O
,	O
a	O
significant	O
c	B
##ys	I
##tein	I
##e	I
increase	O
was	O
also	O
observed	O
when	O
compared	O
to	O
O	O
##D	O
,	O
suggesting	O
that	O
the	O
active	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
in	O
the	O
OS	O
##CC	O
group	O
forms	O
the	O
background	O
.	O

Post	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##ami	I
##c	I
acid	I
levels	O
,	O
however	O
,	O
followed	O
expected	O
outcome	O
,	O
with	O
increased	O
levels	O
associated	O
with	O
increased	O
insulin	O
and	O
H	O
##OM	O
##A	O
post	O
treatment	O
.	O

Eight	O
out	O
of	O
46	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
in	O
our	O
series	O
had	O
H	O
##E	O
at	O
hospital	O
##ization	O
(	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##1	O
)	O
,	O
and	O
the	O
H	O
##E	O
risk	O
was	O
raised	O
by	O
Met	B
##hyl	I
##ob	I
##act	I
##eri	I
##um	I
ex	O
##tor	O
##que	O
##ns	O
and	O
St	O
##eno	O
##tro	O
##ph	O
##omo	O
##nas	O
p	O
##avan	O
##ii	O
in	O
the	O
peripheral	O
blood	O
.	O

We	O
##ak	O
wash	O
solvent	S
was	S
H	S
_	S
2	S
O	S
-	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
and	O
strong	O
wash	O
solvent	O
was	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
3	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
fold	O
change	O
(	O
FC	O
)	O
for	O
c	B
##it	I
##rate	I
,	O
1	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
,	O
4	B
-	I
de	I
##ox	I
##yt	I
##hr	I
##eon	I
##ic	I
acid	I
,	O
c	B
##rea	I
##tine	I
,	O
2	B
-	I
amino	I
##but	I
##yra	I
##te	I
,	O
and	O
su	B
##cci	I
##nate	I
was	O
greater	O
than	O
1	O
.	O
5	O
.	O

Gala	B
##ct	I
##ose	I
reached	O
its	O
highest	O
serum	O
levels	O
1	O
h	O
after	O
milk	O
intake	O
while	O
la	B
##ct	I
##ose	I
,	O
gal	B
##act	I
##ito	I
##l	I
,	O
gal	B
##act	I
##ona	I
##te	I
,	O
and	O
gal	B
##act	I
##ono	I
-	I
1	I
,	I
5	I
-	I
la	I
##cton	I
##e	I
reached	O
their	O
maximum	O
at	O
2	O
h	O
.	O

Furthermore	O
,	O
we	O
cannot	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
observed	O
protective	O
effects	O
of	O
these	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
could	O
be	O
by	O
chance	O
.	O

There	O
is	O
an	O
increasing	O
interest	O
in	O
the	O
use	O
of	O
met	B
##had	I
##one	I
in	O
p	O
##all	O
##ia	O
##tive	O
care	O
,	O
particularly	O
in	O
the	O
context	O
of	O
op	O
##io	O
##id	O
rotation	O
[	O
,	O
,	O
]	O
.	O

When	O
the	O
age	O
19	O
–	O
33	O
AD	O
##HD	O
subgroup	O
(	O
N	O
=	O
97	O
)	O
was	O
compared	O
to	O
the	O
control	O
group	O
(	O
18	O
–	O
33	O
,	O
N	O
=	O
131	O
)	O
,	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
[	O
0	O
.	O
71	O
(	O
0	O
.	O
51	O
–	O
0	O
.	O
99	O
,	O
0	O
.	O
05	O
)	O
]	O
,	O
H	O
##AA	O
[	O
0	O
.	O
66	O
(	O
0	O
.	O
47	O
–	O
0	O
.	O
91	O
,	O
0	O
.	O
01	O
)	O
]	O
and	O
rib	B
##of	I
##lav	I
##in	I
[	O
0	O
.	O
53	O
(	O
0	O
.	O
37	O
–	O
0	O
.	O
75	O
,	O
<	O
0	O
.	O
00	O
##1	O
)	O
]	O
,	O
and	O
higher	O
levels	O
of	O
co	B
##tin	I
##ine	I
[	O
7	O
.	O
84	O
(	O
4	O
.	O
63	O
–	O
14	O
.	O
22	O
,	O
<	O
0	O
.	O
00	O
##1	O
)	O
]	O
were	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
having	O
AD	O
##HD	O
.	O

Luca	O
##ci	O
##u	O
et	O
al	O
.	O
also	O
reported	O
that	O
ha	O
##rz	O
##ian	O
##ins	O
increase	O
per	O
##me	O
##ability	O
of	O
the	O
membrane	O
##s	O
made	O
of	O
egg	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
at	O
higher	O
concentrations	O
and	O
form	O
voltage	O
-	O
dependent	O
channels	O
at	O
lower	O
concentrations	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
between	O
groups	O
as	O
measured	O
by	O
repeated	O
measures	O
-	O
AN	O
##O	O
##VA	O
,	O
n	O
=	O
13	O
.	O
r	O
##HD	O
##L	O
,	O
re	O
##con	O
##stituted	O
HD	O
##L	O
;	O
T	B
##G	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
.	O

Performance	O
of	O
OS	O
##CC	O
bio	O
##mark	O
##er	O
candidates	O
in	O
the	O
valid	O
##ation	O
set	O
B	O
##io	O
##mark	O
##er	O
candidates	O
revealed	O
a	O
high	O
value	O
of	O
≥	O
0	O
.	O
85	O
except	O
c	B
##ys	I
##tein	I
##e	I
in	O
the	O
AU	O
##C	O
,	O
but	O
it	O
was	O
somewhat	O
low	O
as	O
0	O
.	O
77	O
for	O
c	B
##ys	I
##tein	I
##e	I
,	O
but	O
it	O
still	O
showed	O
moderate	O
accuracy	O
as	O
a	O
bio	O
##mark	O
##er	O
candidate	O
.	O

Interest	O
##ingly	O
,	O
up	O
-	O
regulation	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
bio	O
##sy	O
##nt	O
##hesis	O
caused	O
by	O
am	O
##p	O
##lification	O
of	O
p	O
##hos	O
##ph	O
##og	O
##ly	O
##cer	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
gene	O
copy	O
number	O
was	O
also	O
reported	O
to	O
contribute	O
to	O
on	O
##co	O
##genesis	O
in	O
me	O
##lan	O
##oma	O
and	O
breast	O
cancer	O
[	O
,	O
]	O
.	O

Recovery	O
efficiency	O
test	O
was	O
performed	O
with	O
three	O
injection	O
##s	O
of	O
the	O
extract	O
##s	O
of	O
standard	O
urine	O
solution	O
containing	O
0	O
.	O
1	O
ng	O
/	O
m	O
##L	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
and	O
1	O
.	O
0	O
ng	O
/	O
m	O
##L	O
of	O
AM	O
-	O
2	O
.	O

A	O
mixed	O
stock	O
solution	O
of	O
six	O
est	O
##rogen	O
##s	O
or	O
the	O
corresponding	O
internal	O
standards	O
at	O
1	O
µ	O
##g	O
/	O
m	O
##L	O
was	O
prepared	O
by	O
adding	O
10	O
µ	O
##L	O
of	O
each	O
est	B
##rogen	I
standard	O
stock	O
solution	O
to	O
a	O
10	O
m	O
##L	O
volume	O
##tric	O
fl	O
##ask	O
with	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
.	O

The	O
u	B
##rea	I
cycle	O
is	O
an	O
entry	O
to	O
the	O
pathway	O
for	O
the	O
synthesis	O
of	O
p	B
##ola	I
##yam	I
##ines	I
,	O
which	O
are	O
essential	O
hormones	O
in	O
cell	O
proliferation	O
,	O
a	O
hall	O
##mark	O
of	O
k	O
##era	O
##tino	O
##cy	O
##tosis	O
in	O
ps	O
##oria	O
##sis	O
.	O

These	O
profiles	O
were	O
used	O
to	O
construct	O
P	O
##LS	O
-	O
D	O
##A	O
analyses	O
to	O
determine	O
whether	O
patients	O
who	O
develop	O
AP	S
from	O
ER	O
##CP	O
show	O
differences	O
in	O
metabolism	O
relative	O
to	O
those	O
who	O
do	O
not	O
.	O

Since	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
and	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
cells	O
have	O
up	O
##re	O
##gu	O
##lated	O
FA	O
##SN	O
and	O
CO	O
##X	O
-	O
2	O
pathways	O
,	O
we	O
screened	O
the	O
effects	O
of	O
FA	O
##SN	O
inhibitor	O
C	O
##75	O
and	O
CO	O
##X	O
-	O
2	O
inhibitor	O
c	B
##ele	I
##co	I
##xi	I
##b	I
or	O
both	O
in	O
combination	O
on	O
the	O
breast	O
cancer	O
cell	O
lines	O
using	O
ca	O
##sp	O
##ase	O
9	O
and	O
ca	O
##sp	O
##ase	O
3	O
/	O
7	O
ass	O
##ays	O
.	O

As	O
indicated	O
in	O
,	O
the	O
ass	O
##ay	O
is	O
more	O
sensitive	O
for	O
the	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
D	O
##A	O
,	O
detect	O
##ing	O
re	O
##p	O
##rod	O
##uc	O
##ibly	O
down	O
to	O
25	O
ng	O
/	O
m	O
##L	O
,	O
which	O
translates	O
to	O
0	O
.	O
625	O
ng	O
of	O
material	O
on	O
column	O
of	O
which	O
0	O
.	O
13	O
and	O
500	O
p	B
##g	I
are	O
delivered	O
to	O
the	O
MS	O
and	O
EC	O
-	O
array	O
,	O
respectively	O
.	O

So	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
;	O
So	O
##1	O
##P	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
;	O
S	O
##B	O
##P	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
;	O
DB	B
##P	I
,	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
;	O
T	O
##2	O
##DM	O
,	O
type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
;	O
B	O
##F	O
,	O
body	O
fat	O
;	O
B	O
##MI	O
,	O
body	O
mass	O
index	O
;	O
L	O
##MI	O
,	O
lean	O
mass	O
index	O
;	O
WC	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
;	O
HC	O
,	O
hip	O
c	O
##ir	O
##cum	O
##ference	O
.	O

P	O
##las	O
##mas	O
were	O
al	O
##iq	O
##uo	O
##ted	O
in	O
0	O
.	O
5	O
m	O
##l	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
and	O
stored	O
at	O
−	O
80	O
°C	O
until	O
analysis	O
.	O

The	O
11	B
-	I
de	I
##hy	I
##dr	I
##o	I
meta	O
##bol	O
##ite	O
is	O
the	O
most	O
appropriate	O
anal	O
##ytic	O
target	O
to	O
detect	O
p	O
##has	O
##ic	O
release	O
of	O
TX	O
##A	O
##2	O
in	O
the	O
human	O
circulation	O
,	O
such	O
as	O
might	O
occur	O
in	O
human	O
syndrome	O
##s	O
of	O
plate	O
##let	O
activation	O
.	O

-	B
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I

O	B
##xa	I
##lo	I
##ace	I
##tate	I
is	O
very	O
unstable	O
and	O
its	O
concentration	O
in	O
most	O
tissues	O
is	O
so	O
low	O
(	O
about	O
5	O
µ	O
##M	O
)	O
that	O
it	O
is	O
imp	O
##ractical	O
to	O
accurately	O
measure	O
its	O
concentration	O
.	O

The	O
ions	O
of	O
m	O
/	O
z	O
256	O
and	O
257	O
come	O
from	O
the	O
c	O
##lea	O
##vage	O
of	O
est	B
##rone	I
ring	O
B	O
,	O
that	O
of	O
m	O
/	O
z	O
385	O
from	O
consecutive	O
losses	O
of	O
NH	O
_	O
3	O
+	O
H	O
_	O
2	O
O	O
,	O
and	O
that	O
of	O
m	O
/	O
z	O
39	O
##1	O
from	O
loss	O
of	O
CH	O
_	O
2	O
NH	O
.	O

In	O
the	O
absence	O
of	O
metabolic	O
disorders	O
higher	O
VA	O
##T	O
was	O
associated	O
with	O
molecular	O
signatures	O
previously	O
implicated	O
in	O
the	O
onset	O
of	O
T	O
##2	O
##DM	O
and	O
card	O
##iovascular	O
diseases	O
such	O
as	O
impaired	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
,	O
sur	O
##rogate	O
##s	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
diminished	O
gut	O
micro	O
##bial	O
diversity	O
,	O
and	O
further	O
with	O
the	O
potential	O
p	O
##har	O
##ma	O
##cological	O
agent	O
pipe	B
##rine	I
and	O
related	O
cat	O
##ab	O
##oli	O
##tes	O
.	O

Our	O
findings	O
of	O
an	O
association	O
between	O
4	B
-	I
c	I
##res	I
##yl	I
su	I
##lf	I
##ate	I
and	O
ad	O
##ip	O
##os	O
##ity	O
is	O
consistent	O
with	O
previous	O
findings	O
regarding	O
differences	O
in	O
the	O
Fi	O
##rm	O
##ic	O
##utes	O
/	O
Ba	O
##cter	O
##oid	O
##ete	O
##s	O
ratio	O
in	O
o	O
##bes	O
##e	O
versus	O
lean	O
individuals	O
,	O
although	O
there	O
remains	O
debate	O
regarding	O
the	O
me	O
##chan	O
##istic	O
connection	O
between	O
this	O
micro	O
##bial	O
ratio	O
and	O
ad	O
##ip	O
##os	O
##ity	O
.	O

H	B
##V	I
group	O
.	O

It	O
was	O
recently	O
reported	O
that	O
acute	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
in	O
young	O
AD	O
-	O
model	O
mice	O
had	O
increased	O
A	O
##β	O
production	O
in	O
the	O
inter	O
##st	O
##iti	O
##al	O
fluid	O
,	O
which	O
was	O
augmented	O
in	O
aged	O
AD	O
-	O
mice	O
with	O
marked	O
A	O
##β	O
plaque	O
path	O
##ology	O
,	O
identifying	O
a	O
mechanism	O
by	O
which	O
systemic	O
glucose	S
elevation	O
could	O
damage	O
brain	O
cells	O
.	O

Likewise	O
,	O
metabolic	O
syndrome	O
characteristics	O
followed	O
increasing	O
LP	O
##IR	O
q	O
##ua	O
##rt	O
##iles	O
:	O
blood	O
pressure	O
,	O
HD	O
##L	O
-	O
c	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
and	O
h	O
##s	O
-	O
CR	O
##P	O
.	O

A	O
##que	O
##ous	O
phase	O
was	O
removed	O
while	O
the	O
lower	O
ch	B
##lor	I
##of	I
##orm	I
phase	O
containing	O
lip	O
##ids	O
was	O
recovered	O
and	O
concentrated	O
under	O
nitrogen	O
stream	O
to	O
a	O
volume	O
of	O
0	O
.	O
5	O
m	O
##L	O
.	O
The	O
sample	O
was	O
di	O
##lut	O
##ed	O
to	O
1	O
.	O
0	O
m	O
##L	O
final	O
volume	O
with	O
met	B
##han	I
##ol	I
.	O

For	O
N	O
##MR	O
analysis	O
,	O
dried	O
polar	O
extract	O
##s	O
were	O
then	O
re	O
##sus	O
##pen	O
##ded	O
in	O
100	O
m	O
##M	O
sodium	B
phosphate	I
,	O
pH	O
7	O
,	O
with	O
0	O
.	O
5	O
m	O
##M	O
T	O
##SP	O
as	O
internal	O
reference	O
and	O
10	O
%	O
D	O
##2	O
##O	O
as	O
lock	O
solvent	O
.	O

Three	O
meta	O
##bol	O
##ites	O
,	O
9	O
-	O
H	O
##OT	O
##r	O
##E	O
(	B
h	B
##ydro	I
##xy	I
##oc	I
##tad	I
##eca	I
##tri	I
##eno	I
##ic	I
acid	O
)	O
,	O
9	B
-	I
K	I
##OD	I
##E	I
(	O
o	O
##x	O
##oo	O
##ct	O
##ade	O
##ca	O
##die	O
##no	O
##ic	O
acid	O
,	O
)	O
and	O
9	B
-	I
H	I
##OD	I
##E	I
(	I
h	I
##ydro	I
##xy	I
##oc	I
##tad	I
##eca	I
##die	I
##no	I
##ic	I
acid	I
)	I
,	O
which	O
belong	O
to	O
5	O
-	O
L	O
##OX	O
pathway	O
o	B
##xy	I
##lip	I
##ins	I
and	O
put	O
##ative	O
o	O
##xi	O
##da	O
##tive	O
stress	O
markers	O
,	O
showed	O
approximately	O
2	O
-	O
fold	O
higher	O
levels	O
in	O
elderly	O
women	O
than	O
in	O
elderly	O
men	O
.	O

Each	O
16	O
##S	O
library	O
was	O
checked	O
for	O
size	O
with	O
an	O
A	O
##gi	O
##lent	O
220	O
##0	O
Ta	O
##pes	O
##tation	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
United	O
States	O
)	O
and	O
q	O
##uant	O
##ified	O
with	O
a	O
Q	O
##ubi	O
##t	O
2	O
.	O
0	O
flu	B
##oro	I
##meter	I
using	O
the	O
Q	O
##ubi	O
##t	O
d	O
##s	O
##D	O
##NA	O
H	O
##S	O
As	O
##say	O
Kit	O
(	O
cat	O
#	O
Q	O
##32	O
##8	O
##51	O
,	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
,	O
MA	O
,	O
United	O
States	O
)	O
.	O

P	O
##las	O
##ma	O
concentration	O
profiles	O
from	O
o	O
##bes	O
##e	O
patients	O
for	O
(	O
a	O
)	O
si	B
##m	I
##vas	I
##tat	I
##in	I
and	O
si	B
##m	I
##vas	I
##tat	I
##in	I
acid	I
,	O
(	O
b	O
)	O
at	B
##or	I
##vas	I
##tat	I
##in	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
at	I
##or	I
##vas	I
##tat	I
##in	I
,	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
at	I
##or	I
##vas	I
##tat	I
##in	I
,	O
and	O
(	O
c	O
)	O
r	B
##os	I
##u	I
##vas	I
##tat	I
##in	I
pre	O
-	O
and	O
post	O
-	O
surgery	O
at	O
base	O
##line	O
,	O
3	O
M	O
,	O
6	O
M	O
and	O
12	O
M	O
post	O
GB	O
##S	O
.	O

Likewise	O
,	O
the	O
bio	O
##mark	O
##er	O
of	O
pro	O
-	O
inflammatory	O
event	O
(	B
IL	B
-	I
1	I
##β	I
)	O
in	O
s	O
##put	O
##um	O
super	O
##nat	O
##ant	O
was	O
significantly	O
increased	O
in	O
as	O
##th	O
##matic	O
subjects	O
with	O
o	O
##besity	O
compared	O
with	O
lean	O
ones	O
.	O

However	O
,	O
only	O
higher	O
plasma	O
T	B
##MA	I
##O	I
levels	O
was	O
associated	O
with	O
poor	O
pro	O
##gno	O
##sis	O
after	O
adjustment	O
for	O
card	O
##io	O
-	O
re	O
##nal	O
in	O
##dices	O
.	O

This	O
study	O
suggested	O
that	O
sa	B
##rc	I
##os	I
##ine	I
could	O
be	O
a	O
potential	O
pro	O
##gno	O
##stic	O
bio	O
##mark	O
##er	O
that	O
could	O
be	O
detected	O
non	O
-	O
invasive	O
##ly	O
in	O
the	O
urine	O
and	O
may	O
be	O
a	O
useful	O
approach	O
to	O
follow	O
PC	O
##a	O
disease	O
progression	O
.	O

Using	O
this	O
method	O
together	O
with	O
the	O
VIP	O
from	O
the	O
O	O
##PL	O
##S	O
‐	O
D	O
##A	O
model	O
described	O
above	O
,	O
a	O
total	O
of	O
15	O
meta	O
##bol	O
##ites	O
with	O
VIP	O
>	O
1	O
were	O
selected	O
,	O
including	O
elevated	O
levels	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
l	B
##ys	I
##ine	I
,	O
su	B
##cci	I
##nate	I
,	O
ch	B
##olin	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
5	B
‐	I
h	I
##ydro	I
##xy	I
##ly	I
##sin	I
##e	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
my	O
##o	O
‐	O
in	O
##os	O
##ito	O
##l	O
,	O
g	B
##ly	I
##co	I
##cho	I
##late	I
,	O
1	B
‐	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
and	O
glucose	S
and	O
decreased	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
fatty	O
acid	O
,	O
le	B
##uc	I
##ine	I
,	O
n	B
‐	I
ace	I
##ty	I
##l	I
##g	I
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
car	B
##ni	I
##tine	I
,	O
c	B
##it	I
##rate	I
,	O
4	B
‐	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
ma	B
##late	I
,	O
and	O
al	B
##ani	I
##ne	I
.	O

This	O
phenomenon	O
has	O
already	O
been	O
described	O
for	O
p	B
##oly	I
##amine	I
##s	I
in	O
biological	O
matrices	O
by	O
H	O
##ä	O
##k	O
##kin	O
##en	O
et	O
al	O
.	O
.	O

In	O
##jection	O
volume	O
was	O
5	O
μ	O
##l	O
,	O
is	O
##oc	O
##ratic	O
flow	O
was	O
performed	O
at	O
a	O
flow	O
rate	O
of	O
500	O
n	O
##L	O
/	O
min	O
,	O
with	O
60	O
%	O
mobile	O
phase	O
A	O
:	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
40	O
%	O
mobile	O
phase	O
B	O
(	O
90	O
%	O
AC	O
##N	O
,	O
10	O
%	O
H	O
_	O
2	O
O	O
,	O
+	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
)	O
with	O
a	O
total	O
run	O
time	O
of	O
15	O
min	O
.	O

The	O
PP	O
##P	O
was	O
activated	S
,	O
as	O
found	O
by	O
Kelly	O
et	O
al	O
.	O
,	O
who	O
showed	O
that	O
in	O
patients	O
submitted	O
to	O
AD	O
##T	O
for	O
pro	O
##state	O
cancer	O
,	O
the	O
m	O
##RNA	O
expression	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
G	O
##6	O
##PD	O
)	O
was	O
elevated	O
.	O

The	O
patients	O
presented	O
with	O
developmental	O
delay	O
,	O
seizure	O
##s	O
,	O
autism	O
,	O
abnormal	O
magnetic	O
resonance	O
imaging	O
,	O
and	O
significantly	O
elevated	O
levels	O
of	O
N	B
-	I
car	I
##ba	I
##my	I
##l	I
-	I
β	I
-	I
al	I
##ani	I
##ne	I
and	O
N	B
-	I
car	I
##ba	I
##my	I
##l	I
-	I
β	I
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
in	O
urine	O
.	O

In	O
the	O
meta	O
##static	O
cases	O
we	O
also	O
detected	O
a	O
remarkable	O
strong	O
and	O
significant	O
inverse	O
correlation	O
between	O
medium	O
-	O
chain	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
##s	O
and	O
try	B
##pt	I
##op	I
##han	I
detected	O
in	O
positive	O
and	O
negative	O
ion	O
##ization	O
mode	O
(	O
this	O
effect	O
was	O
consistent	O
also	O
in	O
primary	O
cases	O
)	O
.	O

The	O
lower	O
panel	O
shows	O
in	O
##tens	O
##ities	O
of	O
the	O
meta	O
##bol	O
##ite	O
matching	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
,	O
a	O
key	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
present	O
the	O
cell	O
wall	O
of	O
my	O
##co	O
##ba	O
##cter	O
##ia	O
,	O
that	O
was	O
increased	O
in	O
T	O
##B	O
subjects	O
.	O

The	O
increased	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolism	O
and	O
increased	O
meta	O
##bol	O
##ites	O
of	O
la	B
##ct	I
##ate	I
,	O
which	O
are	O
u	O
##bi	O
##quito	O
##us	O
in	O
various	O
tumor	O
cells	O
,	O
called	O
as	O
the	O
War	O
##burg	O
effect	O
[	O
,	O
]	O
.	O

HP	O
##LA	O
is	O
a	O
micro	O
##bio	O
##me	O
meta	O
##bol	O
##ite	O
of	O
t	B
##yr	I
##os	I
##ine	I
.	O

Overall	O
,	O
the	O
results	O
presented	O
here	O
are	O
supported	O
by	O
prior	O
references	O
and	O
in	O
con	O
##cor	O
##dance	O
with	O
our	O
previous	O
results	O
obtained	O
by	O
ultra	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
UP	O
##LC	O
-	O
MS	O
)	O
showing	O
the	O
per	O
##tur	O
##bation	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
metabolic	O
pathways	O
,	O
among	O
others	O
,	O
in	O
N	O
##MI	O
##BC	O
.	O

The	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
dominated	O
by	O
high	O
-	O
intensity	O
signals	O
of	O
sugar	O
##s	O
(	O
α	O
and	O
β	O
glucose	S
)	O
and	O
some	O
high	O
molecular	O
weight	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
lip	O
##op	O
##rote	O
##ins	O
(	O
very	O
low	O
and	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
,	O
V	O
##LD	O
##L	O
/	O
L	O
##D	O
##L	O
)	O
.	O

Then	O
,	O
800	O
μ	O
##L	O
el	O
##uen	O
##t	O
was	O
e	O
##va	O
##porated	O
and	O
dissolved	O
in	O
50	O
μ	O
##L	O
met	B
##han	I
##ol	I
for	O
lip	O
##ido	O
##mic	O
##s	O
analysis	O
.	O

The	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
SM	O
,	O
and	O
Ce	B
##r	I
signaling	O
pathway	O
is	O
altered	O
by	O
stress	O
,	O
including	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
and	O
is	O
critically	O
involved	O
in	O
cell	O
proliferation	O
and	O
death	O
as	O
well	O
as	O
the	O
contraction	O
of	O
card	O
##io	O
##my	O
##ocytes	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
[	O
,	O
]	O
.	O

According	O
to	O
the	O
K	O
##EG	O
##G	O
database	O
and	O
other	O
references	O
,	O
several	O
enzymes	O
,	O
including	O
g	B
##lut	I
##ath	I
##ion	I
S	O
-	O
transfer	O
##ases	O
(	O
G	O
##ST	O
##s	O
)	O
,	O
le	O
##uc	O
##ine	O
amino	O
##pe	O
##pt	O
##idas	O
##e	O
(	O
LA	O
##P	O
)	O
,	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
CO	O
##X	O
)	O
,	O
hormone	O
-	O
sensitive	O
lip	O
##ase	O
(	O
H	O
##SL	O
)	O
,	O
and	O
fatty	O
acid	O
s	O
##ynth	O
##ase	O
(	O
FA	O
##S	O
)	O
are	O
involved	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
degradation	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
.	O

Low	O
levels	O
of	O
glucose	S
and	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
probably	O
result	O
from	O
the	O
rapid	O
oxidation	O
of	O
these	O
meta	O
##bol	O
##ites	O
into	O
p	B
##yr	I
##u	I
##vate	I
and	O
reflect	O
increasing	O
energy	O
demands	O
during	O
se	O
##ptic	O
shock	O
.	O

To	O
our	O
best	O
knowledge	O
,	O
there	O
are	O
very	O
few	O
studies	O
about	O
the	O
meta	O
##bol	O
##ites	O
of	O
P	O
and	O
IP	S
;	O
through	O
the	O
research	O
about	O
the	O
micro	O
##bial	O
transformation	O
of	O
P	O
,	O
which	O
was	O
performed	O
with	O
the	O
fungus	O
G	O
##lo	O
##mere	O
##lla	O
c	O
##ing	O
##ulate	O
,	O
Shin	O
##suke	O
et	O
al	O
.	O
obtained	O
P	O
-	O
1	O
for	O
the	O
first	O
time	O
,	O
and	O
the	O
β	O
-	O
secret	O
##ase	O
inhibitor	O
##y	O
activity	O
of	O
P	O
-	O
1	O
and	O
P	O
-	O
2	O
in	O
v	O
##it	O
##ro	O
were	O
proceeded	O
.	O

c	O
In	O
##ser	O
##t	O
with	O
plot	O
A	O
displays	O
the	O
correlation	O
among	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
all	O
the	O
an	O
##not	O
##ated	O
meta	O
##bol	O
##ites	O
in	O
primary	O
cases	O
.	O

As	O
a	O
result	O
,	O
two	O
values	O
was	O
discovered	O
to	O
identify	O
lung	O
and	O
liver	O
cancer	O
,	O
which	O
were	O
the	O
product	O
of	O
the	O
plasma	O
concentration	O
of	O
put	B
##res	I
##cine	I
and	O
sperm	B
##id	I
##ine	I
;	O
and	O
the	O
ratio	O
of	O
the	O
urine	O
concentration	O
of	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
and	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mi	I
##dine	I
.	O

The	O
decreased	O
levels	O
of	O
LP	O
##Cs	O
were	O
associated	O
with	O
an	O
activated	S
inflammatory	O
status	O
in	O
cancer	O
patients	O
.	O

A	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ite	O
,	O
me	B
##lat	I
##oni	I
##n	I
,	O
was	O
also	O
decreased	O
in	O
the	O
urine	O
of	O
patients	O
with	O
BC	O
##A	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
potential	O
con	O
##found	O
##ing	O
factors	O
on	O
the	O
plasma	O
levels	O
of	O
ne	B
##r	I
##von	I
##ic	I
acid	I
,	O
we	O
applied	O
an	O
AN	O
##CO	O
##VA	O
with	O
a	O
dependent	O
variable	O
of	O
the	O
meta	O
##bol	O
##ite	O
levels	O
,	O
an	O
independent	O
variable	O
of	O
diagnosis	O
,	O
and	O
the	O
co	O
##var	O
##iate	O
##s	O
of	O
age	O
and	O
sex	O
.	O

Nevertheless	O
,	O
this	O
does	O
not	O
de	O
##tract	O
from	O
the	O
insights	O
evident	O
where	O
there	O
were	O
clear	O
differences	O
in	O
the	O
patterns	O
of	O
associations	O
(	O
e	O
.	O
g	O
.	O
,	O
when	O
comparing	O
small	O
and	O
large	O
HD	O
##L	O
particles	O
,	O
or	O
when	O
comparing	B
T	I
##G	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
HD	O
##L	O
particles	O
)	O
.	O

For	O
measurement	O
of	O
trim	B
##eth	I
##yla	I
##mine	I
in	O
plasma	O
,	O
a	O
sample	O
al	O
##iq	O
##uo	O
##t	O
was	O
acid	O
##ified	O
to	O
a	O
final	O
concentration	O
of	O
60	O
m	O
##M	O
of	O
h	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
before	O
storage	O
at	O
−	O
##80	O
##°	O
##C	O
.	O

Am	B
##lo	I
##di	I
##pine	I
administration	O
caused	O
a	O
notably	O
consistent	O
decrease	O
of	O
plasma	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
P	O
values	O
down	O
to	O
0	O
.	O
00	O
##1	O
)	O
,	O
without	O
affecting	O
the	O
level	O
of	O
the	O
parent	O
compound	O
(	B
car	B
##ni	I
##tine	I
)	O
itself	O
.	O

f	O
##ow	O
##ler	O
##i	O
t	O
##rop	O
##ho	O
##zo	O
##ites	O
(	O
1	O
##×	O
##10	O
_	O
4	O
)	O
were	O
treated	O
with	O
pairs	O
of	O
compounds	O
(	O
is	O
##av	O
##uc	O
##ona	O
##zo	O
##le	O
/	O
e	O
##pi	O
##min	O
##ola	O
##nos	O
##tero	O
##l	O
,	O
is	O
##av	O
##uc	O
##ona	O
##zo	O
##le	O
/	O
ta	O
##mo	O
##xi	O
##fen	O
and	O
e	O
##pi	O
##min	O
##ola	O
##nos	O
##tero	O
##l	O
/	O
ta	O
##mo	O
##xi	O
##fen	O
)	O
mixed	O
at	O
concentrations	O
that	O
provided	O
the	O
highest	O
C	O
##I	O
at	O
48	O
h	O
.	O
Cell	O
##s	O
treated	O
with	O
0	O
.	O
5	O
%	O
D	B
##MS	I
##O	I
were	O
used	O
as	O
control	O
.	O

Important	O
##ly	O
,	O
la	B
##ct	I
##ate	I
induced	O
the	O
trapping	O
of	O
T	O
cells	O
at	O
the	O
site	O
of	O
inflammation	O
and	O
thus	O
the	O
per	O
##sistence	O
of	O
pro	O
-	O
inflammatory	O
signaling	O
.	O

Standard	O
compounds	O
,	O
including	O
L	B
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
,	O
est	B
##rone	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
ch	B
##olic	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
u	B
##ro	I
##can	I
##ic	I
acid	I
,	O
L	B
-	I
f	I
##uc	I
##ose	I
,	O
L	B
-	I
car	I
##ni	I
##tine	I
,	O
u	B
##ric	I
acid	I
,	O
de	B
##ox	I
##y	I
##cy	I
##ti	I
##dine	I
,	O
c	O
##AM	O
##P	O
,	O
and	O
c	O
##GM	O
##P	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
USA	O
)	O
.	O

Met	B
##han	I
##ol	I
extraction	O
utilized	O
five	O
volumes	O
of	O
met	B
##han	I
##ol	I
(	O
5	O
:	O
1	O
met	O
##han	O
##ol	O
/	O
water	O
)	O
with	O
vigorous	O
shaking	O
at	O
room	O
temperature	O
for	O
2	O
min	O
followed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
680	O
×	O
##g	O
for	O
3	O
min	O
.	O

A	O
re	O
##gression	O
model	O
on	O
work	O
set	O
data	O
using	O
my	B
##rist	I
##ic	I
acid	I
alone	O
showed	O
a	O
sensitivity	O
of	O
0	O
.	O
91	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
77	O
–	O
0	O
.	O
97	O
)	O
and	O
a	O
specific	O
##ity	O
of	O
0	O
.	O
70	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
50	O
–	O
0	O
.	O
85	O
)	O
with	O
an	O
AU	O
##C	O
of	O
0	O
.	O
86	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
75	O
–	O
0	O
.	O
96	O
)	O
.	O

The	O
first	O
of	O
five	O
Q	O
##C	O
samples	O
that	O
were	O
analyzed	O
before	O
samples	O
from	O
the	O
different	O
in	O
##cu	O
##bation	O
groups	O
during	O
the	O
analysis	O
of	O
alpha	B
-	I
P	I
##EP	I
using	O
H	O
##IL	O
##IC	O
and	O
positive	O
ion	O
##ization	O
mode	O
had	O
to	O
be	O
excluded	O
due	O
to	O
a	O
high	O
sensitivity	O
loss	O
of	O
the	O
MS	O
during	O
the	O
analysis	O
.	O

The	O
elevated	O
u	B
##rea	I
and	O
c	B
##rea	I
##tin	I
##ine	I
could	O
be	O
caused	O
by	O
reduced	O
re	O
##nal	O
function	O
.	O

Kendall	O
’	O
s	O
τ	O
values	O
ranged	O
between	O
−	O
##0	O
.	O
51	O
##6	O
(	B
as	B
##par	I
##tic	I
acid	I
with	O
g	B
##lut	I
##amine	I
)	O
and	O
0	O
.	O
70	O
##9	O
(	B
th	B
##re	I
##oni	I
##ne	I
with	O
g	B
##lut	I
##amine	I
)	O
,	O
the	O
P	O
values	O
between	O
0	O
.	O
00	O
##1	O
and	O
0	O
.	O
97	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Se	B
##do	I
##he	I
##pt	I
##ulos	I
##e	I
was	O
also	O
important	O
for	O
the	O
correct	O
prediction	O
of	O
age	O
in	O
men	O
,	O
but	O
with	O
a	O
lower	O
rank	O
than	O
in	O
women	O
.	O

CO	O
_	O
2	O
H	O
,	O
whereas	O
the	O
product	O
ion	O
spectrum	O
of	O
N	B
-	I
h	I
##ydro	I
##xy	I
-	I
N	I
-	I
ace	I
##ty	I
##l	I
-	I
Ph	I
##IP	I
contains	O
a	O
base	O
peak	O
ion	O
at	O
m	O
/	O
z	O
241	O
.	O
1	O
,	O
which	O
is	O
attributed	O
to	O
the	O
loss	O
of	O
k	O
##ete	O
##ne	O
(	O
CH	O
_	O
2	O
CO	O
)	O
.	O

The	O
est	B
##rogen	I
(	O
ER	O
+	O
/	O
−	O
)	O
and	O
pro	B
##ges	I
##tero	I
##ne	I
(	O
PR	O
+	O
/	O
−	O
)	O
receptors	O
data	O
were	O
available	O
for	O
40	O
breast	O
cancer	O
patients	O
.	O

Among	O
the	O
9	O
meta	O
##bol	O
##ites	O
,	O
serum	O
levels	O
of	O
five	O
types	O
of	O
l	O
##ys	O
##o	O
##PC	O
(	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
0	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
2	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##24	I
:	I
0	I
)	O
,	O
and	O
one	O
PC	O
(	O
PC	O
a	B
##e	I
C	I
##42	I
:	I
1	I
)	O
were	O
found	O
to	O
decrease	O
gradually	O
from	O
CH	O
##B	O
to	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
to	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
.	O

To	O
eliminate	O
the	O
effect	O
of	O
the	O
residual	O
water	O
peak	O
,	O
for	O
each	O
peak	O
,	O
the	O
4	O
.	O
315	O
-	O
6	O
.	O
65	O
pp	O
##m	O
segment	O
containing	O
the	O
residual	O
water	O
peak	O
and	O
u	B
##rea	I
peak	O
signals	O
was	O
removed	O
.	O

For	O
instance	O
,	O
decreases	O
in	O
gang	B
##lio	I
##side	I
GM	I
##3	I
in	O
G	O
##ne	O
_	O
M	O
##7	O
##12	O
##T	O
/	O
M	O
##7	O
##12	O
##T	O
mouse	O
muscle	O
was	O
recently	O
reported	O
to	O
be	O
potential	O
marker	O
for	O
H	O
##IB	O
##M	O
(	O
Here	O
##dit	O
##ary	O
Inc	O
##lusion	O
Body	O
My	O
##op	O
##athy	O
)	O
diseases	O
.	O

It	O
is	O
important	O
to	O
mention	O
here	O
that	O
the	O
SL	O
##E	O
and	O
L	O
##N	O
patients	O
involved	O
in	O
this	O
study	O
were	O
all	O
on	O
im	O
##mu	O
##nos	O
##up	O
##pressive	O
medications	O
including	O
h	B
##ydro	I
##xy	I
##ch	I
##lor	I
##o	I
##quin	I
##e	I
(	O
HC	O
##Q	O
)	O
,	O
A	B
##za	I
##thi	I
##op	I
##rine	I
(	O
A	O
##Z	O
##A	O
)	O
,	O
Cy	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
,	O
My	O
##co	O
##phe	O
##no	O
##late	O
and	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
(	O
see	O
)	O
.	O

All	O
anal	O
##yte	O
##s	O
in	O
the	O
range	O
had	O
C	O
##V	O
values	O
of	O
<	O
15	O
%	O
except	O
for	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
rib	I
##os	I
##ide	I
,	O
which	O
had	O
a	O
%	O
C	O
##V	O
of	O
20	O
%	O
.	O

The	O
combination	O
##al	O
marker	O
ABC	O
,	O
which	O
comprises	O
D	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
ch	B
##olin	I
##e	I
,	O
displayed	O
an	O
AU	O
##C	O
value	O
of	O
0	O
.	O
92	O
##7	O
(	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
87	O
##5	O
–	O
0	O
.	O
97	O
##9	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
while	O
its	O
diagnostic	O
effectiveness	O
reached	O
90	O
.	O
5	O
%	O
sensitivity	O
and	O
83	O
.	O
3	O
%	O
specific	O
##ity	O
for	O
the	O
prediction	O
of	O
A	B
##F	I
in	O
plasma	O
samples	O
(	O
Fi	O
##g	O
.	O

The	O
aim	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
of	O
serum	O
levels	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
meta	O
##bol	O
##ites	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
breast	O
cancer	O
outcomes	O
and	O
the	O
C	O
##YP	O
##2	O
##D	O
##6	O
gene	O
.	O

C	O
##LL	O
cells	O
have	O
been	O
reported	O
to	O
exhibit	O
a	O
greater	O
depend	O
##ency	O
on	O
per	O
##ox	O
##is	O
##ome	O
pro	O
##life	O
##rator	O
activated	S
receptor	O
–	O
alpha	O
(	B
PP	B
##AR	I
-	I
α	I
)	O
regulated	O
oxidation	O
of	O
fatty	O
acids	O
leading	O
to	O
these	O
cells	O
having	O
a	O
higher	O
fat	O
-	O
burning	O
rate	O
than	O
such	O
as	O
my	O
##ocytes	O
,	O
that	O
is	O
not	O
related	O
to	O
diet	O
.	O

Interest	O
##ingly	O
,	O
a	O
recent	O
Chinese	O
study	O
reported	O
a	O
significant	O
reduction	O
of	O
o	B
##le	I
##ic	I
acid	I
levels	O
in	O
color	O
##ec	O
##tal	O
cancer	O
tumors	O
.	O

Multiple	O
groups	O
of	O
the	O
mobile	O
phase	O
,	O
including	O
Me	O
##OH	O
–	O
water	O
and	O
can	O
–	O
water	O
,	O
which	O
contain	O
different	O
pH	O
m	O
##od	O
##ifier	O
##s	O
(	O
am	O
##mon	O
##ium	O
ace	B
##tate	I
,	O
form	B
##ic	I
acid	I
,	O
and	O
am	O
##monia	O
)	O
,	O
were	O
tried	O
to	O
choose	O
the	O
optimal	O
mobile	O
phase	O
system	O
.	O

As	O
SM	O
lip	O
##ids	O
were	O
not	O
elevated	O
in	O
fatalities	O
[	O
with	O
the	O
exception	O
of	O
SM	B
(	I
d	I
##18	I
:	I
0	I
_	I
18	I
:	I
0	I
)	I
]	O
,	O
and	O
L	O
##D	O
##L	O
lip	O
##op	O
##rote	O
##ins	O
are	O
known	O
to	O
be	O
lower	O
in	O
cases	O
of	O
critical	O
illness	O
(	O
,	O
)	O
,	O
the	O
increased	O
Ce	B
##r	I
signature	O
is	O
likely	O
from	O
additional	O
sources	O
.	O

Such	O
a	O
negative	O
relationship	O
would	O
be	O
consistent	O
with	O
possible	O
up	O
##take	O
and	O
metabolism	O
of	O
cap	B
##ryl	I
##ic	I
acid	I
by	O
R	O
.	O
g	O
##na	O
##vu	O
##s	O
(	O
in	O
which	O
case	O
,	O
as	O
the	O
species	O
’	O
abundance	O
increases	O
,	O
more	O
cap	B
##ryl	I
##ic	I
acid	I
is	O
used	O
up	O
)	O
.	O

Level	O
##s	O
of	O
format	B
##e	I
,	O
most	O
of	O
the	O
identified	O
amino	O
acids	O
,	O
glucose	S
and	O
la	B
##ct	I
##ate	I
differed	O
between	O
I	O
##BS	O
and	O
healthy	O
samples	O
.	O

The	O
features	O
identified	O
in	O
the	O
data	O
as	O
most	O
relevant	O
to	O
a	O
genetic	O
mutation	O
in	O
mitochondrial	O
a	O
##con	O
##itas	O
##e	O
were	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
and	O
is	B
##oc	I
##it	I
##rate	I
.	O

Alternatively	O
,	O
less	O
free	O
g	B
##lu	I
##cu	I
##rona	I
##te	I
may	O
be	O
present	O
in	O
the	O
cancer	O
samples	O
due	O
to	O
its	O
heavy	O
incorporation	O
into	O
pro	B
##te	I
##og	I
##ly	I
##cans	I
,	O
such	O
as	O
h	B
##yal	I
##uron	I
##an	I
,	O
or	O
to	O
toxic	O
/	O
waste	O
substances	O
in	O
the	O
de	O
##to	O
##x	O
metabolism	O
through	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
.	O

I	O
##dent	O
##ified	O
meta	O
##bol	O
##ites	O
:	O
1	O
,	O
all	B
##ant	I
##oi	I
##n	I
;	O
2	O
,	O
ace	B
##tate	I
;	O
3	O
,	O
ace	B
##tone	I
;	O
4	B
,	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
5	O
,	O
ace	B
##to	I
##ace	I
##tate	I
;	O
6	O
,	O
v	B
##ali	I
##ne	I
;	O
7	O
,	O
la	B
##ct	I
##ate	I
;	O
8	O
,	O
al	B
##ani	I
##ne	I
;	O
9	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
10	O
,	O
c	B
##it	I
##rate	I
;	O
11	O
,	O
his	B
##ti	I
##dine	I
;	O
12	O
,	O
format	B
##e	I
;	O
13	O
,	O
c	B
##rea	I
##tin	I
##ine	I
;	O
14	O
,	O
g	O
##ly	O
##co	O
##p	O
##rote	O
##in	O
N	O
-	O
ace	O
##ty	O
##l	O
groups	O
;	O
15	O
,	O
lip	O
##id	O
:	O
CH	O
_	O
3	O
;	O
16	O
,	O
lip	O
##id	O
:	O
CH	O
_	O
2	O
;	O
17	O
,	O
lip	O
##id	O
:	O
CH	O
_	O
2	O
CH	O
_	O
2	O
-	O
CO	O
;	O
18	O
,	O
lip	O
##id	O
:	O
CH	O
_	O
2	O
-	O
C	O
=	O
C	O
;	O
19	O
,	O
Li	O
##pid	O
:	O
fatty	O
a	O
##cy	O
##l	O
groups	O
=	O
CH	O
.	O

Hence	O
,	O
we	O
provide	O
the	O
first	O
evidence	O
showing	O
a	O
significant	O
rise	O
of	O
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
in	O
the	O
plasma	O
of	O
breast	O
cancer	O
patients	O
after	O
surgical	O
removal	O
of	O
tumors	O
.	O

Cell	O
##s	O
were	O
shipped	O
overnight	O
on	O
cold	O
preservation	O
media	O
,	O
and	O
,	O
upon	O
re	O
##ceipt	O
,	O
media	O
were	O
replaced	O
with	O
serum	O
-	O
free	O
Williams	O
'	O
E	O
media	O
(	O
without	O
p	B
##hen	I
##ol	I
red	O
)	O
and	O
supplement	O
##s	O
as	O
described	O
previously	O
.	O

L	B
-	I
As	I
##par	I
##tic	I
acid	I
,	O
which	O
is	O
a	O
non	O
-	O
essential	O
amino	O
acid	O
synthesized	O
from	O
G	B
##lut	I
##ami	I
##c	I
acid	I
and	O
has	O
important	O
roles	O
in	O
the	O
u	B
##rea	I
cycle	O
and	O
DNA	O
metabolism	O
,	O
was	O
elevated	O
in	O
HIV	O
/	O
AIDS	O
patients	O
and	O
reduced	O
following	O
AR	O
##T	O
but	O
not	O
to	O
the	O
levels	O
found	O
in	O
healthy	O
individuals	O
.	O

In	O
v	O
##ivo	O
_	O
1	O
H	O
MR	O
##S	O
of	O
brain	O
meta	O
##sta	O
##ses	O
showed	O
that	O
by	O
using	O
the	O
signals	O
from	O
la	B
##ct	I
##ate	I
,	O
lip	O
##id	O
and	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
the	O
t	O
##umour	O
##s	O
can	O
be	O
categorized	O
into	O
the	O
early	O
,	O
intermediate	O
and	O
late	O
stages	O
of	O
meta	O
##sta	O
##ses	O
[	O
]	O
.	O

We	O
observed	O
a	O
reduction	O
in	O
glucose	S
up	O
##take	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
.	O

The	O
re	O
##age	O
##nt	O
also	O
contains	O
a	O
UV	O
-	O
trace	O
##able	O
link	O
##er	O
that	O
allows	O
for	O
simple	O
and	O
direct	O
UV	O
q	O
##uant	O
##ification	O
(	O
at	O
35	O
##4	O
nm	O
)	O
of	O
total	O
incorporated	O
bio	B
##tin	I
on	O
the	O
antibodies	O
.	O

Hz	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
b	I
)	O
,	O
1	O
.	O
81	O
(	O
s	O
,	O
3	O
##H	O
,	O
Me	O
)	O
,	O
1	O
.	O
66	O
-	O
1	O
.	O
55	O
(	O
m	O
,	O
3	O
##H	O
,	O
H	O
##2	O
,	O
H	O
##4	O
_	O
a	O
)	O
,	O
1	O
.	O
51	O
-	O
1	O
.	O
46	O
(	O
m	O
,	O
1	O
##H	O
,	O
H	O
##4	O
_	O
b	O
)	O
,	O
1	O
.	O
27	O
-	O
1	O
.	O
22	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##3	O
)	O
;	O
13	O
##C	O
N	O
##MR	O
(	O
150	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
125	O
.	O
6	O
,	O
122	O
.	O
5	O
,	O
113	O
.	O
5	O
,	O
70	O
.	O
3	O
,	O
52	O
.	O
5	O
,	O
49	O
.	O
7	O
,	O
39	O
.	O
2	O
,	O
34	O
.	O
1	O
,	O
31	O
.	O
4	O
,	O
23	O
.	O
2	O
,	O
22	O
.	O
6	O
.	O

More	O
extensive	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
parent	O
est	O
##rogen	O
##s	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
,	O
and	O
less	O
extensive	O
met	O
##hyl	O
##ation	O
of	O
potentially	O
g	O
##eno	O
##to	O
##xi	O
##c	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
is	O
associated	O
with	O
higher	O
risk	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
.	O

However	O
,	O
protective	O
effects	O
of	O
or	B
##otic	I
acid	I
were	O
seen	O
in	O
rats	O
treated	O
with	O
et	B
##hi	I
##oni	I
##ne	I
,	O
and	O
in	O
mice	O
treated	O
with	O
met	B
##hyl	I
##cho	I
##lant	I
##hren	I
##e	I
.	O

In	O
brief	O
,	O
a	O
solution	O
of	O
race	O
##mic	O
re	O
##v	O
-	O
BP	O
##DE	O
(	O
2	O
.	O
4	O
mg	O
,	O
0	O
.	O
00	O
##8	O
mm	O
##ol	O
)	O
in	O
2	O
.	O
0	O
m	O
##l	O
of	O
dry	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##ura	I
##n	I
was	O
added	O
to	O
2	O
m	O
##l	O
of	O
N	O
##AC	O
(	O
3	O
.	O
0	O
M	O
)	O
(	O
adjusted	O
to	O
pH	O
10	O
.	O
0	O
)	O
.	O

The	O
total	O
volume	O
of	O
the	O
sample	O
cell	O
was	O
40	O
μ	O
##l	O
,	O
and	O
tissue	O
samples	O
weighing	O
an	O
average	O
of	O
25	O
mg	O
were	O
placed	O
in	O
the	O
cell	O
with	O
the	O
remaining	O
volume	O
filled	O
with	O
D	O
_	O
2	O
O	O
containing	O
0	O
.	O
01	O
%	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
prop	I
##ion	I
##ic	I
acid	I
(	O
T	O
##SP	O
)	O
.	O

Dec	O
##reased	O
labeled	O
as	B
##par	I
##tate	I
,	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
from	O
U	O
-	O
_	O
13	O
C	B
_	I
6	I
-	I
glucose	I
or	O
U	O
-	O
_	O
13	O
C	B
_	I
5	I
-	I
g	I
##lut	I
##amine	I
in	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##se	O
(	O
PC	O
)	O
knock	O
##down	O
cell	O
lines	O
derived	O
from	O
MD	O
##A	O
-	O
MB	O
231	O
breast	O
cancer	O
cell	O
line	O
.	O

It	O
was	O
apparent	O
that	O
the	O
doses	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
used	O
in	O
the	O
trial	O
(	O
30	O
mg	O
/	O
day	O
)	O
were	O
much	O
higher	O
than	O
the	O
range	O
of	O
normal	O
diet	O
##ary	O
intake	O
##s	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
disease	O
in	O
the	O
observation	O
##al	O
studies	O
.	O

En	O
##han	O
##ced	O
degradation	O
of	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
indicates	O
an	O
a	O
##gg	O
##ra	O
##vated	O
stress	O
in	O
the	O
non	O
-	O
survivors	O
.	O

B	O
)	O
S	O
##ynth	O
##etic	O
standard	O
of	O
su	B
##lf	I
##oxide	I
15	O
.	O

The	O
only	O
common	O
feature	O
is	O
the	O
decreased	O
level	O
of	O
c	B
##it	I
##rate	I
–	O
thus	O
the	O
feature	O
that	O
presumably	O
reflects	O
the	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

)	O
was	O
s	O
##ynth	O
##eti	O
##zed	O
utilizing	O
previously	O
described	O
conditions	O
of	O
Luc	O
##he	O
reduction	O
from	O
3	B
-	I
A	I
##c	I
##O	I
-	I
7	I
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
,	O
an	O
intermediate	O
compound	O
in	O
the	O
synthesis	O
of	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
.	O

As	O
##p	O
may	O
be	O
actively	O
consumed	O
as	O
a	O
precursor	O
for	O
nuclei	O
##c	O
acids	O
and	O
these	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
,	O
because	O
tumor	O
concentrations	O
of	O
ma	B
##late	I
,	O
f	B
##uma	I
##rate	I
and	O
su	B
##cci	I
##nate	I
were	O
significantly	O
higher	O
than	O
the	O
normal	O
levels	O
.	O

Regarding	O
meta	O
##bol	O
##omi	O
##c	O
differences	O
in	O
the	O
CS	O
##F	O
,	O
MR	O
##S	O
analyses	O
have	O
revealed	O
differences	O
in	O
the	O
levels	O
of	O
small	O
meta	O
##bol	O
##ites	O
(	O
increase	O
of	O
ch	B
##olin	I
##e	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
and	O
th	B
##re	I
##ona	I
##te	I
and	O
decrease	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
c	B
##it	I
##rate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
and	O
man	O
##nose	O
)	O
associated	O
with	O
energy	O
and	O
lip	O
##id	O
metabolism	O
in	O
patients	O
with	O
MS	O
,	O
as	O
well	O
as	O
increased	O
levels	O
of	O
lip	O
##id	O
(	B
8	B
-	I
is	I
##o	I
-	I
pro	I
##sta	I
##g	I
##land	I
##in	I
F	I
##2	I
##α	I
)	O
or	O
protein	O
per	O
##ox	O
##ida	O
##tion	O
products	O
(	O
car	O
##box	O
##yme	O
##thy	O
##lated	O
,	O
ne	O
##uro	O
##ket	O
##al	O
,	O
and	O
ma	O
##lon	O
##dial	O
##de	O
##hy	O
##de	O
-	O
mediated	O
protein	O
modifications	O
)	O
.	O

(	O
a	O
)	O
Co	O
##mp	O
##aris	O
##on	O
of	O
median	O
s	O
##pect	O
##ra	O
of	O
c	B
##rea	I
##tin	I
##ine	I
(	O
4	O
.	O
06	O
pp	O
##m	O
)	O
.	O

This	O
shuttle	O
also	O
facilitate	O
##s	O
the	O
transfer	O
of	O
N	B
##AD	I
##H	I
produced	O
in	O
the	O
c	O
##yt	O
##op	O
##las	O
##m	O
to	O
the	O
mit	O
##och	O
##ond	O
##rion	O
for	O
ATP	S
production	O
via	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

In	O
##tens	O
##ities	O
were	O
log	O
_	O
10	O
transformed	O
and	O
variables	O
were	O
mean	O
-	O
centered	O
and	O
unit	O
-	O
variance	O
scaled	O
,	O
prior	O
to	O
principal	O
component	O
analysis	O
(	O
PC	O
##A	O
)	O
and	O
partial	O
least	O
-	O
squares	O
(	O
P	O
##LS	O
)	O
analysis	O
with	O
two	O
components	O
(	O
with	O
the	O
storage	O
duration	S
as	O
Y	O
response	O
)	O
.	O

SF	S
content	O
at	O
time	O
of	O
use	O
was	O
202	O
μ	O
##mo	O
##l	O
/	O
g	O
powder	O
and	O
represented	O
91	O
%	O
of	O
the	O
total	O
is	B
##oth	I
##io	I
##cy	I
##ana	I
##te	I
content	O
in	O
the	O
powder	O
.	O

Try	B
##pt	I
##op	I
##han	I
(	O
a	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
b	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
/	O
try	O
##pt	O
##op	O
##han	O
ratio	O
(	O
c	O
)	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
K	O
##Y	O
##NA	O
)	O
(	O
d	O
)	O
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
Q	O
##UI	O
##N	O
)	O
(	O
e	O
)	O
,	O
and	O
Q	O
##UI	O
##N	O
/	O
K	O
##Y	O
##NA	O
ratio	O
(	O
f	O
)	O
,	O
in	O
the	O
plasma	O
from	O
un	O
##ip	O
##olar	O
depressed	O
patients	O
before	O
and	O
after	O
three	O
EC	O
##T	O
treatments	O
(	O
n	O
=	O
15	O
)	O
.	O

Additionally	O
the	O
decreased	O
level	O
of	O
amino	O
acids	O
especially	O
relative	O
integral	O
of	O
serum	O
t	B
##yr	I
##os	I
##ine	I
,	O
could	O
not	O
only	O
be	O
related	O
to	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
but	O
also	O
for	O
the	O
synthesis	O
cat	B
##ech	I
##ola	I
##mine	I
##s	I
.	O

ex	B
##p	I
{	I
β	I
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
1	I
+	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
1	I
+	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
ex	O
##p	O
{	B
β	B
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	O
{	O
{	O
β	B
##0	I
+	I
[UNK]	B
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
β	O
##0	O
β	O
##0	O
β	O
β	O
β	O
0	O
0	O
+	O
[UNK]	B
=	O
1	O
[UNK]	B
=	O
1	O
[UNK]	B
[UNK]	B
m	O
m	O
j	O
=	O
1	O
j	O
=	O
1	O
j	O
=	O
1	O
β	O
##j	O
##X	O
##i	O
##j	O
β	O
##j	O
β	O
##j	O
β	O
β	O
β	O

[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I
[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I
[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I

High	O
levels	O
of	O
BC	O
##AA	O
(	O
including	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
are	O
associated	O
with	O
insulin	O
resistance	O
,	O
diabetes	O
,	O
and	O
co	O
##rona	O
##ry	O
artery	O
disease	O
and	O
predict	O
development	O
of	O
diabetes	O
.	O
38	O
K	O
##ho	O
##o	O
et	O
al	O
observed	O
that	O
R	O
##Y	O
##GB	O
improve	O
##s	O
metabolic	O
flexibility	O
with	O
removal	O
of	O
glucose	S
and	O
amino	O
acids	O
including	O
BC	O
##AA	O
as	O
early	O
as	O
2	O
weeks	O
post	O
‐	O
surgery	O
.	O
15	O

From	O
this	O
well	O
-	O
controlled	O
study	O
of	O
trans	O
vs	O
.	O
c	O
##is	O
C	B
##18	I
:	I
1	I
fat	O
in	O
over	O
##weight	O
women	O
we	O
report	O
that	O
both	O
_	O
1	O
H	O
N	O
##MR	O
and	O
L	O
##C	O
-	O
MS	O
plasma	O
metabolic	O
profiles	O
were	O
altered	O
with	O
T	O
##FA	O
intake	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
advanced	O
stages	O
of	O
the	O
disease	O
low	O
levels	O
of	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
in	O
C	O
##NS	O
(	O
and	O
consequently	O
in	O
the	O
circulation	O
)	O
,	O
would	O
even	O
accelerate	O
beta	O
-	O
am	O
##yl	O
##oid	O
deposition	O
and	O
the	O
progression	O
of	O
L	O
##OA	O
##D	O
.	O

In	O
S	O
##9	O
cells	O
,	O
the	O
most	O
affected	O
amino	O
acids	O
at	O
30	O
min	O
were	O
g	B
##ly	I
##cine	I
,	O
as	B
##par	I
##tate	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
pro	B
##line	I
,	O
se	B
##rine	I
and	O
g	B
##lut	I
##ama	I
##te	I
with	O
decreases	O
in	O
concentrations	O
between	O
82	O
%	O
–	O
75	O
%	O
compared	O
to	O
the	O
respective	O
control	O
cells	O
.	O

The	O
first	O
2	O
-	O
min	O
period	O
consisted	O
of	O
5	O
%	O
solution	O
A	O
[	O
2	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
water	O
]	O
,	O
60	O
%	O
water	O
,	O
35	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
followed	O
by	O
a	O
4	O
-	O
min	O
linear	O
gradient	O
to	O
5	O
%	O
solution	O
A	O
,	O
0	O
%	O
water	O
,	O
95	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

These	O
regions	O
were	O
integrated	O
and	O
evaluated	O
by	O
UV	O
##A	O
,	O
and	O
the	O
data	O
allows	O
to	O
conclude	O
that	O
la	B
##ct	I
##ate	I
,	O
v	B
##ali	I
##ne	I
and	O
lip	O
##ids	O
were	O
statistical	O
##ly	O
significant	O
with	O
a	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
.	O

We	O
did	O
correlation	O
analysis	O
and	O
built	O
linear	O
re	O
##gression	O
models	O
as	O
well	O
as	O
Random	O
Forest	O
re	O
##gression	O
models	O
to	O
identify	O
meta	O
##bol	O
##ites	O
that	O
predict	O
the	O
development	O
of	O
fast	O
##ing	O
glucose	S
in	O
our	O
co	O
##hor	O
##t	O
.	O

Furthermore	O
,	O
3	O
of	O
the	O
14	O
meta	O
##bol	O
##ites	O
(	B
C	B
##8	I
-	I
c	I
##era	I
##mi	I
##de	I
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
and	O
g	B
##lut	I
##amine	I
)	O
were	O
selected	O
as	O
candidate	O
diagnostic	O
bio	O
##mark	O
##ers	O
for	O
H	O
##AP	O
##E	O
using	O
metabolic	O
pathway	O
impact	O
analysis	O
.	O

One	O
example	O
is	O
shown	O
in	O
,	O
where	O
an	O
examination	O
of	O
the	O
space	O
defined	O
by	O
the	O
precursor	O
ion	O
m	O
/	O
z	O
and	O
drift	O
time	O
reveals	O
the	O
ch	O
##roma	O
##to	O
##graphic	O
co	O
##el	O
##ution	O
of	O
a	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
PC	B
36	I
:	I
1	I
,	O
and	O
two	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
SM	B
d	I
##40	I
:	I
2	I
and	O
SM	B
d	I
##38	I
:	I
1	I
.	O

We	O
concluded	O
that	O
poor	O
survival	O
was	O
due	O
to	O
the	O
increase	O
of	O
PC	B
(	I
42	I
:	I
11	I
)	I
and	O
with	O
the	O
decrease	O
of	O
LP	B
##E	I
(	I
22	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
matrix	O
effects	O
(	O
%	O
)	O
in	O
serum	O
samples	O
with	O
the	O
four	O
approaches	O
assessed	O
to	O
extract	O
p	B
##oly	I
##amine	I
##s	I
and	O
related	O
compounds	O
(	O
n	O
=	O
3	O
)	O
.	O

But	O
in	O
our	O
study	O
although	O
we	O
measured	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
we	O
did	O
not	O
observe	O
a	O
significant	O
difference	O
,	O
with	O
respect	O
to	O
this	O
group	O
of	O
lip	O
##id	O
species	O
,	O
between	O
cases	O
and	O
controls	O
.	O

High	O
resolution	O
G	O
##C	O
-	O
F	O
##ID	O
analysis	O
of	O
fatty	O
acid	O
profiles	O
of	O
test	O
foods	O
revealed	O
that	O
total	O
lip	O
##ids	O
of	O
both	O
dairy	O
products	O
were	O
dominated	O
by	O
palm	B
##itic	I
acid	I
C	I
##16	I
:	I
0	I
(	O
30	O
%	O
in	O
milk	O
,	O
26	O
%	O
in	O
cheese	O
)	O
,	O
o	B
##le	I
##ic	I
acid	I
C	I
##18	I
:	I
1	I
(	O
16	O
%	O
in	O
milk	O
,	O
18	O
%	O
in	O
cheese	O
)	O
,	O
my	B
##rist	I
##ic	I
acid	I
C	I
##14	I
:	I
0	I
(	O
11	O
%	O
in	O
milk	O
,	O
26	O
%	O
in	O
cheese	O
)	O
,	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
C	I
##18	I
:	I
0	I
(	O
9	O
%	O
in	O
milk	O
,	O
10	O
%	O
in	O
cheese	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
the	O
role	O
of	O
g	B
##lut	I
##ama	I
##te	I
as	O
a	O
selective	O
inflammatory	O
marker	O
in	O
lung	O
diseases	O
.	O

This	O
difference	O
in	O
the	O
stability	O
of	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
between	O
su	B
##lf	I
##ate	I
and	O
ta	B
##uri	I
##ne	I
can	O
be	O
explained	O
by	O
a	O
low	O
contribution	O
of	O
the	O
end	O
##ogen	O
##ously	O
produced	O
ta	B
##uri	I
##ne	I
to	O
total	O
u	O
##rina	O
##ry	O
ta	B
##uri	I
##ne	I
and	O
therefore	O
a	O
higher	O
depend	O
##ency	O
of	O
the	O
total	O
u	O
##rina	O
##ry	O
ta	B
##uri	I
##ne	I
on	O
variable	O
diet	O
##ary	O
ta	B
##uri	I
##ne	I
intake	O
.	O

G	B
##lu	I
##cos	I
##e	I
is	O
the	O
o	O
##b	O
##liga	O
##tory	O
energy	O
-	O
generating	O
substrate	O
in	O
the	O
brain	O
,	O
and	O
impaired	O
brain	B
-	I
glucose	I
up	O
##take	O
and	O
u	O
##til	O
##ization	O
is	O
a	O
key	O
metabolic	O
defect	O
in	O
AD	O
:	O
this	O
phenomenon	O
is	O
generally	O
worse	O
in	O
brain	O
regions	O
with	O
greater	O
his	O
##to	O
##logical	O
_	O
,	O
,	O
functional	O
and	O
molecular	O
evidence	O
of	O
damage	O
,	O
consistent	O
with	O
the	O
operation	O
of	O
a	O
specific	O
disease	O
process	O
_	O
,	O
.	O

Important	O
##ly	O
,	O
the	O
T	B
##G	I
within	O
all	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
B	O
and	O
most	O
HD	O
##L	O
particles	O
were	O
associated	O
with	O
higher	O
risk	O
of	O
MI	O
and	O
,	O
to	O
a	O
slightly	O
lesser	O
extent	O
,	O
of	O
IS	O
.	O

Study	O
subjects	O
were	O
participants	O
in	O
the	O
S	O
##U	O
##pp	O
##lé	O
##mentation	O
en	O
VI	B
##tamine	I
##s	I
Mine	O
##ra	O
##ux	O
et	O
Anti	B
##o	I
##X	I
##yd	I
##ants	I
2	O
(	O
S	O
##U	O
.	O
VI	O
.	O
MA	O
##X	O
2	O
)	O
co	O
##hor	O
##t	O
.	O

During	O
the	O
1970s	O
–	O
1980s	O
,	O
investigations	O
rapidly	O
advanced	O
on	O
the	O
characterization	O
of	O
reactive	O
meta	O
##bol	O
##ites	O
of	O
car	O
##cin	O
##ogen	O
##s	O
and	O
other	O
x	O
##eno	O
##biotics	O
with	O
DNA	O
,	O
blood	O
proteins	O
,	O
and	O
low	O
molecular	O
weight	O
compounds	O
such	O
as	O
g	B
##lut	I
##ath	I
##ione	I
in	O
biological	O
systems	O
.	O
_	O
−	O

On	O
the	O
other	O
hand	O
,	O
one	O
meta	O
##bol	O
##ite	O
was	O
present	O
in	O
speed	O
-	O
vacuum	O
##ed	O
samples	O
but	O
absent	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
,	O
i	O
.	O
e	O
.	O
,	O
trim	B
##eth	I
##yla	I
##mine	I
,	O
which	O
was	O
only	O
present	O
in	O
Pan	O
##c	O
-	O
1	O
cell	O
extract	O
##s	O
prepared	O
by	O
Speed	O
##V	O
##ac	O
.	O

Furthermore	O
,	O
the	O
overall	O
increased	O
ex	O
##cre	O
##tion	O
in	O
most	O
amino	O
acids	O
and	O
the	O
sulfur	O
containing	O
amino	O
acids	O
c	O
##ys	O
##tein	O
##e	O
and	O
met	B
##hi	I
##oni	I
##ne	I
(	O
Table	O
)	O
,	O
indicates	O
a	O
different	O
protein	O
metabolism	O
and	O
handling	O
of	O
nitrogen	O
in	O
p	O
##ediatric	O
I	O
##B	O
##D	O
patients	O
when	O
compared	O
to	O
healthy	O
matched	O
controls	O
.	O

Additionally	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
was	O
significantly	O
increased	O
in	O
the	O
AM	O
##S	O
-	O
S	O
group	O
com	O
##pair	O
##ed	O
with	O
that	O
in	O
the	O
AM	O
##S	O
-	O
R	O
group	O
,	O
which	O
suggests	O
in	O
##hibition	O
of	O
X	O
##O	O
would	O
be	O
expected	O
to	O
at	O
##ten	O
##uate	O
AM	O
##S	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolic	O
pathways	O
and	O
concentration	O
levels	O
of	O
the	O
related	O
meta	O
##bol	O
##ites	O
in	O
each	O
of	O
the	O
three	O
trim	O
##ester	O
##s	O
of	O
pregnancy	O
and	O
post	O
part	O
##um	O
as	O
follow	O
:	O
black	O
bars	O
for	O
the	O
first	O
trim	O
##ester	O
of	O
pregnancy	O
,	O
red	O
bars	O
for	O
the	O
second	O
trim	O
##ester	O
of	O
pregnancy	O
,	O
blue	O
bars	O
for	O
the	O
third	O
trim	O
##ester	O
of	O
pregnancy	O
,	O
and	O
green	O
bars	O
for	O
the	O
post	O
-	O
part	O
##um	O
period	O
.	O

After	O
these	O
analyses	O
,	O
it	O
was	O
discovered	O
that	O
the	O
liquid	O
ch	O
##roma	O
##tography	O
method	O
did	O
not	O
separate	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
from	O
another	O
anal	O
##yte	O
or	O
anal	O
##yte	O
##s	O
,	O
present	O
at	O
low	O
concentrations	O
,	O
which	O
we	O
presumed	O
based	O
on	O
el	O
##ution	O
time	O
and	O
fragment	O
##ation	O
pattern	O
to	O
be	O
23	B
##S	I
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
and	O
/	O
or	O
25	B
,	I
26	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
.	O

The	O
measurement	O
of	O
the	O
major	O
meta	O
##bol	O
##ite	O
of	O
E	O
##D	O
##DP	O
is	O
,	O
therefore	O
,	O
mandatory	O
if	O
the	O
patient	O
on	O
met	B
##had	I
##one	I
maintenance	O
therapy	O
can	O
lose	O
his	O
prescription	O
after	O
a	O
false	O
negative	O
laboratory	O
result	O
.	O

The	O
T	B
##G	I
content	O
was	O
significantly	O
decreased	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
AS	O
while	O
its	O
meta	O
##bol	O
##ite	O
level	O
in	O
plasma	O
(	B
g	B
##ly	I
##cer	I
##ol	I
)	O
was	O
significantly	O
increased	O
.	O

From	O
these	O
,	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
is	O
the	O
predominant	O
pathway	O
identified	O
,	O
with	O
c	B
##it	I
##rate	I
showing	O
a	O
common	O
association	O
to	O
all	O
the	O
I	O
##MI	O
##Ds	O
.	O

ATP	S
is	O
the	O
cell	O
energy	O
currency	O
,	O
which	O
is	O
primarily	O
existed	O
in	O
brain	O
and	O
muscle	O
tissue	O
in	O
ve	O
##rte	O
##bra	O
##tes	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
use	O
a	O
g	O
##eno	O
##mic	O
##s	O
-	O
meta	O
##bol	O
##omi	O
##cs	O
in	O
##te	O
##gra	O
##tive	O
approach	O
to	O
identify	O
novel	O
genetic	O
markers	O
associated	O
with	O
blood	O
pressure	O
response	O
to	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
.	O

In	O
as	O
##tro	O
##cy	O
##tes	O
,	O
Le	O
##u	O
donate	O
##s	O
the	O
amino	S
group	O
to	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
converting	O
g	B
##lut	I
##ami	I
##c	I
acid	I
into	O
g	B
##lut	I
##amine	I
in	O
the	O
g	O
##lial	O
cells	O
.	O

This	O
information	O
was	O
confirmed	O
with	O
the	O
levels	O
of	O
3	B
-	I
et	I
##hen	I
##yl	I
##py	I
##rid	I
##ine	I
(	O
3	O
-	O
EP	O
)	O
in	O
air	O
samples	O
.	O

Similar	O
to	O
other	O
studies	O
,	O
9	B
-	I
h	I
##ydro	I
##xy	I
##oc	I
##tad	I
##eca	I
##die	I
##no	I
##ic	I
acid	I
(	O
H	O
##OD	O
##E	O
)	O
,	O
9	O
-	O
o	O
##x	O
##oo	O
##ct	O
##ade	O
##ca	O
##die	O
##no	O
##ic	O
acid	O
(	O
K	O
##OD	O
##E	O
)	O
,	O

If	O
these	O
bio	O
##mark	O
##ers	O
of	O
est	B
##rogen	I
metabolism	O
are	O
confirmed	O
as	O
predict	O
##ors	O
of	O
breast	O
cancer	O
risk	O
,	O
they	O
may	O
become	O
useful	O
clinical	O
##ly	O
and	O
may	O
suggest	O
targets	O
for	O
prevent	O
##ive	O
interventions	O
.	O

We	O
observed	O
some	O
overlap	O
between	O
the	O
plasma	O
profiles	O
of	O
patients	O
with	O
ma	O
##li	O
##gna	O
##ncy	O
and	O
those	O
with	O
T	O
##B	O
in	O
that	O
the	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
k	B
##eton	I
##e	I
bodies	O
were	O
elevated	O
relative	O
to	O
healthy	O
controls	O
,	O
although	O
the	O
mechanism	O
may	O
be	O
very	O
different	O
.	O

They	O
were	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
10	O
min	O
at	O
14	O
,	O
000	O
×	O
g	O
,	O
and	O
the	O
super	O
##nat	O
##ant	O
was	O
collected	O
,	O
dried	O
in	O
a	O
Speed	O
##V	O
##ac	O
and	O
re	O
##sus	O
##pen	O
##ded	O
in	O
50	O
μ	O
##L	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

The	O
apparent	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
formation	O
rates	O
fit	O
better	O
to	O
a	O
single	O
-	O
site	O
Michael	O
##is	O
-	O
Men	O
##ten	O
equation	O
.	O

Although	O
smoking	O
history	O
is	O
thought	O
to	O
be	O
a	O
risk	O
factor	O
of	O
S	O
##q	O
##CC	O
,	O
in	O
a	O
large	O
-	O
scale	O
lip	O
##ido	O
##mic	O
##s	O
analysis	O
no	O
associations	O
were	O
identified	O
for	O
the	O
plasma	O
concentration	O
in	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
between	O
smoke	O
##rs	O
and	O
non	O
-	O
smoke	O
##rs	O
.	O

These	O
findings	O
partially	O
indicated	O
that	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
specific	O
##ities	O
reflected	O
aspects	O
of	O
the	O
P	O
##BC	O
induction	O
phase	O
.	O

In	O
addition	O
,	O
SM	B
C	I
##16	I
:	I
1	I
(	I
category	I
A	I
)	I
was	O
also	O
disc	O
##rim	O
##ina	O
##nt	O
for	O
one	O
out	O
of	O
3	O
learning	O
methods	O
(	O
i	O
.	O
e	O
Random	O
Forest	O
)	O
.	O

As	O
shown	O
in	O
,	O
serum	O
levels	O
of	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
,	O
Ph	O
##e	O
##P	O
##he	O
,	O
u	B
##rid	I
##ine	I
,	O
ta	B
##uri	I
##ne	I
,	O
L	B
-	I
th	I
##re	I
##oni	I
##ne	I
,	O
and	O
(	B
R	I
)	I
-	I
3	I
-	I
H	I
##ydro	I
##xy	I
-	I
he	I
##xa	I
##de	I
##cano	I
##ic	I
acid	I
were	O
significantly	O
correlated	O
with	O
activity	O
scores	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
A	O
##OS	O
##D	O
patients	O
.	O

The	O
pathway	O
analysis	O
also	O
revealed	O
the	O
significance	O
of	O
the	O
pu	B
##rine	I
metabolic	O
pathway	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
providing	O
cellular	O
energy	O
,	O
and	O
indicates	O
cancer	O
cell	O
survival	O
and	O
proliferation	O
(	O
,	O
)	O
.	O

The	O
calculated	O
L	O
##OD	O
was	O
~	O
1	O
.	O
1	O
pm	O
##ol	O
/	O
m	O
##L	O
.	O
Mean	O
##s	O
and	O
other	O
summary	O
statistics	O
for	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
in	O
this	O
study	O
are	O
shown	O
in	O
and	O
.	O

A	O
working	O
buffer	O
solution	O
of	O
0	O
.	O
2	O
##ug	O
/	O
m	O
##L	O
was	O
prepared	O
by	O
di	O
##lut	O
##ing	O
into	O
a	O
20	O
##mm	O
solution	O
of	O
potassium	B
phosphate	I
t	O
##ri	O
##hy	O
##dra	O
##te	O
,	O
pH	O
7	O
.	O
0	O
.	O

The	O
largest	O
meta	O
##bol	O
##ite	O
class	O
that	O
was	O
covered	O
was	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
n	O
=	O
196	O
)	O
followed	O
by	O
g	B
##ly	I
##cer	I
##ides	I
(	O
n	O
=	O
60	O
)	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
n	O
=	O
55	O
)	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
n	O
=	O
40	O
)	O
,	O
amino	O
acids	O
(	O
n	O
=	O
21	O
)	O
,	O
bio	O
##genic	O
am	O
##ines	O
(	O
n	O
=	O
21	O
)	O
,	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
(	O
n	O
=	O
14	O
)	O
and	O
mon	B
##osa	I
##cc	I
##hari	I
##des	I
(	O
n	O
=	O
1	O
)	O
which	O
included	O
the	O
sum	O
of	O
he	O
##x	O
##ose	O
##s	O
(	O
including	O
glucose	S
)	O
.	O

Effect	O
of	O
the	O
concentration	O
of	O
form	B
##ic	I
acid	I
in	O
B	O
##GE	O
on	O
the	O
signal	O
to	O
noise	O
ratio	O
(	O
S	O
/	O
N	O
)	O
of	O
20	O
protein	O
##ogenic	O
amino	O
acids	O
in	O
water	O
solution	O
.	O

We	O
found	O
that	O
Me	O
##OH	O
+	O
1	O
%	O
FA	S
gave	O
on	O
overall	O
the	O
best	O
mass	O
spectral	O
peak	O
in	O
##tens	O
##ities	O
and	O
shapes	O
.	O

From	O
the	O
41	O
measured	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
24	O
provided	O
quantitative	O
data	O
,	O
whereas	O
the	O
remaining	O
17	O
were	O
below	O
the	O
limit	O
of	O
detection	O
(	O
L	O
##OD	O
)	O
.	O

Group	O
##e	O
Hospital	O
##ier	O
Paris	O
Seine	B
-	I
Saint	I
-	I
Denis	I
B	O
##B	O
-	O
00	O
##33	O
–	O
000	O
##27	O
”	O
.	O

shows	O
the	O
leaning	O
effect	O
of	O
two	O
double	O
##ts	O
of	O
c	B
##it	I
##rate	I
.	O

R	O
##he	O
##uma	O
##to	O
##id	O
art	O
##hr	O
##itis	O
,	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
Di	B
##met	I
##hyl	I
##ar	I
##gin	I
##ines	I
,	O
A	O
##rg	O
##inas	O
##e	O
,	O
Ni	B
##tric	I
oxide	I
l	O

The	O
loading	O
##s	O
plot	O
of	O
this	O
model	O
was	O
dominated	O
by	O
the	O
spectral	O
regions	O
that	O
belonged	O
to	O
one	O
of	O
the	O
most	O
commonly	O
used	O
over	O
-	O
the	O
-	O
counter	O
anal	O
##ges	O
##ic	O
,	O
para	B
##ce	I
##tam	I
##ol	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

In	O
our	O
lip	O
##ido	O
##mic	O
##s	O
analyses	O
,	O
we	O
did	O
not	O
monitor	O
circulating	O
levels	O
of	O
di	B
##acy	I
##l	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dic	I
acids	I
in	O
control	O
or	O
infected	O
cows	O
.	O

Based	O
on	O
the	O
distribution	O
of	O
Y	O
-	O
predicted	O
scores	O
of	O
the	O
model	O
PC	O
##T	O
,	O
415	O
(	O
4	O
.	O
9	O
%	O
)	O
of	O
the	O
remaining	O
8	O
,	O
43	O
##6	O
urine	O
s	O
##pect	O
##ra	O
were	O
predicted	O
as	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
;	O
the	O
remaining	O
8	O
,	O
02	O
##1	O
(	O
95	O
.	O
1	O
%	O
)	O
urine	O
s	O
##pect	O
##ra	O
were	O
predicted	O
as	O
not	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
.	O

A	O
very	O
consistent	O
finding	O
in	O
the	O
M	O
##MCA	O
plots	O
was	O
the	O
negative	O
correlation	O
##s	O
of	O
the	O
1	O
.	O
3	O
##pp	O
##m	O
fatty	O
acid	O
signals	O
with	O
la	B
##ct	I
##ate	I
,	O
t	O
##G	O
##lut	O
,	O
t	O
##C	O
##r	O
and	O
t	O
##C	O
##ho	O
(	O
see	O
and	O
)	O
;	O
this	O
was	O
observed	O
in	O
four	O
of	O
the	O
five	O
t	O
##umour	O
types	O
,	O
while	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
had	O
significant	O
negative	O
correlation	O
##s	O
of	O
the	O
fatty	O
acids	O
with	O
la	B
##ct	I
##ate	I
and	O
t	O
##C	O
##r	O
but	O
not	O
with	O
t	O
##G	O
##lut	O
or	O
t	O
##C	O
##ho	O
.	O

The	O
running	O
time	O
for	O
every	O
sample	O
(	O
injection	O
volume	O
:	O
15	O
μ	O
##l	O
for	O
Ce	B
##r	I
and	O
d	O
##h	O
##C	O
##er	O
determination	O
and	O
10	O
μ	O
##l	O
for	O
the	O
other	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
)	O
was	O
16	O
min	O
.	O

The	O
observed	O
negative	O
correlation	O
between	O
g	B
##ly	I
##cine	I
and	O
the	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
,	O
a	O
measure	O
thought	O
to	O
best	O
represent	O
male	O
ad	O
##ip	O
##os	O
##ity	O
and	O
fat	O
distribution	O
,	O
reached	O
bi	O
##var	O
##iate	O
statistical	O
significance	O
(	O
r	O
=	O
−	O
##0	O
.	O
47	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
addition	O
to	O
the	O
positive	O
correlation	O
found	O
between	O
g	B
##ly	I
##cine	I
and	O
vigorous	O
physical	O
activity	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Co	B
##p	I
##ros	I
##tano	I
##l	I
(	O
CO	O
##PR	O
)	O
did	O
not	O
co	O
##rrel	O
##ate	O
with	O
the	O
other	O
diet	O
##ary	O
s	O
##tero	O
##ls	O
and	O
was	O
negatively	O
correlated	O
with	O
L	O
##D	O
##L	O
-	O
C	O
response	O
to	O
s	B
##tat	I
##ins	I
,	O
while	O
β	B
-	I
S	I
##IT	I
##O	I
,	O
ST	O
##IG	O
and	O
CA	O
##MP	O
were	O
slightly	O
positively	O
correlated	O
with	O
L	O
##D	O
##L	O
-	O
C	O
response	O
.	O

Initial	O
experiments	O
using	O
commercially	O
available	O
J	B
##W	I
##H	I
-	I
01	I
##8	I
5	I
-	I
h	I
##ydro	I
##xy	I
##pent	I
##yl	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
showed	O
that	O
in	O
##cu	O
##bation	O
using	O
2000	O
units	O
of	O
beta	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
adjusted	O
to	O
pH	O
4	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
55	O
°C	O
for	O
two	O
hours	O
,	O
achieved	O
optimal	O
h	O
##ydro	O
##lysis	O
.	O

Form	B
##ic	I
acid	I
,	O
met	B
##han	I
##ol	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
were	O
purchased	O
from	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Furthermore	O
,	O
Jung	O
et	O
al	O
.	O
found	O
a	O
significant	O
association	O
between	O
elevated	O
g	B
##ly	I
##cola	I
##te	I
levels	O
in	O
plasma	O
and	O
cerebral	O
in	O
##far	O
##ction	O
.	O

Low	O
(	O
1	O
µ	O
##m	O
)	O
and	O
high	O
(	O
20	O
µ	O
##m	O
)	O
concentrations	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
micro	O
##some	O
##s	O
from	O
different	O
characterized	O
human	O
liver	O
##s	O
.	O

Only	O
a	O
single	O
spot	O
urine	O
was	O
available	O
for	O
analysis	O
despite	O
the	O
short	O
-	O
lived	O
nature	O
of	O
para	B
##ce	I
##tam	I
##ol	I
.	O

Two	O
double	O
##ts	O
at	O
6	O
.	O
89	O
–	O
6	O
.	O
95	O
and	O
7	O
.	O
17	O
–	O
7	O
.	O
25	O
pp	O
##m	O
indicated	O
an	O
increased	O
post	O
##pra	O
##ndi	O
##al	O
appearance	O
of	O
t	B
##yr	I
##os	I
##ine	I
after	O
cheese	O
intake	O
,	O
compared	O
to	O
milk	O
and	O
so	O
##y	O
drink	O
intake	O
.	O

Additionally	O
,	O
in	O
##cu	O
##bation	O
##s	O
were	O
performed	O
not	O
containing	O
pH	O
##LM	O
but	O
corresponding	O
amounts	O
of	O
phosphate	S
buffer	O
and	O
25	O
µ	O
##M	O
substrate	O
(	O
enzyme	O
blank	O
)	O
.	O

Likewise	O
,	O
changes	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
peaks	O
were	O
more	O
prominent	O
in	O
F	O
##GR	O
f	O
##etus	O
##es	O
vs	O
.	O
controls	O
(	O
Table	O
)	O
.	O

The	O
combination	O
of	O
these	O
approaches	O
enabled	O
the	O
detection	O
of	O
145	O
##0	O
meta	O
##bol	O
##ites	O
in	O
total	O
,	O
of	O
which	O
95	O
were	O
significantly	O
altered	O
in	O
BC	O
##P	O
,	O
including	O
amino	O
acids	O
(	O
7	O
)	O
,	O
organic	O
acids	O
(	O
3	O
)	O
,	O
sugar	O
alcohol	O
##s	O
(	O
1	O
)	O
,	O
fatty	O
a	O
##cy	O
##ls	O
(	O
15	O
)	O
,	O
fatty	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
10	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
24	O
)	O
and	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
(	O
35	O
)	O
.	O

Ser	O
##um	O
samples	O
of	O
SL	O
##E	O
and	O
L	O
##N	O
patients	O
contained	O
significantly	O
increased	O
levels	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
(	O
N	O
##AG	O
##s	O
)	O
and	O
decreased	O
levels	O
of	O
ch	B
##olin	I
##e	I
.	O

This	O
analysis	O
failed	O
to	O
disc	O
##ern	O
differences	O
among	O
the	O
3	O
groups	O
in	O
their	O
re	O
##gio	O
##is	O
##omer	O
##ic	O
composition	O
;	O
the	O
14	B
,	I
15	I
-	I
E	I
##ET	I
pre	O
##dom	O
##inated	O
and	O
the	O
11	B
,	I
12	I
-	I
E	I
##ET	I
was	O
least	O
.	O

Z	O
##in	O
##c	O
ace	B
##tate	I
(	O
0	O
.	O
5	O
M	O
)	O
was	O
delivered	O
post	O
-	O
column	O
##ar	O
by	O
a	O
Ph	O
##arma	O
##cia	O
P	O
-	O
500	O
(	O
GE	O
Healthcare	O
,	O
Up	O
##ps	O
##ala	O
,	O
Sweden	O
)	O
at	O
a	O
flow	O
rate	O
of	O
10	O
m	O
##L	O
/	O
h	O
.	O

In	O
order	O
to	O
solve	O
this	O
problem	O
we	O
adopted	O
a	O
similar	O
approach	O
to	O
one	O
described	O
by	O
Di	O
Gang	O
##i	O
and	O
co	O
-	O
workers	O
in	O
2010	O
where	O
changes	O
in	O
the	O
met	B
##hyl	I
##ar	I
##gin	I
##ine	I
compound	O
structures	O
could	O
be	O
associated	O
to	O
changes	O
in	O
m	O
/	O
z	O
(	O
transitions	O
)	O
.	O

Studies	O
of	O
MC	O
##I	O
and	O
L	O
##OA	O
##D	O
in	O
several	O
laboratories	O
have	O
demonstrated	O
de	O
##cre	O
##ments	O
in	O
ethanol	B
##amine	I
plasma	O
##log	O
##en	O
levels	O
in	O
plasma	O
and	O
brain	O
and	O
increased	O
levels	O
of	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
in	O
plasma	O
and	O
brain	O
.	O

Several	O
meta	O
##bol	O
##ite	O
markers	O
(	O
eight	O
of	O
ten	O
)	O
overlap	O
##ped	O
between	O
pan	O
##cre	O
##atic	O
cancer	O
and	O
color	O
##ec	O
##tal	O
cancer	O
including	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	O
18	O
:	O
2	O
)	O
,	O
al	B
##ani	I
##ne	I
,	O
ch	B
##olin	I
##e	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
suggesting	O
a	O
generic	O
metabolic	O
per	O
##tur	O
##bation	O
pattern	O
that	O
under	O
##sco	O
##res	O
a	O
cancer	O
##ous	O
meta	O
##bot	O
##ype	O
.	O

Dec	B
##ened	I
##io	I
##ic	I
acid	I
is	O
a	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acid	I
.	O

After	O
en	O
##zy	O
##matic	O
h	O
##ydro	O
##lysis	O
,	O
the	O
robotic	O
system	O
automatically	O
added	O
met	B
##han	I
##ol	I
(	O
175	O
μ	O
##L	O
)	O
to	O
all	O
sample	O
wells	O
,	O
mixed	O
the	O
solution	O
,	O
re	O
##sea	O
##led	O
the	O
plate	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
~	O
15	O
minutes	O
at	O
5000	O
rpm	O
(	O
59	O
##00	O
r	O
##c	O
##f	O
)	O
.	O

Indeed	O
,	O
these	O
side	O
effects	O
of	O
te	O
##ms	O
##iro	O
##lim	O
##us	O
correspond	O
to	O
meta	O
##bol	O
##ites	O
with	O
the	O
highest	O
disc	O
##rim	O
##inator	O
##y	O
power	O
in	O
our	O
metabolic	O
signature	O
between	O
samples	O
before	O
and	O
after	O
treatment	O
,	O
that	O
is	O
,	O
lip	O
##ids	O
,	O
L	O
##D	O
##L	O
,	O
and	O
V	O
##LD	O
##L	O
lip	O
##op	O
##rote	O
##ins	O
,	O
which	O
allow	O
the	O
transport	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
end	O
##ogen	O
##ous	O
lip	O
##ids	O
,	O
respectively	O
,	O
end	O
-	O
products	O
of	O
β	B
-	I
oxidation	I
(	I
ace	I
##to	I
##ace	I
##tate	I
and	O
ace	B
##tone	I
)	I
,	O
glucose	S
,	O
and	O
g	B
##lut	I
##amine	I
.	O

Figure	O
a	O
shows	O
the	O
change	O
in	O
relative	O
abundance	O
at	O
genus	O
level	O
for	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
,	O
R	O
##umi	O
##no	O
##co	O
##cc	O
##us	O
and	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
for	O
O	O
##EP	O
and	O
CT	O
##RL	O
treatments	O
between	O
V	O
##1	O
and	O
V	O
##2	O
.	O

The	O
dashed	O
line	O
represents	O
the	O
L	O
##OD	O
studies	O
with	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yla	I
##ni	I
##line	I
as	O
the	O
matrix	O
(	O
T	O
##FA	O
1	O
pm	O
##ol	O
;	O
T	O
##CA	O
2	O
.	O
5	O
pm	O
##ol	O
;	O
PA	O
10	O
pm	O
##ol	O
;	O
SA	O
20	O
pm	O
##ol	O
)	O
.	O

A	O
mechanism	O
previously	O
proposed	O
to	O
link	O
insulin	O
resistance	O
with	O
2	O
-	O
H	O
##BA	O
suggests	O
channel	O
##ing	O
through	O
the	O
precursor	O
2	B
-	I
k	I
##eto	I
##but	I
##yric	I
acid	I
(	O
2	O
-	O
K	O
##BA	O
)	O
,	O
which	O
increases	O
as	O
a	O
consequence	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
-	O
related	O
g	B
##lut	I
##ath	I
##ione	I
synthesis	O
,	O
thus	O
driving	O
increased	O
g	B
##lut	I
##ama	I
##te	I
and	O
c	B
##ys	I
##tein	I
##e	I
,	O
and	O
decreased	O
g	B
##ly	I
##cine	I
.	O

A	O
different	O
degree	O
of	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
is	O
again	O
observed	O
in	O
different	O
samples	O
.	O

In	O
contrast	O
,	O
an	O
over	O
##ab	O
##unda	O
##nce	O
of	O
l	B
##ys	I
##ine	I
,	O
caused	O
by	O
ineffective	O
cat	O
##ab	O
##olis	O
##m	O
,	O
can	O
cause	O
severe	O
ne	O
##uro	O
##logical	O
issues	O
.	O

In	O
plasma	O
sub	O
##type	O
analyses	O
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
were	O
higher	O
among	O
PR	O
##P	O
samples	O
compared	O
with	O
PP	O
##P	O
and	O
P	O
##FP	O
by	O
N	O
##MR	O
while	O
lip	O
##ids	O
in	O
V	O
##LD	O
##L	O
/	O
L	O
##D	O
##L	O
,	O
c	B
##it	I
##rate	I
,	O
and	O
g	B
##lut	I
##amine	I
were	O
lower	O
.	O

U	O
##rina	O
##ly	O
o	B
##xy	I
##lip	I
##in	I
levels	O
were	O
compared	O
between	O
the	O
young	O
and	O
elderly	O
subjects	O
of	O
both	O
sex	O
.	O

The	O
data	O
##set	O
was	O
then	O
normal	O
##ized	O
using	O
the	O
Con	O
##stant	O
Su	O
##m	O
method	O
,	O
where	O
each	O
spectrum	O
is	O
set	O
to	O
have	O
a	O
unit	O
total	O
area	O
and	O
each	O
data	O
point	O
(	O
bin	O
)	O
is	O
a	O
fraction	O
of	O
the	O
total	O
spectral	O
integral	O
(	O
with	O
the	O
regions	O
corresponding	O
to	O
water	O
and	O
u	B
##rea	I
removed	O
)	O
.	O

S	O
##pect	O
##ra	O
in	O
D	O
and	O
E	O
show	O
only	O
cop	O
##ious	O
matrix	O
clusters	O
with	O
no	O
signal	O
for	O
the	O
de	O
##p	O
##rot	O
##ona	O
##ted	O
s	B
##te	I
##arate	I
ion	O
at	O
m	O
/	O
z	O
28	O
##3	O
(	O
transparent	O
red	O
bar	O
)	O
;	O
single	O
ion	O
at	O
m	O
/	O
z	O
28	O
##3	O
corresponding	O
to	O
s	B
##te	I
##arate	I
an	O
##ion	O
is	O
observed	O
,	O
with	O
no	O
additional	O
matrix	O
peaks	O
(	O
F	O
)	O
.	O

Fifteen	O
c	B
##era	I
##mi	I
##des	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
and	O
four	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
lip	O
##ids	O
were	O
increased	O
.	O

Sub	O
##jects	O
were	O
instructed	O
to	O
r	O
##ins	O
##e	O
out	O
with	O
warm	O
water	O
and	O
avoid	O
use	O
of	O
mouth	O
##wash	O
##es	O
or	O
flu	B
##ori	I
##de	I
r	O
##ins	O
##es	O
.	O

Co	O
-	O
in	O
##cu	O
##bation	O
with	O
T	O
##EX	O
induced	O
significant	O
(	O
p	O
<	O
0	O
.	O
00	O
##7	O
##4	O
)	O
up	O
##re	O
##gu	O
##lation	O
of	O
in	B
##os	I
##ine	I
production	O
in	O
T	O
##re	O
##g	O
but	O
not	O
in	O
CD	O
##4	O
_	O
+	O
T	O
cells	O
,	O
probably	O
because	O
of	O
large	O
differences	O
among	O
the	O
three	O
cell	O
donors	O
.	O

In	O
addition	O
to	O
the	O
amino	O
acid	O
metabolism	O
pathways	O
,	O
ho	O
##rmon	O
##al	O
pathways	O
such	O
as	O
17	O
-	O
beta	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
III	O
deficiency	O
and	O
and	O
##rogen	O
and	O
est	B
##rogen	I
metabolism	O
were	O
also	O
significant	O
.	O

Alan	B
##ine	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
.	O

One	O
is	O
related	O
to	O
the	O
small	O
sample	O
amount	O
available	O
for	O
analysis	O
,	O
limiting	O
the	O
detection	O
of	O
less	O
abundant	O
meta	O
##bol	O
##ites	O
,	O
although	O
the	O
small	O
diameter	O
of	O
these	O
bio	O
##ps	O
##ies	O
allows	O
for	O
consistent	O
and	O
complete	O
extraction	O
of	O
the	O
met	B
##han	I
##ol	I
extract	O
##able	O
meta	O
##bol	O
##ites	O
.	O

Low	O
serum	O
levels	O
of	O
2	B
,	I
4	I
-	I
he	I
##xa	I
##die	I
##no	I
##ic	I
acid	I
,	O
4	B
-	I
met	I
##hyl	I
##phe	I
##ny	I
##l	I
do	I
##de	I
##cano	I
##ate	I
and	O
g	B
##ly	I
##cer	I
##ol	I
t	I
##ri	I
##but	I
##ano	I
##ate	I
may	O
be	O
important	O
independent	O
pro	O
##gno	O
##stic	O
factors	O
of	O
G	O
##C	O
.	O

In	O
case	O
of	O
tissue	O
,	O
samples	O
(	O
50	O
mg	O
)	O
were	O
ho	O
##mo	O
##gen	O
##ized	O
in	O
400	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
using	O
Pre	O
##cell	O
##ys	O
ho	O
##mo	O
##gen	O
##iser	O
(	O
Bert	O
##in	O
Corp	O
,	O
USA	O
)	O
and	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
.	O

Cell	O
via	O
##bility	O
was	O
assessed	O
by	O
adding	O
3	B
-	I
(	I
4	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
##thi	I
##az	I
##ol	I
-	I
2	I
-	I
y	I
##l	I
)	I
-	I
2	I
,	I
5	I
-	I
dip	I
##hen	I
##yl	I
te	I
##tra	I
##zo	I
##lium	I
br	I
##omi	I
##de	I
(	O
M	O
##TT	O
)	O
.	O

Super	O
##vise	O
##d	O
multi	O
##var	O
##iate	O
analysis	O
of	O
meta	O
##bol	O
##omi	O
##cs	O
data	O
from	O
patients	O
with	O
R	O
##R	O
##MS	O
and	O
A	O
##b	O
-	O
N	O
##MO	O
##SD	O
identified	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
format	B
##e	I
as	O
the	O
most	O
disc	O
##rim	O
##inator	O
##y	O
meta	O
##bol	O
##ites	O
(	O
both	O
higher	O
in	O
R	O
##R	O
##MS	O
)	O
.	O

Met	B
##han	I
##ol	I
performs	O
most	O
optimal	O
##ly	O
over	O
a	O
wide	O
range	O
and	O
met	O
##han	O
##ol	O
-	O
to	O
-	O
serum	O
ratio	O
of	O
2	O
:	O
1	O
provides	O
the	O
best	O
performance	O
.	O

Te	O
##mper	O
##ature	O
ca	O
##li	O
##bra	O
##tion	O
was	O
performed	O
using	O
a	O
100	O
%	O
d	B
_	I
4	I
-	I
met	I
##han	I
##ol	I
sample	O
.	O

The	O
positive	O
correlation	O
##s	O
were	O
generally	O
similar	O
in	O
the	O
as	O
##tro	O
##cy	O
##tom	O
##a	O
s	O
##pect	O
##ra	O
:	O
la	B
##ct	I
##ate	I
correlated	O
positively	O
with	O
al	B
##ani	I
##ne	I
,	O
t	O
##C	O
##r	O
,	O
t	O
##C	O
##ho	O
and	O
t	O
##G	O
##lut	O
;	O
t	O
##C	O
##ho	O
correlated	O
positively	O
with	O
t	O
##G	O
##lut	O
and	O
with	O
la	B
##ct	I
##ate	I
.	O

H	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
is	O
generated	O
by	O
pro	B
##line	I
through	O
pro	O
##line	O
h	O
##ydro	O
##xy	O
##lase	O
,	O
and	O
pro	B
##line	I
is	O
a	O
peculiar	O
amino	O
acid	O
in	O
co	O
##lla	O
##gen	O
.	O

The	O
top	O
and	O
bottom	O
bars	O
(	O
“	O
w	O
##his	O
##kers	O
”	O
)	O
represent	O
the	O
entire	O
spread	O
of	O
the	O
data	O
points	O
for	O
α	B
-	I
H	I
##B	I
and	O
each	O
group	O
,	O
excluding	O
“	O
extreme	O
”	O
points	O
,	O
which	O
are	O
indicated	O
with	O
black	O
squares	O
.	O

A	O
total	O
of	O
27	O
differential	O
meta	O
##bol	O
##ites	O
based	O
on	O
VIP	O
>	O
1	O
with	O
S	O
-	O
plot	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
including	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
and	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
,	O
were	O
identified	O
and	O
used	O
to	O
establish	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
.	O

(	O
G	O
)	O
G	O
##rap	O
##hs	O
showing	O
the	O
levels	O
of	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
and	O
AL	O
##D	O
##H1	O
##A	O
##1	O
m	O
##RNA	O
in	O
cells	O
trans	O
##duced	O
with	O
control	O
s	O
##h	O
##RNA	O
or	O
g	B
##lut	I
##ami	I
##nas	I
##e	I
-	I
s	I
##h	I
##RNA	I
.	O

Structure	O
##s	O
of	O
the	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##nio	I
##ds	I
were	O
synthesized	O
(	O
indicated	O
by	O
[	O
S	O
]	O
)	O
,	O
pu	O
##rified	O
,	O
and	O
characterized	O
for	O
this	O
study	O
.	O

In	O
addition	O
,	O
the	O
retention	O
time	O
de	O
##viation	O
profiles	O
of	O
all	O
urine	O
samples	O
resulted	O
from	O
R	O
-	O
software	O
exhibited	O
±	O
##20	O
s	O
flu	O
##ct	O
##uation	O
in	O
most	O
of	O
the	O
L	B
##C	I
-	I
(	I
±	I
)	I
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
)	O
-	O
MS	O
analyses	O
.	O

Mass	O
levels	O
of	O
many	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
and	O
c	B
##era	I
##mi	I
##de	I
species	O
were	O
correlated	O
with	O
AD	O
severity	O
.	O

Ex	O
##pect	O
##edly	O
,	O
higher	O
consumption	O
of	O
glucose	S
and	O
la	B
##ct	I
##ate	I
production	O
in	O
T	O
##AC	O
##E	O
group	O
confirmed	O
that	O
re	O
##current	O
or	O
meta	O
##static	O
HC	O
##C	O
is	O
more	O
active	O
in	O
c	B
##it	I
##ric	I
acid	I
cycle	O
and	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Data	O
were	O
analyzed	O
with	O
the	O
comparative	O
CT	O
method	O
(	O
Δ	O
##Δ	O
##CT	O
)	O
and	O
expressed	O
as	O
fold	O
induction	O
relative	O
to	O
D	B
##MS	I
##O	I
as	O
the	O
negative	O
control	O
.	O

In	O
g	O
##lio	O
##mas	O
,	O
the	O
on	O
##come	O
##ta	O
##bol	O
##ite	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##era	I
##te	I
was	O
detected	O
by	O
DE	O
##SI	O
-	O
MS	O
##I	O
from	O
g	O
##lio	O
##ma	O
tissue	O
in	O
tumors	O
presenting	O
a	O
genetic	O
mutation	O
of	O
the	O
is	O
##oc	O
##it	O
##rate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
1	O
(	O
ID	O
##H1	O
)	O
enzyme	O
.	O

All	O
patients	O
presented	O
micro	O
##al	O
##bu	O
##min	O
##uria	O
values	O
below	O
30	O
mg	O
/	O
L	O
,	O
normal	O
re	B
##tina	I
##l	I
exam	O
by	O
direct	O
and	O
indirect	O
re	O
##tino	O
##sco	O
##py	O
,	O
normal	O
peripheral	O
ne	O
##uro	O
##log	O
##ic	O
evaluation	O
by	O
clinical	O
exploration	O
and	O
bio	O
##the	O
##sio	O
##metry	O
(	O
B	O
##io	O
-	O
the	O
##sio	O
##meter	O
,	O
B	O
##io	O
-	O
Medical	O
In	O
##st	O
##rum	O
##ent	O
Company	O
,	O
New	O
##bury	O
,	O
OH	O
,	O
U	O
.	O
S	O
.	O
)	O
,	O
and	O
normal	O
.	O
resting	O
12	O
-	O
lead	O
electro	O
##card	O
##io	O
##gram	O
(	O
EC	O
##G	O
)	O
and	O
normal	O
exercise	O
testing	O
by	O
upright	O
cycle	O
-	O
er	O
##go	O
##meter	O
(	O
25	O
W	O
/	O
3	O
min	O
)	O
.	O

HP	O
##LC	O
-	O
grade	O
met	B
##han	I
##ol	I
and	O
ch	B
##lor	I
##of	I
##orm	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Fair	O
##law	O
##n	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

Our	O
data	O
showed	O
an	O
increase	O
in	O
5	O
amino	O
acids	O
,	O
including	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
a	O
decrease	O
in	O
g	B
##ly	I
##cine	I
,	O
and	O
al	B
##ani	I
##ne	I
in	O
se	O
##ra	O
from	O
T	O
##B	O
patients	O
relative	O
to	O
those	O
of	O
healthy	O
controls	O
,	O
suggesting	O
alterations	O
in	O
protein	O
metabolism	O
during	O
active	O
T	O
##B	O
.	O

Dr	O
##ied	O
polar	O
meta	O
##bol	O
##ites	O
were	O
dissolved	O
in	O
15	O
µ	O
##L	O
of	O
2	O
%	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
at	O
40	O
°C	O
under	O
shaking	O
.	O

The	O
up	O
and	O
down	O
arrows	O
indicate	O
a	O
respective	O
increased	O
or	O
decreased	O
concentration	O
of	O
each	O
meta	O
##bol	O
##ite	O
in	O
the	O
T	O
##2	O
##DM	O
vs	O
.	O
H	B
##V	I
group	O
.	O

However	O
,	O
try	B
##pt	I
##op	I
##han	I
and	O
its	O
S	O
##IL	O
internal	O
standard	O
were	O
analyzed	O
with	O
a	O
low	O
cap	O
##illa	O
##ry	O
voltage	O
(	O
0	O
.	O
25	O
k	O
##V	O
)	O
.	O

To	O
achieve	O
these	O
aims	O
three	O
regions	O
of	O
the	O
molecular	O
s	O
##ca	O
##ff	O
##old	O
were	O
modified	O
and	O
tested	O
,	O
the	O
an	B
##ili	I
##ne	I
m	O
##oi	O
##ety	O
(	O
R	O
_	O
1	O
)	O
,	O
the	O
a	O
##romatic	O
im	O
##ine	O
(	O
R	O
_	O
2	O
)	O
and	O
the	O
central	O
carbon	O
chain	O
(	O
n	O
)	O
,	O
resulting	O
in	O
over	O
twenty	O
novel	O
compounds	O
.	O

V	O
##eno	O
##us	O
blood	O
samples	O
were	O
collected	O
after	O
overnight	O
fast	O
##ing	O
in	O
Be	O
##cton	O
Dickinson	O
V	O
##ac	O
##uta	O
##iner	O
CP	O
##T	O
tubes	O
with	O
sodium	B
he	I
##par	I
##in	I
.	O

The	O
24	O
-	O
h	O
variation	O
in	O
several	O
meta	O
##bol	O
##ite	O
classes	O
(	O
amino	O
acids	O
,	O
bio	O
##genic	O
am	O
##ines	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
)	O
has	O
also	O
been	O
characterized	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
night	O
’	O
s	O
sleep	O
.	O

However	O
,	O
the	O
D	O
##20	O
##47	O
##fs	O
is	O
in	O
the	O
latter	O
half	O
of	O
the	O
AT	O
##C	O
##ase	O
domain	O
of	O
CA	O
##D	O
,	O
which	O
is	O
activated	S
by	O
co	O
-	O
operative	O
binding	O
.	O

This	O
occurred	O
alongside	O
an	O
increased	O
T	B
##G	I
52	I
:	I
4	I
(	O
CH	O
##E	O
##BI	O
:	O
84	O
##6	O
##60	O
)	O
and	O
in	O
the	O
most	O
abundant	O
non	O
-	O
est	O
##eri	O
##fied	O
fatty	O
acids	O
within	O
ad	O
##ip	O
##ose	O
tissue	O
.	O

α	O
–	O
H	O
##B	O
negatively	O
correlated	O
with	O
total	O
glucose	S
disposal	O
for	O
both	O
M	O
_	O
FF	O
##M	O
(	O
fat	O
free	O
mass	O
,	O
µ	O
##mo	O
##l	O
·	O
min	O
_	O
−	O
##1	O
·	O
kg	O
_	O
FF	O
##M	O
_	O
−	O
##1	O
)	O
and	O
M	O
_	O
W	O
##BM	O
(	O
whole	O
body	O
mass	O
,	O
mg	O
·	O
min	O
_	O
−	O
##1	O
·	O
kg	O
_	O
−	O
##1	O
,	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
g	B
##ly	I
##cine	I
could	O
also	O
be	O
useful	O
as	O
a	O
m	O
##od	O
##ulator	O
of	O
the	O
inflammatory	O
state	O
observed	O
in	O
PC	O
##OS	O
.	O

Lac	B
##tate	I
still	O
correlated	O
positively	O
with	O
al	B
##ani	I
##ne	I
,	O
but	O
it	O
correlated	O
negatively	O
rather	O
than	O
positively	O
with	O
t	O
##C	O
##r	O
;	O
further	O
##more	O
,	O
la	B
##ct	I
##ate	I
correlated	O
negatively	O
with	O
t	O
##C	O
##ho	O
and	O
t	O
##G	O
##lut	O
,	O
and	O
t	O
##G	O
##lut	O
correlated	O
positively	O
with	O
t	O
##C	O
##ho	O
(	O
and	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
responsible	O
for	O
a	O
significant	O
contribution	O
to	O
the	O
separation	O
of	O
two	O
groups	O
were	O
indicated	O
in	O
the	O
corresponding	O
S	O
-	O
plot	O
and	O
marked	O
with	O
number	O
containing	O
g	B
##lut	I
##amine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
T	B
##MA	I
##O	I
,	O
c	B
##it	I
##rate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
glucose	S
.	O

Sam	O
##ple	O
β	O
-	O
g	O
##lu	O
##cos	O
##idas	O
##e	O
activities	O
were	O
determined	O
by	O
the	O
Q	O
##uant	O
##i	O
##C	O
##hr	O
##om	O
β	O
-	O
G	O
##lu	O
##cos	O
##idas	O
##e	O
As	O
##say	O
Kit	O
(	O
B	O
##io	O
##As	O
##say	O
Systems	O
,	O
Hayward	O
,	O
CA	O
)	O
,	O
which	O
evaluate	O
##s	O
β	O
-	O
g	O
##lu	O
##cos	O
##idas	O
##e	O
h	O
##ydro	O
##lysis	O
of	O
p	B
-	I
ni	I
##tro	I
##phe	I
##ny	I
##l	I
-	I
β	I
-	I
D	I
-	I
g	I
##lu	I
##copy	I
##rano	I
##side	I
to	O
a	O
ch	O
##roma	O
##genic	O
product	O
.	O

For	O
example	O
,	O
Man	O
##jar	O
##eek	O
##a	O
,	O
Nan	O
##da	O
found	O
that	O
B	O
##MI	O
had	O
a	O
very	O
weak	O
association	O
with	O
L	O
##D	O
##L	O
-	O
C	O
,	O
HD	O
##L	O
-	O
C	O
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
with	O
no	O
disc	O
##ern	O
##ible	O
differences	O
between	O
normal	O
(	O
B	O
##MI	O
=	O
20	O
–	O
25	O
kg	O
/	O
m	O
_	O
2	O
)	O
and	O
over	O
##weight	O
or	O
o	O
##bes	O
##e	O
subjects	O
(	O
B	O
##MI	O
>	O
25	O
kg	O
/	O
m	O
_	O
2	O
)	O
.	O

Our	O
analyses	O
suggest	O
that	O
o	O
##ste	O
##op	O
##oro	O
##sis	O
is	O
related	O
to	O
test	B
##osterone	I
deficiency	O
_	O
–	O
and	O
is	O
independent	O
from	O
insulin	O
activity	O
.	O

This	O
molecular	O
mass	O
corresponds	O
to	O
the	O
mass	O
of	O
the	O
amino	O
acid	O
sequence	O
191	O
–	O
197	O
of	O
SA	O
(	O
AS	O
##SA	O
##K	O
##Q	O
##R	O
,	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
74	O
##7	O
.	O
4	O
)	O
plus	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
or	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
,	O
respectively	O
(	O
addition	O
of	O
207	O
or	O
212	O
Da	O
)	O
.	O

Nevertheless	O
,	O
data	O
from	O
our	O
prior	O
studies	O
suggested	O
that	O
the	O
overall	O
plasma	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
beta	B
##ine	I
levels	O
,	O
albeit	O
flu	O
##ct	O
##uate	O
##s	O
shortly	O
after	O
feeding	O
,	O
appears	O
to	O
maintain	O
within	O
a	O
confined	O
range	O
[	O
]	O
.	O

This	O
is	O
because	O
insulin	O
resistance	O
and	O
/	O
or	O
metabolic	O
syndrome	O
can	O
be	O
also	O
originated	O
by	O
disturbance	O
##s	O
in	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
metabolism	O
,	O
as	O
shown	O
in	O
cases	O
of	O
ad	O
##ren	O
##oc	O
##ort	O
##ical	O
t	O
##umour	O
##s	O
.	O
60	O
Lower	O
values	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
in	O
plasma	O
of	O
cache	O
##ctic	O
patients	O
has	O
been	O
shown	O
in	O
other	O
studies	O
,	O
29	O
,	O
36	O
but	O
our	O
study	O
has	O
not	O
been	O
able	O
to	O
detect	O
it	O
.	O

The	O
et	B
##hyl	I
ace	I
##tate	I
layers	O
were	O
combined	O
and	O
e	O
##va	O
##porated	O
under	O
nitrogen	O
.	O

The	O
productions	O
of	O
la	B
##ct	I
##ate	I
and	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
for	O
example	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
palm	O
##ic	O
acid	O
and	O
s	O
##te	O
##ari	O
##c	O
acid	O
)	O
were	O
induced	O
,	O
whereas	O
the	O
production	O
of	O
glucose	S
was	O
in	O
##hibit	O
##ed	O
in	O
PC	O
##OS	O
groups	O
,	O
which	O
was	O
consistent	O
with	O
_	O
1	O
H	O
N	O
##MR	O
data	O
(	O
Table	O
)	O
.	O

Ce	B
##r	I
,	O
D	O
##G	O
,	O
LP	O
##C	O
,	O
LP	O
##E	O
,	O
LP	O
##I	O
,	O
LP	O
##G	O
,	O
T	B
##G	I
,	O
PC	O
,	O
P	O
##I	O
,	O
P	O
##E	O
,	O
PS	O
,	O
P	B
##G	I
,	O
and	O
SM	O
.	O

Individual	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
within	O
either	O
the	O
low	O
or	O
high	O
molecular	O
weight	O
groups	O
were	O
highly	O
correlated	O
,	O
as	O
were	O
the	O
primary	O
and	O
secondary	O
meta	O
##bol	O
##ites	O
of	O
DE	O
##HP	O
and	O
Di	O
##NP	O
(	O
Table	O
##s	O
S	O
##9	O
and	O
S	O
##10	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Material	O
)	O
.	O

Sol	O
##vent	O
A	O
was	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
solvent	O
B	O
was	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

In	O
brief	O
,	O
25	O
μ	O
##L	O
of	O
serum	O
was	O
mixed	O
with	O
350	O
μ	O
##L	O
of	O
1	O
:	O
1	O
met	O
##han	O
##ol	O
/	O
ch	O
##lor	O
##of	O
##orm	O
mixture	O
(	O
v	O
/	O
v	O
)	O
containing	O
anti	O
##ox	O
##ida	O
##nts	O
:	O
0	O
.	O
01	O
%	O
(	O
w	O
/	O
v	O
)	O
2	B
,	I
6	I
-	I
di	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
-	I
4	I
-	I
met	I
##hyl	I
##phe	I
##no	I
##l	I
and	O
0	O
.	O
00	O
##5	O
%	O
(	O
w	O
/	O
v	O
)	O
re	B
##tino	I
##l	I
.	O

Despite	O
the	O
accumulation	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
during	O
the	O
study	O
protocol	O
,	O
most	O
of	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
q	O
##uant	O
##ified	O
here	O
exhibited	O
a	O
significant	O
fit	O
to	O
a	O
co	O
##sin	O
##e	O
curve	O
regardless	O
of	O
sleep	O
status	O
and	O
meal	O
pulses	O
.	O

,	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##6	O
)	O
,	O
especially	O
those	O
for	O
SC	O
##FA	O
(	O
k	O
##o	O
##00	O
##65	O
##0	O
but	B
##ano	I
##ate	I
,	O
k	O
##o	O
##00	O
##64	O
##0	O
prop	B
##ano	I
##ate	I
)	O
,	O
carbon	O
(	O
k	O
##o	O
##01	O
##20	O
##0	O
)	O
and	O
met	B
##hane	I
(	O
k	O
##o	O
##00	O
##6	O
##80	O
)	O
metabolism	O
.	O

K	B
##yn	I
##uren	I
##ic	I
acid	I
is	O
a	O
N	O
##MD	O
##A	O
(	B
N	B
-	I
Met	I
##hyl	I
-	I
D	I
-	I
as	I
##par	I
##tate	I
)	O
receptor	O
antagonist	O
[	O
,	O
,	O
]	O
,	O
unlike	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
a	O
N	O
##MD	O
##A	O
receptor	O
ago	O
##nist	O
which	O
causes	O
ex	O
##ci	O
##to	O
##to	O
##xi	O
##c	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
changes	O
[	O
,	O
]	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
ch	B
##olin	I
##e	I
plasma	O
##log	O
##ens	O
in	O
PT	O
##B	O
positive	O
versus	O
negative	O
cows	O
(	O
N	O
=	O
12	O
per	O
group	O
)	O
.	O

L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
and	O
AD	B
##MA	I
levels	O
measured	O
in	O
plasma	O
by	O
both	O
U	O
##HP	O
##LC	O
-	O
MS	O
/	O
MS	O
or	O
E	O
##L	O
##IS	O
##A	O
showed	O
similar	O
relative	O
concentrations	O
and	O
patterns	O
of	O
change	O
after	O
bypass	O
surgery	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Le	B
##uc	I
##yl	I
-	I
le	I
##uc	I
##ine	I
is	O
a	O
product	O
of	O
incomplete	O
protein	O
breakdown	O
,	O
and	O
,	O
to	O
our	O
knowledge	O
,	O
has	O
not	O
previously	O
been	O
studied	O
in	O
relation	O
to	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
CB	O
,	O
c	O
##ere	O
##bell	O
##um	O
;	O
C	O
##G	O
,	O
c	O
##ing	O
##ulate	O
g	O
##yr	O
##us	O
;	O
E	O
##NT	O
,	O
en	O
##tor	O
##hin	O
##al	O
cortex	O
;	O
HP	S
,	O
hip	O
##po	O
##cam	O
##pus	O
;	O
MC	O
##x	O
,	O
motor	O
cortex	O
;	O
M	O
##T	O
##G	O
,	O
middle	O
temporal	O
g	O
##yr	O
##us	O
;	O
SC	O
##x	O
,	O
sensory	O
cortex	O
.	O

However	O
,	O
further	O
investigation	O
is	O
needed	O
to	O
assess	O
the	O
value	O
of	O
T	B
##MA	I
##O	I
for	O
disease	O
activity	O
analysis	O
and	O
to	O
el	O
##uc	O
##ida	O
##te	O
the	O
relationship	O
between	O
T	B
##MA	I
##O	I
and	O
those	O
micro	O
##bio	O
##ta	O
.	O

Similarly	O
,	O
GP	O
-	O
tag	O
##ged	O
3	B
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
CA	O
_	O
4	O
-	O
3	O
-	O
one	O
)	O
was	O
only	O
identified	O
following	O
treatment	O
with	O
bacterial	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
and	O
thus	O
must	O
originate	O
from	O
end	O
##ogen	O
##ous	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

(	O
E	O
)	O
AL	O
-	O
con	O
##ju	O
##gated	O
protein	O
levels	O
were	O
increased	O
in	O
the	O
superior	O
frontal	O
cortex	O
of	O
F	O
##T	O
##D	O
brain	O
(	O
N	O
=	O
10	O
)	O
compared	O
to	O
control	O
brain	O
(	O
N	O
=	O
11	O
)	O
as	O
detected	O
by	O
western	O
b	O
##lot	O
##ting	O
;	O
normal	O
##ized	O
by	O
the	O
housekeeper	O
β	B
-	I
act	I
##in	I
(	I
β	I
-	I
a	I
)	I
(	O
F	O
)	O
AL	O
-	O
con	O
##ju	O
##gated	O
protein	O
levels	O
were	O
increased	O
in	O
the	O
superior	O
frontal	O
cortex	O
of	O
AD	O
brain	O
(	O
N	O
=	O
10	O
)	O
compared	O
to	O
control	O
brain	O
(	O
N	O
=	O
11	O
)	O
.	O

Meanwhile	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
trim	B
##eth	I
##yla	I
##mi	I
##de	I
N	I
-	I
oxide	I
,	O
dim	B
##eth	I
##yla	I
##mi	I
##de	I
,	O
c	B
##it	I
##rate	I
and	O
la	B
##ct	I
##ate	I
are	O
the	O
most	O
significant	O
meta	O
##bol	O
##ites	O
found	O
in	O
the	O
_	O
1	O
H	O
N	O
##MR	O
u	O
##rina	O
##ry	O
s	O
##pect	O
##ra	O
.	O

The	O
kit	O
is	O
designed	O
for	O
the	O
measurement	O
of	O
a	O
total	O
of	O
40	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
42	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
,	O
15	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
90	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
1	O
group	O
of	O
meta	O
##bol	O
##ites	O
(	O
sum	O
of	O
he	O
##x	O
##ose	O
##s	O
)	O
.	O

For	O
some	O
compounds	O
(	O
i	O
.	O
e	O
.	O
t	B
##rig	I
##one	I
##llin	I
##e	I
,	O
1	B
,	I
7	I
dim	I
##eth	I
##yl	I
##uri	I
##c	I
acid	I
,	O
para	B
##xa	I
##nt	I
##hine	I
)	O
the	O
mean	O
intensity	O
in	O
non	O
-	O
consumers	O
was	O
relatively	O
high	O
,	O
suggesting	O
other	O
possible	O
origins	O
than	O
coffee	O
.	O

Try	O
##ptic	O
##ally	O
dig	O
##ested	O
β	B
-	I
case	I
##in	I
was	O
then	O
used	O
to	O
demonstrate	O
the	O
via	O
##bility	O
of	O
the	O
methodology	O
for	O
the	O
complex	O
CS	O
##F	O
matrix	O
from	O
hem	O
##or	O
##r	O
##ha	O
##gic	O
stroke	O
patients	O
while	O
also	O
analyzing	O
for	O
native	O
p	B
##hos	I
##ph	I
##ope	I
##pt	I
##ides	I
in	O
the	O
CS	O
##F	O
.	O

This	O
might	O
be	O
expected	O
to	O
increase	O
beta	B
##ine	I
ex	O
##cre	O
##tion	O
in	O
subjects	O
such	O
as	O
the	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
cases	O
who	O
have	O
a	O
low	O
re	O
##nal	O
threshold	O
for	O
glucose	S
.	O

Cat	B
##ech	I
##ol	I
-	I
q	I
##uin	I
##ones	I
,	O
formed	O
by	O
oxidation	O
of	O
cat	B
##ech	I
##ols	I
,	O
have	O
long	O
been	O
proposed	O
to	O
be	O
reactive	O
intermediate	O
##s	O
that	O
are	O
responsible	O
for	O
car	O
##cin	O
##ogenic	O
##ity	O
of	O
est	O
##rogen	O
##s	O
(	O
pathway	O
C	O
)	O
,	O
,	O
.	O

MR	B
##S	I
=	I
1	I
##−	I
##S	I
##0	I
(	I
t	I
)	I
[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I
=	I
1	I
##−	I
##ex	I
##p	I
{	I
[UNK]	B
}	I
[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I
MR	I
##S	I
=	I
1	I
##−	I
##S	I
##0	I
(	I
t	I
)	I
[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I
=	I
1	I
##−	I
##ex	I
##p	I
{	I
[UNK]	B
}	I
[UNK]	B
=	I
[UNK]	B
(	I
[UNK]	B
)	I

In	O
##tra	O
-	O
and	O
inter	O
-	O
ass	O
##ay	O
accuracy	O
and	O
precision	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I

B	O
##rief	O
##ly	O
,	O
8	O
.	O
66	O
g	O
sodium	B
chloride	I
,	O
0	O
.	O
224	O
g	O
potassium	B
chloride	I
,	O
0	O
.	O
206	O
g	O
calcium	B
chloride	I
,	O
and	O
0	O
.	O
163	O
g	O
ma	B
##gnesium	I
chloride	I
were	O
dissolved	O
in	O
trip	O
##ly	O
dei	O
##onized	O
water	O
and	O
prepared	O
in	O
0	O
.	O
5	O
L	O
of	O
volume	O
##tric	O
fl	O
##ask	O
(	O
solution	O
A	O
)	O
.	O

Our	O
results	O
do	O
not	O
support	O
good	O
longitudinal	O
within	O
subject	O
stability	O
of	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
levels	O
in	O
cigarette	O
smoke	O
##rs	O
.	O

No	O
significant	O
associations	O
between	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
incident	O
type	O
2	O
diabetes	O
were	O
observed	O
.	O

As	O
might	O
be	O
expected	O
,	O
most	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
are	O
very	O
h	B
##ydro	I
##phi	I
##lic	I
,	O
although	O
there	O
are	O
clearly	O
trace	O
amounts	O
of	O
lip	O
##ids	O
and	O
fatty	O
acids	O
that	O
contribute	O
a	O
significant	O
number	O
of	O
chemicals	O
to	O
the	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ome	O
(	O
83	O
##6	O
fatty	O
acids	O
and	O
lip	O
##ids	O
)	O
.	O

Ho	B
##mo	I
##car	I
##nos	I
##ine	I
is	O
a	O
dip	O
##eptide	O
composed	O
of	O
L	B
-	I
his	I
##ti	I
##dine	I
and	O
GA	B
##BA	I
,	O
and	O
is	O
well	O
-	O
known	O
for	O
its	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
ne	O
##uro	O
##p	O
##rote	O
##ctive	O
activity	O
_	O
,	O
_	O
,	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
##s	O
,	O
and	O
GP	O
##I	O
-	O
anchor	O
bio	O
##sy	O
##nt	O
##hesis	O
(	O
A	O
)	O
.	O

C	B
##rea	I
##tine	I
is	O
transformed	O
into	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
,	O
an	O
energy	O
reservoir	O
,	O
by	O
c	B
##rea	I
##tine	I
kinase	O
is	O
##oe	O
##nz	O
##yme	O
B	O
##B	O
,	O
an	O
enzyme	O
that	O
has	O
been	O
shown	O
to	O
exhibit	O
high	O
serum	O
levels	O
in	O
N	O
##SC	O
##LC	O
patients	O
[	O
,	O
]	O
.	O

Thus	O
,	O
the	O
DC	O
##M	O
leaf	O
extract	O
exhibited	O
lower	O
(	O
18	O
.	O
52	O
%	O
±	O
##13	O
.	O
5	O
%	O
)	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
activity	O
than	O
the	O
a	O
##que	O
##ous	O
leaf	O
extract	O
(	O
70	O
.	O
76	O
%	O
±	O
##17	O
.	O
4	O
%	O
)	O
which	O
was	O
also	O
faster	O
acting	O
(	O
0	O
.	O
5	O
h	O
)	O
.	O

His	O
##to	O
##log	O
##ic	O
examination	O
of	O
s	O
##yn	O
##ov	O
##ial	O
in	O
##fi	O
##lt	O
##rates	O
in	O
early	O
RA	O
has	O
shown	O
mast	O
cells	O
to	O
be	O
present	O
,	O
suggesting	O
that	O
these	O
cells	O
could	O
be	O
the	O
source	O
of	O
the	O
disc	O
##rim	O
##inating	O
his	B
##tamine	I
.	O

Nevertheless	O
,	O
several	O
reports	O
showed	O
that	O
E	O
##Vs	O
derived	O
from	O
cell	O
cultures	O
contained	O
higher	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
levels	O
than	O
the	O
parental	O
cell	O
lines	O
[	O
,	O
]	O
.	O

Regardless	O
of	O
ion	O
##ization	O
mode	O
,	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
##s	O
of	O
primarily	O
polar	O
meta	O
##bol	O
##ites	O
were	O
performed	O
on	O
a	O
X	O
##bridge	O
B	O
##E	O
##H	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
ch	O
##roma	O
##tography	O
column	O
(	O
Waters	O
Corporation	O
,	O
Milford	O
,	O
MA	O
,	O
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
3	O
.	O
0	O
µ	O
##m	O
)	O
.	O

However	O
,	O
similar	O
to	O
donor	O
D	O
##1	O
,	O
these	O
micro	O
##bio	O
##ta	O
were	O
not	O
able	O
to	O
meta	O
##bol	O
##ize	O
th	B
##una	I
##l	I
##ben	I
##e	I
to	O
is	O
##ores	O
##ver	O
##at	O
##rol	O
.	O

(	O
B	O
)	O
Star	O
##ch	O
and	O
su	B
##c	I
##rose	I
metabolism	O
.	O

This	O
lip	O
##ido	O
##mic	O
study	O
,	O
by	O
highlighting	O
re	O
##tina	O
specific	O
gang	B
##lio	I
##side	I
species	O
,	O
opens	O
up	O
novel	O
research	O
directions	O
for	O
a	O
better	O
understanding	O
of	O
the	O
biological	O
role	O
of	O
gang	B
##lio	I
##side	I
##s	I
in	O
the	O
re	O
##tina	O
.	O

Met	B
##han	I
##ol	I
(	O
4	O
m	O
##l	O
per	O
gram	O
of	O
tissue	O
)	O
and	O
double	O
di	O
##st	O
##ille	O
##d	O
water	O
(	O
0	O
.	O
85	O
m	O
##l	O
per	O
gram	O
of	O
tissue	O
)	O
were	O
added	O
and	O
the	O
mixture	O
##s	O
were	O
v	O
##ortex	O
##ed	O
for	O
1	O
min	O
.	O

Le	O
##uk	O
##ot	O
##rien	O
##es	O
are	O
bio	O
##sy	O
##nt	O
##hesis	O
##ed	O
from	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
via	O
5	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
5	O
-	O
L	O
##O	O
)	O
in	O
the	O
body	O
by	O
my	O
##elo	O
##id	O
cells	O
and	O
B	O
l	O
##ymph	O
##ocytes	O
.	O

The	O
mobile	O
phase	O
was	O
prepared	O
by	O
mixing	O
of	O
70	O
%	O
met	B
##han	I
##ol	I
and	O
30	O
%	O
of	O
a	O
mixture	O
of	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
0	O
.	O
2	O
m	O
##M	O
form	B
##ic	I
acid	I
,	O
while	O
the	O
stationary	O
phase	O
was	O
R	O
##P	O
-	O
C	O
##18	O
column	O
(	O
50	O
×	O
4	O
.	O
0	O
mm	O
ID	O
,	O
5	O
μ	O
m	O
)	O
.	O

This	O
was	O
achieved	O
by	O
performing	O
targeted	O
x	O
##eno	O
##met	O
##ab	O
##olo	O
##me	O
analyses	O
for	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
from	O
un	O
##tar	O
##get	O
##ed	O
_	O
1	O
H	O
N	O
##MR	O
u	O
##rina	O
##ry	O
s	O
##pect	O
##ra	O
previously	O
acquired	O
for	O
participants	O
in	O
the	O
International	O
Study	O
of	O
Mac	O
##ro	O
-	O
/	O
Micro	O
-	O
N	O
##ut	O
##rient	O
##s	O
and	O
Blood	O
Press	O
##ure	O
(	O
IN	O
##TE	O
##R	O
##MA	O
##P	O
Study	O
)	O
.	O

Ace	B
##tone	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
ethanol	S
,	O
h	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
,	O
met	B
##han	I
##ol	I
,	O
perch	B
##lor	I
##ic	I
acid	I
,	O
potassium	B
chloride	I
,	O
potassium	B
h	I
##ydro	I
##xi	I
##de	I
,	O
sodium	B
chloride	I
and	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

Co	O
##mp	O
##aris	O
##on	O
between	O
the	O
two	O
studied	O
groups	O
according	O
to	O
the	O
relative	O
in	O
##tens	O
##ities	O
of	O
the	O
five	O
identified	O
plasma	O
meta	O
##bol	O
##ites	O
U	O
–	O
Mann	O
-	O
Whitney	O
test	O
,	O
t	O
–	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
p	O
–	O
p	O
value	O
for	O
comparison	O
between	O
the	O
two	O
studied	O
groups	O
Re	O
##lation	O
between	O
relative	O
in	O
##tens	O
##ities	O
of	O
the	O
five	O
plasma	O
meta	O
##bol	O
##ites	O
and	O
different	O
patient	O
and	O
tumor	O
characteristics	O
CT	B
##P	I
–	O
Child	O
-	O
Tu	O
##rc	O
##otte	O
-	O
P	O
##ugh	O
,	O
BC	O
##LC	O
–	O
Barcelona	O
Clinic	O
Live	O
##r	O
Cancer	O
(	O
*	O
Intermediate	O
stage	O
patients	O
were	O
excluded	O
from	O
analysis	O
due	O
to	O
small	O
sample	O
size	O
,	O
n	O
=	O
2	O
)	O

Al	B
##ame	I
##thi	I
##cin	I
,	O
which	O
was	O
used	O
in	O
this	O
study	O
as	O
a	O
reference	O
compound	O
,	O
also	O
showed	O
membrane	O
-	O
modify	O
##ing	O
activity	O
at	O
a	O
higher	O
concentration	O
(	O
50	O
μ	O
##g	O
m	O
##l	O
_	O
−	O
##1	O
)	O
and	O
specific	O
mitochondrial	O
activity	O
at	O
a	O
lower	O
concentration	O
(	O
5	O
μ	O
##g	O
m	O
##l	O
_	O
−	O
##1	O
)	O
(	O
Table	O
)	O
when	O
A	O
##5	O
##4	O
##9	O
cells	O
were	O
used	O
as	O
test	O
cells	O
.	O

White	O
bars	O
,	O
awake	O
,	O
90	O
l	O
##x	O
,	O
free	O
to	O
move	O
;	O
gray	O
bars	O
,	O
awake	O
,	O
<	O
5	O
l	O
##x	O
,	O
semi	O
##re	O
##cum	O
##bent	O
;	O
black	O
bars	O
,	O
sleeping	O
with	O
eye	O
masks	O
,	O
0	O
l	O
##x	O
,	O
su	B
##pine	I
.	O

This	O
modified	O
procedure	O
facilitated	O
the	O
as	O
##piration	O
of	O
the	O
super	O
##nat	O
##ant	O
from	O
above	O
the	O
p	O
##elle	O
##t	O
containing	O
the	O
labeled	O
25	O
(	O
OH	O
)	O
D	O
.	O
The	O
W	O
##H	O
##NR	O
##C	O
participates	O
in	O
the	O
DE	O
##Q	O
##AS	O
Vita	B
##min	I
D	I
External	O
Quality	O
Assessment	O
Scheme	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
de	O
##qa	O
##s	O
.	O
org	O
/	O
)	O
and	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
from	O
DE	O
##Q	O
##AS	O
analyzed	O
during	O
this	O
period	O
were	O
all	O
within	O
acceptable	O
limits	O
.	O

Interest	O
##ingly	O
,	O
the	O
authors	O
of	O
this	O
study	O
were	O
able	O
to	O
demonstrate	O
that	O
the	O
supplement	O
##ation	O
of	O
such	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
in	O
the	O
culture	O
medium	O
suppressed	O
the	O
N	O
##I	O
##H	O
-	O
3	O
##T	O
##3	O
transformation	O
by	O
K	O
-	O
Ra	O
##s	O
as	O
well	O
as	O
the	O
in	O
v	O
##it	O
##ro	O
growth	O
of	O
4	O
out	O
of	O
8	O
G	O
##C	O
cell	O
lines	O
.	O

Then	O
,	O
50	O
µ	O
##L	O
of	O
this	O
solution	O
was	O
transferred	O
to	O
96	O
-	O
well	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
plates	O
(	O
300	O
µ	O
##L	O
)	O
for	O
analysis	O
.	O

The	O
branched	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
have	O
recently	O
been	O
shown	O
to	O
be	O
precursor	O
##s	O
of	O
fatty	O
acid	O
synthesis	O
in	O
human	O
pre	O
##adi	O
##po	O
##cy	O
##tes	O
(	O
;	O
;	O
)	O
,	O
and	O
are	O
associated	O
with	O
growth	O
p	O
##hen	O
##otype	O
##s	O
in	O
C	O
.	O
El	O
##egan	O
##s	O
,	O
but	O
have	O
not	O
previously	O
been	O
observed	O
in	O
cancer	O
cells	O
.	O

(	O
E	O
)	O
CD	O
##8	O
T	O
cells	O
were	O
activated	S
,	O
treated	O
with	O
10	O
μ	O
##M	O
Ah	O
##R	O
##a	O
or	O
vehicle	O
control	O
(	O
D	O
##MS	O
##O	O
)	O
,	O
and	O
ass	O
##ay	O
##ed	O
for	O
cell	O
death	O
.	O

This	O
may	O
be	O
because	O
se	O
##psis	O
pro	O
##voke	O
##s	O
significant	O
alterations	O
in	O
energy	O
metabolism	O
home	O
##ost	O
##asis	O
with	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
u	B
##ric	I
acid	I
,	O
offering	O
possibly	O
useful	O
sur	O
##rogate	O
markers	O
of	O
infection	O
,	O
.	O

In	O
addition	O
,	O
the	O
low	O
levels	O
of	O
c	B
##rea	I
##tin	I
##ine	I
in	O
the	O
body	O
could	O
be	O
a	O
sign	O
that	O
the	O
liver	O
or	O
muscles	O
are	O
not	O
working	O
well	O
.	O

In	O
the	O
present	O
study	O
the	O
total	O
ch	B
##olin	I
##e	I
m	O
##oi	O
##ety	O
concentration	O
in	O
milk	O
was	O
lower	O
than	O
that	O
reported	O
by	O
USD	O
##A	O
throughout	O
la	O
##ct	O
##ation	O
;	O
with	O
mid	O
la	O
##ct	O
##ation	O
levels	O
less	O
than	O
half	O
of	O
late	O
la	O
##ct	O
##ation	O
levels	O
(	O
averaged	O
8	O
.	O
3	O
,	O
5	O
.	O
0	O
and	O
11	O
.	O
1	O
mg	O
/	O
100	O
g	O
in	O
early	O
,	O
mid	O
and	O
late	O
la	O
##ct	O
##ation	O
,	O
respectively	O
)	O
.	O

Anti	O
##ba	O
##cter	O
##ial	O
compounds	O
,	O
f	O
##usa	O
##ru	O
##bin	O
(	O
7	O
)	O
,	O
b	O
##ost	O
##ry	O
##co	O
##id	O
##in	O
(	O
12	O
)	O
,	O
and	O
an	B
##hy	I
##dr	I
##of	I
##usa	I
##ru	I
##bin	I
(	O
13	O
)	O
were	O
also	O
isolated	O
from	O
extract	O
of	O
F	O
.	O
so	O
##lani	O
,	O
end	O
##op	O
##hy	O
##te	O
from	O
the	O
root	O
of	O
C	O
.	O
al	O
##ata	O
(	O
Khan	O
et	O
al	O
.	O
2018	O
)	O
.	O

(	O
A	O
)	O
LP	O
##C	O
(	O
C	O
18	O
:	O
2	O
)	O
,	O
(	O
B	O
)	O
LP	O
##C	O
(	O
C	O
18	O
:	O
1	O
)	O
,	O
(	O
C	O
)	O
LP	O
##C	O
(	O
C	O
18	O
:	O
0	O
)	O
,	O
(	O
D	O
)	O
LP	O
##C	O
(	O
C	O
20	O
:	O
4	O
)	O
,	O
(	O
E	O
)	O
PC	O
(	O
C	O
16	O
:	O
0	O
,	O
C	B
20	I
:	I
5	I
)	O
,	O
(	O
F	O
)	O
PC	O
(	O
C	O
18	O
:	O
0	O
,	O
C	B
20	I
:	I
4	I
)	O
.	O

We	O
characterized	O
distributions	O
for	O
exposure	O
##s	O
and	O
co	O
##var	O
##iate	O
##s	O
,	O
and	O
imp	O
##uted	O
u	O
##rina	O
##ry	O
co	B
##tin	I
##ine	I
,	O
a	O
##rsen	O
##ic	O
,	O
and	O
p	O
##ht	O
##hala	O
##tes	O
values	O
below	O
the	O
method	O
L	O
##OD	O
##s	O
as	O
L	O
##OD	O
/	O
√	O
##2	O
prior	O
to	O
analysis	O
.	O

N	B
##AA	I
##G	I
is	O
one	O
of	O
the	O
three	O
most	O
prevalent	O
dip	O
##eptide	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
in	O
the	O
ma	O
##mmal	O
##ian	O
nervous	O
system	O
.	O

We	O
developed	O
and	O
valid	O
##ated	O
a	O
comprehensive	O
,	O
simple	O
and	O
rapid	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
can	B
##na	I
##bino	I
##id	I
urine	O
method	O
for	O
q	O
##uant	O
##ification	O
of	O
11	O
can	B
##na	I
##bino	I
##ids	I
and	O
meta	O
##bol	O
##ites	O
.	O

St	B
##ati	I
##ns	I
are	O
considered	O
the	O
first	O
line	O
treatment	O
of	O
h	O
##yper	O
##lip	O
##ide	O
##mia	O
,	O
especially	O
for	O
their	O
effect	O
in	O
reducing	O
the	O
risk	O
of	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
card	O
##iovascular	O
diseases	O
.	O

Important	O
##ly	O
,	O
u	O
##rina	O
##ry	O
P	O
##GE	O
-	O
M	O
levels	O
were	O
nearly	O
double	O
in	O
ever	O
(	O
n	O
=	O
13	O
)	O
versus	O
never	O
(	O
n	O
=	O
16	O
)	O
smoke	O
##rs	O
among	O
healthy	O
tumor	O
-	O
free	O
controls	O
(	O
15	O
.	O
2	O
versus	O
7	O
.	O
8	O
ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
P	O
=	O
0	O
.	O
00	O
##1	O
;	O
)	O
.	O

Despite	O
the	O
lack	O
of	O
interaction	O
in	O
our	O
study	O
,	O
however	O
,	O
there	O
remains	O
the	O
possibility	O
that	O
the	O
associations	O
we	O
observed	O
may	O
differ	O
for	O
non	O
##smo	O
##kers	O
,	O
by	O
alcohol	O
consumption	O
,	O
or	O
within	O
those	O
supplemented	O
with	O
a	O
different	O
dose	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
.	O

In	O
the	O
case	O
of	O
bi	O
##so	O
##p	O
##rol	O
##ol	O
,	O
the	O
most	O
significant	O
correlation	O
emerged	O
between	O
s	O
##ys	O
##to	O
##lic	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
di	O
##ast	O
##olic	O
(	O
P	O
=	O
0	O
.	O
00	O
##5	O
)	O
blood	O
pressure	O
lowering	O
vs	O
.	O
decrease	O
in	O
plasma	O
f	B
##ru	I
##ct	I
##ose	I
level	O
.	O

There	O
were	O
also	O
significant	O
differences	O
between	O
women	O
from	O
Guatemala	O
and	O
Pakistan	O
regarding	O
pp	O
##BM	O
##I	O
,	O
maternal	O
height	O
,	O
SE	O
##S	O
score	O
,	O
mode	O
of	O
delivery	O
,	O
infant	O
sex	O
,	O
and	O
f	B
##olate	I
supplement	O
##ation	O
.	O

With	O
increased	O
post	O
##pra	O
##ndi	O
##al	O
intake	O
of	O
both	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
and	O
lip	O
##ids	O
(	O
Fed	O
/	O
post	O
##pra	O
##ndi	O
##al	O
)	O
,	O
or	O
when	O
fatty	O
acids	O
(	O
FA	O
)	O
serve	O
as	O
the	O
major	O
fuel	O
(	O
Fast	O
##ing	O
)	O
,	O
β	O
-	O
oxidation	O
is	O
stimulate	O
##d	O
by	O
EPA	O
+	O
D	O
##HA	O
via	O
PP	O
##AR	O
##α	O
-	O
signaling	O
,	O
which	O
results	O
in	O
reduced	O
glucose	S
u	O
##til	O
##ization	O
(	O
red	O
dashed	O
lines	O
)	O
by	O
several	O
mechanisms	O
involving	O
the	O
Rand	O
##le	O
cycle	O
(	O
55	O
)	O
.	O

E	O
##rre	O
et	O
al	O
.	O
showed	O
that	O
AD	B
##MA	I
is	O
not	O
associated	O
with	O
art	O
##erial	O
stiff	O
##ness	O
in	O
patients	O
with	O
RA	O
.	O

However	O
,	O
this	O
finding	O
does	O
agree	O
with	O
the	O
hypothesis	O
that	O
2	O
-	O
pathway	O
cat	B
##ech	I
##ols	I
,	O
in	O
contrast	O
to	O
est	B
##rad	I
##iol	I
and	O
16	O
-	O
pathway	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
do	O
not	O
increase	O
est	B
##rogen	I
receptor	O
-	O
mediated	O
signaling	O
and	O
cell	O
proliferation	O
in	O
the	O
breast	O
since	O
they	O
bind	O
weakly	O
to	O
the	O
receptor	O
[	O
–	O
]	O
.	O

Although	O
the	O
supplement	O
##s	O
recommended	O
in	O
this	O
study	O
did	O
not	O
contain	O
car	B
##ni	I
##tine	I
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
patients	O
were	O
taking	O
car	B
##ni	I
##tine	I
on	O
their	O
own	O
.	O

U	O
##rine	O
and	O
serum	O
(	O
from	O
lit	B
##hium	I
he	I
##par	I
##in	I
tubes	O
)	O
samples	O
were	O
collected	O
before	O
the	O
ER	O
##CP	O
procedure	O
,	O
2	O
h	O
after	O
the	O
procedure	O
,	O
and	O
daily	O
thereafter	O
if	O
the	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
.	O

The	O
frequency	O
of	O
activated	S
(	O
H	O
##LA	O
-	O
DR	O
_	O
+	O
CD	O
##38	O
_	O
+	O
)	O
T	O
cells	O
was	O
significantly	O
lower	O
in	O
the	O
heavy	O
cannabis	O
-	O
using	O
group	O
compared	O
to	O
non	O
-	O
cannabis	O
-	O
using	O
individuals	O
for	O
both	O
CD	O
##4	O
_	O
+	O

Each	O
compound	O
concentration	O
was	O
then	O
normal	O
##ized	O
to	O
a	O
total	O
concentration	O
of	O
all	O
meta	O
##bol	O
##ites	O
in	O
the	O
sample	O
(	O
excluding	O
glucose	S
and	O
la	B
##ct	I
##ate	I
for	O
serum	O
and	O
plasma	O
samples	O
and	O
u	B
##rea	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
c	B
##it	I
##rate	I
for	O
urine	O
samples	O
because	O
of	O
excessive	O
##ly	O
large	O
volumes	O
that	O
otherwise	O
would	O
have	O
dominated	O
the	O
normal	O
##ization	O
)	O
.	O

At	O
##ten	O
##tion	O
was	O
given	O
to	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
of	O
o	B
##xy	I
##ster	I
##ol	I
is	I
##omer	I
##s	I
;	O
24	O
-	O
OH	O
##C	O
,	O
25	O
-	O
OH	O
##C	O
and	O
27	O
-	O
OH	O
##C	O
.	O

We	O
note	O
that	O
we	O
detected	O
two	O
test	O
##osterone	O
-	O
related	O
derivatives	O
,	O
5	B
##a	I
-	I
D	I
##HT	I
and	O
test	B
##osterone	I
su	I
##lf	I
##ate	I
(	O
or	O
e	B
##pit	I
##est	I
##osterone	I
su	I
##lf	I
##ate	I
or	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
)	O
,	O
which	O
are	O
positively	O
correlated	O
with	O
each	O
other	O
.	O

Analysis	O
of	O
N	O
##MR	O
s	O
##pect	O
##ra	O
by	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
of	O
high	O
compared	O
with	O
low	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
classes	O
.	O

As	O
in	O
our	O
study	O
of	O
breast	O
cancer	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
considered	O
parent	O
est	O
##rogen	O
##s	O
(	B
est	B
##rone	I
plus	O
est	O
##rad	O
##iol	O
)	O
,	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
grouped	O
into	O
three	O
major	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
(	O
2	O
-	O
,	O
4	O
-	O
,	O
and	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
)	O
;	O
the	O
ratio	O
of	O
meta	O
##bol	O
##ites	O
to	O
parent	O
est	B
##rogen	I
(	O
overall	O
and	O
separately	O
for	O
each	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
)	O
;	O
the	O
ratio	O
of	O
2	O
-	O
pathway	O
to	O
16	O
-	O
pathway	O
meta	O
##bol	O
##ites	O
;	O
total	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
and	O
total	O
E	O
##Ms	O
(	O
total	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
)	O
.	O

Other	O
compounds	O
potentially	O
derived	O
from	O
pharmaceutical	O
##s	O
included	O
the	O
as	B
##pi	I
##rin	I
meta	O
##bol	O
##ite	O
sa	B
##lic	I
##yl	I
##uri	I
##c	I
acid	I
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ite	O
2	B
-	I
h	I
##ydro	I
##xy	I
##ace	I
##tam	I
##ino	I
##phe	I
##n	I
su	I
##lf	I
##ate	I
.	O

Accordingly	O
,	O
Ke	O
##sler	O
et	O
al	O
.	O
reported	O
an	O
increased	O
level	O
of	O
pre	O
##front	O
##al	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
in	O
a	O
group	O
of	O
19	O
breast	O
cancer	O
survivors	O
after	O
ch	O
##em	O
##otherapy	O
.	O

P	O
##las	O
##ma	O
ch	B
##ole	I
##ster	I
##ol	I
concentration	O
in	O
control	O
,	O
h	O
##yper	O
##tensive	O
patients	O
with	O
normal	O
L	O
##V	O
size	O
(	O
H	O
##T	O
##N	O
normal	O
L	O
##V	O
)	O
and	O
h	O
##yper	O
##tensive	O
patients	O
with	O
L	O
##V	O
h	O
##yper	O
##tro	O
##phy	O
(	O
H	O
##T	O
##N	O
L	O
##V	O
##H	O
)	O
.	O

(	O
Sigma	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
)	O
(	O
3	O
)	O
,	O
Tax	O
##oter	O
##e	O
(	O
1	O
)	O
,	O
CE	O
##F	O
(	O
Cy	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
+	O
E	B
##pi	I
##ru	I
##bic	I
##in	I
,	O
+	O
5	B
-	I
F	I
##lu	I
##oro	I
##ura	I
##ci	I
##l	I
(	O
CE	O
##F	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
)	O

p	B
(	I
x	I
,	I
y	I
;	I
Θ	I
)	I
[UNK]	B
(	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
+	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##ρ	I
##s	I
##j	I
(	I
y	I
##j	I
)	I
x	I
##s	I
+	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##φ	I
##r	I
##j	I
(	I
y	I
##r	I
,	I
y	I
##j	I
)	I
)	I
.	O

Fun	O
##ctional	O
differences	O
in	O
serum	O
metabolic	O
networks	O
related	O
to	O
as	B
##par	I
##tate	I
metabolism	O
were	O
identified	O
in	O
patients	O
with	O
AP	S
.	O

A	O
consisted	O
of	O
0	O
.	O
1	O
%	O
FA	S
in	O
water	O
,	O
while	O
mobile	O
phase	O
B	O
consisted	O
of	O
0	O
.	O
1	O
%	O
FA	S
in	O
met	B
##han	I
##ol	I
.	O

As	O
a	O
result	O
,	O
it	O
is	O
reasonable	O
to	O
use	O
the	O
product	O
of	O
put	B
##res	I
##cine	I
and	O
sperm	B
##id	I
##ine	I
concentration	O
as	O
a	O
diagnostic	O
marker	O
to	O
character	O
##ize	O
liver	O
and	O
lung	O
cancer	O
.	O

cigarettes	O
smoked	O
per	O
day	O
(	O
CP	O
##D	O
)	O
,	O
ni	B
##cot	I
##ine	I
dependence	O
scores	O
(	O
F	O
##ager	O
##st	O
##röm	O
Test	O
for	O
Nico	B
##tine	I
De	O
##pen	O
##dence	O
,	O
F	O
##T	O
##ND	O
;	O
Hook	O
##ed	O
On	O
Nico	B
##tine	I
Check	O
##list	O
,	O
H	O
##ON	O
##C	O
)	O
,	O
and	O
ceremonial	O
traditional	O
tobacco	O
use	O
.	O

pH	O
11	O
.	O
0	O
,	O
–	O
15	O
k	B
##V	I
was	O
used	O
on	O
AM	O
##PS	O
and	O
V	O
##B	O
##TA	O
coated	O
cap	O
##illa	O
##ry	O
,	O
respectively	O
.	O

Because	O
g	B
##lut	I
##ama	I
##te	I
is	O
a	O
highly	O
polar	O
meta	O
##bol	O
##ite	O
,	O
it	O
el	O
##utes	O
early	O
under	O
reversed	O
-	O
phase	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
and	O
is	O
represented	O
by	O
poorly	O
shaped	O
ch	O
##roma	O
##to	O
##graphic	O
peak	O
,	O
which	O
leads	O
to	O
less	O
accurate	O
results	O
.	O

Ser	O
##um	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
were	O
similar	O
in	O
both	O
groups	O
,	O
so	O
is	O
unlikely	O
to	O
have	O
contributed	O
to	O
u	O
##rina	O
##ry	O
differences	O
.	O

Therefore	O
,	O
identification	O
of	O
intact	O
G	O
##H	O
and	O
the	O
c	O
##13	O
ion	O
fragment	O
,	O
co	O
##rro	O
##bor	O
##ated	O
with	O
a	O
disruption	O
of	O
re	B
##tic	I
##ulin	I
fiber	O
network	O
diagnosed	O
G	O
##H	O
-	O
secret	O
##ing	O
PA	O
.	O

A	O
##ffin	O
##ity	O
label	O
##ing	O
of	O
c	B
##ys	I
##tein	I
##e	I
28	O
##2	O
with	O
N	B
-	I
(	I
2	I
,	I
3	I
-	I
e	I
##pox	I
##y	I
##p	I
##rop	I
##yl	I
)	I
-	I
N	I
-	I
amid	I
##ino	I
##gly	I
##cine	I
.	O

L	O
D	O
##TT	O
as	O
a	O
stab	O
##ili	O
##zing	O
medium	O
for	O
T	O
##P	O
##N	O
in	O
RB	O
##C	O
l	O
##ys	O
##ates	O
}	O
demonstrated	O
the	O
suit	O
##ability	O
of	O
such	O
protocol	O
for	O
a	O
well	O
-	O
defined	O
and	O
reliable	O
routine	O
use	O
in	O
studies	O
on	O
th	B
##io	I
##pur	I
##ines	I
TD	O
##M	O
.	O

However	O
,	O
the	O
opposite	O
change	O
has	O
been	O
observed	O
in	O
patients	O
with	O
inflammatory	O
disorders	O
:	O
none	O
##ster	O
##ified	O
car	B
##ni	I
##tine	I
was	O
extremely	O
decreased	O
,	O
while	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
significantly	O
increased	O
in	O
patient	O
plasma	O
.	O

Accordingly	O
,	O
alterations	O
in	O
se	B
##rot	I
##oni	I
##n	I
metabolism	O
may	O
be	O
fundamental	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
G	O
##DM	O
.	O

A	O
test	O
of	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
coefficients	O
between	O
post	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
and	O
meta	O
##bol	O
##ites	O
at	O
base	O
##line	O
adjusting	O
for	O
pre	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
showed	O
that	O
greater	O
L	O
##D	O
##L	O
-	O
C	O
lowering	O
was	O
correlated	O
with	O
lower	O
levels	O
of	O
u	B
##rid	I
##ine	I
(	O
p	O
<	O
0	O
.	O
04	O
##10	O
,	O
q	O
<	O
0	O
.	O
68	O
)	O
and	O
higher	O
levels	O
of	O
pseudo	B
##uri	I
##dine	I
(	O
p	O
<	O
0	O
.	O
01	O
##40	O
,	O
q	O
<	O
0	O
.	O
60	O
)	O
.	O

Ex	O
##c	O
##lu	O
##ding	O
c	B
##rea	I
##tin	I
##ine	I
and	O
demographic	O
##s	O
still	O
led	O
to	O
a	O
meta	O
##bol	O
##ite	O
equation	O
with	O
good	O
accuracy	O
(	O
>	O
30	O
%	O
from	O
m	O
##G	O
##F	O
##R	O
,	O
1	O
-	O
P	O
_	O
30	O
<	O
6	O
.	O
4	O
%	O
)	O
,	O
suggesting	O
a	O
path	O
to	O
e	O
##G	O
##F	O
##R	O
tests	O
that	O
are	O
accurate	O
and	O
independent	O
of	O
c	B
##rea	I
##tin	I
##ine	I
and	O
demographic	O
##s	O
.	O

In	O
order	O
to	O
determine	O
add	O
##uc	O
##ts	O
of	O
to	B
##lue	I
##ne	I
di	O
##is	O
##oc	O
##yana	O
##tes	O
(	O
TD	O
##I	O
)	O
with	O
blood	O
proteins	O
,	O
several	O
reaction	O
products	O
of	O
2	B
,	I
4	I
-	I
to	I
##lue	I
##ne	I
di	O
##is	O
##oc	O
##yana	O
##te	O
(	O
24	O
##T	O
##DI	O
)	O
and	O
2	B
,	I
6	I
-	I
to	I
##lue	I
##ne	I
di	O
##is	O
##oc	O
##yana	O
##te	O
(	O
26	O
##T	O
##DI	O
)	O
with	O
amino	O
acids	O
were	O
synthesized	O
in	O
v	O
##it	O
##ro	O
.	O

Medium	O
,	O
a	O
significant	O
higher	O
concentration	O
of	O
la	B
##ct	I
##ate	I
was	O
registered	O
.	O

Yi	B
##j	I
=	I
β	I
##o	I
##j	I
+	I
Xi	I
##1	I
##β	I
##1	I
##j	I
+	I
Xi	I
##2	I
##β	I
##2	I
##j	I
+	I
…	I
+	I
Xi	I
##p	I
##β	I
##p	I
##j	I
+	I
ε	I
##i	I
##j	I

For	O
the	O
lip	O
##id	O
fraction	O
,	O
tandem	O
-	O
MS	O
experiments	O
made	O
the	O
observation	O
of	O
specific	O
transitions	O
possible	O
that	O
are	O
typical	O
for	O
certain	O
lip	O
##id	O
classes	O
,	O
especially	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

In	O
fifteen	O
cases	O
with	O
detection	O
of	O
D	O
##MA	O
##P	O
or	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
,	O
four	O
cases	O
did	O
not	O
visit	O
the	O
clinic	O
again	O
.	O

The	O
paired	O
Student	O
’	O
s	O
t	O
test	O
results	O
(	O
cancer	O
versus	O
his	O
##to	O
-	O
ben	O
##ign	O
from	O
the	O
same	O
patients	O
)	O
for	O
principal	O
component	O
13	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
ch	B
##olin	I
##e	I
are	O
0	O
.	O
01	O
##2	O
,	O
0	O
.	O
00	O
##4	O
,	O
and	O
0	O
.	O
00	O
##1	O
.	O

Inc	O
##uba	O
##tions	O
(	O
200	O
µ	O
##l	O
)	O
contained	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
500	O
µ	O
##m	O
)	O
,	O
50	O
mm	O
Tri	O
##s	O
-	O
HC	O
##l	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
5	O
mm	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
,	O
0	O
.	O
5	O
mg	O
m	O
##l	O
_	O
−	O
##1	O
micro	O
##some	O
##s	O
/	O
re	O
##comb	O
##ina	O
##nt	O
U	O
##G	O
##T	O
##s	O
and	O
5	O
mm	O
U	O
##DP	O
-	O
g	O
##lu	O
##cu	O
##ronic	O
acid	O
(	O
U	O
##DP	O
##GA	O
)	O
,	O
and	O
were	O
carried	O
out	O
at	O
37	O
##°	O
##C	O
for	O
90	O
min	O
.	O

We	O
found	O
that	O
plasma	O
levels	O
of	O
beta	B
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
(	O
N	O
##AG	O
)	O
were	O
notice	O
##ably	O
increased	O
.	O

He	B
##pta	I
##f	I
##lu	I
##oro	I
##but	I
##yric	I
acid	I
(	O
H	O
##FB	O
##A	O
)	O
was	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
.	O

Unfortunately	O
,	O
due	O
to	O
the	O
large	O
variations	O
of	O
o	B
##le	I
##ic	I
acid	I
content	O
between	O
samples	O
,	O
the	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
B	O
##MI	O
,	O
body	O
mass	O
index	O
;	O
FA	S
,	O
fatty	O
acid	O
;	O
HD	O
##L	O
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
.	O

The	O
abnormal	O
levels	O
of	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
and	O
Met	O
and	O
the	O
abnormal	O
ratio	O
##n	O
of	O
these	O
two	O
meta	O
##bol	O
##ites	O
did	O
not	O
significantly	O
change	O
after	O
8	O
weeks	O
of	O
treatment	O
with	O
anti	O
##de	O
##press	O
##ants	O
.	O

By	O
hazard	O
ratio	O
(	O
H	O
##R	O
)	O
analysis	O
,	O
the	O
H	O
##R	O
of	O
p	B
-	I
c	I
##res	I
##ol	I
,	O
pro	B
##line	I
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
was	O
2	O
.	O
68	O
##8	O
(	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
40	O
##3	O
-	O
5	O
.	O
150	O
)	O
,	O
2	O
.	O
47	O
##3	O
(	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
29	O
##3	O
-	O
4	O
.	O
72	O
##8	O
)	O
and	O

F	B
##oll	I
##ista	I
##tin	I
was	O
increased	O
at	O
C	O
##1	O
(	O
1	O
,	O
71	O
##5	O
±	O
87	O
##6	O
p	O
##g	O
/	O
m	O
##l	O
)	O
in	O
comparison	O
to	O
base	O
##line	O
.	O

Interest	O
##ingly	O
,	O
those	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
that	O
were	O
not	O
significantly	O
correlated	O
with	O
sperm	O
concentration	O
were	O
linked	O
to	O
sperm	O
m	O
##ot	O
##ility	O
.	O

The	O
meta	O
##bol	O
##ite	O
samples	O
were	O
first	O
der	O
##iva	O
##tized	O
by	O
met	O
##ho	O
##xy	O
##ami	O
##nation	O
by	O
adding	O
50	O
μ	O
##L	O
of	O
20	O
mg	O
/	O
m	O
##L	O
solution	O
of	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
in	O
p	B
##yr	I
##id	I
##ine	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
##°	O
##C	O
for	O
two	O
hours	O
.	O

In	O
an	O
initial	O
assessment	O
of	O
the	O
meta	O
##bol	O
##ites	O
,	O
we	O
investigated	O
t	B
##rig	I
##one	I
##llin	I
##e	I
as	O
a	O
potential	O
bio	O
##mark	O
##er	O
for	O
kidney	O
rejection	O
.	O

The	O
sample	O
preparation	O
protocol	O
included	O
in	O
the	O
first	O
step	O
an	O
in	O
##cu	O
##bation	O
of	O
a	O
mixture	O
containing	O
100	O
μ	O
##L	O
plasma	O
,	O
25	O
μ	O
##L	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
8	O
mg	O
/	O
m	O
##L	O
(	O
corresponding	O
to	O
an	O
activity	O
of	O
113	O
.	O
2	O
U	O
)	O
;	O
25	O
μ	O
##L	O
su	O
##lf	O
##ata	O
##se	O
,	O
50	O
units	O
/	O
m	O
##L	O
;	O
10	O
μ	O
##L	O
para	B
##ce	I
##tam	I
##ol	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
10	O
μ	O
##g	O
/	O
m	O
##L	O
;	O
40	O
μ	O
##L	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
,	O
1	O
mg	O
/	O
m	O
##L	O
(	O
all	O
solutions	O
prepared	O
in	O
sodium	B
ace	I
##tate	I
0	O
.	O
2	O
M	O
,	O
pH	O
4	O
.	O
5	O
)	O
;	O
and	O
200	O
μ	O
##L	O
sodium	B
ace	I
##tate	I
,	O
0	O
.	O
2	O
M	O
(	O
pH	O
4	O
.	O
5	O
)	O
,	O
for	O
12	O
h	O
at	O
37	O
°C	O
,	O
with	O
constant	O
mixing	O
(	O
Me	O
##mmer	O
##t	O
)	O
.	O

E	B
##stro	I
##gen	I
metabolism	O
and	O
cat	O
##ab	O
##olis	O
##m	O
and	O
potential	O
modifications	O
by	O
di	B
##ox	I
##ins	I
or	O
di	O
##ox	O
##in	O
-	O
like	O
compounds	O
.	O

Intermediate	O
##s	O
of	O
the	O
g	B
##ly	I
##cer	I
##ol	I
shuttle	O
(	O
c	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
T	O
##IC	O
##L	O
t	B
##ic	I
##lop	I
##id	I
##ine	I
(	O
C	O
##YP	O
##2	O
##B	O
##6	O
and	O
C	O
##YP	O
##2	O
##C	O
##19	O
)	O
,	O
Q	O
##UE	O
##RC	O
que	B
##rc	I
##eti	I
##n	I
(	O
C	O
##YP	O
##2	O
##C	O
##8	O
)	O
,	O
T	O
##MP	O
trim	O
##eth	O
##op	O
##rim	O
(	O
C	O
##YP	O
##2	O
##C	O
##8	O
)	O
,	O
T	O
##A	O
##O	O
t	B
##rol	I
##ean	I
##dom	I
##y	I
##cin	I
(	O
C	O
##YP	O
##3	O
##A	O
)	O
,	O
Ke	O
##to	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
(	O
C	O
##YP	O
##3	O
##A	O
)	O
,	O
P	O
##IL	O
##O	O
p	B
##ilo	I
##car	I
##pine	I
(	O
C	O
##YP	O
##2	O
##A	O
##6	O
)	O
,	O
DE	O
##DC	O
##A	O
diet	B
##hyl	I
##dio	I
##thi	I
##car	I
##ba	I
##mate	I
(	O
C	O
##YP	O
##2	O
##E	O
##1	O
)	O
,	O
S	O
##U	O
##LP	O
##H	O
su	B
##lf	I
##aph	I
##ena	I
##zo	I
##le	I
(	O
C	O
##YP	O
##2	O
##C	O
##9	O
)	O
,	O
F	O
##UR	O
##A	O
fur	B
##af	I
##yl	I
##line	I
(	O
C	O
##YP	O
##1	O
##A	O
##2	O
)	O
,	O
Q	O
##UI	O
##N	O
q	B
##uin	I
##id	I
##ine	I
m	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
ch	O
##roma	O
##to	O
##graphic	O
purity	O
)	O
and	O
form	B
##ic	I
acid	I
(	O
ch	O
##roma	O
##to	O
##graphic	O
purity	O
)	O
were	O
purchased	O
from	O
Me	O
##rc	O
##k	O
(	O
Germany	O
)	O
.	O

All	O
the	O
participants	O
gave	O
their	O
written	O
informed	O
consent	O
before	O
entering	O
the	O
study	O
,	O
which	O
was	O
approved	O
by	O
the	O
relevant	O
national	O
authority	O
(	O
l	O
’	O
Age	O
##nce	O
national	O
##e	O
de	O
s	O
##é	O
##cu	O
##rit	O
##é	O
du	O
me	O
##dic	O
##ament	O
et	O
des	S
pro	O
##du	O
##its	O
de	O
sa	O
##nt	O
##é	O
)	O
and	O
by	O
the	O
Il	O
##e	O
de	O
France	O
VII	O
ethics	O
committee	O
.	O

The	O
authors	O
found	O
that	O
certain	O
intermediate	O
##s	O
of	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
and	O
meta	O
##bol	O
##ites	O
relating	O
to	O
energy	O
metabolism	O
,	O
amino	O
acids	O
,	O
and	O
gut	O
micro	O
##bial	O
metabolism	O
,	O
were	O
per	O
##tur	O
##bed	O
.	O

The	O
levels	O
of	O
al	O
##chor	O
##no	O
##ic	O
acid	O
,	O
P	O
##I	O
(	O
13	O
:	O
0	O
/	O
22	O
:	O
1	O
)	O
,	O
15	B
-	I
o	I
##x	I
##o	I
-	I
18	I
##Z	I
-	I
te	I
##tra	I
##cos	I
##eno	I
##ic	I
acid	I
,	O
2	B
-	I
o	I
##x	I
##o	I
-	I
do	I
##cos	I
##ano	I
##ic	I
acid	I
,	O
and	O
an	B
##hy	I
##dr	I
##or	I
##ho	I
##do	I
##vi	I
##bri	I
##n	I
were	O
decreased	O
in	O
the	O
newly	O
diagnosed	O
T	O
##2	O
##DM	O
group	O
with	O
fold	O
changes	O
of	O
9	O
.	O
74	O
,	O
5	O
.	O
97	O
,	O
4	O
.	O
07	O
,	O
3	O
.	O
51	O
,	O
and	O
3	O
.	O
27	O
,	O
respectively	O
.	O

Ad	O
##ju	O
##sting	O
for	O
sex	O
,	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
K	O
##A	O
,	O
X	O
##A	O
,	O
H	O
##AA	O
and	O
vitamin	B
B	I
##2	I
were	O
associated	O
with	O
increased	O
risk	O
of	O
having	O
AD	O
##HD	O
.	O

For	O
method	O
development	O
and	O
valid	O
##ation	O
,	O
2	O
-	O
m	O
##l	O
al	O
##iq	O
##uo	O
##ts	O
of	O
charcoal	O
-	O
treated	O
human	O
urine	O
samples	O
were	O
spike	O
##d	O
with	O
a	O
total	O
of	O
250	O
,	O
500	O
or	O
1	O
,	O
000	O
p	O
##g	O
of	O
the	O
40	O
est	O
##rogen	O
-	O
related	O
compounds	O
(	O
final	O
concentration	O
0	O
.	O
125	O
,	O
0	O
.	O
25	O
and	O
0	O
.	O
50	O
p	O
##g	O
/	O
μ	O
##l	O
)	O
and	O
loaded	O
onto	O
the	O
p	O
##hen	O
##yl	O
100	O
-	O
mg	O
cartridges	O
pre	O
##con	O
##dition	O
##ed	O
with	O
CH	O
_	O
3	O
OH	O
and	O
the	O
loading	O
buffer	O
,	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
pH	O
7	O
.	O

O	B
##xy	I
##ster	I
##ols	I
are	O
present	O
in	O
their	O
un	O
##con	O
##ju	O
##gated	O
form	O
in	O
CS	O
##F	O
at	O
low	O
levels	O
(	O
<	O
1	O
ng	O
/	O
m	O
##l	O
)	O
;	O
therefore	O
,	O
to	O
further	O
ma	O
##xi	O
##mize	O
the	O
sensitivity	O
of	O
analysis	O
,	O
an	O
MR	O
##M	O
-	O
like	O
experiment	O
was	O
performed	O
in	O
the	O
L	O
##IT	O
in	O
parallel	O
to	O
the	O
acquisition	O
of	O
high	O
resolution	O
mass	O
scan	O
##s	O
in	O
the	O
Or	O
##bit	O
##rap	O
(	O
see	O
the	O
second	O
experimental	O
method	O
under	O
“	O
Experimental	O
Pro	O
##ced	O
##ures	O
”	O
)	O
.	O

C	B
##it	I
##rate	I
is	O
a	O
known	O
potent	O
all	O
##ost	O
##eric	O
inhibitor	O
of	O
p	O
##yr	O
##u	O
##vate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
which	O
is	O
why	O
increased	O
in	O
##tra	O
##cellular	O
c	B
##it	I
##rate	I
levels	O
red	O
##ire	O
##ct	O
the	O
conversion	O
of	O
p	B
##yr	I
##u	I
##vate	I
from	O
ace	O
##ty	O
##l	O
co	O
##en	O
##zy	O
##me	O
A	O
to	O
la	B
##ct	I
##ate	I
,	O
consequently	O
leading	O
to	O
increased	O
la	B
##ct	I
##ate	I
plasma	O
levels	O
.	O

Try	B
##pt	I
##op	I
##han	I
(	O
_	O
15	O
N	O
_	O
2	O
)	O
and	O
k	B
##yn	I
##uren	I
##ine	I
(	I
ring	I
-	I
D	I
_	I
4	I
,	I
3	I
,	I
3	I
-	I
D	I
_	I
2	I
)	I
were	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
Incorporated	O
.	O

We	O
discarded	O
3	O
patients	O
due	O
to	O
the	O
confirmation	O
of	O
clan	B
##destine	I
high	O
consumption	O
of	O
alcohol	O
or	O
prescribed	O
medication	O
that	O
could	O
alter	O
liver	O
function	O
.	O

Only	O
by	O
applying	O
blood	O
in	O
##cu	O
##bation	O
periods	O
of	O
more	O
than	O
15	O
h	O
were	O
ta	B
##uri	I
##ne	I
concentrations	O
significantly	O
increased	O
.	O

7	B
-	I
(	I
N	I
-	I
Ace	I
##ty	I
##l	I
##cs	I
##yte	I
##in	I
##yl	I
)	I
-	I
8	I
,	I
9	I
,	I
10	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
7	I
,	I
8	I
,	I
9	I
,	I
10	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##obe	I
##nz	I
##o	I
[	I
a	I
]	I
p	O
##yre	O
##ne	O
(	O
re	O
##v	O
-	O
BP	O
##DE	O
-	O
7	O
-	O
N	O
##AC	O
)	O
was	O
prepared	O
essentially	O
as	O
described	O
previously	O
.	O

Generally	O
,	O
3	B
##α	I
##HS	I
##Ds	I
enzymes	O
are	O
expressed	O
tissue	O
specific	O
and	O
are	O
important	O
for	O
the	O
metabolism	O
of	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oids	I
,	O
pro	B
##ges	I
##tero	I
##nes	I
,	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
,	O
and	O
bi	O
##le	O
acid	O
precursor	O
##s	O
.	O

Finally	O
,	O
targeted	O
UP	O
##LC	O
-	O
MS	O
/	O
MS	O
based	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
was	O
performed	O
on	O
human	O
breast	O
tissues	O
to	O
investigate	O
total	O
est	B
##rogen	I
an	O
##ab	O
##olic	O
/	O
cat	O
##ab	O
##olic	O
pathways	O
using	O
total	O
42	O
s	O
##tero	O
##ids	O
and	O
est	B
##rogen	I
related	O
reference	O
standards	O
.	O

It	O
should	O
be	O
noted	O
that	O
e	B
##ico	I
##san	I
##oid	I
precursor	O
##s	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Alpha	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
(	O
A	O
##FP	O
)	O
,	O
the	O
most	O
widely	O
used	O
tumor	O
marker	O
for	O
detect	O
##ing	O
liver	O
cancer	O
,	O
is	O
affected	O
by	O
different	O
path	O
##op	O
##hy	O
##sio	O
##logical	O
conditions	O
,	O
including	O
pregnancy	O
,	O
he	O
##pa	O
##titis	O
,	O
and	O
the	O
involvement	O
of	O
other	O
types	O
of	O
cancer	O
.	O

Two	O
meta	O
##bol	O
##ites	O
,	O
2	B
-	I
met	I
##hyl	I
##hip	I
##pur	I
##ic	I
acid	I
and	O
5	B
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
6	I
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
##ura	I
##ci	I
##l	I
,	O
were	O
marked	O
##ly	O
increased	O
in	O
CO	O
##PD	O
smoke	O
##rs	O
compared	O
to	O
healthy	O
non	O
-	O
smoke	O
##rs	O
,	O
and	O
also	O
showed	O
a	O
trend	O
of	O
increase	O
in	O
comparison	O
with	O
healthy	O
smoke	O
##rs	O
,	O
with	O
P	O
values	O
approaching	O
significance	O
.	O

hi	B
hi	I
h	O

To	O
evaluate	O
linear	O
##ity	O
of	O
standard	O
curves	O
,	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
were	O
prepared	O
at	O
concentrations	O
of	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
100	O
and	O
200	O
p	O
##g	O
/	O
m	O
##L	O
of	O
each	O
est	B
##rogen	I
in	O
charcoal	O
stripped	O
human	O
serum	O
,	O
except	O
for	O
4	B
-	I
OH	I
-	I
E	I
##2	I
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
,	O
which	O
were	O
prepared	O
at	O
10	O
times	O
higher	O
concentration	O
.	O

The	O
al	B
##ip	I
##hat	I
##ic	I
region	O
at	O
0	O
.	O
8	O
–	O
4	O
.	O
5	O
pp	O
##m	O
in	O
all	O
s	O
##pect	O
##ra	O
included	O
strong	O
signals	O
from	O
water	O
-	O
soluble	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
la	B
##ct	I
##ate	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
ace	B
##tone	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##one	I
,	O
ma	B
##lon	I
##ate	I
,	O
and	O
ch	B
##olin	I
##e	I
.	O

The	O
detail	O
regulation	O
of	O
his	B
##ti	I
##dine	I
-	I
his	I
##tamine	I
pathway	O
and	O
its	O
role	O
in	O
AD	O
need	O
more	O
research	O
to	O
evaluate	O
.	O

Lac	B
##tate	I
is	O
known	O
to	O
a	O
##cc	O
##um	O
##ulate	O
at	O
sites	O
of	O
inflammation	O
,	O
not	O
only	O
due	O
to	O
h	O
##y	O
##pox	O
##ic	O
conditions	O
forcing	O
the	O
switch	O
to	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
,	O
but	O
also	O
to	O
meet	O
the	O
general	O
demands	O
of	O
the	O
highly	O
pro	O
##life	O
##rative	O
immune	O
cells	O
.	O

The	O
obtained	O
results	O
demonstrate	O
the	O
discovery	O
of	O
a	O
surprising	O
and	O
unexpected	O
phenomenon	O
,	O
a	O
massive	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
in	O
processed	O
human	O
blood	O
serum	O
.	O

In	O
this	O
study	O
with	O
young	O
and	O
middle	O
-	O
aged	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
women	O
,	O
we	O
found	O
that	O
insulin	O
resistance	O
was	O
associated	O
with	O
increased	O
serum	O
BC	O
##AA	O
levels	O
,	O
independent	O
of	O
o	O
##besity	O
.	O

First	O
,	O
we	O
confirmed	O
the	O
potential	O
pro	O
##gno	O
##stic	O
utility	O
of	O
AD	B
##MA	I
in	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
severity	O
and	O
related	O
events	O
in	O
a	O
large	O
co	O
##hor	O
##t	O
of	O
patients	O
undergoing	O
elect	O
##ive	O
diagnostic	O
cardiac	O
cat	O
##he	O
##ter	O
##ization	O
.	O

Ser	O
##um	O
meta	O
##bol	O
##omi	O
##cs	O
has	O
unveiled	O
changed	O
levels	O
of	O
glucose	S
,	O
g	B
##lut	I
##amine	I
,	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
_	I
,	O
consistent	O
with	O
enhanced	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
and	O
g	B
##lut	I
##ami	I
##no	I
##ly	I
##tic	I
activities	O
,	O
showed	O
potential	O
in	O
ne	O
##ph	O
##re	O
##ct	O
##omy	O
follow	O
-	O
up	O
and	O
patient	O
staging	O
,	O
and	O
more	O
recently	O
produced	O
a	O
possible	O
bio	O
##mark	O
##er	O
cluster	O
of	O
7	O
meta	O
##bol	O
##ites	O
(	B
al	B
##ani	I
##ne	I
,	O
c	B
##rea	I
##tine	I
,	O
ch	B
##olin	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
)	O
for	O
early	O
RC	O
##C	O
.	O

C	O
##ir	O
##cula	O
##ting	O
s	O
##tero	O
##ls	O
are	O
composed	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
an	O
essential	O
component	O
of	O
membrane	O
##s	O
by	O
regulating	O
the	O
fluid	O
##ity	O
of	O
the	O
bi	O
##layer	O
,	O
several	O
precursor	O
##s	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
as	O
la	B
##nos	I
##tero	I
##l	I
which	O
are	O
markers	O
for	O
ch	B
##ole	I
##ster	I
##ol	I
synthesis	O
,	O
and	O
plant	O
s	O
##tero	O
##ls	O
which	O
are	O
exclusively	O
derived	O
from	O
diet	O
##ary	O
sources	O
(	O
Ku	O
##ks	O
##is	O
)	O
.	O

Given	O
established	O
di	O
##sp	O
##arity	O
between	O
bio	O
##psy	O
and	O
R	B
##P	I
his	O
##top	O
##ath	O
##ology	O
,	O
risk	O
classification	O
accuracy	O
was	O
op	O
##ti	O
##mized	O
using	O
which	O
##ever	O
his	O
##top	O
##ath	O
##ology	O
best	O
described	O
tumor	O
characteristics	O
.	O

Op	O
##po	O
##site	O
variation	O
directions	O
of	O
certain	O
meta	O
##bol	O
##ites	O
observed	O
with	O
BT	O
were	O
not	O
observed	O
for	O
other	O
meta	O
##bol	O
##ites	O
such	O
as	O
ben	B
##zo	I
##ate	I
and	O
g	B
##lut	I
##arate	I
.	O

As	O
in	O
pool	O
##ed	O
human	O
serum	O
,	O
c	B
##it	I
##rate	I
concentration	O
was	O
lower	O
in	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
human	O
serum	O
from	O
se	O
##psis	O
patients	O
than	O
in	O
Me	B
##OH	I
:	O

The	O
levels	O
of	O
the	O
14	O
disc	O
##rim	O
##ina	O
##tive	O
L	O
##MI	O
##s	O
were	O
higher	O
in	O
the	O
PC	O
and	O
BT	O
##C	O
groups	O
than	O
in	O
the	O
control	O
,	O
CR	O
##C	O
and	O
O	O
##VC	O
groups	O
,	O
but	O
only	O
two	O
L	O
##MI	O
##s	O
disc	O
##rim	O
##inated	O
between	O
PC	O
and	O
BT	O
##C	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
L	O
##ys	O
##o	O
##PC	O
)	O
(	O
16	O
:	O
0	O
)	O
and	O
L	B
##ys	I
##o	I
##PC	I
(	I
20	I
:	I
4	I
)	I
.	O

The	O
median	O
(	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
)	O
for	O
pro	B
##ges	I
##tero	I
##ne	I
in	O
women	O
sampled	O
in	O
the	O
f	O
##oll	O
##icular	O
phase	O
(	O
n	O
=	O
19	O
)	O
at	O
T	O
##P	O
##1	O
was	O
0	O
.	O
9	O
(	O
0	O
.	O
9	O
–	O
1	O
.	O
0	O
)	O
nm	O
##ol	O
/	O
L	O
and	O
1	O
.	O
5	O
(	O
1	O
.	O
0	O
–	O
3	O
.	O
3	O
)	O
nm	O
##ol	O
/	O
L	O
at	O
T	O
##P	O
2	O
,	O
and	O
for	O
women	O
sampled	O
in	O
the	O
l	O
##ute	O
##al	O
phase	O
(	O
n	O
=	O
4	O
)	O
at	O
T	O
##P	O
##1	O
it	O
was	O
3	O
.	O
6	O
(	O
0	O
.	O
9	O
–	O
13	O
.	O
3	O
)	O
nm	O
##ol	O
/	O
L	O
and	O
at	O
T	O
##P	O
##2	O
it	O
was	O
12	O
(	O
1	O
–	O
27	O
)	O
nm	O
##ol	O
/	O

For	O
example	O
,	O
the	O
try	B
##pt	I
##op	I
##han	I
concentrations	O
observed	O
in	O
the	O
afternoon	O
and	O
at	O
night	O
were	O
significantly	O
decreased	O
in	O
comparison	O
with	O
those	O
detected	O
in	O
the	O
morning	O
(	O
and	O
)	O
,	O
and	O
these	O
differences	O
might	O
have	O
been	O
due	O
to	O
the	O
effects	O
of	O
diet	O
and	O
/	O
or	O
daily	O
activity	O
.	O

Specifically	O
,	O
high	O
f	O
##eca	O
##l	O
micro	O
##bial	O
diversity	O
,	O
as	O
measured	O
by	O
whole	O
-	O
tree	O
phylogenetic	O
diversity	O
,	O
was	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
a	O
high	O
ratio	O
of	O
meta	O
##bol	O
##ites	O
to	O
parent	O
est	B
##rogen	I
;	O
these	O
measures	O
of	O
micro	O
##bial	O
diversity	O
had	O
similar	O
correlation	O
##s	O
with	O
analogous	O
ratios	O
for	O
each	O
metabolic	O
pathway	O
(	O
2	O
-	O
,	O
4	O
-	O
,	O
and	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
)	O
.	O

Specifically	O
,	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
and	O
n	O
##uc	O
##leo	O
##tide	O
meta	O
##bol	O
##ite	O
pools	O
were	O
significantly	O
decreased	O
.	O

The	O
time	O
course	O
(	O
0	O
–	O
8	O
h	O
)	O
of	O
plasma	O
concentrations	O
of	O
the	O
met	B
##had	I
##one	I
meta	O
##bol	O
##ite	O
E	O
##D	O
##DP	O
(	O
mean	O
(	O
s	O
.	O
d	O
.	O
)	O
)	O
in	O
seven	O
healthy	O
subjects	O
after	O
IV	O
-	O
re	O
##ct	O
##al	O
,	O
and	O
oral	O
-	O
re	O
##ct	O
##al	O
administration	O
of	O
met	B
##had	I
##one	I
-	I
HC	I
##l	I
(	O
5	O
mg	O
IV	O
,	O
10	O
mg	O
re	O
##ct	O
##ally	O
(	O
de	O
##uter	O
##ated	O
met	B
##had	I
##one	I
)	O
and	O
oral	O
##ly	O
)	O
.	O

Of	O
the	O
meta	O
##bol	O
##ites	O
that	O
changed	O
with	O
limo	B
##nen	I
##e	I
treatment	O
,	O
several	O
could	O
be	O
grouped	O
as	O
specific	O
classes	O
of	O
meta	O
##bol	O
##ites	O
or	O
along	O
metabolic	O
pathways	O
as	O
described	O
below	O
(	O
Q	O
’	O
s	O
≤	O
0	O
.	O
10	O
)	O
.	O

Inc	O
##reased	O
concentrations	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
car	B
##nos	I
##ine	I
,	O
t	B
##4	I
-	I
h	I
##ydro	I
##xy	I
-	I
pro	I
##line	I
(	I
t	I
##4	I
-	I
OH	I
-	I
pro	I
##line	I
)	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
,	O
alpha	B
-	I
amino	I
##adi	I
##pic	I
acid	I
(	B
alpha	B
-	I
AAA	I
)	O
and	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
SD	O
##MA	O
)	O
and	O
decreased	O
concentrations	O
of	O
amino	O
acids	O
(	O
particularly	O
the	O
branched	O
chain	O
amino	S
acids	O
)	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
sa	B
##rc	I
##os	I
##ine	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
observed	O
in	O
the	O
HD	O
sheep	O
.	O

Important	O
##ly	O
,	O
24	B
,	I
25	I
-	I
(	I
OH	I
)	I
_	I
2	I
D	I
_	I
3	I
,	I
1	I
,	I
25	I
-	I
(	I
OH	I
)	I
_	I
2	I
D	O
,	O
and	O
25	O
-	O
OH	O
D	O
were	O
fully	O
separated	O
and	O
monitored	O
in	O
different	O
time	O
windows	O
of	O
the	O
MR	O
##M	O
sequence	O
,	O
thus	O
avoiding	O
ion	O
suppression	O
effects	O
for	O
low	O
level	O
compound	O
such	O
as	O
1	B
,	I
25	I
-	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
induced	O
by	O
compounds	O
circulating	O
at	O
high	O
concentration	O
levels	O
,	O
e	O
.	O
g	O
.	O
,	O
25	O
-	O
OH	O
D	O
.	O
U	O
##HP	O
##LC	O
-	O
MR	O
##M	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
for	O
5	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
Two	O
e	O
##pi	O
##mers	O
,	O
6	O
##S	O
and	O
6	O
##R	O
,	O
are	O
produced	O
by	O
der	O
##iva	O
##ti	O
##zation	O
with	O
PT	O
##AD	O
because	O
the	O
re	O
##age	O
##nt	O
react	O
##s	O
with	O
the	O
s	O

Cancer	O
cells	O
use	O
g	B
##lut	I
##amine	I
as	O
a	O
source	O
of	O
carbon	O
for	O
further	O
an	O
##ab	O
##olic	O
pathways	O
(	O
oxidation	O
)	O
and	O
g	B
##lut	I
##amine	I
is	O
here	O
##to	O
transported	O
into	O
the	O
cells	O
by	O
the	O
al	B
##ani	I
##ne	I
-	I
se	I
##rine	I
-	I
c	I
##ys	I
##tein	I
##e	I
-	I
transport	I
##er	I
-	I
2	I
.	O

A	O
meta	O
##bol	O
##omi	O
##c	O
study	O
performed	O
by	O
Ka	O
##mis	O
##og	O
##lu	O
et	O
al	O
has	O
found	O
that	O
5	O
l	B
##ys	I
##o	I
-	I
PC	I
species	O
decreased	O
significantly	O
in	O
the	O
experimental	O
and	O
clinical	O
studies	O
of	O
se	O
##psis	O
.	O

A	B
##cy	I
##l	I
##gly	I
##cine	I
##s	I
in	O
urine	O
have	O
been	O
reported	O
as	O
the	O
direct	O
expression	O
of	O
accumulation	O
of	O
the	O
correspondent	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
est	I
##ers	I
in	O
the	O
mit	O
##och	O
##ond	O
##rion	O
(	O
Bon	O
##af	O
##e	O
et	O
al	O
.	O
)	O
.	O

Additionally	O
,	O
levels	O
of	O
the	O
ch	B
##olin	I
##e	I
precursor	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
were	O
decreased	O
in	O
CR	O
##C	O
patient	O
urine	O
samples	O
.	O

Sam	O
##ples	O
were	O
di	O
##lut	O
##ed	O
with	O
either	O
40	O
%	O
met	B
##han	I
##ol	I
in	O
water	O
for	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
(	O
15	O
:	O
1	O
)	O
or	O
running	O
solvent	O
(	O
a	O
proprietary	O
mixture	O
provided	O
by	O
B	O
##io	O
##crates	O
)	O
for	O
FIA	O
-	O
MS	O
/	B
MS	B
(	I
20	I
:	I
1	I
)	I
.	O

Previous	O
studies	O
[	O
–	O
]	O
have	O
not	O
addressed	O
the	O
presence	O
of	O
phase	O
II	O
meta	O
##bol	O
##ites	O
(	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
or	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
)	O
of	O
G	O
##L	O
##Y	O
meta	O
##bol	O
##ites	O
in	O
urine	O
.	O

For	O
instance	O
,	O
Alexander	O
et	O
al	O
.	O
detected	O
a	O
decrease	O
in	O
u	O
##rina	O
##ry	O
t	B
##yr	I
##os	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
met	B
##hi	I
##oni	I
##ne	I
meta	O
##bol	O
##ites	O
,	O
whereas	O
Ni	O
##shi	O
##umi	O
et	O
al	O
.	O
reported	O
enhanced	O
concentrations	O
of	O
these	O
amino	O
acids	O
.	O

Although	O
the	O
analytical	O
platforms	O
applied	O
in	O
the	O
current	O
work	O
were	O
not	O
optimal	O
for	O
the	O
coverage	O
of	O
the	O
entire	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
profile	O
,	O
3	O
out	O
of	O
4	O
species	O
observed	O
as	O
format	B
##e	I
add	O
##uc	O
##ts	O
in	O
the	O
met	B
##han	I
##ol	I
serum	O
extract	O
(	O
platform	O
1	O
)	O
were	O
significantly	O
increased	O
in	O
m	O
##or	O
##bid	O
##ly	O
o	O
##bes	O
##e	O
NAS	O
##H	O
as	O
compared	O
to	O
s	O
##te	O
##ato	O
##sis	O
patients	O
.	O

In	O
multi	O
##var	O
##iate	O
analyses	O
,	O
C	O
##YP	O
##2	O
##D	O
##6	O
p	O
##hen	O
##otype	O
was	O
a	O
significant	O
predict	O
##or	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ites	O
and	O
MR	O
##s	O
across	O
all	O
time	O
points	O
(	O
Table	O
)	O
.	O

After	O
v	O
##ortex	O
##ing	O
,	O
a	O
volume	O
of	O
100	O
μ	O
##l	O
mixture	O
was	O
transferred	O
to	O
a	O
glass	O
via	O
##l	O
spike	O
##d	O
with	O
internal	O
standards	O
(	O
10	O
μ	O
##l	O
he	B
##pta	I
##de	I
##cano	I
##ic	I
acid	I
at	O
1	O
mg	O
/	O
m	O
##l	O
and	O
4	B
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
at	O
0	O
.	O
3	O
mg	O
/	O
m	O
##l	O
)	O
.	O

This	O
study	O
investigate	O
##s	O
how	O
the	O
relative	O
abundance	O
of	O
oxygen	O
##ated	O
meta	O
##bol	O
##ites	O
of	O
P	O
##U	O
##FA	O
,	O
o	B
##xy	I
##lip	I
##ins	I
,	O
is	O
altered	O
in	O
T	O
##GR	O
##L	O
post	O
##pra	O
##ndi	O
##ally	O
,	O
and	O
how	O
these	O
changes	O
promote	O
end	O
##oth	O
##eli	O
##al	O
inflammation	O
.	O

Meanwhile	O
,	O
of	O
the	O
2	O
fatty	O
acids	O
with	O
te	B
##tra	I
##de	I
##cano	I
##ic	I
acid	I
(	B
12	B
-	I
met	I
##hyl	I
-	I
,	O
met	B
##hyl	I
est	I
##er	I
,	O
and	O
(	O
S	O
)	O
-	O
)	O
,	O
one	O
of	O
the	O
branch	O
fatty	O
acids	O
was	O
increased	O
,	O
but	O
ma	B
##rga	I
##ric	I
acid	I
,	O
a	O
saturated	O
fatty	O
acid	O
,	O
was	O
decreased	O
.	O

These	O
linear	O
models	O
highlighted	O
that	O
CE	O
##MA	O
,	O
M	O
##H	O
##BM	O
##A	O
,	O
P	O
##H	O
##EM	O
##A	O
,	O
and	O
SP	O
##MA	O
were	O
significantly	O
different	O
between	O
controls	O
and	O
workers	O
,	O
with	O
levels	O
about	O
2	O
-	O
fold	O
(	O
CE	O
##MA	O
,	O
M	O
##H	O
##BM	O
##A	O
,	O
and	O
P	O
##H	O
##EM	O
##A	O
)	O
and	O
10	O
-	O
fold	O
(	O
SP	O
##MA	O
)	O
higher	O
in	O
workers	O
,	O
thus	O
showing	O
an	O
exposure	O
to	O
ben	B
##zen	I
##e	I
and	O
,	O
with	O
a	O
lower	O
impact	O
,	O
an	O
exposure	O
to	O
a	O
##c	O
##ryl	O
##oni	O
##tri	O
##le	O
,	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
,	O
and	O
s	B
##ty	I
##rene	I
.	O

Me	O
##as	O
##ure	O
##ments	O
of	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
were	O
performed	O
on	O
an	O
A	O
##gi	O
##lent	O
Technologies	O
(	O
Pa	O
##lo	O
Alto	O
,	O
CA	O
,	O
USA	O
)	O
1100	O
series	O
L	O
##C	O
coupled	O
to	O
an	O
SL	S
series	O
mass	O
s	O
##pect	O
##rome	O
##tric	O
detector	O
.	O

Am	O
##ino	O
acids	O
such	O
as	O
g	B
##lut	I
##amine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##ys	I
##tein	I
##e	I
play	O
a	O
vital	O
role	O
in	O
im	O
##mu	O
##no	O
##mo	O
##du	O
##lation	O
,	O
particularly	O
through	O
the	O
T	O
-	O
cell	O
proliferation	O
and	O
activation	O
.	O

As	O
summarized	O
in	O
Table	O
2	O
,	O
we	O
then	O
ran	O
the	O
per	O
##mu	O
##tation	O
procedure	O
for	O
two	O
different	O
models	O
(	O
Models	O
1	O
and	O
2	O
)	O
,	O
for	O
both	O
types	O
of	O
N	O
##MR	O
data	O
sets	O
(	O
NO	O
##ES	O
##Y	O
and	O
CP	O
##MG	O
)	O
and	O
3	O
versions	O
of	O
glucose	S
blood	O
concentrations	O
:	O
raw	O
,	O
log	O
##10	O
transformed	O
and	O
t	O
##runcated	O
(	O
removing	O
129	O
out	O
##lying	O
observations	O
which	O
were	O
outside	O
the	O
2	O
standard	O
de	O
##viation	O
range	O
from	O
the	O
mean	O
glucose	S
level	O
)	O
.	O

The	O
use	O
of	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
water	O
also	O
resulted	O
in	O
narrower	O
peaks	O
,	O
with	O
median	O
width	O
##s	O
of	O
19	O
.	O
4	O
(	O
mean	O
of	O
25	O
.	O
6	O
s	O
)	O
and	O
20	O
.	O
1	O
s	O
(	O
mean	O
of	O
33	O
.	O
2	O
s	O
)	O
respectively	O
.	O

Con	O
##sist	O
##ent	O
with	O
increased	O
fat	O
oxidation	O
,	O
plasma	O
g	B
##ly	I
##cer	I
##ol	I
significantly	O
increased	O
throughout	O
the	O
place	O
##bo	O
in	O
##fusion	O
;	O
however	O
,	O
this	O
was	O
completely	O
in	O
##hibit	O
##ed	O
during	O
r	O
##HD	O
##L	O
in	O
##fusion	O
(	O
%	O
change	O
at	O
end	O
of	O
in	O
##fusion	O
:	O
place	O
##bo	O
=	O
43	O
±	O
19	O
.	O
5	O
%	O
,	O
r	O
##HD	O
##L	O
=	O
−	O
##3	O
±	O
10	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
03	O
and	O
P	O
=	O
0	O
.	O
78	O
,	O
respectively	O
;	O
)	O
.	O

We	O
found	O
that	O
at	O
least	O
five	O
meta	O
##bol	O
##ites	O
,	O
including	O
2	B
-	I
h	I
##ydro	I
##xy	I
##cin	I
##nam	I
##ic	I
acid	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
,	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
and	O
be	B
##hen	I
##ic	I
acid	I
,	O
can	O
be	O
used	O
as	O
good	O
bio	O
##mark	O
##ers	O
.	O

(	O
Go	O
##nza	O
##lo	O
et	O
al	O
.	O
)	O
performed	O
targeted	O
lip	O
##ido	O
##me	O
analyses	O
comprising	O
several	O
o	O
##xi	O
##dized	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
-	O
derived	O
al	O
##de	O
##hy	O
##des	O
,	O
o	B
##xy	I
##ster	I
##ols	I
,	O
and	O
o	O
##xi	O
##dized	O
lip	O
##ids	O
.	O

After	O
that	O
,	O
the	O
di	O
##sper	O
##sion	O
was	O
filtered	O
and	O
washed	O
with	O
several	O
litre	O
##s	O
of	O
di	O
##st	O
##ille	O
##d	O
water	O
until	O
no	O
traces	O
of	O
chloride	B
##s	I
were	O
detected	O
by	O
the	O
A	O
##g	O
##N	O
##O	O
_	O
3	O
test	O
.	O

The	O
concentrations	O
of	O
g	B
##ly	I
##co	I
##lic	I
acid	I
and	O
man	B
##nose	I
were	O
higher	O
in	O
S	O
##IB	O
##O	O
-	O
positive	O
children	O
,	O
whereas	O
the	O
concentrations	O
of	O
v	B
##ali	I
##ne	I
,	O
p	B
-	I
c	I
##res	I
##yl	I
##sul	I
##phate	I
(	O
PC	O
##S	O
)	O
,	O
but	B
##yra	I
##te	I
and	O
ad	B
##ip	I
##ic	I
acid	I
were	O
higher	O
in	O
S	O
##IB	O
##O	O
-	O
negative	O
children	O
.	O

In	O
##hibition	O
of	O
c	B
##era	I
##mi	I
##de	I
synthesis	O
decreased	O
β	O
-	O
cell	O
a	O
##pop	O
##tosis	O
and	O
defect	O
##ive	O
protein	O
trafficking	O
in	O
β	O
-	O
cells	O
exposed	O
to	O
lip	O
##oto	O
##xi	O
##city	O
.	O

Car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
amino	O
acids	O
and	O
fat	O
##s	O
can	O
be	O
used	O
to	O
generate	O
reducing	O
equivalent	O
##s	O
(	O
N	O
##AD	O
##H	O
)	O
and	O
ATP	S
.	O

This	O
was	O
reflected	O
in	O
the	O
reduced	O
c	B
##it	I
##rate	I
level	O
and	O
elevated	O
levels	O
of	O
plasma	O
th	B
##re	I
##oni	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
in	O
##ducing	O
a	O
drop	O
in	O
su	B
##cci	I
##ny	I
##l	I
-	I
Co	I
##A	I
and	O
f	B
##uma	I
##rate	I
.	O

In	O
addition	O
25	O
participants	O
with	O
self	O
-	O
reported	O
as	B
##par	I
##tam	I
##e	I
sensitivity	O
and	O
25	O
matched	O
control	O
participants	O
were	O
recruited	O
to	O
look	O
at	O
no	O
##ce	O
##bo	O
effect	O
where	O
they	O
were	O
given	O
two	O
lots	O
of	O
place	O
##bo	O
(	O
second	O
part	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
1	O
)	O
the	O
10	O
µ	O
##L	O
internal	O
standard	O
solution	O
(	O
l	O
-	O
le	O
##uc	O
##ine	O
-	O
13	O
##C	O
##6	O
,	O
0	O
.	O
02	O
mg	O
/	O
m	O
##L	O
)	O
and	O
15	O
µ	O
##L	O
al	O
##iq	O
##uo	O
##t	O
of	O
urine	O
were	O
mixed	O
and	O
v	O
##ortex	O
##ed	O
;	O
2	O
)	O
into	O
the	O
mixed	O
solution	O
,	O
15	O
µ	O
##L	O
u	O
##rease	O
was	O
added	O
to	O
de	O
##grade	O
the	O
u	B
##rea	I
(	O
37	O
##°	O
##C	O
,	O
60	O
minutes	O
)	O
;	O
3	O
)	O
the	O
mixture	O
was	O
successively	O
extracted	O
using	O
240	O
µ	O
##L	O
and	O
80	O
µ	O
##L	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
,	O
and	O
the	O
obtained	O
mixture	O
was	O
v	O
##ortex	O
##ed	O
for	O
30	O
seconds	O
;	O
4	O
)	O
after	O
cent	O
##ri	O
##fu	O
##gation	O
(	O
4	O
##°	O
##C	O
,	O
14	O
,	O
000	O
rpm	O
and	O
5	O
minutes	O
)	O
,	O
224	O
µ	O
##L	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
a	O
glass	O
via	O
##l	O
for	O
vacuum	O
drying	O
at	O
room	O
temperature	O
,	O
and	O
then	O
30	O
µ	O
##L	O
of	O
met	B
##ho	I
##xy	I
##amine	I
(	O
20	O
mg	O
/	O
m	O
##L	O
)	O
was	O
used	O
to	O
der	O
##iva	O
##ti	O
##ze	O
the	O
dried	O
metabolic	O
extract	O
(	O
37	O
##°	O
##C	O
,	O
90	O
minutes	O
)	O
;	O
5	O
)	O
30	O
µ	O
##L	O
of	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
with	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
was	O
added	O
into	O
the	O
dried	O
metabolic	O
extract	O
,	O
and	O
then	O
the	O
mixture	O
was	O
heated	O
(	O
70	O
##°	O
##C	O
,	O
60	O
minutes	O
)	O
to	O
obtain	O

Mi	O
##gra	O
##ine	O
was	O
associated	O
with	O
decreased	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
A1	O
levels	O
(	O
a	O
##po	O
##A	O
##1	O
,	O
an	O
a	O
##pop	O
##rote	O
##in	O
with	O
specific	O
association	O
with	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
[	O
HD	O
##L	O
]	O
)	O
(	O
β	O
−	O
##0	O
.	O
10	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
C	O
##I	O
]	O
−	O
##0	O
.	O
16	O
,	O
−	O
##0	O
.	O
05	O
,	O
adjusted	O
p	O
=	O
0	O
.	O
02	O
##9	O
)	O
and	O
decreased	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
total	O
lip	O
##id	O
ratio	O
in	O
small	O
HD	O
##L	O
(	O
S	O
-	O
HD	O
##L	O
-	O
FC	O
ratio	O
;	O
β	O
−	O
##0	O
.	O
10	O
,	O
95	O
%	O
C	O
##I	O
−	O
##0	O
.	O
15	O
,	O
−	O
##0	O
.	O
05	O
,	O
adjusted	O
p	O
=	O
0	O
.	O
02	O
##9	O
)	O
.	O

This	O
analysis	O
revealed	O
that	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
,	O
s	O
##tero	O
##id	O
hormone	O
bio	O
##sy	O
##nt	O
##heses	O
,	O
bi	O
##le	O
acid	O
metabolism	O
,	O
metabolism	O
of	O
essential	O
fatty	O
acids	O
(	O
l	O
##ino	O
##le	O
##ic	O
and	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	O
)	O
and	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
comprise	O
the	O
highest	O
number	O
of	O
intensity	O
differences	O
in	O
known	O
detected	O
meta	O
##bol	O
##ites	O
between	O
the	O
two	O
groups	O
.	O

The	O
fortified	O
levels	O
of	O
concentrations	O
for	O
ni	O
##ten	O
##py	O
##ram	O
,	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
,	O
ace	B
##tam	I
##ip	I
##rid	I
and	O
th	B
##iac	I
##lop	I
##rid	I
were	O
set	O
at	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
0	O
.	O
6	O
,	O
0	O
.	O
9	O
,	O
and	O
1	O
.	O
2	O
ng	O
/	O
m	O
##L	O
,	O
for	O
cloth	B
##ian	I
##id	I
##in	I
at	O
0	O
.	O
2	O
,	O
0	O
.	O
6	O
,	O
1	O
.	O
2	O
,	O
1	O
.	O
8	O
,	O
and	O
2	O
.	O
4	O
ng	O
/	O
m	O
##L	O
,	O
and	O
for	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
and	O
D	O
##MA	O
##P	O
at	O
0	O
.	O
5	O
,	O
1	O
.	O
5	O
,	O
3	O
.	O
0	O
,	O
4	O
.	O
5	O
,	O
and	O
6	O
.	O
0	O
ng	O
/	O
m	O
##L	O
.	O
Ana	O
##ly	O
##te	O
levels	O
in	O
the	O
samples	O
were	O
determined	O
using	O
the	O
external	O
standard	O
methods	O
.	O

L	O
##ø	O
##nning	O
P	O
##E	O
,	O
S	O
##ku	O
##ls	O
##tad	O
P	O
.	O
Alt	O
##eration	O
##s	O
in	O
the	O
urine	O
ex	O
##cre	O
##tion	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
breast	O
cancer	O
women	O
treated	O
with	O
amino	B
##g	I
##lut	I
##eth	I
##im	I
##ide	I
.	O

He	B
##x	I
##ose	I
-	I
phosphate	I
and	O
de	B
##ox	I
##yr	I
##ib	I
##ose	I
-	I
phosphate	I
represent	O
structural	O
is	O
##omer	O
##s	O
of	O
compounds	O
that	O
are	O
involved	O
in	O
the	O
PP	O
##P	O
,	O
g	O
##ly	O
##co	O
##lysis	O
,	O
and	O
n	O
##uc	O
##leo	O
##tide	O
metabolism	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
identify	O
early	O
metabolic	O
alterations	O
associated	O
with	O
insulin	O
resistance	O
in	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
women	O
with	O
varying	O
degree	O
of	O
ad	O
##ip	O
##os	O
##ity	O
.	O

Moreover	O
,	O
in	O
our	O
study	O
,	O
women	O
had	O
higher	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
than	O
men	O
,	O
in	O
accordance	O
with	O
general	O
population	O
findings	O
.	O

About	O
60	O
%	O
of	O
N	B
##AD	I
##P	I
##H	I
is	O
produced	O
by	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
under	O
base	O
##line	O
conditions	O
.	O

The	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
oral	O
m	B
##or	I
##phine	I
is	O
variable	O
,	O
reported	O
between	O
15	O
%	O
and	O
65	O
%	O
,	O
and	O
that	O
of	O
injected	O
m	B
##or	I
##phine	I
is	O
approximately	O
95	O
%	O
of	O
the	O
dose	O
administered	O
.	O

Before	O
analysis	O
,	O
the	O
c	B
##rea	I
##tin	I
##ine	I
in	O
each	O
pool	O
##ed	O
samples	O
were	O
q	O
##uant	O
##ified	O
according	O
to	O
previously	O
reported	O
method	O
_	O
,	O
_	O
,	O
_	O
,	O
.	O

Car	B
##ni	I
##tine	I
is	O
required	O
for	O
the	O
transport	O
of	O
fatty	O
acids	O
into	O
the	O
mit	O
##och	O
##ond	O
##rion	O
for	O
FA	O
##O	O
.	O

This	O
is	O
the	O
first	O
time	O
,	O
as	O
far	O
as	O
we	O
know	O
,	O
that	O
this	O
genetic	O
variant	O
of	O
the	O
T	O
##CF	O
##7	O
##L	O
##2	O
gene	O
,	O
which	O
media	O
##tes	O
high	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
to	O
T	O
##2	O
##D	O
,	O
is	O
reported	O
to	O
interact	O
with	O
pu	B
##rine	I
-	I
cat	I
##ab	I
##olis	I
##m	I
meta	O
##bol	O
##ites	O
.	O

The	O
super	O
##nat	O
##ant	O
a	O
##que	O
##ous	O
layer	O
was	O
separated	O
,	O
dried	O
using	O
a	O
vacuum	O
con	O
##cent	O
##rator	O
and	O
mixed	O
with	O
600	O
μ	O
##L	O
buffer	O
containing	O
25	O
μ	O
##M	O
T	O
##SP	O
(	O
sodium	O
salt	O
of	O
3	B
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
prop	I
##ion	I
##ic	I
acid	I
-	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
d	I
_	I
4	I
)	O
for	O
N	O
##MR	O
analysis	O
.	O

This	O
finding	O
does	O
not	O
discount	O
the	O
possibility	O
that	O
reduced	O
me	B
##lat	I
##oni	I
##n	I
,	O
especially	O
early	O
in	O
the	O
night	O
,	O
may	O
be	O
linked	O
to	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
I	O
##BS	O
through	O
other	O
mechanisms	O
.	O

Pro	O
##tein	O
removal	O
via	O
ultra	O
##fi	O
##ltration	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
precipitation	O
are	O
complementary	O
techniques	O
and	O
both	O
are	O
required	O
to	O
obtain	O
a	O
clear	O
meta	O
##bol	O
##ome	O
profile	O
.	O

Fu	B
##sar	I
##ith	I
##io	I
##ami	I
##de	I
B	O
(	O
50	O
)	O
isolated	O
from	O
the	O
same	O
extract	O
was	O
strongly	O
potent	O
and	O
selective	O
towards	O
BT	O
-	O
54	O
##9	O
,	O
MC	O
##F	O
-	O
7	O
,	O
SK	O
##O	O
##V	O
-	O
3	O
,	O
and	O
HC	O
##T	O
-	O
116	O
cell	O
lines	O
with	O
I	O
##C	O
_	O
50	O
values	O
of	O
0	O
.	O
09	O
,	O
0	O
.	O
21	O
,	O
1	O
.	O
23	O
,	O
and	O
0	O
.	O
59	O
##µ	O
##M	O
,	O
respectively	O
(	O
Ibrahim	O
et	O
al	O
.	O
2018	O
##b	O
)	O
.	O

The	O
ch	B
##lor	I
##of	I
##orm	I
layers	O
from	O
the	O
two	O
extraction	O
##s	O
were	O
combined	O
and	O
dried	O
under	O
nitrogen	O
flow	O
.	O

As	O
a	O
higher	O
proportion	O
of	O
patients	O
in	O
the	O
N	O
##MO	O
##SD	O
-	O
like	O
and	O
L	O
##BL	O
subgroup	O
##s	O
were	O
on	O
im	O
##mu	O
##nos	O
##up	O
##press	O
##ants	O
and	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
at	O
the	O
time	O
of	O
plasma	O
sampling	O
compared	O
with	O
the	O
MS	O
-	O
like	O
subgroup	O
,	O
it	O
was	O
explored	O
whether	O
these	O
accounted	O
for	O
the	O
differences	O
in	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
format	B
##e	I
levels	O
.	O

Ace	B
##tone	I
,	O
ace	B
##tate	I
,	O
ethanol	S
,	O
and	O
met	B
##han	I
##ol	I
were	O
also	O
detected	O
but	O
were	O
excluded	O
from	O
analysis	O
as	O
they	O
are	O
volatile	O
and	O
samples	O
were	O
dried	O
by	O
l	O
##yo	O
##phi	O
##li	O
##zation	O
.	O

In	O
addition	O
,	O
for	O
the	O
measurement	O
of	O
di	B
##os	I
##met	I
##in	I
itself	O
,	O
without	O
and	O
with	O
en	O
##zy	O
##matic	O
dig	O
##est	O
##ion	O
,	O
in	O
urine	O
,	O
ca	O
##li	O
##bra	O
##tion	O
curves	O
were	O
spike	O
##d	O
at	O
0	O
–	O
10	O
–	O
25	O
–	O
75	O
–	O
200	O
–	O
500	O
–	O
1	O
,	O
000	O
ng	O
/	O
m	O
##L	O
(	O
CC	O
)	O
and	O
Q	O
##C	O
at	O
30	O
–	O
375	O
–	O
750	O
ng	O
/	O
m	O
##L	O

The	O
E	O
##ppe	O
##ndo	O
##rf	O
con	O
##cent	O
##rator	O
was	O
vent	O
##ed	O
with	O
a	O
##rgon	O
to	O
prevent	O
degradation	O
of	O
e	B
##ico	I
##san	I
##oids	I
and	O
do	B
##cos	I
##ano	I
##ids	I
.	O

R	O
##T	O
##s	O
were	O
0	O
.	O
5	O
–	O
4	O
minutes	O
for	O
l	B
##ys	I
##op	I
##hos	I
##poli	I
##pid	I
##s	I
including	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
species	O
,	O
3	O
–	O
8	O
.	O
1	O
minutes	O
for	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
including	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
,	O
c	B
##era	I
##mi	I
##de	I
and	O
la	B
##ct	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
g	B
##lu	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
,	O
and	O
gal	B
##act	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
species	O
,	O
4	O
–	O
7	O
.	O
8	O
minutes	O
for	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
species	O
,	O
7	O
.	O
8	O
–	O
9	O
.	O
5	O
minutes	O
for	O
dig	B
##ly	I
##cer	I
##ide	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
and	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##er	I
species	O
in	O
P	O
##IM	O
(	O
,	O
)	O
,	O
0	O
.	O
5	O
–	O
4	O
minutes	O
for	O
l	B
##ys	I
##op	I
##hos	I
##poli	I
##pid	I
##s	I
and	O
FF	O

Ser	O
##um	O
se	B
##rot	I
##oni	I
##n	I
levels	O
(	O
nm	O
##ol	O
/	O
L	O
)	O
in	O
relation	O
to	O
circulating	O
T	O
##P	O
##H	O
-	O
1	O
and	O
AA	O
##DC	O
A	O
##ab	O
##s	O
.	O

Pro	B
##sta	I
##g	I
##land	I
##ins	I
are	O
produced	O
through	O
the	O
CO	O
##X	O
pathway	O
,	O
and	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
through	O
the	O
L	O
##OX	O
pathway	O
.	O

We	O
calculated	O
correlation	O
##s	O
between	O
statistical	O
##ly	O
significant	O
meta	O
##bol	O
##ites	O
(	B
glucose	S
,	O
c	B
##it	I
##rate	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
g	O
##ly	O
##co	O
##p	O
##rote	O
##in	O
ace	O
##ty	O
##ls	O
)	O
and	O
clinical	O
variables	O
(	O
30	O
-	O
day	O
mortality	O
,	O
se	O
##ptic	O
shock	O
,	O
AP	O
##AC	O
##H	O
##E	O
II	O
score	O
on	O
admission	O
,	O
S	O
##O	O
##FA	O
score	O
on	O
admission	O
,	O
maximum	O
S	O
##O	O
##FA	O
score	O
during	O
the	O
I	O
##CU	O
period	O
,	O
length	O
of	O
stay	O
at	O
the	O
I	O
##CU	O
)	O
.	O

The	O
intake	O
of	O
his	B
##ti	I
##dine	I
in	O
a	O
mouse	O
model	O
of	O
he	O
##pa	O
##tic	O
injury	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
levels	O
of	O
inflammatory	O
c	O
##yt	O
##oki	O
##nes	O
in	O
the	O
liver	O
.	O

æ	B
–	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
is	O
an	O
important	O
intermediate	O
meta	O
##bol	O
##ite	O
in	O
the	O
T	O
##CA	O
cycle	O
that	O
can	O
also	O
improve	O
is	O
##che	O
##mia	O
-	O
induced	O
brain	O
disorders	O
.	O

The	O
upper	O
phase	O
water	O
/	B
met	B
##han	I
##ol	I
was	O
separated	O
from	O
the	O
inter	O
##pha	O
##se	O
and	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
for	O
2	O
hours	O
to	O
remove	O
water	O
and	O
met	B
##han	I
##ol	I
.	O

I	O
##AA	O
at	O
u	O
##rem	O
##ic	O
concentrations	O
was	O
previously	O
linked	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
contribution	O
to	O
development	O
of	O
C	O
##VD	O
in	O
C	O
##K	O
##D	O
patients	O
via	O
activation	O
of	O
the	O
A	B
##ryl	I
H	I
##ydro	I
##car	I
##bon	I
Re	O
##ceptor	O
.	O

Extra	O
##cts	O
re	O
##con	O
##stituted	O
in	O
acidic	O
conditions	O
were	O
gradient	O
el	O
##uted	O
using	O
water	O
and	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
while	O
the	O
basic	O
extract	O
##s	O
,	O
which	O
also	O
used	O
water	O
/	B
met	B
##han	I
##ol	I
,	O
contained	O
6	O
.	O
5	O
##m	O
##M	O
Am	B
##mon	I
##ium	I
B	O
##ica	O
##rb	O
##ona	O
##te	O
.	O

Furthermore	O
,	O
multiple	O
linear	O
re	O
##gression	O
analyses	O
showed	O
a	O
relative	O
increase	O
in	O
k	B
##yn	I
##uren	I
##ine	I
accompanied	O
with	O
decreased	O
try	B
##pt	I
##op	I
##han	I
in	O
T	O
##B	O
patients	O
.	O

In	O
this	O
study	O
,	O
the	O
glucose	S
levels	O
significantly	O
decreased	O
and	O
la	B
##ct	I
##ate	I
,	O
as	O
the	O
end	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
apparently	O
increased	O
in	O
the	O
L	O
##N	O
##M	O
-	O
negative	O
and	O
L	O
##N	O
##M	O
-	O
positive	O
G	O
##C	O
specimens	O
compared	O
with	O
controls	O
,	O
which	O
was	O
not	O
surprised	O
because	O
of	O
the	O
well	O
-	O
known	O
War	O
##burg	O
effect	O
(	O
Van	O
##der	O
He	O
##iden	O
et	O
al	O
.	O
)	O
.	O

Moreover	O
,	O
a	O
recent	O
G	O
##C	O
/	O
MS	O
-	O
base	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
of	O
CH	O
##B	O
patients	O
identified	O
the	O
meta	O
##bol	O
##ites	O
g	B
##ly	I
##cine	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
palm	B
##itic	I
acid	I
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
and	O
o	B
##le	I
##ic	I
acid	I
as	O
disc	O
##rim	O
##inator	O
##y	O
meta	O
##bol	O
##ites	O
which	O
co	O
##rro	O
##bor	O
##ate	O
the	O
finding	O
in	O
this	O
study	O
(	O
Yang	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

Go	O
to	O
:	O
C	B
##lo	I
##za	I
##pine	I
is	O
indicated	O
for	O
the	O
treatment	O
of	O
s	O
##chi	O
##zophrenia	O
and	O
related	O
ps	O
##ych	O
##otic	O
disorders	O
.	O

(	O
a	O
)	O
PC	O
##A	O
score	O
plot	O
of	O
all	O
base	O
##line	O
sub	O
##tracted	O
plasma	O
samples	O
showing	O
the	O
different	O
protein	O
sources	O
:	O
orange	O
-	O
triangle	O
,	O
control	O
;	O
black	O
-	O
box	O
,	O
w	B
##hey	I
protein	O
;	O
grey	O
-	O
dot	O
,	O
calcium	B
case	I
##inate	I
protein	O
.	O

Mo	O
##di	O
##fying	O
the	O
mobile	O
phase	O
pH	O
and	O
add	O
##itive	O
type	O
would	O
afford	O
better	O
control	O
of	O
electro	O
##static	O
interactions	O
,	O
especially	O
re	O
##pulsion	O
between	O
the	O
amino	S
groups	O
of	O
so	O
##rb	O
##ent	O
and	O
anal	O
##yte	O
##s	O
.	O

Using	O
all	O
identified	O
meta	O
##bol	O
##ites	O
,	O
the	O
top	O
three	O
pathways	O
identified	O
were	O
:	O
G	B
##ly	I
##cer	I
##ol	I
phosphate	I
shuttle	O
,	O
k	B
##eton	I
##e	I
body	O
metabolism	O
,	O
and	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
metabolism	O
.	O

These	O
data	O
show	O
that	O
once	O
taken	O
up	O
by	O
tissues	O
,	O
_	O
13	O
C	B
-	I
glucose	I
was	O
meta	O
##bol	O
##ized	O
quickly	O
to	O
_	O
13	O
C	B
-	I
la	I
##ct	I
##ate	I
and	O
secret	O
##ed	O
back	O
into	O
the	O
blood	O
.	O

Moreover	O
,	O
Is	O
##hi	O
##kawa	O
et	O
al	O
.	O
showed	O
a	O
comparable	O
SM	O
##s	O
level	O
in	O
young	O
and	O
elderly	O
women	O
(	O
55	O
–	O
64	O
years	O
old	O
)	O
,	O
despite	O
a	O
marked	O
##ly	O
decreased	O
est	B
##rogen	I
level	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
elderly	O
women	O
.	O

Sol	O
##vent	O
amounts	O
were	O
op	O
##ti	O
##mise	O
##d	O
to	O
500	O
μ	O
##L	O
met	B
##han	I
##ol	I
(	O
added	O
directly	O
after	O
cell	O
harvesting	O
)	O
,	O
650	O
μ	O
##L	O
of	O
ch	B
##lor	I
##of	I
##orm	I
(	O
added	O
in	O
two	O
times	O
,	O
before	O
and	O
after	O
cell	O
break	O
##age	O
)	O
and	O
400	O
μ	O
##L	O
of	O
water	O
(	O
added	O
after	O
cell	O
break	O
##age	O
,	O
to	O
avoid	O
ice	O
-	O
building	O
during	O
the	O
freeze	O
-	O
th	O
##aw	O
cycles	O
)	O
per	O
20	O
million	O
cells	O
.	O

Report	O
##ed	O
anal	O
##ges	O
##ic	O
users	O
for	O
whom	O
the	O
name	O
of	O
the	O
anal	O
##ges	O
##ic	O
was	O
not	O
recorded	O
were	O
excluded	O
from	O
comparisons	O
with	O
_	O
1	O
H	O
N	O
##MR	O
-	O
detected	O
u	O
##rina	O
##ry	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
;	O
therefore	O
,	O
216	O
(	O
98	O
.	O
2	O
%	O
)	O
of	O
220	O
participants	O
from	O
Belfast	O
and	O
280	O
(	O
88	O
.	O
9	O
%	O
)	O
of	O
315	O
participants	O
from	O
Chicago	O
were	O
available	O
for	O
these	O
analyses	O
.	O

The	O
T	O
##1	O
##D	O
patients	O
participating	O
in	O
the	O
study	O
had	O
diabetes	O
for	O
a	O
total	O
of	O
14	O
##±	O
##8	O
.	O
4	O
years	O
,	O
und	O
##ete	O
##ct	O
##able	O
C	O
-	O
p	O
##eptide	O
levels	O
and	O
good	O
g	B
##ly	I
##ce	I
##mic	I
control	O
,	O
as	O
determined	O
by	O
g	O
##ly	O
##cated	O
hem	O
##og	O
##lo	O
##bin	O
A1	O
##c	O
.	O

c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
2D	O
##6	O
(	O
C	O
##YP	O
##2	O
##D	O
##6	O
)	O
is	O
a	O
key	O
factor	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
metabolism	O
,	O
however	O
,	O
genetic	O
variants	O
only	O
partially	O
explain	O
the	O
var	O
##iability	O
of	O
plasma	O
concentrations	O
of	O
the	O
active	O
meta	O
##bol	O
##ite	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
.	O

Forty	O
micro	O
##lit	O
##res	O
of	O
each	O
sample	O
was	O
added	O
to	O
160	O
μ	O
##L	O
of	O
water	O
and	O
480	O
μ	O
##L	O
of	O
extraction	O
liquid	O
(	O
V	O
_	O
M	O
##T	O
##BE	O
:	O
V	O
_	O
Me	O
##OH	O
=	I
5	I
:	I
1	I
,	O
containing	O
10	O
μ	O
##L	O
of	O
160	O
μ	O
##g	O
/	O
m	O
##L	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
0	I
)	I
(	I
d	I
##7	I
)	I
)	O
and	O
vigorously	O
v	O
##ortex	O
##ed	O
for	O
60	O
s	O
.	O

Additionally	O
,	O
D	O
##HA	O
is	O
considered	O
vital	O
in	O
maintaining	O
brain	O
health	O
and	O
co	O
##gnition	O
,	O
and	O
higher	O
levels	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
D	O
##HA	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
decreased	O
mortality	O
due	O
to	O
late	O
-	O
life	O
disease	O
.	O

Ke	O
et	O
al	O
reported	O
altered	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
in	O
BC	O
##a	O
;	O
they	O
discovered	O
four	O
single	O
-	O
n	O
##uc	O
##leo	O
##tide	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
in	O
the	O
g	B
##lut	I
##ath	I
##ione	I
s	O
##ynth	O
##eta	O
##se	O
gene	O
,	O
and	O
these	O
changes	O
were	O
associated	O
with	O
BC	O
##a	O
re	O
##cu	O
##rrence	O
after	O
T	O
##UR	O
and	O
Ba	O
##ci	O
##llus	O
Cal	O
##mett	O
##e	O
G	O
##uer	O
##in	O
treatment	O
.	O

The	O
meta	O
##bol	O
##ites	O
that	O
most	O
disc	O
##rim	O
##inate	O
between	O
rapid	O
and	O
slow	O
fi	O
##bro	O
##ser	O
##s	O
in	O
the	O
multi	O
##var	O
##iate	O
analysis	O
(	O
with	O
the	O
highest	O
loading	O
##s	O
absolute	O
values	O
)	O
were	O
mainly	O
BA	O
,	O
PC	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
LP	O
##C	O
)	O
,	O
and	O
SM	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##1	O
,	O
sheet	O
“	O
Su	O
##pp	O
.	O

Met	B
##hyl	I
##ar	I
##gin	I
##ines	I
are	O
removed	O
from	O
the	O
circulation	O
by	O
metabolism	O
by	O
DD	O
##A	O
##H	O
and	O
AG	O
##XT	O
##2	O
enzymes	O
and	O
by	O
ex	O
##cre	O
##tion	O
in	O
the	O
kidney	O
.	O

For	O
170	O
of	O
the	O
175	O
(	O
97	O
.	O
1	O
%	O
)	O
s	O
##pect	O
##ra	O
selected	O
from	O
group	O
A	O
,	O
presence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
was	O
confirmed	O
whilst	O
270	O
of	O
the	O
275	O
s	O
##pect	O
##ra	O
(	O
98	O
.	O
2	O
%	O
)	O
selected	O
from	O
group	O
B	O
did	O
not	O
have	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
as	O
verified	O
visually	O
.	O

Upon	O
el	O
##uc	O
##ida	O
##tion	O
of	O
weight	O
gain	O
-	O
associated	O
bio	O
##mark	O
##ers	O
,	O
it	O
was	O
possible	O
to	O
demonstrate	O
the	O
presence	O
of	O
A	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nate	I
[	O
m	O
/	O
z	O
308	O
.	O
156	O
##5	O
]	O
,	O
a	O
basic	O
amino	O
acid	O
and	O
immediate	O
precursor	O
of	O
a	B
##rg	I
##ini	I
##ne	I
in	O
the	O
u	B
##rea	I
cycle	O
.	O

Un	O
##con	O
##ju	O
##gated	O
bi	O
##le	O
acid	O
,	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
,	O
and	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
on	O
the	O
other	O
hand	O
,	O
was	O
at	O
lower	O
level	O
in	O
HC	O
##C	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

This	O
study	O
found	O
that	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
is	O
up	O
-	O
regulated	O
in	O
serum	O
during	O
the	O
progression	O
from	O
H	O
##U	O
to	O
H	O
##U	O
+	O
N	O
##AF	O
##LD	O
,	O
which	O
suggests	O
that	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
insulin	O
resistance	O
due	O
to	O
up	O
-	O
regulated	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
metabolism	O
appear	O
at	O
least	O
partially	O
responsible	O
for	O
the	O
development	O
of	O
s	O
##te	O
##ato	O
##sis	O
in	O
H	O
##U	O
.	O

Li	O
##po	O
##genesis	O
is	O
slightly	O
activated	S
,	O
whereas	O
β	O
-	O
fatty	O
acid	O
oxidation	O
is	O
slowed	O
.	O

Is	B
##of	I
##lav	I
##ones	I
in	O
al	O
##iq	O
##uo	O
##ts	O
(	O
10	O
μ	O
##l	O
)	O
of	O
the	O
clarified	O
extract	O
##s	O
were	O
analyzed	O
by	O
L	O
##C	O
on	O
an	O
A	O
##gi	O
##lent	O
HP	S
1100	O
instrument	O
.	O

T	B
##G	I
also	O
had	O
the	O
highest	O
number	O
of	O
lip	O
##id	O
species	O
with	O
1	O
,	O
115	O
species	O
identified	O
(	O
Table	O
)	O
.	O

Con	O
##sist	O
##ent	O
with	O
these	O
observations	O
,	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
treatment	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
plasma	O
FF	O
##A	O
concentration	O
after	O
enhanced	O
ad	O
##ip	O
##oc	O
##yte	O
insulin	O
sensitivity	O
and	O
decreased	O
lip	O
##oly	O
##sis	O
,	O
leading	O
to	O
a	O
decrease	O
in	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
and	O
enhanced	O
skeletal	O
muscle	O
insulin	O
sensitivity	O
.	O

Met	O
##ab	O
##olic	O
pathway	O
analysis	O
revealed	O
alter	O
##ation	O
in	O
multiple	O
pathways	O
including	O
g	O
##ly	O
##co	O
##lysis	O
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
prop	B
##ano	I
##ate	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
,	O
gal	B
##act	I
##ose	I
,	O
fatty	O
acid	O
,	O
star	O
##ch	O
and	O
su	B
##c	I
##rose	I
metabolism	O
along	O
with	O
fatty	O
acid	O
el	O
##ong	O
##ation	O
in	O
mit	O
##och	O
##ond	O
##ria	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
,	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
di	B
##car	I
##box	I
##yla	I
##te	I
metabolism	O
pointing	O
towards	O
the	O
shift	O
of	O
metabolism	O
in	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
patients	O
in	O
comparison	O
to	O
healthy	O
individuals	O
.	O

Lac	B
##tate	I
is	O
reported	O
to	O
suppress	O
proliferation	O
,	O
c	O
##yt	O
##oly	O
##tic	O
activity	O
of	O
c	O
##yt	O
##oto	O
##xi	O
##c	O
T	O
l	O
##ymph	O
##ocytes	O
(	O
CT	O
##L	O
##s	O
)	O
,	O
and	O
production	O
of	O
c	O
##yt	O
##oki	O
##ne	O
[	O
,	O
]	O
.	O

These	O
data	O
provide	O
the	O
first	O
evidence	O
suggesting	O
a	O
role	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
of	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
in	O
K	O
##S	O
path	O
##ogen	O
##esis	O
and	O
may	O
explain	O
why	O
some	O
K	O
##S	O
##H	O
##V	O
-	O
infected	O
individuals	O
with	O
advanced	O
AIDS	O
fail	O
to	O
develop	O
K	O
##S	O
.	O

Pro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
c	O
##yt	O
##oki	O
##nes	O
associated	O
with	O
SL	O
##E	O
and	O
disease	O
activity	O
,	O
that	O
is	O
,	O
IP	O
-	O
10	O
,	O
T	O
##NF	O
-	O
α	O
and	O
IL	O
-	O
16	O
,	O
correlated	O
with	O
k	B
##yn	I
##uren	I
##ine	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
and	O
k	B
##yn	I
##uren	I
##ine	I
/	I
try	I
##pt	I
##op	I
##han	I
ratio	O
,	O
but	O
not	O
with	O
try	B
##pt	I
##op	I
##han	I
,	O
in	O
our	O
study	O
.	O

The	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
were	O
positively	O
detected	O
in	O
nearly	O
all	O
urine	O
samples	O
analyzed	O
.	O

Our	O
sample	O
work	O
up	O
required	O
a	O
combination	O
of	O
sample	O
clean	O
##up	O
and	O
two	O
consecutive	O
der	O
##iva	O
##ti	O
##zation	O
reactions	O
with	O
et	B
##hyl	I
##hy	I
##dr	I
##ox	I
##yla	I
##mine	I
and	O
M	O
##T	O
##BS	O
##TF	O
##A	O
for	O
sufficient	O
sensitivity	O
and	O
accuracy	O
.	O

Que	B
##rc	I
##eti	I
##n	I
is	O
a	O
fl	B
##av	I
##ono	I
##id	I
found	O
in	O
many	O
fruits	O
and	O
vegetables	O
.	O

Our	O
medium	O
design	O
,	O
where	O
glucose	S
and	O
the	O
amino	O
acids	O
are	O
_	O
13	O
C	O
while	O
serum	O
-	O
derived	O
nutrients	O
are	O
_	O
12	O
C	O
,	O
allows	O
us	O
to	O
detect	O
de	O
no	O
##vo	O
synthesis	O
of	O
most	O
cellular	O
meta	O
##bol	O
##ites	O
.	O

Given	O
the	O
clinical	O
importance	O
of	O
al	O
##de	O
##hy	O
##des	O
,	O
as	O
potential	O
sur	O
##rogate	O
##s	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
[	O
–	O
]	O
,	O
we	O
will	O
concentrate	O
in	O
discussing	O
our	O
findings	O
for	O
a	O
series	O
of	O
three	O
classes	O
of	O
fatty	O
al	O
##de	O
##hy	O
##des	O
:	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
al	I
##ken	I
##als	I
(	O
C	O
_	O
x	O
H	O
##O	O
_	O
2	O
)	O
,	O
2	O
-	O
al	O
##ken	O
##als	O
(	O
C	O
_	O
x	O
H	O
##O	O
)	O
,	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
,	I
6	I
-	I
al	I
##ka	I
##die	I
##nal	I
##s	I
(	O
C	O
_	O
x	O
H	O
##O	O
_	O
2	O
)	O
with	O
chain	O
lengths	O
ranging	O
from	O
C	O
_	O
8	O
to	O
C	O
_	O
16	O
.	O

This	O
application	O
was	O
subsequently	O
implemented	O
to	O
assess	O
the	O
rates	O
of	O
glucose	S
de	O
##ple	O
##tion	O
as	O
well	O
as	O
la	B
##ct	I
##ate	I
production	O
via	O
the	O
la	B
##ct	I
##ate	I
bio	O
##sen	O
##sor	O
,	O
Lac	O
##onic	O
,	O
to	O
indicate	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolism	O
in	O
response	O
to	O
h	O
##y	O
##pox	O
##ia	O
in	O
breast	O
cancer	O
cells	O
.	O

St	O
##rik	O
##ingly	O
,	O
in	O
##hibition	O
of	O
pu	B
##rine	I
metabolism	O
by	O
sur	O
##ami	O
##n	O
,	O
a	O
competitive	O
antagonist	O
at	O
P	O
##2	O
##X	O
and	O
P	O
##2	O
##Y	O
pu	B
##rine	I
##rg	I
##ic	I
receptors	O
,	O
reverse	O
##s	O
behavioral	O
,	O
ne	O
##uro	O
##chemical	O
,	O
transcription	O
##al	O
,	O
and	O
meta	O
##bol	O
##omi	O
##cs	O
abnormal	O
##ities	O
both	O
in	O
the	O
F	O
##m	O
##r	O
##1	O
knock	O
-	O
out	O
mouse	O
and	O
in	O
MI	O
##A	O
mice	O
exposed	O
to	O
p	O
##oly	O
(	O
I	O
:	O
C	O
)	O
during	O
pregnancy	O
[	O
–	O
]	O
.	O

C	B
##rea	I
##tine	I
,	O
phosphate	S
,	O
g	B
##ly	I
##cine	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
C	B
##18	I
:	I
1	I
,	O
and	O
several	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
on	O
the	O
other	O
hand	O
,	O
have	O
positive	O
weights	O
,	O
i	O
.	O
e	O
.	O
tend	O
to	O
show	O
higher	O
concentrations	O
in	O
women	O
.	O

For	O
each	O
data	O
pair	O
the	O
%	O
difference	O
was	O
calculated	O
(	O
[	O
ass	O
##ay	O
2	O
–	O
ass	O
##ay	O
##1	O
/	O
ass	O
##ay	O
1	O
]	O
×	O
100	O
%	O
)	O
,	O
and	O
the	O
2	O
distributions	O
of	O
the	O
%	O
errors	O
were	O
presented	O
(	O
Figure	O
)	O
in	O
addition	O
to	O
the	O
%	O
difference	O
observed	O
for	O
o	B
##lan	I
##za	I
##pine	I
(	O
as	O
worst	O
case	O
)	O
in	O
this	O
study	O
.	O

The	O
mitochondrial	O
ma	O
##lic	O
enzyme	O
ME	O
##3	O
regulate	O
##s	O
the	O
p	B
##yr	I
##u	I
##vate	I
-	I
ma	I
##late	I
cycle	O
in	O
which	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
is	O
reduced	O
to	O
ma	B
##late	I
by	O
mitochondrial	O
ma	O
##late	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
and	O
then	O
is	O
converted	O
to	O
p	B
##yr	I
##u	I
##vate	I
by	O
o	O
##xi	O
##da	O
##tive	O
de	O
##car	O
##box	O
##yla	O
##tion	O
cat	O
##aly	O
##zed	O
by	O
ME	O
##3	O
.	O

More	O
precisely	O
,	O
co	O
##el	O
##ution	O
was	O
observed	O
for	O
g	B
##uan	I
##os	I
##ine	I
and	O
u	B
##rid	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
##s	I
,	O
and	O
all	O
detected	O
dip	B
##hos	I
##phate	I
##s	I
on	O
B	O
and	O
E	O
.	O
All	O
investigated	O
columns	O
showed	O
only	O
marginal	O
select	O
##ivity	O
toward	O
is	O
##omer	O
##ic	O
sugar	O
phosphate	B
##s	I
such	O
as	O
f	B
##ru	I
##ct	I
##ose	I
-	I
,	O
glucose	B
-	I
and	O
man	B
##nose	I
-	I
6	I
-	I
phosphate	I
.	O

Important	O
##ly	O
,	O
GA	B
##BA	I
increased	O
dramatically	O
along	O
with	O
the	O
progression	O
of	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

(	O
SM	O
d	B
##16	I
:	I
1	I
/	I
18	I
:	I
0	I
was	O
not	O
evaluated	O
.	O
)	O

In	O
the	O
pathway	O
,	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
is	O
then	O
synthesized	O
into	O
c	B
##rea	I
##tine	I
by	O
g	O
##uan	O
##ido	O
##ace	O
##tic	O
acid	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
which	O
is	O
subsequently	O
cat	O
##aly	O
##zed	O
by	O
c	O
##rea	O
##tina	O
##se	O
to	O
produce	O
u	B
##rea	I
and	O
sa	B
##rc	I
##os	I
##ine	I
,	O
both	O
of	O
which	O
correlated	O
significantly	O
with	O
D	O
##AS	O
##28	O
-	O
E	O
##SR	O
in	O
plasma	O
.	O

In	O
patients	O
undergoing	O
planned	O
withdrawal	O
from	O
la	B
##ct	I
##ulos	I
##e	I
,	O
co	O
##gnition	O
was	O
linked	O
to	O
stool	O
Pre	O
##vo	O
##tel	O
##la	O
s	O
##pp	O
.	O

The	O
association	O
between	O
change	O
in	O
each	O
meta	O
##bol	O
##ite	O
over	O
time	O
and	O
trial	O
assignment	O
(	B
β	B
-	I
car	I
##ote	I
##ne	I
or	O
no	O
β	B
-	I
car	I
##ote	I
##ne	I
)	O
was	O
estimated	O
by	O
linear	O
re	O
##gression	O
.	O

In	O
the	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
,	O
de	O
##ter	O
##ior	O
##ation	O
of	O
the	O
D	O
##I	O
,	O
a	O
measure	O
of	O
β	O
-	O
cell	O
function	O
relative	O
to	O
insulin	O
sensitivity	O
,	O
showed	O
a	O
robust	O
correlation	O
with	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
AU	O
##C	O
(	O
r	O
=	O
−	O
##0	O
.	O
50	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
and	O
its	O
levels	O
at	O
fast	O
##ing	O
(	O
r	O
=	O
−	O
##0	O
.	O
53	O
;	O
P	O
=	O
0	O
.	O
03	O
##6	O
)	O
,	O
90	O
minutes	O
(	O
r	O
=	O
−	O
##0	O
.	O
50	O
;	O
P	O
=	O
0	O
.	O
04	O
##8	O
)	O
,	O
and	O
120	O
minutes	O
(	O
r	O
=	O
−	O
##0	O
.	O
53	O
;	O
P	O
=	O
0	O
.	O
03	O
##6	O
)	O
at	O
the	O
outs	O
##et	O
of	O
our	O
study	O
.	O

The	O
D	O
##M	O
##N	O
consists	O
of	O
mid	O
##line	O
regions	O
such	O
as	O
the	O
m	O
##P	O
##FC	O
,	O
pre	O
##cu	O
##ne	O
##us	O
,	O
and	O
posterior	O
c	O
##ing	O
##ulate	O
cortex	O
,	O
and	O
is	O
shown	O
to	O
be	O
more	O
activated	S
in	O
the	O
absence	O
of	O
goal	O
-	O
directed	O
behavior	O
.	O

Li	O
##quid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
was	O
used	O
to	O
establish	O
reference	O
intervals	O
for	O
16	O
s	O
##tero	O
##ids	O
(	B
pre	B
##gne	I
##no	I
##lone	I
,	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
al	B
##dos	I
##tero	I
##ne	I
,	O
18	B
-	I
o	I
##x	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
18	B
-	I
h	I
##ydro	I
##xy	I
##cor	I
##tis	I
##ol	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
21	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ison	I
##e	I
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
-	I
su	I
##lf	I
##ate	I
,	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
test	B
##osterone	I
)	O
measured	O
in	O
plasma	O
from	O
52	O
##5	O
volunteers	O
with	O
(	O
n	O
=	O
227	O
)	O
and	O
without	O
(	O
n	O
=	O

The	O
concentrations	O
of	O
the	O
free	O
Sa	O
##FA	O
##s	O
palm	B
##itic	I
acid	I
(	O
16	O
:	O
0	O
)	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
18	O
:	O
0	O
)	O
were	O
increased	O
significantly	O
in	O
the	O
HIV	O
+	O
group	O
and	O
proportions	O
of	O
inflammatory	O
mon	O
##ocytes	O
were	O
positively	O
associated	O
with	O
levels	O
of	O
both	O
palm	B
##itic	I
acid	I
(	O
16	O
:	O
0	O
)	O
(	O
r	O
=	O
0	O
.	O
72	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
18	O
:	O
0	O
)	O
(	O
r	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
whereas	O
proportions	O
of	O
traditional	O
mon	O
##ocytes	O
were	O
negatively	O
associated	O
with	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
18	O
:	O
0	O
)	O
(	O
r	O
=	O
−	O
##0	O
.	O
86	O
,	O
p	O
=	O
0	O
.	O
00	O
##2	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
a	O
simple	O
,	O
none	O
##ssent	O
##ial	O
amino	O
acid	O
,	O
g	B
##ly	I
##cine	I
was	O
involved	O
in	O
the	O
production	O
of	O
DNA	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
co	O
##lla	O
##gen	O
as	O
well	O
as	O
the	O
release	O
of	O
energy	O
.	O

Moreover	O
,	O
only	O
about	O
30	O
%	O
of	O
the	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
-	I
3	I
-	I
phosphate	I
is	O
used	O
for	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
while	O
most	O
of	O
it	O
being	O
transformed	O
into	O
g	B
##ly	I
##cer	I
##one	I
and	O
then	O
into	O
g	B
##ly	I
##cer	I
##ol	I
(	O
Fi	O
##g	O
.	O

With	O
the	O
exception	O
of	O
ant	B
##hra	I
##ni	I
##lic	I
acid	I
,	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
,	O
and	O
in	B
##do	I
##le	I
p	I
##yr	I
##u	I
##vate	I
,	O
the	O
slope	O
of	O
T	O
##rp	O
across	O
the	O
night	O
was	O
positively	O
correlated	O
with	O
the	O
slopes	O
of	O
its	O
meta	O
##bol	O
##ites	O
.	O

Under	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
N	B
##AD	I
##H	I
metabolism	O
within	O
the	O
mit	O
##och	O
##ond	O
##ria	O
in	O
association	O
with	O
the	O
K	O
##re	O
##bs	O
cycle	O
is	O
disrupted	O
.	O

The	O
R	O
##GC	O
-	O
5	O
cells	O
were	O
treated	O
ex	O
##ogen	O
##ously	O
with	O
a	O
mixture	O
of	O
three	O
different	O
G	O
##S	O
(	O
S	O
)	O
_	O
n	O
S	O
##G	O
:	O
G	O
##SS	O
##S	O
##G	O
(	O
84	O
%	O
)	O
,	O
G	O
##SS	O
##SS	O
##G	O
(	O
15	O
%	O
)	O
,	O
and	O
G	O
##SS	O
##SS	O
##S	O
##G	O
(	O
1	O
%	O
)	O
(	O
i	O
.	O
e	O
.	O
,	O
excluding	O
G	O
##SS	O
##G	O
)	O
in	O
the	O
presence	O
of	O
hydrogen	B
per	I
##oxide	I
(	O
H	O
_	O
2	O
O	O
_	O
2	O
)	O
after	O
15	O
hours	O
of	O
in	O
##cu	O
##bation	O
with	O
a	O
g	B
##lut	I
##ath	I
##ione	I
synthesis	O
inhibitor	O
,	O
but	B
##hi	I
##oni	I
##ne	I
su	O
##l	O
##ph	O
##ox	O
##im	O
##ine	O
(	O
BS	O
##O	O
)	O
.	O

Furthermore	O
,	O
they	O
disc	O
##rim	O
##inated	O
between	O
c	O
##yt	O
##oso	O
##lic	O
and	O
mitochondrial	O
N	B
##AD	I
##P	I
##H	I
production	O
by	O
evaluating	O
the	O
label	O
##ing	O
of	O
thy	B
##mi	I
##dine	I
trip	I
##hos	I
##phate	I
,	O
a	O
con	O
##com	O
##ita	O
##nt	O
by	O
##p	O
##rod	O
##uc	O
##t	O
of	O
this	O
one	O
-	O
carbon	O
metabolism	O
.	O

Important	O
##ly	O
,	O
4	B
-	I
met	I
##hyl	I
##non	I
##ano	I
##ic	I
acid	I
,	O
he	B
##xa	I
##no	I
##ic	I
acid	I
and	O
6	B
-	I
pen	I
##ty	I
##lo	I
##xa	I
##n	I
-	I
2	I
-	I
one	I
were	O
absent	O
in	O
the	O
cellular	O
medium	O
,	O
suggesting	O
its	O
origin	O
from	O
cellular	O
metabolism	O
,	O
thus	O
un	O
##ve	O
##iling	O
great	O
potential	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
to	O
be	O
further	O
valid	O
##ated	O
in	O
bio	O
##f	O
##lu	O
##ids	O
from	O
PC	O
##a	O
patients	O
.	O

In	O
the	O
case	O
of	O
high	O
fat	O
and	O
pig	O
##mented	O
samples	O
,	O
addition	O
of	O
graph	O
##iti	O
##zed	O
carbon	O
black	O
(	O
G	O
##C	O
##B	O
)	O
and	O
C	O
_	O
18	O
-	O
reversed	O
phase	O
si	B
##lica	I
gel	O
at	O
the	O
extract	O
pu	O
##rification	O
step	O
is	O
recommended	O
.	O

We	O
employed	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
to	O
measure	O
meta	O
##bol	O
##ites	O
and	O
metals	O
in	O
seven	O
post	O
-	O
m	O
##ort	O
##em	O
brain	O
regions	O
of	O
nine	O
AD	O
patients	O
and	O
nine	O
controls	O
,	O
and	O
plasma	B
-	I
glucose	I
and	O
plasma	O
-	O
copper	O
levels	O
in	O
an	O
ant	O
##e	O
-	O
m	O
##ort	O
##em	O
case	O
-	O
control	O
study	O
.	O

All	O
the	O
Q	O
##C	O
samples	O
were	O
prepared	O
in	O
human	O
plasma	O
,	O
and	O
the	O
end	O
##ogen	O
##ous	O
levels	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
were	O
determined	O
by	O
mean	O
of	O
multiple	O
replica	O
##tes	O
(	O
n	O
=	O
12	O
)	O
.	O

Chemical	O
##ly	O
in	O
##hibit	O
##ing	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
activity	O
with	O
6	B
-	I
di	I
##az	I
##o	I
-	I
5	I
-	I
o	I
##x	I
##o	I
-	I
L	I
-	I
nor	I
##le	I
##uc	I
##ine	I
(	O
D	O
##ON	O
)	O
,	O
a	O
g	B
##lut	I
##amine	I
antagonist	O
,	O
led	O
to	O
suppression	O
of	O
tumors	O
##phere	O
formation	O
and	O
decreased	O
g	B
##lut	I
##ama	I
##te	I
levels	O
in	O
H	O
##NS	O
##CC	O
cells	O
in	O
v	O
##it	O
##ro	O
.	O

Met	B
##han	I
##ol	I
was	O
used	O
as	O
the	O
organic	O
m	O
##od	O
##ifier	O
throughout	O
the	O
method	O
development	O
phase	O
,	O
and	O
contained	O
one	O
of	O
nine	O
different	O
add	O
##itive	O
##s	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
%	O
v	O
/	O
v	O
(	O
for	O
form	B
##ic	I
acid	I
,	O
ace	B
##tic	I
acid	I
,	O
is	B
##op	I
##rop	I
##yla	I
##mine	I
,	O
is	B
##ob	I
##ut	I
##yla	I
##mine	I
and	O
is	O
##ope	O
##nt	O
##yla	O
##mine	O
)	O
,	O
20	O
m	O
##M	O
(	O
for	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
ace	B
##tate	I
and	O
h	B
##ydro	I
##xi	I
##de	I
)	O
,	O
or	O
5	O
%	O
v	O
/	O
v	O
(	O
for	O
water	O
)	O
.	O

A	O
smaller	O
proportion	O
of	O
the	O
N	O
##P	O
tribal	O
population	O
were	O
C	O
##YP	O
##2	O
##A	O
##6	O
g	O
##eno	O
##type	O
reduced	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##izer	O
##s	O
compared	O
to	O
the	O
S	O
##W	O
tribal	O
population	O
(	O
N	O
##P	O
27	O
.	O
5	O
%	O
vs	O
.	O
S	O
##W	O
41	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
000	O
##6	O
)	O
.	O

C	O
_	O
27	O
bi	O
##le	O
acids	O
,	O
including	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
,	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
,	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
,	O
are	O
prevalent	O
in	O
blood	O
(	O
,	O
)	O
(	O
see	O
supplement	O
##al	O
Table	O
S	O
##1	O
)	O
and	O
have	O
been	O
identified	O
in	O
cells	O
of	O
the	O
rode	O
##nt	O
central	O
nervous	O
system	O
following	O
in	O
##cu	O
##bation	O
with	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
whereas	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
has	O
been	O
identified	O
as	O
an	O
export	O
product	O
from	O
human	O
brain	O
into	O
plasma	O
.	O

Furthermore	O
,	O
the	O
higher	O
glucose	S
level	O
of	O
AD	O
##V	O
patients	O
is	O
in	O
line	O
with	O
the	O
increased	O
serum	O
amount	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##in	I
found	O
in	O
AD	O
##V	O
with	O
respect	O
to	O
EA	O
##R	O
patients	O
.	O

It	O
is	O
additionally	O
utilized	O
in	O
a	O
number	O
of	O
an	O
##ab	O
##olic	O
pathways	O
,	O
such	O
as	O
is	B
##op	I
##ren	I
##oid	I
and	O
fatty	O
acid	O
synthesis	O
,	O
.	O

(	O
l	O
##1	O
)	O
(	O
l	O
##2	O
)	O
l	O
##2	O
l	O
##2	O
l	O
##1	O
l	O
##2	O
β	B
##0	I
,	I
β	I
##∈	I
##ℝ	I
##p	I
+	I
1	I
##min	I
[	I
[UNK]	O
=	I
1	I
##n	I
(	I
Yi	I
##−	I
##β	I
##0	I
##−	I
##X	I
##i	I
##T	I
##×	I
##β	I
)	I
2	I
+	I
λ	I
(	I
1	I
##−	I
##α	I
##2	I
‖	I
β	I
‖	I
l	I
##22	I
+	I
α	I
‖	I
β	I
‖	I
l	I
##1	I
)	I
]	I

Given	O
that	O
subjects	O
with	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
are	O
known	O
to	O
have	O
a	O
low	O
re	O
##nal	O
threshold	O
for	O
glucose	S
,	O
we	O
calculated	O
both	O
u	O
##rina	O
##ry	O
glucose	S
/	O
c	O
##rea	O
##tin	O
##ine	O
(	O
U	O
##G	O
/	O
C	O
##r	O
)	O
ratio	O
and	O
plasma	O
glucose	S
to	O
u	O
##rina	O
##ry	O
glucose	S
/	O
c	O
##rea	O
##tin	O
##ine	O
ratio	O
P	O
##G	O
/	O
(	O
U	O
##G	O
/	O
C	O
##r	O
)	O
.	O

The	O
method	O
involves	O
liquid	O
-	O
liquid	O
extraction	O
followed	O
by	O
conversion	O
to	O
the	O
he	B
##xa	I
##no	I
##ate	I
est	I
##er	I
derivative	O
.	O

We	O
also	O
characterized	O
the	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
derived	O
from	O
Ph	B
##e	I
-	I
9	I
,	I
10	I
-	I
e	I
##pox	I
##ide	I
in	O
smoke	O
##rs	O
’	O
urine	O
(	O
mean	O
0	O
.	O
05	O
##8	O
pm	O
##ol	O
/	O
m	O
##L	O
urine	O
)	O
,	O
and	O
its	O
formation	O
was	O
related	O
to	O
G	O
##ST	O
##M	O
##1	O
status	O
,	O
being	O
lower	O
in	O
the	O
G	O
##ST	O
##M	O
##1	O
-	O
null	O
individuals	O
.	O

We	O
found	O
that	O
fast	O
##ing	O
plasma	O
concentrations	O
of	O
BC	O
##AA	O
##s	O
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
pro	B
##line	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
di	B
##acy	I
##l	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
and	O
LP	O
##C	O
##a	O
C	B
##16	I
:	I
1	I
were	O
higher	O
in	O
the	O
o	O
##bes	O
##e	O
participants	O
,	O
while	O
circulating	O
as	B
##par	I
##agi	I
##ne	I
,	O
se	B
##rine	I
,	O
a	B
##cy	I
##l	I
-	I
al	I
##ky	I
##l	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
and	O
other	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
were	O
higher	O
in	O
controls	O
.	O

d	O
l	O
During	O
our	O
pro	O
##fi	O
##ling	O
studies	O
for	O
o	B
##xy	I
##ster	I
##ols	I
,	O
we	O
monitored	O
the	O
MR	O
##M	O
transition	O
53	O
##4	O
##→	O
##45	O
##5	O
##→	O

L	O
##C	O
–	O
MS	O
(	O
Ch	O
##roma	O
##sol	O
##v	O
)	O
grade	O
met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
is	B
##op	I
##rop	I
##ano	I
##l	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Poole	O
,	O
UK	O
)	O
;	O
water	O
was	O
obtained	O
from	O
an	O
ultra	O
-	O
pure	O
water	O
pu	O
##rification	O
system	O
(	O
Mill	O
##ip	O
##ore	O
,	O
UK	O
)	O
and	O
‘	O
food	O
fresh	O
’	O
liquid	O
CO	O
_	O
2	O
(	O
99	O
.	O
8	O
%	O
purity	O
)	O
was	O
obtained	O
from	O
B	O
##OC	O
(	O
UK	O
)	O
.	O

Bet	O
,	O
beta	B
##ine	I
;	O
G	B
##S	I
##H	I
,	O
g	B
##lut	I
##ath	I
##ione	I
;	O
H	O
##y	O
##po	O
-	O
Tau	O
,	O
h	B
##y	I
##pot	I
##au	I
##rine	I
;	O
MC	O
##I	O
,	O
my	O
##o	O
-	O
I	O
–	O
to	O
–	O
t	O
##CH	O
##O	O
index	O
;	O
P	O
##E	O
,	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
.	O

AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
A	O
##rg	O
,	O
a	B
##rg	I
##ini	I
##ne	I
;	O
C	O
##it	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
;	O
EA	O
##A	O
,	O
essential	O
amino	O
acid	O
;	O
NE	O
##AA	O
,	O
none	O
##ssent	O
##ial	O
amino	O
acid	O
;	O
OH	O
-	O
K	O
##yn	O
,	O
h	B
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
;	O
Or	O
##n	O
,	O
or	B
##ni	I
##thin	I
##e	I
;	O
Ph	O
##e	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
Pro	O
,	O
pro	B
##line	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
T	O
##rp	O
,	O
try	B
##pt	I
##op	I
##han	I
;	O
Ty	O
##r	O
,	O
t	B
##yr	I
##os	I
##ine	I
.	O

Sam	O
##ples	O
without	O
measures	O
of	O
meta	O
##bol	O
##ites	O
or	O
fast	O
##ing	O
glucose	S
,	O
or	O
available	O
g	O
##eno	O
##type	O
data	O
for	O
family	O
kin	O
##ship	O
adjustment	O
were	O
excluded	O
.	O

500	O
µ	O
##l	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
added	O
and	O
mixed	O
on	O
a	O
v	O
##ortex	O
shake	O
##r	O
for	O
3	O
min	O
,	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
10	O
000	O
rpm	O
/	O
min	O
for	O
10	O
min	O
.	O

While	O
AM	O
##P	O
##K	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
was	O
not	O
significantly	O
increased	O
by	O
HD	O
##L	O
,	O
this	O
finding	O
is	O
consistent	O
with	O
the	O
previously	O
well	O
-	O
described	O
phenomenon	O
that	O
AM	O
##P	O
##K	O
is	O
generally	O
trans	O
##ient	O
##ly	O
activated	S
,	O
with	O
con	O
##se	O
##quent	O
sustained	O
stimulation	O
of	O
downstream	O
targets	O
,	O
such	O
as	O
ACC	O
(	O
,	O
,	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
such	O
as	O
v	B
##ali	I
##ne	I
,	O
sa	B
##rc	I
##os	I
##ine	I
,	O
he	B
##xa	I
##ned	I
##io	I
##ic	I
acid	I
,	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
could	O
be	O
possibly	O
potential	O
bio	O
##mark	O
##ers	O
and	O
need	O
to	O
be	O
valid	O
##ated	O
.	O

As	O
the	O
rib	B
##ose	I
-	I
5	I
-	I
phosphate	I
is	O
also	O
the	O
backbone	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
the	O
lowered	O
level	O
of	O
total	O
rib	B
##ose	I
-	I
5	I
-	I
phosphate	I
in	O
the	O
knock	O
##down	O
cells	O
as	O
shown	O
in	O
and	O
may	O
also	O
contribute	O
to	O
the	O
decreased	O
levels	O
of	O
some	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
and	O
their	O
derivatives	O
i	O
.	O
e	O
.	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
AD	B
##P	I
-	I
glucose	I
,	O
U	B
##DP	I
,	O
GDP	O
,	O
GDP	O
-	O
man	O
##nose	O
and	O
GDP	B
-	I
f	I
##uc	I
##ose	I
.	O

That	O
is	O
,	O
the	O
lip	O
##ids	O
are	O
identified	O
by	O
their	O
total	O
a	O
##cy	O
##l	O
/	O
al	O
##ky	O
##l	O
chain	O
content	O
(	O
i	O
.	O
e	O
.	O
PC	B
(	I
38	I
:	I
4	I
)	I
)	O
as	O
opposed	O
to	O
their	O
precise	O
chemical	O
structure	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
t	O
-	O
test	O
was	O
used	O
for	O
statistical	O
analyses	O
between	O
di	O
##abe	O
##tic	O
and	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
women	O
at	O
M	O
##0	O
and	O
M1	O
##2	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
the	O
most	O
abundant	O
ch	B
##ole	I
##ster	I
##ol	I
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
be	O
C	O
_	O
27	O
and	O
C	O
_	O
24	O
intermediate	O
##s	O
of	O
the	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hetic	O
pathways	O
with	O
structures	O
corresponding	O
to	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
7	O
.	O
170	O
±	O
2	O
.	O
82	O
##6	O
ng	O
/	O
m	O
##l	O
,	O
mean	O
±	O
S	O
.	O
D	O
.	O
,	O
six	O
subjects	O
)	O
,	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
0	O
.	O
41	O
##6	O
±	O
0	O
.	O
193	O
ng	O
/	O
m	O
##l	O
)	O
,	O
7	B
##α	I
,	I
x	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
1	O
.	O
330	O
±	O
0	O
.	O
54	O
##3	O
ng	O
/	O
m	O
##l	O
)	O
,	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ol	I
-	I
4	I
-	I
en	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
(	O
0	O
.	O
172	O
±	O
0	O
.	O
08	O
##5	O
ng	O
/	O
m	O
##l	O
)	O
,	O
and	O
the	O
C	O
_	O
26	O
s	B
##tero	I
##l	I
7	I
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
26	I
-	I
nor	I
##cho	I
##les	I
##t	I
-	I
4	I
-	I
en	I
##e	I
-	I
3	I
,	I
x	I
-	I
di	I
##one	I
(	O
0	O
.	O
204	O
±	O
0	O
.	O
08	O
##3	O
ng	O
/	O
m	O
##l	O
)	O

After	O
the	O
withdrawal	O
of	O
anti	O
##biotics	O
and	O
subsequent	O
re	O
##ap	O
##pear	O
##ance	O
of	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
over	O
a	O
period	O
of	O
1	O
month	O
or	O
longer	O
,	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
challenge	O
during	O
visit	O
3	O
again	O
resulted	O
in	O
readily	O
detect	O
##able	O
and	O
time	O
-	O
dependent	O
changes	O
in	O
T	B
##MA	I
##O	I
and	O
d	O
##9	O
-	O
T	O
##MA	O
##O	O
in	O
plasma	O
and	O
urine	O
.	O

A	O
1	O
.	O
0	O
m	O
##M	O
solution	O
of	O
the	O
LP	O
##O	O
product	O
of	O
interest	O
was	O
made	O
up	O
in	O
ethanol	S
and	O
100	O
μ	O
##l	O
was	O
added	O
to	O
the	O
MA	O
##d	O
_	O
3	O
solution	O
(	O
10	O
-	O
fold	O
m	O
##olar	O
excess	O
)	O
.	O

Moreover	O
,	O
decreased	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
may	O
indicate	O
lip	O
##oly	O
##sis	O
followed	O
by	O
β	O
-	O
oxidation	O
of	O
fatty	O
acids	O
that	O
may	O
exist	O
to	O
deliver	O
bio	O
##ener	O
##gy	O
for	O
rapid	O
tumor	O
cell	O
proliferation	O
and	O
growth	O
.	O

Although	O
plasma	O
ho	B
##mo	I
##lant	I
##hi	I
##oni	I
##ne	I
concentrations	O
were	O
notably	O
higher	O
than	O
la	B
##nt	I
##hi	I
##oni	I
##ne	I
concentrations	O
in	O
all	O
subjects	O
,	O
ho	B
##mo	I
##lant	I
##hi	I
##oni	I
##ne	I
concentrations	O
were	O
not	O
different	O
between	O
the	O
groups	O
(	O
P	O
=	O
0	O
.	O
101	O
)	O
.	O

The	O
g	B
##ly	I
##cer	I
##ol	I
signal	O
was	O
assigned	O
using	O
the	O
Chen	O
##om	O
##x	O
Reference	O
Co	O
##mpo	O
##und	O
library	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
collected	O
and	O
stored	O
prior	O
to	O
analysis	O
at	O
−	O
##80	O
##°	O
##C	O
after	O
di	O
##lution	O
with	O
100	O
µ	O
##L	O
80	O
%	O
met	B
##han	I
##ol	I
in	O
water	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
162	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
species	O
were	O
q	O
##uant	O
##ified	O
in	O
He	O
##p	O
##G	O
##2	O
and	O
He	O
##p	O
##G	O
##2	O
.	O
2	O
.	O
15	O
cells	O
(	O
Table	O
_	O
S	O
##3	O
and	O
Su	O
##pp	O
##lement	O
##ary	O
data	O
##set	O
2	O
)	O
,	O
and	O
among	O
these	O
,	O
56	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
species	O
were	O
significantly	O
different	O
between	O
He	O
##p	O
##G	O
##2	O
and	O
He	O
##p	O
##G	O
##2	O
.	O
2	O
.	O
15	O
cells	O
(	O
Fi	O
##g	O
.	O

S	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
correlated	O
positively	O
with	O
selected	O
T	B
##G	I
and	O
D	O
##G	O
species	O
,	O
but	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
did	O
not	O
co	O
##rrel	O
##ate	O
with	O
any	O
plasma	O
lip	O
##id	O
.	O

The	O
relation	O
to	O
e	O
##G	O
##F	O
##R	O
and	O
c	B
##rea	I
##tin	I
##ine	I
is	O
further	O
described	O
for	O
the	O
full	O
co	O
##hor	O
##t	O
by	O
Pearson	O
correlation	O
tests	O
in	O
Table	O
.	O

Seven	O
of	O
the	O
19	O
patients	O
had	O
significant	O
CA	O
##D	O
and	O
a	O
conversion	O
to	O
an	O
##ae	O
##ro	O
##bic	O
metabolism	O
(	O
net	O
la	B
##ct	I
##ate	I
release	O
)	O
indicating	O
clear	O
my	O
##oc	O
##ard	O
##ial	O
is	O
##che	O
##mia	O
.	O

By	O
contrast	O
,	O
the	O
subsequent	O
exclusion	O
##s	O
among	O
non	O
-	O
hormone	O
users	O
(	O
due	O
to	O
insufficient	O
base	O
##line	O
serum	O
for	O
bio	O
##chemical	O
ass	O
##ays	O
,	O
extreme	O
values	O
for	O
total	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
or	O
in	O
sit	O
##u	O
rather	O
than	O
invasive	O
breast	O
cancer	O
,	O
if	O
a	O
case	O
subject	O
)	O
resulted	O
in	O
only	O
one	O
statistical	O
##ly	O
significant	O
difference	O
between	O
the	O
included	O
and	O
excluded	O
case	O
and	O
control	O
subjects	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
##s	O
4	O
and	O
5	O
,	O
available	O
online	O
)	O
.	O

Proto	O
##n	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
(	O
_	O
1	O
H	O
N	O
##MR	O
)	O
,	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
H	O
##IL	O
##IC	O
-	O
MS	O
)	O
and	O
in	O
##duct	O
##ively	O
coupled	O
plasma	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
I	O
##CP	O
-	O
MS	O
)	O
were	O
applied	O
to	O
q	O
##uant	O
##ify	O
meta	O
##bol	O
##ites	O
and	O
metal	O
elements	O
in	O
plasma	O
samples	O
.	O

Pre	O
-	O
weighted	O
kits	O
for	O
extraction	O
,	O
containing	O
an	B
##hy	I
##dr	I
##ous	I
ma	I
##gnesium	I
su	I
##lf	I
##ate	I
(	O
M	O
##g	O
##SO	O
_	O
4	O
)	O
,	O
sodium	B
chloride	I
(	O
Na	O
##C	O
##l	O
)	O
,	O
sodium	B
c	I
##it	I
##rate	I
(	O
C	O
_	O
6	O
H	O
_	O
5	O
Na	O
_	O
3	O
O	O
_	O
7	O
)	O
,	O
and	O
di	B
##so	I
##dium	I
c	I
##it	I
##rate	I
se	O
##s	O
##qui	O
##hy	O
##dra	O
##te	O
,	O
and	O
pre	O
-	O
weighted	O
clean	O
-	O
up	O
mixture	O
##s	O
in	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
containing	O
different	O
amounts	O
of	O
M	O
##g	O
##SO	O
_	O
4	O
,	O
primary	O
secondary	O
am	O
##ine	O
(	O
PS	O
##A	O
)	O
,	O
graph	O
##iti	O
##zed	O
carbon	O
black	O
(	O
G	O
##C	O
##B	O
)	O
,	O
and	O
si	B
##lica	I
reversed	O
-	O
phase	O
so	O
##rb	O
##ent	O
C	O
_	O
18	O
were	O
purchased	O
from	O
A	O
##gi	O
##lent	O
Technologies	O
(	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Sign	O
##ificant	O
decrease	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
in	O
NHL	O
urine	O
.	O

This	O
suggested	O
that	O
H	O
.	O
p	O
##oma	O
##tia	O
extract	O
is	O
contaminated	O
with	O
3	B
##β	I
-	I
H	I
##SD	I
or	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
activity	O
and	O
could	O
con	O
##found	O
studies	O
,	O
such	O
as	O
ours	O
,	O
in	O
which	O
the	O
anal	O
##yte	O
##s	O
of	O
interest	O
are	O
3	B
##β	I
-	I
H	I
##SD	I
substrates	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
with	O
ST	O
##AT	O
##A	O
⁄	O
##SE	O
11	O
.	O
2	O
(	O
St	O
##ata	O
##C	O
##or	O
##p	O
LP	S
,	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
and	O
SP	O
##SS	O
Statistics	O
v	O
##23	O
(	O
IBM	O
Corp	O
,	O
Arm	O
##on	O
##k	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Pi	O
##n	O
##point	O
##ing	O
the	O
identity	O
of	O
PC	B
37	I
:	I
5	I
and	O
PC	B
O	I
-	I
38	I
:	I
5	I
in	O
human	O
plasma	O
.	O

Am	O
##ino	O
acid	O
metabolic	O
pathways	O
are	O
grouped	O
according	O
to	O
their	O
points	O
of	O
entry	O
into	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
,	O
g	O
##ly	O
##co	O
##lysis	O
,	O
k	O
##eto	O
##genesis	O
,	O
lip	O
##oly	O
##sis	O
,	O
pro	O
##te	O
##oly	O
##sis	O
and	O
u	B
##rea	I
cycles	O
.	O

The	O
calculated	O
concentration	O
of	O
HP	O
##HP	O
##A	O
in	O
these	O
samples	O
ranged	O
from	O
0	O
.	O
99	O
##5	O
to	O
16	O
.	O
6	O
µ	O
##M	O
/	O
m	O
##M	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Previous	O
work	O
by	O
also	O
demonstrated	O
rapid	O
alterations	O
in	O
my	B
##ost	I
##ati	I
##n	I
m	O
##RNA	O
in	O
response	O
to	O
exercise	O
performed	O
even	O
under	O
moderately	O
cold	O
conditions	O
.	O

B	O
##rac	O
##hia	O
##l	O
-	O
ankle	O
pulse	O
wave	O
velocity	O
was	O
measured	O
using	O
an	O
automatic	O
wave	O
##form	O
analyze	O
##r	O
(	O
Model	O
VP	O
-	O
1000	O
;	O
Nippon	O
Colin	S
Ltd	O
.	O
,	O
Ko	O
##ma	O
##ki	O
,	O
Japan	O
)	O
according	O
to	O
a	O
previously	O
published	O
method	O
.	O

Yi	O
##eld	O
of	O
SF	S
equivalent	O
##s	O
in	O
the	O
current	O
study	O
ranged	O
from	O
6	O
.	O
4	O
%	O
to	O
48	O
.	O
9	O
%	O
,	O
butt	O
##ressed	O
at	O
the	O
lower	O
end	O
by	O
the	O
inclusion	O
of	O
some	O
SF	S
in	O
the	O
formulation	O
.	O

The	O
pathway	O
analysis	O
of	O
group	O
with	O
fever	O
duration	S
1	O
–	O
5	O
days	O
revealed	O
four	O
significant	O
pathways	O
namely	O
,	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
00	O
##7	O
##46	O
)	O
,	O
U	B
##bi	I
##quin	I
##one	I
and	O
other	O
te	B
##rp	I
##eno	I
##id	I
-	I
q	I
##uin	I
##one	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
01	O
##30	O
##7	O
)	O
,	O
Ni	O
##tro	O
##gen	O
metabolism	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
01	O
##5	O
##24	O
)	O
and	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
metabolism	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
02	O
##00	O
##3	O
)	O
.	O

There	O
were	O
fewer	O
male	O
patients	O
in	O
the	O
A	B
##F	I
group	O
than	O
in	O
the	O
non	O
-	O
A	O
##F	O
group	O
(	O
27	O
(	O
55	O
.	O
10	O
%	O
)	O
vs	O
.	O
89	O
(	O
76	O
.	O
72	O
%	O
)	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Ara	B
##chi	I
##don	I
##ic	I
acid	I
is	O
present	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
also	O
works	O
as	O
a	O
second	O
messenger	O
for	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
activation	O
and	O
as	O
a	O
key	O
inflammatory	O
media	O
##tor	O
.	O

Also	O
,	O
the	O
gut	O
micro	O
##bio	O
##me	O
contributes	O
to	O
altered	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
yielding	O
increased	O
levels	O
of	O
in	O
##do	O
##ly	O
##l	O
3	O
-	O
ace	O
##tic	O
acid	O
and	O
in	B
##do	I
##ly	I
##l	I
la	I
##ct	I
##ate	I
.	O

Tea	O
##r	O
lip	O
##ido	O
##mic	O
##s	O
showed	O
30	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
significantly	O
m	O
##od	O
##ulated	O
and	O
,	O
notably	O
,	O
many	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
resulted	O
lower	O
in	O
Mu	O
##S	O
.	O
Moreover	O
,	O
the	O
meta	O
##bol	O
##omi	O
##cs	O
approach	O
carried	O
out	O
both	O
on	O
tears	O
and	O
serum	O
highlighted	O
the	O
diagnostic	O
potential	O
of	O
specific	O
amino	B
##ac	I
##ids	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

GA	B
##BA	I
decline	O
is	O
associated	O
with	O
a	O
build	O
-	O
up	O
of	O
its	O
precursor	O
meta	O
##bol	O
##ites	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##put	I
##res	I
##cine	I
and	O
4	B
-	I
amino	I
##but	I
##ana	I
##l	I
.	O

Ad	O
##e	O
##qua	O
##te	O
as	B
##pi	I
##rin	I
action	O
was	O
defined	O
as	O
complete	O
in	O
##hibition	O
of	O
plate	O
##let	O
-	O
CO	O
##X	O
-	O
1	O
activity	O
as	O
assessed	O
by	O
<	O
10	O
%	O
change	O
in	O
light	O
transmission	O
a	O
##gg	O
##re	O
##go	O
##metry	O
to	O
≥	O
1	O
mm	O
##ol	O
/	O
L	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

as	B
##par	I
##agi	I
##ne	I
(	O
55	O
%	O
)	O
,	O
and	O
as	B
##par	I
##tate	I
(	O
70	O
%	O
)	O
.	O

Of	O
the	O
44	O
meta	O
##bol	O
##ites	O
with	O
significantly	O
changed	O
concentrations	O
at	O
R	O
##T	O
,	O
35	O
showed	O
increasing	O
concentrations	O
after	O
24	O
h	O
(	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
,	O
and	O
)	O
whereas	O
9	O
showed	O
decreasing	O
concentrations	O
,	O
including	O
[UNK]	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
se	O
##rot	O
##oni	O
##n	O
*	O
,	O
four	O
PC	O
a	O
##a	O
’	O
s	O
(	O
PC	O
a	O
##a	O
[UNK]	O
,	O
PC	O
a	O
##a	O
[UNK]	O
,	O
PC	O
a	O
##a	O
[UNK]	O
and	O
PC	O
a	O
##a	O
[UNK]	O
,	O
see	O
)	O
and	O
he	B
##x	I
##ose	I
.	O

Conversely	O
,	O
there	O
was	O
a	O
slight	O
but	O
significant	O
increase	O
in	O
my	B
##risto	I
##lea	I
##te	I
,	O
L	O
##ys	O
##oli	O
##pid	O
##s	O
:	O
There	O
was	O
a	O
general	O
increase	O
in	O
all	O
detected	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##GP	O
##Cs	O
)	O
with	O
limo	B
##nen	I
##e	I
treatment	O
.	O

L	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
was	O
found	O
significantly	O
lower	O
in	O
Class	O
C	O
than	O
in	O
Class	O
A	O
and	O
Class	O
B	O
in	O
both	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
groups	O
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
decreased	O
with	O
increased	O
ME	O
##LD	O
score	O
in	O
3	O
groups	O
.	O

The	O
reaction	O
cat	O
##aly	O
##zed	O
by	O
CT	B
##P	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
c	O
##yt	O
##idy	O
##ly	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
(	O
CC	O
##T	O
)	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
.	O

Although	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
is	O
a	O
commonly	O
used	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
tool	O
for	O
assessment	O
of	O
I	O
##R	O
and	O
β	O
-	O
cell	O
function	O
,	O
and	O
has	O
been	O
shown	O
to	O
co	O
##rrel	O
##ate	O
with	O
more	O
complicated	O
and	O
costly	O
‘	O
gold	O
standard	O
’	O
measures	O
of	O
I	O
##R	O
(	O
i	O
.	O
e	O
.	O
e	B
##ug	I
##ly	I
##ca	I
##em	I
##ic	I
–	I
h	I
##yper	I
##ins	I
##ulin	I
##ae	I
##mic	I
c	O
##lamp	O
)	O
,	O
it	O
may	O
not	O
perform	O
as	O
well	O
in	O
certain	O
subgroup	O
##s	O
.	O

Instead	O
,	O
duration	S
of	O
maintenance	O
therapy	O
was	O
better	O
correlated	O
with	O
W	O
##BC	O
(	O
r	O
=	O
0	O
.	O
35	O
##2	O
,	O
P	O
=	O
0	O
.	O
00	O
##2	O
)	O
and	O
AN	O
##C	O
(	O
r	O
=	O
0	O
.	O
44	O
##8	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Although	O
the	O
en	O
##rich	O
##ment	O
of	O
plasma	O
glucose	S
was	O
below	O
2	O
%	O
,	O
we	O
detected	O
_	O
13	O
C	O
label	O
##ing	O
in	O
12	O
out	O
of	O
25	O
target	O
meta	O
##bol	O
##ites	O
(	O
and	O
Su	O
##pp	O
##lement	O
##ary	O
Materials	O
Figure	O
S	O
##1	O
)	O
,	O
and	O
could	O
trace	O
the	O
metabolism	O
of	O
the	O
wheat	O
compounds	O
to	O
meta	O
##bol	O
##ites	O
located	O
further	O
downstream	O
of	O
glucose	S
.	O

Chemical	O
shifts	O
were	O
referenced	O
to	O
the	O
an	O
##omer	O
##ic	O
pro	O
##ton	O
of	O
α	B
-	I
glucose	I
at	O
δ	O
##5	O
.	O
233	O
and	O
the	O
s	O
##pect	O
##ra	O
were	O
put	O
into	O
2	O
,	O
83	O
##4	O
integrated	O
regions	O
of	O
0	O
.	O
00	O
##3	O
pp	O
##m	O
,	O
corresponding	O
to	O
δ	O
##H	O
=	O
9	O
.	O
0	O
,	O
to	O
0	O
.	O
5	O
pp	O
##m	O
.	O

The	O
typical	O
positive	O
ion	O
E	O
##SI	O
conditions	O
were	O
:	O
cap	O
##illa	O
##ry	O
voltage	O
,	O
+	O
5	O
k	B
##V	I
;	O
de	O
##c	O
##luster	O
##ing	O
potential	O
##s	O
(	O
D	O
##P	O
##1	O
)	O
,	O
60	O
V	O
;	O
D	O
##P	O
##2	O
,	O
10	O
V	O
;	O
focusing	O
potential	O
,	O
250	O
V	O
.	O
The	O
typical	O
negative	O
ion	O
E	O
##SI	O
conditions	O
were	O
:	O
cap	O
##illa	O
##ry	O
voltage	O
,	O
-	O
4	O
.	O
5	O
k	B
##V	I
;	O
D	O
##P	O
##1	O
,	O
60	O
V	O
;	O
D	O
##P	O
##2	O
,	O
10	O
V	O
;	O
focusing	O
potential	O
,	O
250	O
V	O
.	O
Full	O
scan	O
mass	O
s	O
##pect	O
##ra	O
were	O
recorded	O
over	O
the	O
mass	O
range	O
of	O
m	O
/	O
z	O
50	O
–	O
2000	O
using	O
a	O
time	O
-	O
of	O
flight	O
(	O
TO	O
##F	O
)	O
analyze	O
##r	O
at	O
a	O
resolution	O
of	O
10	O
,	O
000	O
Full	O
W	O
##id	O
##th	O
Half	O
Maximum	O
.	O

A	O
100	O
µ	O
L	O
al	O
##iq	O
##uo	O
##t	O
of	O
sample	O
was	O
transferred	O
to	O
a	O
10	O
m	O
##L	O
glass	O
cent	O
##ri	O
##fu	O
##ge	O
tube	O
prior	O
to	O
adding	O
3	O
m	O
##L	O
extraction	O
solvent	O
(	B
et	B
##hyl	I
ace	I
##tate	I
:	I
is	I
##op	I
##rop	I
##ano	I
##l	I
=	I
19	I
:	I
1	I
,	O
vol	O
:	O
vol	O
)	O
.	O

The	O
signal	O
originating	O
from	O
the	O
β	O
-	O
pro	O
##ton	O
of	O
glucose	S
was	O
removed	O
during	O
the	O
multi	O
##var	O
##iate	O
analysis	O
but	O
considered	O
in	O
un	O
##iva	O
##ria	O
##te	O
statistics	O
.	O

Fast	O
##ing	O
and	O
2	O
h	O
post	O
##pra	O
##ndi	O
##al	O
plasma	O
glucose	S
(	O
an	O
O	O
##G	O
##TT	O
test	O
)	O
and	O
insulin	O
levels	O
(	B
G	B
##lu	I
##cos	I
##e	I
##0	I
,	O
G	O
##lu	O
##cos	O
##e	O
##12	O
##0	O
,	O
IN	O
##S	O
##0	O
,	O
and	O
IN	O
##S	O
##12	O
##0	O
)	O
,	O
serum	O
lip	O
##id	O
profiles	O
(	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
T	O
##C	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
T	I
##G	I
,	O
high	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
HD	I
##L	I
,	O
low	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
L	O
##D	O
##L	O
)	O
,	O
blood	O
pressure	O
(	O
s	O
##ys	O
##to	O
##lic	O
and	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
SP	S
and	O
D	O
##P	O
)	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
,	O
and	O
liver	O
and	O
kidney	O
functions	O
were	O
determined	O
as	O
previously	O
described	O
[	O
]	O
.	O

Some	O
of	O
these	O
meta	O
##bol	O
##ites	O
are	O
among	O
the	O
most	O
abundant	O
fur	B
##an	I
meta	O
##bol	O
##ites	O
present	O
in	O
urine	O
as	O
judged	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
,	O
indicating	O
that	O
the	O
oxidation	O
of	O
fur	B
##an	I
to	O
B	O
##DA	O
and	O
B	O
##DA	O
’	O
s	O
subsequent	O
reaction	O
with	O
cellular	O
c	B
##ys	I
##tein	I
##e	I
and	O
l	B
##ys	I
##ine	I
residues	O
may	O
represent	O
a	O
significant	O
in	O
v	O
##ivo	O
pathway	O
of	O
fur	B
##an	I
bio	O
##tra	O
##ns	O
##formation	O
.	O

Mobile	O
phases	O
A	O
and	O
B	O
were	O
D	O
##W	O
with	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
carbon	I
##ate	I
(	O
pH	O
9	O
.	O
0	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
respectively	O
.	O

In	O
our	O
study	O
the	O
β	B
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
and	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
(	O
total	O
E	O
##2	O
-	O
un	O
##con	O
##ju	O
##gated	O
E	O
##2	O
)	O
correspond	O
##ed	O
to	O
18	O
p	O
##g	O
/	O
m	O
##L	O
suggesting	O
that	O
the	O
su	B
##lf	I
##ate	I
was	O
the	O
major	O
con	O
##ju	O
##gate	O
of	O
E	O
##2	O
that	O
was	O
present	O
in	O
the	O
serum	O
.	O

The	O
method	O
was	O
tested	O
ex	O
v	O
##ivo	O
using	O
p	B
##or	I
##cine	I
and	O
human	O
brain	O
cancer	O
##s	O
in	O
the	O
laboratory	O
,	O
and	O
besides	O
commonly	O
observed	O
fatty	O
acid	O
and	O
complex	O
lip	O
##ids	O
,	O
allowed	O
the	O
detection	O
of	O
other	O
tissue	O
constituents	O
such	O
as	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
and	O
p	O
##eptide	O
##s	O
.	O

The	O
o	O
##le	O
##ic	O
acid	O
-	O
is	O
##ole	O
##uc	O
##ine	O
negative	O
correlation	O
(	O
a	O
)	O
is	O
consistent	O
with	O
the	O
observations	O
that	O
plasma	O
o	B
##le	I
##ic	I
acid	I
was	O
greater	O
in	O
H	O
##B	O
##V	O
than	O
in	O
the	O
controls	O
and	O
that	O
plasma	O
is	B
##ole	I
##uc	I
##ine	I
was	O
lower	O
in	O
H	O
##B	O
##V	O
than	O
in	O
the	O
controls	O
.	O

The	O
results	O
revealed	O
a	O
direct	O
correlation	O
between	O
2	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
(	O
r	O
##ho	O
0	O
.	O
61	O
,	O
p	O
=	O
0	O
.	O
000	O
##4	O
)	O
,	O
B	O
##MI	O
(	O
r	O
##ho	O
=	O
0	O
.	O
79	O
p	O
=	O
0	O
.	O
000	O
##00	O
##0	O
##7	O
)	O
and	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
(	O
r	O
##ho	O
=	O
0	O
.	O
75	O
,	O
p	O
=	O
000	O
##00	O
##00	O
##23	O
)	O
.	O

The	O
highest	O
value	O
amongst	O
these	O
individuals	O
was	O
14	O
μ	O
##mo	O
##l	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
per	O
24	O
h	O
##r	O
.	O

a	B
##rg	I
##ini	I
##ne	I

Not	O
##ably	O
,	O
when	O
we	O
predicted	O
the	O
successful	O
management	O
of	O
the	O
blood	O
glucose	S
based	O
on	O
the	O
predicted	O
H	O
##b	O
##A	O
##1	O
##c	O
values	O
(	O
a	O
di	O
##cho	O
##tom	O
##ic	O
decision	O
:	O
successful	O
management	O
of	O
H	O
##b	O
##A	O
##1	O
##c	O
##≤	O
##7	O
.	O
0	O
;	O
unsuccessful	O
management	O
of	O
H	O
##b	O
##A	O
##1	O
##c	O
>	O
7	O
.	O
0	O
)	O
,	O
the	O
model	O
correctly	O
classified	O
the	O
management	O
status	O
in	O
17	O
out	O
of	O
21	O
patients	O
(	O
81	O
%	O
correct	O
)	O
.	O

In	O
a	O
co	O
##hor	O
##t	O
of	O
early	O
-	O
stage	O
lung	O
cancer	O
patients	O
,	O
the	O
pre	O
##oper	O
##ative	O
in	O
##fusion	O
of	O
_	O
13	O
C	B
-	I
glucose	I
led	O
to	O
the	O
discovery	O
of	O
enhanced	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##se	O
(	O
PC	O
)	O
flux	O
in	O
lung	O
tumors	O
relative	O
to	O
ben	O
##ign	O
lung	O
,	O
which	O
correlated	O
with	O
increased	O
PC	O
expression	O
.	O

In	O
F	O
##S	O
##GS	O
patients	O
,	O
u	O
##rina	O
##ry	O
levels	O
of	O
glucose	S
,	O
dim	B
##eth	I
##yla	I
##mine	I
and	O
trim	B
##eth	I
##yla	I
##mine	I
increased	O
compared	O
with	O
healthy	O
controls	O
,	O
while	O
p	B
##yr	I
##u	I
##vate	I
,	O
v	B
##ali	I
##ne	I
,	O
hip	B
##pura	I
##te	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
,	O
c	B
##it	I
##rate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
decreased	O
.	O

Ser	O
##um	O
g	B
##ly	I
##cer	I
##ol	I
levels	O
were	O
going	O
back	O
to	O
the	O
normal	O
range	O
after	O
H	O
##U	O
medication	O
because	O
of	O
reduction	O
of	O
metabolic	O
stress	O
in	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
patients	O
as	O
less	O
g	B
##ly	I
##cer	I
##ol	I
is	O
consumed	O
for	O
energy	O
production	O
.	O

Stock	O
solutions	O
,	O
10	O
m	O
##M	O
each	O
,	O
of	O
the	O
is	O
##oto	O
##pe	O
-	O
labeled	O
compounds	O
were	O
prepared	O
by	O
di	O
##sso	O
##lving	O
the	O
accurately	O
weighed	O
solid	O
##s	O
in	O
75	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
.	O

They	O
observed	O
that	O
a	O
few	O
lip	O
##ids	O
like	O
L	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
,	O
LP	B
##A	I
(	I
16	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
and	O
LP	B
##A	I
(	I
0	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
were	O
a	O
##ber	O
##rant	O
##ly	O
expressed	O
in	O
CT	O
##CL	O
plasma	O
in	O
positive	O
and	O
negative	O
modes	O
.	O

O	O
##wing	O
to	O
increased	O
an	O
##gio	O
##genesis	O
and	O
tissue	O
growth	O
in	O
women	O
with	O
advanced	O
stages	O
of	O
end	O
##ome	O
##tri	O
##osis	O
,	O
it	O
is	O
likely	O
that	O
the	O
format	B
##e	I
molecules	O
are	O
incorporated	O
into	O
the	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
synthesis	O
leading	O
to	O
its	O
de	O
##ple	O
##tion	O
.	O

The	O
loading	O
plot	O
shows	O
increased	O
concentrations	O
of	O
g	B
##ly	I
##cine	I
,	O
ta	B
##uri	I
##ne	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
,	O
car	B
##ni	I
##tine	I
and	O
c	B
##it	I
##rate	I
,	O
and	O
decreased	O
concentrations	O
of	O
c	B
##rea	I
##tin	I
##ine	I
(	O
mean	O
concentration	O
of	O
c	B
##rea	I
##tin	I
##ine	I
over	O
time	O
is	O
shown	O
in	O
)	O
and	O
dim	B
##eth	I
##yla	I
##mine	I
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
.	O

Additionally	O
,	O
a	O
comparison	O
of	O
CP	O
and	O
PC	O
diagnostic	O
groups	O
yielded	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
la	B
##ct	I
##ate	I
,	O
v	B
##ali	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
al	B
##ani	I
##ne	I
as	O
being	O
up	O
-	O
regulated	O
in	O
chronic	O
pan	O
##cre	O
##ati	O
##tis	O
.	O

Compared	O
to	O
I	O
##BS	O
subjects	O
who	O
typically	O
go	O
to	O
bed	O
early	O
and	O
get	O
up	O
early	O
,	O
those	O
who	O
stay	O
up	O
late	O
and	O
sleep	O
later	O
in	O
the	O
morning	O
have	O
lower	O
mean	O
levels	O
of	O
most	O
of	O
the	O
meta	O
##bol	O
##ites	O
,	O
with	O
this	O
trend	O
being	O
statistical	O
##ly	O
significant	O
for	O
me	B
##lat	I
##oni	I
##n	I
,	O
try	B
##pta	I
##mine	I
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
.	O

In	O
healthy	O
controls	O
,	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
were	O
predicted	O
by	O
SD	O
##MA	O
(	O
r	O
_	O
p	O
=	O
0	O
.	O
50	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
,	O
the	O
var	O
##iability	O
in	O
which	O
was	O
responsible	O
for	O
25	O
%	O
of	O
a	B
##rg	I
##ini	I
##ne	I
var	O
##iability	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
246	O
;	O
F	O
=	O
12	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
.	O

Second	O
,	O
this	O
was	O
a	O
cross	O
-	O
section	O
##al	O
study	O
that	O
was	O
designed	O
to	O
investigate	O
the	O
relationship	O
between	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
meta	O
##bol	O
##ites	O
and	O
pro	O
-	O
inflammatory	O
c	O
##yt	O
##oki	O
##nes	O
and	O
GM	O
volume	O
of	O
two	O
regions	O
widely	O
implicated	O
in	O
MD	O
##D	O
:	O
the	O
hip	O
##po	O
##cam	O
##pus	O
and	O
am	O
##y	O
##g	O
##dal	O
##a	O
.	O

We	O
used	O
publicly	O
available	O
gene	O
expression	O
data	O
on	O
a	O
subset	O
of	O
the	O
DL	O
##BC	O
##L	O
cell	O
lines	O
to	O
determine	O
if	O
can	B
##na	I
##bino	I
##id	I
receptor	O
-	O
1	O
(	O
C	O
##NR	O
##1	O
)	O
,	O
C	O
##NR	O
##2	O
,	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
55	O
(	O
GP	O
##R	O
##55	O
)	O
,	O
fatty	O
acid	O
amid	O
##e	O
h	O
##ydro	O
##lase	O
(	O
FAA	O
##H	O
)	O
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
lip	O
##ase	O
(	O
MA	O
##G	O
##L	O
)	O
,	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
-	O
1	O
(	O
CO	O
##X	O
##1	O
)	O
and	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
-	O
2	O
(	O
CO	O
##X	O
##2	O
)	O
gene	O
expression	O
correlated	O
with	O
the	O
response	O
of	O
DL	O
##BC	O
##L	O
cell	O
lines	O
to	O
2	O
-	O
AG	O
.	O

Sub	O
##jects	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
also	O
had	O
slightly	O
,	O
but	O
significantly	O
,	O
higher	O
B	O
##MI	O
##s	O
(	O
in	O
kg	O
/	O
m	O
_	O
2	O
)	O

This	O
was	O
a	O
prospective	O
study	O
conducted	O
in	O
an	O
adult	O
medical	O
I	O
##CU	O
of	O
the	O
Hospital	O
Un	O
##ivers	O
##it	O
##á	O
##rio	O
São	O
Francisco	O
na	O
Pro	O
##vid	O
##ê	O
##ncia	O
de	O
De	O
##us	O
(	O
B	O
##raga	O
##n	O
##ça	O
Paul	O
##ista	O
,	O
SP	S
,	O
Brazil	O
)	O
.	O

Cell	O
##s	O
were	O
plate	O
##d	O
in	O
drops	O
of	O
10	O
–	O
15	O
µ	O
##L	O
.	O
For	O
organ	B
##oid	I
formation	O
,	O
AK	O
##P	O
organ	B
##oids	I
were	O
seeded	O
at	O
13	O
,	O
000	O
single	O
cells	O
per	O
drop	O
in	O
12	O
-	O
well	O
plates	O
.	O

A	O
reference	O
library	O
was	O
developed	O
consisting	O
of	O
145	O
met	O
##hyl	O
and	O
et	B
##hyl	I
ch	I
##lor	I
##of	I
##orm	I
##ate	I
(	O
MC	O
##F	O
and	O
EC	O
##F	O
)	O
der	O
##iva	O
##tized	O
compounds	O
with	O
their	O
mass	O
spectral	O
and	O
retention	O
index	O
information	O
for	O
meta	O
##bol	O
##ite	O
identification	O
.	O

7	O
%	O
,	O
p	O
=	O
0	O
.	O
000	O
##8	O
)	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##lut	I
##amine	I
(	O
−	O
##37	O
±	O
7	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
##5	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
−	O
##34	O
±	O
6	O
%	O
,	O
p	O
=	O
0	O
.	O
02	O
##5	O
)	O
,	O
c	B
##yt	I
##id	I
##ine	I
(	O
−	O
##50	O
±	O

Fat	O
##ty	O
acids	O
were	O
transformed	O
into	O
met	B
##hyl	I
est	I
##ers	I
,	O
using	O
either	O
T	B
##MS	I
-	I
di	I
##az	I
##ome	I
##than	I
##e	I
or	O
met	B
##han	I
##olic	I
trans	O
##ester	O
##ification	O
for	O
NE	O
##FA	O
and	O
T	O
##FA	O
,	O
respectively	O
.	O

Lin	B
##ole	I
##ic	I
was	O
en	O
##rich	O
##ed	O
in	O
the	O
so	O
##y	O
drink	O
following	O
the	O
addition	O
of	O
vegetable	O
fat	O
.	O

High	O
levels	O
of	O
pro	B
##line	I
can	O
in	O
##hibit	O
AL	O
##T	O
enzyme	O
and	O
cause	O
al	B
##ani	I
##ne	I
concentration	O
reduction	O
.	O

Edo	B
##xa	I
##ban	I
is	O
a	O
substrate	O
for	O
these	O
transport	O
##ers	O
.	O

In	O
addition	O
,	O
we	O
found	O
three	O
novel	O
,	O
suggest	O
##ively	O
significant	O
lo	O
##ci	O
:	O
T	O
##NP	O
##1	O
with	O
p	B
##yr	I
##u	I
##vate	I
(	O
P	O
-	O
value	O
=	O
1	O
.	O
26	O
##×	O
##10	O
_	O
−	O
##8	O
)	O
,	O
KC	O
##N	O
##J	O
##16	O
with	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
P	O
-	O
value	O
=	O
1	O
.	O
65	O
##×	O
##10	O
_	O
−	O
##8	O
)	O
and	O
2	O
##p	O
##12	O
lo	O
##cus	O
with	O
v	B
##ali	I
##ne	I
(	O
P	O
-	O
value	O
=	O
3	O
.	O
49	O
##×	O
##10	O
_	O
−	O
##8	O
)	O
.	O

In	O
order	O
to	O
determine	O
more	O
precisely	O
the	O
extent	O
of	O
ethanol	S
production	O
after	O
24	O
h	O
of	O
f	O
##er	O
##mentation	O
in	O
these	O
2	O
groups	O
,	O
the	O
area	O
under	O
the	O
ethanol	S
resonance	O
of	O
the	O
met	O
##hyl	O
pro	O
##tons	O
at	O
1	O
.	O
18	O
pp	O
##m	O
was	O
integrated	O
at	O
0	O
h	O
and	O
24	O
h	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
metabolic	O
profiles	O
in	O
subjects	O
with	O
improved	O
g	B
##ly	I
##ce	I
##mic	I
control	O
could	O
be	O
differentiated	O
from	O
those	O
without	O
improvement	O
as	O
early	O
as	O
7	O
days	O
after	O
metabolic	O
surgery	O
,	O
and	O
that	O
the	O
metabolic	O
profile	O
is	O
correlated	O
with	O
H	O
##b	O
##A	O
##1	O
##c	O
values	O
at	O
3	O
months	O
after	O
surgery	O
.	O

Ana	B
##stro	I
##zo	I
##le	I
(	O
0	O
–	O
100	O
µ	O
##m	O
)	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
30	O
min	O
at	O
37	O
##°	O
##C	O
with	O
each	O
is	O
##of	O
##orm	O
(	O
52	O
pm	O
##ol	O
m	O
##l	O
_	O
−	O
##1	O
)	O
.	O

O	O
0	O
.	O
01	O
g	O
/	O
L	O
,	O
Na	O
##HC	O
##O	O
_	O
3	O
2	O
g	O
/	O
L	O
,	O
T	O
##we	O
##en	O
80	O
2	O
m	O
##L	O
(	O
B	O
##D	O
##H	O
,	O
Poole	O
,	O
UK	O
)	O
,	O
ha	O
##em	O
##in	O
0	O
.	O
05	O
g	O
/	O
L	O
,	O
vitamin	B
K	I
##1	I
10	O
µ	O
##L	O
,	O
c	B
##ys	I
##tein	I
##e	I
.	O

Inc	O
##reased	O
ace	B
##to	I
##ace	I
##tate	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
lower	O
al	B
##ani	I
##ne	I
,	O
la	B
##ct	I
##ate	I
and	O
q	B
##uin	I
##olin	I
##ate	I
separated	O
early	O
samples	O
from	O
mid	O
/	O
survivor	O
samples	O
.	O

However	O
Men	O
##del	O
##ian	O
random	O
##ization	O
studies	O
,	O
which	O
should	O
be	O
un	O
##af	O
##fected	O
by	O
con	O
##found	O
##ing	O
and	O
reverse	O
ca	O
##usa	O
##tion	O
,	O
provide	O
ambiguous	O
results	O
on	O
the	O
relationship	O
between	O
vitamin	B
D	I
and	O
card	O
##io	O
##met	O
##ab	O
##olic	O
health	O
.	O

An	O
al	O
##iq	O
##uo	O
##t	O
of	O
the	O
sample	O
(	O
50	O
μ	O
##L	O
)	O
was	O
di	O
##lut	O
##ed	O
with	O
met	B
##han	I
##ol	I
(	O
200	O
μ	O
##L	O
)	O
,	O
v	O
##ortex	O
mixed	O
,	O
and	O
stored	O
at	O
−	O
##20	O
##°	O
##C	O
overnight	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
a	O
new	O
tube	O
and	O
the	O
p	O
##elle	O
##t	O
re	O
-	O
extracted	O
with	O
1	O
.	O
0	O
m	O
##L	O
M	B
##T	I
##BE	I
.	O

The	O
test	B
##osterone	I
in	O
##cu	O
##bation	O
##s	O
also	O
contained	O
17	B
##β	I
-	I
N	I
,	I
N	I
diet	I
##hyl	I
##car	I
##ba	I
##mo	I
##yl	I
-	I
4	I
-	I
met	I
##hyl	I
-	I
3	I
-	I
o	I
##to	I
-	I
4	I
-	I
a	I
##za	I
-	I
5	I
##α	I
-	I
and	I
##ros	I
##tan	I
##e	I
-	I
17	I
##β	I

Of	O
29	O
serum	O
meta	O
##bol	O
##ites	O
,	O
8	O
meta	O
##bol	O
##ites	O
were	O
directly	O
related	O
to	O
ca	B
##ffe	I
##ine	I
metabolism	O
,	O
and	O
3	O
of	O
these	O
meta	O
##bol	O
##ites	O
,	O
the	B
##op	I
##hyl	I
##line	I
(	O
OR	O
for	O
90	O
##th	O
compared	O
with	O
10th	O
percent	O
##iles	O
:	O
0	O
.	O
44	O
;	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
25	O
,	O
0	O
.	O
79	O
;	O
P	O
-	O
linear	O
trend	O
=	O
0	O
.	O
00	O
##6	O
)	O
,	O
ca	B
##ffe	I
##ine	I
(	O
OR	O
for	O
90	O
##th	O
compared	O
with	O
10th	O
percent	O
##iles	O
:	O
0	O
.	O
56	O
;	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
35	O
,	O
0	O
.	O
89	O
;	O
P	O
-	O
linear	O
trend	O
=	O
0	O
.	O
01	O
##5	O
)	O
,	O
and	O
para	B
##xa	I
##nt	I
##hine	I
(	O
OR	O
for	O
90	O
##th	O
compared	O
with	O
10th	O
percent	O
##iles	O
:	O
0	O
.	O
58	O
;	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
36	O
,	O
0	O
.	O
94	O
;	O
P	O
-	O
linear	O
trend	O
=	O
0	O
.	O
02	O
##7	O
)	O
,	O
were	O
inverse	O
##ly	O
associated	O
with	O
color	O
##ec	O
##tal	O
cancer	O
.	O

Interest	O
##ingly	O
,	O
the	O
medium	O
chain	O
fatty	O
acid	O
,	O
C	B
##12	I
:	I
0	I
,	O
which	O
is	O
known	O
to	O
be	O
a	O
poor	O
substrate	O
for	O
re	O
-	O
est	O
##eri	O
##fication	O
into	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
before	O
systemic	O
transport	O
,	O
showed	O
a	O
post	O
##pra	O
##ndi	O
##al	O
increase	O
between	O
0	O
and	O
6	O
h	O
in	O
the	O
se	O
##ra	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
results	O
is	O
that	O
the	O
cancer	O
cells	O
of	O
the	O
low	O
SUV	O
_	O
ma	O
##x	O
tumors	O
require	O
alterations	O
in	O
CA	O
##F	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
metabolism	O
,	O
whereas	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolism	O
of	O
the	O
cancer	O
cells	O
of	O
the	O
high	O
SUV	O
_	O
ma	O
##x	O
tumors	O
is	O
sufficiently	O
robust	O
independent	O
of	O
accommodation	O
in	O
the	O
metabolism	O
of	O
CA	O
##F	O
##s	O
within	O
the	O
tumor	O
.	O

Therefore	O
,	O
both	O
50	O
%	O
and	O
80	O
%	O
Me	B
##OH	I
solutions	O
were	O
tested	O
as	O
que	O
##nch	O
##ing	O
and	O
extraction	O
buffer	O
##s	O
for	O
harvesting	O
of	O
ad	O
##here	O
##nt	O
cells	O
culture	O
##d	O
in	O
10	O
%	O
and	O
20	O
%	O
FC	O
##S	O
.	O

On	O
-	O
treatment	O
samples	O
display	O
higher	O
concentrations	O
of	O
ace	B
##to	I
##ace	I
##tate	I
,	O
ace	B
##tone	I
,	O
al	B
##ani	I
##ne	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
glucose	S
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
lip	O
##ids	O
,	O
L	O
##D	O
##L	O
and	O
V	O
##LD	O
##L	O
lip	O
##op	O
##rote	O
##ins	O
and	O
v	B
##ali	I
##ne	I
,	O
and	O
lower	O
concentration	O
of	O
ethanol	S
and	O
ace	B
##tate	I
,	O
when	O
compared	O
with	O
pre	O
-	O
treatment	O
specimens	O
.	O

Ex	O
##er	O
##cise	O
significantly	O
increased	O
g	B
##ly	I
##cer	I
##ol	I
and	O
o	O
##le	O
##ic	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
concentrations	O
in	O
the	O
control	O
group	O
exclusively	O
.	O

D	O
##z	O
##f	O
##18	O
isolated	O
from	O
G	O
##ar	O
##cini	O
##a	O
par	O
##vi	O
##folia	O
(	O
Si	O
##m	O
et	O
al	O
.	O
2010	O
)	O
,	O
end	O
##op	O
##hy	O
##tic	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
(	O
Musa	O
##vi	O
and	O
Ba	O
##lak	O
##ris	O
##hn	O
##an	O
2013	O
)	O
,	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
isolated	O
from	O
C	O
.	O
odor	O
##ata	O
(	O
To	O
##gh	O
##ue	O
##o	O
et	O
al	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
concluded	O
that	O
di	B
##os	I
##met	I
##in	I
is	O
essentially	O
present	O
in	O
plasma	O
as	O
3	O
-	O
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
with	O
minor	O
levels	O
of	O
3	B
,	I
7	I
-	I
O	I
-	I
dig	I
##lu	I
##cu	I
##ron	I
##ide	I
while	O
free	O
and	O
su	B
##lf	I
##ates	I
are	O
absent	O
and	O
combined	O
su	B
##lf	I
##o	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##o	I
con	O
##ju	O
##gate	O
##s	O
are	O
questionable	O
.	O

Specifically	O
,	O
12	B
,	I
13	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
o	O
##ct	O
##ade	O
##ca	O
##eno	O
##ic	O
acid	O
(	B
12	B
,	I
13	I
-	I
Di	I
##H	I
##OM	I
##E	I
)	O
,	O
9	B
,	I
10	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
o	O
##ct	O
##ade	O
##ca	O
##eno	O
##ic	O
acid	O
(	B
9	B
,	I
10	I
-	I
Di	I
##H	I
##OM	I
##E	I
)	O
,	O
and	O
15	B
,	I
16	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
o	O
##ct	O
##ade	O
##ca	O
##die	O
##no	O
##ic	O
acid	O
(	B
15	B
,	I
16	I
-	I
Di	I
##H	I
##OD	I
##E	I
)	O
post	O
##pra	O
##ndi	O
##ally	O
increased	O
in	O
abundance	O
in	O
both	O
the	O
est	O
##eri	O
##fied	O
and	O
non	O
-	O
est	O
##eri	O
##fied	O
pools	O
.	O

P	O
##lot	O
showing	O
correlation	O
between	O
health	O
survey	O
data	O
and	O
selected	O
lip	O
##id	O
levels	O
for	O
A	O
)	O
controls	O
and	O
B	O
)	O
pre	O
-	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
individuals	O
;	O
the	O
color	O
and	O
size	O
of	O
the	O
circles	O
correspond	O
to	O
the	O
strength	O
of	O
the	O
correlation	O
,	O
with	O
increasing	O
circle	O
size	O
and	O
color	O
intensity	O
indicating	O
increasing	O
correlation	O
;	O
shades	O
of	O
blue	O
are	O
used	O
for	O
negative	O
correlation	O
##s	O
and	O
shades	O
of	O
red	O
for	O
positive	O
correlation	O
##s	O
,	O
squares	O
indicate	O
correlation	O
##s	O
that	O
were	O
statistical	O
##ly	O
significant	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
(	O
ii	O
)	O
the	O
upper	O
panel	O
shows	O
the	O
corresponding	O
Pearson	O
’	O
s	O
correlation	O
coefficient	O
r	O
.	O
P	O
##lot	O
showing	O
correlation	O
between	O
health	O
survey	O
data	O
and	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
detected	O
with	O
L	O
##C	O
-	O
MS	O
approach	O
for	O
A	O
)	O
controls	O
and	O
B	O
)	O
pre	O
-	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
individuals	O
;	O
the	O
color	O
and	O
size	O
of	O
the	O
circles	O
correspond	O
to	O
the	O
strength	O
of	O
the	O
correlation	O
,	O
with	O
increasing	O
circle	O
size	O
and	O
color	O
intensity	O
indicating	O
increasing	O
correlation	O
;	O
shades	O
of	O
blue	O
are	O
used	O
for	O
negative	O
correlation	O
##s	O
and	O
shades	O
of	O
red	O
for	O
positive	O
correlation	O
##s	O
,	O
squares	O
indicate	O
correlation	O
##s	O
that	O
were	O
statistical	O
##ly	O
significant	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
first	O
concerns	O
the	O
action	O
of	O
the	O
gut	O
micro	O
##bio	O
##ta	O
on	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
to	O
produce	O
T	O
##MA	O
via	O
ch	B
##olin	I
##e	I
T	O
##MA	O
-	O
l	O
##yas	O
##es	O
,	O
with	O
subsequent	O
conversion	O
of	O
T	O
##MA	O
to	O
T	B
##MA	I
-	I
N	I
-	I
oxide	I
via	O
the	O
FM	O
##O	O
##3	O
enzyme	O
.	O

Di	B
##met	I
##hyl	I
-	I
g	I
##ly	I
##cine	I
particularly	O
correlated	O
with	O
measures	O
of	O
kidney	O
function	O
;	O
u	B
##ric	I
acid	I
(	O
r	O
=	O
0	O
.	O
21	O
,	O
P	O
-	O
value	O
=	O
2	O
.	O
42	O
##×	O
##10	O
_	O
−	O
##9	O
)	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
(	O
e	O
##G	O
##F	O
##R	O
)	O
(	O
r	O
=	O
−	O
##0	O
.	O
14	O
,	O
P	O
-	O
value	O
=	O
2	O
.	O
53	O
##×	O
##10	O
_	O
−	O
##10	O
)	O
,	O
u	B
##rea	I
(	O
r	O
=	O
0	O
.	O
18	O
,	O
P	O
-	O
value	O
=	O
1	O
.	O
20	O
##×	O
##10	O
_	O
−	O
##7	O
)	O
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
(	O
r	O
=	O
0	O
.	O
22	O
,	O
P	O
-	O
value	O
=	O
1	O
.	O
35	O
##×	O
##10	O
_	O
−	O
##22	O
)	O
.	O

Thus	O
,	O
un	O
##altered	O
peripheral	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
have	O
been	O
reported	O
in	O
depressed	O
patients	O
after	O
single	O
or	O
repeated	O
EC	O
##T	O
administration	O
##s	O
[	O
,	O
,	O
]	O
,	O
whereas	O
two	O
other	O
studies	O
showed	O
increased	O
plasma	O
try	B
##pt	I
##op	I
##han	I
levels	O
after	O
EC	O
##T	O
[	O
,	O
]	O
.	O

The	O
levels	O
of	O
two	O
saturated	O
fatty	O
acid	O
(	O
SF	O
##A	O
)	O
est	O
##er	O
,	O
including	O
g	B
##ly	I
##cer	I
##yl	I
palm	I
##itate	I
and	O
g	B
##ly	I
##cer	I
##ol	I
mon	I
##ost	I
##ear	I
##ate	I
,	O
increased	O
in	O
SA	O
male	O
in	O
##fer	O
##tility	O
.	O

Then	O
40	O
µ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
containing	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
(	O
T	O
##MC	O
##S	O
)	O
was	O
added	O
at	O
37	O
##°	O
##C	O
for	O
30	O
min	O
.	O

(	O
)	O
Ad	O
##duct	O
##s	O
levels	O
ranged	O
from	O
1	O
to	O
9	O
per	O
10	O
_	O
8	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
with	O
d	O
##G	O
-	O
C	O
##8	O
-	O
Ph	O
##IP	O
being	O
found	O
most	O
frequently	O
and	O
present	O
in	O
15	O
out	O
of	O
37	O
subjects	O
,	O
whereas	O
d	O
##G	O
-	O
C	O
##8	O
-	O
A	O
##α	O
##C	O
and	O
d	O
##G	O
-	O
C	O
##8	O
-	O
Me	O
##I	O
##Q	O
##x	O
were	O
detected	O
in	O
3	O
current	O
smoke	O
##rs	O
and	O
d	B
##G	I
-	I
C	I
##8	I
-	I
4	I
-	I
AB	I
##P	I
,	O
from	O
2	O
current	O
smoke	O
##rs	O
.	O

A	O
composite	O
N	O
-	O
ace	O
##ty	O
##l	O
signal	O
from	O
mixed	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
from	O
the	O
_	O
1	O
H	O
N	O
##MR	O
-	O
detected	O
meta	O
##bol	O
##ite	O
panel	O
has	O
a	O
strong	O
and	O
significant	O
association	O
with	O
B	O
##MI	O
(	O
P	O
=	O
2	O
.	O
04	O
×	O
10	O
_	O
−	O
##36	O
)	O

It	O
was	O
then	O
extracted	O
with	O
et	B
##hyl	I
ace	I
##tate	I
,	O
3	O
×	O
1	O
m	O
##l	O
,	O
e	O
##va	O
##porated	O
under	O
nitrogen	O
using	O
a	O
Z	O
##ym	O
##ark	O
Turbo	O
##V	O
##ap	O
L	O
##V	O
(	O
Cal	O
##iper	O
Life	O
Sciences	O
,	O
Hop	O
##kin	O
##ton	O
,	O
MA	O
)	O
,	O
and	O
re	O
##con	O
##stituted	O
in	O
1	O
.	O
0	O
m	O
##l	O
of	O
2	O
:	O
8	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
-	O
H	O
_	O
2	O
O	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
yielding	O
a	O
nominal	O
LP	O
##O	O
-	O
MA	O
##d	O
_	O
3	O
concentration	O
of	O
100	O
μ	O
##M	O
.	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analyses	O
were	O
used	O
to	O
verify	O
con	O
##ju	O
##gate	O
formation	O
.	O

(	O
d	O
##17	O
##S	O
##o	O
##1	O
##P	O
)	O
,	O
Ce	B
##ram	I
##ide	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
(	O
C	O
##17	O
##C	O
##er	O
)	O
,	O
and	O
g	B
##lu	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
(	O
C	O
##17	O
##G	O
##l	O
##c	O
##C	O
##er	O
)	O
were	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
.	O

B	O
##rief	O
##ly	O
,	O
c	B
##ys	I
##tine	I
(	O
5	O
.	O
3	O
mm	O
##ol	O
)	O
was	O
added	O
to	O
13	O
m	O
##l	O
of	O
a	O
1	O
.	O
5	O
M	O
Na	O
##OH	O
solution	O
and	O
the	O
mixture	O
was	O
cooled	O
in	O
an	O
ice	O
bath	O
with	O
stirring	O
.	O

While	O
of	O
interest	O
as	O
a	O
cancer	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
,	O
the	O
biological	O
activity	O
of	O
limo	B
##nen	I
##e	I
in	O
humans	O
is	O
poorly	O
understood	O
.	O

E	O
##stro	O
##gens	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
can	O
also	O
be	O
con	O
##ju	O
##gated	O
via	O
su	O
##lf	O
##ation	O
or	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
,	O
each	O
of	O
which	O
m	O
##od	O
##ifies	O
bio	O
##ava	O
##ila	O
##bility	O
.	O

The	O
transitions	O
monitored	O
were	O
m	O
/	O
z	O
220	O
→	O
m	O
/	O
z	O
91	O
for	O
3	O
-	O
HP	O
##MA	O
,	O
m	O
/	O
z	O
223	O
→	O
m	O
/	O
z	O
91	O
for	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
3	O
-	O
HP	O
##MA	O
,	O
m	O
/	O
z	O
234	O
→	O
m	O
/	O
z	O
105	O
for	O
HM	O
##PM	O
##A	O
,	O
and	O
m	O
/	O
z	O
237	O
→	O
m	O
/	O
z	O
105	O
for	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
HM	O
##PM	O
##A	O
.	O

Four	O
potential	O
bio	O
##mark	O
##ers	O
(	B
glucose	S
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
with	O
an	O
AU	O
##C	O
value	O
of	O
0	O
.	O
98	O
##5	O
for	O
distinguishing	O
the	O
two	O
groups	O
,	O
were	O
further	O
selected	O
for	O
the	O
bio	O
##mark	O
##er	O
panel	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
extracted	O
by	O
adding	O
four	O
volumes	O
of	O
cold	O
met	B
##han	I
##ol	I
to	O
the	O
plasma	O
sample	O
(	O
10	O
μ	O
##L	O
)	O
;	O
samples	O
were	O
v	O
##ortex	O
##ed	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
1	O
h	O
.	O

p	O
<	O
0	O
.	O
000	O
##1	O
)	O
,	O
car	B
##ni	I
##tine	I
(	I
14	I
:	I
1	I
)	I
(	O
β	O
=	O
0	O
.	O
33	O
##2	O
;	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
,	O
and	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
(	O
β	O
=	O
0	O
.	O
224	O
;	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

Ever	O
smoking	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
u	O
##rina	O
##ry	O
P	O
##GE	O
-	O
M	O
even	O
when	O
as	B
##pi	I
##rin	I
users	O
(	O
n	O
=	O
20	O
)	O
and	O
pipe	O
smoke	O
##rs	O
(	O
n	O
=	O
4	O
)	O
were	O
excluded	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

[	O
AC	O
##N	O
/	O
water	O
(	O
50	O
:	O
50	O
,	O
v	O
/	O
v	O
)	O
]	O
and	O
mobile	O
phase	O
B	O
[	O
AC	O
##N	O
/	O
water	O
(	O
90	O
:	O
10	O
,	O
v	O
/	O
v	O
)	O
]	O
was	O
used	O
,	O
both	O
A	O
and	O
B	O
contained	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

Wei	O
##gh	O
##ed	O
breast	O
tissue	O
samples	O
were	O
ground	O
and	O
suspended	O
in	O
4	O
m	O
##l	O
of	O
[UNK]	O
water	O
:	O
met	B
##han	I
##ol	I
mixture	O
.	O

9	O
%	O
,	O
p	O
=	O
0	O
.	O
02	O
##7	O
)	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
−	O
##45	O
±	O
10	O
%	O
,	O
p	O
=	O
0	O
.	O
03	O
##2	O
)	O
,	O
c	O
##AM	O
##P	O
(	O
−	O
##5	O
##8	O
±	O
6	O
%	O
,	O
p	O
=	O
0	O
.	O
03	O
##3	O
)	O
,	O
met	B
##hyl	I
-	I
ma	I
##lon	I
##ic	I
acid	I
(	O
−	O
##33	O
±	O
7	O
%	O
,	O
p	O
=	O
0	O
.	O
03	O
##5	O
)	O
,	O
ace	B
##ty	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
(	O
−	O
##27	O
±	O
4	O
%	O
,	O
p	O
=	O
0	O
.	O
04	O
##4	O
)	O
,	O
fl	B
##av	I
##one	I
(	O
−	O
##46	O
±	O
11	O
%	O
,	O
p	O
=	O
0	O
.	O
04	O
##5	O
)	O
,	O
and	O
CDP	B
-	I
ch	I
##olin	I
##e	I
(	O
−	O
##28	O
±	O
7	O
%	O
,	O
p	O
=	O
0	O
.	O
04	O
##8	O
)	O
.	O

Third	O
,	O
the	O
G	O
##G	O
extract	O
##s	O
were	O
des	O
##al	O
##ted	O
on	O
a	O
C	O
##18	O
si	B
##lica	I
gel	O
column	O
(	O
Sep	O
-	O
Pak	O
V	O
##ac	O
6	O
##cc	O
,	O
500	O
mg	O
,	O
Waters	O
,	O
USA	O
)	O
washed	O
with	O
7	O
m	O
##L	O
CH	O
_	O
3	O
OH	O
and	O
pre	O
-	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
with	O
7	O
m	O
##L	O
CH	O
_	O
3	O
OH	O
/	O
PBS	O
10	O
##m	O
##M	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

Lower	O
plasma	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
was	O
associated	O
with	O
longer	O
duration	S
of	O
diabetes	O
and	O
white	O
race	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
2	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
related	O
to	O
medication	O
(	O
e	O
.	O
g	O
.	O
,	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
ace	B
##tam	I
##ide	I
)	O
were	O
eliminated	O
from	O
the	O
statistical	O
evaluation	O
.	O

+	B
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##ρ	I
##s	I
##j	I
(	I
y	I
##j	I
)	I
x	I
##s	I
+	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##φ	I
##r	I
##j	I
(	I
y	I
##r	I
,	I
y	I
##j	I
)	I
)	O
.	O

Both	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
and	O
c	B
##rea	I
##tine	I
play	O
important	O
roles	O
in	O
energy	O
metabolism	O
.	O

Tri	B
##met	I
##hyl	I
##amine	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
,	O
Cho	B
##line	I
,	O
G	O
##ut	O
micro	O
##bio	O
##ta	O
meta	O
##bol	O
##ite	O
,	O
Live	O
##r	O
cancer	O
,	O

The	O
is	B
##ole	I
##uc	I
##ine	I
is	O
k	O
##eto	O
##genic	O
amino	O
acid	O
which	O
de	O
##com	O
##posed	O
into	O
ace	B
##ty	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
and	O
su	B
##cci	I
##nate	I
##the	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
,	O
the	O
important	O
substances	O
of	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
,	O
which	O
were	O
greatly	O
required	O
during	O
the	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
so	O
the	O
is	B
##ole	I
##uc	I
##ine	I
level	O
is	O
higher	O
in	O
the	O
cancer	O
group	O
compared	O
to	O
the	O
normal	O
group	O
.	O

The	O
concentration	O
of	O
the	O
DS	O
##S	O
solution	O
was	O
ca	O
##li	O
##bra	O
##ted	O
using	O
_	O
1	O
H	O
N	O
##MR	O
against	O
a	O
primary	O
s	O
##to	O
##ichi	O
##ometric	O
standard	O
,	O
t	B
##ris	I
(	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
)	I
amino	I
##met	I
##hane	I
(	O
22	O
.	O
4	O
m	O
##M	O
)	O
,	O
prepared	O
in	O
the	O
lab	O
.	O

Al	O
##b	O
add	O
##uc	O
##ts	O
of	O
(	B
+	I
)	I
-	I
anti	I
-	I
BA	I
##P	I
-	I
di	I
##ol	I
e	I
##pox	I
##ide	I
(	O
BP	O
##DE	O
)	O
were	O
analyzed	O
in	O
animal	O
and	O
human	O
samples	O
.	O

Standard	O
solutions	O
were	O
run	O
using	O
the	O
U	O
##HP	O
##LC	O
-	O
MS	O
/	O
MS	O
method	O
with	O
these	O
transitions	O
and	O
a	O
single	O
peak	O
for	O
AD	B
##MA	I
was	O
obtained	O
using	O
the	O
‘	O
AD	O
##MA	O
-	O
specific	O
’	O
transitions	O
,	O
while	O
SD	O
##MA	O
consistently	O
produced	O
a	O
double	O
peak	O
despite	O
using	O
‘	O
SD	O
##MA	O
-	O
specific	O
’	O
transitions	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Value	O
##s	O
for	O
so	B
##rb	I
##ito	I
##l	I
,	O
3	O
.	O
6	O
(	O
1	O
.	O
7	O
–	O
7	O
.	O
8	O
)	O
,	O
and	O
f	B
##ru	I
##ct	I
##ose	I
,	O
5	O
.	O
1	O
(	O
2	O
.	O
1	O
–	O
12	O
.	O
2	O
)	O
did	O
not	O
differ	O
significantly	O
across	O
regions	O
.	O

In	O
this	O
large	O
patient	O
population	O
,	O
27	O
s	O
##tero	O
##ls	O
and	O
vitamin	B
D	I
derivatives	O
were	O
consistently	O
detected	O
and	O
each	O
showed	O
marked	O
inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
in	O
their	O
serum	O
levels	O
.	O

We	O
determined	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
mon	O
##oes	O
##ter	O
meta	O
##bol	O
##ites	O
of	O
di	B
##but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
DB	O
##P	O
)	O
,	O
including	O
mon	B
##o	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
MB	O
##P	O
)	O
,	O
ben	B
##zy	I
##l	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
B	O
##z	O
##B	O
##P	O
)	O
,	O
including	O
mon	B
##o	I
-	I
ben	I
##zy	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
MB	O
##z	O
##P	O
)	O
,	O
and	O
di	B
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
DE	O
##HP	O
)	O
,	O
including	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##HP	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##he	I
##xy	I
##l	I
)	I

who	O
observed	O
58	O
–	O
68	O
%	O
overlap	O
between	O
the	O
two	O
methods	O
and	O
ability	O
to	O
detect	O
600	O
additional	O
features	O
when	O
comparing	O
SP	O
##E	O
to	O
met	B
##han	I
##ol	I
precipitation	O
.	O

The	O
blank	O
##s	O
remained	O
as	O
such	O
through	O
addition	O
of	O
150	O
µ	O
##l	O
ch	B
##lor	I
##of	I
##orm	I
instead	O
of	O
internal	O
standard	O
.	O

However	O
,	O
combined	O
with	O
CE	O
##A	O
and	O
g	B
##ly	I
##cine	I
,	O
it	O
surprisingly	O
is	O
part	O
of	O
the	O
overall	O
best	O
disc	O
##rim	O
##inating	O
model	O
,	O
suggesting	O
that	O
its	O
contribution	O
to	O
the	O
select	O
##ivity	O
of	O
the	O
model	O
features	O
aspects	O
,	O
which	O
are	O
different	O
from	O
or	O
stronger	O
than	O
other	O
amino	O
acids	O
,	O
even	O
if	O
the	O
latter	O
(	O
e	O
.	O
g	O
.	O
his	B
##ti	I
##dine	I
or	O
al	B
##ani	I
##ne	I
)	O
individually	O
are	O
stronger	O
disc	O
##rim	O
##inator	O
##s	O
.	O

Aside	O
from	O
my	O
##of	O
##ib	O
##rilla	O
##r	O
protein	O
degradation	O
,	O
a	O
##ber	O
##rations	O
in	O
his	B
##ti	I
##dine	I
meta	O
##bol	O
##ites	O
may	O
also	O
be	O
in	O
##dicative	O
of	O
tissue	O
repair	O
,	O
tissue	O
damage	O
,	O
alterations	O
in	O
the	O
inflammatory	O
signals	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Although	O
ca	B
##ffe	I
##ine	I
cannot	O
be	O
labeled	O
by	O
the	O
dans	O
##yla	O
##tion	O
re	O
##age	O
##nt	O
,	O
some	O
of	O
its	O
meta	O
##bol	O
##ites	O
are	O
labeled	O
and	O
were	O
detected	O
as	O
significantly	O
changed	O
meta	O
##bol	O
##ites	O
.	O

G	O
##ly	O
##co	O
##lysis	O
can	O
supplement	O
the	O
intermediate	O
##s	O
of	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
(	O
PP	O
##P	O
)	O
,	O
required	O
for	O
n	O
##uc	O
##leo	O
##tide	O
bio	O
##sy	O
##nt	O
##hesis	O
in	O
tumor	O
cells	O
.	O

The	O
h	B
##ydro	I
##xy	I
##lated	I
est	I
##rogen	I
meta	O
##bol	O
##ite	O
,	O
3	B
,	I
4	I
-	I
cat	I
##ech	I
##ol	I
-	I
est	I
##rogen	I
q	I
##uin	I
##one	I
,	O
can	O
react	O
with	O
DNA	O
,	O
to	O
form	O
4	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rogen	I
-	I
1	I
-	I
N	I
7	O
-	O
g	O
##uan	O
##ine	O
(	B
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
7	O
-	O
G	O
##ua	O
)	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rogen	I
-	I
1	I
-	I
N	I
3	O
-	O
ad	O
##eni	O
##ne	O
(	B
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
-	O
Ad	O
##e	O
)	O
,	O
which	O
are	O
lab	O
##ile	O
and	O
undergo	O
de	O
##pur	O
##ination	O
.	O

The	O
positive	O
controls	O
used	O
were	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
and	O
camp	B
##to	I
##the	I
##cin	I
at	O
50	O
μ	O
##g	O
/	O
m	O
##L	O
.	O
The	O
plates	O
were	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
##°	O
##C	O
with	O
5	O
%	O
CO	O
_	O
2	O
for	O
48	O
hours	O
.	O

Subsequent	O
correlation	O
analysis	O
revealed	O
that	O
G	O
##N	O
##OE	O
,	O
MG	B
(	I
18	I
:	I
2	I
)	I
and	O
P	B
##E	I
(	I
18	I
:	I
2	I
)	I
had	O
the	O
highest	O
correlation	O
with	O
BA	O
##V	O
.	O

For	O
processed	O
samples	O
(	O
auto	O
##sa	O
##mple	O
##r	O
stability	O
)	O
,	O
the	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
were	O
stable	O
for	O
3	O
days	O
at	O
room	O
temperature	O
.	O

We	O
have	O
demonstrated	O
previously	O
that	O
various	O
lip	O
##id	O
species	O
belonging	O
to	O
the	O
di	B
##acy	I
##l	I
##gy	I
##l	I
##cer	I
##ol	I
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
di	B
##hy	I
##dr	I
##oc	I
##era	I
##mi	I
##de	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
classes	O
can	O
provide	O
clinical	O
##ly	O
meaningful	O
information	O
relating	O
to	O
complex	O
diseases	O
like	O
o	O
##besity	O
,	O
h	O
##yper	O
##tens	O
##ion	O
,	O
type	O
2	O
diabetes	O
and	O
metabolic	O
syndrome	O
in	O
this	O
population	O
.	O

We	O
have	O
also	O
found	O
that	O
all	O
of	O
these	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##nal	I
##s	I
and	O
,	O
specifically	O
,	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
are	O
present	O
in	O
fresh	O
can	O
##tal	O
##ou	O
##pe	O
and	O
orange	O
-	O
flesh	O
##ed	O
me	O
##lons	O
;	O
thus	O
,	O
these	O
compounds	O
may	O
be	O
absorbed	O
directly	O
from	O
the	O
diet	O
.	O

On	O
the	O
other	O
hand	O
,	O
compared	O
to	O
the	O
control	O
group	O
,	O
the	O
L	O
##C	O
group	O
showed	O
11	O
meta	O
##bol	O
##ites	O
having	O
significantly	O
higher	O
peak	O
in	O
##tens	O
##ities	O
;	O
su	B
##cci	I
##ny	I
##lace	I
##tone	I
(	O
q	O
=	O
3	O
.	O
242	O
×	O
10	O
_	O
–	O
10	O
)	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
q	O
=	O
0	O
.	O
02	O
##3	O
)	O
,	O
t	B
##yr	I
##os	I
##ine	I
(	O
q	O
=	O
0	O
.	O
00	O
##4	O
)	O
,	O
in	B
##do	I
##lea	I
##c	I
##ryl	I
##ic	I
acid	I
(	O
q	O
=	O
2	O
.	O
93	O
##1	O
×	O
10	O
_	O
–	O
6	O
)	O
,	O
try	B
##pt	I
##op	I
##han	I
(	O
q	O
=	O
5	O
.	O
01	O
##7	O
×	O
10	O
_	O
–	O
6	O
)	O
,	O
palm	B
##itic	I
acid	I
(	O
q	O
=	O
0	O
.	O
04	O
##3	O
)	O
,	O
palm	B
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
q	O
=	O
8	O
.	O
62	O
##4	O
×	O
10	O
_	O
–	O
4	O
)	O
,	O
o	B
##leo	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
q	O
=	O
7	O
.	O
05	O
##3	O
×	O
10	O
_	O
–	O
4	O
)	O
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
(	O
q	O
=	O
0	O
.	O
00	O
##6	O
)	O
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
18	O
:	O
2	O
)	O
(	O
q	O
=	O
0	O
.	O
01	O
##7	O
)	O
,	O
and	O
l	O
##ys	O
##o	O
##PC	O
(	O
22	O
:	O
6	O
)	O
(	O
q	O
=	O
0	O
.	O
02	O
##6	O
)	O
.	O

Sam	O
##ples	O
were	O
th	O
##awed	O
on	O
ice	O
and	O
2	O
m	O
##l	O
ice	O
cold	O
ch	B
##lor	I
##of	I
##orm	I
was	O
added	O
to	O
each	O
sample	O
to	O
perform	O
a	O
met	O
##han	O
##ol	O
:	O
water	O
:	B
ch	B
##lor	I
##of	I
##orm	I
extraction	O
with	O
a	O
volume	O
ratio	O
of	O
[UNK]	O
(	O
modified	O
after	O
Wu	O
et	O
al	O
.	O
)	O
.	O

The	O
amounts	O
of	O
C	B
##15	I
:	I
0	I
and	O
C	B
##17	I
:	I
0	I
,	O
the	O
two	O
dairy	O
-	O
specific	O
odd	O
-	O
chain	O
fatty	O
acids	O
,	O
were	O
low	O
(	O
0	O
.	O
3	O
g	O
of	O
C	B
##15	I
:	I
0	I
in	O
600	O
m	O
##L	O
milk	O
,	O
0	O
.	O
3	O
g	O
of	O
C	B
##15	I
:	I
0	I
in	O
100	O
g	O
cheese	O
;	O
0	O
.	O
1	O
g	O
of	O
C	B
##17	I
:	I
0	I
in	O
600	O
m	O
##L	O
milk	O
,	O
0	O
.	O
2	O
g	O
of	O
C	B
##17	I
:	I
0	I
in	O
100	O
g	O
cheese	O
)	O
.	O

NO	O
##S	O
is	O
regulated	O
by	O
levels	O
of	O
(	O
i	O
)	O
the	O
substrate	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
(	O
ii	O
)	O
amino	O
acids	O
which	O
cycle	O
with	O
a	B
##rg	I
##ini	I
##ne	I
and	O
(	O
ii	O
##i	O
)	O
met	B
##hyl	I
##ar	I
##gin	I
##ine	I
inhibitor	O
##s	O
of	O
NO	O
##S	O
.	O

Specifically	O
,	O
strong	O
negative	O
associations	O
between	O
insulin	O
sensitivity	O
(	O
IS	O
)	O
and	O
the	O
branched	O
-	O
chain	O
AA	O
##s	O
(	O
BC	O
##AA	O
##s	O
)	O
(	B
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
and	O
the	O
a	O
##romatic	O
AA	O
##s	O
(	O
AAA	O
##s	O
)	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
)	O
are	O
reported	O
in	O
adults	O
(	O
–	O
)	O
.	O

Both	O
su	B
##cci	I
##nic	I
acid	I
and	O
ma	B
##late	I
are	O
intermediate	O
##s	O
within	O
the	O
K	O
##re	O
##bs	O
cycle	O
,	O
a	O
pathway	O
of	O
a	O
##ero	O
##bic	O
metabolism	O
,	O
up	O
-	O
stream	O
from	O
the	O
reduction	O
-	O
oxidation	O
reaction	O
converting	O
N	O
##AD	O
_	O
+	O
or	O
FA	O
##D	O
_	O
+	O
+	O
to	O
N	B
##AD	I
##H	I
or	O
FA	O
##D	O
##H	O
##2	O
respectively	O
.	O

D	O
##AG	O
is	O
another	O
substrate	O
for	O
s	O
##ynth	O
##esi	O
##zing	O
PC	O
in	O
addition	O
to	O
CDP	B
-	I
ch	I
##olin	I
##e	I
(	O
Fi	O
##g	O
.	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
that	O
were	O
not	O
found	O
by	O
the	O
meta	O
##bol	O
##omi	O
##c	O
approach	O
were	O
primarily	O
those	O
that	O
resulted	O
from	O
de	O
##hy	O
##dr	O
##ogen	O
##ation	O
,	O
as	O
well	O
as	O
the	O
car	B
##box	I
##yl	I
##ic	I
acid	I
that	O
likely	O
resulted	O
from	O
h	O
##ydro	O
##lysis	O
of	O
the	O
la	O
##ct	O
##am	O
meta	O
##bol	O
##ite	O
.	O

Recently	O
,	O
studies	O
have	O
revealed	O
that	O
there	O
is	O
a	O
change	O
in	O
the	O
amino	O
acid	O
metabolism	O
in	O
addition	O
to	O
the	O
changes	O
in	O
glucose	S
and	O
fatty	O
acid	O
metabolism	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

Level	O
##s	O
of	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
and	O
fatty	O
acids	O
in	O
serum	O
and	O
g	B
##ly	I
##co	I
##lic	I
acid	I
in	O
urine	O
of	O
Ta	O
##e	O
-	O
E	O
##um	O
type	O
were	O
higher	O
than	O
those	O
of	O
So	O
-	O
E	O
##um	O
and	O
So	O
-	O
Yang	O
type	O
.	O

Form	B
##ate	I
was	O
marked	O
##ly	O
decreased	O
in	O
the	O
se	O
##ra	O
of	O
T	O
##B	O
patients	O
in	O
this	O
study	O
.	O

an	B
##ast	I
##ro	I
##zo	I
##le	I
concentrations	O
to	O
a	O
single	O
-	O
or	O
two	O
-	O
site	O
Michael	O
##is	O
-	O
Men	O
##ten	O
enzyme	O
kinetic	O
equation	O
using	O
non	O
##linear	O
re	O
##gression	O
analysis	O
software	O
(	O
G	O
##rap	O
##h	O
##Pad	O
P	O
##rism	O
Software	O
Inc	O
,	O
Version	O
5	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
or	O
the	O
En	O
##zy	O
##me	O
Ki	O
##net	O
##ics	O
Mo	O
##du	O
##le	O
of	O
Sigma	O
##P	O
##lot	O
(	O
S	O
##ys	O
##tat	O
Software	O
,	O
Inc	O
.	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Our	O
in	O
-	O
depth	O
analyses	O
of	O
patients	O
with	O
established	O
diabetes	O
me	O
##lli	O
##tus	O
confirm	O
previously	O
described	O
predict	O
##ors	O
of	O
diabetes	O
re	O
##mission	O
after	O
bar	O
##ia	O
##tric	O
surgery	O
such	O
as	O
age	O
and	O
diabetes	O
duration	S
at	O
the	O
time	O
of	O
the	O
surgery	O
.	O

One	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
lip	O
##id	O
(	O
PS	O
18	O
:	O
0	O
/	O
18	O
:	O
1	O
)	O
was	O
decreased	O
by	O
22	O
%	O
(	O
Z	O
-	O
score	O
=	O
-	O
0	O
.	O
66	O
)	O
in	O
veterans	O
with	O
G	O
##WI	O
.	O

The	O
ma	B
##late	I
-	I
p	I
##yr	I
##u	I
##vate	I
and	O
c	B
##it	I
##rate	I
-	I
p	I
##yr	I
##u	I
##vate	I
cycles	O
are	O
very	O
active	O
in	O
pan	O
##cre	O
##atic	O
beta	O
cells	O
where	O
PC	O
protein	O
and	O
enzyme	O
activity	O
are	O
high	O
and	O
support	O
these	O
cycles	O
[	O
,	O
]	O
.	O

Published	O
methods	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
s	B
##tat	I
##ins	I
and	O
their	O
active	O
meta	O
##bol	O
##ites	O
did	O
not	O
test	O
for	O
matrix	O
effect	O
of	O
or	O
valid	O
##ate	O
the	O
method	O
in	O
h	O
##yper	O
##lip	O
##ide	O
##mic	O
plasma	O
.	O

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
LP	O
##E	O
)	O
,	O
another	O
L	O
##GP	O
##L	O
class	O
detected	O
by	O
our	O
lip	O
##id	O
-	O
pro	O
##fi	O
##ling	O
platform	O
,	O
was	O
inverse	O
##ly	O
associated	O
with	O
o	O
##besity	O
in	O
the	O
F	O
##HS	O
;	O
all	O
three	O
LP	O
##Es	O
associated	O
with	O
o	O
##besity	O
in	O
the	O
F	O
##HS	O
replica	O
##ted	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
2	O
)	O
.	O

Finally	O
,	O
when	O
the	O
analysis	O
was	O
conducted	O
by	O
comparing	O
the	O
two	O
di	O
##abe	O
##tic	O
groups	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
branched	O
-	O
chain	O
amino	O
acid	O
(	O
BC	O
##AA	O
)	O
metabolism	O
resulted	O
per	O
##tur	O
##bed	O
and	O
disc	O
##rim	O
##ina	O
##nt	O
of	O
the	O
two	O
di	O
##abe	O
##tic	O
stages	O
(	O
C	O
)	O
.	O

It	O
is	O
of	O
interest	O
to	O
note	O
that	O
there	O
is	O
no	O
end	O
##ogen	O
##ous	O
3	B
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
in	O
CS	O
##F	O
in	O
light	O
of	O
its	O
ability	O
to	O
activate	O
the	O
D	O
##AF	O
-	O
12	O
orphan	O
nuclear	O
receptor	O
in	O
C	O
.	O
el	O
##egan	O
##s	O
.	O

O	B
##xy	I
##ster	I
##ols	I
(	O
OH	O
##C	O
)	O
are	O
biological	O
##ly	O
active	O
ch	B
##ole	I
##ster	I
##ol	I
meta	O
##bol	O
##ites	O
circulating	O
in	O
plasma	O
that	O
may	O
be	O
formed	O
en	O
##zy	O
##matical	O
##ly	O
(	O
e	O
.	O
g	O
.	O
24	O
##S	O
-	O
OH	O
##C	O
,	O
25	O
-	O
OH	O
##C	O
and	O
27	O
-	O
OH	O
##C	O
)	O
or	O
by	O
auto	O
##xi	O
##da	O
##tive	O
mechanisms	O
(	O
e	O
.	O
g	O
.	O
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
,	O
7	B
##β	I
-	I
OH	I
##C	I
and	O
25	O
-	O
OH	O
##C	O
)	O
.	O

Two	O
additional	O
meta	O
##bol	O
##ites	O
(	O
a	O
##rac	O
##hi	O
##don	O
##yl	O
l	O
##ys	O
##ole	O
##ci	O
##thin	O
and	O
di	B
##ole	I
##oy	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
)	O
,	O
which	O
performed	O
well	O
in	O
the	O
global	O
analysis	O
(	O
lowest	O
p	O
-	O
values	O
and	O
good	O
fold	O
changes	O
)	O
but	O
which	O
had	O
not	O
been	O
previously	O
associated	O
with	O
liver	O
diseases	O
,	O
were	O
added	O
to	O
the	O
list	O
of	O
five	O
characteristic	O
meta	O
##bol	O
##ites	O
.	O

Normally	O
associated	O
with	O
disorders	O
in	O
energy	O
metabolism	O
,	O
o	O
##xi	O
##da	O
##tive	O
status	O
,	O
and	O
aging	O
,	O
more	O
recently	O
these	O
meta	O
##bol	O
##ites	O
have	O
been	O
associated	O
with	O
breast	O
(	B
beta	B
-	I
al	I
##ani	I
##ne	I
)	O
and	O
liver	O
cancer	O
##s	O
,	O
.	O

The	O
mobile	O
lip	O
##op	O
##rote	O
##in	O
-	O
(	O
CH	O
_	O
2	O
-	O
)	O
_	O
n	O
V	O
##LD	O
##L	O
,	O
-	O
CH	O
_	O
3	O
V	O
##LD	O
##L	O
,	O
and	O
la	B
##ct	I
##ate	I
spectral	O
regions	O
load	O
strongly	O
on	O
component	O
one	O
suggesting	O
a	O
correlation	O
.	O

X	O
-	O
axis	O
indicates	O
the	O
mean	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
(	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
of	O
cap	O
##illa	O
##ry	O
electro	O
##ph	O
##ores	O
##is	O
-	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
CE	O
-	O
MS	O
)	O
and	O
clinical	O
ass	O
##ay	O
,	O
and	O
Y	O
-	O
axis	O
indicates	O
percentage	O
of	O
differences	O
between	O
these	O
two	O
methods	O
.	O

Aden	B
##yla	I
##te	I
and	O
g	B
##uan	I
##yla	I
##te	I
energy	O
charges	O
(	O
(	O
[	O
R	O
##TP	O
]	O
+	O
0	O
.	O
5	O
×	O
[	O
R	O
##DP	O
]	O
)	O
/	O
(	O
[	O
R	O
##TP	O
]	O
+	O

Compared	O
to	O
Me	B
##OH	I
pp	O
##t	O
with	O
and	O
without	O
U	O
##F	O
and	O
Me	B
##OH	I
:	O

Our	O
data	O
also	O
revealed	O
decreased	O
serum	O
levels	O
of	O
several	O
amino	O
acids	O
(	O
such	O
as	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
pro	B
##line	I
and	O
his	B
##ti	I
##dine	I
)	O
in	O
both	O
SL	O
##E	O
and	O
L	O
##N	O
patients	O
.	O

Mann	B
##ito	I
##l	I
was	O
found	O
at	O
higher	O
levels	O
in	O
GB	O
##M	O
compared	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##ma	O
and	O
in	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##ma	O
grade	O
III	O
compared	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##ma	O
grade	O
II	O
.	O

In	O
contrast	O
,	O
the	O
levels	O
of	O
p	B
##yr	I
##u	I
##vate	I
and	O
the	O
amino	O
acids	O
c	O
##ys	O
##tein	O
##e	O
and	O
c	B
##ys	I
##tine	I
were	O
reduced	O
over	O
the	O
analyzed	O
storage	O
period	O
(	O
D	O
–	O
F	O
)	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
cigarette	O
smoke	O
is	O
also	O
a	O
known	O
induce	O
##r	O
of	O
C	O
##YP	O
##1	O
##A	O
##2	O
and	O
C	O
##YP	O
##2	O
##E	O
##1	O
,	O
and	O
alcohol	O
intake	O
is	O
a	O
known	O
induce	O
##r	O
of	O
C	O
##YP	O
##2	O
##E	O
##1	O
;	O
experimental	O
data	O
show	O
f	O
##er	O
##ret	O
lung	O
C	O
##YP	O
##1	O
##A	O
##2	O
induction	O
in	O
response	O
to	O
both	O
β	B
-	I
car	I
##ote	I
##ne	I
and	O
cigarette	O
smoke	O
,	O
with	O
the	O
strongest	O
change	O
resulting	O
from	O
exposure	O
to	O
both	O
,	O
and	O
the	O
original	O
trial	O
finding	O
in	O
AT	O
##BC	O
of	O
an	O
increased	O
risk	O
of	O
lung	O
cancer	O
for	O
those	O
supplemented	O
with	O
β	B
-	I
car	I
##ote	I
##ne	I
was	O
stronger	O
among	O
men	O
who	O
drank	O
more	O
.	O

The	O
plate	O
was	O
washed	O
with	O
0	O
.	O
7	O
m	O
##L	O
2	O
%	O
NH	O
_	O
4	O
OH	O
and	O
0	O
.	O
7	O
m	O
##L	O
Me	B
##OH	I
,	O
then	O
dried	O
with	O
a	O
stream	O
of	O
N	O
_	O
2	O
for	O
5	O
min	O
.	O

Following	O
12	O
weeks	O
of	O
therapy	O
,	O
independent	O
of	O
treatment	O
arm	O
,	O
change	O
in	O
plasma	O
HIV	O
V	B
##L	I
was	O
predict	O
##ive	O
of	O
change	O
in	O
three	O
lip	O
##id	O
species	O
;	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
34	O
:	O
0	O
(	O
beta	O
-	O
coefficient	O
11	O
.	O
66	O
[	O
95	O
%	O
C	O
##I	O
6	O
.	O
11	O
–	O
17	O
.	O
22	O
]	O
,	O
p	O
=	O
0	O
.	O
00	O
##8	O
)	O
;	O
D	B
##G	I
16	I
:	I
0	I
/	I
20	I
:	I
4	I
(	O
beta	O
-	O
coefficient	O
51	O
.	O
32	O
[	O
95	O
%	O
C	O
##I	O
32	O
.	O
22	O
–	O
70	O
.	O
31	O
]	O
,	O
p	O
=	O
0	O
.	O
000	O
##2	O
)	O
and	O
D	B
##G	I
16	I
:	I
0	I
/	I
22	I
:	I
6	I
(	O
beta	O
-	O
coefficient	O
25	O
.	O
09	O
[	O
95	O
%	O
C	O
##I	O
14	O
.	O
91	O
–	O
35	O
.	O
28	O
]	O
,	O
p	O
=	O
0	O
.	O
000	O
##7	O
)	O
.	O

Interest	O
##ingly	O
in	O
kinetic	O
experiments	O
,	O
when	O
healthy	O
humans	O
were	O
injected	O
with	O
lip	B
##op	I
##oly	I
##sa	I
##cc	I
##hari	I
##de	I
(	O
LP	O
##S	O
)	O
,	O
NO	O
-	O
dependent	O
v	O
##as	O
##od	O
##ila	O
##tation	O
increased	O
but	O
no	O
changes	O
in	O
the	O
concentrations	O
of	O
l	O
##A	O
##rg	O
in	O
the	O
blood	O
were	O
observed	O
.	O

Better	O
understanding	O
of	O
the	O
me	O
##chan	O
##istic	O
under	O
##pin	O
##ning	O
##s	O
of	O
metabolic	O
and	O
vascular	O
abnormal	O
##ities	O
may	O
provide	O
the	O
basis	O
for	O
further	O
investigations	O
to	O
explore	O
the	O
impact	O
of	O
a	O
variety	O
of	O
treatment	O
strategies	O
aiming	O
to	O
improve	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
and	O
reduce	O
card	O
##iovascular	O
risks	O
.	O

E	O
##IC	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
Me	O
##T	O
##GM	O
##P	O
;	O
T	O
##GM	O
##P	O
;	O
Me	O
##TI	O
##MP	O
and	O
T	O
##IM	O
##P	O
obtained	O
with	O
addition	O
of	O
E	O
##D	O
##TA	O
and	O
phosphate	S
buffer	O
(	O
P	O
##B	O
)	O
as	O
stab	O
##ili	O
##zing	O
agents	O
.	O

Interest	O
##ingly	O
,	O
some	O
organic	O
acids	O
(	O
do	O
##de	O
##cano	O
##ic	O
,	O
a	O
##zel	O
##aic	O
and	O
ad	O
##ip	O
##ic	O
acid	O
)	O
were	O
found	O
to	O
be	O
slightly	O
reduced	O
in	O
abundance	O
while	O
de	B
##cano	I
##ic	I
acid	I
was	O
slightly	O
increased	O
in	O
I	O
##BS	O
patients	O
compared	O
to	O
healthy	O
controls	O
,	O
the	O
author	O
did	O
not	O
specify	O
whether	O
their	O
study	O
group	O
consisted	O
of	O
patients	O
with	O
I	O
##BS	O
-	O
D	O
or	O
whether	O
patients	O
with	O
con	O
##st	O
##ip	O
##ation	O
predominant	O
I	O
##BS	O
or	O
mixed	O
-	O
I	O
##BS	O
were	O
included	O
.	O

The	O
per	O
##tur	O
##bation	O
of	O
se	B
##rine	I
bio	O
##sy	O
##nt	O
##hesis	O
may	O
occur	O
during	O
the	O
conversion	O
of	O
3	B
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
to	O
se	B
##rine	I
.	O

Super	O
##nat	O
##ant	O
organic	O
solution	O
was	O
transferred	O
,	O
speed	O
-	O
vacuum	O
dried	O
at	O
room	O
temperature	O
and	O
re	O
##con	O
##stituted	O
in	O
50	O
μ	O
##L	O
of	O
mobile	O
phase	O
(	O
50	O
%	O
met	B
##han	I
##ol	I
solution	O
containing	O
0	O
.	O
1	O
%	O
NH	O
_	O
4	O
OH	O
and	O
10	O
m	O
##M	O
NH	O
_	O
4	O
O	O
##AC	O
)	O
ready	O
for	O
injection	O
.	O

This	O
as	O
yet	O
und	O
##es	O
##cribed	O
pathway	O
may	O
be	O
related	O
to	O
the	O
T	O
##CA	O
cycle	O
since	O
er	B
##yt	I
##hr	I
##onic	I
acid	I
was	O
negatively	O
correlated	O
with	O
c	B
##it	I
##ric	I
acid	I
in	O
HC	O
##V	O
urine	O
(	O
d	O
)	O
.	O

no	O
AP	S
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

O	O
##PL	O
##S	O
-	O
D	O
##A	O
score	O
plots	O
based	O
on	O
the	O
data	O
from	O
(	O
A	O
)	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
and	O
(	O
B	O
)	O
R	B
##RL	I
##C	I
-	I
(	I
-	I
)	I
E	I
##SI	I
-	I
MS	I
of	O
the	O
E	O
##SC	O
##C	O
patients	O
and	O
controls	O
(	O
E	O
##SC	O
##C	O
and	O
NC	O
)	O
.	O

In	O
addition	O
,	O
the	O
H	O
##T	O
##G	O
group	O
exhibited	O
reduced	O
levels	O
of	O
c	O
##is	O
-	O
4	O
-	O
o	O
##ct	O
##ened	O
##io	O
##ic	O
acid	O
(	O
q	O
<	O
1	O
.	O
0	O
##E	O
-	O
9	O
)	O
and	O
do	B
##cos	I
##ana	I
##mi	I
##de	I
(	O
q	O
=	O
0	O
.	O
00	O
##2	O
)	O
.	O

The	O
key	O
SP	O
##T	O
subunit	O
involved	O
in	O
the	O
generation	O
of	O
SP	O
##s	O
with	O
shorter	O
backbone	O
##s	O
is	O
SP	O
##TL	O
##C	O
##3	O
,	O
which	O
cat	O
##aly	O
##zes	O
the	O
formation	O
of	O
d	B
##16	I
:	I
1	I
SP	I
##H	I
.	O

Both	O
al	O
##iq	O
##uo	O
##ts	O
were	O
treated	O
according	O
to	O
the	O
procedure	O
3	O
.	O
3	O
(	O
in	O
sa	B
##line	I
,	O
RB	O
##C	O
l	O
##ys	O
##is	O
and	O
24	O
h	O
storage	O
at	O
−	O
##20	O
°C	O
)	O
,	O
one	O
al	O
##iq	O
##uo	O
##t	O
immediately	O
after	O
drawing	O
while	O
another	O
one	O
after	O
4	O
h	O
holding	O
at	O
4	O
°C	O
.	O

K	B
##yn	I
##uren	I
##ine	I
pathway	O
meta	O
##bol	O
##ites	O
in	O
Ch	O
##ronic	O
and	O
E	O
##pis	O
##od	O
##ic	O
C	O
##luster	O
Head	O
##ache	O
groups	O
No	O
significant	O
correlation	O
##s	O
were	O
found	O
between	O
any	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ite	O
and	O
daily	O
frequency	O
of	O
headache	O
attacks	O
(	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
,	O
the	O
levels	O
of	O
1	B
,	I
3	I
-	I
D	I
##AP	I
,	O
P	O
##UT	O
,	O
and	O
CA	O
##D	O
in	O
urine	O
were	O
significantly	O
lower	O
in	O
men	O
than	O
those	O
in	O
women	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
was	O
higher	O
than	O
the	O
total	O
explained	O
variance	O
in	O
for	O
g	B
##ly	I
##cine	I
level	O
by	O
age	O
and	O
sex	O
.	O
.	O

The	O
valid	O
##ation	O
process	O
also	O
identified	O
nodes	O
that	O
represented	O
specific	O
atomic	O
is	O
##oto	O
##pes	O
(	O
in	O
ch	O
##lor	O
##ine	O
-	O
containing	O
drugs	O
like	O
am	O
##lop	O
##id	O
##ine	O
)	O
or	O
add	O
##uc	O
##ts	O
with	O
co	O
-	O
el	O
##uti	O
##ng	O
abundant	O
meta	O
##bol	O
##ites	O
like	O
u	B
##rea	I
,	O
which	O
were	O
removed	O
from	O
further	O
analysis	O
and	O
an	O
##not	O
##ation	O
.	O

Yang	O
et	O
al	O
.	O
suggested	O
that	O
decreased	O
serum	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##16	I
:	I
0	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
0	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
1	I
and	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
2	I
,	O
together	O
with	O
increased	O
serum	O
levels	O
of	O
g	B
##ly	I
##coe	I
##hen	I
##ode	I
##ox	I
##ych	I
##oli	I
##e	I
acid	I
(	O
G	O
##CD	O
##CA	O
)	O
or	O
its	O
is	B
##omer	I
g	I
##ly	I
##code	I
##ox	I
##ych	I
##olic	I
acid	I
(	O
G	O
##DC	O
##A	O
)	O
were	O
potential	O
bio	O
##mark	O
##ers	O
for	O
acute	O
de	O
##ter	O
##ior	O
##ation	O
of	O
liver	O
function	O
in	O
CH	O
##B	O
.	O

The	O
he	B
##x	I
##osa	I
##mine	I
end	O
-	O
product	O
,	O
U	B
##DP	I
-	I
N	I
-	I
ace	I
##ty	I
##l	I
##g	I
##lu	I
##cos	I
##amine	I
(	O
U	O
##DP	O
-	O
G	O
##l	O
##c	O
##N	O
##ac	O
)	O
,	O
was	O
also	O
strongly	O
and	O
positively	O
related	O
to	O
base	O
##line	O
levels	O
of	O
fast	O
##ing	O
and	O
2	O
-	O
hour	O
insulin	O
,	O
insulin	O
AU	O
##C	O
,	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
observed	O
low	O
levels	O
of	O
PC	B
(	I
O	I
-	I
16	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
LP	B
##C	I
(	I
16	I
:	I
0	I
)	I
,	O
LP	B
##C	I
(	I
18	I
:	I
0	I
)	I
and	O
LP	B
##E	I
(	I
20	I
:	I
0	I
)	I
and	O
high	O
levels	O
of	O
PC	B
(	I
34	I
:	I
2	I
)	I
,	O
LP	O
##C	O

Whereas	O
bat	O
##ata	O
##sin	O
III	O
and	O
pin	B
##ost	I
##il	I
##ben	I
##e	I
did	O
not	O
produce	O
any	O
meta	O
##bol	O
##ites	O
,	O
re	B
##s	I
##ver	I
##at	I
##rol	I
,	O
o	B
##xy	I
##res	I
##ver	I
##at	I
##rol	I
,	O
p	O
##ice	O
##ata	O
##nn	O
##ol	O
,	O
and	O
th	B
##una	I
##l	I
##ben	I
##e	I
were	O
intensive	O
##ly	O
meta	O
##bol	O
##ized	O
by	O
co	O
##lon	O
micro	O
##bio	O
##ta	O
.	O

(	O
d	O
)	O
;	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
e	O
)	O
;	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
f	O
)	O
;	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
g	O
)	O
.	O

We	O
also	O
observed	O
a	O
shift	O
,	O
in	O
terms	O
of	O
fold	O
difference	O
between	O
HC	O
##C	O
cases	O
and	O
their	O
matched	O
controls	O
,	O
from	O
g	B
##lut	I
##amine	I
to	O
g	B
##lut	I
##ama	I
##te	I
,	O
indicating	O
a	O
possible	O
defect	O
in	O
am	B
##mon	I
##ium	I
de	O
##to	O
##xi	O
##fication	O
,	O
as	O
also	O
observed	O
in	O
the	O
study	O
by	O
Nah	O
##on	O
et	O
al	O
.	O
.	O

The	O
identity	O
and	O
sequence	O
of	O
key	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
based	O
on	O
VIP	O
-	O
analysis	O
was	O
un	O
##altered	O
following	O
the	O
exclusion	O
of	O
the	O
ex	O
##ogen	O
##ous	O
meta	O
##bol	O
##ites	O
with	O
the	O
exception	O
of	O
the	O
inclusion	O
of	O
1	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
(	O
precursor	O
molecule	O
to	O
co	O
##en	O
##zy	O
##mes	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
-	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
(	O
N	O
##AD	O
+	O
)	O
and	O
ni	O
##cot	O
##ina	O
##m	O
##die	O
-	O
ad	O
##eni	O
##ne	O
din	O
##uc	O
##leo	O
##tide	O
phosphate	S
(	O
N	O
##AD	O
##P	O
+	O
)	O
,	O
meta	O
##bol	O
##ites	O
involved	O
in	O
energy	O
metabolism	O
)	O
,	O
4	O
-	O
h	O
##ydro	O
##xy	O
##phe	O
##ny	O
##lace	O
##tate	O
(	O
amino	O
acid	O
derivative	O
)	O
and	O
is	O
##ole	O
##uc	O
##ine	O
(	O
amino	O
acid	O
)	O
.	O

To	O
increase	O
the	O
sample	O
size	O
used	O
in	O
our	O
previous	O
publication	O
between	O
p	O
##ht	O
##hala	O
##tes	O
and	O
is	B
##op	I
##ros	I
##tan	I
##e	I
(	O
N	O
=	O
50	O
)	O
,	O
we	O
analyzed	O
an	O
additional	O
49	O
samples	O
.	O

Lac	O
:	O
la	B
##ct	I
##ate	I
;	O
Cho	O
:	O
ch	B
##olin	I
##e	I
;	O
C	O
##re	O
:	O
c	B
##rea	I
##tin	I
##ine	I
;	O
Su	O
##c	O
:	O
su	B
##cci	I
##nate	I
;	O
Ace	O
:	O
ace	B
##tate	I
;	O
Al	O
##a	O
:	O
al	B
##ani	I
##ne	I
;	O
3	O
##H	O
##B	O
:	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
2	O
##H	O
##B	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

Moreover	O
,	O
we	O
found	O
statistical	O
##ly	O
significant	O
positive	O
correlation	O
##s	O
between	O
the	O
Lac	O
##tate	O
De	O
##hy	O
##dr	O
##ogen	O
##ase	O
levels	O
and	O
the	O
following	O
meta	O
##bol	O
##ites	O
:	O
Oct	B
##ade	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
r	O
=	O
0	O
.	O
41	O
,	O
p	O
=	O
0	O
.	O
04	O
##4	O
)	O
,	O
Doc	B
##osa	I
##he	I
##xa	I
##eno	I
##ic	I
A	I
##cid	I
(	O
r	O
=	O
0	O
.	O
45	O
,	O
p	O
=	O
0	O
.	O
02	O
##3	O
)	O
,	O
S	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
r	O
=	O
0	O
.	O
46	O
,	O
p	O
=	O
0	O
.	O
02	O
##2	O
)	O
,	O
and	O
significant	O
negative	O
correlation	O
##s	O
with	O
Val	B
##ine	I
(	O
r	O
=	O
−	O
##0	O
.	O
41	O
,	O
p	O
=	O
0	O
.	O
04	O
##3	O
)	O
and	O
trip	B
##ent	I
##ade	I
##cano	I
##ate	I
T	O
##G	O
##15	O
(	O
r	O
=	O
−	O
##0	O
.	O
43	O
,	O
p	O
=	O
0	O
.	O
03	O
##0	O
)	O
levels	O
,	O
among	O
PC	O
patients	O
.	O

The	O
post	O
##pra	O
##ndi	O
##al	O
GA	B
##BA	I
significantly	O
increased	O
in	O
the	O
H	O
##LP	O
subjects	O
after	O
glucose	S
loading	O
(	O
Δ	O
##GA	O
##BA	O
,	O
79	O
.	O
06	O
%	O
)	O
,	O
whereas	O
a	O
post	O
##pra	O
##ndi	O
##ally	O
low	O
level	O
of	O
γ	B
-	I
amino	I
##but	I
##yric	I
acid	I
was	O
observed	O
in	O
the	O
controls	O
(	O
Δ	O
##GA	O
##BA	O
,	O
−	O
##39	O
.	O
95	O
%	O
;	O
)	O
.	O

This	O
might	O
explain	O
the	O
findings	O
of	O
lower	O
short	O
-	O
chain	O
and	O
long	O
-	O
chain	O
car	B
##ni	I
##tine	I
ratio	O
-	O
C	O
##3	O
##DC	O
/	O
C	O
##10	O
in	O
the	O
HC	O
##C	O
group	O
.	O

[UNK]	O
The	O
dual	O
monitoring	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
(	O
sur	O
##rogate	O
for	O
ad	O
##herence	O
)	O
and	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
(	O
sur	O
##rogate	O
for	O
clinical	O
response	O
)	O
plasma	O
levels	O
could	O
be	O
a	O
strategy	O
to	O
improve	O
ta	B
##mo	I
##xi	I
##fen	I
outcome	O
in	O
the	O
future	O
.	O

Conversely	O
,	O
pre	O
##cor	O
##rin	O
-	O
2	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
was	O
positively	O
associated	O
with	O
cap	B
##roi	I
##c	I
acid	I
(	O
another	O
control	O
-	O
en	O
##rich	O
##ed	O
compound	O
;	O
r	O
=	O
0	O
.	O
50	O
##7	O
)	O
.	O

Other	O
mechanisms	O
include	O
decreased	O
he	O
##pa	O
##tic	O
clearance	O
of	O
I	O
##g	O
##A	O
##1	O
and	O
decreased	O
activity	O
of	O
β	O
##1	O
,	O
3	O
-	O
gal	O
##act	O
##osy	O
##l	O
transfer	O
##ase	O
that	O
normally	O
adds	O
gal	B
##act	I
##ose	I
to	O
I	O
##g	O
##A	O
##1	O
molecule	O
.	O

Di	O
##fference	O
##s	O
in	O
the	O
levels	O
of	O
su	B
##cci	I
##nate	I
,	O
ma	B
##lic	I
acid	I
,	O
al	B
##ani	I
##ne	I
and	O
la	B
##ctic	I
acid	I
between	O
40	O
CS	O
##F	O
samples	O
from	O
patients	O
with	O
no	O
history	O
of	O
cancer	O
(	O
controls	O
)	O
or	O
patients	O
with	O
g	O
##lio	O
##mas	O
ID	O
##H	O
-	O
W	O
##T	O
,	O
g	O
##lio	O
##mas	O
ID	O
##H	O
-	O
mutant	O
,	O
or	O
meta	O
##static	O
lung	O
or	O
breast	O
cancer	O
to	O
the	O
C	O
##NS	O
.	O

In	O
contrast	O
to	O
a	B
##rg	I
##ini	I
##ne	I
pathway	O
meta	O
##bol	O
##ites	O
,	O
the	O
association	O
of	O
ID	O
##O	O
-	O
T	O
##Ms	O
with	O
P	O
##H	O
in	O
humans	O
has	O
not	O
been	O
established	O
.	O

An	O
##throp	O
##ometric	O
and	O
clinical	O
parameters	O
,	O
mean	O
(	O
±	O
standard	O
de	O
##viation	O
)	O
,	O
before	O
(	O
T	O
##0	O
)	O
and	O
after	O
(	O
T	O
##1	O
)	O
diet	O
##ary	O
intervention	O
with	O
olive	O
-	O
en	O
##rich	O
##ed	O
product	O
(	O
O	O
##EP	O
)	O
or	O
control	O
(	O
C	O
##tr	O
##l	O
)	O
p	O
value	O
is	O
relative	O
to	O
one	O
-	O
way	O
AN	O
##O	O
##VA	O
on	O
the	O
difference	O
between	O
T	O
##0	O
and	O
T	O
##1	O
S	O
##Y	O
##S	O
s	O
##ys	O
##to	O
##lic	O
pressure	O
,	O
D	O
##IA	O
di	O
##ast	O
##olic	O
pressure	O
,	O
W	O
##M	O
waist	O
measure	O
,	O
HM	O
hips	O
measure	O
,	O
B	O
##MI	O
body	O
mass	O
index	O
,	O
T	O
##C	O
plasma	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	O
##L	O
plasma	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
,	O
L	O
##D	O
##L	O
plasma	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
,	O
T	B
##G	I
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
A	O
##po	O
A	O
##poli	O
##pop	O
##rote	O
##ins	O
in	O
plasma	O
,	O
G	O
##lu	O
plasma	O
glucose	S
,	O
In	O
##s	O
plasma	O
insulin	O
,	O
CR	O
##P	O
plasma	O
reactive	O
C	O
protein	O
,	O
o	O
##x	O
##LD	O
##L	O
plasma	O
o	O
##xi	O
##dized	O
L	O
##D	O
##L	O
,	O
F	O
##2	O
Is	O
##p	O
total	O
24	O
-	O
h	O
urine	O
Is	B
##op	I
##ros	I
##tan	I
##e	I
F	O
##2	O

Therefore	O
,	O
the	O
goal	O
of	O
the	O
present	O
investigation	O
was	O
to	O
examine	O
the	O
relationships	O
between	O
β	O
-	O
cell	O
function	O
relative	O
to	O
IS	O
,	O
D	O
##I	O
,	O
and	O
plasma	O
AA	O
concentrations	O
in	O
youth	O
across	O
the	O
glucose	S
tolerance	O
spectrum	O
.	O

However	O
,	O
co	O
-	O
treatment	O
with	O
AT	O
##RA	O
and	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
or	O
the	O
β	B
-	I
a	I
##po	I
-	I
14	I
′	I
-	I
car	I
##ote	I
##no	I
##ids	I
led	O
to	O
marked	O
in	O
##hibition	O
of	O
the	O
AT	O
##RA	O
-	O
induced	O
gene	O
expression	O
(	O
B	O
)	O
.	O

Second	O
##ly	O
,	O
we	O
are	O
the	O
first	O
to	O
q	O
##uant	O
##ify	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
,	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
and	O
total	O
para	B
##ce	I
##tam	I
##ol	I
in	O
both	O
partners	O
at	O
the	O
time	O
that	O
they	O
began	O
trying	O
for	O
pregnancy	O
.	O

Although	O
the	O
inflammation	O
marker	O
CR	O
##P	O
concentration	O
was	O
not	O
significantly	O
different	O
,	O
the	O
higher	O
PA	O
##r	O
in	O
subjects	O
with	O
high	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
reflects	O
increased	O
vitamin	O
B	O
-	O
6	O
cat	O
##ab	O
##olis	O
##m	O
due	O
to	O
inflammation	O
.	O

Li	B
##th	I
##och	I
##olic	I
acid	I
plasma	O
levels	O
of	O
MC	O
##I	O
patients	O
(	O
41	O
±	O
4	O
n	O
##M	O
)	O
were	O
not	O
significantly	O
different	O
from	O
healthy	O
subjects	O
or	O
AD	O
patients	O
.	O

No	O
carry	O
##over	O
,	O
end	O
##ogen	O
##ous	O
or	O
ex	O
##ogen	O
##ous	O
interference	O
##s	O
were	O
observed	O
,	O
with	O
anal	O
##yte	O
stability	O
at	O
room	O
temperature	O
,	O
4	O
°C	O
,	O
and	O
−	O
##20	O
°C	O
and	O
on	O
the	O
auto	O
##sa	O
##mple	O
##r	O
>	O
70	O
%	O
,	O
except	O
for	O
6	B
-	I
ace	I
##ty	I
##lm	I
##or	I
##phine	I
,	O
h	B
##ydro	I
##co	I
##don	I
##e	I
,	O
o	B
##xy	I
##co	I
##don	I
##e	I
,	O
and	O
m	B
##or	I
##phine	I
.	O

In	O
##set	O
:	O
all	O
co	O
##en	O
##zy	O
##mes	O
peaks	O
seen	O
in	O
the	O
whole	O
blood	O
spectrum	O
arise	O
from	O
the	O
lone	O
hydrogen	O
atom	O
on	O
the	O
five	O
member	O
##ed	O
ring	O
of	O
the	O
ad	B
##eni	I
##ne	I
m	O
##oi	O
##ety	O
as	O
indicated	O
by	O
an	O
arrow	O
.	O

Section	O
##s	O
of	O
5	O
μ	O
##m	O
were	O
de	O
##par	O
##af	O
##fin	O
##ized	O
in	O
x	B
##yle	I
##ne	I
and	O
re	O
##hy	O
##dra	O
##ted	O
in	O
a	O
graded	O
ethanol	S
series	O
.	O

To	O
a	O
volume	O
of	O
0	O
.	O
2	O
m	O
##l	O
of	O
human	O
urine	O
was	O
added	O
5	O
μ	O
##l	O
of	O
10	O
μ	O
##M	O
co	B
##tin	I
##ine	I
-	I
d	I
_	I
3	I
as	O
an	O
internal	O
standard	O
.	O

5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pta	I
##mine	I
(	O
5	O
-	O
H	O
##T	O
)	O
,	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
(	O
D	O
##OP	O
##AC	O
)	O
and	O
5	B
-	I
H	I
##ydro	I
##xy	I
##ind	I
##ole	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
(	O
5	O
-	O
H	O
##IA	O
##A	O
)	O
and	O
form	B
##ic	I
acid	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Stein	O
##heim	O
,	O
Germany	O
)	O
.	O

Strong	O
suppression	O
of	O
PC	O
expression	O
(	O
cell	O
line	O
PC	O
209	O
##6	O
4	O
##B	O
)	O
marked	O
##ly	O
decreased	O
the	O
levels	O
of	O
both	O
c	B
##it	I
##rate	I
and	O
ma	B
##late	I
and	O
decreased	O
the	O
incorporation	O
of	O
carbon	O
from	O
glucose	S
and	O
g	B
##lut	I
##amine	I
into	O
c	B
##it	I
##rate	I
and	O
ma	B
##late	I
.	O

Re	O
##ct	O
##al	O
administration	O
of	O
met	B
##had	I
##one	I
results	O
in	O
rapid	O
absorption	O
,	O
a	O
high	O
bio	O
##ava	O
##ila	O
##bility	O
and	O
long	O
duration	S
of	O
action	O
.	O

I	O
##mm	O
##uno	O
-	O
on	O
##cology	O
related	O
protein	O
profile	O
and	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
were	O
analyzed	O
by	O
proximity	O
extension	O
ass	O
##ay	O
(	O
P	O
##EA	O
)	O
and	O
L	O
##C	O
/	O
MS	O
-	O
MS	O
,	O
respectively	O
.	O

To	O
further	O
examine	O
this	O
,	O
we	O
looked	O
at	O
markers	O
of	O
protein	O
degradation	O
,	O
specifically	O
gamma	O
-	O
g	O
##lut	O
##am	O
##yl	O
amino	O
acids	O
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
(	O
10	O
.	O
4	O
-	O
fold	O
)	O
,	O
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
3	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
(	O
2	O
.	O
1	O
-	O
fold	O
)	O
,	O
which	O
were	O
significantly	O
higher	O
after	O
le	O
##pt	O
##in	O
treatment	O
(	O
–	O
2D	O
)	O
.	O

Met	O
##ab	O
##oli	O
##te	O
sets	O
en	O
##rich	O
##ment	O
analysis	O
for	O
the	O
PT	O
##C	O
altered	O
meta	O
##bol	O
##ites	O
and	O
metabolic	O
network	O
modules	O
demonstrated	O
that	O
as	B
##par	I
##tate	I
metabolism	O
,	O
u	B
##rea	I
cycle	O
,	O
and	O
metabolism	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
beta	B
##ine	I
were	O
the	O
most	O
significant	O
pathways	O
involved	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
p	O
##ap	O
##illa	O
##ry	O
thy	O
##roid	O
cancer	O
.	O

Both	O
der	O
##iva	O
##tized	O
and	O
non	O
##der	O
##iva	O
##tized	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
containing	O
a	O
h	O
##ydro	O
##xy	O
##l	O
group	O
at	O
position	O
25	O
easily	O
lose	O
water	O
in	O
the	O
Z	O
-	O
spray	O
source	O
probably	O
due	O
to	O
the	O
formation	O
of	O
a	O
stable	O
tertiary	O
car	O
##bo	O
##cation	O
.	O

S	O
##phi	O
##ngo	O
##my	O
##elin	O
##ase	O
(	O
EC	O
##3	O
.	O
1	O
.	O
4	O
.	O
12	O
)	O
cat	O
##aly	O
##zes	O
the	O
c	O
##lea	O
##vage	O
of	O
the	O
p	B
##hos	I
##ph	I
##odies	I
##ter	I
bond	O
in	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
to	O
form	O
c	B
##era	I
##mi	I
##de	I
and	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
.	O

Car	B
##ni	I
##tine	I
and	O
its	O
derivatives	O
are	O
well	O
-	O
known	O
for	O
their	O
role	O
in	O
the	O
transport	O
of	O
fatty	O
acids	O
to	O
mit	O
##och	O
##ond	O
##ria	O
for	O
beta	O
-	O
oxidation	O
.	O

Group	O
1	O
and	O
Group	O
2	O
(	O
n	O
=	O
6	O
)	O
received	O
physiological	O
sa	B
##line	I
(	O
O	O
##tsu	O
##ka	O
Normal	O
Sal	B
##ine	I
,	O
O	O
##tsu	O
##ka	O
Ph	O
##arma	O
##ce	O
##utical	O
Factory	O
Inc	O
.	O
,	O
To	O
##kushima	O
,	O
Japan	O
)	O
,	O
Group	O
3	O
received	O
0	O
.	O
1	O
%	O
di	O
##c	O
##lo	O
##fen	O
##ac	O
sodium	O
op	O
##ht	O
##hal	O
##mic	O
solution	O
(	O
n	O
=	O
7	O
)	O
,	O
Group	O
4	O
received	O
0	O
.	O
1	O
%	O
br	O
##om	O
##fen	O
##ac	O
sodium	O
h	O
##yd	O
##rate	O
op	O
##ht	O
##hal	O
##mic	O
solution	O
(	O
n	O
=	O
6	O
)	O
,	O
Group	O
5	O
received	O
0	O
.	O
1	O
%	O
ne	O
##pa	O
##fen	O
##ac	O
op	O
##ht	O
##hal	O
##mic	O
suspension	O
(	O
n	O
=	O
6	O
)	O
,	O
and	O
Group	O
6	O
received	O
sub	O
##cut	O
##aneous	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
as	O
a	O
positive	O
control	O
(	O
n	O
=	O
6	O
)	O
.	O

Path	O
##way	O
analysis	O
showing	O
the	O
put	O
##ative	O
role	O
of	O
the	O
bi	O
##le	O
acid	O
meta	O
##bol	O
##ites	O
in	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
-	I
pathway	I
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
was	O
decreased	O
by	O
20	O
%	O
(	O
Z	O
=	O
-	O
0	O
.	O
84	O
)	O
.	O

In	O
addition	O
to	O
a	O
reduction	O
in	O
hip	B
##pura	I
##te	I
,	O
as	O
previously	O
shown	O
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
compared	O
to	O
healthy	O
controls	O
(	O
Baja	O
##j	O
;	O
Sharif	O
##f	O
et	O
al	O
.	O
)	O
,	O
in	O
this	O
co	O
##hor	O
##t	O
we	O
have	O
also	O
identified	O
a	O
reduction	O
in	O
al	B
##ani	I
##ne	I
,	O
ace	B
##tate	I
,	O
g	B
##ly	I
##cine	I
,	O
N	B
-	I
met	I
##hyl	I
ni	I
##cot	I
##ini	I
##c	I
acid	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
with	O
a	O
con	O
##com	O
##ita	O
##nt	O
an	O
increase	O
in	O
1	B
-	I
met	I
##hol	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
.	O

During	O
this	O
period	O
,	O
we	O
kept	O
the	O
urine	O
and	O
serum	O
samples	O
stored	O
in	O
the	O
fridge	O
(	O
4	O
–	O
8	O
°C	O
)	O
,	O
in	O
order	O
to	O
give	O
us	O
an	O
indication	O
of	O
ta	B
##uri	I
##ne	I
stability	O
under	O
these	O
conditions	O
.	O

They	O
all	O
underwent	O
bilateral	O
op	O
##ht	O
##hal	O
##mic	O
examinations	O
,	O
including	O
visual	O
a	O
##cu	O
##ity	O
measurements	O
,	O
slit	O
-	O
lamp	O
bio	O
##mic	O
##ros	O
##copy	O
,	O
op	O
##ht	O
##hal	O
##mos	O
##copy	O
,	O
colour	O
fund	O
##us	O
photography	O
,	O
flu	B
##ores	I
##ce	I
##in	I
an	O
##gio	O
##graphy	O
,	O
in	B
##do	I
##cy	I
##ani	I
##ne	I
green	O
an	O
##gio	O
##graphy	O
(	O
I	O
##C	O
##GA	O
)	O
and	O
optical	O
co	O
##herence	O
to	O
##mo	O
##graphy	O
.	O

D	O
##H	O
:	O
di	B
##hy	I
##dr	I
##o	I
;	O
T	O
##H	O
:	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
.	O

The	O
results	O
of	O
our	O
study	O
showed	O
that	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	O
##D	O
##L	O
,	O
eight	O
l	O
##ys	O
##o	O
##PC	O
##s	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
were	O
significantly	O
lower	O
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
group	O
,	O
correlated	O
with	O
the	O
Child	O
-	O
P	O
##ugh	O
score	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
which	O
suggesting	O
that	O
lip	O
##id	O
metabolism	O
was	O
overall	O
impaired	O
in	O
patients	O
with	O
he	O
##pa	O
##titis	O
B	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

Sam	O
##ples	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
with	O
met	B
##han	I
##ol	I
under	O
vigorous	O
shaking	O
,	O
cent	O
##ri	O
##fu	O
##ged	O
,	O
and	O
separated	O
into	O
5	O
fraction	O
##s	O
for	O
analysis	O
.	O

Hence	O
,	O
it	O
is	O
recommended	O
to	O
determine	O
serum	O
se	B
##rot	I
##oni	I
##n	I
as	O
well	O
as	O
T	O
##P	O
##H1	O
and	O
AA	O
##DC	O
A	O
##ab	O
##s	O
in	O
AP	O
##EC	O
##ED	O
patients	O
presenting	O
with	O
G	O
##I	O
symptoms	O
.	O

The	O
enhanced	O
insulin	O
sensitivity	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
treatment	O
is	O
strongly	O
correlated	O
with	O
a	O
reduction	O
in	O
skeletal	O
muscle	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
.	O

PA	B
##G	I
is	O
an	O
a	B
##cy	I
##l	I
g	I
##ly	I
##cine	I

Sam	O
##ple	O
preparation	O
involved	O
a	O
liquid	O
-	O
liquid	O
extraction	O
by	O
the	O
addition	O
of	O
0	O
.	O
25	O
m	O
##l	O
of	O
plasma	O
with	O
10	O
##μ	O
##l	O
of	O
1	O
##M	O
Na	O
##OH	O
and	O
1	O
.	O
0	O
m	O
##l	O
et	B
##hyl	I
ace	I
##tate	I
containing	O
50	O
ng	O
/	O
m	O
##l	O
of	O
the	O
internal	O
standard	O
z	O
##ile	O
##uto	O
##n	O
.	O

Our	O
study	O
reveals	O
that	O
glucose	S
is	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
serum	O
of	O
G	O
##4	O
patients	O
with	O
advanced	O
L	B
##F	I
as	O
compared	O
to	O
G	O
##0	O
control	O
patients	O
.	O

Nico	B
##tin	I
##ic	I
acid	I
mon	O
##on	O
##uc	O
##leo	O
##tide	O
was	O
obtained	O
at	O
maximum	O
purity	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
.	O

For	O
example	O
,	O
plasma	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
displayed	O
a	O
1	O
.	O
8	O
-	O
fold	O
relative	O
increase	O
in	O
AC	O
##O	O
##2	O
plasma	O
when	O
compared	O
to	O
matched	O
controls	O
.	O

To	O
op	O
##ti	O
##mize	O
the	O
precision	O
of	O
our	O
p	O
##hen	O
##ot	O
##y	O
##ping	O
of	O
R	O
##V	O
-	O
P	O
##V	O
d	O
##ys	O
##function	O
,	O
we	O
also	O
measured	O
the	O
degree	O
of	O
imp	O
##air	O
##ment	O
in	O
exercise	O
capacity	O
(	O
peak	O
oxygen	O
up	O
##take	O
[	O
V	O
##O	O
_	O
2	O
]	O
)	O
and	O
performed	O
minute	O
-	O
by	O
-	O
minute	O
hem	O
##ody	O
##nam	O
##ic	O
measurements	O
across	O
varying	O
R	B
##V	I
loading	O
conditions	O
during	O
exercise	O
to	O
probe	O
the	O
capacity	O
of	O
the	O
R	O
##V	O
-	O
P	O
##V	O
unit	O
to	O
accommodate	O
increased	O
blood	O
flow	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
damage	O
and	O
d	O
##ys	O
##function	O
are	O
common	O
in	O
a	O
h	B
##yper	I
##gly	I
##ce	I
##mic	I
environment	O
.	O

Sign	O
##ificant	O
increases	O
in	O
P	B
##G	I
species	O
,	O
which	O
are	O
precursor	O
##s	O
for	O
card	O
##iol	O
##ip	O
##in	O
bio	O
##sy	O
##nt	O
##hesis	O
in	O
mit	O
##och	O
##ond	O
##ria	O
,	O
were	O
found	O
in	O
fast	O
##ed	O
di	O
##abe	O
##tic	O
monkeys	O
(	O
n	O
=	O
8	O
)	O
.	O

4	B
-	I
H	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
is	O
a	O
specific	O
amino	O
acid	O
in	O
co	O
##lla	O
##gen	O
protein	O
that	O
plays	O
a	O
key	O
role	O
in	O
co	O
##lla	O
##gen	O
stability	O
and	O
reflects	O
the	O
co	O
##lla	O
##gen	O
content	O
or	O
fi	O
##bro	O
##sis	O
stage	O
.	O

As	O
can	O
be	O
seen	O
in	O
a	O
,	O
the	O
central	O
node	O
of	O
the	O
H	O
##B	O
##V	O
plasma	O
network	O
is	O
is	B
##ole	I
##uc	I
##ine	I
,	O
which	O
is	O
connected	O
to	O
o	B
##le	I
##ic	I
acid	I
,	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
pro	B
##line	I
,	O
and	O
se	B
##rine	I
,	O
the	O
last	O
of	O
which	O
is	O
a	O
node	O
connected	O
to	O
v	B
##ali	I
##ne	I
and	O
le	B
##uc	I
##ine	I
and	O
then	O
to	O
glucose	S
.	O

There	O
are	O
no	O
natural	O
sources	O
of	O
sa	B
##cc	I
##hari	I
##n	I
and	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
so	O
accumulation	O
of	O
sa	B
##cc	I
##hari	I
##n	I
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##ace	I
##tam	I
##ino	I
##phe	I
##n	I
su	I
##lf	I
##ate	I
in	O
re	O
##nal	O
failure	O
is	O
presumably	O
due	O
exclusively	O
to	O
intake	O
of	O
the	O
synthetic	O
compounds	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
per	O
##tur	O
##bation	O
##s	O
on	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
altering	O
membrane	O
lip	O
##id	O
composition	O
may	O
imp	O
##air	O
inn	O
##ate	O
immune	O
responses	O
.	O

The	O
elevated	O
level	O
of	O
p	B
##yr	I
##u	I
##vate	I
in	O
the	O
se	O
##ra	O
of	O
T	O
##B	O
patients	O
suggests	O
increased	O
cat	O
##ab	O
##olis	O
##m	O
of	O
all	O
three	O
major	O
nutrients	O
,	O
as	O
well	O
as	O
increased	O
energy	O
consumption	O
.	O

For	O
the	O
separation	O
of	O
anal	O
##yte	O
##s	O
in	O
human	O
urine	O
,	O
urine	O
samples	O
were	O
obtained	O
from	O
healthy	O
individuals	O
and	O
pool	O
##ed	O
to	O
form	O
a	O
reference	O
urine	O
sample	O
;	O
this	O
was	O
spike	O
##d	O
with	O
ca	B
##ffe	I
##ine	I
,	O
u	B
##rid	I
##ine	I
and	O
c	B
##yt	I
##os	I
##ine	I
as	O
a	O
##que	O
##ous	O
stock	O
solutions	O
.	O

Character	O
##istic	O
voltage	O
(	O
V	O
_	O
c	O
)	O
of	O
the	O
B	O
##LM	O
as	O
a	O
function	O
of	O
di	O
##lution	O
##s	O
of	O
the	O
semi	O
##pur	O
##ified	O
p	O
##ept	O
##ai	O
##bol	O
mixture	O
(	O
el	O
##uted	O
with	O
90	O
%	O
met	B
##han	I
##ol	I
from	O
a	O
Sep	O
##P	O
##ak	O
C	O
_	O
18	O
cartridge	O
)	O
of	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
.	O

Interest	O
##ingly	O
,	O
vitamin	B
B	I
##6	I
deficiency	O
was	O
demonstrated	O
in	O
o	O
##besity	O
.	O

PA	O
##A	O
is	O
synthesized	O
from	O
the	O
amino	O
acid	O
p	O
##hen	O
##yla	O
##lani	O
##ne	O
(	O
PA	O
)	O
via	O
p	B
##hen	I
##yl	I
##py	I
##ru	I
##vate	I
.	O

Box	O
plots	O
showing	O
the	O
levels	O
of	O
sa	O
##liva	O
##ry	O
g	B
##lut	I
##ama	I
##te	I
in	O
H	O
##NS	O
##CC	O
patients	O
(	O
cancer	O
;	O
n	O
=	O
10	O
)	O
and	O
normal	O
healthy	O
controls	O
(	O
control	O
;	O
n	O
=	O
8	O
)	O
,	O
and	O
(	O
D	O
)	O
plasma	O
g	B
##lut	I
##ama	I
##te	I
levels	O
in	O
H	O
##NS	O
##CC	O
patients	O
(	O
cancer	O
;	O
n	O
=	O
7	O
)	O
and	O
normal	O
healthy	O
controls	O
(	O
control	O
;	O
n	O
=	O
7	O
)	O
based	O
on	O
is	O
##oto	O
##pe	O
di	O
##lution	O
G	O
##C	O
-	O
MS	O
.	O

Dec	O
##reased	O
1	O
-	O
M	O
##N	O
in	O
CO	O
##PD	O
patients	O
indicates	O
imp	O
##air	O
##ment	O
of	O
the	O
ni	B
##cot	I
##inate	I
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
metabolism	O
which	O
has	O
also	O
been	O
observed	O
in	O
urine	O
samples	O
from	O
lung	O
cancer	O
.	O

At	O
1	O
h	O
,	O
the	O
%	O
blood	O
glucose	S
reduction	O
of	O
Solo	O
##sa	O
(	O
29	O
.	O
46	O
%	O
±	O
##17	O
.	O
4	O
%	O
)	O
is	O
significantly	O
different	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
from	O
the	O
negative	O
control	O
(	O
6	O
.	O
49	O
±	O
13	O
.	O
6	O
%	O
)	O
.	O

However	O
,	O
it	O
is	O
also	O
worth	O
noting	O
that	O
a	O
decrease	O
in	O
plasma	O
glucose	S
may	O
result	O
from	O
increased	O
insulin	O
secret	O
##ion	O
,	O
which	O
has	O
been	O
shown	O
previously	O
to	O
occur	O
upon	O
altitude	O
exposure	O
.	O

Fast	O
##ing	O
glucose	S
levels	O
were	O
measured	O
using	O
the	O
glucose	S
o	O
##xi	O
##das	O
##e	O
method	O
with	O
a	O
Beck	O
##man	O
G	B
##lu	I
##cos	I
##e	I
Ana	O
##ly	O
##zer	O
(	O
Beck	O
##man	O
Instruments	O
,	O
Irvine	O
,	O
CA	O
)	O
.	O

It	O
is	O
coupled	O
with	O
the	O
as	O
##tro	O
##cy	O
##te	O
-	O
ne	O
##uron	O
la	B
##ct	I
##ate	I
shuttle	O
which	O
supplies	O
its	O
energy	O
demands	O
.	O

M	O
##4	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
en	O
##rich	O
##ment	O
after	O
supplement	O
##ing	O
[	B
U	I
_	I
13	I
C	I
_	I
6	I
]	I
glucose	I
in	O
whole	O
blood	O
.	O

Interest	O
##ingly	O
,	O
our	O
recent	O
gas	O
##tric	O
bypass	O
surgery	O
study	O
[	O
]	O
(	O
n	O
=	O
33	O
)	O
showed	O
that	O
base	O
##line	O
serum	O
try	B
##pt	I
##op	I
##han	I
level	O
was	O
negatively	O
associated	O
with	O
diabetes	O
duration	S
.	O

A	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
,	O
fundamental	O
to	O
the	O
transport	O
of	O
fatty	O
acids	O
into	O
mit	O
##och	O
##ond	O
##ria	O
,	O
was	O
less	O
highly	O
produced	O
from	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
(	O
a	O
)	O
.	O

The	O
increased	O
levels	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
la	B
##ct	I
##ate	I
,	O
ace	B
##tate	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
seem	O
to	O
support	O
the	O
hypothesis	O
that	O
the	O
virus	O
induce	O
##s	O
g	O
##ly	O
##co	O
##lysis	O
over	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
in	O
a	O
similar	O
manner	O
to	O
the	O
War	O
##burg	O
effect	O
in	O
cancer	O
.	O

represents	O
the	O
metabolic	O
pathways	O
involved	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
,	O
in	O
particular	O
,	O
the	O
de	O
no	O
##vo	O
synthesis	O
pathway	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
pathway	O
,	O
cat	O
##ab	O
##olic	O
pathway	O
,	O
and	O
g	B
##lu	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
synthesis	O
pathway	O
,	O
as	O
described	O
in	O
Panel	O
##s	O
A	O
–	O
D	O
,	O
respectively	O
.	O

53	O
##4	O
.	O
405	O
##4	O
corresponding	O
to	O
the	O
m	O
/	O
z	O
of	O
the	O
[	O
M	O
]	O
_	O
+	O
ion	O
of	O
a	O
GP	O
-	O
tag	O
##ged	O
mon	B
##oh	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
.	O

In	O
2017	O
,	O
I	O
##jar	O
##e	O
et	O
al	O
.	O
used	O
ex	O
v	O
##ivo	O
N	O
##MR	O
s	O
##pect	O
##rome	O
##try	O
to	O
assess	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
of	O
post	O
##oper	O
##ative	O
pit	O
##uit	O
##ary	O
tissue	O
sampled	O
from	O
patients	O
with	O
go	O
##nado	O
##tro	O
##pin	O
-	O
and	O
PR	O
##L	O
-	O
secret	O
##ing	O
PA	O
,	O
respectively	O
,	O
with	O
the	O
main	O
finding	O
that	O
both	O
types	O
of	O
PA	O
contain	O
central	O
nervous	O
system	O
meta	O
##bol	O
##ites	O
such	O
as	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
,	O
as	B
##par	I
##tate	I
,	O
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
.	O

This	O
speculation	O
is	O
supported	O
by	O
the	O
existing	O
knowledge	O
regarding	O
the	O
role	O
of	O
mitochondrial	O
d	O
##ys	O
##function	O
in	O
drug	O
he	O
##pa	O
##to	O
##to	O
##xi	O
##city	O
as	O
well	O
as	O
functional	O
implications	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
specific	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
in	O
he	O
##pa	O
##tic	O
mitochondrial	O
d	O
##ys	O
##function	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

The	O
levels	O
of	O
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
##A	O
##de	O
are	O
approximately	O
two	O
orders	O
lower	O
than	O
previously	O
reported	O
in	O
breast	O
tissue	O
from	O
a	O
cancer	O
patient	O
.	O

Also	O
,	O
in	O
all	O
12	O
patients	O
with	O
drug	O
-	O
susceptible	O
T	O
##B	O
with	O
detect	O
##able	O
plasma	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
(	O
s	O
)	O
meta	O
##bol	O
##ite	O
,	O
both	O
the	O
t	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
and	O
the	O
P	O
##I	O
meta	O
##bol	O
##ites	O
were	O
detected	O
.	O

An	O
intervention	O
study	O
in	O
il	O
##eo	O
##sto	O
##my	O
volunteers	O
showed	O
that	O
both	O
are	O
well	O
absorbed	O
in	O
the	O
small	O
in	O
##test	O
##ine	O
but	O
little	O
is	O
ex	O
##cre	O
##ted	O
as	O
con	O
##ju	O
##gate	O
##s	O
of	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
or	O
su	B
##lf	I
##ate	I
in	O
urine	O
,	O
suggesting	O
other	O
metabolic	O
routes	O
such	O
as	O
oxidation	O
.	O

Of	O
interest	O
,	O
the	O
plant	O
lip	O
##id	O
MG	O
##D	O
##G	O
correlated	O
positively	O
with	O
all	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
in	O
particular	O
PS	O
(	O
r	O
=	O
0	O
.	O
66	O
##9	O
,	O
p	O
=	O
5	O
.	O
9	O
×	O
10	O
_	O
−	O
##8	O
)	O
and	O
P	O
##I	O
(	O
r	O
=	O
0	O
.	O
69	O
##7	O
,	O
p	O
=	O
9	O
.	O
7	O
×	O
10	O
_	O
−	O
##9	O
)	O
.	O

Furthermore	O
,	O
in	O
negative	O
ion	O
mode	O
,	O
the	O
fragment	O
##ation	O
of	O
the	O
format	B
##e	I
add	O
##uc	O
##t	O
(	O
[	O
M	O
−	O
H	O
+	O
CH	O
##O	O
_	O
2	O
]	O
_	O
−	O
)	O
ion	O
related	O
to	O
this	O
PC	O
##34	O
##a	O
:	O
1	O
species	O
led	O
to	O
an	O
[	O
M	O
−	O
15	O
]	O
_	O
−	O
ion	O
corresponding	O
to	O
a	O
neutral	O
loss	O
of	O
a	O
met	B
##hyl	I
group	I
(	O
Harrison	O
and	O
Murphy	O
)	O
detected	O
at	O
m	O
/	O
z	O
74	O
##4	O
.	O
55	O
##55	O
and	O
enable	O
the	O
detection	O
of	O
the	O
two	O
fatty	O
acids	O
FA	O
C	O
##18	O
:	O
1	O
(	O
m	O
/	O
z	O
281	O
.	O
248	O
##7	O
)	O
and	O
FA	B
C	I
##16	I
:	I
0	I
(	O
m	O
/	O
z	O
255	O
.	O
232	O
##9	O
)	O
of	O
this	O
lip	O
##id	O
species	O
(	O
Fi	O
##g	O
.	O

Di	B
##met	I
##hyl	I
‐	I
su	I
##lf	I
##oxide	I
(	O
D	O
##MS	O
##O	O
,	O
Se	O
##cco	O
##sol	O
##v	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
,	O
Li	O
##ch	O
##ros	O
##ol	O
##v	O
)	O
were	O
purchased	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

We	O
further	O
performed	O
additional	O
analysis	O
to	O
adjust	O
for	O
c	B
##rea	I
##tin	I
##ine	I
in	O
the	O
model	O
.	O

T	O
##NBC	O
,	O
Triple	O
negative	O
breast	O
cancer	O
;	O
C	O
##N	O
,	O
healthy	O
controls	O
;	O
ER	O
##−	O
,	O
negative	O
expression	O
of	O
est	B
##rogen	I
receptor	O
;	O
PR	O
##−	O
,	O
negative	O
expression	O
of	O
pro	B
##ges	I
##tero	I
##ne	I
receptor	O
;	O
H	O
##ER	O
##2	O
##−	O
,	O
negative	O
expression	O
of	O
human	O
e	O
##pid	O
##er	O
##mal	O
growth	O
factor	O
receptor	O
.	O

Tri	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
T	O
##AG	O
##s	O
)	O
with	O
lower	O
carbon	O
numbers	O
and	O
double	O
bonds	O
were	O
increased	O
in	O
subjects	O
with	O
NAS	O
##H	O
.	O

shows	O
that	O
serum	O
co	B
##rt	I
##is	I
##ol	I
(	O
MS	O
data	O
,	O
fold	O
changes	O
)	O
increased	O
significantly	O
in	O
both	O
groups	O
(	O
time	O
effect	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
;	O
interaction	O
effect	O
,	O
P	O
=	O
0	O
.	O
46	O
##6	O
)	O
,	O
with	O
an	O
average	O
fold	O
increase	O
of	O
1	O
.	O
54	O
immediately	O
post	O
-	O
exercise	O
for	O
all	O
subjects	O
,	O
and	O
1	O
.	O
44	O
the	O
next	O
morning	O
(	O
each	O
time	O
point	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

A	O
blank	O
(	O
70	O
%	O
met	B
##han	I
##ol	I
;	O
J	O
.	O
T	O
.	O
Baker	O
,	O
HP	O
##LC	O
grade	O
)	O
was	O
also	O
included	O
every	O
tenth	O
sample	O
for	O
column	O
cleaning	O
.	O

In	O
the	O
model	O
with	O
cases	O
up	O
to	O
5	O
years	O
until	O
diagnosis	O
,	O
the	O
LA	O
##SS	O
##O	O
re	O
##gression	O
model	O
selected	O
small	O
V	O
##LD	O
##L	O
and	O
g	B
##lut	I
##amine	I
(	O
consistent	O
with	O
the	O
prominent	O
decrease	O
of	O
g	B
##lut	I
##amine	I
levels	O
in	O
cases	O
between	O
2	O
and	O
5	O
years	O
before	O
diagnosis	O
)	O
.	O

It	O
possess	O
anti	O
-	O
cancer	O
,	O
anti	O
##mic	O
##ro	O
##bial	O
,	O
anti	O
-	O
o	O
##xi	O
##dant	O
,	O
anti	O
-	O
inflammatory	O
and	O
some	O
vascular	O
effects	O
,	O
therefore	O
it	O
is	O
possible	O
that	O
g	B
##eran	I
##iol	I
is	O
increased	O
as	O
a	O
result	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
inflammation	O
and	O
decreased	O
RB	O
##Cs	O
membrane	O
integrity	O
in	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
.	O

An	O
exception	O
was	O
c	B
##it	I
##ric	I
acid	I
,	O
which	O
exhibited	O
a	O
wide	O
range	O
of	O
standard	O
error	O
,	O
as	O
shown	O
in	O
Table	O
S	O
##2	O
.	O

H	B
##ydro	I
##phi	I
##lic	I
residues	O
were	O
incorporated	O
into	O
derivative	O
compounds	O
in	O
an	O
attempt	O
to	O
increase	O
so	O
##lub	O
##ility	O
(	O
as	O
reflected	O
in	O
lower	O
c	O
##log	O
##P	O
values	O
)	O
to	O
obtain	O
lower	O
MI	O
##C	O
_	O
50	O
values	O
.	O

Sign	O
##ificant	O
decreases	O
in	O
levels	O
of	O
HP	O
##HP	O
##A	O
(	O
mean	O
value	O
from	O
302	O
.	O
78	O
to	O
37	O
.	O
06	O
mm	O
##ol	O
/	O
m	O
##ol	O
c	B
##rea	I
##tin	I
##ine	I
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O

Both	O
E	O
_	O
1	O
(	B
E	I
_	I
2	I
)	I
-	I
3	I
,	I
4	I
-	I
Q	I
and	O
E	O
_	O
1	O
(	B
E	I
_	I
2	I
)	I
-	I
2	I
,	I
3	I
-	I
Q	I
form	O
much	O
lower	O
levels	O
of	O
stable	O
DNA	O
add	O
##uc	O
##ts	O
than	O
de	O
##pur	O
##inating	O
add	O
##uc	O
##ts	O
.	O

The	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
also	O
underwent	O
serum	O
collection	O
of	O
peripheral	O
vein	O
blood	O
samples	O
(	O
2	O
m	O
##L	O
)	O
for	O
c	O
##yt	O
##oki	O
##ne	O
t	O
##it	O
##ration	O
(	O
T	O
##NF	O
-	O
α	O
,	O
IL	B
##1	I
##β	I
,	O
IL	O
##6	O
)	O
and	O
blood	O
micro	O
##bio	O
##ta	O
assessment	O
.	O

During	O
PP	O
##T	O
method	O
optimization	O
,	O
individual	O
organic	O
solvent	O
##s	O
(	O
e	O
.	O
g	O
.	O
,	O
met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
is	O
##op	O
##rop	O
##ano	O
##l	O
)	O
,	O
alone	O
or	O
combined	O
in	O
different	O
ratios	O
with	O
ch	B
##lor	I
##of	I
##orm	I
,	O
were	O
evaluated	O
.	O

Our	O
results	O
also	O
showed	O
six	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
significantly	O
increased	O
in	O
the	O
AM	O
##S	O
-	O
S	O
group	O
,	O
which	O
may	O
contribute	O
to	O
ma	O
##lad	O
##ap	O
##tation	O
to	O
high	O
altitude	O
.	O

The	O
study	O
of	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
in	O
models	O
of	O
mi	O
##gra	O
##ine	O
has	O
been	O
focused	O
on	O
K	O
##Y	O
##NA	O
,	O
which	O
displays	O
p	O
##le	O
##iot	O
##ropic	O
actions	O
in	O
the	O
C	O
##NS	O
by	O
in	O
##hibit	O
##ing	O
N	O
##MD	O
##A	O
receptors	O
and	O
α	O
##7	O
-	O
ni	O
##cot	O
##ini	O
##c	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
receptors	O
,	O
and	O
act	O
##ivating	O
the	O
GP	O
##R	O
##35	O
G	O
-	O
protein	O
coupled	O
receptor	O
.	O

P	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ctic	I
acid	I
ratios	O
have	O
already	O
been	O
shown	O
to	O
be	O
a	O
significant	O
determine	O
##r	O
of	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
given	O
our	O
HC	O
##C	O
co	O
##hor	O
##t	O
it	O
is	O
un	O
##su	O
##rp	O
##rising	O
that	O
an	O
or	O
##th	O
##olo	O
##go	O
##us	O
small	O
molecule	O
,	O
D	O
-	O
le	O
##uc	O
##ic	O
acid	O
,	O
is	O
shown	O
to	O
be	O
reflective	O
of	O
this	O
tissue	O
damage	O
.	O

However	O
,	O
the	O
G	O
##WA	O
##S	O
hit	O
(	O
r	O
##s	O
##11	O
##7	O
##16	O
##14	O
)	O
located	O
5	O
′	O
U	O
##TR	O
of	O
SL	O
##C	O
##16	O
##A	O
##9	O
influences	O
the	O
expression	O
of	O
SL	O
##C	O
##16	O
##A	O
##9	O
in	O
both	O
GT	O
##EX	O
and	O
GE	O
##U	O
##VA	O
##DI	O
##S	O
databases	O
,	O
indicating	O
that	O
the	O
effect	O
on	O
car	B
##ni	I
##tine	I
level	O
is	O
possibly	O
through	O
expression	O
,	O
rather	O
than	O
the	O
change	O
in	O
protein	O
function	O
.	O

The	O
flow	O
-	O
through	O
and	O
a	O
column	O
wash	O
of	O
4	O
m	O
##l	O
of	O
70	O
%	O
ethanol	S
were	O
collected	O
(	B
SP	B
##E	I
##1	I
-	I
Fr	I
-	I
1	I
,	O
Scheme	O
1	O
)	O
.	O

We	O
investigate	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
of	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
and	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
in	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
##s	O
.	O

Important	O
meta	O
##bol	O
##ites	O
in	O
urine	O
were	O
largely	O
identical	O
to	O
the	O
ones	O
important	O
for	O
prediction	O
of	O
continuous	O
age	O
in	O
women	O
,	O
such	O
as	O
se	B
##do	I
##he	I
##pt	I
##ulos	I
##e	I
,	O
1	B
,	I
5	I
-	I
an	I
##hy	I
##dr	I
##o	I
-	I
d	I
-	I
so	I
##rb	I
##ito	I
##l	I
,	O
and	O
u	B
##rac	I
##il	I
.	O

(	O
C	O
)	O
Total	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
concentration	O
according	O
to	O
sex	O
.	O

When	O
glucose	S
serves	O
as	O
the	O
major	O
energy	O
substrate	O
(	O
C	O
##lamp	O
)	O
,	O
glucose	S
u	O
##til	O
##ization	O
is	O
only	O
marginal	O
##ly	O
affected	O
.	O

Post	O
ho	O
##c	O
comparisons	O
were	O
performed	O
for	O
age	O
,	O
gender	O
,	O
E	O
##DS	O
##S	O
,	O
and	O
disease	O
duration	S
for	O
SP	O
##MS	O
and	O
R	O
##R	O
##MS	O
patients	O
.	O

AM	B
##P	I
can	O
also	O
exist	O
as	O
c	O
##yclic	O
Aden	O
##os	O
##ine	O
mon	O
##op	O
##hos	O
##phate	O
(	O
c	O
##AM	O
##P	O
)	O
through	O
c	O
##AM	O
##P	O
p	O
##hos	O
##ph	O
##odies	O
##tera	O
##se	O
,	O
a	O
common	O
mechanism	O
for	O
de	O
##act	O
##ivation	O
of	O
c	O
##AM	O
##P	O
-	O
dependent	O
pathways	O
.	O

The	O
da	O
##run	O
##avi	O
##r	O
-	O
based	O
regime	O
##ns	O
were	O
as	O
follows	O
:	O
plus	O
ten	O
##of	O
##ov	O
##ir	O
di	O
##so	O
##p	O
##ro	O
##xi	O
##l	O
f	O
##uma	O
##rate	O
/	O
em	O
##tric	O
##ita	O
##bine	O
in	O
10	O
patients	O
,	O
plus	O
a	O
##ba	O
##ca	O
##vir	O
/	B
la	B
##mi	I
##vu	I
##dine	I
in	O
five	O
patients	O
,	O
dual	O
therapy	O
plus	O
la	B
##mi	I
##vu	I
##dine	I
in	O
five	O
patients	O
and	O
da	O
##run	O
##avi	O
##r	O
/	O
co	O
##bic	O
##ista	O
##t	O
mon	O
##otherapy	O
in	O
five	O
patients	O
.	O

Three	O
hundred	O
and	O
five	O
patients	O
(	B
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
21	O
patients	O
;	O
p	B
##ali	I
##per	I
##ido	I
##ne	I
,	O
24	O
patients	O
;	O
que	B
##tia	I
##pine	I
,	O
82	O
patients	O
;	O
o	B
##lan	I
##za	I
##pine	I
,	O
95	O
patients	O
;	O
and	O
a	B
##rip	I
##ip	I
##raz	I
##ole	I
,	O
83	O
patients	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
of	O
whom	O
304	O
patients	O
completed	O
the	O
study	O
.	O

By	O
contrast	O
,	O
no	O
alterations	O
in	O
the	O
circulating	O
levels	O
of	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
were	O
monitored	O
in	O
patients	O
with	O
breast	O
cancer	O
or	O
g	O
##lio	O
##blast	O
##oma	O
multi	O
##form	O
##e	O
(	O
;	O
upper	O
figure	O
)	O
.	O

We	O
also	O
note	O
that	O
the	O
increase	O
in	O
t	B
##yr	I
##os	I
##ine	I
has	O
been	O
observed	O
in	O
two	O
liver	O
cancer	O
studies	O
(	O
-	O
)	O
.	O

After	O
addition	O
of	O
d	O
##4	O
internal	O
standard	O
(	B
d	B
##4	I
-	I
11	I
-	I
d	I
##T	I
##x	I
##B	I
_	I
2	I
)	O
to	O
each	O
sample	O
,	O
the	O
samples	O
were	O
positive	O
pressure	O
-	O
filtered	O
,	O
and	O
the	O
11	O
-	O
d	O
##T	O
##x	O
##B	O
_	O
2	O
was	O
separated	O
from	O
the	O
urine	O
matrix	O
via	O
t	O
##ur	O
##bo	O
##flow	O
online	O
extraction	O
.	O

According	O
to	O
the	O
G	O
##C	O
/	O
MS	O
T	O
##IC	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
displayed	O
in	O
,	O
the	O
majority	O
of	O
the	O
peaks	O
in	O
the	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
were	O
identified	O
by	O
N	O
##IS	O
##T	O
mass	O
s	O
##pect	O
##ra	O
library	O
,	O
including	O
k	B
##eton	I
##es	I
,	O
al	O
##de	O
##hy	O
##des	O
,	O
fatty	O
acids	O
,	O
amino	O
acids	O
,	O
organic	O
acids	O
,	O
and	O
so	O
on	O
.	O

Several	O
pen	B
##tos	I
##e	I
con	O
##ju	O
##gate	O
##s	O
were	O
observed	O
and	O
MS	O
data	O
shows	O
they	O
are	O
consistent	O
with	O
a	B
##rab	I
##ino	I
##se	I
g	I
##ly	I
##cos	I
##ides	I
in	O
blue	O
##berry	O
(	O
and	O
)	O
.	O

Mal	B
##ate	I
was	O
also	O
significantly	O
increased	O
by	O
as	O
##phy	O
##xia	O
.	O

The	O
final	O
solutions	O
were	O
neutral	O
##ized	O
with	O
h	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
and	O
acid	O
##ified	O
with	O
form	B
##ic	I
acid	I
for	O
a	O
final	O
concentration	O
of	O
1	O
mg	O
/	O
m	O
##L	O
of	O
the	O
respective	O
product	O
.	O

h	B
##ydro	I
##xy	I
##ch	I
##lor	I
##zo	I
##xa	I
##zone	I
,	O
d	B
_	I
5	I
-	I
7	I
-	I
h	I
##ydro	I
##xy	I
##co	I
##uma	I
##rin	I
,	O
d	B
_	I
4	I
-	I
4	I
′	I
-	I
h	I
##ydro	I
##xy	I
##dic	I
##lo	I
##fen	I
##ac	I
,	O
d	B
_	I
3	I
-	I
4	I
′	I
-	I
h	I
##ydro	I
##xy	I
##me	I
##phe	I
##ny	I
##to	I
##in	I
,	O
d	B
_	I
3	I
-	I
1	I
′	I
-	I
h	I
##ydro	I
##xy	I
##mi	I
##da	I
##zo	I
##lam	I
,	O
and	O
d	B
_	I
3	I
-	I
6	I
##β	I
-	I
h	I
##ydro	I
##xy	I
##test	I
##osterone	I
.	O

Furthermore	O
,	O
P	O
##f	O
##N	O
##M	O
##NA	O
##T	O
is	O
well	O
conserved	O
across	O
all	O
species	O
of	O
P	O
##las	O
##mo	O
##dium	O
as	O
well	O
as	O
in	O
other	O
para	O
##sitic	O
organisms	O
in	O
the	O
A	B
##pic	I
##om	I
##plex	I
##an	I
p	O
##hyl	O
##um	O
such	O
as	O
Babe	O
##sia	O
b	O
##ov	O
##is	O
and	O
The	O
##iler	O
##ia	O
an	O
##nu	O
##lat	O
##a	O
,	O
,	O
imp	O
##lica	O
##ting	O
N	O
##M	O
##NA	O
##T	O
##s	O
as	O
a	O
drug	O
target	O
beyond	O
P	O
.	O
f	O
##al	O
##ci	O
##par	O
##um	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
significant	O
interaction	O
between	O
sex	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
P	O
=	O
0	O
.	O
15	O
)	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
P	O
=	O
0	O
.	O
72	O
)	O
,	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
P	O
=	O
0	O
.	O
14	O
)	O
,	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
intake	O
(	O
P	O
=	O
0	O
.	O
40	O
)	O
,	O
or	O
the	O
ratio	O
of	O
n	O
##−	O
##6	O
P	O
##U	O
##FA	O
##s	O
to	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
(	O
P	O
=	O
0	O
.	O
17	O
)	O
and	O
any	O
ad	O
##eno	O
##mat	O
##ous	O
p	O
##oly	O
##p	O
risk	O
.	O

These	O
indicated	O
lung	O
SC	O
##C	O
-	O
linked	O
re	O
##wi	O
##ring	O
metabolism	O
in	O
n	O
##uc	O
##leo	O
##tide	O
,	O
sugar	O
,	O
amino	O
acid	O
and	O
th	B
##iol	I
pathways	O
.	O

In	B
##os	I
##ito	I
##l	I
,	O
a	O
water	O
-	O
soluble	O
vitamin	O
,	O
can	O
play	O
insulin	O
-	O
like	O
roles	O
on	O
a	O
metabolic	O
enzyme	O
.	O

Con	O
##cer	O
##ning	O
the	O
in	O
##cu	O
##bation	O
##s	O
using	O
alpha	B
-	I
P	I
##B	I
##P	I
,	O
significant	O
features	O
consisted	O
of	O
six	O
is	O
##oto	O
##pes	O
,	O
three	O
artifacts	O
,	O
five	O
meta	O
##bol	O
##ites	O
,	O
one	O
add	O
##uc	O
##t	O
,	O
and	O
one	O
imp	O
##urity	O
.	O

Our	O
data	O
show	O
a	O
characteristic	O
ho	O
##rmon	O
##al	O
flu	O
##ct	O
##uation	O
,	O
as	O
expected	O
,	O
for	O
est	O
##rogen	O
##s	O
(	O
E	O
##1	O
,	O
E	O
##2	O
)	O
and	O
PR	O
##O	O
##G	O
,	O
while	O
describing	O
other	O
interesting	O
ho	O
##rmon	O
##al	O
alterations	O
for	O
CO	O
##RT	O
,	O
CC	O
##ON	O
##E	O
,	O
11	O
-	O
DE	O
##CO	O
##L	O
,	O
17	B
-	I
OH	I
##P	I
,	O
and	O
T	O
##ES	O
##TO	O
.	O

The	O
increased	O
up	O
##take	O
of	O
glucose	S
in	O
cancer	O
is	O
in	O
large	O
part	O
due	O
to	O
the	O
up	O
-	O
regulation	O
of	O
glucose	S
transport	O
##ers	O
such	O
as	O
G	O
##L	O
##UT	O
##1	O
.	O

Multi	O
##var	O
##iate	O
P	O
##LS	O
-	O
D	O
##A	O
analysis	O
of	O
the	O
targeted	O
meta	O
##bol	O
##omi	O
##c	O
data	O
revealed	O
a	O
significant	O
separation	O
by	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
groups	O
,	O
which	O
reflects	O
overall	O
differences	O
in	O
the	O
meta	O
##bol	O
##ite	O
profiles	O
between	O
the	O
groups	O
.	O

Full	O
mass	O
spectrum	O
of	O
GP	S
in	O
positive	O
ion	O
##ization	O
mode	O
with	O
fragment	O
##or	O
voltage	O
of	O
50	O
V	O
using	O
direct	O
injection	O
of	O
GP	S
(	O
25	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
in	O
1	O
:	O
1	O
met	O
##han	O
##ol	O
:	O
water	O
(	O
C	O
)	O
.	O

L	O
##C	O
-	O
TO	O
##FM	O
##S	O
analysis	O
was	O
conducted	O
by	O
an	O
A	O
##gi	O
##lent	O
1200	O
series	O
R	O
##RL	O
##C	O
system	O
SL	S
and	O
an	O
A	O
##gi	O
##lent	O
62	O
##30	O
TO	O
##FM	O
##S	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
)	O
equipped	O
with	O
O	O
##DS	O
column	O
(	O
2	O
×	O
50	O
mm	O
,	O
2	O
μ	O
##m	O
)	O
.	O

The	O
nuclear	O
and	O
mitochondrial	O
fraction	O
##s	O
were	O
removed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
and	O
1	O
mg	O
/	O
m	O
##l	O
of	O
the	O
l	O
##ys	O
##ate	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
1	O
h	O
at	O
37	O
##°	O
##C	O
in	O
the	O
presence	O
of	O
100	O
%	O
O	O
_	O
2	O
with	O
ex	O
##ogen	O
##ous	O
AA	O
(	O
40	O
μ	O
##M	O
)	O
,	O
1	O
m	O
##M	O
N	B
##AD	I
##P	I
##H	I
and	O
2	O
μ	O
##M	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
(	O
to	O
prevent	O
metabolism	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
by	O
CO	O
##X	O
)	O
.	O

Recent	O
studies	O
in	O
animals	O
have	O
shown	O
a	O
me	O
##chan	O
##istic	O
link	O
between	O
in	O
##test	O
##inal	O
micro	O
##bial	O
metabolism	O
of	O
the	O
ch	B
##olin	I
##e	I
m	O
##oi	O
##ety	O
in	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
le	O
##ci	O
##thin	O
)	O
and	O
co	O
##rona	O
##ry	O
artery	O
disease	O
through	O
the	O
production	O
of	O
a	O
pro	O
##ather	O
##os	O
##cle	O
##rot	O
##ic	O
meta	O
##bol	O
##ite	O
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
.	O

Besides	O
,	O
we	O
also	O
found	O
other	O
significantly	O
altered	O
meta	O
##bol	O
##ites	O
in	O
T	O
##2	O
##DM	O
including	O
c	B
##it	I
##rate	I
,	O
man	B
##nose	I
,	O
2	O
-	O
H	O
##B	O
,	O
N	O
##AG	O
,	O
P	O
##U	O
##FA	O
,	O
and	O
ace	B
##tate	I
.	O

The	O
final	O
volume	O
of	O
fi	O
##lt	O
##rate	O
ranged	O
from	O
100	O
to	O
400	O
μ	O
##L	O
.	O
Sam	O
##ples	O
were	O
brought	O
to	O
650	O
μ	O
##L	O
by	O
addition	O
of	O
D	O
_	O
2	O
O	O
,	O
130	O
μ	O
##L	O
of	O
sodium	B
phosphate	I
buffer	O
(	O
final	O
concentration	O
0	O
.	O
1	O
M	O
)	O
containing	O
dim	B
##eth	I
##yl	I
-	I
si	I
##lap	I
##ent	I
##ane	I
-	I
su	I
##lf	I
##ona	I
##te	I
(	O
final	O
concentration	O
0	O
.	O
5	O
m	O
##M	O
)	O
for	O
N	O
##MR	O
chemical	O
shift	O
reference	O
and	O
concentration	O
ca	O
##li	O
##bra	O
##tion	O
,	O
and	O
10	O
μ	O
##L	O
of	O
1	O
M	O
sodium	O
a	O
##zi	O
##de	O
to	O
prevent	O
growth	O
of	O
bacteria	O
.	O

However	O
,	O
recent	O
clinical	O
trials	O
reported	O
little	O
evidence	O
of	O
benefit	O
of	O
supplement	O
##ation	O
on	O
incident	O
or	O
re	O
##current	O
A	B
##F	I
,	O
therefore	O
,	O
further	O
studies	O
on	O
the	O
correlation	O
between	O
c	O
##yt	O
##oki	O
##nes	O
expression	O
and	O
lip	O
##id	O
levels	O
would	O
be	O
helpful	O
to	O
evaluate	O
the	O
association	O
between	O
inflammatory	O
c	O
##yt	O
##oki	O
##ne	O
m	O
##RNA	O
and	O
lip	O
##id	O
species	O
.	O

_	O
b	O
Mann	O
-	O
Whitney	O
U	O
test	O
;	O
p	O
-	O
value	O
for	O
un	O
##ad	O
##ju	O
##sted	O
level	O
of	O
each	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
was	O
shown	O
in	O
the	O
parent	O
##heses	O
.	O

L	B
-	I
Is	I
##ole	I
##uc	I
##ine	I
.	O

One	O
of	O
these	O
plasma	O
al	O
##iq	O
##uo	O
##ts	O
was	O
used	O
for	O
di	O
##lut	O
##ed	O
plasma	O
_	O
1	O
H	O
N	O
##MR	O
analysis	O
(	O
250	O
µ	O
##l	O
was	O
di	O
##lut	O
##ed	O
into	O
75	O
##5	O
µ	O
##l	O
final	O
mixture	O
of	O
500	O
µ	O
##l	O
0	B
,	I
9	I
%	I
sa	I
##line	I
in	O
D	O
_	O
2	O
O	O
and	O
5	O
µ	O
##l	O
100	O
m	O
##M	O
sodium	B
3	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I

A	O
,	O
Met	O
##ab	O
##oli	O
##tes	O
of	O
ad	O
##rena	O
##l	O
and	O
##rogen	O
precursor	O
##s	O
and	O
active	O
and	O
##rogen	O
##s	O
;	O
B	O
,	O
meta	O
##bol	O
##ites	O
of	O
mineral	O
##oc	O
##ort	O
##ico	O
##ids	O
and	O
their	O
precursor	O
##s	O
;	O
C	O
,	O
meta	O
##bol	O
##ites	O
of	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
precursor	O
##s	O
;	O
D	O
,	O
co	B
##rt	I
##is	I
##ol	I
and	O
co	B
##rt	I
##ison	I
##e	I
meta	O
##bol	O
##ites	O
.	O

Compared	O
to	O
patients	O
with	O
T	O
##B	O
,	O
plasma	O
levels	O
of	O
lip	O
##ids	O
,	O
k	B
##eton	I
##e	I
bodies	O
,	O
la	B
##ct	I
##ate	I
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
were	O
increased	O
and	O
those	O
of	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
branched	O
-	O
chain	O
amino	O
acids	O
,	O
glucose	S
,	O
ni	B
##cot	I
##inate	I
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
were	O
decreased	O
in	O
the	O
CA	O
##P	O
group	O
.	O

Following	O
this	O
,	O
media	O
was	O
collected	O
and	O
analyzed	O
for	O
NE	O
##FA	O
and	O
g	B
##ly	I
##cer	I
##ol	I
release	O
as	O
described	O
above	O
.	O

The	O
ch	B
##ole	I
##ster	I
##yl	I
l	I
##ino	I
##lea	I
##te	I
C	I
(	I
18	I
:	I
2	I
)	I
CE	I
is	O
identified	O
as	O
one	O
of	O
the	O
three	O
major	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
present	O
in	O
human	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
,	O
and	O
the	O
o	O
##xi	O
##di	O
##zation	O
of	O
C	B
(	I
18	I
:	I
2	I
)	I
CE	I
is	O
believed	O
to	O
be	O
correlated	O
with	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
.	O

Furthermore	O
,	O
eleven	O
of	O
the	O
resulting	O
28	O
differential	O
meta	O
##bol	O
##ites	O
after	O
valid	O
##ation	O
test	O
were	O
tentatively	O
identified	O
as	O
potential	O
therapeutic	O
bio	O
##mark	O
##ers	O
:	O
two	O
amino	O
acids	O
,	O
five	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
and	O
four	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
summarized	O
in	O
)	O
.	O

However	O
the	O
reduction	O
of	O
glucose	S
up	O
##take	O
was	O
more	O
pronounced	O
in	O
MC	O
##F	O
7	O
and	O
MD	O
##MB	O
##A	O
-	O
231	O
cells	O
as	O
compared	O
to	O
MC	O
##F	O
1	O
##OA	O
cells	O
.	O

These	O
cellular	O
responses	O
support	O
the	O
assumption	O
that	O
L	O
##ys	O
##o	O
##P	O
##G	O
acts	O
as	O
a	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
media	O
##tor	O
through	O
possible	O
G	O
protein	O
–	O
coupled	O
receptors	O
(	O
GP	O
##CR	O
##s	O
)	O
for	O
L	O
##ys	O
##o	O
##P	O
##G	O
.	O

multiple	O
s	O
##cle	O
##rosis	O
,	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
,	O
meta	O
##bol	O
##omi	O
##cs	O
,	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I

Ultimately	O
,	O
this	O
study	O
was	O
not	O
able	O
to	O
identify	O
a	O
metabolic	O
response	O
to	O
ER	O
##CP	O
that	O
is	O
uniquely	O
dependent	O
upon	O
whether	O
or	O
not	O
the	O
subject	O
developed	O
AP	S
from	O
the	O
procedure	O
.	O

All	O
of	O
the	O
compounds	O
were	O
so	O
##lub	O
##ilized	O
in	O
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##xi	I
##de	I
(	O
D	O
##MS	O
##O	O
)	O
and	O
tested	O
against	O
live	O
,	O
s	O
##ync	O
##hr	O
##ono	O
##us	O
P	O
.	O
f	O
##al	O
##ci	O
##par	O
##um	O
3D	O
##7	O
culture	O
to	O
determine	O
experimental	O
MI	O
##C	O
_	O
50	O
concentrations	O
,	O
which	O
are	O
reported	O
in	O
.	O

We	O
used	O
MS	O
/	O
MS	O
to	O
confirm	O
this	O
finding	O
;	O
the	O
MS	O
/	O
MS	O
pattern	O
of	O
the	O
L	O
##MI	O
##s	O
at	O
137	O
.	O
04	O
##55	O
m	O
/	O
z	O
was	O
identical	O
to	O
that	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
.	O

SP	O
##E	O
H	O
_	O
2	O
O	O
,	O
after	O
protein	O
precipitation	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
e	O
##va	O
##porated	O
and	O
water	O
was	O
added	O
.	O

In	O
order	O
to	O
keep	O
the	O
ratio	O
of	O
the	O
final	O
solvent	O
composition	O
constant	O
,	O
the	O
extracted	O
volumes	O
of	O
H	O
_	O
2	O
O	O
and	O
Me	B
##OH	I
needed	O
to	O
be	O
adjusted	O
accordingly	O
to	O
account	O
for	O
whether	O
50	O
%	O
or	O
80	O
%	O
Me	B
##OH	I
was	O
used	O
in	O
the	O
first	O
extraction	O
step	O
.	O

The	O
species	O
differences	O
regarding	O
protein	O
size	O
(	O
i	O
.	O
e	O
.	O
human	O
album	O
##in	O
consists	O
of	O
58	O
##5	O
A	O
##a	O
)	O
and	O
PA	O
##H	O
metabolic	O
pathways	O
can	O
potentially	O
be	O
a	O
##cc	O
##ele	O
##rating	O
and	O
/	O
or	O
limiting	O
factors	O
of	O
the	O
add	O
##uc	O
##t	O
formation	O
potential	O
of	O
the	O
Atlantic	S
co	O
##d	O
album	O
##in	O
-	O
like	O
protein	O
.	O

High	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
that	O
co	O
##rrel	O
##ate	O
with	O
disease	O
severity	O
have	O
been	O
recently	O
described	O
for	O
UC	O
.	O

Besides	O
c	B
##it	I
##rate	I
also	O
O	O
##AA	O
,	O
a	O
potential	O
precursor	O
of	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
is	O
significantly	O
elevated	O
being	O
produced	O
from	O
v	B
##ali	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
as	B
##par	I
##tate	I
or	O
t	B
##yr	I
##os	I
##ine	I
(	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
was	O
performed	O
in	O
gradient	O
el	O
##ution	O
with	O
ultra	O
##pur	O
##e	O
water	O
,	O
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
)	O
as	O
the	O
mobile	O
phases	O
,	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
5	O
m	O
##L	O
/	O
min	O
.	O

Although	O
the	O
relationship	O
between	O
u	O
##rina	O
##ry	O
AM	O
-	O
2	O
levels	O
and	O
plasma	O
ace	B
##tam	I
##ip	I
##rid	I
levels	O
is	O
unknown	O
,	O
it	O
can	O
be	O
concluded	O
that	O
Case	O
#	O
1	O
had	O
an	O
exposure	O
to	O
ace	B
##tam	I
##ip	I
##rid	I
at	O
a	O
toxic	O
level	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
shown	O
that	O
an	O
elevated	O
level	O
of	O
CS	O
##F	O
la	B
##ct	I
##ate	I
is	O
also	O
present	O
in	O
human	O
patients	O
,	O
and	O
the	O
response	O
is	O
related	O
to	O
injury	O
severity	O
.	O

C	B
##abe	I
##rgo	I
##line	I
and	O
br	B
##omo	I
##cript	I
##ine	I
are	O
the	O
two	O
drugs	O
prescribed	O
to	O
the	O
patients	O
with	O
PR	O
##L	O
-	O
secret	O
##ing	O
pit	O
##uit	O
##ary	O
tumors	O
.	O

For	O
the	O
N	O
-	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
of	O
proteins	O
,	O
a	O
g	B
##ly	I
##can	I
precursor	O
is	O
assembled	O
from	O
mon	B
##osa	I
##cc	I
##hari	I
##de	I
units	O
on	O
an	O
anchor	O
##ing	O
is	B
##op	I
##ren	I
##oid	I
alcohol	I
,	O
do	B
##lich	I
##ol	I
,	O
in	O
the	O
membrane	O
of	O
the	O
end	O
##op	O
##las	O
##mic	O
re	O
##tic	O
##ulum	O
.	O

The	O
th	O
##iol	O
##ation	O
and	O
β	O
-	O
oxidation	O
reactions	O
are	O
carried	O
out	O
by	O
bi	O
##le	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
s	O
##ynth	O
##eta	O
##se	O
(	O
liver	O
-	O
specific	O
)	O
or	O
very	O
long	O
chain	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
s	O
##ynth	O
##eta	O
##se	O
and	O
s	O
##tero	O
##l	O
carrier	O
protein	O
x	O
,	O
respectively	O
,	O
the	O
latter	O
two	O
of	O
which	O
are	O
expressed	O
in	O
rode	O
##nt	O
brain	O
(	O
Swiss	O
-	O
Pro	O
##t	O
O	O
##35	O
##48	O
##8	O
,	O
P	O
##11	O
##9	O
##15	O
)	O
.	O
_	O
7	O
We	O
thus	O
searched	O
for	O
the	O
presence	O
of	O
C	O
_	O
24	O
precursor	O
##s	O
of	O
primary	O
bi	O
##le	O
acids	O
in	O
CS	O
##F	O
.	O

Met	O
##ab	O
##oli	O
##te	O
an	O
##not	O
##ation	O
:	O
We	O
an	O
##not	O
##ated	O
ch	O
##roma	O
##to	O
##graphic	O
peaks	O
based	O
on	O
four	O
different	O
levels	O
:	O
Level	O
1	O
:	O
Au	O
##the	O
##nti	O
##c	O
reference	O
standard	O
available	O
;	O
level	O
2	O
:	O
El	O
##ec	O
##tron	O
impact	O
(	O
E	O
##I	O
)	O
spectral	O
match	O
(	O
>	O
75	O
%	O
)	O
and	O
Ko	O
##vat	O
##s	O
retention	O
in	O
##dices	O
(	O
R	O
##I	O
)	O
match	O
(	O
20	O
)	O
to	O
the	O
N	O
##IS	O
##T	O
2011	O
database	O
;	O
level	O
3	O
:	O
Only	O
E	B
##I	I
spectral	O
match	O
(	O
>	O
75	O
%	O
)	O
to	O
multiple	O
components	O
of	O
a	O
chemical	O
class	O
(	O
i	O
.	O
e	O
.	O
,	O
sugar	O
acids	O
)	O
;	O
level	O
4	O
:	O
Unknown	O
meta	O
##bol	O
##ite	O
.	O

The	O
key	O
differences	O
were	O
the	O
shift	O
of	O
H	O
##2	O
and	O
H	O
##6	O
(	O
δ	O
_	O
H	O
7	O
.	O
71	O
)	O
,	O
C	O
##2	O
and	O
C	O
##6	O
(	O
δ	O
_	O
C	O
126	O
.	O
4	O
)	O
,	O
and	O
C	O
##1	O
(	O
δ	O
_	O
C	O
141	O
.	O
1	O
)	O
compared	O
to	O
Te	O
##m	O
due	O
to	O
the	O
presence	O
of	O
a	O
su	B
##lf	I
##oxide	I
(	O
S	O
=	O
O	O
)	O
group	O
,	O
which	O
was	O
evidenced	O
in	O
the	O
I	O
##R	O
spectrum	O
at	O
1	O
,	O
02	O
##5	O
cm	O
_	O
−	O
##1	O
(	O
Resource	O
_	O
9	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
10	O
u	O
##g	O
/	O
m	O
##l	O
[	O
_	O
13	O
C	O
_	O
1	O
]	O
ch	B
##olic	I
acid	I
was	O
added	O
to	O
the	O
serum	O
prior	O
to	O
extraction	O
and	O
the	O
samples	O
se	O
##quential	O
##ly	O
extract	O
##ing	O
using	O
equal	O
volumes	O
of	O
serum	O
with	O
1	O
%	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
and	O
et	B
##hyl	I
ace	I
##tate	I
(	O
E	O
##t	O
##OA	O
##c	O
)	O
four	O
times	O
.	O

L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
/	O
water	O
solutions	O
in	O
combination	O
with	O
either	O
met	B
##han	I
##ol	I
or	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

This	O
is	O
also	O
to	O
some	O
extent	O
supported	O
by	O
m	O
/	O
z	O
32	O
##8	O
,	O
formed	O
by	O
the	O
loss	O
of	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
the	O
di	B
##f	I
##lu	I
##oro	I
##ben	I
##zen	I
##es	I
##ulf	I
##ona	I
##mi	I
##de	I
m	O
##oi	O
##ety	O
.	O

For	O
3	O
-	O
M	O
##T	O
at	O
the	O
same	O
concentration	O
,	O
285	O
n	O
##C	O
of	O
charge	O
was	O
transferred	O
in	O
the	O
one	O
-	O
electron	O
oxidation	O
process	O
,	O
e	O
##qua	O
##ting	O
to	O
49	O
##6	O
p	B
##g	I
.	O

Using	O
the	O
weight	O
##ings	O
plot	O
,	O
we	O
found	O
that	O
increases	O
in	O
hip	B
##pur	I
##ic	I
acid	I
,	O
c	B
##it	I
##rate	I
,	O
and	O
la	B
##ctic	I
acid	I
were	O
seen	O
with	O
in	O
##f	O
##lix	O
##ima	O
##b	O
treatment	O
and	O
increases	O
in	O
ch	B
##olin	I
##e	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
,	O
u	B
##rea	I
,	O
c	B
##rea	I
##tine	I
,	O
and	O
met	B
##hyl	I
##amine	I
were	O
seen	O
with	O
et	O
##ane	O
##rc	O
##ept	O
treatment	O
.	O

Tu	O
##mor	O
cells	O
also	O
utilized	O
g	B
##lut	I
##amine	I
as	O
another	O
energy	O
supply	O
,	O
which	O
was	O
called	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
.	O

In	O
particular	O
,	O
the	O
combination	O
of	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
shows	O
the	O
potential	O
to	O
predict	O
re	O
##cu	O
##rrence	O
prior	O
to	O
treatment	O
.	O

On	O
the	O
other	O
hand	O
,	O
appearance	O
of	O
fully	O
labeled	O
free	O
amino	O
acids	O
originating	O
from	O
protein	O
(	O
g	O
##lut	O
##en	O
)	O
h	O
##ydro	O
##lysis	O
represented	O
by	O
g	B
##lut	I
##ama	I
##te	I
M	O
##5	O
reaches	O
ma	O
##ximal	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
already	O
after	O
100	O
min	O
.	O

HP	O
##LC	O
grade	O
to	B
##lue	I
##ne	I
,	O
1	B
-	I
but	I
##ano	I
##l	I
,	O
pen	B
##tan	I
##e	I
and	O
et	B
##hyl	I
ace	I
##tate	I
from	O
Fisher	O
were	O
used	O
for	O
extraction	O
##s	O
.	O

-	B
P	I
##G	I
##F	I
_	I
2	I
##α	I
-	I
d	I
_	I
4	I
were	O
pro	O
##cure	O
##d	O
from	O
C	O
##ayman	O
Chemical	O
(	O
Ann	O
Arbor	O
,	O
MI	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
among	O
the	O
differences	O
between	O
the	O
groups	O
As	O
shown	O
in	O
the	O
:	O
compare	O
group	O
T	O
and	O
group	O
H	O
,	O
the	O
content	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
l	B
##ys	I
##ine	I
a	I
##rg	I
##ini	I
##ne	I
,	O
g	B
##ly	I
##cine	I
are	O
increased	O
;	O
the	O
content	O
of	O
lip	O
##ids	O
,	O
ch	B
##olin	I
##e	I
and	O
t	B
##yr	I
##os	I
##ine	I
are	O
decreased	O
.	O

Or	B
##ni	I
##thin	I
##e	I
is	O
then	O
converted	O
back	O
to	O
a	B
##rg	I
##ini	I
##ne	I
through	O
the	O
intermediate	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
completing	O
the	O
cycle	O
.	O

The	O
chemical	O
shifts	O
identified	O
(	O
δ	O
4	O
.	O
38	O
(	O
m	O
)	O
and	O
δ	O
3	O
.	O
10	O
(	O
m	O
)	O
,	O
with	O
probability	O
>	O
0	O
.	O
99	O
)	O
indeed	O
come	O
from	O
the	O
same	O
meta	O
##bol	O
##ite	O
;	O
however	O
,	O
δ	O
3	O
.	O
30	O
(	O
m	O
)	O
was	O
not	O
observed	O
as	O
its	O
signals	O
are	O
heavily	O
overlap	O
##ped	O
with	O
other	O
multiple	O
##ts	O
(	O
such	O
as	O
met	B
##hyl	I
##his	I
##ti	I
##dine	I
##s	I
)	O
in	O
the	O
same	O
region	O
.	O

In	O
fact	O
,	O
significant	O
mon	B
##oc	I
##ar	I
##box	I
##yla	I
##te	I
u	O
##til	O
##ization	O
by	O
the	O
brain	O
was	O
also	O
reported	O
in	O
different	O
path	O
##ological	O
states	O
such	O
as	O
diabetes	O
and	O
pro	O
##long	O
starvation	O
[	O
,	O
]	O
.	O

El	O
##eva	O
##tion	O
of	O
u	O
##rina	O
##ry	O
sa	B
##rc	I
##os	I
##ine	I
in	O
the	O
absence	O
of	O
serum	O
sa	B
##rc	I
##os	I
##ine	I
differences	O
was	O
surprising	O
,	O
and	O
likely	O
the	O
result	O
of	O
differential	O
re	O
##nal	O
sa	B
##rc	I
##os	I
##ine	I
ex	O
##cre	O
##tion	O
.	O

illustrate	O
##s	O
the	O
direct	O
and	O
indirect	O
relations	O
between	O
vitamin	O
B	O
-	O
12	O
and	O
one	O
-	O
carbon	O
metabolism	O
,	O
mitochondrial	O
function	O
,	O
FA	S
oxidation	O
,	O
plasma	O
##log	O
##en	O
synthesis	O
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ide	I
production	O
and	O
breakdown	O
,	O
in	O
the	O
context	O
of	O
our	O
findings	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
T	B
##MA	I
##O	I
were	O
marked	O
##ly	O
suppressed	O
after	O
the	O
administration	O
of	O
anti	O
##biotics	O
and	O
then	O
reappeared	O
after	O
withdrawal	O
of	O
anti	O
##biotics	O
.	O

Pre	O
##oper	O
##ative	O
p	O
##el	O
##vic	O
magnetic	O
resonance	O
imaging	O
(	O
MR	O
##I	O
)	O
was	O
performed	O
in	O
all	O
patients	O
on	O
a	O
1	O
.	O
5	O
Te	O
##sla	O
MR	O
##I	O
scan	O
##ner	O
(	O
Siemens	O
Ava	O
##nto	O
running	O
S	O
##yn	O
##go	O
v	O
.	O
B	O
##17	O
,	O
Germany	O
)	O
using	O
a	O
six	O
-	O
channel	O
body	O
coil	O
and	O
a	O
standardized	O
imaging	O
protocol	O
[	O
,	O
]	O
20	O
mg	O
but	B
##yl	I
-	I
s	I
##co	I
##pol	I
##amine	I
br	I
##omi	I
##de	I
(	O
Bus	O
##co	O
##pan	O
;	O
Bo	O
##eh	O
##ring	O
##er	O
,	O
Germany	O
)	O
was	O
administered	O
in	O
##tra	O
##ven	O
##ously	O
prior	O
to	O
scanning	O
in	O
order	O
to	O
reduce	O
motion	O
art	O
##ef	O
##acts	O
.	O

Another	O
amino	S
sugar	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lu	I
##cos	I
##amine	I
(	O
G	O
##l	O
##c	O
##NA	O
##c	O
)	O
is	O
reported	O
to	O
media	O
##te	O
cell	O
signaling	O
directly	O
and	O
indirectly	O
,	O
promoting	O
t	O
##umour	O
cell	O
invasion	O
.	O

The	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
diversity	O
was	O
higher	O
in	O
the	O
I	O
##BS	O
samples	O
than	O
in	O
the	O
n	O
##IB	O
##S	O
samples	O
.	O

The	O
effect	O
of	O
car	B
##nos	I
##ine	I
on	O
human	O
plasma	O
lip	O
##ido	O
##me	O
has	O
thus	O
far	O
not	O
been	O
investigated	O
.	O

In	O
addition	O
,	O
patients	O
with	O
a	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
≥	O
48	O
.	O
1	O
cm	O
##³	O
have	O
higher	O
plasma	O
concentrations	O
of	O
the	O
amino	B
-	I
acids	I
as	I
##par	I
##agi	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
se	B
##rine	I
and	O
t	B
##yr	I
##os	I
##ine	I
.	O

Furthermore	O
,	O
OS	O
##B	O
##PL	O
##2	O
over	O
##ex	O
##press	O
##ion	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
increased	O
cell	O
e	O
##ff	O
##lux	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
a	O
##po	O
##A	O
##1	O
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
ve	O
##si	O
##cles	O
to	O
serum	O
.	O

Less	O
strongly	O
retained	O
c	B
##rea	I
##tin	I
##ine	I
(	O
mean	O
t	O
_	O
R	O
=	O
6	O
.	O
8	O
min	O
,	O
k	O
=	O
3	O
.	O
9	O
)	O
gave	O
an	O
RS	O
##D	O
of	O
0	O
.	O
2	O
%	O
.	O

a	O
.	O
The	O
comparison	O
of	O
[	B
3	I
-	I
H	I
##B	I
]	I
/	I
[	I
glucose	I
]	I
ratio	O
between	O
the	O
improved	O
and	O
non	O
-	O
improved	O
groups	O
with	O
all	O
the	O
samples	O
.	O

Proto	O
##n	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
(	O
_	O
1	O
H	O
-	O
MR	O
##S	O
)	O
and	O
pro	O
##ton	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
imaging	O
(	O
_	O
1	O
H	O
-	O
MR	O
##SI	O
)	O
are	O
advanced	O
magnetic	O
resonance	O
techniques	O
that	O
can	O
mark	O
the	O
presence	O
of	O
meta	O
##bol	O
##ites	O
such	O
as	O
c	B
##it	I
##rate	I
,	O
ch	B
##olin	I
##e	I
,	O
c	B
##rea	I
##tine	I
and	O
p	B
##oly	I
##amine	I
##s	I
in	O
a	O
selected	O
v	O
##ox	O
##el	O
,	O
or	O
in	O
an	O
array	O
of	O
v	O
##ox	O
##els	O
(	O
in	O
MR	O
##SI	O
)	O
inside	O
pro	O
##static	O
tissue	O
.	O

B	O
##rief	O
##ly	O
,	O
H	O
##NS	O
##CC	O
cells	O
(	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
)	O
were	O
try	O
##ps	O
##ini	O
##zed	O
and	O
washed	O
with	O
PBS	O
,	O
and	O
then	O
the	O
Al	B
##de	I
##f	I
##lu	I
##or	I
substrate	O
was	O
added	O
to	O
1	O
×	O
10	O
_	O
6	O
cells	O
/	O
m	O
##L	O
suspended	O
in	O
Al	B
##de	I
##f	I
##lu	I
##or	I
ass	O
##ay	O
buffer	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
°C	O
for	O
45	O
min	O
.	O

In	O
the	O
extraction	O
procedure	O
,	O
it	O
was	O
important	O
to	O
separate	O
ch	B
##ole	I
##ster	I
##ol	I
from	O
its	O
o	O
##xi	O
##dized	O
meta	O
##bol	O
##ites	O
,	O
i	O
.	O
e	O
.	O
o	B
##xy	I
##ster	I
##ols	I
and	O
bi	O
##le	O
acids	O
,	O
at	O
an	O
initial	O
stage	O
,	O
as	O
ch	B
##ole	I
##ster	I
##ol	I
can	O
be	O
o	O
##xi	O
##dized	O
in	O
air	O
to	O
give	O
auto	O
##xi	O
##dation	O
products	O
that	O
can	O
be	O
confused	O
with	O
those	O
of	O
biological	O
origin	O
(	O
,	O
)	O
.	O

This	O
study	O
describes	O
for	O
the	O
first	O
time	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolic	O
pathways	O
and	O
the	O
enzymes	O
involved	O
,	O
which	O
may	O
serve	O
as	O
the	O
scientific	O
basis	O
for	O
p	O
##har	O
##ma	O
##co	O
##gene	O
##tic	O
and	O
drug	O
-	O
interaction	O
assessments	O
.	O

DB	B
##P	I
:	O
di	O
##ast	O
##olic	O
blood	O
pressure	O

Di	O
##sting	O
##ui	O
##shing	O
al	B
##ky	I
##l	I
-	I
(	I
O	I
)	I
and	O
al	O
##ken	O
##yl	O
(	O
P	O
)	O
linked	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
from	O
di	O
##acy	O
##l	O
PC	O
##s	O
have	O
been	O
hampered	O
due	O
to	O
their	O
similar	O
masses	O
and	O
the	O
overlapping	O
characteristic	O
fragment	O
ions	O
generated	O
upon	O
C	O
##ID	O
.	O

For	O
T	B
##G	I
concentrations	O
within	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##c	O
##lass	O
##es	O
,	O
there	O
were	O
strong	O
positive	O
associations	O
with	O
risk	O
of	O
MI	O
for	O
T	B
##G	I
in	O
all	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
B	O
–	O
containing	O
(	O
V	O
##LD	O
##L	O
,	O
ID	O
##L	O
,	O
and	O
L	O
##D	O
##L	O
)	O
lip	O
##op	O
##rote	O
##in	O
particles	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
related	O
to	O
pu	B
##rine	I
cat	O
##ab	O
##olis	O
##m	O
,	O
including	O
u	B
##ric	I
acid	I
,	O
all	B
##ant	I
##oi	I
##n	I
,	O
x	B
##ant	I
##hine	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
in	B
##os	I
##ine	I
,	O
ad	B
##eno	I
##sin	I
##e	I
and	O
g	B
##uan	I
##os	I
##ine	I
,	O
were	O
semi	O
-	O
quantitative	O
##ly	O
profile	O
##d	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
)	O
on	O
a	O
system	O
comprised	O
of	O
a	O
Shi	O
##mad	O
##zu	O
N	O
##ex	O
##era	O
X	O
##2	O
U	O
-	O
HP	O
##LC	O
(	O
Shi	O
##mad	O
##zu	O
Corp	O
.	O
,	O
Marlborough	O
,	O
MA	O
,	O
USA	O
)	O
,	O
coupled	O
to	O
a	O
Q	O
Ex	O
##active	O
hybrid	O
q	O
##uad	O
##rup	O
##ole	O
##or	O
##bit	O
##rap	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
)	O
.	O

Devi	O
##ant	O
metabolic	O
pathways	O
counting	O
lip	O
##op	O
##rote	O
##in	O
changes	O
,	O
g	O
##ly	O
##co	O
##lysis	O
,	O
T	O
##CA	O
cycle	O
,	O
fatty	O
acid	O
and	O
ch	B
##olin	I
##e	I
metabolism	O
##s	O
were	O
identified	O
as	O
having	O
significant	O
differences	O
among	O
study	O
groups	O
.	O

Both	O
T	O
##IC	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
show	O
separation	O
of	O
the	O
n	O
##uc	O
##leo	O
##base	O
test	O
mixture	O
(	O
1	O
:	O
ca	O
##ffe	O
##ine	O
,	O
2	O
:	O
u	O
##rac	O
##il	O
,	O
3	O
:	O
ad	O
##eno	O
##sin	O
##e	O
,	O
4	O
:	O
c	O
##yt	O
##os	O
##ine	O
and	O
5	O
:	O
c	O
##yt	O
##id	O
##ine	O
)	O
using	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
in	O
met	B
##han	I
##ol	I
as	O
a	O
m	O
##od	O
##ifier	O
at	O
the	O
relevant	O
temperature	O
,	O
using	O
the	O
7	O
.	O
35	O
min	O
gradient	O
described	O
in	O
Section	O
2	O
.	O
3	O
.	O
4	O
.	O

The	O
9	B
,	I
10	I
-	I
E	I
##OA	I
is	O
a	O
per	O
##ox	O
##ida	O
##tion	O
product	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
which	O
consume	O
##s	O
excessive	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
,	O
such	O
as	O
D	O
##HA	O
,	O
and	O
leads	O
to	O
a	O
lower	O
level	O
of	O
D	O
##HA	O
.	O

Is	B
##ole	I
##uc	I
##ine	I
was	O
present	O
in	O
both	O
samples	O
but	O
at	O
a	O
higher	O
abundance	O
in	O
those	O
dried	O
by	O
l	O
##yo	O
##phi	O
##li	O
##zation	O
(	O
D	O
)	O
.	O

All	O
G	O
##C	O
–	O
MS	O
analyses	O
were	O
performed	O
on	O
a	O
Trace	O
G	O
##C	O
131	O
##0	O
gas	O
ch	O
##roma	O
##to	O
##graph	O
equipped	O
with	O
an	O
IS	O
##Q	O
L	O
##T	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
using	O
the	O
cap	O
##illa	O
##ry	O
column	O
T	O
##R	O
-	O
5	O
##ms	O
(	O
95	O
%	O
p	B
##oly	I
(	I
dim	I
##eth	I
##yl	I
##si	I
##lo	I
##xa	I
##ne	I
)	I
+	O
5	O
%	O
p	B
##hen	I
##yl	I
p	I
##oly	I
##si	I
##l	I
##phe	I
##ny	I
##lene	I
-	I
si	I
##lo	I
##xa	I
##ne	I
phase	O
,	O
30	O
m	O
×	O
0	O
.	O
25	O
mm	O
,	O
d	O
##f	O
=	O
0	O
.	O
25	O
µ	O
##m	O
)	O
obtained	O
from	O
The	O
##rm	O
##o	O
Scientific	O
(	O
The	O
##rm	O
##o	O
El	O
##ec	O
##tron	O
Corporation	O
,	O
USA	O
)	O
.	O

The	O
ne	O
##gli	O
##gible	O
or	O
absent	O
incorporation	O
of	O
_	O
13	O
C	O
from	O
glucose	S
and	O
g	B
##lut	I
##amine	I
into	O
both	O
amino	O
acids	O
is	O
due	O
to	O
the	O
short	O
in	O
##cu	O
##bation	O
time	O
of	O
the	O
cells	O
in	O
the	O
presence	O
of	O
the	O
labeled	O
glucose	S
or	O
g	B
##lut	I
##amine	I
and	O
indicates	O
that	O
the	O
levels	O
of	O
these	O
two	O
amino	O
acids	O
was	O
low	O
before	O
two	O
cells	O
were	O
in	O
##cu	O
##bate	O
##d	O
in	O
the	O
presence	O
of	O
the	O
labeled	O
fuels	O
.	O

Another	O
study	O
also	O
showed	O
that	O
decreasing	O
the	O
levels	O
of	O
L	B
-	I
car	I
##ni	I
##tine	I
and	O
its	O
derivatives	O
can	O
at	O
##ten	O
##uate	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
path	O
##ogen	O
##esis	O
.	O

2	B
-	I
Am	I
##ino	I
-	I
1	I
,	I
7	I
-	I
dim	I
##eth	I
##yl	I
##im	I
##ida	I
##zo	I
[	I
4	I
,	I
5	I
-	I
g	I
]	I
q	I
##uin	I
##ox	I
##ali	I
##ne	I
(	O
Me	O
##I	O
##g	O
Q	O
##x	O
)	O
was	O
synthesized	O
as	O
previously	O
reported	O
.	O

The	O
concentrations	O
of	O
3	O
meta	O
##bol	O
##ites	O
—	O
ho	O
##mo	O
##ar	O
##gin	O
##ine	O
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	O
##ali	O
##ne	O
—	O
were	O
positively	O
associated	O
with	O
pp	O
##BM	O
##I	O
.	O

Con	O
##cent	O
##rations	O
of	O
co	B
##rt	I
##is	I
##ol	I
and	O
6	B
-	I
β	I
-	I
h	I
##ydro	I
##xy	I
##cor	I
##tis	I
##ol	I
were	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
using	O
the	O
A	O
##gi	O
##lent	O
G	O
##19	O
##7	O
##8	O
##B	O
Multi	O
##mo	O
##de	O
Source	O
for	O
64	O
##10	O
Triple	O
Q	O
##uad	O
##e	O
L	O
##C	O
/	O
MS	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
2008	O
)	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
changes	O
from	O
before	O
to	O
after	O
treatment	O
included	O
increases	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
in	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
plasma	O
##log	O
##ens	O
,	O
and	O
other	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
whereas	O
pro	B
##line	I
and	O
other	O
inter	O
##media	O
##ries	O
of	O
one	O
-	O
carbon	O
metabolism	O
—	O
that	O
is	O
,	O
met	B
##hi	I
##oni	I
##ne	I
and	O
c	O
##ys	O
##tein	O
##e	O
—	O
were	O
reduced	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

We	O
analyzed	O
the	O
survival	O
data	O
of	O
these	O
patients	O
,	O
and	O
found	O
that	O
the	O
serum	O
level	O
of	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
and	O
CA	O
##19	O
-	O
9	O
are	O
strongly	O
correlated	O
with	O
B	O
##D	O
##TT	O
patient	O
overall	O
survival	O
(	O
Table	O
)	O
.	O

According	O
to	O
the	O
current	O
r	O
##aft	O
concept	O
,	O
G	O
##G	O
##s	O
co	O
##loc	O
##ali	O
##ze	O
with	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
form	O
ordered	O
membrane	O
micro	O
##dom	O
##ain	O
##s	O
within	O
a	O
more	O
fluid	O
bi	O
##layer	O
mainly	O
composed	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

The	O
points	O
and	O
horizontal	O
lines	O
indicate	O
the	O
re	O
##gression	O
coefficient	O
slopes	O
(	O
β	O
)	O
for	O
test	B
##osterone	I
with	O
their	O
95	O
%	O
confidence	O
intervals	O
in	O
cases	O
and	O
controls	O
.	O

inflammatory	O
bow	O
##el	O
diseases	O
,	O
therapeutic	O
drug	O
monitoring	O
,	O
pro	O
##fi	O
##ling	O
of	O
th	B
##io	I
##pur	I
##ines	I
,	O
comprehensive	O
stability	O
study	O
,	O
sample	O
treatment	O
,	O
clinical	O
analysis	O
,	O
high	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
,	O
mass	O
s	O
##pect	O
##rome	O
##try	O

We	O
measured	O
exhaled	O
ni	B
##tric	I
oxide	I
(	O
Fe	O
##N	O
##O	O
)	O
before	O
s	B
##pi	I
##rome	I
##tric	I
testing	O
using	O
a	O
N	O
##IO	O
##X	O
analyze	O
##r	O
(	O
Aero	O
##c	O
##rine	O
,	O
Sol	O
##na	O
,	O
Sweden	O
)	O
,	O
according	O
to	O
American	O
Thor	O
##ac	O
##ic	O
Society	O
/	O
European	O
Re	O
##sp	O
##ira	O
##tory	O
Society	O
(	O
AT	O
##S	O
/	O
ER	O
##S	O
)	O
recommendations	O
.	O

P	B
##yr	I
##u	I
##vate	I
levels	O
co	O
##rrel	O
##ate	O
with	O
g	B
##yn	I
##oid	I
ad	O
##ip	O
##ose	O
tissue	O
mass	O
,	O
B	O
##MI	O
,	O
waist	O
hip	O
ratio	O
,	O
T	B
##G	I
,	O
glucose	S
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
and	O
le	O
##pt	O
##in	O
in	O
the	O
ER	O
##F	O
population	O
.	O

A	B
##V	I
differences	O
,	O
expressed	O
as	O
percentage	O
##s	O
of	O
extraction	O
or	O
release	O
,	O
were	O
generated	O
by	O
taking	O
the	O
difference	O
of	O
the	O
[	O
meta	O
##bol	O
##ite	O
]	O
_	O
peripheral	O
–	O
[	O
meta	O
##bol	O
##ite	O
]	O
_	O
CS	O
and	O
dividing	O
by	O
the	O
[	O
meta	O
##bol	O
##ite	O
]	O
_	O
peripheral	O
.	O

The	O
same	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
24	I
:	I
1	I
)	I
meta	O
##bol	O
##ite	O
was	O
down	O
##re	O
##gu	O
##lated	O
in	O
pan	O
##cre	O
##atic	O
cancer	O
patients	O
.	O

L	O
,	O
non	O
-	O
HD	O
##L	O
ch	B
##ole	I
##ster	I
##ol	I
concentration	O
3	O
.	O
5	O
-	O
6	O
.	O
5	O
mm	O
##ol	O
/	O
L	O
,	O
and	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
concentration	O
<	O
2	O
.	O
5	O
##mm	O
##ol	O
/	O

The	O
same	O
discussion	O
applies	O
for	O
a	O
small	O
peak	O
at	O
m	O
/	O
z	O
41	O
##9	O
from	O
the	O
PC	B
18	I
:	I
1	I
/	I
16	I
:	I
0	I
sample	O
,	O
which	O
contains	O
13	O
±	O
2	O
%	O
s	O
##n	O
-	O
is	O
##omer	O
##s	O
.	O

In	O
fact	O
,	O
several	O
pre	O
##c	O
##lini	O
##cal	O
studies	O
demonstrated	O
the	O
media	O
##tory	O
and	O
m	O
##od	O
##ulatory	O
role	O
of	O
K	O
##Y	O
##NA	O
for	O
g	B
##lut	I
##ama	I
##te	I
and	O
its	O
receptors	O
in	O
central	O
and	O
peripheral	O
pain	O
processing	O
.	O

Chemical	O
shifts	O
were	O
referenced	O
to	O
the	O
g	B
##ly	I
##cine	I
peak	O
in	O
the	O
H	O
##S	O
##Q	O
##C	O
s	O
##pect	O
##ra	O
.	O

We	O
also	O
found	O
significant	O
coding	O
variations	O
associated	O
with	O
dim	B
##eth	I
##yl	I
-	I
g	I
##ly	I
##cine	I
,	O
car	B
##ni	I
##tine	I
,	O
p	B
##yr	I
##u	I
##vate	I
and	O
l	B
##ys	I
##ine	I
however	O
all	O
those	O
signals	O
vanished	O
after	O
adjustment	O
by	O
the	O
leading	O
G	O
##WA	O
##S	O
S	O
##NP	O
,	O
indicating	O
that	O
these	O
associations	O
so	O
far	O
are	O
best	O
explained	O
by	O
the	O
leading	O
G	O
##WA	O
##S	O
hits	O
in	O
these	O
regions	O
.	O

Of	O
the	O
13	O
base	O
##line	O
meta	O
##bol	O
##ites	O
that	O
were	O
strongly	O
correlated	O
to	O
post	O
-	O
drug	O
treatment	O
clinical	O
measures	O
,	O
two	O
were	O
not	O
correlated	O
to	O
pre	O
-	O
drug	O
treatment	O
clinical	O
measures	O
:	O
ethanol	B
##amine	I
and	O
th	B
##re	I
##oni	I
##ne	I
.	O

Changes	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
were	O
prominent	O
in	O
growth	O
-	O
restricted	O
f	O
##etus	O
##es	O
indicating	O
significant	O
alterations	O
in	O
their	O
abundance	O
and	O
bio	O
##physical	O
properties	O
.	O

Neither	O
of	O
these	O
fatty	O
acids	O
co	O
##rrel	O
##ates	O
with	O
any	O
T	O
##AG	O
reduction	O
indicating	O
that	O
the	O
decrease	O
in	O
18	O
:	O
3	O
and	O
20	O
:	O
3	O
fatty	O
acids	O
prefer	O
##ential	O
##ly	O
affect	O
PC	O
lip	O
##ids	O
rather	O
than	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

As	O
listed	O
in	O
,	O
for	O
our	O
method	O
the	O
L	O
##OD	O
was	O
between	O
0	O
.	O
1	O
and	O
1	O
.	O
5	O
n	O
##M	O
(	O
0	O
.	O
18	O
–	O
2	O
.	O
7	O
p	B
##g	I
on	O
column	O
)	O
for	O
the	O
most	O
sensitive	O
transition	O
,	O
whereas	O
for	O
alternative	O
transitions	O
similarly	O
low	O
or	O
higher	O
L	O
##OD	O
##s	O
were	O
determined	O
.	O

B	O
,	O
we	O
observed	O
a	O
light	O
increase	O
in	O
a	B
##rg	I
##ini	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
levels	O
,	O
as	O
well	O
as	O
in	O
as	B
##par	I
##tate	I
in	O
the	O
tumor	O
tissue	O
compared	O
with	O
the	O
healthy	O
tissue	O
.	O

Op	O
##ti	O
##mis	O
##ation	O
of	O
the	O
met	B
##hyl	I
##ar	I
##gin	I
##ine	I
detection	O
method	O
.	O

Whether	O
or	O
not	O
T	B
##MA	I
##O	I
is	O
a	O
useful	O
marker	O
for	O
C	O
##VR	O
factors	O
in	O
patients	O
undergoing	O
bar	O
##ia	O
##tric	O
surgery	O
needs	O
to	O
be	O
studied	O
further	O
.	O

3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
also	O
named	O
β	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
or	O
3	B
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
met	I
##hyl	I
##but	I
##yric	I
acid	I
,	O
is	O
a	O
final	O
product	O
of	O
le	B
##uc	I
##ine	I
cat	O
##ab	O
##olis	O
##m	O
,	O
which	O
is	O
not	O
further	O
de	O
##graded	O
and	O
,	O
therefore	O
,	O
can	O
be	O
contemplated	O
as	O
a	O
useful	O
bio	O
##mark	O
##er	O
.	O

Compared	O
with	O
the	O
data	O
reported	O
in	O
the	O
published	O
paper	O
,	O
this	O
compound	O
was	O
identified	O
as	O
5	B
,	I
6	I
-	I
fur	I
##ano	I
-	I
h	I
##ydro	I
##co	I
##uma	I
##ric	I
acid	I
.	O

However	O
,	O
more	O
recently	O
Re	O
##em	O
##ts	O
##ma	O
et	O
al	O
.	O
reported	O
a	O
median	O
of	O
1300	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
and	O
95	O
%	O
percent	O
##ile	O
of	O
28	O
,	O
600	O
p	O
##g	O
m	O
##L	O
_	O
−	O
##1	O
D	O
##PP	O
in	O
human	O
urine	O
in	O
Germany	O
.	O

To	O
predict	O
the	O
presence	O
or	O
absence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
the	O
calculated	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
(	O
from	O
here	O
on	O
,	O
this	O
prediction	O
model	O
is	O
known	O
as	O
the	O
PC	O
##T	O
model	O
)	O
using	O
one	O
predict	O
##ive	O
component	O
and	O
one	O
or	O
##th	O
##ogo	O
##nal	O
component	O
,	O
described	O
80	O
.	O
1	O
%	O
of	O
the	O
variation	O
in	O
X	O
(	O
R	O
_	O
2	O
X	O
=	O
0	O
.	O
80	O
##1	O
)	O
,	O
87	O
.	O
0	O
%	O
of	O
the	O
variation	O
in	O
response	O
Y	O
(	O
R	O
_	O
2	O
Y	O
=	O
0	O
.	O
87	O
##0	O
)	O
and	O
predicted	O
85	O
.	O
7	O
%	O
(	O
Q	O
_	O
2	O
Y	O
=	O
0	O
.	O
85	O
##7	O
)	O
of	O
the	O
variation	O
in	O
response	O
Y	O
,	O
as	O
determined	O
by	O
seven	O
fold	O
cross	O
-	O
valid	O
##ation	O
.	O

Q	O
##uant	O
##itation	O
of	O
this	O
meta	O
##bol	O
##ite	O
provides	O
the	O
first	O
method	O
for	O
p	O
##hen	O
##ot	O
##y	O
##ping	O
human	O
PA	O
##H	O
metabolism	O
by	O
the	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
pathway	O
.	O

The	O
up	O
##re	O
##gu	O
##lated	O
g	B
##lut	I
##ama	I
##te	I
in	O
the	O
different	O
##iating	O
plasma	O
profile	O
of	O
this	O
co	O
##hor	O
##t	O
of	O
T	O
##B	O
disease	O
subjects	O
may	O
thus	O
be	O
a	O
result	O
of	O
increased	O
Mt	O
##b	O
g	B
##lut	I
##ama	I
##te	I
synthesis	O
and	O
represent	O
a	O
potential	O
host	O
-	O
path	O
##ogen	O
metabolic	O
interaction	O
.	O

Since	O
c	B
##ys	I
##te	I
##amine	I
was	O
converted	O
to	O
c	B
##ys	I
##tamine	I
during	O
the	O
pre	O
-	O
treatment	O
procedure	O
,	O
c	B
##ys	I
##te	I
##amine	I
was	O
detected	O
as	O
c	B
##ys	I
##tamine	I
by	O
our	O
system	O
.	O

From	O
this	O
analysis	O
,	O
the	O
try	B
##pt	I
##op	I
##han	I
and	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
(	O
k	O
##yn	O
##uren	O
##ine	O
,	O
h	B
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
X	O
##A	O
,	O
k	O
##en	O
##uren	O
##ic	O
acid	O
)	O
,	O
PA	O
##r	O
index	O
,	O
MMA	O
,	O
ch	B
##olin	I
##e	I
,	O
la	B
##nt	I
##hi	I
##oni	I
##ne	I
,	O
plasma	O
total	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
plasma	O
total	O
g	B
##lut	I
##ath	I
##ione	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
diabetes	O
,	O
fast	O
##ing	O
,	O
and	O
age	O
were	O
significant	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
with	O
99	O
%	O
confidence	O
in	O
P	O
##LS	O
-	O
D	O
##A	O
analysis	O
.	O

Analysis	O
of	O
spectral	O
data	O
by	O
P	O
##LS	O
-	O
D	O
##A	O
revealed	O
significant	O
separation	O
between	O
subjects	O
with	O
low	O
or	O
high	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
.	O

They	O
found	O
that	O
only	O
seven	O
out	O
of	O
63	O
investigated	O
meta	O
##bol	O
##ites	O
,	O
mainly	O
amino	O
acids	O
,	O
were	O
altered	O
when	O
urine	O
was	O
stored	O
at	O
9	O
and	O
20	O
°C	O
for	O
24	O
h	O
but	O
not	O
2	O
or	O
8	O
h	O
,	O
and	O
detected	O
a	O
statistical	O
##ly	O
significant	O
interaction	O
between	O
storage	O
duration	S
and	O
storage	O
temperature	O
on	O
meta	O
##bol	O
##ite	O
concentrations	O
.	O

The	O
double	O
##t	O
splitting	O
pattern	O
of	O
C	O
##ω	O
and	O
C	O
##2	O
suggests	O
the	O
dominance	O
of	O
a	O
##cy	O
##l	O
chain	O
is	O
##oto	O
##po	O
##mers	O
containing	O
the	O
_	O
13	O
CH	O
_	O
3	O
–	O
_	O
13	O
CH	O
_	O
2	O
–	O
_	O
12	O
CH	O
_	O
2	O
–	O
fragment	O
while	O
the	O
double	O
##t	O
pattern	O
for	O
C	O
##3	O
and	O
C	O
##1	O
,	O
and	O
triple	O
##t	O
pattern	O
for	O
C	O
##2	O
of	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
is	O
consistent	O
with	O
_	O
13	O
C	O
label	O
##ing	O
in	O
all	O
three	O
carbon	O
##s	O
.	O

We	O
observed	O
therefore	O
an	O
up	O
##re	O
##gu	O
##lation	O
in	O
PC	O
and	O
a	O
down	O
##re	O
##gu	O
##lation	O
in	O
l	B
##ys	I
##o	I
-	I
PC	I
species	O
in	O
lip	O
##id	O
extract	O
##s	O
of	O
both	O
plasma	O
and	O
er	O
##yt	O
##hr	O
##ocytes	O
.	O

L	O
##D	O
##LC	O
,	O
Low	O
-	O
Den	O
##sity	O
Li	O
##pop	O
##rote	O
##in	O
Cho	B
##les	I
##tero	I
##l	I
;	O
N	O
##IS	O
##T	O
,	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology	O
.	O

The	O
6	O
meta	O
##bol	O
##ites	O
with	O
the	O
strongest	O
ability	O
to	O
separate	O
b	O
##act	O
##ere	O
##mic	O
se	O
##psis	O
from	O
ER	O
-	O
controls	O
were	O
an	O
##not	O
##ated	O
as	O
my	B
##rist	I
##ic	I
acid	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
nor	B
##le	I
##uc	I
##ine	I
,	O
p	B
##yr	I
##u	I
##vic	I
acid	I
and	O
a	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
like	O
derivative	O
.	O

After	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
200	O
g	O
and	O
4	O
°C	O
for	O
10	O
min	O
(	O
All	O
##eg	O
##ra	O
X	O
##15	O
##R	O
,	O
Beck	O
##man	O
Co	O
##ulter	O
,	O
B	O
##rea	O
,	O
CA	O
)	O
,	O
the	O
culture	O
media	O
was	O
carefully	O
removed	O
and	O
the	O
cells	O
were	O
washed	O
twice	O
with	O
50	O
m	O
##L	O
freshly	O
-	O
prepared	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
PBS	O
)	O
.	O

Furthermore	O
,	O
the	O
AU	O
##C	O
of	O
L	B
-	I
as	I
##par	I
##ty	I
##l	I
-	I
4	I
-	I
phosphate	I
and	O
L	O
##ys	O
##o	O
##PC	O
[	O
20	O
:	O
5	O
(	O
5	O
##Z	O
,	O
8	O
##Z	O
,	O
11	O
##Z	O
,	O
14	O
##Z	O
,	O
17	O
##Z	O
)	O
]	O
in	O
the	O
stage	O
A	O
vs	O
.	O
B	O
comparison	O
were	O
increased	O
compared	O
with	O
that	O
of	O
A	O
##FP	O
,	O
but	O
were	O
decreased	O
in	O
the	O
comparison	O
between	O
stage	O
B	O
and	O
C	O
.	O
The	O
present	O
study	O
succeeded	O
in	O
screening	O
metabolic	O
ions	O
that	O
reflect	O
the	O
progress	O
of	O
HC	O
##C	O
with	O
high	O
diagnostic	O
value	O
.	O

Level	O
##s	O
of	O
bi	O
##s	O
(	B
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##o	I
-	I
2	I
-	I
prop	I
##yl	I
)	I
phosphate	I
(	O
B	O
##DC	O
##PP	O
)	O
and	O
dip	B
##hen	I
##yl	I
phosphate	I
(	O
D	O
##PP	O
)	O
extracted	O
in	O
nine	O
urine	O
samples	O
.	O

On	O
the	O
other	O
hand	O
,	O
patients	O
in	O
the	O
AI	O
##S	O
C	O
category	O
did	O
not	O
show	O
significant	O
change	O
in	O
c	B
##it	I
##ru	I
##llin	I
##e	I
level	O
compared	O
to	O
the	O
non	O
-	O
injured	O
controls	O
.	O

To	O
c	O
##lar	O
##ify	O
the	O
temporal	O
relation	O
of	O
the	O
association	O
between	O
plasma	O
T	B
##MA	I
##O	I
and	O
odds	O
of	O
G	O
##DM	O
,	O
we	O
conducted	O
a	O
nest	O
##ed	O
case	O
-	O
control	O
study	O
within	O
an	O
ongoing	O
prospective	O
co	O
##hor	O
##t	O
study	O
,	O
namely	O
the	O
Tong	O
##ji	O
Mat	O
##ern	O
##al	O
and	O
Child	O
Health	O
Co	O
##hor	O
##t	O
(	O
T	O
##MC	O
##HC	O
)	O
.	O

This	O
analysis	O
was	O
performed	O
only	O
for	O
ER	B
(	I
+	I
)	I
patients	O
because	O
within	O
the	O
ER	O
(	O
−	O
)	O
group	O
too	O
few	O
re	O
##lap	O
##ses	O
were	O
observed	O
(	O
8	O
vs	O
3	O
respectively	O
)	O
.	O

Based	O
on	O
exact	O
mass	O
,	O
retention	O
time	O
and	O
is	O
##oto	O
##pic	O
distribution	O
we	O
identified	O
9	O
molecules	O
including	O
re	O
##sol	O
##vin	O
D	O
and	O
specific	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
associated	O
with	O
blood	O
flow	O
,	O
and	O
hence	O
with	O
a	O
potentially	O
regulatory	O
role	O
relevant	O
in	O
end	O
##ome	O
##tri	O
##al	O
cancer	O
.	O

shows	O
characteristic	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
urine	O
samples	O
(	O
A	O
)	O
ben	O
##ign	O
,	O
(	O
B	O
)	O
cancer	O
;	O
visually	O
differential	O
meta	O
##bol	O
##ites	O
include	O
increased	O
3	B
-	I
amino	I
##but	I
##yra	I
##te	I
,	O
reduced	O
c	B
##it	I
##rate	I
and	O
trim	B
##eth	I
##yla	I
##mine	I
,	O
reduced	O
g	B
##ly	I
##cine	I
and	O
t	B
##rig	I
##one	I
##llin	I
##e	I
in	O
RC	O
##C	O
relative	O
to	O
controls	O
.	O

(	O
D	O
)	O
L	O
##ys	O
##o	O
##PC	O
a	O
C	B
##16	I
:	I
0	I
presented	O
higher	O
delta	O
t	O
##35	O
(	O
p	O
=	O
2	O
.	O
6	O
##E	O
-	O
03	O
)	O
and	O
delta	O
##t	O
##24	O
##0	O
(	O
p	O
=	O
7	O
.	O
9	O
##E	O
-	O
04	O
)	O
in	O
the	O
subjects	O
carrying	O
the	O
T	O
##CF	O
##7	O
##L	O
##2	O
r	O
##s	O
##7	O
##90	O
##31	O
##46	O
risk	O
all	O
##ele	O
.	O

Met	O
##S	O
components	O
were	O
the	O
ones	O
established	O
by	O
the	O
International	O
Di	O
##abe	O
##tes	O
Federation	O
,	O
including	O
central	O
o	O
##besity	O
,	O
raised	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
(	O
s	O
##ys	O
##B	O
##P	O
)	O
,	O
fast	O
##ing	O
raised	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
T	O
##G	O
)	O
,	O
glucose	S
,	O
and	O
reduced	O
high	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
.	O

This	O
would	O
explain	O
the	O
adverse	O
health	O
effects	O
observed	O
after	O
block	O
##age	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
in	O
mice	O
models	O
of	O
RA	O
[	O
,	O
]	O
,	O
and	O
the	O
correlation	O
of	O
try	B
##pt	I
##op	I
##han	I
degradation	O
with	O
the	O
severity	O
of	O
the	O
disease	O
in	O
humans	O
.	O

(	O
a	O
)	O
First	O
order	O
neighborhood	O
of	O
C	O
##K	O
##D	O
-	O
EP	O
##I	O
e	O
##G	O
##F	O
##R	O
values	O
based	O
on	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
(	O
e	O
##G	O
##F	O
##R	O
)	O
.	O

Cy	O
##tok	O
##ines	O
were	O
anal	O
##ys	O
##ed	O
in	O
E	O
##D	O
##TA	O
plasma	O
samples	O
from	O
the	O
SL	O
##E	O
co	O
##hor	O
##t	O
using	O
the	O
MS	O
##D	O
V	O
-	O
P	O
##LE	O
##X	O
Human	O
Cy	O
##tok	O
##ine	O
30	O
-	O
p	O
##lex	O
kit	O
(	O
K	O
##15	O
##0	O
##5	O
##4	O
##D	O
;	O
Me	B
##so	I
##sca	I
##le	I
Discovery	O
,	O
G	O
##ait	O
##hers	O
##burg	O
,	O
Maryland	B
,	I
USA	I
)	O
and	O
c	O
##yt	O
##oki	O
##nes	O
,	O
which	O
previously	O
have	O
been	O
suggested	O
to	O
be	O
increased	O
in	O
patients	O
with	O
SL	O
##E	O
,	O
that	O
is	O
,	O
t	O
##umour	O
ne	O
##c	O
##rosis	O
factor	O
alpha	O
(	O
T	O
##NF	O
-	O
α	O
)	O
,	O
IF	O
##N	O
-	O
γ	O
-	O
induced	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
,	O
inter	O
##le	O
##uki	O
##n	O
(	O
IL	O
)	O
-	O
16	O
,	O
mac	O
##rop	O
##hage	O
inflammatory	O
proteins	O
1	O
beta	O
(	B
MI	B
##P	I
-	I
1	I
##β	I
)	O
,	O
and	O
IL	O
-	O
6	O
were	O
studied	O
in	O
this	O
work	O
.	O

The	O
transitions	O
301	O
.	O
11	O
/	O
286	O
.	O
0	O
and	O
305	O
.	O
11	O
/	O
286	O
.	O
0	O
were	O
used	O
to	O
monitor	O
di	B
##os	I
##met	I
##in	I
and	O
_	O
13	O
C	B
,	I
d	I
_	I
3	I
-	I
di	I
##os	I
##met	I
##in	I
,	O
respectively	O
,	O
while	O
the	O
para	B
##ce	I
##tam	I
##ol	I
resulted	O
from	O
en	O
##zy	O
##matic	O
degradation	O
and	O
d	B
_	I
4	I
-	I
para	I
##ce	I
##tam	I
##ol	I
were	O
detected	O
on	O
the	O
transitions	O
152	O
.	O
02	O
/	O
110	O
.	O
1	O
and	O
156	O
.	O
0	O
/	O
114	O
.	O
1	O
,	O
respectively	O
.	O

The	O
heat	O
##ma	O
##ps	O
clearly	O
show	O
that	O
the	O
metabolic	O
profiles	O
of	O
the	O
A	B
##F	I
group	O
were	O
more	O
easily	O
distinguished	O
from	O
those	O
of	O
the	O
non	O
-	O
A	O
##F	O
group	O
in	O
the	O
at	O
##rial	O
app	O
##end	O
##age	O
samples	O
than	O
in	O
the	O
plasma	O
samples	O
.	O

RA	O
mi	O
##R	O
-	O
146	O
##a	O
was	O
associated	O
with	O
greater	O
concentrations	O
of	O
card	O
##io	O
##met	O
##ab	O
##olic	O
risk	O
markers	O
(	O
plasma	O
short	O
-	O
chain	O
di	O
##car	O
##box	O
##yl	O
/	O
h	O
##ydro	O
##xy	O
##l	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
large	O
V	O
##LD	O
##L	O
particles	O
,	O
and	O
small	O
HD	O
##L	O
particles	O
)	O
and	O
lower	O
concentrations	O
of	O
muscle	O
energy	O
substrates	O
(	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
p	O
##yr	O
##u	O
##vate	O
)	O
.	O

Inter	O
##actions	O
between	O
o	B
##xa	I
##p	I
##ro	I
##zin	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
and	O
human	O
serum	O
album	O
##in	O
.	O

The	O
patients	O
reported	O
a	O
varied	O
drug	O
history	O
:	O
the	O
majority	O
of	O
the	O
CH	O
##B	O
group	O
were	O
taking	O
multi	O
##vi	O
##tam	O
##ins	O
,	O
although	O
some	O
were	O
also	O
taking	O
an	O
oral	O
anti	O
##vir	O
##al	O
drug	O
(	O
n	O
=	O
10	O
,	O
en	O
##teca	O
##vir	O
or	O
ten	O
##of	O
##ov	O
##ir	O
)	O
and	O
/	O
or	O
an	O
oral	O
pro	O
##ton	O
pump	O
inhibitor	O
(	O
PP	O
##I	O
)	O
(	B
o	B
##me	I
##pra	I
##zo	I
##le	I
,	O
pan	B
##top	I
##raz	I
##ole	I
)	O
;	O
the	O
C	O
##IR	O
group	O
reported	O
a	O
combination	O
of	O
non	O
-	O
absorb	O
##able	O
sugar	O
##s	O
(	O
la	O
##ct	O
##ulos	O
##e	O
)	O
,	O
PP	B
##I	I
(	I
o	I
##me	I
##pra	I
##zo	I
##le	I
,	I
pan	I
##top	I
##raz	I
##ole	I
)	I
,	O
oral	O
anti	O
##vir	O
##al	O
(	O
n	O
=	O
7	O
,	O
en	O
##teca	O
##vir	O
,	O
ten	O
##of	O
##ov	O
##ir	O
or	O
te	O
##l	O
##bi	O
##vu	O
##dine	O
)	O
,	O
and	O
/	O
or	O
multi	O
##vi	O
##tam	O
##ins	O
;	O
and	O
the	O
HC	O
##C	O
co	O
##hor	O
##t	O
reported	O
a	O
wider	O
range	O
of	O
medication	O
,	O
including	O
an	O
oral	O
anti	O
##vir	O
##al	O
(	O
en	O
##teca	O
##vir	O
,	O
ten	O
##of	O
##ov	O
##ir	O
)	O
,	O
ho	O
##rmon	O
##al	O
therapy	O
(	B
ta	B
##mo	I
##xi	I
##fen	I
)	O
,	O
PP	B
##I	I
(	I
o	I
##me	I
##pra	I
##zo	I
##le	I
,	I
pan	I
##top	I
##raz	I
##ole	I
)	I
,	O
beta	O
block	O
##ers	O
,	O
non	O
-	O
absorb	O
##able	O
sugar	O
##s	O
(	O
la	O
##ct	O
##ulos	O
##e	O
)	O
,	O
multi	O
##vi	O
##tam	O
##ins	O
,	O
and	O
pain	O
killers	O
(	O
including	O
tram	O
##ado	O
##l	O
)	O
.	O

Mass	O
s	O
##pect	O
##rome	O
##try	O
was	O
conducted	O
using	O
positive	O
ion	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
in	O
the	O
multiple	O
reaction	O
monitoring	O
mode	O
on	O
a	O
q	O
##uad	O
##rup	O
##ole	O
–	O
q	O
##uad	O
##rup	O
##ole	O
-	O
linear	O
ion	O
trap	O
instrument	O
after	O
pre	O
-	O
column	O
addition	O
of	O
met	B
##hyl	I
##amine	I
to	O
increase	O
the	O
ion	O
##ization	O
efficiency	O
.	O

Furthermore	O
,	O
Fi	O
##rm	O
##ic	O
##utes	O
(	B
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
)	O
was	O
en	O
##rich	O
##ed	O
in	O
the	O
H	O
group	O
,	O
which	O
al	O
##ign	O
##s	O
well	O
with	O
the	O
increased	O
la	B
##ct	I
##ose	I
in	O
this	O
group	O
.	O

Mo	O
##chal	O
##ski	O
P	O
et	O
al	O
.	O
reported	O
two	O
potential	O
pathways	O
that	O
could	O
be	O
involved	O
in	O
k	B
##eton	I
##e	I
production	O
:	O
(	O
i	O
)	O
the	O
oxidation	O
of	O
secondary	O
alcohol	O
##s	O
cat	O
##aly	O
##zed	O
by	O
AD	O
##H	O
##s	O
and	O
(	O
ii	O
)	O
the	O
β	O
-	O
oxidation	O
of	O
branched	O
-	O
chain	O
fatty	O
acids	O
.	O

The	O
ion	O
at	O
m	O
/	O
z	O
104	O
in	O
the	O
low	O
mass	O
region	O
corresponds	O
to	O
the	O
ch	B
##olin	I
##e	I
group	O
.	O

Lower	O
plasma	O
plate	O
##let	O
content	O
was	O
associated	O
with	O
higher	O
g	B
##lut	I
##amine	I
,	O
c	B
##it	I
##rate	I
,	O
and	O
V	O
##LD	O
##L	O
/	O
L	O
##D	O
##L	O
lip	O
##id	O
m	O
##oi	O
##eti	O
##es	O
.	O

The	O
spectral	O
regions	O
containing	O
water	O
and	O
u	B
##rea	I
(	O
δ	O
6	O
.	O
4	O
to	O
4	O
.	O
5	O
)	O
,	O
the	O
internal	O
standard	O
(	O
δ	O
0	O
.	O
2	O
to	O
−	O
##0	O
.	O
2	O
)	O
,	O
and	O
regions	O
δ	O
0	O
.	O
5	O
to	O
0	O
.	O
2	O
,	O
δ	O
−	O
##0	O
.	O
2	O
to	O
−	O
##4	O
.	O
5	O
,	O
and	O
δ	O
15	O
.	O
5	O
to	O
9	O
.	O
5	O
were	O
removed	O
before	O
normal	O
##ization	O
via	O
the	O
median	O
fold	O
change	O
method	O
.	O

Level	O
##s	O
of	O
a	B
##rg	I
##ini	I
##ne	I
-	I
NO	I
meta	O
##bol	O
##ites	O
(	O
A	O
##rg	O
-	O
Ms	O
:	O
a	B
##rg	I
##ini	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
,	O
and	O
symmetric	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
)	O
were	O
related	O
to	O
index	O
##es	O
of	O
R	O
##V	O
-	O
P	O
##V	O
d	O
##ys	O
##function	O
(	O
,	O
)	O
.	O

Li	O
##pid	O
##s	O
were	O
extracted	O
from	O
tissue	O
samples	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
q	O
##uant	O
##ified	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
,	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
E	O
##SI	O
##MS	O
/	O
MS	O
,	O
4000	O
Q	O
##TR	O
##AP	O
,	O
AB	O
##I	O
)	O
as	O
described	O
previously	O
at	O
Virginia	O
Commonwealth	O
University	O
Li	O
##pid	O
##omi	O
##cs	O
Core	O
[	O
,	O
]	O
.	O

However	O
,	O
associations	O
of	O
e	O
##G	O
##F	O
##R	O
with	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
were	O
more	O
consistent	O
and	O
much	O
stronger	O
than	O
associations	O
of	O
PT	O
##H	O
or	O
F	O
##G	O
##F	O
-	O
23	O
with	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
suggesting	O
that	O
regulation	O
of	O
C	O
##YP	O
##24	O
##A	O
##1	O
transcription	O
is	O
not	O
the	O
predominant	O
mechanism	O
of	O
reduced	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
in	O
C	O
##K	O
##D	O
.	O

He	B
##xa	I
##de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
;	O
4	O
.	O

As	O
shown	O
in	O
,	O
met	B
##han	I
##ol	I
-	I
ethanol	I
(	I
1	I
:	I
1	I
)	I
precipitation	O
results	O
in	O
a	O
higher	O
number	O
of	O
molecular	O
features	O
(	O
1	O
,	O
620	O
)	O
compared	O
to	O
met	B
##han	I
##ol	I
alone	O
(	O
1	O
,	O
410	O
)	O
,	O
with	O
over	O
70	O
%	O
features	O
(	O
1	O
,	O
138	O
)	O
in	O
common	O
.	O

A	O
s	O
##che	O
##matic	O
diagram	O
of	O
the	O
study	O
design	O
for	O
generation	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
prediction	O
models	O
is	O
shown	O
in	O
.	O

Mass	O
spectral	O
data	O
and	O
retention	O
times	O
for	O
the	O
u	O
##rina	O
##ry	O
fur	B
##an	I
meta	O
##bol	O
##ites	O
and	O
their	O
synthetic	O
standards	O
.	O

These	O
are	O
meta	O
##bol	O
##ites	O
of	O
the	B
##op	I
##hyl	I
##line	I
,	O
a	O
drug	O
used	O
to	O
treat	O
as	O
##th	O
##ma	O
and	O
chronic	O
o	O
##bs	O
##truct	O
##ive	O
pulmonary	O
disease	O
and	O
a	O
meta	O
##bol	O
##ite	O
of	O
ca	B
##ffe	I
##ine	I
,	O
and	O
5	B
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
6	I
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
##ura	I
##ci	I
##l	I
—	I
a	I
ca	I
##ffe	I
##ine	I
meta	O
##bol	O
##ite	O
.	O

Note	O
that	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
de	I
##ce	I
##nal	I
,	O
2	B
-	I
o	I
##ct	I
##ena	I
##l	I
and	O
2	O
-	O
de	O
##ce	O
##nal	O
do	O
not	O
pass	O
the	O
correlation	O
cut	O
##off	O
and	O
hence	O
are	O
shown	O
at	O
the	O
bottom	O
-	O
left	O
side	O
.	O

CA	O
##F	O
##s	O
and	O
N	O
##F	O
##s	O
similarly	O
induced	O
auto	O
##pha	O
##gy	O
when	O
acute	O
##ly	O
challenged	O
with	O
the	O
severe	O
nut	O
##rient	O
restriction	O
of	O
removing	O
glucose	S
and	O
g	B
##lut	I
##amine	I
from	O
the	O
medium	O
.	O

Based	O
on	O
the	O
optimal	O
parameters	O
,	O
models	O
for	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
showed	O
sensitivity	O
greater	O
than	O
98	O
%	O
in	O
identifying	O
urine	O
specimens	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
.	O

MD	O
##A	O
MB	O
231	O
,	O
MD	O
##A	O
MB	O
45	O
##3	O
,	O
H	O
##S	O
##5	O
##7	O
##8	O
##T	O
,	O
and	O
MC	O
##F	O
-	O
7	O
L	O
,	O
were	O
grown	O
in	O
Du	O
##l	O
##be	O
##cco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
so	O
##lut	O
##in	O
(	B
D	I
##ME	I
##M	I
)	I
–	I
G	I
##lut	I
##a	I
##MA	I
##X	I
media	O
(	O
In	O
##vi	O
##tro	O
##gen	O
Corp	O
,	O
Carl	O
##s	O
##bad	O
,	O
CA	O
)	O
supplemented	O
with	O
10	O
%	O

At	O
base	O
##line	O
,	O
there	O
was	O
no	O
statistical	O
##ly	O
significant	O
difference	O
in	O
clinical	O
characteristics	O
including	O
age	O
,	O
gender	O
,	O
body	O
mass	O
index	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
and	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	I
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
levels	O
between	O
the	O
2	O
groups	O
.	O

L	O
##ys	O
##o	O
##PC	O
##s	O
transport	O
fatty	O
acids	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
and	O
ch	B
##olin	I
##es	I
between	O
different	O
tissues	O
,	O
but	O
also	O
activate	O
signaling	O
pathways	O
leading	O
to	O
the	O
release	O
of	O
second	O
messenger	O
##s	O
as	O
l	O
##igan	O
##ds	O
for	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

[	O
0	O
.	O
000	O
##2	O
]	O
vs	O
0	O
.	O
00	O
##19	O
[	O
0	O
.	O
000	O
##3	O
]	O
arbitrary	O
units	O
[	O
AU	O
]	O
;	O
p	O
=	O
0	O
.	O
04	O
##1	O
)	O
;	O
format	B
##e	I
(	O
0	O
.	O
00	O
##27	O
[	O
0	O
.	O
000	O
##6	O
]	O
vs	O
0	O
.	O
00	O
##19	O
[	O
0	O
.	O
000	O
##6	O
]	O
AU	O
;	O
p	O
=	O
0	O
.	O
01	O
##0	O
)	O
(	O
AU	O
)	O
.	O

Alan	B
##ine	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
and	O
o	B
##ct	I
##ade	I
##cano	I
##l	I
correlated	O
to	O
H	O
##OM	O
##A	O
prior	O
to	O
p	O
value	O
adjustment	O
.	O

2	O
:	O
Part	O
##ici	O
##pation	O
of	O
vitamin	O
B	O
-	O
12	O
in	O
f	B
##olate	I
metabolism	O
and	O
met	B
##hi	I
##oni	I
##ne	I
sa	O
##l	O
##va	O
##ging	O
.	O

The	O
cells	O
were	O
maintained	O
in	O
D	O
##ME	O
##M	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
F	O
##BS	O
,	O
100	O
units	O
/	O
m	O
##l	O
pen	B
##ici	I
##llin	I
,	O
100	O
µ	O
##g	O
/	O
m	O
##l	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
,	O
and	O
0	O
.	O
5	O
µ	O
##g	O
/	O
m	O
##l	O
pu	B
##rom	I
##y	I
##cin	I
.	O

Cell	O
##s	O
may	O
use	O
c	B
##it	I
##rate	I
directly	O
to	O
fuel	O
their	O
metabolism	O
and	O
proliferation	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
α	B
-	I
O	I
##G	I
almost	O
completely	O
suppress	O
##es	O
ten	O
-	O
eleven	O
trans	O
##location	O
(	O
T	O
##ET	O
)	O
activity	O
,	O
but	O
does	O
not	O
affect	O
DNA	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
D	O
##N	O
##MT	O
)	O
activity	O
.	O

Further	O
,	O
we	O
observed	O
a	O
strongly	O
significant	O
down	O
##re	O
##gu	O
##lation	O
of	O
se	B
##rine	I
,	O
g	B
##ly	I
##cine	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
vs	O
.	O
healthy	O
controls	O
,	O
consistent	O
with	O
the	O
notion	O
that	O
an	O
emerge	O
##nt	O
HC	O
##C	O
would	O
in	O
##tens	O
##ify	O
an	O
##ab	O
##olic	O
demands	O
.	O

Moreover	O
,	O
in	B
##os	I
##ito	I
##l	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cans	I
comprise	O
a	O
major	O
family	O
of	O
in	O
##tra	O
##cellular	O
signaling	O
molecules	O
,	O
including	O
the	O
media	O
##tion	O
of	O
insulin	O
action	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
for	O
the	O
first	O
time	O
,	O
a	O
single	O
step	O
oxidation	O
of	O
est	B
##rogen	I
to	O
q	B
##uin	I
##one	I
met	O
##hi	O
##de	O
both	O
in	O
v	O
##ivo	O
and	O
in	O
v	O
##it	O
##ro	O
,	O
by	O
involvement	O
of	O
LP	O
##O	O
.	O

In	O
particular	O
,	O
we	O
found	O
higher	O
levels	O
of	O
Ser	O
,	O
His	O
,	O
As	O
##p	O
,	O
C	O
##5	O
##OH	O
/	O
C	O
##4	O
##DC	O
,	O
C	B
##10	I
:	I
1	I
,	O
and	O
C	B
##8	I
:	I
1	I
in	O
tears	O
from	O
Mu	O
##S	O
patients	O
,	O
while	O
lower	O
levels	O
of	O
C	O
##12	O
,	O
C	B
##14	I
:	I
1	I
,	O
and	O
C	B
##18	I
:	I
1	I
##OH	I
were	O
found	O
in	O
Mu	O
##S	O
tear	O
samples	O
.	O

Additionally	O
,	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
of	O
12	O
randomly	O
selected	O
urine	O
samples	O
were	O
verified	O
using	O
non	O
-	O
N	O
##MR	O
,	O
laboratory	O
-	O
based	O
color	O
##ime	O
##tric	O
techniques	O
using	O
a	O
commercially	O
available	O
kit	O
(	O
Arbor	O
As	O
##say	O
##s	O
,	O
Det	O
##ec	O
##t	O
##X	O
U	O
##rina	O
##ry	O
C	B
##rea	I
##tin	I
##ine	I
Kit	O
,	O
Cat	O
K	O
##00	O
##2	O
-	O
H	O
##5	O
,	O
Ann	O
A	O
##rb	O
##our	O
,	O
Michigan	O
,	O
USA	O
)	O
,	O
and	O
95	O
%	O
correlation	O
was	O
achieved	O
.	O

Dec	O
##reased	O
plasma	O
levels	O
of	O
g	B
##ly	I
##cine	I
in	O
patients	O
with	O
go	O
##ut	O
might	O
be	O
caused	O
by	O
the	O
increased	O
production	O
of	O
u	B
##ric	I
acid	I
in	O
these	O
patients	O
.	O

This	O
is	O
supported	O
by	O
experimental	O
observations	O
in	O
animals	O
and	O
humans	O
;	O
supplement	O
##ation	O
of	O
l	O
##A	O
##rg	O
in	O
rabbits	O
can	O
restore	O
vascular	O
relaxation	O
and	O
end	O
##oth	O
##eli	O
##al	O
function	O
,	O
whereas	O
in	O
humans	O
in	O
##fusion	O
of	O
AD	B
##MA	I
results	O
in	O
increased	O
systemic	O
vascular	O
resistance	O
(	O
SV	O
##R	O
)	O
and	O
mean	O
art	O
##erial	O
blood	O
pressure	O
(	O
MA	O
##P	O
)	O

In	O
the	O
current	O
study	O
,	O
efforts	O
were	O
therefore	O
made	O
to	O
identify	O
the	O
predicted	O
album	O
##in	O
-	O
like	O
protein	O
of	O
Atlantic	S
co	O
##d	O
by	O
analyzing	O
fraction	O
##ated	O
plasma	O
samples	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

This	O
may	O
arise	O
due	O
to	O
increased	O
lip	O
##id	O
oxidation	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
because	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
is	O
produced	O
from	O
th	B
##re	I
##oni	I
##ne	I
and	O
met	B
##hi	I
##oni	I
##ne	I
cat	O
##ab	O
##olis	O
##m	O
as	O
well	O
as	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
.	O

Each	O
of	O
the	O
three	O
male	O
d	O
##d	O
##Y	O
mice	O
was	O
in	B
##tra	I
-	I
per	I
##ito	I
##nea	I
##lly	I
administered	O
with	O
ace	B
##tam	I
##ip	I
##rid	I
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
(	O
10	O
mg	O
/	O
kg	O
)	O
or	O
cloth	B
##ian	I
##id	I
##in	I
(	O
20	O
mg	O
/	O
kg	O
)	O
as	O
solutions	O
of	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##oxide	I
.	O

H	O
##y	O
##po	O
##gly	O
##ce	O
##mia	O
was	O
defined	O
as	O
a	O
fast	O
##ing	O
glucose	S
level	O
of	O
less	O
than	O
2	O
.	O
2	O
mm	O
##ol	O
per	O
liter	O
(	O
40	O
mg	O
per	O
de	O
##ci	O
##lite	O
##r	O
)	O
.	O

The	O
up	O
##re	O
##gu	O
##lation	O
of	O
glucose	S
in	O
serum	O
from	O
G	O
##4	O
patients	O
is	O
also	O
accompanied	O
by	O
a	O
down	O
##re	O
##gu	O
##lation	O
of	O
g	B
##ly	I
##cer	I
##ol	I
that	O
can	O
be	O
converted	O
to	O
glucose	S
in	O
the	O
liver	O
and	O
provides	O
energy	O
for	O
cellular	O
metabolism	O
.	O

In	O
the	O
context	O
of	O
high	O
altitude	O
exposure	O
,	O
the	O
changes	O
observed	O
support	O
prior	O
observations	O
of	O
decreasing	O
blood	O
glucose	S
concentrations	O
,	O
increasing	O
muscle	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
and	O
increasing	O
blood	O
la	B
##ct	I
##ate	I
levels	O
in	O
lowland	O
##ers	O
ascending	O
to	O
high	O
altitude	O
.	O

Sign	O
##ificant	O
meta	O
##bol	O
##ites	O
for	O
C	O
##a	O
##P	O
status	O
(	B
ch	B
##olin	I
##e	I
,	O
le	B
##uc	I
##ine	I
)	O
and	O
c	O
##s	O
##C	O
##a	O
##P	O
(	B
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
)	O
did	O
not	O
significantly	O
improve	O
diagnosis	O
compared	O
with	O
serum	O
PS	O
##A	O
meta	O
##bol	O
##ite	O
predict	O
##ability	O
.	O

Sign	O
##ificant	O
differential	O
expression	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
the	O
following	O
meta	O
##bol	O
##ites	O
was	O
noted	O
:	O
glucose	S
,	O
higher	O
in	O
the	O
patients	O
with	O
longer	O
T	O
##TP	O
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
both	O
higher	O
in	O
the	O
patients	O
with	O
shorter	O
T	O
##TP	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
p	B
##ico	I
##lini	I
##c	I
acid	I
analytical	O
standards	O
showed	O
signs	O
of	O
long	O
-	O
term	O
instability	O
in	O
solution	O
(	O
83	O
.	O
3	O
%	O
after	O
2	O
weeks	O
at	O
−	O
##20	O
°C	O
)	O
.	O

In	O
accordance	O
with	O
our	O
findings	O
,	O
HC	O
use	O
has	O
been	O
associated	O
with	O
higher	O
HD	O
##L	O
-	O
C	O
and	O
low	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
(	O
higher	O
than	O
in	O
males	O
in	O
our	O
data	O
)	O
,	O
T	B
##G	I
(	O
lower	O
in	O
HC	O
females	O
compared	O
to	O
that	O
in	O
males	O
and	O
non	O
-	O
HC	O
females	O
in	O
our	O
data	O
)	O
concentrations	O
.	O

1	B
##α	I
,	I
25	I
-	I
Di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	I
_	I
3	I
,	I
25	I
-	I
H	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	I
_	I
3	I
,	I
24	I
##R	I
,	I
25	I
-	I
Di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
,	O
UP	O
##LC	O
,	O
L	O
##C	O
-	O
MS	O
,	O
Met	O
##ab	O
##olic	O
pro	O
##fi	O
##ling	O
,	O
Der	O
##iva	O
##ti	O
##zation	O

Conversely	O
,	O
no	O
significant	O
relationship	O
between	O
the	O
SM	B
(	I
OH	I
)	I
22	I
:	I
1	I
meta	O
##bol	O
##ite	O
and	O
age	O
(	O
b	O
)	O
was	O
reported	O
.	O

103	O
th	B
##iol	I
candidates	O
were	O
discovered	O
in	O
all	O
cancer	O
##s	O
and	O
6	O
th	B
##iol	I
##s	I
were	O
identified	O
by	O
their	O
standards	O
.	O

For	O
the	O
N	O
##P	O
samples	O
,	O
the	O
principal	O
component	O
analysis	O
(	O
PC	O
##A	O
)	O
score	O
plots	O
showed	O
that	O
controls	O
(	O
−	O
##20	O
°C	O
)	O
and	O
4	O
°C	O
samples	O
were	O
cluster	O
##ed	O
together	O
,	O
indicating	O
that	O
urine	O
meta	O
##bol	O
##ites	O
remained	O
stable	O
at	O
4	O
°C	O
in	O
both	O
PA	O
##BA	O
(	O
A	O
)	O
and	O
no	O
PA	O
##BA	O
(	O
B	O
)	O
pool	O
##ed	O
samples	O
,	O
regardless	O
of	O
storage	O
duration	S
(	O
24	O
or	O
48	O
h	O
)	O
.	O

The	O
one	O
subject	O
without	O
detect	O
##able	O
d	O
##A	O
-	O
Al	O
-	O
I	O
had	O
no	O
recorded	O
history	O
of	O
Ari	O
##sto	O
##loc	O
##hia	O
s	B
##p	I
.	O

Cho	B
##line	I
kinase	O
-	O
α	O
(	B
Ch	B
##k	I
-	I
α	I
)	O
activity	O
,	O
an	O
enzyme	O
in	O
the	O
Kennedy	O
pathway	O
that	O
p	B
##hos	I
##ph	I
##ory	I
##lates	I
free	O
ch	B
##olin	I
##e	I
to	O
PC	O
,	O
and	O
PC	O
levels	O
were	O
increased	O
in	O
co	O
##lon	O
cancer	O
and	O
ad	O
##eno	O
##ma	O
tissue	O
.	O

In	O
order	O
to	O
assess	O
whether	O
the	O
DNA	O
met	B
##hyl	I
##ome	I
is	O
changed	O
by	O
α	B
-	I
O	I
##G	I
,	O
EP	O
##IC	O
array	O
was	O
performed	O
.	O

The	O
prospective	O
molecular	O
formula	O
##s	O
of	O
B	B
##Q	I
##B	I
-	I
th	I
##iol	I
derivatives	O
were	O
generated	O
based	O
on	O
the	O
accurate	O
mass	O
and	O
is	O
##oto	O
##pe	O
patterns	O
of	O
elemental	O
composition	O
using	O
B	O
##ruk	O
##er	O
Dalton	O
##ics	O
Data	O
analysis	O
4	O
.	O
0	O
software	O
.	O

The	O
phosphate	S
area	O
average	O
value	O
was	O
1	O
.	O
83	O
##5	O
vs	O
.	O
2	O
.	O
54	O
e	O
_	O
6	O
±	O
87	O
##3	O
,	O
000	O
μ	O
##m	O
_	O
2	O
in	O
di	O
##abe	O
##tic	O
versus	O
non	O
##dia	O
##bet	O
##ic	O
subjects	O
,	O
respectively	O
(	O
P	O
=	O
not	O
significant	O
)	O
.	O

T	O
##hr	O
,	O
C	O
##3	O
##DC	O
/	O
C	O
##10	O
and	O
C	B
##18	I
:	I
1	I
seemed	O
to	O
be	O
the	O
risk	O
factors	O
for	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

However	O
,	O
it	O
could	O
reflect	O
the	O
activation	O
of	O
the	O
me	B
##val	I
##ona	I
##te	I
pathway	O
leading	O
to	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
increases	O
in	O
α	B
-	I
to	I
##co	I
##pher	I
##ol	I
accumulation	O
(	O
Vita	O
##min	O
E	O
)	O
,	O
which	O
will	O
preserve	O
membrane	O
integrity	O
under	O
o	O
##xi	O
##da	O
##tive	O
stress	O
conditions	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##4	O
)	O
.	O

C	O
##aut	O
##ion	O
is	O
needed	O
in	O
patients	O
with	O
conflict	O
##ive	O
results	O
,	O
i	O
.	O
e	O
.	O
P	O
##ET	O
-	O
positive	O
patients	O
with	O
a	O
high	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
or	O
P	O
##ET	O
-	O
negative	O
patients	O
with	O
a	O
low	O
relative	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
.	O

The	O
exceptions	O
to	O
this	O
general	O
pattern	O
were	O
the	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
:	O
in	O
those	O
t	O
##umour	O
##s	O
,	O
the	O
only	O
significant	O
positive	O
correlation	O
##s	O
were	O
between	O
la	B
##ct	I
##ate	I
and	O
t	O
##G	O
##lut	O
and	O
between	O
t	O
##C	O
##r	O
and	O
la	B
##ct	I
##ate	I
.	O

For	O
example	O
,	O
in	O
ne	O
##uro	O
##logy	O
,	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
allow	O
exploring	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
function	O
(	B
g	B
##lut	I
##ama	I
##te	I
,	O
do	B
##pa	I
##mine	I
,	O
se	O
##rot	O
##oni	O
##n	O
)	O
or	O
u	B
##rea	I
cycle	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
;	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
may	O
shed	O
light	O
on	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
associated	O
with	O
mitochondrial	O
metabolism	O
imp	O
##air	O
##ment	O
;	O
lip	O
##id	O
metabolism	O
enables	O
exploring	O
my	B
##elin	I
sheath	O
##s	O
,	O
which	O
main	O
components	O
are	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
.	O

Two	O
different	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
species	O
were	O
associated	O
with	O
a	O
lower	O
C	O
-	O
p	O
##eptide	O
level	O
at	O
1	O
month	O
(	O
Table	O
)	O
.	O

Finally	O
,	O
there	O
were	O
18	O
metabolic	O
signatures	O
associated	O
both	O
with	O
o	O
##besity	O
and	O
as	O
##th	O
##ma	O
,	O
which	O
were	O
p	B
##yr	I
##op	I
##hos	I
##phate	I
3	O
,	O
d	B
-	I
g	I
##lu	I
##co	I
##he	I
##pt	I
##ose	I
1	O
,	O
s	B
##hi	I
##kim	I
##ic	I
acid	I
,	O
as	B
##par	I
##tic	I
acid	I
,	O
beta	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
1	I
,	I
4	I
-	I
amino	I
##but	I
##yric	I
acid	I
1	O
,	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
2	O
,	O
x	B
##ant	I
##hine	I
,	O
3	B
-	I
amino	I
##p	I
##rop	I
##ion	I
##it	I
##ril	I
##e	I
1	I
,	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
g	B
##ly	I
-	I
pro	I
in	O
s	O
##put	O
##um	O
(	O
n	O
=	O
11	O
)	O
,	O
and	O
v	B
##ali	I
##ne	I
,	O
u	B
##ric	I
acid	I
,	O
d	B
-	I
g	I
##ly	I
##cer	I
##ic	I
acid	I
,	O
N	B
-	I
Met	I
##hyl	I
-	I
DL	I
-	I
al	I
##ani	I
##ne	I
in	O
serum	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
l	B
##ino	I
##len	I
##ic	I
acid	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##nor	I
##val	I
##ine	I
2	O
,	O
is	B
##ole	I
##uc	I
##ine	I
in	O
P	O
##BM	O
##Cs	O
samples	O
(	O
n	O
=	O
3	O
)	O
.	O

The	O
measured	O
beta	B
##ine	I
values	O
agreed	O
well	O
with	O
expected	O
concentrations	O
(	O
slope	O
=	O
0	O
.	O
99	O
##8	O
,	O
intercept	O
=	O
0	O
.	O
89	O
##0	O
,	O
r	O
_	O
2	O
=	O
0	O
.	O
99	O
##6	O
)	O
.	O

The	O
tested	O
SF	O
##C	O
columns	O
included	O
both	O
the	O
recently	O
introduced	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##C	O
_	O
2	O
Tor	O
##us	O
columns	O
,	O
designed	O
for	O
improved	O
robust	O
##ness	O
and	O
stability	O
in	O
mixed	O
CO	B
_	I
2	I
-	I
met	I
##han	I
##ol	I
mobile	O
phases	O
,	O
,	O
and	O
the	O
older	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##C	O
_	O
2	O
range	O
.	O

Short	O
‐	O
term	O
stability	O
experiment	O
in	O
treated	O
patients	O
on	O
1000	O
mg	O
once	O
daily	O
a	B
##bir	I
##ater	I
##one	I
ace	I
##tate	I
.	O

After	O
oral	O
van	B
##com	I
##y	I
##cin	I
treatment	O
,	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
HP	O
##HP	O
##A	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
3	O
##HP	O
##A	O
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
)	O
,	O
and	O
3	O
##H	O
##HA	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
decreased	O
marked	O
##ly	O
,	O
which	O
indicated	O
that	O
these	O
compounds	O
may	O
also	O
be	O
from	O
gut	O
C	O
##los	O
##tri	O
##dium	O
species	O
.	O

As	O
expected	O
,	O
the	O
base	O
##line	O
serum	O
try	B
##pt	I
##op	I
##han	I
level	O
was	O
significantly	O
higher	O
in	O
T	O
##2	O
##D	O
,	O
compared	O
to	O
matched	O
N	O
##G	O
##T	O
,	O
with	O
a	O
fold	O
change	O
of	O
3	O
.	O
06	O
and	O
a	O
p	O
value	O
lower	O
than	O
0	O
.	O
01	O
(	O
and	O
)	O
.	O

The	O
identified	O
six	O
-	O
meta	O
##bol	O
##ite	O
combination	O
is	O
al	B
##ani	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
.	O

Then	O
samples	O
were	O
acid	O
##ified	O
using	O
200	O
μ	O
L	O
of	O
form	B
##ic	I
acid	I
,	O
cent	O
##ri	O
##fu	O
##ged	O
again	O
,	O
and	O
the	O
super	O
##nat	O
##ants	O
were	O
loaded	O
on	O
the	O
SP	O
##E	O
Bond	O
El	O
##ut	O
Ce	O
##rt	O
##ify	O
L	O
##RC	O
cartridges	O
which	O
had	O
previously	O
been	O
conditioned	O
.	O

Sol	O
##vent	O
2	O
:	O
A	O
,	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
5	O
m	O
##M	O
met	B
##hyl	I
##amine	I
in	O
H	O
_	O
2	O
O	O
,	O
and	O
B	O
,	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
.	O

The	O
s	O
##phi	O
##ngo	O
##sin	O
##e	O
-	O
derived	O
fragment	O
ions	O
have	O
been	O
commonly	O
used	O
on	O
Q	O
##q	O
##Q	O
instruments	O
for	O
the	O
quantitative	O
analysis	O
of	O
c	B
##era	I
##mi	I
##des	I
by	O
P	O
##IS	O
and	O
MR	O
##M	O
[	O
,	O
]	O
.	O

Among	O
them	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##cho	I
##line	I
(	O
P	O
##t	O
##d	O
##C	O
##ho	O
)	O
and	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
(	O
Le	O
##u	O
/	O
Il	O
##e	O
)	O
were	O
positively	O
and	O
negatively	O
correlated	O
with	O
the	O
N	O
##DI	O
S	O
##ym	O
##pt	O
##om	O
Index	O
(	O
N	O
##DS	O
##I	O
)	O
respectively	O
.	O

The	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
layer	O
is	O
collected	O
and	O
dried	O
under	O
nitrogen	O
.	O

Nico	B
##tina	I
##te	I
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
metabolic	O
pathways	O
were	O
specifically	O
decreased	O
in	O
infants	O
with	O
RS	O
##V	O
AR	O
##I	O
compared	O
to	O
healthy	O
controls	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
were	O
measured	O
by	O
photo	O
##metry	O
(	O
Di	O
##men	O
##sion	O
VI	O
##ST	O
##A	O
,	O
Siemens	O
Healthcare	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
E	O
##sch	O
##born	O
,	O
Germany	O
)	O
.	O

The	O
standard	O
curve	O
for	O
q	O
##uant	O
##ifying	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
was	O
linear	O
from	O
34	O
to	O
83	O
##1	O
nm	O
,	O
and	O
the	O
correlation	O
coefficient	O
was	O
>	O
0	O
.	O
99	O
.	O

Ace	B
##tate	I
was	O
the	O
dominant	O
SC	O
##FA	O
produced	O
after	O
24	O
h	O
f	O
##er	O
##mentation	O
with	O
all	O
bread	O
##s	O
and	O
in	O
both	O
I	O
##BS	O
and	O
healthy	O
donors	O
.	O

Co	O
##rrel	O
##ation	O
analysis	O
revealed	O
a	O
significantly	O
positive	O
association	O
between	O
fast	O
##ing	O
insulin	O
levels	O
and	O
sperm	B
##ine	I
.	O

For	O
liver	O
function	O
test	O
,	O
total	O
protein	O
will	O
be	O
determined	O
using	O
bi	O
##ure	O
##t	O
end	O
##point	O
,	O
album	O
##in	O
will	O
be	O
determined	O
by	O
direct	O
color	O
##ime	O
##tric	O
determination	O
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
will	O
be	O
determined	O
by	O
di	B
##az	I
##onium	I
salt	O
method	O
whereas	O
al	O
##kal	O
##ine	O
p	O
##hos	O
##pha	O
##tase	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
and	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
will	O
be	O
determined	O
by	O
the	O
kinetic	O
method	O
.	O

This	O
compound	O
,	O
which	O
is	O
derived	O
from	O
the	O
cat	O
##ab	O
##olis	O
##m	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
a	O
precursor	O
of	O
cat	B
##ech	I
##ola	I
##mine	I
##s	I
)	O
,	O
is	O
also	O
a	O
common	O
food	O
add	O
##itive	O
.	O

Of	O
the	O
pathways	O
reduced	O
following	O
bypass	O
surgery	O
all	O
8	O
(	O
AD	O
##MA	O
,	O
L	B
-	I
N	I
##MM	I
##A	I
,	O
SD	O
##MA	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
or	O
##ni	O
##thin	O
##e	O
)	O
of	O
the	O
amino	O
acids	O
and	O
met	B
##hyl	I
##ar	I
##gin	I
##ines	I
associated	O
(	O
directly	O
or	O
indirectly	O
)	O
with	O
the	O
NO	O
##S	O
pathway	O
were	O
included	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

It	O
should	O
be	O
pointed	O
out	O
however	O
that	O
the	O
findings	O
from	O
the	O
present	O
study	O
may	O
not	O
be	O
applicable	O
to	O
other	O
s	B
##tat	I
##ins	I
,	O
whose	O
interactions	O
with	O
bi	O
##le	O
acid	O
metabolism	O
and	O
transport	O
may	O
differ	O
from	O
those	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
.	O

As	O
a	O
fact	O
,	O
En	O
##tero	O
##co	O
##cc	O
##us	O
s	B
##p	I
.	O
is	O
found	O
in	O
great	O
abundance	O
in	O
CD	O
patients	O
and	O
could	O
thus	O
contribute	O
to	O
higher	O
x	B
##yl	I
##ose	I
production	O
and	O
urine	O
levels	O
seen	O
in	O
our	O
CD	O
patients	O
.	O

Women	O
with	O
breast	O
cancer	O
who	O
met	O
eligibility	O
criteria	O
were	O
prescribed	O
1	O
mg	O
day	O
_	O
−	O
##1	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
to	O
be	O
taken	O
oral	O
##ly	O
.	O

The	O
comparisons	O
of	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
and	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
distributions	O
for	O
female	O
and	O
male	O
partners	O
by	O
pregnancy	O
status	O
are	O
displayed	O
in	O
Table	O
.	O

In	O
addition	O
,	O
an	O
up	O
##re	O
##gu	O
##lation	O
of	O
the	O
genes	O
LP	O
##CA	O
##T	O
##1	O
and	O
L	O
##CA	O
##T	O
(	O
B	O
)	O
that	O
en	O
##code	O
enzymes	O
involved	O
in	O
the	O
synthesis	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
,	O
respectively	O
,	O
was	O
also	O
observed	O
.	O

Likewise	O
,	O
the	O
most	O
significant	O
pathways	O
(	O
F	O
##DR	O
<	O
1	O
)	O
after	O
PP	O
##CI	O
(	O
24	O
h	O
and	O
48	O
h	O
after	O
re	O
##per	O
##fusion	O
)	O
representing	O
late	O
response	O
to	O
re	O
##per	O
##fusion	O
were	O
found	O
to	O
be	O
associated	O
with	O
the	O
metabolism	O
of	O
following	O
compounds	O
:	O
(	O
1	O
)	O
p	B
##hen	I
##yl	I
al	I
##ani	I
##ne	I
,	O
(	O
2	O
)	O
t	B
##yr	I
##os	I
##ine	I
,	O
(	O
3	O
)	O
l	B
##ino	I
##le	I
##ic	I
acid	I
and	O
(	O
4	O
)	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
(	O
Fi	O
##g	O
.	O
)	O
.	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
metabolism	O
has	O
been	O
associated	O
with	O
abnormal	O
##ity	O
in	O
cerebral	O
white	O
matter	O
,	O
_	O
,	O
and	O
recent	O
studies	O
have	O
provided	O
support	O
for	O
the	O
hypothesis	O
of	O
an	O
abnormal	O
developmental	O
trajectory	O
of	O
white	O
matter	O
in	O
patients	O
with	O
autism	O
.	O
_	O
,	O

However	O
,	O
a	O
recent	O
report	O
on	O
in	O
-	O
v	O
##it	O
##ro	O
culture	O
of	O
H	O
##NS	O
##CC	O
cell	O
lines	O
shows	O
that	O
only	O
glucose	S
(	O
not	O
g	B
##lut	I
##amine	I
)	O
is	O
the	O
dominant	O
energy	O
source	O
required	O
for	O
proliferation	O
and	O
growth	O
,	O
therefore	O
the	O
exact	O
role	O
of	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
is	O
unclear	O
in	O
H	O
##NS	O
##CC	O
.	O

The	O
average	O
results	O
for	O
5	O
normal	O
healthy	O
volunteers	O
were	O
27	O
.	O
7	O
T	O
##TR	O
%	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
,	O
0	O
.	O
4	O
T	O
##TR	O
%	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##ox	I
##yla	I
##te	I
,	O
0	O
.	O
4	O
T	O
##TR	O
%	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
o	I
##xa	I
##late	I
,	O
and	O
10	O
.	O
8	O
T	O
##TR	O
%	O
for	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
.	O

Sixteen	O
300	O
μ	O
##L	O
serum	O
samples	O
were	O
mixed	O
with	O
met	B
##han	I
##ol	I
in	O
1	O
:	O
1	O
,	O
1	O
:	O
2	O
,	O
1	O
:	O
3	O
or	O
1	O
:	O
4	O
ratios	O
(	O
v	O
/	O
v	O
)	O

This	O
further	O
confirms	O
an	O
increase	O
in	O
the	O
extraction	O
of	O
h	O
##ydro	O
##phobic	O
lip	O
##ids	O
when	O
ethanol	B
-	I
met	I
##han	I
##ol	I
is	O
used	O
.	O

Besides	O
measuring	O
the	O
ratio	O
of	O
la	B
##ct	I
##ate	I
to	O
p	B
##yr	I
##u	I
##vate	I
,	O
the	O
change	O
in	O
signal	O
can	O
be	O
measured	O
over	O
time	O
and	O
the	O
data	O
fit	O
to	O
kinetic	O
models	O
.	O

A	O
significant	O
alter	O
##ation	O
in	O
a	O
##romatic	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
,	O
such	O
as	O
nap	B
##ht	I
##hale	I
##ne	I
and	O
1	B
,	I
4	I
-	I
x	I
##yle	I
##ne	I
,	O
in	O
the	O
culture	O
media	O
of	O
cancer	O
cell	O
lines	O
was	O
also	O
observed	O
.	O

Thereafter	O
,	O
100	O
µ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
a	O
96	O
well	O
plates	O
where	O
each	O
sample	O
was	O
spike	O
##d	O
with	O
5	O
µ	O
##L	O
of	O
an	O
internal	O
standard	O
solution	O
containing	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
-	I
D	I
_	I
5	I
(	O
Cambridge	O
Is	O
##oto	O
##pes	O
Laboratory	O
Inc	O
.	O
,	O
And	O
##over	O
,	O
MA	O
,	O
USA	O
)	O
,	O
ca	B
##ffe	I
##ine	I
-	I
D	I
_	I
9	I
(	O
Toronto	O
Research	O
Chemical	O
##s	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
)	O
,	O
le	O
##uki	O
##ne	O
en	O
##ke	O
##pha	O
##lin	O

However	O
,	O
the	O
contribution	O
and	O
regulatory	O
mechanism	O
of	O
the	O
car	B
##ni	I
##tine	I
metabolic	O
pathway	O
to	O
BC	O
##A	O
remains	O
unclear	O
.	O

Future	O
studies	O
should	O
investigate	O
whether	O
plasma	O
g	B
##lut	I
##amine	I
can	O
serve	O
as	O
a	O
bio	O
##mark	O
##er	O
to	O
identify	O
AD	O
patients	O
susceptible	O
to	O
ex	O
##ci	O
##to	O
##to	O
##xi	O
##city	O
.	O

*	O
This	O
amino	B
-	I
acid	I
group	O
consists	O
of	O
as	B
##par	I
##agi	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
se	B
##rine	I
and	O
t	B
##yr	I
##os	I
##ine	I
.	O

The	O
PP	O
##T	O
,	O
which	O
usually	O
utilized	O
organic	O
solvent	O
(	B
met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
etc	O
.	O
)	O
to	O
strip	O
the	O
proteins	O
in	O
the	O
bio	O
##f	O
##lu	O
##id	O
by	O
destroying	O
the	O
structure	O
of	O
them	O
,	O
had	O
the	O
lowest	O
ability	O
to	O
eliminate	O
the	O
co	O
##ex	O
##ist	O
##ing	O
interfering	O
materials	O
.	O

This	O
revealed	O
small	O
changes	O
(	O
effect	O
sizes	O
<	O
1	O
)	O
in	O
cc	O
##RC	O
##C	O
cases	O
(	O
higher	O
levels	O
of	O
trim	B
##eth	I
##yla	I
##mine	I
(	O
T	O
##MA	O
)	O
,	O
ta	B
##uri	I
##ne	I
and	O
un	O
##ass	O
##ign	O
##ed	O
double	O
##ts	O
at	O
δ	O
0	O
.	O
75	O
,	O
0	O
.	O
78	O
and	O
1	O
.	O
25	O
,	O
and	O
lower	O
levels	O
of	O
c	B
##rea	I
##tine	I
and	O
t	B
##rig	I
##one	I
##llin	I
##ami	I
##de	I
)	O
,	O
compared	O
to	O
other	O
types	O
.	O

The	O
fi	O
##lt	O
##rate	O
was	O
des	O
##ic	O
##cated	O
and	O
then	O
dissolved	O
with	O
80	O
µ	O
##L	O
of	O
is	B
##op	I
##rop	I
##ano	I
##l	I
and	O
Mill	O
##i	O
-	O
Q	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
for	O
the	O
L	O
##C	O
-	O
TO	O
##FM	O
##S	O
analysis	O
.	O

These	O
findings	O
demonstrate	O
the	O
potential	O
influence	O
of	O
le	O
##pt	O
##in	O
on	O
try	B
##pt	I
##op	I
##han	I
,	O
k	B
##yn	I
##uren	I
##ine	I
and	O
se	B
##rot	I
##oni	I
##n	I
metabolism	O
,	O
gut	O
micro	O
##bio	O
##me	O
,	O
and	O
im	O
##mu	O
##no	O
##mo	O
##du	O
##lation	O
.	O

U	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
c	B
##rea	I
##tin	I
##ine	I
is	O
constant	O
between	O
different	O
individuals	O
,	O
within	O
an	O
individual	O
over	O
time	O
.	O

Cheng	O
et	O
al	O
.	O
reported	O
that	O
when	O
radio	O
##la	O
##bel	O
##ed	O
ch	B
##olin	I
##e	I
forms	O
were	O
added	O
to	O
infant	O
formula	O
fed	O
to	O
suck	O
##ling	O
rat	O
pu	O
##ps	O
,	O
Cho	O
and	O
PC	O
##ho	O
rapidly	O
appeared	O
in	O
blood	O
and	O
the	O
liver	O
,	O
whereas	O
PC	O
took	O
longer	O
to	O
appear	O
in	O
blood	O
and	O
was	O
meta	O
##bol	O
##ized	O
differently	O
by	O
the	O
liver	O
.	O

In	O
particular	O
,	O
the	O
intermediate	O
free	O
radical	O
in	B
##do	I
##le	I
species	O
formed	O
by	O
h	O
##ydro	O
##xy	O
##l	O
radical	O
attack	O
have	O
been	O
implicated	O
in	O
protein	O
a	O
##gg	O
##regation	O
[	O
;	O
]	O
,	O
and	O
may	O
be	O
involved	O
in	O
cross	O
##link	O
##ing	O
mechanisms	O
similar	O
to	O
those	O
of	O
the	O
p	B
##oly	I
##g	I
##lut	I
##amine	I
##s	I
which	O
are	O
elevated	O
in	O
HD	O
.	O

H	B
##ydro	I
##xy	I
##bu	I
##p	I
##rop	I
##ion	I
was	O
purchased	O
from	O
B	O
##D	O
Gen	O
##test	O
(	O
W	O
##ob	O
##urn	O
,	O
MA	O
)	O
.	O

Level	O
##s	O
of	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
were	O
decreased	O
in	O
MS	O
##A	O
and	O
PS	O
##P	O
.	O

Based	O
on	O
the	O
chemical	O
logic	O
,	O
studies	O
were	O
undertaken	O
to	O
investigate	O
if	O
est	O
##rogen	O
##s	O
could	O
generate	O
q	B
##uin	I
##one	I
met	O
##hi	O
##des	O
in	O
an	O
o	O
##xi	O
##da	O
##tive	O
environment	O
which	O
then	O
could	O
cause	O
DNA	O
damage	O
in	O
humans	O
.	O

Interest	O
##ingly	O
,	O
cross	O
talk	O
between	O
the	O
a	B
##cy	I
##l	I
-	I
ethanol	I
##amine	I
and	O
o	B
##xy	I
##lip	I
##in	I
pathways	O
have	O
also	O
been	O
reported	O
.	O

This	O
may	O
be	O
the	O
possible	O
explanation	O
for	O
decreased	O
format	B
##e	I
levels	O
observed	O
in	O
end	O
##ome	O
##tri	O
##al	O
tissue	O
of	O
women	O
with	O
severe	O
end	O
##ome	O
##tri	O
##osis	O
.	O

Stock	O
solutions	O
were	O
prepared	O
at	O
a	O
concentration	O
of	O
10	O
mg	O
/	O
m	O
##L	O
in	O
D	B
##MS	I
##O	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
##ri	O
##b	O
##rna	O
S	O
##kal	O
##ice	O
,	O
Czech	O
Rep	O
)	O
and	O
kept	O
at	O
4	O
°C	O
.	O

Interest	O
##ingly	O
,	O
sustained	O
ch	B
##olin	I
##e	I
de	O
##p	O
##ri	O
##vation	O
stimulate	O
##s	O
cell	O
survival	O
through	O
nuclear	O
factor	O
-	O
ka	O
##ppa	O
B	O
activation	O
,	O
leading	O
to	O
sustained	O
inflammation	O
and	O
on	O
##co	O
##genesis	O
.	O

X	B
##ant	I
##hine	I
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ctic	I
acid	I
also	O
decreased	O
and	O
increased	O
in	O
LA	O
##L	O
##I	O
and	O
H	O
##A	O
##H	O
##I	O
,	O
respectively	O
.	O

The	O
identified	O
bio	O
##mark	O
##er	O
candidates	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
(	O
P	O
##Es	O
)	O
were	O
further	O
external	O
##ly	O
valid	O
##ated	O
in	O
a	O
co	O
##hor	O
##t	O
including	O
30	O
early	O
-	O
stage	O
N	O
##SC	O
##LC	O
,	O
30	O
L	O
##B	O
##D	O
,	O
and	O
30	O
HC	O
by	O
a	O
targeted	O
lip	O
##ido	O
##mic	O
analysis	O
.	O

All	O
three	O
BC	O
##AA	O
##s	O
and	O
AD	B
##MA	I
were	O
increased	O
in	O
healthy	O
subjects	O
.	O

It	O
is	O
known	O
since	O
the	O
80s	O
that	O
P	O
.	O
be	O
##rg	O
##he	O
##i	O
malaria	O
##l	O
infection	O
results	O
in	O
an	O
increase	O
of	O
the	O
un	O
##sat	O
##uration	O
level	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
in	O
the	O
liver	O
of	O
mice	O
(	O
Des	O
##lau	O
##rier	O
##s	O
et	O
al	O
.	O
)	O
.	O

O	O
##PL	O
##S	O
-	O
D	O
##A	O
score	O
plots	O
based	O
on	O
the	O
data	O
from	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
of	O
the	O
E	O
##SC	O
##C	O
,	O
E	O
##SC	O
##C	O
-	O
M	O
and	O
E	O
##SC	O
##C	O
-	O
P	O
patients	O
and	O
controls	O
.	O

The	O
system	O
was	O
ca	O
##li	O
##bra	O
##ted	O
routinely	O
with	O
L	O
##T	O
##Q	O
F	B
##T	I
ca	O
##li	O
##bra	O
##tion	O
solution	O
prepared	O
according	O
to	O
the	O
instrument	O
instructions	O
.	O

The	O
level	O
of	O
chemical	O
modification	O
of	O
SA	O
by	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
was	O
estimated	O
at	O
~	O
170	O
pm	O
##ol	O

The	O
p	B
##yr	I
##rol	I
##id	I
##ine	I
ring	O
underwent	O
metabolism	O
resulting	O
in	O
an	O
o	O
##x	O
##o	O
and	O
a	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
meta	O
##bol	O
##ite	O
as	O
well	O
as	O
a	O
ring	O
opened	O
h	B
##ydro	I
##xy	I
meta	O
##bol	O
##ite	O
.	O

Rain	O
##ey	O
et	O
al	O
.	O
already	O
suggested	O
an	O
interaction	O
of	O
5	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
-	I
2	I
-	I
fur	I
##an	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
with	O
gal	B
##act	I
##onic	I
acid	I
(	O
Mr	O
##och	O
##eck	O
and	O
Rain	O
##ey	O
)	O
.	O

Un	O
##iva	O
##ria	O
##te	O
analysis	O
has	O
shown	O
statistical	O
##ly	O
significant	O
differences	O
in	O
the	O
concentration	O
of	O
:	O
L	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
(	O
G	O
##lu	O
)	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
;	O
L	B
-	I
g	I
##lut	I
##amine	I
(	O
G	O
##ln	O
)	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
;	O
3	O
-	O
met	O
##hyl	O
-	O
L	O
-	O
his	O
##ti	O
##dine	O
(	O
3	O
##M	O
##H	O
##is	O
)	O
,	O
p	O
=	O
0	O
.	O
02	O
##2	O
and	O
L	B
-	I
met	I
##hi	I
##oni	I
##ne	I
(	O
Met	O
)	O
,	O
p	O
=	O
0	O
.	O
02	O
##4	O
.	O

G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
are	O
important	O
membrane	O
lip	O
##ids	O
and	O
play	O
a	O
vital	O
role	O
in	O
cellular	O
functions	O
,	O
such	O
as	O
signal	O
trans	O
##duction	O
##s	O
,	O
regulations	O
of	O
transport	O
processes	O
and	O
protein	O
functions	O
.	O

N	O
-	O
3	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
,	O
such	O
as	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
22	O
:	O
6	O
)	O
,	O
are	O
precursor	O
##s	O
of	O
molecules	O
implicated	O
in	O
the	O
re	O
##sol	O
##ving	O
phase	O
of	O
inflammation	O
.	O

I	O
##mp	O
##air	O
##ment	O
of	O
mitochondrial	O
fatty	O
acid	O
β	O
-	O
oxidation	O
has	O
been	O
associated	O
with	O
elevated	O
circulating	O
fatty	O
acid	O
derivatives	O
such	O
as	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
reduced	O
k	B
##eton	I
##e	I
bodies	O
in	O
plasma	O
.	O

Four	O
lip	O
##ids	O
were	O
associated	O
with	O
longitudinal	O
changes	O
in	O
body	O
mass	O
index	O
and	O
four	O
were	O
associated	O
with	O
changes	O
in	O
fast	O
##ing	O
blood	O
glucose	S
in	O
the	O
F	O
##HS	O
.	O

The	O
median	O
(	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
)	O
for	O
o	B
##est	I
##rad	I
##iol	I
in	O
women	O
sampled	O
in	O
the	O
f	O
##oll	O
##icular	O
phase	O
(	O
n	O
=	O
19	O
)	O
at	O
T	O
##P	O
##1	O
was	O
48	O
##2	O
(	O
187	O
–	O
79	O
##8	O
)	O
p	O
##M	O
##ol	O
/	O
L	O
and	O
at	O
T	O
##P	O
##2	O
it	O
was	O
63	O
##7	O
(	O
47	O
##4	O
–	O
118	O
##1	O
)	O
p	O
##M	O
##ol	O
/	O
L	O
,	O
and	O
for	O
women	O
sampled	O
in	O
the	O
l	O
##ute	O
##al	O
phase	O
(	O
n	O
=	O
4	O
)	O
at	O
T	O
##P	O
##1	O
it	O
was	O
310	O
(	O
254	O
–	O
610	O
)	O
p	O
##M	O
##ol	O
/	O
L	O
and	O
at	O
T	O
##P	O
##2	O
it	O
was	O
312	O
(	O
151	O
–	O
49	O
##1	O
)	O

Likewise	O
,	O
cancer	O
-	O
specific	O
elevations	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
may	O
represent	O
an	O
underlying	O
enhanced	O
capacity	O
for	O
DNA	O
synthesis	O
in	O
association	O
with	O
tumor	O
growth	O
.	O

The	O
induced	O
culture	O
was	O
p	O
##elle	O
##ted	O
,	O
re	O
##sus	O
##pen	O
##ded	O
in	O
buffer	O
(	O
20	O
m	O
##M	O
im	B
##ida	I
##zo	I
##le	I
in	O
1	O
##×	O
PBS	O
)	O
and	O
then	O
mechanical	O
##ly	O
l	O
##ys	O
##ed	O
.	O

P	O
##up	O
##illo	O
##metry	O
confirmed	O
the	O
long	O
duration	S
of	O
action	O
of	O
a	O
single	O
dose	O
of	O
re	O
##ct	O
##al	O
met	B
##had	I
##one	I
.	O

b	O
##ol	O
##us	O
of	O
B	O
##EN	O
(	O
2	O
mg	O
/	O
m	O
##L	O
in	O
50	O
%	O
h	B
##ydro	I
##xy	I
##l	I
-	I
prop	I
##yl	I
-	I
β	I
-	I
c	I
##y	I
##c	I
##lo	I
##de	I
##x	I
##tri	I
##n	I
in	O
sa	B
##line	I
)	O
or	O
50	O
%	O
h	B
##ydro	I
##xy	I
##l	I
-	I
prop	I
##yl	I
-	I
β	I
-	I
c	I
##y	I
##c	I
##lo	I
##de	I
##x	I
##tri	I
##n	I
vehicle	O
at	O
0	O
.	O
01	O
m	O
##L	O
/	O
g	O
body	O
weight	O
.	O

Plate	O
##lets	O
,	O
common	O
sources	O
of	O
MV	O
##s	O
,	O
have	O
been	O
shown	O
to	O
external	O
##ize	O
PS	B
(	I
18	I
:	I
0	I
_	I
18	I
:	I
1	I
)	I
and	O
PS	B
(	I
18	I
:	I
0	I
_	I
20	I
:	I
4	I
)	I
from	O
the	O
inner	O
to	O
outer	O
membrane	O
when	O
activated	S
by	O
th	O
##rom	O
##bin	O
.	O

The	O
meta	O
##bol	O
##ites	O
are	O
numbered	O
accordingly	O
:	O
1	O
:	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##10	O
)	O
;	O
2	O
:	O
te	B
##tra	I
##de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
C	O
##14	O
:	O
1	O
)	O
;	O
3	O
:	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##8	O
)	O
;	O
4	O
:	O
non	B
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##9	O
)	O
;	O
5	O
:	O
a	B
##rg	I
##ini	I
##ne	I
;	O
6	O
:	O
k	B
##yn	I
##uren	I
##ine	I
;	O
7	O
:	O
l	O
##ys	O
##op	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
a	O
##cy	O
##l	O
(	O
l	O
##ys	O
##o	O
##PC	O
a	O
)	O
C	O
##16	O
:	O
0	O
;	O
8	O
:	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	O
##18	O
:	O
0	O
;	O
9	O
:	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	O
##20	O
:	O
4	O
;	O
10	O
:	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
di	O
##acy	O
##l	O
(	O
PC	O
a	O
##a	O
)	O

Based	O
on	O
previous	O
identification	O
of	O
u	O
##rina	O
##ry	O
sa	B
##rc	I
##os	I
##ine	I
as	O
a	O
meta	O
##static	O
marker	O
,	O
we	O
tested	O
whether	O
met	B
##hi	I
##oni	I
##ne	I
meta	O
##bol	O
##ites	O
in	O
urine	O
and	O
serum	O
could	O
serve	O
as	O
pre	O
-	O
surgical	O
markers	O
for	O
aggressive	O
disease	O
.	O

The	O
two	O
other	O
models	O
,	O
FA	B
vs	I
HC	O
and	O
T	O
##C	O
vs	O
HC	O
,	O
were	O
on	O
the	O
same	O
level	O
of	O
discrimination	O
(	O
AU	O
##C	O
test	O
set	O
equal	O
to	O
0	O
.	O
71	O
and	O
0	O
.	O
73	O
)	O
but	O
did	O
not	O
pass	O
the	O
test	O
of	O
model	O
significance	O
.	O

b	O
)	O
and	O
9	O
.	O
1	O
min	O
for	O
the	O
su	B
##lf	I
##ati	I
##de	I
(	O
Fi	O
##g	O
.	O

In	O
am	O
##nio	O
##tic	O
fluid	O
,	O
T	O
##2	O
to	O
T	O
##3	O
transition	O
was	O
associated	O
with	O
decreasing	O
levels	O
of	O
glucose	S
,	O
car	B
##ni	I
##tine	I
,	O
amino	O
acids	O
(	B
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
)	O
and	O
increasing	O
levels	O
of	O
c	B
##rea	I
##tin	I
##ine	I
,	O
su	B
##cci	I
##nate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
ch	B
##olin	I
##e	I
,	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
and	O
u	B
##ro	I
##can	I
##ate	I
.	O

MS	O
_	O
2	O
results	O
give	O
3	O
fragments	O
that	O
would	O
be	O
suspected	O
with	O
the	O
small	O
p	B
##hos	I
##ph	I
##ope	I
##pt	I
##ide	I
P	O
##60	O
##c	O
-	O
s	O
##rc	O
,	O
m	O
/	O
z	O
values	O
of	O
27	O
##7	O
.	O
2	O
,	O
33	O
##4	O
.	O
2	O
,	O
57	O
##7	O
.	O
2	O
.	O

While	O
none	O
of	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
specifically	O
associated	O
with	O
base	O
##line	O
HIV	O
viral	O
load	O
levels	O
or	O
change	O
in	O
viral	O
load	O
with	O
treatment	O
it	O
is	O
plausible	O
that	O
the	O
effect	O
seen	O
in	O
the	O
at	O
##az	O
##ana	O
##vir	O
/	O
r	O
and	O
z	O
##ido	O
##vu	O
##dine	O
/	O
a	O
##ba	O
##ca	O
##vir	O
arms	O
may	O
be	O
the	O
consequence	O
of	O
HIV	O
suppression	O
rather	O
than	O
a	O
direct	O
effect	O
of	O
the	O
agents	O
themselves	O
on	O
lip	O
##id	O
metabolism	O
(	O
i	O
.	O
e	O
.	O
a	O
“	O
return	O
to	O
health	O
”	O
phenomena	O
)	O
.	O

The	O
residue	O
was	O
dissolved	O
in	O
met	B
##han	I
##ol	I
and	O
fraction	O
##ated	O
for	O
substances	O
of	O
different	O
polar	O
##ities	O
with	O
Sep	O
##P	O
##ak	O
C	O
_	O
18	O
column	O
ch	O
##roma	O
##tography	O
met	B
##han	I
##ol	I
as	O
an	O
el	O
##uen	O
##t	O
.	O

However	O
,	O
this	O
study	O
found	O
no	O
association	O
between	O
AG	O
##Es	O
when	O
anal	O
##ys	O
##ed	O
separately	O
or	O
combined	O
and	O
markers	O
of	O
glucose	S
metabolism	O
.	O

However	O
,	O
due	O
to	O
its	O
effects	O
on	O
downstream	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
and	O
mineral	O
##oc	O
##ort	O
##ico	O
##id	O
metabolism	O
,	O
these	O
patients	O
are	O
also	O
administered	O
pre	B
##dn	I
##ison	I
##e	I
.	O

Among	O
them	O
,	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##ate	I
and	O
c	B
##rea	I
##tin	I
##ine	I
have	O
been	O
reported	O
to	O
be	O
critical	O
for	O
cancer	O
metabolism	O
.	O

Data	O
processing	O
method	O
files	O
are	O
provided	O
in	O
the	O
data	O
record	O
(	B
ad	B
##ni	I
##1	I
-	I
q	I
##ual	I
-	I
method	I
.	I
z	I
##ip	I
)	O
.	O

A	O
##bs	O
##ol	O
##ute	O
and	O
Re	O
##lative	O
Con	O
##cent	O
##rations	O
of	O
U	O
##rina	O
##ry	O
E	O
##stro	O
##gens	O
and	O
E	B
##stro	I
##gen	I
Met	O
##ab	O
##oli	O
##tes	O
(	O
E	O
##M	O
)	O
in	O
Pre	O
##men	O
##op	O
##aus	O
##al	O
-	O
l	O
##ute	O
##al	O
(	O
n	O
=	O
26	O
##3	O
)	O
and	O
Post	O
##men	O
##op	O
##aus	O
##al	O
(	O
n	O
=	O
167	O
)	O
Asian	O
-	O
American	O
women	O
.	O

In	O
each	O
of	O
these	O
studies	O
,	O
investigators	O
observed	O
that	O
breast	O
cancer	O
risk	O
was	O
increased	O
with	O
circulating	O
concentrations	O
of	O
the	O
parent	O
est	O
##rogen	O
##s	O
and	O
was	O
reduced	O
with	O
increasing	O
ratios	O
of	O
2	O
-	O
and	O
4	O
-	O
pathway	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
to	O
parent	O
est	O
##rogen	O
##s	O
.	O

Go	O
to	O
:	O
Background	O
:	O
G	O
##ut	O
micro	O
##bio	O
##ta	O
-	O
related	O
meta	O
##bol	O
##ites	O
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
,	O
ch	B
##olin	I
##e	I
,	O
and	O
beta	B
##ine	I
,	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
card	O
##iovascular	O
disease	O
(	O
C	O
##VD	O
)	O
risk	O
.	O

In	O
this	O
regard	O
,	O
it	O
should	O
be	O
noted	O
that	O
of	O
the	O
twelve	O
meta	O
##bol	O
##ites	O
used	O
in	O
the	O
L	O
##DA	O
only	O
3	B
-	I
de	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
##3	O
significantly	O
correlated	O
with	O
age	O
of	O
the	O
patients	O
;	O
a	O
finding	O
that	O
was	O
confirmed	O
by	O
calculation	O
of	O
the	O
Part	O
##ial	O
Co	O
##rrel	O
##ation	O
Co	O
##ef	O
##ficient	O
(	O
PC	O
##C	O
)	O
that	O
measures	O
the	O
association	O
between	O
the	O
three	O
variables	O
.	O

The	O
levels	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
largely	O
un	O
##altered	O
in	O
b	O
##v	O
##FT	O
##D	O
and	O
AD	O
co	O
##hor	O
##ts	O
.	O

2	B
,	I
3	I
,	I
4	I
,	I
5	I
,	I
6	I
-	I
D	I
_	I
5	I
-	I
ben	I
##zoic	I
acid	I
(	O
internal	O
standard	O
,	O
≥	O
99	O
atom	O
%	O
D	O
,	O
≥	O
99	O
%	O
)	O
,	O
ben	B
##zoic	I
acid	I
(	O
BA	O
,	O
≥	O
99	O
.	O
5	O
%	O
)	O
,	O
p	B
##hen	I
##yl	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
(	O
Ph	O
##PA	O
,	O
≥	O
99	O
%	O
)	O
,	O
p	B
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
(	O
Ph	O
##LA	O
,	O
≥	O
98	O
%	O
)	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
(	O
p	O
-	O
HP	O
##h	O
##AA	O
,	O
≥	O
98	O
%	O
)	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lla	I
##ctic	I
acid	I
(	O
p	O
-	O
HP	O
##h	O
##LA	O
,	O
≥	O
97	O
%	O
)	O
,	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
(	O
internal	O
standard	O
,	O
≥	O
98	O
%	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
≥	O
99	O
%	O
)	O
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
(	O
≥	O
98	O
%	O
)	O
,	O
f	B
##uma	I
##ric	I
acid	I
(	O
≥	O
99	O
%	O
)	O
,	O
it	B
##acon	I
##ic	I
acid	I
(	O
≥	O
99	O
%	O
)	O
,	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
contains	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
,	O
99	O
%	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
)	O
,	O
he	B
##xa	I
##ne	I
(	O
≥	O
97	O

The	O
inclusion	O
of	O
the	O
classic	O
Ko	O
##vat	O
##s	O
R	B
##I	I
parameter	O
ensures	O
that	O
this	O
newly	O
compiled	O
library	O
is	O
more	O
reliable	O
for	O
un	O
##am	O
##bi	O
##guous	O
meta	O
##bol	O
##ite	O
identification	O
than	O
previous	O
libraries	O
with	O
only	O
reference	O
mass	O
spectral	O
or	O
with	O
both	O
mass	O
spectral	O
and	O
retention	O
time	O
.	O

(	O
C	O
)	O
Co	O
##rrel	O
##ations	O
involving	O
the	O
c	B
##rea	I
##tine	I
pool	O
.	O

In	O
both	O
animals	O
and	O
humans	O
,	O
harmful	O
effects	O
of	O
T	B
##MA	I
##O	I
have	O
been	O
related	O
to	O
card	O
##iovascular	O
diseases	O
(	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
[	O
,	O
]	O
,	O
th	O
##rom	O
##bos	O
##is	O
,	O
h	O
##yper	O
##tens	O
##ion	O
)	O
,	O
chronic	O
kidney	O
disease	O
,	O
and	O
N	O
##AF	O
##LD	O
.	O

The	O
H	O
##FS	O
group	O
experienced	O
general	O
side	O
effects	O
,	O
including	O
post	O
##oper	O
##ative	O
pan	O
##cre	O
##atic	O
fist	O
##ula	O
(	O
P	O
##OP	O
##F	O
)	O
(	O
2	O
)	O
,	O
bow	O
##el	O
il	O
##eus	O
(	O
1	O
)	O
,	O
anxiety	O
and	O
pain	O
(	O
1	O
)	O
,	O
bi	B
##li	I
##ru	I
##bin	I
elevation	O
(	O
1	O
)	O
,	O
pan	O
##cre	O
##ati	O
##tis	O
(	O
1	O
)	O
,	O
and	O
generalized	O
ed	O
##ema	O
(	O
1	O
)	O
.	O

(	O
)	O
In	O
studies	O
examining	O
other	O
markers	O
of	O
liver	O
injury	O
,	O
positive	O
associations	O
were	O
reported	O
between	O
P	O
##FA	O
##S	O
(	O
including	O
P	O
##F	O
##OA	O
and	O
P	O
##F	O
##H	O
##x	O
##S	O
)	O
and	O
c	B
##yt	I
##oker	I
##ati	I
##n	I
18	O
,	O
a	O
marker	O
for	O
liver	O
a	O
##pop	O
##tosis	O
,	O
but	O
inverse	O
relationships	O
were	O
reported	O
between	O
P	O
##FA	O
##S	O
and	O
serum	O
pro	O
-	O
inflammatory	O
c	O
##yt	O
##oki	O
##nes	O
in	O
adults	O
.	O

These	O
methods	O
q	O
##uant	O
##ify	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
[	O
sum	O
##med	O
to	O
evaluate	O
total	O
25	O
(	O
OH	O
)	O
D	O
]	O
,	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
2	O
and	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
[	O
sum	O
##med	O
to	O
evaluate	O
total	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
]	O
,	O
and	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
[	O
referred	O
to	O
throughout	O
as	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
]	O
(	O
–	O
)	O
.	O

In	O
##tra	O
##ven	O
##ous	O
insulin	O
(	B
Hu	B
##mu	I
##lin	I
;	O
Lilly	O
,	O
Indianapolis	O
,	O
IN	O
)	O
was	O
in	O
##fused	O
at	O
a	O
rate	O
of	O
80	O
m	O
##U	O
/	O
m	O
_	O
2	O
·	O
min	O
in	O
o	O
##bes	O
##e	O
individuals	O
to	O
suppress	O
he	O
##pa	O
##tic	O
glucose	S
production	O
,	O
and	O
40	O
m	O
##U	O
/	O
m	O
_	O
2	O
·	O
min	O
in	O
NW	O
participants	O
,	O
and	O
plasma	O
glucose	S
was	O
clamped	O
at	O
100	O
mg	O
/	O
d	O
##l	O
(	O
5	O
.	O
5	O
mm	O
##ol	O
/	O
liter	O
)	O
with	O
a	O
variable	O
-	O
rate	O
in	O
##fusion	O
of	O
20	O
%	O
de	B
##x	I
##tro	I
##se	I
based	O
on	O
art	O
##erial	O
##ized	O
plasma	O
glucose	S
determination	O
##s	O
every	O
5	O
min	O
.	O

The	O
remaining	O
three	O
add	O
##itive	O
##s	O
were	O
al	B
##ky	I
##lam	I
##ines	I
,	O
and	O
their	O
use	O
was	O
consequently	O
restricted	O
to	O
SF	O
##C	O
-	O
UV	O
–	O
v	O
##is	O
only	O
.	O

The	O
meta	O
##bol	O
##ite	O
with	O
the	O
strongest	O
positive	O
association	O
with	O
T	O
##B	O
was	O
3	B
-	I
met	I
##ho	I
##xy	I
##ty	I
##ros	I
##ine	I
,	O
a	O
meta	O
##bol	O
##ite	O
of	O
le	B
##vo	I
##do	I
##pa	I
which	O
is	O
mostly	O
associated	O
with	O
a	O
##romatic	O
L	O
-	O
amino	O
acid	O
de	O
##car	O
##box	O
##yla	O
##se	O
(	O
AA	O
##DC	O
)	O
deficiency	O
.	O

P	O
##LS	O
-	O
D	O
##A	O
models	O
were	O
used	O
explore	O
the	O
metabolic	O
discrimination	O
between	O
norm	B
##og	I
##ly	I
##ca	I
##em	I
##ic	I
controls	O
and	O
the	O
various	O
di	O
##abe	O
##tic	O
sub	O
##type	O
##s	O
.	O

The	O
significant	O
changes	O
in	O
serum	O
pre	B
##gna	I
##net	I
##rio	I
##l	I
between	O
children	O
with	O
autism	O
and	O
controls	O
indicated	O
per	O
##tur	O
##bation	O
##s	O
in	O
est	B
##rogen	I
metabolism	O
in	O
children	O
with	O
autism	O
.	O

The	O
flow	O
rate	O
for	O
m	B
##or	I
##phine	I
and	O
its	O
meta	O
##bol	O
##ites	O
was	O
0	O
.	O
2	O
m	O
##L	O
/	O
min	O
.	O

Then	O
,	O
an	O
increase	O
of	O
al	B
##ani	I
##ne	I
(	O
Al	O
##a	O
)	O
(	O
1	O
.	O
5	O
pp	O
##m	O
)	O
is	O
observed	O
close	O
to	O
the	O
3	O
o	O
’	O
clock	O
position	O
.	O

It	O
seems	O
that	O
the	O
reduction	O
in	O
ATP	S
production	O
due	O
to	O
the	O
in	O
##hibition	O
of	O
c	B
##it	I
##rate	I
cycle	O
induced	O
by	O
the	O
h	O
##y	O
##po	O
##bari	O
##c	O
h	O
##y	O
##pox	O
##ia	O
of	O
high	O
altitude	O
could	O
lead	O
to	O
the	O
u	O
##til	O
##ization	O
of	O
branched	O
-	O
chain	O
amino	O
acids	O
as	O
energy	O
compensation	O
.	O

Each	O
white	O
circle	O
represents	O
a	O
known	O
lo	O
##cus	O
for	O
g	B
##ly	I
##cine	I
(	O
a	O
)	O
or	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
b	O
)	O
.	O

(	O
B	O
)	O
Sc	O
##hem	O
##atic	O
illustration	O
of	O
oxidation	O
of	O
l	O
##ys	O
##yl	O
residues	O
to	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	I
under	O
o	O
##xi	O
##dized	O
conditions	O
.	O

The	O
X	O
-	O
axis	O
shows	O
the	O
groups	O
and	O
the	O
Y	O
-	O
axis	O
shows	O
the	O
relative	O
normal	O
##ized	O
intensity	O
for	O
α	B
-	I
H	I
##B	I
median	O
scaled	O
to	O
1	O
.	O

Within	O
the	O
group	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
Yang	O
et	O
al	O
.	O
showed	O
decreasing	O
concentrations	O
of	O
[UNK]	O
,	O
[UNK]	O
and	O
[UNK]	O
and	O
stable	O
concentrations	O
of	O
car	B
##ni	I
##tine	I
and	O
eight	O
other	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
C	O
##2	O
,	O
C	O
##3	O
,	O
C	O
##4	O
,	O
C	O
##5	O
,	O
C	O
##6	O
,	O
C	O
##14	O
,	O
C	O
##16	O
,	O
[UNK]	O
)	O
after	O
24	O
h	O
at	O
37	O
##°	O
##C	O
.	O

Me	O
##chan	O
##isms	O
of	O
action	O
are	O
not	O
yet	O
established	O
but	O
is	O
noteworthy	O
to	O
remember	O
that	O
met	B
##form	I
##in	I
can	O
suppress	O
plasma	O
MI	O
##F	O
concentrations	O
in	O
o	O
##bes	O
##e	O
patients	O
.	O

The	O
score	O
plot	O
of	O
the	O
two	O
-	O
component	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
for	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
of	O
N	O
##MR	O
data	O
;	O
to	O
[	O
1	O
]	O
represents	O
within	O
class	O
variation	O
in	O
the	O
first	O
or	O
##th	O
##ogo	O
##nal	O
component	O
,	O
whereas	O
t	O
[	O
1	O
]	O
represents	O
between	O
class	O
variation	O
in	O
the	O
first	O
predict	O
##ive	O
component	O
.	O

Therefore	O
,	O
glucose	S
can	O
be	O
produced	O
through	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
a	O
last	O
resource	O
alternative	O
to	O
obtain	O
energy	O
.	O

The	O
association	O
between	O
t	B
##yr	I
##os	I
##ine	I
and	O
re	O
##nal	O
imp	O
##air	O
##ment	O
was	O
further	O
investigated	O
by	O
assessing	O
the	O
H	O
##R	O
##s	O
across	O
te	O
##rt	O
##iles	O
of	O
e	O
##G	O
##F	O
##R	O
and	O
AC	O
##R	O
.	O

Li	O
##pid	O
per	O
##ox	O
##ida	O
##tion	O
is	O
a	O
de	O
##gene	O
##rative	O
process	O
affecting	O
the	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
in	O
the	O
cell	O
membrane	O
that	O
leads	O
to	O
the	O
formation	O
of	O
lip	O
##id	O
h	B
##ydro	I
##per	I
##oxide	I
##s	I
.	O

Number	O
of	O
missing	O
values	O
per	O
variable	O
in	O
the	O
NE	O
##O	O
study	O
:	O
ethnicity	O
,	O
4	O
;	O
education	O
,	O
26	O
;	O
h	O
##yper	O
##tens	O
##ion	O
,	O
6	O
;	O
diabetes	O
me	O
##lli	O
##tus	O
,	O
7	O
;	O
metabolic	O
syndrome	O
,	O
7	O
;	O
smoking	O
,	O
3	O
;	O
physical	O
activity	O
,	O
11	O
;	O
di	O
##ast	O
##olic	O
BP	O
,	O
1	O
;	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
6	O
;	O
HD	O
##L	O
‐	O
C	O
,	O
6	O
;	O
and	O
fast	O
##ing	O
glucose	S
,	O
9	O
(	O
no	O
missing	O
values	O
for	O
other	O
variables	O
)	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
meta	O
##bol	O
##ites	O
from	O
met	B
##han	I
##ol	I
precipitation	O
(	O
Me	O
##OH	O
)	O
and	O
M	B
##T	I
##BE	I
extraction	O
(	O
M	O
##T	O
##BE	O
)	O
on	O
R	O
##PC	O
and	O
H	O
##IL	O
##IC	O
column	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
##ization	O
mode	O
.	O

This	O
second	O
reaction	O
afford	O
##s	O
the	O
q	O
##uant	O
##ification	O
of	O
the	O
su	O
##lf	O
##ated	O
and	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
k	B
##eto	I
-	I
and	I
##rogen	I
##s	I
.	O

Con	O
##cent	O
##rations	O
for	O
g	B
##ly	I
##cine	I
and	O
total	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
are	O
in	O
micro	O
##mo	O
##lars	O
and	O
for	O
SA	O
##H	O
and	O
SA	O
##M	O
in	O
na	O
##no	O
##mo	O
##lars	O
.	O

The	O
base	O
##line	O
was	O
corrected	O
and	O
referenced	O
to	O
the	O
met	O
##hyl	O
peak	O
signal	O
of	O
la	B
##ct	I
##ate	I
at	O
chemical	O
shift	O
(	O
1	O
.	O
33	O
pp	O
##m	O
)	O
.	O

To	O
each	O
serum	O
sample	O
750	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
:	O
water	O
(	O
4	O
:	O
1	O
)	O
containing	O
20	O
μ	O
##l	O
spike	O
##d	O
internal	O
standard	O
(	O
IS	O
##T	O
##D	O
)	O
was	O
added	O
.	O

Further	O
,	O
a	O
recent	O
study	O
showed	O
that	O
AD	B
##MA	I
levels	O
were	O
inverse	O
##ly	O
correlated	O
with	O
flow	O
-	O
mediated	O
di	O
##lation	O
in	O
patients	O
with	O
RA	O
.	O

As	B
##par	I
##tam	I
##e	I
and	O
control	O
bars	O
affected	O
G	O
##LP	O
-	O
1	O
,	O
G	O
##IP	O
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
levels	O
equally	O
in	O
both	O
as	B
##par	I
##tam	I
##e	I
sensitive	O
and	O
non	O
-	O
sensitive	O
subjects	O
.	O

R	B
##ib	I
##ona	I
##te	I
has	O
previously	O
been	O
observed	O
in	O
human	O
plasma	O
and	O
was	O
recently	O
associated	O
with	O
risk	O
for	O
high	O
-	O
grade	O
g	O
##lio	O
##ma	O
,	O
but	O
has	O
to	O
our	O
knowledge	O
not	O
previously	O
been	O
shown	O
to	O
be	O
synthesized	O
by	O
human	O
cells	O
,	O
and	O
its	O
function	O
in	O
humans	O
is	O
unknown	O
.	O

T	B
##G	I
was	O
negatively	O
correlated	O
with	O
Ch	O
##E	O
(	O
r	O
=	O
−	O
##0	O
.	O
405	O
,	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
and	O
Z	O
##y	O
##E	O
(	O
r	O
=	O
−	O
##0	O
.	O
501	O
,	O
p	O
=	O
0	O
.	O
000	O
##2	O
)	O
.	O

In	O
addition	O
to	O
su	B
##cci	I
##ny	I
##lace	I
##tone	I
,	O
levels	O
of	O
t	B
##yr	I
##os	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
also	O
have	O
been	O
reported	O
to	O
increase	O
in	O
genetic	O
deficiency	O
of	O
FA	O
##H	O
-	O
induced	O
type	O
1	O
t	O
##yr	O
##os	O
##ine	O
##mia	O
.	O

The	O
retention	O
time	O
of	O
the	O
signal	O
for	O
m	O
/	O
z	O
570	O
.	O
2	O
→	O
m	O
/	O
z	O
45	O
##4	O
.	O
148	O
##7	O
–	O
45	O
##4	O
.	O
153	O
##3	O
(	O
19	O
.	O
12	O
min	O
)	O
,	O
corresponding	O
to	O
loss	O
of	O
de	B
##ox	I
##yr	I
##ib	I
##ose	I
(	O
with	O
transfer	O
of	O
H	O
to	O
d	O
##G	O
-	O
containing	O
fragment	O
ion	O
)	O
from	O
the	O
pro	O
##ton	O
##ated	O
molecular	O
ion	O
matches	O
that	O
of	O
the	O
internal	O
standard	O
,	O
m	O
/	O
z	O
580	O
.	O
2	O
→	O
m	O
/	O
z	O
45	O
##9	O
.	O
165	O
##5	O
–	O
45	O
##9	O
.	O
170	O
##1	O
(	O
19	O
.	O
12	O
min	O
)	O
and	O
the	O
peaks	O
have	O
similar	O
shapes	O
although	O
there	O
appears	O
to	O
be	O
additional	O
signal	O
in	O
the	O
anal	O
##yte	O
channel	O
,	O
possibly	O
due	O
to	O
other	O
PA	O
##H	O
add	O
##uc	O
##ts	O
such	O
as	O
those	O
derived	O
from	O
ben	B
##zo	I
##f	I
##lu	I
##oran	I
##the	I
##nes	I
.	O

U	B
##ric	I
acid	I
(	O
Panel	O
A	O
)	O
is	O
up	O
##re	O
##gu	O
##lated	O
in	O
pneumonia	O
plasma	O
levels	O
,	O
although	O
not	O
statistical	O
##ly	O
significant	O
(	O
p	O
=	O
0	O
.	O
119	O
)	O
.	O

Co	O
##rrel	O
##ation	O
matrix	O
in	O
the	O
total	O
group	O
of	O
participants	O
,	O
NW	O
,	O
o	O
##bes	O
##e	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
,	O
and	O
o	O
##bes	O
##e	O
d	B
##ys	I
##gly	I
##ce	I
##mic	I
youth	O
Co	O
##rrel	O
##ation	O
coefficients	O
are	O
presented	O
.	O

Here	O
,	O
we	O
observed	O
a	O
number	O
of	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
metabolic	O
pathways	O
,	O
such	O
as	O
metabolism	O
of	O
x	O
##eno	O
##biotics	O
by	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
,	O
amino	S
sugar	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
metabolism	O
.	O

Thus	O
,	O
the	O
concentrations	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##lut	I
##amine	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
ace	B
##tate	I
,	O
and	O
ace	B
##to	I
##ace	I
##tate	I
were	O
disqualified	O
.	O

Several	O
other	O
classes	O
of	O
molecules	O
including	O
vitamin	B
K	I
and	O
re	B
##tino	I
##l	I
,	O
and	O
bi	O
##le	O
acids	O
such	O
as	O
ch	B
##olic	I
acid	I
and	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
-	I
ch	I
##ole	I
##sten	I
##oi	I
##c	I
acid	I
also	O
did	O
not	O
show	O
comparable	O
fragment	O
##ation	O
patterns	O
.	O

The	O
Daily	O
Pre	O
##ci	O
##pit	O
##ation	O
Sol	O
##ution	O
(	O
D	O
##PS	O
)	O
containing	O
Internal	O
Standards	O
was	O
prepared	O
by	O
di	O
##lut	O
##ing	O
1	O
:	O
100	O
the	O
IS	O
mix	O
with	O
AC	O
##N	O
,	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##28	I
:	I
0	I
;	O
67	O
.	O

Since	O
cells	O
in	O
v	O
##ivo	O
are	O
exposed	O
to	O
a	O
suite	O
of	O
fatty	O
acids	O
,	O
o	B
##xy	I
##lip	I
##ins	I
,	O
and	O
other	O
meta	O
##bol	O
##ites	O
present	O
in	O
lip	O
##op	O
##rote	O
##ins	O
which	O
could	O
have	O
opposing	O
effects	O
on	O
inflammation	O
,	O
character	O
##izing	O
the	O
integrated	O
response	O
to	O
the	O
native	O
o	B
##xy	I
##lip	I
##in	I
profile	O
and	O
evaluating	O
co	O
##rrel	O
##ative	O
trends	O
with	O
inflammatory	O
response	O
ex	O
-	O
v	O
##ivo	O
provides	O
physiological	O
relevance	O
.	O

For	O
instance	O
,	O
op	O
##ti	O
##mized	O
Hybrid	O
##SP	O
##E	O
[UNK]	O
successfully	O
removed	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
order	O
to	O
lower	O
matrix	O
effects	O
while	O
maintaining	O
acceptable	O
recover	O
##ies	O
and	O
repeat	O
##ability	O
.	O

Representative	O
product	O
ion	O
spectrum	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
proposed	O
structures	O
of	O
main	O
product	O
ions	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
,	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
,	O
[	B
_	I
2	I
H	I
_	I
4	I
]	I
Ce	I
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
[	B
_	I
2	I
H	I
_	I
4	I
]	I
Ce	I
##r	I
(	I
24	I
:	I
0	I
)	I

Two	O
sample	O
injection	O
##s	O
(	O
2	O
μ	O
##L	O
and	O
10	O
μ	O
##L	O
)	O
were	O
used	O
for	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
in	O
positive	O
and	O
negative	O
modes	O
,	O
respectively	O
.	O
_	O
13	O
C	B
-	I
la	I
##ct	I
##ate	I
and	O
_	O
13	O
C	B
-	I
t	I
##yr	I
##os	I
##ine	I
were	O
added	O
to	O
each	O
serum	O
sample	O
,	O
after	O
de	O
##p	O
##rote	O
##ini	O
##zation	O
,	O
to	O
monitor	O
the	O
system	O
performance	O
.	O

A	O
contained	O
0	O
.	O
1	O
M	O
ace	B
##tic	I
acid	I
in	O
water	O
and	O
solvent	O
B	O
contained	O
0	O
.	O
1	O
M	O
ace	B
##tic	I
acid	I
in	O
100	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
at	O
a	O
flow	O
rate	O
of	O
300	O
n	O
##l	O
/	O
min	O
.	O

Performance	O
parameters	O
of	O
the	O
I	O
##EC	O
-	O
MS	O
/	O
MS	O
method	O
for	O
determination	O
of	O
twelve	O
th	B
##io	I
##pur	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
in	O
spike	O
##d	O
RB	O
##C	O
l	O
##ys	O
##ate	O
matrix	O
_	O
a	O
.	O
_	O
a	O

c	O
Ad	O
##ju	O
##sted	O
for	O
base	O
##line	O
fast	O
##ing	O
glucose	S
(	O
mg	O
/	O
d	O
##l	O
)	O
(	O
centered	O
on	O
the	O
sample	O
mean	O
and	O
adding	O
q	O
##uad	O
##ratic	O
term	O
)	O
,	O
age	O
(	O
years	O
)	O
,	O
sex	O
(	O
male	O
,	O
female	O
)	O
,	O
intervention	O
group	O
(	O
Me	O
##d	O
##D	O
##iet	O
+	O
E	O
##VO	O
##O	O
,	O
Me	O
##d	O
##D	O
##iet	O
+	O
nuts	O
)	O
,	O
body	O
mass	O
index	O
(	O
kg	O
/	O
m	O
_	O
2	O
)	O
,	O
smoking	O
(	O
never	O
,	O
current	O
,	O
former	O
)	O
,	O
leisure	O
-	O
time	O
physical	O
activity	O
(	O
metabolic	O
equivalent	O
tasks	O
in	O
minutes	O
/	O
day	O
)	O
,	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
and	O
h	O
##yper	O
##tens	O
##ion	O
.	O

This	O
was	O
an	O
unexpected	O
finding	O
since	O
these	O
ant	B
##hra	I
##cy	I
##cline	I
##s	I
differ	O
by	O
only	O
one	O
h	O
##ydro	O
##xy	O
##l	O
group	O
,	O
and	O
they	O
are	O
cleared	O
by	O
similar	O
is	O
##oe	O
##nz	O
##yme	O
##s	O
.	O

We	O
next	O
evaluated	O
whether	O
ad	O
##herence	O
or	O
C	O
##YP	O
##2	O
##D	O
##6	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
had	O
a	O
stronger	O
effect	O
on	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
concentrations	O
based	O
on	O
standardized	O
beta	O
coefficients	O
(	O
Table	O
)	O
.	O

GP	O
-	O
tag	O
##ged	O
7	B
##α	I
,	I
x	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
appears	O
as	O
s	O
##yn	O
and	O
anti	O
conform	O
##ers	O
appearing	O
at	O
2	O
.	O
67	O
and	O
3	O
.	O
79	O
min	O
in	O
R	O
##IC	O
(	O
b	O
)	O
.	O

Co	O
##rrel	O
##ations	O
between	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
its	O
derivatives	O
’	O
levels	O
,	O
and	O
a	O
broad	O
range	O
of	O
art	O
##hr	O
##itic	O
,	O
inflammatory	O
,	O
and	O
C	O
##V	O
parameters	O
were	O
assessed	O
using	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
.	O

As	O
expected	O
,	O
major	O
contributions	O
(	O
loading	O
in	O
##tens	O
##ities	O
)	O
come	O
from	O
compounds	O
that	O
ion	O
##ize	O
well	O
in	O
electro	O
##sp	O
##ray	O
conditions	O
,	O
such	O
as	O
c	B
##rea	I
##tine	I
,	O
amino	O
acids	O
,	O
multiple	O
car	B
##ni	I
##tine	I
derivatives	O
,	O
and	O
others	O
,	O
as	O
shown	O
in	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
reported	O
that	O
cancer	O
tissue	O
can	O
ul	O
##til	O
##ize	O
GA	B
##BA	I
to	O
produce	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
a	O
precursor	O
of	O
p	B
##yr	I
##u	I
##vate	I
derived	O
from	O
g	B
##ly	I
##cine	I
.	O

Meanwhile	O
,	O
L	B
-	I
pro	I
##line	I
,	O
a	O
non	O
-	O
essential	O
amino	O
acid	O
,	O
was	O
found	O
to	O
be	O
lowered	O
in	O
L	O
##CP	O
##s	O
,	O
confirming	O
a	O
previously	O
reported	O
study	O
.	O

Interest	O
##ingly	O
,	O
higher	O
c	B
##ys	I
##tein	I
##e	I
values	O
are	O
associated	O
with	O
o	O
##besity	O
–	O
.	O

Ser	B
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
had	O
the	O
largest	O
distribution	O
differences	O
(	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
;	O
however	O
,	O
the	O
distribution	O
of	O
these	O
meta	O
##bol	O
##ites	O
in	O
the	O
h	O
##yper	O
##tensive	O
ne	O
##ph	O
##ros	O
##cle	O
##rosis	O
group	O
and	O
the	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
still	O
showed	O
substantial	O
overlap	O
.	O

Furthermore	O
,	O
several	O
meta	O
##bol	O
##ites	O
were	O
identified	O
by	O
at	O
least	O
2	O
of	O
the	O
3	O
different	O
methods	O
,	O
including	O
p	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##py	I
##ru	I
##vic	I
acid	I
,	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
,	O
thy	B
##mine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
,	O
and	O
x	B
##ant	I
##hine	I
.	O

The	O
formation	O
of	O
o	O
##xi	O
##dized	O
in	O
##do	O
##les	O
has	O
been	O
shown	O
to	O
lead	O
to	O
toxicity	O
in	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
diseases	O
[	O
;	O
;	O
]	O
;	O
for	O
example	O
,	O
a	O
##ber	O
##rations	O
in	O
the	O
try	B
##pt	I
##op	I
##han	I
pathway	O
are	O
well	O
known	O
to	O
occur	O
in	O
HD	O
[	O
;	O
]	O
.	O

However	O
,	O
the	O
sum	O
of	O
resolutions	O
(	O
Σ	O
R	O
_	O
s	O
)	O
was	O
not	O
significantly	O
enhanced	O
by	O
any	O
add	O
##itive	O
,	O
ranging	O
from	O
a	O
median	O
value	O
of	O
4	O
.	O
0	O
for	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
to	O
4	O
.	O
7	O
for	O
water	O
(	O
B	O
)	O
.	O

E	O
##pid	O
##em	O
##iol	O
##ogical	O
studies	O
have	O
reported	O
on	O
the	O
importance	O
of	O
vitamin	B
D	I
in	O
cancer	O
prevention	O
and	O
treatment	O
.	O

In	O
the	O
control	O
cultures	O
of	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
,	O
a	O
drop	O
of	O
160	O
µ	O
##mo	O
##l	O
/	O
l	O
in	O
the	O
extra	O
##cellular	O
concentration	O
of	O
as	B
##par	I
##tate	I
was	O
detected	O
during	O
the	O
culture	O
period	O
of	O
2	O
h	O
.	O
During	O
r	O
##H	O
##la	O
-	O
treatment	O
of	O
cells	O
for	O
2	O
h	O
,	O
however	O
,	O
the	O
extra	O
##cellular	O
as	B
##par	I
##tate	I
concentration	O
increased	O
by	O
145	O
µ	O
##mo	O
##l	O
/	O
l	O
.	O

After	O
the	O
presence	O
of	O
q	B
##uin	I
##one	I
met	O
##hi	O
##des	O
in	O
the	O
reaction	O
mixture	O
was	O
established	O
,	O
then	O
their	O
potential	O
DNA	O
add	O
##uc	O
##ts	O
were	O
synthesized	O
in	O
a	O
one	O
pot	O
reaction	O
.	O

Several	O
groups	O
have	O
also	O
previously	O
reported	O
increased	O
c	B
##era	I
##mi	I
##de	I
levels	O
in	O
high	O
risk	O
smoke	O
##rs	O
,	O
whereas	O
the	O
molecular	O
mechanisms	O
through	O
which	O
cigarette	O
smoke	O
and	O
c	B
##era	I
##mi	I
##de	I
accumulation	O
lead	O
to	O
lung	O
cancer	O
,	O
are	O
still	O
largely	O
unknown	O
.	O

(	O
95	O
:	O
5	O
,	O
v	O
/	O
v	O
)	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
after	O
every	O
injection	O
.	O

The	O
f	O
##em	O
##oral	O
artery	O
of	O
the	O
exercise	O
leg	O
was	O
can	O
##nu	O
##lated	O
under	O
local	O
an	O
##est	O
##hetic	O
treatment	O
(	B
lid	B
##oc	I
##aine	I
,	O
1	O
%	O
)	O
.	O

A	O
200	O
-	O
mg	O
Sep	O
-	O
Pak	O
t	O
##C	O
_	O
18	O
cartridge	O
(	O
SP	O
##E	O
##2	O
)	O
was	O
washed	O
with	O
6	O
m	O
##l	O
of	O
100	O
%	O
met	B
##han	I
##ol	I
,	O
6	O
m	O
##l	O
of	O
10	O
%	O
met	B
##han	I
##ol	I
and	O
conditioned	O
with	O
4	O
m	O
##l	O
of	O
70	O
%	O
met	B
##han	I
##ol	I
.	O

de	O
Jong	O
et	O
al	O
.	O
has	O
revealed	O
that	O
k	B
##yn	I
##uren	I
##ine	I
and	O
k	B
##yn	I
##uren	I
##ine	I
/	O
try	O
##pt	O
##op	O
##han	O
ratios	O
were	O
higher	O
in	O
the	O
pre	O
##tre	O
##at	O
##ment	O
serum	O
samples	O
from	O
patients	O
with	O
end	O
##ome	O
##tri	O
##al	O
,	O
o	O
##var	O
##ian	O
,	O
and	O
v	O
##ul	O
##var	O
cancer	O
##s	O
,	O
than	O
that	O
of	O
controls	O
.	O

The	O
median	O
levels	O
of	O
1	B
,	I
2	I
-	I
N	I
##P	I
##Q	I
-	I
Al	I
##b	I
were	O
26	O
##8	O
and	O
203	O
(	O
pm	O
##ol	O
/	O
g	O
)	O
in	O
male	O
(	O
n	O
=	O
11	O
)	O
and	O
female	O
(	O
n	O
=	O
11	O
)	O
subjects	O
,	O
respectively	O
.	O

G	B
##lut	I
##ath	I
##ione	I
is	O
also	O
involved	O
in	O
cellular	O
de	O
##to	O
##xi	O
##fication	O
,	O
and	O
is	O
required	O
in	O
several	O
aspects	O
of	O
the	O
immune	O
response	O
.	O

The	O
apparent	O
in	O
##con	O
##sistence	O
with	O
the	O
Asian	O
study	O
might	O
be	O
the	O
result	O
of	O
different	O
para	B
##ben	I
use	O
in	O
commercial	O
products	O
from	O
one	O
country	O
to	O
another	O
,	O
yielding	O
to	O
different	O
exposure	O
between	O
populations	O
.	O

The	O
underlying	O
fatty	O
acid	O
signals	O
were	O
q	O
##uant	O
##ified	O
by	O
the	O
peak	O
in	O
##tens	O
##ities	O
of	O
the	O
di	O
##acy	O
##l	O
fragment	O
ions	O
normal	O
##ized	O
against	O
the	O
di	O
##acy	O
##l	O
fragment	O
ion	O
signal	O
of	O
the	O
pre	O
-	O
extraction	O
spike	O
##d	O
synthetic	O
T	B
##AG	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
standard	O
and	O
plasma	O
volume	O
.	O

Considering	O
the	O
small	O
size	O
and	O
al	B
##ip	I
##hat	I
##ic	I
structure	O
of	O
p	B
##oly	I
##amine	I
##s	I
,	O
dans	B
##yl	I
chloride	I
was	O
used	O
as	O
a	O
derivative	O
agent	O
to	O
increase	O
their	O
retention	O
and	O
ion	O
##ization	O
.	O

Further	O
analysis	O
identified	O
a	O
potential	O
bio	O
##mark	O
##er	O
panel	O
consisting	O
of	O
five	O
potential	O
bio	O
##mark	O
##ers	O
–	O
format	B
##e	I
,	O
su	B
##cci	I
##nate	I
,	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
α	B
-	I
glucose	I
and	O
dim	B
##eth	I
##yla	I
##mine	I
.	O

U	O
##rina	O
##ry	O
co	B
##tin	I
##ine	I
levels	O
declined	O
and	O
then	O
reached	O
a	O
plateau	O
,	O
presumably	O
due	O
to	O
use	O
of	O
trans	O
##der	O
##mal	O
ni	B
##cot	I
##ine	I
.	O

However	O
,	O
these	O
effects	O
as	O
well	O
as	O
the	O
presence	O
of	O
SP	O
##Ms	O
in	O
per	B
##ito	I
##nea	I
##l	I
lava	O
##ges	O
were	O
mostly	O
shown	O
in	O
z	O
##ym	O
##osa	O
##n	O
induced	O
m	B
##uri	I
##ne	I
per	O
##ito	O
##ni	O
##tis	O
models	O
and	O
data	O
on	O
human	O
clinical	O
samples	O
are	O
scarce	O
.	O

The	O
notable	O
exception	O
is	O
that	O
AP	S
patients	O
had	O
more	O
instances	O
of	O
multiple	O
di	O
##ag	O
##nose	O
##s	O
than	O
non	O
-	O
AP	O
patients	O
.	O

Only	O
the	O
following	O
significant	O
meta	O
##bol	O
##ites	O
are	O
labeled	O
in	O
the	O
three	O
tissue	O
metabolic	O
profiles	O
:	O
1	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
2	O
,	O
le	B
##uc	I
##ine	I
;	O
3	O
,	O
v	B
##ali	I
##ne	I
;	O
4	O
,	O
la	B
##ct	I
##ate	I
;	O
5	O
,	O
al	B
##ani	I
##ne	I
;	O
6	O
,	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
;	O
7	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
8	O
,	O
α	B
-	I
glucose	I
;	O
9	O
,	O
β	B
-	I
glucose	I
;	O
10	O
,	O
met	B
##hi	I
##oni	I
##ne	I
;	O
11	O
,	O
c	B
##rea	I
##tine	I
;	O
12	O
,	O
ace	B
##tate	I
;	O
13	O
,	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
;	O
14	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
15	O
,	O
met	B
##hyl	I
##p	I
##rol	I
##ine	I
;	O
16	O
,	O
g	B
##ly	I
##cine	I
;	O
and	O
17	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
.	O

Although	O
the	O
association	O
between	O
SF	O
##A	O
intake	O
and	O
CH	O
##D	O
risk	O
is	O
debated	O
,	O
strong	O
positive	O
associations	O
have	O
been	O
identified	O
between	O
CH	O
##D	O
development	O
and	O
palm	B
##itic	I
acid	I
intake	O
.	O

Matrix	O
and	O
cross	O
-	O
talk	O
interference	O
##s	O
Select	O
##ivity	O
was	O
additionally	O
evaluated	O
by	O
analyzing	O
the	O
highest	O
ca	O
##li	O
##bra	O
##tion	O
standard	O
sample	O
(	O
2000	O
ng	O
/	O
m	O
##L	O
)	O
processed	O
with	O
pure	O
Me	B
##OH	I
and	O
a	O
blank	O
human	O
plasma	O
processed	O
with	O
only	O
internal	O
standards	O
solution	O
at	O
40	O
ng	O
/	O
m	O
##L	O
,	O
to	O
identify	O
potential	O
(	O
i	O
)	O
interference	O
##s	O
affecting	O
co	O
-	O
el	O
##uti	O
##ng	O
anal	O
##yte	O
##s	O
and	O
internal	O
standards	O
due	O
to	O
the	O
MS	O
-	O
based	O
cross	O
-	O
talk	O
phenomenon	O
or	O
(	O
ii	O
)	O
presence	O
of	O
is	O
##ob	O
##ari	O
##c	O
imp	O
##uri	O
##ties	O
.	O

As	O
far	O
as	O
PC	O
##aa	O
are	O
concerned	O
,	O
O	O
##ber	O
##bach	O
et	O
al	O
.	O
showed	O
an	O
increase	O
of	O
several	O
PC	O
##aa	O
including	O
C	B
##32	I
:	I
0	I
,	O
C	B
##32	I
:	I
1	I
and	O
C	B
##40	I
:	I
5	I
levels	O
among	O
o	O
##bes	O
##e	O
as	O
compared	O
to	O
lean	O
individuals	O
[	O
,	O
]	O
,	O
a	O
trend	O
that	O
was	O
also	O
observed	O
for	O
PC	O
##aa	O
C	B
##32	I
:	I
1	I
and	O
C	B
##40	I
:	I
5	I
in	O
the	O
present	O
study	O
.	O

Di	O
##mini	O
##shed	O
E	O
##ET	O
levels	O
will	O
au	O
##gment	O
20	B
-	I
H	I
##ET	I
##E	I
v	O
##as	O
##oc	O
##ons	O
##tric	O
##tor	O
activity	O
,	O
because	O
11	B
,	I
12	I
-	I
E	I
##ET	I
functions	O
as	O
a	O
physiological	O
antagonist	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
.	O

Sam	O
##ple	O
pre	O
##tre	O
##at	O
##ment	O
was	O
performed	O
on	O
O	O
##stro	O
[UNK]	O
96	O
-	O
well	O
plate	O
to	O
remove	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
proteins	O
(	O
Waters	O
,	O
Milford	O
,	O
MA	O
,	O
USA	O
)	O
.	O

PC	B
(	I
18	I
:	I
1	I
/	I
22	I
:	I
6	I
)	I
is	O
an	O
##not	O
##ated	O
by	O
the	O
algorithm	O
whereas	O
SM	B
(	I
18	I
:	I
1	I
/	I
18	I
:	I
2	I
)	I
was	O
characterised	O
by	O
MS	O
/	O
MS	O
analysis	O
using	O
Li	O
in	O
##fusion	O
.	O

The	O
pool	O
##ed	O
extract	O
##s	O
were	O
dried	O
under	O
nitrogen	B
gas	I
.	O

Although	O
an	O
initial	O
report	O
suggested	O
that	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
was	O
only	O
present	O
in	O
serum	O
from	O
infants	O
and	O
neon	O
##ates	O
,	O
subsequent	O
studies	O
have	O
now	O
confirmed	O
that	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
is	O
nearly	O
always	O
present	O
in	O
adult	O
serum	O
.	O

A	O
second	O
limitation	O
was	O
our	O
as	O
##cer	O
##tain	O
##ment	O
of	O
diet	O
##ary	O
P	O
##U	O
##FA	O
use	O
was	O
based	O
on	O
FF	O
##Q	O
##s	O
,	O
which	O
have	O
been	O
shown	O
to	O
have	O
a	O
wide	O
range	O
of	O
correlation	O
##s	O
with	O
various	O
bio	O
##mark	O
##ers	O
of	O
fatty	O
acid	O
intake	O
from	O
0	O
.	O
15	O
for	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
to	O
0	O
.	O
50	O
for	O
EPA	O
(	O
–	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
several	O
meta	O
##bol	O
##ites	O
useful	O
as	O
CR	O
##N	O
discrimination	O
factors	O
including	O
ta	B
##uri	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
3	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
(	O
BA	O
##IB	O
)	O
,	O
v	B
##ali	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
hip	B
##pura	I
##te	I
,	O
as	B
##cor	I
##bate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
c	B
##it	I
##rate	I
.	O

Cal	O
##ib	O
##ration	O
standards	O
were	O
prepared	O
by	O
s	O
##pi	O
##king	O
appropriate	O
amounts	O
of	O
the	O
working	O
standard	O
solution	O
to	O
charcoal	O
-	O
stripped	O
human	O
serum	O
to	O
make	O
the	O
concentrations	O
of	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
100	O
,	O
200	O
p	O
##g	O
/	O
m	O
##L	O
(	O
10	O
times	O
higher	O
concentration	O
for	O
4	B
-	I
OH	I
-	I
E	I
##2	I
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
)	O
.	O

When	O
combining	O
the	O
after	O
-	O
treatment	O
results	O
with	O
the	O
current	O
on	O
-	O
treatment	O
data	O
,	O
it	O
may	O
be	O
supposed	O
that	O
the	O
decrease	O
in	O
blood	O
ch	B
##olin	I
##e	I
after	O
the	O
therapy	O
completion	O
may	O
reflect	O
the	O
increased	O
ch	B
##olin	I
##e	I
up	O
##take	O
due	O
to	O
the	O
prevalence	O
of	O
the	O
cell	O
membrane	O
regeneration	O
processes	O
.	O

Thus	O
,	O
plasma	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
and	O
Q	O
##UI	O
##N	O
significantly	O
decreased	O
after	O
a	O
series	O
of	O
three	O
EC	O
##T	O
administration	O
##s	O
whereas	O
plasma	O
levels	O
of	O
K	O
##Y	O
##NA	O
did	O
not	O
change	O
.	O

_	O
a	O
,	O
b	O
,	O
c	O
Sign	O
##ificant	O
differences	O
compared	O
with	O
Place	O
##bo	O
,	O
Pi	O
##o	O
,	O
and	O
Omega	B
-	I
3	I
,	O

r	O
##0	O
:	O
un	O
##ad	O
##ju	O
##sted	O
;	O
r	O
##1	O
:	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
fast	O
##ing	O
glucose	S
.	O

Ali	O
##q	O
##uo	O
##ts	O
of	O
200	O
μ	O
##l	O
human	O
plasma	O
were	O
mixed	O
with	O
5	O
μ	O
##l	O
Master	O
IS	O
##D	O
##T	O
before	O
loading	O
onto	O
96	O
-	O
well	O
SP	O
##E	O
cartridges	O
(	O
30	O
mg	O
,	O
H	O
##L	O
##B	O
,	O
Waters	O
,	O
Milford	O
,	O
MA	O
)	O
,	O
which	O
had	O
been	O
pre	O
-	O
conditioned	O
with	O
1	O
m	O
##l	O
Me	B
##OH	I
and	O
followed	O
by	O
1	O
m	O
##l	O
water	O
.	O

S	B
##per	I
##mine	I
,	O
sperm	B
##id	I
##ine	I
and	O
c	B
##yt	I
##os	I
##ine	I
were	O
elevated	O
in	O
N	O
##MI	O
##BC	O
urine	O
##s	O
as	O
well	O
,	O
but	O
not	O
at	O
statistical	O
##ly	O
significant	O
levels	O
.	O

Analysis	O
of	O
the	O
distribution	O
of	O
est	O
##eri	O
##fied	O
9	O
-	O
H	O
##SA	O
among	O
cellular	O
lip	O
##ids	O
revealed	O
that	O
the	O
fatty	O
acid	O
was	O
present	O
only	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
;	O
9	O
-	O
H	O
##SA	O
was	O
conspicuous	O
##ly	O
absent	O
of	O
all	O
neutral	O
lip	O
##id	O
classes	O
,	O
including	O
mon	O
##o	O
-	O
di	O
-	O
or	O
t	B
##ri	I
-	I
a	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
.	O

Fifty	O
micro	O
##lite	O
##rs	O
of	O
T	O
##CE	O
##P	O
solution	O
and	O
then	O
140	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
+	I
1	I
%	I
FA	I
were	O
then	O
added	O
to	O
the	O
mixture	O
.	O

Tau	B
##rine	I
was	O
found	O
to	O
exhibit	O
a	O
much	O
higher	O
in	O
##tra	O
-	O
individual	O
var	O
##iability	O
than	O
su	B
##lf	I
##ate	I
.	O

presents	O
results	O
from	O
multi	O
##var	O
##iable	O
re	O
##gression	O
models	O
for	O
associations	O
between	O
m	O
##t	O
##D	O
##NA	O
##del	O
and	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
or	O
is	B
##op	I
##ros	I
##tan	I
##e	I
concentrations	O
for	O
the	O
study	O
population	O
.	O

Not	O
##ably	O
,	O
HD	O
##L	O
,	O
which	O
is	O
known	O
to	O
transport	O
SM	O
##s	O
,	O
correlated	O
positively	O
with	O
most	O
SM	O
##s	O
but	O
negatively	O
with	O
most	O
c	B
##era	I
##mi	I
##des	I
,	O
which	O
are	O
prefer	O
##ential	O
##ly	O
transported	O
by	O
L	O
##D	O
##L	O
.	O

5	O
.	O
5	O
mm	O
##ol	O
/	O
l	O
by	O
continuous	O
in	O
##fusion	O
of	O
15	O
%	O
glucose	S
.	O

Six	O
##ty	O
-	O
five	O
subjects	O
self	O
-	O
identified	O
as	O
daily	O
cannabis	S
users	O
,	O
while	O
133	O
participants	O
self	O
-	O
identified	O
as	O
never	O
using	O
cannabis	S
.	O

Therefore	O
,	O
ch	B
##olin	I
##e	I
may	O
be	O
a	O
valuable	O
potential	O
bio	O
##mark	O
##er	O
for	O
neo	O
##p	O
##las	O
##m	O
progression	O
,	O
re	O
##cu	O
##rrence	O
,	O
ch	O
##em	O
##ora	O
##dio	O
##ther	O
##ap	O
##y	O
,	O
or	O
pro	O
##gno	O
##sis	O
.	O

El	O
##eva	O
##ted	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acid	O
levels	O
were	O
also	O
observed	O
playing	O
a	O
distinct	O
role	O
in	O
pro	O
##life	O
##rating	O
and	O
cancer	O
cells	O
in	O
early	O
stage	O
E	O
##SC	O
##C	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
of	O
the	O
s	B
##phi	I
##nga	I
##nine	I
/	I
s	I
##phi	I
##ngo	I
##sin	I
##e	I
pathway	O
including	O
s	B
##phi	I
##nga	I
##nine	I
,	O
s	B
##phi	I
##nga	I
##nine	I
1	I
-	I
phosphate	I
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
,	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
1	I
-	I
phosphate	I
were	O
all	O
significantly	O
increased	O
in	O
Re	O
##tt	O
syndrome	O
subjects	O
compared	O
to	O
controls	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
total	O
-	O
C	O
)	O
and	O
T	B
##G	I
levels	O
were	O
determined	O
from	O
plasma	O
and	O
lip	O
##op	O
##rote	O
##in	O
fraction	O
##s	O
using	O
the	O
O	O
##ly	O
##mpus	O
AU	O
##40	O
##0	O
##e	O
system	O
(	O
P	O
##ly	O
##mpus	O
America	O
Inc	O
.	O
,	O
Melville	O
,	O
NY	O
,	O
USA	O
)	O
.	O

The	O
−	O
##CH	O
_	O
2	O
resonance	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
i	I
##bu	I
##p	I
##ro	I
##fen	I
(	O
M1	O
)	O
at	O
δ	O
2	O
.	O
79	O
(	O
r	O
=	O
0	O
.	O
96	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
94	O
–	O
0	O
.	O
97	O
)	O
and	O
the	O
-	O
CH	O
_	O
2	O
resonance	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
i	I
##bu	I
##p	I
##ro	I
##fen	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
(	O
M	O
##6	O
)	O
at	O
δ	O
2	O
.	O
80	O
(	O
r	O
=	O
0	O
.	O
92	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
9	O
–	O
0	O
.	O
94	O
)	O
were	O
also	O
strongly	O
correlated	O
with	O
the	O
δ	O
1	O
.	O
21	O
met	O
##hyl	O
signal	O
.	O

The	O
LL	O
##E	O
with	O
the	O
et	B
##hyl	I
ace	I
##tate	I
method	O
had	O
very	O
good	O
recover	O
##ies	O
(	O
over	O
90	O
%	O
)	O
for	O
all	O
the	O
anal	O
##yte	O
##s	O
except	O
for	O
AR	O
##G	O
and	O
GA	B
##BA	I
,	O
and	O
the	O
recover	O
##ies	O
for	O
these	O
anal	O
##yte	O
##s	O
were	O
very	O
low	O
.	O

Fresh	O
solutions	O
prepared	O
in	O
met	B
##han	I
##ol	I
were	O
used	O
for	O
subsequent	O
analysis	O
.	O

Meanwhile	O
,	O
only	O
a	O
single	O
lip	O
##id	O
metabolism	O
(	B
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
)	O
was	O
found	O
to	O
be	O
increased	O
.	O

4	O
-	B
[	B
bi	I
##s	I
[	I
2	I
–	I
h	I
##ydro	I
##xy	I
-	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
ben	I
##zal	I
##de	I
##hy	I
##de	I
(	O
B	O
##EN	O
-	O
(	O
OH	O
)	O
_	O
2	O
)	O
was	O
generated	O
by	O
heating	O
13	O
.	O
6	O
mg	O
B	O
##EN	O
in	O
approximately	O
4	O
m	O
##L	O
of	O
0	O
.	O
05	O
N	O
a	O
##que	O
##ous	O
Na	O
##OH	O
for	O
48	O
h	O
at	O
50	O
°C	O
.	O

In	O
O	O
##VC	O
patients	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
completely	O
reversed	O
the	O
c	O
##yt	O
##oto	O
##xi	O
##city	O
induced	O
by	O
met	O
##hot	O
##re	O
##xa	O
##te	O
and	O
met	O
##hot	O
##re	O
##xa	O
##te	O
plus	O
dip	B
##yr	I
##ida	I
##mo	I
##le	I
.	O

A	O
##b	O
##nor	O
##mal	O
ch	B
##olin	I
##e	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
has	O
been	O
implicated	O
in	O
car	O
##cin	O
##ogen	O
##esis	O
and	O
tumor	O
progression	O
.	O

We	O
were	O
able	O
to	O
detect	O
three	O
9	O
-	O
H	O
##SA	O
-	O
containing	O
FA	O
##HF	O
##A	O
in	O
our	O
color	O
##ec	O
##tal	O
tumor	O
samples	O
and	O
adjacent	O
normal	O
tissue	O
,	O
namely	O
those	O
est	O
##eri	O
##fying	O
o	O
##le	O
##ic	O
,	O
palm	B
##itic	I
,	O
and	O
s	O
##te	O
##ari	O
##c	O
acids	O
:	O
9	O
-	O
O	O
##A	O
##HS	O
##A	O
(	O
o	O
##le	O
##ic	O
acid	O
est	O
##er	O
of	O
9	B
-	I
h	I
##ydro	I
##xy	I
##ste	I
##ari	I
##c	I
acid	O
)	O
,	O
9	O
-	O
PA	O
##HS	O
##A	O
(	B
palm	B
##itic	I
acid	I
est	I
##er	I
of	O
9	B
-	I
h	I
##ydro	I
##xy	I
##ste	I
##ari	I
##c	I
acid	O
)	O
and	O
9	O
-	O
SA	O
##HS	O
##A	O
(	O
s	O
##te	O
##ari	O
##c	O
acid	O
est	O
##er	O
of	O
9	B
-	I
h	I
##ydro	I
##xy	I
##ste	I
##ari	I
##c	I
acid	O
)	O
,	O
respectively	O
(	O
A	O
,	O
B	O
)	O
.	O

The	O
flow	O
rate	O
was	O
0	O
.	O
7	O
m	O
##L	O
/	O
min	O
with	O
the	O
following	O
mobile	O
phases	O
:	O
mobile	O
phase	O
A	O
was	O
water	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
and	O
mobile	O
phase	O
B	O
was	O
60	O
:	O
36	O
:	O
4	O
is	O
##op	O
##rop	O
##yl	O
alcohol	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
water	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

These	O
b	O
##lot	O
##s	O
were	O
stripped	O
and	O
b	O
##lot	O
##ted	O
with	O
total	O
antibodies	O
against	O
E	O
##rk	O
and	O
G	B
##S	I
##K	I
##3	I
##β	I
.	O

We	O
investigated	O
the	O
presence	O
in	O
human	O
urine	O
of	O
twelve	O
potential	O
meta	O
##bol	O
##ites	O
of	O
Ph	O
##e	O
(	O
1	O
,	O
)	O
which	O
could	O
result	O
from	O
de	O
##to	O
##xi	O
##fication	O
of	O
Ph	O
##e	O
e	B
##pox	I
##ides	I
2	O
and	O
12	O
by	O
the	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
pathway	O
:	O
e	B
##pox	I
##ide	I
ring	O
opening	O
products	O
6	O
,	O
9	O
,	O
13	O
,	O
and	O
16	O
;	O
their	O
de	O
##hy	O
##dra	O
##ted	O
analogue	O
##s	O
7	O
,	O
10	O
,	O
14	O
,	O
and	O
17	O
;	O
and	O
the	O
corresponding	O
su	B
##lf	I
##oxide	I
##s	I
8	O
,	O
11	O
,	O
15	O
,	O
and	O
18	O
.	O

The	O
pro	O
##ximal	O
co	O
##lon	O
##ic	O
metabolism	O
of	O
p	O
##oly	O
##phe	O
##no	O
##lic	O
compounds	O
(	O
including	O
cat	B
##ech	I
##ins	I
and	O
ch	B
##lor	I
##ogenic	I
acid	O
)	O
results	O
in	O
production	O
of	O
ben	B
##zoic	I
acid	I
,	O
which	O
is	O
absorbed	O
and	O
then	O
phase	O
2	O
g	O
##ly	O
##cine	O
-	O
con	O
##ju	O
##gated	O
to	O
form	O
hip	B
##pura	I
##te	I
in	O
the	O
host	O
he	O
##pa	O
##tic	O
mit	O
##och	O
##ond	O
##ria	O
.	O

C	O
.	O
Lac	B
##tate	I
release	O
was	O
determined	O
by	O
color	O
##ime	O
##tric	O
ass	O
##ay	O
utilizing	O
culture	O
medium	O
of	O
vector	O
control	O
and	O
p	O
##c	O
##D	O
##NA	O
##3	O
-	O
c	O
##M	O
##Y	O
##C	O
trans	O
##fected	O
Col	O
##o	O
##35	O
##7	O
-	O
s	O
##h	O
##S	O
##c	O
##r	O
,	O
Col	O
##o	O
##35	O
##7	O
-	O
s	O
##h	O
##MU	O
##C	O
##16	O
,	O
Cap	O
##an	O
##1	O
-	O
s	O
##h	O
##S	O
##c	O
##r	O
,	O
and	O
Cap	O
##an	O
##1	O
-	O
s	O
##h	O
##MU	O
##C	O
##16	O
cells	O
.	O

The	O
2	O
-	O
m	O
##l	O
al	O
##iq	O
##uo	O
##ts	O
of	O
activated	S
charcoal	O
-	O
treated	O
human	O
urine	O
samples	O
were	O
spike	O
##d	O
with	O
the	O
total	O
(	O
a	O
)	O
250	O
,	O
(	O
b	O
)	O
500	O
and	O
(	O
c	O
)	O
1	O
,	O
000	O
p	O
##g	O
of	O
40	O
est	O
##rogen	O
-	O
related	O
compounds	O
before	O
and	O
after	O
(	O
control	O
)	O
passing	O
over	O
p	O
##hen	O
##yl	O
SP	O
##E	O
cartridges	O
.	O

The	O
fi	O
##lt	O
##rates	O
were	O
then	O
transferred	O
to	O
clean	O
micro	O
##cent	O
##ri	O
##fu	O
##ge	O
tubes	O
and	O
phosphate	S
buffer	O
,	O
sodium	O
a	O
##zi	O
##de	O
and	O
D	O
_	O
2	O
O	O
were	O
added	O
.	O

For	O
example	O
,	O
levels	O
of	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
,	O
and	O
o	B
##ct	I
##ade	I
##cane	I
##dio	I
##ate	I
were	O
significantly	O
higher	O
in	O
C	O
-	O
P	O
(	O
fold	O
changes	O
:	O
1	O
.	O
72	O
and	O
1	O
.	O
64	O
)	O
and	O
C	O
-	O
3	O
##N	O
(	O
fold	O
changes	O
:	O
1	O
.	O
71	O
and	O
1	O
.	O
72	O
)	O
subjects	O
than	O
C	O
-	O
C	O
subjects	O
after	O
the	O
adjustment	O
of	O
multiple	O
comparisons	O
.	O

L	B
-	I
pro	I
##line	I
(	O
≥	O
99	O
.	O
5	O
%	O
pure	O
)	O
,	O
L	B
-	I
pro	I
##line	I
-	I
_	I
13	I
C	O
_	O
5	O
,	O
_	O
15	O
N	O
(	O
98	O
atom	O
%	O
_	O
13	O
C	O
,	O
98	O
atom	O
%	O
_	O
15	O
N	O
,	O
95	O
%	O
pure	O
,	O
internal	O
standard	O
,	O
IS	O
)	O
,	O
b	O
##ov	O
##ine	O
serum	O
album	O
##in	O
(	O
BS	O
##A	O
)	O
,	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
PBS	O
)	O
,	O
form	B
##ic	I
acid	I
,	O
and	O
HP	O
##LC	O
grade	O
met	B
##han	I
##ol	I
and	O
water	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Der	O
##iva	O
##tized	O
s	O
##tero	O
##ls	O
were	O
then	O
el	O
##uted	O
in	O
three	O
1	O
-	O
m	O
##l	O
portions	O
of	O
100	O
%	O
met	B
##han	I
##ol	I
(	I
SP	I
##E	I
##2	I
-	I
Fr	I
-	I
1	I
,	I
Fr	I
-	I
2	I
,	O
and	O
Fr	B
-	I
3	I
)	I
followed	O
by	O
1	O
m	O
##l	O
of	O
99	O
.	O
9	O
%	O
ethanol	B
(	I
SP	I
##E	I
##2	I
-	I
Fr	I
-	I
4	I
)	I
.	O

(	B
R	I
)	I
-	I
3	I
-	I
H	I
##ydro	I
##xy	I
##but	I
##ano	I
##ate	I
.	O

The	O
method	O
is	O
specific	O
for	O
compounds	O
that	O
will	O
undergo	O
L	O
##C	O
-	O
EC	O
##A	O
oxidation	O
or	O
reduction	O
,	O
and	O
includes	O
multiple	O
compounds	O
from	O
the	O
t	B
##yr	I
##os	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
sulfur	O
amino	O
acid	O
and	O
pu	B
##rine	I
pathways	O
,	O
as	O
well	O
as	O
markers	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
protection	O
(	O
see	O
Additional	O
file	O
:	O
Table	O
S	O
##1	O
)	O
.	O

Thus	O
,	O
our	O
work	O
suggests	O
that	O
one	O
mechanism	O
by	O
which	O
cannabis	S
may	O
ex	O
##ert	O
an	O
anti	O
-	O
inflammatory	O
impact	O
in	O
HIV	O
-	O
infected	O
individuals	O
is	O
by	O
increasing	O
the	O
frequency	O
of	O
CD	O
##16	O
_	O
–	O
mon	O
##oc	O
##yte	O
subset	O
##s	O
and	O
decreasing	O
the	O
frequency	O
of	O
CD	O
##16	O
_	O
+	O
mon	O
##oc	O
##yte	O
subset	O
##s	O
.	O

Tu	O
##mor	O
la	B
##ct	I
##ate	I
levels	O
were	O
higher	O
than	O
normal	O
levels	O
in	O
both	O
lung	O
and	O
pro	O
##state	O
tissues	O
,	O
indicating	O
their	O
enhanced	O
g	O
##ly	O
##co	O
##lysis	O
and	O
la	B
##ct	I
##ate	I
f	O
##er	O
##mentation	O
,	O
which	O
re	O
##af	O
##firmed	O
the	O
War	O
##burg	O
effect	O
in	O
cancer	O
.	O

The	O
urine	O
samples	O
were	O
anal	O
##ys	O
##ed	O
for	O
the	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ites	O
co	B
##tin	I
##ine	I
(	O
Co	O
##t	O
)	O
and	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
(	O
T	O
##3	O
##HC	O
##ot	O
)	O
and	O
the	O
PA	O
##H	O
meta	O
##bol	O
##ites	O
2	B
-	I
nap	I
##ht	I
##hol	I
(	O
2	O
-	O
Na	O
##p	O
)	O
,	O
1	B
-	I
h	I
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##ne	I
(	O
1	O
-	O
H	O
##F	O
##l	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##ne	I
(	O
2	O
-	O
H	O
##F	O
##l	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##ne	I
(	O
3	O
-	O
H	O
##F	O
##l	O
)	O
,	O
1	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##nant	I
##hren	I
##e	I
(	O
1	O
-	O
HP	O
##he	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##nant	I
##hren	I
##e	I
(	O
2	O
-	O
HP	O
##he	O
)	O
,	O
3	B
+	I
4	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##nant	I
##hren	I
##e	I
(	I
3	I
+	I
4	I
-	I
HP	I
##he	I
)	I
and	O
1	B
-	I
h	I
##ydro	I
##xy	I
##py	I
##rene	I
(	O
1	O
-	O
HP	O
##yr	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
whose	O
concentrations	O
were	O
impacted	O
by	O
either	O
bacterial	O
metabolism	O
or	O
chemical	O
instability	O
were	O
sorted	O
by	O
increasing	O
corrected	O
p	O
-	O
values	O
associated	O
with	O
correlation	O
with	O
room	O
temperature	O
,	O
4	O
°C	O
and	O
pre	O
##ser	O
##vat	O
##ive	O
storage	O
duration	S
.	O

One	O
possible	O
reason	O
we	O
did	O
not	O
detect	O
a	O
difference	O
is	O
that	O
that	O
a	O
high	O
portion	O
of	O
the	O
−	O
##L	O
##NS	O
subjects	O
were	O
consuming	O
additional	O
f	B
##olate	I
(	O
84	O
.	O
6	O
%	O
in	O
Guatemala	O
)	O
.	O

Six	O
m	O
##L	O
of	O
plasma	O
pools	O
from	O
both	O
base	O
##line	O
and	O
treated	O
HD	O
subjects	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
with	O
24	O
m	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
containing	O
0	O
.	O
4	O
%	O
glacial	B
ace	I
##tic	I
acid	I
at	O
20	O
°C	O
.	O

ii	O
)	O
a	O
panel	O
consisting	O
of	O
4	B
-	I
et	I
##ho	I
##xy	I
##met	I
##hyl	I
##phe	I
##no	I
##l	I
,	O
pro	B
##sta	I
##g	I
##land	I
##in	I
F	O
##2	O
##b	O
,	O
th	B
##rom	I
##box	I
##ane	I
B	I
##3	I
,	O
h	B
##ydro	I
##xy	I
##but	I
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ph	I
##lore	I
##tin	I
and	O
N	B
′	I
-	I
form	I
##yl	I
##ky	I
##nu	I
##ren	I
##ine	I
shows	O
a	O
good	O
ability	O
to	O
differentiate	O
BC	O
patients	O
from	O
RC	O
##C	O
patients	O
without	O
ha	O
##ema	O
##tur	O
##ia	O
.	O

Through	O
the	O
Dean	O
’	O
s	O
switch	O
,	O
the	O
flow	O
was	O
either	O
directed	O
to	O
the	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
un	O
##coat	O
##ed	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
,	O
1	O
.	O
8	O
m	O
,	O
0	O
.	O
180	O
mm	O
)	O
or	O
to	O
waste	O
(	O
un	O
##coat	O
##ed	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
,	O
1	O
.	O
3	O
m	O
,	O
0	O
.	O
180	O
mm	O
)	O
.	O

Thus	O
try	B
##pt	I
##op	I
##han	I
can	O
be	O
considered	O
a	O
G	O
##F	O
##R	O
marker	O
even	O
though	O
it	O
is	O
not	O
a	O
retained	O
so	O
##lut	O
##e	O
.	O

Alt	O
##ered	O
plasma	O
pu	B
##rine	I
pools	O
may	O
reflect	O
systemic	O
alter	O
##nation	O
##s	O
in	O
pu	O
##rine	O
##rg	O
##ic	O
signaling	O
associated	O
with	O
mitochondrial	O
metabolism	O
,	O
healing	O
,	O
and	O
the	O
cell	O
danger	O
response	O
[	O
,	O
,	O
]	O
_	O
1	O

Trans	O
##formed	O
s	O
##pect	O
##ra	O
were	O
automatically	O
corrected	O
for	O
phase	O
and	O
base	O
##line	O
distortion	O
##s	O
and	O
ca	O
##li	O
##bra	O
##ted	O
to	O
an	O
##omer	O
##ic	O
glucose	S
double	O
##t	O
at	O
5	O
.	O
24	O
pp	O
##m	O
using	O
an	O
N	O
##MR	O
processing	O
software	O
(	O
Top	O
##sp	O
##in	O
version	O
3	O
.	O
5	O
p	O
##l	O
7	O
B	O
##ruk	O
##er	O
B	O
##io	O
##S	O
##pin	O
s	O
##rl	O
)	O
.	O

P	O
##las	O
##ma	O
concentrations	O
for	O
all	O
other	O
s	O
##tero	O
##ids	O
were	O
higher	O
in	O
men	O
than	O
women	O
,	O
with	O
the	O
largest	O
difference	O
(	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
observed	O
for	O
test	B
##osterone	I
,	O
which	O
showed	O
no	O
overlap	O
between	O
males	O
and	O
females	O
.	O

E	O
##ster	O
##ified	O
o	B
##xy	I
##lip	I
##ins	I
were	O
transformed	O
into	O
o	B
##xy	I
##lip	I
##in	I
free	O
acids	O
by	O
base	O
h	O
##ydro	O
##lysis	O
,	O
and	O
isolated	O
by	O
subsequent	O
h	O
##ydro	O
##phi	O
##lic	O
/	O
lip	O
##op	O
##hil	O
##ic	O
interaction	O
solid	O
phase	O
extraction	O
.	O

(	O
22	O
:	O
6	O
)	O
,	O
and	O
su	B
##cci	I
##ny	I
##lace	I
##tone	I
(	O
=	O
0	O
.	O
83	O
##7	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Pat	O
##ients	O
with	O
CA	O
##D	O
had	O
significantly	O
lower	O
GA	O
##BR	O
[	O
median	O
(	O
I	O
##Q	O
##R	O
)	O
;	O
1	O
.	O
06	O
(	O
0	O
.	O
75	O
,	O
1	O
.	O
31	O
)	O
versus	O
1	O
.	O
27	O
(	O
0	O
.	O
96	O
,	O
1	O
.	O
73	O
)	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
]	O
and	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
[	O
mean	O
:	O
68	O
±	O
##20	O
μ	O
##M	O
versus	O
74	O
±	O
##24	O
μ	O
##M	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
than	O
those	O
without	O
CA	O
##D	O
.	O

Met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
,	O
and	O
form	B
##ic	I
acid	I
,	O
ace	B
##tic	I
acid	I
,	O
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Meanwhile	O
,	O
5	B
-	I
H	I
##EP	I
##E	I
is	O
also	O
a	O
meta	O
##bol	O
##ite	O
processed	O
by	O
5	O
-	O
L	O
##OX	O
from	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##20	I
:	I
5	I
)	O
.	O

Time	O
-	O
dependent	O
increases	O
in	O
levels	O
of	O
both	O
T	B
##MA	I
##O	I
and	O
its	O
d	O
##9	O
is	O
##oto	O
##pol	O
##ogue	O
,	O
as	O
well	O
as	O
other	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
,	O
were	O
detected	O
after	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
challenge	O
.	O

Try	B
##pt	I
##op	I
##han	I
starvation	O
is	O
a	O
recognized	O
anti	O
##mic	O
##ro	O
##bial	O
defense	O
mechanism	O
through	O
Indo	O
##leam	O
##ine	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
ID	O
##O	O
)	O
and	O
media	O
##tes	O
im	O
##mu	O
##nor	O
##eg	O
##ulatory	O
effects	O
.	O

Males	O
,	O
HC	O
(	O
ho	O
##rmon	O
##al	O
con	O
##tra	O
##ceptive	O
-	O
taking	O
females	O
)	O
and	O
non	O
-	O
HC	O
(	O
non	O
-	O
ho	O
##rmon	O
##al	O
-	O
taking	O
females	O
)	O
are	O
indicated	O
In	O
re	O
##gression	O
models	O
s	O
##tra	O
##ti	O
##fied	O
by	O
sex	O
group	O
,	O
we	O
found	O
that	O
41	O
of	O
these	O
meta	O
##bol	O
##ites	O
had	O
significantly	O
different	O
between	O
-	O
group	O
β	O
coefficients	O
,	O
whereas	O
a	B
##cy	I
##l	I
-	I
Car	I
##n	I
C	I
##3	I
:	I
0	I
,	O
PC	O
##aa	O
C	B
##34	I
:	I
2	I
,	O
PC	O
##aa	O
C	B
##40	I
:	I
4	I
,	O
SM	O
##a	O
C	B
##38	I
:	I
2	I
and	O
NE	B
##FA	I
C	I
##26	I
:	I
1	I
showed	O
no	O
significant	O
difference	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S	O
##5	O
)	O
.	O

Co	O
##mpo	O
##nent	O
2	O
(	O
K	O
##A	O
,	O
T	O
##RP	O
,	O
and	O
K	O
##Y	O
##N	O
)	O
appears	O
to	O
represent	O
the	O
activity	O
of	O
the	O
K	O
##A	O
branch	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
,	O
whereas	O
component	O
3	O
(	O
3	O
##H	O
##K	O
,	O
B	O
##D	O
##NF	O
,	O
and	O
T	O
##RP	O
)	O
is	O
more	O
difficult	O
to	O
interpret	O
but	O
con	O
##ce	O
##iva	O
##bly	O
suggests	O
an	O
interaction	O
between	O
B	O
##D	O
##NF	O
and	O
3	O
##H	O
##K	O
.	O

S	O
##pecific	O
volumes	O
from	O
the	O
super	O
##nat	O
##ant	O
(	O
typically	O
100	O
or	O
50	O
μ	O
##l	O
)	O
were	O
taken	O
and	O
10	O
vol	O
%	O
al	O
##iq	O
##uo	O
##ts	O
of	O
a	O
1	O
M	O
ace	B
##tic	I
acid	I
solution	O
(	O
adjusted	O
to	O
pH	O
6	O
.	O
0	O
with	O
solid	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
)	O
were	O
added	O
and	O
stored	O
in	O
via	O
##ls	O
.	O

Ana	O
##ly	O
##tical	O
liquid	O
ch	O
##roma	O
##tography	O
was	O
performed	O
using	O
1	O
g	O
/	O
L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
pH	O
5	O
.	O
5	O
,	O
adjusted	O
by	O
glacial	B
ace	I
##tic	I
acid	I
)	O

A	O
Ph	O
##eno	O
##men	O
##ex	O
Lu	O
##x	O
5	O
##u	O
Cell	B
##ulos	I
##e	I
-	I
1	I
column	O
(	O
250	O
×	O
4	O
.	O
6	O
mm	O
)	O
was	O
used	O
for	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
with	O
40	O
%	O
met	B
##han	I
##ol	I
in	O
0	O
.	O
05	O
%	O
form	B
##ic	I
acid	I
a	O
##que	O
##ous	O
solution	O
as	O
a	O
mobile	O
phase	O
.	O

Because	O
Xu	O
et	O
al	O
.	O
found	O
that	O
est	B
##rogen	I
metabolism	O
changes	O
over	O
the	O
course	O
of	O
the	O
men	O
##st	O
##ru	O
##al	O
cycle	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
thought	O
to	O
be	O
in	O
other	O
phases	O
of	O
the	O
men	O
##st	O
##ru	O
##al	O
cycle	O
at	O
the	O
time	O
of	O
urine	O
collection	O
have	O
been	O
excluded	O
from	O
most	O
analyses	O
.	O

This	O
is	O
a	O
nice	O
contrast	O
with	O
respect	O
to	O
the	O
Penn	O
##ington	O
co	O
##hor	O
##t	O
and	O
indicates	O
the	O
important	O
role	O
that	O
diet	O
##ary	O
habits	O
play	O
in	O
the	O
o	B
##xy	I
##lip	I
##in	I
composition	O
of	O
blood	O
.	O

Extra	O
##cellular	O
g	B
##lut	I
##ama	I
##te	I
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
found	O
to	O
significantly	O
increase	O
upon	O
r	O
##H	O
##la	O
-	O
exposure	O
in	O
both	O
cell	O
types	O
in	O
amounts	O
corresponding	O
to	O
approximately	O
87	O
%	O
of	O
the	O
consumed	O
g	B
##lut	I
##amine	I
.	O

Similarly	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
transporting	O
lip	O
##op	O
##rote	O
##ins	O
,	O
ID	O
##L	O
and	O
HD	O
##L	O
,	O
were	O
significantly	O
lower	O
in	O
mothers	O
of	O
f	O
##etus	O
##es	O
with	O
sub	O
-	O
optimal	O
f	O
##etal	O
growth	O
compared	O
to	O
AG	O
##A	O
mothers	O
(	O
p	O
=	O
0	O
.	O
01	O
,	O
0	O
.	O
03	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
(	O
Table	O
)	O
.	O

It	O
is	O
post	O
##ulated	O
that	O
there	O
is	O
a	O
developmental	O
window	O
in	O
u	O
##tero	O
when	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
has	O
the	O
most	O
potent	O
adverse	O
effects	O
.	O

O	O
##xy	O
##gen	O
consumption	O
and	O
carbon	B
dioxide	I
production	O
were	O
measured	O
every	O
5	O
s	O
for	O
at	O
least	O
20	O
min	O
and	O
R	O
##EE	O
was	O
defined	O
as	O
the	O
mean	O
energy	O
expenditure	O
over	O
the	O
measured	O
period	O
.	O

There	O
was	O
no	O
evidence	O
for	O
metabolic	O
s	O
##c	O
##ram	O
##bling	O
of	O
the	O
is	O
##oto	O
##pe	O
in	O
the	O
three	O
carbon	O
##s	O
,	O
which	O
suggests	O
that	O
they	O
were	O
derived	O
from	O
glucose	S
via	O
g	O
##ly	O
##co	O
##lysis	O
.	O

Among	O
these	O
were	O
x	B
##ant	I
##hine	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##vale	I
##ric	I
acid	I
,	O
su	B
##cci	I
##nic	I
acid	I
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
and	O
f	B
##ru	I
##ct	I
##ose	I
.	O

HP	O
##LC	O
-	O
grade	O
water	O
(	O
J	O
##T	O
Baker	O
,	O
Philips	O
##burg	O
,	O
NJ	O
)	O
,	O
Me	B
##OH	I
(	O
E	O
##MD	O
,	O
Gibbs	O
##town	O
,	O
NJ	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
(	O
B	O
##D	O
##H	O
,	O
West	O
Chester	O
,	O
PA	O
)	O
were	O
used	O
in	O
the	O
SP	O
##E	O
procedure	O
described	O
below	O
.	O

In	O
our	O
population	O
,	O
we	O
observed	O
a	O
significant	O
increase	O
in	O
plasma	O
or	B
##ni	I
##thin	I
##e	I
concentrations	O
in	O
patients	O
with	O
C	O
##K	O
##D	O
##4	O
–	O
5	O
compared	O
with	O
C	O
##K	O
##D	O
##2	O
–	O
3	O
.	O

Among	O
signals	O
contributing	O
to	O
the	O
discrimination	O
(	O
p	O
(	O
co	O
##rr	O
)	O
>	O
05	O
##0	O
)	O
,	O
we	O
identified	O
and	O
confirmed	O
G	O
##ln	O
(	O
2	O
.	O
45	O
pp	O
##m	O
)	O
in	O
HC	O
##C	O
exhibiting	O
a	O
high	O
G	O
##S	O
stain	O
##ing	O
whereas	O
G	O
##S	O
##X	O
(	O
2	O
.	O
55	O
pp	O
##m	O
)	O
and	O
l	B
##ys	I
##ine	I
(	O
2	O
.	O
96	O
pp	O
##m	O
)	O
were	O
found	O
in	O
HC	O
##C	O
with	O
a	O
weak	O
G	O
##S	O
stain	O
##ing	O
(	O
D	O
)	O
.	O

A	O
targeted	O
meta	O
##bol	O
##omi	O
##c	O
study	O
of	O
patients	O
tested	O
after	O
se	O
##pta	O
##l	O
a	O
##bla	O
##tion	O
treatment	O
for	O
h	O
##yper	O
##tro	O
##phic	O
o	O
##bs	O
##truct	O
##ive	O
card	O
##io	O
##my	O
##op	O
##athy	O
identified	O
changes	O
in	O
the	O
circulating	O
concentrations	O
of	O
meta	O
##bol	O
##ites	O
in	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
,	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
cycle	O
,	O
and	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
.	O

HD	O
##L	O
,	O
high	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
h	O
##s	O
-	O
CR	O
##P	O
,	O
high	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
;	O
h	O
##s	O
-	O
IL	O
##6	O
,	O
high	O
sensitivity	O
inter	O
##le	O
##uki	O
##n	O
-	O
6	O
;	O
L	O
##D	O
##L	O
,	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
m	O
##t	O
##D	O
##NA	O
,	O
mitochondrial	O
de	B
##ox	I
##yr	I
##ib	I
##on	I
##uc	I
##le	I
##ic	I
acid	I
.	O

The	O
dried	O
residue	O
was	O
dissolved	O
in	O
580	O
µ	O
##L	O
of	O
D	O
_	O
2	O
O	O
,	O
which	O
contained	O
30	O
µ	O
##M	O
phosphate	S
buffer	O
solution	O
(	O
PBS	O
,	O
pH	O
7	O
.	O
4	O
)	O
,	O
providing	O
the	O
de	O
##uter	O
##ium	O
lock	O
signal	O
for	O
the	O
N	O
##MR	O
s	O
##pect	O
##rome	O
##ter	O
,	O
and	O
0	O
.	O
5	O
m	O
##M	O
sodium	B
(	I
3	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
-	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
te	I
##tra	I
##de	I
##uter	I
##io	I
##p	I
##rop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
,	O
providing	O
the	O
chemical	O
shift	O
reference	O
(	O
δ	O
##0	O
.	O
0	O
)	O
and	O
internal	O
concentration	O
standard	O
.	O

One	O
-	O
and	O
2	O
-	O
dimensional	O
N	O
##MR	O
analyses	O
demonstrated	O
that	O
this	O
der	O
##iva	O
##tized	O
product	O
is	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
5	I
-	I
met	I
##ho	I
##xy	I
##im	I
##ino	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
su	I
##lf	I
##oxide	I
(	O
11	O
,	O
and	O
)	O
.	O

Pro	O
##tein	O
precipitation	O
were	O
done	O
for	O
each	O
sample	O
by	O
using	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Fast	O
##ing	O
plasma	O
glucose	S
was	O
not	O
measured	O
in	O
W	O
##HS	O
.	O

The	O
smoking	O
status	O
was	O
confirmed	O
by	O
analysis	O
of	O
total	O
co	B
##tin	I
##ine	I
which	O
averaged	O
1785	O
ng	O
/	O
m	O
##l	O
.	O

Blood	O
levels	O
of	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ctic	I
acid	I
reflect	O
bacterial	O
as	O
well	O
as	O
diet	O
and	O
liver	O
metabolism	O
.	O

Moreover	O
,	O
one	O
meta	O
##bol	O
##ite	O
,	O
ta	B
##uri	I
##ne	I
,	O
was	O
definitive	O
##ly	O
identified	O
by	O
matching	O
the	O
retention	O
time	O
and	O
accurate	O
mass	O
with	O
its	O
authentic	O
standard	O
under	O
the	O
same	O
experimental	O
condition	O
.	O

Five	O
metabolic	O
pathways	O
were	O
statistical	O
##ly	O
significant	O
at	O
the	O
P	O
<	O
0	O
.	O
05	O
level	O
among	O
women	O
,	O
including	O
bi	O
##le	O
acid	O
metabolism	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
01	O
##2	O
)	O
,	O
to	B
##co	I
##pher	I
##ol	I
metabolism	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
02	O
##2	O
)	O
,	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
02	O
##7	O
)	O
,	O
K	O
##re	O
##b	O
’	O
s	O
cycle	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
03	O
##2	O
)	O
,	O
and	O
dip	O
##eptide	O
##s	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
04	O
##3	O
)	O
;	O
however	O
,	O
after	O
correct	O
##ing	O
for	O
multiple	O
testing	O
for	O
44	O
different	O
pathways	O
,	O
none	O
of	O
these	O
remained	O
statistical	O
##ly	O
significant	O
.	O

Inc	O
##rea	O
##sing	O
evidence	O
points	O
towards	O
an	O
important	O
role	O
for	O
lip	O
##ids	O
in	O
car	O
##cin	O
##ogen	O
##esis	O
,	O
and	O
altered	O
cellular	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
composition	O
has	O
recently	O
been	O
reported	O
across	O
a	O
variety	O
of	O
cancer	O
sub	O
‐	O
types	O
(	O
Do	O
##ria	O
et	O
al	O
.	O

Additionally	O
,	O
ad	O
##rena	O
##l	O
tumors	O
are	O
frequently	O
associated	O
with	O
lower	O
levels	O
of	O
autonomous	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
in	O
patients	O
lacking	O
over	O
##t	O
clinical	O
features	O
of	O
C	O
##ushing	O
'	O
s	O
syndrome	O
.	O

Ten	O
of	O
13	O
T	O
##rp	O
meta	O
##bol	O
##ites	O
decreased	O
across	O
the	O
night	O
,	O
while	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
increased	O
in	O
both	O
groups	O
.	O

Furthermore	O
,	O
there	O
are	O
distinct	O
differences	O
in	O
chemistry	O
of	O
pathway	O
C	O
,	O
and	O
the	O
newly	O
proposed	O
pathway	O
D	O
.	O
Cat	B
##ech	I
##ol	I
-	I
q	I
##uin	I
##one	I
add	O
##uc	O
##ts	O
are	O
mainly	O
formed	O
at	O
A	O
ring	O
(	O
C	O
-	O
1	O
)	O
of	O
the	O
s	O
##tero	O
##id	O
through	O
1	B
,	I
4	I
-	I
Michael	I
addition	O
,	O
whereas	O
est	O
##rogen	O
-	O
met	O
##hi	O
##de	O
add	O
##uc	O
##ts	O
are	O
formed	O
at	O
the	O
junction	O
of	O
B	O
and	O
C	O
ring	O
(	O
C	O
-	O
9	O
)	O
of	O
the	O
s	O
##tero	O
##id	O
by	O
1	B
,	I
6	I
-	I
Michael	I
addition	O
.	O

The	O
short	O
-	O
term	O
(	O
bench	O
-	O
top	O
)	O
stability	O
of	O
the	O
FA	O
##U	O
and	O
FM	O
##A	O
##U	O
in	O
met	B
##han	I
##ol	I
(	O
working	O
solution	O
)	O
at	O
the	O
concentration	O
of	O
1	O
and	O
100	O
μ	O
##g	O
/	O
m	O
##l	O
as	O
well	O
as	O
in	O
plasma	O
at	O
the	O
concentration	O
of	O
30	O
and	O
1600	O
ng	O
/	O
m	O
##l	O
for	O
FA	O
##U	O
and	O
6	O
and	O
800	O
ng	O
/	O
m	O
##l	O
for	O
FM	O
##A	O
##U	O
were	O
tested	O
at	O
ambient	O
temperature	O
(	O
25	O
##°	O
##C	O
)	O
for	O
6	O
hour	O
.	O

Only	O
one	O
molecule	O
,	O
is	B
##oc	I
##it	I
##rate	I
,	O
achieved	O
statistical	O
sign	O
##i	O
##ﬁ	O
##can	O
##ce	O
between	O
patients	O
with	O
strict	O
##ures	O
and	O
healthy	O
controls	O
.	O

Ana	B
##stro	I
##zo	I
##le	I
(	O
1	O
µ	O
##m	O
or	O
20	O
µ	O
##m	O
)	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
30	O
min	O
at	O
37	O
##°	O
##C	O
with	O
H	O
##LM	O
##s	O
(	O
0	O
.	O
5	O
mg	O
m	O
##l	O
_	O
−	O
##1	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
D	O
##H	O
##EA	O
:	O
De	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
.	O

Inc	O
##reased	O
serum	O
c	B
##it	I
##rate	I
levels	O
in	O
patients	O
who	O
died	O
within	O
three	O
months	O
after	O
onset	O
of	O
A	O
##HF	O
further	O
sub	O
##stant	O
##iate	O
an	O
increased	O
supply	O
of	O
the	O
liver	O
and	O
other	O
tissues	O
with	O
fatty	O
acids	O
.	O

De	B
##ox	I
##yi	I
##nos	I
##ine	I
correlated	O
with	O
c	O
##AM	O
##P	O
(	O
r	O
=	O
0	O
.	O
52	O
;	O

Among	O
the	O
other	O
10	O
samples	O
,	O
9	O
samples	O
classified	O
for	O
PC	O
##OS	O
according	O
to	O
and	B
##ros	I
##tan	I
##ed	I
##iol	I
levels	O
,	O
while	O
6	O
of	O
10	O
samples	O
qualified	O
for	O
PC	O
##OS	O
according	O
to	O
the	O
more	O
complex	O
best	O
ratio	O
calculation	O
including	O
four	O
meta	O
##bol	O
##ites	O
.	O

Region	O
##s	O
containing	O
residual	O
water	O
and	O
met	B
##han	I
##ol	I
signals	O
were	O
removed	O
,	O
and	O
the	O
s	O
##pect	O
##ra	O
were	O
bin	O
##ned	O
into	O
integrated	O
segments	O
with	O
equal	O
width	O
##s	O
of	O
0	O
.	O
01	O
pp	O
##m	O
and	O
adjusted	O
by	O
pro	O
##ba	O
##bil	O
##istic	O
q	O
##uo	O
##tien	O
##t	O
normal	O
##ization	O
and	O
par	O
##eto	O
-	O
s	O
##cal	O
##ing	O
prior	O
to	O
multi	O
##var	O
##iate	O
analysis	O
.	O

Additionally	O
,	O
some	O
peaks	O
not	O
easily	O
observed	O
by	O
visual	O
inspection	O
of	O
the	O
mass	O
s	O
##pect	O
##ra	O
,	O
such	O
as	O
PS	B
(	I
40	I
:	I
5	I
)	I
,	O
m	O
/	O
z	O
83	O
##6	O
.	O
2	O
,	O
were	O
recognized	O
by	O
the	O
class	O
##ifier	O
.	O

The	O
shift	O
from	O
lip	O
##id	O
up	O
##take	O
to	O
de	O
no	O
##vo	O
lip	O
##ogen	O
##esis	O
in	O
cancer	O
cells	O
leads	O
to	O
increased	O
membrane	O
lip	O
##id	O
sat	O
##uration	O
,	O
resulting	O
in	O
higher	O
levels	O
of	O
saturated	O
and	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
potentially	O
protecting	O
cancer	O
cells	O
from	O
o	O
##xi	O
##da	O
##tive	O
damage	O
by	O
reducing	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
.	O

Similarly	O
,	O
levels	O
of	O
se	B
##rot	I
##oni	I
##n	I
,	O
a	O
derivative	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
increased	O
(	O
2	O
.	O
4	O
fold	O
)	O
after	O
le	O
##pt	O
##in	O
replacement	O
.	O

combined	O
with	O
stain	O
##ing	O
with	O
prop	O
##id	O
##ium	O
i	B
##od	I
##ide	I
.	O

T	O
##iss	O
##ue	O
distributions	O
and	O
inter	O
-	O
donor	O
variations	O
in	O
oral	O
m	O
##uc	O
##osa	O
##l	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
-	I
relevant	I
metabolic	O
enzymes	O
.	O

In	O
the	O
case	O
of	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
the	O
effects	O
appear	O
to	O
be	O
seen	O
in	O
the	O
accumulation	O
of	O
se	B
##rot	I
##oni	I
##n	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
##try	I
##pta	I
##mine	I
,	I
5	I
-	I
H	I
##T	I
)	I
,	O
to	O
the	O
de	O
##tri	O
##ment	O
of	O
me	B
##lat	I
##oni	I
##n	I
.	O

L	O
##MI	O
was	O
positively	O
associated	O
with	O
S	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
phosphate	I
.	O

This	O
meta	O
##bol	O
##ite	O
represented	O
the	O
main	O
circulating	O
meta	O
##bol	O
##ite	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
,	O
with	O
wide	O
inter	O
##patient	O
var	O
##iability	O
.	O

However	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
were	O
elevated	O
only	O
in	O
tissue	O
bio	O
##ps	O
##ies	O
with	O
a	O
G	O
##lea	O
##son	O
pattern	O
of	O
8	O
or	O
worse	O
in	O
the	O
M	O
##c	O
##D	O
##un	O
##n	O
et	O
al	O
report	O
.	O

The	O
largest	O
lip	O
##id	O
%	O
decrease	O
was	O
that	O
of	O
T	B
##G	I
48	I
:	I
1	I
(	O
CH	O
##E	O
##BI	O
:	O
85	O
##7	O
##26	O
)	O
,	O
with	O
a	O
median	O
decrease	O
of	O
43	O
.	O
1	O
%	O
.	O

Similar	O
with	O
D	O
##PI	O
method	O
,	O
the	O
peak	O
in	O
##tens	O
##ities	O
of	O
m	O
/	O
z	O
333	O
and	O
340	O
from	O
B	O
##Q	O
##B	O
and	O
B	O
##Q	O
##B	O
-	O
d	O
_	O
7	O
labeled	O
th	B
##iol	I
##s	I
at	O
retention	O
times	O
of	O
14	O
.	O
4	O
and	O
16	O
.	O
3	O
min	O
in	O
the	O
MR	O
##M	O
mode	O
were	O
also	O
same	O
.	O

Ser	B
##ine	I
not	O
only	O
activate	O
##s	O
this	O
enzyme	O
upon	O
binding	O
,	O
but	O
de	O
##ple	O
##tion	O
of	O
se	B
##rine	I
results	O
in	O
an	O
at	O
##ten	O
##uation	O
of	O
P	O
##K	O
##M	O
##2	O
activity	O
.	O

K	O
##b	O
distant	O
from	O
pro	O
##line	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
o	O
##xi	O
##das	O
##e	O
)	O
1	O
(	O
PR	O
##OD	O
##H	O
)	O
gene	O
(	O
P	O
-	O
value	O
=	O
1	O
.	O
11	O
##×	O
##10	O
_	O
−	O
##19	O
)	O
associated	O
with	O
pro	B
##line	I
levels	O
and	O
r	O
##s	O
##11	O
##7	O
##16	O
##14	O
in	O
the	O
5	O
’	O
U	O
##TR	O
of	O
SL	O
##C	O
##16	O
##A	O
##9	O
(	O
so	O
##lut	O
##e	O
carrier	O
family	O
16	O
,	O
member	O
9	O
)	O
associated	O
with	O
car	B
##ni	I
##tine	I
level	O
(	O
P	O
-	O
value	O
=	O
4	O
.	O
81	O
##×	O
##10	O
_	O
−	O
##14	O
)	O
–	O
.	O

Analysis	O
revealed	O
that	O
specific	O
meta	O
##bol	O
##ite	O
changes	O
overlap	O
##ped	O
across	O
both	O
metric	O
##s	O
,	O
including	O
glucose	S
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
c	B
##it	I
##rate	I
,	O
g	B
##ly	I
##cine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
ta	B
##uri	I
##ne	I
,	O
indicating	O
that	O
the	O
networks	O
for	O
metabolic	O
pathway	O
per	O
##tur	O
##bation	O
##s	O
in	O
EC	O
,	O
potentially	O
involved	O
in	O
but	O
not	O
limited	O
to	O
disruption	O
of	O
fatty	O
acid	O
metabolism	O
,	O
glucose	S
and	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolism	O
,	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
and	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
.	O

Dec	O
##line	O
in	O
the	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
in	O
R	O
##VD	O
was	O
suggested	O
to	O
reflect	O
decreased	O
20	B
-	I
H	I
##ET	I
##E	I
production	O
by	O
the	O
T	O
##AL	O
and	O
pro	O
##ximal	O
tub	O
##ules	O
that	O
may	O
contribute	O
to	O
increased	O
Na	O
_	O
+	O
re	O
##ab	O
##sor	O
##ption	O
in	O
these	O
tub	O
##ular	O
segments	O
.	O

Of	O
particular	O
interest	O
are	O
the	O
significantly	O
lower	O
levels	O
of	O
the	O
met	B
##ho	I
##xy	I
##cate	I
##cho	I
##l	I
est	O
##rogen	O
##s	O
in	O
the	O
women	O
with	O
breast	O
cancer	O
or	O
at	O
high	O
risk	O
compared	O
to	O
the	O
control	O
women	O
,	O
because	O
this	O
represents	O
a	O
major	O
protective	O
pathway	O
in	O
est	B
##rogen	I
metabolism	O
.	O

In	O
contrast	O
,	O
patients	O
with	O
ACC	O
ex	O
##cre	O
##ted	O
less	O
of	O
the	O
meta	O
##bol	O
##ite	O
all	B
##o	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##ico	I
##ster	I
##one	I
(	O
all	O
##o	O
-	O
T	O
##H	O
##B	O
)	O
compared	O
to	O
subjects	O
without	O
ACC	O
(	O
P	O
=	O
0	O
.	O
01	O
##9	O
)	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
obtained	O
at	O
base	O
##line	O
from	O
all	O
study	O
participants	O
when	O
they	O
were	O
in	O
an	O
un	O
##fast	O
##ed	O
state	O
,	O
given	O
that	O
these	O
were	O
people	O
with	O
type	O
2	O
diabetes	O
at	O
risk	O
of	O
h	B
##y	I
##po	I
##gly	I
##ca	I
##em	I
##ic	I
episodes	O
.	O

β	B
-	I
ion	I
##yl	I
##iden	I
##ea	I
##ce	I
##tic	I
acid	O
)	O
had	O
no	O
effect	O
on	O
AT	O
##RA	O
-	O
induced	O
gene	O
expression	O
in	O
He	O
##p	O
##G	O
##2	O
cells	O
.	O

In	O
a	O
prospective	O
Finnish	O
study	O
,	O
it	O
was	O
found	O
that	O
children	O
who	O
developed	O
T	O
##1	O
##DM	O
have	O
reduced	O
serum	O
levels	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
at	O
birth	O
,	O
next	O
to	O
lower	O
levels	O
of	O
multiple	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
throughout	O
the	O
follow	O
-	O
up	O
.	O

Stock	O
solutions	O
at	O
about	O
1	O
mg	O
/	O
m	O
##l	O
were	O
prepared	O
in	O
met	B
##han	I
##ol	I
and	O
stored	O
at	O
−	O
##70	O
°C	O
.	O

PC	O
##A	O
loading	O
plot	O
shows	O
that	O
the	O
control	O
group	O
samples	O
signals	O
were	O
more	O
intense	O
at	O
δ	O
3	O
.	O
16	O
–	O
3	O
.	O
24	O
pp	O
##m	O
,	O
indicating	O
that	O
healthy	O
volunteers	O
had	O
ch	B
##olin	I
##e	I
and	O
ta	B
##uri	I
##ne	I
serum	O
levels	O
higher	O
than	O
the	O
o	O
##ste	O
##ope	O
##nia	O
/	O
o	O
##ste	O
##op	O
##oro	O
##sis	O
patients	O
.	O

We	O
must	O
precise	O
that	O
for	O
those	O
meta	O
##bol	O
##ites	O
q	O
##uant	O
##ified	O
also	O
in	O
the	O
targeted	O
approach	O
(	O
i	O
.	O
e	O
.	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
his	B
##ti	I
##dine	I
)	O
,	O
we	O
used	O
the	O
concentration	O
values	O
instead	O
of	O
peak	O
in	O
##tens	O
##ities	O
as	O
they	O
are	O
more	O
reliable	O
.	O

Apparently	O
,	O
glucose	S
in	O
the	O
N	O
##DR	O
group	O
was	O
even	O
more	O
poorly	O
controlled	O
than	O
in	O
the	O
PD	O
##R	O
group	O
.	O

Mal	B
##tos	I
##e	I
is	O
a	O
di	B
##sa	I
##cc	I
##hari	I
##de	I
derived	O
from	O
two	O
units	O
of	O
glucose	S
and	O
is	O
found	O
largely	O
in	O
vegetables	O
,	O
fruits	O
and	O
grains	O
.	O

We	O
also	O
used	O
Mass	O
Hunter	O
Q	O
##uant	O
##itative	O
Analysis	O
B	O
.	O
07	O
.	O
00	O
to	O
q	O
##uant	O
##ify	O
the	O
15	B
-	I
H	I
##ET	I
##E	I
in	O
which	O
the	O
de	O
##uter	O
##ated	O
internal	O
standard	O
15	B
-	I
H	I
##ET	I
##E	I
-	I
d	I
##8	I
(	O
C	O
##ayman	O
Chemical	O
)	O
was	O
used	O
.	O

Ali	O
##q	O
##uo	O
##ts	O
of	O
ch	B
##lor	I
##of	I
##orm	I
extract	O
##s	O
were	O
analyzed	O
directly	O
by	O
electro	O
##sp	O
##ray	O
as	O
described	O
in	O
method	O
section	O
.	O

)	O
,	O
suggesting	O
a	O
possible	O
reservoir	O
for	O
Met	B
##hyl	I
##ob	I
##act	I
##eri	I
##um	I
ex	O
##tor	O
##que	O
##ns	O
toxic	O
activity	O
within	O
the	O
peripheral	O
blood	O
.	O

C	B
##it	I
##rate	I
and	O
his	B
##ti	I
##dine	I
correlated	O
with	O
the	O
severity	O
of	O
organ	O
d	O
##ys	O
##function	O
.	O

Furthermore	O
,	O
a	O
third	O
study	O
by	O
Qi	O
##u	O
et	O
al	O
.	O
used	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
to	O
prove	O
that	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
and	O
palm	B
##itic	I
acid	I
were	O
potential	O
fatty	O
acid	O
bio	O
##mark	O
##ers	O
of	O
HC	O
##C	O
patients	O
.	O

urine	O
c	B
##rea	I
##tin	I
##ine	I

Pro	O
##mine	O
##ntly	O
,	O
three	O
branched	O
-	O
chain	O
amino	O
acids	O
(	B
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
displayed	O
low	O
concentrations	O
in	O
N	O
##DM	O
##M	O
patients	O
,	O
indicating	O
a	O
possible	O
higher	O
consumption	O
of	O
these	O
meta	O
##bol	O
##ites	O
(	O
up	O
##take	O
by	O
the	O
M	O
##M	O
cells	O
in	O
the	O
bone	O
ma	O
##rrow	O
)	O
.	O

As	O
even	O
lower	O
post	O
-	O
training	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
were	O
demonstrated	O
in	O
our	O
study	O
(	O
see	O
and	O
b	O
)	O
,	O
the	O
question	O
arises	O
if	O
adaptations	O
in	O
pu	B
##rine	I
metabolism	O
as	O
a	O
response	O
to	O
the	O
exhaust	O
##ing	O
H	O
##II	O
##T	O
have	O
occurred	O
,	O
resulting	O
in	O
a	O
reduced	O
muscular	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
loss	O
into	O
blood	O
even	O
in	O
resting	O
conditions	O
and	O
finally	O
leading	O
to	O
a	O
decreased	O
delivery	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
to	O
the	O
kidney	O
##s	O
and	O
consequently	O
to	O
a	O
lower	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
ex	O
##cre	O
##tion	O
via	O
urine	O
.	O

Fast	O
##ing	O
glucose	S
levels	O
have	O
not	O
been	O
measured	O
in	O
previous	O
SA	O
##L	O
##IA	O
examinations	O
so	O
that	O
we	O
could	O
not	O
anal	O
##ys	O
##e	O
associations	O
between	O
AG	O
##E	O
levels	O
and	O
duration	S
of	O
IF	O
##G	O
.	O

We	O
also	O
demonstrated	O
higher	O
amounts	O
of	O
car	B
##ni	I
##tine	I
and	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
in	O
M	O
##NG	O
group	O
but	O
PT	O
##C	O
samples	O
did	O
not	O
show	O
significant	O
alterations	O
of	O
these	O
meta	O
##bol	O
##ites	O
.	O

We	O
could	O
not	O
identify	O
significant	O
treatment	O
-	O
related	O
changes	O
in	O
meta	O
##bol	O
##ite	O
profiles	O
of	O
the	O
urine	O
samples	O
in	O
the	O
H	B
##V	I
group	O
.	O

These	O
separation	O
##s	O
were	O
associated	O
with	O
a	O
total	O
(	O
i	O
.	O
e	O
.	O
,	O
identified	O
and	O
non	O
-	O
identified	O
)	O
of	O
66	O
compounds	O
for	O
o	B
##lan	I
##za	I
##pine	I
(	O
Figure	O
)	O
,	O
24	O
compounds	O
for	O
r	B
##is	I
##per	I
##ido	I
##ne	I
(	O
Figure	O
)	O
and	O
52	O
compounds	O
for	O
que	B
##tia	I
##pine	I
(	O
Figure	O
)	O
.	O

After	O
that	O
period	O
,	O
sample	O
was	O
washed	O
with	O
cent	O
##ri	O
##fu	O
##gation	O
and	O
re	O
##sus	O
##pen	O
##ded	O
in	O
50	O
μ	O
##l	O
of	O
hybrid	O
##ization	O
buffer	O
[	O
0	O
.	O
9	O
M	O
Na	O
##C	O
##l	O
,	O
20	O
m	O
##M	O
Tri	O
##s	O
–	O
HC	O
##l	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
0	O
.	O
1	O
%	O
[	O
w	O
##t	O
/	O
vol	O
]	O
sodium	B
do	I
##de	I
##cy	I
##l	I
su	I
##l	I
##phate	I
(	O
SD	O
##S	O
)	O
]	O
with	O
5	O
μ	O
##l	O
of	O
50	O
ng	O
/	O
μ	O
##l	O
fluorescent	O
##ly	O
Cy	O
##5	O
-	O
labelled	O
o	O
##li	O
##gon	O
##uc	O
##leo	O
##tide	O
probe	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
the	O
appropriate	O
hybrid	O
##ization	O
temperature	O
(	O
Table	O
)	O
.	O

During	O
the	O
period	O
of	O
two	O
hours	O
,	O
we	O
detected	O
a	O
distinctive	O
decrease	O
in	O
the	O
concentration	O
of	O
glucose	S
in	O
the	O
extra	O
##cellular	O
medium	O
of	O
S	O
##9	O
and	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
.	O

G	B
##la	I
##cial	I
ace	I
##tic	I
acid	I
,	O
sodium	O
bi	O
##car	O
##bon	O
##ate	O
,	O
and	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
were	O
purchased	O
from	O
J	O
##T	O
Baker	O
(	O
Phillips	O
##burg	O
,	O
NJ	O
,	O
USA	O
)	O
and	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
and	O
sodium	B
ace	I
##tate	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Fair	O
Lawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

For	O
example	O
,	O
body	O
burden	O
of	O
1	B
,	I
2	I
,	I
3	I
,	I
4	I
,	I
6	I
,	I
7	I
,	I
8	I
-	I
he	I
##pta	I
##CD	I
##F	I
was	O
positively	O
associated	O
with	O
serum	O
levels	O
of	O
2	B
-	I
OH	I
-	I
E	I
_	I
2	I
,	O
after	O
the	O
adjustment	O
for	O
other	O
con	O
##gene	O
##rs	O
and	O
maternal	O
age	O
.	O

Based	O
on	O
these	O
results	O
and	O
reports	O
that	O
ma	O
##ximal	O
meta	O
##bol	O
##ite	O
disturbance	O
##s	O
are	O
observed	O
in	O
low	O
-	O
and	O
intermediate	B
-	I
risk	I
tumors	O
,	O
we	O
analyzed	O
with	O
P	O
##LS	O
a	O
subgroup	O
of	O
11	O
samples	O
co	O
##rrel	O
##ating	O
to	O
these	O
grades	O
confirmed	O
by	O
R	B
##P	I
his	O
##tology	O
only	O
(	O
A	O
–	O
5	O
##C	O
,	O
Table	O
S	O
##1	O
M	O
##5	O
)	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
Ce	B
##r	I
provides	O
additional	O
pro	O
##gno	O
##stic	O
utility	O
for	O
C	O
##VD	O
beyond	O
that	O
from	O
L	O
##D	O
##L	O
-	O
C	O
–	O
perhaps	O
because	O
it	O
acts	O
as	O
a	O
pro	O
##xy	O
to	O
standard	O
##ize	O
changes	O
in	O
L	O
##D	O
##L	O
-	O
C	O
mass	O
by	O
changes	O
in	O
a	O
##po	O
##B	O
concentration	O
,	O
which	O
is	O
the	O
biological	O
de	O
##ter	O
##mina	O
##nt	O
of	O
at	O
##her	O
##ogenic	O
##ity	O
of	O
a	O
high	O
L	O
##D	O
##L	O
-	O
C	O
level	O
.	O

Take	O
##n	O
together	O
,	O
these	O
findings	O
support	O
the	O
importance	O
of	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
in	O
MS	O
and	O
in	O
particular	O
in	O
the	O
SP	O
##MS	O
stage	O
of	O
the	O
disease	O
,	O
and	O
suggest	O
them	O
as	O
potential	O
markers	O
of	O
disease	O
progression	O
.	O

1	O
-	O
_	O
13	O
C	B
-	I
G	I
##ly	I
##cine	I
en	O
##rich	O
##ment	O
for	O
the	O
is	O
##oto	O
##pe	O
in	O
##fusion	O
protocol	O
was	O
analyzed	O
using	O
a	O
previously	O
developed	O
method	O
.	O
_	O
−	O
For	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
,	O
g	B
##ly	I
##cola	I
##te	I
,	O
and	O
o	B
##xa	I
##late	I
,	O
several	O
different	O
der	O
##iva	O
##ti	O
##zation	O
techniques	O
and	O
sample	O
preparation	O
methods	O
were	O
investigated	O
.	O

It	O
is	O
not	O
possible	O
to	O
ass	O
##ay	O
the	O
entire	O
meta	O
##bol	O
##ome	O
with	O
one	O
platform	O
due	O
to	O
large	O
differences	O
in	O
the	O
p	O
##hy	O
##sio	O
##chemical	O
properties	O
of	O
the	O
different	O
meta	O
##bol	O
##ites	O
(	O
e	O
.	O
g	O
.	O
lip	O
##op	O
##hil	O
##ic	O
and	O
h	B
##ydro	I
##phi	I
##lic	I
meta	O
##bol	O
##ites	O
)	O
.	O

E	O
##2	O
could	O
increase	O
breast	O
cancer	O
risk	O
through	O
mechanisms	O
in	O
which	O
E	O
##2	O
acts	O
either	O
as	O
a	O
hormone	O
to	O
stimulate	O
a	O
##ber	O
##rant	O
cell	O
proliferation	O
or	O
as	O
the	O
precursor	O
to	O
the	O
formation	O
of	O
g	O
##eno	O
##to	O
##xi	O
##c	O
cat	B
##ech	I
##ol	I
meta	O
##bol	O
##ites	O
[	O
,	O
,	O
]	O
.	O

Statistical	O
analysis	O
shows	O
l	B
##ino	I
##len	I
##ic	I
acid	I
to	O
be	O
significantly	O
different	O
between	O
p	O
##CR	O
and	O
SD	O
groups	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Two	O
further	O
targeted	O
meta	O
##bol	O
##ites	O
,	O
β	O
##N	O
##M	O
and	O
se	B
##rot	I
##oni	I
##n	I
used	O
neo	O
##pt	O
##eri	O
##n	O
-	O
_	O
13	O
C	O
_	O
5	O
and	O
do	B
##pa	I
##mine	I
-	I
D	I
_	I
4	I
as	O
sur	O
##rogate	O
internal	O
standards	O
to	O
enable	O
at	O
least	O
semi	O
##qua	O
##nti	O
##fication	O
.	O

(	O
A	O
)	O
UP	O
##LC	O
-	O
E	O
##SI	O
/	O
MS	O
analysis	O
of	O
reaction	O
products	O
formed	O
by	O
reaction	O
of	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
with	O
ace	B
##tic	I
an	I
##hy	I
##dr	I
##ide	I
,	O
following	O
SP	O
##E	O
.	O

The	O
human	O
metabolism	O
of	O
ca	B
##ffe	I
##ine	I
,	O
which	O
is	O
naturally	O
present	O
in	O
green	O
coffee	O
beans	O
and	O
largely	O
un	O
##af	O
##fected	O
by	O
r	O
##oast	O
##ing	O
,	O
has	O
been	O
well	O
documented	O
(	O
,	O
,	O
)	O
;	O
ca	B
##ffe	I
##ine	I
and	O
7	O
ca	B
##ffe	I
##ine	I
meta	O
##bol	O
##ites	O
(	O
highlighted	O
in	O
blue	O
in	O
)	O
were	O
significantly	O
associated	O
with	O
coffee	O
intake	O
in	O
our	O
study	O
.	O

Forward	O
and	O
reverse	O
prime	O
##r	O
probe	O
##s	O
used	O
for	O
R	O
##T	O
-	O
PC	O
##R	O
of	O
mitochondrial	O
de	O
##hy	O
##dr	O
##ogen	O
##ases	O
,	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##se	O
,	O
and	O
g	B
##lut	I
##ami	I
##nas	I
##e	I
_	I
A	I
_	O

In	O
contrast	O
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
concentrations	O
in	O
PC	O
##OS	O
samples	O
were	O
notably	O
enhanced	O
as	O
compared	O
with	O
the	O
normal	O
controls	O
independently	O
of	O
o	O
##besity	O
or	O
I	O
##R	O
,	O
indicating	O
opposite	O
impacts	O
of	O
PC	O
##OS	O
and	O
its	O
two	O
common	O
features	O
on	O
the	O
metabolism	O
of	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
(	O
Additional	O
files	O
and	O
)	O
.	O

The	O
most	O
down	O
-	O
regulated	O
pathway	O
in	O
the	O
ad	O
##ip	O
##ose	O
tissue	O
was	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
degradation	O
(	O
p	O
=	O
1	O
.	O
1	O

The	O
long	O
chain	O
saturated	O
fatty	O
acids	O
and	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
of	O
the	O
n	O
-	O
3	O
,	O
n	O
-	O
6	O
,	O
n	O
-	O
7	O
and	O
n	O
-	O
9	O
series	O
can	O
be	O
synthesized	O
from	O
my	B
##rist	I
##ic	I
acid	I
(	B
C	B
##14	I
:	I
0	I
)	O
and	O
palm	B
##itic	I
acid	I
(	B
C	B
##16	I
:	I
0	I
)	O
produced	O
by	O
ACC	O
and	O
FA	O
##SN	O
.	O

Inter	B
##fer	I
##on	I
-	I
α	I
-	I
2	I
##a	I
,	O
a	O
s	O
##ter	O
##ile	O
protein	O
product	O
for	O
use	O
by	O
injection	O
,	O
binds	O
to	O
type	O
I	O
inter	O
##fer	O
##on	O
receptors	O
(	O
IF	O
##NA	O
##R	O
##1	O
and	O
IF	O
##NA	O
##R	O
##2	O
##c	O
)	O
,	O
which	O
upon	O
dim	O
##eri	O
##sation	O
activate	O
##s	O
two	O
J	O
##A	O
##K	O
##s	O
(	O
Jan	O
##us	O
kinase	O
##s	O
)	O
:	O
J	O
##A	O
##K	O
##1	O
and	O
T	O
##Y	O
##K	O
##2	O
.	O

H	O
##NE	O
-	O
MA	O
was	O
present	O
in	O
the	O
range	O
of	O
0	O
.	O
17	O
-	O
12	O
.	O
19	O
mg	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
(	O
7	O
.	O
4	O
-	O
225	O
n	O
##M	O
)	O
and	O
D	O
##H	O
##N	O
-	O
MA	O
at	O
levels	O
of	O
0	O
.	O
22	O
-	O
17	O
.	O
90	O
mg	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
(	O
6	O
.	O
6	O
-	O
316	O
n	O
##M	O
)	O
.	O

Studies	O
have	O
shown	O
g	B
##lut	I
##amine	I
metabolism	O
re	O
##p	O
##rog	O
##ram	O
##ming	O
in	O
a	O
tissue	O
-	O
dependent	O
and	O
tumor	O
-	O
he	O
##tero	O
##gene	O
##ous	O
manner	O
.	O

In	O
89	O
%	O
of	O
samples	O
,	O
levels	O
of	O
D	O
##PP	O
(	O
non	O
-	O
normal	O
##ized	O
)	O
were	O
higher	O
than	O
those	O
of	O
B	O
##DC	O
##PP	O
,	O
ranging	O
from	O
287	O
to	O
74	O
##43	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
,	O
with	O
a	O
median	O
of	O
80	O
##3	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
.	O

Each	O
micro	O
##so	O
##mal	O
in	O
##cu	O
##bation	O
experiment	O
was	O
carried	O
out	O
in	O
du	O
##plicate	O
m	O
A	O
##ppa	O
##rent	O
rates	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
1	O
µ	O
##m	O
and	O
20	O
µ	O
##m	O
)	O
h	O
##ydro	O
##xy	O
##lation	O
in	O
a	O
panel	O
of	O
11	O
pre	O
-	O
p	O
##hen	O
##otype	O
##d	O
H	O
##LM	O
##s	O
were	O
characterized	O
by	O
inter	O
##ind	O
##iv	O
##id	O
##ual	O
var	O
##iability	O
.	O

A	O
total	O
of	O
239	O
lip	O
##ids	O
were	O
identified	O
in	O
the	O
serum	O
,	O
including	O
neutral	O
lip	O
##ids	O
(	O
CE	O
:	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##er	I
;	O
D	O
##AG	O
:	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
;	O
T	O
##AG	O
:	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
)	O
;	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
PC	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
LP	O
##C	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
P	O
##E	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
;	O
LP	O
##E	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
;	O
P	O
##I	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
;	O
LP	O
##I	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
)	O
;	O
plasma	O
##log	O
##ens	O
(	O
PC	O
-	O
O	O
:	O
ch	B
##olin	I
##e	I
plasma	O
##log	O
##en	O
and	O
P	O
##E	O
-	O
O	O
:	O
ethanol	B
##amine	I
plasma	O
##log	O
##en	O
;	O
LP	O
##C	O
-	O
O	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
plasma	O
##log	O
##en	O
;	O
LP	O
##E	O
-	O
O	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
plasma	O
##log	O
##en	O
)	O
;	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
SM	O
:	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
Ce	B
##r	I
:	O
c	B
##era	I
##mi	I
##de	I
;	O
He	O
##x	O
##C	O
##er	O
:	O
he	B
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
)	O
,	O
and	O
free	O
fatty	O
acids	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
)	O
.	O

While	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
is	O
widely	O
considered	O
as	O
the	O
premier	O
bio	O
##mark	O
##er	O
for	O
detection	O
of	O
chemical	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
,	O
it	O
has	O
been	O
noted	O
that	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
via	O
en	O
##zy	O
##matic	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
by	O
pro	B
##sta	I
##g	I
##land	I
##in	I
-	I
end	I
##oper	I
##oxide	I
s	O
##ynth	O
##ases	O
,	O
which	O
are	O
induced	O
in	O
inflammation	O
,	O
could	O
also	O
contribute	O
,	O
thus	O
in	O
##f	O
##lue	O
##ncing	O
its	O
longitudinal	O
stability	O
.	O

Other	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
that	O
increased	O
after	O
le	O
##pt	O
##in	O
treatment	O
were	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
5	O
.	O
9	O
-	O
fold	O
)	O
and	O
palm	B
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
1	O
.	O
4	O
-	O
fold	O
)	O
(	O
and	O
)	O
.	O

4	B
-	I
Met	I
##hyl	I
-	I
p	I
##hen	I
##ol	I
(	O
p	O
-	O
c	O
##res	O
##ol	O
)	O
seemed	O
to	O
be	O
over	O
-	O
synthesized	O
in	O
I	O
##g	O
##AN	O
patients	O
.	O

F	O
.	O
L	B
##F	I
by	O
L	B
##C	I
-	I
MS	I
(	I
-	I
)	I
:	I
R	I
_	O
2	O
=	O
0	O
.	O
82	O
##9	O
.	O

Pro	B
##py	I
##lene	I
g	I
##ly	I
##co	I
##l	I
was	O
detected	O
in	O
CS	O
##F	O
samples	O
in	O
our	O
series	O
.	O

Ten	O
classes	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
detected	O
:	O
l	B
##ys	I
##o	I
-	I
PC	I
(	O
LP	O
##C	O
)	O
,	O
et	O
##her	O
-	O
type	O
LP	O
##C	O
(	O
LP	O
##C	O
##e	O
)	O
,	O
l	O
##ys	O
##o	O
-	O
P	O
##E	O
(	O
LP	O
##E	O
)	O
,	O
l	O
##ys	O
##o	O
-	O
P	O
##I	O
(	O
LP	O
##I	O
)	O
,	O
PC	O
,	O
et	O
##her	O
-	O
type	O
PC	O
(	O
PC	O
##e	O
)	O
,	O
o	O
##xi	O
##dized	O
PC	O
(	O
PC	O
+	O
O	O
)	O
,	O
P	O
##E	O
,	O
et	O
##her	O
-	O
type	O
P	O
##E	O
(	O
P	O
##E	O
##e	O
)	O
,	O
and	O
P	O
##I	O
.	O

The	O
only	O
significant	O
un	O
##i	O
-	O
var	O
##iate	O
change	O
in	O
urine	O
meta	O
##bol	O
##ites	O
was	O
a	O
minor	O
increase	O
in	O
urine	O
su	B
##cci	I
##nic	I
acid	I
.	O

At	O
the	O
same	O
time	O
si	B
##m	I
##vas	I
##tat	I
##in	I
and	O
bi	O
##le	O
acids	O
also	O
regulate	O
the	O
expression	O
of	O
these	O
transport	O
##ers	O
,	O
,	O
,	O
.	O

The	O
increase	O
in	O
beta	B
##ine	I
and	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
is	O
consistent	O
with	O
our	O
recent	O
findings	O
in	O
a	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
of	O
the	O
effect	O
of	O
W	O
##G	O
r	O
##ye	O
intervention	O
on	O
pro	O
##state	O
cancer	O
patients	O
.	O

Western	O
b	O
##lot	O
analysis	O
showed	O
that	O
compared	O
to	O
control	O
HM	O
##EC	O
cells	O
,	O
expression	O
of	O
the	O
G	O
-	O
protein	O
coupled	O
EP	O
receptors	O
,	O
EP	O
##1	O
-	O
4	O
,	O
CO	O
##X	O
-	O
2	O
and	O
micro	O
##so	O
##mal	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	I
s	O
##ynth	O
##ase	O
-	O
1	O
(	O
m	O
##P	O
##GE	O
##S	O
-	O
1	O
)	O
were	O
significantly	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
breast	O
cancer	O
cells	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
and	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
(	O
Figure	O
)	O
.	O

S	O
##pect	O
##ra	O
were	O
manually	O
phased	O
and	O
the	O
base	O
##line	O
was	O
corrected	O
and	O
referenced	O
to	O
3	B
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
1	I
-	I
[	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
²	I
##H	I
##4	I
]	I
prop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
at	O
δ	O
0	O
.	O
0	O
.	O

The	O
association	O
between	O
the	O
meta	O
##bol	O
##ites	O
and	O
B	O
##MI	O
,	O
insulin	O
and	O
DB	B
##P	I
was	O
determined	O
using	O
a	O
linear	O
re	O
##gression	O
model	O
with	O
meta	O
##bol	O
##ites	O
as	O
outcome	O
and	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
status	O
(	O
long	O
##evity	O
family	O
member	O
or	O
control	O
)	O
,	O
lip	O
##id	O
lowering	O
medication	O
,	O
h	O
##yper	O
##tens	O
##ion	O
medication	O
(	O
fixed	O
effects	O
)	O
and	O
household	O
(	O
random	O
effects	O
)	O
.	O

O	O
##PL	O
##S	O
-	O
D	O
##A	O
score	O
plot	O
of	O
pre	O
-	O
treatment	O
(	O
E	O
##SC	O
##C	O
)	O
and	O
post	O
-	O
treatment	O
(	O
E	O
##SC	O
##C	O
-	O
P	O
)	O
patients	O
based	O
on	O
data	O
from	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
(	O
A	O
)	O
●	O
E	O
##SC	O
##C	O
and	O
■	O
E	O
##SC	O
##C	O
-	O
P	O
;	O
all	O
patients	O
,	O
(	O
C	O
)	O

Panel	O
##s	O
A2	O
to	O
D	O
##2	O
show	O
the	O
expression	O
of	O
P	O
##K	O
##M	O
##2	O
,	O
CP	O
##T	O
##1	O
,	O
G	B
##S	I
##K	I
##3	I
##β	I
,	O
and	O
GA	O
##D	O
##1	O
,	O
respectively	O
in	O
C	O
##IN	O
.	O

When	O
we	O
contrasted	O
E	O
##Vs	O
with	O
separately	O
isolated	O
HD	O
##L	O
and	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
,	O
we	O
found	O
that	O
:	O
(	O
a	O
)	O
the	O
E	O
##Vs	O
isolated	O
by	O
the	O
method	O
developed	O
in	O
this	O
study	O
presented	O
with	O
ne	O
##gli	O
##gible	O
HD	O
##L	O
and	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
contamination	O
;	O
(	O
b	O
)	O
the	O
absolute	O
lip	O
##id	O
level	O
per	O
unit	O
of	O
protein	O
content	O
in	O
the	O
E	O
##Vs	O
was	O
more	O
than	O
eight	O
times	O
lower	O
than	O
those	O
of	O
the	O
lip	O
##op	O
##rote	O
##ins	O
;	O
(	O
c	O
)	O
the	O
E	O
##V	O
lip	O
##id	O
profiles	O
marked	O
##ly	O
differed	O
from	O
those	O
of	O
the	O
lip	O
##op	O
##rote	O
##ins	O
;	O
(	O
d	O
)	O
a	O
high	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
content	O
is	O
characteristic	O
of	O
circulating	O
human	O
E	O
##Vs	O
;	O
and	O
(	O
e	O
)	O
comparable	O
results	O
were	O
obtained	O
for	O
human	O
plasma	O
and	O
serum	O
.	O

-	B
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I

Four	O
meta	O
##bol	O
##ites	O
:	O
K	B
##yn	I
##uren	I
##ine	I
,	O
Ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
PC	B
(	I
42	I
:	I
11	I
)	I
,	O
and	O
LP	B
##E	I
(	I
22	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
were	O
selected	O
as	O
potential	O
predict	O
##ive	O
bio	O
##mark	O
##ers	O
.	O

After	O
sample	O
loading	O
,	O
the	O
solid	O
phase	O
was	O
washed	O
with	O
300	O
μ	O
##L	O
of	O
water	O
and	O
meta	O
##bol	O
##ites	O
were	O
el	O
##uted	O
with	O
600	O
μ	O
##L	O
met	B
##han	I
##ol	I
and	O
collected	O
in	O
a	O
96	O
well	O
collection	O
plate	O
.	O

Conversely	O
,	O
in	O
moderate	O
to	O
severe	O
s	O
##te	O
##ato	O
##sis	O
,	O
the	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
and	O
some	O
amino	O
acids	O
were	O
high	O
but	O
there	O
was	O
a	O
significant	O
de	O
##ple	O
##tion	O
of	O
P	O
##U	O
##FA	O
.	O

The	O
criteria	O
for	O
G	O
##DM	O
diagnosis	O
were	O
to	O
have	O
≥	O
1	O
abnormal	O
value	O
for	O
fast	O
##ing	O
glucose	S
(	O
≥	O
5	O
.	O
1	O
mm	O
##ol	O
/	O
L	O
;	O
92	O
mg	O
/	O
d	O
##L	O
)	O
,	O
1	O
-	O
h	O
glucose	S
(	O
≥	O
10	O
.	O
0	O
mm	O
##ol	O
/	O
L	O
;	O
180	O
mg	O
/	O
d	O
##L	O
)	O
,	O
or	O
2	O
-	O
h	O
glucose	S
(	O
≥	O
8	O
.	O
5	O
mm	O
##ol	O
/	O
L	O
;	O
153	O
mg	O
/	O
d	O
##L	O
)	O
.	O

G	B
##lut	I
##amine	I
and	O
as	B
##par	I
##agi	I
##ne	I
were	O
unstable	O
in	O
the	O
serum	O
,	O
and	O
were	O
transformed	O
into	O
g	B
##lut	I
##ama	I
##te	I
and	O
as	B
##par	I
##tate	I
on	O
a	O
large	O
scale	O
when	O
stored	O
at	O
4	O
##°	O
##C	O
for	O
4	O
h	O
.	O

In	O
he	O
##pa	O
##titis	O
-	O
free	O
HC	O
##C	O
cases	O
,	O
the	O
risk	O
associations	O
of	O
g	B
##lut	I
##amine	I
(	O
OR	O
=	O
0	O
.	O
56	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
34	O
–	O
0	O
.	O
92	O
)	O
and	O
g	B
##lut	I
##ama	I
##te	I
(	O
OR	O
=	O
2	O
.	O
06	O
;	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
18	O
–	O
3	O
.	O
61	O
)	O
were	O
significantly	O
different	O
from	O
matched	O
controls	O
(	O
Table	O
)	O
.	O

Finally	O
,	O
o	B
##xy	I
##ster	I
##ols	I
were	O
el	O
##uted	O
with	O
1	O
.	O
8	O
m	O
##l	O
of	O
but	B
##yl	I
ace	I
##tate	I
and	O
collected	O
in	O
2	O
m	O
##l	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tube	O
.	O

Twenty	O
plasma	O
meta	O
##bol	O
##ites	O
were	O
identified	O
based	O
on	O
their	O
characteristic	O
chemical	O
shifts	O
and	O
multi	O
##p	O
##licit	O
##ies	O
and	O
q	O
##uant	O
##ified	O
by	O
integrating	O
peak	O
areas	O
relative	O
to	O
a	O
reference	O
signal	O
from	O
3	B
-	I
(	I
Tri	I
##met	I
##hyl	I
##si	I
##ly	I
##l	I
)	I
prop	I
##ion	I
##ic	I
acid	O
-	O
d	O
_	O
4	O
sodium	O
salt	O
(	O
T	O
##SP	O
)	O
.	O

G	B
##ly	I
##cine	I
was	O
also	O
strongly	O
associated	O
with	O
HC	O
##C	O
presence	O
,	O
exhibiting	O
a	O
1	O
.	O
36	O
-	O
fold	O
increase	O
in	O
HC	O
##C	O
patients	O
vs	O
.	O
DC	O
##s	O
(	O
P	O
<	O
2	O
.	O
58	O
×	O
10	O
_	O
−	O
##5	O
)	O
.	O

In	O
the	O
cross	O
-	O
over	O
trial	O
we	O
reported	O
that	O
104	O
μ	O
##mo	O
##l	O
of	O
SF	S
equivalent	O
##s	O
were	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
following	O
the	O
initial	O
dose	O
of	O
SF	S
(	O
150	O
μ	O
##mo	O
##l	O
)	O
and	O
32	O
μ	O
##mo	O
##l	O
following	O
the	O
initial	O
dose	O
of	O
G	O
##R	O
(	O
800	O
μ	O
##mo	O
##l	O
)	O
.	O

There	O
might	O
also	O
be	O
non	O
##ca	O
##usal	O
explanations	O
of	O
the	O
observed	O
association	O
between	O
T	B
##MA	I
##O	I
and	O
G	O
##DM	O
.	O

Several	O
sa	B
##cc	I
##hari	I
##des	I
,	O
such	O
as	O
la	B
##ct	I
##ose	I
,	O
gal	B
##act	I
##ose	I
,	O
ma	B
##lt	I
##ose	I
,	O
and	O
x	B
##yl	I
##ose	I
,	O
however	O
,	O
which	O
were	O
typically	O
increased	O
in	O
CD	O
,	O
were	O
not	O
higher	O
in	O
UC	O
patients	O
.	O

Our	O
results	O
confirm	O
that	O
fast	O
##ing	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
concentrations	O
are	O
negatively	O
related	O
to	O
insulin	O
sensitivity	O
,	O
as	O
it	O
has	O
been	O
reported	O
in	O
adults	O
(	O
–	O
,	O
,	O
)	O
and	O
in	O
children	O
[	O
and	O
]	O
.	O

The	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
of	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
were	O
improved	O
quantitative	O
##ly	O
for	O
maximum	O
analytical	O
peak	O
quality	O
with	O
short	O
run	O
time	O
,	O
using	O
a	O
mobile	O
phase	O
prepared	O
by	O
mixing	O
of	O
70	O
%	O
met	B
##han	I
##ol	I
and	O
30	O
%	O
of	O
a	O
mixture	O
of	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
0	O
.	O
2	O
m	O
##M	O
form	B
##ic	I
acid	I
and	O
was	O
el	O
##uted	O
is	O
##oc	O
##ratic	O
##ally	O
with	O
a	O
flow	O
rate	O
of	O
1	O
m	O
##L	O
min	O
_	O
−	O
##1	O
through	O
AC	O
##E	O
[UNK]	O
C	O
##18	O
(	O
50	O
×	O
2	O
.	O
1	O
mm	O
,	O
5	O
μ	O
m	O
)	O
column	O
for	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

The	O
increased	O
BC	O
##AA	O
##s	O
may	O
generate	O
more	O
cat	O
##ab	O
##olic	O
intermediate	O
##s	O
prop	O
##ion	O
##yl	O
Co	O
##A	O
and	O
su	O
##cci	O
##ny	O
##l	O
Co	O
##A	O
,	O
leading	O
to	O
accumulation	O
of	O
incomplete	O
##ly	O
o	O
##xi	O
##dized	O
fatty	O
acids	O
and	O
glucose	S
,	O
mitochondrial	O
stress	O
,	O
impaired	O
insulin	O
action	O
,	O
and	O
ultimate	O
per	O
##tur	O
##bation	O
of	O
glucose	S
home	O
##ost	O
##asis	O
.	O

The	O
level	O
of	O
t	B
##yr	I
##os	I
##ine	I
was	O
decreased	O
in	O
the	O
urine	O
of	O
post	O
##par	O
##tum	O
depressed	O
patients	O
in	O
this	O
study	O
,	O
which	O
was	O
consistent	O
with	O
the	O
previous	O
studies	O
that	O
showed	O
the	O
decrease	O
in	O
the	O
blood	O
of	O
depressed	O
patients	O
and	O
supported	O
the	O
hypothesis	O
that	O
do	O
##pa	O
##mine	O
##rg	O
##ic	O
factors	O
are	O
involved	O
in	O
clinical	O
depression	O
.	O

53	O
##4	O
.	O
405	O
##4	O
corresponding	O
to	O
the	O
m	O
/	O
z	O
of	O
the	O
[	O
M	O
]	O
_	O
+	O
ion	O
of	O
a	O
GP	O
-	O
tag	O
##ged	O
mon	B
##oh	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
.	O

Similarly	O
,	O
a	O
rise	O
in	O
inter	O
##st	O
##iti	O
##al	O
la	B
##ct	I
##ate	I
has	O
also	O
been	O
observed	O
in	O
the	O
brain	O
injury	O
of	O
rats	O
_	O
,	O
.	O

Low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
indirectly	O
estimated	O
in	O
subjects	O
with	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
concentrations	O
of	O
<	O
400	O
mg	O
/	O
d	O
##l	O
using	O
the	O
Fr	O
##ied	O
##ew	O
##ald	O
formula	O
.	O

Con	O
##ditions	O
were	O
as	O
follows	O
:	O
cap	O
##illa	O
##ry	O
voltage	O
4	O
.	O
0	O
k	B
##V	I
;	O
des	O
##ol	O
##vation	O
gas	O
flow	O
,	O
10	O
L	O
/	O
min	O
;	O
330	O
##°	O
##C	O
,	O
and	O
nitrogen	B
gas	I
.	O

In	O
summary	O
,	O
our	O
findings	O
highlight	O
the	O
potential	O
role	O
of	O
GM	B
##3	I
in	O
id	O
##io	O
##pathic	O
PD	O
.	O

Finally	O
,	O
the	O
extent	O
of	O
_	O
13	O
C	O
label	O
##ing	O
in	O
la	B
##ct	I
##ate	I
,	O
Al	O
##a	O
,	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
was	O
higher	O
in	O
R	O
##h	O
##30	O
cells	O
grown	O
in	O
f	O
##etal	O
calf	O
serum	O
(	O
FC	O
##S	O
)	O
than	O
cells	O
grown	O
in	O
BS	O
##A	O
(	O
Table	O
)	O
.	O

In	O
an	O
attempt	O
to	O
highlight	O
those	O
features	O
and	O
test	O
their	O
statistical	O
significance	O
,	O
molecular	O
species	O
were	O
grouped	O
according	O
to	O
different	O
structural	O
parameters	O
linked	O
to	O
the	O
chain	O
length	O
or	O
number	O
of	O
un	O
##sat	O
##uration	O
##s	O
of	O
the	O
c	B
##era	I
##mi	I
##de	I
.	O

2013	O
)	O
,	O
r	O
##oh	O
##it	O
##uki	O
##ne	O
(	O
Kumar	O
##a	O
et	O
al	O
.	O
2014	O
)	O
,	O
g	O
##ink	O
##gol	O
##ide	O
B	O
(	O
C	O
##ui	O
et	O
al	O
.	O
2012	O
)	O
,	O
q	O
##uin	O
##ine	O
and	O
c	B
##in	I
##cho	I
##ni	I
##dine	I
(	O
Hi	O
##day	O
##at	O
et	O
al	O
.	O
2015	O
)	O
have	O
been	O
reported	O
as	O
products	O
of	O
in	O
v	O
##it	O
##ro	O
f	O
##er	O
##mentation	O
of	O
several	O
Fu	O
##sar	O
##ium	O
species	O
.	O

Interest	O
##ingly	O
,	O
it	O
found	O
some	O
differential	O
meta	O
##bol	O
##ites	O
such	O
as	O
as	B
##par	I
##tic	I
acid	I
2	O
,	O
beta	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
1	O
,	O
p	B
##yr	I
##rol	I
##e	I
-	I
2	I
-	I
car	I
##box	I
##yl	I
##ic	I
acid	I
,	O
4	B
-	I
amino	I
##but	I
##yric	I
acid	I
1	O
,	O
g	B
##lu	I
##con	I
##ic	I
la	I
##cton	I
##e	I
2	O
in	O
induced	O
s	O
##put	O
##um	O
positively	O
correlated	O
to	O
F	O
##E	O
##V	O
##1	O
%	O
and	O
F	O
##E	O
##V	O
##1	O
/	O
F	O
##VC	O
%	O
reflecting	O
air	O
##way	O
o	O
##bs	O
##truction	O
(	O
r	O
<	O
0	O
.	O
45	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Perhaps	O
counter	O
-	O
in	O
##tu	O
##itive	O
##ly	O
,	O
over	O
expression	O
of	O
G	O
##lo	O
##1	O
is	O
a	O
bio	O
##mark	O
##er	O
for	O
t	O
##umour	O
growth	O
,	O
but	O
this	O
is	O
likely	O
to	O
reflect	O
high	B
-	I
g	I
##ly	I
##co	I
##ly	I
##tic	I
activity	O
,	O
as	O
we	O
observed	O
in	O
SC	O
##C	O
tissues	O
.	O

Main	O
effects	O
of	O
participant	O
type	O
were	O
found	O
on	O
total	O
symptoms	O
(	B
F	B
(	I
1	I
,	I
77	I
)	I
=	O
10	O
.	O
57	O
,	O
p	O
=	O
0	O
.	O
00	O
##2	O
and	O
nasal	O
congestion	O
(	B
F	B
(	I
1	I
,	I
84	I
)	I
=	O

Yun	O
et	O
al	O
.	O
ass	O
##ay	O
##ed	O
for	O
d	O
##A	O
-	O
Al	O
-	O
I	O
add	O
##uc	O
##t	O
in	O
ex	O
##folia	O
##ted	O
u	O
##rina	O
##ry	O
cells	O
from	O
patients	O
who	O
had	O
ing	O
##ested	O
traditional	O
Chinese	O
herb	O
##al	O
medicines	O
containing	O
Ari	O
##sto	O
##loc	O
##hia	O
s	B
##p	I
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
performed	O
a	O
multiple	O
re	O
##gression	O
to	O
identify	O
independent	O
predict	O
##ors	O
of	O
the	O
fast	O
##ing	O
T	B
##G	I
level	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
was	O
positively	O
associated	O
with	O
risk	O
of	O
mortality	O
,	O
while	O
g	B
##lut	I
##amine	I
,	O
le	B
##uc	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
his	B
##ti	I
##dine	I
and	O
v	B
##ali	I
##ne	I
were	O
all	O
inverse	O
##ly	O
associated	O
with	O
risk	O
of	O
mortality	O
in	O
model	O
1	O
(	O
E	O
##SM	O
Table	O
10	O
)	O
.	O

Although	O
the	O
sperm	O
concentration	O
of	O
e	O
##ja	O
##culate	O
##s	O
tended	O
to	O
be	O
negatively	O
associated	O
with	O
their	O
amino	O
acid	O
and	O
bio	O
##genic	O
am	O
##ine	O
content	O
(	O
significant	O
for	O
k	B
##yn	I
##uren	I
##ine	I
(	O
-	O
0	O
.	O
52	O
##6	O
)	O
,	O
se	B
##rot	I
##oni	I
##n	I
(	O
-	O
0	O
.	O
54	O
##5	O
)	O
and	O
sperm	B
##id	I
##ine	I
(	O
-	O
0	O
.	O
58	O
##5	O
)	O
)	O
,	O
a	O
significant	O
positive	O
correlation	O
was	O
found	O
for	O
G	O
##ln	O
(	O
0	O
.	O
530	O
)	O
.	O

In	O
##verse	O
normal	O
-	O
rank	O
transformations	O
were	O
applied	O
to	O
the	O
c	O
##yt	O
##oki	O
##nes	O
,	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
,	O
K	O
##TR	O
,	O
and	O
P	O
##LP	O
to	O
make	O
them	O
satisfy	O
the	O
normal	O
##ity	O
assumption	O
before	O
examination	O
of	O
associations	O
with	O
any	O
of	O
the	O
c	O
##yt	O
##oki	O
##nes	O
through	O
multiple	O
linear	O
re	O
##gression	O
analysis	O
.	O

Go	O
to	O
:	O
We	O
recently	O
demonstrated	O
that	O
re	O
##con	O
##stituted	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
r	O
##HD	O
##L	O
)	O
m	O
##od	O
##ulates	O
glucose	S
metabolism	O
in	O
humans	O
via	O
both	O
AM	O
##P	O
-	O
activated	O
protein	O
kinase	O
(	O
AM	O
##P	O
##K	O
)	O
in	O
muscle	O
and	O
by	O
increasing	O
plasma	O
insulin	O
.	O

As	O
reported	O
in	O
our	O
previous	O
work	O
(	O
Bo	O
##gus	O
##ze	O
##wicz	O
et	O
al	O
.	O
)	O
,	O
in	O
a	O
week	O
after	O
R	O
##T	O
/	O
CH	O
##RT	O
completion	O
the	O
ch	B
##olin	I
##e	I
levels	O
lower	O
marked	O
##ly	O
which	O
co	O
##rrel	O
##ate	O
with	O
the	O
intensive	O
##ness	O
of	O
AR	O
##S	O
.	O

A	O
stripped	O
sample	O
that	O
had	O
undergone	O
preparation	O
procedure	O
was	O
injected	O
into	O
the	O
column	O
,	O
and	O
the	O
effect	O
of	O
matrix	O
suppression	O
on	O
the	O
response	O
of	O
the	O
in	O
##fused	O
o	B
##xy	I
##ster	I
##ols	I
was	O
monitored	O
.	O

A	O
su	B
##c	I
##rose	I
tune	O
file	O
in	O
negative	O
/	O
positive	O
modes	O
at	O
normal	O
L	O
##C	O
flow	O
rate	O
was	O
used	O
.	O

The	O
90	O
%	O
p	O
##elle	O
##t	O
,	O
which	O
represented	O
the	O
mature	O
sperm	O
fraction	O
,	O
was	O
re	O
##sus	O
##pen	O
##ded	O
in	O
phosphate	B
-	I
buffer	I
##ed	I
sa	I
##line	I
(	O
PBS	O
,	O
pH	O
7	O
.	O
4	O
)	O
.	O

El	O
##eva	O
##ted	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
and	O
as	B
##par	I
##tate	I
might	O
be	O
related	O
to	O
the	O
der	O
##eg	O
##ulation	O
of	O
amino	O
##tra	O
##ns	O
##fer	O
##ases	O
such	O
as	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
trans	O
##pe	O
##pt	O
##idas	O
##e	O
(	O
G	O
##G	O
##T	O
)	O
and	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AS	O
##T	O
)	O
in	O
the	O
case	O
of	O
HC	O
##C	O
[	O
,	O
]	O
.	O

Re	O
##mo	O
##val	O
of	O
the	O
g	B
##lut	I
##ama	I
##te	I
meta	O
##bol	O
##ite	O
results	O
in	O
an	O
increase	O
of	O
MC	O
##E	O
(	O
38	O
%	O
)	O
and	O
a	O
decrease	O
of	O
both	O
sensitivity	O
and	O
specific	O
##ity	O
(	O
62	O
%	O
)	O
,	O
demonstrating	O
the	O
importance	O
of	O
g	B
##lut	I
##ama	I
##te	I
for	O
discrimination	O
.	O

B	B
##is	I
##phe	I
##no	I
##l	I
A	O
(	O
211	O
.	O
11	O
,	O
[	O
M	O
+	O
H	O
-	O
H	O
_	O
2	O
O	O
]	O
_	O
+	O
)	O
,	O
re	B
##tino	I
##l	I
(	O
287	O
.	O
23	O
,	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
and	O
L	B
-	I
pro	I
##line	I
(	O
116	O
.	O
07	O
,	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
were	O
among	O
the	O
significant	O
compounds	O
found	O
to	O
have	O
contributed	O
in	O
the	O
discrimination	O
between	O
these	O
groups	O
,	O
suggesting	O
that	O
these	O
compounds	O
might	O
be	O
related	O
in	O
the	O
development	O
of	O
lung	O
cancer	O
.	O

It	O
is	O
also	O
one	O
of	O
the	O
degradation	O
products	O
of	O
th	B
##re	I
##oni	I
##ne	I
,	O
which	O
can	O
be	O
converted	O
to	O
prop	B
##ion	I
##yl	I
-	I
Co	I
##A	I
(	O
and	O
subsequently	O
met	O
##hyl	O
##mal	O
##ony	O
##l	O
Co	O
##A	O
,	O
which	O
can	O
be	O
converted	O
to	O
su	O
##cci	O
##ny	O
##l	O
Co	O
##A	O
,	O
a	O
c	B
##it	I
##ric	I
acid	I
cycle	O
intermediate	O
)	O
,	O
and	O
thus	O
enter	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
.	O

These	O
meta	O
##bol	O
##ites	O
(	O
c	O
##it	O
##ru	O
##llin	O
##e	O
,	O
v	B
##ali	I
##ne	I
,	O
PC	B
a	I
##a	I
C	I
##40	I
:	I
4	I
,	O
PC	B
a	I
##a	I
C	I
##36	I
:	I
5	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##17	I
:	I
0	I
,	O
SM	O
(	O
OH	O
)	O
C	B
##24	I
:	I
1	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
C	B
##14	I
:	I
1	I
)	O
come	O
from	O
4	O
of	O
the	O
5	O
meta	O
##bol	O
##ite	O
classes	O
q	O
##uant	O
##ified	O
.	O

The	O
upper	O
n	B
-	I
he	I
##xa	I
##ne	I
layer	O
was	O
removed	O
to	O
a	O
fresh	O
12	O
×	O
75	O
mm	O
glass	O
tube	O
,	O
containing	O
a	O
little	O
an	B
##hy	I
##dr	I
##ous	I
sodium	I
su	I
##l	I
##phate	I
,	O
as	O
drying	O
agent	O
.	O

The	O
fi	O
##lt	O
##rate	O
and	O
Q	O
##C	O
solutions	O
were	O
subjected	O
to	O
drying	O
by	O
pure	O
nitrogen	B
gas	I
at	O
50	O
##°	O
##C	O
.	O

Ni	B
##tro	I
##gen	I
gas	I
was	O
used	O
for	O
both	O
ne	O
##bul	O
##izing	O
and	O
drying	O
.	O

After	O
ing	O
##est	O
##ion	O
of	O
a	O
[	B
U	I
_	I
13	I
C	I
]	I
glucose	I
trace	O
##r	O
,	O
is	O
##oto	O
##pical	O
##ly	O
en	O
##rich	O
##ed	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
was	O
detected	O
in	O
the	O
blood	O
of	O
the	O
donor	O
.	O

The	O
involvement	O
of	O
sa	B
##rc	I
##os	I
##ine	I
in	O
PC	O
##a	O
has	O
been	O
the	O
subject	O
of	O
many	O
studies	O
(	O
Khan	O
et	O
al	O
.	O
;	O

Sub	O
##stant	O
##ial	O
variations	O
in	O
measures	O
of	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
have	O
been	O
noted	O
across	O
laboratories	O
,	O
ass	O
##ay	O
protocols	O
,	O
and	O
ass	O
##ay	O
kit	O
manufacturing	O
lots	O
(	O
,	O
)	O
.	O

pathway	O
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
.	O

Thus	O
,	O
in	B
##os	I
##ine	I
was	O
selected	O
as	O
an	O
independent	O
diagnostic	O
bio	O
##mark	O
##er	O
for	O
child	O
-	O
and	O
adolescent	O
-	O
onset	O
D	O
##N	O
-	O
MD	O
##D	O
.	O

Furthermore	O
,	O
several	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
intermediate	O
##s	O
,	O
including	O
v	B
##ali	I
##ne	I
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
were	O
found	O
at	O
a	O
lower	O
concentration	O
in	O
patients	O
with	O
C	O
##IN	O
and	O
CS	O
##CC	O
,	O
suggesting	O
a	O
suppressed	O
T	O
##CA	O
cycle	O
.	O

Active	O
UC	O
,	O
in	O
turn	O
,	O
can	O
be	O
distinguished	O
from	O
inactive	O
disease	O
by	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
correlation	O
with	O
both	O
AD	B
##MA	I
and	O
SD	O
##MA	O
.	O

The	O
results	O
were	O
within	O
7	O
.	O
5	O
%	O
of	O
nominal	O
a	B
##bir	I
##ater	I
##one	I
concentrations	O
of	O
5	O
,	O
300	O
and	O
400	O
ng	O
/	O
m	O
##L	O
.	O
Vice	O
versa	O
Pittsburgh	O
exchanged	O
one	O
blinded	O
set	O
of	O
Q	O
##Cs	O
with	O
our	O
laboratory	O
at	O
three	O
concentration	O
levels	O
which	O
we	O
analyzed	O
.	O

Previous	O
studies	O
involving	O
is	O
##oto	O
##pic	O
en	O
##rich	O
##ment	O
below	O
1	O
%	O
were	O
mainly	O
focused	O
on	O
single	O
or	O
a	O
few	O
target	O
meta	O
##bol	O
##ites	O
e	O
.	O
g	O
.	O
,	O
glucose	S
,	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
different	O
species	O
,	O
or	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
le	B
##uc	I
##ine	I
in	O
muscle	O
protein	O
synthesis	O
.	O

Our	O
study	O
revealed	O
a	O
trend	O
for	O
PC	O
##s	O
to	O
be	O
increased	O
in	O
serum	O
of	O
lung	O
cancer	O
patients	O
,	O
which	O
can	O
relate	O
to	O
up	O
##re	O
##gu	O
##lation	O
/	O
activation	O
of	O
enzymes	O
involved	O
in	O
PC	O
##s	O
synthesis	O
,	O
i	O
.	O
e	O
.	O
,	O
ch	B
##olin	I
##e	I
kinase	O
.	O

As	O
shown	O
in	O
and	O
,	O
the	O
method	O
provides	O
a	O
suitable	O
select	O
##ivity	O
,	O
a	O
satisfactory	O
control	O
of	O
matrix	O
effects	O
and	O
a	O
ne	O
##gli	O
##gible	O
carry	O
##over	O
also	O
for	O
this	O
inactive	O
Met	O
amino	S
.	O

The	O
se	B
##rine	I
residue	O
198	O
at	O
the	O
active	O
site	O
center	O
makes	O
a	O
co	O
##valent	O
bond	O
with	O
the	O
phosphate	S
group	O
of	O
para	O
##ox	O
##on	O
releasing	O
the	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ni	I
##tro	I
##ben	I
##zen	I
##e	I
ring	O
structure	O
.	O

(	O
H	O
)	O
ATP	S
levels	O
were	O
decreased	O
in	O
F	O
##T	O
##D	O
.	O

Nonetheless	O
,	O
thy	B
##mo	I
##l	I
scores	O
generated	O
a	O
much	O
narrower	O
95	O
%	O
confidence	O
region	O
than	O
un	O
##tre	O
##ated	O
samples	O
(	O
N	O
##P	O
)	O
,	O
indicating	O
less	O
meta	O
##bol	O
##ite	O
changes	O
in	O
T	O
##hy	O
samples	O
as	O
compared	O
to	O
N	O
##P	O
and	O
BA	O
.	O

Power	O
transformation	O
was	O
performed	O
for	O
L	O
##H	O
,	O
F	O
##S	O
##H	O
,	O
in	O
##h	O
##B	O
,	O
Test	B
##osterone	I
,	O
E	O
##1	O
,	O
and	O
E	O
##2	O
.	O

In	O
the	O
case	O
of	O
HC	O
##V	O
infection	O
,	O
the	O
liver	O
appeared	O
not	O
to	O
import	O
glucose	S
but	O
rather	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
it	O
by	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
using	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
in	O
part	O
derived	O
from	O
BC	O
##AA	O
##s	O
.	O

Cho	B
##line	I
is	O
also	O
associated	O
with	O
many	O
cancer	O
types	O
.	O

One	O
to	O
four	O
tumor	O
tissue	O
samples	O
from	O
each	O
patient	O
were	O
designated	O
as	O
5	B
-	I
mm	I
-	I
diameter	I
spherical	O
targets	O
on	O
co	O
-	O
registered	O
MR	O
images	O
using	O
Brain	O
##LA	O
##B	O
surgical	O
navigation	O
software	O
(	O
Brain	O
##LA	O
##B	O
Inc	O
.	O
)	O
.	O

Blood	O
samples	O
for	O
the	O
L	O
##C	O
-	O
MS	O
analyses	O
of	O
met	B
##had	I
##one	I
and	O
it	O
'	O
s	O
meta	O
##bol	O
##ite	O
E	O
##D	O
##DP	O
were	O
drawn	O
for	O
up	O
to	O
96	O
h	O
.	O
Non	O
##in	O
##vasive	O
infrared	O
pupil	O
##lo	O
##metry	O
was	O
p	O
##ef	O
##orm	O
##ed	O
at	O
the	O
same	O
time	O
as	O
blood	O
sampling	O
.	O

The	O
reasons	O
for	O
these	O
differences	O
could	O
be	O
secondary	O
to	O
variations	O
in	O
underlying	O
diet	O
##ary	O
intake	O
,	O
f	B
##olate	I
supplement	O
##ation	O
,	O
or	O
other	O
differences	O
in	O
subject	O
characteristics	O
between	O
the	O
2	O
populations	O
,	O
including	O
ethnicity	O
(	O
,	O
)	O
.	O

The	O
injected	O
sample	O
volume	O
was	O
1	O
μ	O
L	O
.	O
Data	O
acquisition	O
and	O
processing	O
were	O
performed	O
with	O
the	O
acquisition	O
software	O
Ana	O
##ly	O
##st	O
T	O
##F	O
(	O
version	O
1	O
.	O
7	O
.	O
1	O
,	O
AB	O
SC	O
##IE	O
##X	O
,	O
USA	O
)	O
,	O
which	O
could	O
acquire	O
high	O
resolution	O
MS	O
and	O
tandem	O
-	O
MS	O
data	O
simultaneously	O
by	O
TO	O
##F	O
MS	O
full	O
scan	O
and	O
information	O
-	O
dependent	O
acquisition	O
(	O
ID	O
##A	O
)	O
in	O
both	O
E	B
##SI	I
(	I
+	I
)	I
and	O
E	O
##SI	O
(	O
−	O
)	O
modes	O
.	O

In	O
comparison	O
with	O
is	B
##of	I
##lav	I
##ones	I
alone	O
,	O
I	O
##CI	O
182	O
,	O
78	O
##0	O
pre	O
##tre	O
##at	O
##ment	O
did	O
not	O
significantly	O
m	O
##od	O
##ulate	O
C	O
##YP	O
##1	O
##B	O
##1	O
expression	O
(	O
B	O
,	O
D	O
)	O
.	O

Other	O
than	O
the	O
in	O
##or	O
##gan	O
##ic	O
ions	O
and	O
gases	O
such	O
as	O
sodium	O
(	O
144	O
m	O
##M	O
)	O
,	O
ch	O
##lor	O
##ine	O
(	O
110	O
m	O
##M	O
)	O
,	O
bi	O
##car	O
##bon	O
##ate	O
/	O
carbon	O
dioxide	S
(	O
25	O
m	O
##M	O
)	O
,	O
iron	O
(	O
9	O
m	O
##M	O
)	O
,	O
oxygen	O
(	O
6	O
m	O
##M	O
)	O
,	O
potassium	O
(	O
4	O
.	O
5	O
m	O
##M	O
)	O
,	O
calcium	O
(	O
2	O
.	O
5	O
m	O
##M	O
)	O
,	O
p	O
##hos	O
##phorus	O
/	O
phosphate	O
and	O
sulfur	O
/	O
su	O
##lf	O
##ide	O
(	O
[UNK]	O
m	O
##M	O
)	O
and	O
ma	O
##gnesium	O
(	O
800	O
µ	O
##M	O
)	O
,	O
the	O
12	O
most	O
abundant	O
organic	O
meta	O
##bol	O
##ites	O
found	O
in	O
serum	O
are	O
D	B
-	I
glucose	I
(	O
5	O
m	O
##M	O
)	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
5	O
m	O
##M	O
)	O
,	O
me	B
##lani	I
##n	I
(	O
5	O
m	O
##M	O
)	O
,	O
u	B
##rea	I
(	O
4	O
m	O
##M	O
)	O
,	O
ATP	S
(	O
3	O
m	O
##M	O
)	O
,	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
(	O
1	O
.	O
5	O
m	O
##M	O
)	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
(	O
0	O
.	O
4	O
–	O
1	O
.	O
5	O
m	O
##M	O
)	O
,	O
L	B
-	I
la	I
##ctic	I
acid	I
and	O
f	B
##ru	I
##ct	I
##osa	I
##mine	I
(	O
[UNK]	O
m	O
##M	O
)	O
,	O
L	B
-	I
g	I
##lut	I
##amine	I
(	O
500	O
µ	O
##M	O
)	O
,	O
L	B
-	I
al	I
##ani	I
##ne	I
(	O
500	O
µ	O
##M	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
460	O
µ	O
##M	O
)	O
,	O
g	B
##ly	I
##cine	I
,	O
L	B
-	I
l	I
##ys	I
##ine	I
,	O
u	B
##ric	I
acid	I
(	O
350	O
µ	O
##M	O
)	O
,	O

N	O
##MR	O
-	O
based	O
meta	O
##bol	O
##omi	O
##cs	O
coupled	O
with	O
sophisticated	O
bio	O
##in	O
##formatics	O
is	O
indeed	O
capable	O
of	O
identifying	O
rapid	O
changes	O
in	O
global	O
meta	O
##bol	O
##ite	O
profiles	O
in	O
urine	O
and	O
plasma	O
(	O
treatment	O
‘	O
finger	O
##prints	O
’	O
)	O
,	O
which	O
may	O
be	O
linked	O
to	O
the	O
well	O
-	O
documented	O
early	O
changes	O
in	O
he	O
##pa	O
##tic	O
insulin	O
se	O
##nst	O
##iti	O
##vity	O
following	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
intervention	O
in	O
T	O
##2	O
##DM	O
patients	O
.	O

In	O
the	O
I	O
##R	O
s	O
##pect	O
##ra	O
,	O
the	O
phosphate	S
band	O
at	O
1	O
,	O
160	O
cm	O
_	O
−	O
##1	O
partially	O
overlap	O
##s	O
with	O
the	O
hydrogen	B
carbon	I
##ate	I
band	O
,	O
and	O
it	O
is	O
extremely	O
sensitive	O
to	O
pH	O
changes	O
in	O
the	O
range	O
of	O
10	O
_	O
−	O
##2	O
around	O
its	O
p	O
##K	O
_	O
A	O
value	O
.	O

In	O
the	O
T	O
##2	O
##DM	O
group	O
,	O
B	O
##MI	O
at	O
start	O
of	O
pregnancy	O
was	O
higher	O
than	O
in	O
the	O
N	O
##G	O
##T	O
group	O
,	O
G	O
##DM	O
was	O
diagnosed	O
earlier	O
,	O
fast	O
##ing	O
glucose	S
was	O
higher	O
at	O
G	O
##DM	O
diagnosis	O
,	O
and	O
higher	O
percentage	O
##s	O
required	O
insulin	O
during	O
pregnancy	O
or	O
were	O
non	O
-	O
Nordic	O
.	O

There	O
were	O
no	O
statistical	O
##ly	O
significant	O
correlation	O
##s	O
between	O
co	B
##rt	I
##is	I
##ol	I
and	O
T	O
##RP	O
meta	O
##bol	O
##ites	O
in	O
either	O
the	O
I	O
##BS	O
or	O
HC	O
group	O
,	O
though	O
two	O
correlation	O
##s	O
with	O
co	B
##rt	I
##is	I
##ol	I
trend	O
##ed	O
toward	O
significance	O
in	O
the	O
I	O
##BS	O
group	O
:	O
me	O
##lat	O
##oni	O
##n	O
/	O
T	O
##RP	O
with	O
r	O
=	O
−	O
.	O
27	O
,	O
p	O
=	O
.	O
113	O
,	O
and	O
x	O
##ant	O
##hur	O
##ena	O
##te	O
/	O
T	O
##RP	O
with	O
r	O
=	O
.	O
28	O
,	O
p	O
=	O
.	O
09	O
##7	O
.	O

The	O
recovery	O
of	O
24	B
(	B
RS	I
)	I
-	I
[	I
26	I
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
,	I
27	I
-	I
_	I
2	I

Risk	O
of	O
a	O
Major	O
Ad	O
##verse	O
Card	O
##iovascular	O
Event	O
at	O
3	O
Years	O
,	O
According	O
to	O
Q	O
##ua	O
##rt	O
##ile	O
of	O
T	B
##MA	I
##O	I
Level	O
.	O
_	O

Ph	B
##en	I
##yle	I
##thy	I
##lam	I
##ine	I
,	O
t	B
##yra	I
##mine	I
,	O
and	O
do	B
##pa	I
##mine	I
are	O
substrates	O
of	O
Mao	O
##A	O
and	O
Pa	O
##d	O
##A	O
,	O
leading	O
to	O
formation	O
of	O
the	O
corresponding	O
a	O
##romatic	O
acids	O
,	O
that	O
is	O
,	O
p	B
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
,	O
and	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
,	O
respectively	O
[	O
,	O
]	O
.	O

An	O
alternative	O
pathway	O
to	O
ex	O
##cre	O
##te	O
am	O
##monia	O
excess	O
is	O
through	O
AK	O
##G	O
to	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
g	B
##lut	I
##amine	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
(	O
PA	O
##G	O
)	O
,	O
which	O
then	O
exits	O
the	O
body	O
via	O
the	O
urine	O
.	O

Other	O
Tor	O
##us	O
columns	O
such	O
as	O
the	O
2	O
-	O
P	O
##IC	O
can	O
be	O
used	O
instead	O
of	O
the	O
Di	B
##ol	I
without	O
a	O
significant	O
loss	O
of	O
resolution	O
or	O
peak	O
symmetry	O
,	O
and	O
the	O
combination	O
of	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
water	O
as	O
m	O
##od	O
##ifier	O
add	O
##itive	O
##s	O
might	O
improve	O
separation	O
more	O
than	O
the	O
use	O
of	O
either	O
one	O
by	O
itself	O
.	O

One	O
of	O
the	O
pathways	O
that	O
may	O
potentially	O
contribute	O
to	O
the	O
regulation	O
of	O
hydrogen	B
su	I
##lf	I
##ide	I
is	O
the	O
successive	O
met	O
##hyl	O
##ation	O
reactions	O
via	O
the	O
th	O
##iol	O
S	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
enzyme	O
into	O
dim	B
##eth	I
##yl	I
##sul	I
##fi	I
##de	I
.	O

The	O
weak	O
wash	S
solvent	S
was	S
ace	S
##ton	S
##it	S
##ril	S
##e	S
-	S
is	S
##op	S
##rop	S
##ano	S
##l	S
(	S
3	S
:	S
1	S
,	S
v	S
/	S
v	S
)	S
and	S
the	S
strong	S
wash	S
solvent	S
is	S
H	S
_	S
2	S
O	S
-	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
convergence	O
of	O
selected	O
meta	O
##bol	O
##ites	O
in	O
the	O
nitrogen	O
metabolism	O
pathway	O
,	O
serving	O
as	O
nitrogen	O
donors	O
for	O
the	O
u	B
##rea	I
cycle	O
,	O
suggests	O
that	O
this	O
pathway	O
may	O
influence	O
the	O
early	O
path	O
##ogen	O
##esis	O
of	O
type	O
2	O
diabetes	O
.	O

The	O
authors	O
did	O
not	O
detect	O
d	B
##G	I
-	I
C	I
##8	I
-	I
4	I
-	I
AB	I
##P	I
in	O
urine	O
of	O
non	O
-	O
smoke	O
##rs	O
;	O
urine	O
of	O
smoke	O
##rs	O
were	O
not	O
screened	O
for	O
add	O
##uc	O
##ts	O
.	O

(	O
B	O
)	O
Chemical	O
structures	O
of	O
t	B
##yra	I
##mine	I
and	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
are	O
shown	O
.	O

The	O
correlation	O
between	O
his	O
##to	O
##logical	O
percentage	O
##s	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
accumulation	O
and	O
he	O
##pa	O
##tic	O
fat	O
fraction	O
obtained	O
by	O
MR	O
##I	O
was	O
considered	O
excellent	O
(	O
Figure	O
)	O
.	O

Ph	B
##en	I
##yla	I
##ce	I
##tate	I
which	O
originates	O
from	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
is	O
another	O
degradation	O
meta	O
##bol	O
##ite	O
associated	O
with	O
a	O
high	O
intake	O
of	O
protein	O
[	O
,	O
]	O
but	O
as	O
with	O
BC	O
##FA	O
no	O
toxicity	O
to	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
has	O
yet	O
been	O
reported	O
.	O

Against	O
L	O
.	O
don	O
##ova	O
##ni	O
,	O
the	O
moderate	O
activity	O
of	O
met	B
##han	I
##ol	I
extract	O
of	O
end	O
##op	O
##hy	O
##te	O
F	O
.	O
t	O
##ric	O
##in	O
##ct	O
##um	O
isolated	O
from	O
the	O
fruits	O
of	O
Ho	O
##rde	O
##um	O
sat	O
##iv	O
##um	O
was	O
reported	O
by	O
Z	O
##ah	O
##er	O
et	O
al	O
.	O

⋅	O
l	O
n	O
p	O
##i	O
p	O
##i	O
p	O
p	O
i	O
i	O
D	O
##2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
D	O
##2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
D	O
##2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
D	O
##2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
D	O
##2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
D	O
##2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
D	O
##2	O
D	O
##2	O
D	O
D	O
2	O
2	O
=	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
1	O
##Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
1	O
1	O
Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
Σ	O
##R	O
##i	O
=	O
1	O
##p	O
##2	O
##i	O
Σ	O
Σ	O
R	O
R	O
i	O
=	O
1	O
##p	O
##2	O
##i	O
i	O
=	O
1	O
##p	O
##2	O
##i	O
i	O
=	O
1	O
p	O
##2	O
##i	O
p	O
##2	O
##i	O
p	O
p	O
2	O
2	O
i	O
i	O
Pearson	O
Co	O
##rrel	O
##ations	O
(	O
R	O
,	O
P	O
Value	O
)	O
Between	O
Me	O
##asures	O
of	O
Di	O
##versity	O
of	O
the	O
Fe	O
##cal	O
Micro	O
##bio	O
##me	O
and	O
Me	O
##asures	O
of	O
E	B
##stro	I
##gen	I
Met	O
##ab	O
##olis	O
##m	O
in	O
60	O
Post	O
##men	O
##op	O
##aus	O
##al	O
Women	O
Line	O
##ar	O
association	O
(	O
with	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
whole	O
-	O
tree	O
phylogenetic	O
diversity	O
with	O
the	O
ratio	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
to	O
parent	O
est	B
##rogen	I
.	O

Additionally	O
,	O
relative	O
to	O
those	O
in	O
HC	O
,	O
the	O
levels	O
of	O
9	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
PC	O
##s	O
,	O
namely	O
,	O
PC	B
(	I
17	I
:	I
2	I
/	I
2	I
:	I
0	I
)	I
,	O
PC	B
(	I
18	I
:	I
4	I
/	I
3	I
:	I
0	I
)	I
,	O
and	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
and	O
so	O
on	O
were	O
significantly	O
decreased	O
in	O
N	O
##SC	O
##LC	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
high	O
ω	B
-	I
6	I
P	I
##U	I
##FA	I
to	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
ratio	O
induced	O
by	O
large	O
amount	O
of	O
consumption	O
of	O
ω	B
-	I
6	I
P	I
##U	I
##FA	I
##s	I
is	O
observed	O
in	O
liver	O
diseases	O
;	O
and	O
a	O
study	O
demonstrated	O
that	O
high	O
intake	O
of	O
ω	B
-	I
6	I
P	I
##U	I
##FA	I
##s	I
should	O
be	O
avoid	O
for	O
mit	O
##iga	O
##ting	O
progression	O
of	O
liver	O
disease	O
due	O
to	O
their	O
pro	O
-	O
inflammatory	O
characteristics	O
.	O

Analysis	O
of	O
blank	O
injection	O
##s	O
throughout	O
the	O
method	O
valid	O
##ation	O
showed	O
no	O
indication	O
of	O
auto	O
##sa	O
##mple	O
##r	O
carry	O
##over	O
when	O
met	B
##han	I
##ol	I
was	O
used	O
as	O
the	O
needle	O
r	O
##ins	O
##e	O
solvent	O
.	O

Because	O
men	O
##op	O
##aus	O
##al	O
status	O
is	O
an	O
important	O
de	O
##ter	O
##mina	O
##nt	O
of	O
circulating	O
and	O
u	O
##rina	O
##ry	O
end	O
##ogen	O
##ous	O
est	B
##rogen	I
levels	O
and	O
so	O
many	O
of	O
the	O
participants	O
in	O
this	O
study	O
were	O
aged	O
45	O
–	O
55	O
years	O
and	O
potentially	O
per	O
##ime	O
##no	O
##pa	O
##usal	O
,	O
we	O
assessed	O
men	O
##op	O
##aus	O
##al	O
status	O
carefully	O
using	O
data	O
from	O
multiple	O
sources	O
,	O
including	O
self	O
-	O
reported	O
histories	O
of	O
men	O
##op	O
##aus	O
##e	O
and	O
surgical	O
procedures	O
from	O
the	O
base	O
##line	O
interview	O
,	O
surgical	O
procedures	O
reported	O
in	O
interviews	O
at	O
the	O
time	O
of	O
urine	O
collection	O
,	O
a	O
post	O
##card	O
mail	O
##ed	O
by	O
participants	O
to	O
study	O
investigators	O
recording	O
the	O
day	O
of	O
the	O
first	O
men	O
##st	O
##ru	O
##al	O
period	O
following	O
urine	O
collection	O
,	O
and	O
levels	O
of	O
f	O
##oll	O
##icle	O
s	O
##ti	O
##mulating	O
hormone	O
(	O
F	O
##S	O
##H	O
)	O
,	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
and	O
est	B
##rad	I
##iol	I
in	O
serum	O
collected	O
on	O
the	O
same	O
day	O
as	O
urine	O
.	O

Line	O
##ar	O
re	O
##gression	O
showed	O
that	O
the	O
significant	O
de	O
##ter	O
##mina	O
##nts	O
of	O
u	O
##rina	O
##ry	O
beta	O
##ine	O
/	O
C	O
##r	O
were	O
u	O
##rina	O
##ry	O
glucose	S
(	O
p	O
=	O
0	O
.	O
02	O
##1	O
)	O
and	O
type	O
of	O
diabetes	O
(	O
p	O
=	O
0	O
.	O
03	O
##8	O
)	O
.	O

S	O
-	O
Mon	O
##ove	O
##tte	O
(	O
Sa	O
##rst	O
##ed	O
##t	O
,	O
N	O
##ü	O
##mbre	O
##cht	O
,	O
Germany	O
)	O
or	O
in	O
c	B
##it	I
##rate	I
phosphate	I
de	I
##x	I
##tro	I
##se	I
ad	I
##eni	I
##ne	I
(	O
CP	O
##DA	O
-	O
1	O
)	O
blood	O
bag	O
(	O
Co	O
##mpo	O
##F	O
##lex	O
,	O
Fr	O
##ese	O
##nius	O
Ka	O
##bi	O
,	O
O	O
##ber	O
##dorf	O
,	O
Switzerland	O
)	O
.	O

However	O
,	O
can	B
##na	I
##bino	I
##ids	I
may	O
induce	O
cell	O
growth	O
depending	O
on	O
cancer	O
cell	O
type	O
,	O
the	O
specific	O
can	O
##na	O
##bino	O
##id	O
/	O
end	O
##oc	O
##anna	O
##bino	O
##id	O
compounds	O
,	O
and	O
meta	O
##bol	O
##ite	O
concentrations	O
.	O

Consequently	O
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
does	O
not	O
participate	O
in	O
g	B
##ly	I
##cer	I
##ol	I
shut	O
##tling	O
(	O
Fi	O
##g	O
.	O
)	O
,	O
as	O
indicated	O
by	O
the	O
accumulation	O
of	O
di	B
##hy	I
##dr	I
##ox	I
##ya	I
##ce	I
##tone	I
in	O
I	O
##R	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
with	O
a	O
parallel	O
lower	O
N	B
##AD	I
##H	I
production	O
.	O

We	O
did	O
not	O
find	O
significant	O
associations	O
of	O
test	B
##osterone	I
with	O
low	O
molecular	O
weight	O
meta	O
##bol	O
##ites	O
in	O
overall	O
analyses	O
or	O
by	O
WC	O
s	O
##trata	O
.	O

Considering	O
the	O
accepted	O
physiological	O
relevance	O
of	O
olive	O
p	O
##oly	O
##phe	O
##no	O
##ls	O
,	O
their	O
apparent	O
ability	O
to	O
protect	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
particles	O
from	O
o	O
##xi	O
##da	O
##tive	O
damage	O
,	O
and	O
the	O
fact	O
that	O
the	O
gut	O
micro	O
##bio	O
##ta	O
appears	O
to	O
be	O
intimate	O
##ly	O
related	O
to	O
their	O
metabolism	O
in	O
v	O
##ivo	O
,	O
we	O
measured	O
changes	O
in	O
key	O
olive	O
-	O
derived	O
p	O
##oly	O
##phe	O
##no	O
##ls	O
,	O
including	O
t	B
##yr	I
##oso	I
##l	I
and	O
H	O
##T	O
,	O
and	O
their	O
derived	O
cat	O
##ab	O
##oli	O
##tes	O
using	O
a	O
quantitative	O
L	O
##C	O
–	O
MS	O
-	O
based	O
strategy	O
.	O

Nevertheless	O
,	O
a	O
structural	O
analogue	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
LP	O
##A	O
)	O
,	O
the	O
c	O
##yclic	O
p	O
##hos	O
##pha	O
##ti	O
##dic	O
acid	O
c	O
##PA	O
(	O
18	O
:	O
0	O
)	O
was	O
found	O
to	O
be	O
down	O
-	O
regulated	O
,	O
which	O
is	O
consistent	O
with	O
its	O
activity	O
to	O
in	O
##hibit	O
cell	O
proliferation	O
,	O
plate	O
##let	O
a	O
##gg	O
##regation	O
,	O
and	O
meta	O
##sta	O
##sis	O
in	O
cancer	O
.	O

Among	O
the	O
control	O
subjects	O
,	O
the	O
parent	O
est	O
##rogen	O
##s	O
(	O
con	O
##ju	O
##gated	O
est	B
##rone	I
,	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rone	I
,	O
con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
,	O
and	O
un	O
##con	O
##ju	O
##gated	O
est	O
##rad	O
##iol	O
)	O
constituted	O
approximately	O
39	O
%	O
of	O
total	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
(	O
31	O
%	O
,	O
5	O
%	O
,	O
1	O
.	O
8	O
%	O
,	O
and	O
1	O
.	O
4	O
%	O
,	O
respectively	O
)	O
.	O

Go	O
to	O
:	O
This	O
paper	O
describes	O
an	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
to	O
determine	O
the	O
concentration	O
of	O
s	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
and	O
its	O
meta	O
##bol	O
##ites	O
7	B
-	I
alpha	I
-	I
met	I
##hyl	I
##thi	I
##os	I
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
and	O
can	B
##ren	I
##one	I
in	O
blood	O
plasma	O
samples	O
.	O

B	O
##rief	O
##ly	O
,	O
The	O
γ	B
-	I
MA	I
##PS	I
was	O
dissolved	O
in	O
Me	B
##OH	I
at	O
1	O
:	O
1	O
(	O
v	O
/	O
v	O
)	O
,	O
then	O
filled	O
through	O
the	O
above	O
pre	O
-	O
treated	O
cap	O
##illa	O
##ry	O
under	O
vacuum	O
.	O

Treatment	O
with	O
the	O
known	O
induce	O
##rs	O
resulted	O
in	O
a	O
35	O
.	O
6	O
-	O
fold	O
increase	O
in	O
activity	O
of	O
C	O
##YP	O
##1	O
##A	O
##2	O
with	O
o	B
##me	I
##pra	I
##zo	I
##le	I
;	O
a	O
10	O
.	O
7	O
-	O
fold	O
increase	O
in	O
C	O
##YP	O
##2	O
##B	O
##6	O
with	O
p	O
##hen	O
##ob	O
##ar	O
##bit	O
##al	O
;	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
2	O
.	O
6	O
-	O
fold	O
increase	O
in	O
C	O
##YP	O
##2	O
##E	O
##1	O
with	O
is	O
##onia	O
##zi	O
##d	O
;	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
increases	O
in	O
C	O
##YP	O
##2	O
##C	O
##9	O
(	O
1	O
.	O
9	O
-	O
fold	O
)	O
and	O
C	O
##YP	O
##3	O
##A	O
##4	O
/	O
5	O
(	O
6	O
.	O
6	O
-	O
fold	O
)	O
with	O
r	O
##if	O
##amp	O
##in	O
;	O
and	O
a	O
4	O
.	O
2	O
-	O
fold	O
increase	O
in	O
C	O
##YP	O
##2	O
##C	O
##19	O
with	O
r	O
##if	O
##amp	O
##in	O
.	O

Therefore	O
,	O
increasing	O
level	O
of	O
P	O
##t	O
##d	O
##cho	O
may	O
relate	O
to	O
the	O
F	B
##D	I
symptoms	O
through	O
CC	O
##K	O
pathway	O
.	O

Our	O
data	O
is	O
consistent	O
with	O
earlier	O
findings	O
that	O
both	O
ATP	S
level	O
and	O
ATP	S
s	O
##ynth	O
##ase	O
expression	O
/	O
activity	O
are	O
decreased	O
in	O
F	O
##T	O
##D	O
brain	O
and	O
F	O
##T	O
##D	O
mouse	O
models	O
.	O

Sign	O
##ificant	O
##ly	O
increased	O
trans	O
##cript	O
and	O
protein	O
levels	O
of	O
g	B
##ly	I
##co	I
##gen	I
s	O
##ynth	O
##ase	O
kinase	O
3	O
beta	O
(	B
G	B
##S	I
##K	I
##3	I
##β	I
)	O
and	O
g	O
##lut	O
##ama	O
##te	O
de	O
##car	O
##box	O
##yla	O
##se	O
1	O
(	O
GA	O
##D	O
##1	O
)	O
and	O
decreased	O
trans	O
##cript	O
and	O
protein	O
levels	O
of	O
p	B
##yr	I
##u	I
##vate	I
kinase	O
muscle	O
is	O
##oz	O
##yme	O
2	O
(	O
P	O
##K	O
##M	O
##2	O
)	O
and	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
1A	O
(	O
CP	O
##T	O
##1	O
##A	O
)	O
were	O
observed	O
in	O
the	O
patient	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

a	O
,	O
b	O
)	O
,	O
MS	O
/	O
MS	O
fragment	O
##ation	O
of	O
the	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
ion	O
at	O
m	O
/	O
z	O
760	O
.	O
58	O
##44	O
enabled	O
to	O
confirm	O
the	O
presence	O
of	O
the	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
polar	O
head	O
thanks	O
to	O
the	O
characteristic	O
fragment	O
ions	O
at	O
m	O
/	O
z	O
184	O
.	O
07	O
##26	O
,	O
m	O
/	O
z	O
104	O
.	O
107	O
##0	O
and	O
m	O
/	O
z	O
86	O
.	O
09	O
##6	O
##6	O
(	O
Fi	O
##g	O
.	O

A	O
total	O
of	O
six	O
meta	O
##bol	O
##ites	O
with	O
significantly	O
altered	O
serum	O
features	O
were	O
selected	O
:	O
se	B
##rine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
gal	B
##act	I
##ose	I
,	O
palm	B
##itic	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
and	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

Running	O
buffer	O
,	O
15	O
mm	O
##ol	O
/	O
L	O
NH	O
_	O
4	O
O	O
##A	O
##c	O
,	O
pH	O
7	O
.	O
0	O
,	O
+	O
15	O
k	B
##V	I
and	O
15	O
mm	O
##ol	O
/	O
L	O
(	O
NH	O
_	O
4	O
)	O
_	O
2	O
CO	O
_	O
3	O

T	B
##G	I
=	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
.	O

For	O
Met	O
##S	O
_	O
zero	O
women	O
,	O
se	B
##rine	I
and	O
a	B
##rg	I
##ini	I
##ne	I
were	O
found	O
to	O
be	O
higher	O
with	O
high	O
levels	O
of	O
A	O
##EE	O
/	O
kg	O
_	O
DL	O
##W	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
32	O
,	O
Q	O
_	O
2	O
=	O
0	O
.	O
21	O
)	O
and	O
PA	O
##L	O
_	O
DL	O
##W	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
40	O
,	O
Q	O
_	O
2	O
=	O
0	O
.	O
33	O
)	O
compared	O
with	O
low	O
levels	O
in	O
Met	O
##S	O
_	O
zero	O
women	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

In	O
contrast	O
,	O
P	O
##LT	O
##P	O
and	O
L	O
##CA	O
##T	O
activity	O
were	O
correlated	O
positively	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
inverse	O
##ly	O
with	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
ex	O
##t	O
+	O
U	O
##F	O
,	O
n	O
=	O
8	O
for	O
Me	B
##OH	I
pp	O
##t	O
samples	O
)	O
with	O
the	O
cross	O
-	O
bar	O
being	O
the	O
median	O
and	O
the	O
w	O
##his	O
##kers	O
representing	O
minimum	O
and	O
maximum	O
concentrations	O
.	O

Interest	O
##ingly	O
,	O
many	O
of	O
these	O
meta	O
##bol	O
##ites	O
are	O
involved	O
in	O
try	B
##pt	I
##op	I
##han	I
and	O
his	B
##ti	I
##dine	I
metabolism	O
.	O

Additionally	O
,	O
2	B
-	I
p	I
##yr	I
##ido	I
##ne	I
-	I
3	I
-	I
car	I
##box	I
##ami	I
##de	I
(	O
2	O
-	O
P	O
##Y	O
)	O
is	O
increased	O
in	O
AS	O
urine	O
,	O
which	O
is	O
reported	O
to	O
be	O
related	O
to	O
fat	O
metabolism	O
as	O
well	O
.	O

The	O
method	O
also	O
enabled	O
the	O
analysis	O
of	O
the	O
re	O
##gio	O
##is	O
##omer	O
##s	O
of	O
the	O
con	O
##ju	O
##gate	O
##s	O
,	O
and	O
several	O
intact	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
were	O
identified	O
and	O
q	O
##uant	O
##ified	O
for	O
the	O
first	O
time	O
in	O
the	O
human	O
brain	O
micro	O
##dial	O
##ys	O
##is	O
and	O
CS	O
##F	O
samples	O
.	O

A	O
composition	O
of	O
68	O
%	O
met	B
##han	I
##ol	I
was	O
found	O
to	O
have	O
the	O
best	O
separation	O
of	O
the	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
while	O
maintaining	O
acceptable	O
signal	O
levels	O
in	O
the	O
MS	O
.	O

For	O
example	O
,	O
‘	O
‘	O
PC	O
a	B
##e	I
C	I
##38	I
:	I
1	I
”	I
denotes	O
a	O
plasma	O
##log	O
##en	O
/	O
p	O
##las	O
##min	O
##ogen	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
with	O
38	O
carbon	O
##s	O
in	O
the	O
two	O
fatty	O
acid	O
side	O
chains	O
and	O
a	O
single	O
double	O
bond	O
in	O
one	O
of	O
them	O
.	O

P	B
##yr	I
##op	I
##hos	I
##phate	I
release	O
was	O
visual	O
##ized	O
using	O
the	O
P	O
_	O
i	O
Per	O
P	B
##yr	I
##op	I
##hos	I
##phate	I
As	O
##say	O
Kit	O
(	O
In	O
##vi	O
##tro	O
##gen	O
)	O
.	O

These	O
ions	O
were	O
chosen	O
because	O
is	O
##ob	O
##ari	O
##c	O
interference	O
##s	O
were	O
observed	O
in	O
the	O
most	O
abundant	O
transition	O
for	O
the	O
internal	O
standard	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
→	O
[	O
M	O
+	O
H	O
–	O
194	O
]	O
_	O
+	O
(	O
loss	O
of	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
H	O
_	O
2	O
O	O
)	O
,	O
resulting	O
in	O
less	O
reliable	O
estimates	O
of	O
the	O
u	O
##rina	O
##ry	O
anal	O
##yte	O
##s	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
f	O
##er	O
##mentation	O
super	O
##nat	O
##ant	O
from	O
all	O
time	O
points	O
was	O
freeze	O
-	O
dried	O
,	O
dissolved	O
in	O
600	O
µ	O
##L	O
of	O
phosphate	S
buffer	O
0	O
.	O
2	O
M	O
(	O
pH	O
7	O
.	O
4	O
)	O
in	O
D	O
_	O
2	O
O	O
plus	O
0	O
.	O
00	O
##1	O
%	O
T	O
##SP	O
and	O
550	O
µ	O
##L	O
transferred	O
into	O
5	O
mm	O
N	O
##MR	O
tubes	O
for	O
analysis	O
.	O

E	B
##ico	I
##san	I
##oids	I
,	O
including	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
(	O
P	O
##G	O
##s	O
)	O
and	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
(	O
L	O
##T	O
##s	O
)	O
are	O
synthesized	O
by	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
-	O
2	O
(	O
CO	O
##X	O
-	O
2	O
)	O
and	O
5	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
5	O
-	O
L	O
##OX	O
)	O
from	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

In	O
addition	O
,	O
the	O
detector	O
response	O
was	O
lower	O
than	O
in	O
the	O
case	O
of	O
a	O
mixture	O
of	O
am	O
##ine	O
and	O
an	B
##hy	I
##dr	I
##ous	I
ma	I
##gnesium	I
su	I
##lf	I
##ate	I
.	O

Integrated	O
s	O
##che	O
##matic	O
illustration	O
of	O
metabolic	O
alterations	O
in	O
his	B
##ti	I
##dine	I
and	O
g	O
##lut	O
##ama	O
##te	O
/	O
nitrogen	O
metabolism	O
induced	O
by	O
H	O
##T	O
##K	O
.	O

To	O
evaluate	O
the	O
relative	O
amount	O
of	O
product	O
ex	O
##cre	O
##ted	O
as	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
con	O
##ju	O
##gate	O
##s	O
,	O
human	O
urine	O
samples	O
were	O
in	O
##cu	O
##bate	O
##d	O
in	O
the	O
presence	O
and	O
absence	O
of	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
(	O
from	O
E	O
.	O
co	O
##li	O
,	O
Type	O
VII	O
-	O
A	O
,	O
200	O
units	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
at	O
37	O
##°	O
##C	O
for	O
one	O
hour	O
.	O

As	O
higher	O
consumption	O
of	O
g	B
##lut	I
##amine	I
in	O
tumor	O
cells	O
has	O
been	O
reported	O
to	O
be	O
essential	O
for	O
the	O
production	O
of	O
mac	O
##rom	O
##ole	O
##cule	O
##s	O
such	O
as	O
fatty	O
acid	O
and	O
nuclear	O
acids	O
,	O
_	O
,	O
more	O
circulating	O
g	B
##lut	I
##ama	I
##te	I
may	O
be	O
transformed	O
to	O
g	B
##lut	I
##amine	I
in	O
CR	O
##C	O
patients	O
to	O
compensate	O
the	O
higher	O
consumption	O
in	O
tumor	O
tissue	O
cells	O
.	O

(	O
B	O
)	O
Rep	O
##res	O
##entation	O
of	O
the	O
molecular	O
structure	O
(	O
C	O
_	O
24	O
H	O
_	O
48	O
NO	O
_	O
6	O
P	O
)	O
m	O
/	O
z	O
47	O
##8	O
identified	O
as	O
l	B
##is	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
[	O
LP	O
##C	O
(	B
P	B
-	I
16	I
:	I
1	I
)	O
]	O
.	O

Cal	O
##ib	O
##ration	O
curves	O
for	O
each	O
est	B
##rogen	I
anal	O
##yte	O
were	O
constructed	O
by	O
plotting	O
peak	O
area	O
ratio	O
between	O
target	O
anal	O
##yte	O
and	O
its	O
internal	O
standard	O
versus	O
the	O
amount	O
of	O
target	O
anal	O
##yte	O
.	O

G	B
##all	I
##ic	I
acid	I
,	O
ca	B
##ffe	I
##ine	I
and	O
the	O
fl	O
##avan	O
-	O
3	O
-	O
o	O
##l	O
standards	O
:	O
gal	B
##loc	I
##ate	I
##chin	I
(	O
G	O
##C	O
)	O
;	O
e	B
##pi	I
##gall	I
##oc	I
##ate	I
##chin	I
(	O
E	O
##GC	O
)	O
;	O
epic	B
##ate	I
##chin	I
(	O
EC	O
)	O
;	O
cat	B
##ech	I
##in	I
(	O
C	O
)	O
;	O
e	B
##pi	I
##gall	I
##oc	I
##ate	I
##chin	I
gal	I
##late	I
(	O
E	O
##GC	O
##G	O
)	O
;	O
gal	B
##loc	I
##ate	I
##chin	I
gal	I
##late	I
(	O
G	O
##C	O
##G	O
)	O
;	O
cat	B
##ech	I
##in	I
gal	I
##late	I
(	O
C	O
##G	O
)	O
and	O
epic	B
##ate	I
##chin	I
gal	I
##late	I
(	O
EC	O
##G	O
)	O
were	O
all	O
obtained	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Si	O
##lani	O
##zed	O
glass	O
tubes	O
decreased	O
the	O
recovery	O
of	O
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
(	O
U	O
-	O
_	O
15	O
N	O
)	O
Ad	O
##e	O
from	O
these	O
tubes	O
to	O
approximately	O
25	O
%	O
.	O

p	O
-	O
C	O
##res	O
##ol	O
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
might	O
therefore	O
reflect	O
an	O
inflammatory	O
response	O
of	O
the	O
gut	O
micro	O
##bio	O
##ta	O
.	O

This	O
finding	O
is	O
supported	O
by	O
previous	O
studies	O
in	O
man	O
,	O
reporting	O
no	O
association	O
between	O
C	B
##ML	I
and	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
media	O
##tors	O
as	O
well	O
as	O
molecules	O
for	O
end	O
##oth	O
##eli	O
##al	O
cell	O
activation	O
[	O
,	O
,	O
,	O
]	O
.	O

–	O
Our	O
observed	O
positive	O
and	O
negative	O
correlation	O
##s	O
of	O
F	O
##G	O
##F	O
-	O
23	O
and	O
PT	O
##H	O
with	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
suggest	O
that	O
these	O
regulatory	O
effects	O
explain	O
inter	O
-	O
individual	O
differences	O
in	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
to	O
some	O
extent	O
.	O

The	O
peaks	O
of	O
all	O
difference	O
s	O
##pect	O
##ra	O
were	O
aligned	O
at	O
full	O
resolution	O
using	O
“	O
i	O
##cos	O
##hi	O
##ft	O
”	O
,	O
initially	O
on	O
the	O
la	B
##ct	I
##ate	I
double	O
##t	O
at	O
1	O
.	O
32	O
pp	O
##m	O
and	O
subsequently	O
on	O
manually	O
defined	O
segments	O
.	O

The	O
pair	O
of	O
p	O
##eptide	O
add	O
##uc	O
##ts	O
detected	O
in	O
Fr	O
##action	O
10	O
were	O
consistent	O
with	O
the	O
amino	O
acid	O
residues	O
149	O
–	O
159	O
of	O
SA	O
(	O
F	O
##Y	O
*	O
AP	O
##EL	O
##LF	O
##FA	O
##K	O
,	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
77	O
##7	O
.	O
1	O
and	O
77	O
##9	O
.	O
6	O
)	O
having	O
add	O
##uction	O
##s	O
with	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
and	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
m	O
##oi	O
##eti	O
##es	O
at	O
Y	O
,	O
respectively	O
.	O

Was	O
##hes	O
(	O
500	O
μ	O
##L	O
)	O
with	O
met	B
##han	I
##ol	I
followed	O
by	O
he	O
##xa	O
##ne	O
/	O
et	O
##hyl	O
ace	B
##tate	I
(	I
3	I
:	I
2	I
)	I
,	O
between	O
samples	O
,	O
were	O
used	O
to	O
minimize	O
ghost	O
effects	O
.	O

As	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
format	B
##e	I
could	O
accurately	O
disc	O
##rim	O
##inate	O
between	O
R	O
##R	O
##MS	O
and	O
A	O
##b	O
-	O
N	O
##MO	O
##SD	O
,	O
we	O
explored	O
whether	O
these	O
meta	O
##bol	O
##ites	O
are	O
different	O
between	O
the	O
MS	O
-	O
like	O
and	O
N	O
##MO	O
##SD	O
-	O
like	O
clinic	O
##o	O
-	O
radio	O
##log	O
##ic	O
subgroup	O
##s	O
within	O
the	O
anti	O
##body	O
-	O
negative	O
co	O
##hor	O
##t	O
.	O

Pearson	O
correlation	O
coefficients	O
reflect	O
moderate	O
to	O
high	O
correlation	O
among	O
the	O
meta	O
##bol	O
##ites	O
in	O
each	O
pattern	O
,	O
with	O
correlation	O
coefficients	O
ranging	O
from	O
0	O
.	O
77	O
to	O
0	O
.	O
93	O
among	O
k	B
##eton	I
##e	I
bodies	O
and	O
from	O
0	O
.	O
23	O
to	O
0	O
.	O
58	O
among	O
meta	O
##bol	O
##ites	O
in	O
the	O
second	O
pattern	O
.	O

In	O
this	O
method	O
,	O
the	O
IL	O
-	O
D	O
##PI	O
-	O
L	O
##C	O
-	O
MS	O
was	O
firstly	O
applied	O
for	O
non	O
-	O
targeted	O
pro	O
##fi	O
##ling	O
of	O
th	B
##iol	I
##s	I
in	O
5	O
cancer	O
urine	O
##s	O
.	O

An	O
exception	O
was	O
the	O
analysis	O
of	O
alpha	B
-	I
P	I
##EP	I
using	O
H	O
##IL	O
##IC	O
in	O
negative	O
mode	O
(	O
Fi	O
##g	O
.	O

Cell	O
##s	O
were	O
washed	O
with	O
complete	O
medium	O
,	O
and	O
fixed	O
with	O
freshly	O
prepared	O
pre	O
-	O
warmed	O
1640	O
medium	O
containing	O
3	O
.	O
7	O
%	O
formal	B
##de	I
##hy	I
##de	I
at	O
37	O
°C	O
for	O
15	O
min	O
.	O

First	O
##ly	O
,	O
the	O
bi	O
##car	O
##bon	O
##ate	O
an	O
##ion	O
in	O
the	O
ion	O
complex	O
abstract	O
##s	O
a	O
met	O
##hyl	O
pro	O
##ton	O
in	O
ch	B
##olin	I
##e	I
and	O
leaves	O
as	O
H	O
_	O
2	O
CO	O
_	O
3	O
,	O
which	O
is	O
supported	O
by	O
MS	O
_	O
2	O
C	O
##ID	O
of	O
the	O
bi	O
##car	O
##bon	O
##ate	O
add	O
##uc	O
##t	O
of	O
d	O
##9	O
-	O
PC	O
16	O
:	O
0	O
/	O
16	O
:	O
0	O
(	O
all	O
nine	O
ch	B
##olin	I
##e	I
hydrogen	I
atoms	O
are	O
labeled	O
with	O
de	O
##uter	O
##ium	O
,	O
Fi	O
##g	O
.	O

For	O
example	O
,	O
as	B
##par	I
##tic	I
acid	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
and	O
4	B
-	I
amino	I
##but	I
##yric	I
acid	I
participate	O
in	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
,	O
which	O
is	O
associated	O
with	O
g	O
##ly	O
##co	O
##lysis	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
and	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
by	O
trans	O
##ami	O
##nation	O
to	O
g	B
##lut	I
##ami	I
##c	I
acid	I
.	O

Ch	O
##roma	O
##to	O
##graphic	O
grade	O
met	B
##han	I
##ol	I
was	O
purchased	O
from	O
T	O
##ED	O
##IA	O
Co	O
.	O
Inc	O
.	O
(	O
Ohio	O
,	O
USA	O
)	O
.	O

MS	O
##EA	O
indicated	O
that	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
al	B
##ani	I
##ne	I
metabolism	O
pathways	O
,	O
as	O
well	O
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
,	O
am	O
##monia	O
recycling	O
,	O
u	B
##rea	I
cycle	O
,	O
k	B
##eton	I
##e	I
body	O
metabolism	O
,	O
glucose	B
-	I
al	I
##ani	I
##ne	I
cycle	O
and	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
degradation	O
pathways	O
are	O
significantly	O
associated	O
with	O
M	O
##T	O
##B	O
infection	O
.	O

In	O
multiple	O
re	O
##gression	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
was	O
an	O
independent	O
predict	O
##or	O
of	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
in	O
active	O
(	O
r	O
_	O
p	O
=	O
0	O
.	O
50	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
and	O
inactive	O
CD	O
(	O
r	O
_	O
p	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
0	O
.	O
04	O
##5	O
)	O
,	O
explaining	O
,	O
respectively	O
,	O
25	O
%	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
253	O
;	O
F	O
=	O
12	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
and	O
41	O
%	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
41	O
##4	O
;	O
F	O
=	O
5	O
.	O
7	O
,	O
p	O
=	O
0	O
.	O
04	O
##5	O
)	O
in	O
its	O
var	O
##iability	O
.	O

HP	O
##LC	O
-	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
met	B
##han	I
##ol	I
were	O
purchased	O
from	O
Ted	O
##ia	O
(	O
Fairfield	O
,	O
Ohio	O
)	O
.	O

The	O
S	O
‐	O
plot	O
(	O
Figure	O
F	O
)	O
and	O
the	O
variables	O
with	O
high	O
VIP	O
revealed	O
the	O
metabolic	O
effect	O
of	O
pre	O
‐	O
cache	O
##xia	O
,	O
including	O
elevated	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
le	B
##uc	I
##ine	I
,	O
fatty	O
acid	O
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
N	B
‐	I
ace	I
##ty	I
##l	I
##g	I
##lut	I
##ama	I
##te	I
,	O
1	B
‐	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
al	B
##ani	I
##ne	I
,	O
N	B
‐	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
,	O
met	B
##hyl	I
##mal	I
##ona	I
##te	I
,	O
an	B
##ser	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
my	O
##o	O
‐	O
in	O
##os	O
##ito	O
##l	O
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
5	B
‐	I
h	I
##ydro	I
##xy	I
##ly	I
##sin	I
##e	I
,	O
ta	B
##uri	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
c	B
##it	I
##rate	I
,	O
ma	B
##late	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
3	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
su	B
##cci	I
##nate	I
,	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##co	I
##cho	I
##late	I
,	O
ace	B
##tone	I
,	O
c	O
##is	O
‐	O
a	O
##con	O
##itate	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
decreased	O
levels	O
of	O
4	B
‐	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
g	B
##ly	I
##cine	I
,	O
car	B
##ni	I
##tine	I
,	O
glucose	S
,	O
and	O
ch	B
##olin	I
##e	I
.	O

The	O
following	O
gradient	O
was	O
used	O
with	O
pure	O
CO	O
_	O
2	O
as	O
solvent	O
A	O
and	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
with	O
30	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
1	O
.	O
89	O
##2	O
g	O
dissolved	O
prior	O
in	O
5	O
m	O
##L	O
water	O
for	O
1	O
L	O
Me	O
##OH	O
)	O
as	O
m	O
##od	O
##ifier	O
(	O
solvent	O
B	O
)	O
:	O
0	O
–	O
4	O
.	O
0	O
min	O
5	O
%	O
B	O
,	O
4	O
.	O
0	O
–	O
17	O
.	O
0	O
min	O
ramp	O
to	O
55	O
%	O
B	O
,	O
17	O
.	O
0	O
–	O
25	O
.	O
0	O
min	O
55	O
%	O
B	O
,	O
25	O
.	O
0	O
–	O
25	O
.	O
5	O
min	O
ramp	O
down	O
to	O
5	O
%	O
B	O
,	O
and	O
25	O
.	O
5	O
–	O
27	O
.	O
0	O
min	O
5	O
%	O
B	O
as	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
step	O
.	O

Pat	O
##ients	O
with	O
large	O
active	O
tumor	O
volumes	O
and	O
high	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
burden	O
have	O
significantly	O
higher	O
plasma	O
concentrations	O
of	O
glucose	S
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
N	O
##AG	O
##s	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
v	B
##ali	I
##ne	I
on	O
one	O
hand	O
but	O
lower	O
concentrations	O
of	O
SM	O
and	O
PC	O
on	O
the	O
other	O
hand	O
(	O
Table	O
)	O
.	O

Furthermore	O
,	O
up	O
-	O
regulation	O
of	O
c	B
##yt	I
##os	I
##ine	I
and	O
its	O
is	O
##omer	O
is	O
##oc	O
##yt	O
##os	O
##ine	O
in	O
CR	O
##C	O
tumors	O
found	O
in	O
our	O
study	O
has	O
been	O
observed	O
previously	O
in	O
le	O
##uka	O
##emia	O
.	O

Lac	B
##tate	I
levels	O
increased	O
post	O
##che	O
##mother	O
##ap	O
##y	O
(	O
Figure	O
S	O
##3	O
)	O
,	O
probably	O
reflecting	O
the	O
War	O
##burg	O
effect	O
in	O
ma	O
##li	O
##gnant	O
tissues	O
.	O

The	O
levels	O
of	O
nor	B
##le	I
##uc	I
##ine	I
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
like	O
molecule	O
and	O
c	B
##it	I
##ric	I
acid	I
were	O
lower	O
for	O
b	O
##act	O
##ere	O
##mic	O
se	O
##psis	O
cases	O
compared	O
to	O
ER	O
controls	O
.	O

The	O
statistical	O
analysis	O
revealed	O
that	O
car	B
##ni	I
##tine	I
and	O
/	O
or	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
were	O
indeed	O
increased	O
in	O
samples	O
from	O
patients	O
with	O
active	O
disease	O
both	O
before	O
(	O
group	O
A	O
)	O
and	O
after	O
treatment	O
(	O
i	O
.	O
e	O
.	O
re	O
##lap	O
##sed	O
,	O
group	O
C	O
##2	O
)	O
.	O

However	O
,	O
in	O
v	O
##it	O
##ro	O
,	O
hip	B
##pura	I
##te	I
does	O
not	O
demonstrate	O
an	O
O	O
##AT	O
-	O
dependent	O
toxic	O
effect	O
.	O

We	O
found	O
that	O
the	O
levels	O
of	O
or	B
##ni	I
##thin	I
##e	I
and	O
put	B
##res	I
##cine	I
were	O
higher	O
in	O
patients	O
with	O
breast	O
or	O
pan	O
##cre	O
##atic	O
cancer	O
,	O
and	O
were	O
marked	O
##ly	O
higher	O
in	O
patients	O
with	O
oral	O
cancer	O
,	O
than	O
in	O
our	O
healthy	O
controls	O
,	O
while	O
there	O
was	O
no	O
significant	O
difference	O
between	O
patients	O
with	O
period	O
##ont	O
##al	O
disease	O
and	O
the	O
controls	O
.	O

In	O
contrast	O
,	O
there	O
were	O
no	O
statistical	O
##ly	O
significant	O
correlation	O
##s	O
noted	O
between	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
beta	B
##ine	I
in	O
L	O
##V	O
e	O
##jection	O
fraction	O
or	O
L	O
##V	O
dimensions	O
.	O

Dock	O
##ing	O
results	O
of	O
the	O
synthesized	O
compounds	O
D	O
##HP	O
##M	O
##1	O
–	O
D	O
##HP	O
##M	O
##8	O
against	O
human	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
in	O
complex	O
with	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
M	O
##OE	O
,	O
Molecular	O
Operating	O
Environment	O
;	O
D	O
##HP	O
##M	O
,	O
di	B
##hy	I
##dr	I
##opy	I
##rim	I
##id	I
##ine	I
.	O

As	O
β	O
‐	O
oxidation	O
usually	O
takes	O
place	O
in	O
the	O
mit	O
##och	O
##ond	O
##ria	O
,	O
FA	O
##s	O
then	O
bind	O
to	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
carriers	O
)	O
that	O
transport	O
FA	O
##s	O
to	O
the	O
mit	O
##och	O
##ond	O
##ria	O
.	O

Although	O
we	O
did	O
not	O
find	O
any	O
association	O
between	O
CO	O
##H	O
levels	O
and	O
card	O
##io	O
##met	O
##ab	O
##olic	O
parameters	O
,	O
which	O
could	O
be	O
due	O
to	O
that	O
our	O
participants	O
were	O
all	O
healthy	O
,	O
the	O
observed	O
role	O
of	O
car	B
##nos	I
##ine	I
on	O
CO	O
##H	O
levels	O
may	O
help	O
to	O
delay	O
the	O
development	O
of	O
T	O
##2	O
##DM	O
and	O
C	O
##VD	O
through	O
improving	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
.	O

U	O
##rina	O
##ry	O
D	O
##MA	O
##P	O
can	O
be	O
a	O
specific	O
bio	O
##mark	O
##er	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
exposure	O
;	O
and	O
consumption	O
of	O
local	O
produce	O
is	O
a	O
plausible	O
source	O
of	O
exposure	O
unless	O
there	O
is	O
an	O
incident	O
##al	O
exposure	O
,	O
such	O
as	O
in	O
aerial	O
spray	O
##ing	O
or	O
domestic	O
treatment	O
.	O

The	O
same	O
considerations	O
hold	O
true	O
for	O
two	O
other	O
meta	O
##bol	O
##ites	O
measured	O
in	O
this	O
study	O
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
la	B
##ct	I
##ate	I
,	O
which	O
showed	O
blunt	O
##ed	O
ex	O
##cursions	O
in	O
response	O
to	O
the	O
O	O
##G	O
##TT	O
in	O
insulin	O
-	O
resistant	O
adults	O
(	O
,	O
)	O
but	O
not	O
in	O
our	O
younger	O
population	O
.	O

In	O
the	O
pre	O
##hy	O
##pert	O
##ens	O
##ive	O
group	O
,	O
the	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
positively	O
and	O
significantly	O
correlated	O
with	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
,	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
,	O
8	B
-	I
e	I
##pi	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
,	O
b	O
##a	O
-	O
P	O
##W	O
##V	O
,	O
and	O
IL	O
-	O
6	O
before	O
and	O
after	O
adjusting	O
for	O
con	O
##found	O
##ing	O
variables	O
.	O

The	O
ratios	O
appeared	O
to	O
disc	O
##rim	O
##inate	O
AD	O
versus	O
controls	O
more	O
robust	O
##ly	O
than	O
the	O
differences	O
seen	O
with	O
individual	O
c	B
##era	I
##mi	I
##de	I
or	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
(	O
and	O
compared	O
to	O
and	O
and	O
and	O
,	O
respectively	O
)	O
.	O

However	O
,	O
maximum	O
and	O
minimum	O
distribution	O
error	O
rates	O
were	O
smaller	O
for	O
PC	O
##T	O
##10	O
than	O
PC	O
##T	O
##12	O
for	O
predict	O
##ing	O
both	O
s	O
##pect	O
##ra	O
with	O
and	O
without	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
based	O
on	O
the	O
1	O
,	O
000	O
it	O
##eration	O
re	O
-	O
sampling	O
procedure	O
.	O

Line	O
##ar	O
re	O
##gression	O
analysis	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
base	O
##line	O
BP	O
,	O
and	O
PC	O
##s	O
1	O
and	O
2	O
,	O
revealed	O
that	O
individuals	O
with	O
a	O
higher	O
score	O
had	O
a	O
better	O
HC	O
##T	O
##Z	O
S	O
##B	O
##P	O
(	O
p	O
=	O
1	O
##×	O
##10	O
_	O
−	O
##8	O
)	O
and	O
DB	B
##P	I
(	O
p	O
=	O
3	O
##×	O
##10	O
_	O
−	O
##9	O
)	O
responses	O
compared	O
to	O
lower	O
score	O
participants	O
(	O
,	O
respectively	O
)	O
.	O

The	O
solution	O
B	O
was	O
prepared	O
by	O
di	O
##sso	O
##lving	O
0	O
.	O
214	O
g	O
sodium	B
phosphate	I
di	O
##bas	O
##ic	O
he	O
##pta	O
##hy	O
##dra	O
##te	O
and	O
0	O
.	O
02	O
##7	O
g	O
sodium	B
phosphate	I
mon	O
##ob	O
##asi	O
##c	O
mon	O
##oh	O
##yd	O
##rate	O
in	O
0	O
.	O
5	O
L	O
of	O
trip	O
##ly	O
dei	O
##onized	O
water	O
in	O
another	O
volume	O
##tric	O
fl	O
##ask	O
.	O

In	O
this	O
modified	O
method	O
,	O
cells	O
were	O
culture	O
##d	O
for	O
72	O
h	O
and	O
MC	O
##F	O
-	O
7	O
cells	O
were	O
plate	O
##d	O
in	O
6	O
-	O
well	O
plates	O
in	O
R	O
##PM	O
##I	O
1640	O
media	O
without	O
p	B
##hen	I
##ol	I
red	O
and	O
supplemented	O
with	O
10	O
%	O
charcoal	O
-	O
stripped	O
F	O
##BS	O
,	O
1	O
%	O
g	B
##lut	I
##a	I
##MA	I
##X	I
,	O
1	O
%	O
AB	O
/	O
AM	O
,	O
1	O
%	O
none	O
##ssent	O
##ial	O
amino	O
acids	O
,	O
and	O
insulin	O
(	O
6	O
ng	O
/	O
m	O
##L	O
)	O
at	O
3	O
.	O
5	O
×	O
10	O
_	O
5	O
cells	O
/	O
well	O
.	O

Not	O
##ably	O
,	O
inter	O
-	O
patient	O
differences	O
in	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
bio	O
##act	O
##ivation	O
and	O
enter	O
##ic	O
recycling	O
would	O
impact	O
treatment	O
as	O
retention	O
of	O
bio	O
##activated	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ives	O
at	O
the	O
target	O
site	O
would	O
sustain	O
therapeutic	O
effectiveness	O
.	O

In	O
this	O
study	O
,	O
we	O
chose	O
to	O
adjust	O
with	O
u	O
##rina	O
##ry	O
specific	O
gravity	O
,	O
which	O
is	O
thought	O
to	O
be	O
less	O
impacted	O
by	O
changes	O
with	O
age	O
,	O
body	O
composition	O
,	O
physical	O
activity	O
,	O
urine	O
flow	O
,	O
time	O
of	O
day	O
,	O
diet	O
,	O
disease	O
,	O
and	O
pregnancy	O
than	O
other	O
measures	O
such	O
as	O
c	B
##rea	I
##tin	I
##ine	I
[	O
,	O
]	O
.	O

The	O
k	O
##yn	O
##uren	O
##ine	O
/	O
try	O
##pt	O
##op	O
##han	O
ratio	O
was	O
not	O
significantly	O
different	O
comparing	O
patients	O
with	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
(	O
0	O
.	O
01	O
##8	O
,	O
SD	O
=	O
0	O
.	O
01	O
##0	O
,	O
n	O
=	O
80	O
)	O
to	O
patients	O
without	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
(	O
0	O
.	O
02	O
##2	O
,	O
SD	O
=	O
0	O
.	O
01	O
##9	O
,	O
n	O
=	O
52	O
)	O
.	O

A	O
Student	O
’	O
s	O
t	O
test	O
followed	O
by	O
the	O
Benjamin	O
##i	O
–	O
Ho	O
##ch	O
##berg	O
multiple	O
hypothesis	O
test	O
identified	O
ace	B
##tate	I
and	O
c	B
##rea	I
##tin	I
##ine	I
as	O
statistical	O
##ly	O
different	O
between	O
healthy	O
controls	O
and	O
MS	O
patients	O
.	O

The	O
predict	O
##ive	O
performance	O
of	O
the	O
combined	O
score	O
improved	O
after	O
taking	O
try	B
##pt	I
##op	I
##han	I
into	O
account	O
.	O

Is	O
##op	O
##rene	O
is	O
the	O
basic	O
unit	O
of	O
te	B
##rp	I
##ene	I
##s	I
and	O
is	O
generated	O
during	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
in	O
the	O
me	B
##val	I
##ona	I
##te	I
pathway	O
.	O

Further	O
studies	O
are	O
required	O
to	O
determine	O
whether	O
these	O
three	O
novel	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
are	O
derived	O
from	O
5	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
or	O
other	O
un	O
##cha	O
##rac	O
##ter	O
##ized	O
h	O
##ydro	O
##xy	O
##lated	O
Ph	O
##IP	O
meta	O
##bol	O
##ites	O
.	O

The	O
second	O
laser	O
ex	O
##cite	O
##s	O
the	O
fluorescent	O
con	O
##ju	O
##gate	O
(	B
s	B
##tre	I
##pta	I
##vid	I
##in	I
-	I
p	I
##hy	I
##coe	I
##ry	I
##th	I
##rin	I
)	O
that	O
has	O
been	O
bound	O
to	O
the	O
beads	O
during	O
the	O
ass	O
##ay	O
.	O

Also	O
,	O
future	O
research	O
character	O
##izing	O
specific	O
foods	O
or	O
food	O
groups	O
that	O
contribute	O
to	O
ex	O
##ogen	O
##ous	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
exposure	O
,	O
or	O
variation	O
in	O
human	O
end	O
##ogen	O
##ous	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
synthesis	O
,	O
could	O
improve	O
the	O
understanding	O
of	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
exposure	O
,	O
and	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
factors	O
contributing	O
to	O
end	O
##ogen	O
##ous	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
concentration	O
,	O
increased	O
ad	O
##ip	O
##os	O
##ity	O
,	O
or	O
both	O
.	O

Previously	O
De	O
##uch	O
##ler	O
et	O
al	O
.	O
reported	O
ch	B
##olin	I
##e	I
levels	O
in	O
milk	O
of	O
cows	O
,	O
also	O
when	O
not	O
supplemented	O
ch	B
##olin	I
##e	I
,	O
in	O
early	O
la	O
##ct	O
##ation	O
(	O
2	O
.	O
6	O
g	O
/	O
d	O
)	O
and	O
mid	O
-	O
la	O
##ct	O
##ation	O
(	O
2	O
.	O
1	O
g	O
/	O
d	O
)	O
that	O
is	O
within	O
the	O
range	O
observed	O
in	O
our	O
study	O
.	O

Two	O
features	O
matched	O
ions	O
derived	O
from	O
s	B
##phi	I
##ngo	I
##fu	I
##ng	I
##in	I
A	O
,	O
a	O
natural	O
anti	O
##fu	O
##nga	O
##l	O
produced	O
by	O
As	O
##per	O
##gill	O
##us	O
species	O
.	O

A	O
/	O
B	O
;	O
MA	O
##T	O
,	O
met	O
##hi	O
##oni	O
##ne	O
ad	O
##eno	O
##sy	O
##l	O
-	O
transfer	O
##ase	O
;	O
MS	O
,	O
met	B
##hi	I
##oni	I
##ne	I
s	O
##ynth	O
##ase	O
;	O
M	O
##TH	O
##F	O
##R	O
,	O
5	B
,	I
10	I
-	I
met	I
##hyl	I
##ene	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
red	O
##uc	O
##tase	O
;	O
NO	O
,	O
ni	B
##tric	I
oxide	I
;	O
n	O
.	O
s	O
.	O
,	O
not	O
significant	O
;	O
PA	O
##H	O
,	O
p	O
##hen	O
##yla	O
##lani	O
##ne	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
;	O
P	O
##EP	O
##C	O
##K	O
,	O
p	O
##hos	O
##ph	O
##oe	O
##no	O
##l	O
##py	O
##ru	O
##vate	O
car	O
##box	O
##yk	O
##inas	O
##e	O
;	O
R	O
##NL	O
##S	O
,	O
re	O
##nal	O
##ase	O
;	O
T	O
##CA	O
,	O
c	B
##it	I
##ric	I
acid	I
;	O
T	O
##H	O
,	O
t	O
##yr	O
##os	O
##ine	O
h	O
##ydro	O
##xy	O
##lase	O
.	O

Con	O
##se	O
##cut	O
##ive	O
reaction	O
monitoring	O
was	O
performed	O
at	O
the	O
MS	O
_	O
3	O
and	O
MS	O
_	O
4	O
scan	O
stages	O
for	O
several	O
fragment	O
ions	O
of	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
Y	I
to	O
determine	O
the	O
site	O
of	O
bond	O
formation	O
between	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
and	O
t	B
##yr	I
##os	I
##ine	I
.	O

A	O
Con	O
##over	O
-	O
In	O
##man	O
test	O
for	O
multiple	O
comparison	O
between	O
milk	O
and	O
so	O
##y	O
drink	O
intake	O
further	O
revealed	O
significant	O
differences	O
for	O
C	B
##15	I
:	I
0	I
,	O
which	O
were	O
suggest	O
##ive	O
of	O
a	O
disc	O
##rim	O
##inating	O
potential	O
of	O
this	O
molecule	O
.	O

Total	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
the	O
ratio	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
to	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ides	I
,	O
o	B
##me	I
##ga	I
-	I
9	I
and	O
saturated	O
fatty	O
acids	O
,	O
the	O
ratio	O
of	O
o	B
##me	I
##ga	I
-	I
9	I
and	O
saturated	O
fatty	O
acids	O
to	O
total	O
fatty	O
acids	O
and	O
the	O
average	O
number	O
of	O
met	B
##hyl	I
##ene	I
groups	O
per	O
double	O
bond	O
showed	O
positive	O
association	O
with	O
levels	O
of	O
test	B
##osterone	I
in	O
PC	O
##OS	O
women	O
but	O
not	O
in	O
controls	O
(	O
β	O
>	O
0	O
.	O
17	O
,	O
P	O
<	O
1	O
.	O
9	O
×	O
10	O
_	O
−	O
##3	O
)	O
.	O

Moreover	O
,	O
the	O
high	O
-	O
resolution	O
spectrum	O
revealed	O
_	O
13	O
C	O
coupling	O
patterns	O
of	O
β	O
##G	O
##6	O
##P	O
carbon	O
##s	O
,	O
i	O
.	O
e	O
.	O
double	O
##t	O
for	O
C	O
##1	O
,	O
triple	O
##t	O
for	O
C	O
##3	O
-	O
5	O
,	O
as	O
well	O
as	O
double	O
##t	O
for	O
C	O
##6	O
,	O
which	O
indicate	O
the	O
presence	O
of	O
uniform	O
##ly	O
labeled	O
β	O
##G	O
##6	O
##P	O
and	O
thus	O
its	O
origin	O
from	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
glucose	I
.	O

Straight	O
-	O
chain	O
SC	O
##FA	O
(	B
but	B
##yra	I
##te	I
,	O
prop	B
##ion	I
##ate	I
,	O
ace	B
##tate	I
and	O
v	O
##ale	O
##rate	O
)	O
are	O
products	O
of	O
sa	B
##cc	I
##hari	I
##des	I
and	O
amino	O
acids	O
while	O
branched	O
SC	O
##FA	O
(	O
BC	O
##FA	O
)	O
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
is	B
##ova	I
##ler	I
##ate	I
and	O
2	B
-	I
met	I
##hyl	I
##but	I
##yra	I
##te	I
are	O
specifically	O
attributed	O
to	O
the	O
degradation	O
of	O
branched	O
amino	O
acids	O
(	O
BA	O
##A	O
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
)	O
.	O

Cal	O
##ib	O
##ration	O
curves	O
in	O
sur	O
##rogate	O
serum	O
were	O
created	O
by	O
plotting	O
the	O
peak	O
area	O
ratio	O
of	O
pro	B
##line	I
to	O
IS	O
against	O
the	O
known	O
concentrations	O
of	O
the	O
pro	B
##line	I
.	O

The	O
significantly	O
different	O
meta	O
##bol	O
##ites	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
diabetes	O
,	O
and	O
h	O
##yper	O
##tens	O
##ion	O
status	O
between	O
the	O
F	O
##S	O
##GS	O
and	O
healthy	O
control	O
groups	O
included	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
,	O
trans	B
-	I
a	I
##con	I
##itate	I
,	O
al	B
##ani	I
##ne	I
,	O
beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
c	B
##it	I
##rate	I
,	O
ethanol	B
##amine	I
,	O
f	B
##uma	I
##rate	I
,	O
glucose	S
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##uan	I
##ido	I
##ace	I
##tate	I
,	O
his	B
##ti	I
##dine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
3	B
-	I
in	I
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
le	B
##uc	I
##ine	I
,	O
man	B
##ni	I
##to	I
##l	I
,	O
met	B
##hyl	I
##amine	I
,	O
1	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
,	O
su	B
##c	I
##rose	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
u	B
##rac	I
##il	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##1	O
)	O
.	O

The	O
ratio	O
of	O
these	O
three	O
o	B
##xy	I
##ster	I
##ols	I
in	O
CS	O
##F	O
thus	O
gives	O
an	O
indication	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
in	O
brain	O
with	O
respect	O
to	O
o	B
##xy	I
##ster	I
##ol	I
transport	O
from	O
the	O
periphery	O
into	O
CS	O
##F	O
.	O

Consequently	O
,	O
this	O
approach	O
(	O
upon	O
proper	O
valid	O
##ation	O
)	O
comprises	O
an	O
important	O
new	O
addition	O
to	O
the	O
early	O
clinical	O
development	O
‘	O
proof	O
of	O
concept	O
’	O
tool	O
##box	O
for	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
##s	I
,	O
and	O
may	O
also	O
be	O
applicable	O
to	O
other	O
classes	O
of	O
drugs	O
.	O

Fast	O
##ing	O
morning	O
midst	O
##rea	O
##m	O
clean	O
-	O
catch	O
urine	O
samples	O
were	O
collected	O
at	O
three	O
visits	O
(	O
V	O
##1	O
:	O
g	O
##esta	O
##tional	O
week	O
8	O
–	O
20	O
;	O
V	O
##2	O
:	O
week	O
28	O
##±	O
##2	O
;	O
[UNK]	O
–	O
16	O
weeks	O
post	O
part	O
##um	O
)	O
,	O
and	O
routine	O
tests	O
for	O
ni	B
##tri	I
##te	I
,	O
protein	O
##uria	O
and	O
g	O
##lu	O
##cos	O
##uria	O
were	O
performed	O
using	O
dip	O
##stick	O
##s	O
.	O

U	O
##rine	O
t	B
##yr	I
##os	I
##ine	I
has	O
previously	O
been	O
found	O
to	O
be	O
reduced	O
in	O
early	O
C	O
##K	O
##D	O
,	O
and	O
in	O
patients	O
with	O
end	O
-	O
stage	O
re	O
##nal	O
disease	O
,	O
,	O
and	O
this	O
is	O
caused	O
by	O
reduced	O
p	O
##hen	O
##yla	O
##lani	O
##ne	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
enzyme	O
activity	O
,	O
also	O
demonstrated	O
in	O
our	O
study	O
.	O

This	O
explanation	O
may	O
also	O
apply	O
to	O
the	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
an	O
inflammation	O
promoting	O
compound	O
.	O

In	O
T	O
##2	O
##DM	O
subjects	O
separately	O
,	O
beta	B
##ine	I
also	O
(	O
tended	O
to	O
be	O
)	O
inverse	O
##ly	O
related	O
to	O
P	O
##LT	O
##P	O
activity	O
(	O
r	O
=	O
−	O
##0	O
.	O
44	O
##7	O
,	O

The	O
levels	O
of	O
SM	B
(	I
36	I
:	I
3	I
)	I
and	O
PC	B
(	I
40	I
:	I
7	I
)	I
were	O
increased	O
at	O
w	O
##16	O
and	O
declined	O
to	O
the	O
levels	O
observed	O
before	O
intervention	O
(	O
w	O
##0	O
)	O
at	O
w	O
##28	O
for	O
the	O
T	O
##FA	O
group	O
,	O
whereas	O
there	O
was	O
no	O
change	O
for	O
the	O
CT	O
##R	O
group	O
.	O

These	O
observations	O
are	O
consistent	O
with	O
results	O
of	O
our	O
earlier	O
study	O
,	O
where	O
similar	O
association	O
between	O
dose	B
-	I
volume	I
effects	O
and	O
features	O
of	O
the	O
low	O
-	O
molecular	O
-	O
weight	O
fraction	O
of	O
serum	O
pro	O
##te	O
##ome	O
has	O
been	O
observed	O
in	O
similar	O
group	O
of	O
head	O
and	O
neck	O
cancer	O
patients	O
.	O

Fifty	O
μ	O
##l	O
al	O
##iq	S
##uo	S
##ts	S
of	S
samples	S
were	S
treated	S
with	S
ace	S
##ton	O
##it	O
##ril	O
##e	O
(	O
1	O
:	O
4	O
,	O
v	O
/	O
v	O
)	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
14	O
,	O
000	O
x	O
g	O
for	O
5	O
min	O
at	O
4	O
°C	O
for	O
protein	O
separating	O
.	O

C	O
illustrate	O
##s	O
the	O
improvement	O
in	O
separation	O
observed	O
when	O
using	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
Am	O
##F	O
##orm	O
)	O
as	O
a	O
m	O
##od	O
##ifier	O
add	O
##itive	O
rather	O
than	O
0	O
.	O
5	O
%	O
v	O
/	O
v	O
form	B
##ic	I
acid	I
(	O
FA	O
)	O
.	O

Pre	O
##par	O
##ation	O
of	O
samples	O
:	O
The	O
established	O
and	O
valid	O
##ated	O
extraction	O
procedure	O
consisted	O
of	O
100	O
-	O
µ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
serum	O
samples	O
[	O
corresponding	O
to	O
the	O
blank	O
,	O
zero	O
,	O
ca	O
##li	O
##bra	O
##tion	O
controls	O
,	O
quality	O
controls	O
(	O
Q	O
##CA	O
,	O
Q	O
##C	O
##B	O
,	O
Q	O
##CC	O
)	O
and	O
unknown	O
samples	O
]	O
in	O
2	O
.	O
0	O
-	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
.	O

Li	O
##pid	O
##s	O
were	O
extracted	O
according	O
to	O
B	O
##li	O
##gh	O
and	O
Dyer	O
,	O
and	O
the	O
following	O
internal	O
standards	O
were	O
added	O
:	O
20	O
pm	O
##ol	O
each	O
of	O
1	B
,	I
2	I
-	I
dim	I
##yr	I
##ist	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ol	I
,	O
1	B
,	I
2	I
-	I
di	I
##lau	I
##roy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
1	B
,	I
2	I
-	I
dim	I
##yr	I
##ist	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
1	B
,	I
2	I
-	I
di	I
-	I
he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
1	B
,	I
2	I
-	I
dim	I
##yr	I
##ist	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##ose	I
##rine	I
,	O
1	B
,	I
2	I
-	I
dim	I
##yr	I
##ist	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
phosphate	I
,	O
1	B
,	I
2	I
-	I
dip	I
##ent	I
##ade	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
1	B
,	I
2	I
-	I
di	I
-	I
he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
1	B
,	I
2	I
-	I
din	I
##ona	I
##de	I
##cano	I
##yl	I
-	I
s	I

G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
mock	O
-	O
infected	O
vs	O
.	O
HC	O
##M	O
##V	O
-	O
infected	O
fi	O
##bro	O
##blast	O
##s	O
.	O

After	O
isolation	O
,	O
cells	O
were	O
labeled	O
with	O
car	B
##box	I
##y	I
##f	I
##lu	I
##ores	I
##ce	I
##in	I
su	I
##cci	I
##ni	I
##mi	I
##dy	I
##l	I
est	I
##er	I
(	O
CF	O
##SE	O
,	O
In	O
##vi	O
##tro	O
##gen	O
)	O
according	O
to	O
manufacturer	O
’	O
s	O
instructions	O
,	O
then	O
re	O
##sus	O
##pen	O
##ded	O
in	O
R	O
##PM	O
##I	O
medium	O
containing	O
10	O
%	O
F	O
##BS	O
,	O
P	O
/	O
S	O
,	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
sodium	B
p	I
##yr	I
##u	I
##vate	I
,	O
and	O
H	O
##EP	O
##ES	O
.	O

This	O
is	O
ex	O
##em	O
##plified	O
by	O
147	O
individuals	O
initially	O
volunteer	O
##ing	O
for	O
the	O
study	O
before	O
one	O
as	B
##par	I
##tam	I
##e	I
sensitive	O
individual	O
participated	O
;	O
this	O
likely	O
reflects	O
their	O
genuine	O
fear	O
of	O
as	B
##par	I
##tam	I
##e	I
consumption	O
.	O

Pearson	O
correlation	O
##s	O
between	O
the	O
two	O
laboratory	O
methods	O
for	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
meta	O
##bol	O
##ites	O
were	O
:	O
end	B
##ox	I
##ife	I
##n	I
r	O
=	O
0	O
.	O
95	O
,	O
ta	B
##mo	I
##xi	I
##fen	I
r	O
=	O
0	O
.	O
94	O
,	O
4	O
##OH	O
-	O
ta	O
##m	O
r	O
=	O
0	O
.	O
49	O
overall	O
and	O
r	O
=	O
0	O
.	O
81	O
excluding	O
one	O
out	O
##lier	O
,	O
and	O
N	O
##D	O
-	O
ta	O
##m	O
r	O
=	O
0	O
.	O
98	O
.	O

In	O
##spect	O
##ion	O
of	O
the	O
complete	O
Is	O
##o	O
##P	O
,	O
P	B
##G	I
and	O
NO	O
_	O
2	O
-	O
FA	O
target	O
panel	O
found	O
that	O
H	O
.	O
p	O
##oma	O
##tia	O
G	O
##US	O
contained	O
the	O
highest	O
blank	O
effect	O
compared	O
with	O
E	O
.	O
co	O
##li	O
and	O
b	O
##ov	O
##ine	O
liver	O
(	O
see	O
E	O
##SM	O
Table	O
S	O
##7	O
)	O
.	O

Cal	O
##ib	O
##ration	O
standards	O
were	O
prepared	O
by	O
di	O
##lution	O
of	O
standard	O
stock	O
solutions	O
in	O
AC	O
##N	O
/	O
H	O
_	O
2	O
O	O
(	O
5	O
/	O
95	O
;	O
v	O
/	O
v	O
)	O
to	O
obtain	O
seven	O
ca	O
##li	O
##bra	O
##tion	O
solutions	O
(	O
ca	O
##li	O
##bra	O
##nts	O
1	O
to	O
7	O
)	O
in	O
micro	O
##mo	O
##lar	O
range	O
for	O
H	B
##A	I
,	O
ta	B
##uri	I
##ne	I
,	O
se	B
##rine	I
,	O
c	B
##ys	I
##tine	I
,	O
g	B
##ly	I
##cine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
HC	O
##y	O
##2	O
,	O
D	B
##MG	I
,	O
beta	B
##ine	I
,	O
and	O
ch	B
##olin	I
##e	I
and	O
in	O
na	O
##no	O
##mo	O
##lar	O
range	O
for	O
rib	B
##of	I
##lav	I
##in	I
,	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
p	B
##yr	I
##ido	I
##xa	I
##mine	I
,	O
SA	O
##H	O
,	O
SA	O
##M	O
,	O
and	O
5	O
-	O
M	O
##TH	O
##F	O
as	O
described	O
in	O
Table	O
S	O
##2	O
(	O
see	O
E	O
##SM	O
)	O
.	O

P	B
##yr	I
##u	I
##vate	I
flu	O
##ct	O
##uation	O
in	O
plasma	O
moderately	O
correspond	O
##ed	O
to	O
the	O
level	O
of	O
glucose	S
,	O
which	O
was	O
higher	O
in	O
T	O
##2	O
than	O
in	O
the	O
subsequent	O
periods	O
of	O
pregnancy	O
.	O

The	O
form	B
##ic	I
acid	I
solution	O
was	O
prepared	O
by	O
adding	O
2	O
##m	O
##L	O
of	O
form	B
##ic	I
acid	I
to	O
a	O
final	O
volume	O
of	O
100	O
##m	O
##L	O
with	O
HP	O
##LC	O
grade	O
water	O
.	O

After	O
extraction	O
with	O
MC	O
##W	O
(	B
met	B
##han	I
##ol	I
,	O
ch	B
##lor	I
##of	I
##orm	I
,	O
water	O
in	O
a	O
one	O
phase	O
mixture	O
)	O
no	O
further	O
phase	O
separation	O
was	O
performed	O
and	O
the	O
complete	O
MC	O
##W	O
extract	O
was	O
injected	O
into	O
G	O
##C	O
-	O
MS	O
.	O

Those	O
results	O
pro	B
##mpt	I
that	O
the	O
age	O
and	O
B	O
##MI	O
with	O
significant	O
difference	O
between	O
deficiency	O
and	O
excess	O
groups	O
do	O
not	O
affect	O
our	O
final	O
meta	O
##bol	O
##omi	O
##cs	O
results	O
.	O

Considering	O
our	O
data	O
,	O
although	O
we	O
observed	O
no	O
difference	O
in	O
K	O
##P	O
##m	O
concentrations	O
between	O
the	O
di	O
##abe	O
##tic	O
and	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
groups	O
,	O
after	O
weight	O
loss	O
adjustment	O
,	O
we	O
found	O
that	O
a	O
prefer	O
##ential	O
decreased	O
activation	O
of	O
the	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
branch	O
was	O
associated	O
with	O
glucose	S
control	O
improvement	O
one	O
year	O
after	O
bar	O
##ia	O
##tric	O
surgery	O
.	O

Both	O
T	B
##MA	I
##O	I
and	O
d	O
##9	O
-	O
T	O
##MA	O
##O	O
were	O
readily	O
detected	O
in	O
plasma	O
after	O
the	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
challenge	O
at	O
visit	O
1	O
.	O

Sign	O
##ificant	O
amounts	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
T	B
##G	I
(	I
17	I
:	I
2	I
/	I
17	I
:	I
2	I
/	I
18	I
:	I
0	I
)	I
were	O
detected	O
following	O
M	B
##T	I
##BE	I
extraction	O
,	O
and	O
these	O
could	O
not	O
be	O
detected	O
when	O
met	B
##han	I
##ol	I
alone	O
was	O
used	O
.	O

G	B
##lut	I
##amine	I
and	O
as	B
##par	I
##agi	I
##ne	I
were	O
unstable	O
in	O
the	O
serum	O
,	O
and	O
were	O
transformed	O
into	O
g	B
##lut	I
##ama	I
##te	I
and	O
as	B
##par	I
##tate	I
on	O
a	O
large	O
scale	O
when	O
stored	O
at	O
4	O
##°	O
##C	O
for	O
4	O
h	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
NO	O
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
levels	O
are	O
also	O
regulated	O
by	O
activation	O
of	O
a	O
##rg	O
##inas	O
##e	O
,	O
an	O
enzyme	O
that	O
cat	O
##aly	O
##zes	O
a	O
competing	O
reaction	O
and	O
consume	O
##s	O
a	B
##rg	I
##ini	I
##ne	I
.	O

Met	B
##han	I
##ol	I
performs	O
most	O
optimal	O
##ly	O
over	O
a	O
wide	O
range	O
of	O
concentrations	O
,	O
whereas	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
shows	O
a	O
surprisingly	O
poor	O
performance	O
.	O

Dec	O
##reased	O
ch	B
##ole	I
##ster	I
##ol	I
flux	O
can	O
result	O
in	O
decreased	O
substrate	O
for	O
bi	O
##le	O
acid	O
synthesis	O
needed	O
for	O
normal	O
fat	O
dig	O
##est	O
##ion	O
and	O
micro	O
##bio	O
##me	O
signaling	O
.	O

The	O
SP	S
classes	O
most	O
broadly	O
associated	O
with	O
age	O
were	O
the	O
c	B
##era	I
##mi	I
##des	I
,	O
which	O
largely	O
increased	O
with	O
increasing	O
age	O
,	O
and	O
the	O
he	B
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##des	I
(	O
He	O
##x	O
##C	O
##er	O
and	O
He	O
##x	O
##2	O
##C	O
##er	O
)	O
,	O
which	O
almost	O
uniform	O
##ly	O
decreased	O
with	O
increasing	O
age	O
(	O
,	O
,	O
and	O
)	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
##s	O
pro	O
##fi	O
##ling	O
can	O
also	O
predict	O
long	O
-	O
term	O
survival	O
:	O
the	O
assessment	O
of	O
ethanol	B
##amine	I
concentration	O
can	O
be	O
clinical	O
##ly	O
relevant	O
as	O
a	O
single	O
metabolic	O
bio	O
##mark	O
##er	O
.	O

This	O
panel	O
included	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
car	B
##ni	I
##tine	I
and	O
ace	B
##tone	I
,	O
that	O
mirror	O
an	O
alter	O
##ation	O
of	O
energy	O
metabolism	O
and	O
cellular	O
growth	O
in	O
such	O
group	O
of	O
patients	O
.	O

[	O
,	O
,	O
]	O
,	O
x	B
##ant	I
##hine	I
(	O
p	O
=	O
5	O
.	O
2	O
##E	O
-	O
03	O
)	O

L	O
##C	O
-	O
MS	O
measurement	O
of	O
18	O
amino	O
acids	O
in	O
p	B
##or	I
##cine	I
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
,	O
stored	O
at	O
R	O
##T	O
for	O
up	O
to	O
2	O
h	O
,	O
showed	O
increased	O
concentrations	O
in	O
ten	O
amino	O
acids	O
(	B
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
his	B
##ti	I
##dine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
)	O
,	O
which	O
is	O
in	O
line	O
with	O
our	O
observations	O
,	O
except	O
that	O
g	B
##ly	I
##cine	I
concentration	O
is	O
stable	O
in	O
our	O
experiments	O
.	O

Moreover	O
,	O
stock	O
solutions	O
,	O
1	O
mg	O
/	O
m	O
##L	O
in	O
ethanol	S
,	O
were	O
prepared	O
for	O
E	O
##1	O
,	O
E	O
##2	O
,	O
2	O
##H	O
##4	O
-	O
E	O
##1	O
,	O
and	O
2	O
##H	O
##4	O
-	O
E	O
##2	O
and	O
stored	O
at	O
−	O
##20	O
°C	O
until	O
required	O
.	O

3	B
-	I
H	I
##ydro	I
##xy	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
,	O
et	B
##hyl	I
br	I
##omo	I
##ace	I
##tate	I
,	O
and	O
in	O
##dium	O
metal	O
powder	O
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

This	O
bio	O
##ana	O
##ly	O
##tical	O
-	O
method	O
was	O
successfully	O
valid	O
##ated	O
and	O
applied	O
to	O
determine	O
plasma	O
concentrations	O
of	O
a	B
##bir	I
##ater	I
##one	I
in	O
clinical	O
studies	O
and	O
in	O
regular	O
patient	O
care	O
for	O
patients	O
with	O
meta	O
##static	O
cast	O
##ration	O
resistant	O
pro	O
##state	O
cancer	O
.	O

In	O
nine	O
out	O
of	O
17	O
tumor	O
samples	O
examined	O
,	O
o	B
##le	I
##ic	I
acid	I
levels	O
were	O
>	O
50	O
%	O
lower	O
than	O
those	O
found	O
in	O
their	O
healthy	O
tissue	O
counterparts	O
.	O

Clinical	O
studies	O
have	O
found	O
that	O
regular	O
use	O
of	O
as	B
##pi	I
##rin	I
,	O
which	O
can	O
reduce	O
systemic	O
inflammation	O
,	O
is	O
associated	O
with	O
lower	O
circulating	O
est	B
##rogen	I
levels	O
among	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
(	O
,	O
)	O
.	O

The	O
multi	O
##var	O
##iate	O
pattern	O
of	O
decreased	O
A	O
##po	O
A1	O
,	O
HD	O
##L	O
-	O
C	O
and	O
HD	B
##L	I
-	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
have	O
been	O
previously	O
linked	O
to	O
inflammation	O
-	O
associated	O
d	O
##ys	O
##lip	O
##idae	O
##mia	O
in	O
o	O
##besity	O
.	O

(	O
A	O
)	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
loading	O
coefficient	O
plot	O
showing	O
that	O
the	O
basis	O
of	O
differentiation	O
between	O
these	O
two	O
groups	O
(	B
i	B
##bu	I
##p	I
##ro	I
##fen	I
users	O
and	O
non	O
##user	O
##s	O
)	O
primarily	O
results	O
from	O
the	O
presence	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
,	O
car	B
##box	I
##y	I
,	O
and	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
.	O

The	O
association	O
between	O
SL	O
##C	O
##7	O
##A	O
##9	O
and	O
v	B
##ali	I
##ne	I
has	O
previously	O
been	O
shown	O
.	O

In	O
addition	O
to	O
this	O
,	O
other	O
car	B
##box	I
##yl	I
##ic	I
acid	I
standards	O
with	O
a	O
pre	O
##gna	O
##ne	O
ring	O
system	O
,	O
as	O
in	O
15	O
(	O
for	O
example	O
,	O
ch	B
##eno	I
##de	I
##ox	I
##ych	I
##olic	I
acid	I
and	O
ch	O
##olic	O
acid	O
)	O
,	O
do	O
not	O
show	O
losses	O
of	O
CO	O
_	O
2	O
upon	O
MS	O
/	O
MS	O
fragment	O
##ation	O
(	O
not	O
shown	O
)	O
.	O

The	O
15	O
-	O
lip	O
##oo	O
##xy	O
##gen	O
##ase	O
product	O
15	B
-	I
H	I
##ET	I
##E	I
,	O
a	O
lip	O
##id	O
signalling	O
e	B
##ico	I
##san	I
##oid	I
involved	O
in	O
inflammation	O
and	O
end	O
##oth	O
##eli	O
##al	O
cell	O
ad	O
##hesion	O
,	O
was	O
also	O
identified	O
as	O
a	O
potentially	O
important	O
metabolic	O
signature	O
of	O
HC	O
##C	O
,	O
possessing	O
a	O
sensitivity	O
of	O
83	O
.	O
3	O
and	O
a	O
specific	O
##ity	O
of	O
59	O
.	O
3	O
for	O
HC	O
##C	O
presence	O
(	O
AU	O
##C	O
=	O
0	O
.	O
70	O
##5	O
,	O
P	O
=	O
0	O
.	O
00	O
##11	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
participants	O
were	O
60	O
years	O
of	O
age	O
with	O
pre	O
-	O
treatment	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
between	O
160	O
and	O
400	O
mg	O
/	O
d	O
##L	O
.	O
The	O
plasma	O
samples	O
used	O
in	O
the	O
present	O
study	O
were	O
collected	O
at	O
base	O
##line	O
and	O
at	O
6	O
weeks	O
of	O
therapy	O
after	O
an	O
overnight	O
fast	O
.	O

In	O
the	O
current	O
study	O
,	O
G	O
##RA	O
##CE	O
risk	O
scores	O
were	O
calculated	O
using	O
age	O
,	O
heart	O
rate	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
Kill	O
##ip	O
class	O
,	O
presence	O
or	O
absence	O
of	O
cardiac	O
arrest	O
on	O
admission	O
,	O
presence	O
or	O
absence	O
of	O
ST	O
-	O
segment	O
elevation	O
,	O
and	O
cardiac	O
enzyme	O
concentrations	O
on	O
admission	O
.	O

Therefore	O
,	O
by	O
He	O
plasma	O
treatment	O
,	O
beta	B
-	I
al	I
##ani	I
##ne	I
metabolism	O
in	O
my	O
##elo	O
##ma	O
tumor	O
cells	O
was	O
suppressed	O
,	O
which	O
disturbing	O
the	O
energy	O
and	O
material	O
metabolism	O
of	O
the	O
tumor	O
cells	O
and	O
results	O
in	O
tumor	O
cells	O
death	O
.	O

The	O
combination	O
of	O
serum	O
PS	O
##A	O
with	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
and	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
as	O
markers	O
could	O
improve	O
decision	O
-	O
making	O
for	O
primary	O
treatment	O
and	O
earlier	O
subsequent	O
ad	O
##ju	O
##vant	O
therapy	O
.	O

We	O
also	O
confirmed	O
different	O
metabolic	O
signatures	O
resulting	O
from	O
acute	O
inflammatory	O
responses	O
and	O
up	O
##re	O
##gu	O
##lated	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
in	O
patients	O
with	O
MI	O
.	O

In	O
addition	O
,	O
H	O
##B	O
##x	O
has	O
been	O
shown	O
to	O
activate	O
fatty	O
acid	O
oxidation	O
,	O
fuel	O
##ing	O
the	O
T	O
##CA	O
cycle	O
with	O
increased	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
and	O
thus	O
will	O
decrease	O
the	O
demand	O
on	O
amino	O
acid	O
an	O
##ap	O
##ler	O
##osis	O
.	O

Met	B
##hyl	I
##hip	I
##pur	I
##ic	I
acid	I
is	O
an	O
a	B
##cy	I
##l	I
g	I
##ly	I
##cine	I
that	O
is	O
normally	O
minor	O
meta	O
##bol	O
##ites	O
of	O
fatty	O
acids	O
.	O

The	O
up	O
##re	O
##gu	O
##lation	O
of	O
fatty	O
acid	O
β	O
-	O
oxidation	O
,	O
including	O
saturated	O
fatty	O
acid	O
(	O
SF	O
##A	O
)	O
and	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
(	O
P	O
##U	O
##FA	O
)	O
,	O
leads	O
to	O
excessive	O
consumption	O
of	O
g	B
##ly	I
##cer	I
##ol	I
and	O
free	O
fatty	O
acids	O
(	O
FF	O
##A	O
)	O
.	O

The	O
bench	O
-	O
top	O
stability	O
study	O
showed	O
that	O
the	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
were	O
stable	O
in	O
human	O
plasma	O
for	O
14	O
hours	O
at	O
room	O
temperature	O
.	O

The	O
beta	B
##ine	I
peak	O
is	O
not	O
affected	O
by	O
the	O
change	O
in	O
pH	O
,	O
however	O
,	O
the	O
T	B
##MA	I
##O	I
peak	O
is	O
shifted	O
down	O
##field	O
in	O
the	O
N	O
##MR	O
spectrum	O
which	O
allows	O
for	O
accurate	O
q	O
##uant	O
##ification	O
of	O
both	O
beta	B
##ine	I
and	O
T	B
##MA	I
##O	I
separately	O
.	O

Unlike	O
AD	B
##MA	I
,	O
SD	O
##MA	O
is	O
not	O
a	O
substrate	O
for	O
DD	O
##A	O
##H	O
##s	O
,	O
the	O
up	O
-	O
regulated	O
expression	O
of	O
which	O
would	O
have	O
explained	O
the	O
reduction	O
in	O
its	O
level	O
.	O

A	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
co	B
##rt	I
##ison	I
##e	I
to	O
co	B
##rt	I
##is	I
##ol	I
is	O
11	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##ster	I
##oid	I
de	I
##hy	I
##dr	I
##ogen	I
##ase	I
(	I
11	I
##β	I
-	I
H	I
##SD	I
)	I
but	O
its	O
expression	O
levels	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
are	O
uncertain	O
.	O

Indeed	O
,	O
it	O
was	O
shown	O
that	O
the	O
en	O
##zy	O
##matic	O
activity	O
of	O
the	O
enzyme	O
responsible	O
for	O
the	O
end	O
##ogen	O
##ous	O
production	O
of	O
ta	B
##uri	I
##ne	I
(	O
c	O
##ys	O
##tein	O
##e	O
su	O
##lf	O
##ini	O
##c	O
acid	O
de	O
##car	O
##box	O
##yla	O
##se	O
;	O
EC	O
4	O
.	O
1	O
.	O
1	O
.	O
29	O
)	O
is	O
the	O
rate	O
-	O
limiting	O
factor	O
for	O
ta	B
##uri	I
##ne	I
bio	O
##sy	O
##nt	O
##hesis	O
.	O

Our	O
experiments	O
to	O
find	O
an	O
optimal	O
NH	O
_	O
4	O
F	O
concentration	O
revealed	O
that	O
with	O
plasma	O
sample	O
injection	O
##s	O
,	O
the	O
signal	O
with	O
am	B
##mon	I
##ium	I
flu	I
##ori	I
##de	I
was	O
on	O
average	O
about	O
70	O
times	O
higher	O
than	O
without	O
it	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
unique	O
elemental	O
composition	O
of	O
m	O
/	O
z	O
40	O
##7	O
.	O
152	O
##7	O
was	O
assigned	O
as	O
C	O
_	O
15	O
H	O
_	O
28	O
O	O
_	O
11	O
Na	O
using	O
Mass	O
Works	O
_	O
T	O
##M	O
based	O
on	O
L	O
##C	O
-	O
MS	O
data	O
acquired	O
using	O
HP	O
##LC	O
-	O
L	O
##T	O
##Q	O
F	B
##T	I
Ultra	O
MS	O
at	O
100	O
,	O
000	O
resolution	O
.	O

(	O
B	O
)	O
SM	O
-	O
OH	O
C	B
##24	I
:	I
1	I
plasma	O
levels	O
displayed	O
the	O
strongest	O
difference	O
between	O
the	O
g	O
##eno	O
##type	O
groups	O
in	O
delta	O
t	O
##35	O
(	O
p	O
=	O
8	O
.	O
3	O
##E	O
-	O
04	O
)	O
and	O
delta	O
t	O
##24	O
##0	O
(	O
p	O
=	O
5	O
.	O
4	O
##E	O
-	O
04	O
)	O
.	O

This	O
will	O
induce	O
lip	O
##oly	O
##sis	O
and	O
un	O
##con	O
##tro	O
##lled	O
release	O
of	O
FF	O
##A	O
and	O
g	B
##ly	I
##cer	I
##ol	I
_	I
,	O
_	O
,	O
.	O

The	O
serum	O
levels	O
of	O
met	B
##hi	I
##oni	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
and	O
pro	B
##line	I
progressively	O
increased	O
with	O
disease	O
severity	O
,	O
whereas	O
those	O
of	O
p	B
##ime	I
##ly	I
##l	I
##car	I
##ni	I
##tine	I
and	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
decreased	O
.	O

In	O
comparison	O
with	O
samples	O
with	O
similar	O
B	O
##MI	O
value	O
(	O
normal	O
weight	O
and	O
over	O
##weight	O
)	O
,	O
Ta	O
##e	O
-	O
E	O
##um	O
type	O
showed	O
higher	O
la	B
##ct	I
##ate	I
levels	O
in	O
serum	O
than	O
So	O
-	O
Yang	O
type	O
for	O
both	O
normal	O
weight	O
and	O
over	O
##weight	O
groups	O
(	O
see	O
)	O
.	O

Each	O
sample	O
and	O
Q	O
##C	O
super	O
##nat	O
##ant	O
was	O
concentrated	O
to	O
complete	O
dry	O
##ness	O
at	O
50	O
°C	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	B
gas	I
(	O
Turbo	O
##va	O
##p	O
L	O
##V	O
,	O
Cal	O
##iper	O
Life	O
Sciences	O
)	O
.	O

The	O
metabolism	O
of	O
bi	B
##li	I
##ru	I
##bin	I
is	O
generated	O
by	O
the	O
combination	O
of	O
non	O
-	O
con	O
##ju	O
##gated	O
bi	B
##li	I
##ru	I
##bin	I
(	O
also	O
known	O
as	O
indirect	O
bi	O
##li	O
##ru	O
##bin	O
)	O
and	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
.	O

Those	O
in	O
the	O
high	O
ME	O
##E	O
group	O
had	O
higher	O
fast	O
##ing	O
glucose	S
,	O
very	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
V	O
##LD	O
##L	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
u	B
##ric	I
acid	I
,	O
and	O
B	O
##NP	O
levels	O
and	O
a	O
lower	O
L	O
##VE	O
##F	O
than	O
those	O
in	O
the	O
low	O
ME	O
##E	O
group	O
.	O

An	O
impact	O
of	O
C	O
##YP	O
##2	O
##C	O
##19	O
predicted	O
activity	O
on	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
as	O
well	O
as	O
est	B
##rogen	I
kinetic	O
##s	O
may	O
partly	O
explain	O
the	O
observed	O
association	O
between	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
and	O
est	B
##rogen	I
serum	O
levels	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
pools	O
of	O
N	B
##AD	I
##P	I
##H	I
are	O
in	O
continuous	O
communication	O
with	O
N	B
##AD	I
##H	I
levels	O
through	O
the	O
enzyme	O
N	O
##NT	O
.	O

Lower	O
limits	O
of	O
q	O
##uant	O
##itation	O
(	O
LL	O
##O	O
##Q	O
)	O
in	O
liver	O
samples	O
were	O
0	O
.	O
00	O
##8	O
μ	O
##M	O
for	O
G	O
##S	O
-	O
33	O
##100	O
##7	O
and	O
meta	O
##bol	O
##ite	O
X	O
,	O
0	O
.	O
07	O
##2	O
μ	O
##M	O
for	O
G	O
##S	O
-	O
33	O
##100	O
##7	O
mon	O
##o	O
-	O
,	O
di	O
-	O
,	O
and	O
trip	B
##hos	I
##phate	I
##s	I
,	O
1	O
.	O
3	O
μ	O
##M	O
for	O
rib	B
##avi	I
##rin	I
,	O
0	O
.	O
43	O
μ	O
##M	O
for	O
rib	B
##avi	I
##rin	I
mon	O
##o	O
-	O
,	O
di	O
-	O
,	O
and	O
trip	B
##hos	I
##phate	I
##s	I
,	O
and	O
2	O
.	O
74	O
μ	O
##M	O
for	O
stable	O
-	O
is	O
##oto	O
##pe	O
-	O
labeled	O
AM	B
##P	I
,	O
AD	B
##P	I
,	O
and	O
ATP	S
.	O

The	O
s	O
##pect	O
##ra	O
were	O
referenced	O
using	O
the	O
double	O
##t	O
of	O
Alan	B
##ine	I
at	O
1	O
.	O
47	O
##8	O
pp	O
##m	O
.	O

Mean	O
plasma	O
concentrations	O
of	O
f	O
##ent	O
##any	O
##l	O
,	O
nor	O
##fen	O
##tany	O
##l	O
and	O
mid	B
##az	I
##ola	I
##m	I
(	O
ng	O
/	O
m	O
##L	O
)	O
in	O
relation	O
to	O
mid	B
##az	I
##ola	I
##m	I
administration	O
.	O

The	O
most	O
important	O
parameters	O
(	O
VIP	O
>	O
1	O
)	O
that	O
contributed	O
to	O
class	O
separation	O
were	O
the	O
N	O
##MR	O
signals	O
from	O
ace	B
##tone	I
,	O
ch	B
##olin	I
##e	I
,	O
u	B
##rea	I
,	O
1	B
,	I
3	I
-	I
dim	I
##eth	I
##yl	I
##ura	I
##te	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
3	B
-	I
OH	I
-	I
but	I
##yra	I
##te	I
.	O

Both	O
d	B
##16	I
:	I
1	I
and	O
d	B
##20	I
:	I
1	I
,	O
the	O
most	O
common	O
L	O
##C	O
##B	O
variants	O
reported	O
in	O
the	O
literature	O
were	O
also	O
quite	O
frequently	O
detected	O
.	O

p	B
##hen	I
##ant	I
##hren	I
##e	I
metabolism	O
,	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
,	O
human	O
urine	O

O	O
##bs	O
##erve	O
##d	O
and	O
simulated	O
distribution	O
of	O
o	B
##lan	I
##za	I
##pine	I
%	O
differences	O
with	O
different	O
ass	O
##ay	O
precision	O
.	O

Furthermore	O
,	O
c	B
##rea	I
##tin	I
##ine	I
was	O
a	O
variable	O
associated	O
with	O
a	O
significant	O
increase	O
of	O
all	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
(	O
GM	O
##R	O
from	O
6	O
.	O
7	O
for	O
H	O
##EM	O
##A	O
to	O
145	O
.	O
01	O
for	O
M	O
##H	O
##BM	O
##A	O
)	O
;	O
age	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
of	O
AMC	O
##C	O
,	O
C	O
##ME	O
##MA	O
,	O
D	O
##H	O
##BM	O
##A	O
,	O
and	O
SP	O
##MA	O
;	O
co	B
##tin	I
##ine	I
was	O
associated	O
with	O
a	O
significant	O
increase	O
of	O
AA	O
##MA	O
,	O
AMC	O
##C	O
,	O
CE	O
##MA	O
,	O
and	O
GA	O
##MA	O
;	O
finally	O
,	O
the	O
assessment	O
of	O
activities	O
at	O
home	O
involving	O
exposure	O
during	O
the	O
last	O
3	O
days	O
was	O
significantly	O
associated	O
with	O
an	O
increase	O
of	O
AMC	O
##C	O
,	O
CE	O
##MA	O
,	O
and	O
SP	O
##MA	O
,	O
showing	O
a	O
possible	O
non	O
-	O
occupational	O
exposure	O
.	O

This	O
o	B
##xy	I
##ster	I
##ol	I
is	O
synthesized	O
in	O
the	O
brain	O
by	O
a	O
ne	O
##uron	O
##al	O
enzyme	O
(	O
ch	O
##ole	O
##ster	O
##ol	O
24	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
,	O
C	O
##YP	O
##46	O
##A	O
##1	O
)	O
and	O
thereafter	O
secret	O
##ed	O
into	O
the	O
circulation	O
where	O
it	O
associates	O
with	O
circulating	O
lip	O
##op	O
##rote	O
##ins	O
.	O

Following	O
adjustment	O
for	O
inter	O
-	O
individual	O
variation	O
,	O
we	O
identified	O
several	O
meta	O
##bol	O
##ites	O
,	O
pre	O
##dom	O
##inate	O
##ly	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
lip	O
##op	O
##rote	O
##ins	O
,	O
and	O
amino	O
acids	O
,	O
that	O
disc	O
##rim	O
##inated	O
serum	O
from	O
plasma	O
and	O
distinguished	O
PR	O
##P	O
from	O
PP	O
##P	O
and	O
P	O
##FP	O
samples	O
.	O

In	O
a	O
large	O
prospective	O
co	O
##hor	O
##t	O
study	O
,	O
the	O
plasma	O
concentration	O
of	O
total	O
FF	O
##As	O
was	O
shown	O
to	O
predict	O
the	O
future	O
risk	O
of	O
A	B
##F	I
occurrence	O
.	O

Another	O
study	O
by	O
Qi	O
##u	O
et	O
al	O
.	O
focused	O
on	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
and	O
revealed	O
lower	O
his	B
##ti	I
##dine	I
concentrations	O
in	O
CR	O
##C	O
urine	O
samples	O
.	O

Arte	O
##fa	O
##ct	O
peaks	O
resulting	O
from	O
the	O
der	O
##iva	O
##ti	O
##zation	O
process	O
and	O
interference	O
##s	O
due	O
to	O
u	B
##rea	I
were	O
removed	O
from	O
the	O
data	O
##set	O
.	O

Currently	O
,	O
t	B
##ris	I
(	I
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##op	I
##rop	I
##yl	I
)	I
phosphate	I
(	O
TD	O
##CI	O
##PP	O
)	O
and	O
trip	B
##hen	I
##yl	I
phosphate	I
(	O
T	O
##P	O
##HP	O
)	O
are	O
among	O
the	O
most	O
commonly	O
used	O
flame	O
re	O
##tar	O
##dant	O
##s	O
.	O

Re	O
##comb	O
##ina	O
##nt	O
lent	O
##iv	O
##ir	O
##uses	O
were	O
produced	O
by	O
trans	O
##fect	O
##ing	O
H	O
##E	O
##K	O
##29	O
##3	O
##T	O
Phoenix	O
-	O
am	O
##ph	O
##ot	O
##ropic	O
packaging	O
cells	O
with	O
p	O
##MD	O
##2	O
##G	O
(	O
V	O
##SV	O
-	O
G	O
protein	O
)	O
,	O
p	O
##PA	O
##X	O
##2	O
(	O
lent	O
##iv	O
##ir	O
##us	O
packaging	O
vector	O
)	O
,	O
and	O
lent	O
##iv	O
##ira	O
##l	O
construct	O
##s	O
using	O
Li	B
##po	I
##fect	I
##amine	I
3000	O
.	O

In	O
Re	O
##tt	O
syndrome	O
patients	O
,	O
elevated	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
detected	O
in	O
blood	O
and	O
fi	O
##bro	O
##blast	O
##s	O
and	O
a	O
k	O
##eto	O
##genic	O
diet	O
was	O
found	O
to	O
am	O
##eli	O
##ora	O
##te	O
some	O
ne	O
##uro	O
##be	O
##ha	O
##vior	O
##al	O
symptoms	O
[	O
,	O
]	O
.	O

The	O
other	O
five	O
lip	O
##ids	O
(	O
7	O
-	O
H	O
##OC	O
##A	O
,	O
1	B
-	I
o	I
##leo	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
1	B
-	I
e	I
##ico	I
##sad	I
##ien	I
##oy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
2	B
-	I
l	I
##ino	I
##leo	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
palm	B
##ito	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
)	O
have	O
not	O
been	O
well	O
-	O
characterized	O
with	O
respect	O
to	O
health	O
and	O
could	O
be	O
interesting	O
targets	O
for	O
future	O
research	O
.	O

Although	O
limits	O
of	O
q	O
##uant	O
##itation	O
(	O
L	O
##O	O
##Q	O
##s	O
)	O
were	O
not	O
explicitly	O
determined	O
for	O
this	O
method	O
,	O
results	O
observed	O
during	O
use	O
of	O
the	O
method	O
indicated	O
that	O
L	O
##O	O
##Q	O
##s	O
for	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
,	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
,	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
were	O
consistent	O
with	O
those	O
of	O
the	O
other	O
two	O
methods	O
(	O
0	O
.	O
6	O
ng	O
/	O
m	O
##L	O
)	O
.	O

G	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
su	B
##lf	I
##ate	I
and	O
##rogen	O
meta	O
##bol	O
##ites	O
in	O
the	O
serum	O
,	O
as	O
measured	O
by	O
our	O
meta	O
##bol	O
##omi	O
##cs	O
screen	O
,	O
have	O
been	O
shown	O
to	O
be	O
the	O
most	O
valid	O
and	O
possibly	O
only	O
reliable	O
estimate	O
of	O
the	O
total	O
and	O
##rogen	O
pool	O
including	O
the	O
in	O
##tra	O
##c	O
##rine	O
production	O
in	O
peripheral	O
tissues	O
,	O
_	O
,	O
which	O
is	O
most	O
likely	O
the	O
most	O
important	O
source	O
in	O
o	O
##cular	O
surface	O
tissues	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
Ce	B
##ram	I
##ide	I
(	O
Ce	O
##r	O
)	O
,	O
Mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
M	O
##HC	O
)	O
,	O
Di	B
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
D	O
##HC	O
)	O
,	O
Tri	B
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
T	O
##HC	O
)	O
,	O
GM	B
##3	I
gang	I
##lio	I
##side	I
(	O
GM	O
##3	O
)	O
,	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
)	O
,	O
Al	B
##ky	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
-	O
O	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
plasma	O
##log	O
##en	O
(	O
PC	O
-	O
P	O
)	O
,	O
L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
,	O
L	B
##ys	I
##oa	I
##lk	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
(	O
O	O
)	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
P	O
##E	O
)	O
,	O
A	B
##ky	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
P	O
##E	O
-	O
O	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
plasma	O
##log	O
##en	O
(	O
P	O
##E	O
-	O
P	O
)	O
,	O
L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
LP	O
##E	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
,	O
L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
LP	O
##I	O
)	O
,	O
Ph	B
##os	I

Water	O
(	B
18	B
.	I
2	I
M	I
##Ω	I
)	O
was	O
pu	O
##rified	O
by	O
a	O
Mill	O
##i	O
-	O
Q	O
water	O
pu	O
##rification	O
system	O
(	O
Mill	O
##ip	O
##ore	O
Ltd	O
.	O
,	O
USA	O
)	O
.	O

Car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
is	O
a	O
key	O
protein	O
that	O
uses	O
car	B
##ni	I
##tine	I
to	O
transfer	O
fatty	O
acid	O
into	O
mit	O
##och	O
##ond	O
##ria	O
for	O
oxidation	O
.	O

Previous	O
studies	O
using	O
pure	O
compounds	O
have	O
shown	O
that	O
g	B
##lut	I
##amine	I
undergo	O
##es	O
spontaneous	O
c	O
##y	O
##c	O
##li	O
##zation	O
to	O
form	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
under	O
extreme	O
conditions	O
of	O
pH	O
and	O
temperature	O
;	O
_	O
–	O
however	O
,	O
identification	O
of	O
significant	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
in	O
human	O
blood	O
serum	O
under	O
mild	O
conditions	O
typically	O
used	O
in	O
the	O
meta	O
##bol	O
##omi	O
##cs	O
of	O
human	O
serum	O
/	O
plasma	O
is	O
new	O
.	O

In	O
addition	O
,	O
p	B
##oly	I
##amine	I
##s	I
,	O
which	O
play	O
biological	O
roles	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
N	O
##MD	O
##A	O
receptor	O
activation	O
and	O
auto	O
##pha	O
##gy	O
,	O
have	O
been	O
shown	O
to	O
be	O
altered	O
in	O
patients	O
with	O
AL	O
##S	O
and	O
other	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
diseases	O
.	O

These	O
results	O
taken	O
together	O
merit	O
continued	O
meta	O
##bol	O
##omi	O
##cs	O
investigation	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
in	O
the	O
context	O
of	O
CR	O
##C	O
path	O
##ogen	O
##esis	O
and	O
prevention	O
,	O
specifically	O
v	B
##ale	I
##rate	I
[	O
–	O
]	O
.	O

The	O
results	O
also	O
indicated	O
that	O
the	O
u	O
##rem	O
##ic	O
to	B
##xin	I
##s	I
could	O
be	O
efficiently	O
cleared	O
by	O
dial	O
##ys	O
##is	O
.	O

We	O
used	O
a	O
Cell	O
-	O
T	O
##iter	O
-	O
G	O
##lo	O
_	O
®	O
l	O
##umi	O
##nes	O
##cent	O
cell	O
via	O
##bility	O
ass	O
##ay	O
kit	O
(	O
Pro	O
##me	O
##ga	O
,	O
Madison	O
,	O
W	O
##I	O
,	O
USA	O
)	O
to	O
measure	O
cell	O
via	O
##bility	O
,	O
which	O
was	O
based	O
on	O
q	O
##uant	O
##itation	O
of	O
the	O
ATP	S
(	O
Aden	O
##os	O
##ine	O
trip	B
##hos	I
##phate	I
)	O
to	O
determine	O
the	O
number	O
of	O
viable	O
cells	O
in	O
culture	O
medium	O
.	O

The	O
retention	O
time	O
(	O
R	O
##T	O
)	O
C	O
##V	O
%	O
values	O
of	O
all	O
lip	O
##id	O
IS	O
##T	O
##Ds	O
on	O
reverse	O
phase	O
ch	O
##roma	O
##tography	O
in	O
both	O
met	B
##han	I
##ol	I
and	O
met	B
##han	I
##ol	I
-	I
ethanol	I
precipitation	O
methods	O
are	O
below	O
1	O
%	O
(	O
Show	O
##n	O
in	O
)	O
.	O

It	O
has	O
also	O
been	O
established	O
that	O
especially	O
the	O
N	B
-	I
g	I
##ly	I
##cos	I
##ite	I
o	O
##cc	O
##up	O
##ancy	O
of	O
a	O
protein	O
is	O
associated	O
with	O
the	O
en	O
##zy	O
##matic	O
activity	O
and	O
the	O
physical	O
stability	O
of	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
which	O
might	O
contribute	O
to	O
the	O
meta	O
##sta	O
##sis	O
of	O
HC	O
##C	O
.	O

Additionally	O
,	O
12	O
o	O
##bes	O
##e	O
adults	O
with	O
fast	O
##ing	O
blood	O
glucose	S
levels	O
>	O
=	O
126	O
mg	O
/	O
d	O
##L	O
and	O
one	O
with	O
plasma	O
t	O
##rig	O
##ly	O
##cer	O
##ides	O
=	O
88	O
##5	O
mg	O
/	O
d	O
##L	O
were	O
excluded	O
from	O
the	O
study	O
,	O
leaving	O
the	O
available	O
sample	O
size	O
at	O
200	O
cases	O
and	O
100	O
controls	O
.	O

By	O
constructing	O
a	O
binary	O
log	O
##istic	O
re	O
##gression	O
model	O
,	O
a	O
meta	O
##bol	O
##ite	O
panel	O
containing	O
do	B
##de	I
##can	I
##ami	I
##de	I
and	O
L	O
##T	O
##B	O
##4	O
-	O
D	O
##MA	O
was	O
shown	O
to	O
be	O
highly	O
correlated	O
with	O
ch	O
##em	O
##ose	O
##ns	O
##iti	O
##vity	O
,	O
yielding	O
an	O
AU	O
##C	O
of	O
0	O
.	O
94	O
##5	O
(	O
85	O
.	O
2	O
%	O
sensitivity	O
and	O
88	O
.	O
9	O
%	O
specific	O
##ity	O
)	O
in	O
the	O
training	O
set	O
and	O
0	O
.	O
94	O
##4	O
(	O
84	O
.	O
6	O
%	O
sensitivity	O
and	O
80	O
.	O
0	O
%	O
specific	O
##ity	O
)	O
in	O
the	O
test	O
set	O
.	O

However	O
,	O
in	O
our	O
study	O
,	O
there	O
were	O
no	O
differences	O
in	O
al	B
##ani	I
##ne	I
levels	O
in	O
either	O
the	O
control	O
or	O
the	O
oral	O
cancer	O
subjects	O
.	O

It	O
is	O
likely	O
that	O
these	O
observed	O
trends	O
in	O
the	O
levels	O
of	O
the	O
non	O
##cano	O
##nical	O
sub	O
##c	O
##lass	O
##es	O
of	O
SP	O
##s	O
(	O
considering	O
specific	O
head	O
groups	O
,	O
s	B
##phi	I
##ngo	I
##id	I
backbone	O
##s	O
,	O
and	O
N	O
-	O
a	O
##cy	O
##l	O
fatty	O
acids	O
)	O
are	O
the	O
result	O
of	O
broad	O
,	O
consistent	O
shifts	O
in	O
3	O
key	O
metabolic	O
steps	O
:	O
SP	O
##T	O
-	O
mediated	O
con	O
##den	O
##sation	O
(	B
s	B
##phi	I
##ngo	I
##id	I
backbone	O
variation	O
)	O
,	O
CE	O
##RS	O
-	O
mediated	O
N	O
-	O
ace	O
##ty	O
##lation	O
(	O
fatty	O
acid	O
length	O
)	O
,	O
and	O
he	O
##x	O
##osy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
activity	O
(	O
He	O
##x	O
##C	O
##er	O
accumulation	O
)	O
.	O

In	O
order	O
to	O
analyze	O
sample	O
with	O
an	O
even	O
higher	O
concentration	O
,	O
samples	O
with	O
pro	B
##line	I
concentration	O
of	O
400	O
or	O
800	O
μ	O
##g	O
/	O
m	O
##L	O
were	O
di	O
##lut	O
##ed	O
5	O
or	O
10	O
times	O
before	O
analysis	O
,	O
and	O
evaluated	O
for	O
accuracy	O
and	O
precision	O
.	O

The	O
liquid	O
phases	O
were	O
collected	O
and	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
by	O
Speed	O
##V	O
##ac	O
and	O
then	O
red	O
##iss	O
##ol	O
##ved	O
in	O
150	O
µ	O
##L	O
p	B
##yr	I
##id	I
##ine	I
.	O

Ce	B
##ram	I
##ides	I
36	I
:	I
1	I
and	O
38	O
:	O
1	O
were	O
dominant	O
as	O
well	O
in	O
most	O
op	O
##tic	O
nerve	O
G	O
##G	O
classes	O
.	O

Here	O
,	O
we	O
found	O
that	O
there	O
were	O
relatively	O
moderate	O
correlation	O
##s	O
between	O
p	B
##yr	I
##u	I
##vic	I
acid	I
and	O
other	O
differential	O
meta	O
##bol	O
##ites	O
,	O
and	O
the	O
P	B
##yr	I
##u	I
##vate	I
metabolism	O
was	O
affected	O
in	O
d	O
##H	O
##B	O
.	O

Under	O
the	O
low	O
en	O
##rich	O
##ment	O
conditions	O
,	O
the	O
PD	O
##H	O
activity	O
produces	O
_	O
13	O
C	B
-	I
4	I
,	I
5	I
-	I
α	I
##K	I
##G	I
(	O
and	O
thus	O
_	O
13	O
C	B
-	I
4	I
,	I
5	I
-	I
G	I
##lu	I
)	O
and	O
[	O
_	O
13	O
C	O
_	O
2	O
]	O
-	O
As	O
##p	O
(	O
m	O
##0	O
+	O
2	O
)	O
through	O
the	O
K	O
##re	O
##bs	O
cycle	O
(	O
c	O
##f	O
.	O

A	O
and	O
B	O
(	O
A	O
:	O
99	O
.	O
9	O
%	O
H	O
_	O
2	O
O	O
,	O
0	O
.	O
1	O
%	O
Form	B
##ic	I
A	I
##cid	I
,	O
FA	S
;	O
B	O
:	O
89	O
.	O
9	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
AC	O
##N	O
,	O
10	O
%	O
H	O
_	O
2	O
O	O
,	O
0	O
.	O
1	O
%	O
FA	S
,	O
(	O
%	O
are	O
v	O
/	O
v	O
)	O
)	O
at	O
a	O
flow	O
rate	O
of	O
10	O
.	O
0	O
µ	O
##L	O
/	O
min	O
with	O
the	O
following	O
gradient	O
conditions	O
:	O
0	O
–	O
5	O
min	O
,	O
0	O
%	O
B	O
;	O
5	O
–	O
25	O
min	O
,	O
40	O
%	O
B	O
;	O
25	O
–	O
32	O
min	O
,	O
45	O
%	O
B	O
;	O
32	O
–	O
47	O
min	O
,	O
45	O
%	O
B	O
;	O
47	O
–	O
49	O
min	O
,	O
70	O
%	O
B	O
;	O
49	O
–	O
55	O
0	O
%	O

After	O
adding	O
50	O
μ	O
L	O
of	O
0	O
.	O
4	O
M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
buffer	O
(	O
pH	O
4	O
.	O
0	O
)	O
for	O
pH	O
adjustment	O
and	O
2000	O
units	O
beta	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
(	O
20	O
μ	O
L	O
solution	O
)	O
,	O
samples	O
were	O
v	O
##ortex	O
##ed	O
and	O
in	O
##cu	O
##bate	O
##d	O
for	O
2	O
h	O
at	O
55	O
°C	O
.	O

Runners	O
successfully	O
completing	O
orientation	O
and	O
base	O
##line	O
testing	O
(	O
N	O
=	O
35	O
)	O
were	O
random	O
##ized	O
to	O
40	O
g	O
/	O
d	O
PS	O
##PC	O
(	O
N	O
=	O
17	O
)	O
(	O
2	O
,	O
136	O
mg	O
/	O
d	O
gal	B
##lic	I
acid	I
equivalent	O
##s	O
)	O
or	O
place	O
##bo	O
(	O
N	O
=	O
18	O
)	O
for	O
17	O
d	O
using	O
double	O
-	O
blinded	O
methods	O
and	O
a	O
parallel	O
group	O
design	O
,	O
with	O
a	O
3	O
-	O
d	O
running	O
period	O
inserted	O
at	O
day	O
14	O
(	O
2	O
.	O
5	O
h	O
/	O
d	O
,	O
70	O
%	O
V	O
##O	O
_	O
2	O
##max	O
)	O
.	O

For	O
the	O
H	O
##B	O
##V	O
and	O
HC	O
##V	O
patients	O
,	O
the	O
fast	O
##ing	O
blood	O
glucose	S
levels	O
were	O
5	O
.	O
3	O
±	O
1	O
.	O
4	O
and	O
5	O
.	O
0	O
±	O
0	O
.	O
7	O
(	O
n	O
.	O
s	O
.	O
)	O
,	O
respectively	O
,	O
the	O
plasma	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
levels	O
(	O
AL	O
##T	O
;	O
I	O
##U	O
/	O
l	O
)	O
were	O
49	O
.	O
9	O
±	O
58	O
.	O
2	O
and	O
87	O
.	O
2	O
±	O
62	O
.	O
1	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
age	O
at	O
study	O
entry	O
(	O
mean	O
age	O
±	O
standard	O
de	O
##viation	O
,	O
39	O
.	O
7	O
##±	O
##15	O
.	O
3	O
years	O
versus	O
35	O
.	O
0	O
##±	O
##9	O
.	O
46	O
years	O
)	O
,	O
the	O
proportion	O
of	O
females	O
(	O
33	O
/	O
44	O
,	O
75	O
.	O
0	O
%	O
versus	O
33	O
/	O
42	O
,	O
78	O
.	O
6	O
%	O
)	O
,	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
,	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
,	O
or	O
the	O
proportion	O
of	O
past	O
or	O
present	O
smoke	O
##r	O
between	O
A	O
##OS	O
##D	O
patients	O
and	O
healthy	O
subjects	O
.	O

The	O
reducing	O
solution	O
was	O
prepared	O
just	O
before	O
the	O
experiment	O
from	O
125	O
mg	O
c	B
##ys	I
##tein	I
##e	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
,	O
0	O
.	O
8	O
m	O
##L	O
1	O
##M	O
Na	O
##OH	O
,	O
125	O
mg	O
Na	O
_	O
2	O
S	O
,	O
and	O
di	O
##st	O
##ille	O
##d	O
water	O

The	O
high	O
pH	O
of	O
9	O
.	O
2	O
utilized	O
in	O
method	O
B	O
disrupt	O
##s	O
attraction	O
of	O
the	O
amino	S
terminus	O
by	O
the	O
terminal	O
su	B
##lf	I
##ona	I
##te	I
and	O
results	O
in	O
loss	O
of	O
retention	O
compared	O
to	O
method	O
E	O
’	O
s	O
neutral	O
pH	O
.	O
Despite	O
the	O
lack	O
of	O
long	O
-	O
range	O
ion	O
##ic	O
interactions	O
,	O
the	O
neutral	O
amid	B
##e	I
column	O
F	O
covered	O
72	O
%	O
of	O
the	O
AA	O
library	O
.	O

Met	O
##ab	O
##olic	O
targets	O
in	O
ch	B
##olin	I
##e	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
may	O
provide	O
new	O
therapeutic	O
options	O
for	O
PA	O
##s	O
that	O
have	O
severely	O
limited	O
options	O
.	O

Results	O
from	O
step	O
##wise	O
log	O
##istic	O
re	O
##gression	O
analysis	O
showed	O
that	O
five	O
bio	O
##mark	O
##ers	O
(	B
20	B
-	I
H	I
##ydro	I
##xy	I
-	I
le	I
##uk	I
##ot	I
##rien	I
##e	I
E	O
##4	O
,	O
L	B
##ys	I
##op	I
##c	I
(	I
20	I
:	I
4	I
)	I
,	O
5	B
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
,	O
End	O
##omo	O
##rp	O
##hin	O
-	O
1	O
,	O
L	B
##ys	I
##op	I
##c	I
(	I
20	I
:	I
3	I
)	I
)	O
were	O
good	O
prediction	O
for	O
the	O
restoration	O
to	O
N	O
##GR	O
,	O
and	O
five	O
bio	O
##mark	O
##ers	O
(	B
Is	B
##o	I
-	I
v	I
##ale	I
##ral	I
##de	I
##hy	I
##de	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
L	B
##ys	I
##op	I
##c	I
(	I
18	I
:	I
1	I
)	I
,	O
2	B
-	I
P	I
##yr	I
##rol	I
##oy	I
##l	I
##gly	I
##cine	I
,	O
Di	B
##ty	I
##ros	I
##ine	I
)	O
for	O
the	O
development	O
of	O
D	O
##M	O
.	O

Finally	O
,	O
further	O
toxic	O
##ological	O
studies	O
are	O
needed	O
to	O
c	O
##lar	O
##ify	O
the	O
proposed	O
pathways	O
in	O
which	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
may	O
influence	O
the	O
development	O
of	O
diabetes	O
.	O

In	O
particular	O
la	B
##ct	I
##ate	I
levels	O
are	O
inverse	O
##ly	O
correlated	O
with	O
the	O
tumor	O
size	O
in	O
the	O
E	O
##BC	O
co	O
##hor	O
##t	O
(	O
Pearson	O
correlation	O
r	O
=	O
−	O
##0	O
.	O
30	O
##9	O
;	O
p	O
=	O
0	O
.	O
04	O
##4	O
)	O
.	O

In	O
order	O
to	O
reduce	O
anticipated	O
variance	O
of	O
the	O
bio	O
##mark	O
##er	O
test	O
g	B
##ly	I
##cola	I
##lde	I
##hy	I
##de	I
was	O
excluded	O
to	O
increase	O
the	O
via	O
##bility	O
of	O
widespread	O
adoption	O
of	O
the	O
panel	O
.	O

One	O
important	O
pathway	O
regulated	O
by	O
am	O
##ine	O
levels	O
is	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
(	O
NO	O
##S	O
)	O
.	O

After	O
the	O
extract	O
##s	O
were	O
completely	O
dried	O
by	O
speed	O
vacuum	O
con	O
##cent	O
##rator	O
or	O
by	O
freeze	O
-	O
drying	O
,	O
20	O
µ	O
##L	O
of	O
40	O
mg	O
/	O
m	O
##L	O
met	B
##ho	I
##xy	I
##lam	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
was	O
added	O
,	O
and	O
samples	O
were	O
agitated	O
at	O
30	O
°C	O
for	O
30	O
min	O
.	O

Compared	O
with	O
those	O
in	O
HC	O
,	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
saturated	O
and	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
PC	O
##s	O
such	O
as	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
and	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
1	I
)	I
were	O
observed	O
in	O
N	O
##SC	O
##LC	O
.	O

MA	O
##IL	O
##D	O
TO	O
##F	O
/	O
MS	O
positive	O
-	O
ion	O
s	O
##pect	O
##ra	O
for	O
250	O
pm	O
##ol	O
of	O
t	B
##rie	I
##thy	I
##lam	I
##ine	I
(	O
A	O
)	O
,	O
di	B
##is	I
##op	I
##rop	I
##yla	I
##mine	I
(	O
B	O
)	O
,	O
et	B
##hyl	I
##di	I
##is	I
##op	I
##rop	I
##yla	I
##mine	I
(	O
C	O
)	O
,	O
1	B
,	I
8	I
-	I
di	I
##az	I
##abi	I
##cy	I
##c	I
##lo	I
[	I
5	I
.	I
4	I
.	I
0	I
]	I
und	I
##ec	I
-	I
7	I
-	I
en	I
##e	I
(	O
D	O
)	O
.	O

Vol	O
##cano	O
plots	O
of	O
low	O
temperature	O
(	O
−	O
##20	O
°C	O
,	O
4	O
°C	O
/	O
24	O
h	O
,	O
4	O
°C	O
/	O
48	O
h	O
)	O
versus	O
high	O
temperature	O
(	O
40	O
°C	O
/	O
24	O
h	O
,	O
40	O
°C	O
/	O
48	O
h	O
)	O
in	O
the	O
PA	O
##BA	O
group	O
with	O
(	O
A	O
)	O
no	O
pre	O
##ser	O
##vat	O
##ive	O
,	O
(	O
B	O
)	O
thy	B
##mo	I
##l	I
and	O
in	O
the	O
No	O
PA	O
##BA	O
group	O
with	O
(	O
C	O
)	O
no	O
pre	O
##ser	O
##vat	O
##ive	O
,	O
and	O
(	O
D	O
)	O
thy	B
##mo	I
##l	I
.	O

Ser	O
##um	O
bi	O
##le	O
acids	O
,	O
such	O
as	O
g	B
##ly	I
##co	I
##cho	I
##late	I
(	O
G	O
##CA	O
)	O
,	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
(	O
G	O
##CD	O
##CA	O
)	O
,	O
ta	B
##uro	I
##cho	I
##late	I
(	O
T	O
##CA	O
)	O
and	O
ta	B
##uro	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
(	O
T	O
##CD	O
##CA	O
)	O
,	O
increased	O
significantly	O
in	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
.	O

Among	O
these	O
79	O
patients	O
,	O
we	O
excluded	O
one	O
participant	O
who	O
had	O
type	O
2	O
diabetes	O
(	O
fast	O
##ing	O
plasma	O
glucose	S
greater	O
than	O
200	O
mg	O
/	O
d	O
##l	O
)	O
and	O
another	O
participant	O
who	O
was	O
missing	O
data	O
for	O
B	O
##MI	O
and	O
portal	O
inflammation	O
score	O
.	O

and	O
Zhao	O
et	O
al	O
.	O
,	O
who	O
also	O
found	O
alpha	B
-	I
AAA	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
P	O
##EA	O
in	O
human	O
sperm	O
cells	O
,	O
but	O
with	O
different	O
techniques	O
,	O
namely	O
,	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
or	O
G	O
##C	O
.	O

The	O
2	O
glucose	S
measurements	O
were	O
taken	O
within	O
4	O
hours	O
of	O
each	O
other	O
in	O
all	O
cases	O
;	O
if	O
all	O
samples	O
were	O
obtained	O
at	O
exactly	O
the	O
same	O
time	O
,	O
the	O
agreement	O
would	O
likely	O
have	O
been	O
greater	O
.	O

Inter	O
##p	O
##reta	O
##tion	O
of	O
the	O
model	O
revealed	O
that	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
p	I
##hos	I
##hat	I
##e	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
rib	B
##ito	I
##l	I
and	O
f	B
##ru	I
##ct	I
##ose	I
increased	O
in	O
level	O
with	O
long	O
survival	O
.	O

We	O
observed	O
significant	O
reduction	O
in	O
glucose	S
up	O
##take	O
capacity	O
of	O
Col	O
##o	O
##35	O
##7	O
-	O
s	O
##h	O
##MU	O
##C	O
##16	O
and	O
Cap	O
##an	O
##1	O
-	O
s	O
##h	O
##MU	O
##C	O
##16	O
cells	O
in	O
comparison	O
to	O
scrambled	O
control	O
cells	O
(	O
Figure	O
)	O
.	O

The	O
overall	O
6	O
most	O
increased	O
s	O
##tero	O
##ids	O
comprised	O
the	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
meta	O
##bol	O
##ite	O
,	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
-	I
11	I
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
(	O
T	O
##HS	O
)	O
;	O
the	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
meta	O
##bol	O
##ite	O
,	O
te	B
##tra	I
##hy	I
##dr	I
##ode	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
;	O
the	O
pre	B
##gne	I
##no	I
##lone	I
and	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##re	I
##gne	I
##no	I
##lone	I
meta	O
##bol	O
##ites	O
,	O
5	O
-	O
pre	O
##gne	O
##ned	O
##iol	O
and	O
5	O
-	O
pre	O
##gne	O
##net	O
##rio	O
##l	O
;	O
and	O
the	O
pro	B
##ges	I
##tero	I
##ne	I
and	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
meta	O
##bol	O
##ites	O
,	O
pre	B
##gna	I
##ned	I
##iol	I
and	O
pre	B
##gna	I
##net	I
##rio	I
##l	I
.	O

Ang	B
II	I
can	O
activate	O
the	O
release	O
of	O
re	O
##nal	O
20	B
-	I
H	I
##ET	I
##E	I
by	O
s	O
##ti	O
##mulating	O
the	O
synthesis	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
at	O
critical	O
sites	O
in	O
the	O
kidney	O
:	O
the	O
pre	O
##g	O
##lo	O
##mer	O
##ular	O
micro	O
##ves	O
##sel	O
##s	O
that	O
determine	O
re	O
##nova	O
##s	O
##cular	O
resistance	O
and	O
a	O
ne	B
##ph	I
##ron	I
segment	O
,	O
the	O
me	O
##du	O
##llar	O
##y	O
thick	O
ascending	O
limb	O
,	O
that	O
contributes	O
decisive	O
##ly	O
to	O
salt	O
and	O
water	O
balance	O
.	O

This	O
new	O
N	O
##MP	O
##S	O
est	B
##rogen	I
derivative	O
has	O
made	O
it	O
possible	O
to	O
show	O
that	O
the	O
levels	O
for	O
un	O
##con	O
##ju	O
##gated	O
serum	O
E	O
##2	O
were	O
lower	O
than	O
that	O
found	O
in	O
older	O
men	O
and	O
that	O
con	O
##ju	O
##gated	O
E	O
##2	O
was	O
present	O
in	O
somewhat	O
higher	O
levels	O
in	O
both	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
and	O
older	O
men	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
collected	O
and	O
mixed	O
with	O
ch	B
##lor	I
##of	I
##orm	I
(	O
270	O
µ	O
##L	O
)	O
and	O
dei	O
##onized	O
water	O
(	O
450	O
µ	O
##L	O
)	O
.	O

The	O
last	O
two	O
compounds	O
are	O
downstream	O
meta	O
##bol	O
##ites	O
of	O
a	O
B	O
##DA	O
-	O
derived	O
c	B
##ys	I
##tein	I
##e	I
-	I
l	I
##ys	I
##ine	I
cross	O
##link	O
,	O
S	B
-	I
[	I
1	I
-	I
(	I
5	I
-	I
amino	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
.	O

The	O
ability	O
of	O
limo	B
##nen	I
##e	I
to	O
reduce	O
circulating	O
ad	O
##rena	O
##l	O
s	O
##tero	O
##id	O
levels	O
could	O
be	O
an	O
important	O
contribution	O
to	O
its	O
overall	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
and	O
on	O
##cos	O
##tat	O
##ic	O
properties	O
.	O

Therefore	O
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
status	O
may	O
be	O
an	O
important	O
factor	O
to	O
consider	O
in	O
C	O
##VD	O
meta	O
##bol	O
##omi	O
##c	O
analyses	O
because	O
subjects	O
had	O
significantly	O
different	O
meta	O
##bol	O
##ite	O
profiles	O
according	O
to	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
,	O
which	O
corresponds	O
to	O
differences	O
in	O
the	O
likelihood	O
of	O
disease	O
outcomes	O
.	O

The	O
observed	O
increase	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
may	O
be	O
of	O
clinical	O
importance	O
as	O
they	O
are	O
highly	O
bio	O
##active	O
,	O
contributing	O
to	O
regulation	O
of	O
immune	O
cell	O
migration	O
and	O
enhance	O
ne	O
##ut	O
##rop	O
##hil	O
ad	O
##hesion	O
to	O
vessel	O
walls	O
.	O

D	O
##AG	O
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
;	O
r	O
##HD	O
##L	O
,	O
re	O
##con	O
##stituted	O
HD	O
##L	O
;	O
LP	O
##C	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
PC	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

It	O
was	O
possible	O
to	O
differentiate	O
end	O
##ogen	O
##ous	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
from	O
that	O
generated	O
by	O
treatment	O
with	O
bacterial	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
,	O
as	O
the	O
abundance	O
of	O
the	O
GP	O
-	O
tag	O
##ged	O
compound	O
did	O
not	O
change	O
when	O
der	O
##iva	O
##ti	O
##zation	O
was	O
performed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
bacterial	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
.	O

Researchers	O
have	O
demonstrated	O
that	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
can	O
cause	O
end	O
##oth	O
##eli	O
##al	O
d	O
##ys	O
##function	O
through	O
o	O
##xi	O
##da	O
##tive	O
stress	O
-	O
induced	O
a	O
##pop	O
##tosis	O
.	O

In	O
this	O
study	O
,	O
the	O
ratio	O
of	O
cat	B
##ech	I
##ols	I
to	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
in	O
the	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
was	O
associated	O
with	O
statistical	O
##ly	O
significantly	O
increased	O
risk	O
of	O
breast	O
cancer	O
.	O

(	O
a	O
)	O
Structure	O
of	O
PC	B
18	I
:	I
1	I
(	I
n	I
-	I
12	I
,	I
c	I
##is	I
)	I
/	I
18	I
:	I
1	I
(	I
n	I

T	O
##FA	O
##s	O
,	O
including	O
trans	O
-	O
v	O
##ac	O
##ce	O
##nic	O
acid	O
(	B
Δ	B
##11	I
-	I
trans	I
-	I
18	I
:	I
1	I
)	O
,	O
s	O
##ter	O
##ically	O
resemble	O
saturated	O
fatty	O
acids	O
and	O
might	O
therefore	O
substitute	O
for	O
these	O
in	O
the	O
s	O
##n	O
-	O
1	O
position	O
.	O

These	O
lower	O
t	B
-	I
ch	I
##olin	I
##e	I
levels	O
indicate	O
that	O
De	O
##gar	O
##eli	O
##x	O
has	O
an	O
effect	O
on	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

HC	O
##l	O
,	O
l	B
-	I
4	I
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
u	B
##rid	I
##ine	I
5	I
′	I
-	I
dip	I
##hos	I
##ph	I
##og	I
##lu	I
##cu	I
##ronic	I
acid	I
t	I
##ris	I
##od	I
##ium	I
salt	O
(	O
U	O
##GA	O
)	O
,	O
saturated	O
al	O
##kan	O
##e	O
mixture	O
(	O
C	O
_	O
7	O
–	O
C	O
_	O
40	O
)	O
and	O
all	O
analytical	O
reference	O
standards	O
were	O
purchased	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
(	O
Stein	O
##heim	O
,	O
Germany	O
)	O
at	O
the	O
highest	O
purity	O
available	O
.	O

A	O
total	O
of	O
10	O
meta	O
##bol	O
##ites	O
,	O
including	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##ate	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
g	B
##uan	I
##os	I
##ine	I
,	O
may	O
be	O
potential	O
candidate	O
bio	O
##mark	O
##ers	O
of	O
ma	O
##li	O
##gnant	O
pan	O
##cre	O
##atic	O
tissue	O
samples	O
.	O

The	O
results	O
indicated	O
that	O
bio	B
##tin	I
su	I
##lf	I
##one	I
,	O
5	B
-	I
o	I
##x	I
##o	I
-	I
he	I
##ne	I
##ico	I
##san	I
##oi	I
##c	I
acid	I
,	O
d	B
-	I
G	I
##lu	I
##cos	I
##ami	I
##ni	I
##de	I
and	O
2	B
-	I
met	I
##hyl	I
##hip	I
##pur	I
##ic	I
acid	I
were	O
the	O
most	O
significant	O
differential	O
meta	O
##bol	O
##ites	O
for	O
the	O
classification	O
of	O
the	O
H	O
##B	O
##V	O
and	O
the	O
control	O
.	O

Method	O
performance	O
criteria	O
for	O
extraction	O
of	O
bi	O
##s	O
(	B
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##o	I
-	I
2	I
-	I
prop	I
##yl	I
)	I
phosphate	I
(	O
B	O
##DC	O
##PP	O
)	O
and	O
dip	O
##hen	O
##yl	O
(	O
D	O
##PP	O
)	O
from	O
urine	O
.	O

The	O
in	O
##cu	O
##bation	O
of	O
m	B
##or	I
##phine	I
with	O
liver	O
c	O
##yt	O
##oso	O
##l	O
extract	O
##s	O
resulted	O
in	O
approximately	O
equal	O
rate	O
of	O
formation	O
of	O
both	O
M	O
##3	O
##S	O
and	O
M	O
##6	O
##S	O
.	O
In	O
conclusion	O
,	O
su	O
##lf	O
##ation	O
of	O
m	B
##or	I
##phine	I
is	O
cat	O
##aly	O
##zed	O
in	O
human	O
liver	O
but	O
this	O
minor	O
metabolic	O
pathway	O
probably	O
lacks	O
clinical	O
significance	O
.	O

Despite	O
its	O
use	O
in	O
synthetic	O
and	O
in	O
v	O
##it	O
##ro	O
inhibitor	O
##y	O
reactions	O
,	O
little	O
is	O
known	O
about	O
the	O
end	O
##ogen	O
##ous	O
function	O
of	O
N	B
-	I
met	I
##hyl	I
##alan	I
##ine	I
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
develop	O
a	O
software	O
prototype	O
for	O
automatic	O
q	O
##uant	O
##ification	O
of	O
c	B
##it	I
##rate	I
,	O
ch	B
##olin	I
##e	I
and	O
c	B
##rea	I
##tine	I
in	O
pro	O
##state	O
.	O

Overall	O
,	O
the	O
h	O
##ydro	O
##lysis	O
using	O
G	O
##US	O
from	O
E	O
.	O
co	O
##li	O
showed	O
the	O
largest	O
percentage	O
change	O
for	O
the	O
evaluated	O
IS	O
##T	O
##Ds	O
,	O
suggesting	O
that	O
the	O
75	O
m	O
##M	O
phosphate	S
buffer	O
(	O
pH	O
6	O
.	O
8	O
)	O
or	O
E	O
.	O
co	O
##li	O
G	O
##US	O
affect	O
compound	O
stability	O
.	O

This	O
results	O
in	O
a	O
ho	O
##rmon	O
##al	O
im	O
##bal	O
##ance	O
,	O
disturbing	O
the	O
physiological	O
levels	O
of	O
co	B
##rt	I
##is	I
##ol	I
and	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
(	O
D	O
##H	O
##EA	O
)	O
.	O

P	O
##las	O
##ma	O
NE	O
##FA	O
species	O
after	O
4	O
h	O
in	O
##fusion	O
of	O
r	O
##HD	O
##L	O
or	O
sa	B
##line	I
place	O
##bo	O
r	O
##HD	O
##L	O
,	O
re	O
##con	O
##stituted	O
HD	O
##L	O
.	O

Ser	B
##oto	I
##nin	I
;	O
48	O
.	O

Most	O
of	O
the	O
differential	O
en	O
##rich	O
##ed	O
meta	O
##bol	O
##ites	O
were	O
involved	O
in	O
metabolic	O
processes	O
,	O
including	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
metabolism	O
,	O
star	O
##ch	O
and	O
su	B
##c	I
##rose	I
metabolism	O
,	O
p	B
##hen	I
##yl	I
##p	I
##rop	I
##ano	I
##id	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
amino	O
acids	O
.	O

Further	O
,	O
su	O
##cci	O
##nate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
is	O
the	O
only	O
enzyme	O
shared	O
by	O
the	O
electron	O
transport	O
chain	O
and	O
the	O
T	O
##CA	O
cycle	O
;	O
in	O
cardiac	O
my	O
##ocytes	O
,	O
this	O
link	O
between	O
substrate	O
u	O
##til	O
##ization	O
and	O
the	O
electron	O
transport	O
chain	O
has	O
been	O
reinforced	O
by	O
experiments	O
showing	O
that	O
mitochondrial	O
rate	O
reserve	O
respiratory	O
capacity	O
(	O
the	O
ability	O
of	O
mit	O
##och	O
##ond	O
##ria	O
to	O
increase	O
ATP	S
production	O
as	O
demand	O
increases	O
)	O
was	O
abolished	O
by	O
the	O
absence	O
of	O
su	O
##cci	O
##nate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
activity	O
.	O

Moreover	O
,	O
the	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
g	B
##lu	I
##copy	I
##rano	I
##se	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
g	B
##ly	I
##cer	I
##ic	I
acid	I
,	O
al	B
##ani	I
##ne	I
,	O
but	B
##ane	I
##dio	I
##ic	I
acid	I
,	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
,	O
gal	B
##act	I
##ose	I
,	O
la	B
##ctic	I
acid	I
,	O
g	B
##ly	I
##cine	I
,	O
glucose	S
,	O
pro	B
##line	I
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
were	O
identified	O
relevant	O
to	O
the	O
differentiation	O
between	O
the	O
E	O
##LS	O
/	O
MD	O
##D	O
and	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
.	O

Go	O
to	O
:	O
Human	O
exposure	O
to	O
p	B
##oly	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
(	O
PA	O
##H	O
##s	O
)	O
can	O
be	O
assessed	O
through	O
monitoring	O
of	O
u	O
##rina	O
##ry	O
mon	O
##o	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
PA	O
##H	O
##s	O
(	O
OH	O
-	O
PA	O
##H	O
##s	O
)	O
.	O

Go	O
to	O
:	O
Di	O
##os	O
##min	O
is	O
a	O
fl	B
##av	I
##ono	I
##id	I
often	O
administered	O
in	O
the	O
treatment	O
of	O
chronic	O
ve	O
##nous	O
ins	O
##uff	O
##iciency	O
,	O
hem	O
##or	O
##r	O
##ho	O
##ids	O
,	O
and	O
related	O
affection	O
##s	O
.	O

Select	O
base	O
##line	O
characteristics	O
of	O
this	O
subset	O
of	O
the	O
Alpha	B
-	I
To	I
##co	I
##pher	I
##ol	I
,	O
Beta	B
-	I
Car	I
##ote	I
##ne	I
Cancer	O
Prevention	O
(	O
AT	O
##BC	O
)	O
Study	O
(	O
n	O
=	O
39	O
##2	O
)	O
Of	O
the	O
94	O
##0	O
meta	O
##bol	O
##ites	O
anal	O
##ys	O
##ed	O
,	O
113	O
were	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
at	O
the	O
nominal	O
P	O
<	O
0	O
.	O
05	O
level	O
,	O
of	O
which	O
the	O
majority	O
(	O
55	O
)	O
were	O
lip	O
##ids	O
.	O

There	O
was	O
no	O
statistical	O
##ly	O
significant	O
difference	O
between	O
intake	O
of	O
different	O
mac	O
##ro	O
-	O
,	O
micro	O
##nut	O
##rient	O
##s	O
as	O
well	O
as	O
food	O
groups	O
at	O
base	O
##line	O
in	O
patients	O
with	O
clinical	O
re	O
##lap	O
##se	O
versus	O
re	O
##mission	O
within	O
12	O
m	O
##o	O
of	O
follow	O
-	O
up	O
,	O
except	O
for	O
p	O
##ou	O
##ltry	O
and	O
ma	B
##lt	I
##ose	I
intake	O
which	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
remained	O
in	O
re	O
##mission	O
(	O
Table	O
)	O
.	O

The	O
dried	O
residue	O
of	O
serum	O
extract	O
was	O
red	O
##iss	O
##ol	O
##ved	O
in	O
100	O
μ	O
##l	O
of	O
met	B
##hyl	I
t	I
-	I
but	I
##yl	I
et	I
##her	I
,	O
and	O
then	O
100	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
was	O
added	O
with	O
mixing	O
before	O
cent	O
##ri	O
##fu	O
##ging	O
prior	O
to	O
injection	O
(	O
10	O
μ	O
##l	O
)	O
.	O

Lac	B
##tate	I
is	O
generated	O
by	O
L	O
##D	O
##H	O
,	O
a	O
large	O
complex	O
consisting	O
of	O
L	O
##D	O
##HA	O
and	O
L	O
##D	O
##H	O
##B	O
.	O

B	O
##rief	O
##ly	O
,	O
pro	O
##ton	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
recorded	O
at	O
300	O
K	O
using	O
a	O
700	O
MHz	O
B	O
##ruk	O
##er	O
Ava	O
##nce	O
A	B
##V	I
III	O
s	O
##pect	O
##rome	O
##ter	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
plasma	O
amino	O
acids	O
in	O
IS	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
in	O
agreement	O
with	O
Ma	O
##ura	O
##s	O
et	O
al	O
.	O
,	O
except	O
for	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
,	O
which	O
in	O
fact	O
decreased	O
due	O
to	O
the	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
.	O

Hence	O
,	O
it	O
is	O
proper	O
and	O
fitting	O
in	O
this	O
paper	O
to	O
concentrate	O
on	O
the	O
important	O
factor	O
of	O
abnormal	O
metabolism	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
F	B
##D	I
.	O

CP	O
##M	O
is	O
a	O
common	O
meta	O
##bol	O
##ite	O
for	O
ch	B
##lor	I
##opy	I
##rid	I
##in	I
##yl	I
neon	I
##ico	I
##tino	I
##id	I
;	O
I	O
##CM	O
for	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
and	O
cloth	B
##ian	I
##id	I
##in	I
;	O
and	O
CT	O
##M	O
for	O
cloth	B
##ian	I
##id	I
##in	I
and	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
.	O

A	O
1	O
.	O
0	O
m	O
##M	O
solution	O
of	O
the	O
LP	O
##O	O
product	O
of	O
interest	O
was	O
made	O
up	O
in	O
ethanol	S
and	O
100	O
μ	O
##l	O
was	O
added	O
to	O
the	O
MA	O
##d	O
_	O
3	O
solution	O
(	O
10	O
-	O
fold	O
m	O
##olar	O
excess	O
)	O
.	O

In	O
##verse	O
normal	O
-	O
rank	O
transformations	O
were	O
applied	O
to	O
the	O
c	O
##yt	O
##oki	O
##nes	O
,	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
,	O
K	O
##TR	O
,	O
and	O
P	O
##LP	O
to	O
make	O
them	O
satisfy	O
the	O
normal	O
##ity	O
assumption	O
before	O
examination	O
of	O
associations	O
with	O
any	O
of	O
the	O
c	O
##yt	O
##oki	O
##nes	O
through	O
multiple	O
linear	O
re	O
##gression	O
analysis	O
.	O

(	O
P	O
=	O
4	O
x	O
10	O
_	O
−	O
##5	O
)	O
,	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
but	B
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
P	O
=	O
0	O
.	O
00	O
##4	O
)	O
levels	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
has	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
not	O
been	O
described	O
in	O
the	O
context	O
of	O
sex	O
before	O
.	O

L	O
##C	O
-	O
MS	O
/	O
MS	O
MR	O
##M	O
identification	O
of	O
the	O
im	B
##ida	I
##zo	I
##lino	I
##ne	I
product	O
.	O

Con	O
##sist	O
##ent	O
with	O
this	O
interpretation	O
,	O
we	O
observe	O
statistical	O
##ly	O
significant	O
elevation	O
of	O
both	O
α	B
-	I
K	I
##B	I
and	O
c	B
##ys	I
##tein	I
##e	I
with	O
increasing	O
insulin	O
resistance	O
from	O
the	O
global	O
screening	O
data	O
(	O
&	O
,	O
)	O
,	O
similar	O
to	O
the	O
trend	O
observed	O
with	O
α	B
-	I
H	I
##B	I
.	O

The	O
met	B
##hi	I
##oni	I
##ne	I
cycle	O
is	O
a	O
key	O
pathway	O
contributing	O
to	O
the	O
regulation	O
of	O
human	O
health	O
,	O
with	O
well	O
-	O
established	O
involvement	O
in	O
card	O
##iovascular	O
diseases	O
and	O
cognitive	O
function	O
.	O

The	O
only	O
exceptions	O
were	O
T	B
##MA	I
##O	I
and	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
where	O
significant	O
de	O
##viation	O
##s	O
between	O
L	O
##C	O
-	O
MS	O
and	O
N	O
##MR	O
were	O
observed	O
.	O

The	O
fragment	O
##or	O
voltage	O
was	O
set	O
at	O
120	O
V	O
and	O
ski	O
##mmer	O
voltage	O
was	O
set	O
at	O
60	O
V	O
.	O
All	O
analyses	O
were	O
acquired	O
using	O
a	O
mixture	O
of	O
10	O
m	O
##M	O
pu	B
##rine	I
(	O

Ion	O
transfer	O
/	O
detection	O
parameters	O
were	O
op	O
##ti	O
##mized	O
using	O
a	O
standard	O
mix	O
of	O
se	B
##rine	I
,	O
te	B
##tra	I
-	I
al	I
##ani	I
##ne	I
,	O
re	B
##ser	I
##pine	I
,	O
He	O
##wl	O
##ett	O
-	O
Packard	O
tuning	O
mix	O
and	O
the	O
ad	O
##ren	O
##oc	O
##ort	O
##ico	O
##tro	O
##phic	O
hormone	O
fragment	O
4	O
-	O
10	O
.	O

So	B
##fo	I
##s	I
##bu	I
##vir	I
(	O
Gil	O
##ead	O
Sciences	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
at	O
400	O
mg	O
was	O
administered	O
once	O
daily	O
,	O
along	O
with	O
rib	B
##avi	I
##rin	I
(	O
R	O
##iba	O
##sp	O
##here	O
;	O
Ka	O
##d	O
##mon	O
,	O
Warren	O
##dale	O
,	O
PA	O
)	O
administered	O
twice	O
daily	O
and	O
dose	O
##d	O
according	O
to	O
body	O
weight	O
(	O
1	O
,	O
000	O
mg	O
/	O
day	O
for	O
patients	O
weighing	O
<	O
75	O
kg	O
and	O
1	O
,	O
200	O
mg	O
/	O
day	O
for	O
those	O
weighing	O
≥	O
75	O
kg	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
evaluating	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
and	O
diabetes	O
status	O
,	O
and	O
suggests	O
that	O
some	O
p	O
##ht	O
##hala	O
##tes	O
might	O
influence	O
diabetes	O
status	O
.	O

After	O
in	O
##cu	O
##bation	O
,	O
the	O
filter	O
wells	O
were	O
dried	O
,	O
and	O
300	O
μ	O
##l	O
met	B
##han	I
##ol	I
containing	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
were	O
added	O
into	O
each	O
filter	O
well	O
to	O
extract	O
the	O
meta	O
##bol	O
##ites	O
.	O

The	O
recover	O
##ies	O
of	O
all	O
p	B
##oly	I
##amine	I
and	O
precursor	O
##s	O
were	O
above	O
82	O
%	O
in	O
the	O
serum	O
matrix	O
.	O

This	O
finding	O
is	O
most	O
likely	O
due	O
to	O
the	O
concurrent	O
release	O
of	O
both	O
O	O
##C	O
##N	O
and	O
g	B
##ly	I
##cy	I
##l	I
##p	I
##rol	I
##ine	I
during	O
bone	O
re	O
##mo	O
##del	O
##ing	O
.	O

The	O
de	O
##uter	O
##ated	O
internal	O
standards	O
(	O
IS	O
)	O
26	B
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
,	I
27	I
-	I
he	I
##xa	I
##de	I
##uter	I
##ium	I
-	I
1	I
##α	I
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	O
Medical	O
Is	O
##oto	O
##pes	O
)	O
and	O
26	B
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
,	I
27	I
-	I
he	I
##xa	I
##de	I
##uter	I
##ium	I
-	I
25	I
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	O
S	O
##ynth	O
##etic	O
##a	O
)	O
were	O
dissolved	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
to	O
prepare	O
stock	O
solutions	O
.	O

Whereas	O
the	O
serum	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
or	B
##ni	I
##thin	I
##e	I
were	O
lower	O
in	O
T	O
##2	O
##D	O
subjects	O
,	O
put	B
##res	I
##cine	I
,	O
which	O
is	O
directly	O
produced	O
from	O
or	B
##ni	I
##thin	I
##e	I
by	O
the	O
en	O
##zy	O
##matic	O
activity	O
of	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
(	O
O	O
##DC	O
)	O
,	O
was	O
increased	O
.	O

However	O
,	O
the	O
common	O
name	O
is	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
on	O
account	O
of	O
its	O
formation	O
via	O
the	O
mitochondrial	O
C	O
##YP	O
##27	O
##A	O
##1	O
-	O
cat	O
##aly	O
##zed	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
this	O
will	O
be	O
the	O
name	O
used	O
here	O
,	O
although	O
we	O
will	O
use	O
the	O
abbreviation	O
C	B
_	I
5	I
-	I
3	I
##β	I
,	I
26	I
-	I
di	I
##ol	I
in	O
accord	O
with	O
the	O
systematic	O
name	O
ch	B
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
26	I
-	I
di	I
##ol	I
recommended	O
by	O
F	O
##ah	O
##y	O
et	O
al	O
.	O
.	O

By	O
contrast	O
,	O
inverse	O
correlation	O
##s	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
found	O
between	O
vitamin	O
B	O
-	O
12	O
status	O
and	O
peripheral	O
nerve	O
function	O
with	O
u	B
##ric	I
acid	I
,	O
trans	B
-	I
4	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
su	B
##c	I
##rose	I
,	O
su	B
##cci	I
##nic	I
acid	I
,	O
p	B
##yr	I
##u	I
##vic	I
acid	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
o	B
##xa	I
##lic	I
acid	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
man	B
##ni	I
##to	I
##l	I
,	O
ma	B
##lt	I
##ose	I
,	O
ma	B
##lic	I
acid	I
,	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ct	I
##ate	I
,	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
α	I
-	I
phosphate	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
c	B
##it	I
##rama	I
##lic	I
acid	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
2	B
-	I
k	I
##eto	I
##is	I
##oc	I
##ap	I
##roi	I
##c	I
acid	I
,	O
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ano	I
##ic	I
acid	I
.	O

Gala	B
##ct	I
##ose	I
reached	O
its	O
highest	O
serum	O
levels	O
1	O
h	O
after	O
milk	O
intake	O
while	O
la	B
##ct	I
##ose	I
,	O
gal	B
##act	I
##ito	I
##l	I
,	O
gal	B
##act	I
##ona	I
##te	I
,	O
and	O
gal	B
##act	I
##ono	I
-	I
1	I
,	I
5	I
-	I
la	I
##cton	I
##e	I
reached	O
their	O
maximum	O
at	O
2	O
h	O
.	O

T	O
##rp	O
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ctic	I
acid	I
show	O
similar	O
positive	O
associations	O
with	O
abdominal	O
pain	O
after	O
eating	O
.	O

Is	O
pre	O
##con	O
##ception	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
(	I
ace	I
##tam	I
##ino	I
##phe	I
##n	I
)	I
associated	O
with	O
time	O
-	O
to	O
-	O
pregnancy	O
(	O
T	O
##TP	O
)	O
?	O

De	O
##gar	O
##eli	O
##x	O
treatment	O
did	O
not	O
change	O
the	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
levels	O
significantly	O
(	O
Table	O
;	O
supplement	O
##ary	O
Fi	O
##g	O
.	O

One	O
of	O
the	O
tentatively	O
identified	O
V	O
##OC	O
##s	O
is	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
.	O

Cold	O
increased	O
plasma	O
ch	B
##ole	I
##ster	I
##ols	I
,	O
a	O
##poli	O
##pop	O
##rote	O
##ins	O
,	O
total	O
fatty	O
acids	O
,	O
g	B
##lut	I
##amine	I
,	O
ace	B
##tate	I
and	O
album	O
##in	O
(	O
Figure	O
B	O
)	O
,	O
whereas	O
cold	O
had	O
no	O
effect	O
on	O
other	O
meta	O
##bol	O
##ites	O
(	O
Figure	O
B	O
)	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
,	O
end	O
##ogen	O
##ous	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
[	O
NO	O
##S	O
]	O
inhibitor	O
)	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
SD	O
##MA	O
,	O
which	O
lacks	O
NO	O
##S	O
inhibitor	O
##y	O
activity	O
)	O
,	O
N	B
-	I
mon	I
##o	I
-	I
met	I
##hyl	I
##ar	I
##gin	I
##ine	I
(	O
MMA	O
,	O
a	O
potent	O
NO	O
##S	O
inhibitor	O
)	O
,	O
met	O
##hyl	O
-	O
l	O
##ys	O
##ine	O
(	O
Met	O
##hyl	O
-	O
L	O
##ys	O
,	O
an	O
unrelated	O
met	O
##hyl	O
##ated	O
amino	O
acid	O
)	O
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
its	O
major	O
cat	O
##ab	O
##oli	O
##tes	O
(	O
c	O
##it	O
##ru	O
##llin	O
##e	O
and	O
or	O
##ni	O
##thin	O
##e	O
)	O
were	O
q	O
##uant	O
##ified	O
simultaneously	O
by	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
HP	O
##LC	O
with	O
on	O
-	O
line	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
and	O
adjusted	O
for	O
traditional	O
risk	O
factors	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
estimated	O
c	B
##rea	I
##tin	I
##ine	I
clearance	O
.	O

Part	O
##icular	O
##ly	O
notable	O
were	O
the	O
enhanced	O
production	O
of	O
the	O
As	O
##p	O
is	O
##oto	O
##po	O
##mer	O
with	O
three	O
_	O
13	O
C	O
-	O
labeled	O
carbon	O
##s	O
and	O
the	O
build	O
##up	O
of	O
_	O
13	O
C	B
-	I
2	I
,	I
3	I
-	I
G	I
##lu	I
is	O
##oto	O
##po	O
##mer	O
in	O
lung	O
tumor	O
tissues	O
.	O

C	B
##rea	I
##tin	I
##ine	I
,	O
an	O
important	O
index	O
in	O
urine	O
test	O
,	O
was	O
statistical	O
##ly	O
at	O
the	O
same	O
level	O
in	O
BC	O
##a	O
patients	O
and	O
controls	O
(	O
p	O
value	O
=	O
0	O
.	O
203	O
)	O
.	O

G	B
##lut	I
##ami	I
##c	I
acid	I
positively	O
correlated	O
to	O
glucose	S
,	O
insulin	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
with	O
q	O
<	O
0	O
.	O
2	O
.	O

Higher	O
ch	B
##olin	I
##e	I
(	O
Ha	O
##zard	O
ratio	O
(	O
H	O
##R	O
)	O
1	O
.	O
64	O
[	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
22	O
2	O
.	O
20	O
]	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
,	O
beta	B
##ine	I
(	O
H	O
##R	O
1	O
.	O
51	O
[	O
1	O
.	O
10	O
–	O
2	O
.	O
08	O
]	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
T	B
##MA	I
##O	I
(	O
H	O
##R	O
1	O
.	O
48	O
[	O
1	O
.	O
10	O
–	O
1	O
.	O
96	O
]	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
predicted	O
increased	O
risk	O
for	O
5	O
-	O
year	O
adverse	O
clinical	O
events	O
(	O
death	O
/	O
transplant	O
)	O
.	O

Li	O
##quid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
was	O
used	O
to	O
q	O
##uant	O
##ify	O
cannabis	S
meta	O
##bol	O
##ites	O
in	O
the	O
plasma	O
of	O
human	O
im	O
##mu	O
##no	O
##de	O
##ficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
–	O
infected	O
,	O
anti	O
##ret	O
##rov	O
##ira	O
##l	O
-	O
treated	O
individuals	O
who	O
self	O
-	O
identified	O
as	O
non	O
##can	O
##na	O
##bis	O
users	O
or	O
daily	O
cannabis	S
users	O
.	O

F	O
##ae	O
##cal	O
En	O
##tero	O
##ba	O
##cter	O
##iac	O
##eae	O
and	O
trim	B
##eth	I
##yla	I
##mine	I
were	O
positively	O
correlated	O
with	O
blood	O
pro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
c	O
##yt	O
##oki	O
##nes	O
,	O
while	O
R	O
##umi	O
##no	O
##co	O
##cca	O
##ceae	O
and	O
SC	O
##FA	O
##s	O
played	O
a	O
protective	O
role	O
.	O

Reg	O
##ression	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
(	O
sex	O
)	O
,	O
smoking	O
behavior	O
,	O
alcohol	O
consumption	O
,	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
and	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
.	O

In	O
line	O
with	O
the	O
pro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
character	O
of	O
PR	O
##MT	O
##s	O
over	O
##ex	O
##press	O
##ion	O
,	O
all	O
PR	O
##MT	O
##s	O
evaluated	O
in	O
the	O
current	O
study	O
were	O
correlated	O
with	O
local	O
expression	O
of	O
inflammatory	O
c	O
##yt	O
##oki	O
##nes	O
,	O
more	O
pronounced	O
##ly	O
in	O
q	O
##ui	O
##es	O
##cent	O
tissue	O
,	O
and	O
were	O
positively	O
correlated	O
with	O
the	O
clinical	O
activity	O
disease	O
in	O
##dices	O
,	O
CD	O
##A	O
##I	O
and	O
R	B
##I	I
.	O

In	O
fact	O
,	O
a	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
by	O
Di	O
Po	O
##to	O
et	O
al	O
.	O
identified	O
g	B
##ly	I
##cine	I
as	O
having	O
better	O
performance	O
than	O
A	O
##FP	O
,	O
and	O
o	B
##xa	I
##lic	I
acid	I
as	O
clearly	O
distinguishing	O
HC	O
##C	O
cases	O
from	O
HC	O
##V	O
-	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
controls	O
.	O

Ser	O
##um	O
T	O
,	O
A	O
##4	O
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
(	O
D	O
##H	O
##EA	O
)	O
,	O
11	B
##OH	I
##A	I
##4	I
,	I
11	I
##β	I
-	I
h	I
##ydro	I
##xy	I
##test	I
##osterone	I
(	O
11	O
##OH	O
##T	O
)	O
,	O
and	O
11	O
##K	O
##T	O
were	O
q	O
##uant	O
##ified	O
using	O
a	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
X	O
##evo	O
T	O
##Q	O
-	O
S	O
;	O
Waters	O
)	O
coupled	O
to	O
an	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
system	O
(	O
Waters	O
)	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
urine	O
sediments	O
(	O
n	O
=	O
49	O
,	O
Wilcox	O
##on	O
P	O
=	O
0	O
.	O
000	O
##4	O
,	O
)	O
and	O
super	O
##nat	O
##ants	O
(	O
n	O
=	O
59	O
,	O
Wilcox	O
##on	O
P	O
=	O
0	O
.	O
00	O
##25	O
,	O
)	O
derived	O
from	O
bio	O
##psy	O
positive	O
pro	O
##state	O
cancer	O
patients	O
as	O
compared	O
to	O
bio	O
##psy	O
negative	O
controls	O
(	O
n	O
=	O
44	O
and	O
n	O
=	O
51	O
,	O
respectively	O
,	O
)	O
.	O

Total	O
album	O
##in	O
in	O
the	O
sample	O
was	O
determined	O
by	O
the	O
addition	O
of	O
serum	O
to	O
br	B
##omo	I
##cre	I
##sol	I
green	O
,	O
in	O
##cu	O
##bation	O
and	O
absorb	O
##ance	O
measurement	O
at	O
660	O
nm	O
;	O
followed	O
by	O
concentration	O
determined	O
by	O
comparison	O
to	O
a	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
.	O

A	O
suggested	O
mechanism	O
is	O
that	O
disruption	O
of	O
CC	O
##AA	O
##T	O
-	O
enhance	O
##r	O
-	O
binding	O
proteins	O
(	O
C	O
/	O
E	O
##B	O
##P	O
)	O
activity	O
by	O
mutant	O
hunting	O
##tin	O
causes	O
suppression	O
of	O
the	O
expression	O
of	O
two	O
key	O
enzymes	O
(	B
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nic	I
acid	I
s	O
##ynth	O
##eta	O
##se	O
and	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nas	I
##e	I
acid	I
l	O
##yas	O
##e	O
)	O
of	O
the	O
u	B
##rea	I
cycle	O
.	O

Novel	O
aspects	O
in	O
SC	O
##C	O
tissue	O
were	O
increased	O
in	O
Vita	O
##min	O
B	O
complex	O
co	O
##fa	O
##ctors	O
,	O
se	B
##rot	I
##oni	I
##n	I
and	O
a	O
reduction	O
of	O
γ	B
-	I
amino	I
##but	I
##yric	I
acid	I
(	O
GA	O
##BA	O
)	O
.	O

This	O
theory	O
is	O
further	O
supported	O
by	O
animal	O
studies	O
led	O
by	O
Beck	O
and	O
T	O
##is	O
##dale	O
who	O
observed	O
an	O
initial	O
increase	O
in	O
u	O
##rina	O
##ry	O
u	B
##rea	I
ex	O
##cre	O
##tion	O
after	O
transplant	O
##ation	O
of	O
co	O
##lon	O
ad	O
##eno	O
##car	O
##ino	O
##mas	O
in	O
mice	O
,	O
but	O
a	O
decrease	O
below	O
the	O
base	O
##line	O
level	O
at	O
late	O
stages	O
of	O
tumor	O
growth	O
.	O

The	O
online	O
method	O
,	O
initially	O
employed	O
in	O
ex	O
v	O
##ivo	O
fresh	O
p	B
##or	I
##cine	I
samples	O
,	O
was	O
used	O
in	O
v	O
##ivo	O
during	O
can	O
##ine	O
on	O
##cological	O
surgery	O
and	O
enabled	O
discrimination	O
between	O
a	O
variety	O
of	O
tissue	O
types	O
and	O
diagnosis	O
in	O
combination	O
with	O
PC	O
##A	O
.	O

Among	O
the	O
111	O
patients	O
with	O
residual	O
drug	O
concentrations	O
,	O
57	O
(	O
38	O
.	O
5	O
%	O
)	O
had	O
more	O
than	O
one	O
drug	O
(	O
note	O
that	O
parent	O
drug	O
and	O
meta	O
##bol	O
##ite	O
or	O
combined	O
regime	O
##ns	O
such	O
as	O
SP	S
are	O
considered	O
as	O
one	O
)	O
:	O
43	O
(	O
29	O
.	O
1	O
%	O
)	O
had	O
both	O
l	O
##ume	O
##fant	O
##rine	O
and	O
SP	S
,	O
6	O
(	O
4	O
.	O
1	O
%	O
)	O
had	O
both	O
l	O
##ume	O
##fant	O
##rine	O
and	O
q	O
##uin	O
##ine	O
,	O
1	O
(	O
0	O
.	O
7	O
%	O
)	O
had	O
both	O
SP	S
and	O
q	O
##uin	O
##ine	O
,	O
and	O
7	O
(	O
4	O
.	O
7	O
%	O
)	O
had	O
all	O
three	O
agents	O
.	O

580	O
.	O
37	O
##45	O
with	O
a	O
retention	O
time	O
compatible	O
with	O
a	O
GP	O
-	O
tag	O
##ged	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

Allan	B
##to	I
##in	I
was	O
not	O
sufficiently	O
detect	O
##able	O
by	O
our	O
quantitative	O
methods	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
believed	O
that	O
sex	O
differences	O
largely	O
are	O
the	O
result	O
of	O
the	O
immune	O
-	O
enhancing	O
effects	O
of	O
est	O
##rogen	O
##s	O
and	O
im	O
##mu	O
##nos	O
##up	O
##pressive	O
effects	O
of	O
and	O
##rogen	O
##s	O
and	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
giving	O
women	O
a	O
stronger	O
humor	O
##al	O
immune	O
response	O
,	O
but	O
also	O
a	O
higher	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
to	O
auto	O
##im	O
##mu	O
##nity	O
.	O

Branch	O
##ed	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
##s	O
)	O
show	O
higher	O
connectivity	O
in	O
deceased	O
patients	O
,	O
in	O
particular	O
is	B
##ole	I
##uc	I
##ine	I
in	O
low	O
-	O
risk	O
networks	O
and	O
v	B
##ali	I
##ne	I
in	O
high	O
-	O
risk	O
networks	O
,	O
thus	O
implying	O
a	O
central	O
role	O
of	O
their	O
metabolism	O
in	O
AM	O
##I	O
.	O

PC	B
a	I
##a	I
C	I
##34	I
:	I
2	I
;	O
65	O
.	O

On	O
the	O
basis	O
of	O
its	O
structure	O
,	O
we	O
assume	O
that	O
it	O
is	O
a	O
direct	O
meta	O
##bol	O
##ite	O
of	O
S	B
-	I
prop	I
##en	I
##yl	I
-	I
c	I
##ys	I
##tein	I
##e	I
-	I
su	I
##lf	I
##oxide	I
(	O
SP	O
##CS	O
##O	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
a	O
general	O
Spanish	O
population	O
and	O
identified	O
an	O
MS	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
associated	O
to	O
changes	O
in	O
amino	O
acid	O
metabolism	O
,	O
glucose	S
home	O
##ost	O
##asis	O
,	O
lip	O
##id	O
β	O
-	O
oxidation	O
,	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
,	O
u	B
##rea	I
cycle	O
and	O
micro	O
##bio	O
##ta	O
-	O
host	O
co	O
-	O
metabolism	O
.	O

We	O
generated	O
multiple	O
stable	O
PC	O
knock	O
##down	O
cell	O
lines	O
from	O
the	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
cell	O
line	O
and	O
used	O
mass	O
s	O
##pect	O
##rome	O
##try	O
with	O
_	O
13	O
C	B
_	I
6	I
-	I
glucose	I
and	O
_	O
13	O
C	B
_	I
5	I
-	I
g	I
##lut	I
##amine	I
to	O
disc	O
##ern	O
the	O
pathways	O
that	O
use	O
PC	O
in	O
support	O
of	O
cell	O
growth	O
.	O

56	O
##2	O
.	O
36	O
##39	O
(	O
580	O
.	O
37	O
##45	O
−	O
H	O
_	O
2	O
O	O
)	O
and	O
54	O
##6	O
.	O
36	O
##90	O
(	O
56	O
##4	O
.	O
37	O
##9	O
##6	O
−	O
H	O
_	O
2	O
O	O
)	O
assigned	O
to	O
h	B
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##sta	I
-	I
4	I
,	I
6	I
-	I
die	I
##n	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	B
CA	B
_	I
4	I
,	I
6	I
-	I
x	I
-	I
o	I
##l	I
-	I
3	I
-	I
one	I
,	O
0	O
.	O
45	O
##3	O
±	O
0	O
.	O
204	O
ng	O
/	O
m	O
##l	O
)	O
and	O
3	B
-	I
o	I
##x	I
##och	I
##ole	I
##sta	I
-	I
4	I
,	I
6	I
-	I
die	I
##n	I
-	I
26	I
-	I
o	I
##ic	I
acid	I

Li	O
##pid	O
##s	O
were	O
separated	O
using	O
a	O
Ki	O
##net	O
##ex	O
H	O
##IL	O
##IC	O
column	O
with	O
a	O
mobile	O
phase	O
A	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
B	O
with	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
in	O
water	O
at	O
pH	O
3	O
.	O
2	O
following	O
a	O
gradient	O
and	O
the	O
injection	O
volume	O
was	O
5	O
μ	O
##L	O
.	O
Sam	O
##ple	O
solutions	O
were	O
analyzed	O
using	O
an	O
A	O
##gi	O
##lent	O
129	O
##0	O
UP	O
##LC	O
system	O
coupled	O
to	O
a	O
G	O
##64	O
##60	O
triple	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
)	O
and	O
using	O
Mass	O
##H	O
##unt	O
##er	O
software	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
)	O
for	O
data	O
acquisition	O
and	O
analysis	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
collected	O
into	O
anti	O
##coa	O
##gu	O
##lant	O
he	B
##par	I
##in	I
v	O
##ac	O
##uta	O
##iner	O
##s	O
from	O
patients	O
(	O
n	O
=	O
18	O
;	O
14	O
male	O
and	O
4	O
female	O
;	O
66	O
±	O
11	O
.	O
6	O
years	O
)	O
before	O
card	O
##io	O
##pu	O
##lm	O
##ona	O
##ry	O
bypass	O
surgery	O
(	O
pre	O
-	O
surgical	O
)	O
and	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
48	O
and	O
72	O
h	O
post	O
-	O
surgery	O
at	O
Royal	O
B	O
##rom	O
##pton	O
Hospital	O
,	O
UK	O
.	O

Apart	O
from	O
previously	O
identified	O
ace	B
##tone	I
(	O
m	O
/	O
z	O
59	O
.	O
05	O
)	O
and	O
in	B
##do	I
##le	I
(	O
m	O
/	O
z	O
118	O
.	O
07	O
)	O
,	O
the	O
finger	O
##print	O
##ing	O
strategy	O
used	O
here	O
to	O
describe	O
overall	O
24	O
-	O
hours	O
changes	O
does	O
not	O
allow	O
for	O
the	O
un	O
##am	O
##bi	O
##guous	O
identification	O
of	O
compounds	O
,	O
but	O
it	O
does	O
provide	O
their	O
most	O
likely	O
molecular	O
formula	O
##s	O
.	O

In	O
our	O
study	O
,	O
we	O
did	O
observe	O
slightly	O
elevated	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
indeed	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
but	O
not	O
reduced	O
g	B
##lut	I
##ama	I
##te	I
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
cannabis	S
use	O
on	O
indicators	O
of	O
inflammation	O
and	O
immune	O
activation	O
in	O
HIV	O
-	O
infected	O
,	O
AR	O
##T	O
-	O
treated	O
individuals	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
from	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
(	O
n	O
=	O
5	O
)	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
(	O
n	O
=	O
4	O
)	O
appear	O
in	O
the	O
first	O
component	O
.	O

It	O
was	O
found	O
that	O
1	O
-	O
M	O
##N	O
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
la	B
##ct	I
##ate	I
were	O
reduced	O
in	O
CO	O
##PD	O
patients	O
relative	O
to	O
healthy	O
subjects	O
.	O

In	O
contrast	O
,	O
metabolic	O
specific	O
##ities	O
were	O
displayed	O
in	O
boxes	O
on	O
horizontal	O
and	O
vertical	O
axis	O
:	O
(	O
i	O
)	O
in	O
HC	O
##C	O
-	O
C	O
##ir	O
##r	O
##hos	O
##is	O
:	O
a	O
high	O
level	O
of	O
β	B
-	I
H	I
##B	I
(	O
signals	O
at	O
1	O
.	O
18	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
>	O
0	O
.	O
5	O
and	O
signals	O
at	O
1	O
.	O
19	O
–	O
1	O
.	O
20	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
=	O
0	O
.	O
45	O
)	O
(	O
A	O
)	O
,	O
Ty	O
##r	O
(	O
signals	O
at	O
3	O
.	O
94	O
–	O
3	O
.	O
95	O
pp	O
##m	O
and	O
6	O
.	O
88	O
–	O
6	O
.	O
91	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
>	O
0	O
.	O
5	O
;	O
signals	O
at	O
7	O
.	O
17	O
–	O
7	O
.	O
18	O
pp	O
##m	O
,	O
with	O
p	O
(	O
co	O
##rr	O
)	O
=	O
0	O
.	O
45	O
)	O
,	O
Ph	O
##e	O
(	O
signal	O
7	O
.	O
34	O
–	O
7	O
.	O
37	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
>	O
0	O
.	O
5	O
;	O
signal	O
7	O
.	O
40	O
–	O
7	O
.	O
44	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
=	O
0	O
.	O
45	O
)	O
and	O
His	O
(	O
signal	O
7	O
.	O
07	O
–	O
7	O
.	O
09	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
>	O
0	O
.	O
5	O
)	O
;	O
signal	O
7	O
.	O
91	O
pp	O
##m	O
with	O
p	O
(	O
co	O
##rr	O
)	O
=	O
0	O
.	O
45	O
)	O
(	O
B	O
)	O
;	O
(	O
ii	O
)	O
in	O
HC	O
##C	O
-	O
N	O
##AF	O
##LD	O
:	O
high	O
level	O
of	O
G	B
##lut	I
##ama	I
##te	I
(	O
G	O
##lu	O
)	O

The	O
specimens	O
were	O
th	O
##awed	O
at	O
room	O
temperature	O
,	O
met	B
##han	I
##ol	I
was	O
added	O
to	O
the	O
serum	O
samples	O
according	O
to	O
the	O
ratio	O
1	O
:	O
3	O
(	O
200	O
:	O
600	O
µ	O
##l	O
)	O
.	O

Re	B
##tina	I
##l	I
plays	O
an	O
essential	O
role	O
in	O
molecular	O
signaling	O
in	O
vision	O
,	O
and	O
serves	O
mainly	O
as	O
a	O
re	B
##tino	I
##ic	I
acid	I
(	O
an	O
active	O
form	O
of	O
vitamin	O
A	O
)	O
precursor	O
outside	O
the	O
eye	O
.	O

The	O
optimal	O
conditions	O
providing	O
separation	O
from	O
the	O
sample	O
matrix	O
while	O
maintaining	O
an	O
acceptable	O
retention	O
factor	O
were	O
found	O
to	O
be	O
7	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
at	O
pH	O
=	O
9	O
.	O
0	O
.	O

In	O
summary	O
,	O
higher	O
levels	O
of	O
man	B
##ni	I
##to	I
##l	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
where	O
found	O
in	O
GB	O
##Ms	O
compared	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
in	O
tissue	O
while	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
4	B
-	I
Am	I
##ino	I
##but	I
##yric	I
acid	I
(	O
GA	O
##BA	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
2	I
-	I
phosphate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
rib	B
##ito	I
##l	I
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
showed	O
higher	O
levels	O
in	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
as	O
compared	O
to	O
GB	O
##M	O
.	O

An	O
exception	O
was	O
noted	O
again	O
for	O
re	B
##tina	I
##l	I
GT	O
##3	O
and	O
A	O
##c	O
##G	O
##T	O
##3	O
in	O
which	O
42	O
carbon	O
c	B
##era	I
##mi	I
##des	I
accounted	O
for	O
about	O
30	O
%	O
of	O
all	O
molecular	O
species	O
,	O
followed	O
by	O
G	O
##D	O
##3	O
(	O
18	O
%	O
)	O
.	O

E	B
##stro	I
##ne	I
su	I
##lf	I
##ate	I
:	O
production	O
rate	O
and	O
metabolism	O
in	O
man	O
.	O

After	O
adding	O
100	O
μ	O
##l	O
of	O
l	B
-	I
2	I
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
(	O
0	O
.	O
1	O
mg	O
/	O
m	O
##l	O
)	O
,	O
400	O
μ	O
##l	O
of	O
an	B
##hy	I
##dr	I
##ous	I
ethanol	I
,	O
and	O
100	O
μ	O
##l	O
of	O
p	B
##yr	I
##id	I
##ine	I
to	O
the	O
urine	O
sample	O
,	O
50	O
μ	O
##l	O
of	O
et	B
##hyl	I
ch	I
##lor	I
##of	I
##orm	I
##ate	I
was	O
added	O
for	O
first	O
der	O
##iva	O
##ti	O
##zation	O
at	O
20	O
.	O
0	O
±	O
0	O
.	O
1	O
°C	O
.	O

After	O
multi	O
##var	O
##iable	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
,	O
socio	O
##economic	O
status	O
,	O
smoking	O
,	O
physical	O
activity	O
,	O
glucose	S
and	O
lip	O
##id	O
‐	O
lowering	O
medication	O
use	O
,	O
and	O
B	O
##MI	O
,	O
210	O
##4	O
spectral	O
variables	O
representing	O
24	O
non	O
##lip	O
##id	O
(	O
Table	O
)	O
and	O
49	O
lip	O
##id	O
/	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##c	O
##lass	O
meta	O
##bol	O
##ites	O
(	O
Table	O
)	O
remained	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
VA	O
##T	O
(	O
P	O
=	O
4	O
.	O
88	O
##×	O
##10	O
_	O
−	O
##20	O

For	O
example	O
,	O
we	O
found	O
lower	O
concentrations	O
of	O
beta	B
##ine	I
(	O
,	O
)	O
,	O
al	B
##ani	I
##ne	I
(	O
,	O
)	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
g	B
##lut	I
##amine	I
at	O
12	O
w	O
##k	O
compared	O
to	O
before	O
pregnancy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mean	O
levels	O
of	O
the	O
rest	O
of	O
o	B
##xy	I
##ster	I
##ols	I
we	O
analyzed	O
are	O
comparable	O
to	O
other	O
published	O
data	O
in	O
humans	O
.	O

Three	O
hours	O
later	O
,	O
a	O
significant	O
fraction	O
(	O
8	O
.	O
3	O
–	O
32	O
%	O
)	O
of	O
the	O
plasma	O
glucose	S
remained	O
_	O
13	O
C	O
-	O
labeled	O
but	O
by	O
12	O
h	O
##rs	O
,	O
the	O
%	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
dropped	O
to	O
2	O
–	O
5	O
%	O
,	O
as	O
illustrated	O
for	O
four	O
patients	O
.	O

L	O
##ys	O
##o	O
##PC	O
##s	O
represent	O
5	O
–	O
20	O
%	O
of	O
the	O
total	O
plasma	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
are	O
formed	O
by	O
the	O
action	O
of	O
le	B
##ci	I
##thin	I
ch	I
##ole	I
##ster	I
##ol	I
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
(	O
L	O
##CA	O
##T	O
)	O
in	O
plasma	O
.	O

Although	O
not	O
statistical	O
##ly	O
significant	O
,	O
there	O
was	O
a	O
trend	O
toward	O
a	O
positive	O
relationship	O
between	O
u	O
##PC	O
##r	O
and	O
log	O
-	O
transformed	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
in	O
the	O
F	O
##S	O
##GS	O
patients	O
.	O

Le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
are	O
reported	O
as	O
a	O
single	O
anal	O
##yte	O
because	O
they	O
are	O
not	O
resolved	O
by	O
this	O
MS	O
/	O
MS	O
method	O
.	O

After	O
in	O
##cu	O
##bation	O
,	O
100	O
μ	O
##L	O
of	O
D	B
##MS	I
##O	I
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
1	O
hour	O
at	O
37	O
##°	O
##C	O
in	O
a	O
humid	O
##ified	O
in	O
##cu	O
##bat	O
##or	O
with	O
5	O
%	O
CO	O
_	O
2	O
.	O

Gang	B
##lio	I
##side	I
GM	I
##3	I
,	O
Ce	B
##r	I
and	O
G	O
##lu	O
##C	O
##er	O
also	O
showed	O
di	O
##ssi	O
##mi	O
##lar	O
trend	O
in	O
the	O
distribution	O
of	O
each	O
lip	O
##id	O
species	O
.	O

Lac	B
##tate	I
was	O
an	O
important	O
meta	O
##bol	O
##ite	O
that	O
disc	O
##rim	O
##inated	O
between	O
the	O
AC	O
##LF	O
and	O
C	O
##LF	O
groups	O
.	O

The	O
appropriate	O
quantity	O
of	O
the	O
stock	O
solution	O
was	O
added	O
to	O
glucose	O
-	O
free	O
R	O
##PM	O
##I	O
medium	O
to	O
a	O
final	O
concentration	O
of	O
10	O
.	O
7	O
m	O
##M	O
(	O
excluding	O
the	O
0	O
.	O
54	O
m	O
##M	O
un	O
##la	O
##bel	O
##ed	O
glucose	S
from	O
the	O
FC	O
##S	O
)	O
.	O

Since	O
a	O
major	O
portion	O
of	O
ace	B
##tate	I
in	O
the	O
brain	O
is	O
u	O
##til	O
##ised	O
in	O
fatty	O
acid	O
and	O
lip	O
##id	O
synthesis	O
,	O
the	O
decreased	O
ace	B
##tate	I
concentration	O
may	O
suggest	O
a	O
compromised	O
synthesis	O
of	O
my	O
##elin	O
-	O
related	O
fatty	O
acids	O
and	O
lip	O
##ids	O
in	O
the	O
s	O
##chi	O
##zophrenia	O
brain	O
.	O

After	O
pre	O
-	O
processing	O
and	O
visual	O
checking	O
of	O
the	O
N	O
##MR	O
data	O
##set	O
,	O
specific	O
_	O
1	O
H	O
regions	O
of	O
di	B
##acy	I
##l	I
##gy	I
##cer	I
##ols	I
,	O
T	O
##G	O
##s	O
and	O
total	O
lip	O
##ids	O
based	O
on	O
terminal	O
met	O
##hyl	O
and	O
met	B
##hyl	I
##ene	I
signals	O
were	O
identified	O
in	O
the	O
s	O
##pect	O
##ra	O
using	O
a	O
comparison	O
in	O
the	O
AM	O
##IX	O
3	O
.	O
9	O
software	O
(	O
B	O
##ruk	O
##er	O
,	O
Germany	O
)	O
.	O

De	O
##fin	O
##ite	O
non	O
-	O
meta	O
##bol	O
##ite	O
con	O
##tam	O
##ina	O
##nts	O
(	O
equipment	O
components	O
and	O
unknown	O
##s	O
,	O
98	O
)	O
and	O
re	O
##age	O
##nt	O
derivatives	O
(	O
E	O
##D	O
##TA	O
,	O
MS	O
##TF	O
##A	O
and	O
p	B
##yr	I
##id	I
##ine	I
derivatives	O
,	O
5	O
)	O
were	O
excluded	O
from	O
further	O
analysis	O
.	O

As	O
noted	O
in	O
,	O
major	O
meta	O
##bol	O
##ites	O
identified	O
in	O
serum	O
included	O
amino	O
acids	O
(	B
v	B
##ali	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
g	B
##ly	I
##cine	I
)	O
,	O
organic	O
acid	O
(	B
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
la	B
##ct	I
##ate	I
,	O
ace	B
##tone	I
,	O
su	B
##cci	I
##nate	I
,	O
c	B
##rea	I
##tine	I
)	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
and	O
V	O
##LD	O
##L	O
,	O
glucose	S
,	O
ch	B
##olin	I
##e	I
and	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
N	B
-	I
Ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
and	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
.	O

The	O
results	O
indicate	O
that	O
while	O
only	O
one	O
of	O
the	O
individual	O
meta	O
##bol	O
##ites	O
(	B
v	B
##ali	I
##ne	I
)	O
is	O
slightly	O
associated	O
with	O
diagnosis	O
,	O
the	O
effects	O
of	O
diagnosis	O
on	O
the	O
metabolic	O
activities	O
of	O
several	O
groups	O
of	O
biological	O
##ly	O
related	O
meta	O
##bol	O
##ites	O
are	O
indeed	O
quite	O
significant	O
.	O

The	O
ABC	O
##D	O
##2	O
+	O
LA	O
##A	O
+	O
L	B
##ys	I
##o	I
##PC	I
(	I
20	I
:	I
4	I
)	I
model	O
showed	O
the	O
highest	O
ca	O
##li	O
##bra	O
##tion	O
(	O
χ	O
_	O
2	O
3	O
.	O
58	O
,	O
p	O
=	O
0	O
.	O
30	O
##9	O
)	O
,	O
whereas	O
the	O
ABC	O
##D	O
##2	O
+	O
LA	O
##A	O
+	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
model	O
showed	O
the	O
lowest	O
ca	O
##li	O
##bra	O
##tion	O
values	O
(	O
χ	O
_	O
2	O
17	O
.	O
33	O
,	O
p	O

A	O
possible	O
candidate	O
meta	O
##bol	O
##ite	O
is	O
1	B
##α	I
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
e	I
##pi	I
-	I
vitamin	I
D	O
_	O
3	O
,	O
a	O
biological	O
##ly	O
active	O
product	O
of	O
the	O
cat	O
##ab	O
##olic	O
e	O
##pi	O
##mer	O
##ization	O
of	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
.	O

All	O
tested	O
samples	O
showed	O
detect	O
##able	O
amounts	O
of	O
T	B
##MA	I
##O	I
,	O
in	O
a	O
range	O
between	O
0	O
.	O
11	O
and	O
6	O
.	O
43	O
µ	O
##mo	O
##l	O
/	O
L	O
(	O
median	O
:	O
0	O
.	O
66	O
##5	O
µ	O
##mo	O
##l	O
/	O
L	O
,	O
95	O
%	O
C	O
##I	O
-	O
0	O
.	O
490	O
to	O
0	O
.	O
87	O
##0	O
µ	O
##mo	O
##l	O
/	O
L	O
)	O
.	O

We	O
previously	O
showed	O
that	O
this	O
compound	O
was	O
also	O
the	O
most	O
effective	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##id	I
in	O
in	O
##hibit	O
##ing	O
the	O
trans	O
##act	O
##ivation	O
of	O
R	O
##X	O
##R	O
##α	O
by	O
its	O
ago	O
##nist	O
,	O
9	O
-	O
c	O
##is	O
-	O
re	O
##tino	O
##ic	O
acid	O
,	O
and	O
molecular	O
modeling	O
studies	O
demonstrated	O
that	O
it	O
could	O
potentially	O
bind	O
to	O
the	O
transcription	O
##ally	O
silent	O
te	O
##tra	O
##mer	O
of	O
R	O
##X	O
##R	O
##α	O
.	O

Per	O
##ip	O
##her	O
##al	O
ve	O
##nous	O
blood	O
was	O
collected	O
from	O
all	O
study	O
participants	O
using	O
et	B
##hyl	I
##ene	I
di	I
##amine	I
te	O
##tra	O
-	O
ace	O
##tic	O
acid	O
(	O
E	O
##D	O
##TA	O
)	O
for	O
anti	O
##coa	O
##gu	O
##lation	O
.	O

Ph	O
##arma	O
##co	O
##kin	O
##etic	O
parameters	O
for	O
the	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
meta	O
##bol	O
##ite	O
G	O
##S	O
-	O
33	O
##100	O
##7	O
and	O
rib	B
##avi	I
##rin	I
were	O
estimated	O
by	O
plotting	O
the	O
data	O
from	O
across	O
study	O
visits	O
based	O
on	O
the	O
time	O
the	O
sample	O
was	O
collected	O
post	O
##dos	O
##e	O
and	O
fitting	O
the	O
data	O
to	O
a	O
non	O
##com	O
##par	O
##tment	O
##al	O
model	O
(	O
see	O
Fi	O
##g	O
.	O

ATP	S
,	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
;	O
AD	B
##P	I
,	O
ad	B
##eno	I
##sin	I
##e	I
dip	I
##hos	I
##phate	I
;	O
AM	B
##P	I
,	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##op	I
##hos	I
##phate	I
,	O
GM	O
##P	O
,	O
g	B
##uan	I
##os	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
.	O

Ana	O
##ly	O
##tical	O
standard	O
stock	O
solutions	O
for	O
L	O
##C	O
/	O
MS	O
were	O
prepared	O
in	O
met	B
##han	I
##ol	I
(	O
1	O
mg	O
/	O
m	O
##L	O
)	O
and	O
stored	O
at	O
−	O
##80	O
°C	O
.	O

The	O
lip	O
##id	O
profile	O
of	O
PC	O
##OS	O
women	O
with	O
abdominal	O
o	O
##besity	O
was	O
highly	O
associated	O
with	O
test	B
##osterone	I
(	O
;	O
)	O
.	O

The	O
correlation	O
value	O
of	O
the	O
two	O
characteristic	O
variables	O
was	O
0	O
.	O
85	O
##9	O
,	O
which	O
indicated	O
a	O
positive	O
correlation	O
between	O
put	B
##res	I
##cine	I
and	O
sperm	B
##id	I
##ine	I
.	O

We	O
identified	O
associations	O
between	O
index	O
##es	O
of	O
R	O
##V	O
-	O
P	O
##V	O
d	O
##ys	O
##function	O
and	O
the	O
cat	B
##ech	I
##ola	I
##mine	I
van	I
##ill	I
##yl	I
##mand	I
##eli	I
##c	I
acid	I
,	O
as	O
well	O
as	O
amino	B
##is	I
##ob	I
##ut	I
##yric	I
acid	I
and	O
c	O
##yclic	O
ad	O
##eno	O
##sin	O
##e	O
mon	O
##op	O
##hos	O
##phate	O
,	O
2	O
additional	O
meta	O
##bol	O
##ites	O
potentially	O
related	O
to	O
sympathetic	O
nervous	O
system	O
activation	O
(	O
,	O
)	O
.	O

Moreover	O
,	O
the	O
levels	O
of	O
N	O
##1	O
-	O
A	O
##c	O
##SP	O
##M	O
in	O
serum	O
and	O
the	O
levels	O
of	O
N	O
-	O
A	O
##c	O
##CA	O
##D	O
,	O
GA	B
##BA	I
,	O
and	O
N	O
##8	O
-	O
A	O
##c	O
##SP	O
##D	O
in	O
urine	O
were	O
also	O
significantly	O
different	O
between	O
men	O
and	O
women	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Box	O
-	O
and	O
-	O
w	O
##his	O
##ker	O
plots	O
show	O
the	O
distribution	O
of	O
abundance	O
values	O
of	O
5	B
-	I
O	I
##x	I
##op	I
##rol	I
##inate	I
,	O
E	B
##ry	I
##th	I
##ronic	I
acid	I
and	O
N	B
-	I
Ace	I
##ty	I
##lasp	I
##art	I
##ic	I
acid	I
in	O
HP	B
##V	I
-	I
vs	I
HP	O
##V	O
+	O
H	O
samples	O
with	O
the	O
optimal	O
cut	O
-	O
off	O
as	O
a	O
horizontal	O
dotted	O
red	O
line	O
.	O

Met	B
##hane	I
ex	O
##cre	O
##tion	O
was	O
found	O
to	O
be	O
associated	O
with	O
alterations	O
in	O
in	O
##test	O
##inal	O
m	O
##ot	O
##ility	O
,	O
higher	O
met	B
##hane	I
ex	O
##cre	O
##tion	O
favor	O
##ing	O
con	O
##st	O
##ip	O
##ation	O
–	O
.	O

Furthermore	O
,	O
the	O
disturbed	O
lip	O
##id	O
metabolism	O
would	O
be	O
reflected	O
by	O
changes	O
in	O
serum	O
lip	O
##id	O
meta	O
##bol	O
##ite	O
concentrations	O
,	O
notably	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
##s	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
AC	O
)	O
,	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
)	O
.	O

This	O
consequently	O
leads	O
to	O
changes	O
in	O
fatty	O
acid	O
synthesis	O
and	O
glucose	S
u	O
##til	O
##ization	O
.	O

S	O
##pect	O
##ra	O
were	O
scaled	O
to	O
dry	O
weight	O
to	O
show	O
the	O
difference	O
in	O
absolute	O
concentrations	O
of	O
meta	O
##bol	O
##ites	O
Alan	B
##ine	I
and	O
Lac	B
##tate	I
is	O
##oto	O
##po	O
##mer	O
patterns	O
in	O
R	O
##h	O
##30	O
cell	O
extract	O
.	O
_	O
1	O
H	O
N	O
##MR	O
spectrum	O
expansion	O
of	O
the	O
R	O
##h	O
##30	O
cell	O
extract	O
spectrum	O
from	O
Figure	O
5	O
showing	O
the	O
satellite	O
peaks	O
of	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
.	O

The	O
plasma	O
concentrations	O
for	O
SM	O
##V	O
,	O
SM	O
##V	O
-	O
A	O
,	O
AT	O
##V	O
,	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
and	O
RS	O
##V	O
from	O
three	O
o	O
##bes	O
##e	O
patients	O
pre	O
-	O
and	O
post	O
-	O
surgery	O
are	O
presented	O
in	O
.	O

For	O
example	O
,	O
reduced	O
levels	O
of	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
upstream	O
of	O
α	B
-	I
K	I
##B	I
formation	O
may	O
be	O
consistent	O
with	O
increased	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
which	O
is	O
observed	O
with	O
I	O
##R	O
in	O
d	O
##b	O
-	O
/	O
d	O
##b	O
-	O
mice	O
.	O

Det	O
##ailed	O
analysis	O
of	O
the	O
meta	O
##bol	O
##ome	O
revealed	O
several	O
candidate	O
meta	O
##bol	O
##ites	O
and	O
per	O
##tur	O
##bed	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
and	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
##s	O
as	O
put	O
##ative	O
bio	O
##mark	O
##ers	O
.	O

The	O
largest	O
%	O
lip	O
##id	O
increase	O
was	O
identified	O
as	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
(	O
T	O
##G	O
)	O
with	O
carbon	O
chain	O
:	O
double	O
bond	O
ratios	O
of	O
52	O
:	O
3	O
,	O
with	O
a	O
median	O
increase	O
from	O
L	O
##D	O
##N	O
to	O
E	O
##BC	O
of	O
53	O
.	O
9	O
%	O
.	O

It	O
is	O
easy	O
to	O
see	O
that	O
synthesis	O
of	O
la	B
##ct	I
##ate	I
might	O
be	O
in	O
##hibit	O
##ed	O
in	O
order	O
to	O
increase	O
flux	O
towards	O
fatty	O
acid	O
formation	O
(	O
and	O
vice	O
versa	O
)	O
which	O
would	O
account	O
for	O
this	O
negative	O
correlation	O
.	O

The	O
app	O
##lica	O
##bility	O
of	O
this	O
ass	O
##ay	O
was	O
investigated	O
in	O
samples	O
of	O
a	O
patient	O
treated	O
with	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
(	O
160	O
mg	O
once	O
daily	O
)	O
due	O
to	O
clinical	O
problems	O
that	O
were	O
encountered	O
in	O
his	O
treatment	O
.	O

The	O
later	O
el	O
##uti	O
##ng	O
is	O
##omer	O
of	O
PC	B
(	I
40	I
:	I
6	I
)	I
co	O
##el	O
##uted	O
with	O
our	O
standard	O
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
22	I
:	I
6	I
)	I
.	O

[	B
P	I
##G	I
(	I
14	I
:	I
0	I
/	I
14	I
:	I
0	I
]	I
,	I
1	I
-	I
O	I
-	I
He	I
##xa	I
##de	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
[	I
l	I
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
]	I
and	O
1	B
,	I
2	I
-	I
dip	I
##al	I
##mit	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##o	I
-	I
L	I
-	I
se	I
##rine	I
[	I
PS	I
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
]	I
,	O
each	O
at	O
the	O
concentration	O
of	O
5	O
µ	O
##g	O
/	O
m	O
##l	O
,	O
was	O
added	O
to	O
102	O
##0	O
µ	O
##l	O
of	O
each	O
di	O
##lution	O
.	O

Since	O
some	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
intermediate	O
##s	O
were	O
high	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
,	O
we	O
further	O
determined	O
the	O
N	B
##AD	I
##P	I
##H	I
and	O
R	O
##OS	O
level	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
.	O

Additionally	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
precursor	O
##s	O
for	O
cat	B
##ech	I
##ola	I
##mine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
were	O
significantly	O
altered	O
in	O
post	O
-	O
surgery	O
patients	O
.	O

Omega	B
-	I
3	I
Ph	O
##L	O
Index	O
was	O
similar	O
in	O
all	O
subgroup	O
##s	O
at	O
the	O
base	O
##line	O
,	O
while	O
at	O
week	O
24	O
it	O
was	O
not	O
affected	O
by	O
either	O
Place	O
##bo	O
or	O
Pi	O
##o	O
,	O
but	O
increased	O
to	O
a	O
similar	O
extent	O
(	O
1	O
.	O
6	O
–	O
1	O
.	O
7	O
-	O
fold	O
;	O
p	O
<	O
0	O
.	O
000	O
##1	O
and	O
p	O
=	O
0	O
.	O
000	O
##1	O
,	O
respectively	O
)	O
in	O
response	O
to	O
both	O
Omega	B
-	I
3	I
and	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
(	O
Table	O
)	O
.	O

In	O
the	O
in	O
##te	O
##gra	O
##se	O
inhibitor	O
-	O
based	O
group	O
,	O
the	O
use	O
of	O
ten	O
##of	O
##ov	O
##ir	O
al	B
##af	I
##ena	I
##mi	I
##de	I
f	I
##uma	I
##rate	I
significantly	O
increases	O
the	O
majority	O
of	O
lip	O
##id	O
fraction	O
##s	O
,	O
when	O
compared	O
with	O
ten	O
##of	O
##ov	O
##ir	O
di	O
##so	O
##p	O
##ro	O
##xi	O
##l	O
f	B
##uma	I
##rate	I
.	O

So	O
we	O
could	O
de	O
##du	O
##ce	O
that	O
a	O
higher	O
level	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
accompanying	O
physical	O
symptoms	O
would	O
indicate	O
a	O
state	O
of	O
psychological	O
sub	O
##op	O
##ti	O
##mal	O
health	O
and	O
imply	O
that	O
damages	O
to	O
the	O
nervous	O
system	O
were	O
in	O
progress	O
,	O
and	O
if	O
it	O
was	O
ignored	O
,	O
mental	O
disorder	O
would	O
emerge	O
soon	O
.	O

The	O
majority	O
of	O
anal	O
##yte	O
##s	O
which	O
were	O
not	O
detected	O
under	O
these	O
conditions	O
were	O
organic	O
acids	O
,	O
such	O
as	O
la	B
##ctic	I
acid	I
,	O
and	O
amino	O
acids	O
such	O
,	O
as	O
his	B
##ti	I
##dine	I
:	O
in	O
order	O
to	O
detect	O
these	O
,	O
additional	O
op	O
##ti	O
##mis	O
##ation	O
of	O
MS	O
source	O
or	O
solvent	O
conditions	O
,	O
or	O
the	O
use	O
of	O
MR	O
##M	O
analyses	O
,	O
may	O
be	O
required	O
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
T	O
##EX	O
-	O
induced	O
im	O
##mu	O
##nos	O
##up	O
##press	O
##ion	O
involves	O
signaling	O
of	O
F	O
##as	O
##L	O
_	O
+	O
ex	O
##oso	O
##mes	O
via	O
CD	O
##9	O
##5	O
(	O
F	O
##as	O
)	O
receptor	O
on	O
activated	S
CD	O
##8	O
_	O
+	O
T	O
cells	O
.	O

All	O
subjects	O
in	O
the	O
two	O
studies	O
also	O
underwent	O
CS	O
##F	O
collection	O
via	O
l	O
##umba	O
##r	O
pu	O
##nc	O
##ture	O
with	O
a	O
24	O
‐	O
gauge	O
at	O
##ra	O
##umatic	O
spinal	O
needle	O
into	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
(	O
B	O
##D	O
Falcon	O
)	O
,	O
immediately	O
al	O
##iq	O
##uo	O
##ted	O
(	O
0	O
.	O
5	O
m	O
##L	O
)	O
,	O
labeled	O
,	O
frozen	O
,	O
and	O
stored	O
at	O
−	O
##80	O
##°	O
##C	O
until	O
analysis	O
within	O
30	O
min	O
of	O
collection	O
.	O

A	O
h	O
##y	O
##pot	O
##hetical	O
population	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
with	O
est	B
##rogen	I
metabolism	O
profiles	O
similar	O
to	O
those	O
observed	O
in	O
the	O
P	O
##LC	O
##O	O
co	O
##hor	O
##t	O
was	O
considered	O
.	O

There	O
were	O
significant	O
correlation	O
##s	O
between	O
protein	O
##uria	O
and	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
12	O
AA	O
##s	O
(	O
ρ	O
=	O
0	O
.	O
74	O
–	O
0	O
.	O
29	O
for	O
pro	B
##line	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
se	B
##rine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
try	B
##pt	I
##op	I
##han	I
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

m	O
Mo	B
##rp	I
##hine	I
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
had	O
been	O
previously	O
measured	O
in	O
the	O
same	O
set	O
of	O
liver	O
micro	O
##some	O
##s	O
using	O
0	O
.	O
5	O
mm	O
m	B
##or	I
##phine	I
.	O

So	O
##matic	O
si	O
##len	O
##cing	O
of	O
the	O
AS	O
##S	O
##1	O
enzyme	O
in	O
the	O
u	B
##rea	I
cycle	O
was	O
exhibited	O
in	O
many	O
cancer	O
##s	O
and	O
tumor	O
tissues	O
,	O
and	O
it	O
was	O
reported	O
that	O
loss	O
of	O
the	O
AS	O
##S	O
##1	O
is	O
associated	O
with	O
poor	O
outcomes	O
.	O

Therefore	O
,	O
the	O
accumulation	O
of	O
la	B
##ct	I
##ate	I
could	O
be	O
an	O
index	O
of	O
tissue	O
h	O
##y	O
##pox	O
##ia	O
and	O
extent	O
of	O
ne	O
##c	O
##rosis	O
as	O
the	O
infection	O
progresses	O
.	O

Path	O
##way	O
analysis	O
of	O
the	O
differential	O
meta	O
##bol	O
##ites	O
:	O
(	O
A	O
)	O
gal	B
##act	I
##ose	I
metabolism	O
was	O
significantly	O
affected	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
,	O
impact	O
>	O
0	O
and	O
false	O
discovery	O
rate	O
(	O
F	O
##DR	O
)	O
<	O
0	O
.	O
1	O
)	O
;	O
(	O
B	O
)	O
meta	O
##bol	O
##ite	O
–	O
meta	O
##bol	O
##ite	O
interaction	O
analysis	O
of	O
the	O
differential	O
meta	O
##bol	O
##ites	O
.	O

PC	B
a	I
##e	I
C	I
##36	I
:	I
1	I
;	O
69	O
.	O

Our	O
analyses	O
identified	O
primary	O
and	O
secondary	O
bi	O
##le	O
acids	O
for	O
which	O
pre	O
##tre	O
##at	O
##ment	O
concentrations	O
were	O
correlated	O
with	O
on	O
-	O
treatment	O
plasma	O
si	B
##m	I
##vas	I
##tat	I
##in	I
acid	I
levels	O
.	O

Twenty	O
-	O
three	O
meta	O
##bol	O
##ites	O
contributed	O
to	O
the	O
separation	O
,	O
notably	O
an	O
increase	O
in	O
ad	O
##eno	O
##ma	O
cases	O
of	O
the	O
inflammatory	O
meta	O
##bol	O
##ite	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	I
##2	I
and	O
a	O
decrease	O
in	O
anti	O
##ox	O
##ida	O
##nt	O
-	O
related	O
meta	O
##bol	O
##ites	O
5	B
-	I
o	I
##x	I
##op	I
##rol	I
##ine	I
and	O
di	O
##ket	O
##og	O
##ulon	O
##ic	O
acid	O
.	O

In	O
addition	O
to	O
the	O
c	O
##y	O
##c	O
##lo	O
##arte	O
##no	O
##l	O
##→	O
##er	O
##gos	O
##tero	O
##l	O
bio	O
##sy	O
##nt	O
##hetic	O
route	O
,	O
our	O
data	O
suggest	O
a	O
route	O
leading	O
to	O
de	O
no	O
##vo	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
with	O
a	O
single	O
,	O
yet	O
to	O
be	O
experimental	O
##ly	O
observed	O
,	O
en	O
##zy	O
##matic	O
step	O
separating	O
N	O
.	O

Studies	O
have	O
shown	O
that	O
le	B
##uc	I
##ine	I
-	I
is	I
##ole	I
##uc	I
##ine	I
plays	O
an	O
active	O
role	O
in	O
in	O
##hibit	O
##ing	O
an	O
excessive	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
and	O
ex	O
##ci	O
##to	O
##to	O
##xi	O
##city	O
induced	O
by	O
stroke	O
,	O
and	O
it	O
is	O
also	O
an	O
important	O
component	O
of	O
energy	O
metabolism	O
.	O

After	O
de	O
##ple	O
##tion	O
of	O
the	O
he	O
##pa	O
##tic	O
g	B
##ly	I
##co	I
##gen	I
stores	O
,	O
glucose	S
is	O
formed	O
in	O
liver	O
cells	O
from	O
non	O
-	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
precursor	O
##s	O
such	O
as	O
la	B
##ct	I
##ate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
amino	O
acids	O
.	O

Additionally	O
,	O
patients	O
with	O
a	O
greater	O
response	O
to	O
vitamin	B
D	I
supplement	O
##ation	O
tended	O
to	O
have	O
lower	O
concentrations	O
of	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
,	O
as	O
shown	O
in	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

According	O
to	O
this	O
analysis	O
,	O
we	O
focused	O
on	O
p	B
##oly	I
##amine	I
##s	I
as	O
potential	O
bio	O
##mark	O
##ers	O
,	O
as	O
these	O
were	O
the	O
abundant	O
meta	O
##bol	O
##ites	O
identified	O
in	O
the	O
CR	O
##C	O
group	O
.	O

Therefore	O
,	O
these	O
compounds	O
were	O
tentatively	O
identified	O
for	O
the	O
selected	O
o	B
##lan	I
##za	I
##pine	I
,	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
and	O
que	B
##tia	I
##pine	I
signals	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
##s	O
–	O
;	O
non	O
-	O
identified	O
m	O
/	O
z	O
signals	O
are	O
provided	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
)	O
.	O

Re	O
##ceive	O
##r	O
operating	O
characteristics	O
for	O
individual	O
s	O
##tero	O
##id	O
meta	O
##bol	O
##ites	O
with	O
sensitivity	O
for	O
detect	O
##ing	O
ACC	O
>	O
90	O
%	O
AU	O
##C	O
area	O
under	O
curve	O
,	O
T	O
##HS	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
-	I
11	I
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
P	O
##2	O
pre	B
##gna	I
##ned	I
##iol	I
,	O
P	O
##3	O
pre	B
##gna	I
##net	I
##rio	I
##l	I
,	O
E	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
,	O
A	O
and	B
##ros	I
##tero	I
##ne	I
,	O
T	O
##HF	O
te	B
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
THE	O
te	B
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##ison	I
##e	I
,	O
PD	O
##L	O
pre	O
##gna	O
##ned	O
##iol	O
##on	O
,	O
11	O
-	O
K	O
##E	O
11	B
-	I
k	I
##eto	I
-	I
et	I
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
,	O
11	O
-	O
H	O
##A	O
11	B
-	I
h	I
##ydro	I
##xy	I
-	I
and	I
##ros	I
##tero	I
##ne	I
,	O
11	O
-	O
H	O
##E	O
11	B
-	I
h	I
##ydro	I
##xy	I
-	I
et	I
##ich	I
##ola	I
##no	I
##lone	I
,	O
Polo	B
##ne	I
e	I
##pi	I
-	I
pre	I
##gna	I
##no	I
##lone	I
a	O
–	O
d	O
.	O
Re	O
##ceive	O
##r	O
operating	O
characteristic	O
(	O
R	O
##OC	O
)	O
curve	O
for	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
-	I
11	I
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
pre	B
##gna	I
##ned	I
##iol	I
,	O
pre	B
##gna	I
##net	I
##rio	I
##l	I
,	O
and	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
for	O
the	O
diagnosis	O
of	O
ad	O
##ren	O
##oc	O
##ort	O
##ical	O
car	O
##cin	O
##oma	O
a	O
–	O
d	O
.	O
Relations	O
##hip	O
between	O
cut	O
-	O
off	O
values	O
,	O
reference	O
values	O
,	O
and	O
measured	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
-	I
11	I
-	I
de	I
##ox	I
##y	I

The	O
qualified	O
participants	O
without	O
a	O
self	O
-	O
reported	O
history	O
of	O
T	O
##2	O
##D	O
were	O
given	O
a	O
2	O
-	O
hour	O
75	O
-	O
g	O
oral	O
glucose	S
tolerance	O
test	O
.	O

Although	O
changes	O
in	O
the	O
abundance	O
of	O
2	O
compounds	O
(	O
Pro	O
##pan	O
##oi	O
##c	O
acid	O
,	O
2	B
-	I
(	I
met	I
##ho	I
##xy	I
##im	I
##ino	I
)	I
-	I
,	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
est	I
##er	I
and	O
Non	B
##ano	I
##ic	I
acid	I
,	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
est	I
##er	I
)	O
were	O
statistical	O
##ly	O
significant	O
(	O
un	O
##ad	O
##ju	O
##sted	O
p	O
-	O
values	O
≤	O
0	O
.	O
05	O
)	O
in	O
a	O
paired	O
-	O
sample	O
comparison	O
of	O
patients	O
before	O
and	O
after	O
treatment	O
,	O
they	O
failed	O
to	O
meet	O
the	O
established	O
criterion	O
of	O
F	O
##DR	O
.	O

[	O
fast	O
##ing	O
serum	O
insulin	O
(	O
μ	O
##U	O
/	O
m	O
##L	O
)	O
×	O
fast	O
##ing	O
blood	O
glucose	S
(	O
mm	O
##ol	O
/	O
L	O
)	O
]	O
/	O
22	O
.	O
5	O
.	O

The	O
extent	O
to	O
which	O
circulating	O
T	O
##CA	O
cycle	O
or	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
accurately	O
reflect	O
mitochondrial	O
d	O
##ys	O
##function	O
in	O
P	O
##H	O
will	O
be	O
an	O
important	O
area	O
of	O
future	O
investigation	O
.	O

=	O
0	O
.	O
26	O
)	O
and	O
significantly	O
,	O
at	O
the	O
met	B
##hyl	I
##ene	I
single	O
##t	O
at	O
4	O
.	O
06	O
pp	O
##m	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

As	O
shown	O
in	O
Table	O
,	O
significant	O
elevation	O
of	O
11	O
out	O
of	O
34	O
GT	O
##As	O
analyzed	O
were	O
seen	O
in	O
R	O
##R	O
##MS	O
patients	O
with	O
disease	O
duration	S
less	O
than	O
13	O
years	O
(	O
vs	O
controls	O
)	O
.	O

For	O
example	O
,	O
DE	O
##SI	O
-	O
MS	O
##I	O
of	O
test	O
##icular	O
cancer	O
##s	O
revealed	O
that	O
lip	O
##ids	O
from	O
a	O
specific	O
class	O
exclusive	O
to	O
g	O
##er	O
##m	O
line	O
cells	O
,	O
the	O
semi	O
##no	O
##lip	O
##ids	O
[	O
semi	O
##no	O
##lip	O
##id	O
(	O
16	O
:	O
0	O
/	O
16	O
:	O
0	O
)	O
and	O
semi	B
##no	I
-	I
lip	I
##id	I
(	I
30	I
:	I
0	I
)	I
]	O
,	O
were	O
present	O
in	O
normal	O
tub	O
##ule	O
test	O
##is	O
tissue	O
while	O
und	O
##ete	O
##ct	O
##able	O
in	O
semi	O
##no	O
##ma	O
tissue	O
.	O

In	O
MS	O
/	O
MS	O
mode	O
,	O
scan	O
type	O
was	O
product	O
ion	O
,	O
accumulation	O
time	O
was	O
1	O
.	O
000	O
##0	O
s	O
,	O
scan	O
range	O
between	O
50	O
and	O
650	O
Da	O
and	O
duration	S
time	O
55	O
min	O
.	O

Alan	B
##ine	I
and	O
g	B
##lut	I
##ama	I
##te	I
were	O
absent	O
in	O
D	O
##ME	O
##M	O
and	O
24	O
h	O
D	O
##ME	O
##M	O
but	O
were	O
clearly	O
perceived	O
in	O
the	O
Co	O
##m	O
.	O

Path	O
##ways	O
with	O
F	O
##DR	O
<	O
0	O
.	O
3	O
are	O
listed	O
below	O
Multi	O
##var	O
##iate	O
re	O
##gression	O
analysis	O
of	O
post	O
-	O
treatment	O
levels	O
resulted	O
in	O
two	O
meta	O
##bol	O
##ites	O
with	O
a	O
significant	O
inverse	O
relationship	O
to	O
glucose	S
post	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
:	O
a	O
u	O
##rid	O
##ine	O
-	O
like	O
compound	O
(	O
negative	O
correlation	O
)	O
and	O
gal	B
##act	I
##osy	I
##l	I
-	I
g	I
##ly	I
##cer	I
##ate	I
(	O
negative	O
correlation	O
)	O

Finally	O
,	O
we	O
identified	O
L	B
##ys	I
##o	I
##PC	I
(	I
22	I
:	I
6	I
)	I
as	O
a	O
potential	O
LA	O
##A	O
bio	O
##mark	O
##er	O
.	O

B	O
##rief	O
##ly	O
,	O
proteins	O
of	O
plasma	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
by	O
adding	O
met	B
##han	I
##ol	I
including	O
internal	O
standards	O
.	O

The	O
samples	O
were	O
di	O
##lut	O
##ed	O
in	O
1	O
:	O
10	O
in	O
di	O
##st	O
##ille	O
##d	O
water	O
before	O
HP	S
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

A	O
similar	O
increase	O
of	O
serum	O
C	B
##15	I
:	I
0	I
at	O
1	O
year	O
post	O
‐	O
R	O
##Y	O
##GB	O
has	O
been	O
previously	O
reported	O
.	O
11	O
P	O
##las	O
##ma	O
odd	O
chain	O
saturated	O
FA	S
(	O
such	O
as	O
C	B
##15	I
:	I
0	I
and	O
C	B
##17	I
:	I
0	I
)	O
have	O
a	O
positive	O
association	O
with	O
dairy	O
fat	O
intake	O
while	O
an	O
inverse	O
association	O
exists	O
with	O
development	O
of	O
card	O
##iovascular	O
disease	O
and	O
type	O
2	O
diabetes	O
.	O
33	O
Therefore	O
,	O
elevation	O
of	O
C	B
##15	I
:	I
0	I
post	O
‐	O
R	O
##Y	O
##GB	O
may	O
be	O
due	O
to	O
changes	O
in	O
diet	O
##ary	O
patterns	O
and	O
may	O
be	O
associated	O
with	O
improved	O
card	O
##iovascular	O
health	O
.	O

The	O
accumulation	O
of	O
a	O
large	O
amount	O
of	O
p	B
##yr	I
##u	I
##vate	I
promotes	O
the	O
reaction	O
shift	O
between	O
p	B
##yr	I
##u	I
##vate	I
and	O
al	B
##ani	I
##ne	I
synthesis	O
,	O
resulting	O
in	O
elevated	O
al	B
##ani	I
##ne	I
in	O
the	O
ma	O
##li	O
##gnant	O
tumor	O
in	O
the	O
body	O
.	O

These	O
findings	O
agree	O
with	O
earlier	O
reports	O
connecting	O
larger	O
V	O
##LD	O
##L	O
particles	O
with	O
lower	O
insulin	O
sensitivity	O
,	O
worse	O
g	B
##ly	I
##ce	I
##mic	I
control	O
and	O
higher	O
T	O
##2	O
##DM	O
risk	O
[	O
,	O
]	O
.	O

The	O
men	O
had	O
undergone	O
complete	O
historical	O
and	O
physical	O
examinations	O
and	O
measurement	O
of	O
hormones	O
as	O
well	O
as	O
routine	O
se	O
##men	O
analysis	O
;	O
their	O
partners	O
had	O
undergone	O
complete	O
historical	O
and	O
physical	O
examinations	O
,	O
including	O
conventional	O
g	O
##yne	O
##cological	O
examination	O
,	O
serum	O
hormone	O
level	O
measurements	O
,	O
tub	O
##al	O
assessment	O
,	O
o	O
##var	O
##ian	O
function	O
testing	O
,	O
h	O
##yster	O
##os	O
##copy	O
,	O
β	B
-	I
ultra	I
##sonic	I
examination	O
,	O
im	O
##mu	O
##no	O
##log	O
##ic	O
test	O
,	O
micro	O
##bial	O
inspection	O
,	O
and	O
ka	O
##ryo	O
##type	O
analysis	O
.	O

Majority	O
of	O
the	O
species	O
identified	O
are	O
in	O
the	O
class	O
of	O
T	B
##G	I
,	O
PC	O
,	O
SM	O
,	O
P	O
##E	O
,	O
and	O
LP	O
##C	O
,	O
which	O
is	O
proportional	O
to	O
the	O
composition	O
of	O
lip	O
##id	O
library	O
.	O

One	O
clinical	O
study	O
has	O
shown	O
that	O
lowering	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
in	O
plasma	O
by	O
Vita	B
##min	I
B	I
##12	I
slow	O
##s	O
the	O
rate	O
of	O
brain	O
at	O
##rop	O
##hy	O
,	O
however	O
without	O
effect	O
on	O
cognitive	O
parameters	O
.	O

Interest	O
##ingly	O
,	O
even	O
u	O
##rina	O
##ry	O
si	B
##ali	I
##c	I
acid	I
levels	O
rose	O
under	O
inflammatory	O
conditions	O
,	O
particularly	O
in	O
respect	O
to	O
fi	O
##bri	O
##no	O
##gen	O
levels	O
but	O
also	O
to	O
h	O
##s	O
##CR	O
##P	O
within	O
the	O
present	O
study	O
.	O

PC	O
was	O
the	O
largest	O
number	O
in	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
class	O
and	O
PC	B
(	I
34	I
:	I
2	I
;	I
16	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
was	O
the	O
most	O
abundant	O
PC	O
.	O

The	O
c	B
##rea	I
##tin	I
##ine	I
corrected	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
concentrations	O
were	O
used	O
in	O
the	O
study	O
as	O
per	O
World	O
Health	O
Organization	O
guidelines	O
and	O
mentioned	O
in	O
the	O
earlier	O
reference	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
pro	O
##fi	O
##ling	O
by	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
found	O
that	O
the	O
serum	O
levels	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
2	O
-	O
H	O
##B	O
)	O
,	O
3	B
-	I
h	I
##yd	I
##ox	I
##y	I
##but	I
##yra	I
##te	I
(	O
3	O
-	O
H	O
##B	O
)	O
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##it	I
##rate	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
were	O
higher	O
in	O
patients	O
who	O
died	O
within	O
3	O
months	O
compared	O
to	O
those	O
who	O
were	O
alive	O
3	O
months	O
after	O
onset	O
of	O
A	O
##HF	O
,	O
which	O
was	O
confirmed	O
by	O
un	O
##iva	O
##ria	O
##ble	O
log	O
##istic	O
re	O
##gression	O
analyses	O
(	O
p	O
=	O
0	O
.	O
00	O
##9	O
,	O
p	O
=	O
0	O
.	O
00	O
##5	O
,	O
p	O
=	O
0	O
.	O
00	O
##8	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
and	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
respectively	O
)	O
.	O

Un	O
##ique	O
positive	O
associations	O
regarding	O
VA	O
##T	O
and	O
urine	O
meta	O
##bol	O
##ites	O
in	O
women	O
included	O
several	O
s	O
##tero	O
##ids	O
,	O
e	O
.	O
g	O
.	O
te	B
##tra	I
##hy	I
##dr	I
##oc	I
##rot	I
##ison	I
##e	I
and	O
likely	O
related	O
unknown	O
compounds	O
as	O
indicated	O
from	O
the	O
estimated	O
metabolic	O
network	O
(	O
see	O
Method	O
##s	O
,	O
Fi	O
##gs	O
.	O

A	O
gradient	O
of	O
mobile	O
phase	O
consisting	O
100	O
%	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
Sol	O
##vent	O
A	O
)	O
,	O
100	O
%	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
Sol	O
##vent	O
B	O
)	O
was	O
resolved	O
for	O
12	O
minutes	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
4	O
m	O
##l	O
/	O
min	O
.	O

Val	B
##ine	I
,	O
together	O
with	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
belong	O
to	O
the	O
branched	O
-	O
chain	O
amino	O
acids	O
class	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
alternative	O
energy	O
supply	O
of	O
cancer	O
cells	O
[	O
,	O
]	O
.	O

Eleven	O
cancer	O
patients	O
,	O
six	O
females	O
and	O
five	O
males	O
aged	O
30	O
–	O
81	O
,	O
treated	O
with	O
m	B
##or	I
##phine	I
in	O
slow	O
-	O
release	O
tablets	O
(	O
Do	O
##l	O
##con	O
##tin	O
,	O
P	O
##fi	O
##zer	O
,	O
New	O
York	O
,	O
NY	O
)	O
or	O
treated	O
with	O
m	B
##or	I
##phine	I
via	O
continuous	O
,	O
sub	O
##cut	O
##aneous	O
in	O
##fusion	O
with	O
a	O
C	O
##ad	O
##d	O
-	O
Legacy	O
pump	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
a	O
linear	O
gradient	O
el	O
##ution	O
,	O
previously	O
described	O
,	O
and	O
was	O
performed	O
at	O
0	O
.	O
4	O
m	O
##L	O
/	O
min	O
using	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Am	O
##ino	O
acids	O
,	O
such	O
as	O
Ph	O
##e	O
,	O
Pro	O
,	O
Al	O
##a	O
,	O
L	O
##ys	O
,	O
5	B
-	I
o	I
##x	I
##o	I
-	I
Pro	I
,	O
Val	O
,	O
Le	O
##u	O
,	O
and	O
Or	O
##n	O
,	O
were	O
also	O
over	O
##re	O
##p	O
##res	O
##ented	O
in	O
the	O
CR	O
##C	O
group	O
.	O

C	B
##rea	I
##tine	I
has	O
a	O
direct	O
function	O
in	O
cellular	O
energy	O
transport	O
,	O
and	O
it	O
may	O
be	O
that	O
c	B
##rea	I
##tine	I
is	O
elevated	O
in	O
rapidly	O
growing	O
cells	O
;	O
and	O
,	O
indeed	O
,	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tine	I
levels	O
may	O
be	O
increased	O
24	O
h	O
after	O
partial	O
he	O
##pate	O
##ct	O
##omy	O
in	O
rats	O
[	O
]	O
.	O

Known	O
to	O
be	O
involved	O
in	O
the	O
degradation	O
of	O
th	B
##re	I
##oni	I
##ne	I
and	O
also	O
be	O
converted	O
to	O
su	O
##cci	O
##ny	O
##l	O
Co	O
##A	O
and	O
enter	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
,	O
this	O
compound	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
plant	O
defense	O
.	O

Alan	B
##ine	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
,	O
l	B
##ys	I
##ine	I
metabolism	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
amino	S
sugar	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
metabolism	O
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
,	O
l	B
##ys	I
##ine	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
metabolism	O
,	O
resulted	O
in	O
the	O
most	O
relevant	O
meta	O
##bol	O
##ome	O
views	O
potentially	O
involved	O
in	O
the	O
observed	O
variation	O
of	O
EA	O
##R	O
and	O
AD	O
##V	O
HC	O
##C	O
serum	O
meta	O
##bol	O
##ites	O
,	O
according	O
to	O
the	O
p	O
-	O
value	O
(	O
−	O
##log	O
(	O
p	O
)	O
)	O
and	O
the	O
impact	O
value	O
.	O

Selected	O
ion	O
monitoring	O
ch	O
##roma	O
##to	O
##gram	O
for	O
50	O
ng	O
/	O
m	O
##L	O
of	O
GP	S
(	O
m	O
/	O
z	O
,	O
44	O
##6	O
.	O
2	O
)	O
(	O
E	O
)	O
.	O

NE	O
##FA	O
was	O
extracted	O
using	O
a	O
scaled	O
-	O
down	O
Do	O
##le	O
extraction	O
,	O
followed	O
by	O
der	O
##iva	O
##ti	O
##zation	O
to	O
its	O
corresponding	O
N	B
,	I
N	I
,	I
N	I
-	I
trim	I
##eth	I
##yle	I
##thy	I
##lene	I
##dia	I
##mine	I
(	O
T	O
##ME	O
##N	O
)	O
i	B
##od	I
##ide	I
salt	I
by	O
a	O
method	O
similar	O
to	O
that	O
described	O
by	O
Johnson	O
for	O
the	O
trim	B
##eth	I
##yla	I
##min	I
##oe	I
##thy	I
##les	I
##ter	I
i	I
##od	I
##ide	I
salt	I
(	O
,	O
)	O
.	O

Additionally	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
correlated	O
well	O
with	O
cell	O
invasive	O
##ness	O
(	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
coefficient	O
:	O
0	O
.	O
94	O
##3	O
,	O
P	O
=	O
0	O
.	O
00	O
##48	O
)	O
.	O

The	O
largest	O
portion	O
of	O
the	O
class	O
of	O
substances	O
ex	O
##cre	O
##ted	O
in	O
urine	O
was	O
k	B
##eton	I
##es	I
(	O
21	O
.	O
0	O
%	O
)	O
,	O
followed	O
by	O
te	B
##rp	I
##ene	I
##s	I
(	O
16	O
.	O
0	O
%	O
)	O
and	O
fur	O
##ans	O
(	O
14	O
.	O
8	O
%	O
)	O
.	O

Based	O
on	O
our	O
results	O
,	O
we	O
s	O
##pec	O
##ulate	O
that	O
AD	O
##V	O
patients	O
might	O
have	O
increased	O
la	B
##ct	I
##ate	I
u	O
##til	O
##ization	O
,	O
or	O
alternatively	O
a	O
decreased	O
glucose	S
metabolism	O
to	O
la	B
##ct	I
##ate	I
,	O
considering	O
the	O
higher	O
serum	O
glucose	S
level	O
in	O
AD	O
##V	O
with	O
respect	O
to	O
EA	O
##R	O
patients	O
.	O

S	O
##pect	O
##ros	O
##copy	O
grade	O
met	B
##han	I
##ol	I
,	O
ch	B
##lor	I
##of	I
##orm	I
,	O
and	O
to	B
##lue	I
##ne	I
were	O
obtained	O
from	O
Ted	O
##ia	O
.	O

Su	B
##c	I
##rose	I
(	O
B	O
##io	O
##X	O
##tra	O
,	O
purity	O
≥	O
99	O
.	O
5	O
%	O
)	O
,	O
d	B
-	I
(	I
+	I
)	I
-	I
glucose	I
(	O
purity	O
99	O
.	O
5	O
%	O
)	O
,	O
hip	B
##pur	I
##ic	I
acid	I
(	O
purity	O
98	O
%	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
purity	O
≥	O
99	O
%	O
)	O
,	O
d	B
-	I
al	I
##ani	I
##ne	I
(	O
purity	O
≥	O
99	O
%	O
)	O
,	O
sodium	O
a	O
##zi	O
##de	O
(	O
B	O
##io	O
##X	O
##tra	O
)	O
,	O
sodium	B
phosphate	I
di	O
##bas	O
##ic	O
(	O
purity	O
≥	O
99	O
.	O
0	O
%	O
)	O
,	O
and	O
ni	B
##tric	I
acid	I
(	O
purity	O
≥	O
65	O
%	O
)	O
were	O
obtained	O
from	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
(	O
B	O
##uch	O
##s	O
,	O
Switzerland	O
)	O
.	O

These	O
C	O
_	O
27	O
bi	O
##le	O
acids	O
could	O
originate	O
in	O
plasma	O
and	O
be	O
transferred	O
to	O
CS	O
##F	O
or	O
alternatively	O
be	O
formed	O
in	O
brain	O
from	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
,	O
)	O
,	O
which	O
is	O
itself	O
suggested	O
to	O
be	O
imported	O
into	O
brain	O
from	O
plasma	O
.	O

In	O
humans	O
,	O
R	O
##EG	O
is	O
a	O
C	O
##YP	O
##3	O
##A	O
##4	O
substrate	O
and	O
primarily	O
meta	O
##bol	O
##ized	O
in	O
the	O
liver	O
to	O
form	O
two	O
meta	O
##bol	O
##ites	O
,	O
a	O
N	B
-	I
oxide	I
derivative	O
and	O
a	O
dem	B
##eth	I
##yla	I
##ted	I
N	I
-	I
oxide	I
derivative	O
with	O
similar	O
kinase	O
inhibitor	O
##y	O
properties	O
.	O

s	O
##E	O
##H	O
in	O
##hibition	O
is	O
associated	O
with	O
anti	O
-	O
inflammatory	O
and	O
vascular	O
relaxation	O
properties	O
mediated	O
by	O
elevated	O
e	B
##pox	I
##ides	I
such	O
as	O
E	O
##ET	O
##s	O
and	O
E	O
##p	O
##OM	O
##Es	O
.	O

Although	O
serum	O
is	O
widely	O
used	O
in	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
studies	O
as	O
an	O
indicator	O
of	O
ta	B
##uri	I
##ne	I
status	O
in	O
the	O
human	O
body	O
,	O
urine	O
is	O
less	O
expensive	O
and	O
more	O
convenient	O
to	O
collect	O
.	O

Co	O
##mp	O
##ens	O
##ation	O
mechanisms	O
can	O
increase	O
the	O
activity	O
of	O
the	O
remaining	O
neurons	O
to	O
an	O
extent	O
that	O
the	O
levels	O
of	O
do	B
##pa	I
##mine	I
or	O
H	O
##VA	O
in	O
CS	O
##F	O
appear	O
unchanged	O
until	O
late	O
into	O
the	O
course	O
of	O
the	O
disease	O
.	O

A	O
detailed	O
analysis	O
of	O
this	O
pathway	O
also	O
shows	O
a	O
significant	O
increase	O
in	O
its	O
first	O
products	O
,	O
such	O
as	O
AM	B
##P	I
or	O
I	B
##MP	I
;	O
Fi	O
##g	O
.	O

They	O
employed	O
this	O
system	O
to	O
determine	O
the	O
competitive	O
fitness	O
of	O
a	O
panel	O
of	O
cell	O
lines	O
culture	O
##d	O
simultaneously	O
in	O
glucose	O
-	O
depleted	O
media	O
and	O
found	O
that	O
cells	O
harbor	O
##ing	O
def	O
##ici	O
##encies	O
in	O
o	O
##xi	O
##da	O
##tive	O
capacity	O
had	O
compromised	O
fitness	O
in	O
the	O
presence	O
of	O
low	O
glucose	S
.	O

We	O
further	O
performed	O
S	O
##pear	O
##man	O
correlation	O
analysis	O
between	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
and	O
Child	O
-	O
P	O
##ugh	O
scores	O
,	O
as	O
well	O
as	O
AL	O
##T	O
,	O
AS	O
##T	O
,	O
T	O
##BI	O
##L	O
,	O
DB	O
##IL	O
,	O
AL	O
##P	O
,	O
G	O
##G	O
##T	O
,	O
T	O
##P	O
,	O
AL	O
##B	O
,	O
L	O
##D	O
##H	O
,	O
T	O
##BA	O
,	O
CH	O
##E	O
,	O
T	O
##C	O
,	O
T	B
##G	I
,	O
CR	O
##EA	O
,	O
G	O
##L	O
##U	O
,	O
PT	O
,	O
IN	O
##R	O
,	O
A	O
##FP	O
,	O
CE	O
##A	O
,	O
V	O
##ira	O
##l	O
load	O
,	O
RB	O
##C	O
,	O
H	O
##GB	O
,	O
and	O
P	O
##LT	O
.	O

Try	B
##pt	I
##op	I
##han	I
was	O
decreased	O
in	O
all	O
five	O
cancer	O
##s	O
in	O
Mi	O
##ya	O
##gi	O
’	O
s	O
study	O
,	O
which	O
we	O
also	O
identified	O
as	O
decreasing	O
in	O
our	O
two	O
studies	O
.	O

The	O
mass	O
spectrum	O
of	O
G	O
##L	O
##Y	O
,	O
GP	S
(	O
25	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
M1	O
and	O
M	O
##2	O
(	O
10	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
was	O
determined	O
by	O
direct	O
injection	O
of	O
neat	O
solutions	O
of	O
each	O
compound	O
in	O
1	O
:	O
1	O
met	O
##han	O
##ol	O
:	O
water	O
into	O
a	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
set	O
in	O
a	O
positive	O
ion	O
mode	O
.	O

While	O
it	O
was	O
not	O
feasible	O
to	O
obtain	O
stable	O
is	O
##oto	O
##pe	O
-	O
labeled	O
internal	O
standards	O
for	O
the	O
nine	O
meta	O
##bol	O
##ites	O
being	O
monitored	O
,	O
ch	B
##lor	I
##o	I
-	I
ATP	I
was	O
used	O
to	O
correct	O
for	O
sample	O
processing	O
and	O
standard	O
curves	O
,	O
and	O
quality	O
control	O
samples	O
were	O
prepared	O
in	O
a	O
human	O
liver	O
section	O
from	O
a	O
donor	O
not	O
on	O
therapy	O
,	O
obtained	O
from	O
Life	O
Technologies	O
.	O

2	O
##ei	O
2	O
##ei	O
2	O
e	B
##i	I
e	I
##i	I
e	O
e	O
i	O
i	O
k	O
##i	O
(	O
k	O
##i	O
##−	O
##1	O
)	O
k	O
##i	O
(	O
k	O
##i	O
##−	O
##1	O
)	O

Furthermore	O
,	O
x	B
##ant	I
##hine	I
produced	O
from	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
by	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
was	O
also	O
lower	O
in	O
NHL	O
urine	O
##s	O
,	O
and	O
showed	O
a	O
similar	O
NHL	O
-	O
disc	O
##rim	O
##inating	O
power	O
(	O
76	O
.	O
0	O
%	O
specific	O
##ity	O
and	O
78	O
.	O
1	O
%	O
sensitivity	O
;	O
Figure	O
)	O
.	O

For	O
g	B
##ly	I
##cola	I
##te	I
,	O
the	O
in	O
##tra	O
-	O
and	O
inter	O
##day	O
precision	O
C	O
##Vs	O
were	O
<	O
2	O
.	O
4	O
%	O
and	O
<	O
2	O
.	O
2	O
%	O
,	O
respectively	O
.	O

Using	O
AN	O
##O	O
##VA	O
,	O
co	B
##tin	I
##ine	I
was	O
higher	O
in	O
smoke	O
##rs	O
compared	O
to	O
non	O
-	O
smoke	O
##rs	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
to	O
former	O
smoke	O
##rs	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
has	O
been	O
reported	O
in	O
other	O
disease	O
conditions	O
ranging	O
from	O
HIV	O
to	O
cancer	O
_	O
,	O
.	O

5	B
-	I
o	I
##x	I
##op	I
##rol	I
##ine	I
is	O
involved	O
in	O
the	O
metabolism	O
of	O
g	B
##lut	I
##ath	I
##ione	I
,	O
a	O
major	O
anti	O
##ox	O
##ida	O
##nt	O
,	O
in	O
both	O
synthetic	O
and	O
de	O
##grad	O
##ative	O
pathways	O
.	O

At	O
the	O
concentration	O
of	O
25	O
ng	O
/	O
m	O
##L	O
,	O
625	O
p	B
##g	I
of	O
each	O
was	O
injected	O
on	O
column	O
and	O
80	O
%	O
or	O
500	O
p	B
##g	I
was	O
directed	O
to	O
the	O
EC	O
-	O
array	O
.	O

In	O
the	O
study	O
by	O
Gao	O
et	O
al	O
.	O
,	O
higher	O
levels	O
of	O
AAA	O
were	O
associated	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
HC	O
##C	O
,	O
together	O
with	O
lower	O
levels	O
of	O
BC	O
##AA	O
,	O
ch	B
##olin	I
##e	I
,	O
and	O
un	O
##sat	O
##ura	O
##ted	O
lip	O
##ids	O
.	O

GA	O
##BR	O
may	O
serve	O
as	O
a	O
more	O
comprehensive	O
concept	O
of	O
reduced	O
NO	O
synthetic	O
capacity	O
compared	O
to	O
systemic	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
.	O

Al	O
##b	O
contains	O
17	O
in	O
##tra	O
##cha	O
##in	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
,	O
which	O
makes	O
the	O
protein	O
resistant	O
to	O
den	O
##at	O
##uration	O
.	O
_	O
,	O
For	O
dig	O
##est	O
##ion	O
with	O
try	O
##ps	O
##in	O
or	O
other	O
se	B
##rine	I
pro	O
##te	O
##ases	O
,	O
Al	O
##b	O
is	O
commonly	O
den	O
##ature	O
##d	O
by	O
heat	O
treatment	O
at	O
50	O
–	O
60	O
°C	O
,	O
and	O
internal	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
are	O
reduced	O
with	O
di	B
##thi	I
##oth	I
##re	I
##ito	I
##l	I
or	O
t	B
##ris	I
(	I
2	I
-	I
car	I
##box	I
##ye	I
##thy	I
##l	I
)	I
p	I
##hos	I
##phine	I
in	O
the	O
presence	O
of	O
den	O
##at	O
##ura	O
##nts	O
,	O
followed	O
by	O
al	O
##ky	O
##lation	O
of	O
the	O
newly	O
formed	O
su	O
##lf	O
##hy	O
##dr	O
##yl	O
groups	O
with	O
i	B
##od	I
##oa	I
##ce	I
##tam	I
##ide	I
,	O
to	O
expose	O
as	O
many	O
sites	O
as	O
possible	O
prior	O
to	O
pro	O
##te	O
##oly	O
##tic	O
dig	O
##est	O
##ion	O
.	O
_	O
,	O
The	O
pro	O
##te	O
##oly	O
##tic	O
dig	O
##est	O
##ion	O
of	O
Al	O
##b	O
produces	O
p	O
##oly	O
##pe	O
##pt	O
##ides	O
of	O
various	O
lengths	O
according	O
to	O
the	O
specific	O
##ity	O
of	O
the	O
enzymes	O
employed	O
.	O

3	B
-	I
(	I
N	I
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##yl	I
)	I
p	I
##hen	I
##ant	I
##hren	I
##e	I
su	I
##lf	I
##oxide	I
(	O
15	O
)	O
.	O

Compared	O
to	O
Place	O
##bo	O
,	O
metabolic	O
flexibility	O
was	O
improved	O
by	O
all	O
interventions	O
in	O
the	O
following	O
order	O
of	O
effect	O
:	O
Pi	B
##o	I
<	I
Omega	I
-	I
3	I
<	I
Pi	I
##o	I
&	I
Omega	I
-	I
3	I
(	O
see	O
the	O
PR	O
##CF	O
curve	O
shifts	O
in	O
the	O
legend	O
to	O
Fi	O
##g	O
.	O

The	O
method	O
was	O
originally	O
developed	O
for	O
the	O
analysis	O
of	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
and	O
five	O
related	O
compounds	O
in	O
plasma	O
samples	O
(	O
see	O
[	O
,	O
]	O
)	O
,	O
but	O
was	O
adapted	O
to	O
urine	O
and	O
extended	O
to	O
28	O
anal	O
##yte	O
##s	O
in	O
this	O
study	O
.	O

His	B
##ti	I
##dine	I
is	O
an	O
essential	O
amino	O
acid	O
involved	O
in	O
many	O
functions	O
in	O
the	O
body	O
;	O
it	O
controls	O
gene	O
expression	O
and	O
enzyme	O
activity	O
through	O
met	O
##hyl	O
##ation	O
.	O

Stock	O
solutions	O
(	O
1	O
mg	O
/	O
m	O
##L	O
)	O
for	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
(	O
5	O
-	O
H	O
##IA	O
##A	O
)	O
,	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
(	O
N	O
##AD	O
_	O
+	O
)	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
do	B
##pa	I
##mine	I
,	O
p	B
##ico	I
##lini	I
##c	I
acid	I
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
(	O
3	O
-	O
HK	O
)	O
,	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
β	B
-	I
ni	I
##cot	I
##ina	I
##mi	I
##de	I
mon	O
##on	O
##uc	O
##leo	O
##tide	O
(	O
β	O
##N	O
##M	O
)	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
rib	I
##os	I
##ide	I
were	O
dissolved	O
in	O
100	O
%	O
di	O
##lue	O
##nt	O
-	O
D	O
##1	O
.	O

It	O
has	O
recently	O
been	O
reported	O
that	O
the	O
protein	O
encoded	O
by	O
p	O
##53	O
(	O
T	O
##P	O
##53	O
)	O
interact	O
##s	O
with	O
s	O
##tero	O
##l	O
regulatory	O
element	O
-	O
binding	O
proteins	O
(	O
SR	O
##E	O
##B	O
##Ps	O
)	O
and	O
g	O
##uan	O
##id	O
##ino	O
##ace	O
##tate	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
GA	O
##MT	O
)	O
resulting	O
in	O
the	O
elevated	O
expression	O
of	O
enzymes	O
involved	O
in	O
fatty	O
acid	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
and	O
the	O
in	O
##hibition	O
of	O
fatty	O
acid	O
oxidation	O
leading	O
to	O
lip	O
##id	O
an	O
##ab	O
##olis	O
##m	O
and	O
accelerated	O
tumor	O
growth	O
and	O
progression	O
.	O

depicts	O
relative	O
concentrations	O
of	O
nine	O
meta	O
##bol	O
##ites	O
in	O
the	O
try	B
##pt	I
##op	I
##han	I
pathway	O
q	O
##uant	O
##ified	O
in	O
plasma	O
samples	O
from	O
G	O
##C	O
and	O
P	O
##L	O
##GC	O
patients	O
.	O

These	O
concentrations	O
may	O
also	O
have	O
been	O
influenced	O
by	O
more	O
recent	O
food	O
intake	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
because	O
plasma	O
try	B
##pt	I
##op	I
##han	I
also	O
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

El	O
##eva	O
##ted	O
circulating	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
specific	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
i	O
##rino	O
##teca	O
##n	O
-	O
induced	O
mitochondrial	O
d	O
##ys	O
##function	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
the	O
liver	O
.	O

On	O
one	O
hand	O
,	O
increased	O
format	B
##e	I
levels	O
(	O
compared	O
to	O
control	O
subjects	O
)	O
in	O
serum	O
of	O
UC	O
patients	O
are	O
in	O
accordance	O
with	O
increased	O
met	B
##han	I
##ol	I
levels	O
.	O

They	O
were	O
beta	B
##ine	I
(	O
m	O
/	O
z	O
118	O
.	O
08	O
##6	O
)	O
,	O
E	O
##SI	O
_	O
+	O
)	O
and	O
glucose	S
(	O
m	O
/	O
z	O
219	O
.	O
01	O
##6	O
,	O
E	O
##SI	O
_	O
+	O
)	O
.	O

Sep	O
##arate	O
working	O
can	B
##na	I
##bino	I
##ids	I
ca	O
##li	O
##bra	O
##tor	O
and	O
quality	O
control	O
stock	O
solutions	O
were	O
prepared	O
in	O
met	B
##han	I
##ol	I
.	O

MC	O
##RI	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
insulin	O
dose	O
over	O
the	O
in	O
##cre	O
##mental	O
area	O
under	O
the	O
curve	O
of	O
insulin	O
from	O
20	O
min	O
to	O
in	O
##finity	O
using	O
the	O
following	O
equation	O
:	O
where	O
Do	O
##se	O
represents	O
the	O
amount	O
of	O
insulin	O
injected	O
at	O
20	O
min	O
,	O
In	O
##s	O
(	O
t	O
)	O
the	O
plasma	O
insulin	O
concentration	O
in	O
standard	O
units	O
at	O
each	O
F	O
##SI	O
##G	O
##TT	O
sampling	O
point	O
,	O
and	O
In	O
##s	O
(	O
0	O
)	O
the	O
fast	O
##ing	O
plasma	O
insulin	O
concentration	O
determined	O
before	O
injection	O
of	O
glucose	S
in	O
the	O
F	O
##SI	O
##G	O
##TT	O
.	O

Sun	B
##iti	I
##ni	I
##b	I
is	O
an	O
oral	O
,	O
small	O
##mo	O
##le	O
##cule	O
,	O
multi	O
-	O
targeted	O
inhibitor	O
of	O
receptor	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
##s	O
(	O
e	O
.	O
g	O
.	O
,	O
plate	O
##let	O
-	O
derived	O
growth	O
factor	O
receptors	O
(	O
PD	O
##G	O
##F	O
##R	O
)	O
and	O
vascular	O
end	O
##oth	O
##eli	O
##al	O
growth	O
factor	O
receptors	O
(	O
V	O
##EG	O
##F	O
##R	O
)	O
)	O
,	O
some	O
of	O
which	O
are	O
implicated	O
in	O
t	O
##umour	O
growth	O
,	O
path	O
##olo	O
##gic	O
an	O
##gio	O
##genesis	O
,	O
and	O
meta	O
##static	O
progression	O
of	O
cancer	O
.	O

The	O
method	O
confirmed	O
significant	O
changes	O
in	O
the	O
levels	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
alpha	B
to	I
##co	I
##pher	I
##ol	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
so	B
##rb	I
##ose	I
in	O
HC	O
##C	O
cases	O
vs	O
.	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

Take	O
##n	O
together	O
,	O
S	O
##9	O
and	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
-	O
cells	O
show	O
largely	O
similar	O
metabolic	O
profiles	O
and	O
a	O
comparable	O
ad	B
##en	I
##yla	I
##te	I
energy	O
charge	O
of	O
0	O
.	O
96	O
for	O
S	O
##9	O
cells	O
and	O
0	O
.	O
95	O
for	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
which	O
is	O
in	O
##dicative	O
for	O
a	O
high	O
energy	O
status	O
of	O
both	O
cell	O
types	O
under	O
our	O
culture	O
conditions	O
.	O

The	O
tight	O
connection	O
to	O
fast	O
##ing	O
is	O
also	O
shown	O
by	O
the	O
strong	O
correlation	O
between	O
3	O
-	O
H	O
##IB	O
and	O
both	O
fast	O
##ing	O
glucose	S
and	O
insulin	O
.	O

Try	B
##pt	I
##op	I
##han	I
was	O
detected	O
at	O
lower	O
levels	O
in	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
combined	O
metabolic	O
profile	O
,	O
but	O
the	O
difference	O
reached	O
significance	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
only	O
in	O
one	O
of	O
the	O
anal	O
##ys	O
##ed	O
batch	O
##es	O
of	O
samples	O
.	O

A	O
:	O
400	O
MHz	O
representative	O
urine	O
pro	O
##ton	O
nuclear	O
magnetic	O
resonance	O
(	O
_	O
1	O
H	O
-	O
N	O
##MR	O
)	O
s	O
##pect	O
##ra	O
obtained	O
from	O
es	O
##op	O
##hage	O
##al	O
cancer	O
(	O
EC	O
)	O
patient	O
(	O
a	O
)	O
and	O
healthy	O
control	O
(	O
b	O
)	O
;	O
B	O
:	O
T	O
##iss	O
##ue	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
obtained	O
from	O
EC	O
tissue	O
(	O
c	O
)	O
and	O
adjacent	O
non	O
##can	O
##cer	O
##ous	O
tissue	O
(	O
d	O
)	O
referenced	O
to	O
te	B
##tra	I
##de	I
##uter	I
##io	I
##p	I
##rop	I
##ion	I
##ate	I
(	O
0	O
.	O
0	O
pp	O
##m	O
)	O
.	O

G	O
##C	O
-	O
MS	O
analysis	O
also	O
revealed	O
a	O
significant	O
presence	O
of	O
mass	O
is	O
##oto	O
##po	O
##mers	O
of	O
la	B
##ct	I
##ate	I
with	O
one	O
or	O
two	O
_	O
13	O
C	O
labels	O
for	O
patients	O
#	O
8	O
–	O
10	O
,	O
which	O
is	O
consistent	O
with	O
an	O
active	O
Co	O
##ri	O
cycle	O
.	O

These	O
analyses	O
revealed	O
that	O
the	O
metabolic	O
profile	O
associated	O
with	O
o	O
##bes	O
##e	O
patients	O
was	O
characterized	O
by	O
increased	O
levels	O
of	O
2	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
,	O
in	B
##os	I
##ine	I
and	O
ace	B
##tate	I
,	O
and	O
decreased	O
levels	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
and	O
g	B
##ly	I
##cine	I
.	O

Most	O
of	O
the	O
identified	O
lip	O
##ids	O
in	O
E	O
##OC	O
re	O
##current	O
patients	O
were	O
decreased	O
compared	O
with	O
the	O
non	O
-	O
re	O
##current	O
ones	O
,	O
except	O
up	O
-	O
regulated	O
PC	B
(	I
31	I
:	I
2	I
)	I
and	O
P	B
##E	I
-	I
P	I
(	I
42	I
:	I
4	I
)	I
in	O
E	O
##OC	O
re	O
##current	O
patients	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
E	O
##D	O
##DP	O
showed	O
significant	O
inter	O
individual	O
variation	O
,	O
and	O
were	O
much	O
lower	O
than	O
those	O
of	O
met	B
##had	I
##one	I
.	O

Wilcox	O
##on	O
rank	O
sum	O
tests	O
revealed	O
significant	O
differences	O
in	O
the	O
q	O
##uant	O
##ified	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
between	O
the	O
AD	O
and	O
control	O
groups	O
.	O

To	O
identify	O
the	O
shift	O
in	O
fatty	O
acid	O
and	O
o	B
##xy	I
##lip	I
##in	I
constituents	O
different	O
##iating	O
pro	O
-	O
and	O
anti	O
-	O
at	O
##her	O
##ogenic	O
T	O
##GR	O
##L	O
,	O
a	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
(	O
P	O
##LS	O
-	O
D	O
##A	O
)	O
was	O
performed	O
.	O

The	O
anti	O
##biotic	O
administration	O
induce	O
##s	O
the	O
suppression	O
of	O
the	O
gut	O
micro	O
##bio	O
##ta	O
and	O
it	O
results	O
in	O
a	O
reduction	O
in	O
the	O
ex	O
##cre	O
##tion	O
of	O
hip	B
##pura	I
##te	I
levels	O
.	O

Am	O
##ino	O
acids	O
were	O
mixed	O
at	O
a	O
concentration	O
of	O
2	O
.	O
5	O
µ	O
##mo	O
##l	O
/	O
m	O
##L	O
in	O
0	O
.	O
1	O
M	O
HC	O
##l	O
except	O
L	B
-	I
c	I
##ys	I
##tine	I
at	O
1	O
.	O
25	O
µ	O
##mo	O
##l	O
/	O
m	O
##L	O
.	O
The	O
fatty	O
acids	O
and	O
organic	O
acids	O
were	O
prepared	O
by	O
mixing	O
the	O
0	O
.	O
5	O
mg	O
/	O
m	O
##L	O
fatty	O
acid	O
standards	O
and	O
0	O
.	O
5	O
mg	O
/	O
m	O
##L	O
organic	O
acid	O
standards	O
in	O
p	B
##yr	I
##id	I
##ine	I
,	O
respectively	O
.	O

As	O
a	O
class	O
,	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
increased	O
with	O
the	O
decrease	O
c	O
##y	O
##c	O
##lin	O
D	O
##1	O
expression	O
,	O
with	O
the	O
exception	O
of	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
which	O
decreased	O
(	O
R	O
_	O
2	O
’	O
s	O
>	O
0	O
.	O
4	O
)	O
.	O

These	O
measures	O
showed	O
a	O
significant	O
difference	O
across	O
the	O
three	O
groups	O
,	O
with	O
the	O
least	O
u	O
##rina	O
##ry	O
glucose	S
found	O
in	O
those	O
with	O
G	O
##C	O
##K	O
-	O
M	O
##OD	O
##Y	O
and	O
the	O
most	O
in	O
those	O
with	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
.	O

First	O
,	O
understanding	O
why	O
patient	O
with	O
advancing	O
s	O
##ys	O
##to	O
##lic	O
H	O
##F	O
have	O
increased	O
levels	O
of	O
T	B
##MA	I
##O	I
will	O
be	O
important	O
.	O

The	O
connectivity	O
patterns	O
for	O
these	O
meta	O
##bol	O
##ites	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
[	O
_	O
13	O
C	O
-	O
1	O
-	O
5	O
]	O
-	O
β	O
##G	O
##6	O
##P	O
and	O
[	B
U	I
-	I
_	I
13	I
C	I
-	I
glucose	I
]	I
-	I
g	I
##ly	I
##co	I
##gen	I
,	O
in	O
addition	O
to	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
la	I
##ct	I
##ate	I
,	O
[	O
U	O
-	O
_	O
13	O
C	O
]	O
-	O
Al	O
##a	O
,	O
and	O
[	B
_	I
13	I
C	I
-	I
2	I
,	I
3	I
,	I
4	I
]	I
-	I
G	I
##lu	I
.	O

The	O
rank	O
of	O
the	O
mean	O
mass	O
levels	O
of	O
all	O
determined	O
individual	O
SM	O
and	O
c	B
##era	I
##mi	I
##de	I
species	O
indicates	O
that	O
the	O
reduction	O
of	O
SM	O
mass	O
levels	O
and	O
the	O
increases	O
in	O
c	B
##era	I
##mi	I
##de	I
mass	O
levels	O
in	O
AD	O
plasma	O
samples	O
are	O
essentially	O
in	O
uniform	O
##ity	O
,	O
with	O
only	O
a	O
few	O
exceptions	O
(	O
two	O
SM	O
species	O
and	O
four	O
c	B
##era	I
##mi	I
##de	I
species	O
which	O
are	O
located	O
at	O
the	O
end	O
of	O
small	O
changes	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
above	O
the	O
horizontal	O
line	O
with	O
significant	O
P	O
value	O
are	O
al	B
##ani	I
##ne	I
,	O
trans	B
-	I
4	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
N	B
-	I
alpha	I
-	I
ace	I
##ty	I
##l	I
-	I
l	I
-	I
l	I
##ys	I
##ine	I
,	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
in	B
##os	I
##ine	I
-	I
5	I
′	I
-	I
dip	I
##hos	I
##phate	I
,	O
u	B
##rate	I
,	O
in	B
##os	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
d	B
-	I
g	I
##lu	I
##cos	I
##amine	I
-	I
6	I
-	I
su	I
##lf	I
##ate	I
,	O
(	O
2	O
##R	O
,	O
3	O
##R	O
)	O
–	O
(	B
−	I
)	I
-	I
2	I
,	I
3	I
-	I
but	I
##ane	I
##dio	I
##l	I
.	O

Nevertheless	O
,	O
Ba	O
##cter	O
##oid	O
##es	O
f	O
##rag	O
##ilis	O
group	O
,	O
which	O
s	O
##ynth	O
##esi	O
##zes	O
lip	B
##op	I
##oly	I
##sa	I
##cc	I
##hari	I
##de	I
(	O
LP	O
##S	O
)	O
as	O
an	O
important	O
bacterial	O
v	O
##ir	O
##ule	O
##nce	O
factor	O
,	O
did	O
not	O
increase	O
in	O
the	O
f	O
##eca	O
##l	O
samples	O
of	O
N	O
##P	O
and	O
/	O
or	O
P	O
patients	O
.	O

The	O
matrix	O
molecule	O
,	O
2	B
,	I
5	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
(	O
D	O
##H	O
##B	O
)	O
,	O
was	O
detected	O
as	O
three	O
add	O
##uc	O
##t	O
ions	O
,	O
including	O
[	O
M	O
+	O
H	O
-	O
H	O
_	O
2	O
O	O
]	O
_	O
+	O
(	O
m	O
/	O
z	O
=	O
137	O
.	O
1	O
)	O
,	O

This	O
finding	O
indicates	O
low	O
en	O
##zy	O
##matic	O
activity	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
de	O
##grading	O
and	O
s	O
##ynth	O
##esi	O
##zing	O
enzymes	O
at	O
4	O
##°	O
##C	O
and	O
R	O
##T	O
.	O

In	O
the	O
case	O
of	O
l	B
##ys	I
##o	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
##s	O
)	O
,	O
the	O
two	O
platforms	O
actually	O
measure	O
not	O
the	O
same	O
but	O
similar	O
molecules	O
:	O
while	O
Met	O
##ab	O
##olo	O
##n	O
can	O
differentiate	O
between	O
the	O
position	O
of	O
the	O
fatty	O
acid	O
residue	O
on	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
(	O
e	O
.	O
g	O
.	O
1	B
-	I
a	I
##rac	I
##hi	I
##don	I
##oy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
2	B
-	I
a	I
##rac	I
##hi	I
##don	I
##oy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	O
,	O
B	O
##io	O
##crates	O
measures	O
the	O
sum	O
concentration	O
of	O
both	O
molecules	O
(	O
e	O
.	O
g	O
.	O
l	O
##ys	O
##o	O
##PC	O
a	O
##a	O
C	B
##20	I
:	I
4	I
)	O
.	O

The	O
in	O
v	O
##it	O
##ro	O
f	O
##ae	O
##cal	O
f	O
##er	O
##mentation	O
system	O
,	O
using	O
fresh	O
f	O
##ae	O
##ces	O
from	O
five	O
different	O
donors	O
(	O
D	O
)	O
as	O
in	O
##oc	O
##ulum	O
,	O
was	O
performed	O
to	O
analyze	O
the	O
metabolism	O
of	O
selected	O
s	B
##til	I
##ben	I
##oids	I
(	O
bat	O
##ata	O
##sin	O
III	O
,	O
o	B
##xy	I
##res	I
##ver	I
##at	I
##rol	I
,	O
p	O
##ice	O
##ata	O
##nn	O
##ol	O
,	O
pin	B
##ost	I
##il	I
##ben	I
##e	I
,	O
re	B
##s	I
##ver	I
##at	I
##rol	I
,	O
th	O
##una	O
##l	O
##ben	O
##e	O
)	O
in	O
the	O
human	O
co	O
##lon	O
.	O

Chen	O
et	O
al	O
.	O
reported	O
l	B
##ys	I
##ine	I
modifications	O
as	O
molecular	O
markers	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
cancer	O
.	O

Fat	O
##ty	O
acid	O
oxidation	O
and	O
k	O
##eto	O
##genesis	O
were	O
induced	O
by	O
exercise	O
in	O
both	O
groups	O
,	O
with	O
more	O
k	B
##eton	I
##es	I
at	O
14	O
-	O
h	O
post	O
-	O
exercise	O
in	O
PS	O
##PC	O
(	B
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
1	O
.	O
8	O
-	O
fold	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Background	O
:	O
Two	O
ch	O
##em	O
##op	O
##re	O
##vention	O
trials	O
found	O
that	O
supplement	O
##ation	O
with	O
β	B
-	I
car	I
##ote	I
##ne	I
increased	O
the	O
risk	O
of	O
lung	O
cancer	O
and	O
overall	O
mortality	O
.	O

A	O
significantly	O
higher	O
level	O
of	O
met	B
##hi	I
##oni	I
##ne	I
was	O
observed	O
in	O
H	O
##AP	O
##E	O
subjects	O
relative	O
to	O
healthy	O
controls	O
,	O
suggesting	O
the	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
pathway	O
is	O
per	O
##tur	O
##bed	O
in	O
H	O
##AP	O
##E	O
subjects	O
.	O

The	O
potential	O
bio	O
##mark	O
##er	O
panel	O
,	O
which	O
reflects	O
metabolic	O
changes	O
including	O
g	O
##ly	O
##co	O
##lysis	O
,	O
ch	B
##olin	I
##e	I
,	O
amino	O
acids	O
,	O
and	O
n	O
##uc	O
##leo	O
##tide	O
metabolism	O
,	O
could	O
significantly	O
differentiate	O
early	O
E	O
##SC	O
##C	O
patients	O
from	O
CT	O
##RL	O
.	O

High	O
sample	O
through	O
##put	O
(	O
≤	O
16	O
min	O
total	O
cycle	O
time	O
per	O
sample	O
,	O
<	O
7	O
min	O
for	O
MS	O
##1	O
portion	O
)	O
was	O
achieved	O
using	O
the	O
na	O
##no	O
##ele	O
##ct	O
##ros	O
##pra	O
##y	O
Tri	O
##V	O
##ers	O
##a	O
Nan	O
##o	O
##M	O
##ate	O
(	O
Ad	O
##vio	O
##n	O
B	O
##ios	O
##cie	O
##nces	O
,	O
It	O
##ha	O
##ca	O
,	O
NY	O
,	O
USA	O
)	O
with	O
1	O
.	O
5	O
k	B
##V	I
electro	O
##sp	O
##ray	O
voltage	O
and	O
0	O
.	O
4	O
ps	O
##i	O
head	O
pressure	O
.	O

Lim	O
##it	O
of	O
q	O
##uant	O
##ification	O
(	O
Lo	O
##Q	O
)	O
of	O
D	O
##G	O
and	O
T	B
##G	I
species	O
was	O
determined	O
from	O
serial	O
di	O
##lution	O
##s	O
of	O
f	O
##eca	O
##l	O
samples	O
.	O

We	O
estimate	O
that	O
two	O
rounds	O
of	O
washing	O
reduces	O
medium	O
concentrations	O
by	O
a	O
factor	O
~	O
10	O
_	O
6	O
,	O
bringing	O
glucose	S
(	O
the	O
most	O
severe	O
con	O
##tam	O
##ina	O
##nt	O
)	O
from	O
11	O
m	O
##M	O
to	O
11	O
u	O
##M	O
.	O
Met	O
##ab	O
##oli	O
##tes	O
were	O
then	O
extracted	O
using	O
4	O
.	O
5	O
m	O
##l	O
(	O
10	O
cm	O
tissue	O
culture	O
dishes	O
)	O
or	O
1	O
m	O
##l	O
(	O
6	O
-	O
well	O
plates	O
)	O
of	O
−	O
##80	O
°C	O
pre	O
-	O
cooled	O
HP	O
##LC	O
grade	O
met	B
##han	I
##ol	I
.	O

While	O
meta	O
##bol	O
##ites	O
may	O
be	O
detect	O
##able	O
in	O
para	B
##ffin	I
embedded	O
tissue	O
,	O
the	O
ass	O
##ay	O
of	O
meta	O
##bol	O
##ites	O
retrieved	O
from	O
para	B
##ffin	I
should	O
be	O
carefully	O
considered	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
HP	O
##LC	O
–	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
(	O
A	O
)	O
,	O
na	O
##no	O
-	O
L	O
##C	O
–	O
Chip	O
/	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
(	O
B	O
)	O
and	O
CE	O
-	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
(	O
C	O
and	O
D	O
)	O
for	O
the	O
simultaneous	O
separation	O
of	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
Q	O
##A	O
)	O
and	O
p	B
##ico	I
##lini	I
##c	I
acid	I
(	O
PA	O
)	O
dissolved	O
in	O
trip	O
##ly	O
dei	O
##onized	O
water	O
.	O

Furthermore	O
,	O
a	O
k	O
##eto	O
##genic	O
diet	O
(	O
high	O
fat	O
,	O
low	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
content	O
)	O
has	O
shown	O
to	O
have	O
a	O
protective	O
/	O
therapeutic	O
effect	O
on	O
cancer	O
probably	O
because	O
it	O
dim	O
##ini	O
##shes	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
in	O
cancer	O
cells	O
_	O
,	O
.	O

Col	O
##um	O
##n	O
performance	O
was	O
monitored	O
at	O
the	O
start	O
of	O
each	O
day	O
of	O
analysis	O
using	O
repeated	O
injection	O
##s	O
of	O
ca	B
##ffe	I
##ine	I
,	O
ad	B
##eno	I
##sin	I
##e	I
and	O
to	B
##lue	I
##ne	I
(	O
used	O
as	O
an	O
approximate	O
measure	O
of	O
column	O
dead	O
-	O
volume	O
by	O
UV	O
)	O
and	O
an	O
is	O
##oc	O
##ratic	O
method	O
with	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
water	O
in	O
met	B
##han	I
##ol	I
as	O
the	O
organic	O
m	O
##od	O
##ifier	O
.	O

Beta	B
##ine	I
,	O
Le	O
##ci	O
##thin	O
:	O
ch	O
##ole	O
##ster	O
##ol	O
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
,	O
Li	O
##pop	O
##rote	O
##ins	O
,	O
Ph	B
##os	I
##ph	I
##oli	I
##pid	I
transfer	O
protein	O
,	O
Type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O

As	O
a	O
result	O
,	O
both	O
the	O
pu	B
##rine	I
and	O
the	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
were	O
increased	O
in	O
u	O
##roth	O
##eli	O
##al	O
cancer	O
,	O
suggesting	O
the	O
accelerated	O
synthesis	O
and	O
degradation	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
.	O

A	O
total	O
of	O
12	O
fatty	O
acids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
identified	O
in	O
serum	O
samples	O
from	O
ST	O
##EM	O
##I	O
patients	O
,	O
U	O
##A	O
patients	O
and	O
healthy	O
controls	O
using	O
G	O
##C	O
/	O
MS	O
,	O
where	O
they	O
were	O
separately	O
subjected	O
to	O
multi	O
##var	O
##iate	O
data	O
analysis	O
.	O

These	O
data	O
show	O
that	O
f	O
##olate	O
##s	O
are	O
important	O
not	O
only	O
in	O
met	O
##hyl	O
##ation	O
reactions	O
but	O
also	O
in	O
regulating	O
in	O
##tra	O
##cellular	O
red	O
##ox	O
and	O
N	B
##AD	I
##P	I
##H	I
levels	O
.	O

Our	O
larger	O
study	O
comparing	O
119	O
patients	O
with	O
RA	O
and	O
148	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
control	O
subjects	O
showed	O
a	O
robust	O
increase	O
in	O
a	O
##rg	O
##inas	O
##e	O
activity	O
along	O
with	O
a	O
reduced	O
level	O
of	O
its	O
substrate	O
,	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
in	O
the	O
RA	O
plasma	O
.	O

In	O
our	O
study	O
,	O
meta	O
##bol	O
##ite	O
ratios	O
normal	O
##ised	O
to	O
t	B
-	I
c	I
##rea	I
##tine	I
levels	O
did	O
not	O
change	O
significantly	O
after	O
De	O
##gar	O
##eli	O
##x	O
treatment	O
whereas	O
the	O
absolute	O
concentration	O
of	O
t	B
-	I
ch	I
##olin	I
##e	I
was	O
significantly	O
lower	O
.	O

Moreover	O
,	O
in	O
most	O
cases	O
is	O
positively	O
correlated	O
with	O
its	O
precursor	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
except	O
tissue	O
T	O
##C	O
vs	O
HC	O
)	O
.	O

Our	O
results	O
indicate	O
the	O
disturbance	O
of	O
ch	B
##olin	I
##e	I
metabolism	O
in	O
es	O
##op	O
##hage	O
##al	O
cancer	O
tissue	O
,	O
which	O
is	O
supported	O
by	O
previous	O
findings	O
that	O
ch	B
##olin	I
##e	I
and	O
its	O
meta	O
##bol	O
##ites	O
allow	O
a	O
distinct	O
differentiation	O
in	O
human	O
oral	O
cancer	O
.	O

Here	O
,	O
we	O
present	O
a	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
method	O
developed	O
to	O
resolve	O
and	O
detect	O
a	B
##bir	I
##ater	I
##one	I
and	O
its	O
seven	O
meta	O
##bol	O
##ites	O
in	O
human	O
serum	O
using	O
an	O
AB	O
Sc	O
##ie	O
##x	O
Q	O
##tra	O
##p	O
550	O
##0	O
mass	O
analyze	O
##r	O
coupled	O
with	O
a	O
Shi	O
##mad	O
##zu	O
N	O
##ex	O
##era	O
UP	O
##LC	O
station	O
.	O

There	O
was	O
a	O
positive	O
association	O
of	O
c	B
##rea	I
##tin	I
##ine	I
with	O
MI	O
(	O
OR	O
per	O
SD	O
:	O
1	O
.	O
38	O
;	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
09	O
to	O
1	O
.	O
75	O
)	O
and	O
nominally	O
with	O
I	O
##CH	O
(	O
OR	O
per	O
SD	O
:	O
1	O
.	O
33	O
;	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
11	O
to	O
1	O
.	O
59	O
)	O
,	O
but	O
no	O
association	O
with	O
IS	O
(	O
OR	O
per	O
SD	O
:	O
1	O
.	O
00	O
;	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
82	O
to	O
1	O
.	O
22	O
)	O
.	O

G	B
##ly	I
##cine	I
supplement	O
##ation	O
in	O
v	O
##ivo	O
has	O
been	O
shown	O
to	O
protect	O
against	O
muscle	O
loss	O
in	O
o	O
##bes	O
##e	O
mice	O
on	O
ca	O
##lor	O
##ic	O
restriction	O
.	O

20	B
-	I
H	I
##ET	I
##E	I
producing	O
C	O
##YP	O
##45	O
##0	O
is	O
##of	O
##orm	O
specific	O
prime	O
##r	O
sequences	O
were	O
as	O
follows	O
:	O
C	O
##YP	O
##4	O
##A	O
##11	O
-	O
F	O
(	O
AT	O
##GA	O
##AG	O
##T	O
##G	O
##T	O
##GC	O
##CT	O
##TC	O
##AG	O
##CC	O
##A	O
)	O
,	O
C	O
##YP	O
##4	O
##A	O
##11	O
-	O
R	O
(	O
AA	O
##G	O
G	O
##CA	O
##TT	O
##CC	O
T	O
##CA	O
##CA	O
##C	O
##G	O
##G	O
##G	O
)	O
,	O
C	O
##YP	O
##4	O
##A	O
##22	O
-	O
F	O
(	O
AA	O
##T	O
##G	O
##G	O
##GA	O
##AG	O
##AG	O
##CT	O
##CC	O
##TT	O
##G	O
##GC	O
)	O
,	O
C	O
##YP	O
##4	O
##A	O
##22	O
-	O
R	O
(	O
AA	O
##G	O
##GC	O
##AT	O
##TC	O
##CT	O
##CA	O
##TA	O
##CA	O
##GC	O
)	O
,	O
C	O
##YP	O
##4	O
##F	O
##2	O
-	O
F	O
(	O
AA	O
##GC	O
##A	O
CC	O
##CA	O
##GA	O
##AT	O
##AC	O
##CA	O
##G	O
##GA	O
)	O
,	O
C	O
##YP	O
##4	O
##F	O
##2	O
-	O
R	O
(	O
T	O
##CA	O
##T	O
##GC	O
##AC	O
##A	O
T	O
##G	O
##G	O
##TC	O
##AG	O
GAA	O
##G	O
)	O
,	O
C	O
##YP	O
##4	O
##F	O
##3	O
-	O
F	O
(	O
CT	O
##G	O
##TC	O
##G	O
##GC	O
##AG	O
##GA	O
##G	O
##G	O
##TA	O
##CA	O
##AG	O
)	O
,	O
C	O
##YP	O
##4	O
##F	O
##3	O
-	O
R	O
(	O
CC	O
##TC	O
##AG	O
##GC	O
##TC	O
##TC	O
##CT	O
##TA	O
##AT	O
##GC	O
)	O
.	O

Inc	O
##reased	O
levels	O
of	O
k	B
##eton	I
##e	I
bodies	O
,	O
such	O
as	O
h	B
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
and	O
ace	B
##tone	I
,	O
are	O
signs	O
of	O
fatty	O
acid	O
breakdown	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
operated	O
in	O
the	O
positive	O
or	O
negative	O
ion	O
##ization	O
mode	O
with	O
spray	O
voltage	O
##s	O
of	O
3	O
.	O
0	O
and	O
4	O
.	O
5	O
k	B
##V	I
,	O
respectively	O
,	O
and	O
at	O
a	O
cap	O
##illa	O
##ry	O
temperature	O
of	O
390	O
°C	O
;	O
sheath	O
gas	O
was	O
maintained	O
at	O
60	O
(	O
arbitrary	O
units	O
)	O
,	O
ion	O
sweep	O
gas	O
at	O
0	O
.	O
3	O
(	O
arbitrary	O
units	O
)	O
,	O
auxiliary	O
gas	O
at	O
5	O
(	O
arbitrary	O
units	O
)	O
.	O

Neither	O
IF	O
##N	O
##γ	O
nor	O
any	O
of	O
the	O
other	O
measured	O
IL	O
##s	O
were	O
associated	O
with	O
any	O
of	O
the	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
measured	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
3	O
)	O
.	O

The	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
and	O
g	B
##lut	I
##amine	I
were	O
normal	O
##ized	O
to	O
the	O
tissue	O
weight	O
.	O

However	O
,	O
War	O
##burg	O
found	O
that	O
tumor	O
cells	O
are	O
still	O
prevalent	O
with	O
high	O
rates	O
of	O
glucose	S
up	O
##take	O
even	O
under	O
oxygen	O
##ated	O
conditions	O
.	O

G	B
##lu	I
##cos	I
##e	I
up	O
##take	O
in	O
MC	O
##F	O
-	O
7	O
cells	O
was	O
analyzed	O
using	O
N	O
##B	O
##D	O
##G	O
a	O
fluorescent	O
##ly	O
labeled	O
de	B
##ox	I
##y	I
glucose	I
analogue	O
as	O
a	O
probe	O
for	O
detection	O
of	O
glucose	S
taken	O
up	O
by	O
culture	O
##d	O
cells	O
.	O

(	O
D	O
)	O
3	B
-	I
H	I
##ydro	I
##xy	I
##xa	I
##nt	I
##hra	I
##ni	I
##lli	I
##c	I
acid	I
is	O
up	O
regulated	O
in	O
D	O
##OC	O
##K	O
##8	O
-	O
def	O
##icient	O
patients	O
.	O

Ch	B
##lor	I
##he	I
##xi	I
##dine	I
g	I
##lu	I
##cona	I
##te	I
:	O
This	O
is	O
the	O
anti	O
##mic	O
##ro	O
##bial	O
agent	O
used	O
in	O
oral	O
health	O
care	O
products	O
for	O
treatment	O
of	O
period	O
##ont	O
##al	O
disease	O
e	O
.	O
g	O
.	O
Per	O
##ide	O
##x	O
®	O
,	O
G	O
##um	O
®	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
g	I
##lu	I
##cona	I
##te	I
oral	O
r	O
##ins	O
##e	O
.	O

[	O
_	O
13	O
C	O
_	O
1	O
]	O
ch	O
##olic	O
acid	O
to	O
the	O
serum	O
prior	O
to	O
extraction	O
(	O
resulting	O
in	O
a	O
final	O
et	B
##hyl	I
ace	I
##tate	I
concentration	O
of	O
[	O
_	O
13	O
C	O
_	O
1	O
]	O
ch	O
##olic	O
acid	O
of	O
36	O
n	O
##M	O
.	O
The	O
et	B
##hyl	I
ace	I
##tate	I
organic	O
fraction	O
was	O
used	O
for	O
the	O
analysis	O
of	O
each	O
sample	O
.	O

I	O
##BS	O
,	O
i	O
##rri	O
##table	O
bow	O
##el	O
syndrome	O
;	O
I	O
##B	O
##D	O
,	O
inflammatory	O
bow	O
##el	O
disease	O
;	O
CD	O
,	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
;	O
UC	O
,	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
;	O
F	O
/	O
M	O
,	O
female	O
to	O
male	O
ratio	O
;	O
y	O
##rs	O
.	O
,	O
years	O
;	O
SD	O
,	O
standard	O
de	O
##viation	O
;	O
CD	O
##A	O
##I	O
,	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
activity	O
index	O
;	O
R	B
##I	I
,	O
Ra	O
##ch	O
##mile	O
##witz	O
index	O
;	O
_	O
1	O
for	O
comparison	O
between	O
controls	O
and	O
I	O
##BS	O
and	O
I	O
##B	O
##D	O
patients	O
;	O
_	O
2	O
for	O
comparison	O
between	O
controls	O
and	O
patients	O
with	O
I	O
##BS	O
,	O
active	O
and	O
inactive	O
CD	O
and	O
active	O
and	O
inactive	O
UC	O
;	O
_	O
3	O
Χ	O
_	O
2	O
-	O
test	O
;	O
_	O
4	O
one	O
-	O
way	O
AN	O
##O	O
##VA	O
;	O
_	O
5	O
Fisher	O
’	O
s	O
exact	O
test	O
.	O

Despite	O
being	O
one	O
of	O
the	O
largest	O
samples	O
sizes	O
reported	O
to	O
date	O
regarding	O
the	O
role	O
of	O
AD	B
##MA	I
and	O
card	O
##iovascular	O
risks	O
,	O
the	O
subject	O
population	O
is	O
he	O
##tero	O
##gene	O
##ous	O
and	O
location	O
specific	O
(	O
patients	O
undergoing	O
elect	O
##ive	O
diagnostic	O
cardiac	O
cat	O
##he	O
##ter	O
##ization	O
)	O
,	O
the	O
majority	O
of	O
which	O
with	O
varying	O
degrees	O
of	O
CA	O
##D	O
and	O
co	O
-	O
m	O
##or	O
##bid	O
##ities	O
.	O

Pearson	O
correlation	O
results	O
revealed	O
a	O
highly	O
negative	O
relation	O
of	O
4	B
-	I
OH	I
-	I
E	I
_	I
2	I
:	I
2	I
-	I
OH	I
-	I
E	I
_	I
2	I
to	O
the	O
concentrations	O
of	O
T	O
##CD	O
##D	O
,	O
1	B
,	I
2	I
,	I
3	I
,	I
7	I
,	I
8	I
-	I
pen	I
##ta	I
##CD	I
##D	I
,	O
and	O
total	O
PC	O
##D	O
##D	O
.	O

However	O
,	O
standard	O
diet	O
##ary	O
recommendations	O
,	O
if	O
adopted	O
,	O
will	O
limit	O
the	O
intake	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
-	I
and	O
ch	O
##olin	O
##eric	O
##h	O
foods	O
,	O
since	O
these	O
foods	O
are	O
also	O
typically	O
high	O
in	O
fat	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
content	O
.	O

According	O
to	O
the	O
method	O
describe	O
in	O
a	O
previous	O
report	O
,	O
G	O
##C	O
/	O
MS	O
analysis	O
was	O
performed	O
using	O
a	O
G	O
##CM	O
##S	O
-	O
Q	O
##P	O
##20	O
##10	O
Ultra	O
(	O
Shi	O
##mad	O
##zu	O
Co	O
.	O
,	O
Kyoto	O
,	O
Japan	O
)	O
with	O
a	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
column	O
(	O
CP	O
-	O
S	O
##IL	O
8	O
CB	O
low	O
bleed	O
/	O
MS	O
;	O
30	O
m	O
×	O
0	O
.	O
25	O
mm	O
inner	O
diameter	O
,	O
film	O
thickness	O
:	O
0	O
.	O
25	O
µ	O
##m	O
;	O
A	O
##gi	O
##lent	O
Co	O
.	O
,	O
Pa	O
##lo	O
Alto	O
,	O
CA	O
)	O
.	O

So	B
##dium	I
h	I
##y	I
##po	I
##ch	I
##lor	I
##ite	I
(	O
C	O
##lora	O
##lex	O
_	O
®	O
,	O
5	O
%	O
ch	O
##lor	O
##ine	O
solution	O
)	O
was	O
acquired	O
from	O
Al	O
##en	O
del	O
Norte	O
,	O
S	O
.	O
A	O
.	O
de	O
C	O
.	O
V	O
.	O
(	O
Monte	O
##rrey	O
,	O
NL	O
,	O
Mexico	O
)	O
.	O

The	O
post	O
##pra	O
##ndi	O
##al	O
concentration	O
of	O
this	O
organic	O
acid	O
,	O
which	O
is	O
an	O
intermediate	O
in	O
the	O
cat	O
##ab	O
##olis	O
##m	O
of	O
v	B
##ali	I
##ne	I
,	O
was	O
also	O
increased	O
in	O
infants	O
fed	O
a	O
milk	O
-	O
based	O
formula	O
.	O

In	B
##os	I
##ito	I
##l	I
,	O
or	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
and	O
its	O
various	O
bio	O
##chemical	O
derivatives	O
,	O
are	O
readily	O
found	O
in	O
ma	O
##mmal	O
##ian	O
cells	O
and	O
organs	O
,	O
including	O
the	O
brain	O
,	O
kidney	O
,	O
secret	O
##ory	O
tissues	O
,	O
test	O
##is	O
,	O
e	O
##pid	O
##idy	O
##mal	O
,	O
ve	O
##si	O
##cular	O
,	O
and	O
pro	O
##static	O
fluid	O
,	O
and	O
is	O
involved	O
in	O
various	O
aspects	O
of	O
reproduction	O
.	O

In	O
this	O
co	O
##hor	O
##t	O
study	O
of	O
maternal	O
–	O
f	O
##etal	O
pairs	O
,	O
we	O
examined	O
the	O
relationship	O
of	O
PC	O
##D	O
##D	O
/	O
PC	O
##DF	O
and	O
PC	O
##B	O
exposure	O
to	O
levels	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
the	O
se	O
##ra	O
of	O
50	O
pregnant	O
women	O
25	O
–	O
34	O
years	O
of	O
age	O
from	O
central	O
Taiwan	O
.	O

All	O
individual	O
BC	O
##AA	O
##s	O
were	O
highly	O
significantly	O
correlated	O
with	O
fast	O
##ing	O
insulin	O
,	O
S	O
_	O
I	O
,	O
and	O
MC	O
##RI	O
;	O
however	O
,	O
only	O
v	B
##ali	I
##ne	I
was	O
significantly	O
correlated	O
with	O
AI	O
##R	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
5	O
)	O
.	O

Conversely	O
,	O
significant	O
decreases	O
in	O
l	B
##ys	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
observed	O
in	O
the	O
pro	O
##gno	O
##stic	O
model	O
which	O
were	O
not	O
observed	O
in	O
the	O
model	O
of	O
end	O
##os	O
##copic	O
activity	O
.	O

Total	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
concentration	O
was	O
higher	O
in	O
males	O
than	O
in	O
females	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
and	O
so	O
was	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
activity	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
(	O
A	O
)	O
Score	O
##s	O
plot	O
from	O
O	O
##PL	O
##S	O
multi	O
##var	O
##iate	O
analysis	O
,	O
cross	O
-	O
valid	O
##ated	O
score	O
plot	O
resulting	O
from	O
O	O
##PL	O
##S	O
modeling	O
of	O
gender	O
.	O

These	O
multi	O
-	O
source	O
data	O
correspond	O
to	O
the	O
ex	O
##p	O
##lana	O
##tory	O
variables	O
(	O
input	O
variables	O
)	O
in	O
our	O
analysis	O
except	O
for	O
the	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
(	O
used	O
to	O
calculate	O
the	O
target	O
)	O
.	O

One	O
m	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
the	O
pool	O
##ed	O
smoke	O
##rs	O
’	O
urine	O
sample	O
were	O
spike	O
##d	O
with	O
the	O
su	B
##lf	I
##oxide	I
standards	O
15	O
and	O
18	O
in	O
increasing	O
amounts	O
:	O
50	O
f	O
##mo	O
##l	O
,	O
100	O
f	O
##mo	O
##l	O
,	O
250	O
f	O
##mo	O
##l	O
,	O
500	O
f	O
##mo	O
##l	O
,	O
and	O
1000	O
f	O
##mo	O
##l	O
.	O

Given	O
the	O
strong	O
predict	O
##ive	O
value	O
of	O
ad	O
##herence	O
for	O
the	O
var	O
##iability	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
plasma	O
concentrations	O
we	O
propose	O
that	O
drug	O
monitoring	O
is	O
a	O
powerful	O
sur	O
##rogate	O
to	O
assess	O
ta	B
##mo	I
##xi	I
##fen	I
ad	O
##herence	O
for	O
which	O
we	O
identified	O
a	O
threshold	O
concentration	O
of	O
157	O
n	O
##M	O
(	O
±	O
67	O
n	O
##M	O
)	O
to	O
s	O
##tra	O
##ti	O
##fy	O
patients	O
into	O
low	O
vs	O
.	O
medium	O
/	O
high	O
ta	B
##mo	I
##xi	I
##fen	I
ad	O
##here	O
##nt	O
.	O

show	O
the	O
zoo	O
##m	O
-	O
in	O
s	O
##pect	O
##ra	O
obtained	O
from	O
positive	O
and	O
negative	O
ion	O
##ization	O
modes	O
,	O
respectively	O
,	O
in	O
the	O
m	O
/	O
z	O
range	O
of	O
700	O
–	O
91	O
##0	O
,	O
which	O
cover	O
the	O
intact	O
masses	O
of	O
almost	O
all	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
P	O
##L	O
##s	O
)	O
and	O
the	O
SM	O
class	O
of	O
SP	O
##s	O
.	O

Interest	O
##ingly	O
,	O
we	O
found	O
that	O
the	O
fatty	O
acids	O
,	O
t	O
##ri	O
and	O
dig	B
##ly	I
##cer	I
##ides	I
are	O
altered	O
in	O
PC	O
##a	O
patient	O
’	O
s	O
serum	O
along	O
with	O
p	B
##hos	I
##ph	I
##oli	I
##p	I
##ds	I
.	O

We	O
used	O
a	O
G	O
##C	O
-	O
MS	O
meta	O
##bol	O
##omi	O
##cs	O
platform	O
to	O
measure	O
and	O
investigate	O
changes	O
in	O
inter	O
##media	O
##ry	O
metabolism	O
and	O
the	O
associated	O
possibility	O
of	O
developing	O
elevated	O
plasma	O
glucose	S
as	O
an	O
adverse	O
response	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
.	O

BC	O
##AA	O
##s	O
are	O
essential	O
amino	O
acids	O
in	O
humans	O
and	O
play	O
central	O
roles	O
in	O
protein	O
metabolism	O
,	O
that	O
include	O
improving	O
glucose	S
metabolism	O
and	O
regulating	O
le	O
##pt	O
##in	O
secret	O
##ion	O
during	O
food	O
intake	O
.	O

In	O
addition	O
,	O
higher	O
levels	O
of	O
co	B
##tin	I
##ine	I
were	O
strongly	O
associated	O
with	O
AD	O
##HD	O
.	O

C	B
##rea	I
##tine	I
,	O
o	B
##ct	I
##ano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
de	B
##cano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
palm	B
##ito	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
,	O
o	B
##leo	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
and	O
l	B
##ino	I
##leo	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
were	O
el	O
##uted	O
with	O
a	O
0	O
.	O
01	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
-	O
water	O
-	O
am	O
##mon	O
##ium	O
format	O
##e	O
(	O
[UNK]	B
.	O
7	O
)	O
gradient	O
on	O
a	O
The	O
##rm	O
##o	O
,	O
B	O
##io	O
##B	O
##asi	O
##c	O
SC	O
##X	O
column	O
(	O
50	O
mm	O
##×	O
##2	O
.	O
1	O
mm	O
,	O
5	O
µ	O
##m	O
)	O
at	O
a	O
mobile	O
phase	O
flow	O
rate	O
of	O
0	O
.	O
5	O
m	O
##l	O
/	O
min	O
at	O
40	O
##°	O
##C	O
.	O

Basel	O
##ine	O
o	B
##me	I
##ga	I
-	I
3	I
fatty	O
acid	O
levels	O
do	O
not	O
influence	O
T	O
##x	O
##A	O
_	O
2	O
generation	O
in	O
##patient	O
##s	O
with	O
or	O
at	O
high	O
risk	O
for	O
C	O
##VD	O
receiving	O
adequate	O
as	B
##pi	I
##rin	I
therapy	O
.	O

The	O
filters	O
were	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	O
,	O
the	O
amino	O
acids	O
in	O
the	O
sample	O
were	O
der	O
##iva	O
##tized	O
with	O
5	O
%	O
p	B
##hen	I
##yl	I
##is	I
##oth	I
##io	I
##cy	I
##ana	I
##te	I
re	O
##age	O
##nt	O
(	O
P	O
##IT	O
##C	O
)	O
,	O
and	O
the	O
filters	O
were	O
dried	O
again	O
.	O

O	O
##xi	O
##dized	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
levels	O
at	O
1	O
month	O
were	O
predict	O
##ing	O
an	O
increase	O
in	O
C	O
-	O
p	O
##eptide	O
after	O
6	O
and	O
12	O
months	O
although	O
this	O
was	O
not	O
significant	O
after	O
Benjamin	O
##i	O
–	O
Ho	O
##ch	O
##berg	O
correction	O
.	O

This	O
new	O
method	O
allowed	O
calculation	O
of	O
kinetic	O
features	O
of	O
these	O
meta	O
##bol	O
##ites	O
,	O
thus	O
enabling	O
a	O
detailed	O
analysis	O
of	O
the	O
various	O
pathways	O
involved	O
in	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
metabolism	O
.	O

He	O
##p	O
##G	O
##2	O
cells	O
or	O
human	O
primary	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
(	O
HP	O
##H	O
)	O
were	O
treated	O
with	O
each	O
lip	O
##id	O
individually	O
or	O
with	O
the	O
lip	O
##id	O
mix	O
during	O
24	O
h	O
.	O
Li	O
##pot	O
##ox	O
##icit	O
##y	O
was	O
assessed	O
by	O
the	O
content	O
of	O
total	O
ATP	S
into	O
the	O
cells	O
(	O
Cell	O
##T	O
##iter	O
-	O
G	O
##lo	O
_	O

The	O
enzyme	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##es	O
A	O
_	O
2	O
(	O
P	O
##LA	O
_	O
2	O
)	O
is	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
h	O
##ydro	O
##lysis	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
especially	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
,	O
which	O
leads	O
to	O
accumulation	O
of	O
FF	O
##A	O
including	O
(	O
non	O
-	O
est	O
##eri	O
##fied	O
)	O
AA	O
and	O
D	O
##HA	O
.	O

We	O
also	O
observed	O
a	O
consistent	O
down	O
##re	O
##gu	O
##lation	O
of	O
dip	O
##eptide	O
##s	O
p	B
##yr	I
##og	I
##lut	I
##am	I
##yl	I
##gly	I
##cine	I
,	O
g	B
##ly	I
##cy	I
##l	I
##val	I
##ine	I
,	O
al	B
##any	I
##lal	I
##ani	I
##ne	I
and	O
as	B
##par	I
##ty	I
##le	I
##uc	I
##ine	I
in	O
DC	O
vs	O
.	O
NH	O
##C	O
.	O

Other	O
research	O
reported	O
that	O
in	O
missed	O
abortion	O
,	O
metabolism	O
was	O
disturbed	O
significantly	O
and	O
g	B
##ly	I
##cer	I
##ic	I
acid	I
,	O
in	B
##do	I
##le	I
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
were	O
found	O
satisfactory	O
meta	O
##bol	O
##ites	O
in	O
diagnosis	O
for	O
missed	O
abortion	O
.	O

Mobile	O
phases	O
were	O
water	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
with	O
a	O
linear	O
gradient	O
.	O

We	O
also	O
tested	O
the	O
effects	O
of	O
a	O
reference	O
compound	O
,	O
al	B
##ame	I
##thi	I
##cin	I
(	O
from	O
T	O
.	O
v	O
##iri	O
##de	O
)	O
and	O
found	O
that	O
it	O
also	O
dissipated	O
the	O
Δ	O
##ψ	O
_	O
m	O
of	O
A	O
##5	O
##4	O
##9	O
cells	O
similarly	O
to	O
the	O
sperm	O
-	O
toxic	O
HP	O
##LC	O
fraction	O
3	O
(	O
Table	O
)	O
.	O

Rep	O
##rod	O
##uc	O
##ibility	O
is	O
improved	O
when	O
M	B
##T	I
##BE	I
is	O
used	O
with	O
C	O
##V	O
’	O
s	O
less	O
than	O
8	O
%	O
for	O
lip	O
##ids	O
and	O
5	O
%	O
for	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
versus	O
29	O
%	O
and	O
15	O
%	O
for	O
the	O
met	B
##han	I
##ol	I
method	O
.	O

It	O
was	O
suggested	O
that	O
est	B
##rogen	I
levels	O
might	O
be	O
the	O
reason	O
.	O

S	O
##pear	O
##man	O
'	O
s	O
rank	O
correlation	O
was	O
used	O
to	O
evaluate	O
the	O
associations	O
among	O
plasma	O
x	B
##yl	I
##ito	I
##l	I
,	O
1	B
,	I
5	I
‐	I
AG	I
,	O
his	B
##ti	I
##dine	I
,	O
in	B
##os	I
##ito	I
##l	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
a	B
##rab	I
##ino	I
##se	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
l	B
##ys	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
u	B
##ric	I
acid	I
levels	O
.	O

This	O
meta	O
##bol	O
##ite	O
is	O
involved	O
in	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
red	O
##ox	O
reactions	O
,	O
which	O
are	O
essential	O
to	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
and	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Sign	O
##ificant	O
associations	O
between	O
specific	O
meta	O
##bol	O
##ites	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
and	O
acute	O
inflammation	O
markers	O
(	O
C	O
)	O
.	O

The	O
paternal	O
all	O
##ele	O
is	O
normally	O
not	O
met	O
##hyl	O
##ated	O
in	O
sperm	O
,	O
but	O
over	O
##ex	O
##press	O
##ion	O
of	O
G	O
##rb	O
##10	O
in	O
trans	O
##genic	O
mice	O
has	O
been	O
associated	O
with	O
growth	O
re	O
##tar	O
##dation	O
,	O
glucose	S
into	O
##ler	O
##ance	O
and	O
insulin	O
resistance	O
[	O
,	O
]	O
.	O

His	O
##to	O
##gram	O
##s	O
of	O
overall	O
distribution	O
,	O
number	O
of	O
errors	O
for	O
model	O
I	O
##B	O
##U	O
##1	O
,	O
based	O
on	O
mean	O
-	O
centred	O
data	O
,	O
for	O
predict	O
##ing	O
(	O
A	O
)	O
s	O
##pect	O
##ra	O
with	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
and	O
(	O
B	O
)	O
without	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
related	O
meta	O
##bol	O
##ites	O
.	O

Whereas	O
sa	B
##rc	I
##os	I
##ine	I
was	O
not	O
detected	O
in	O
ben	O
##ign	O
tissue	O
,	O
a	O
significant	O
increase	O
in	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
in	O
PC	O
##a	O
and	O
meta	O
##static	O
tissue	O
samples	O
was	O
reported	O
,	O
co	O
##rro	O
##bor	O
##ating	O
their	O
un	O
##tar	O
##get	O
##ed	O
approach	O
.	O

Value	O
##s	O
represent	O
ATP	S
concentration	O
mean	O
values	O
±	O
S	O
.	O
D	O
.	O
of	O
3	O
independent	O
experiments	O
(	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
consists	O
of	O
a	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
head	O
group	O
,	O
a	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
and	O
a	O
fatty	O
acid	O
tail	O
.	O

Although	O
%	B
cat	I
##ech	I
##ol	I
est	O
##rogen	O
##s	O
in	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
and	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
each	O
increased	O
significantly	O
with	O
so	O
##y	O
intake	O
,	O
trends	O
in	O
%	B
met	I
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
differed	O
by	O
pathway	O
.	O

S	B
-	I
[	I
2	I
-	I
[	I
(	I
h	I
##ydro	I
##xy	I
##eth	I
##yl	I
)	I
th	I
##io	I
]	I
et	I
##hyl	I
]	I
Cy	I
##s	I
-	I
Pro	I
-	I
Ph	I
##e	I
(	O
H	O
##ET	O
##E	O
-	O
CP	O
##F	O
)	O
.	O

Ser	O
##um	O
(	O
150	O
µ	O
##L	O
)	O
was	O
mixed	O
with	O
0	O
.	O
24	O
M	O
sodium	B
phosphate	I
N	O
##MR	O
buffer	O
prepared	O
in	O
D	O
_	O
2	O
O	O

Our	O
data	O
could	O
be	O
interpreted	O
as	O
signs	O
of	O
an	O
activation	O
of	O
neo	O
##g	O
##lu	O
##co	O
##genesis	O
in	O
BC	O
patients	O
,	O
using	O
la	B
##ct	I
##ate	I
and	O
neo	B
##g	I
##lu	I
##co	I
##genic	I
AA	O
##s	O
,	O
increased	O
proteins	O
muscle	O
cat	O
##ab	O
##olis	O
##m	O
with	O
release	O
of	O
AA	O
##s	O
.	O

The	O
sum	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
including	O
PC	O
,	O
P	O
##E	O
and	O
SM	O
,	O
did	O
not	O
differ	O
between	O
diabetes	O
(	O
n	O
=	O
18	O
)	O
and	O
non	O
-	O
diabetes	O
N	O
##AF	O
##LD	O
patients	O
(	O
n	O
=	O
49	O
)	O

Our	O
findings	O
suggest	O
that	O
ch	O
##em	O
##otherapy	O
recipients	O
experience	O
changes	O
in	O
lip	O
##id	O
metabolism	O
,	O
leading	O
to	O
a	O
trans	O
##ient	O
inflammatory	O
lip	O
##id	O
profile	O
consisting	O
of	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
V	O
##LD	O
##L	O
,	O
increased	O
small	O
L	O
##D	O
##L	O
,	O
low	O
HD	O
##L	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
en	O
##rich	O
##ment	O
of	O
L	O
##D	O
##L	O
and	O
HD	O
##L	O
and	O
increased	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

It	O
is	O
likely	O
that	O
the	O
terminal	O
amino	S
group	O
,	O
the	O
common	O
feature	O
of	O
columns	O
E	O
and	O
G	O
,	O
is	O
crucial	O
for	O
their	O
select	O
##ivity	O
towards	O
n	O
##uc	O
##leo	O
##side	O
##s	O
.	O

An	O
A	O
##gi	O
##lent	O
Z	O
##or	O
##ba	O
##x	O
X	O
##D	O
##B	O
-	O
C	O
##8	O
(	O
2	O
.	O
1	O
×	O
50	O
mm	O
,	O
5	O
μ	O
##m	O
)	O
analytical	O
column	O
with	O
a	O
Ph	O
##eno	O
##men	O
##ex	O
Security	O
Guard	O
C	O
##18	O
(	O
2	O
.	O
0	O
×	O
4	O
mm	O
)	O
guard	O
column	O
were	O
used	O
with	O
a	O
gradient	O
mobile	O
phase	O
system	O
to	O
ch	O
##roma	O
##to	O
##graphical	O
##ly	O
separate	O
G	O
##L	O
##Y	O
,	O
M1	O
,	O
M	O
##2	O
and	O
GP	S
.	O

Not	O
##ably	O
,	O
the	O
AA	O
##S	O
##K	O
meta	O
##bol	O
##ite	O
equation	O
excluding	O
c	B
##rea	I
##tin	I
##ine	I
and	O
demographic	O
##s	O
has	O
numerical	O
##ly	O
higher	O
1	O
-	O
P	O
_	O
30	O
than	O
e	O
##G	O
##F	O
##R	O
##c	O
##r	O
-	O
c	O
##ys	O
,	O
but	O
this	O
difference	O
could	O
have	O
been	O
due	O
to	O
chance	O
(	O
6	O
.	O
4	O
%	O
versus	O
3	O
.	O
7	O
%	O
;	O
P	O
=	O
0	O
.	O
30	O
)	O
.	O

Radio	O
##active	O
forms	O
of	O
est	B
##rad	I
##iol	I
,	O
labeled	O
with	O
t	O
##rit	O
##ium	O
in	O
the	O
17	O
##α	O
,	O
2	O
-	O
,	O
or	O
16	B
##α	I
-	I
positions	I
of	O
the	O
s	O
##tero	O
##id	O
ring	O
,	O
were	O
injected	O
into	O
the	O
women	O
;	O
and	O
the	O
rate	O
and	O
extent	O
of	O
oxidation	O
-	O
-	O
-	O
at	O
the	O
17	O
-	O
position	O
,	O
which	O
converts	O
est	B
##rad	I
##iol	I
to	O
est	B
##rone	I
,	O
and	O
at	O
the	O
2	O
-	O
and	O
16	O
-	O
positions	O
,	O
which	O
,	O
respectively	O
,	O
estimate	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
and	O
16	O
##α	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
-	O
-	O
-	O
were	O
measured	O
in	O
serial	O
blood	O
##s	O
.	O

Ser	O
##a	O
were	O
recovered	O
,	O
collected	O
in	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
,	O
and	O
snap	O
-	O
frozen	O
at	O
−	O
##80	O
°C	O
.	O

Mobile	O
phase	O
A	O
was	O
95	O
:	O
5	O
(	O
v	O
:	O
v	O
)	O
water	O
:	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
(	O
pH	O
9	O
.	O
5	O
)	O
.	O

The	O
column	O
was	O
el	O
##uted	O
is	O
##oc	O
##ratic	O
##ally	O
at	O
a	O
flow	O
rate	O
of	O
250	O
μ	O
##L	O
/	O
min	O
with	O
5	O
%	O
mobile	O
phase	O
A	O
(	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
)	O
for	O
1	O
minute	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
40	O
%	O
mobile	O
phase	O
B	O
(	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
with	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
)	O
over	O
10	O
minutes	O
.	O

Thus	O
,	O
compared	O
to	O
young	O
men	O
,	O
young	O
women	O
had	O
approximately	O
3	O
–	O
4	O
fold	O
higher	O
content	O
of	O
three	O
P	O
##U	O
##FA	O
##s	O
including	O
AA	O
,	O
Doc	B
##osa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	O
D	O
##PA	O
)	O
,	O
and	O
E	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	O
EPA	O
)	O
.	O

To	O
this	O
end	O
,	O
NE	O
##FA	O
serum	O
levels	O
were	O
analyzed	O
in	O
a	O
subgroup	O
of	O
biological	O
-	O
na	O
##ï	O
##ve	O
RA	O
patients	O
(	O
n	O
=	O
13	O
)	O
before	O
and	O
3	O
months	O
after	O
T	B
##NF	I
##α	I
-	I
blockade	I
initiation	O
.	O

In	O
this	O
context	O
,	O
mac	B
##oz	I
##ino	I
##ne	I
(	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
)	O
,	O
a	O
promising	O
drug	O
candidate	O
with	O
an	O
unique	O
mode	O
of	O
action	O
and	O
highly	O
potent	O
in	O
v	O
##it	O
##ro	O
tube	O
##rc	O
##ulo	O
##cid	O
##al	O
properties	O
against	O
MD	O
##R	O
My	O
##co	O
##ba	O
##cter	O
##ium	O
strains	O
,	O
has	O
now	O
reached	O
the	O
clinical	O
phase	O
and	O
has	O
been	O
notably	O
tested	O
in	O
healthy	O
male	O
volunteers	O
in	O
Switzerland	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
a	O
naturally	O
occurring	O
pu	B
##rine	I
derivative	O
that	O
is	O
involved	O
in	O
ATP	S
cat	O
##ab	O
##olis	O
##m	O
and	O
the	O
salvage	O
pathway	O
for	O
pu	B
##rine	I
synthesis	O
.	O

The	O
sperm	O
-	O
toxic	O
substance	O
was	O
el	O
##uted	O
with	O
90	O
and	O
100	O
%	O
met	B
##han	I
##ol	I
.	O

Since	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
age	O
between	O
F	O
##DR	O
and	O
G	O
##C	O
patients	O
(	O
median	O
age	O
of	O
53	O
vs	O
.	O
61	O
for	O
the	O
F	O
##DR	O
and	O
G	O
##C	O
groups	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
)	O
,	O
we	O
further	O
investigated	O
the	O
relationship	O
between	O
the	O
level	O
of	O
meta	O
##bol	O
##ites	O
SM	B
(	I
OH	I
)	I
22	I
:	I
1	I
and	O
C	O
##16	O
and	O
the	O
age	O
of	O
individuals	O
.	O

Taking	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
as	O
an	O
example	O
,	O
there	O
was	O
a	O
significantly	O
lower	O
level	O
in	O
patients	O
than	O
in	O
controls	O
,	O
which	O
was	O
consistent	O
with	O
a	O
previous	O
report	O
.	O

Low	O
concentrations	O
of	O
sperm	B
##ine	I
and	O
or	B
##ni	I
##thin	I
##e	I
(	O
a	O
precursor	O
of	O
put	O
##res	O
##cine	O
)	O
in	O
seminal	O
plasma	O
were	O
associated	O
with	O
higher	O
frequencies	O
of	O
neck	O
/	O
mid	O
##piece	O
defects	O
in	O
sperm	O
cells	O
.	O

N	B
##AD	I
##P	I
##H	I
is	O
critical	O
for	O
an	O
##ab	O
##olic	O
metabolism	O
such	O
as	O
fatty	O
acid	O
synthesis	O
and	O
_	O
2	O
H	O
-	O
tracing	O
has	O
been	O
particularly	O
useful	O
for	O
the	O
interrogation	O
of	O
this	O
pathway	O
.	O

Den	O
##ker	O
##t	O
et	O
al	O
.	O
reported	O
lower	O
levels	O
of	O
an	O
in	B
##os	I
##ito	I
##l	I
stereo	O
##is	O
##omer	O
in	O
co	O
##lon	O
cancer	O
tissue	O
compared	O
to	O
normal	O
co	O
##lon	O
m	O
##uc	O
##osa	O
,	O
in	O
con	O
##cor	O
##dance	O
with	O
the	O
observed	O
lower	O
u	O
##rina	O
##ry	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
levels	O
in	O
pre	O
-	O
surgery	O
,	O
tumor	O
bearing	O
patients	O
in	O
our	O
study	O
.	O

Our	O
prior	O
description	O
of	O
this	O
co	O
##hor	O
##t	O
showed	O
that	O
the	O
percentage	O
time	O
in	O
R	O
##EM	O
sleep	O
throughout	O
the	O
night	O
,	O
sleep	O
efficiency	O
,	O
as	O
well	O
as	O
self	O
-	O
reported	O
sleep	O
quality	O
,	O
were	O
lower	O
and	O
serum	O
co	B
##rt	I
##is	I
##ol	I
levels	O
were	O
higher	O
in	O
those	O
participants	O
with	O
I	O
##BS	O
relative	O
to	O
HC	O
##s	O
.	O

Response	O
##post	O
##−	O
##ex	O
##traction	O
##sp	O
##ike	O
Response	O
##post	O
##−	O
##ex	O
##traction	O
##sp	O
##ike	O
Response	O
##post	O
##−	O
##ex	O
##traction	O
##sp	O
##ike	O
Response	O
Response	O
post	O
##−	O
##ex	O
##traction	O
##sp	O
##ike	O
post	O
##−	O
##ex	O
##traction	O
##sp	O
##ike	O
post	O
−	O
extraction	O
spike	O
×	O
100	O
%	O
where	O
Response	O
_	O
pre	O
-	O
extraction	O
spike	O
is	O
the	O
mean	O
peak	O
area	O
count	O
for	O
pro	B
##line	I
samples	O
been	O
through	O
the	O
extraction	O
process	O
,	O
and	O
Response	O
_	O
post	O
-	O
extraction	O
spike	O
is	O
for	O
pro	B
##line	I
spike	O
##d	O
into	O
extracted	O
matrix	O
after	O
the	O
extraction	O
procedure	O
.	O

A	O
200	O
-	O
mg	O
Sep	O
-	O
Pak	O
t	O
##C	O
_	O
18	O
cartridge	O
(	O
SP	O
##E	O
##2	O
)	O
was	O
washed	O
with	O
6	O
m	O
##l	O
of	O
100	O
%	O
met	B
##han	I
##ol	I
,	O
6	O
m	O
##l	O
of	O
10	O
%	O
met	B
##han	I
##ol	I
and	O
conditioned	O
with	O
4	O
m	O
##l	O
of	O
70	O
%	O
met	B
##han	I
##ol	I
.	O

Di	O
##fference	O
##s	O
in	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
2	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
and	O
g	B
##ly	I
##cine	I
could	O
be	O
clearly	O
reproduced	O
,	O
while	O
changes	O
in	O
in	B
##os	I
##ine	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
and	O
ace	B
##tate	I
were	O
less	O
significant	O
.	O

The	O
elevated	O
levels	O
of	O
2	B
-	I
o	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tine	I
phosphate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
are	O
mainly	O
associated	O
with	O
an	O
enhanced	O
muscular	O
protein	O
turnover	O
,	O
amino	O
acid	O
oxidation	O
,	O
decreased	O
energy	O
supply	O
,	O
and	O
organ	O
failure	O
during	O
se	O
##ptic	O
shock	O
(	O
–	O
)	O
.	O

Other	O
authors	O
have	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
that	O
increasing	O
AD	B
##MA	I
levels	O
may	O
contribute	O
to	O
poor	O
se	O
##psis	O
outcome	O
.	O

The	O
vertical	O
line	O
at	O
x	O
=	O
_	O
~	O
0	O
in	O
,	O
Panel	O
I	O
.	O
D	O
-	O
F	O
shows	O
that	O
,	O
when	O
M	B
##T	I
##BE	I
is	O
the	O
solvent	O
,	O
PC	O
##T	O
extract	O
##s	O
a	O
series	O
of	O
high	O
abundance	O
compounds	O
from	O
f	O
##eca	O
##l	O
material	O
that	O
are	O
either	O
poorly	O
or	O
not	O
extracted	O
in	O
the	O
absence	O
of	O
pressure	O
.	O

2	O
##h	O
-	O
insulin	O
:	O
2	O
h	O
Post	O
##pra	O
##ndi	O
##al	O
plasma	O
glucose	S
.	O

Thus	O
,	O
we	O
excluded	O
models	O
not	O
containing	O
la	B
##ct	I
##ate	I
yielding	O
33	O
and	O
54	O
candidates	O
for	O
the	O
strict	O
and	O
extended	O
setting	O
,	O
respectively	O
.	O

We	O
previously	O
showed	O
that	O
ad	O
##ip	O
##ocytes	O
protect	O
m	B
##uri	I
##ne	I
le	O
##uke	O
##mia	O
cells	O
from	O
D	O
##NR	O
in	O
both	O
direct	O
contact	O
,	O
and	O
when	O
separated	O
by	O
semi	O
-	O
per	O
##me	O
##able	O
membrane	O
##s	O
.	O

In	O
the	O
HC	O
##C	O
-	O
related	O
metabolic	O
network	O
(	O
Figure	O
)	O
,	O
eleven	O
bio	O
##chemical	O
pathways	O
,	O
including	O
energy	O
metabolism	O
like	O
g	O
##ly	O
##co	O
##lysis	O
,	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
amino	O
acids	O
,	O
metabolism	O
##s	O
of	O
amino	O
acids	O
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
pu	B
##rine	I
and	O
but	B
##ano	I
##ate	I
,	O
and	O
T	O
##CA	O
cycle	O
,	O
were	O
involved	O
in	O
path	O
##ological	O
changes	O
of	O
HC	O
##C	O
patients	O
.	O

An	O
elevated	O
u	O
##rina	O
##ry	O
elimination	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
its	O
downstream	O
meta	O
##bol	O
##ite	O
,	O
u	B
##ric	I
acid	I
,	O
are	O
seen	O
as	O
the	O
end	O
##point	O
of	O
pu	B
##rine	I
metabolism	O
,	O
representing	O
an	O
indirect	O
marker	O
of	O
the	O
exercise	O
-	O
induced	O
net	O
ATP	S
loss	O
from	O
muscle	O
to	O
plasma	O
[	O
,	O
]	O
.	O

These	O
improved	O
g	B
##ly	I
##ce	I
##mic	I
control	O
by	O
3	O
-	O
H	O
##B	O
was	O
attributed	O
to	O
enhanced	O
le	O
##pt	O
##in	O
and	O
insulin	O
signaling	O
in	O
the	O
h	O
##y	O
##pot	O
##hala	O
##mus	O
rather	O
than	O
increased	O
insulin	O
secret	O
##ion	O
.	O

In	O
contrast	O
with	O
the	O
Omega	B
-	I
3	I
Ph	O
##L	O
Index	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
EPA	O
and	O
D	O
##HA	O
in	O
serum	O
p	O
##hos	O
##poli	O
##pid	O
##s	O
)	O
,	O
LA	O
content	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
not	O
affected	O
by	O
any	O
intervention	O
and	O
no	O
differences	O
in	O
LA	O
content	O
between	O
the	O
subgroup	O
##s	O
of	O
patients	O
were	O
found	O
,	O
either	O
before	O
or	O
after	O
the	O
intervention	O
(	O
see	O
Additional	O
file	O
2	O
)	O
.	O

B	O
##ias	O
(	O
%	O
)	O
and	O
precision	O
(	O
RS	O
##D	O
)	O
for	O
q	O
##uant	O
##ification	O
of	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
and	O
active	O
meta	O
##bol	O
##ites	O
in	O
plasma	O
with	O
different	O
anti	O
##coa	O
##gu	O
##lants	O
(	O
E	O
##D	O
##TA	O
and	O
he	B
##par	I
##in	I
)	O
and	O
in	O
serum	O
by	O
using	O
valid	O
##ated	O
c	O
##it	O
##rated	O
plasma	O
ca	O
##li	O
##bra	O
##tion	O
were	O
assessed	O
with	O
Q	O
##C	O
samples	O
(	O
n	O
=	O
3	O
)	O
spike	O
##d	O
at	O
10	O
,	O
150	O
and	O
1500	O
ng	O
/	O
m	O
##L	O
.	O
Additionally	O
,	O
E	O
##D	O
##TA	O
plasma	O
spike	O
##d	O
at	O
ca	O
##li	O
##bra	O
##tors	O
levels	O
were	O
also	O
q	O
##uant	O
##ified	O
using	O
reference	O
ca	O
##li	O
##bra	O
##tion	O
set	O
prepared	O
in	O
c	O
##it	O
##rated	O
plasma	O
.	O

In	O
addition	O
,	O
Mi	O
##ya	O
##jima	O
et	O
al	O
_	O
36	O
pointed	O
out	O
the	O
possibility	O
that	O
t	B
##yr	I
##os	I
##ine	I
is	O
incorporated	O
into	O
activated	S
T	O
cells	O
in	O
l	O
##ymph	O
nodes	O
,	O
which	O
are	O
observed	O
in	O
patients	O
with	O
pan	O
##cre	O
##atic	O
cancer	O
.	O

In	O
contrast	O
,	O
the	O
levels	O
of	O
a	O
few	O
meta	O
##bol	O
##ites	O
including	O
the	O
k	B
##eton	I
##e	I
body	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
as	O
well	O
as	O
the	O
free	O
fatty	O
acids	O
palm	O
##itate	O
,	O
s	B
##te	I
##arate	I
and	O
o	B
##ct	I
##ade	I
##ce	I
##no	I
##ate	I
declined	O
directly	O
after	O
flat	O
##bre	O
##ad	O
intake	O
and	O
reached	O
a	O
minimum	O
between	O
105	O
and	O
150	O
min	O
.	O

I	O
##mp	O
##aire	O
##d	O
u	B
##rea	I
metabolism	O
leads	O
to	O
decreased	O
am	O
##monia	O
de	O
##to	O
##xi	O
##fication	O
and	O
is	O
responsible	O
for	O
the	O
increase	O
levels	O
of	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
.	O

L	O
each	O
of	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##one	I
and	O
2	O
-	O
(	O
N	O
-	O
m	O
##or	O
##ph	O
##olin	O
##o	O
)	O
-	O
et	O
##hane	O
##sul	O
-	O
f	O
##onic	O
acid	O
]	O
.	O

Pro	O
##tein	O
precipitation	O
using	O
met	B
##han	I
##ol	I
provided	O
well	O
-	O
resolved	O
_	O
1	O
H	O
##N	O
##MR	O
s	O
##pect	O
##ra	O
for	O
all	O
the	O
serum	O
samples	O
.	O

The	O
meta	O
##bol	O
##ites	O
with	O
significance	O
were	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
and	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
.	O

The	O
SR	O
##M	O
conditions	O
for	O
the	O
pro	O
##ton	O
##ated	O
molecules	O
[	O
M	O
##H	O
_	O
+	O
]	O
of	O
E	O
##M	O
-	O
Dan	O
##sy	O
##l	O
and	O
d	O
-	O
E	O
##M	O
-	O
Dan	O
##sy	O
##l	O
were	O
as	O
follows	O
:	O
E	O
_	O
1	O
m	O
/	O
z	O
50	O
##4	O
→	O
171	O
collision	O
energy	O
:	O
42	O
e	O
##V	O
;	O
E	O
_	O
2	O
m	O
/	O
z	O
50	O
##6	O
→	O
171	O
collision	O
energy	O
:	O
43	O
e	O
##V	O
;	O
E	O
_	O
3	O
,	O
16	O
-	O
e	O
##pi	O
E	O
_	O
3	O
,	O
and	O
17	O
-	O
e	O
##pi	O
E	O
_	O
3	O
m	O
/	O
z	O
52	O
##2	O
→	O
171	O
collision	O
energy	O
:	O
43	O
e	O
##V	O
;	O
16	O
-	O
k	O
##eto	O
##E	O
_	O
2	O
,	O
and	O
16	B
##α	I
-	I
OH	I
##E	I
_	I
1	I
m	O
/	O
z	O
520	O
→	O
171	O
collision	O
energy	O
:	O
43	O
e	O
##V	O
;	O
2	O
-	O
Me	O
##OE	O
_	O
1	O
,	O
4	O
-	O
Me	O
##OE	O
_	O
1	O
,	O
and	O
3	O
-	O
Me	O
##OE	O
_	O
1	O
m	O
/	O
z	O
53	O
##4	O
→	O
171	O
collision	O
energy	O
:	O
42	O
e	O
##V	O
;	O
2	O
-	O
Me	O
##OE	O
_	O
2	O
and	O
4	O
-	O
Me	O
##OE	O
_	O
2	O
m	O
/	O
z	O
53	O
##6	O
→	O
171	O
collision	O
energy	O
:	O
43	O
e	O
##V	O
;	O
2	O
-	O
OH	O
##E	O
_	O
1	O
and	O
4	O
-	O
OH	O
##E	O
_	O
1	O
m	O
/	O
z	O
75	O
##3	O
→	O
170	O
collision	O
energy	O
:	O
44	O
e	O
##V	O
;	O
2	O
-	O
OH	O
##E	O
_	O
2	O
m	O
/	O
z	O
75	O
##5	O
→	O
170	O
collision	O
energy	O
:	O
43	O
e	O
##V	O
;	O
d	O
_	O
4	O
-	O
E	O
_	O
2	O
m	O
/	O
z	O
510	O
→	O

First	O
,	O
the	O
sum	O
of	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
in	O
urine	O
might	O
not	O
be	O
the	O
best	O
parameter	O
to	O
analyze	O
the	O
circa	O
##dian	O
variation	O
of	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
,	O
considering	O
the	O
possible	O
delayed	O
metabolism	O
of	O
co	B
##rt	I
##is	I
##ol	I
in	O
AN	O
,	O
especially	O
in	O
un	O
##tre	O
##ated	O
and	O
under	O
##weight	O
patients	O
.	O

Another	O
drug	O
-	O
like	O
cluster	O
was	O
an	O
##not	O
##ated	O
by	O
G	O
##NP	O
##S	O
with	O
ran	B
##iti	I
##dine	I
,	O
a	O
his	B
##tamine	I
H	O
##2	O
-	O
receptor	O
antagonist	O
(	O
in	O
##hibit	O
##ing	O
stomach	O
acid	O
production	O
)	O
,	O
with	O
20	O
separate	O
meta	O
##bol	O
##ites	O
present	O
in	O
one	O
sample	O
,	O
indicating	O
the	O
extensive	O
metabolism	O
to	O
which	O
this	O
drug	O
is	O
subject	O
.	O

For	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
,	O
a	O
clear	O
separation	O
was	O
observed	O
in	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
(	O
A	O
)	O
,	O
indicating	O
a	O
significant	O
impact	O
of	O
CR	O
##T	O
treatment	O
on	O
global	O
metabolism	O
.	O

On	O
one	O
-	O
way	O
AN	O
##O	O
##VA	O
,	O
(	O
B	O
)	O
format	B
##e	I
was	O
significantly	O
different	O
across	O
the	O
3	O
subgroup	O
##s	O
,	O
and	O
post	O
ho	O
##c	O
comparisons	O
using	O
the	O
Tu	O
##key	O
H	O
##SD	O
test	O
showed	O
format	B
##e	I
to	O
be	O
significantly	O
higher	O
in	O
the	O
MS	O
-	O
like	O
subgroup	O
compared	O
with	O
the	O
N	O
##MO	O
##SD	O
-	O
like	O
subgroup	O
,	O
as	O
well	O
as	O
to	O
the	O
L	O
##BL	O
subgroup	O
.	O

Individual	O
ratios	O
of	O
de	O
##pur	O
##inating	O
est	O
##rogen	O
-	O
DNA	O
add	O
##uc	O
##ts	O
to	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
in	O
urine	O
of	O
healthy	O
control	O
men	O
and	O
men	O
with	O
non	O
-	O
Ho	O
##d	O
##g	O
##kin	O
l	O
##ymph	O
##oma	O
(	O
NHL	O
)	O
.	O

Although	O
the	O
validity	O
of	O
C	O
##YP	O
##2	O
##D	O
##6	O
as	O
a	O
predict	O
##or	O
of	O
T	O
##AM	O
outcome	O
remains	O
controversial	O
,	O
the	O
definite	O
association	O
between	O
plasma	O
concentrations	O
of	O
end	B
##ox	I
##ife	I
##n	I
and	O
C	O
##YP	O
##2	O
##D	O
##6	O
genetic	O
p	O
##oly	O
##mor	O
##phism	O
has	O
been	O
consistently	O
demonstrated	O
by	O
prospective	O
p	O
##har	O
##ma	O
##cological	O
studies	O
.	O

While	O
that	O
sounds	O
like	O
a	O
plausible	O
explanation	O
for	O
the	O
negative	O
correlation	O
##s	O
between	O
fatty	O
acids	O
and	O
t	O
##G	O
##lut	O
,	O
t	O
##C	O
##r	O
and	O
t	O
##C	O
##ho	O
,	O
the	O
negative	O
correlation	O
with	O
la	B
##ct	I
##ate	I
is	O
harder	O
to	O
understand	O
since	O
there	O
are	O
many	O
reports	O
in	O
the	O
literature	O
that	O
la	B
##ct	I
##ate	I
is	O
found	O
along	O
with	O
lip	O
##ids	O
in	O
ne	O
##c	O
##rot	O
##ic	O
and	O
pre	O
-	O
ne	O
##c	O
##rot	O
##ic	O
regions	O
of	O
brain	O
t	O
##umour	O
##s	O
(	O
most	O
of	O
these	O
studies	O
have	O
been	O
on	O
g	O
##lio	O
##mas	O
)	O
both	O
in	O
v	O
##ivo	O
(	O
e	O
.	O
g	O
.	O
by	O
MR	O
##S	O
)	O
and	O
ex	O
v	O
##ivo	O
.	O

In	O
our	O
study	O
,	O
α	B
-	I
CE	I
##HC	I
was	O
up	O
##re	O
##gu	O
##lated	O
in	O
cancer	O
patients	O
compared	O
to	O
that	O
in	O
the	O
healthy	O
controls	O
,	O
and	O
the	O
fold	O
change	O
was	O
4	O
.	O
38	O
,	O
which	O
confirms	O
an	O
accelerated	O
vitamin	B
E	I
metabolism	O
.	O

The	O
serum	O
metabolic	O
profiles	O
that	O
we	O
measured	O
indicate	O
that	O
T	O
##BI	O
patients	O
with	O
cognitive	O
imp	O
##air	O
##ment	O
had	O
higher	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
levels	O
and	O
lower	O
palm	B
##itic	I
acid	I
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
levels	O
.	O

HP	O
##LC	O
grade	O
met	B
##han	I
##ol	I
and	O
water	O
from	O
B	O
##ur	O
##dick	O
and	O
Jackson	O
(	O
Mu	O
##ske	O
##gon	O
,	O
MI	O
)	O
were	O
used	O
to	O
prepare	O
the	O
L	O
##C	O
mobile	O
phase	O
.	O

Similarly	O
,	O
k	B
##eton	I
##es	I
were	O
also	O
positively	O
correlated	O
with	O
several	O
amino	O
acids	O
such	O
as	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
during	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
,	O
but	O
this	O
correlation	O
became	O
negative	O
with	O
insulin	O
treatment	O
.	O

The	O
cooked	O
meat	O
car	O
##cin	O
##ogen	O
Ph	O
##IP	O
and	O
the	O
non	O
-	O
n	O
##uc	O
##leo	O
##side	O
reverse	O
trans	O
##cript	O
##ase	O
inhibitor	O
N	B
##eva	I
##rip	I
##ine	I
also	O
form	O
add	O
##uc	O
##ts	O
at	O
the	O
T	O
##rp	O
##21	O
##4	O
of	O
human	O
Al	O
##b	O
in	O
v	O
##it	O
##ro	O
.	O
_	O
−	O
Since	O
rat	O
and	O
human	O
Al	O
##b	O
contain	O
only	O
a	O
single	O
try	B
##pt	I
##op	I
##han	I
residue	O
at	O
T	O
##rp	O
##21	O
##4	O
situated	O
in	O
a	O
h	O
##ydro	O
##phobic	O
drug	O
-	O
binding	O
site	O
,	O
its	O
high	O
select	O
##ivity	O
for	O
car	O
##cin	O
##ogen	O
binding	O
suggests	O
a	O
unique	O
role	O
for	O
Al	O
##b	O
in	O
the	O
de	O
##to	O
##xi	O
##fication	O
and	O
/	O
or	O
transport	O
of	O
ultimate	O
car	O
##cin	O
##ogenic	O
/	O
toxic	O
meta	O
##bol	O
##ites	O
.	O

However	O
,	O
the	O
suspected	O
increased	O
availability	O
of	O
beta	B
##ine	I
might	O
be	O
blunt	O
##ed	O
through	O
a	O
general	O
down	O
regulation	O
of	O
this	O
pathway	O
.	O

The	O
major	O
part	O
of	O
the	O
library	O
–	O
as	O
well	O
as	O
a	O
substantial	O
fraction	O
of	O
the	O
meta	O
##bol	O
##ome	O
–	O
is	O
comprised	O
of	O
compounds	O
that	O
are	O
appropriate	O
targets	O
for	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
L	O
##C	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
o	O
##xi	O
##das	O
##e	O
h	O
##ydro	O
##ly	O
##zes	O
sa	O
##rc	O
##os	O
##ine	O
to	O
g	B
##ly	I
##cine	I
,	O
formal	B
##de	I
##hy	I
##de	I
and	O
per	B
##oxide	I
.	O

El	O
##eva	O
##ted	O
levels	O
of	O
AM	B
##P	I
can	O
be	O
attributed	O
to	O
increased	O
conversion	O
of	O
ad	B
##eno	I
##sin	I
##e	I
to	O
AM	B
##P	I
by	O
ad	B
##eno	I
##sin	I
##e	I
kinase	O
enzymes	O
during	O
cell	O
proliferation	O
.	O

In	O
this	O
pilot	O
,	O
we	O
sought	O
to	O
examine	O
associations	O
between	O
blood	O
K	B
##P	I
ne	O
##uro	O
-	O
toxic	O
/	O
t	O
##rop	O
##hic	O
measures	O
and	O
an	O
##hed	O
##onia	O
/	O
depression	O
associated	O
networks	O
in	O
youth	O
with	O
major	O
depression	O
(	O
MD	O
##D	O
)	O
and	O
healthy	O
controls	O
(	O
HC	O
)	O
.	O

Medium	O
-	O
chain	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
##s	O
and	O
sub	B
##eric	I
acid	I
displayed	O
the	O
same	O
inverse	O
association	O
with	O
try	B
##pt	I
##op	I
##han	I
,	O
while	O
in	B
##do	I
##lea	I
##ce	I
##tic	I
acid	I
,	O
a	O
breakdown	O
product	O
of	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
was	O
strongly	O
associated	O
with	O
PS	O
##A	O
(	O
p	O
=	O
0	O
.	O
00	O
##8	O
##1	O
,	O
Lo	O
##g	O
-	O
Rank	O
test	O
)	O
and	O
l	O
##ymph	O
node	O
progression	O
(	O
p	O
=	O
0	O
.	O
02	O
##5	O
,	O
Lo	O
##g	O
-	O
Rank	O
test	O
)	O
.	O

Blood	O
was	O
collected	O
into	O
E	O
##D	O
##TA	O
and	O
sodium	B
c	I
##it	I
##rate	I
v	O
##ac	O
##uta	O
##iner	O
tubes	O
.	O

Finally	O
,	O
Co	O
##Q	O
_	O
10	O
,	O
which	O
is	O
a	O
key	O
component	O
of	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
that	O
generates	O
ATP	S
by	O
a	O
##ero	O
##bic	O
re	O
##spiration	O
and	O
also	O
a	O
component	O
of	O
serum	O
lip	O
##op	O
##rote	O
##ins	O
,	O
was	O
40	O
%	O
reduced	O
in	O
AM	O
##L	O
plasma	O

However	O
,	O
they	O
share	O
a	O
common	O
mechanism	O
of	O
action	O
associated	O
with	O
the	O
interaction	O
with	O
th	B
##iol	I
groups	O
.	O

We	O
demonstrate	O
that	O
meta	O
##bol	O
##ites	O
identified	O
using	O
a	O
high	O
-	O
through	O
##put	O
method	O
(	O
G	O
##C	O
-	O
MS	O
)	O
perform	O
well	O
in	O
predict	O
##ing	O
the	O
development	O
of	O
fast	O
##ing	O
plasma	O
glucose	S
over	O
several	O
years	O
.	O

The	O
PC	O
##A	O
models	O
derived	O
from	O
the	O
_	O
1	O
H	O
-	O
N	O
##MR	O
analysis	O
show	O
that	O
N	O
##MR	O
signals	O
belonging	O
to	O
la	B
##ctic	I
acid	I
,	O
α	B
-	I
glucose	I
and	O
β	B
-	I
glucose	I
were	O
the	O
most	O
significant	O
in	O
contributing	O
to	O
sample	O
group	O
separation	O
(	O
and	O
)	O
.	O

For	O
lip	O
##ido	O
##mic	O
analyses	O
,	O
type	O
2	O
diabetes	O
patients	O
(	O
n	O
=	O
21	O
)	O
and	O
individuals	O
treated	O
with	O
lip	O
##id	O
‐	O
lowering	O
medications	O
(	B
s	B
##tat	I
##ins	I
[	O
n	O
=	O
8	O
]	O
or	O
e	O
##ze	O
##ti	O
##mi	O
##be	O
[	O
n	O
=	O
1	O
]	O
)	O
were	O
excluded	O
;	O
therefore	O
,	O
findings	O
for	O
n	O
=	O
51	O
are	O
reported	O
.	O

The	O
decreased	O
level	O
of	O
total	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
the	O
most	O
apparent	O
effect	O
observed	O
during	O
the	O
first	O
step	O
of	O
the	O
treatment	O
.	O

Sign	O
##ificant	O
differences	O
in	O
six	O
-	O
month	O
changes	O
between	O
R	O
##Y	O
##GB	O
and	O
W	O
##LM	O
therefore	O
mostly	O
reflect	O
changes	O
for	O
R	O
##Y	O
##GB	O
(	O
with	O
W	O
##LM	O
mostly	O
unchanged	O
)	O
and	O
since	O
weight	O
loss	O
was	O
equivalent	O
between	O
groups	O
,	O
suggest	O
an	O
association	O
with	O
g	B
##ly	I
##ce	I
##mic	I
improvement	O
.	O

On	O
the	O
contrary	O
,	O
markers	O
of	O
insulin	O
sensitivity	O
included	O
large	O
HD	B
##L	I
t	I
##rig	I
##ly	I
##cer	I
##ides	I
,	O
fraction	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
to	O
total	O
lip	O
##ids	O
in	O
medium	O
HD	O
##L	O
,	O
g	B
##ly	I
##cine	I
,	O
and	O
ace	B
##tate	I
.	O

Ad	O
##ding	O
this	O
pharmaceutical	O
to	O
the	O
standard	O
therapy	O
of	O
C	O
##K	O
##D	O
patients	O
showed	O
reduced	O
serum	O
levels	O
of	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
[	O
,	O
]	O
,	O
improvement	O
in	O
some	O
of	O
the	O
u	O
##rae	O
##mia	O
symptoms	O
and	O
a	O
decrease	O
in	O
markers	O
for	O
card	O
##iovascular	O
disease	O
.	O

For	O
amino	O
acid	O
fragment	O
##ation	O
the	O
collision	O
energy	O
of	O
30	O
V	O
was	O
applied	O
,	O
except	O
from	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nic	I
acid	I
(	O
As	O
##a	O
)	O
,	O
L	B
-	I
or	I
##ni	I
##thin	I
##e	I
(	O
Or	O
##n	O
)	O
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
(	O
C	O
##th	O
)	O
,	O
L	B
-	I
c	I
##ys	I
##tine	I
(	O
Cy	O
##s	O
)	O
,	O
δ	B
-	I
h	I
##ydro	I
##xy	I
##ly	I
##sin	I
##e	I
(	O
H	O
##yl	O
)	O
,	O
L	B
-	I
l	I
##ys	I
##ine	I
(	O
L	O
##ys	O
)	O
and	O
L	B
-	I
ho	I
##mo	I
##cy	I
##st	I
##ine	I
(	O
H	O
##cy	O
)	O
(	O
50	O
V	O
)	O
.	O

Each	O
sample	O
was	O
injected	O
in	O
a	O
split	O
ratio	O
of	O
1	O
:	O
10	O
,	O
and	O
then	O
separation	O
was	O
carried	O
out	O
on	O
a	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
column	O
(	O
BP	O
##X	O
##5	O
;	O
inner	O
diameter	O
:	O
30	O
m	O
×	O
0	O
.	O
25	O
mm	O
,	O
film	O
thickness	O
:	O
0	O
.	O
25	O
μ	O
##m	O
;	O
S	O
##GE	O
Ana	O
##ly	O
##tical	O
Science	O
)	O
.	O

Final	O
extract	O
##s	O
were	O
than	O
analyzed	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
for	O
amino	O
acids	O
and	O
bio	O
##active	O
am	O
##ines	O
PT	O
##C	O
-	O
derivatives	O
using	O
a	O
Z	O
##or	O
##ba	O
##x	O
S	O
##B	O
100	O
×	O
2	O
.	O
1	O
mm	O
column	O
(	O
A	O
##gi	O
##lent	O
,	O
Santa	O
Clara	O
CA	O
,	O
USA	O
)	O
,	O
while	O
direct	O
flow	O
injection	O
analysis	O
(	O
FIA	O
-	O
MS	O
/	O
MS	O
)	O
was	O
used	O
for	O
the	O
analysis	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
p	O
##hos	O
##poli	O
##pid	O
##es	O
.	O

Con	O
##sist	O
##ent	O
with	O
this	O
idea	O
,	O
cap	B
##ryl	I
##ic	I
acid	I
was	O
(	O
weakly	O
)	O
positively	O
correlated	O
with	O
a	O
number	O
of	O
health	O
-	O
associated	O
gut	O
an	O
##ae	O
##robe	O
##s	O
,	O
including	O
Ali	O
##st	O
##ip	O
##es	O
s	O
##ha	O
##hi	O
##i	O
,	O
A	O
.	O
put	O
##red	O
##ini	O
##s	O
,	O
and	O
A	O
.	O
fine	O
##gold	O
##ii	O
.	O

U	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
and	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
concentrations	O
by	O
pregnancy	O
status	O
,	O
L	O
##IF	O
##E	O
Study	O
,	O
2005	O
–	O
2009	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
a	O
pu	B
##rine	I
derivative	O
and	O
a	O
reaction	O
intermediate	O
in	O
the	O
metabolism	O
of	O
ad	B
##eno	I
##sin	I
##e	I
and	O
in	O
the	O
formation	O
of	O
nuclei	O
acids	O
by	O
the	O
salvage	O
pathway	O
.	O

B	O
##rief	O
##ly	O
,	O
freshly	O
isolated	O
ex	O
##oso	O
##mes	O
were	O
put	O
on	O
a	O
copper	O
grid	O
coated	O
with	O
0	O
.	O
125	O
%	O
Form	O
##var	O
in	O
ch	B
##lor	I
##of	I
##orm	I
.	O

Moreover	O
,	O
it	O
has	O
been	O
suggested	O
that	O
g	B
##ly	I
##cine	I
promotes	O
cancer	O
cell	O
growth	O
in	O
lung	O
tumor	O
‐	O
in	O
##iti	O
##ating	O
cells	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Water	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
were	O
of	O
CH	O
##RO	O
##MA	O
##SO	O
##L	O
##V	O
grade	O
.	O

Common	O
key	O
exclusion	O
criteria	O
for	O
both	O
studies	O
were	O
as	O
follows	O
:	O
con	O
##com	O
##ita	O
##nt	O
treatment	O
with	O
any	O
other	O
anti	O
##can	O
##cer	O
drugs	O
;	O
presence	O
of	O
ma	O
##la	O
##bs	O
##or	O
##ption	O
syndrome	O
or	O
disease	O
significantly	O
affecting	O
gas	O
##tro	O
-	O
in	O
##test	O
##inal	O
function	O
or	O
major	O
re	O
##section	O
of	O
the	O
stomach	O
or	O
pro	O
##ximal	O
small	O
bow	O
##el	O
that	O
could	O
affect	O
absorption	O
of	O
oral	O
v	O
##ino	O
##rel	O
##bine	O
;	O
known	O
h	O
##yper	O
##sen	O
##si	O
##ti	O
##vity	O
to	O
drugs	O
with	O
similar	O
chemical	O
structures	O
of	O
study	O
drugs	O
;	O
con	O
##com	O
##ita	O
##nt	O
treatment	O
with	O
co	O
##rt	O
##ico	O
##ster	O
##oids	O
except	O
chronic	O
treatment	O
lasting	O
more	O
than	O
1	O
month	O
,	O
given	O
at	O
low	O
doses	O
(	O
≤	O
20	O
mg	O
/	O
day	O
of	O
met	B
##hyl	I
##p	I
##red	I
##nis	I
##olo	I
##ne	I
or	O
equivalent	O
)	O
.	O

Currently	O
MA	O
##LD	O
##I	O
‐	O
MS	O
##I	O
can	O
be	O
used	O
to	O
analyze	O
acidic	O
meta	O
##bol	O
##ites	O
,	O
lip	O
##ids	O
,	O
g	B
##ly	I
##cans	I
,	O
end	O
##ogen	O
##ous	O
p	O
##eptide	O
##s	O
,	O
pro	O
##te	O
##oly	O
##tic	O
p	O
##eptide	O
##s	O
,	O
and	O
proteins	O
.	O

I	O
##mm	O
##uno	O
##his	O
##to	O
##chemistry	O
was	O
utilized	O
for	O
ER	O
##BB	O
##2	O
(	O
er	O
##b	O
-	O
b	O
##2	O
receptor	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
2	O
)	O
testing	O
,	O
3	O
+	O
scores	O
were	O
considered	O
positive	O
and	O
1	O
+	O
as	O
negative	O
.	O

Fu	B
##mar	I
##ic	I
acid	I
is	O
a	O
small	O
-	O
molecule	O
meta	O
##bol	O
##ite	O
that	O
recently	O
be	O
identified	O
as	O
an	O
e	O
##pi	O
##gene	O
##tic	O
m	O
##od	O
##ifier	O
.	O

The	O
increase	O
of	O
la	B
##ct	I
##ate	I
in	O
the	O
CS	O
##F	O
of	O
N	O
##MO	O
##SD	O
may	O
support	O
the	O
d	O
##ys	O
##function	O
of	O
mit	O
##och	O
##ond	O
##ria	O
because	O
glucose	S
is	O
s	O
##hun	O
##ted	O
primarily	O
to	O
la	B
##ct	I
##ate	I
through	O
an	O
##ae	O
##ro	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
in	O
the	O
abnormal	O
state	O
of	O
o	O
##xi	O
##da	O
##tive	O
glucose	S
metabolism	O
.	O

B	O
##ile	O
acid	O
levels	O
of	O
ch	B
##eno	I
##de	I
##ox	I
##ych	I
##olic	I
acid	I
,	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
,	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
,	O
ch	B
##olic	I
acid	I
,	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olic	I
acid	I
,	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
,	O
and	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
were	O
quantitative	O
##ly	O
determined	O
and	O
compared	O
among	O
ben	O
##ign	O
liver	O
tumor	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
,	O
HC	O
##C	O
with	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
,	O
HC	O
##C	O
without	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
,	O
and	O
healthy	O
controls	O
,	O
as	O
shown	O
in	O
.	O

The	O
distribution	O
of	O
individual	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
can	O
vary	O
,	O
and	O
therefore	O
further	O
study	O
is	O
needed	O
for	O
temporal	O
assessment	O
over	O
time	O
.	O

Both	O
cell	O
types	O
were	O
culture	O
##d	O
in	O
R	O
##PM	O
##I	O
1640	O
with	O
L	B
-	I
g	I
##lut	I
##amine	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
inactivated	O
dial	O
##y	O
##zed	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
(	O
F	O
##BS	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
and	O
anti	O
##biotics	O
(	B
pen	B
##ici	I
##llin	I
100	O
units	O
/	O
m	O
##l	O
;	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
100	O
µ	O
##g	O
/	O
m	O
##l	O
,	O
B	O
##io	O
##ch	O
##rom	O
AG	O
)	O
at	O
37	O
##°	O
##C	O
with	O
5	O
%	O
CO	O
_	O
2	O
in	O
a	O
humid	O
##ified	O
atmosphere	O
.	O

Finally	O
,	O
we	O
opted	O
for	O
LL	O
##E	O
with	O
et	B
##hyl	I
ace	I
##tate	I
.	O

Path	O
##way	O
analysis	O
only	O
showed	O
an	O
influence	O
on	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
mainly	O
through	O
K	O
##yn	O
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
and	O
A	O
##c	O
-	O
Co	O
##A	O
,	O
and	O
lesser	O
effects	O
on	O
G	B
##S	I
##H	I
metabolism	O
and	O
fatty	O
acid	O
el	O
##ong	O
##ation	O
in	O
mit	O
##och	O
##ond	O
##ria	O
;	O
none	O
of	O
these	O
pathway	O
effects	O
survived	O
F	O
##DR	O
correction	O
(	O
Fi	O
##g	O
.	O

The	O
coefficient	O
of	O
0	O
.	O
32	O
–	O
0	O
.	O
48	O
was	O
used	O
as	O
the	O
cut	O
-	O
off	O
value	O
in	O
the	O
different	O
models	O
(	O
according	O
to	O
number	O
of	O
samples	O
)	O
for	O
the	O
evaluation	O
of	O
significant	O
differences	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
CD	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
,	O
GP	B
##C	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
HD	O
##L	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
,	O
N	O
##AG	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
Re	O
##m	O
re	O
##mission	O
,	O
U	O
##1	O
,	O
U2	O
,	O
U	O
##3	O
unknown	O
meta	O
##bol	O
##ites	O
,	O
UC	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
,	O

The	O
der	O
##iva	O
##ti	O
##zation	O
of	O
the	O
p	B
##oly	I
##amine	I
species	O
was	O
carried	O
out	O
with	O
dans	B
##yl	I
chloride	I
in	O
an	O
al	B
##kal	I
##ine	I
medium	O
.	O

Also	O
,	O
deficiency	O
in	O
g	B
##lut	I
##amine	I
but	O
not	O
glucose	S
induce	O
##s	O
M	O
##Y	O
##C	O
-	O
dependent	O
a	O
##pop	O
##tosis	O
in	O
human	O
cancer	O
cells	O
.	O

Ad	O
##ju	O
##sting	O
for	O
age	O
,	O
B	O
##MI	O
,	O
current	O
smoking	O
,	O
race	O
,	O
and	O
measurement	O
batch	O
,	O
u	O
##rina	O
##ry	O
mon	B
##oc	I
##ar	I
##box	I
##y	I
-	I
is	I
##ono	I
##ny	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
MC	O
##NP	O
)	O
concentrations	O
were	O
positively	O
associated	O
with	O
m	O
##t	O
##D	O
##NA	O
##c	O
##n	O
(	O
β	O
=	O
1	O
.	O
63	O
,	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
14	O
,	O
3	O
.	O
11	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
gut	O
micro	O
##bio	O
##ta	O
and	O
its	O
composition	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
association	O
between	O
plasma	O
T	B
##MA	I
##O	I
and	O
G	O
##DM	O
.	O

13	O
different	O
concentrations	O
of	O
meta	O
##bol	O
##ites	O
were	O
found	O
between	O
R	O
##R	O
##MM	O
and	O
N	O
##DM	O
##M	O
patients	O
(	O
free	O
car	B
##ni	I
##tine	I
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
five	O
L	O
##ys	O
##o	O
##PC	O
##s	O
and	O
PC	O
##s	O
)	O
.	O

The	O
SL	S
metabolic	O
pathway	O
is	O
an	O
important	O
cellular	O
pathway	O
that	O
represents	O
a	O
highly	O
coordinated	O
system	O
in	O
which	O
S	O
##1	O
##P	O
induce	O
##s	O
cell	O
survival	O
,	O
while	O
c	B
##era	I
##mi	I
##de	I
induce	O
##s	O
programmed	O
cell	O
death	O
.	O

V	O
##eno	O
##us	O
blood	O
samples	O
were	O
drawn	O
for	O
measurement	O
of	O
blood	O
glucose	S
,	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
as	O
well	O
as	O
“	O
classical	O
”	O
markers	O
of	O
inflammation	O
such	O
as	O
high	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
h	O
##s	O
-	O
CR	O
##P	O
)	O
and	O
inter	O
##le	O
##uki	O
##n	O
-	O
6	O
(	O
h	O
##s	O
-	O
IL	O
-	O
6	O
)	O
.	O

Gala	B
##ct	I
##ose	I
levels	O
in	O
whole	O
blood	O
were	O
determined	O
in	O
a	O
healthy	O
volunteer	O
after	O
the	O
oral	O
consumption	O
of	O
250	O
m	O
##l	O
of	O
water	O
in	O
which	O
0	O
.	O
3	O
g	O
of	O
gal	B
##act	I
##ose	I
per	O
k	O
##ilo	O
##gram	O
of	O
body	O
weight	O
had	O
been	O
dissolved	O
.	O

E	O
##H	O
c	O
##lamp	O
was	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
car	B
##ni	I
##tine	I
(	O
C	O
##0	O
)	O
levels	O
in	O
control	O
subjects	O
but	O
not	O
in	O
T	O
##CF	O
##7	O
##L	O
##2	O
risk	O
all	O
##ele	O
carriers	O
and	O
a	O
marked	O
decrease	O
of	O
short	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
C	O
##2	O
,	O
C	O
##3	O
)	O
and	O
NE	O
##FA	O
##s	O
levels	O
in	O
both	O
groups	O
.	O

All	O
plasma	O
samples	O
were	O
th	O
##awed	O
in	O
a	O
4	O
°C	O
water	O
bath	O
and	O
v	O
##ortex	O
##ed	O
for	O
15	O
s	O
.	O
A	O
50	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##t	O
was	O
extracted	O
with	O
100	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
and	O
v	O
##ortex	O
##ed	O
for	O
2	O
min	O
.	O

In	O
addition	O
,	O
a	O
detailed	O
correlation	O
of	O
A	O
##po	O
##E	O
g	O
##eno	O
##type	O
,	O
plasma	O
levels	O
of	O
glucose	S
and	O
insulin	O
,	O
medication	O
,	O
liver	O
enzymes	O
and	O
/	O
or	O
post	O
-	O
p	O
##rand	O
##ial	O
intervals	O
may	O
help	O
to	O
follow	O
up	O
the	O
changes	O
at	O
a	O
more	O
me	O
##chan	O
##istic	O
level	O
,	O
which	O
was	O
,	O
however	O
,	O
not	O
in	O
focus	O
in	O
this	O
study	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
such	O
as	O
ace	B
##tone	I
,	O
ethanol	S
,	O
met	B
##han	I
##ol	I
,	O
2	B
-	I
prop	I
##ano	I
##l	I
,	O
dim	O
##eth	O
##yl	O
am	O
##ine	O
,	O
and	O
u	B
##rea	I
,	O
however	O
,	O
were	O
not	O
detected	O
here	O
due	O
to	O
sample	O
drying	O
or	O
dissolution	O
in	O
de	O
##uter	O
##ated	O
solvent	O
,	O
as	O
described	O
in	O
our	O
previous	O
study	O
.	O

Down	O
##ward	O
peaks	O
indicate	O
higher	O
concentrations	O
of	O
the	O
respective	O
meta	O
##bol	O
##ites	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
,	O
and	O
upward	O
peaks	O
indicate	O
higher	O
concentrations	O
of	O
respective	O
meta	O
##bol	O
##ites	O
in	O
the	O
low	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
.	O

It	O
is	O
therefore	O
con	O
##ce	O
##ivable	O
that	O
the	O
increased	O
risk	O
associated	O
with	O
relatively	O
low	O
plasma	O
level	O
of	O
MMA	O
is	O
a	O
reflection	O
of	O
heightened	O
post	O
translation	O
##al	O
modification	O
of	O
proteins	O
through	O
di	O
-	O
met	O
##hyl	O
##ation	O
reactions	O
and	O
pro	O
##te	O
##oly	O
##sis	O
,	O
producing	O
AD	B
##MA	I
and	O
SD	O
##MA	O
in	O
patients	O
with	O
card	O
##iovascular	O
diseases	O
or	O
those	O
at	O
risk	O
of	O
card	O
##iovascular	O
events	O
.	O

However	O
,	O
both	O
try	B
##pt	I
##op	I
##han	I
and	O
se	B
##rot	I
##oni	I
##n	I
were	O
increased	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
in	O
plasma	O
samples	O
obtained	O
from	O
the	O
same	O
study	O
participants	O
.	O

Multi	O
##var	O
##iable	O
log	O
##istic	O
re	O
##gression	O
models	O
are	O
used	O
to	O
estimate	O
the	O
OR	O
##s	O
associated	O
with	O
various	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
among	O
RA	O
and	O
control	O
subjects	O
.	O

Studies	O
in	O
animals	O
have	O
shown	O
the	O
consequences	O
of	O
met	O
##hyl	O
donor	O
–	O
def	O
##icient	O
diet	O
##s	O
imp	O
##air	O
##ing	O
mitochondrial	O
FA	S
oxidation	O
and	O
consequently	O
decreasing	O
free	O
and	O
total	O
circulating	O
car	B
##ni	I
##tine	I
##s	I
.	O

A	O
study	O
that	O
compared	O
pro	O
##static	O
fluid	O
samples	O
showed	O
that	O
the	O
m	O
##olar	O
ratio	O
of	O
c	B
##it	I
##rate	I
:	O
sperm	B
##ine	I
is	O
5	O
:	O
1	O
in	O
normal	O
pro	O
##static	O
fluid	O
,	O
but	O
a	O
relatively	O
higher	O
level	O
of	O
sperm	B
##ine	I
was	O
found	O
in	O
pro	O
##static	O
fluid	O
from	O
men	O
with	O
PC	O
##a	O
.	O

The	O
liver	O
regulate	O
##s	O
and	O
maintains	O
the	O
he	O
##pa	O
##tic	O
pools	O
of	O
u	B
##rid	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
via	O
de	O
no	O
##vo	O
u	B
##rid	I
##ine	I
synthesis	O
and	O
degradation	O
which	O
is	O
essential	O
for	O
the	O
ho	O
##mo	O
##eo	O
##static	O
control	O
of	O
plasma	O
u	B
##rid	I
##ine	I
pools	O
.	O

Rather	O
,	O
these	O
correlation	O
##s	O
suggest	O
that	O
a	O
more	O
complex	O
der	O
##ang	O
##ement	O
of	O
SP	S
metabolism	O
results	O
from	O
increased	O
ad	O
##ip	O
##os	O
##ity	O
and	O
/	O
or	O
contributes	O
to	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
to	O
o	O
##besity	O
.	O

[	O
]	O
This	O
t	O
_	O
r	O
corresponds	O
to	O
an	O
A	O
##F	O
##4	O
-	O
calculated	O
spherical	O
h	B
##ydro	I
##dynamic	I
diameter	O
of	O
~	O
10	O
nm	O
and	O
is	O
within	O
the	O
expected	O
~	O
7	O
nm	O
to	O
15	O
nm	O
span	O
for	O
HD	O
##L	O
.	O

The	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
competed	O
for	O
9	O
-	O
c	O
##is	O
-	O
re	O
##tino	O
##ic	O
acid	O
binding	O
with	O
an	O
affinity	O
(	O
7	O
–	O
8	O
nm	O
)	O
identical	O
to	O
9	O
-	O
c	O
##is	O
-	O
re	O
##tino	O
##ic	O
acid	O
itself	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
A	O
)	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
)	O
,	O
and	O
the	O
flow	O
rate	O
was	O
0	O
.	O
35	O
m	O
##L	O
/	O
min	O
.	O

In	O
addition	O
,	O
the	O
rapid	O
proliferation	O
of	O
ma	O
##li	O
##gnant	O
tumor	O
cells	O
requires	O
the	O
synthesis	O
of	O
a	O
large	O
number	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
and	O
proteins	O
,	O
leading	O
to	O
the	O
increase	O
of	O
g	B
##ly	I
##cine	I
as	O
the	O
synthesis	O
of	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
.	O

Twenty	O
portions	O
of	O
serum	O
(	O
350	O
μ	O
L	O
each	O
)	O
were	O
mixed	O
with	O
met	B
##han	I
##ol	I
in	O
a	O
1	O
:	O
2	O
ratio	O
(	O
v	O
/	O
v	O
)	O
,	O
v	O
##ortex	O
##ed	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
20	O
min	O
.	O

Intermediate	O
2	O
was	O
synthesized	O
by	O
react	O
##ing	O
the	O
intermediate	O
1	O
with	O
p	B
##hos	I
##ph	I
##orous	I
o	I
##xy	I
##ch	I
##lor	I
##ide	I
for	O
15	O
hours	O
.	O

Two	O
positive	O
transitions	O
(	O
q	O
##uant	O
##ifier	O
MR	O
##M	O
and	O
confirmed	O
with	O
the	O
qualifier	O
MR	O
##M	O
transition	O
)	O
were	O
used	O
for	O
the	O
measurement	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
+	O
29	O
##4	O
/	O
225	O
and	O
+	O
29	O
##4	O
/	O
115	O
)	O
,	O
h	B
##ydro	I
##xy	I
-	I
an	I
##ast	I
##ro	I
##zo	I
##le	I
(	O
+	O
310	O
.	O
2	O
/	O
241	O
.	O
5	O
and	O
+	O
310	O
.	O
2	O
/	O
214	O
.	O
5	O
)	O
and	O
the	O
internal	O
standard	O
des	B
##met	I
##hyl	I
##dia	I
##ze	I
##pa	I
##m	I
(	O
+	O
27	O
##1	O
/	O
140	O
and	O
+	O
27	O
##1	O
/	O
208	O
)	O
.	O

The	O
severe	O
der	O
##eg	O
##ulation	O
in	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
metabolism	O
suggests	O
that	O
HIV	O
infection	O
leads	O
to	O
def	O
##ici	O
##encies	O
in	O
mitochondrial	O
function	O
.	O

Next	O
,	O
a	O
10	O
μ	O
##l	O
mixture	O
of	O
t	B
##ri	I
##f	I
##lu	I
##ora	I
##ce	I
##ty	I
##lant	I
##hra	I
##ce	I
##en	I
,	O
di	O
##cy	O
##c	O
##lo	O
##he	O
##xy	O
##l	O
##ph	O
##thal	O
##ate	O
(	O
DC	O
##HP	O
)	O
and	O
di	O
##f	O
##lu	O
##oro	O
##bi	O
##phe	O
##ny	O
##l	O
(	O
each	O
at	O
a	O
concentration	O
of	O
250	O
μ	O
##g	O
/	O
m	O
##l	O
in	O
p	B
##yr	I
##id	I
##ine	I
)	O
was	O
mixed	O
with	O
the	O
extract	O
##s	O
and	O
the	O
mixture	O
##s	O
were	O
si	O
##ly	O
##lated	O
for	O
50	O
min	O
at	O
40	O
##°	O
##C	O
with	O
200	O
μ	O
##l	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
.	O

The	O
ratio	O
of	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
to	O
parent	O
est	O
##rogen	O
##s	O
and	O
the	O
ratio	O
of	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
to	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
were	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
,	O
even	O
after	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

We	O
suggest	O
that	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
,	O
through	O
the	O
involvement	O
in	O
de	O
no	O
##vo	O
synthesis	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
such	O
as	O
c	B
##era	I
##mi	I
##des	I
may	O
play	O
an	O
important	O
part	O
in	O
the	O
development	O
of	O
metabolic	O
disease	O
from	O
o	O
##besity	O
.	O

To	O
verify	O
that	O
the	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
ass	O
##ays	O
yielded	O
consistent	O
results	O
across	O
the	O
populations	O
,	O
we	O
regularly	O
measured	O
a	O
set	O
of	O
20	O
quality	O
control	O
serum	O
samples	O
collected	O
from	O
healthy	O
donors	O
.	O

Media	O
##n	O
,	O
5th	O
,	O
and	O
95	O
##th	O
percent	O
##ile	O
for	O
the	O
levels	O
of	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
in	O
subjects	O
’	O
urine	O
samples	O
,	O
expressed	O
as	O
µ	O
##g	O
/	O
g	O
of	O
c	B
##rea	I
##tin	I
##ine	I
,	O
after	O
grouping	O
by	O
controls	O
and	O
workers	O
.	O

These	O
data	O
suggested	O
that	O
in	O
normal	O
breast	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
RC	O
##E	O
has	O
no	O
effect	O
on	O
the	O
chemical	O
est	B
##rogen	I
car	O
##cin	O
##ogen	O
##esis	O
pathway	O
.	O

The	O
mass	O
spectrum	O
under	O
this	O
peak	O
,	O
,	O
revealed	O
a	O
peak	O
with	O
m	O
/	O
z	O
212	O
.	O
00	O
##20	O
with	O
two	O
fragment	O
ions	O
at	O
m	O
/	O
z	O
132	O
.	O
04	O
##44	O
and	O
m	O
/	O
z	O
79	O
.	O
95	O
##60	O
,	O
suggesting	O
the	O
meta	O
##bol	O
##ite	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
(	O
IS	O
##A	O
)	O
.	O

In	O
the	O
case	O
of	O
FF	O
##P	O
##E	O
samples	O
,	O
the	O
ad	O
##here	O
##nt	O
cells	O
were	O
directly	O
que	O
##nched	O
with	O
1	O
m	O
##L	O
of	O
4	O
%	O
formal	B
##in	I
.	O

As	O
we	O
observed	O
reduced	O
glucose	S
up	O
##take	O
by	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
,	O
we	O
further	O
analyzed	O
the	O
role	O
of	O
M	O
##UC	O
##16	O
in	O
cell	O
m	O
##ot	O
##ility	O
and	O
invasion	O
.	O

Subsequently	O
,	O
the	O
E	O
##H	O
c	O
##lamp	O
was	O
initiated	O
by	O
an	O
insulin	O
b	O
##ol	O
##us	O
followed	O
by	O
a	O
continuous	O
insulin	O
in	O
##fusion	O
(	O
1	O
.	O
05	O
m	O
##I	O
##U	O
/	O
kg	O
/	O
hour	O
of	O
short	O
-	O
acting	O
human	O
insulin	O
)	O
and	O
a	O
variable	O
in	O
##fusion	O
of	O
a	O
20	O
%	O
glucose	S
in	O
##fusion	O
to	O
maintain	O
the	O
plasma	O
glucose	S
concentration	O
at	O
80	O
mg	O
/	O
d	O
##l	O
for	O
120	O
minutes	O
.	O

The	O
reaction	O
was	O
started	O
by	O
addition	O
of	O
5	O
μ	O
##L	O
da	O
##bra	O
##fen	O
##ib	O
stock	O
solution	O
(	O
5	O
m	O
##M	O
in	O
D	O
##MS	O
##O	O
)	O
and	O
terminated	O
by	O
addition	O
of	O
150	O
μ	O
##L	O
of	O
in	O
##cu	O
##bate	O
to	O
four	O
volumes	O
of	O
ice	O
-	O
cold	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

The	O
cause	O
of	O
separation	O
of	O
these	O
groups	O
can	O
be	O
seen	O
in	O
the	O
loading	O
##s	O
plot	O
in	O
:	O
it	O
is	O
due	O
to	O
the	O
higher	O
meta	O
##bol	O
##ite	O
signals	O
of	O
c	O
##rea	O
##tine	O
-	O
containing	O
and	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
in	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
and	O
higher	O
la	B
##ct	I
##ate	I
signals	O
in	O
men	O
##ing	O
##io	O
##mas	O
.	O

The	O
higher	O
level	O
of	O
c	O
##ir	O
##cula	O
##tory	O
T	O
##NF	O
-	O
α	O
observed	O
in	O
the	O
G	O
##R	O
patients	O
within	O
the	O
ER	B
(	I
+	I
)	I
group	O
seems	O
to	O
support	O
the	O
hypothesis	O
of	O
a	O
more	O
pro	O
##ficient	O
immune	O
system	O
in	O
these	O
patients	O
.	O

For	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
,	O
which	O
is	O
the	O
second	O
most	O
abundant	O
and	O
##rogen	O
meta	O
##bol	O
##ite	O
in	O
urine	O
,	O
a	O
higher	O
night	O
time	O
ex	O
##cre	O
##tion	O
rate	O
has	O
been	O
revealed	O
in	O
women	O
,	O
but	O
not	O
in	O
men	O
.	O

For	O
example	O
,	O
three	O
intermediate	O
##s	O
of	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
7	B
##α	I
,	I
27	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##ster	I
##ol	I
,	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
were	O
significantly	O
lower	O
in	O
females	O
than	O
in	O
males	O
,	O
confirming	O
an	O
earlier	O
study	O
.	O

Aden	B
##os	I
##ine	I
and	O
g	B
##uan	I
##os	I
##ine	I
phosphate	I
##s	I
,	O
total	O
ad	O
##en	O
##yla	O
##tes	O
and	O
g	O
##uan	O
##yla	O
##tes	O
,	O
and	O
ad	B
##en	I
##yla	I
##te	I
and	O
g	B
##uan	I
##yla	I
##te	I
energy	O
charges	O
of	O
normal	O
(	O
left	O
,	O
open	O
dots	O
)	O
and	O
tumor	O
(	O
right	O
,	O
filled	O
dots	O
)	O
tissues	O
obtained	O
from	O
lung	O
(	O
a	O
)	O
and	O
pro	O
##state	O
(	O
b	O
)	O
cancer	O
patients	O
.	O

When	O
overwhelming	O
o	O
##xi	O
##da	O
##tive	O
stress	O
eclipse	O
##s	O
g	B
##lut	I
##ath	I
##ione	I
anti	O
##ox	O
##ida	O
##nt	O
capacity	O
,	O
the	O
liver	O
produces	O
anti	O
##ox	O
##ida	O
##nt	O
2	O
##H	O
##B	O
through	O
an	O
‘	O
emergency	O
’	O
trans	O
##sul	O
##fu	O
##ration	O
pathway	O
.	O

The	O
prevalence	O
and	O
severity	O
of	O
CA	O
##C	O
tended	O
to	O
be	O
lower	O
—	O
not	O
higher	O
—	O
with	O
lower	O
concentrations	O
of	O
each	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
.	O

L	B
##ys	I
##ine	I
;	O
76	O
.	O

Tan	O
##de	O
##m	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
/	O
MS	O
)	O
experiments	O
confirmed	O
the	O
assignment	O
of	O
m	O
/	O
z	O
760	O
.	O
6	O
as	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
‐	I
ch	I
##olin	I
##e	I
(	O
PC	O
)	O
species	O
16	O
:	O
0	O
/	O
18	O
:	O
1	O
,	O
m	O
/	O
z	O
47	O
##8	O
.	O
3	O
as	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
and	O
m	O
/	O
z	O
50	O
##4	O
.	O
3	O
as	O
L	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
1	I
)	I
.	O

For	O
analysis	O
under	S
negative	S
E	S
##SI	S
conditions	S
,	S
sample	S
extract	S
B	S
was	S
di	S
##lut	S
##ed	S
10	S
-	S
fold	S
in	S
met	S
##han	S
##ol	S
:	S
0	S
.	S
1	S
%	S
(	S
v	S
/	S
v	S
)	S
am	S
##mon	O
##ium	O
h	O
##ydro	O
##xi	O
##de	O
(	O
50	O
:	O
50	O
,	O
v	O
/	O
v	O
)	O
prior	O
to	O
direct	O
in	O
##fusion	O
.	O

Higher	O
pre	O
##nat	O
##al	O
stress	O
exposure	O
generated	O
alterations	O
in	O
metabolic	O
pathways	O
involved	O
in	O
energy	O
metabolism	O
and	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
such	O
as	O
branched	O
-	O
chain	O
amino	O
acid	O
synthesis	O
,	O
al	B
##ani	I
##ne	I
metabolism	O
,	O
and	O
k	B
##eton	I
##e	I
body	O
metabolism	O
.	O

Next	O
,	O
the	O
protected	O
ben	B
##zal	I
##de	I
##hy	I
##de	I
2	O
was	O
subjected	O
to	O
a	O
Reform	O
##ats	O
##ky	O
reaction	O
in	O
the	O
presence	O
of	O
zinc	O
and	O
et	B
##hyl	I
br	I
##omo	I
##ace	I
##tate	I
to	O
afford	O
the	O
h	O
##yd	O
##rac	O
##ryl	O
##ic	O
est	O
##er	O
,	O
which	O
was	O
then	O
h	O
##ydro	O
##ly	O
##zed	O
to	O
the	O
corresponding	O
car	B
##box	I
##yl	I
##ic	I
acid	I
derivative	O
3	O
.	O

Thirty	O
micro	O
##lite	O
##rs	O
of	O
75	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
was	O
then	O
added	O
to	O
each	O
well	O
,	O
followed	O
by	O
the	O
addition	O
of	O
25	O
μ	O
##L	O
each	O
of	O
the	O
following	O
three	O
solutions	O
:	O
3	O
-	O
N	O
##P	O
##H	O
(	B
3	B
-	I
ni	I
##tro	I
##phe	I
##ny	I
##l	I
##hy	I
##dra	I
##zine	I
,	O
250	O
m	O
##M	O
in	O
50	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
)	O
,	O
E	O
##DC	O
(	B
1	B
-	I
et	I
##hyl	I
-	I
3	I
-	I
(	I
3	I
-	I
dim	I
##eth	I
##yla	I
##min	I
##op	I
##rop	I
##yl	I
)	I
car	I
##bo	I
##di	I
##im	I
##ide	I
,	O
150	O
m	O
##M	O
in	O
met	B
##han	I
##ol	I
)	O
,	O
and	O
p	B
##yr	I
##id	I
##ine	I
(	O
7	O
.	O
5	O
%	O
in	O
75	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
)	O
.	O

Unlike	O
the	O
pu	B
##rine	I
ring	O
that	O
is	O
not	O
c	O
##lea	O
##ved	O
in	O
humans	O
,	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
ring	O
can	O
be	O
opened	O
and	O
finally	O
de	O
##graded	O
to	O
highly	O
water	O
-	O
soluble	O
products	O
,	O
including	O
β	B
-	I
al	I
##ani	I
##ne	I
(	O
from	O
degradation	O
of	O
c	B
##yt	I
##os	I
##ine	I
and	O
u	O
##rac	O
##il	O
)	O
and	O
β	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
(	O
from	O
degradation	O
of	O
thy	O
##mine	O
)	O
,	O
which	O
are	O
ex	O
##cre	O
##ted	O
into	O
urine	O
.	O

After	O
production	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
by	O
CP	O
##T	O
##1	O
,	O
the	O
mitochondrial	O
inner	O
membrane	O
transport	O
##er	O
car	O
##ni	O
##tine	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
trans	O
##loc	O
##ase	O
(	O
CA	O
##CT	O
,	O
or	O
SL	O
##C	O
##25	O
##A	O
##20	O
)	O
transports	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
into	O
the	O
mitochondrial	O
matrix	O
.	O

To	O
predict	O
which	O
meta	O
##bol	O
##ites	O
were	O
involved	O
in	O
the	O
progression	O
from	O
H	O
##U	O
to	O
H	O
##U	O
+	O
N	O
##AF	O
##LD	O
,	O
we	O
designed	O
two	O
novel	O
indicators	O
:	O
R	B
##V	I
represents	O
the	O
power	O
of	O
the	O
meta	O
##bol	O
##ites	O
to	O
reflect	O
the	O
abnormal	O
##ity	O
of	O
the	O
disease	O
,	O
and	O
T	O
##I	O
reveals	O
the	O
ability	O
of	O
the	O
meta	O
##bol	O
##ites	O
to	O
indicate	O
the	O
progression	O
.	O

MS	O
/	O
MS	O
fragment	O
##ation	O
of	O
the	O
pseudo	O
##mo	O
##l	O
##cular	O
ion	O
of	O
PC	B
(	I
40	I
:	I
7	I
)	I

The	O
evaluation	O
was	O
performed	O
by	O
NC	O
##SS	O
2007	O
software	O
using	O
a	O
standard	O
linear	O
re	O
##gression	O
with	O
total	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
set	O
as	O
the	O
independent	O
variable	O
and	O
di	O
##os	O
##met	O
##ine	O
after	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
dig	O
##est	O
##ion	O
as	O
dependent	O
variable	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
f	O
##ent	O
##any	O
##l	O
,	O
nor	O
##fen	O
##tany	O
##l	O
and	O
mid	B
##az	I
##ola	I
##m	I
in	O
relation	O
to	O
mid	B
##az	I
##ola	I
##m	I
administration	O
are	O
shown	O
in	O
Fi	O
##g	O
.	O

Sign	O
##ificant	O
changes	O
with	O
respect	O
to	O
g	O
##eno	O
##type	O
were	O
observed	O
in	O
89	O
/	O
130	O
identified	O
meta	O
##bol	O
##ites	O
,	O
including	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
bio	O
##genic	O
am	O
##ines	O
,	O
amino	O
acids	O
and	O
u	B
##rea	I
.	O

Apart	O
from	O
this	O
,	O
T	B
##G	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
ace	B
##tone	I
,	O
3	O
-	O
H	O
##B	O
,	O
and	O
l	B
##ys	I
##ine	I
were	O
bio	O
##mark	O
##ers	O
that	O
could	O
reflect	O
the	O
abnormal	O
metabolism	O
.	O

Media	O
##n	O
levels	O
of	O
the	O
24	O
-	O
hour	O
ex	O
##cre	O
##tion	O
of	O
SF	S
meta	O
##bol	O
##ites	O
increased	O
from	O
54	O
to	O
56	O
to	O
62	O
μ	O
##mo	O
##le	O
.	O

Ana	O
##ly	O
##tical	O
liquid	O
ch	O
##roma	O
##tography	O
was	O
performed	O
using	O
1	O
g	O
/	O
L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
pH	O
5	O
.	O
5	O
,	O
adjusted	O
by	O
glacial	B
ace	I
##tic	I
acid	I
)	O

The	O
decreased	O
activity	O
of	O
the	O
des	O
##at	O
##ura	O
##se	O
FA	O
##DS	O
##1	O
appeared	O
as	O
a	O
bottle	O
##neck	O
,	O
leading	O
upstream	O
to	O
an	O
accumulation	O
of	O
fatty	O
acids	O
and	O
downstream	O
to	O
a	O
deficiency	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
resulting	O
to	O
impaired	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
synthesis	O
.	O

Co	O
##rre	O
##cting	O
for	O
S	O
##G	O
is	O
frequently	O
used	O
as	O
an	O
alternative	O
to	O
c	B
##rea	I
##tin	I
##ine	I
correction	O
,	O
because	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
may	O
vary	O
within	O
and	O
between	O
persons	O
.	O

In	O
addition	O
,	O
side	O
reaction	O
products	O
derived	O
from	O
Norris	O
##h	O
type	O
I	O
c	O
##lea	O
##vage	O
of	O
ace	B
##tone	I
became	O
more	O
abundant	O
,	O
leading	O
to	O
increased	O
chemical	O
interference	O
.	O

The	O
measurement	O
conditions	O
were	O
as	O
follows	O
:	O
E	O
##SI	O
:	O
source	O
voltage	O
5	O
.	O
5	O
k	B
##V	I
or	O
−	O
##4	O
.	O
5	O
k	B
##V	I
,	O
vapor	O
##izer	O
temperature	O
:	O
375	O
°C	O
,	O
t	O
##ur	O
##bo	O
gas	O
:	O
75	O
ps	O
##i	O
,	O
ne	O
##bul	O
##izer	O
gas	O
:	O
65	O
ps	O
##i	O
,	O
curtain	O
gas	O
:	O
40	O
ps	O
##i	O
,	O
and	O
de	O
##c	O
##luster	O
##ing	O
potential	O
:	O

The	O
h	B
##ydro	I
##xy	I
p	I
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
derivative	O
of	O
P	O
increased	O
in	O
the	O
first	O
8	O
h	O
,	O
and	O
was	O
then	O
maintained	O
smoothly	O
.	O

To	O
test	O
that	O
the	O
identified	O
o	O
##xi	O
##da	O
##tive	O
and	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
metabolic	O
routes	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
in	O
v	O
##it	O
##ro	O
are	O
also	O
present	O
in	O
v	O
##ivo	O
,	O
the	O
plasma	O
concentrations	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
and	O
its	O
meta	O
##bol	O
##ites	O
were	O
measured	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
with	O
early	O
-	O
stage	O
breast	O
cancer	O
who	O
were	O
taking	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
1	O
mg	O
day	O
_	O
−	O
##1	O
)	O
.	O

Unless	O
specifically	O
mentioned	O
,	O
all	O
cell	O
lines	O
were	O
culture	O
##d	O
in	O
high	O
glucose	S
D	O
##ME	O
##M	O
(	O
Du	O
##l	O
##be	O
##cco	O
’	O
s	O
Mo	O
##dified	O
Eagle	O
Medium	O
;	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
with	O
10	O
%	O
Fe	O
##tal	O
Cal	O
##f	O
Ser	O
##um	O
(	O
Sigma	O
)	O
and	O
1	O
%	O
Pen	B
##ici	I
##llin	I
-	I
St	I
##re	I
##pt	I
##omy	I
##cin	I
(	O
Sigma	O
)	O
,	O
1	O
%	O
[UNK]	O
-	I
I	I
(	O
G	O
##ib	O
##co	O
)	O
and	O
1	O
%	O
p	B
##yr	I
##u	I
##vate	I
.	O

These	O
findings	O
point	O
to	O
the	O
possibility	O
of	O
increased	O
R	O
##R	O
##M	O
##2	O
expression	O
as	O
being	O
a	O
downstream	O
consequence	O
of	O
activated	S
E	O
##SR	O
##1	O
in	O
patients	O
,	O
a	O
hypothesis	O
that	O
needs	O
to	O
be	O
valid	O
##ated	O
.	O

Stock	O
solutions	O
of	O
20	O
naturally	O
occurring	O
amino	O
acids	O
(	O
0	O
.	O
1	O
M	O
each	O
)	O
in	O
20	O
m	O
##M	O
phosphate	S
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
were	O
prepared	O
in	O
separate	O
tubes	O
.	O

Level	O
##s	O
of	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
(	O
S	O
##1	O
##P	O
)	O
and	O
other	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
.	O

According	O
to	O
the	O
un	O
##mat	O
##ched	O
P	O
##LS	O
-	O
D	O
##A	O
models	O
,	O
some	O
meta	O
##bol	O
##ite	O
variations	O
emerged	O
as	O
possibly	O
related	O
to	O
smoking	O
habits	O
(	O
increased	O
t	B
##rig	I
##one	I
##llin	I
##e	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
a	O
number	O
of	O
un	O
##ass	O
##ign	O
##ed	O
resonance	O
##s	O
,	O
and	O
decreased	O
3	B
-	I
h	I
##ydro	I
##xy	I
-	I
but	I
##yra	I
##te	I
(	O
3	O
-	O
H	O
##BA	O
)	O
,	O
4	B
-	I
de	I
##ox	I
##yt	I
##hr	I
##eon	I
##ic	I
acid	I
,	O
all	B
##ant	I
##oi	I
##n	I
,	O
beta	B
##ine	I
,	O
g	B
##uan	I
##id	I
##ino	I
##ace	I
##tate	I
(	O
GAA	O
)	O
glucose	S
,	O
la	B
##ct	I
##ose	I
and	O
s	O
##cy	O
##llo	O
-	O
in	O
##os	O
##ito	O
##l	O
)	O
and	O
to	O
B	O
##MI	O
(	O
increased	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
and	O
decreased	O
3	B
-	I
h	I
##ydro	I
##xy	I
-	I
is	I
##ova	I
##ler	I
##ate	I
(	O
3	O
-	O
HIV	O
##A	O
)	O
,	O
c	B
##it	I
##rate	I
and	O
su	B
##cci	I
##nate	I
.	O

In	O
addition	O
,	O
up	O
-	O
regulation	O
of	O
branched	O
-	O
chain	O
AA	O
##s	O
and	O
c	B
##rea	I
##tine	I
production	O
in	O
cancer	O
cells	O
can	O
provide	O
substrates	O
for	O
energy	O
and	O
protein	O
synthesis	O
,	O
which	O
are	O
required	O
for	O
cell	O
proliferation	O
.	O

After	O
10	O
-	O
14	O
days	O
,	O
cells	O
were	O
washed	O
with	O
1	O
##×	O
##P	O
##BS	O
,	O
fixed	O
in	O
met	B
##han	I
##ol	I
for	O
20	O
min	O
and	O
stained	O
with	O
crystal	O
violet	O
for	O
15	O
min	O
at	O
room	O
temperature	O
.	O

This	O
en	O
##rich	O
##ment	O
procedure	O
,	O
followed	O
by	O
DD	O
##A	O
with	O
an	O
Or	O
##bit	O
##rap	O
,	O
led	O
to	O
the	O
detection	O
of	O
43	O
features	O
at	O
T	O
##3	O
,	O
including	O
Cy	O
##s	O
##34	O
su	B
##lf	I
##ini	I
##c	I
and	O
su	B
##lf	I
##onic	I
acids	I
,	O
several	O
mixed	O
di	B
##sul	I
##fi	I
##des	I
,	O
and	O
small	O
molecular	O
weight	O
al	O
##ky	O
##lating	O
agents	O
.	O

The	O
e	O
##fa	O
##vir	O
##en	O
##z	O
arm	O
demonstrated	O
the	O
weak	O
##est	O
association	O
with	O
only	O
five	O
lip	O
##id	O
species	O
and	O
two	O
classes	O
significantly	O
associated	O
with	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
at	O
week	O
48	O
(	O
see	O
)	O
.	O

Lower	O
##ed	O
in	B
##os	I
##ine	I
may	O
reflect	O
a	O
physiological	O
com	O
##pen	O
##sat	O
##ory	O
mechanism	O
counter	O
##act	O
##ing	O
increased	O
u	B
##ric	I
acid	I
to	O
maintain	O
the	O
home	O
##ost	O
##asis	O
of	O
an	O
organism	O
.	O

Here	O
we	O
compared	O
the	O
serum	O
concentrations	O
of	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
,	O
measured	O
using	O
high	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
with	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
across	O
49	O
un	O
##med	O
##ica	O
##ted	O
subjects	O
meeting	O
DS	O
##M	O
-	O
IV	O
-	O
T	O
##R	O
criteria	O
for	O
MD	O
##D	O
,	O
21	O
un	O
##med	O
##ica	O
##ted	O
subjects	O
meeting	O
DS	O
##M	O
-	O
IV	O
-	O
T	O
##R	O
criteria	O
for	O
r	O
##MD	O
##D	O
,	O
and	O
58	O
healthy	O
controls	O
(	O
HC	O
##s	O
)	O
.	O

T	B
##MA	I
##O	I
has	O
been	O
recently	O
proposed	O
as	O
a	O
novel	O
pro	O
##gno	O
##stic	O
marker	O
of	O
card	O
##iovascular	O
events	O
,	O
given	O
the	O
association	O
of	O
its	O
plasma	O
levels	O
with	O
index	O
##es	O
of	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
plaque	O
vulnerability	O
,	O
major	O
cardiac	O
events	O
,	O
and	O
death	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
Sol	O
##vent	O
A	O
,	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
water	O
,	O
and	O
Sol	O
##vent	O
B	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
.	O

Other	O
studies	O
reported	O
serum	O
free	O
m	B
##or	I
##phine	I
concentrations	O
above	O
200	O
ng	O
/	O
m	O
##L	O
to	O
be	O
considered	O
toxic	O
though	O
much	O
lower	O
concentrations	O
(	O
~	O
100	O
ng	O
/	O
m	O
##L	O
)	O
have	O
also	O
been	O
reported	O
in	O
post	O
##mor	O
##tem	O
samples	O
from	O
patients	O
who	O
died	O
of	O
op	O
##iate	O
over	O
##dos	O
##e	O
.	O

Once	O
matched	O
for	O
u	O
##rina	O
##ry	O
glucose	S
levels	O
,	O
there	O
was	O
no	O
difference	O
observed	O
in	O
the	O
levels	O
of	O
the	O
u	O
##rina	O
##ry	O
amino	O
acids	O
v	O
##ali	O
##ne	O
and	O
g	B
##ly	I
##cine	I
,	O
which	O
were	O
noted	O
in	O
the	O
Discovery	O
study	O
to	O
be	O
increased	O
in	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
subjects	O
.	O

A	O
single	O
punch	O
con	O
##stituting	O
approximately	O
40	O
%	O
of	O
the	O
blood	O
volume	O
was	O
extracted	O
with	O
100	O
%	O
met	B
##han	I
##ol	I
,	O
using	O
the	O
5	O
μ	O
##L	O
DB	O
##S	O
protocol	O
described	O
above	O
.	O

K	B
##yn	I
##uren	I
##ine	I
is	O
generated	O
by	O
some	O
cancer	O
##s	O
and	O
is	O
thought	O
to	O
suppress	O
immune	O
cell	O
responses	O
.	O

G	B
##lut	I
##ama	I
##te	I
is	O
the	O
meta	O
##bol	O
##ite	O
of	O
g	B
##lut	I
##amine	I
,	O
whereas	O
the	O
active	O
metabolism	O
of	O
g	B
##lut	I
##amine	I
is	O
an	O
important	O
form	O
of	O
energy	O
metabolism	O
of	O
tumor	O
cells	O
.	O

Rev	O
##erse	O
-	O
phase	O
(	O
R	O
##P	O
)	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
was	O
performed	O
using	O
as	O
phase	O
A	O
water	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
v	O
/	O
v	O
)	O
and	O
as	O
phase	O
B	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
v	O
/	O
v	O
)	O
.	O

V	O
##aria	O
##tion	O
in	O
specific	O
lip	O
##ids	O
correlated	O
with	O
di	O
##sp	O
##ari	O
##ties	O
in	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
,	O
ethnicity	O
,	O
sex	O
,	O
age	O
,	O
genetic	O
variation	O
,	O
anatomy	O
,	O
and	O
clinical	O
p	O
##hen	O
##otype	O
##s	O
.	O

Am	O
##ino	O
acid	O
or	O
##ni	O
##thin	O
##e	O
,	O
with	O
the	O
highest	O
concentration	O
of	O
meta	O
##bol	O
##ites	O
in	O
the	O
u	O
##E	O
##Vs	O
and	O
15	O
_	O
th	O
highest	O
in	O
p	O
##E	O
##Vs	O
,	O
and	O
several	O
other	O
members	O
of	O
the	O
u	B
##rea	I
cycle	O
were	O
present	O
in	O
>	O
50	O
µ	O
##M	O
to	O
m	O
##M	O
concentrations	O
in	O
the	O
E	O
##Vs	O
.	O

[	O
,	O
]	O
,	O
k	B
##yn	I
##uren	I
##ine	I
and	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
play	O
key	O
roles	O
in	O
the	O
regulation	O
of	O
insulin	O
resistance	O
,	O
pan	O
##cre	O
##atic	O
beta	O
-	O
cell	O
function	O
,	O
and	O
glucose	S
level	O
home	O
##ost	O
##asis	O
.	O

2	O
)	O
Sub	O
##jects	O
received	O
a	O
3	O
-	O
h	O
80	O
m	O
##U	O
/	O
min	O
·	O
m	O
_	O
2	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
insulin	O
c	O
##lamp	O
in	O
combination	O
with	O
3	O
-	B
[	B
_	I
3	I
H	I
]	I
glucose	I
and	O
vast	O
##us	O
lateral	O
##is	O
muscle	O
bio	O
##psy	O
60	O
min	O
before	O
the	O
h	O
##yper	O
##ins	O
##ulin	O
##em	O
##ic	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
for	O
measurement	O
of	O
muscle	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
content	O
(	O
n	O
=	O
7	O
)	O
;	O
they	O
were	O
subsequently	O
treated	O
with	O
45	O
mg	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
per	O
day	O
for	O
4	O
months	O
,	O
and	O
the	O
insulin	O
c	O
##lamp	O
/	O
vast	O
##us	O
lateral	O
##is	O
muscle	O
bio	O
##psy	O
studies	O
for	O
insulin	O
sensitivity	O
and	O
muscle	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
content	O
were	O
repeated	O
.	O

Examination	O
of	O
women	O
-	O
only	O
revealed	O
that	O
lower	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ctic	I
acid	I
levels	O
distinguished	O
the	O
ME	O
/	O
CF	O
##S	O
from	O
HC	O
##s	O
.	O

We	O
anticipated	O
a	O
reduced	O
and	O
/	O
or	O
disrupted	O
transformation	O
of	O
glucose	B
-	I
carbon	I
into	O
the	O
intermediate	O
##s	O
of	O
the	O
K	O
##re	O
##bs	O
cycle	O
,	O
based	O
on	O
the	O
commonly	O
recognized	O
concept	O
of	O
mitochondrial	O
""""	O
d	O
##ys	O
##function	O
""""	O
in	O
cancer	O
[	O
-	O
]	O
.	O

If	O
the	O
cancer	O
cells	O
in	O
a	O
t	O
##umour	O
co	O
-	O
op	O
##t	O
the	O
as	O
##tro	O
##cy	O
##te	O
-	O
ne	O
##uron	O
la	B
##ct	I
##ate	I
shuttle	O
to	O
export	O
their	O
g	B
##ly	I
##co	I
##ly	I
##tically	I
formed	O
la	B
##ct	I
##ate	I
for	O
oxidation	O
in	O
g	O
##lial	O
cells	O
,	O
as	O
shown	O
in	O
,	O
then	O
la	B
##ct	I
##ate	I
levels	O
,	O
which	O
would	O
be	O
an	O
aggregate	O
concentration	O
of	O
the	O
la	B
##ct	I
##ate	I
pools	O
in	O
the	O
cancer	O
cells	O
,	O
the	O
extra	O
##cellular	O
space	O
and	O
the	O
g	O
##lial	O
cells	O
,	O
might	O
co	O
##rrel	O
##ate	O
positively	O
with	O
the	O
t	O
##C	O
##r	O
levels	O
in	O
the	O
c	O
##yt	O
##oso	O
##l	O
of	O
the	O
g	O
##lial	O
cells	O
.	O

Finally	O
,	O
although	O
cannabis	S
use	O
was	O
not	O
associated	O
with	O
changes	O
in	O
the	O
frequency	O
of	O
inter	O
##le	O
##uki	O
##n	O
6	O
(	O
IL	O
-	O
6	O
)	O
_	O
+	O
B	O
cells	O
,	O
the	O
frequency	O
of	O
tumor	O
ne	O
##c	O
##rosis	O
factor	O
alpha	O
(	O
T	O
##NF	O
-	O
α	O
)	O
–	O
producing	O
B	O
cells	O
was	O
significantly	O
lower	O
in	O
heavy	O
cannabis	S
users	O
compared	O
to	O
frequencies	O
within	O
non	O
##can	O
##na	O
##bis	O
users	O
(	O
P	O
=	O
.	O
04	O
##5	O
##8	O
;	O
)	O
.	O

(	O
a	O
)	O
G	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
;	O
(	O
b	O
)	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
;	O
(	O
c	O
)	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
;	O
(	O
d	O
)	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
;	O
(	O
e	O
)	O
l	B
##ys	I
##ine	I
degradation	O
;	O
(	O
f	O
)	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
di	B
##car	I
##box	I
##yla	I
##te	I
metabolism	O
;	O
(	O
g	O
)	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
;	O
(	O
h	O
)	O
l	B
##ys	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
;	O
(	O
i	O
)	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
;	O
(	O
j	O
)	O
nitrogen	O
metabolism	O
.	O

In	O
the	O
mit	O
##och	O
##ond	O
##ria	O
,	O
ATP	S
is	O
produced	O
via	O
the	O
T	O
##CA	O
cycle	O
,	O
the	O
electron	O
transport	O
chain	O
(	O
respiratory	O
chain	O
)	O
,	O
and	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Different	O
##iated	O
and	O
lip	O
##id	O
-	O
loaded	O
3	O
##T	O
##3	O
-	O
L	O
##1	O
ad	O
##ip	O
##ocytes	O
were	O
treated	O
for	O
4	O
h	O
##rs	O
with	O
AI	B
##CA	I
##R	I
(	O
2	O
m	O
##M	O
)	O
,	O
P	B
##F	I
(	O
1	O
m	O
##M	O
)	O
,	O
ISO	O
(	O
10	O
μ	O
##M	O
)	O
,	O
and	O
HD	O
##L	O
(	O
50	O
μ	O
##g	O
/	O
m	O
##l	O
)	O
before	O
cells	O
and	O
media	O
were	O
harvested	O
.	O

Next	O
to	O
D	O
##MS	O
##O	O
_	O
2	O
and	O
2	O
-	O
H	O
##IB	O
##A	O
,	O
the	O
present	O
study	O
showed	O
that	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
p	B
-	I
c	I
##res	I
##yl	I
su	I
##l	I
##phate	I
,	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
,	O
pseudo	B
##uri	I
##dine	I
,	O
beta	B
##ine	I
,	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
and	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
were	O
elevated	O
in	O
stage	O
3	O
–	O
4	O
C	O
##K	O
##D	O
patients	O
.	O

Inc	O
##rea	O
##sing	O
evidence	O
prove	O
that	O
vitamin	B
B	I
##6	I
(	O
of	O
which	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
is	O
part	O
of	O
its	O
family	O
)	O
has	O
a	O
protective	O
effect	O
on	O
co	O
##lon	O
cancer	O
cells	O
.	O

Ana	O
##ly	O
##ses	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
in	O
plasma	O
derived	O
from	O
NH	O
##Ps	O
can	O
easily	O
be	O
achieved	O
using	O
methods	O
employed	O
in	O
humans	O
.	O

CA	O
##D	O
events	O
occurred	O
in	O
16	O
subjects	O
out	O
of	O
176	O
(	O
9	O
.	O
1	O
%	O
)	O
during	O
the	O
observation	O
period	O
,	O
and	O
from	O
the	O
160	O
subjects	O
without	O
CA	O
##D	O
,	O
39	O
control	O
subjects	O
who	O
were	O
matched	O
to	O
the	O
CA	O
##D	O
group	O
for	O
F	O
##RS	O
,	O
diabetes	O
duration	S
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
were	O
selected	O
.	O

Re	O
##lated	O
studies	O
have	O
indicated	O
that	O
N	B
-	I
car	I
##ba	I
##my	I
##l	I
-	I
β	I
-	I
al	I
##ani	I
##ne	I
and	O
N	B
-	I
car	I
##ba	I
##my	I
##l	I
-	I
β	I
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
were	O
weak	O
inhibitor	O
##s	O
of	O
di	O
##hy	O
##dr	O
##opy	O
##rim	O
##id	O
##inas	O
##e	O
.	O

Ke	B
##tone	I
bodies	O
can	O
migrate	O
into	O
the	O
blood	O
##stream	O
for	O
use	O
in	O
peripheral	O
tissues	O
where	O
they	O
are	O
meta	O
##bol	O
##ized	O
for	O
the	O
production	O
of	O
ATP	S
,	O
especially	O
3	B
-	I
OH	I
-	I
but	I
##yra	I
##te	I
.	O

However	O
,	O
it	O
remains	O
unknown	O
whether	O
C	B
##18	I
:	I
2	I
CE	O
o	O
##xi	O
##di	O
##zation	O
is	O
involved	O
in	O
lung	O
cancer	O
tumor	O
##ige	O
##nes	O
##is	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
is	O
decreased	O
in	O
HIV	O
patients	O
compared	O
to	O
healthy	O
controls	O
(	O
T	O
Test	O
=	O
0	O
.	O
01	O
##21	O
##28	O
)	O
particularly	O
in	O
the	O
IN	O
##R	O
group	O
after	O
anti	O
##ret	O
##rov	O
##ira	O
##l	O
treatment	O
(	O
arrow	O
)	O
as	O
demonstrated	O
by	O
the	O
AN	O
##O	O
##VA	O
analysis	O
of	O
S	O
##GP	O
##P	O
##1	O
activity	O
(	O
p	O
=	O
2	O
.	O
52	O
##6	O
##6	O
##E	O
-	O
7	O
,	O
-	O
log	O
##10	O
(	O
p	O
)	O

There	O
are	O
several	O
reports	O
that	O
se	B
##rot	I
##oni	I
##n	I
metabolism	O
and	O
especially	O
se	B
##rot	I
##oni	I
##n	I
transport	O
is	O
impaired	O
in	O
G	O
##DM	O
(	O
Li	O
et	O
al	O
.	O
,	O
)	O
.	O

In	O
##sul	O
##in	O
resistance	O
not	O
only	O
increases	O
u	B
##ric	I
acid	I
synthesis	O
and	O
reduces	O
the	O
re	O
##nal	O
ex	O
##cre	O
##tion	O
of	O
u	B
##ric	I
acid	I
but	O
also	O
promotes	O
lip	O
##oly	O
##sis	O
of	O
peripheral	O
ad	O
##ip	O
##ose	O
tissue	O
and	O
increases	O
free	O
fatty	O
acid	O
influx	O
into	O
the	O
liver	O
,	O
leading	O
to	O
N	O
##AF	O
##LD	O

(	O
A	O
)	O
Con	O
##tribution	O
of	O
a	O
_	O
1	O
H	O
N	O
##MR	O
characteristic	O
signal	O
of	O
la	B
##ct	I
##ate	I
at	O
1	O
.	O
36	O
pp	O
##m	O
to	O
the	O
spectrum	O
of	O
a	O
##que	O
##ous	O
fraction	O
of	O
the	O
plasma	O
extract	O
(	O
A	O
##q	O
spectrum	O
)	O
.	O

The	O
Di	B
##ol	I
column	O
had	O
the	O
lowest	O
median	O
peak	O
width	O
of	O
12	O
.	O
6	O
s	O
(	O
mean	O
of	O
14	O
.	O
1	O
s	O
)	O
,	O
though	O
the	O
2	O
-	O
P	O
##IC	O
column	O
had	O
a	O
very	O
similar	O
median	O
width	O
(	O
13	O
.	O
4	O
s	O
)	O

Dal	B
##fa	I
##mp	I
##rid	I
##ine	I
-	I
ER	I
is	O
an	O
extended	O
release	O
formulation	O
of	O
4	B
-	I
amino	I
##py	I
##rid	I
##ine	I
(	O
4	O
-	O
AP	O
)	O
.	O

The	O
resulting	O
super	O
##nat	O
##ant	O
was	O
removed	O
and	O
added	O
to	O
a	O
1	O
.	O
5	O
m	O
##L	O
E	O
##ppe	O
##ndo	O
##rf	O
tube	O
;	O
300	O
µ	O
##L	O
of	O
this	O
super	O
##nat	O
##ant	O
was	O
added	O
to	O
700	O
µ	O
##L	O
met	B
##han	I
##ol	I
and	O
the	O
mixture	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
again	O
(	O
13	O
,	O
000	O
rpm	O
)	O
at	O
4	O
°C	O
for	O
30	O
min	O
##s	O
.	O

A	O
##boa	O
##gy	O
##e	O
et	O
al	O
.	O
showed	O
that	O
ma	O
##li	O
##gnant	O
transformation	O
was	O
the	O
cause	O
of	O
abnormal	O
ch	B
##olin	I
##e	I
metabolism	O
rather	O
than	O
cell	O
proliferation	O
.	O

The	O
album	O
##in	O
-	O
like	O
protein	O
of	O
Atlantic	S
co	O
##d	O
is	O
therefore	O
small	O
in	O
comparison	O
to	O
most	O
reported	O
album	O
##in	O
/	O
album	O
##in	O
-	O
like	O
proteins	O
.	O

Met	B
##had	I
##one	I
is	O
therefore	O
often	O
preferred	O
when	O
m	B
##or	I
##phine	I
fails	O
,	O
either	O
due	O
to	O
lack	O
of	O
adequate	O
anal	O
##ges	O
##ia	O
or	O
into	O
##ler	O
##able	O
side	O
-	O
effects	O
.	O

The	O
in	O
##hibition	O
of	O
K	O
##MO	O
has	O
suggested	O
that	O
K	O
##MO	O
regulate	O
##s	O
the	O
production	O
of	O
downstream	O
K	B
##P	I
meta	O
##bol	O
##ites	O
.	O

Nine	O
of	O
the	O
patients	O
(	O
47	O
%	O
)	O
were	O
classified	O
as	O
having	O
developed	O
cardiac	O
is	O
##che	O
##mia	O
at	O
peak	O
pacing	O
by	O
either	O
la	B
##ct	I
##ate	I
el	O
##ution	O
or	O
h	O
##s	O
-	O
c	O
##T	O
##n	O
##T	O
criteria	O
.	O

As	O
can	O
be	O
readily	O
observed	O
,	O
a	O
broad	O
lip	O
##id	O
polar	O
##ity	O
range	O
was	O
covered	O
(	O
from	O
non	O
-	O
polar	O
lip	O
##ids	O
such	O
as	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
T	O
##G	O
)	O
to	O
polar	O
lip	O
##ids	O
such	O
as	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
LP	O
##C	O
)	O
)	O
.	O

B	B
##ili	I
##ru	I
##bin	I
,	O
a	O
degradation	O
product	O
of	O
free	O
hem	B
##e	I
groups	O
,	O
protected	O
LLC	O
-	O
P	O
##K	O
##1	O
cells	O
against	O
c	O
##is	O
##p	O
##lat	O
##in	O
-	O
induced	O
death	O
.	O

The	O
long	O
-	O
term	O
stability	O
for	O
FA	O
##U	O
and	O
FM	O
##A	O
##U	O
in	O
met	B
##han	I
##ol	I
and	O
in	O
human	O
plasma	O
is	O
continuously	O
monitored	O
.	O

In	O
the	O
subjects	O
whose	O
periods	O
of	O
time	O
from	O
blood	O
sample	O
collection	O
to	O
diagnosis	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
were	O
from	O
0	O
to	O
6	O
years	O
,	O
decreasing	O
levels	O
of	O
1	B
,	I
5	I
‐	I
AG	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
u	B
##ric	I
acid	I
were	O
related	O
to	O
an	O
increased	O
risk	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
(	O
Table	O
)	O
.	O

The	O
median	O
age	O
of	O
the	O
study	O
population	O
was	O
54	O
years	O
(	O
range	O
47	O
–	O
62	O
)	O
,	O
and	O
34	O
%	O
had	O
impaired	O
glucose	S
tolerance	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
several	O
cell	O
types	O
,	O
including	O
cancer	O
cells	O
,	O
g	B
##lut	I
##amine	I
metabolism	O
via	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
is	O
up	O
regulated	O
and	O
important	O
for	O
cell	O
proliferation	O
and	O
survival	O
,	O
which	O
makes	O
g	B
##lut	I
##amine	I
a	O
conditional	O
##ly	O
essentially	O
amino	O
acid	O
.	O

After	O
removal	O
of	O
non	O
-	O
reactive	O
re	O
##age	O
##nts	O
through	O
a	O
micro	O
-	O
des	O
##al	O
##ting	O
spin	O
column	O
,	O
absorption	O
ma	O
##xi	O
##ma	O
at	O
35	O
##4	O
nm	O
were	O
recorded	O
for	O
bio	B
##tin	I
and	O
at	O
280	O
nm	O
for	O
the	O
presence	O
of	O
anti	O
##body	O
.	O

9	O
compounds	O
showed	O
correlation	O
with	O
all	O
three	O
disease	O
activity	O
scores	O
:	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
-	I
ace	I
##tone	I
-	I
phosphate	I
(	O
D	O
##HA	O
##P	O
)	O
,	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
(	O
O	O
##AA	O
)	O
,	O
glucose	B
1	I
-	I
phosphate	I
(	O
G	O
##1	O
##P	O
)	O
,	O
he	B
##x	I
##ose	I
-	I
phosphate	I
,	O
de	B
##ox	I
##yr	I
##ib	I
##ose	I
-	I
phosphate	I
,	O
u	B
##rac	I
##il	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
g	B
##eran	I
##yl	I
p	I
##yr	I
##op	I
##hos	I
##phate	I
(	O
GP	O
##P	O
)	O
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
car	I
##box	I
##yl	I
##ic	I
acid	I
.	O

However	O
,	O
it	O
is	O
noteworthy	O
that	O
this	O
study	O
also	O
reported	O
total	O
serum	O
est	B
##rogen	I
concentrations	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
that	O
were	O
much	O
higher	O
than	O
has	O
been	O
reported	O
previously	O
.	O

Indeed	O
,	O
brain	O
tissue	O
analysis	O
by	O
electro	O
##sp	O
##ray	O
identified	O
higher	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
and	O
lower	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
content	O
in	O
normal	O
-	O
appearing	O
gray	O
matter	O
of	O
patients	O
with	O
MS	O
associated	O
with	O
a	O
metabolic	O
defect	O
that	O
causes	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
to	O
be	O
shuttle	O
##d	O
to	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
production	O
.	O

SA	O
##M	O
plays	O
a	O
pivotal	O
role	O
as	O
a	O
met	O
##hyl	O
donor	O
,	O
being	O
formed	O
from	O
met	B
##hi	I
##oni	I
##ne	I
and	O
converted	O
into	O
SA	O
##H	O
after	O
don	O
##ating	O
its	O
met	B
##hyl	I
group	I
.	O

Analysis	O
of	O
l	O
##uc	O
##ifer	O
##ase	O
activity	O
in	O
S	O
##N	O
##47	O
##41	O
cells	O
trans	O
##fected	O
with	O
an	O
L	O
##X	O
##R	O
-	O
re	O
##sp	O
##ons	O
##ive	O
l	O
##uc	O
##ifer	O
##ase	O
reporter	O
construct	O
(	O
L	O
##X	O
##RE	O
)	O
and	O
L	O
##X	O
##R	O
##α	O
,	O
as	O
indicated	O
,	O
and	O
stimulate	O
##d	O
for	O
24	O
h	O
with	O
22	B
(	B
R	I
)	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I

B	O
##is	O
(	B
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##o	I
-	I
2	I
-	I
prop	I
##yl	I
)	I
phosphate	I
(	O
B	O
##DC	O
##PP	O
)	O
and	O
dip	B
##hen	I
##yl	I
phosphate	I
(	O
D	O
##PP	O
)	O
in	O
nine	O
individual	O
urine	O
samples	O
and	O
pool	O
##ed	O
urine	O
sample	O
(	O
composite	O
of	O
equal	O
volumes	O
of	O
individual	O
samples	O
)	O
presented	O
as	O
concentrations	O
normal	O
##ized	O
to	O
urine	O
specific	O
gravity	O
.	O

B	O
)	O
Media	O
##n	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
la	B
##ct	I
##ate	I
,	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
or	O
t	B
##rig	I
##one	I
##llin	I
##e	I
by	O
te	O
##rt	O
##iles	O
of	O
F	O
##T	O
##4	O
in	O
Inter	O
##9	O
##9	O
and	O
Health	O
##20	O
##0	O
##6	O
/	O
08	O
.	O

Furthermore	O
,	O
a	O
recent	O
report	O
shows	O
that	O
the	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
may	O
vary	O
over	O
a	O
large	O
scale	O
and	O
that	O
variance	O
##s	O
in	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
concentrations	O
are	O
not	O
due	O
to	O
urine	O
di	O
##lution	O
effects	O
;	O
rather	O
,	O
they	O
reflect	O
actual	O
meta	O
##bol	O
##ite	O
variance	O
##s	O
(	O
Jan	O
##ke	O
##vic	O
##s	O
et	O
al	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
in	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
treated	O
samples	O
were	O
not	O
statistical	O
##ly	O
different	O
than	O
those	O
un	O
##tre	O
##ated	O
with	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
(	O
;	O
P	O
=	O
0	O
.	O
82	O
)	O
.	O

Individual	O
meta	O
##bol	O
##ites	O
in	O
the	O
t	B
##yr	I
##os	I
##ine	I
pathway	O
that	O
differed	O
between	O
N	O
##VA	O
##MD	O
and	O
controls	O
included	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
do	B
##pa	I
##quin	I
##one	I
.	O

Lac	B
##tate	I
on	O
the	O
other	O
hand	O
,	O
is	O
in	O
the	O
current	O
study	O
only	O
found	O
in	O
greater	O
abundance	O
in	O
active	O
UC	O
—	O
a	O
result	O
that	O
parallels	O
previous	O
studies	O
(	O
Ho	O
##ve	O
et	O
al	O
.	O
;	O

*	O
indicates	O
a	O
partially	O
identified	O
compound	O
:	O
pen	O
##ton	O
##ic	O
acid	O
is	O
an	O
al	O
##don	O
##ic	O
acid	O
with	O
five	O
carbon	O
##s	O
and	O
he	B
##xa	I
##ric	I
acid	I
is	O
an	O
al	O
##don	O
##ic	O
acid	O
with	O
six	O
carbon	O
##s	O
.	O

IT	O
##Cs	O
are	O
released	O
from	O
g	B
##lu	I
##cos	I
##ino	I
##lates	I
(	O
G	O
##L	O
##s	O
)	O
,	O
by	O
the	O
enzyme	O
my	O
##ros	O
##inas	O
##e	O
,	O
which	O
occur	O
in	O
the	O
same	O
plants	O
,	O
separated	O
cellular	O
##ly	O
from	O
the	O
G	O
##L	O
##s	O
.	O

The	O
lowest	O
mean	O
Pearson	O
correlation	O
coefficient	O
was	O
reported	O
for	O
se	B
##rine	I
(	O
r	O
=	O
−	O
0	O
.	O
02	O
)	O
.	O

P	O
and	O
IP	S
were	O
separately	O
in	O
##cu	O
##bate	O
##d	O
with	O
the	O
bacterial	O
suspension	O
an	O
##ae	O
##ro	O
##bic	O
##ally	O
,	O
and	O
the	O
metabolic	O
samples	O
were	O
in	O
##cu	O
##bate	O
##d	O
for	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
,	O
then	O
extracted	O
with	O
et	B
##hyl	I
ace	I
##tate	I
(	O
E	O
##t	O
##OA	O
##c	O
)	O
,	O
and	O
analyzed	O
by	O
HP	O
##LC	O
.	O

This	O
yielded	O
a	O
re	O
##gression	O
equation	O
of	O
y	O
=	O
-	O
0	O
.	O
94	O
-	O
7	O
.	O
97	O
C	O
##10	O
+	O
9	O
.	O
31	O
C	B
##10	I
:	I
1	I
-	I
2	I
.	I
71	I
C	I
##18	I
:	I
1	I
+	O
21	O
.	O
42	O
C	O
##3	O
/	O
Met	O
-	O
0	O
.	O
84	O
##1	O
C	O
##3	O
##DC	O
/	O
C	O
##10	O
-	O
1	O
.	O
04	O
##8	O
C	O
##4	O
/	O
C	O
##8	O
+	O
2	O
.	O
53	O
C	O
##4	O
##DC	O
+	O
188	O
.	O
6	O
C	O
##5	O
-	O
OH	O
/	O
C	O
##0	O
+	O
0	O
.	O
01	O
##6	O
##24	O
G	O
##lu	O
-	O
0	O
.	O
09	O
##44	O
T	O
##hr	O
+	O
1	O
.	O
00	O
##3	O
Val	O
/	O
Ph	O
##e	O
.	O

L	O
##C	O
-	O
MS	O
measurement	O
of	O
18	O
amino	O
acids	O
in	O
p	B
##or	I
##cine	I
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
,	O
stored	O
at	O
R	O
##T	O
for	O
up	O
to	O
2	O
h	O
,	O
showed	O
increased	O
concentrations	O
in	O
ten	O
amino	O
acids	O
(	B
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
his	B
##ti	I
##dine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
)	O
,	O
which	O
is	O
in	O
line	O
with	O
our	O
observations	O
,	O
except	O
that	O
g	B
##ly	I
##cine	I
concentration	O
is	O
stable	O
in	O
our	O
experiments	O
.	O

Overall	O
,	O
T	B
##MA	I
##O	I
correlated	O
with	O
ch	B
##olin	I
##e	I
(	O
r	O
=	O
0	O
.	O
40	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
but	O
not	O
beta	B
##ine	I
(	O
r	O
=	O
0	O
.	O
08	O
,	O
p	O
=	O
0	O
.	O
43	O
)	O
,	O
and	O
ch	B
##olin	I
##e	I
correlated	O
with	O
beta	B
##ine	I
(	O
r	O
=	O
0	O
.	O
46	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

From	O
the	O
160	O
subjects	O
without	O
CA	O
##D	O
,	O
39	O
control	O
subjects	O
who	O
were	O
matched	O
to	O
the	O
CA	O
##D	O
group	O
for	O
Fr	O
##ami	O
##ng	O
##ham	O
Co	O
##rona	O
##ry	O
Heart	O
Disease	O
Risk	O
Score	O
,	O
diabetes	O
duration	S
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
were	O
selected	O
as	O
the	O
non	O
-	O
CA	O
##D	O
group	O
.	O

Under	O
these	O
conditions	O
,	O
formation	O
of	O
E	B
_	I
1	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
and	O
E	B
_	I
2	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
was	O
not	O
observed	O
.	O

The	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
index	O
(	O
home	O
##ost	O
##atic	O
model	O
assessment	O
of	O
insulin	O
resistance	O
)	O
was	O
calculated	O
as	O
(	O
fast	O
##ing	O
glucose	S
x	O
fast	O
##ing	O
insulin	O
/	O
22	O
.	O
5	O
)	O
.	O

In	O
addition	O
,	O
there	O
were	O
some	O
di	O
##sp	O
##ari	O
##ties	O
in	O
the	O
removal	O
e	O
##ff	O
##ici	O
##encies	O
of	O
H	O
##F	O
##D	O
and	O
HD	O
in	O
some	O
amino	O
acids	O
and	O
al	B
##kal	I
##ine	I
compounds	O
.	O

Interest	O
##ingly	O
,	O
this	O
included	O
an	O
inverse	O
relationship	O
between	O
c	B
##era	I
##mi	I
##des	I
and	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
.	O

p	O
##70	O
S	O
##6	O
kinase	O
(	O
S	O
##6	O
K	O
,	O
Cat	O
no	O
s	O
##c	O
-	O
84	O
##18	O
)	O
and	O
p	B
##hos	I
##ph	I
##o	I
-	I
p	I
##70	I
S	O
##6	O
kinase	O
(	O
p	O
##S	O
##6	O
##K	O
T	O
##hr	O
38	O
##9	O
,	O
Cat	O
no	O
s	O
##c	O
-	O
84	O
##16	O
)	O
were	O
from	O
Santa	O
Cruz	O
B	O
##iot	O
##ech	O
##nology	O
.	O

Am	B
##ino	I
##mal	I
##onic	I
was	O
first	O
identified	O
in	O
human	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
plaque	O
##s	O
,	O
and	O
later	O
was	O
associated	O
with	O
the	O
presence	O
of	O
foam	O
cells	O
and	O
mac	O
##rop	O
##hage	O
-	O
rich	O
tissues	O
in	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
rabbits	O
(	O
a	O
##ort	O
##a	O
,	O
blood	O
,	O
s	O
##ple	O
##en	O
,	O
lungs	O
)	O
.	O

Chemical	O
##s	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Austria	O
)	O
if	O
not	O
stated	O
otherwise	O
:	O
Met	B
##han	I
##ol	I
(	O
CH	O
##RO	O
##MA	O
##SO	O
##L	O
##V	O
®	O
,	O
HP	O
##LC	O
grade	O
)	O
,	O
ch	O
##lor	O
##of	O
##orm	O
(	O
an	O
##hy	O
##dr	O
##ous	O
≥	O
99	O
%	O
,	O
stab	O
##ilized	O
with	O
0	O
.	O
5	O
–	O
1	O
%	O
ethanol	O
)	O
.	O

An	O
a	O
##cy	O
##lated	O
car	B
##ni	I
##tine	I
compound	O
,	O
tentatively	O
id	O
##ent	O
##i	O
##ﬁ	O
##ed	O
as	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
C	O
##9	O
-	O
OH	O
,	O
was	O
sign	O
##i	O
##ﬁ	O
##can	O
##tly	O
greater	O
abundance	O
in	O
CC	O
##A	O
metabolic	O
pro	O
##ﬁ	O
##les	O
compared	O
to	O
all	O
groups	O
,	O
except	O
patients	O
with	O
pan	O
##cre	O
##atic	O
and	O
meta	O
##static	O
tumors	O
.	O

_	O
,	O
The	O
decrease	O
in	O
L	O
##ys	O
##o	O
##PC	O
##s	O
was	O
reported	O
to	O
be	O
associated	O
with	O
body	O
weight	O
loss	O
and	O
activated	S
inflammatory	O
status	O
in	O
cancer	O
patients	O
.	O

Milk	O
samples	O
from	O
consecutive	O
milk	O
##ings	O
(	O
pm	O
,	O
am	O
)	O
on	O
each	O
sampling	O
day	O
were	O
composite	O
##d	O
proportional	O
to	O
milk	O
yield	O
at	O
each	O
milk	O
##ing	O
prior	O
to	O
extraction	O
for	O
ch	B
##olin	I
##e	I
analysis	O
.	O

[	O
0	O
.	O
97	O
##7	O
–	O
1	O
.	O
000	O
]	O
)	O
,	O
followed	O
by	O
his	B
##ti	I
##dine	I
and	O
g	B
##ly	I
##cine	I
.	O

Because	O
se	B
##rot	I
##oni	I
##n	I
and	O
intermediate	O
##s	O
are	O
only	O
weakly	O
covered	O
by	O
G	O
##C	O
-	O
MS	O
we	O
applied	O
a	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
direct	O
-	O
in	O
##fusion	O
method	O
(	B
S	B
##ID	I
##E	I
-	I
MS	I
ass	O
##ay	O
,	O
see	O
section	O
Materials	O
and	O
Method	O
##s	O
)	O
.	O

34	O
##8	O
##75	O
-	O
100	O
M	O
##L	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
Fisher	O
,	O
cat	O
.	O

Different	O
##ial	O
meta	O
##bol	O
##ites	O
identified	O
from	O
the	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
suggest	O
a	O
disrupted	O
the	O
metabolism	O
of	O
x	O
##eno	O
##biotics	O
by	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
,	O
amino	S
sugar	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
metabolism	O
.	O

Several	O
fatty	O
acids	O
,	O
h	B
##ydro	I
##xy	I
acids	I
and	O
other	O
organic	O
acids	O
as	O
well	O
as	O
k	B
##eton	I
##e	I
bodies	O
and	O
sugar	O
##s	O
show	O
differences	O
.	O

F	B
##olate	I
was	O
measured	O
micro	O
##bio	O
##logical	O
##ly	O
as	O
described	O
by	O
Horne	O
.	O

The	O
urine	O
,	O
plasma	O
and	O
polar	O
tissue	O
extract	O
samples	O
contained	O
mainly	O
a	O
series	O
of	O
amino	O
acids	O
,	O
glucose	S
and	O
lip	O
##ids	O
,	O
while	O
the	O
non	O
-	O
polar	O
tissue	O
extract	O
samples	O
contained	O
the	O
minimum	O
meta	O
##bol	O
##ites	O
,	O
dominated	O
mainly	O
by	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
.	O

As	O
##p	O
is	O
a	O
direct	O
crucial	O
precursor	O
to	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

P	O
##las	O
##mal	O
##ogen	O
##s	O
are	O
bio	O
##sy	O
##nt	O
##hes	O
##ized	O
in	O
per	O
##ox	O
##is	O
##ome	O
##s	O
;	O
this	O
involves	O
the	O
trans	O
##ester	O
##ification	O
of	O
di	B
##hy	I
##dr	I
##ox	I
##ya	I
##ce	I
##tone	I
phosphate	I
with	O
a	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
(	O
,	O
)	O
.	O

Analysis	O
of	O
u	O
##rina	O
##ry	O
4	B
-	I
(	I
met	I
##hyl	I
##ni	I
##tro	I
##sa	I
##min	I
##o	I
)	I
-	I
1	I
-	I
(	I
3	I
-	I
p	I
##yr	I
##idy	I
##l	I
)	I
-	I
1	I
-	I
but	I
##ano	I
##l	I
(	O
N	O
##NA	O
##L	O
)	O
and	O
N	O
'	B
-	I
Ni	I
##tro	I
##son	I
##orn	I
##ico	I
##tine	I

Secondary	O
end	O
##points	O
included	O
the	O
changes	O
in	O
fast	O
##ing	O
g	O
##ly	O
##ce	O
##mia	O
and	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
,	O
and	O
post	O
##pra	O
##ndi	O
##al	O
change	O
in	O
glucose	S
,	O
NE	O
##FA	O
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
levels	O
(	O
meal	O
test	O
)	O
,	O
metabolic	O
flexibility	O
assessed	O
by	O
indirect	O
ca	O
##lor	O
##ime	O
##try	O
,	O
and	O
inflammatory	O
markers	O
.	O

Overall	O
,	O
treatment	O
with	O
si	B
##m	I
##vas	I
##tat	I
##in	I
lowered	O
L	O
##D	O
##L	O
-	O
C	O
by	O
54	O
mg	O
/	O
d	O
##l	O
and	O
increased	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
by	O
2	O
mg	O
/	O
d	O
##l	O
.	O

(	O
[	O
M	O
+	O
H	O
-	O
HC	O
##O	O
_	O
2	O
H	O
]	O
_	O
+	O
)	O
contained	O
the	O
prominent	O
fragment	O
ion	O
at	O
m	O
/	O
z	O
226	O
.	O
1	O
,	O
attributed	O
to	O
2	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
(	O
m	O
/	O
z	O
231	O
.	O
1	O
for	O
2	B
-	I
H	I
##O	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
)	O
,	O
as	O
was	O
observed	O
in	O
the	O
s	O
##pect	O
##ra	O
of	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
Y	I
.	O
A	O
##cc	O
##ura	O
##te	O
mass	O
measurement	O
of	O
the	O
mon	O
##ois	O
##oto	O
##pic	O
elemental	O
mass	O
of	O
synthetic	O
Y	O
*	O
T	O
##K	O
and	O
its	O
product	O
ion	O
s	O
##pect	O
##ra	O
confirmed	O
the	O
assignment	O
.	O

Among	O
the	O
an	O
##not	O
##ated	O
compounds	O
,	O
nearly	O
all	O
of	O
the	O
well	O
-	O
known	O
and	O
clinical	O
##ly	O
relevant	O
meta	O
##bol	O
##ites	O
were	O
present	O
:	O
amino	O
acids	O
,	O
hormones	O
,	O
fatty	O
acids	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
its	O
derivatives	O
,	O
etc	O
.	O

The	O
2D	O
rules	O
are	O
represented	O
with	O
their	O
variable	O
conditions	O
,	O
i	O
.	O
e	O
.	O
,	O
ranges	O
of	O
bucket	O
##s	O
bin	O
##s	O
for	O
the	O
bucket	O
##s	O
1	O
.	O
28	O
(	B
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
)	O
(	O
x	O
-	O
axis	O
)	O
and	O
3	O
.	O
16	O
(	B
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
)	O
(	O
y	O
-	O
axis	O
)	O
and	O
their	O
frequency	O
over	O
the	O
100	O
models	O
(	O
color	O
scale	O
)	O
.	O

As	O
ad	O
##ip	O
##ose	O
tissue	O
is	O
the	O
main	O
fatty	O
acid	O
storage	O
site	O
,	O
with	O
a	O
T	B
##G	I
half	O
-	O
life	O
of	O
6	O
–	O
9	O
m	O
##o	O
,	O
and	O
acting	O
as	O
a	O
reservoir	O
of	O
diet	O
##ary	O
history	O
,	O
it	O
is	O
possible	O
that	O
these	O
fatty	O
acids	O
are	O
coming	O
from	O
ad	O
##ip	O
##ose	O
(	O
or	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
)	O
tissue	O
.	O

Level	O
##s	O
of	O
MMA	O
,	O
SD	O
##MA	O
,	O
AD	B
##MA	I
,	O
met	B
##hyl	I
-	I
L	I
##ys	I
,	O
and	O
A	O
##rg	O
##MI	O
were	O
divided	O
into	O
q	O
##ua	O
##rt	O
##iles	O
for	O
analyses	O
.	O

D	O
##H	O
##U	O
is	O
a	O
u	B
##rid	I
##ine	I
derivative	O
,	O
modified	O
through	O
en	O
##zy	O
##matic	O
reduction	O
of	O
u	B
##rid	I
##ine	I
.	O

The	O
slope	O
of	O
me	B
##lat	I
##oni	I
##n	I
over	O
the	O
night	O
correlated	O
with	O
several	O
self	O
-	O
reported	O
measures	O
,	O
with	O
better	O
sleep	O
quality	O
associated	O
with	O
a	O
steep	O
##er	O
decrease	O
in	O
me	B
##lat	I
##oni	I
##n	I
.	O

On	O
the	O
next	O
day	O
,	O
1	O
m	O
##L	O
of	O
freshly	O
prepared	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
in	O
Me	B
##OH	I
was	O
added	O
to	O
the	O
dry	O
residue	O
,	O
followed	O
by	O
son	O
##ica	O
##tion	O
and	O
v	O
##ortex	O
##ing	O
to	O
completely	O
dissolve	O
the	O
sample	O
.	O

Prof	O
##iling	O
PC	O
##s	O
at	O
the	O
is	O
##omer	O
level	O
,	O
however	O
,	O
remains	O
challenging	O
in	O
lip	O
##ido	O
##mic	O
settings	O
,	O
especially	O
for	O
character	O
##izing	O
the	O
positions	O
of	O
fatty	O
a	O
##cy	O
##ls	O
on	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
(	O
s	O
##n	O
-	O
positions	O
)	O
and	O
the	O
locations	O
of	O
carbon	O
–	O
carbon	O
double	O
bonds	O
(	O
CC	O
##s	O
)	O
in	O
un	O
##sat	O
##ura	O
##ted	O
a	O
##cy	O
##l	O
chains	O
.	O

El	O
##ec	O
##tro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
)	O
was	O
used	O
in	O
positive	O
mode	O
at	O
3	O
.	O
5	O
k	B
##V	I
with	O
a	O
concurrent	O
35	O
ps	O
##ig	O
em	O
##itte	O
##r	O
ne	O
##bul	O
##ization	O
pressure	O
.	O

PC	B
a	I
##a	I
C	I
##36	I
:	I
2	I
;	O
71	O
.	O

N	O
##uc	O
##leo	O
##side	O
##s	O
:	O
The	O
research	O
for	O
a	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##er	O
of	O
HC	O
##C	O
dates	O
back	O
to	O
the	O
1970s	O
when	O
high	O
levels	O
of	O
met	B
##hyl	I
##ated	I
pu	I
##rine	I
##s	I
(	I
7	I
-	I
met	I
##hyl	I
##gua	I
##nine	I
,	I
1	I
-	I
met	I
##hyl	I
##hy	I
##pox	I
##ant	I
##hine	I
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gua	I
##nine	I
,	I
1	I
-	I
met	I
##hyl	I
##gua	I
##nine	I
and	O
ad	B
##eni	I
##ne	I
)	I
were	O
detected	O
in	O
the	O
urine	O
of	O
patients	O
with	O
HC	O
##C	O
compared	O
to	O
both	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
and	O
healthy	O
controls	O
[	O
]	O
(	O
Table	O
)	O
.	O

Only	O
as	B
##par	I
##tic	I
acid	I
(	O
post	O
-	O
H	O
##F	O
##D	O
vs	O
.	O
control	O
FC	O
=	O
2	O
.	O
52	O
,	O
F	O
##DR	O
<	O
0	O
.	O
00	O
##1	O
;	O
post	O
-	O
HD	O
vs	O
.	O
control	O
FC	O
=	O
2	O
.	O
31	O
,	O
F	O
##DR	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
N	B
-	I
ace	I
##ty	I
##lor	I
##ni	I
##thin	I
##e	I
(	O
6	O
.	O
04	O
,	O
<	O
0	O
.	O
00	O
##1	O
;	O
4	O
.	O
10	O
,	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
and	O
p	B
##yr	I
##u	I
##vic	I
acid	I
(	O
0	O
.	O
12	O
,	O
<	O
0	O
.	O
00	O
##1	O
;	O
0	O
.	O
11	O
,	O
<	O
0	O
.	O
00	O
##1	O
)	O
showed	O
no	O
significant	O
differences	O
after	O
dial	O
##ys	O
##is	O
.	O

Specifically	O
,	O
400	O
μ	O
##L	O
of	O
urine	O
was	O
added	O
to	O
160	O
μ	O
##L	O
of	O
phosphate	S
buffer	O
solution	O
(	O
0	O
.	O
2	O
m	O
##ol	O
/	O
L	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
/	O
0	O
.	O
2	O
m	O
##ol	O
/	O
L	O
Na	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
,	O
pH	O
7	O
.	O
4	O
)	O
and	O
40	O
μ	O
##L	O
of	O
3	B
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
(	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
d	I
_	I
4	I
)	I
-	I
1	I
-	I
prop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
/	O
D	O
_	O
2	O
O	O
solution	O
.	O

Random	O
selection	O
of	O
100	O
s	O
##pect	O
##ra	O
was	O
repeated	O
1	O
,	O
000	O
times	O
for	O
mean	O
-	O
centred	O
data	O
as	O
described	O
for	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
modeling	O
.	O

Shi	O
##mming	O
quality	O
,	O
expressed	O
as	O
%	O
v	O
/	O
p	O
of	O
an	O
##omer	O
##ic	O
pro	O
##ton	O
of	O
su	B
##c	I
##rose	I
.	O

From	O
this	O
chart	O
we	O
could	O
clear	O
figure	O
out	O
that	O
beta	B
-	I
al	I
##ani	I
##ne	I
metabolism	O
pathway	O
was	O
the	O
most	O
significant	O
changes	O
after	O
He	O
gas	O
plasma	O
treatment	O
in	O
LP	O
-	O
1	O
cells	O
.	O

Our	O
data	O
indicated	O
that	O
the	O
levels	O
of	O
as	B
##par	I
##tate	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
le	B
##uc	I
##ine	I
were	O
higher	O
,	O
while	O
the	O
levels	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
lower	O
,	O
in	O
serum	O
samples	O
from	O
lung	O
cancer	O
patients	O
compared	O
to	O
controls	O
.	O

U	O
##rina	O
##ry	O
N	B
-	I
met	I
##hyl	I
ni	I
##cot	I
##ini	I
##c	I
acid	I
ex	O
##cre	O
##tion	O
was	O
impaired	O
in	O
patients	O
with	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
further	O
impaired	O
in	O
patents	O
with	O
OH	O
##E	O
.	O

In	O
light	O
of	O
low	O
correlation	O
between	O
both	O
partners	O
'	O
bio	O
##mark	O
##er	O
levels	O
(	O
r	O
=	O
0	O
.	O
11	O
for	O
para	B
##ce	I
##tam	I
##ol	I
and	O
r	O
=	O
0	O
.	O
10	O
for	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
)	O
,	O
we	O
re	O
-	O
ran	O
models	O
with	O
the	O
same	O
co	O
##var	O
##iate	O
##s	O
including	O
the	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
the	O
other	O
partner	O
to	O
assess	O
T	O
##TP	O
as	O
a	O
couple	O
-	O
dependent	O
outcome	O
.	O

Interest	O
##ingly	O
,	O
the	O
short	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
but	I
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
tended	O
to	O
increase	O
in	O
all	O
but	O
the	O
am	B
##lo	I
##di	I
##pine	I
plasma	O
##s	O
,	O
which	O
runs	O
counter	O
to	O
the	O
directional	O
change	O
of	O
the	O
long	O
-	O
and	O
medium	O
-	O
chain	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
##s	O
.	O

Among	O
the	O
five	O
AA	O
##s	O
,	O
v	B
##ali	I
##ne	I
stands	O
out	O
with	O
a	O
251	O
%	O
increased	O
odds	O
(	O
per	O
s	O
.	O
d	O
.	O
)	O
of	O
developing	O
diabetes	O
in	O
the	O
future	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
,	O
)	O
.	O

The	O
CS	O
##F	O
samples	O
were	O
prepared	O
by	O
addition	O
of	O
630	O
μ	O
##L	O
of	O
th	O
##awed	O
CS	O
##F	O
sample	O
to	O
70	O
μ	O
##L	O
of	O
D	O
_	O
2	O
O	O
solution	O
[	O
1	O
m	O
##M	O
3	B
-	I
(	I
Tri	I
##met	I
##hyl	I
##si	I
##ly	I
##l	I
)	I
prop	O
##ion	O
##ic	O
-	O
2	O
,	O
2	O
,	O
3	O
,	O
3	O
-	O
d	O
##4	O
acid	O
(	O
T	O
##SP	O
)	O
,	O
3	O
m	O
##M	O
Na	O
##N	O
_	O
3	O
]	O
in	O
an	O
E	O
##ppe	O
##ndo	O
##rf	O
tube	O
.	O

Inc	O
##reased	O
ch	B
##olin	I
##e	I
has	O
also	O
been	O
detected	O
in	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
pro	O
##fi	O
##ling	O
P	O
##ca	O
tissue	O
relative	O
to	O
ben	O
##ign	O
tissue	O
_	O
,	O
.	O

The	O
T	B
##G	I
correlation	O
did	O
not	O
vary	O
by	O
fast	O
##ing	O
status	O
(	O
data	O
not	O
shown	O
)	O
,	O
and	O
when	O
using	O
log	O
transformed	O
T	B
##G	I
,	O
the	O
correlation	O
was	O
higher	O
,	O
at	O
0	O
.	O
91	O
.	O

To	O
determine	O
the	O
influence	O
of	O
these	O
co	O
##var	O
##iate	O
##s	O
on	O
the	O
relationship	O
between	O
SP	O
##s	O
and	O
B	O
##MI	O
,	O
we	O
performed	O
a	O
multi	O
##var	O
##iate	O
analysis	O
correct	O
##ing	O
for	O
age	O
,	O
sex	O
,	O
L	O
##D	O
##L	O
,	O
HD	O
##L	O
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
and	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
in	O
subjects	O
converting	O
to	O
AD	O
put	B
##res	I
##cine	I
is	O
channel	O
##led	O
towards	O
the	O
production	O
of	O
sperm	B
##id	I
##ines	I
and	O
sperm	O
##ines	O
,	O
whereas	O
in	O
stable	O
MC	O
##I	O
put	B
##res	I
##cine	I
has	O
other	O
fate	O
##s	O
(	O
production	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
##put	I
##res	I
##cine	I
or	O
4	B
-	I
amino	I
##but	I
##ana	I
##l	I
)	O
.	O

≥	O
90	O
mm	O
H	O
##g	O
or	O
re	O
##ceipt	O
of	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
drugs	O
]	O
,	O
type	O
2	O
diabetes	O
[	O
American	O
Di	O
##abe	O
##tes	O
Association	O
criteria	O
_	O
,	O
]	O
and	O
metabolic	O
syndrome	O
defined	O
as	O
:	O
presence	O
of	O
central	O
o	O
##besity	O
combined	O
with	O
any	O
two	O
of	O
the	O
following	O
:	O
raised	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
low	O
HD	O
##L	O
-	O
C	O
,	O
high	O
blood	O
pressure	O
and	O
raised	O
fast	O
##ing	O
plasma	O
glucose	S
(	O
≥	O
5	O
.	O
6	O
mm	O
##ol	O
/	O
l	O
)	O
,	O
previously	O
diagnosed	O
type	O
2	O
diabetes	O
or	O
receiving	O
anti	O
-	O
di	O
##abe	O
##tic	O
medication	O
[	O
International	O
Di	O
##abe	O
##tes	O
Federation	O
definition	O
]	O
.	O

Tam	B
##ox	I
##ife	I
##n	I
and	O
its	O
meta	O
##bol	O
##ites	O
were	O
measured	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

U	O
##rine	O
c	B
##rea	I
##tin	I
##ine	I
was	O
measured	O
at	O
the	O
University	O
of	O
Minnesota	O
Medical	O
Center	O
using	O
V	O
##it	O
##ros	O
C	O
##rea	O
slides	O
(	O
Or	O
##th	O
##o	O
-	O
Clinical	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Rochester	O
,	O
NY	O
)	O

In	O
the	O
q	O
##uant	O
##itation	O
experiments	O
based	O
on	O
de	O
##con	O
##ju	O
##gation	O
,	O
to	O
measure	O
di	B
##os	I
##met	I
##in	I
in	O
plasma	O
,	O
dig	O
##est	O
##ion	O
either	O
with	O
β	O
-	O
d	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
or	O
with	O
su	O
##lf	O
##ata	O
##se	O
,	O
or	O
with	O
both	O
enzymes	O
together	O
was	O
performed	O
.	O

Various	O
α	B
-	I
k	I
##eto	I
acids	I
,	O
which	O
are	O
the	O
by	O
##p	O
##rod	O
##uc	O
##ts	O
of	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
,	O
such	O
as	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ate	I
,	O
increased	O
after	O
le	O
##pt	O
##in	O
therapy	O
(	O
2	O
.	O
4	O
-	O
fold	O
)	O
and	O
levels	O
of	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ob	I
##ut	I
##yra	I
##te	I
(	O
11	O
-	O
fold	O
)	O
tended	O
to	O
increase	O
(	O
and	O
)	O
.	O

It	O
is	O
crucial	O
to	O
use	O
is	O
##oto	O
##pical	O
##ly	O
labeled	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
to	O
assign	O
the	O
correct	O
retention	O
time	O
to	O
this	O
anal	O
##yte	O
.	O

In	O
this	O
analysis	O
,	O
a	O
number	O
of	O
characteristic	O
changes	O
in	O
metabolic	O
profile	O
are	O
noted	O
in	O
HK	O
-	O
2	O
cells	O
following	O
exposure	O
to	O
5	O
m	O
##M	O
and	O
25	O
m	O
##M	O
glucose	S
.	O

and	O
it	O
is	O
a	O
g	B
##ly	I
##cine	I
con	O
##ju	O
##gate	O
of	O
p	B
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
,	O
which	O
is	O
normally	O
a	O
minor	O
meta	O
##bol	O
##ite	O
of	O
fatty	O
acids	O
,	O
so	O
decreased	O
level	O
of	O
PA	B
##G	I
indicated	O
the	O
decreased	O
cat	O
##ab	O
##olis	O
##m	O
of	O
lip	O
##id	O
.	O

We	O
determined	O
that	O
6	O
weeks	O
of	O
daily	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
increased	O
plasma	O
glucose	S
and	O
insulin	O
in	O
some	O
subjects	O
,	O
indicating	O
development	O
of	O
insulin	O
resistance	O
.	O

High	O
sample	O
through	O
##put	O
(	O
≤	O
16	O
min	O
total	O
cycle	O
time	O
per	O
sample	O
,	O
<	O
7	O
min	O
for	O
MS	O
##1	O
portion	O
)	O
was	O
achieved	O
using	O
the	O
na	O
##no	O
##ele	O
##ct	O
##ros	O
##pra	O
##y	O
Tri	O
##V	O
##ers	O
##a	O
Nan	O
##o	O
##M	O
##ate	O
(	O
Ad	O
##vio	O
##n	O
B	O
##ios	O
##cie	O
##nces	O
,	O
It	O
##ha	O
##ca	O
,	O
NY	O
,	O
USA	O
)	O
with	O
1	O
.	O
5	O
k	B
##V	I
electro	O
##sp	O
##ray	O
voltage	O
and	O
0	O
.	O
4	O
ps	O
##i	O
head	O
pressure	O
.	O

However	O
,	O
many	O
car	B
##box	I
##yl	I
##ic	I
acid	I
containing	O
drugs	O
including	O
NSA	O
##ID	O
##S	O
are	O
meta	O
##bol	O
##ized	O
by	O
U	O
##G	O
##T	O
##s	O
to	O
form	O
β	O
-	O
1	O
-	O
O	O
-	O
a	O
##cy	O
##l	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
(	O
AG	O
##s	O
)	O
,	O
which	O
are	O
able	O
to	O
form	O
add	O
##uc	O
##ts	O
with	O
n	O
##uc	O
##leo	O
##phi	O
##les	O
in	O
proteins	O
and	O
may	O
contribute	O
to	O
toxicity	O
of	O
NSA	O
##ID	O
##S	O
.	O

Its	O
well	O
-	O
known	O
role	O
in	O
circa	O
##dian	O
rhythmic	O
##ity	O
makes	O
it	O
an	O
ideal	O
candidate	O
to	O
explain	O
the	O
frequent	O
occurrence	O
,	O
especially	O
at	O
the	O
onset	O
of	O
AS	O
##D	O
and	O
during	O
early	O
infancy	O
,	O
of	O
sleep	O
disorders	O
highly	O
re	O
##sp	O
##ons	O
##ive	O
to	O
me	B
##lat	I
##oni	I
##n	I
as	O
a	O
p	O
##har	O
##ma	O
##cological	O
therapy	O
.	O

In	O
contrast	O
to	O
published	O
findings	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
was	O
found	O
positively	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
negatively	O
associated	O
with	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

Ba	O
##P	O
car	O
##cin	O
##ogenic	O
##ity	O
is	O
believed	O
to	O
occur	O
mainly	O
through	O
its	O
co	O
##valent	O
modification	O
of	O
DNA	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
BP	O
##DE	O
-	O
-	O
d	O
##G	O
,	O
an	O
add	O
##uc	O
##t	O
formed	O
between	O
de	B
##ox	I
##y	I
##gua	I
##nos	I
##ine	I
and	O
a	O
di	B
##ol	I
e	I
##pox	I
##ide	I
meta	O
##bol	O
##ite	O
of	O
Ba	O
##P	O
,	O
with	O
subsequent	O
mutation	O
of	O
critical	O
growth	O
control	O
genes	O
.	O

The	O
second	O
step	O
involved	O
al	B
##kal	I
##ine	I
and	O
acid	O
h	O
##ydro	O
##ly	O
##ses	O
of	O
the	O
_	O
15	O
N	O
substituted	O
p	O
##ht	O
##hali	O
##mi	O
##de	O
to	O
yield	O
the	O
smart	O
is	O
##oto	O
##pe	O
tag	O
,	O
_	O
15	O
N	O
-	O
ch	O
##ola	O
##im	O
##ne	O
.	O

Level	O
##s	O
of	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
were	O
significantly	O
enhanced	O
in	O
plasma	O
of	O
AD	O
patients	O
(	O
50	O
±	O
6	O
n	O
##M	O
,	O
p	O
=	O
0	O
.	O
00	O
##4	O
)	O
compared	O
to	O
healthy	O
controls	O
(	O
32	O
±	O
3	O
n	O
##M	O
;	O
Table	O
)	O
.	O

Once	O
collected	O
,	O
1	O
m	O
##l	O
u	O
##rina	O
sang	O
##uin	O
##is	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
4000	O
r	O
/	O
min	O
for	O
10	O
min	O
and	O
300	O
μ	O
##L	O
super	O
##nat	O
##ant	O
was	O
taken	O
and	O
added	O
with	O
600	O
μ	O
##L	O
met	B
##han	I
##ol	I
.	O

Our	O
data	O
indicate	O
that	O
smoking	O
contributes	O
to	O
the	O
longitudinal	O
instability	O
of	O
P	O
##GE	O
-	O
M	O
because	O
correction	O
for	O
both	O
c	B
##rea	I
##tin	I
##ine	I
and	O
total	O
ni	B
##cot	I
##ine	I
equivalent	O
##s	O
results	O
in	O
an	O
improved	O
ICC	O
value	O
of	O
0	O
.	O
47	O
(	O
0	O
.	O
40	O
,	O
0	O
.	O
53	O
)	O
.	O

S	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
and	O
can	B
##ren	I
##one	I
were	O
purchased	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
,	O
7	B
-	I
alpha	I
-	I
met	I
##hyl	I
##thi	I
##os	I
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
from	O
Ph	O
##arma	O
##S	O
##ynth	O
(	O
Ta	O
##rt	O
##u	O
,	O
Estonia	O
)	O
,	O
and	O
s	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
-	I
D	I
_	I
3	I
(	O
used	O
as	O
an	O
internal	O
standard	O
,	O
IS	O
)	O
from	O
T	O
##LC	O
Ph	O
##arma	O
##ce	O
##utical	O
Standards	O
(	O
Aurora	O
,	O
Ontario	O
,	O
Canada	O
)	O
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
from	O
SD	O
##S	O
(	O
P	O
##ey	O
##pin	O
,	O
France	O
)	O
and	O
form	B
##ic	I
acid	I
from	O
Me	O
##rc	O
##k	O
(	O
B	O
##ria	O
##re	O
-	O
le	O
-	O
Canal	O
,	O
France	O
)	O
.	O

Ph	O
##e	O
:	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
P	O
##y	O
:	O
p	B
##yr	I
##u	I
##vate	I
;	O
Sa	O
##r	O
:	O
sa	B
##rc	I
##os	I
##ine	I
;	O
T	O
##hr	O
:	O
th	B
##re	I
##oni	I
##ne	I
;	O
T	B
##MA	I
##O	I
:	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
;	O
Ty	O
##r	O
:	O
t	B
##yr	I
##os	I
##ine	I
;	O
Val	O
:	O
v	B
##ali	I
##ne	I
;	O
V	O
##LD	O
##L	O
:	O
very	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
α	B
-	I
G	I
##l	I
##c	I
:	O
α	B
-	I
glucose	I
;	O
β	B
-	I
G	I
##l	I
##c	I
:	O
β	B
-	I
glucose	I
.	O

In	O
addition	O
to	O
the	O
above	O
meta	O
##bol	O
##ites	O
,	O
the	O
W	O
##B	O
showed	O
the	O
presence	O
of	O
peaks	O
arising	O
from	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ath	I
##ione	I
(	O
G	O
##SS	O
##G	O
,	O
o	O
##xi	O
##dized	O
form	O
)	O
and	O
co	O
##fa	O
##ctors	O
involved	O
in	O
the	O
cellular	O
red	O
##ox	O
reactions	O
–	O
ATP	S
,	O
AD	B
##P	I
,	O
AM	B
##P	I
,	O
N	O
##AD	O
_	O
+	O
,	O
and	O
N	O
##AD	O
##P	O
_	O
+	O
.	O

The	O
general	O
increase	O
of	O
la	B
##ct	I
##ose	I
is	O
a	O
well	O
-	O
known	O
phenomenon	O
and	O
is	O
linked	O
to	O
la	O
##ct	O
##ation	O
and	O
the	O
pro	O
##la	O
##ct	O
##in	O
levels	O
in	O
blood	O
.	O

TV	O
was	O
calculated	O
,	O
se	O
##men	O
analysis	O
performed	O
by	O
WHO	O
approved	O
methods	O
,	O
and	O
serum	O
concentrations	O
of	O
go	O
##nado	O
##tro	O
##phi	O
##ns	O
,	O
in	O
##hi	O
##bin	O
B	O
,	O
and	O
test	B
##osterone	I
measured	O
.	O

+	B
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##ρ	I
##s	I
##j	I
(	I
y	I
##j	I
)	I
x	I
##s	I
+	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##φ	I
##r	I
##j	I
(	I
y	I
##r	I
,	I
y	I
##j	I
)	I
)	O
.	O

Tau	B
##rine	I
,	O
which	O
is	O
a	O
sulfur	O
##ic	O
amino	O
acid	O
,	O
can	O
be	O
synthesized	O
by	O
the	O
human	O
body	O
from	O
c	B
##ys	I
##tein	I
##e	I
.	O

The	O
meta	O
##bol	O
##ites	O
will	O
be	O
also	O
con	O
##ju	O
##gated	O
to	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
eliminated	O
via	O
the	O
urine	O
.	O

For	O
the	O
H	O
##EM	O
##O	O
co	O
##hor	O
##t	O
,	O
im	O
##mu	O
##no	O
##af	O
##finity	O
en	O
##rich	O
##ment	O
was	O
added	O
to	O
the	O
newer	O
ch	O
##roma	O
##to	O
##graphic	O
method	O
to	O
measure	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
and	O
1	B
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
##D	I
_	I
2	I
in	O
addition	O
to	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
and	O
the	O
interfering	O
anal	O
##yte	O
(	O
s	O
)	O
.	O

The	O
Q	O
##C	O
stock	O
solution	O
was	O
di	O
##lut	O
##ed	O
with	O
AC	O
##N	O
to	O
yield	O
Q	O
##C	O
concentration	O
levels	O
of	O
1000	O
,	O
1500	O
##0	O
,	O
and	O
4000	O
##0	O
ng	O
/	O
m	O
##L	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
,	O
which	O
were	O
also	O
subsequently	O
di	O
##lut	O
##ed	O
ten	O
-	O
fold	O
with	O
the	O
album	O
##an	O
solution	O
/	O
plasma	O
(	O
90	O
:	O
10	O
)	O
.	O

Higher	O
meta	O
##bol	O
##ite	O
concentrations	O
of	O
end	B
##ox	I
##ife	I
##n	I
were	O
related	O
to	O
26	O
%	O
lower	O
breast	O
cancer	O
re	O
##cu	O
##rrence	O
rate	O
.	O

It	O
should	O
be	O
mentioned	O
,	O
however	O
,	O
that	O
the	O
concentration	O
is	O
only	O
marginal	O
##ly	O
higher	O
in	O
older	O
women	O
,	O
and	O
some	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
show	O
lower	O
concentrations	O
in	O
older	O
women	O
.	O

In	O
contrast	O
to	O
the	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
concentration	O
,	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
levels	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
exhibited	O
a	O
marked	O
increase	O
at	O
the	O
end	O
of	O
the	O
diet	O
##ary	O
intervention	O
.	O

This	O
study	O
concluded	O
that	O
differential	O
##ly	O
presented	O
meta	O
##bol	O
##ites	O
were	O
mainly	O
linked	O
with	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
pathway	O
.	O

Ace	B
##tone	I
,	O
ace	B
##tate	I
,	O
ethanol	S
,	O
and	O
met	B
##han	I
##ol	I
were	O
also	O
detected	O
but	O
were	O
excluded	O
from	O
analysis	O
as	O
they	O
are	O
volatile	O
and	O
samples	O
were	O
dried	O
by	O
l	O
##yo	O
##phi	O
##li	O
##zation	O
.	O

Interest	O
##ingly	O
,	O
plasma	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
concentration	O
has	O
been	O
shown	O
to	O
be	O
increased	O
in	O
inflammatory	O
diseases	O
,	O
including	O
u	O
##rem	O
##ia	O
.	O

Our	O
first	O
step	O
was	O
to	O
profile	O
,	O
with	O
an	O
MS	O
-	O
based	O
meta	O
##bol	O
##omi	O
##c	O
method	O
,	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
and	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
in	O
the	O
a	O
##que	O
##ous	O
humor	O
,	O
v	O
##it	O
##re	O
##ous	O
humor	O
,	O
and	O
plasma	O
of	O
patients	O
with	O
PD	O
##R	O
and	O
control	O
subjects	O
.	O

The	O
mean	O
me	B
##lat	I
##oni	I
##n	I
was	O
significantly	O
higher	O
in	O
participants	O
who	O
slept	O
longer	O
than	O
45	O
##5	O
minutes	O
.	O

However	O
,	O
the	O
immune	O
-	O
m	O
##od	O
##ulatory	O
properties	O
of	O
other	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
such	O
as	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
and	O
ant	B
##hra	I
##ni	I
##lic	I
acid	I
are	O
poorly	O
understood	O
.	O

The	O
fact	O
that	O
the	O
‘	B
D	I
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
’	O
pathway	O
had	O
an	O
impact	O
value	O
greater	O
than	O
0	O
.	O
10	O
(	O
0	O
.	O
33	O
)	O
suggests	O
that	O
the	O
‘	B
D	I
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
’	O
pathway	O
and	O
the	O
meta	O
##bol	O
##ite	O
D	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
are	O
prominent	O
features	O
of	O
A	B
##F	I
in	O
card	O
##iovascular	O
disease	O
patients	O
.	O

Normal	O
##ised	O
,	O
relative	O
abundance	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
(	O
2	O
-	O
H	O
##G	O
)	O
levels	O
in	O
blood	O
plasma	O
samples	O
comparing	O
in	O
##tra	O
##he	O
##pa	O
##tic	O
ch	O
##ola	O
##ng	O
##io	O
##car	O
##cin	O
##oma	O
(	O
ICC	O
)	O
patients	O
and	O
controls	O
.	O

Dec	O
##reased	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
(	O
G	O
##F	O
##R	O
)	O
leads	O
to	O
reduced	O
production	O
of	O
1	B
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
from	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
)	O
.	O

To	O
predict	O
PC	O
##OS	O
,	O
the	O
best	O
combination	O
including	O
up	O
to	O
four	O
s	O
##tero	O
##ids	O
was	O
a	O
ratio	O
comprising	O
and	B
##ros	I
##tan	I
##ed	I
##iol	I
,	O
est	B
##rio	I
##l	I
,	O
20	B
##β	I
##D	I
##H	I
##cor	I
##tis	I
##one	I
and	O
co	B
##rt	I
##is	I
##ol	I
.	O

Technical	O
replica	O
##tes	O
of	O
these	O
samples	O
underwent	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
(	O
n	O
=	O
4	O
)	O
or	O
Me	B
##OH	I
:	O

Seven	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
were	O
associated	O
with	O
a	O
decrease	O
in	O
C	O
-	O
p	O
##eptide	O
at	O
6	O
months	O
.	O

Due	O
to	O
an	O
insufficient	O
separation	O
,	O
the	O
analysis	O
using	O
a	O
Ph	O
##en	O
##yl	O
##H	O
##ex	O
##yl	O
column	O
merely	O
revealed	O
one	O
feature	O
identified	O
as	O
a	O
di	B
##hy	I
##dr	I
##o	I
meta	O
##bol	O
##ite	O
(	O
M	O
##26	O
##2	O
##T	O
##32	O
##5	O
in	O
Table	O
)	O
.	O

Peak	O
areas	O
of	O
identified	O
meta	O
##bol	O
##ites	O
by	O
L	O
##C	O
-	O
MS	O
analysis	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
modes	O
that	O
had	O
a	O
VIP	O
score	O
of	O
>	O
2	O
_	O
1	O
l	O
Un	O
##tar	O
##get	O
##ed	O
_	O
1	O
H	O
-	O
N	O
##MR	O
analysis	O
revealed	O
spectral	O
differences	O
according	O
to	O
grouping	O
##s	O
of	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
.	O

In	O
addition	O
,	O
fatty	O
acids	O
of	O
the	O
o	B
##me	I
##ga	I
-	I
3	I
class	O
were	O
shown	O
to	O
be	O
associated	O
with	O
mi	O
##gra	O
##ine	O
,	O
but	O
only	O
in	O
male	O
participants	O
.	O

The	O
time	O
-	O
dependent	O
level	O
changes	O
(	O
slope	O
)	O
of	O
se	B
##rot	I
##oni	I
##n	I
positively	O
correlated	O
with	O
worse	O
di	O
##ar	O
##r	O
##hea	O
and	O
loose	O
##r	O
and	O
more	O
frequent	O
stool	O
##s	O
.	O

spike	O
:	O
Internal	O
standard	O
spike	O
##d	O
into	O
human	O
serum	O
,	O
followed	O
by	O
M	B
##T	I
##BE	I
extraction	O
and	O
der	O
##iva	O
##ti	O
##zation	O
.	O

Ki	O
##net	O
##ic	O
studies	O
for	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
were	O
conducted	O
at	O
conditions	O
linear	O
for	O
duration	S
of	O
in	O
##cu	O
##bation	O
and	O
protein	O
concentration	O
in	O
four	O
different	O
H	O
##LM	O
preparations	O
.	O

Among	O
the	O
p	B
##oly	I
##amine	I
##s	I
analyzed	O
in	O
serum	O
by	O
our	O
platform	O
,	O
SPD	O
was	O
the	O
most	O
predominant	O
(	O
152	O
.	O
5	O
±	O
63	O
.	O
7	O
n	O
##M	O
)	O
,	O
although	O
significant	O
levels	O
of	O
other	O
p	B
##oly	I
##amine	I
##s	I
,	O
such	O
as	O
P	O
##UT	O
(	O
77	O
.	O
7	O
±	O
28	O
.	O
3	O
n	O
##M	O
)	O
,	O
SP	O
##M	O
(	O
25	O
.	O
4	O
±	O
10	O
.	O
0	O
n	O
##M	O
)	O
,	O
and	O
the	O
SPD	O
ace	O
##ty	O
##lated	O
forms	O
N	O
##1	O
-	O
A	O
##c	O
##SP	O
##D	O
(	O
76	O
.	O
8	O
±	O
27	O
.	O
4	O
n	O
##M	O
)	O
and	O

The	O
increase	O
in	O
V	O
##LD	O
##L	O
size	O
is	O
typically	O
associated	O
with	O
the	O
reduction	O
in	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
concentration	O
,	O
in	O
part	O
related	O
to	O
the	O
transfer	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##er	I
from	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
rich	O
lip	O
##op	O
##rote	O
##ins	O
to	O
HD	O
##L	O
.	O

HM	O
##PM	O
##A	O
is	B
##omer	I
1	I
:	I
3	I
-	I
h	I
##ydro	I
##xy	I
-	I
1	I
-	I
(	I
S	I
or	I
R	I
)	I
-	I
met	I
##hyl	I
##p	I
##rop	I
##yl	I
##mer	I
##cap	I
##tur	I
##ic	I
acid	I
(	O
retention	O
time	O
,	O
7	O
.	O
11	O
min	O
)	O
:	O
_	O
1	O
H	O
N	O
##MR	O
(	O
500	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
8	O
.	O
24	O
-	O
8	O
.	O
21	O
(	O
m	O
,	O
1	O
##H	O
,	O
-	O
NH	O
-	O
)	O
,	O
4	O
.	O
40	O
-	O
4	O
.	O
33	O
(	O
m	O
,	O
1	O
##H	O
,	O
-	O
CH	O
##CO	O
##OH	O
)	O
,	O
4	O
.	O
18	O
(	O
t	O
,	O
J	O
=	O
7	O
.	O
5	O

Met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
an	O
oxidation	O
product	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
a	O
possible	O
bio	O
##mark	O
##er	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
was	O
able	O
to	O
disc	O
##rim	O
##inate	O
medication	O
-	O
free	O
MD	O
##D	O
patients	O
from	O
the	O
control	O
subjects	O
,	O
and	O
showed	O
the	O
best	O
AU	O
##C	O
among	O
35	O
meta	O
##bol	O
##ites	O
examined	O
(	O
AU	O
##C	O
=	O
0	O
.	O
97	O
,	O
sensitivity	O
0	O
.	O
91	O
,	O
and	O
specific	O
##ity	O
0	O
.	O
97	O
)	O
.	O

Important	O
##ly	O
,	O
this	O
is	O
in	O
the	O
range	O
of	O
normal	O
concentrations	O
of	O
re	B
##tino	I
##ic	I
acid	I
in	O
plasma	O
and	O
approximately	O
the	O
same	O
as	O
the	O
binding	O
constant	O
of	O
the	O
compound	O
for	O
the	O
re	B
##tino	I
##id	I
receptors	O
.	O

P	O
##las	O
##ma	O
glucose	S
was	O
maintained	O
at	O
e	O
##ug	O
##ly	O
##ce	O
##mia	O
(	O
~	O
5	O
mm	O
##ol	O
/	O
L	O
)	O
by	O
a	O
prime	O
##d	O
and	O
then	O
continuous	O
insulin	O
in	O
##fusion	O
at	O
40	O
m	O
##U	O
/	O
body	O
surface	O
area	O
m	O
_	O
2	O
/	O
min	O
and	O
20	O
%	O
glucose	S
in	O
##fusion	O
based	O
on	O
plasma	O
glucose	S
measurements	O
taken	O
every	O
5	O
to	O
10	O
minutes	O
.	O

The	O
levels	O
of	O
C	B
##15	I
:	I
0	I
,	O
C	B
##17	I
:	I
0	I
,	O
and	O
unknown	O
C	O
##17	O
were	O
then	O
increased	O
at	O
6	O
h	O
compared	O
to	O
0	O
h	O
,	O
after	O
milk	O
intake	O
(	B
C	B
##15	I
:	I
0	I
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##4	O
,	O
C	B
##17	I
:	I
0	I
p	O
=	O
2	O
.	O
0	O
×	O
10	O
_	O
−	O
##3	O
,	O
unknown	O
C	O
##17	O
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##4	O
)	O
and	O
cheese	O
intake	O
(	B
C	B
##15	I
:	I
0	I
p	O
=	O
2	O
.	O
0	O
×	O
10	O
_	O
−	O
##3	O
,	O
C	B
##17	I
:	I
0	I
p	O
=	O
2	O
.	O
0	O
×	O
10	O
_	O
−	O
##3	O
,	O
unknown	O
C	O
##17	O
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##4	O
)	O
but	O
not	O
after	O
so	O
##y	O
drink	O
intake	O
(	B
C	B
##15	I
:	I
0	I
p	O
=	O

Mal	B
##ond	I
##ial	I
##de	I
##hy	I
##de	I
will	O
be	O
measured	O
by	O
th	B
##io	I
##bar	I
##bit	I
##uri	I
##c	I
acid	I
reactive	O
substances	O
ass	O
##ay	O
using	O
UV	O
s	O
##pect	O
##rop	O
##hot	O
##ometer	O
(	O
UV	O
-	O
160	O
##1	O
,	O
Shi	O
##mad	O
##zu	O
,	O
Japan	O
)	O
.	O

(	O
specifically	O
D	O
##HC	O
##R	O
##7	O
)	O
and	O
T	O
##2	O
##D	O
,	O
suggesting	O
a	O
possible	O
ca	O
##usal	O
relationship	O
between	O
serum	O
vitamin	B
D	I
and	O
this	O
disease	O
.	O

Most	O
cancer	O
cells	O
produce	O
energy	O
by	O
g	O
##ly	O
##co	O
##lysis	O
rather	O
than	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
via	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
,	O
termed	O
as	O
War	O
##burg	O
effect	O
.	O

The	O
association	O
between	O
intro	O
##nic	O
S	O
##NP	O
r	O
##s	O
##24	O
##8	O
##38	O
##6	O
within	O
D	O
##MG	O
##D	O
##H	O
(	O
dim	O
##eth	O
##yl	O
-	O
g	O
##ly	O
##cine	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
)	O
and	O
dim	B
##eth	I
##yl	I
-	I
g	I
##ly	I
##cine	I
level	O
is	O
a	O
novel	O
finding	O
(	O
P	O
-	O
value	O
=	O
1	O
.	O
65	O
##×	O
##10	O
_	O
−	O
##19	O
)	O
.	O

The	O
f	O
##eca	O
##l	O
ratio	O
of	O
lit	O
##hot	O
##omi	O
##c	O
acid	O
to	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
,	O
a	O
risk	O
factor	O
for	O
co	O
##lon	O
cancer	O
is	O
also	O
reduced	O
in	O
rats	O
fed	O
on	O
a	O
high	O
-	O
fat	O
diet	O
along	O
with	O
vitamin	B
B	I
##6	I
.	O

This	O
approach	O
has	O
been	O
used	O
in	O
the	O
past	O
for	O
humans	O
,	O
where	O
the	O
diet	O
##ary	O
reference	O
intake	O
for	O
ch	B
##olin	I
##e	I
is	O
30	O
%	O
higher	O
(	O
125	O
mg	O
/	O
d	O
)	O
for	O
breast	O
##fe	O
##eding	O
women	O
than	O
it	O
is	O
for	O
non	O
-	O
breast	O
##fe	O
##eding	O
woman	O
,	O
with	O
the	O
higher	O
level	O
of	O
intake	O
calculated	O
based	O
on	O
predicted	O
levels	O
of	O
ch	B
##olin	I
##e	I
secret	O
##ed	O
daily	O
in	O
milk	O
.	O

The	O
strongest	O
association	O
with	O
progression	O
to	O
E	O
##SR	O
##D	O
was	O
for	O
pseudo	B
##uri	I
##dine	I
,	O
odds	O
ratio	O
7	O
.	O
8	O
(	O
95	O
%	O
C	O
##I	O
;	O
3	O
.	O
1	O
,	O
19	O
)	O
.	O

standard	O
regent	O
of	O
T	O
##RP	O
,	O
K	O
##Y	O
##N	O
,	O
K	O
##Y	O
##NA	O
,	O
Q	O
##UI	O
##N	O
(	O
si	O
##gma	O
)	O
;	O
Met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
am	I
##mon	I
##ium	I
ace	I
##tate	I
,	O
and	O
glacial	B
ace	I
##tic	I
acid	I
(	O
Shanghai	O
An	O
##pu	O
Experimental	O
Technology	O
Company	O
)	O
.	O

Cox	O
proportional	O
hazards	O
re	O
##gression	O
model	O
test	O
for	O
D	O
##FS	O
of	O
all	O
patients	O
L	O
##N	O
+	O
,	O
l	O
##ymph	O
node	O
meta	O
##sta	O
##sis	O
;	O
ER	O
,	O
est	B
##rogen	I
receptor	O
;	O
PR	O
,	O
pro	B
##ges	I
##tero	I
##ne	I
;	O
H	O
##ER	O
##2	O
,	O
human	O
e	O
##pid	O
##er	O
##mal	O
growth	O
factor	O
receptor	O
-	O
2	O
;	O
Gen	O
##otype	O
-	O
grouping	O
,	O
three	O
groups	O
for	O
g	O
##eno	O
##type	O
C	O
/	O
C	O
,	O
C	O
/	O
T	O
and	O
T	O
/	O
T	O
carriers	O
.	O

Ace	B
##tic	I
acid	I
,	O
form	B
##ic	I
acid	I
and	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
were	O
obtained	O
from	O
B	O
##ios	O
##ol	O
##ve	O
(	O
Val	O
##ken	O
##s	O
##wa	O
##ard	O
,	O
The	O
Netherlands	O
)	O
,	O
A	O
##c	O
##ros	O
Organic	O
##s	O
(	O
Gee	O
##l	O
,	O
Belgium	O
)	O
and	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
,	O
respectively	O
.	O

Similarly	O
,	O
A	O
##bal	O
##one	O
en	O
##tra	O
##ils	O
su	O
##lf	O
##ata	O
##se	O
activity	O
was	O
t	O
##it	O
##rated	O
using	O
a	O
standard	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
-	I
su	I
##lf	I
##ate	I
ass	O
##ay	O
in	O
which	O
one	O
unit	O
of	O
enzyme	O
activity	O
is	O
defined	O
as	O
1	O
μ	O
##mo	O
##le	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
-	I
su	I
##lf	I
##ate	I
h	O
##ydro	O
##ly	O
##zed	O
/	O
h	O
at	O
pH	O
5	O
.	O
0	O
and	O
37	O
°C	O
.	O

Our	O
results	O
demonstrated	O
that	O
control	O
exercise	O
##rs	O
presented	O
a	O
significant	O
reduction	O
in	O
le	B
##uc	I
##ine	I
levels	O
.	O

The	O
difference	O
for	O
pro	B
##ges	I
##tero	I
##ne	I
reflected	O
high	O
concentrations	O
in	O
younger	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
particularly	O
those	O
in	O
the	O
l	O
##ute	O
##al	O
phase	O
of	O
the	O
men	O
##st	O
##ru	O
##al	O
cycle	O
.	O

P	B
-	I
c	I
##res	I
##ol	I
has	O
been	O
noted	O
to	O
be	O
toxic	O
in	O
high	O
doses	O
,	O
especially	O
in	O
the	O
context	O
of	O
re	O
##nal	O
imp	O
##air	O
##ment	O
,	O
and	O
is	O
associated	O
with	O
the	O
micro	O
##bio	O
##me	O
.	O

Lac	B
##tate	I
,	O
sodium	B
su	I
##cci	I
##nate	I
,	O
al	B
##ani	I
##ne	I
,	O
pro	B
##line	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
palm	B
##itic	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
u	B
##ric	I
acid	I
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
were	O
obtained	O
from	O

Among	O
the	O
20	O
identified	O
plasma	O
meta	O
##bol	O
##ites	O
,	O
the	O
normal	O
##ized	O
peak	O
in	O
##tens	O
##ities	O
of	O
3	O
amino	O
acids	O
(	B
le	B
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
try	O
##pt	O
##op	O
##han	O
)	O
were	O
significantly	O
higher	O
in	O
pre	O
##hy	O
##pert	O
##ens	O
##ive	O
subjects	O
than	O
in	O
control	O
subjects	O
;	O
however	O
,	O
these	O
differences	O
disappeared	O
after	O
adjusting	O
for	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
smoking	O
,	O
alcohol	O
consumption	O
,	O
serum	O
lip	O
##id	O
profiles	O
,	O
glucose	S
,	O
and	O
insulin	O
.	O

The	O
cells	O
were	O
maintained	O
in	O
D	O
##ME	O
##M	O
cell	O
culture	O
medium	O
(	O
contains	O
25	O
m	O
##M	O
glucose	S
and	O
4	O
m	O
##M	O
g	B
##lut	I
##amine	I
)	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
F	O
##BS	O
100	O
units	O
/	O
m	O
##l	O
pen	B
##ici	I
##llin	I
and	O
100	O
µ	O
##g	O
/	O
m	O
##l	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
with	O
0	O
.	O
5	O
µ	O
##g	O
/	O
m	O
##l	O
pu	B
##rom	I
##y	I
##cin	I
on	O
150	O
mm	O
.	O

It	O
is	O
proposed	O
that	O
p	O
##ht	O
##hala	O
##tes	O
may	O
ex	O
##ert	O
their	O
end	O
##oc	O
##rine	O
-	O
disrupt	O
##ing	O
effects	O
by	O
in	O
##hibition	O
of	O
test	B
##osterone	I
and	O
est	B
##rad	I
##iol	I
synthesis	O
(	O
,	O
,	O
,	O
,	O
)	O
,	O
a	O
##roma	O
##tase	O
activity	O
in	O
##hibition	O
,	O
alterations	O
in	O
est	B
##rogen	I
metabolism	O
(	O
–	O
)	O
,	O
and	O
pro	B
##sta	I
##g	I
##land	I
##in	I
synthesis	O
.	O

Changes	O
in	O
the	O
branched	O
chain	O
amino	O
acids	O
le	O
##uc	O
##ine	O
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
U	B
##DP	I
-	I
G	I
##l	I
##c	I
##NA	I
##c	I
were	O
inverse	O
##ly	O
associated	O
with	O
changes	O
in	O
CR	O
##F	O
(	O
m	O
##l	O
/	O
kg	O
/	O
min	O
)	O
,	O
whereas	O
change	O
in	O
the	O
T	O
##CA	O
cycle	O
intermediate	O
,	O
is	B
##oc	I
##it	I
##ric	I
acid	I
,	O
was	O
positively	O
correlated	O
.	O

By	O
American	O
Di	O
##abe	O
##tes	O
Association	O
criteria	O
,	O
15	O
of	O
the	O
41	O
Phase	O
2	O
subjects	O
had	O
pre	O
##dia	O
##bet	O
##es	O
based	O
on	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
and	O
/	O
or	O
fast	O
##ing	O
glucose	S
levels	O
;	O
none	O
had	O
over	O
##t	O
diabetes	O
.	O

Finally	O
,	O
serum	O
u	B
##ric	I
acid	I
has	O
long	O
been	O
known	O
as	O
a	O
significant	O
risk	O
factor	O
for	O
excessive	O
cancer	O
risk	O
,	O
re	O
##cu	O
##rrence	O
,	O
and	O
mortality	O
.	O

The	O
use	O
of	O
glucose	S
by	O
t	O
##umour	O
cells	O
to	O
generate	O
energy	O
under	O
conditions	O
of	O
adequate	O
oxygen	O
supply	O
is	O
called	O
the	O
War	O
##burg	O
effect	O
(	O
;	O
)	O
.	O

During	O
the	O
analytical	O
column	O
el	O
##ution	O
,	O
the	O
SP	O
##E	O
cartridge	O
was	O
washed	O
with	O
100	O
%	O
met	B
##han	I
##ol	I
for	O
5	O
min	O
at	O
a	O
flow	O
rate	O
of	O
4	O
m	O
##L	O
min	O
_	O
−	O
##1	O
,	O
and	O
then	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
with	O
10	O
%	O
met	B
##han	I
##ol	I
in	O
0	O
.	O
1	O
%	O
a	O
##que	O
##ous	O
ace	B
##tic	I
acid	I
for	O
2	O
min	O
to	O
prepare	O
for	O
the	O
next	O
injection	O
.	O

The	O
T	O
##2	O
##D	O
subjects	O
used	O
in	O
the	O
extended	O
study	O
were	O
independent	O
of	O
those	O
used	O
in	O
the	O
Discovery	O
study	O
,	O
and	O
represented	O
a	O
more	O
typical	O
mixture	O
of	O
T	O
##2	O
##D	O
cases	O
(	O
longer	O
duration	S
,	O
treated	O
with	O
diet	O
,	O
oral	O
agents	O
or	O
insulin	O
)	O
.	O

In	O
(	O
A	O
)	O
,	O
T	O
##EX	O
but	O
not	O
the	O
parent	O
PC	O
##I	O
-	O
13	O
tumor	O
cells	O
induced	O
a	O
large	O
increase	O
in	O
in	B
##os	I
##ine	I
production	O
by	O
CD	O
##4	O
_	O
+	O
CD	O
##39	O
_	O
+	O
T	O
##re	O
##g	O
.	O

Pat	O
##ients	O
receiving	O
ha	O
##em	O
##od	O
##ial	O
##ys	O
##is	O
did	O
not	O
have	O
reduced	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
pre	O
-	O
dial	O
##ys	O
##is	O
compared	O
to	O
non	O
-	O
dial	O
##ys	O
##ed	O
patients	O
with	O
e	O
##G	O
##F	O
##R	O
<	O
15	O
.	O

Met	O
##ab	O
##olic	O
syndrome	O
,	O
In	O
##sul	O
##in	O
resistance	O
,	O
Nuclear	O
magnetic	O
resonance	O
relax	O
##ome	O
##try	O
,	O
Trans	O
##verse	O
relaxation	O
time	O
constant	O
,	O
He	O
##pa	O
##to	O
##cy	O
##te	O
growth	O
factor	O
,	O
G	O
##lu	O
##co	O
##kin	O
##ase	O
regulatory	O
protein	O
,	O
Re	O
##ceptor	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
FL	O
##T	O
##3	O
,	O
S	O
##OM	O
##As	O
##can	O
a	O
##pta	O
##mer	O
ass	O
##ay	O
,	O
Random	O
forests	O
,	O
Classification	O
and	O
re	O
##gression	O
tree	O
analysis	O

The	O
reaction	O
mixture	O
was	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
##°	O
##C	O
for	O
3	O
h	O
.	O
To	O
remove	O
the	O
phosphate	S
backbone	O
,	O
the	O
T	O
-	O
c	O
##lea	O
##vage	O
/	O

B	O
##lad	O
##der	O
tissue	O
samples	O
were	O
collected	O
from	O
the	O
same	O
patient	O
immediately	O
prior	O
to	O
and	O
30	O
min	O
after	O
sub	O
##mu	O
##cos	O
##al	O
injection	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
(	O
50	O
mg	O
,	O
dissolved	O
in	O
20	O
m	O
##l	O
normal	O
sa	B
##line	I
)	O
.	O

Cell	O
proliferation	O
was	O
suppressed	O
in	O
response	O
to	O
α	B
-	I
O	I
##G	I
treatment	O
.	O

Furthermore	O
,	O
we	O
tested	O
whether	O
these	O
newly	O
identified	O
alterations	O
related	O
to	O
I	O
##R	O
could	O
predict	O
de	O
##ter	O
##ior	O
##ations	O
of	O
g	B
##ly	I
##ce	I
##mic	I
control	O
in	O
youth	O
.	O

52	O
##2	O
.	O
39	O
Da	O
]	O
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
:	O
PC	B
(	I
34	I
:	I
1	I
)	I
[	O
m	O
/	O
z	O
=	O
760	O
.	O
63	O
Da	O
]	O
and	O
PC	B
(	I
36	I
:	I
1	I
)	I

Due	O
to	O
disease	O
per	O
##sistence	O
,	O
after	O
surgery	O
the	O
patient	O
required	O
treatment	O
with	O
so	B
##mat	I
##ost	I
##ati	I
##n	I
analog	O
##s	O
(	O
la	O
##n	O
##re	O
##ot	O
##ide	O
120	O
mg	O
/	O
4	O
weeks	O
)	O
.	O

Sep	O
##ara	O
##tion	O
between	O
low	O
-	O
(	O
green	O
dots	O
)	O
and	O
intermediate	B
-	I
(	I
yellow	I
diamonds	I
)	I
risk	O
patients	O
based	O
on	O
R	B
##P	I
his	O
##tology	O
due	O
to	O
elevated	O
la	B
##ct	I
##ate	I
,	O
lip	O
##ids	O
/	O
lip	O
##op	O
##rote	O
##ins	O
and	O
p	B
##yr	I
##u	I
##vate	I
and	O
reduced	O
c	B
##it	I
##rate	I
,	O
f	B
##ru	I
##ct	I
##ose	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
and	O
sperm	B
##ine	I
in	O
intermediate	B
-	I
risk	I
samples	O
(	O
A	O
,	O
C	O
)	O
.	O

2013	O
demonstrated	O
that	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
are	O
reduced	O
in	O
acute	O
is	O
##che	O
##mic	O
stroke	O
,	O
and	O
here	O
,	O
we	O
observed	O
that	O
le	B
##uc	I
##ine	I
is	O
increased	O
in	O
chronic	O
is	O
##che	O
##mic	O
stroke	O
.	O

The	O
his	O
##tology	O
of	O
tissue	O
processed	O
using	O
m	O
##PR	O
##EF	O
is	O
equivalent	O
to	O
that	O
of	O
formal	B
##in	I
fixed	O
tissues	O
and	O
is	O
suitable	O
for	O
im	O
##mu	O
##no	O
##his	O
##to	O
##chemistry	O
(	O
I	O
##HC	O
)	O
.	O

The	O
Di	B
##ol	I
column	O
had	O
the	O
lowest	O
median	O
peak	O
width	O
of	O
12	O
.	O
6	O
s	O
(	O
mean	O
of	O
14	O
.	O
1	O
s	O
)	O
,	O
though	O
the	O
2	O
-	O
P	O
##IC	O
column	O
had	O
a	O
very	O
similar	O
median	O
width	O
(	O
13	O
.	O
4	O
s	O
)	O

C	O
##inn	O
##abar	O
##ini	O
##c	O
acid	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
and	O
se	B
##rot	I
##oni	I
##n	I
levels	O
were	O
elevated	O
in	O
[UNK]	O
%	O
of	O
the	O
patients	O
(	O
F	O
)	O
.	O

This	O
analysis	O
excluded	O
12	O
individuals	O
in	O
the	O
AA	O
##S	O
##K	O
with	O
missing	O
c	B
##ys	I
##tat	I
##in	I
C	O
data	O
to	O
allow	O
comparison	O
with	O
established	O
equations	O
including	O
c	B
##ys	I
##tat	I
##in	I
C	O
as	O
well	O
as	O
c	B
##rea	I
##tin	I
##ine	I
.	O

It	O
has	O
been	O
reported	O
that	O
4	B
-	I
he	I
##pta	I
##non	I
##e	I
is	O
produced	O
from	O
the	O
in	O
v	O
##ivo	O
metabolism	O
of	O
plastic	O
##izer	O
##s	O
in	O
man	O
(	O
Walker	O
and	O
Mills	O
,	O
2001	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
,	O
Swiss	O
-	O
Pro	O
##t	O
accession	O
number	O
,	O
and	O
reference	O
to	O
the	O
enzyme	O
,	O
where	O
applicable	O
(	O
or	O
m	O
##RNA	O
trans	O
##cript	O
)	O
,	O
in	O
brain	O
are	O
as	O
follows	O
:	O
C	O
##YP	O
##27	O
##A	O
##1	O
,	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
27	O
##A	O
##1	O
,	O
Q	O
##0	O
##23	O
##18	O
;	O
C	O
##YP	O
##46	O
##A	O
##1	O
,	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
46	O
##A	O
##1	O
,	O
Q	O
##9	O
##Y	O
##6	O
##A	O
##2	O
;	O
C	O
##YP	O
##7	O
##B	O
##1	O
,	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
7	O
##B	O
##1	O
,	O
O	O
##75	O
##8	O
##8	O
##1	O
;	O
C	O
##YP	O
##39	O
##A	O
##1	O
,	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
39	O
##A	O
##1	O
,	O
Q	O
##9	O
##N	O
##Y	O
##L	O
##5	O
;	O
H	O
##SD	O
##3	O
##B	O
##7	O
,	O
3	O
##β	O
-	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
type	O
7	O
,	O
Q	O
##9	O
##H	O
##2	O
##F	O
##3	O
;	O
V	O
##LC	O
##S	O
,	O
very	O
long	O
chain	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
s	O
##ynth	O
##eta	O
##se	O
,	O
O	O
##35	O
##48	O
##8	O
;	O
AM	O
##AC	O
##R	O
,	O
α	B
-	I
met	I
##hyl	I
##acy	I
##l	I
-	I
Co	I
##A	I
race	O
##mas	O
##e	O
,	O
Q	O
##9	O
##U	O
##H	O
##K	O
##6	O
;	O
BC	O
##OX	O
,	O
branched	O
chain	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
o	O
##xi	O
##das	O
##e	O
,	O
Q	O
##9	O
##9	O
##42	O
##4	O
;	O
DB	B
##P	I
,	O
d	O
-	O
bi	O
##function	O
##al	O
protein	O
,	O
P	O
##51	O
##65	O
##9	O
;	O
L	O
##B	O
##P	O
,	O
l	O
-	O
bi	O
##function	O
##al	O
protein	O
,	O
Q	O
##0	O

Me	O
##as	O
##uring	O
plasma	O
concentrations	O
of	O
substances	O
other	O
than	O
mid	B
##az	I
##ola	I
##m	I
was	O
pre	O
##de	O
##fine	O
##d	O
in	O
the	O
study	O
protocol	O
and	O
approved	O
by	O
the	O
ethics	O
committee	O
.	O

In	O
addition	O
,	O
our	O
data	O
revealed	O
that	O
p	B
##yr	I
##ido	I
##xa	I
##l	I
5	I
′	I
-	I
phosphate	I
,	O
the	O
metabolic	O
##ally	O
active	O
form	O
of	O
vitamin	O
B	O
_	O
6	O
,	O
was	O
significantly	O
increased	O
among	O
H	O
##T	O
##K	O
users	O
,	O
indicating	O
a	O
vitamin	O
B	O
_	O
6	O
status	O
sufficient	O
for	O
the	O
process	O
of	O
de	O
##grading	O
surplus	O
amino	O
acids	O
.	O

Para	B
##ce	I
##tam	I
##ol	I
(	O
resulted	O
from	O
para	B
##ce	I
##tam	I
##ol	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
degradation	O
)	O
and	O
d	B
_	I
4	I
-	I
para	I
##ce	I
##tam	I
##ol	I
were	O
monitored	O
in	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
,	O
and	O
the	O
ratio	O
between	O
them	O
was	O
used	O
to	O
evaluate	O
the	O
efficiency	O
of	O
the	O
de	O
##g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
process	O
,	O
keeping	O
in	O
mind	O
that	O
e	O
##qui	O
##mo	O
##lar	O
amount	O
of	O
para	B
##ce	I
##tam	I
##ol	I
and	O
de	B
##uter	I
##ated	I
-	I
para	I
##ce	I
##tam	I
##ol	I
were	O
added	O
in	O
the	O
reaction	O
and	O
the	O
ion	O
##ization	O
efficiency	O
of	O
the	O
two	O
anal	O
##yte	O
##s	O
.	O

(	O
Per	O
##C	O
##p	O
##C	O
##y	O
##5	O
·	O
5	O
)	O
,	O
CD	B
##4	I
-	I
p	I
##hy	I
##coe	I
##ry	I
##th	I
##rin	I
(	O
P	O
##E	O
)	O
Cy	O
##5	O
,	O
CD	O
##8	O
-	O
Alex	O
##a	O
##70	O
##0	O
,	O
CD	O
##25	O
-	O
P	O
##E	O
,	O
CD	O
##12	O
##7	O
-	O
P	O
##EC	O
##y	O
##7	O
,	O
CD	O
##27	O
-	O
Alex	O
##a	O
##70	O
##0	O
,	O
human	O
le	O
##uc	O
##oc	O
##yte	O
anti	O
##gen	O
D	O
-	O
related	O
(	B
H	I
##LA	I
-	I
DR	I
)	I
-	I
all	I
##op	I
##hy	I
##co	I
##cy	I
##ani	I
##n	I
(	O
AP	O
##C	O
)	O
-	O
Cy	O
##7	O
,	O
CD	O
##38	O
-	O
AP	O
##C	O
and	O
IF	O
##N	O
-	O
γ	O
-	O
Alex	O
##a	O
##70	O
##0	O
(	O
B	O
##D	O
B	O
##ios	O
##cie	O
##nce	O
)	O
;	O
CD	O
##45	O
##RA	O
-	O
EC	O
##D	O
from	O
Beck	O
##man	O
Co	O
##ulter	O
(	O
Miss	O
##issa	O
##uga	O
,	O
Ontario	O
,	O
Canada	O
)	O
and	O
IL	O
-	O
17	O
-	O
P	O
##E	O
,	O
CD	O
##8	O
-	O
AP	O
##C	O
##e	O
##F	O
##lu	O
##or	O
##7	O
##80	O
,	O
fork	O
##head	O
box	O
protein	O
3	O
(	O
Fox	O
##P	O
##3	O
)	O
-	O
Alex	O
##a	O
##48	O
##8	O
and	O
Fox	O
##P	O
##3	O
stain	O
##ing	O
buffer	O
from	O
e	O
##B	O
##ios	O
##cie	O
##nce	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

K	O
##yn	O
can	O
also	O
function	O
as	O
an	O
end	O
##ogen	O
##ous	O
l	O
##igan	O
##d	O
for	O
the	O
basic	O
he	O
##lix	O
–	O
loop	O
–	O
he	O
##lix	O
(	O
b	O
##HL	O
##H	O
)	O
-	O
PA	O
##S	O
transcription	O
factor	O
a	B
##ryl	I
h	I
##ydro	I
##car	I
##bon	I
receptor	O
(	O
A	O
##H	O
##R	O
)	O
,	O
suggesting	O
a	O
cell	O
-	O
autonomous	O
role	O
.	O

High	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
with	O
online	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
HP	O
##LC	O
-	O
MS	O
/	O
MS	O
)	O
was	O
used	O
to	O
measure	O
serum	O
T	B
##MA	I
##O	I
and	O
ch	B
##olin	I
##e	I
.	O

In	O
human	O
plasma	O
,	O
11	B
-	I
de	I
##hy	I
##dr	I
##oth	I
##rom	I
##box	I
##ane	I
(	O
TX	O
)	O
B	O
##2	O
is	O
a	O
major	O
long	O
lived	O
meta	O
##bol	O
##ite	O
(	O
t	O
##1	O
/	O
2	O
45	O
min	O
)	O
formed	O
from	O
in	O
##fused	O
TX	O
##B	O
##2	O
,	O
the	O
h	O
##yd	O
##ration	O
product	O
of	O
biological	O
##ly	O
active	O
TX	O
##A	O
##2	O
.	O

Two	O
ID	O
##s	O
,	O
corresponding	O
to	O
e	B
##pit	I
##est	I
##osterone	I
su	I
##lf	I
##ate	I
and	O
5	O
-	O
D	O
##HT	O
were	O
not	O
found	O
in	O
the	O
Con	O
##sen	O
##sus	O
##P	O
##ath	O
##D	O
##B	O
database	O
.	O

I	O
##B	O
##D	O
,	O
inflammatory	O
bow	O
##el	O
disease	O
;	O
I	O
##BS	O
,	O
i	O
##rri	O
##table	O
bow	O
##el	O
syndrome	O
;	O
n	O
,	O
number	O
of	O
observations	O
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
D	B
##MA	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
;	O
_	O
a	O
significantly	O
different	O
from	O
I	O
##BS	O
;	O
_	O
b	O
significantly	O
different	O
from	O
I	O
##B	O
##D	O
;	O
_	O
c	O
significantly	O
different	O
from	O
controls	O
.	O

The	O
center	O
bars	O
show	O
median	O
and	O
inter	O
##qua	O
##rt	O
##ile	O
values	O
normal	O
##ized	O
to	O
respective	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
by	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
.	O

Moreover	O
,	O
Sven	O
##sson	O
et	O
al	O
.	O
,	O
used	O
a	O
G	O
##C	O
–	O
MS	O
-	O
based	O
fatty	O
acid	O
pro	O
##fi	O
##ling	O
approach	O
to	O
measure	O
palm	B
##itate	I
and	O
s	B
##te	I
##arate	I
and	O
demonstrated	O
a	O
necessity	O
for	O
de	O
no	O
##vo	O
fatty	O
acid	O
synthesis	O
in	O
sustaining	O
lung	O
tumor	O
growth	O
,	O
and	O
an	O
associated	O
sensitivity	O
of	O
multiple	O
N	O
##SC	O
##LC	O
models	O
to	O
ace	O
##ty	O
##l	O
-	O
Co	O
##A	O
car	O
##box	O
##yla	O
##se	O
(	O
ACC	O
)	O
in	O
##hibition	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
pro	B
##line	I
,	O
g	B
##lut	I
##amine	I
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
levels	O
were	O
all	O
normal	O
.	O

We	O
also	O
observed	O
an	O
alter	O
##ation	O
in	O
the	O
pu	B
##rine	I
metabolism	O
pathway	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
AM	O
##D	O
.	O

Try	B
##pt	I
##op	I
##han	I
and	O
its	O
meta	O
##bol	O
##ites	O
have	O
previously	O
been	O
q	O
##uant	O
##ified	O
using	O
L	O
##C	O
-	O
UV	O
and	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

Only	O
2	O
/	O
34	O
altered	O
meta	O
##bol	O
##ites	O
were	O
depleted	O
,	O
c	B
##ys	I
##tein	I
##e	I
and	O
in	B
##os	I
##ine	I
Met	O
##ab	O
##olo	O
##me	O
effects	O
of	O
l	O
##up	O
##us	O
by	O
quantitative	O
en	O
##rich	O
##ment	O
analysis	O
of	O
209	O
meta	O
##bol	O
##ites	O
in	O
P	O
##BL	O
of	O
SL	O
##E	O
patients	O
in	O
comparison	O
to	O
those	O
of	O
healthy	O
controls	O
matched	O
for	O
age	O
within	O
10	O
years	O
,	O
gender	O
,	O
and	O
ethnic	O
background	O

It	O
should	O
also	O
be	O
noted	O
that	O
,	O
since	O
4	O
-	O
AP	O
was	O
dissolved	O
in	O
D	B
##MS	I
##O	I
and	O
the	O
pro	O
##to	O
##ty	O
##pical	O
C	O
##YP	O
##2	O
##E	O
##1	O
induce	O
##r	O
(	O
is	O
##onia	O
##zi	O
##d	O
)	O
was	O
dissolved	O
in	O
sa	B
##line	I
,	O
the	O
potential	O
of	O
4	O
-	O
AP	O
to	O
induce	O
C	O
##YP	O
##2	O
##E	O
##1	O
activity	O
could	O
not	O
be	O
evaluated	O
based	O
on	O
effectiveness	O
.	O

Furthermore	O
,	O
a	O
modified	O
p	O
##eptide	O
,	O
in	B
##do	I
##ly	I
##la	I
##c	I
##ryl	I
##oy	I
##l	I
##gly	I
##cine	I
(	O
I	O
##AG	O
)	O
,	O
was	O
abundant	O
in	O
u	O
##rogen	O
##ital	O
s	O
##chi	O
##sto	O
##so	O
##mia	O
##sis	O
associated	O
-	O
bladder	O
path	O
##ology	O
.	O

This	O
study	O
showed	O
that	O
subjects	O
consuming	O
the	O
PS	O
##PC	O
product	O
rich	O
in	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
and	O
cat	B
##ech	I
##ins	I
exhibited	O
an	O
increase	O
in	O
simple	O
p	O
##hen	O
##ols	O
and	O
ben	B
##zoic	I
acid	I
derivatives	O
such	O
as	O
hip	B
##pura	I
##te	I
and	O
4	B
-	I
met	I
##hyl	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
.	O

However	O
,	O
we	O
can	O
measure	O
the	O
levels	O
of	O
compounds	O
which	O
are	O
the	O
products	O
of	O
cycles	O
with	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
participation	O
which	O
is	O
necessary	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
FA	S
and	O
k	B
##eton	I
##e	I
bodies	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
equations	O
,	O
prefer	O
##ably	O
excluding	O
c	B
##rea	I
##tin	I
##ine	I
and	O
demographic	O
characteristics	O
,	O
should	O
be	O
tested	O
for	O
robust	O
##ness	O
and	O
general	O
##iza	O
##bility	O
as	O
a	O
potential	O
confirm	O
##atory	O
test	O
when	O
e	O
##G	O
##F	O
##R	O
##c	O
##r	O
is	O
unreliable	O
.	O

And	O
this	O
study	O
also	O
found	O
the	O
lower	O
plasma	O
level	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
MD	O
##D	O
(	O
including	O
E	O
##LS	O
/	O
MD	O
##D	O
and	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
)	O
and	O
this	O
finding	O
was	O
consistent	O
with	O
the	O
several	O
previous	O
reports	O
'	O
findings	O
,	O
.	O

The	O
p	O
##elle	O
##t	O
was	O
discarded	O
and	O
the	O
super	O
##nat	O
##ant	O
dried	O
in	O
a	O
vacuum	O
cent	O
##ri	O
##fu	O
##ge	O
and	O
re	O
##con	O
##stituted	O
in	O
100	O
μ	O
##L	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
IPA	O
)	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
AC	O
##N	O
)	O
/	O
water	O
(	O
2	O
:	O
1	O
:	O
1	O
v	O
:	O
v	O
:	O
v	O
)	O
.	O

c	O
)	O
:	O
the	O
median	O
absolute	O
difference	O
between	O
the	O
AU	O
##C	O
of	O
the	O
models	O
containing	O
D	B
##MA	I
and	O
their	O
counterparts	O
w	O
/	O
o	O
the	O
meta	O
##bol	O
##ite	O
was	O
0	O
.	O
00	O
##8	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
to	O
measure	O
the	O
abundance	O
of	O
plasma	O
amino	O
acids	O
and	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
,	O
which	O
reflect	O
the	O
balance	O
between	O
AA	O
up	O
##take	O
and	O
release	O
by	O
various	O
tissues	O
that	O
are	O
influenced	O
by	O
changes	O
in	O
protein	O
metabolism	O
in	O
response	O
to	O
the	O
presence	O
or	O
absence	O
of	O
insulin	O
and	O
k	B
##eton	I
##e	I
levels	O
.	O

A	O
br	O
##occo	O
##li	O
s	O
##p	O
##rout	O
-	O
derived	O
beverage	O
providing	O
daily	O
doses	O
of	O
600	O
μ	O
##mo	O
##l	O
g	B
##lu	I
##cor	I
##aph	I
##ani	I
##n	I
and	O
40	O
μ	O
##mo	O
##l	O
su	B
##lf	I
##ora	I
##pha	I
##ne	I
was	O
evaluated	O
for	O
magnitude	O
and	O
duration	S
of	O
p	O
##har	O
##ma	O
##co	O
##dynamic	O
action	O
in	O
a	O
12	O
-	O
week	O
random	O
##ized	O
clinical	O
trial	O
.	O

Cold	O
atmospheric	O
plasma	O
treatment	O
could	O
significantly	O
alter	O
the	O
meta	O
##bol	O
##ite	O
pro	O
##fi	O
##ling	O
of	O
my	O
##elo	O
##ma	O
tumor	O
cells	O
,	O
among	O
which	O
,	O
the	O
beta	B
-	I
al	I
##ani	I
##ne	I
metabolism	O
pathway	O
is	O
the	O
most	O
susceptible	O
to	O
He	O
gas	O
plasma	O
treatment	O
.	O

From	O
each	O
sample	O
,	O
5	O
μ	O
##L	O
was	O
injected	O
onto	O
a	O
reverse	O
-	O
phase	O
50	O
×	O
2	O
.	O
1	O
mm	O
AC	O
##Q	O
##UI	O
##TY	O
1	O
.	O
7	O
-	O
μ	O
##m	O
C	O
##18	O
column	O
(	O
Waters	O
Corp	O
,	O
Milford	O
,	O
MA	O
)	O
using	O
an	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
system	O
(	O
Waters	O
)	O
with	O
a	O
gradient	O
mobile	O
phase	O
consisting	O
of	O
2	O
%	O
AC	O
##N	O
in	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
A	O
)	O
and	O
2	O
%	O
water	O
in	O
AC	O
##N	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
B	O
)	O
.	O

To	O
further	O
understand	O
the	O
mechanisms	O
related	O
to	O
the	O
a	O
##ber	O
##rant	O
regulation	O
of	O
meta	O
##bol	O
##ites	O
in	O
distinct	O
metabolic	O
pathways	O
,	O
the	O
expression	O
of	O
four	O
rate	O
-	O
limiting	O
enzymes	O
in	O
sugar	O
and	O
lip	O
##id	O
metabolism	O
,	O
namely	O
,	O
g	B
##ly	I
##co	I
##gen	I
s	O
##ynth	O
##ase	O
kinase	O
3	O
beta	O
(	B
G	B
##S	I
##K	I
##3	I
##β	I
)	O

Mean	O
duration	S
of	O
park	O
##ins	O
##onia	O
##n	O
symptoms	O
before	O
initial	O
(	O
base	O
##line	O
)	O
assessment	O
was	O
11	O
.	O
4	O
±	O
4	O
.	O
7	O
months	O
(	O
range	O
3	O
.	O
0	O
–	O
22	O
.	O
3	O
months	O
)	O
.	O

S	B
##phi	I
##ngo	I
##sin	I
##e	I
1	I
-	I
phosphate	I
(	O
S	O
##1	O
##P	O
)	O
was	O
originally	O
considered	O
an	O
in	O
##tra	O
##cellular	O
second	O
messenger	O
that	O
is	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
death	O
signaling	O
pathways	O
.	O

As	O
a	O
positive	O
control	O
,	O
we	O
observed	O
that	O
Lo	O
##F	O
sites	O
in	O
PC	O
##S	O
##K	O
##9	O
had	O
lower	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
compared	O
to	O
the	O
non	O
##car	O
##rier	O
##s	O
(	O
P	O
=	O
5	O
.	O
4	O
×	O
10	O
_	O
−	O
##9	O
)	O
.	O

It	O
is	O
easy	O
to	O
see	O
that	O
synthesis	O
of	O
la	B
##ct	I
##ate	I
might	O
be	O
in	O
##hibit	O
##ed	O
in	O
order	O
to	O
increase	O
flux	O
towards	O
fatty	O
acid	O
formation	O
(	O
and	O
vice	O
versa	O
)	O
which	O
would	O
account	O
for	O
this	O
negative	O
correlation	O
.	O

In	O
particular	O
,	O
mass	O
errors	O
of	O
ad	B
##ren	I
##ic	I
acid	I
and	O
U	O
##A	O
were	O
21	O
.	O
13	O
and	O
23	O
.	O
95	O
,	O
respectively	O
,	O
and	O
were	O
identified	O
using	O
both	O
databases	O
and	O
reference	O
compounds	O
,	O
suggesting	O
that	O
the	O
analysis	O
was	O
appropriate	O
for	O
compound	O
identification	O
.	O

Moreover	O
,	O
Der	O
##bal	O
-	O
Wolf	O
##rom	O
et	O
al	O
.	O
post	O
##ulated	O
that	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
t	I
##ris	I
##py	I
##rop	I
##hos	I
##phate	I
treatment	O
increased	O
the	O
oxygen	O
load	O
to	O
result	O
in	O
in	O
##hibition	O
of	O
co	O
##lon	O
tumor	O
growth	O
and	O
stimulation	O
of	O
home	O
##ob	O
##ox	O
gene	O
C	O
##d	O
##x	O
##2	O
expression	O
within	O
the	O
in	O
##test	O
##inal	O
wall	O
.	O

The	O
presence	O
of	O
uniform	O
##ly	O
_	O
13	O
C	O
-	O
labeled	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
was	O
also	O
evident	O
in	O
the	O
high	O
-	O
resolution	O
2	O
-	O
D	O
_	O
1	O
H	O
-	O
_	O
13	O
C	O
H	O
##S	O
##Q	O
##C	O
or	O
the	O
1	O
-	O
D	O
_	O
13	O
C	O
projection	O
s	O
##pect	O
##ra	O
of	O
R	O
##h	O
##30	O
and	O
my	O
##oc	O
##yte	O
cell	O
extract	O
##s	O
,	O
as	O
illustrated	O
in	O
Figure	O
.	O

The	O
q	O
##ual	O
##itative	O
analysis	O
of	O
th	B
##iol	I
##s	I
in	O
cancer	O
urine	O
##s	O
by	O
IL	O
-	O
L	O
##C	O
-	O
D	O
##PI	O
-	O
MS	O
method	O
was	O
performed	O
according	O
to	O
our	O
previous	O
work	O
.	O

B	O
##io	O
##mark	O
##ers	O
are	O
needed	O
to	O
further	O
assess	O
the	O
possible	O
relationship	O
between	O
a	B
##c	I
##rol	I
##ein	I
up	O
##take	O
and	O
cancer	O
.	O

We	O
selected	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
as	O
el	O
##ution	O
solvent	O
because	O
et	B
##hyl	I
ace	I
##tate	I
and	O
especially	O
met	B
##han	I
##ol	I
negatively	O
affected	O
the	O
yield	O
of	O
the	O
der	O
##iva	O
##ti	O
##zation	O
reaction	O
,	O
as	O
monitored	O
with	O
the	O
der	O
##iva	O
##ti	O
##zation	O
control	O
compound	O
ca	O
##l	O
##ci	O
##pot	O
##rio	O
##l	O
in	O
the	O
extraction	O
matrix	O
.	O

The	O
median	O
disease	O
duration	S
from	O
the	O
T	O
##2	O
##DM	O
diagnosis	O
among	O
the	O
T	O
##2	O
##DM	O
patients	O
was	O
8	O
.	O
7	O
±	O
5	O
.	O
5	O
years	O
.	O

Number	O
of	O
meta	O
##bol	O
##ites	O
by	O
chemical	O
class	O
and	O
the	O
association	O
with	O
β	B
-	I
car	I
##ote	I
##ne	I
supplement	O
##ation	O
in	O
the	O
AT	O
##BC	O
Study	O
_	O
1	O

One	O
al	O
##iq	O
##uo	O
##t	O
was	O
analyzed	O
using	O
acidic	O
positive	O
ion	O
conditions	O
,	O
ch	O
##roma	O
##to	O
##graphical	O
##ly	O
op	O
##ti	O
##mized	O
for	O
more	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
.	O

In	O
addition	O
,	O
some	O
studies	O
also	O
showed	O
that	O
the	O
h	O
##y	O
##pox	O
##ia	O
-	O
induced	O
accumulation	O
of	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
repeated	O
episodes	O
of	O
is	O
##che	O
##mia	O
may	O
cause	O
chronic	O
accumulation	O
of	O
short	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
in	O
plasma	O
in	O
patients	O
with	O
peripheral	O
vascular	O
disease	O
.	O

Col	O
##um	O
##n	O
:	O
Hal	O
##o	O
C	O
##18	O
(	O
0	O
.	O
3	O
×	O
50	O
mm	O
,	O
2	O
.	O
7	O
μ	O
##m	O
,	O
90	O
##a	O
)	O
;	O
mobile	O
phase	O
gradient	O
of	O
water	O
with	O
0	O
.	O
5	O
%	O
form	B
##ic	I
acid	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
5	O
%	O
form	B
##ic	I
acid	I
.	O

(	O
E	O
)	O
Am	B
##ino	I
sugar	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
metabolism	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
distinction	O
of	O
L	B
-	I
g	I
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
with	O
G	O
##C	O
-	O
MS	O
is	O
very	O
difficult	O
,	O
while	O
the	O
identification	O
of	O
L	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
can	O
be	O
complicated	O
.	O

The	O
panel	O
including	O
pro	B
##line	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
a	B
##rg	I
##ini	I
##ne	I
had	O
the	O
highest	O
values	O
of	O
mean	O
AU	O
##C	O
in	O
the	O
test	O
set	O
[	O
0	O
.	O
83	O
##5	O
,	O
95	O
%	O
C	O
##I	O
(	O
confidence	O
interval	O
)	O
:	O
(	O
0	O
.	O
75	O
##6	O
,	O
0	O
.	O
91	O
##3	O
)	O
]	O

Alan	B
##ine	I
,	O
g	B
##lut	I
##amine	I
,	O
as	B
##par	I
##tic	I
acid	I
,	O
and	O
ace	B
##to	I
##ace	I
##tate	I
combined	O
had	O
better	O
diagnostic	O
capabilities	O
than	O
any	O
single	O
meta	O
##bol	O
##ite	O
alone	O
in	O
disc	O
##rim	O
##inating	O
between	O
early	O
stage	O
CR	O
##C	O
patients	O
and	O
HC	O
##s	O
,	O
with	O
sensitivity	O
,	O
specific	O
##ity	O
,	O
and	O
AU	O
##C	O
values	O
of	O
87	O
.	O
5	O
%	O
,	O
91	O
.	O
3	O
%	O
,	O
and	O
0	O
.	O
93	O
##3	O
,	O
respectively	O
(	O
Figure	O
)	O
.	O

We	O
compared	O
the	O
metabolic	O
urine	O
profile	O
of	O
samples	O
from	O
norm	B
##og	I
##ly	I
##ca	I
##em	I
##ic	I
control	O
and	O
T	O
##2	O
##D	O
subjects	O
with	O
samples	O
from	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
and	O
G	O
##C	O
##K	O
-	O
M	O
##OD	O
##Y	O
subjects	O
.	O

Sign	O
##ificant	O
features	O
of	O
alpha	B
-	I
P	I
##EP	I
after	O
un	O
##tar	O
##get	O
##ed	O
analysis	O
using	O
a	O
reversed	O
phase	O
(	O
Ph	O
##en	O
##yl	O
##H	O
##ex	O
##yl	O
)	O
column	O
.	O

Human	O
plasma	O
total	O
lip	O
##id	O
extract	O
##s	O
were	O
spike	O
##d	O
with	O
the	O
is	O
##ob	O
##ari	O
##c	O
CE	B
##R	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
and	O
CE	B
##R	I
d	I
##17	I
:	I
1	I
/	I
18	I
:	I
0	I
standards	O
and	O
analyzed	O
as	O
described	O
in	O
the	O
Experimental	O
section	O
.	O

Interest	O
##ingly	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
was	O
found	O
by	O
N	O
##MR	O
in	O
higher	O
concentrations	O
in	O
the	O
serum	O
of	O
our	O
subjects	O
after	O
cheese	O
intake	O
.	O

In	O
particular	O
,	O
this	O
buffer	O
contained	O
250	O
m	O
##M	O
potassium	B
phosphate	I
(	O
pH	O
7	O
.	O
0	O
)	O
,	O
5	O
.	O
0	O
m	O
##M	O
2	B
,	I
2	I
-	I
dim	I
##eth	I
##yl	I
-	I
2	I
-	I
si	I
##lap	I
##ent	I
##ane	I
-	I
5	I
su	I
##lf	I
##ona	I
##te	I
(	O
DS	O
##S	O
-	O
d	O
_	O
6	O
)	O
,	O
5	O
.	O
84	O
m	O
##M	O
,	O
2	B
-	I
ch	I
##lor	I
##opy	I
##rim	I
##id	I
##ine	I
-	I
5	I
-	I
car	I
##box	I
##yl	I
##ic	I
acid	I
,	O
and	O

Our	O
study	O
is	O
in	O
accordance	O
with	O
other	O
studies	O
that	O
have	O
found	O
higher	O
levels	O
of	O
ta	B
##uri	I
##ne	I
in	O
different	O
types	O
of	O
cancer	O
,	O
probably	O
due	O
to	O
a	O
##pop	O
##tosis	O
[	O
,	O
]	O
.	O

Especially	O
the	O
diagnostic	O
accuracy	O
of	O
C	B
##16	I
-	I
c	I
##era	I
##mi	I
##de	I
and	O
S	O
##1	O
##P	O
,	O
assessed	O
by	O
receiver	O
operating	O
curve	O
(	O
R	O
##OC	O
)	O
analysis	O
,	O
showed	O
a	O
higher	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
value	O
as	O
compared	O
to	O
alpha	O
f	O
##eto	O
##p	O
##rote	O
##in	O
(	O
A	O
##FP	O
)	O
(	O
0	O
.	O
99	O
##9	O
and	O
0	O
.	O
98	O
##5	O
versus	O
0	O
.	O
82	O
##3	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
respectively	O
)	O
.	O

HP	O
##LC	O
Method	O
##s	O
Col	O
##lis	O
##ion	O
-	O
induced	O
mass	O
s	O
##pect	O
##ra	O
of	O
standards	O
were	O
obtained	O
on	O
an	O
A	O
##gi	O
##lent	O
1100	O
series	O
L	O
##C	O
/	O
MS	O
##D	O
T	O
##rap	O
SL	S
mass	O
s	O
##pect	O
##rome	O
##ter	O
operating	O
in	O
positive	O
ion	O
mode	O
.	O

CR	O
##C	O
:	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
;	O
H	B
##V	I
:	O
healthy	O
volunteers	O
;	O
y	O
.	O
o	O
.	O
:	O
years	O
old	O
;	O
B	O
##MI	O
:	O
body	O
mass	O
index	O
;	O
S	O
.	O
D	O
.	O
:	O
standard	O
de	O
##viation	O
;	O
N	O
.	O
R	O
.	O
:	O
no	O
response	O
;	O
C	O
:	O
c	O
##ec	O
##um	O
;	O
A	O
:	O
ascending	O
co	O
##lon	O
;	O
T	O
:	O

Several	O
un	O
##tar	O
##get	O
##ed	O
meta	O
##bol	O
##omi	O
##cs	O
and	O
lip	O
##ido	O
##mic	O
##s	O
studies	O
have	O
identified	O
AD	O
‐	O
associated	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
alterations	O
.	O
44	O
,	O
45	O
,	O
46	O
,	O
47	O

Additionally	O
,	O
subjects	O
with	O
compromised	O
re	O
##nal	O
function	O
reflected	O
by	O
impaired	O
c	B
##rea	I
##tin	I
##ine	I
clearance	O
were	O
excluded	O
to	O
avoid	O
con	O
##found	O
##ing	O
effects	O
of	O
impaired	O
meta	O
##bol	O
##ite	O
ex	O
##cre	O
##tion	O
.	O

In	O
addition	O
,	O
in	O
rat	O
ad	O
##ip	O
##ocytes	O
,	O
sperm	B
##ine	I
has	O
been	O
shown	O
to	O
enhance	O
glucose	S
transport	O
and	O
the	O
conversion	O
of	O
glucose	S
into	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
,	O
and	O
to	O
increase	O
the	O
ability	O
of	O
insulin	O
to	O
bind	O
to	O
its	O
own	O
receptor	O
.	O

Afterward	O
,	O
the	O
buffer	O
’	O
s	O
pH	O
was	O
modified	O
to	O
7	O
.	O
0	O
by	O
h	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
and	O
stored	O
at	O
4	O
°C	O
for	O
up	O
to	O
one	O
month	O
.	O

C	B
##it	I
##ric	I
acid	I
,	O
in	O
excess	O
,	O
acts	O
as	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
a	O
pre	O
##ser	O
##vat	O
##ive	O
in	O
solution	O
.	O

The	O
anal	O
##yte	O
##s	O
were	O
el	O
##uted	O
with	O
met	B
##han	I
##ol	I
(	O
3	O
m	O
##L	O
)	O
at	O
1	O
m	O
##L	O
/	O
min	O
.	O

Ion	O
##s	O
most	O
likely	O
from	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
,	O
dim	B
##eth	I
##yl	I
su	I
##l	I
##phi	I
##de	I
and	O
dim	B
##eth	I
##yl	I
di	I
##sul	I
##phi	I
##de	I
are	O
statistical	O
##ly	O
significantly	O
higher	O
in	O
samples	O
from	O
high	O
risk	O
rather	O
than	O
low	O
risk	O
subjects	O
.	O

Composition	O
##s	O
of	O
seven	O
is	O
##omer	O
pairs	O
(	B
C	B
##18	I
:	I
1	I
##Δ	I
##9	I
/	I
Δ	I
##11	I
in	O
PC	O
##s	O
and	O
P	O
##Es	O
)	O
have	O
been	O
observed	O
with	O
significant	O
changes	O
,	O
while	O
sub	O
##c	O
##lass	O
level	O
pro	O
##fi	O
##ling	O
failed	O
in	O
identifying	O
any	O
significant	O
difference	O
due	O
to	O
small	O
sampling	O
size	O
used	O
.	O

It	O
is	O
con	O
##ce	O
##ivable	O
that	O
an	O
end	O
##oc	O
##rine	O
disrupt	O
##ing	O
effect	O
would	O
be	O
stronger	O
among	O
men	O
with	O
constant	O
lower	O
base	O
##line	O
est	B
##rogen	I
levels	O
throughout	O
life	O
than	O
among	O
women	O
,	O
though	O
in	O
the	O
women	O
in	O
the	O
current	O
study	O
are	O
at	O
pre	O
##men	O
##op	O
##aus	O
##al	O
age	O
and	O
therefore	O
likely	O
not	O
affected	O
.	O

Given	O
the	O
rapid	O
metabolic	O
clearance	O
of	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
,	O
it	O
is	O
hard	O
to	O
estimate	O
the	O
contribution	O
of	O
4	O
-	O
OH	O
##E	O
##1	O
to	O
cancer	O
risk	O
.	O

G	B
##lu	I
##cos	I
##e	I
into	O
##ler	O
##ance	O
and	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
are	O
common	O
side	O
effects	O
of	O
m	O
##TO	O
##R	O
inhibitor	O
##s	O
used	O
to	O
treat	O
cancer	O
,	O
due	O
to	O
their	O
critical	O
role	O
in	O
glucose	S
home	O
##ost	O
##asis	O
[	O
,	O
,	O
]	O
.	O

We	O
observed	O
moderately	O
higher	O
(	O
1	O
.	O
27	O
-	O
fold	O
,	O
F	O
##DR	O
=	O
0	O
.	O
06	O
##8	O
)	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
the	O
on	O
##come	O
##ta	O
##bol	O
##ite	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
in	O
patients	O
at	O
pre	O
-	O
compared	O
to	O
post	O
-	O
surgery	O
.	O

Ch	O
##roma	O
##to	O
##graphic	O
conditions	O
included	O
the	O
following	O
:	O
Waters	O
,	O
A	O
##c	O
##qui	O
##ty	O
C	O
18	O
B	O
##E	O
##H	O
column	O
,	O
1	O
.	O
7	O
micro	O
##n	O
2	O
.	O
1	O
##×	O
##100	O
mm	O
;	O
mobile	O
phase	O
A	O
:	O
0	O
.	O
01	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
;	O
mobile	O
phase	O
B	O
:	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
-	I
met	I
##han	I
##ol	I
(	I
[UNK]	O
)	O
;	O
flow	O
rate	O
:	O
0	O
.	O
400	O
m	O
##L	O
/	O
min	O
;	O
gradient	O
:	O
initial	O
99	O
%	O
phase	O
A	O
,	O
1	O
.	O
0	O
min	O
60	O
%	O
phase	O
A	O
,	O
linear	O
,	O
1	O
.	O
4	O
min	O
60	O
%	O
phase	O
A	O
,	O
1	O
.	O
5	O
min	O
99	O
%	O
phase	O
A	O
;	O
and	O
linear	O
α	B
-	I
H	I
##B	I
retention	O
time	O
was	O
1	O
.	O
22	O
min	O
.	O

Since	O
no	O
target	O
concentration	O
for	O
efficacy	O
has	O
been	O
identified	O
,	O
the	O
population	O
average	O
concentration	O
of	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
was	O
used	O
.	O

Ch	B
##lor	I
##of	I
##orm	I
-	I
met	I
##han	I
##ol	I
(	S
1	S
:	S
1	S
;	S
v	S
/	S
v	S
)	S
,	S
with	S
2	S
%	S
solution	S
of	S
300	S
m	S
##M	S
pipe	B
##rid	I
##ine	I
,	O
was	S
used	S
as	S
the	S
mobile	S
phase	S
for	S
lip	S
##ids	S
ion	S
##ized	S
in	S
the	S
negative	S
ion	S
mode	S
and	S
ch	S
##lor	O
##of	O
##orm	O
-	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
1	O
;	O
v	O
/	O
v	O
)	O
was	O
used	O
for	O
lip	O
##ids	O
ion	O
##ized	O
in	O
the	O
positive	O
ion	O
mode	O
.	O

Also	O
,	O
correlation	O
analyses	O
and	O
in	O
##hibition	O
with	O
que	B
##rc	I
##eti	I
##n	I
(	O
a	O
non	O
##sp	O
##ec	O
##ific	O
inhibitor	O
of	O
C	O
##YP	O
##2	O
##C	O
##8	O
)	O
implicated	O
C	O
##YP	O
##2	O
##C	O
##8	O
in	O
an	O
##ast	O
##ro	O
##zo	O
##le	O
h	O
##ydro	O
##xy	O
##lation	O
,	O
but	O
data	O
from	O
expressed	O
C	O
##YP	O
##2	O
##C	O
##8	O
show	O
marginal	O
activity	O
towards	O
this	O
reaction	O
,	O
with	O
K	O
_	O
m	O
values	O
over	O
85	O
µ	O
##m	O
,	O
and	O
the	O
extent	O
of	O
in	O
##hibition	O
by	O
trim	O
##eth	O
##op	O
##rim	O
,	O
a	O
more	O
selective	O
inhibitor	O
,	O
was	O
minimal	O
.	O

We	O
can	O
observe	O
clear	O
changes	O
in	O
the	O
CP	O
##MG	O
s	O
##pect	O
##ra	O
from	O
several	O
of	O
the	O
meta	O
##bol	O
##ite	O
signals	O
,	O
including	O
those	O
from	O
glucose	S
,	O
v	B
##ali	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
la	B
##ct	I
##ate	I
and	O
ch	B
##olin	I
##e	I
.	O

Al	O
##bright	O
et	O
al	O
.	O
found	O
that	O
elevated	O
levels	O
of	O
la	B
##ctic	I
acid	I
in	O
pregnant	O
women	O
were	O
associated	O
with	O
adverse	O
maternal	O
outcomes	O
.	O

The	O
I	O
##B	O
##D	O
patients	O
in	O
re	O
##mission	O
were	O
characterized	O
by	O
a	O
significantly	O
higher	O
concentration	O
of	O
dim	B
##eth	I
##yla	I
##mine	I
and	O
a	O
lower	O
level	O
of	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##one	I
.	O

For	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
,	O
mostly	O
sub	O
##mic	O
##rom	O
##olar	O
levels	O
of	O
meta	O
##bol	O
##ite	O
X	O
were	O
detected	O
(	O
median	O
,	O
0	O
.	O
16	O
μ	O
##M	O
[	O
minimum	O
,	O
0	O
.	O
00	O
##7	O
μ	O
##M	O
;	O
maximum	O
,	O
5	O
.	O
08	O
μ	O
##M	O
]	O
)	O
.	O

And	O
if	O
u	O
##rina	O
##ry	O
AM	O
-	O
2	O
consists	O
of	O
10	O
%	O
of	O
exposed	O
dose	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
,	O
the	O
daily	O
intake	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
is	O
estimated	O
to	O
be	O
34	O
–	O
51	O
μ	O
##g	O
,	O
or	O
0	O
.	O
68	O
–	O
1	O
.	O
02	O
μ	O
##g	O
/	O
kg	O
.	O

420	O
µ	O
##l	O
of	O
filtered	O
serum	O
(	O
volume	O
adjusted	O
with	O
water	O
,	O
when	O
needed	O
)	O
were	O
mixed	O
with	O
120	O
µ	O
##l	O
of	O
phosphate	S
buffer	O
0	O
.	O
5	O
M	O
(	O
pH	O
7	O
.	O
0	O
##±	O
##0	O
.	O
1	O
)	O
containing	O
0	O
.	O
75	O
%	O
w	O
/	O
v	O
sodium	O
a	O
##zi	O
##de	O
and	O
60	O
µ	O
##l	O
of	O
5	O
m	O
##M	O
T	O
##MS	O
##P	O
in	O
D	O
_	O
2	O
O	O
(	O
99	O
.	O
9	O
%	O
pure	O
;	O
GO	O
##SS	O
Scientific	O
Instruments	O
Ltd	O
,	O
Essex	O
UK	O
)	O
and	O
transferred	O
to	O
an	O
N	O
##MR	O
tube	O
.	O

Among	O
lip	O
##op	O
##rote	O
##ins	O
measured	O
during	O
cold	O
,	O
training	O
decreased	O
total	O
lip	O
##ids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
within	O
ch	O
##yl	O
##omi	O
##c	O
##rons	O
and	O
all	O
classes	O
of	O
V	O
##LD	O
##L	O
,	O
except	O
very	O
small	O
V	O
##LD	O
##L	O
and	O
increased	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
large	O
HD	O
##L	O
particles	O
(	O
Figure	O
J	O
,	O
K	O
)	O
.	O

As	O
the	O
new	O
analytical	O
method	O
was	O
developed	O
to	O
analyze	O
en	O
##rich	O
##ments	O
of	O
o	B
##xa	I
##late	I
and	O
g	B
##ly	I
##cola	I
##te	I
in	O
P	O
##H1	O
patients	O
in	O
addition	O
to	O
healthy	O
volunteers	O
,	O
sufficient	O
sensitivity	O
was	O
needed	O
to	O
determine	O
these	O
compounds	O
in	O
healthy	O
volunteers	O
(	O
with	O
low	O
plasma	O
concentrations	O
)	O
.	O

Both	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
did	O
not	O
co	O
##rrel	O
##ate	O
with	O
any	O
card	O
##io	O
##met	O
##ab	O
##olic	O
parameters	O
.	O

F	B
##oll	I
##ista	I
##tin	I
was	O
significantly	O
higher	O
at	O
C	O
##1	O
than	O
any	O
other	O
time	O
point	O
of	O
the	O
event	O
(	O
pre	O
-	O
event	O
:	O
87	O
##1	O
±	O
470	O
p	O
##g	O
/	O
m	O
##l	O
,	O
C	O
##1	O
:	O
1	O
,	O
71	O
##5	O
±	O
87	O
##6	O
p	O
##g	O
/	O
m	O
##l	O
,	O
C	O
##2	O
:	O
1	O
,	O
35	O
##5	O
±	O
54	O
##4	O
p	O
##g	O
/	O
m	O
##l	O
,	O
post	O
-	O
event	O
:	O
1	O
,	O
41	O
##7	O
±	O
54	O
##2	O
p	O
##g	O
/	O
m	O
##l	O
)	O
(	O
Figure	O
)	O
.	O

The	O
pathway	O
analysis	O
shows	O
per	O
##tur	O
##bation	O
##s	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
and	O
several	O
amino	O
acids	O
,	O
as	O
well	O
as	O
in	O
the	O
metabolism	O
of	O
fatty	O
acids	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
and	O
)	O
.	O

This	O
feature	O
was	O
put	O
##ative	O
##ly	O
assigned	O
to	O
rib	B
##of	I
##lav	I
##in	I
.	O

We	O
also	O
examined	O
the	O
association	O
between	O
the	O
C	O
##YP	O
##3	O
##A	O
##5	O
g	O
##eno	O
##type	O
##s	O
and	O
serum	O
levels	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
.	O

Mean	O
c	O
##rea	O
##tin	O
##ine	O
-	O
corrected	O
coefficients	O
of	O
variation	O
for	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
over	O
the	O
20	O
week	O
period	O
were	O
31	O
%	O
and	O
54	O
%	O
,	O
respectively	O
,	O
while	O
the	O
corresponding	O
in	O
##tra	O
-	O
class	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
were	O
0	O
.	O
51	O
(	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
45	O
,	O
0	O
.	O
57	O
)	O
and	O
0	O
.	O
36	O
(	O
0	O
.	O
30	O
,	O
0	O
.	O
43	O
)	O
,	O
respectively	O
.	O

The	O
ME	O
##K	O
##C	O
-	O
MS	O
/	O
MS	O
conditions	O
are	O
the	O
same	O
as	O
in	O
except	O
that	O
25	O
m	O
##M	O
p	O
##oly	O
-	O
L	O
,	O
L	O
-	O
S	O
##U	O
##LA	O
and	O
25	O
k	B
##V	I
was	O
used	O
.	O

Multiple	O
connections	O
were	O
identified	O
with	O
primary	O
meta	O
##bol	O
##ites	O
(	O
e	O
.	O
g	O
.	O
,	O
an	O
inverse	O
relation	O
between	O
vitamin	O
B	O
-	O
12	O
markers	O
and	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
p	O
##yr	O
##u	O
##vic	O
,	O
su	B
##cci	I
##nic	I
,	O
and	O
c	O
##it	O
##ric	O
acids	O
,	O
and	O
a	O
direct	O
correlation	O
between	O
the	O
nerve	O
score	O
and	O
a	B
##rg	I
##ini	I
##ne	I
)	O
.	O

Q	O
##uant	O
##itative	O
est	O
##imation	O
of	O
glucose	S
up	O
##take	O
,	O
using	O
a	O
cell	O
based	O
ass	O
##ay	O
kit	O
,	O
was	O
performed	O
as	O
per	O
instructions	O
provided	O
by	O
the	O
manufacturer	O
(	O
C	O
##ayman	O
,	O
USA	O
)	O
.	O

In	O
base	O
##line	O
samples	O
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
format	B
##e	I
significantly	O
decreased	O
from	O
F	O
##4	O
to	O
F	O
##0	O
/	O
F1	O
,	O
and	O
g	B
##lut	I
##amine	I
only	O
increased	O
from	O
F	O
##4	O
to	O
F	O
##0	O
/	O
F1	O
.	O

(	O
a	O
)	O
Heat	O
-	O
map	O
of	O
fold	O
change	O
of	O
56	O
differential	O
meta	O
##bol	O
##ites	O
;	O
(	O
b	O
)	O
Disc	O
##rim	O
##ination	O
of	O
T	O
##2	O
##DM	O
in	O
the	O
training	O
set	O
using	O
Lin	B
##ole	I
##nic	I
A	I
##cid	I
(	O
1	O
)	O
,	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
(	O
2	O
)	O
,	O
and	O
the	O
combination	O
of	O
them	O
(	O
3	O
)	O
.	O

A	O
##bs	O
##ol	O
##ute	O
concentrations	O
were	O
q	O
##uant	O
##ified	O
using	O
a	O
series	O
of	O
standards	O
of	O
known	O
concentrations	O
of	O
ne	B
##r	I
##von	I
##ic	I
acid	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Japan	O
K	O
.	O
K	O
.	O
)	O
mixed	O
with	O
the	O
internal	O
standard	O
.	O

The	O
six	O
-	O
meta	O
##bol	O
##ite	O
combination	O
consists	O
of	O
al	B
##ani	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
.	O

(	O
A	O
)	O
Ex	O
##ample	O
of	O
assessment	O
of	O
the	O
diagnostic	O
performance	O
through	O
R	O
##OC	O
analysis	O
obtained	O
for	O
PC	O
##3	O
vs	O
P	O
##NT	O
##2	O
at	O
pH	O
##7	O
(	B
2	B
-	I
pen	I
##tad	I
##eca	I
##non	I
##e	I
(	O
AU	O
##C	O
=	O
1	O
)	O
and	O
2	B
-	I
met	I
##hyl	I
##und	I
##eca	I
##nal	I
(	O
AU	O
##C	O
=	O
0	O
.	O
84	O
)	O
)	O
and	O
at	O
pH	O
##2	O
(	B
4	B
-	I
met	I
##hyl	I
##he	I
##pta	I
##n	I
-	I
2	I
-	I
one	I
(	O
AU	O
##C	O
=	O
0	O
.	O
89	O
)	O
and	O
ben	B
##zoic	I
acid	I
(	O
AU	O
##C	O
=	O
0	O
.	O
77	O
)	O
.	O

Other	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
include	O
4	B
-	I
p	I
##yr	I
##ido	I
##xi	I
##c	I
acid	I
,	O
g	B
##ly	I
##cine	I
,	O
rib	B
##ose	I
,	O
and	O
amino	B
##mal	I
##onic	I
acid	I
.	O

S	B
##pi	I
##rome	I
##try	I
(	O
Me	O
##d	O
##G	O
##raphic	O
##s	O
Corp	O
.	O
,	O
St	O
.	O
Paul	O
,	O
M	O
##N	O
,	O
USA	O
)	O
was	O
performed	O
in	O
accordance	O
with	O
the	O
AT	O
##S	O
/	O
ER	O
##S	O
guidelines	O
.	O

The	O
alcohol	O
##s	O
may	O
be	O
meta	O
##bol	O
##ized	O
to	O
car	B
##box	I
##yl	I
##ic	I
acids	I
and	O
these	O
acids	O
further	O
used	O
to	O
the	O
synthesis	O
of	O
cellular	O
membrane	O
precursor	O
##s	O
.	O

During	O
the	O
follow	O
-	O
up	O
the	O
ER	B
(	I
+	I
)	I
patients	O
received	O
anti	O
-	O
est	O
##rogen	O
ad	O
##ju	O
##vant	O
therapy	O
based	O
on	O
ta	B
##mo	I
##xi	I
##fen	I
or	O
a	O
##roma	O
##tase	O
inhibitor	O
##s	O
.	O

All	O
chemical	O
shifts	O
were	O
referenced	O
to	O
de	O
##uter	O
##ated	O
sodium	O
2	O
,	O
2	O
,	O
dim	B
##eth	I
##yl	I
-	I
si	I
##lap	I
##ent	I
##ane	I
-	I
1	I
-	I
su	I
##lf	I
##ona	I
##te	I
(	O
DS	O
##S	O
-	O
d	O
##6	O
)	O
as	O
0	O
pp	O
##m	O
.	O

Whenever	O
a	O
molecule	O
of	O
al	B
##ani	I
##ne	I
is	O
formed	O
from	O
p	B
##yr	I
##u	I
##vate	I
via	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
a	O
molecule	O
of	O
g	B
##lut	I
##ama	I
##te	I
will	O
be	O
formed	O
from	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
(	O
E	O
##q	O
2	O
)	O
,	O
and	O
that	O
in	O
turn	O
can	O
be	O
converted	O
(	O
via	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
,	O
E	O
##q	O
4	O
)	O
into	O
g	B
##lut	I
##amine	I
(	O
see	O
)	O
.	O

The	O
absolute	O
concentration	O
(	O
ng	O
/	O
m	O
##L	O
)	O
of	O
each	O
PC	O
was	O
calculated	O
based	O
on	O
the	O
peak	O
area	O
of	O
the	O
PC	O
identified	O
in	O
the	O
sample	O
and	O
the	O
peak	O
area	O
of	O
the	O
internal	O
standard	O
of	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
corresponding	O
to	O
the	O
sample	O
(	O
the	O
formula	O
was	O
shown	O
in	O
Figure	O
_	O
S	O
##1	O
)	O
.	O

Take	O
##n	O
together	O
,	O
the	O
observed	O
increase	O
in	O
the	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
and	O
g	B
##ly	I
##cine	I
suggests	O
that	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
is	O
highly	O
active	O
in	O
H	O
##NS	O
##CC	O
similar	O
to	O
other	O
tumor	O
types	O
.	O

(	O
C	O
)	O
Ex	O
##ample	O
of	O
mass	O
spectral	O
peak	O
pair	O
of	O
a	O
_	O
13	O
C	O
-	O
/	O
_	O
12	O
C	O
-	O
dans	O
##yl	O
labeled	O
meta	O
##bol	O
##ite	O
(	B
D	B
##ns	I
-	I
Alan	I
##ine	I
)	O
.	O

In	O
the	O
examination	O
of	O
subgroup	O
##s	O
of	O
the	O
incident	O
central	O
ad	O
##ip	O
##os	O
##ity	O
gain	O
group	O
,	O
we	O
compared	O
the	O
concentration	O
of	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
across	O
three	O
levels	O
of	O
central	O
ad	O
##ip	O
##os	O
##ity	O
gain	O
,	O
defined	O
by	O
the	O
degree	O
of	O
change	O
.	O

Figure	O
shows	O
an	O
expansion	O
of	O
the	O
la	B
##ct	I
##ate	I
region	O
for	O
the	O
R	O
##h	O
##30	O
cells	O
shown	O
in	O
Fi	O
##g	O
.	O

After	O
processing	O
,	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
should	O
meet	O
the	O
criterion	O
of	O
quality	O
control	O
that	O
the	O
line	O
width	O
at	O
half	O
height	O
of	O
la	B
##ct	I
##ate	I
resonance	O
at	O
1	O
.	O
32	O
pp	O
##m	O
was	O
<	O
1	O
.	O
15	O
Hz	O
.	O

L	B
-	I
try	I
##pt	I
##op	I
##han	I
and	O
its	O
meta	O
##bol	O
##ites	O
se	B
##rot	I
##oni	I
##n	I
(	O
5	O
##HT	O
)	O
and	O
me	B
##lat	I
##oni	I
##n	I
have	O
notable	O
functions	O
in	O
regulating	O
growth	O
and	O
development	O
of	O
the	O
f	O
##etus	O
(	O
Glover	O
,	O
;	O
St	O
-	O
Pierre	O
et	O
al	O
.	O
,	O
;	O
Wu	O
et	O
al	O
.	O
,	O
)	O
and	O
are	O
involved	O
in	O
a	O
ma	O
##gni	O
##fi	O
##que	O
number	O
of	O
physiological	O
pathways	O
and	O
adapt	O
##ion	O
processes	O
during	O
pregnancy	O
(	O
San	O
##o	O
et	O
al	O
.	O
,	O
)	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
.	O

Pro	B
##pion	I
##ate	I
and	O
prop	B
##ion	I
##yl	I
-	I
Co	I
##A	I
are	O
de	O
##to	O
##xi	O
##fied	O
by	O
the	O
mit	O
##och	O
##ond	O
##ria	O
through	O
the	O
met	B
##hyl	I
-	I
ma	I
##lon	I
##yl	I
-	I
Co	I
##A	I
pathway	O
.	O

Because	O
our	O
data	O
suggest	O
that	O
meta	O
##bol	O
##ite	O
differences	O
between	O
PT	O
##SD	O
and	O
control	O
subjects	O
may	O
reflect	O
differences	O
in	O
use	O
of	O
energy	O
sources	O
(	B
glucose	B
vs	I
fatty	O
acids	O
)	O
,	O
we	O
evaluated	O
status	O
of	O
glucose	S
d	O
##ys	O
##re	O
##gu	O
##lation	O
as	O
a	O
co	O
##var	O
##iate	O
.	O

Here	O
the	O
effect	O
of	O
column	O
length	O
(	O
150	O
,	O
75	O
and	O
30	O
mm	O
)	O
and	O
gradient	O
duration	S
(	O
15	O
,	O
7	O
.	O
5	O
and	O
3	O
min	O
respectively	O
)	O
on	O
the	O
number	O
of	O
features	O
detected	O
when	O
un	O
##tar	O
##get	O
##ed	O
metabolic	O
pro	O
##fi	O
##ling	O
of	O
human	O
urine	O
using	O
reversed	O
-	O
phase	O
gradient	O
ultra	O
performance	O
ch	O
##roma	O
##tography	O
with	O
,	O
and	O
without	O
,	O
ion	O
mobility	O
s	O
##pect	O
##rome	O
##try	O
,	O
has	O
been	O
examined	O
.	O

Support	O
##ed	O
by	O
correlation	O
analysis	O
,	O
this	O
pattern	O
suggests	O
a	O
metabolic	O
relationship	O
linking	O
PA	B
##G	I
and	O
try	B
##pt	I
##op	I
##han	I
to	O
changes	O
in	O
%	O
FF	O
##M	O
,	O
growth	O
,	O
and	O
inflammatory	O
conditions	O
in	O
p	O
##ediatric	O
patients	O
in	O
re	O
##mission	O
.	O

The	O
higher	O
levels	O
of	O
c	B
##ys	I
##tein	I
##e	I
,	O
ta	B
##uri	I
##ne	I
,	O
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
were	O
observed	O
in	O
the	O
color	O
##ec	O
##tal	O
cancer	O
tissues	O
compared	O
with	O
the	O
normal	O
tissue	O
,	O
.	O

Li	O
##pid	O
##2	O
originates	O
from	O
lip	O
##id	O
met	B
##hyl	I
##ene	I
(	O
–	O
CH	O
_	O
2	O
–	O
)	O
pro	O
##tons	O
within	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
est	O
##eri	O
##fied	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

The	O
results	O
of	O
our	O
study	O
document	O
beneficial	O
effects	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
on	O
lip	O
##id	O
metabolism	O
when	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
was	O
used	O
as	O
part	O
of	O
the	O
combined	O
intervention	O
with	O
n	O
-	O
3	O
fatty	O
acids	O
.	O

The	O
conversion	O
of	O
3	B
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
to	O
se	B
##rine	I
is	O
mediated	O
through	O
three	O
se	O
##quential	O
reactions	O
(	O
see	O
)	O
.	O

In	O
case	O
of	O
P	O
##Y	O
##RO	O
##X	O
##D	O
##2	O
,	O
meta	O
##bo	O
##mat	O
##ching	O
suggests	O
that	O
the	O
associated	O
N	O
##MR	O
signals	O
correspond	O
to	O
trim	B
##eth	I
##yla	I
##mine	I
.	O

The	O
strength	O
of	O
the	O
combined	O
MR	O
##I	O
/	O
MR	O
##SI	O
exam	O
is	O
demonstrated	O
when	O
changes	O
in	O
all	O
three	O
metabolic	O
markers	O
(	B
ch	B
##olin	I
##e	I
,	O
p	B
##oly	I
##amine	I
##s	I
,	O
and	O
c	O
##it	O
##rate	O
)	O
and	O
imaging	O
findings	O
are	O
con	O
##cor	O
##dant	O
for	O
cancer	O
.	O

At	O
a	O
given	O
level	O
of	O
exposure	O
to	O
a	B
##c	I
##rol	I
##ein	I
,	O
individuals	O
with	O
more	O
efficient	O
g	B
##lut	I
##ath	I
##ione	I
de	O
##to	O
##xi	O
##fication	O
capacity	O
would	O
be	O
expected	O
to	O
have	O
higher	O
levels	O
of	O
u	O
##rina	O
##ry	O
3	O
-	O
HP	O
##MA	O
,	O
and	O
this	O
could	O
contribute	O
to	O
lower	O
add	O
##uc	O
##t	O
levels	O
by	O
s	O
##ca	O
##ven	O
##ging	O
a	B
##c	I
##rol	I
##ein	I
.	O

It	O
is	O
one	O
of	O
the	O
most	O
highly	O
accumulated	O
meta	O
##bol	O
##ites	O
in	O
E	O
##SR	O
##D	O
,	O
the	O
concentrations	O
are	O
up	O
to	O
100	O
times	O
that	O
in	O
normal	O
subjects	B
.	I
(	I
-	I
)	I

The	O
current	O
base	O
width	O
data	O
supports	O
the	O
use	O
of	O
water	O
as	O
an	O
add	O
##itive	O
to	O
improve	O
peak	O
shapes	O
for	O
acids	O
and	O
sugar	O
##s	O
,	O
while	O
its	O
use	O
has	O
previously	O
been	O
demonstrated	O
to	O
give	O
sharp	O
##er	O
peaks	O
for	O
n	O
##uc	O
##leo	O
##base	O
##s	O
on	O
a	O
variety	O
of	O
stationary	O
phases	O
,	O
including	O
di	B
##ol	I
,	O
c	O
##yan	O
##op	O
##rop	O
##yl	O
and	O
2	O
-	O
EP	O
.	O

Hence	O
,	O
we	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
these	O
types	O
of	O
to	B
##xin	I
##s	I
influence	O
the	O
same	O
network	O
of	O
genes	O
that	O
orchestra	O
##tes	O
specific	O
cellular	O
pathways	O
.	O

The	O
present	O
study	O
clearly	O
showed	O
alterations	O
in	O
T	B
##G	I
levels	O
and	O
several	O
other	O
a	O
##que	O
##ous	O
meta	O
##bol	O
##ites	O
in	O
tumor	O
as	O
compared	O
to	O
N	O
##AT	O
,	O
also	O
L	O
##N	O
-	O
Met	O
tissues	O
showed	O
similar	O
changes	O
as	O
observed	O
in	O
tumor	O
.	O

For	O
example	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
has	O
been	O
reported	O
from	O
r	O
##uti	O
##n	O
;	O
5	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
-	I
2	I
-	I
fur	I
##oi	I
##c	I
acid	I
was	O
detected	O
in	O
urine	O
from	O
subjects	O
that	O
consumed	O
dried	O
p	O
##lum	O
juice	O
.	O

The	O
standard	O
curves	O
for	O
ace	B
##tam	I
##ip	I
##rid	I
and	O
AM	O
-	O
2	O
are	O
linear	O
between	O
the	O
highest	O
and	O
the	O
lowest	O
concentrations	O
.	O

The	O
branched	O
chain	O
amino	O
acids	O
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
reported	O
earlier	O
by	O
Mayer	O
##s	O
et	O
al	O
.	O
,	O
were	O
not	O
different	O
between	O
cases	O
and	O
controls	O
(	O
un	O
##ad	O
##ju	O
##sted	O
P	O
values	O
of	O
0	O
.	O
75	O
,	O
0	O
.	O
94	O
,	O
and	O
0	O
.	O
61	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
peak	O
distribution	O
measured	O
by	O
r	O
##−	O
(	O
A	O
)	O
followed	O
a	O
different	O
trend	O
,	O
with	O
the	O
most	O
even	O
distribution	O
seen	O
for	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
median	O
r	O
##−	O
of	O
0	O
.	O
39	O
,	O
mean	O
of	O
0	O
.	O
42	O
)	O
,	O
and	O
the	O
most	O
uneven	O
observed	O
for	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
water	O
,	O
with	O
median	O
r	O
##−	O
values	O
of	O
0	O
.	O
23	O
and	O
0	O
.	O
20	O
respectively	O
.	O

The	O
present	O
study	O
identified	O
27	O
bio	O
##mark	O
##ers	O
and	O
established	O
a	O
combined	O
diagnostic	O
model	O
comprising	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
and	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
for	O
the	O
early	O
diagnosis	O
of	O
G	O
##CA	O
.	O

Diet	O
##ary	O
nutrients	O
assessment	O
confirmed	O
that	O
their	O
diet	O
##s	O
were	O
significantly	O
more	O
ca	O
##lor	O
##ic	O
,	O
rich	O
##er	O
in	O
total	O
and	O
saturated	O
fat	O
##s	O
,	O
and	O
(	O
in	O
o	O
##bes	O
##e	O
with	O
N	O
##AF	O
##LD	O
)	O
in	O
f	B
##ru	I
##ct	I
##ose	I
as	O
well	O
(	O
Table	O
S	O
##1	O
)	O
.	O

For	O
quality	O
control	O
(	O
Q	O
##C	O
)	O
purposes	O
,	O
kits	O
containing	O
mixed	O
standard	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
purchased	O
from	O
Ch	O
##rom	O
##sy	O
##ste	O
##ms	O
(	O
Graf	O
##elf	O
##ing	O
,	O
Germany	O
)	O
.	O

Ke	B
##tone	I
bodies	O
mainly	O
produced	O
from	O
fatty	O
acids	O
β	O
-	O
oxidation	O
,	O
exhibit	O
different	O
patterns	O
of	O
alter	O
##ation	O
in	O
cancer	O
studies	O
.	O

HC	O
##V	O
induce	O
##s	O
insulin	O
resistance	O
and	O
in	O
##hibit	O
##s	O
synthesis	O
of	O
T	B
##G	I
,	O
consistent	O
with	O
the	O
accumulation	O
of	O
g	B
##ly	I
##cer	I
##ol	I
and	O
FF	O
##As	O
in	O
patients	O
with	O
re	O
##lap	O
##se	O
,	O
shown	O
in	O
Figure	O
.	O

They	O
also	O
highlight	O
other	O
interesting	O
ho	O
##rmon	O
##al	O
alterations	O
for	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
4	B
-	I
and	I
##ros	I
##ten	I
##e	I
-	I
3	I
,	I
17	I
-	I
di	I
##one	I
,	O
test	B
##osterone	I
,	O
and	O
17	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
.	O

Like	O
g	B
##lut	I
##ath	I
##ione	I
,	O
as	B
##cor	I
##bic	I
acid	I
is	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
that	O
protects	O
cells	O
against	O
o	O
##xi	O
##da	O
##tive	O
stress	O
from	O
reactive	O
oxygen	O
species	O
.	O

Ser	O
##um	O
u	B
##rea	I
in	O
conjunction	O
with	O
e	O
##G	O
##F	O
##R	O
,	O
recipient	O
age	O
,	O
race	O
,	O
album	O
##in	O
levels	O
,	O
and	O
prior	O
acute	O
rejection	O
significantly	O
predicted	O
overall	O
transplant	O
failure	O
.	O

The	O
later	O
el	O
##uti	O
##ng	O
is	O
##omer	O
of	O
PC	B
(	I
38	I
:	I
4	I
)	I
co	O
##el	O
##uted	O
with	O
our	O
standard	O
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
4	I
)	I
.	O

Thereafter	O
,	O
many	O
genes	O
have	O
been	O
demonstrated	O
partly	O
to	O
contribute	O
to	O
severe	O
L	O
##MCA	O
##D	O
path	O
##ogen	O
##esis	O
,	O
including	O
genes	O
associated	O
with	O
the	O
systems	O
of	O
inter	O
##le	O
##uki	O
##n	O
,	O
inflammation	O
and	O
pro	B
##sta	I
##g	I
##land	I
##in	I
s	O
##ynth	O
##eta	O
##se	O
.	O

Form	B
##ate	I
was	O
also	O
significantly	O
elevated	O
in	O
the	O
MS	O
-	O
like	O
subgroup	O
vs	O
the	O
N	O
##MO	O
##SD	O
-	O
like	O
subgroup	O
(	O
0	O
.	O
00	O
##27	O
[	O
0	O
.	O
000	O
##6	O
]	O
vs	O
0	O
.	O
00	O
##19	O
[	O
0	O
.	O
000	O
##6	O
]	O
AU	O
;	O
p	O
=	O
0	O
.	O
01	O
##0	O
)	O
.	O

Character	O
##istic	O
##s	O
of	O
the	O
study	O
population	O
s	O
##tra	O
##ti	O
##fied	O
by	O
fast	O
##ing	O
glucose	S
levels	O
are	O
sum	O
##mar	O
##ised	O
in	O
.	O

Moreover	O
,	O
L	O
##v	O
et	O
al	O
.	O
demonstrated	O
circulating	O
levels	O
of	O
PC	B
40	I
:	I
1	I
and	O
PC	B
40	I
:	I
4	I
as	O
up	O
##re	O
##gu	O
##lated	O
lip	O
##id	O
molecular	O
species	O
that	O
are	O
specific	O
for	O
small	O
cell	O
lung	O
cancer	O
(	O
SC	O
##LC	O
)	O
.	O

S	O
##yna	O
##ptic	O
ve	O
##si	O
##cle	O
bio	O
##genesis	O
has	O
been	O
linked	O
to	O
two	O
c	O
##lat	O
##hr	O
##in	O
-	O
related	O
pathways	O
,	O
one	O
of	O
which	O
uses	O
b	O
##uddin	O
##g	O
from	O
end	O
##oso	O
##mes	O
and	O
/	O
or	O
the	O
Go	O
##l	O
##gi	O
complex	O
and	O
requires	O
AP	O
##1	O
or	O
AP	O
##3	O
c	B
##lat	I
##hr	I
##in	I
adapt	O
##ors	O
along	O
with	O
the	O
Ra	O
##s	O
-	O
related	O
GT	O
##P	O
##ase	O
AD	O
##P	O
-	O
rib	O
##osy	O
##lation	O
factor	O
(	O
AR	O
##F	O
)	O
,	O
which	O
is	O
sensitive	O
to	O
br	O
##ef	O
##eld	O
##in	O
A	O
.	O
Early	O
end	O
##oso	O
##me	O
markers	O
are	O
at	O
the	O
center	O
of	O
the	O
HC	O
##M	O
##V	O
assembly	O
compartment	O
(	O
,	O
)	O
,	O
c	B
##lat	I
##hr	I
##in	I
and	O
AR	O
##F	O
##4	O
have	O
been	O
detected	O
in	O
the	O
v	O
##iri	O
##on	O
,	O
and	O
trafficking	O
of	O
the	O
p	O
##U	O
##L	O
##9	O
##9	O
v	O
##iri	O
##on	O
protein	O
is	O
br	O
##ef	O
##eld	O
##in	O
sensitive	O
.	O

C	O
##L	O
interact	O
##s	O
with	O
proteins	O
in	O
the	O
mit	O
##och	O
##ond	O
##ria	O
in	O
the	O
regulation	O
of	O
a	O
number	O
of	O
mitochondrial	O
processes	O
,	O
including	O
the	O
electron	O
transport	O
chain	O
(	O
i	O
.	O
e	O
.	O
ATP	S
production	O
)	O
,	O
cell	O
via	O
##bility	O
and	O
a	O
##pop	O
##tosis	O
.	O

In	O
that	O
experimental	O
model	O
,	O
increased	O
levels	O
of	O
te	O
##tra	O
##de	O
##cane	O
##dio	O
##nate	O
,	O
s	B
##te	I
##arate	I
and	O
e	B
##ico	I
##sen	I
##oat	I
##e	I
and	O
other	O
fatty	O
acids	O
were	O
observed	O
with	O
trans	O
##cript	O
##omi	O
##c	O
changes	O
pointing	O
at	O
a	O
shift	O
in	O
energy	O
production	O
towards	O
g	O
##ly	O
##co	O
##lysis	O
and	O
de	O
##ple	O
##tion	O
of	O
a	O
number	O
of	O
amino	O
acids	O
;	O
findings	O
which	O
are	O
parallel	O
to	O
the	O
meta	O
##bol	O
##ite	O
patterns	O
observed	O
in	O
the	O
current	O
study	O
.	O

O	O
##bes	O
##e	O
subjects	O
can	O
have	O
higher	O
la	B
##ct	I
##ate	I
release	O
due	O
to	O
their	O
larger	O
ad	O
##ip	O
##ose	O
mass	O
.	O

,	O
General	O
route	O
for	O
the	O
synthesis	O
of	O
1	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##opy	I
##rim	I
##id	I
##ine	I
analogue	O
##s	O
D	O
##HP	O
##M	O
##1	O
–	O
D	O
##HP	O
##M	O
##8	O
.	O

In	O
addition	O
,	O
the	O
Alpha	B
-	I
To	I
##co	I
##pher	I
##ol	I
,	O
Beta	B
-	I
Car	I
##ote	I
##ne	I
Cancer	O
Prevention	O
(	O
AT	O
##BC	O
)	O
co	O
##hor	O
##t	O
constitutes	O
a	O
relatively	O
ho	O
##mogeneous	O
population	O
of	O
Finnish	O
male	O
smoke	O
##rs	O
of	O
European	O
ancestry	O
,	O
which	O
may	O
limit	O
the	O
general	O
##iza	O
##bility	O
of	O
our	O
findings	O
to	O
other	O
populations	O
.	O

The	O
procedure	O
used	O
by	O
the	O
crime	O
laboratory	O
is	O
capable	O
of	O
detect	O
##ing	O
trace	O
levels	O
of	O
many	O
AA	O
##I	O
##s	O
and	O
other	O
synthetic	O
can	B
##na	I
##bino	I
##ids	I
being	O
used	O
to	O
lace	O
“	O
K	O
##2	O
”	O
products	O
.	O

Directed	O
measurement	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
(	O
2	O
-	O
H	O
##G	O
)	O
.	O

The	O
super	O
##nat	O
##ant	O
(	O
organic	O
phase	O
)	O
was	O
collected	O
,	O
and	O
the	O
p	O
##elle	O
##t	O
was	O
re	O
##sus	O
##pen	O
##ded	O
with	O
0	O
.	O
5	O
m	O
##l	O
of	O
ch	B
##lor	I
##of	I
##orm	I
-	I
met	I
##han	I
##ol	I
and	O
cent	O
##ri	O
##fu	O
##ged	O
.	O

Above	O
all	O
,	O
the	O
volatile	O
meta	O
##bol	O
##ites	O
belonging	O
to	O
the	O
chemical	O
compounds	O
of	O
the	O
al	O
##de	O
##hy	O
##des	O
,	O
k	B
##eton	I
##es	I
,	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
,	O
p	O
##hen	O
##ols	O
,	O
acids	O
and	O
sulfur	O
-	O
containing	O
compounds	O
have	O
been	O
found	O
increased	O
in	O
the	O
urine	O
of	O
H	O
##NS	O
##CC	O
-	O
patients	O
.	O

In	O
line	O
with	O
a	O
recent	O
study	O
,	O
a	O
negative	O
correlation	O
between	O
plasma	O
k	B
##yn	I
##uren	I
##ine	I
and	O
depression	O
scores	O
was	O
observed	O
.	O

Additionally	O
,	O
an	O
enhanced	O
P	O
##LS	O
-	O
D	O
##A	O
model	O
was	O
established	O
by	O
using	O
these	O
seven	O
meta	O
##bol	O
##ites	O
and	O
combining	O
three	O
clinical	O
characteristics	O
(	O
plasma	O
glucose	S
,	O
plasma	O
T	B
##G	I
and	O
HD	O
##L	O
)	O
that	O
also	O
have	O
P	O
values	O
less	O
than	O
0	O
.	O
00	O
##5	O
in	O
comparison	O
to	O
the	O
two	O
groups	O
to	O
test	O
the	O
possibility	O
of	O
model	O
performance	O
enhance	O
##ment	O
.	O

In	O
conditions	O
of	O
low	O
glucose	S
or	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
concentrations	O
,	O
k	B
##eton	I
##e	I
bodies	O
(	O
ace	O
##tone	O
,	O
ace	B
##to	I
##ace	I
##tic	I
acid	I
,	O
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	O
)	O
are	O
produced	O
in	O
mit	O
##och	O
##ond	O
##ria	O
through	O
fatty	O
acid	O
cat	O
##ab	O
##olis	O
##m	O
.	O

If	O
plasma	O
is	O
not	O
acid	O
##ified	O
directly	O
after	O
withdrawal	O
,	O
then	O
o	B
##xa	I
##late	I
will	O
form	O
during	O
storage	O
even	O
when	O
stored	O
at	O
−	O
##20	O
°C	O
or	O
−	O
##70	O
°C	O
.	O
_	O
,	O
As	B
##cor	I
##bic	I
acid	I
is	O
the	O
main	O
source	O
of	O
in	O
v	O
##it	O
##ro	O
o	O
##xa	O
##log	O
##ene	O
##sis	O
,	O
and	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
does	O
not	O
contribute	O
significantly	O
.	O
_	O
,	O

We	O
observed	O
a	O
significant	O
over	O
##ex	O
##press	O
##ion	O
of	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
in	O
DC	O
vs	O
.	O
NH	O
##C	O
and	O
R	O
##OC	O
data	O
of	O
a	B
##zel	I
##ate	I
and	O
se	B
##ba	I
##cate	I
show	O
that	O
each	O
of	O
these	O
meta	O
##bol	O
##ites	O
accurately	O
distinguished	O
DC	O
##s	O
from	O
NH	O
##Cs	O
with	O
100	O
%	O
sensitivity	O
and	O
100	O
%	O
specific	O
##ity	O
(	O
AU	O
##C	O
=	O
1	O
.	O
00	O
,	O
P	O
=	O
0	O
.	O
00	O
)	O
.	O

Specifically	O
,	O
although	O
the	O
maximum	O
plasma	O
concentrations	O
of	O
i	O
##rino	O
##teca	O
##n	O
and	O
S	O
##N	O
-	O
38	O
were	O
achieved	O
at	O
the	O
end	O
of	O
in	O
##fusion	O
(	O
1	O
.	O
5	O
hours	O
)	O
,	O
the	O
most	O
apparent	O
elevations	O
in	O
plasma	O
levels	O
of	O
meta	O
##bol	O
##ites	O
(	O
including	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
derivatives	O
,	O
and	O
p	O
##yr	O
##im	O
##id	O
##ine	O
/	O
pu	O
##rine	O
n	O
##uc	O
##leo	O
##base	O
##s	O
)	O
occurred	O
at	O
5	O
.	O
5	O
and	O
/	O
or	O
28	O
hours	O
(	O
and	O
)	O
.	O

Other	O
meta	O
##bol	O
##ites	O
such	O
as	O
su	B
##cci	I
##nate	I
and	O
f	B
##uma	I
##rate	I
,	O
which	O
a	O
##cc	O
##um	O
##ulate	O
in	O
specific	O
tumor	O
types	O
,	O
may	O
similarly	O
prove	O
to	O
be	O
valuable	O
meta	O
##bol	O
##ite	O
markers	O
for	O
guiding	O
surgery	O
with	O
MS	O
approaches	O
.	O

Higher	O
levels	O
of	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
such	O
as	O
ch	B
##olin	I
##e	I
,	O
PC	O
,	O
GP	B
##C	I
and	O
P	O
##E	O
observed	O
here	O
in	O
CR	O
##C	O
tissues	O
than	O
in	O
AN	O
##IT	O
have	O
been	O
reported	O
in	O
other	O
ma	O
##li	O
##gnant	O
tumors	O
_	O
,	O
_	O
,	O
.	O

We	O
found	O
that	O
different	O
content	O
changes	O
of	O
th	B
##iol	I
##s	I
are	O
associated	O
with	O
different	O
types	O
of	O
cancer	O
##s	O
.	O

Regarding	O
c	B
##rea	I
##tin	I
##ine	I
,	O
relative	O
concentrations	O
obtained	O
,	O
and	O
their	O
respective	O
differences	O
between	O
groups	O
under	O
study	O
,	O
this	O
meta	O
##bol	O
##ite	O
might	O
be	O
considered	O
a	O
potential	O
art	O
##ef	O
##act	O
given	O
that	O
c	B
##rea	I
##tin	I
##ine	I
values	O
may	O
be	O
altered	O
,	O
as	O
the	O
generation	O
of	O
c	B
##rea	I
##tin	I
##ine	I
may	O
not	O
be	O
simply	O
a	O
product	O
of	O
muscle	O
mass	O
but	O
influenced	O
by	O
muscle	O
function	O
,	O
muscle	O
composition	O
,	O
activity	O
,	O
diet	O
,	O
and	O
health	O
status	O
.	O

(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
Q	O
##u	O
##í	O
##mic	O
##a	O
SA	O
,	O
Madrid	O
,	O
Spain	O
)	O
and	O
re	B
##ser	I
##pine	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
Q	O
##u	O
##í	O
##mic	O
##a	O
)	O
in	O
H	O
_	O
2	O
O	O
:	O
CH	O
_	O
3	O
OH	B
(	I
1	I
:	I
1	I
,	I
0	I
.	I
1	I
%	I
v	I
/	I
v	I
HC	I
##O	I
##OH	I
)	I
,	O
at	O
a	O
final	O
concentration	O
of	O
1	O
µ	O
##M	O
each	O
.	O

P	O
##las	O
##ma	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
increased	O
significantly	O
(	O
5	O
.	O
8	O
±	O
0	O
.	O
7	O
to	O
14	O
.	O
2	O
±	O
3	O
.	O
1	O
μ	O
##g	O
/	O
m	O
##l	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
4	O
months	O
of	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
treatment	O
.	O

In	O
the	O
metabolic	O
profile	O
,	O
decreased	O
levels	O
of	O
glucose	S
and	O
elevated	O
levels	O
of	O
la	B
##ct	I
##ate	I
were	O
observed	O
in	O
the	O
cache	O
##xia	O
patients	O
'	O
se	O
##ra	O
,	O
consistent	O
with	O
previous	O
reports	O
.	O
17	O
,	O
18	O
En	O
##han	O
##ced	O
glucose	S
metabolism	O
in	O
cancer	O
has	O
been	O
associated	O
with	O
g	O
##ly	O
##co	O
##lysis	O
,	O
leading	O
to	O
greater	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
formation	O
via	O
non	O
‐	O
o	O
##xi	O
##da	O
##tive	O
pathways	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
systemic	O
meta	O
##bol	O
##ite	O
and	O
gene	O
expression	O
profiles	O
of	O
sub	O
##cut	O
##aneous	O
ad	O
##ip	O
##ose	O
tissue	O
and	O
skeletal	O
muscle	O
in	O
(	O
fast	O
##ing	O
)	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
women	O
but	O
differing	O
in	O
insulin	O
resistance	O
.	O

Cell	O
cycle	O
transition	O
and	O
proliferation	O
were	O
measured	O
in	O
T	O
##RT	O
-	O
H	O
##U	O
##1	O
cells	O
treated	O
with	O
or	O
without	O
10	O
m	O
##M	O
of	O
α	B
-	I
O	I
##G	I
.	O

The	O
R	O
##OC	O
curves	O
for	O
m	O
##uc	O
##osa	O
##l	O
K	B
##P	I
m	O
##RNA	O
expression	O
are	O
depicted	O
in	O
.	O

Evaluation	O
of	O
the	O
home	O
##ost	O
##atic	O
model	O
assessment	O
for	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
)	O
and	O
for	O
beta	O
cell	O
function	O
(	O
H	O
##OM	O
##A	O
-	O
b	O
)	O
indicated	O
that	O
many	O
subjects	O
showed	O
increased	O
insulin	O
resistance	O
(	O
54	O
%	O
)	O
and	O
altered	O
beta	O
cell	O
function	O
(	O
53	O
%	O
)	O
following	O
s	B
##tat	I
##in	I
treatment	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
all	O
examined	O
meta	O
##bol	O
##ites	O
showed	O
significant	O
changes	O
in	O
response	O
to	O
an	O
oral	O
glucose	S
challenge	O
(	O
time	O
effect	O
,	O
P	O
=	O
0	O
.	O
000	O
##1	O
;	O
;	O
)	O
.	O

There	O
is	O
limited	O
evidence	O
of	O
the	O
effect	O
of	O
FA	S
supplement	O
##ation	O
on	O
IF	O
##N	O
##γ	O
in	O
humans	O
.	O

In	O
particular	O
,	O
a	O
comparison	O
of	O
the	O
post	O
##pra	O
##ndi	O
##al	O
kinetic	O
##s	O
of	O
la	B
##ct	I
##ose	I
after	O
milk	O
intake	O
(	O
peak	O
value	O
at	O
2	O
h	O
)	O
,	O
3	B
-	I
p	I
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
after	O
cheese	O
intake	O
(	O
peak	O
value	O
at	O
2	O
h	O
)	O
,	O
and	O
pin	B
##ito	I
##l	I
after	O
so	O
##y	O
intake	O
(	O
peak	O
value	O
at	O
4	O
h	O
)	O
,	O
under	O
cross	O
-	O
over	O
study	O
conditions	O
,	O
provides	O
interesting	O
insights	O
into	O
the	O
in	O
##test	O
##inal	O
processing	O
of	O
these	O
molecules	O
.	O

Information	O
about	O
the	O
particle	O
shape	O
can	O
also	O
be	O
estimated	O
from	O
A	B
##F	I
##4	I
-	I
MA	I
##LS	I
-	I
DL	I
##S	I
using	O
the	O
ratio	O
of	O
r	O
_	O
r	O
##ms	O
/	O
r	O
_	O
h	O
.	O

O	O
##bject	O
##ive	O
:	O
Pol	B
##yam	I
##ines	I
are	O
naturally	O
occurring	O
cat	O
##ion	O
##ic	O
molecules	O
present	O
in	O
all	O
living	O
cells	O
.	O

El	O
##eva	O
##ted	O
he	B
##x	I
##ose	I
levels	O
could	O
not	O
be	O
explained	O
by	O
increased	O
glucose	S
levels	O
,	O
as	O
neither	O
glucose	S
nor	O
H	O
##b	O
##A	O
##1	O
##c	O
were	O
significantly	O
elevated	O
after	O
6	O
months	O
in	O
ch	O
##em	O
##otherapy	O
recipients	O
.	O

Both	O
rat	O
and	O
human	O
studies	O
show	O
that	O
the	O
kidney	O
is	O
the	O
main	O
site	O
of	O
se	B
##rine	I
production	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
mixed	O
with	O
500	O
μ	O
##l	O
of	O
pure	O
water	O
and	O
250	O
μ	O
##l	O
of	O
ch	B
##lor	I
##of	I
##orm	I
,	O
and	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
4	O
,	O
000	O
rpm	O
for	O
15	O
minutes	O
.	O

Gene	O
set	O
analysis	O
for	O
chemical	O
class	O
of	O
meta	O
##bol	O
##ites	O
for	O
serum	O
re	B
##tino	I
##l	I
Gene	O
set	O
analysis	O
for	O
chemical	O
sub	O
-	O
class	O
of	O
meta	O
##bol	O
##ites	O
for	O
serum	O
re	B
##tino	I
##l	I
at	O
8	O
.	O
5	O
×	O
10	O
_	O
−	O
##4	O
level	O
of	O
statistical	O
significance	O
.	O

Pass	O
##ing	O
-	O
Ba	O
##b	O
##lo	O
##k	O
re	O
##gression	O
of	O
plasma	O
concentrations	O
by	O
CE	O
-	O
MS	O
on	O
serum	O
concentrations	O
by	O
standard	O
clinical	O
chemistry	O
ass	O
##ays	O
was	O
conducted	O
for	O
c	B
##rea	I
##tin	I
##ine	I
and	O
u	B
##ric	I
acid	I
.	O

However	O
,	O
this	O
predominant	O
ion	O
was	O
not	O
observed	O
in	O
4	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
and	O
2	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
,	O
where	O
the	O
major	O
product	O
ions	O
arose	O
from	O
the	O
loss	O
of	O
the	O
E	O
##2	O
m	O
##oi	O
##ety	O
from	O
both	O
of	O
the	O
derivatives	O
(	O
m	O
/	O
z	O
158	O
.	O
2	O
;	O
fragment	O
b	O
,	O
)	O
.	O

Likewise	O
,	O
total	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##er	I
concentrations	O
,	O
as	O
opposed	O
to	O
individual	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
,	O
also	O
showed	O
generally	O
good	O
agreement	O
with	O
ch	B
##ole	I
##ster	I
##ol	I
measurements	O
reported	O
in	O
the	O
literature	O
.	O

The	O
s	O
##pect	O
##ra	O
of	O
co	O
##lon	O
##ic	O
tissues	O
contained	O
visible	O
resonance	O
##s	O
from	O
lip	O
##ids	O
,	O
organic	O
acids	O
,	O
amino	O
acids	O
and	O
meta	O
##bol	O
##ites	O
from	O
ch	B
##olin	I
##e	I
and	O
n	O
##uc	O
##leo	O
##side	O
##s	O
.	O

The	O
predominant	O
L	O
##GP	O
##L	O
in	O
our	O
results	O
was	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
.	O

The	O
highest	O
Pearson	O
correlation	O
coefficients	O
were	O
observed	O
between	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
(	O
r	O
=	O
0	O
.	O
87	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
and	O
le	B
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
(	O
r	O
=	O
0	O
.	O
90	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

The	O
following	O
meta	O
##bol	O
##ite	O
pairs	O
have	O
significant	O
S	O
##pear	O
##man	O
’	O
s	O
rank	O
correlation	O
ρ	O
>	O
0	O
.	O
5	O
:	O
T	O
##hr	O
+	O
Lac	O
and	O
al	B
##ani	I
##ne	I
(	O
ρ	O
=	O
0	O
.	O
78	O
)	O
,	O
dim	B
##eth	I
##yla	I
##mine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
(	O
ρ	O
=	O
0	O
.	O
76	O
)	O
,	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
(	O
ρ	O
=	O
0	O
.	O
73	O
)	O
,	O
ace	B
##tate	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
(	O
ρ	O
=	O
0	O
.	O
62	O
)	O
,	O
Unknown	O
1	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
(	O
ρ	O
=	O
0	O
.	O
54	O
)	O
,	O
and	O
ace	B
##tate	I
and	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
(	O
ρ	O
=	O
0	O
.	O
53	O
)	O
.	O

Co	O
##mp	O
##aris	O
##ons	O
of	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
between	O
me	O
##dicated	O
and	O
drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
showed	O
a	O
trend	O
towards	O
lower	O
levels	O
of	O
K	O
##A	O
and	O
H	O
##AA	O
in	O
non	O
-	O
me	O
##dicated	O
patients	O
in	O
preliminary	O
analyses	O
.	O

We	O
identified	O
three	O
metabolic	O
pathway	O
ratios	O
that	O
were	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
even	O
after	O
adjustment	O
for	O
circulating	O
levels	O
of	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
:	O
the	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
parent	O
est	O
##rogen	O
##s	O
,	O
the	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
the	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
,	O
and	O
the	O
ratio	O
of	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
to	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
.	O

Lower	O
protein	O
intake	O
in	O
Pakistan	O
may	O
account	O
for	O
the	O
lower	O
th	B
##re	I
##oni	I
##ne	I
concentration	O
,	O
based	O
on	O
data	O
that	O
th	B
##re	I
##oni	I
##ne	I
decreased	O
in	O
pregnant	O
rats	O
fed	O
a	O
protein	O
-	O
restricted	O
diet	O
.	O

All	O
three	O
BC	O
##AA	O
##s	O
were	O
significantly	O
increased	O
in	O
the	O
T	O
##2	O
##DM	O
group	O
after	O
B	O
##MI	O
adjustment	O
,	O
and	O
there	O
was	O
a	O
tendency	O
to	O
increase	O
for	O
all	O
BC	O
##AA	O
##s	O
in	O
the	O
I	O
##G	O
##T	O
group	O
,	O
but	O
only	O
the	O
increase	O
in	O
le	B
##uc	I
##ine	I
was	O
significant	O
.	O

Also	O
,	O
it	O
is	O
speculated	O
that	O
deteriorated	O
liver	O
function	O
could	O
cause	O
reduced	O
energy	O
production	O
through	O
decreased	O
amino	O
acid	O
synthesis	O
and	O
car	B
##ni	I
##tine	I
deficiency	O
.	O

To	O
each	O
dried	O
sample	O
,	O
100	O
µ	O
##L	O
ace	B
##tone	I
,	O
100	O
µ	O
##L	O
sodium	O
bi	O
##car	O
##bon	O
##ate	O
(	O
100	O
m	O
##M	O
,	O
pH	O
9	O
)	O
,	O
and	O
10	O
µ	O
##L	O
of	O
p	B
##yr	I
##id	I
##ine	I
-	I
3	I
-	I
su	I
##lf	I
##ony	I
##l	I
chloride	I
(	O
10	O
mg	O
/	O
m	O
##L	O
in	O
ace	O
##tone	O
)	O
were	O
added	O
and	O
v	O
##ortex	O
mixed	O
for	O
5	O
se	O
##c	O
.	O

[	O
]	O
,	O
who	O
observed	O
an	O
increase	O
in	O
all	B
##ant	I
##oi	I
##n	I
serum	O
level	O
after	O
o	O
##ste	O
##op	O
##oro	O
##sis	O
prop	O
##hyl	O
##ax	O
##is	O
.	O

Sam	O
##ple	O
preparation	O
and	O
the	O
extraction	O
method	O
(	O
liquid	O
-	O
liquid	O
extraction	O
using	O
et	B
##hyl	I
ace	I
##tate	I
)	O
were	O
simple	O
and	O
efficient	O
.	O

The	O
peaks	O
from	O
5	O
.	O
5	O
to	O
9	O
pp	O
##m	O
were	O
few	O
,	O
including	O
u	B
##rac	I
##il	I
,	O
f	B
##uma	I
##rate	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
several	O
unknown	O
signals	O
.	O

The	O
model	O
components	O
were	O
:	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##26	I
:	I
0	I
;	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##26	I
:	I
1	I
;	O
PC	B
a	I
##a	I
C	I
##42	I
:	I
4	I
;	O
PC	B
a	I
##a	I
C	I
##34	I
:	I
4	I
.	O

An	O
especially	O
remarkable	O
up	O
##re	O
##gu	O
##lation	O
of	O
DC	O
##As	O
was	O
seen	O
in	O
the	O
comparison	O
of	O
c	O
##ir	O
##r	O
##hos	O
##is	O
controls	O
vs	O
.	O
NH	O
##C	O
,	O
where	O
non	O
-	O
an	O
##ed	O
##io	O
##ate	O
(	O
a	O
##zel	O
##ate	O
)	O
,	O
und	B
##eca	I
##ned	I
##io	I
##ate	I
and	O
de	B
##cane	I
##dio	I
##ate	I
(	O
se	O
##ba	O
##cate	O
)	O
showed	O
a	O
strongly	O
significant	O
respective	O
over	O
##ex	O
##press	O
##ion	O
of	O
54	O
-	O
,	O
36	O
-	O
and	O
26	O
-	O
fold	O
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
vs	O
.	O
NH	O
##C	O
.	O

The	O
la	B
##ct	I
##ate	I
concentrations	O
were	O
5	O
.	O
4	O
(	O
2	O
.	O
4	O
–	O
11	O
.	O
0	O
)	O

G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
not	O
only	O
constitute	O
the	O
backbone	O
of	O
neural	O
membrane	O
##s	O
,	O
but	O
also	O
provide	O
the	O
membrane	O
with	O
fluid	O
##ity	O
and	O
ion	O
per	O
##me	O
##ability	O
.	O

Ph	O
##arma	O
##co	O
##kin	O
##etic	O
data	O
of	O
f	O
##ent	O
##any	O
##l	O
as	O
well	O
as	O
mid	B
##az	I
##ola	I
##m	I
are	O
presented	O
in	O
Table	O
.	O

The	O
reverse	O
was	O
true	O
for	O
the	O
pu	B
##rine	I
bases	O
.	O

Furthermore	O
,	O
in	O
o	O
##bes	O
##e	O
adolescent	O
##s	O
,	O
D	O
##I	O
was	O
shown	O
to	O
predict	O
2	O
-	O
h	O
glucose	S
after	O
2	O
y	O
##r	O
and	O
the	O
development	O
of	O
d	O
##ys	O
##gly	O
##ce	O
##mia	O
.	O

In	O
particular	O
,	O
there	O
was	O
statistical	O
##ly	O
significant	O
increased	O
un	O
##ad	O
##ju	O
##sted	O
risk	O
for	O
all	O
-	O
cause	O
mortality	O
at	O
3	O
years	O
across	O
increasing	O
q	O
##ua	O
##rt	O
##iles	O
of	O
SD	O
##MA	O
[	O
H	O
##R	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
5	O
.	O
3	O
(	O
2	O
.	O
5	O
-	O
11	O
.	O
3	O
)	O
]	O
and	O
AD	B
##MA	I
[	O
H	O
##R	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
5	O
.	O
3	O
(	O
2	O
.	O
3	O
-	O
11	O
.	O
8	O
)	O
]	O
)	O
.	O

Assessment	O
of	O
participants	O
’	O
diabetes	O
status	O
was	O
dependent	O
on	O
diabetes	O
diagnosis	O
detected	O
by	O
a	O
nationwide	O
governmental	O
database	O
covering	O
public	O
health	O
care	O
systems	O
or	O
participants	O
’	O
self	O
-	O
reported	O
physician	O
diagnosis	O
based	O
on	O
1	O
or	O
more	O
of	O
the	O
following	O
criteria	O
:	O
fast	O
##ing	O
plasma	O
glucose	S
(	O
≥	O
7	O
.	O
0	O
mm	O
##ol	O
/	O
L	O
)	O
or	O
H	O
##b	O
##A	O
##1	O
##c	O
(	O
≥	O
48	O
mm	O
##ol	O
/	O
m	O
##ol	O
)	O
or	O
concentrations	O
above	O
the	O
American	O
Di	O
##abe	O
##tes	O
Association	O
cut	O
##offs	O
for	O
clinical	O
diabetes	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
associated	O
with	O
I	O
##G	O
##T	O
that	O
were	O
identified	O
from	O
the	O
samples	O
analyzed	O
based	O
on	O
high	O
AU	O
##C	O
values	O
included	O
fatty	O
acids	O
,	O
amid	B
##es	I
of	O
fatty	O
acids	O
,	O
and	O
five	O
other	O
meta	O
##bol	O
##ites	O
:	O
but	B
##ane	I
##dio	I
##l	I
,	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##co	I
##lic	I
acid	I
,	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
the	O
increased	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
meta	O
##bol	O
##ite	O
(	O
Table	O
S	O
##2	O
in	O
)	O
was	O
related	O
to	O
higher	O
recent	O
fat	O
or	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
intake	O
and	O
the	O
increased	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ite	O
from	O
increased	O
intake	O
of	O
ch	O
##olin	O
##e	O
-	O
rich	O
foods	O
such	O
as	O
eggs	O
and	O
meat	O
##s	O
(	O
not	O
shown	O
)	O
.	O

U	O
##rina	O
##ry	O
levels	O
of	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##Ps	O
and	O
its	O
major	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
(	B
2	B
,	I
3	I
-	I
din	I
##or	I
-	I
5	I
,	I
6	I
-	I
di	I
##hy	I
##dr	I
##o	I
-	I
15	I
-	I
F	I
_	I
2	I
##t	I
-	I
Is	I
##o	I
##P	I
,	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##P	O
-	O
M	O
)	O
were	O
measured	O
post	O
-	O
cancer	O
treatment	O
using	O
gas	O
ch	O
##roma	O
##tography	O
/	O
negative	O
ion	O
chemical	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
for	O
57	O
deceased	O
breast	O
cancer	O
patients	O
(	O
cases	O
)	O
and	O
103	O
surviving	O
patients	O
(	O
controls	O
)	O
matched	O
1	O
:	O
2	O
on	O
age	O
at	O
diagnosis	O
,	O
stage	O
,	O
and	O
diagnosis	O
year	O
.	O

G	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
are	O
inter	O
-	O
converted	O
between	O
neurons	O
and	O
as	O
##tro	O
##cy	O
##tes	O
,	O
which	O
is	O
necessary	O
for	O
g	B
##lut	I
##amine	I
home	O
##ost	O
##asis	O
.	O

Subsequently	O
,	O
200	O
μ	O
##L	O
of	O
a	O
met	B
##ho	I
##xy	I
##amine	I
p	I
##yr	I
##id	I
##ine	I
solution	O
(	O
15	O
g	O
/	O
L	O
)	O
was	O
added	O
into	O
the	O
am	O
##po	O
##ule	O
bottle	O
.	O

Cal	O
##ib	O
##ration	O
was	O
performed	O
for	O
the	O
entire	O
mass	O
range	O
with	O
cluster	O
ions	O
produced	O
from	O
a	O
solution	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
.	O

Thus	O
,	O
the	O
m	O
##or	O
##ph	O
##ometric	O
measurement	O
of	O
in	O
##or	O
##gan	O
##ic	O
phosphate	S
can	O
be	O
used	O
to	O
estimate	O
the	O
size	O
of	O
the	O
specimens	O
.	O

The	O
major	O
advantage	O
of	O
this	O
strategy	O
is	O
that	O
two	O
individual	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
-	O
are	O
generated	O
;	O
thus	O
,	O
the	O
B	O
##Q	O
##B	O
and	O
B	O
##Q	O
##B	O
-	O
d	O
_	O
7	O
labeled	O
th	B
##iol	I
##s	I
can	O
be	O
clearly	O
distinguished	O
.	O

In	O
addition	O
to	O
being	O
produced	O
in	O
the	O
u	B
##rea	I
cycle	O
from	O
or	B
##ni	I
##thin	I
##e	I
and	O
car	B
##ba	I
##mo	I
##yl	I
phosphate	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
is	O
derived	O
from	O
a	B
##rg	I
##ini	I
##ne	I
as	O
a	O
by	O
-	O
product	O
of	O
NO	O
synthesis	O
via	O
NO	O
s	O
##ynth	O
##ase	O
.	O

show	O
the	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
in	O
human	O
plasma	O
with	O
internal	O
standards	O
.	O

β	B
-	I
ion	I
##yl	I
##iden	I
##ea	I
##ce	I
##tic	I
acid	O
)	O
had	O
no	O
effect	O
on	O
AT	O
##RA	O
-	O
induced	O
gene	O
expression	O
in	O
He	O
##p	O
##G	O
##2	O
cells	O
.	O

The	O
elevation	O
of	O
plasma	O
none	O
##ster	O
##ified	O
FA	S
levels	O
has	O
been	O
reported	O
to	O
produce	O
important	O
my	O
##oc	O
##ard	O
##ial	O
damage	O
,	O
a	O
##rr	O
##hy	O
##th	O
##mia	O
##s	O
,	O
and	O
reduction	O
in	O
heart	O
rate	O
var	O
##iability	O
in	O
se	O
##ptic	O
patients	O
.	O

R	O
##OC	O
of	O
(	O
B	O
)	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
(	O
C	O
)	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
(	O
D	O
)	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
and	O
(	O
E	O
)	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

;	O
consistent	O
with	O
published	O
N	O
##MR	O
data	O
from	O
long	O
-	O
term	O
stability	O
studies	O
)	O
whereas	O
the	O
levels	O
of	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
and	O
trim	B
##eth	I
##yla	I
##mine	I
were	O
not	O
altered	O
(	O
the	O
time	O
courses	O
of	O
meta	O
##bol	O
##ites	O
monitored	O
by	O
N	O
##MR	O
are	O
provided	O
as	O
supplement	O
##ary	O
material	O
1	O
)	O
.	O

The	O
samples	O
were	O
then	O
dried	O
again	O
,	O
and	O
extracted	O
by	O
the	O
addition	O
of	O
300	O
µ	O
##L	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
and	O
shaking	O
at	O
450	O
rpm	O
for	O
30	O
min	O
.	O

Form	B
##ic	I
acid	I
and	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
were	O
purchased	O
from	O
Sino	O
##pha	O
##rm	O
Chemical	O
Re	O
##age	O
##nt	O
Co	O
.	O
,	O
Ltd	O
.	O

Even	O
the	O
small	O
proportion	O
of	O
total	O
in	O
##tra	O
##cellular	O
rib	B
##avi	I
##rin	I
suggested	O
to	O
be	O
in	O
the	O
mon	B
##op	I
##hos	I
##phate	I
form	O
based	O
on	O
our	O
in	O
v	O
##it	O
##ro	O
primary	O
he	O
##pa	O
##to	O
##cy	O
##te	O
metabolism	O
studies	O
would	O
greatly	O
exceed	O
the	O
reported	O
of	O
250	O
n	O
##M	O
for	O
I	O
##MP	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

The	O
concentration	O
of	O
c	B
##rea	I
##tin	I
##ine	I
is	O
age	O
-	O
and	O
sex	O
dependent	O
,	O
decreasing	O
with	O
age	O
and	O
varying	O
throughout	O
the	O
day	O
.	O

The	O
individual	O
fl	O
##avan	O
-	O
3	O
-	O
o	O
##ls	O
contained	O
in	O
the	O
green	O
tea	B
p	I
##oly	I
##phe	I
##no	I
##l	I
SP	O
##I	O
complex	O
were	O
q	O
##uant	O
##ified	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
(	O
L	O
##T	O
##Q	O
V	O
##elo	O
##s	O
,	O
The	O
##rm	O
##o	O
Scientific	O
)	O
.	O

Det	O
##ails	O
about	O
the	O
CA	O
##TH	O
##GE	O
##N	O
bio	O
##re	O
##pository	O
have	O
been	O
previously	O
published	O
.	O
17	O
,	O
18	O
After	O
obtaining	O
written	O
informed	O
consent	O
,	O
peripheral	O
blood	O
samples	O
were	O
collected	O
from	O
each	O
patient	O
in	O
E	O
##D	O
##TA	O
tubes	O
by	O
f	O
##em	O
##oral	O
artery	O
sheath	O
before	O
he	B
##par	I
##in	I
administration	O
.	O

Then	O
the	O
U	O
-	O
_	O
13	O
C	B
-	I
palm	I
##itate	I
solution	O
was	O
di	O
##lut	O
##ed	O
in	O
serum	O
-	O
containing	O
R	O
##PM	O
##I	O
1640	O
medium	O
to	O
a	O
working	O
concentration	O
of	O
50	O
μ	O
##M	O
.	O
When	O
tracing	O
palm	B
##itate	I
carbon	O
##s	O
,	O
the	O
cells	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
the	O
medium	O
indicated	O
above	O
.	O

Like	O
H	O
##NE	O
and	O
ONE	O
,	O
F	B
_	I
2	I
##α	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
are	O
formed	O
from	O
lip	O
##id	O
h	B
##ydro	I
##per	I
##oxide	I
##s	I
via	O
radical	O
-	O
mediated	O
pathways	O
.	O

Important	O
##ly	O
,	O
the	O
measured	O
ch	O
##em	O
##otype	O
##s	O
include	O
accurate	O
C	O
-	O
3	O
e	O
##pi	O
##mer	O
contributions	O
for	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
and	O
are	O
not	O
s	O
##ke	O
##wed	O
by	O
inter	O
-	O
e	O
##pi	O
##mer	O
response	O
variations	O
as	O
reported	O
before	O
.	O

Zhao	O
et	O
al	O
.	O
reported	O
that	O
L	B
-	I
pro	I
##line	I
was	O
one	O
of	O
the	O
amino	O
acid	O
which	O
its	O
plasma	O
concentration	O
was	O
found	O
to	O
be	O
decreased	O
in	O
L	O
##CP	O
##s	O
,	O
compared	O
with	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

_	O
,	O
Pereira	O
et	O
al	O
.	O
showed	O
a	O
linear	O
relationship	O
between	O
H	O
##b	O
-	O
add	O
##uc	O
##ts	O
and	O
DNA	O
-	O
add	O
##uc	O
##ts	O
for	O
2	B
-	I
ace	I
##ty	I
##lam	I
##ino	I
##f	I
##lu	I
##ore	I
##ne	I
in	O
mice	O
and	O
rats	O
.	O

End	O
##ogen	O
##ous	O
ad	B
##eno	I
##sin	I
##e	I
n	O
##uc	O
##leo	O
##tide	O
concentrations	O
in	O
human	O
liver	O
sections	O
.	O

For	O
example	O
,	O
10	O
pivotal	O
meta	O
##bol	O
##ites	O
in	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
(	O
see	O
)	O
are	O
represented	O
within	O
the	O
standards	O
,	O
and	O
out	O
of	O
20	O
total	O
,	O
8	O
of	O
these	O
molecules	O
exhibited	O
a	O
me	O
##as	O
##urable	O
CC	O
##S	O
(	O
green	O
)	O
,	O
while	O
only	O
2	O
(	O
orange	O
)	O
were	O
o	O
##bs	O
##er	O
##vable	O
in	O
the	O
mass	O
spectrum	O
,	O
but	O
did	O
not	O
result	O
in	O
a	O
collected	O
CC	O
##S	O
,	O
due	O
to	O
low	O
ion	O
intensity	O
.	O

These	O
results	O
were	O
highly	O
correlated	O
with	O
the	O
abundance	O
of	O
la	B
##ct	I
##ob	I
##ac	I
##ill	I
##i	I
and	O
C	O
##los	O
##tri	O
##dium	O
,	O
which	O
indicates	O
an	O
altered	O
metabolism	O
rate	O
associated	O
with	O
these	O
gut	O
micro	O
-	O
organisms	O
.	O

In	O
addition	O
,	O
strong	O
signals	O
arising	O
from	O
the	O
E	O
##D	O
##TA	O
anti	O
##coa	O
##gu	O
##lant	O
obscured	O
most	O
of	O
the	O
c	B
##it	I
##rate	I
resonance	O
##s	O
in	O
the	O
s	O
##pect	O
##ra	O
,	O
but	O
provided	O
information	O
on	O
the	O
metal	O
ion	O
levels	O
in	O
plasma	O
,	O
which	O
allowed	O
C	O
##a	O
_	O
2	O
+	O
-	O
E	O
##D	O
##TA	O
and	O
M	O
##g	O
_	O
2	O
+	O
-	O
E	O
##D	O
##TA	O
complex	O
resonance	O
##s	O
to	O
be	O
included	O
in	O
the	O
analysis	O
.	O

In	O
the	O
HC	O
##T	O
##11	O
##6	O
cells	O
,	O
the	O
conditions	O
were	O
equivalent	O
in	O
terms	O
of	O
number	O
of	O
meta	O
##bol	O
##ites	O
detected	O
,	O
as	O
seen	O
in	O
Figure	O
S	O
##2	O
,	O
except	O
for	O
the	O
detection	O
of	O
f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
,	O
when	O
80	O
%	O
Me	B
##OH	I
was	O
used	O
with	O
10	O
%	O
culture	O
conditions	O
,	O
as	O
seen	O
in	O
Table	O
S	O
##1	O
,	O
comparing	O
50	O
_	O
H	O
##IG	O
##H	O
and	O
80	O
_	O
H	O
##IG	O
##H	O
.	O

In	O
pro	O
##state	O
tissues	O
,	O
however	O
,	O
most	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
were	O
not	O
detected	O
,	O
probably	O
owing	O
to	O
inevitable	O
over	O
-	O
di	O
##lution	O
of	O
the	O
samples	O
for	O
reducing	O
p	B
##oly	I
##amine	I
concentrations	O
,	O
which	O
otherwise	O
adverse	O
##ly	O
interfere	O
with	O
CE	O
-	O
TO	O
##FM	O
##S	O
analysis	O
.	O

The	O
earlier	O
el	O
##uti	O
##ng	O
peak	O
had	O
a	O
mass	O
and	O
gave	O
MS	O
_	O
2	O
and	O
MS	O
_	O
3	O
s	O
##pect	O
##ra	O
compatible	O
with	O
a	O
t	B
##ri	I
##hy	I
##dr	I
##ox	I
##ych	I
##ola	I
##no	I
##ic	I
acid	I
(	O
BA	O
-	O
trio	O
##l	O
)	O
possibly	O
with	O
a	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
##α	I
-	I
hydrogen	I
functionality	O
(	O
i	O
.	O
e	O
.	O
3	B
##β	I
,	I
x	I
,	I
y	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
##α	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
,	O
5	B
##α	I
-	I
BA	I
-	I
3	I
##β	I
,	I
x	I
,	O
y	O
-	O
trio	O
##l	O
)	O
.	O

The	O
meta	O
##bol	O
##ite	O
–	O
meta	O
##bol	O
##ite	O
interaction	O
analysis	O
showed	O
that	O
there	O
were	O
eight	O
differential	O
meta	O
##bol	O
##ites	O
closely	O
related	O
with	O
gal	B
##act	I
##ose	I
metabolism	O
.	O

The	O
CH	O
##B	O
without	O
N	O
##AF	O
##LD	O
group	O
had	O
lower	O
B	O
##MI	O
and	O
T	O
##C	O
and	O
higher	O
levels	O
of	O
AL	O
##T	O
,	O
AS	O
##T	O
,	O
and	O
γ	B
-	I
GT	I
than	O
the	O
control	O
group	O
,	O
whereas	O
B	O
##MI	O
,	O
AL	O
##T	O
,	O
and	O
AS	O
##T	O
were	O
significantly	O
increased	O
in	O
the	O
CH	O
##B	O
with	O
N	O
##AF	O
##LD	O
group	O
.	O

From	O
the	O
originally	O
identified	O
meta	O
##bol	O
##ites	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
v	B
##ali	I
##ne	I
were	O
significantly	O
lower	O
in	O
the	O
H	O
##W	O
##L	O
group	O
compared	O
to	O
the	O
L	O
##W	O
##L	O
group	O
(	O
see	O
and	O
Fi	O
##gs	O
)	O
.	O

For	O
pro	O
##fi	O
##ling	O
experiments	O
,	O
the	O
MS	O
was	O
run	O
in	O
high	O
resolution	O
mode	O
,	O
corresponding	O
to	O
a	O
resolution	O
of	O
60	O
##k	O
and	O
a	O
2	O
Hz	O
scan	O
speed	O
with	O
the	O
spray	O
voltage	O
set	O
to	O
3	O
.	O
5	O
k	B
##V	I
.	O

The	O
dried	O
compounds	O
were	O
prepared	O
for	O
gas	O
ch	O
##roma	O
##tography	O
by	O
adding	O
50	O
μ	O
##L	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
BS	O
##TF	O
##A	O
)	O
and	O
in	O
##cu	O
##bat	O
##ing	O
this	O
mixture	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

Kaplan	O
-	O
Mei	O
##er	O
survival	O
analysis	O
for	O
patients	O
with	O
major	O
adverse	O
cardiac	O
events	O
at	O
3	O
-	O
year	O
follow	O
up	O
according	O
to	O
the	O
q	O
##ua	O
##rt	O
##iles	O
of	O
a	B
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
q	O
##ua	O
##rt	O
##iles	O
(	O
AD	O
##MA	O
,	O
SD	O
##MA	O
,	O
MMA	O
and	O
a	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
index	O
)	O
.	O

Together	O
,	O
the	O
C	O
##YP	O
##39	O
##A	O
##1	O
all	O
##ele	O
##s	O
explained	O
[UNK]	O
.	O
8	O
%	O
of	O
the	O
inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
observed	O
for	O
serum	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
.	O

Under	O
this	O
condition	O
,	O
an	O
augmented	O
fatty	O
acid	O
ß	O
-	O
oxidation	O
gives	O
rise	O
to	O
the	O
increased	O
levels	O
of	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
,	O
including	O
c	B
##it	I
##rate	I
.	O

Ace	B
##tate	I
was	O
found	O
in	O
both	O
samples	O
but	O
at	O
a	O
higher	O
concentration	O
in	O
those	O
dried	O
by	O
speed	O
-	O
vacuum	O
(	O
G	O
)	O
.	O

For	O
O	O
##X	O
##Y	O
and	O
O	B
##X	I
##Y	I
-	I
D	I
_	I
6	I
,	O
the	O
second	O
most	O
abundant	O
transitions	O
(	O
316	O
.	O
1	O
##→	O
##24	O
##1	O
.	O
0	O
and	O
322	O
.	O
3	O
##→	O
##26	O
##2	O
.	O
1	O
)	O
were	O
chosen	O
for	O
q	O
##uant	O
##ification	O
because	O
the	O
most	O
abundant	O
transitions	O
(	O
316	O
.	O
1	O
##→	O
##29	O
##8	O
.	O
1	O
and	O
322	O
.	O
3	O
##→	O
##30	O
##4	O
.	O
2	O
)	O
correspond	O
to	O
a	O
non	O
##sp	O
##ec	O
##ific	O
loss	O
of	O
water	O
.	O

We	O
have	O
previously	O
described	O
the	O
characterization	O
of	O
Ce	O
##rs	O
,	O
pre	O
##no	O
##ls	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
rat	O
liver	O
mit	O
##och	O
##ond	O
##ria	O
_	O
,	O
and	O
T	O
##G	O
##s	O
in	O
rat	O
serum	O
and	O
those	O
examples	O
directly	O
describe	O
the	O
methods	O
used	O
in	O
this	O
application	O
.	O

The	O
concentrations	O
of	O
anal	O
##yte	O
##s	O
in	O
the	O
recovery	O
test	O
were	O
set	O
at	O
0	O
.	O
6	O
ng	O
/	O
m	O
##L	O
for	O
ni	O
##ten	O
##py	O
##ram	O
,	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
,	O
ace	B
##tam	I
##ip	I
##rid	I
and	O
th	B
##iac	I
##lop	I
##rid	I
,	O
at	O
1	O
.	O
2	O
ng	O
/	O
m	O
##L	O
for	O
cloth	B
##ian	I
##id	I
##in	I
,	O
and	O
at	O
3	O
.	O
0	O
ng	O
/	O
m	O
##L	O
for	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
and	O
D	O
##MA	O
##P	O
.	O

Thus	O
,	O
although	O
there	O
seems	O
to	O
be	O
an	O
association	O
between	O
higher	O
age	O
,	O
lower	O
try	B
##pt	I
##op	I
##han	I
and	O
increased	O
K	O
##TR	O
,	O
low	O
level	O
of	O
try	B
##pt	I
##op	I
##han	I
in	O
the	O
AD	O
##HD	O
group	O
cannot	O
be	O
fully	O
explained	O
by	O
higher	O
ID	O
##O	O
or	O
TD	O
##O	O
activity	O
.	O

Pre	O
-	O
treatment	O
and	O
serial	O
on	O
-	O
treatment	O
se	O
##ra	O
were	O
available	O
for	O
121	O
patients	O
participating	O
in	O
the	O
French	O
clinical	O
trial	O
TO	O
##RA	O
##VA	O
,	O
in	O
which	O
171	O
random	O
##ised	O
patients	O
with	O
m	O
##RC	O
##C	O
received	O
a	O
be	O
##va	O
##ci	O
##zu	O
##ma	O
##b	O
and	O
te	O
##ms	O
##iro	O
##lim	O
##us	O
combination	O
(	O
experimental	O
arm	O
A	O
)	O
or	O
a	O
standard	O
treatment	O
:	O
either	O
sun	B
##iti	I
##ni	I
##b	I
(	O
B	O
)	O
or	O
inter	O
##fer	O
##on	O
-	O
α	O
+	O
be	O
##va	O
##ci	O
##zu	O
##ma	O
##b	O
(	O
C	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AU	O
##C	O
=	O
area	O
under	O
the	O
curve	O
;	O
L	B
##ys	I
##o	I
##PC	I
=	I
l	I
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
MR	O
##S	O
,	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
;	O
MS	O
,	O
mass	O
s	O
##pect	O
##rome	O
##try	O
;	O
PC	B
=	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
R	O
##OC	O
=	O
receiver	O
operating	O
characteristics	O
.	O

Especially	O
but	B
##yra	I
##te	I
is	O
a	O
preferred	O
energy	O
source	O
for	O
the	O
co	O
##lon	O
##ocytes	O
(	O
Chapman	O
et	O
al	O
.	O
)	O
and	O
exhibits	O
,	O
along	O
with	O
prop	B
##ion	I
##ate	I
,	O
a	O
well	O
documented	O
anti	O
-	O
inflammatory	O
capacity	O
through	O
an	O
inhibitor	O
##y	O
effect	O
on	O
T	O
##NF	O
-	O
α	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
(	O
N	O
##F	O
)	O
-	O
κ	O
##B	O
pathway	O
(	O
Ted	O
##elin	O
##d	O
et	O
al	O
.	O

P	O
##las	O
##ma	O
p	B
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
(	O
P	O
##LA	O
)	O
was	O
decreased	O
in	O
females	O
(	O
,	O
Females	O
)	O
.	O

Following	O
MS	O
/	O
MS	O
valid	O
##ation	O
,	O
the	O
identities	O
of	O
4	O
of	O
these	O
peaks	O
were	O
determined	O
very	O
likely	O
to	O
be	O
:	O
5	B
##a	I
-	I
D	I
##HT	I
;	O
c	B
##rea	I
##tin	I
##ine	I
;	O
either	O
e	B
##pit	I
##est	I
##osterone	I
su	I
##lf	I
##ate	I
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
,	O
or	O
test	B
##osterone	I
su	I
##lf	I
##ate	I
;	O
and	O
c	B
##rea	I
##tine	I
,	O
corresponding	O
to	O
add	O
##uc	O
##ts	O
with	O
median	O
m	O
/	O
z	O
values	O
of	O
36	O
##9	O
.	O
17	O
,	O
114	O
.	O
07	O
,	O
36	O
##7	O
.	O
16	O
,	O
and	O
132	O
.	O
08	O
in	O
the	O
L	O
##C	O
-	O
MS	O
experiment	O
.	O

P	O
##las	O
##ma	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
levels	O
,	O
a	O
marker	O
of	O
skeletal	O
muscle	O
protein	O
degradation	O
,	O
were	O
similar	O
across	O
all	O
groups	O
.	O

P	O
##las	O
##ma	O
L	O
##CA	O
##T	O
activity	O
(	O
expressed	O
in	O
AU	O
relative	O
to	O
pool	O
plasma	O
)	O
was	O
determined	O
using	O
excess	O
ex	O
##ogen	O
##ous	O
substrate	O
containing	O
[	B
_	I
3	I
H	I
]	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

Although	O
the	O
relationship	O
between	O
p	O
##oly	O
##amine	O
ace	O
##ty	O
##lation	O
and	O
spinal	O
cord	O
injury	O
has	O
not	O
been	O
extensively	O
reported	O
,	O
a	O
recent	O
study	O
demonstrated	O
an	O
enhanced	O
p	B
##oly	I
##amine	I
cat	O
##ab	O
##olis	O
##m	O
,	O
including	O
ace	O
##ty	O
##lation	O
,	O
after	O
traumatic	O
brain	O
injury	O
.	O

The	O
following	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
and	O
D	O
##IN	O
##CH	O
meta	O
##bol	O
##ites	O
and	O
were	O
analyzed	O
:	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##HP	O
)	O
;	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##H	O
##HP	O
)	O
;	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
o	I
##x	I
##oh	I
##ex	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##OH	O
##P	O
)	O
;	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##CP	O
##P	O
)	O
;	O
Mon	B
##oc	I
##ar	I
##b	I
##xy	I
##is	I
##oo	I
##ct	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
MC	O
##OP	O
)	O
;	O
Mon	B
##o	I
-	I
is	I
##ono	I
##ny	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##NP	O
)	O
;	O
Mon	B
##obe	I
##nz	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
MB	O
##z	O
##P	O
)	O
;	O
Mon	O
##o	O
(	O
3	O
-	O
car	O
##box	O
##y	O
##p	O
##rop	O
##yl	O
)	O

Among	O
them	O
,	O
two	O
saturated	O
fatty	O
acids	O
(	B
my	B
##rist	I
##ic	I
and	O
palm	B
##itic	I
acids	O
)	O
were	O
found	O
significantly	O
higher	O
in	O
aggressive	O
C	O
##LL	O
than	O
in	O
controls	O
.	O

The	O
cell	O
l	O
##ys	O
##ates	O
were	O
ho	O
##mo	O
##gen	O
##ized	O
with	O
50	O
µ	O
##L	O
of	O
Mill	O
##ip	O
##ore	O
ultra	O
##pur	O
##e	O
water	O
and	O
extracted	O
with	O
200	O
µ	O
##L	O
of	O
cold	O
met	B
##han	I
##ol	I
.	O

C	O
.	O
29	O
##3	O
cells	O
were	O
trans	O
##fected	O
with	O
control	O
P	O
##X	O
##P	O
##2	O
or	O
various	O
CO	O
##X	O
-	O
2	O
promoter	O
construct	O
##s	O
P	O
##2	O
-	O
1900	O
-	O
l	O
##uc	O
and	O
P	B
##2	I
-	I
43	I
##1	I
-	I
l	I
##uc	I
.	O

Mei	O
##kle	O
and	O
colleagues	O
have	O
reported	O
that	O
T	O
##HC	O
was	O
inverse	O
##ly	O
associated	O
with	O
o	O
##besity	O
,	O
plasma	O
glucose	S
level	O
and	O
decreased	O
with	O
pre	O
##dia	O
##bet	O
##es	O
and	O
T	O
##2	O
##DM	O
.	O

Di	B
##so	I
##dium	I
hydrogen	I
phosphate	I
,	O
potassium	B
di	I
##hy	I
##dr	I
##ogen	I
phosphate	I
,	O
potassium	B
hydrogen	I
phosphate	I
,	O
sodium	B
hydrogen	I
phosphate	I
,	O
and	O
dip	O
##ota	O
##ssi	O
##um	O
hydrogen	B
phosphate	I
were	O
purchased	O
from	O
Mall	O
##in	O
##ck	O
##rod	O
##t	O
Baker	O
(	O
Phillips	O
##burg	O
,	O
NJ	O
)	O
.	O

X	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
levels	O
were	O
measured	O
using	O
a	O
flu	B
##oro	I
##metric	I
method	O
.	O

This	O
is	O
depicted	O
in	O
,	O
where	O
the	O
offset	O
of	O
the	O
left	O
##most	O
peak	O
from	O
the	O
center	O
of	O
the	O
double	O
double	O
##t	O
of	O
as	B
##par	I
##tate	I
is	O
half	O
of	O
the	O
sum	O
of	O
the	O
two	O
J	O
-	O
coupling	O
constant	O
##s	O
.	O

Three	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
23	I
:	I
0	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
14	I
:	I
0	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
2	I
/	I
14	I
:	I
0	I
)	I
were	O
decreased	O
in	O
E	O
##OC	O
re	O
##current	O
patients	O
.	O

T	O
##RP	O
and	O
other	O
K	B
##P	I
meta	O
##bol	O
##ites	O
,	O
including	O
K	O
##A	O
,	O
K	O
##Y	O
##N	O
,	O
Q	O
##UI	O
##N	O
,	O
in	O
plasma	O
were	O
measured	O
by	O
a	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
method	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
significantly	O
decreased	O
u	O
##rina	O
##ry	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
for	O
a	O
##MC	O
##I	O
individuals	O
.	O

Typical	O
L	O
##C	O
/	O
SR	O
##M	O
-	O
MS	O
ch	O
##roma	O
##to	O
##graphic	O
profiles	O
of	O
the	O
six	O
est	O
##rogen	O
-	O
N	O
##MP	O
##S	O
derivatives	O
together	O
with	O
their	O
corresponding	O
six	O
internal	O
standards	O
are	O
shown	O
for	O
the	O
LL	O
##O	O
##Q	O
standard	O
of	O
0	O
.	O
5	O
p	O
##g	O
/	O
m	O
##L	O
for	O
E	O
##2	O
,	O
16	O
α	B
-	I
OH	I
-	I
E	I
##2	I
,	I
4	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
and	O
2	O
-	O
Me	O
##OE	O
##2	O
,	O
and	O
5	O
p	O
##g	O
/	O
m	O
##L	O
for	O
4	O
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
.	O

Our	O
findings	O
shown	O
in	O
also	O
indicate	O
the	O
down	O
-	O
regulation	O
of	O
G	O
##CA	O
,	O
G	O
##DC	O
##A	O
,	O
G	B
##CD	I
##CA	I
,	O
and	O
their	O
in	O
-	O
source	O
fragments	O
in	O
HC	O
##C	O
cases	O
compared	O
to	O
patients	O
with	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

These	O
meta	O
##bol	O
##ites	O
included	O
met	B
##hi	I
##oni	I
##ne	I
,	O
pro	B
##line	I
,	O
and	O
or	B
##ni	I
##thin	I
##e	I
.	O

Although	O
we	O
could	O
identify	O
and	O
q	O
##uant	O
##ify	O
specific	O
serum	O
and	O
urine	O
amino	O
acids	O
using	O
N	O
##MR	O
,	O
we	O
did	O
not	O
find	O
any	O
statistical	O
##ly	O
significant	O
difference	O
in	O
serum	O
his	B
##ti	I
##dine	I
levels	O
between	O
the	O
two	O
UC	O
groups	O
which	O
might	O
be	O
due	O
to	O
sampling	O
from	O
a	O
different	O
population	O
of	O
UC	O
patients	O
or	O
the	O
result	O
of	O
small	O
sample	O
size	O
.	O

We	O
further	O
found	O
that	O
u	O
##rina	O
##ry	O
c	B
##ys	I
##tein	I
##e	I
was	O
significantly	O
elevated	O
in	O
bio	O
##chemical	O
##ly	O
-	O
re	O
##current	O
patients	O
compared	O
to	O
those	O
who	O
remained	O
re	O
##cu	O
##rrence	O
-	O
free	O
five	O
years	O
following	O
pro	O
##state	O
##ct	O
##omy	O
.	O

The	O
immediate	O
product	O
of	O
the	O
PC	O
reaction	O
is	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
which	O
is	O
then	O
directly	O
converted	O
to	O
ma	B
##late	I
and	O
c	B
##it	I
##rate	I
.	O

The	O
co	B
##tin	I
##ine	I
peak	O
in	O
Figure	O
A	O
was	O
only	O
7	O
times	O
greater	O
in	O
intensity	O
than	O
the	O
N	O
##NA	O
##L	O
peak	O
in	O
Figure	O
B	O
.	O
Ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
similar	O
quality	O
were	O
obtained	O
upon	O
analysis	O
of	O
urine	O
samples	O
from	O
smoke	O
##less	O
tobacco	O
users	O
.	O

P	O
##las	O
##ma	O
meta	O
##bol	O
##ite	O
analysis	O
revealed	O
bio	O
##mark	O
##er	O
meta	O
##bol	O
##ites	O
associated	O
with	O
ICC	O
and	O
in	O
particular	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
(	O
2	O
-	O
H	O
##G	O
)	O
levels	O
were	O
elevated	O
in	O
both	O
samples	O
from	O
the	O
only	O
patient	O
showing	O
a	O
variant	O
all	O
##ele	O
in	O
ID	O
##H1	O
.	O

N	B
##er	I
##von	I
##ic	I
acid	I

Then	O
,	O
the	O
samples	O
were	O
extracted	O
three	O
times	O
by	O
2	O
.	O
5	O
m	O
##L	O
et	B
##hyl	I
ace	I
##tate	I
(	O
V	O
##WR	O
Chemical	O
##s	O
,	O
St	O
##ri	O
##b	O
##rna	O
S	O
##kal	O
##ice	O
,	O
Czech	O
Republic	O
)	O
.	O

F	O
##ae	O
##cal	O
samples	O
(	O
0	O
.	O
1	O
g	O
)	O
were	O
ho	O
##mo	O
##gen	O
##ized	O
with	O
300	O
µ	O
##l	O
met	B
##han	I
##ol	I
(	O
4	O
°C	O
)	O
for	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
.	O

U	O
##rine	O
co	B
##tin	I
##ine	I
,	O
the	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ite	O
,	O
and	O
blood	O
CO	O
##H	O
##b	O
were	O
at	O
comparable	O
levels	O
for	O
healthy	O
smoke	O
##rs	O
and	O
CO	O
##PD	O
smoke	O
##rs	O
and	O
,	O
as	O
expected	O
,	O
low	O
or	O
und	O
##ete	O
##cted	O
in	O
non	O
-	O
smoke	O
##rs	O
.	O

In	O
the	O
g	O
##ly	O
##co	O
##lysis	O
-	O
associated	O
meta	O
##bol	O
##ites	O
,	O
a	O
good	O
positive	O
correlation	O
between	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
was	O
observed	O
in	O
all	O
brain	O
t	O
##umour	O
types	O
except	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
(	O
and	O
)	O
.	O

To	O
confirm	O
the	O
mass	O
s	O
##pect	O
##rome	O
##try	O
measurements	O
the	O
levels	O
of	O
ma	B
##late	I
and	O
c	B
##it	I
##rate	I
were	O
measured	O
by	O
al	O
##kal	O
##i	O
-	O
enhanced	O
flu	O
##ores	O
##cence	O
in	O
cell	O
lines	O
maintained	O
in	O
R	O
##PM	O
##I	O
1640	O
tissue	O
culture	O
medium	O
(	O
usually	O
contains	O
11	O
.	O
1	O
m	O
##M	O
glucose	S
and	O
2	O
##m	O
##M	O
g	B
##lut	I
##amine	I
)	O
modified	O
to	O
contain	O
a	O
physiological	O
##ly	O
normal	O
concentration	O
of	O
glucose	S
(	O
5	O
m	O
##M	O
)	O
(	O
and	O
still	O
2	O
m	O
##M	O
g	B
##lut	I
##amine	I
)	O
for	O
one	O
day	O
followed	O
by	O
a	O
brief	O
starvation	O
period	O
in	O
the	O
presence	O
of	O
no	O
fuel	O
and	O
then	O
a	O
35	O
min	O
in	O
##cu	O
##bation	O
period	O
in	O
K	O
##re	O
##bs	O
Ring	O
##er	O
bi	O
##car	O
##bon	O
##ate	O
buffer	O
solution	O
containing	O
10	O
m	O
##M	O
glucose	S
.	O

R	O
##umi	O
##no	O
##co	O
##cca	O
##ceae	O
_	O
UC	O
##G	O
–	O
00	O
##5	O
,	O
Lac	O
##hn	O
##os	O
##pi	O
##race	O
##ae	O
_	O
N	O
##K	O
##4	O
##A	O
##13	O
##6	O
_	O
group	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
,	O
Para	O
##ba	O
##cter	O
##oid	O
##es	O
,	O
Ba	O
##cter	O
##oid	O
##es	O
,	O
In	B
##test	I
##ini	I
##ba	I
##cter	I
,	O
and	O
Sub	O
##do	O
##li	O
##gra	O
##nu	O
##lum	O
were	O
correlated	O
with	O
4	O
f	O
##ae	O
##cal	O
meta	O
##bol	O
##ites	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
)	O
.	O

(	O
;	O
water	O
vs	O
.	O
w	B
##hey	I
:	O

(	O
F	O
)	O
N	B
-	I
met	I
##hyl	I
-	I
α	I
-	I
amino	I
##but	I
##yric	I
acid	I
present	O
only	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
As	O
##PC	O
-	O
1	O
samples	O
.	O

This	O
occurred	O
alongside	O
an	O
increased	O
T	B
##G	I
52	I
:	I
4	I
(	O
CH	O
##E	O
##BI	O
:	O
84	O
##6	O
##60	O
)	O
and	O
in	O
the	O
most	O
abundant	O
non	O
-	O
est	O
##eri	O
##fied	O
fatty	O
acids	O
within	O
ad	O
##ip	O
##ose	O
tissue	O
.	O

This	O
will	O
disrupt	O
the	O
sodium	B
ion	I
home	O
##ost	O
##asis	O
in	O
the	O
as	O
##tro	O
##cy	O
##tes	O
,	O
which	O
will	O
then	O
be	O
re	O
-	O
established	O
by	O
the	O
action	O
of	O
sodium	O
/	O
potassium	O
ATP	O
##ase	O
,	O
an	O
energy	O
-	O
consuming	O
process	O
.	O

This	O
would	O
suggest	O
that	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
can	O
function	O
at	O
physiological	O
concentrations	O
as	O
an	O
end	O
##ogen	O
##ous	O
m	O
##od	O
##ulator	O
of	O
re	B
##tino	I
##id	I
signaling	O
in	O
humans	O
.	O

Higher	O
amounts	O
of	O
g	B
##lut	I
##ama	I
##te	I
,	O
ta	B
##uri	I
##ne	I
,	O
and	O
put	B
##res	I
##cine	I
in	O
milk	O
required	O
higher	O
levels	O
of	O
ca	O
##li	O
##bra	O
##tors	O
than	O
for	O
plasma	O
in	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
mode	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
reduction	O
of	O
ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
levels	O
by	O
am	B
##lo	I
##di	I
##pine	I
(	O
median	O
change	O
-	O
21	O
%	O
,	O
P	O
=	O
9	O
x	O
10	O
_	O
−	O
##4	O
)	O
and	O
elevation	O
of	O
its	O
levels	O
by	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
(	O
median	O
change	O
+	O
16	O
%	O
,	O
P	O
=	O
0	O
.	O
00	O
##4	O
)	O
have	O
any	O
relation	O
to	O
risk	O
reduction	O
of	O
card	O
##iovascular	O
events	O
during	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
treatment	O
.	O

However	O
,	O
since	O
both	O
acute	O
h	O
##yper	O
##ins	O
##ulin	O
##emia	O
and	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
have	O
been	O
shown	O
to	O
induce	O
transcription	O
##al	O
and	O
translation	O
##al	O
regulation	O
of	O
glucose	S
and	O
energy	O
metabolism	O
in	O
the	O
skeletal	O
muscle	O
,	O
it	O
may	O
be	O
that	O
significant	O
differences	O
could	O
exist	O
during	O
h	B
##yper	I
##ins	I
##ulin	I
##em	I
##ic	I
-	I
e	I
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
,	O
glucose	S
challenge	O
or	O
mixed	O
meal	O
feeding	O
.	O

Furthermore	O
,	O
in	O
our	O
study	O
try	B
##pt	I
##op	I
##han	I
levels	O
were	O
higher	O
in	O
pre	O
-	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
individuals	O
con	O
##tra	O
##dict	O
##ing	O
the	O
findings	O
reported	O
for	O
active	O
RA	O
patients	O
[	O
–	O
]	O
,	O
but	O
in	O
agreement	O
with	O
results	O
from	O
the	O
analysis	O
of	O
s	O
##yn	O
##ov	O
##ial	O
fluid	O
from	O
active	O
RA	O
patients	O
.	O

As	O
has	O
been	O
reported	O
previously	O
,	O
we	O
confirmed	O
an	O
increase	O
in	O
levels	O
of	O
is	B
##ova	I
##ler	I
##ate	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
and	O
v	B
##ale	I
##rate	I
that	O
could	O
originate	O
from	O
an	O
increase	O
in	O
in	O
##test	O
##inal	O
s	O
##lough	O
cells	O
u	O
##til	O
##isation	O
or	O
an	O
increase	O
in	O
m	O
##uc	O
##oly	O
##tic	O
activity	O
from	O
a	O
subset	O
of	O
micro	O
##bes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
absolute	O
re	O
##ct	O
##al	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
met	B
##had	I
##one	I
with	O
its	O
oral	O
bio	O
##ava	O
##ila	O
##bility	O
in	O
healthy	O
humans	O
.	O

Seven	O
meta	O
##bol	O
##ites	O
exhibited	O
changes	O
in	O
concentrations	O
both	O
at	O
room	O
temperature	O
(	O
without	O
pre	O
##ser	O
##vat	O
##ive	O
)	O
and	O
with	O
pre	O
##ser	O
##vat	O
##ive	O
or	O
at	O
4	O
°C	O
:	O
u	B
##ro	I
##bil	I
##ino	I
##gen	I
,	O
u	B
##ro	I
##bil	I
##in	I
,	O
as	B
##cor	I
##bic	I
acid	I
,	O
or	B
##otic	I
acid	I
,	O
in	O
addition	O
to	O
is	O
##omer	O
##s	O
of	O
k	O
##eto	O
##ret	O
##ino	O
##ic	O
acid	O
and	O
h	B
##ydro	I
##xy	I
##ret	I
##ino	I
##ic	I
acid	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
,	O
and	O
th	B
##re	I
##ono	I
##la	I
##cton	I
##e	I
(	O
Table	O
;	O
Figure	O
,	O
and	O
graphs	O
provided	O
as	O
supplement	O
##ary	O
material	O
6	O
)	O
.	O

Ace	B
##tate	I
was	O
the	O
dominant	O
SC	O
##FA	O
produced	O
in	O
all	O
f	O
##er	O
##mentation	O
##s	O
in	O
both	O
I	O
##BS	O
and	O
healthy	O
donors	O
.	O

Recent	O
study	O
has	O
proposed	O
that	O
la	B
##ct	I
##ate	I
is	O
also	O
a	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
carbon	O
source	O
for	O
N	O
##SC	O
##LC	O
and	O
sustain	O
tumor	O
metabolism	O
in	O
v	O
##ivo	O
.	O

As	O
depicted	O
in	O
the	O
,	O
monitored	O
end	O
##ogen	O
##ous	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
ch	O
##roma	O
##to	O
##graphical	O
##ly	O
el	O
##uted	O
at	O
retention	O
times	O
that	O
do	O
not	O
interfere	O
with	O
the	O
mass	O
s	O
##pect	O
##rome	O
##tric	O
detection	O
of	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
and	O
meta	O
##bol	O
##ites	O
,	O
reducing	O
the	O
risk	O
of	O
relevant	O
matrix	O
effect	O
[	O
–	O
]	O
.	O

These	O
meta	O
##bol	O
##ites	O
include	O
la	B
##ct	I
##ate	I
,	O
v	B
##ali	I
##ne	I
and	O
lip	O
##id	O
.	O

While	O
below	O
the	O
level	O
of	O
statistical	O
significance	O
,	O
we	O
observed	O
increases	O
in	O
f	B
##ru	I
##ct	I
##ose	I
and	O
the	O
sugar	O
acids	O
pen	O
##ton	O
##ic	O
acid	O
and	O
he	B
##xa	I
##ric	I
acid	I
that	O
correlated	O
with	O
change	O
in	O
L	O
##D	O
##L	O
-	O
C	O
in	O
the	O
good	O
respond	O
##er	O
group	O
(	O
data	O
not	O
shown	O
)	O
and	O
were	O
opposite	O
to	O
the	O
effects	O
seen	O
for	O
these	O
meta	O
##bol	O
##ites	O
in	O
poor	O
respond	O
##ers	O
.	O

These	O
include	O
2	B
-	I
amino	I
##adi	I
##pate	I
(	O
0	O
.	O
93	O
-	O
fold	O
)	O
representing	O
the	O
l	B
##ys	I
##ine	I
metabolic	O
pathway	O
,	O
s	B
##te	I
##aro	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
(	O
0	O
.	O
9	O
-	O
fold	O
)	O
representing	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolic	O
pathway	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##py	I
##ru	I
##vate	I
(	O
0	O
.	O
88	O
-	O
fold	O
)	O
representing	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
metabolic	O
pathways	O
,	O
so	B
##rb	I
##ito	I
##l	I
(	O
0	O
.	O
87	O
-	O
fold	O
)	O
representing	O
f	B
##ru	I
##ct	I
##ose	I
,	O
man	B
##nose	I
,	O
and	O
gal	B
##act	I
##ose	I
metabolic	O
pathways	O
,	O
alpha	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
(	O
0	O
.	O
86	O
-	O
fold	O
)	O
representing	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
metabolic	O
pathways	O
,	O
c	B
##ys	I
-	I
g	I
##ly	I
,	O
o	O
##xi	O
##dized	O
(	O
0	O
.	O
84	O
-	O
fold	O
)	O
representing	O
the	O
g	B
##lut	I
##ath	I
##ione	I
metabolic	O
pathway	O
,	O
try	B
##top	I
##hyl	I
##gly	I
##cine	I
(	O
0	O
.	O
84	O
-	O
fold	O
)	O
,	O
as	B
##par	I
##ty	I
##l	I
##val	I
##ine	I
(	O
0	O
.	O
81	O
-	O
fold	O
)	O
,	O
and	O
as	B
##par	I
##ty	I
##ltry	I
##pt	I
##op	I
##han	I
(	O
0	O
.	O
76	O
-	O
fold	O
)	O
representing	O
the	O
dip	O
##eptide	O
metabolic	O
pathway	O
,	O
de	B
##ox	I
##ych	I
##olate	I
(	O
0	O
.	O
84	O
-	O
fold	O
)	O
and	O
7	B
-	I
k	I
##eto	I
##de	I
##ox	I
##ych	I
##olate	I
(	O
0	O
.	O
81	O
-	O
fold	O
)	O
representing	O
secondary	O
bi	O
##le	O
acid	O
metabolism	O
,	O
as	B
##par	I
##agi	I
##ne	I
(	O
0	O

All	O
solvent	O
##s	O
(	O
water	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
form	B
##ic	I
acid	I
,	O
am	B
##monia	I
solution	I
25	O
%	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Dorset	O
,	O
UK	O
)	O
and	O
were	O
L	O
##C	O
-	O
MS	O
grade	O
or	O
equivalent	O
.	O

S	O
##light	O
##ly	O
less	O
l	B
##ys	I
##ine	I
-	I
d	I
_	I
4	I
was	O
recovered	O
from	O
the	O
M	B
##T	I
##BE	I
a	O
##que	O
##ous	O
fraction	O
,	O
and	O
trace	O
amounts	O
of	O
15	O
:	O
0	O
PC	O
was	O
detected	O
in	O
the	O
M	B
##T	I
##BE	I
a	O
##que	O
##ous	O
fraction	O
,	O
while	O
most	O
of	O
it	O
was	O
extracted	O
into	O
the	O
lip	O
##id	O
fraction	O
.	O

Ace	O
##ty	O
##lation	O
of	O
am	O
##ines	O
directly	O
in	O
a	O
##que	O
##ous	O
medium	O
with	O
1	B
,	I
1	I
′	I
-	I
_	I
13	I
C	I
_	I
2	I
ace	I
##tic	I
an	I
##hy	I
##dr	I
##ide	I
is	O
a	O
simple	O
method	O
that	O
creates	O
a	O
high	O
sensitivity	O
and	O
quantitative	O
label	O
in	O
complex	O
bio	O
##f	O
##lu	O
##ids	O
with	O
minimal	O
sample	O
pre	O
##tre	O
##at	O
##ment	O
.	O

A	O
trend	O
for	O
an	O
increase	O
in	O
le	B
##uc	I
##ine	I
following	O
as	O
##phy	O
##xia	O
was	O
also	O
noted	O
(	O
p	O
=	O
0	O
.	O
08	O
##4	O
)	O
.	O

The	O
mass	O
spectrum	O
is	O
in	O
excellent	O
agreement	O
to	O
the	O
spectrum	O
of	O
synthetic	O
2	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
results	O
obtained	O
from	O
our	O
pathway	O
analysis	O
indicated	O
that	O
the	O
metabolic	O
pathways	O
of	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
,	O
ta	B
##uri	I
##ne	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
metabolism	O
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
were	O
significantly	O
altered	O
between	O
cancer	O
patients	O
and	O
the	O
normal	O
group	O
.	O

The	O
consumption	O
of	O
meat	O
could	O
also	O
significantly	O
increase	O
the	O
concentration	O
of	O
some	O
meta	O
##bol	O
##ites	O
in	O
urine	O
as	O
reported	O
in	O
the	O
case	O
of	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
CA	O
##D	O
,	O
co	O
##rona	O
##ry	O
artery	O
disease	O
;	O
PA	O
##F	O
,	O
plate	O
##let	O
act	O
##ivating	O
factor	O
;	O
H	O
##AM	O
-	O
D	O
,	O
17	O
-	O
item	O
Hamilton	O
Depression	O
Rat	O
##ing	O
Scale	O
;	O
PC	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
;	O
C	O
##I	O
##H	O
##R	O
,	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
.	O

Strong	O
statistical	O
correlation	O
##s	O
between	O
signals	O
der	O
##iving	O
from	O
pro	O
##tons	O
on	O
the	O
same	O
molecule	O
but	O
in	O
different	O
chemical	O
environments	O
were	O
observed	O
in	O
most	O
cases	O
,	O
as	O
demonstrated	O
for	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
the	O
2	B
-	I
h	I
##ydro	I
##xy	I
,	O
car	B
##box	I
##y	I
,	O
and	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
(	O
and	O
)	O
.	O

Beside	O
meta	O
##bol	O
##ites	O
linked	O
to	O
amino	O
acid	O
metabolism	O
,	O
a	O
strong	O
positive	O
association	O
between	O
u	O
##rina	O
##ry	O
t	B
##rig	I
##one	I
##llin	I
##e	I
levels	O
and	O
F	O
##T	O
##4	O
was	O
detected	O
.	O

Not	O
##ably	O
,	O
in	O
this	O
study	O
,	O
9	O
out	O
of	O
10	O
bio	O
##mark	O
##er	O
candidates	O
identified	O
in	O
the	O
urine	O
were	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
##s	I
,	O
suggesting	O
a	O
profound	O
disturbance	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
caused	O
by	O
the	O
repeated	O
administration	O
of	O
me	O
##lo	O
##xi	O
##cam	O
to	O
cats	O
.	O

The	O
second	O
pose	O
of	O
D	O
##HP	O
##M	O
##7	O
showed	O
two	O
hydrogen	O
bonds	O
between	O
C	O
=	O
O	O
of	O
car	B
##box	I
##yla	I
##te	I
side	O
chain	O
and	O
two	O
–	O
NH	O
_	O
2	O
groups	O
of	O
both	O
Ph	O
##e	O
177	O
and	O
G	O
##ln	O
41	O
##3	O
.	O

Ser	B
##ine	I
was	O
the	O
most	O
significantly	O
altered	O
amino	O
acid	O
between	O
HC	O
##C	O
patients	O
and	O
DC	O
##s	O
(	O
P	O
=	O
7	O
.	O
0	O
×	O
10	O
_	O
−	O
##6	O
)	O
.	O

St	B
##ati	I
##ns	I
lower	O
plasma	O
L	O
##D	O
##L	O
-	O
C	O
by	O
blocking	O
the	O
activity	O
of	O
HM	O
##G	O
-	O
Co	O
##A	O
red	O
##uc	O
##tase	O
,	O
thereby	O
decreasing	O
the	O
synthesis	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
modify	O
##ing	O
downstream	O
metabolic	O
pathways	O
.	O

Finally	O
,	O
water	O
losses	O
in	O
the	O
positive	O
ion	O
mode	O
(	O
[	O
M	O
+	O
H	O
−	O
H	O
_	O
2	O
O	O
]	O
_	O
+	O
)	O
were	O
observed	O
for	O
Ce	B
##r	I
,	O
He	O
##x	O
##C	O
##er	O
and	O
D	O
##G	O
lip	O
##id	O
standards	O
,	O
as	O
already	O
described	O
(	O
Christie	O
and	O
Han	O
,	O
)	O
.	O

AL	O
##D	O
##H	O
##7	O
##A	O
##1	O
-	O
depleted	O
cells	O
also	O
showed	O
an	O
increase	O
in	O
invasive	O
##ness	O
using	O
a	O
Mat	O
##rig	O
##el	O
trans	B
-	I
well	I
invasion	O
ass	O
##ay	O
(	O
Fi	O
##g	O
.	O

P	B
##yr	I
##u	I
##vate	I
and	O
k	B
##eton	I
##e	I
bodies	O
(	O
mainly	O
ace	B
##to	I
##ace	I
##tate	I
)	O
were	O
significantly	O
higher	O
in	O
the	O
AC	O
##LF	O
group	O
than	O
in	O
C	O
##LF	O
group	O
.	O

The	O
top	O
ten	O
pathways	O
observed	O
in	O
tissue	O
samples	O
are	O
nitrogen	O
metabolism	O
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
fatty	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
D	B
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
,	O
rib	B
##of	I
##lav	I
##in	I
metabolism	O
,	O
pu	B
##rine	I
metabolism	O
,	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
beta	B
-	I
Alan	I
##ine	I
metabolism	O
.	O

Since	O
3	O
-	O
H	O
##IB	O
can	O
serve	O
as	O
a	O
g	B
##lu	I
##con	I
##eo	I
##genic	I
substrate	O
,	O
elevated	O
plasma	O
3	O
-	O
H	O
##IB	O
may	O
have	O
a	O
p	O
##hy	O
##sio	O
##log	O
##ic	O
function	O
in	O
fast	O
##ing	O
.	O

An	O
interesting	O
observation	O
from	O
our	O
study	O
was	O
that	O
reduced	O
levels	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
b	O
##v	O
##FT	O
##D	O
(	O
indicating	O
reduced	O
numbers	O
of	O
HD	O
##L	O
)	O
co	O
##rro	O
##bor	O
##ates	O
the	O
previous	O
finding	O
that	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
is	O
reduced	O
in	O
b	O
##v	O
##FT	O
##D	O
.	O

Ben	O
##ef	O
##it	O
from	O
the	O
addition	O
of	O
lap	B
##ati	I
##ni	I
##b	I
over	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
alone	O
was	O
restricted	O
to	O
patients	O
with	O
H	O
##ER	O
##2	O
‐	O
positive	O
disease	O
.	O

In	O
fact	O
,	O
3	O
-	O
H	O
##B	O
is	O
formed	O
primarily	O
when	O
the	O
energy	O
source	O
for	O
the	O
peripheral	O
organs	O
are	O
shifted	O
to	O
lip	O
##id	O
from	O
glucose	S
and	O
,	O
therefore	O
,	O
the	O
early	O
stage	O
metabolic	O
shifts	O
by	O
metabolic	O
surgery	O
may	O
be	O
a	O
key	O
factor	O
for	O
the	O
success	O
of	O
the	O
longer	O
term	O
post	O
-	O
operative	O
glucose	S
control	O
.	O

In	O
terms	O
of	O
fatty	O
acid	O
metabolism	O
,	O
a	O
low	O
level	O
of	O
glucose	S
may	O
provide	O
a	O
metabolic	O
environment	O
in	O
which	O
fatty	O
acid	O
degradation	O
into	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
(	O
beta	O
-	O
oxidation	O
)	O
is	O
facilitated	O
.	O

Using	O
a	O
du	O
##mmy	O
matrix	O
of	O
the	O
graded	O
criteria	O
,	O
P	O
##LS	O
-	O
D	O
##A	O
yielded	O
Q	O
_	O
2	O
=	O
2	O
%	O
for	O
the	O
pronounced	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
class	O
G	O
##2	O
at	O
visit	O
V	O
##2	O
,	O
involving	O
c	B
##it	I
##rate	I
,	O
glucose	S
and	O
the	O
unidentified	O
signal	O
at	O
1	O
.	O
08	O
pp	O
##m	O
.	O

Furthermore	O
,	O
v	B
##ac	I
##ce	I
##nic	I
acid	I
was	O
significantly	O
decreased	O
in	O
each	O
HC	O
##C	O
stage	O
compared	O
with	O
in	O
the	O
c	O
##ir	O
##r	O
##hos	O
##is	O
group	O
.	O

I	O
##rino	O
##teca	O
##n	O
(	O
CP	O
##T	O
-	O
11	O
)	O
,	O
a	O
semi	O
##sy	O
##nt	O
##hetic	O
analogue	O
of	O
camp	B
##to	I
##the	I
##cin	I
,	O
is	O
used	O
as	O
the	O
main	O
##sta	O
##y	O
treatment	O
for	O
meta	O
##static	O
color	O
##ec	O
##tal	O
cancer	O
and	O
other	O
solid	O
tumors	O
.	O

Three	O
significant	O
meta	O
##bol	O
##ites	O
(	B
v	B
##ali	I
##ne	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
ch	B
##olin	I
##e	I
)	O
with	O
low	O
(	O
un	O
##cor	O
##re	O
##cted	O
,	O
v	O
##ide	O
in	O
##fra	O
)	O
p	O
-	O
values	O
(	O
<	O
0	O
.	O
05	O
)	O
were	O
selected	O
as	O
potential	O
bio	O
##mark	O
##ers	O
.	O

The	O
change	O
in	O
levels	O
of	O
l	B
##ino	I
##ley	I
##l	I
##car	I
##ni	I
##tine	I
and	O
pipe	B
##co	I
##lic	I
acid	I
was	O
related	O
to	O
palm	B
##ity	I
##l	I
car	I
##ni	I
##tine	I
(	O
r	O
=	O
0	O
.	O
60	O
##2	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
beta	B
##ine	I
(	O
r	O
=	O
0	O
.	O
81	O
##0	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
respectively	O
.	O

All	O
stock	O
standard	O
solutions	O
were	O
prepared	O
in	O
Me	B
##OH	I
or	O
water	O
depending	O
on	O
the	O
so	O
##lub	O
##ility	O
and	O
were	O
stored	O
at	O
−	O
##80	O
°C	O
.	O

This	O
mixture	O
of	O
enzymes	O
efficiently	O
dig	O
##ests	O
a	O
variety	O
of	O
different	O
classes	O
of	O
DNA	O
add	O
##uc	O
##ts	O
,	O
including	O
those	O
formed	O
with	O
a	O
##romatic	O
am	O
##ines	O
,	O
he	B
##tero	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
am	O
##ines	O
,	O
a	O
##risto	O
##loc	O
##hic	O
acid	O
,	O
p	B
##oly	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
,	O
tobacco	O
specific	O
N	O
-	O
ni	O
##tro	O
##so	O
compounds	O
,	O
and	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
add	O
##uc	O
##ts	O
(	O
;	O
;	O
;	O
;	O
)	O
.	O

ACC	O
is	O
a	O
key	O
regulatory	O
enzyme	O
in	O
lip	O
##ogen	O
##esis	O
,	O
and	O
its	O
activity	O
is	O
under	O
ho	O
##rmon	O
##al	O
regulation	O
by	O
insulin	O
,	O
g	O
##lu	O
##ca	O
##gon	O
,	O
and	O
e	B
##pine	I
##ph	I
##rine	I
.	O

Met	O
##ab	O
##oli	O
##te	O
extract	O
##s	O
from	O
125	O
μ	O
##L	O
of	O
P	O
##O	O
##OL	O
were	O
re	O
##con	O
##stituted	O
in	O
either	O
(	O
i	O
)	O
water	O
containing	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
pH	O
3	O
(	O
ii	O
)	O
100	O
m	O
##M	O
P	O
##FA	O
with	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
pH	O
3	O
or	O
(	O
ii	O
##i	O
)	O
100	O
m	O
##M	O
T	O
##EA	O
with	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
pH	O
3	O
.	O

The	O
dried	O
residue	O
was	O
dissolved	O
in	O
40	O
µ	O
##L	O
met	B
##ho	I
##xa	I
##mine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
20	O
mg	O
/	O
m	O
##L	O
p	B
##yr	I
##id	I
##ine	I
)	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
30	O
##°	O
##C	O
for	O
90	O
min	O
with	O
continuous	O
shaking	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
the	O
full	O
repertoire	O
of	O
the	O
s	O
##chi	O
##sto	O
##some	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
is	O
abundant	O
only	O
in	O
the	O
mature	O
##d	O
/	O
developed	O
car	O
##cin	O
##oma	O
cases	O
.	O

Relations	O
##hip	O
between	O
In	O
##test	O
##inal	O
Micro	O
##f	O
##lora	O
-	O
De	O
##pen	O
##dent	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
Met	O
##ab	O
##oli	O
##tes	O
And	O
Di	O
##ast	O
##olic	O
D	O
##ys	O
##function	O
in	O
Ch	O
##ronic	O
S	O
##ys	O
##to	O
##lic	O
Heart	O
F	O
##ail	O
##ure	O
.	O
illustrate	O
##s	O
the	O
Cox	O
proportional	O
hazard	O
models	O
of	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
beta	B
##ine	I
for	O
long	O
-	O
term	O
adverse	O
clinical	O
outcomes	O
.	O

ET	O
##A	O
and	O
D	O
##PA	O
are	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
P	O
##U	O
##FA	O
##s	O
)	O
,	O
and	O
are	O
examples	O
of	O
o	B
##me	I
##ga	I
-	I
3	I
and	O
o	B
##me	I
##ga	I
-	I
6	I
fatty	O
acids	O
,	O
respectively	O
.	O

Un	O
##ique	O
associations	O
with	O
fi	O
##bri	O
##no	O
##gen	O
consisted	O
of	O
3	B
-	I
u	I
##re	I
##ido	I
##p	I
##rop	I
##ion	I
##ate	I
,	O
he	B
##xa	I
##noy	I
##l	I
##gly	I
##cine	I
,	O
5	B
-	I
alpha	I
-	I
pre	I
##gna	I
##n	I
-	I
3	I
-	I
beta	I
,	I
20	I
-	I
alpha	I
-	I
di	I
##ol	I
di	I
##sul	I
##fa	I
##te	I
,	O
o	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
,	O
and	O
the	O
x	O
##eno	O
##biotics	O
3	B
-	I
et	I
##hyl	I
##phe	I
##ny	I
##ls	I
##ulf	I
##ate	I
and	O
co	B
##tin	I
##ine	I
N	I
-	I
oxide	I
.	O

This	O
finding	O
indicates	O
low	O
en	O
##zy	O
##matic	O
activity	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
de	O
##grading	O
and	O
s	O
##ynth	O
##esi	O
##zing	O
enzymes	O
at	O
4	O
##°	O
##C	O
and	O
R	O
##T	O
.	O

These	O
meta	O
##bol	O
##ites	O
comprised	O
the	O
amino	O
acid	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
bio	O
##genic	O
am	O
##ines	O
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
and	O
ta	B
##uri	I
##ne	I
,	O
eight	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
[	I
prop	I
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##3	I
)	I
,	I
v	I
##ale	I
##ryl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##5	I
)	I
,	I
o	I
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##8	I
)	I
,	I
non	I
##ay	I
##l	I
##car	I
##ni	I
##tine	I
(	I
C	I
##9	I
)	I
,	I
de	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##10	I
)	I
,	I
do	I
##de	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##12	I
)	I
,	I
te	I
##tra	I
##de	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##14	I
)	I
,	I
h	I
##ydro	I
##xy	I
##he	I
##xa	I
##de	I
##ca	I
##die	I
##ny	I
##l	I
##car	I
##ni	I
##tine	I
(	I
C	I
##16	I
:	I
2	I
-	I
OH	I
)	I
]	I
,	O
13	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
three	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

The	O
la	B
##ct	I
##ate	I
from	O
t	O
##umour	O
cell	O
is	O
transported	O
to	O
g	O
##lial	O
cells	O
,	O
where	O
it	O
is	O
used	O
a	O
fuel	O
to	O
produce	O
ATP	S
.	O

Among	O
these	O
metabolic	O
changes	O
,	O
four	O
amino	O
acids	O
,	O
as	B
##par	I
##agi	I
##ne	I
(	O
6	O
)	O
,	O
as	B
##par	I
##tic	I
acid	I
(	O
2	O
)	O
,	O
g	B
##lut	I
##amine	I
(	O
7	O
)	O
,	O
and	O
g	B
##lut	I
##ami	I
##c	I
acid	I
(	O
5	O
)	O
,	O
and	O
three	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
1	B
,	I
5	I
-	I
an	I
##hy	I
##dr	I
##og	I
##lu	I
##ci	I
##to	I
##l	I
(	O
14	O
)	O
,	O
f	B
##ru	I
##ct	I
##ose	I
(	O
15	O
)	O
,	O
and	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O

In	O
this	O
study	O
we	O
determine	O
the	O
full	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
of	O
HK	O
-	O
2	O
cells	O
in	O
response	O
to	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
and	O
compare	O
the	O
meta	O
##bol	O
##ite	O
levels	O
between	O
HK	O
-	O
2	O
cells	O
stimulate	O
##d	O
with	O
high	O
glucose	S
,	O
o	O
##smo	O
##tic	O
control	O
,	O
and	O
serum	O
-	O
free	O
medium	O
.	O

A	O
recent	O
plasma	O
lip	O
##ido	O
##mic	O
analysis	O
in	O
rat	O
and	O
mouse	O
models	O
,	O
and	O
22	O
veterans	O
with	O
G	O
##WI	O
showed	O
elevations	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Take	O
##n	O
that	O
the	O
test	O
is	O
considered	O
positive	O
for	O
cancer	O
in	O
case	O
of	O
low	O
g	B
##lut	I
##ama	I
##te	I
concentrations	O
,	O
the	O
optimal	O
cut	O
-	O
off	O
point	O
(	O
highest	O
sensitivity	O
and	O
1	O
-	O
specific	O
##ity	O
)	O
for	O
cancer	O
diagnosis	O
corresponds	O
to	O
a	O
relative	O
g	B
##lut	I
##ama	I
##te	I
level	O
of	O
≤	O
0	O
.	O
31	O
(	O
AU	O
##C	O
of	O
0	O
.	O
88	O
)	O
.	O

S	O
##ynth	O
##esis	O
of	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
involved	O
a	O
two	O
-	O
step	O
reaction	O
and	O
followed	O
the	O
Gabriel	O
synthesis	O
procedure	O
with	O
modifications	O
as	O
described	O
below	O
to	O
yield	O
the	O
pure	O
product	O
.	O
_	O
,	O
The	O
first	O
step	O
involved	O
react	O
##ing	O
potassium	O
_	O
15	O
N	O
-	O
p	O
##ht	O
##hali	O
##mi	O
##de	O
with	O
(	B
2	I
-	I
br	I
##omo	I
##eth	I
##yl	I
)	I
trim	I
##eth	I
##yla	I
##mm	I
##onium	I
br	I
##omi	I
##de	I
in	O
D	O
##MF	O
to	O
obtain	O
the	O
_	O
15	O
N	O
substituted	O
p	O
##ht	O
##hali	O
##mi	O
##de	O
intermediate	O
.	O

[	O
Google	O
Scholar	O
]	O
Ye	O
##m	O
A	B
##W	I
,	O
E	O
##pps	O
DE	O
,	O
Mathews	O
WR	O
,	O
Guido	O
D	O
##M	O
,	O
Richard	O
K	O
##A	O
,	O
St	O
##ait	O
##e	O
N	O
##D	O
,	O
De	O
##ibel	O
MR	O
.	O
,	O
Jr	O
Site	O
-	O
specific	O
chemical	O
modification	O
of	O
inter	O
##le	O
##uki	O
##n	O
-	O
1	O
beta	O
by	O
a	O
##c	O
##ryl	O
##oda	O
##n	O
at	O
c	B
##ys	I
##tein	I
##e	I
8	O
and	O
l	B
##ys	I
##ine	I
103	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
dried	O
in	O
a	O
Speed	O
##V	O
##ac	O
without	O
heat	O
and	O
subsequently	O
re	O
-	O
suspended	O
to	O
one	O
half	O
of	O
the	O
original	O
CS	O
##F	O
volume	O
in	O
an	O
a	O
##que	O
##ous	O
solution	O
of	O
5	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

The	O
mobile	O
phase	O
for	O
positive	O
ion	O
analysis	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
H	O
_	O
2	O
O	O
(	O
solvent	O
A	O
)	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
(	O
solvent	O
B	O
)	O
,	O
while	O
the	O
mobile	O
phase	O
for	O
negative	O
ion	O
analysis	O
consisted	O
of	O
6	O
.	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
,	O
pH	O
8	O
.	O
0	O
(	O
solvent	O
A	O
)	O
and	O
6	O
.	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
in	O
95	O
%	O
met	B
##han	I
##ol	I
(	O
solvent	O
B	O
)	O
.	O

Vita	B
##min	I
D	I
meta	O
##bol	O
##ites	O
are	O
known	O
to	O
be	O
stable	O
during	O
long	O
-	O
term	O
storage	O
.	O

B	O
##rief	O
##ly	O
,	O
plasma	O
samples	O
were	O
spike	O
##d	O
with	O
a	O
cocktail	O
of	O
heavy	O
-	O
is	O
##oto	O
##pe	O
internal	O
standards	O
(	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
MA	O
,	O
USA	O
;	O
C	O
-	O
D	O
-	O
N	O
,	O
Is	O
##oto	O
##pes	O
,	O
Canada	O
)	O
and	O
de	O
##p	O
##rote	O
##inated	O
with	O
met	B
##han	I
##ol	I
.	O

El	O
##ec	O
##tro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
)	O
with	O
a	O
sheath	O
gas	O
of	O
12	O
,	O
a	O
spray	O
voltage	O
of	O
3	O
.	O
7	O
k	B
##V	I
,	O
and	O
a	O
cap	O
##illa	O
##ry	O
temperature	O
of	O
321	O
°C	O
were	O
used	O
.	O

Considering	O
that	O
Mat	O
##su	O
##ta	O
et	O
al	O
.	O
did	O
not	O
find	O
a	O
h	B
##ydro	I
##xy	I
meta	O
##bol	O
##ite	O
in	O
human	O
urine	O
leads	O
to	O
the	O
assumption	O
that	O
this	O
meta	O
##bol	O
##ite	O
is	O
not	O
a	O
primary	O
target	O
and	O
is	O
formed	O
only	O
in	O
very	O
small	O
amounts	O
in	O
v	O
##it	O
##ro	O
,	O
which	O
might	O
explain	O
the	O
non	O
-	O
detection	O
via	O
automated	O
peak	O
picking	O
.	O

The	O
significant	O
increase	O
in	O
the	O
serum	O
concentration	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
is	O
in	O
agreement	O
with	O
the	O
down	O
-	O
regulation	O
of	O
gene	O
modules	O
involved	O
in	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
observed	O
in	O
tissue	O
samples	O
from	O
N	O
##SC	O
##LC	O
patients	O
,	O
and	O
could	O
reflect	O
a	O
limited	O
ability	O
of	O
lung	O
cancer	O
cells	O
to	O
process	O
this	O
amino	O
acid	O
at	O
advanced	O
stages	O
of	O
the	O
disease	O
.	O

Then	O
,	O
the	O
mixture	O
was	O
son	O
##ica	O
##ted	O
in	O
an	O
ultra	O
##sonic	O
bath	O
(	O
ambient	O
temperature	O
×	O
1	O
min	O
)	O
,	O
extracted	O
in	O
dark	O
on	O
an	O
orbital	O
shake	O
##r	O
(	O
Torre	O
##y	O
Pine	B
##s	I
Scientific	O
Inc	O
.	O
;	O
San	O
Marcos	O
,	O
CA	O
,	O
USA	O
)	O
(	O
750	O
rpm	O
at	O
4	O
°C	O
×	O
2	O
h	O
)	O
,	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
4	O
°C	O
(	O
13	O
,	O
000	O
rpm	O
×	O
5	O
min	O
)	O
.	O

Both	O
runs	O
were	O
performed	O
on	O
the	O
S	O
##yne	O
##rg	O
##i	O
H	B
##ydro	I
R	I
##P	I
column	O
(	O
150	O
##×	O
##2	O
.	O
0	O
mm	O
,	O
4	O
μ	O
##m	O
,	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
maintained	O
at	O
ambient	O
temperature	O
and	O
attached	O
to	O
a	O
guard	O
column	O
of	O
the	O
same	O
packing	O
material	O
.	O

In	O
contrast	O
,	O
ex	O
v	O
##ivo	O
H	O
##R	O
-	O
MA	O
##S	O
1	O
##H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
of	O
cell	O
extract	O
##s	O
can	O
resolve	O
individual	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
and	O
q	O
##uant	O
##ify	O
GP	B
##C	I
,	O
PC	O
,	O
and	O
free	O
ch	B
##olin	I
##e	I
.	O

Thus	O
the	O
Tor	O
##us	O
columns	O
,	O
and	O
in	O
particular	O
the	O
Di	B
##ol	I
column	O
,	O
offer	O
improved	O
resolution	O
due	O
to	O
narrower	O
peak	O
base	O
width	O
##s	O
for	O
all	O
classes	O
of	O
polar	O
anal	O
##yte	O
,	O
and	O
a	O
relatively	O
even	O
distribution	O
of	O
peaks	O
across	O
the	O
retention	O
time	O
range	O
.	O

Given	O
that	O
metabolic	O
pathways	O
and	O
associated	O
genes	O
/	O
proteins	O
/	O
meta	O
##bol	O
##ites	O
were	O
altered	O
in	O
BC	O
##A	O
,	O
we	O
next	O
tested	O
whether	O
the	O
expression	O
levels	O
of	O
key	O
genes	O
involved	O
in	O
the	O
car	B
##ni	I
##tine	I
-	I
a	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
metabolic	O
pathway	O
and	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
are	O
also	O
per	O
##tur	O
##bed	O
in	O
bladder	O
tissues	O
obtained	O
from	O
patients	O
with	O
BC	O
##A	O
.	O

Level	O
##s	O
of	O
car	O
##ni	O
##tine	O
-	O
related	O
meta	O
##bol	O
##ites	O
,	O
including	O
ace	B
##ty	I
##l	I
car	I
##ni	I
##tine	I
,	O
de	B
##cano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
and	O
he	B
##xa	I
##noy	I
##l	I
car	I
##ni	I
##tine	I
,	O
were	O
significantly	O
higher	O
in	O
the	O
BS	O
pattern	O
than	O
the	O
non	O
-	O
BS	O
pattern	O
patients	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Here	O
we	O
examined	O
relationships	O
between	O
the	O
serum	O
levels	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
est	O
##rogen	O
##s	O
,	O
f	O
##oll	O
##icle	O
-	O
s	O
##ti	O
##mulating	O
hormone	O
(	O
F	O
##S	O
##H	O
)	O
,	O
and	O
also	O
determined	O
the	O
g	O
##eno	O
##type	O
##s	O
of	O
C	O
##YP	O
##2	O
##C	O
##19	O
,	O
2D	O
##6	O
,	O
3	O
##A	O
##5	O
,	O
and	O
S	O
##U	O
##LT	O
##1	O
##A	O
##1	O
in	O
90	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
patients	O
.	O

(	O
F	O
)	O
Same	O
as	O
in	O
E	O
,	O
for	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
–	O
associated	O
genes	O
and	O
meta	O
##sta	O
##sis	O
-	O
free	O
survival	O
across	O
68	O
##6	O
ER	O
+	O
BC	O
##a	O
tissues	O
.	O

Except	O
for	O
a	B
##rg	I
##ini	I
##ne	I
,	O
significantly	O
different	O
between	O
patients	O
with	O
end	O
##os	O
##copic	O
##ally	O
inactive	O
and	O
the	O
most	O
active	O
disease	O
,	O
systemic	O
meta	O
##bol	O
##ite	O
concentrations	O
were	O
not	O
related	O
to	O
the	O
end	O
##os	O
##copic	O
activity	O
of	O
UC	O
expressed	O
in	O
terms	O
of	O
the	O
Mayo	O
end	O
##os	O
##copic	O
activity	O
score	O
.	O

T	B
##hia	I
##zi	I
##de	I
di	O
##ure	O
##tics	O
have	O
been	O
the	O
main	O
##sta	O
##y	O
anti	O
-	O
H	O
##T	O
##N	O
therapy	O
for	O
decades	O
and	O
are	O
still	O
ranked	O
among	O
the	O
most	O
commonly	O
prescribed	O
medications	O
worldwide	O
.	O

Compared	O
to	O
control	O
conditions	O
,	O
the	O
final	O
amount	O
of	O
la	B
##ct	I
##ate	I
was	O
therefore	O
detected	O
at	O
an	O
almost	O
1	O
.	O
6	O
-	O
fold	O
higher	O
level	O
after	O
r	O
##H	O
##la	O
-	O
treatment	O
.	O

Test	B
##osterone	I
levels	O
were	O
significantly	O
associated	O
with	O
V	O
##LD	O
##L	O
and	O
serum	O
lip	O
##ids	O
in	O
PC	O
##OS	O
cases	O
with	O
large	O
WC	O
but	O
not	O
in	O
the	O
controls	O
.	O

However	O
,	O
despite	O
the	O
high	O
intensity	O
of	O
the	O
training	O
protocol	O
used	O
in	O
our	O
study	O
,	O
we	O
did	O
not	O
observe	O
an	O
increase	O
in	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
concentration	O
one	O
day	O
after	O
the	O
last	O
training	O
session	O
.	O

The	O
primary	O
pathway	O
of	O
gal	B
##act	I
##ose	I
metabolism	O
is	O
the	O
Le	O
##lo	O
##ir	O
pathway	O
,	O
in	O
which	O
U	B
##DP	I
-	I
gal	I
##act	I
##ose	I
and	O
glucose	B
-	I
1	I
-	I
phosphate	I
are	O
produced	O
as	O
intermediate	O
meta	O
##bol	O
##ites	O
.	O

For	O
example	O
,	O
a	O
bare	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
,	O
used	O
in	O
the	O
CE	O
technique	O
as	O
the	O
separation	O
column	O
,	O
is	O
much	O
cheaper	O
than	O
U	O
##HP	O
##LC	O
columns	O
.	O

AP	O
##EC	O
##ED	O
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
di	O
##ar	O
##r	O
##hea	O
,	O
con	O
##st	O
##ip	O
##ation	O
,	O
enter	O
##o	O
-	O
end	O
##ro	O
##c	O
##rine	O
cells	O
,	O
Pan	O
##eth	O
cells	O

Mobile	O
phase	O
A	O
(	O
0	O
.	O
1	O
M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
)	O
was	O
delivered	O
at	O
0	O
.	O
3	O
m	O
##L	O
/	O
min	O
and	O
mobile	O
phase	O
B	O
(	O
60	O
%	O
AC	O
##N	O
/	O
0	O
.	O
1	O
M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
)	O
was	O
delivered	O
at	O
0	O
.	O
2	O
m	O
##L	O
/	O
min	O
.	O

The	O
bio	O
##ps	O
##ies	O
underwent	O
a	O
first	O
wash	O
(	O
30	O
##S	O
mid	O
-	O
speed	O
v	O
##ortex	O
)	O
with	O
0	O
.	O
01	O
##6	O
%	O
di	B
##thi	I
##oe	I
##ry	I
##th	I
##rito	I
##l	I
(	O
D	O
##TT	O
,	O
cat	O
#	O
D	O
##0	O
##6	O
##32	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Milan	O
,	O
Italy	O
)	O
in	O
phosphate	B
-	I
buffer	I
##ed	I
sa	I
##line	I
(	O
PBS	O
,	O
cat	O
#	O
AU	O
-	O
L	O
##0	O
##6	O
##15	O
-	O
500	O
,	O
Au	O
##rogen	O
##e	O
,	O
Rome	O
,	O
Italy	O
)	O
to	O
remove	O
m	O
##uc	O
##us	O
and	O
were	O
then	O
washed	O
three	O
more	O
times	O
with	O
PBS	O
.	O

Although	O
both	O
samples	O
were	O
from	O
healthy	O
individuals	O
,	O
large	O
variations	O
in	O
the	O
concentration	O
of	O
o	B
##xy	I
##lip	I
##ins	I
were	O
observed	O
,	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
work	O
.	O

Most	O
of	O
these	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
eight	O
of	O
nine	O
)	O
were	O
significantly	O
increased	O
only	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
compared	O
with	O
sleep	O
,	O
not	O
between	O
the	O
wake	O
conditions	O
,	O
suggesting	O
an	O
effect	O
of	O
high	O
sleep	O
pressure	O
on	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
.	O

The	O
s	O
##pect	O
##ra	O
in	O
the	O
region	O
10	O
.	O
0	O
–	O
0	O
.	O
5	O
pp	O
##m	O
were	O
integrated	O
with	O
the	O
bucket	O
width	O
set	O
to	O
0	O
.	O
00	O
##5	O
pp	O
##m	O
,	O
leaving	O
out	O
the	O
region	O
6	O
.	O
3	O
–	O
5	O
.	O
5	O
and	O
5	O
.	O
2	O
–	O
4	O
.	O
4	O
pp	O
##m	O
,	O
which	O
included	O
residual	O
water	O
and	O
u	B
##rea	I
,	O
respectively	O
.	O

In	O
contrast	O
,	O
subjects	O
of	O
Group	O
3	O
and	O
the	O
T	O
##T	O
g	O
##eno	O
##type	O
of	O
the	O
r	O
##s	O
##38	O
##0	O
##3	O
p	O
##oly	O
##mor	O
##phism	O
had	O
a	O
lower	O
prevalence	O
of	O
T	O
##2	O
##DM	O
,	O
although	O
they	O
were	O
predominantly	O
males	O
and	O
had	O
higher	O
values	O
of	O
plasma	O
c	B
##rea	I
##tin	I
##ine	I
.	O

L	B
-	I
As	I
##par	I
##tate	I
.	O

Three	O
patients	O
who	O
tested	O
positive	O
for	O
cannabis	S
were	O
found	O
to	O
have	O
highly	O
altered	O
CS	O
##F	O
meta	O
##bol	O
##ite	O
profiles	O
and	O
formed	O
a	O
separate	O
cluster	O
in	O
the	O
P	O
##LS	O
-	O
D	O
##A	O
plot	O
(	O
away	O
from	O
both	O
healthy	O
controls	O
and	O
patients	O
with	O
s	O
##chi	O
##zophrenia	O
)	O
whilst	O
the	O
remaining	O
four	O
cannabis	O
-	O
positive	O
patients	O
cluster	O
##ed	O
with	O
the	O
drug	O
-	O
na	O
##ï	O
##ve	O
s	O
##chi	O
##zophrenia	O
group	O
.	O

This	O
purpose	O
was	O
obtained	O
by	O
performing	O
a	O
rigorous	O
quantum	O
mechanical	O
simulation	O
of	O
the	O
hydrogen	O
nuclei	O
in	O
the	O
two	O
equivalent	O
met	B
##hyl	I
##ene	I
groups	O
of	O
C	O
##it	O
using	O
the	O
GA	O
##MM	O
##A	O
C	O
+	O
+	O
libraries	O
.	O

Our	O
library	O
en	O
##rich	O
##ed	O
the	O
number	O
of	O
MC	O
##F	O
derivatives	O
of	O
amino	O
acids	O
and	O
non	O
-	O
amino	O
organic	O
acids	O
reported	O
by	O
Smart	O
et	O
al	O
,	O
especially	O
previously	O
un	O
##re	O
##port	O
##ed	O
a	O
##romatic	O
ho	B
##mo	I
##cy	I
##c	I
##lic	I
or	O
he	B
##tero	I
##cy	I
##c	I
##lic	I
compounds	O
.	O

G	B
##lut	I
##ama	I
##te	I
(	O
m	O
/	O
z	O
148	O
.	O
05	O
##9	O
##4	O
)	O
and	O
Mt	O
##b	O
-	O
derived	O
t	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
(	O
m	O
/	O
z	O
80	O
##1	O
.	O
57	O
##6	O
##7	O
)	O
were	O
verified	O
by	O
tandem	O
MS	O
/	O
MS	O
and	O
fragment	O
##ation	O
of	O
co	O
-	O
el	O
##uti	O
##ng	O
authentic	O
reference	O
standards	O
added	O
to	O
plasma	O
and	O
prepared	O
for	O
analysis	O
as	O
described	O
previously	O
,	O
.	O

In	O
particular	O
,	O
BC	O
##AA	O
##s	O
such	O
as	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
resulted	O
significant	O
in	O
this	O
analysis	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
degree	O
of	O
in	O
##hibition	O
exhibited	O
by	O
Te	O
##m	O
-	O
do	O
##x	O
-	O
S	O
##O	O
_	O
2	O
on	O
RB	O
##C	O
AC	O
##h	O
##E	O
was	O
more	O
pronounced	O
than	O
the	O
highly	O
toxic	O
meta	O
##bol	O
##ite	O
et	B
##hyl	I
-	I
para	I
##ox	I
##on	I
used	O
as	O
positive	O
control	O
(	O
I	O
##C	O
_	O
50	O
=	O
88	O
.	O
16	O
n	O
##M	O
)	O
(	O
Fi	O
##g	O
.	O

First	O
,	O
the	O
samples	O
were	O
extracted	O
with	O
200	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
:	O
ch	B
##lor	I
##of	I
##orm	I
(	I
3	I
:	I
1	I
)	I
with	O
ho	O
##mo	O
##gen	O
##ization	O
in	O
1	O
.	O
5	O
m	O
##L	O
of	O
screw	O
cap	O
tubes	O
for	O
3	O
min	O
using	O
1	O
mm	O
inner	O
diameter	O
beads	O
in	O
a	O
Bull	O
##et	O
B	O
##len	O
##der	O
(	O
Next	O
Advance	O
,	O
USA	O
)	O
.	O

Control	O
experiments	O
show	O
that	O
the	O
ion	O
-	O
trap	O
responds	O
linear	O
##ly	O
over	O
the	O
range	O
of	O
1	O
-	O
500	O
f	O
##mo	O
##l	O
of	O
native	O
material	O
relative	O
to	O
500	O
f	O
##mo	O
##l	O
of	O
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
(	O
U	O
-	O
_	O
15	O
N	O
)	O
Ad	O
##e	O
internal	O
standard	O
(	O
in	O
supplement	O
##ary	O
information	O
)	O
.	O

Moreover	O
,	O
the	O
connectivity	O
from	O
H	O
##2	O
to	O
H	O
##4	O
of	O
the	O
g	O
##lut	O
##am	O
##yl	O
m	O
##oi	O
##ety	O
of	O
the	O
g	B
##lut	I
##ath	I
##ione	I
##s	I
(	O
G	O
##S	O
##H	O
+	O
G	O
##SS	O
##G	O
)	O
was	O
observed	O
,	O
which	O
corresponds	O
to	O
the	O
is	O
##oto	O
##po	O
##mer	O
_	O
13	O
C	O
##2	O
,	O
_	O
13	O
C	O
##3	O
,	O
_	O
13	O
C	O
##4	O
-	O
G	O
##lu	O
.	O

This	O
question	O
##naire	O
has	O
been	O
successfully	O
used	O
in	O
patients	O
with	O
low	O
literacy	O
and	O
its	O
f	O
##eas	O
##ibility	O
was	O
previously	O
confirmed	O
in	O
our	O
hospital	O
for	O
in	O
##patient	O
##s	O
and	O
out	O
##patient	O
##s	O
with	O
cancer	O
.	O
_	O
35	O
Four	O
trained	O
p	O
##har	O
##ma	O
##cist	O
##s	O
performed	O
the	O
question	O
##naire	O
‐	O
based	O
interviews	O
at	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
starting	O
ta	B
##mo	I
##xi	I
##fen	I
therapy	O
and	O
included	O
the	O
following	O
questions	O
:	O
(	O
i	O
)	O
Do	O
you	O
ever	O
forget	O
to	O
take	O
your	O
medicines	O
?	O
;	O

Allan	B
##to	I
##in	I
is	O
produced	O
from	O
the	O
non	O
-	O
en	O
##zy	O
##matic	O
oxidation	O
of	O
u	B
##ric	I
acid	I
(	O
Fi	O
##g	O
.	O

Approximately	O
1	O
year	O
later	O
marked	O
ad	O
##eno	O
##ma	O
shrink	O
##age	O
and	O
the	O
lack	O
of	O
ch	B
##olin	I
##e	I
peak	O
in	O
the	O
tumor	O
were	O
demonstrated	O
along	O
with	O
a	O
favorable	O
clinical	O
outcome	O
.	O

In	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
,	O
the	O
top	O
six	O
affected	O
amino	O
acids	O
after	O
30	O
min	O
ranked	O
as	O
follows	O
:	O
g	B
##ly	I
##cine	I
(	O
decrease	O
by	O
91	O
%	O
)	O
,	O
as	B
##par	I
##tate	I
(	O
91	O
%	O
)	O
,	O
pro	B
##line	I
(	O
84	O
%	O
)	O
,	O
5	B
-	I
o	I
##x	I
##o	I
-	I
pro	I
##line	I
(	O
83	O
%	O
)	O
and	O
g	B
##lut	I
##ama	I
##te	I
(	O
75	O
%	O
)	O
.	O

Notes	O
:	O
_	O
[UNK]	O
,	O
tested	O
by	O
log	O
-	O
transformed	O
;	O
,	O
tested	O
by	O
Pearson	O
correlation	O
analysis	O
(	O
un	O
##ad	O
##ju	O
##sted	O
)	O
;	O
,	O
tested	O
by	O
partial	O
correlation	O
analysis	O
(	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
smoking	O
,	O
and	O
alcohol	O
consumption	O
)	O
;	O
,	O
tested	O
by	O
partial	O
correlation	O
analysis	O
(	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
smoking	O
,	O
alcohol	O
consumption	O
,	O
and	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
)	O
.	O

Several	O
meta	O
##bol	O
##ites	O
in	O
tumor	O
tissues	O
,	O
such	O
as	O
la	B
##ct	I
##ate	I
,	O
which	O
is	O
derived	O
from	O
tumor	O
exposed	O
to	O
h	O
##y	O
##pox	O
##ia	O
,	O
were	O
altered	O
both	O
with	O
and	O
without	O
meta	O
##sta	O
##sis	O
(	O
Hi	O
##ray	O
##ama	O
et	O
al	O
.	O

15	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ation	O
products	O
were	O
q	O
##uant	O
##ified	O
only	O
in	O
low	O
concentrations	O
(	O
≤	O
1	O
n	O
##M	O
)	O
and	O
SP	O
##M	O
precursor	O
18	B
-	I
H	I
##EP	I
##E	I
was	O
<	O
LL	O
##O	O
##Q	O
in	O
>	O
50	O
%	O
of	O
the	O
samples	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
assigned	O
using	O
Chen	O
##om	O
##x	O
N	O
##MR	O
suite	O
7	O
.	O
7	O
(	O
Chen	O
##om	O
##x	O
Inc	O
.	O
,	O
Alberta	O
,	O
Canada	O
)	O
,	O
the	O
Human	O
Met	O
##ab	O
##olo	O
##me	O
Database	O
,	O
and	O
/	O
or	O
literature	O
values	O
(	B
4	B
-	I
de	I
##ox	I
##yer	I
##yt	I
##hr	I
##onic	I
acid	I
(	O
4	O
-	O
DE	O
##A	O
)	O
_	O
,	O
;	O
4	B
-	I
de	I
##ox	I
##yt	I
##hr	I
##eon	I
##ic	I
acid	I
(	O
4	O
-	O
D	O
##TA	O
)	O
;	O
P	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
_	I
,	O
)	O
;	O
and	O
by	O
2D	O
JR	O
##ES	O
s	O
##pect	O
##ros	O
##copy	O
.	O

Likewise	O
,	O
controlling	O
for	O
the	O
false	O
-	O
discovery	O
rate	O
(	O
F	O
##DR	O
-	O
correction	O
)	O
for	O
the	O
12	O
analyses	O
in	O
the	O
main	O
log	O
##istic	O
re	O
##gression	O
model	O
(	O
Table	O
)	O
would	O
also	O
yield	O
significant	O
differences	O
for	O
try	B
##pt	I
##op	I
##han	I
(	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
X	O
##A	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
H	O
##AA	O
(	O

Changes	O
in	O
ch	B
##olin	I
##e	I
concentration	O
were	O
evident	O
in	O
both	O
the	O
A	B
##F	I
and	O
the	O
P	O
##L	O
.	O

In	O
addition	O
,	O
serum	O
FA	S
were	O
measured	O
using	O
improved	O
direct	O
FA	O
##ME	O
synthesis	O
and	O
G	O
##C	O
‐	O
MS	O
in	O
serum	O
samples	O
of	O
subjects	O
with	O
serum	O
samples	O
available	O
for	O
all	O
three	O
time	O
points	O
.	O

The	O
relatively	O
weak	O
correlation	O
between	O
nap	B
##ht	I
##hale	I
##ne	I
exposure	O
##s	O
and	O
u	O
##rina	O
##ry	O
2	B
-	I
nap	I
##ht	I
##hol	I
(	O
in	O
)	O
is	O
probably	O
due	O
to	O
other	O
non	O
-	O
respiratory	O
sources	O
of	O
nap	B
##ht	I
##hale	I
##ne	I
exposure	O
,	O
of	O
which	O
there	O
are	O
many	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
mainly	O
elevated	O
levels	O
of	O
n	O
##6	O
-	O
and	O
n	O
##3	O
-	O
P	O
##U	O
##FA	O
##s	O
as	O
well	O
as	O
various	O
e	B
##ico	I
##san	I
##oids	I
and	O
do	B
##cos	I
##ano	I
##ids	I
in	O
serum	O
,	O
G	O
##CF	O
and	O
sa	O
##liva	O
of	O
A	O
##g	O
##P	O
patients	O
compared	O
with	O
the	O
healthy	O
controls	O
.	O

Part	O
##ici	O
##pants	O
on	O
CE	B
##R	I
are	O
shown	O
in	O
orange	O
and	O
non	O
-	O
diet	O
##ing	O
controls	O
in	O
black	O
.	O

Despite	O
previous	O
reports	O
that	O
o	B
##les	I
##ox	I
##ime	I
does	O
not	O
affect	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
,	O
its	O
overall	O
impact	O
on	O
lip	O
##id	O
metabolism	O
has	O
never	O
been	O
explored	O
.	O

Using	O
a	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
platform	O
,	O
we	O
identified	O
alterations	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
metabolism	O
in	O
subjects	O
at	O
potentially	O
increased	O
risk	O
for	O
T	O
##2	O
##D	O
defined	O
by	O
the	O
presence	O
of	O
the	O
r	O
##s	O
##7	O
##90	O
##31	O
##46	O
risk	O
g	O
##eno	O
##type	O
.	O

Tri	B
##gly	I
##cer	I
##ides	I
with	O
higher	O
carbon	O
content	O
were	O
negatively	O
correlated	O
with	O
blood	O
glucose	S
levels	O
of	O
the	O
patients	O
.	O

Con	O
##sist	O
##ent	O
with	O
these	O
findings	O
,	O
a	O
previous	O
study	O
reported	O
that	O
the	O
plasma	O
level	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
in	O
MD	O
##D	O
patients	O
was	O
significantly	O
lower	O
than	O
the	O
level	O
of	O
healthy	O
subjects	O
.	O

For	O
ca	O
##li	O
##bra	O
##tion	O
,	O
a	O
standard	O
mixture	O
of	O
p	O
##oly	O
##phe	O
##no	O
##l	O
meta	O
##bol	O
##ites	O
was	O
serial	O
##ly	O
di	O
##lut	O
##ed	O
in	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
(	I
50	I
:	I
50	I
)	I
at	O
a	O
concentration	O
range	O
of	O
0	O
.	O
01	O
–	O
20	O

In	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
(	O
F	O
##4	O
)	O
the	O
prevalence	O
of	O
h	B
##yper	I
##gly	I
##ce	I
##mia	I
’	I
s	I
disorders	O
may	O
be	O
as	O
high	O
as	O
30	O
%	O
;	O
however	O
,	O
most	O
of	O
them	O
may	O
be	O
controlled	O
with	O
glucose	S
nutrition	O
##al	O
restrictions	O
without	O
therapeutic	O
intervention	O
.	O

Besides	O
,	O
we	O
referred	O
to	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
pro	O
##te	O
##ome	O
analysis	O
performed	O
on	O
parental	O
A	O
##37	O
##5	O
and	O
the	O
MA	O
##P	O
##K	O
##I	O
##s	O
-	O
resistant	O
sub	O
##lines	O
(	B
A	B
##37	I
##5	I
##R	I
)	O
(	O
,	O
)	O
.	O

N	O
##utrition	O
##al	O
ch	B
##olin	I
##e	I
supplement	O
##ation	O
may	O
improve	O
liver	O
function	O
and	O
lip	O
##op	O
##rote	O
##in	O
circulation	O
,	O
including	O
mini	O
##mizing	O
instances	O
of	O
fatty	O
liver	O
disease	O
.	O

Information	O
on	O
con	O
##com	O
##ita	O
##nt	O
medication	O
and	O
self	O
‐	O
reported	O
adverse	O
events	O
during	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
were	O
recorded	O
during	O
all	O
visits	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
collected	O
with	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	O
-	O
2	O
##N	O
##a	O
(	O
E	O
##D	O
##TA	O
-	O
2	O
##N	O
##a	O
)	O
as	O
an	O
anti	O
##coa	O
##gu	O
##lant	O
and	O
kept	O
at	O
4	O
##°	O
##C	O
immediately	O
after	O
collection	O
.	O

In	O
our	O
database	O
14	O
out	O
of	O
39	O
individuals	O
were	O
considered	O
di	O
##abe	O
##tics	O
(	O
were	O
prescribed	O
oral	O
anti	O
##dia	O
##bet	O
##ics	O
,	O
insulin	O
or	O
both	O
)	O
at	O
the	O
time	O
of	O
analysis	O
but	O
only	O
one	O
individual	O
(	O
female	O
)	O
showed	O
blood	O
glucose	S
over	O
6	O
.	O
1	O
mm	O
##ol	O
/	O
L	O
(	O
limit	O
to	O
be	O
diagnosed	O
as	O
di	O
##abe	O
##tic	O
)	O
on	O
the	O
sample	O
analyzed	O
.	O

The	O
el	O
##ution	O
from	O
the	O
column	O
was	O
introduced	O
to	O
Q	O
##uad	O
##rup	O
##ole	O
Time	O
of	O
flight	O
Mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
Waters	O
G	O
##2	O
-	O
Q	O
##to	O
##f	O
)	O
by	O
electro	O
##sp	O
##ray	O
Ion	O
##ization	O
in	O
both	O
positive	O
and	O
negative	O
mode	O
at	O
a	O
cap	O
##illa	O
##ry	O
voltage	O
of	O
3	O
.	O
5	O
k	B
##V	I
and	O
sampling	O
cone	O
voltage	O
of	O
35	O
V	O
.	O

In	O
the	O
study	O
of	O
trauma	O
patients	O
,	O
c	B
##it	I
##rate	I
concentrations	O
correlated	O
with	O
later	O
development	O
of	O
se	O
##psis	O
.	O

(	O
T	O
##ID	O
##P	O
)	O
and	O
6	B
-	I
th	I
##io	I
##ino	I
##sin	I
##e	I
5	I
′	I
-	I
trip	I
##hos	I
##phate	I
(	O
T	O
##IT	O
##P	O
)	O
,	O
were	O
obtained	O
from	O
Jen	O
##a	O
B	O
##ios	O
##cie	O
##nce	O
(	O
Jen	O
##a	O
,	O
Germany	O
)	O
at	O
the	O
concentrations	O
of	O
10	O
mm	O
##ol	O
/	O
L	O
.	O
Reference	O
standards	O
of	O
8	B
-	I
br	I
##omo	I
##gua	I
##nos	I
##ine	I
mon	O
##o	O
-	O

In	O
this	O
procedure	O
,	O
organic	O
solvent	O
(	O
s	O
)	O
are	O
added	O
to	O
the	O
serum	O
,	O
which	O
den	O
##ature	O
and	O
pre	O
##ci	O
##pit	O
##ate	O
proteins	O
so	O
that	O
they	O
can	O
be	O
subsequently	O
removed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
while	O
the	O
organic	O
solvent	O
(	O
s	O
)	O
are	O
removed	O
via	O
a	O
rot	O
##ary	O
e	O
##va	O
##por	O
##ator	O
or	O
l	O
##yo	O
##phi	O
##li	O
##zation	O
.	O
_	O
,	O
In	O
&	O
,	O
_	O
1	O
H	O
1	O
##D	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
human	O
serum	O
samples	O
are	O
depicted	O
after	O
they	O
have	O
been	O
treated	O
by	O
the	O
addition	O
of	O
met	B
##han	I
##ol	I
or	O
met	B
##han	I
##ol	I
/	O
ch	O
##lor	O
##of	O
##orm	O
.	O

Accordingly	O
,	O
down	O
-	O
regulation	O
of	O
the	O
fatty	O
acid	O
degradation	O
pathway	O
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
(	O
T	O
##CA	O
cycle	O
)	O
was	O
observed	O
.	O

7	B
-	I
beta	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
2	B
-	I
o	I
##xin	I
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tate	I
were	O
uniquely	O
shared	O
between	O
stool	O
and	O
CR	O
##C	O
and	O
stool	O
and	O
m	O
##uc	O
##osa	O
,	O
respectively	O
.	O

This	O
supports	O
previous	O
literature	O
where	O
k	B
##yn	I
##uren	I
##ine	I
was	O
reported	O
at	O
increased	O
concentrations	O
in	O
the	O
serum	O
of	O
clinical	O
cases	O
of	O
I	O
##B	O
##D	O
patients	O
(	O
UC	O
=	O
7	O
,	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
=	O
5	O
)	O
compared	O
to	O
a	O
control	O
group	O
(	O
n	O
=	O
12	O
)	O
.	O

It	O
is	O
known	O
that	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
regulate	O
a	O
variety	O
of	O
biological	O
processes	O
including	O
cell	O
proliferation	O
,	O
tumor	O
cell	O
invasion	O
,	O
and	O
inflammation	O
_	O
,	O
.	O

In	O
the	O
que	B
##tia	I
##pine	I
group	O
,	O
1	O
patient	O
with	O
increased	O
blood	O
pressure	O
was	O
withdrawn	O
from	O
the	O
study	O
because	O
of	O
this	O
adverse	O
event	O
.	O

For	O
the	O
end	O
##ogen	O
##ous	O
meta	O
##bol	O
##ites	O
,	O
similar	O
amounts	O
of	O
o	B
##le	I
##ic	I
acid	I
(	O
p	O
=	O
0	O
.	O
33	O
)	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
p	O
=	O
0	O
.	O
49	O
)	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
(	O
p	O
=	O
0	O
.	O
53	O
)	O
and	O
PC	B
(	I
19	I
:	I
0	I
/	I
15	I
:	I
1	I
)	I
(	O
p	O
=	O
0	O
.	O
38	O
)	O
were	O
extracted	O
using	O
either	O
method	O
.	O

Meanwhile	O
,	O
a	O
panel	O
of	O
five	O
potential	O
bio	O
##mark	O
##ers	O
–	O
format	B
##e	I
,	O
su	B
##cci	I
##nate	I
,	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
α	B
-	I
glucose	I
and	O
dim	B
##eth	I
##yla	I
##mine	I
–	O
was	O
identified	O
.	O

Finding	O
##s	O
confirmed	O
our	O
hypothesis	O
that	O
the	O
ne	O
##uro	O
##tro	O
##phic	O
branch	O
of	O
the	O
K	B
##P	I
would	O
be	O
associated	O
with	O
an	O
increase	O
in	O
network	O
connectivity	O
,	O
while	O
the	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
branch	O
would	O
be	O
associated	O
with	O
a	O
decrease	O
.	O

The	O
importance	O
of	O
the	O
a	O
##ci	O
##pi	O
##mo	O
##x	O
-	O
induced	O
decrease	O
in	O
the	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
concentration	O
is	O
under	O
##sco	O
##red	O
by	O
its	O
strong	O
correlation	O
with	O
improved	O
whole	O
-	O
body	O
(	O
primarily	O
muscle	O
)	O
glucose	S
disposal	O
during	O
the	O
h	O
##yper	O
##ins	O
##ulin	O
##em	O
##ic	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
.	O

Ice	O
-	O
cold	O
solvent	O
mixture	O
(	O
900	O
µ	O
##l	I
of	I
[UNK]	O
,	O
[UNK]	O
/	O
v	O
)	O
was	O
added	O
to	O
100	O
µ	O
##l	O
of	O
plasma	O
sample	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
in	O
##cu	O
##bate	O
##d	O
on	O
ice	O
in	O
a	O
vacuum	O
chamber	O
in	O
a	O
dark	O
room	O
for	O
1	O
h	O
with	O
agitation	O
.	O

The	O
first	O
factor	O
(	O
FA	O
##C	O
##1	O
)	O
is	O
likely	O
linked	O
to	O
L	O
##D	O
##L	O
-	O
C	O
and	O
A	O
##po	O
##B	O
particles	O
,	O
since	O
the	O
factors	O
that	O
loaded	O
strongly	O
to	O
it	O
included	O
Ce	B
##r	I
,	O
SM	O
,	O
as	O
well	O
as	O
LP	O
##C	O
and	O
P	O
##E	O
,	O
while	O
the	O
second	O
factor	O
(	O
FA	O
##C	O
##2	O
)	O
is	O
likely	O
linked	O
to	O
T	O
##G	O
-	O
rich	O
V	O
##LD	O
##L	O
due	O
to	O
high	O
loading	O
##s	O
by	O
D	O
##G	O
,	O
T	B
##G	I
and	O
PC	O
.	O

The	O
underlying	O
reason	O
might	O
be	O
that	O
this	O
particular	O
m	O
/	O
z	O
channel	O
is	O
dominated	O
by	O
an	O
is	O
##omer	O
of	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
do	I
##de	I
##can	I
##al	I
.	O

As	O
depicted	O
in	O
,	O
,	O
,	O
and	O
,	O
hip	B
##pura	I
##te	I
,	O
4	B
-	I
met	I
##hyl	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pura	I
##te	I
,	O
and	O
c	B
##inn	I
##amo	I
##yl	I
##gly	I
##cine	I
were	O
elevated	O
in	O
PS	O
##PC	O
,	O
especially	O
immediately	O
following	O
the	O
3	O
-	O
day	O
period	O
of	O
exercise	O
(	O
interaction	O
effects	O
,	O
P	O
=	O
0	O
.	O
02	O
##45	O
,	O
0	O
.	O
00	O
##17	O
,	O
0	O
.	O
00	O
##14	O
,	O
and	O
0	O
.	O
00	O
##17	O
,	O
respectively	O
)	O
.	O

The	O
linear	O
gradient	O
started	O
from	O
60	O
%	O
to	O
0	O
%	O
A	O
(	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
AC	O
##N	O
:	O
H	O
_	O
2	O
O	B
=	I
6	I
:	I
4	I
)	O
and	O
40	O
%	O
B	O
(	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
IPA	O
:	O
H	O
_	O
2	O
O	B
=	I
9	I
:	I
1	I
)	O
.	O

The	O
ratio	O
of	O
4	B
-	I
OH	I
-	I
E	I
_	I
2	I
to	O
2	B
-	I
OH	I
-	I
E	I
_	I
2	I
decreased	O
with	O
increasing	O
te	O
##rt	O
##ile	O
levels	O
of	O
T	O
##CD	O
##D	O
from	O
0	O
.	O
74	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
C	O
##I	O
)	O
,	O
0	O
.	O
58	O
–	O
0	O
.	O
89	O
]	O
,	O
to	O
0	O
.	O
48	O
(	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
39	O
–	O
0	O
.	O
56	O
)	O
,	O
to	O
0	O
.	O
46	O
(	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
37	O
–	O
0	O
.	O
55	O
)	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
β	O
=	O
−	O
##0	O
.	O
16	O
,	O
R	O
=	O
0	O
.	O
45	O
by	O
general	O
linear	O
re	O
##gression	O
;	O
data	O
not	O
shown	O
)	O
.	O

Met	B
##han	I
##ol	I
is	O
produced	O
end	O
##ogen	O
##ously	O
in	O
humans	O
.	O

In	O
summary	O
,	O
i	O
##rino	O
##teca	O
##n	O
exposure	O
induce	O
##s	O
a	O
global	O
metabolic	O
change	O
in	O
patient	O
plasma	O
,	O
as	O
represented	O
by	O
elevated	O
circulating	O
levels	O
of	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##base	O
##s	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
and	O
specific	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
.	O

Since	O
2	B
‐	I
amino	I
##but	I
##yric	I
acid	I
and	O
2	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
are	O
known	O
to	O
be	O
related	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
47	O
,	O
48	O
these	O
changes	O
further	O
support	O
reduction	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
post	O
‐	O
R	O
##Y	O
##GB	O
.	O

P	O
##las	O
##ma	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
by	O
adding	O
1	O
##m	O
##L	O
of	O
working	O
solution	O
composed	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
and	O
water	O
(	O
3	O
:	O
3	O
:	O
2	O
)	O
containing	O
is	O
##oto	O
##pe	O
-	O
labeled	O
internal	O
standards	O
at	O
a	O
concentration	O
of	O
1	O
.	O
25	O
##μ	O
##g	O
/	O
m	O
##L	O
(	B
t	B
##yr	I
##os	I
##ine	I
-	I
3	I
,	I
3	I
-	I
d	I
##2	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
-	I
2	I
,	I
3	I
,	I
3	I
,	I
4	I
,	I
4	I
-	I
d	I
##5	I
,	O
al	B
##ani	I
##ne	I
-	I
2	I
,	I
3	I
,	I
3	I
,	I
3	I
-	I
d	I
##4	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
p	I
##hen	I
##yl	I
-	I
d	I
##5	I
-	I
2	I
,	I
3	I
,	I
3	I
,	I
-	I
d	I
##3	I
,	O
my	B
##rist	I
##ic	I
acid	I
d	O
##27	O
)	O
to	O
30	O
##μ	O
##L	O
of	O
plasma	O
.	O

A	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
Mill	O
##i	O
‐	O
Q	O
)	O
and	O
mobile	O
phase	O
B	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
AC	O
##N	O
.	O

S	O
##pear	O
##man	O
rank	O
correlation	O
coefficients	O
were	O
calculated	O
to	O
measure	O
the	O
relationships	O
between	O
the	O
circulating	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
metabolic	O
markers	O
.	O

Take	O
##n	O
together	O
,	O
this	O
evidence	O
suggests	O
that	O
modification	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
in	O
mid	O
-	O
rather	O
than	O
later	O
life	O
may	O
reduce	O
risk	O
for	O
dem	O
##ent	O
##ia	O
.	O

This	O
is	O
of	O
interest	O
;	O
however	O
,	O
when	O
ass	O
##oc	O
##iating	O
the	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
levels	O
with	O
levels	O
of	O
PC	O
##D	O
##Ds	O
/	O
PC	O
##DF	O
##s	O
and	O
PC	O
##B	O
##s	O
,	O
the	O
sex	O
difference	O
was	O
not	O
significant	O
.	O

b	O
,	O
binding	O
a	O
##ffin	O
##ities	O
(	O
in	O
nm	O
)	O
of	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
to	O
RA	O
##R	O
##s	O
calculated	O
from	O
the	O
data	O
shown	O
in	O
a	O
,	O
and	O
additional	O
experiments	O
with	O
β	B
-	I
a	I
##po	I
-	I
12	I
′	I
-	I
and	O
β	B
-	I
a	I
##po	I
-	I
10	I
′	I
-	I
car	I
##ote	I
##no	I
##ic	I
acids	I
.	O

A	O
series	O
of	O
[	O
_	O
13	O
C	O
_	O
1	O
]	O
ch	O
##olic	O
acid	O
di	O
##lution	O
##s	O
in	O
et	B
##hyl	I
ace	I
##tate	I
from	O
Rand	O
##ox	O
serum	O
extract	O
##s	O
was	O
used	O
to	O
generate	O
a	O
standard	O
curve	O
ranging	O
between	O
0	O
.	O
000	O
##22	O
μ	O
##g	O
/	O
m	O
##L	O
and	O
0	O
.	O
222	O
μ	O
##g	O
/	O
m	O
##L	O
.	O
100	O
μ	O
##L	O
of	O
sample	O
were	O
injected	O
by	O
flow	O
-	O
injection	O
analysis	O
into	O
the	O
4000	O
##Q	O
##TR	O
##AP	O
[UNK]	O
equipped	O
with	O
a	O
Turbo	O
##V	O
[UNK]	O
source	O
with	O
an	O
AP	O
##CI	O
probe	O
.	O

The	O
top	O
layer	O
(	B
h	B
##ydro	I
##phi	I
##lic	I
)	O
and	O
the	O
bottom	O
layer	O
(	O
lip	O
##op	O
##hil	O
##ic	O
)	O
were	O
separated	O
and	O
transferred	O
to	O
new	O
E	O
##ppe	O
##ndo	O
##rf	O
tubes	O
.	O

Recent	O
studies	O
have	O
sign	O
##ified	O
the	O
importance	O
of	O
se	B
##rine	I
,	O
g	B
##ly	I
##cine	I
,	O
and	O
one	O
carbon	O
(	O
S	O
##G	O
##OC	O
)	O
metabolism	O
in	O
cancer	O
progression	O
due	O
to	O
its	O
contribution	O
to	O
g	B
##lut	I
##ath	I
##ione	I
and	O
n	O
##uc	O
##leo	O
##tide	O
synthesis	O
and	O
the	O
maintenance	O
of	O
DNA	O
met	B
##hyl	I
##ation	I
_	I
–	I
.	O

All	O
standards	O
,	O
Q	O
##Cs	O
,	O
and	O
samples	O
were	O
processed	O
identical	O
##ly	O
and	O
required	O
2	O
-	O
fold	O
di	O
##lution	O
with	O
a	O
50	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
solution	O
prior	O
to	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
.	O

Despite	O
the	O
abundant	O
expression	O
of	O
5	O
-	O
L	O
##O	O
in	O
B	O
-	O
C	O
##LL	O
cells	O
,	O
L	B
##T	I
##B	I
##4	I
bio	O
##sy	O
##nt	O
##hesis	O
is	O
believed	O
not	O
to	O
occur	O
in	O
low	O
differentiated	O
ma	O
##li	O
##gnant	O
B	O
l	O
##ymph	O
##ocytes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
perform	O
metabolic	O
pro	O
##fi	O
##ling	O
in	O
urine	O
from	O
patients	O
with	O
M	O
##OD	O
##Y	O
due	O
to	O
mutations	O
in	O
the	O
genes	O
encoding	O
g	O
##lu	O
##co	O
##kin	O
##ase	O
(	O
G	O
##C	O
##K	O
)	O
or	O
he	O
##pa	O
##to	O
##cy	O
##te	O
nuclear	O
factor	O
1	O
alpha	O
(	O
H	O
##NF	O
##1	O
##A	O
)	O
,	O
type	O
2	O
diabetes	O
(	O
T	O
##2	O
##D	O
)	O
and	O
norm	B
##og	I
##ly	I
##ca	I
##em	I
##ic	I
control	O
subjects	O
.	O

Table	O
clearly	O
shows	O
that	O
the	O
concentration	O
of	O
several	O
other	O
meta	O
##bol	O
##ites	O
can	O
disc	O
##rim	O
##inate	O
between	O
patients	O
with	O
a	O
small	O
and	O
large	O
metabolic	O
active	O
tumor	O
volume	O
(	O
i	O
.	O
e	O
.	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
≥	O
48	O
.	O
1	O
cm	O
##³	O
)	O
or	O
low	O
and	O
high	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
burden	O
(	O
i	O
.	O
e	O
.	O
T	O
##L	O
##G	O
_	O
W	O
##T	O
##B	O
≥	O
27	O
##6	O
.	O
2	O
cm	O
##³	O
)	O
.	O

CR	O
##P	O
was	O
negatively	O
associated	O
with	O
P	O
##LP	O
(	O
P	O
=	O
0	O
.	O
00	O
##5	O
)	O
,	O
and	O
mon	O
##oc	O
##yte	O
ch	O
##em	O
##oat	O
##tract	O
##ant	O
protein	O
1	O
was	O
positively	O
associated	O
with	O
try	B
##pt	I
##op	I
##han	I
(	O
P	O
=	O
0	O
.	O
00	O
##3	O
)	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
are	O
characterised	O
by	O
the	O
presence	O
of	O
the	O
particular	O
al	B
##ip	I
##hat	I
##ic	I
amino	I
##al	I
##co	I
##hol	I
s	I
##phi	I
##ngo	I
##sin	I
##e	I
,	O
also	O
termed	O
a	O
long	O
-	O
chain	O
base	O
.	O

We	O
also	O
measured	O
inverse	O
relationships	O
between	O
LP	B
##C	I
(	I
20	I
:	I
2	I
)	I
and	O
levels	O
of	O
s	O
##CD	O
##14	O
and	O
T	O
##NF	O
##R	O
##2	O
in	O
HIV	O
–	O
participant	O
serum	O
.	O

c	O
Sal	B
##ine	I
was	O
the	O
vehicle	O
for	O
is	O
##onia	O
##zi	O
##d	O
.	O

The	O
results	O
(	O
B	O
)	O
showed	O
that	O
a	O
panel	O
of	O
potential	O
bio	O
##mark	O
##ers	O
(	B
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
0	I
)	I
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
1	I
)	I
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
and	O
u	O
##ric	O
acid	O
)	O
provided	O
an	O
AU	O
##C	O
of	O
0	O
.	O
96	O
##1	O
.	O

Part	O
##ici	O
##pants	O
underwent	O
continuous	O
s	B
##tat	I
##in	I
or	O
e	O
##ze	O
##ti	O
##mi	O
##be	O
treatment	O
for	O
at	O
least	O
3	O
months	O
before	O
study	O
entry	O
.	O

P	O
and	O
IP	S
with	O
98	O
%	O
purity	O
were	O
isolated	O
from	O
the	O
fruits	O
of	O
PC	O
by	O
our	O
research	O
group	O
;	O
some	O
of	O
the	O
chemical	O
information	O
are	O
listed	O
in	O
the	O
supporting	O
information	O
(	O
Figure	O
##s	O
S	O
##9	O
–	O
S	O
##14	O
)	O
,	O
which	O
were	O
identified	O
by	O
the	O
techniques	O
of	O
I	O
##R	O
,	O
MS	O
,	O
1	O
##H	O
-	O
N	O
##MR	O
,	O
13	O
##C	O
-	O
N	O
##MR	O
,	O
and	O
HP	O
##LC	O
analysis	O
,	O
as	O
well	O
as	O
in	O
comparison	O
with	O
the	O
spectral	O
data	O
reported	O
in	O
the	O
literature	O
.	O

It	O
was	O
found	O
that	O
g	B
##lut	I
##ama	I
##te	I
levels	O
were	O
significantly	O
increased	O
in	O
plasma	O
of	O
G	O
##CT	O
patients	O
.	O

,	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
isolated	O
from	O
R	O
.	O
a	O
##pic	O
##ulate	O
(	O
Mo	O
##ron	O
et	O
al	O
.	O
2018	O
)	O
and	O
F	O
.	O
later	O
##iti	O
##um	O
end	O
##op	O
##hy	O
##te	O
of	O
R	O
##hi	O
##zo	O
##ph	O
##ora	O
m	O
##uc	O
##rona	O
##ta	O
(	O
Ham	O
##za	O
##h	O
et	O
al	O
.	O
2018	O
)	O
were	O
reported	O
to	O
exhibit	O
a	O
broad	O
anti	O
##mic	O
##ro	O
##bial	O
spectrum	O
against	O
various	O
path	O
##ogenic	O
micro	O
##or	O
##gan	O
##isms	O
indicating	O
the	O
con	O
##ce	O
##iva	O
##bility	O
of	O
potential	O
bio	O
##active	O
meta	O
##bol	O
##ites	O
in	O
their	O
crude	O
mixture	O
.	O

However	O
,	O
the	O
is	B
##ole	I
##uc	I
##ine	I
-	I
CH	I
_	I
3	I
function	O
bucket	O
was	O
not	O
selected	O
as	O
a	O
disc	O
##rim	O
##inator	O
##y	O
variable	O
for	O
MG	O
##S	O
-	O
treated	O
samples	O
in	O
this	O
comparison	O
.	O

Furthermore	O
,	O
eleven	O
of	O
the	O
resulting	O
28	O
differential	O
meta	O
##bol	O
##ites	O
after	O
valid	O
##ation	O
test	O
were	O
tentatively	O
identified	O
as	O
potential	O
therapeutic	O
bio	O
##mark	O
##ers	O
:	O
two	O
amino	O
acids	O
,	O
five	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
and	O
four	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
summarized	O
in	O
)	O
.	O

3	O
)	O
Sub	O
##jects	O
received	O
a	O
3	O
-	O
h	O
80	O
m	O
##U	O
/	O
min	O
·	O
m	O
_	O
2	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
insulin	O
c	O
##lamp	O
in	O
combination	O
with	O
3	O
-	B
[	B
_	I
3	I
H	I
]	I
glucose	I
and	O
vast	O
##us	O
lateral	O
##is	O
muscle	O
bio	O
##psy	O
immediately	O
before	O
the	O
h	O
##yper	O
##ins	O
##ulin	O
##em	O
##ic	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
for	O
measurement	O
of	O
muscle	O
D	O
##AG	O
content	O
(	O
n	O
=	O
10	O
)	O
;	O
they	O
were	O
subsequently	O
treated	O
with	O
45	O
mg	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
per	O
day	O
for	O
4	O
months	O
,	O
and	O
the	O
insulin	O
c	O
##lamp	O
/	O
vast	O
##us	O
lateral	O
##is	O
muscle	O
bio	O
##psy	O
studies	O
for	O
insulin	O
sensitivity	O
and	O
muscle	O
D	O
##AG	O
content	O
were	O
repeated	O
.	O

The	O
resulting	O
volcano	O
plots	O
show	O
the	O
differential	O
##ly	O
met	O
##hyl	O
##ated	O
probe	O
##s	O
present	O
between	O
α	B
-	I
O	I
##G	I
treatment	O
and	O
control	O
conditions	O
.	O

Alternatively	O
,	O
the	O
levels	O
of	O
Neo	B
##pt	I
##eri	I
##n	I
and	O
E	O
##pine	O
##ph	O
##rine	O
/	O
Nor	O
##ep	O
##ine	O
##ph	O
##rine	O
were	O
higher	O
in	O
HIV	O
/	O
AIDS	O
patients	O
but	O
lower	O
concentrations	O
were	O
observed	O
in	O
patients	O
receiving	O
AR	O
##T	O
.	O

Su	O
##pp	O
##ression	O
of	O
PC	O
only	O
slightly	O
and	O
ins	O
##ign	O
##ificant	O
##ly	O
lowered	O
the	O
concentrations	O
of	O
ATP	S
and	O
AD	B
##P	I
without	O
affecting	O
the	O
ATP	B
/	I
AD	I
##P	I
ratio	O
and	O
N	O
##AD	O
(	O
P	O
)	O
(	O
H	O
)	O
concentrations	O
indicating	O
suppression	O
of	O
PC	O
did	O
not	O
seriously	O
affect	O
the	O
cell	O
energy	O
charge	O
.	O

In	O
conclusion	O
,	O
we	O
showed	O
that	O
try	B
##pt	I
##op	I
##han	I
and	O
K	O
##P	O
##m	O
concentrations	O
decreased	O
after	O
a	O
bar	O
##ia	O
##tric	O
surgery	O
in	O
women	O
with	O
o	O
##besity	O
,	O
and	O
our	O
results	O
suggest	O
potential	O
interactions	O
between	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ite	O
production	O
,	O
inflammation	O
and	O
glucose	S
metabolism	O
.	O

Finally	O
,	O
la	B
##ct	I
##ate	I
could	O
be	O
correlated	O
with	O
tumor	O
neo	O
##ad	O
##ju	O
##vant	O
ch	O
##em	O
##otherapy	O
in	O
predict	O
##ing	O
responses	O
to	O
this	O
therapy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
higher	O
C	O
##V	O
meta	O
##bol	O
##ites	O
belonged	O
to	O
the	O
unknown	O
##s	O
(	O
six	O
of	O
them	O
)	O
,	O
As	O
##p	O
,	O
se	B
##do	I
##he	I
##pt	I
##ulos	I
##e	I
,	O
v	B
##ale	I
##ric	I
acid	I
,	O
and	O
rib	B
##ose	I
.	O

After	O
1	O
h	O
,	O
30	O
μ	O
##L	O
of	O
he	B
##pta	I
##ne	I
(	O
containing	O
0	O
.	O
5	O
μ	O
##g	O
of	O
met	O
##hyl	O
s	O
##te	O
##arate	O
)	O
was	O
added	O
.	O

Met	B
##hyl	I
##mal	I
##onic	I
acid	I
is	O
a	O
metabolic	O
product	O
of	O
vitamin	O
B	O
_	O
12	O
,	O
whose	O
high	O
level	O
indicates	O
a	O
deficiency	O
of	O
vitamin	O
B	O
_	O
12	O
.	O

Our	O
finding	O
of	O
the	O
elevated	O
ace	B
##ty	I
##lated	I
p	I
##oly	I
##amine	I
##s	I
indicates	O
that	O
the	O
same	O
mechanism	O
may	O
also	O
occur	O
in	O
the	O
acute	O
SC	O
##I	O
scenario	O
.	O

Chen	O
et	O
al	O
[	O
]	O
identified	O
serum	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
as	O
a	O
characteristic	O
meta	O
##bol	O
##ite	O
of	O
HC	O
##C	O
for	O
the	O
first	O
time	O
by	O
a	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
MS	O
-	O
based	O
meta	O
##bol	O
##ome	O
study	O
,	O
and	O
reported	O
that	O
elevation	O
of	O
its	O
serum	O
concentration	O
was	O
applicable	O
as	O
an	O
additional	O
diagnostic	O
bio	O
##mark	O
##er	O
for	O
HC	O
##C	O
,	O
particularly	O
in	O
combination	O
with	O
serum	O
A	O
##FP	O
.	O

Finding	O
##s	O
from	O
correlation	O
analyses	O
and	O
size	O
effect	O
(	O
He	O
##dges	O
’	O
s	O
s	O
##tat	O
##istic	O
)	O
were	O
considered	O
to	O
choose	O
candidate	O
individual	O
FA	S
for	O
in	O
v	O
##it	O
##ro	O
ass	O
##ays	O
.	O

3	B
##H	I
-	I
8	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
(	I
β	I
-	I
D	I
-	I
2	I
′	I
de	I
##ox	I
##yr	I
##ib	I
##of	I
##ura	I
##nos	I
##yl	I
)	I
-	I
5	I
,	I
6	I
,	I
7	I
,	I
8	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##opy	I
##rid	I
##o	I
[	I
3	I
,	I
2	I
-	I
α	I
]	I
pu	I
##rin	I
-	I
9	I
-	I
one	I
(	I
8	I
-	I
OH	I
-	I
P	I
##d	I
##G	I
)	I
and	O
3	B
##H	I
-	I
6	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
(	I
β	I
-	I
D	I
-	I
2	I
′	I
de	I
##ox	I
##yr	I
##ib	I
##of	I
##ura	I
##nos	I
##yl	I
)	I
-	I
5	I
,	I
6	I
,	I
7	I
,	I
8	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##opy	I
##rid	I
##o	I
[	I
3	I
,	I
2	I
-	I
α	I
]	I
pu	I
##rin	I
-	I
9	I
-	I
one	I
(	I
6	I
-	I
OH	I
-	I
P	I
##d	I
##G	I
)	I
.	O

This	O
valid	O
##ated	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
was	O
applied	O
to	O
q	O
##uant	O
##ify	O
the	O
pro	B
##line	I
concentrations	O
in	O
a	O
set	O
of	O
60	O
serum	O
samples	O
comprising	O
EA	O
##C	O
patients	O
(	O
n	O
=	O
30	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
30	O
)	O
matched	O
by	O
age	O
and	O
gender	O
.	O

Current	O
clinical	O
care	O
focuses	O
on	O
measuring	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	I
and	O
PT	O
##H	O
concentrations	O
to	O
direct	O
the	O
initiation	O
and	O
t	O
##it	O
##ration	O
of	O
vitamin	B
D	I
supplement	O
##s	O
and	O
vitamin	B
D	I
receptor	O
ago	O
##nist	O
##s	O
.	O

Car	O
##tri	O
##dges	O
were	O
prime	O
##d	O
with	O
two	O
500	O
µ	O
##L	O
volumes	O
of	O
he	B
##xa	I
##ne	I
,	O
then	O
the	O
lip	O
##id	O
-	O
containing	O
ch	B
##lor	I
##of	I
##orm	I
solution	O
was	O
loaded	O
and	O
the	O
flow	O
through	O
collected	O
.	O

In	O
case	O
of	O
washing	O
and	O
di	O
##lut	O
##ing	O
the	O
RB	O
##C	O
with	O
the	O
sa	B
##line	I
solution	O
,	O
42	O
of	O
the	O
64	O
total	O
measured	O
levels	O
(	O
8	O
meta	O
##bol	O
##ites	O
in	O
several	O
samples	O
were	O
below	O
LL	O
##O	O
##Q	O
)	O
were	O
outside	O
of	O
the	O
acceptance	O
interval	O
(	O
i	O
.	O
e	O
.	O
,	O
65	O
.	O
6	O
%	O
out	O
##liers	O
ranged	O
in	O
the	O
interval	O
of	O
80	O
.	O
2	O
–	O
134	O
.	O
7	O
%	O
)	O
.	O

Two	O
al	O
##iq	O
##uo	O
##ts	O
were	O
treated	O
immediately	O
after	O
drawing	O
(	O
Section	O
3	O
.	O
3	O
,	O
RB	O
##C	O
l	O
##ys	O
##is	O
and	O
24	O
h	O
storage	O
at	O
−	O
##20	O
°C	O
)	O
,	O
in	O
one	O
the	O
RB	O
##C	O
were	O
washed	O
and	O
di	O
##lut	O
##ed	O
with	O
the	O
sa	B
##line	I
solution	O
,	O
in	O
another	O
one	O
the	O
RB	O
##C	O
were	O
washed	O
and	O
di	O
##lut	O
##ed	O
with	O
PBS	O
.	O

The	O
independent	O
variables	O
were	O
study	O
group	O
(	O
controls	O
or	O
workers	O
)	O
,	O
log	O
_	O
10	O
c	B
##rea	I
##tin	I
##ine	I
(	O
g	O
/	O
L	O
)	O
,	O
age	O
(	O
years	O
)	O
,	O
log	O
_	O
10	O
co	B
##tin	I
##ine	I
(	O
µ	O
##g	O
/	O
L	O
)	O
,	O
ho	O
##bb	O
##ies	O
at	O
home	O
involving	O
exposure	O
during	O
the	O
last	O
3	O
days	O
(	O
no	O
or	O
yes	O
)	O
(	O
n	O
=	O
94	O
,	O
four	O
observations	O
removed	O
due	O
to	O
missing	O
values	O
)	O
.	O

Sign	O
##ificant	O
amounts	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
T	B
##G	I
(	I
17	I
:	I
2	I
/	I
17	I
:	I
2	I
/	I
18	I
:	I
0	I
)	I
were	O
detected	O
following	O
M	B
##T	I
##BE	I
extraction	O
,	O
and	O
these	O
could	O
not	O
be	O
detected	O
when	O
met	B
##han	I
##ol	I
alone	O
was	O
used	O
.	O

There	O
were	O
several	O
nitrogen	O
atoms	O
in	O
both	O
Cap	O
and	O
its	O
meta	O
##bol	O
##ites	O
,	O
which	O
would	O
carry	O
out	O
ion	O
-	O
exchange	O
process	O
in	O
given	O
chemical	O
c	O
##ir	O
##cum	O
##stance	O
,	O
but	O
the	O
ring	O
##like	O
structure	O
and	O
s	O
##ter	O
##ic	O
hind	O
##rance	O
might	O
hind	O
##er	O
the	O
formation	O
of	O
am	B
##mon	I
##ium	I
and	O
su	O
##cc	O
##ede	O
##nt	O
ion	O
-	O
exchange	O
.	O

Fifty	O
micro	O
##lit	O
##res	O
of	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
20	O
mg	O
/	O
m	O
##L	O
p	B
##yr	I
##id	I
##ine	I
)	O
was	O
used	O
to	O
dissolve	O
dried	O
residue	O
,	O
which	O
stayed	O
at	O
20	O
##°	O
##C	O
for	O
24	O
h	O
.	O

This	O
concentrated	O
P	O
##O	O
##OL	O
is	O
then	O
fraction	O
collected	O
using	O
the	O
same	O
L	O
##C	O
-	O
EC	O
method	O
used	O
in	O
all	O
pro	O
##fi	O
##ling	O
studies	O
,	O
but	O
with	O
T	O
##EA	O
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
as	O
the	O
buffer	O
add	O
##itive	O
##s	O
.	O

Five	O
metabolic	O
pathways	O
of	O
importance	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
metabolism	O
,	O
gal	B
##act	I
##ose	I
metabolism	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
)	O
were	O
disturbed	O
in	O
the	O
T	O
##BI	O
patients	O
with	O
cognitive	O
imp	O
##air	O
##ment	O
.	O

To	O
analyze	O
amino	O
acids	O
and	O
organic	O
acids	O
simultaneously	O
,	O
1	O
.	O
2	O
M	O
form	B
##ic	I
acid	I
with	O
low	O
pH	O
was	O
used	O
to	O
con	O
##fer	O
positive	O
charges	O
on	O
these	O
ion	O
##ic	O
compounds	O
,	O
making	O
them	O
am	O
##ena	O
##ble	O
to	O
MS	O
analysis	O
.	O

Interest	O
##ingly	O
,	O
L	B
-	I
car	I
##ni	I
##tine	I
supplement	O
##ation	O
has	O
been	O
reported	O
to	O
am	O
##eli	O
##ora	O
##te	O
fatigue	O
in	O
MS	O
patients	O
[	O
,	O
]	O
,	O
lending	O
further	O
support	O
to	O
this	O
hypothesis	O
.	O

Self	O
reporting	O
and	O
co	B
##tin	I
##ine	I
levels	O
were	O
used	O
to	O
verify	O
the	O
success	O
of	O
smoking	O
c	O
##ess	O
##ation	O
.	O

Ana	O
##ly	O
##tes	O
were	O
el	O
##uted	O
with	O
3	O
m	O
##L	O
di	O
##ch	O
##lor	O
##ome	O
##than	O
##e	O
/	O
2	O
-	O
prop	O
##ano	O
##l	O
/	O
am	O
##mon	O
##ium	O
h	B
##ydro	I
##xi	I
##de	I
(	I
78	I
:	I
20	I
:	I
2	I
,	I
v	I
/	I
v	I
)	I
.	O

Re	O
##lative	O
changes	O
in	O
fatty	O
acid	O
classes	O
at	O
s	O
##n	O
-	O
2	O
position	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
##s	I
in	O
Multiple	O
Sc	O
##ler	O
##osis	O
Fat	O
##ty	O
acids	O
at	O
s	O
##n	O
-	O
2	O
position	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
##s	I
are	O
categorized	O
according	O
to	O
their	O
number	O
of	O
double	O
bonds	O
and	O
chain	O
length	O
.	O

Third	O
,	O
D	B
-	I
rib	I
##ose	I
5	I
-	I
phosphate	I
to	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
ratio	O
was	O
equally	O
lowered	O
in	O
pre	O
-	O
pro	O
##state	O
##ct	O
##omy	O
samples	O
>	O
2	O
.	O
0	O
-	O
fold	O
compared	O
to	O
other	O
groups	O
separately	O
or	O
combined	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

To	O
confirm	O
the	O
metabolic	O
changes	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##ys	I
##tein	I
##e	I
in	O
the	O
urine	O
of	O
a	O
##MC	O
##I	O
individuals	O
,	O
it	O
was	O
tested	O
whether	O
the	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##ys	I
##tein	I
##e	I
concentration	O
of	O
a	O
##MC	O
##I	O
patients	O
from	O
a	O
hospital	O
memory	O
clinic	O
were	O
different	O
from	O
those	O
of	O
control	O
subjects	O
.	O

Each	O
additional	O
Lo	O
##F	O
all	O
##ele	O
in	O
CD	O
##36	O
(	O
c	O
.	O
97	O
##5	O
##T	O
>	O
G	O
)	O
had	O
a	O
lowering	O
effect	O
on	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
levels	O
,	O
and	O
each	O
additional	O
Lo	O
##F	O
all	O
##ele	O
in	O
SL	O
##CO	O
##1	O
##B	O
##1	O
(	O
c	O
.	O
48	O
##1	O
+	O
1	O
##G	O
>	O
T	O
)	O
demonstrated	O
an	O
increasing	O
effect	O
on	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
levels	O
.	O

The	O
absolute	O
q	O
##uant	O
##ification	O
of	O
ch	B
##olin	I
##e	I
and	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
at	O
each	O
W	O
##OL	O
was	O
determined	O
using	O
is	O
##oto	O
##pe	O
di	O
##lution	O
MS	O
with	O
the	O
exception	O
of	O
GP	O
##C	O
##ho	O
where	O
an	O
external	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
was	O
used	O
because	O
no	O
commercial	O
internal	O
standard	O
(	O
IS	O
)	O
was	O
available	O
.	O

109	O
.	O
07	O
##60	O
(	O
base	O
peak	O
)	O
,	O
the	O
molecular	O
cat	O
##ion	O
for	O
p	B
##ico	I
##ly	I
##lam	I
##ine	I
(	O
PA	O
,	O
1	O
.	O
9	O
pp	O
##m	O
mass	O
error	O
)	O
.	O

For	O
example	O
,	O
the	O
predicted	O
λ	O
_	O
b	O
:	O
a	O
for	O
2	B
-	I
he	I
##xen	I
##al	I
was	O
111	O
,	O
therefore	O
exchanges	O
almost	O
exclusively	O
in	O
the	O
air	O
##ways	O
.	O

